PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Bagrodia, S; Bailey, D; Lenard, Z; Hart, M; Guan, JL; Premont, RT; Taylor, SJ; Cerione, RA				Bagrodia, S; Bailey, D; Lenard, Z; Hart, M; Guan, JL; Premont, RT; Taylor, SJ; Cerione, RA			A tyrosine-phosphorylated protein that binds to an important regulatory region on the cool family of p21-activated kinase-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; FOCAL ADHESION KINASE; ACTIN STRESS FIBERS; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE EXCHANGE; CDC42 GTPASES; RHO-GTPASES; PAK1; RAC; LOCALIZATION	The pal-activated kinases (Pak) are major targets of the small GTPases Cdc42 and Rac, We, and others, recently identified a family of proteins termed Cool/Pix, which interact with Pak3, In cells, p50(Cool-1) suppresses Pak activation by upstream activators; p85(Cool-1) has a permissive effect on Pak activation, and we now show that the closely related Cool-2 stimulates Pak kinase activity. To understand the differential regulation of Pak by Cool proteins, we screened for Cool-interacting proteins by affinity purification and microsequencing, This has led to the identification of two closely related proteins called Cat (Cool-associated, tyrosine phosphorylated), which contain a zinc finger followed by three ankyrin repeats. Cat-1 is identical to the recently identified binding partner for the beta-adrenergic receptor kinase (beta ARK or GRK-2), which was shown to have Arf-GAP activity. Cat-1 and Cat-2 both bind to the COOH-terminal region of p85(Cool-1) and p85(Cool-2) but not bind to p50(Cool-1), Cat-1 is tyrosine-phosphorylated in growing NIH 3T3 fibroblasts, and its tyrosine phosphorylation is increased following cell spreading on fibronectin, decreased in cells arrested in mitosis, and increased in the ensuing G(1) phase. Cat proteins are tyrosine-phosphorylated when co-expressed in cells with the focal adhesion kinase Fak and Src, These findings suggest that in addition to playing a role in Cool/Pak interactions, Cat proteins may serve as points of convergence between G protein-coupled receptors, integrins, Arf GTPases, cell cycle regulators, and Cdc42/Rac/Pak signaling pathways.	Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA; Cornell Univ, Biochem Mol & Cell Biol Sect, Ithaca, NY 14853 USA; Onyx Pharmaceut, Richmond, CA 94806 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA	Cornell University; Cornell University; Duke University	Cerione, RA (corresponding author), Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA.			Hart, Matthew/0000-0002-2683-480X; Premont, Richard/0000-0002-8053-5026	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040654, R01GM047458] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47458, GM40654] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Benton BK, 1997, MOL CELL BIOL, V17, P5067, DOI 10.1128/MCB.17.9.5067; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; Brown MT, 1998, MOL CELL BIOL, V18, P7038, DOI 10.1128/MCB.18.12.7038; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CUKIERMAN E, 1995, SCIENCE, V270, P1999, DOI 10.1126/science.270.5244.1999; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Dharmawardhane S, 1997, J CELL BIOL, V138, P1265, DOI 10.1083/jcb.138.6.1265; Drechsel DN, 1997, CURR BIOL, V7, P12, DOI 10.1016/S0960-9822(06)00023-6; Frost JA, 1998, J BIOL CHEM, V273, P28191, DOI 10.1074/jbc.273.43.28191; Guan JL, 1997, INT J BIOCHEM CELL B, V29, P1085, DOI 10.1016/S1357-2725(97)00051-4; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HammondsOdie LP, 1996, J BIOL CHEM, V271, P18859, DOI 10.1074/jbc.271.31.18859; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Nikolic M, 1998, NATURE, V395, P194, DOI 10.1038/26034; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Oh WK, 1997, BIOCHEM BIOPH RES CO, V235, P794, DOI 10.1006/bbrc.1997.6875; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Poon PP, 1996, P NATL ACAD SCI USA, V93, P10074, DOI 10.1073/pnas.93.19.10074; Premont RT, 1998, P NATL ACAD SCI USA, V95, P14082, DOI 10.1073/pnas.95.24.14082; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Tjandra H, 1998, CURR BIOL, V8, P991, DOI 10.1016/S0960-9822(07)00419-8; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Zhang CJ, 1998, J BIOL CHEM, V273, P19792, DOI 10.1074/jbc.273.31.19792; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	45	174	182	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22393	22400		10.1074/jbc.274.32.22393	http://dx.doi.org/10.1074/jbc.274.32.22393			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428811	hybrid			2022-12-25	WOS:000081868400041
J	Nilsen, SL; Prorok, M; Castellino, FJ				Nilsen, SL; Prorok, M; Castellino, FJ			Enhancement through mutagenesis of the binding of the isolated Kringle 2 domain of human plasminogen to omega-amino acid ligands and to an internal sequence of a Streptococcal surface protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPSILON-AMINOHEXANOIC ACID; HIGH-AFFINITY BINDING; RECOMBINANT KRINGLE-1; PICHIA-PASTORIS; THERMAL-STABILITY; ACTIVATOR INHIBITOR-1; AMINOCAPROIC ACID; ESCHERICHIA-COLI; SITE; EXPRESSION	In the background of the recombinant K2 module of human plasminogen (K2(Pg)), a triple mutant, K2(Pg)[C4G/ E56D/L72Y], was generated and expressed in Pichia pastoris cells in yields exceeding 100 mg/liter. The binding affinities of a series of lysine analogs, viz. C-aminobutyric acid, 5-aminopentanoic acid, 4-aminocaproic acid, 7-aminoheptanoic acid, and t-4-aminomethylcyclohexane-1-carboxylic acid, to this mutant were measured and showed up to a 15-fold tighter interaction, as compared with wild-type K2(Pg) (K2(Pg)[C4G]). The variant, K2(Pg)[C4G/E56D], afforded up to a 4-fold increase in the binding affinity to these same ligands, whereas the K2(Pg)[C4G/L72Y] mutant decreased the same affinities up to 5-fold, as compared with K2(Pg)[C4G]. The thermal stability of K2(Pg)[C4G/E56D/L72Y] was increased by approximately 13 degrees C, as compared with K2(Pg)[C4G]. The functional consequence of up-regulating the lysine binding property of K2(Pg) was explored, as reflected by its ability to interact with an internal sequence of a plasminogen-binding protein (PAM) on the surface of group A streptococci. A 30-mer peptide of PAM, containing its K2(Pg)-specific binding region, was synthesized, and its binding to each mutant of K2(Pg) was assessed. Only a slight enhancement in peptide binding was observed for K2(Pg)[C4G/E56D], compared with K2(Pg)[C4G] (K-d = 460 nM). A 12-fold decrease in binding affinity was observed for K2(Pg)[C4G/L72Y] (K-d = 2200 nM). However, a 12-fold enhancement in binding to this peptide was observed for K2(Pg)[C4G/E56D/L72Y] (K-d = 37 nM). Results of these PAM peptide binding studies parallel results of omega-amino acid binding to these K2(Pg) mutants, indicating that the high affinity PAM binding by plasminogen, mediated exclusively through K2(Pg), occurs through its lysine-binding site. This conclusion is supported by the 100-fold decrease in PAM peptide binding to K2(Pg)[C4G/ E56D/L72Y] in the presence of 50 mM 6-aminohexanoic acid. Finally, a thermodynamic analysis of PAM peptide binding to each of these mutants reveals that the positions Asp(56) and Tyr(72) in the K2(Pg)[C4G/E56D/L72Y] mutant are synergistically coupled in terms of their contribution to the enhancement of PAM peptide binding.	Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA	University of Notre Dame	Castellino, FJ (corresponding author), Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA.				NHLBI NIH HHS [HL-13423] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL013423, R37HL013423] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERGE A, 1993, J BIOL CHEM, V268, P25417; BYEON IJL, 1991, J MOL BIOL, V222, P1035, DOI 10.1016/0022-2836(91)90592-T; Chang Y, 1997, BIOCHEMISTRY-US, V36, P7652, DOI 10.1021/bi970197g; CHANG Y, BIOCHEMISTRY, V3258, P98; CHIBBER BAK, 1990, INT J PEPT PROT RES, V35, P73; D'Costa SS, 1998, MICROB PATHOGENESIS, V24, P341, DOI 10.1006/mpat.1998.0207; DEGEN SJF, 1991, BIOCHEMISTRY-US, V30, P9781, DOI 10.1021/bi00104a030; DESERRANO VS, 1994, BIOCHEMISTRY-US, V33, P1340, DOI 10.1021/bi00172a008; DESERRANO VS, 1992, BIOCHEMISTRY-US, V31, P3326, DOI 10.1021/bi00128a004; DESERRANO VS, 1994, BIOCHEMISTRY-US, V33, P3509, DOI 10.1021/bi00178a007; DESERRANO VS, 1993, BIOCHEMISTRY-US, V32, P3540, DOI 10.1021/bi00065a004; DESERRANO VS, 1992, ARCH BIOCHEM BIOPHYS, V292, P206, DOI 10.1016/0003-9861(92)90069-9; DESERRANO VS, 1992, BIOCHEMISTRY-US, V31, P11698, DOI 10.1021/bi00162a005; DESERRANO VS, 1992, ARCH BIOCHEM BIOPHYS, V294, P282, DOI 10.1016/0003-9861(92)90170-2; DEVOS AM, 1992, BIOCHEMISTRY-US, V31, P270, DOI 10.1021/bi00116a037; Duman JG, 1998, BIOTECHNOL APPL BIOC, V28, P39; Ellis V, 1997, TRENDS CARDIOVAS MED, V7, P227, DOI 10.1016/S1050-1738(97)00084-4; FLEURY V, 1993, EUR J BIOCHEM, V216, P549, DOI 10.1111/j.1432-1033.1993.tb18173.x; HOOVER GJ, 1993, BIOCHEMISTRY-US, V32, P10936, DOI 10.1021/bi00092a002; HORTIN GL, 1988, BIOCHEM BIOPH RES CO, V155, P591, DOI 10.1016/S0006-291X(88)80535-7; KANEKO M, 1991, BIOCHEM BIOPH RES CO, V178, P1160, DOI 10.1016/0006-291X(91)91014-4; KANEKO M, 1992, J BIOCHEM, V111, P244, DOI 10.1093/oxfordjournals.jbchem.a123744; KELLEY RF, 1989, BIOCHEMISTRY-US, V28, P4047, DOI 10.1021/bi00435a062; MAGNUSSON S, 1975, PROTEASES BIOL CONTR, P123; MARTI D, 1994, EUR J BIOCHEM, V219, P455, DOI 10.1111/j.1432-1033.1994.tb19959.x; Marti DN, 1997, BIOCHEMISTRY-US, V36, P11591, DOI 10.1021/bi971316v; Mathews II, 1996, BIOCHEMISTRY-US, V35, P2567, DOI 10.1021/bi9521351; MCCANCE SG, 1994, J BIOL CHEM, V269, P32405; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MENHART N, 1991, BIOCHEMISTRY-US, V30, P1948, DOI 10.1021/bi00221a031; MENHART N, 1993, BIOCHEMISTRY-US, V32, P8799, DOI 10.1021/bi00085a010; Miele RG, 1997, BIOTECHNOL APPL BIOC, V25, P151; Miele RG, 1997, BIOTECHNOL APPL BIOC, V26, P79; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; MILES LA, 1988, J BIOL CHEM, V263, P11928; MULICHAK AM, 1991, BIOCHEMISTRY-US, V30, P10576, DOI 10.1021/bi00107a029; Nilsen SL, 1997, BIOTECHNOL APPL BIOC, V25, P63, DOI 10.1111/j.1470-8744.1997.tb00415.x; PENNICA D, 1983, NATURE, V301, P214, DOI 10.1038/301214a0; Prorok M, 1996, BIOCHEMISTRY-US, V35, P16528, DOI 10.1021/bi9621122; RAMESH V, 1987, J MOL BIOL, V198, P481, DOI 10.1016/0022-2836(87)90295-6; REJANTE MR, 1994, EUR J BIOCHEM, V221, P939, DOI 10.1111/j.1432-1033.1994.tb18809.x; Ringdahl U, 1998, J BIOL CHEM, V273, P6424, DOI 10.1074/jbc.273.11.6424; SEHL LC, 1990, J BIOL CHEM, V265, P5482; SEKI T, 1991, GENE, V102, P213; SJOBRING U, 1994, MOL MICROBIOL, V14, P443, DOI 10.1111/j.1365-2958.1994.tb02179.x; SOTTRUPJENSEN L, 1978, PROGR CHEM FIBRINOLY, V3, P191; STEFFENS GJ, 1982, H-S Z PHYSIOL CHEM, V363, P1043, DOI 10.1515/bchm2.1982.363.2.1043; SUENSON E, 1981, BIOCHEM J, V197, P619, DOI 10.1042/bj1970619; THEWES T, 1990, J BIOL CHEM, V265, P3906; URANO T, 1987, J BIOL CHEM, V262, P15959; URANO T, 1987, P NATL ACAD SCI USA, V84, P4031, DOI 10.1073/pnas.84.12.4031; VERHEIJEN JH, 1986, EMBO J, V5, P3525, DOI 10.1002/j.1460-2075.1986.tb04678.x; WISTEDT AC, 1995, MOL MICROBIOL, V18, P569, DOI 10.1111/j.1365-2958.1995.mmi_18030569.x; Wistedt AC, 1998, J BIOL CHEM, V273, P24420, DOI 10.1074/jbc.273.38.24420; WU TP, 1991, BIOCHEMISTRY-US, V30, P10589, DOI 10.1021/bi00107a030	55	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22380	22386		10.1074/jbc.274.32.22380	http://dx.doi.org/10.1074/jbc.274.32.22380			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428809	hybrid			2022-12-25	WOS:000081868400039
J	Buettner, C; Harney, JW; Berry, MJ				Buettner, C; Harney, JW; Berry, MJ			The Caenorhabditis elegans homologue of thioredoxin reductase contains a selenocysteine insertion sequence (SECIS) element that differs from mammalian SECIS elements but directs selenocysteine incorporation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I IODOTHYRONINE DEIODINASE; GLUTATHIONE-PEROXIDASE; TARGETED DISRUPTION; GENE; PROTEIN; CLONING; SELENOPROTEIN; TRANSLATION; EFFICIENCY; EUKARYOTES	Thioredoxin reductases (TRR) serve critical roles in maintaining cellular redox states. Two isoforms of TRR have been identified in mammals: both contain a penultimate selenocysteine residue that is essential for catalytic activity. A search of the genome of the invertebrate, Caenorhabditis elegans, reveals a gene highly homologous to mammalian TRR, with a TGA selenocysteine codon at the corresponding position. A selenocysteyl-tRNA was identified in this organism several years ago, but no selenoproteins have been identified experimentally. Herein we report the first identification of a C, elegans selenoprotein. By Se-75 labeling of C. elegans, one major band was identified, which migrated with the predicted mobility of the C. elegans TRR homologue, Western analysis with an antibody against human TRR provides strong evidence for identification of the C. elegans selenoprotein as a member of the TRR family. The 3'-untranslated region of this gene contains a selenocysteine insertion sequence (SECIS) element that deviates at one position from the previously invariant consensus "AUGA." Nonetheless, this element functions to direct selenocysteine incorporation in mammalian cells, suggesting conservation of the factors recognizing SECIS elements from worm to man.	Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Thyroid, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Berry, MJ (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Thyroid, Boston, MA 02115 USA.		Buettner, Christoph/F-5793-2013	Buettner, Christoph/0000-0003-0412-4062	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047320, R56DK047320, R01DK052963] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 52963, DK47320] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRY MJ, 1992, ENDOCRINOLOGY, V131, P1848, DOI 10.1210/en.131.4.1848; BERRY MJ, 1991, J BIOL CHEM, V266, P14155; BERRY MJ, 1993, EMBO J, V12, P3315, DOI 10.1002/j.1460-2075.1993.tb06001.x; Bosl MR, 1997, P NATL ACAD SCI USA, V94, P5531, DOI 10.1073/pnas.94.11.5531; Buettner C, 1998, J BIOL CHEM, V273, P33374, DOI 10.1074/jbc.273.50.33374; Gasdaska PY, 1999, FEBS LETT, V442, P105, DOI 10.1016/S0014-5793(98)01638-X; GASDASKA PY, 1995, FEBS LETT, V373, P5, DOI 10.1016/0014-5793(95)01003-W; Gladyshev VN, 1999, BIOCHEM BIOPH RES CO, V259, P244, DOI 10.1006/bbrc.1999.0765; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; Gladyshev VN, 1998, J BIOL CHEM, V273, P8910, DOI 10.1074/jbc.273.15.8910; Gromer S, 1998, BIOCHEM J, V332, P591, DOI 10.1042/bj3320591; Hatfield D, 1999, COMPREHENSIVE NATURA, P353; HEIDER J, 1992, EMBO J, V11, P3759, DOI 10.1002/j.1460-2075.1992.tb05461.x; Ho YS, 1997, J BIOL CHEM, V272, P16644, DOI 10.1074/jbc.272.26.16644; LEE BJ, 1990, MOL CELL BIOL, V10, P1940, DOI 10.1128/MCB.10.5.1940; Lee SR, 1999, J BIOL CHEM, V274, P4722, DOI 10.1074/jbc.274.8.4722; Low SC, 1996, TRENDS BIOCHEM SCI, V21, P203, DOI 10.1016/0968-0004(96)10025-6; MANDEL SJ, 1992, J CLIN ENDOCR METAB, V75, P1133, DOI 10.1210/jc.75.4.1133; Martin GW, 1996, RNA, V2, P171; Matsui M, 1996, DEV BIOL, V178, P179, DOI 10.1006/dbio.1996.0208; Miranda-Vizuete A, 1999, EUR J BIOCHEM, V261, P405, DOI 10.1046/j.1432-1327.1999.00286.x; Nordberg J, 1998, J BIOL CHEM, V273, P10835, DOI 10.1074/jbc.273.18.10835; Tripp C, 1998, EXP PARASITOL, V88, P43, DOI 10.1006/expr.1998.4217; Walczak R, 1998, RNA, V4, P74	24	62	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21598	21602		10.1074/jbc.274.31.21598	http://dx.doi.org/10.1074/jbc.274.31.21598			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419466	hybrid			2022-12-25	WOS:000081721100019
J	Cheng, LW; Schneewind, O				Cheng, LW; Schneewind, O			Yersinia enterocolitica type III secretion - On the role of SycE in targeting YopE into HeLa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAPERONE-LIKE PROTEIN; ESCHERICHIA-COLI; MAMMALIAN-CELLS; VIRULENCE PLASMID; EFFECTOR PROTEIN; TRANSLOCATION; MEMBRANE; SECB; PSEUDOTUBERCULOSIS; EXPRESSION	Yersinia enterocolitica inject toxic proteins (effector Yops) into the cytosol of eukaryotic cells by a mechanism requiring the type III machinery. Previous work mapped a signal sufficient for the targeting of fused reporter proteins to amino acids 1-100 of YopE. Targeting requires the binding of SycE to YopE residues 15-100 in the bacterial cytoplasm. We asked whether SycE functions only to stabilize YopE in the bacterial cytoplasm, or whether the secretion chaperone itself contributes to substrate recognition by the type III machinery. Fusions of glutathione S-transferase to either the N or C terminus of SycE resulted in hybrid proteins that bound YopE but prevented targeting of the export substrate into HeLa cells. As compared with wild-type SycE, glutathione S-transferase-SycE bound and stabilized YopE in the bacterial cytoplasm but failed to release the polypeptide for export by the type LII machinery. Thus, it appears that SycE functions to deliver YopE to the type III secretion machinery. A model is presented that accounts for substrate recognition of effector Yops, a group of proteins that do not share amino acid sequence or physical similarities.	Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Schneewind, O (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.				NIAID NIH HHS [AI 42797, AI 07323] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042797] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLAOUI A, 1994, J BACTERIOL, V176, P4534, DOI 10.1128/JB.176.15.4534-4542.1994; ALLAOUI A, 1995, MOL MICROBIOL, V18, P343, DOI 10.1111/j.1365-2958.1995.mmi_18020343.x; Anderson DM, 1999, MOL MICROBIOL, V31, P1139, DOI 10.1046/j.1365-2958.1999.01254.x; Anderson DM, 1997, SCIENCE, V278, P1140, DOI 10.1126/science.278.5340.1140; Anderson DM, 1999, CURR OPIN MICROBIOL, V2, P18, DOI 10.1016/S1369-5274(99)80003-4; Boland A, 1996, EMBO J, V15, P5191, DOI 10.1002/j.1460-2075.1996.tb00904.x; Boyd AP, 1998, MOL MICROBIOL, V27, P425, DOI 10.1046/j.1365-2958.1998.00691.x; Cheng LW, 1997, MOL MICROBIOL, V24, P757, DOI 10.1046/j.1365-2958.1997.3831750.x; Cornelis GR, 1998, MICROBIOL MOL BIOL R, V62, P1315, DOI 10.1128/MMBR.62.4.1315-1352.1998; Cornelis GR, 1997, MOL MICROBIOL, V23, P861, DOI 10.1046/j.1365-2958.1997.2731623.x; Creighton T.E., 1993, PROTEINS; Day JB, 1998, MOL MICROBIOL, V30, P777, DOI 10.1046/j.1365-2958.1998.01110.x; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; Fekkes P, 1997, EMBO J, V16, P6105, DOI 10.1093/emboj/16.20.6105; FRITHZLINDSTEN E, 1995, MOL MICROBIOL, V16, P635, DOI 10.1111/j.1365-2958.1995.tb02426.x; Hakansson S, 1996, MOL MICROBIOL, V20, P593, DOI 10.1046/j.1365-2958.1996.5251051.x; HARDY SJS, 1991, SCIENCE, V251, P439, DOI 10.1126/science.1989077; Holmstrom A, 1997, MOL MICROBIOL, V24, P73, DOI 10.1046/j.1365-2958.1997.3211681.x; Iriarte M, 1998, MOL MICROBIOL, V29, P915, DOI 10.1046/j.1365-2958.1998.00992.x; Isberg RR, 1996, CURR TOP MICROBIOL, V209, P1; Jackson MW, 1998, J BACTERIOL, V180, P4912, DOI 10.1128/JB.180.18.4912-4921.1998; KUMAMOTO CA, 1989, P NATL ACAD SCI USA, V86, P5320, DOI 10.1073/pnas.86.14.5320; KUMAMOTO CA, 1983, J BACTERIOL, V154, P253, DOI 10.1128/JB.154.1.253-260.1983; Lee VT, 1998, MOL MICROBIOL, V28, P593, DOI 10.1046/j.1365-2958.1998.00822.x; Lee VT, 1999, MOL MICROBIOL, V31, P1619, DOI 10.1046/j.1365-2958.1999.01270.x; MAYER MP, 1995, GENE, V163, P41, DOI 10.1016/0378-1119(95)00389-N; MICHIELS T, 1991, J BACTERIOL, V173, P4994, DOI 10.1128/jb.173.16.4994-5009.1991; MICHIELS T, 1990, INFECT IMMUN, V58, P2840, DOI 10.1128/IAI.58.9.2840-2849.1990; Mills SD, 1997, P NATL ACAD SCI USA, V94, P12638, DOI 10.1073/pnas.94.23.12638; PERSSON C, 1995, MOL MICROBIOL, V18, P135, DOI 10.1111/j.1365-2958.1995.mmi_18010135.x; PLANO GV, 1991, J BACTERIOL, V173, P7293, DOI 10.1128/jb.173.22.7293-7303.1991; RANDALL LL, 1992, SCIENCE, V257, P241, DOI 10.1126/science.1631545; Reinemer P, 1996, J MOL BIOL, V255, P289, DOI 10.1006/jmbi.1996.0024; ROSQVIST R, 1991, INFECT IMMUN, V59, P4562, DOI 10.1128/IAI.59.12.4562-4569.1991; ROSQVIST R, 1994, EMBO J, V13, P964, DOI 10.1002/j.1460-2075.1994.tb06341.x; ROSQVIST R, 1988, INFECT IMMUN, V56, P2139, DOI 10.1128/IAI.56.8.2139-2143.1988; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SORY MP, 1994, MOL MICROBIOL, V14, P583, DOI 10.1111/j.1365-2958.1994.tb02191.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAKESHITA S, 1987, GENE, V61, P63, DOI 10.1016/0378-1119(87)90365-9; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WATTIAU P, 1993, MOL MICROBIOL, V8, P123, DOI 10.1111/j.1365-2958.1993.tb01209.x; Wattiau P, 1996, MOL MICROBIOL, V20, P255, DOI 10.1111/j.1365-2958.1996.tb02614.x; Woestyn S, 1996, MOL MICROBIOL, V20, P1261, DOI 10.1111/j.1365-2958.1996.tb02645.x	44	63	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					22102	22108		10.1074/jbc.274.31.22102	http://dx.doi.org/10.1074/jbc.274.31.22102			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419539	hybrid			2022-12-25	WOS:000081721100092
J	Marjamaki, A; Frang, H; Pihlavisto, M; Hoffren, AM; Salminen, T; Johnson, MS; Kallio, J; Javitch, JA; Scheinin, M				Marjamaki, A; Frang, H; Pihlavisto, M; Hoffren, AM; Salminen, T; Johnson, MS; Kallio, J; Javitch, JA; Scheinin, M			Chloroethylclonidine and 2-aminoethyl methanethiosulfonate recognize two different conformations of the human alpha(2A)-adrenergic receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-SPANNING SEGMENT; DOPAMINE D2 RECEPTOR; BINDING-SITE CREVICE; BETA(2) ADRENERGIC-RECEPTOR; ALPHA(2)-ADRENOCEPTOR SUBTYPES; CONSTITUTIVE ACTIVATION; MODEL; CHLORETHYLCLONIDINE; RESIDUES; HELICES	The substituted cysteine-accessibility method and two sulfhydryl-specific reagents, the methane-thiosulfonate derivative 2-aminoethyl methanethiosulfonate (MTSEA) and the alpha(2)-adrenergic receptor (alpha(2)-AR) agonist chloroethylclonidine (CEC), were used to determine the relative accessibility of engineered cysteines in the fifth transmembrane domain of the human alpha(2A)-AR (H alpha 2A). The second-order rate constants for the reaction of the receptor with MTSEA and CEC were determined with the wild type H alpha 2A (cysteine at position 201) and receptor mutants containing accessible cysteines at other positions within the binding-site crevice (positions 197, 200, and 204), The rate of reaction of CEC was similar to that of MTSEA at residues Cys-197, Cys-201, and Cys-204. The rate of reaction of CEC with Cys-200, however, was more than 5 times that of MTSEA, suggesting that these compounds may interact with two different receptor conformations. MTSEA, having no recognition specificity for the receptor, likely reacts with the predominant inactive receptor conformation (R), whereas the agonist CEC may stabilize and react preferentially with the active receptor conformation (R*), This hypothesis was consistent with three-dimensional receptor-ligand models, which further suggest that alpha(2A)-AR activation may involve the clockwise rotation of transmembrane domain 5.	Univ Turku, Dept Pharmacol & Clin Pharmacol, FIN-20520 Turku, Finland; Juvantia Pharma Ltd, FIN-20520 Turku, Finland; Abo Akad Univ, Dept Biochem & Pharm, FIN-20520 Turku, Finland; Univ Turku, Turku Ctr Biotechnol, FIN-20520 Turku, Finland; Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA	University of Turku; Abo Akademi University; University of Turku; Columbia University; Columbia University	Marjamaki, A (corresponding author), Univ Turku, Dept Pharmacol & Clin Pharmacol, MediCity,Tykistokatu 6A, FIN-20520 Turku, Finland.		Salminen, Tiina A./AAM-5443-2021; Salminen, Tiina A/G-7492-2019	Salminen, Tiina A./0000-0002-4135-8020; Salminen, Tiina A/0000-0002-4135-8020; Javitch, Jonathan/0000-0001-7395-2967				Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BULTMANN R, 1993, BRIT J PHARMACOL, V108, P336; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Daniel EE, 1997, J CARDIOVASC PHARM, V30, P591, DOI 10.1097/00005344-199711000-00009; Docherty JR, 1997, GEN PHARMACOL, V28, P197, DOI 10.1016/S0306-3623(96)00187-5; Fu DY, 1996, BIOCHEMISTRY-US, V35, P11278, DOI 10.1021/bi960928x; GETHER U, 1995, J BIOL CHEM, V270, P28268; Guimaraes S, 1997, J PHARMACOL EXP THER, V282, P1326; HALME M, 1995, BBA-MOL CELL RES, V1266, P207, DOI 10.1016/0167-4889(95)90410-I; HAN C, 1987, MOL PHARMACOL, V32, P505; JAVITCH JA, 1995, NEURON, V14, P825, DOI 10.1016/0896-6273(95)90226-0; Javitch JA, 1997, J BIOL CHEM, V272, P18546, DOI 10.1074/jbc.272.30.18546; Javitch JA, 1995, BIOCHEMISTRY-US, V34, P16433, DOI 10.1021/bi00050a026; LEFF P, 1995, TRENDS PHARMACOL SCI, V16, P89, DOI 10.1016/S0165-6147(00)88989-0; LOMASNEY JW, 1991, BIOCHIM BIOPHYS ACTA, V1095, P127, DOI 10.1016/0167-4889(91)90075-9; Marjamaki A, 1998, MOL PHARMACOL, V53, P370, DOI 10.1124/mol.53.3.370; MCCONNELL HM, 1992, SCIENCE, V257, P1906, DOI 10.1126/science.1329199; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; MICHEL MC, 1993, MOL PHARMACOL, V44, P1165; MILLIGAN G, 1995, TRENDS PHARMACOL SCI, V16, P10, DOI 10.1016/S0165-6147(00)88963-4; Perez DM, 1996, MOL PHARMACOL, V49, P112; ROBERTS DD, 1986, BIOCHEMISTRY-US, V25, P5595, DOI 10.1021/bi00367a038; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Scheer A, 1996, EMBO J, V15, P3566, DOI 10.1002/j.1460-2075.1996.tb00726.x; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; TIAN WN, 1990, J PHARMACOL EXP THER, V253, P877; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316	30	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21867	21872		10.1074/jbc.274.31.21867	http://dx.doi.org/10.1074/jbc.274.31.21867			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419505	hybrid			2022-12-25	WOS:000081721100058
J	Rodriguez-Crespo, I; Nishida, CR; Knudsen, GM; de Montellano, PRO				Rodriguez-Crespo, I; Nishida, CR; Knudsen, GM; de Montellano, PRO			Mutation of the five conserved histidines in the endothelial nitric-oxide synthase hemoprotein domain - No evidence for a non-heme metal requirement for catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXY-L-ARGININE; ESCHERICHIA-COLI; PTERIN; DIMER; TETRAHYDROBIOPTERIN; OXIDATION; SITE; IDENTIFICATION; ACTIVATION; CITRULLINE	Five conserved histidine residues are found in the human endothelial nitric-oxide synthase (NOS) heme domain: His-420, His-421, and His-461 are close to the heme, whereas His-146 and His-214 are some distance away. To investigate whether the histidines form a nonheme iron-binding site, we have expressed the H146A, H214A, H420A, H421A, and H461A mutants, The H420A mutant could not be isolated, and the H146A and H421A mutants were inactive, The H214A mutant resembled the wild-type enzyme in all respects. The H461A mutant had a low-spin heme, but high concentrations of L-Arg and tetrahydrobiopterin led to partial recovery of activity. Laser atomic emission showed that the only significant metal in NOS other than calcium and iron is zinc, The activities of the NOS isoforms were not increased by incubation with Fe2+, but were inhibited by high Fe2+ or Zn2+ concentrations. The histidine mutations altered the ability of the protein to dimerize and to bind heme, However, the protein metal content, the inability of exogenous Fe2+ to increase catalytic activity, and the absence of evidence that the conserved histidines form a metal site provide no support for a catalytic role for a non-heme redox-active metal.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Complutense Madrid, Fac Ciencias Quim, Dept Bioquim & Biol Mol, E-28040 Madrid, Spain	University of California System; University of California San Francisco; Complutense University of Madrid	de Montellano, PRO (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.		Rodriguez-Crespo, J. Ignacio/M-1966-2018	Rodriguez-Crespo, J. Ignacio/0000-0002-2582-129X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025515, R37GM025515] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25515] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; BOUCHER JL, 1992, BIOCHEM BIOPH RES CO, V184, P1158, DOI 10.1016/S0006-291X(05)80004-X; BOUCHER JL, 1992, BIOCHEM BIOPH RES CO, V187, P880, DOI 10.1016/0006-291X(92)91279-Y; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; Chen DW, 1998, J BIOL CHEM, V273, P25594, DOI 10.1074/jbc.273.40.25594; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Demura Y, 1998, FREE RADICAL BIO MED, V25, P314, DOI 10.1016/S0891-5849(98)00056-2; Everett SA, 1996, BIOCHEM J, V317, P17, DOI 10.1042/bj3170017; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; Goodwill KE, 1998, BIOCHEMISTRY-US, V37, P13437, DOI 10.1021/bi981462g; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; Hegg EL, 1997, EUR J BIOCHEM, V250, P625, DOI 10.1111/j.1432-1033.1997.t01-1-00625.x; Huhmer AFR, 1997, CHEM RES TOXICOL, V10, P618, DOI 10.1021/tx960188t; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; Martasek P, 1998, J BIOL CHEM, V273, P34799, DOI 10.1074/jbc.273.52.34799; Martasek P, 1996, BIOCHEM BIOPH RES CO, V219, P359, DOI 10.1006/bbrc.1996.0238; Masters BSS, 1996, FASEB J, V10, P552, DOI 10.1096/fasebj.10.5.8621055; Mayer B, 1997, BIOCHEMISTRY-US, V36, P8422, DOI 10.1021/bi970144z; Nagase S, 1997, BIOCHEM BIOPH RES CO, V233, P150, DOI 10.1006/bbrc.1997.6428; Perry JM, 1998, P NATL ACAD SCI USA, V95, P11101, DOI 10.1073/pnas.95.19.11101; PERSECHINI A, 1995, BIOCHEMISTRY-US, V34, P15091, DOI 10.1021/bi00046a015; Pfeiffer S, 1997, BIOCHEM J, V328, P349, DOI 10.1042/bj3280349; Pirskanen A, 1996, J BIOL CHEM, V271, P9398, DOI 10.1074/jbc.271.16.9398; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; RodriguezCrespo I, 1996, ARCH BIOCHEM BIOPHYS, V336, P151, DOI 10.1006/abbi.1996.0543; RodriguezCrespo I, 1996, J BIOL CHEM, V271, P11462, DOI 10.1074/jbc.271.19.11462; SENNEQUIER N, 1995, TETRAHEDRON LETT, V36, P6059, DOI 10.1016/0040-4039(95)01242-A; Siddhanta U, 1998, J BIOL CHEM, V273, P18950, DOI 10.1074/jbc.273.30.18950; Venema VJ, 1997, J BIOL CHEM, V272, P28187, DOI 10.1074/jbc.272.45.28187	31	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21617	21624		10.1074/jbc.274.31.21617	http://dx.doi.org/10.1074/jbc.274.31.21617			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419469	hybrid			2022-12-25	WOS:000081721100022
J	Adrain, C; Slee, EA; Harte, MT; Martin, SJ				Adrain, C; Slee, EA; Harte, MT; Martin, SJ			Regulation of apoptotic protease activating factor-1 oligomerization and apoptosis by the WD-40 repeat region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; CYTOCHROME-C; MITOCHONDRIA; CASPASE-8; HOMOLOG; CED-4; BCL-2; RELEASE; COMPLEX; SYSTEM	Apoptotic protease activating factor-1 (Apaf-1) has been identified as a proximal activator of caspase-9 in cell death pathways that trigger mitochondrial damage and cytochrome c release. The mechanism of Apaf-1 action is unclear but has been proposed to involve the clustering of caspase-9 molecules, thereby facilitating autoprocessing of adjacent zymogens, Here we show that Apaf-1 can dimerize via the CED-4 homologous and linker domains of the molecule providing a means by which Apaf-1 can promote the clustering of caspase-9 and facilitate its activation Apaf-1 dimerization was repressed by the C-terminal half of the molecule, which contains multiple WD-40 repeats, but this repression was overcome in the presence of cytochrome c and dATP. Removal of the WD-40 repeat region resulted in a constitutively active Apaf-1 that exhibited greater cytotoxicity in transient transfection assays when compared with full-length Apaf-1. These data suggest a mechanism for Apaf-1 function and reveal an important regulatory role for the WD-40 repeat region.	Natl Univ Ireland, Dept Biol, Mol Cell Biol Lab, Maynooth, Kildare, Ireland	Maynooth University	Martin, SJ (corresponding author), Natl Univ Ireland, Dept Biol, Mol Cell Biol Lab, Maynooth, Kildare, Ireland.		Adrain, Colin/I-6259-2013	Adrain, Colin/0000-0001-7597-4393				Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GU Y, 1995, EMBO J, V14, P1923, DOI 10.1002/j.1460-2075.1995.tb07184.x; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Inohara N, 1998, J BIOL CHEM, V273, P32479, DOI 10.1074/jbc.273.49.32479; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Song QZ, 1999, EMBO J, V18, P167, DOI 10.1093/emboj/18.1.167; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Yang XL, 1998, SCIENCE, V281, P1355, DOI 10.1126/science.281.5381.1355; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; YU Y, 1998, J BIOL CHEM, V273, P33489; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	35	90	94	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					20855	20860		10.1074/jbc.274.30.20855	http://dx.doi.org/10.1074/jbc.274.30.20855			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409627	hybrid			2022-12-25	WOS:000081613100018
J	Franqueza, L; Lin, M; Splawski, I; Keating, MT; Sanguinetti, MC				Franqueza, L; Lin, M; Splawski, I; Keating, MT; Sanguinetti, MC			Long QT syndrome-associated mutations in the S4-S5 linker of KvLQT1 potassium channels modify gating and interaction with minK subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHAKER-K+ CHANNEL; INHERITED CARDIAC-ARRHYTHMIAS; XENOPUS-OOCYTES; INACTIVATION; FORM; HERG; RECTIFICATION; ACTIVATION; K(V)LQT1; PROTEINS	Long QT syndrome is an inherited disorder of cardiac repolarization caused by mutations in cardiac ion channel genes, including KVLQT1. In this study, the functional consequences of three long QT-associated missense mutations in KVLQT1 (R243C, W248R, E261K) were characterized using the Xenopus oocyte heterologous expression system and two-microelectrode voltage clamp techniques. These mutations are located in or near the intracellular linker between the S4 and S5 transmembrane domains, a region implicated in activation gating of potassium channels. The E261K mutation caused loss of function and did not interact with wildtype KvLQT1 subunits, R243C or W248R KVLQT1 subunits formed functional channels, but compared with wild-type KVLQT1 current, the rate of activation was slower, and the voltage dependence of activation and inactivation was shifted to more positive potentials. Co expression of minK and KvLQT1 channel subunits induces a slow delayed rectifier K+ current, I-Ks, characterized by slow activation and a markedly increased magnitude compared with current induced by KVLQT1 subunits alone. Coexpression of minK with R243C or W248R KvLQT1 subunits suppressed current, suggesting that coassembly of mutant subunits with minK prevented normal channel gating. The decrease in I-Ks caused by loss of function or altered gating properties explains the prolonged QT interval and increased risk of arrhythmia and sudden death associated with these mutations in KVLQT1.	Univ Utah, Dept Med, Div Cardiol, Salt Lake City, UT 84112 USA; Univ Utah, Eccles Program Human Mol Biol & Genet, Salt Lake City, UT 84112 USA; Univ Utah, Howard Hughes Med Inst, Salt Lake City, UT 84112 USA; Univ Utah, Dept Human Genet, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Sanguinetti, MC (corresponding author), Univ Utah, Dept Med, Div Cardiol, 15 N 2030 E,Rm 4220, Salt Lake City, UT 84112 USA.		Sanguinetti, Michael/AAN-2615-2020		NHLBI NIH HHS [HL55236, HL52338] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL052338, R01HL055236] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baker OS, 1998, NEURON, V20, P1283, DOI 10.1016/S0896-6273(00)80507-3; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; Chouabe C, 1997, EMBO J, V16, P5472, DOI 10.1093/emboj/16.17.5472; Donger C, 1997, CIRCULATION, V96, P2778, DOI 10.1161/01.CIR.96.9.2778; GOLDIN AL, 1991, METHOD CELL BIOL, V36, P487; Holmgren M, 1996, J GEN PHYSIOL, V108, P195, DOI 10.1085/jgp.108.3.195; ISACOFF EY, 1991, NATURE, V353, P86, DOI 10.1038/353086a0; Keating MT, 1996, SCIENCE, V272, P681, DOI 10.1126/science.272.5262.681; NOBLE D, 1969, J PHYSIOL-LONDON, V200, P205, DOI 10.1113/jphysiol.1969.sp008689; Pusch M, 1998, BIOPHYS J, V75, P785, DOI 10.1016/S0006-3495(98)77568-X; SALATA JJ, 1996, CIRCULATION, V94, P1229; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; SANGUINETTI MC, 1990, J GEN PHYSIOL, V96, P195, DOI 10.1085/jgp.96.1.195; Sanguinetti MC, 1999, J PHYSIOL-LONDON, V514, P667, DOI 10.1111/j.1469-7793.1999.667ad.x; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Schonherr R, 1996, J PHYSIOL-LONDON, V493, P635, DOI 10.1113/jphysiol.1996.sp021410; Sesti F, 1998, J GEN PHYSIOL, V112, P651, DOI 10.1085/jgp.112.6.651; Shalaby FY, 1997, CIRCULATION, V96, P1733, DOI 10.1161/01.CIR.96.6.1733; Shieh CC, 1997, J GEN PHYSIOL, V109, P767, DOI 10.1085/jgp.109.6.767; Smith PL, 1996, NATURE, V379, P833, DOI 10.1038/379833a0; Spector PS, 1996, J GEN PHYSIOL, V107, P611, DOI 10.1085/jgp.107.5.611; Splawski I, 1998, GENOMICS, V51, P86, DOI 10.1006/geno.1998.5361; STUHMER W, 1992, METHOD ENZYMOL, V207, P319; Tristani-Firouzi M, 1998, J PHYSIOL-LONDON, V510, P37, DOI 10.1111/j.1469-7793.1998.037bz.x; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; Wang Z, 1999, J CARDIOVASC ELECTR, V10, P817, DOI 10.1111/j.1540-8167.1999.tb00262.x; Wollnik B, 1997, HUM MOL GENET, V6, P1943, DOI 10.1093/hmg/6.11.1943; Yang YS, 1998, J GEN PHYSIOL, V112, P665, DOI 10.1085/jgp.112.6.665; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	29	89	92	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21063	21070		10.1074/jbc.274.30.21063	http://dx.doi.org/10.1074/jbc.274.30.21063			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409658	hybrid			2022-12-25	WOS:000081613100049
J	Higaki, Y; Wojtaszewski, JFP; Hirshman, MF; Withers, DJ; Towery, H; White, MF; Goodyear, LJ				Higaki, Y; Wojtaszewski, JFP; Hirshman, MF; Withers, DJ; Towery, H; White, MF; Goodyear, LJ			Insulin receptor substrate-2 is not necessary for insulin- and exercise-stimulated glucose transport in skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY; PHOSPHOTYROSINE PROTEIN; INDUCED TRANSLOCATION; CONTRACTION; MICE; WORTMANNIN; RESISTANCE; NIDDM; GLUT4; PHOSPHORYLATION	Insulin receptor substrate-2-deficient (IRS2(-/-)) mice develop type 2 diabetes. The purpose of this study was to determine whether there is a defect in basal, insulin-, and exercise-stimulated glucose transport in the skeletal muscle of these animals. IRS2(-/-) and wild-type (WT) mice (male, 8-10 weeks) exercised on a treadmill for 1 h or remained sedentary. 2-Deoxyglucose (2DG) uptake was measured in isolated soleus muscles incubated in vitro in the presence or absence of insulin. Resting blood glucose concentration in IRS2(-/-) mice (10.3 mM) was higher than WT animals (4.1 mM), but there was a wide range among the IRS2(-/-) mice (3-25 mM), Therefore, IRS2(-/-) mice were divided into two subgroups based on blood glucose concentrations (IRS2(-/-)L < 7.2 mM, IRS2(-/-)H > 7.2 mM), Only IRS2(-/-)H had lower basal, exercise-, and submaximally insulin-stimulated 2DG uptake, while maximal insulin-stimulated 2DG uptake was similar among the three groups. The ED50 for insulin to stimulate 2DG uptake above basal in IRS2(-/-)H was higher than WT and IRS2(-/-)L mice, suggesting insulin resistance in the skeletal muscle from the IRS2(-/-) mice with high blood glucose concentrations. Furthermore, resting blood glucose concentrations from all groups were negatively correlated to submaximally insulin-stimulated 2DG uptake (r(2) = 0.33, p < 0.01). Muscle GLUT4 content was significantly lower in IRS2(-/-)H mice compared with WT and IRS2(-/-)L mice. These results demonstrate that the IRS2 protein in muscle is not necessary for insulin- or exercise-stimulated glucose transport, suggesting that the onset of diabetes in the IRS2(-/-) mice is not due to a defect in skeletal muscle glucose transport; hyperglycemia may cause insulin resistance in the muscle of IRS2(-/-) mice.	Brigham & Womens Hosp, Dept Med, Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA; Brigham & Womens Hosp, Dept Med, Joslin Diabet Ctr, Howard Hughes Med Inst, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Brigham & Women's Hospital; Joslin Diabetes Center, Inc.; Harvard University; Brigham & Women's Hospital; Joslin Diabetes Center, Inc.; Howard Hughes Medical Institute; Harvard University; Harvard Medical School	Goodyear, LJ (corresponding author), Brigham & Womens Hosp, Dept Med, Joslin Diabet Ctr, Div Res, 1 Joslin Pl, Boston, MA 02215 USA.		Wojtaszewski, Jørgen FP/P-6583-2014; Withers, Dominic J/D-7671-2014	Wojtaszewski, Jørgen FP/0000-0001-9785-6830; Withers, Dominic J/0000-0002-8009-7521; wojtaszewski, jorgen/0000-0001-8185-3408	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045670, R01AR042238, R29AR042238] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043808] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-42238, AR-45670] Funding Source: Medline; NIDDK NIH HHS [DK-43808] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Bjornholm M, 1997, DIABETES, V46, P524, DOI 10.2337/diabetes.46.3.524; Bruning JC, 1998, MOL CELL, V2, P559, DOI 10.1016/S1097-2765(00)80155-0; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; DOUEN AG, 1990, FEBS LETT, V261, P256, DOI 10.1016/0014-5793(90)80566-2; GOODYEAR LJ, 1995, J CLIN INVEST, V95, P2195, DOI 10.1172/JCI117909; GOODYEAR LJ, 1995, AM J PHYSIOL-ENDOC M, V268, pE987, DOI 10.1152/ajpendo.1995.268.5.E987; GOODYEAR LJ, 1990, AM J PHYSIOL, V258, pE667, DOI 10.1152/ajpendo.1990.258.4.E667; Hayashi T, 1998, DIABETES, V47, P1369, DOI 10.2337/diabetes.47.8.1369; HEYDRICK SJ, 1993, J CLIN INVEST, V91, P1358, DOI 10.1172/JCI116337; Kawanaka K, 1998, J APPL PHYSIOL, V84, P1852, DOI 10.1152/jappl.1998.84.6.1852; KUBO K, 1986, AM J PHYSIOL, V250, pE100, DOI 10.1152/ajpendo.1986.250.1.E100; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; LEE AD, 1995, FEBS LETT, V361, P51, DOI 10.1016/0014-5793(95)00147-2; LILLIOJA S, 1993, NEW ENGL J MED, V329, P1988, DOI 10.1056/NEJM199312303292703; LUND S, 1995, P NATL ACAD SCI USA, V92, P5817, DOI 10.1073/pnas.92.13.5817; SAAD MJA, 1992, J CLIN INVEST, V90, P1839, DOI 10.1172/JCI116060; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Sherman LA, 1996, ENDOCRINOLOGY, V137, P266, DOI 10.1210/en.137.1.266; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Till M, 1997, AM J CARDIOL, V80, pA85, DOI 10.1016/S0002-9149(97)00461-X; WHITE MF, 1994, J BIOL CHEM, V269, P1; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107	31	82	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					20791	20795		10.1074/jbc.274.30.20791	http://dx.doi.org/10.1074/jbc.274.30.20791			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409618	Green Published, hybrid			2022-12-25	WOS:000081613100009
J	Jin, J; Kaushik, N; Singh, K; Modak, MJ				Jin, J; Kaushik, N; Singh, K; Modak, MJ			Analysis of the role of glutamine 190 in the catalytic mechanism of murine leukemia virus reverse transcriptase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-I; SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; KLENOW FRAGMENT; BINDING; IDENTIFICATION; RESIDUES; PROCESSIVITY; ASSIGNMENT; ENZYMES	To determine the catalytic role of Gln(190), a member of the highly conserved LPQG motif in Moloney murine leukemia virus reverse transcriptase, we carried out site-directed mutagenesis of this residue to generate Q190N and Q190A, Both mutant proteins exhibited a significant loss in their polymerase and pyrophosphorolysis activities with a more pronounced effect noted with the Gin --> Asn substitution. The catalytic efficiencies of the mutants exhibited a 40-70-fold reduction with poly(rC) and poly(dC) templates in the presence of Mg2+ and a 10-20-fold reduction with poly(rA) template in the presence of Mn2+. Interestingly, the K-m for NTP exhibited only a moderate 3-10-fold increase irrespective of the template-primer and the metal ion. Photoaffinity labeling of both the mutant and the WT enzymes exhibited an identical affinity for RNA DNA and DNA DNA template-primers. However, unlike the WT enzyme, the mutant enzymes exhibited a significantly reduced ability to catalyze the nucleotidyltransferase re action on the covalently immobilized template-primer. An examination of the rate constants for the first and the second nucleotide for the mutant enzymes indicated dissimilar rates, indicating that Gln190 may be involved in a rate-limiting, conformational change step both before and after the phosphodiester bond formation. Furthermore, the processivity of DNA synthesis by the mutant enzymes was decreased severely, which may result from the lower catalytic efficiency as well as translocation defect.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA; Univ Med & Dent New Jersey, Grad Sch Biomed Sci, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Modak, MJ (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA.				NIGMS NIH HHS [GM 36307] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASTATKE M, 1995, J BIOL CHEM, V270, P1945, DOI 10.1074/jbc.270.4.1945; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BOYER PL, 1994, J MOL BIOL, V243, P472, DOI 10.1006/jmbi.1994.1673; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chowdhury K, 1996, BIOCHEMISTRY-US, V35, P16610, DOI 10.1021/bi961462l; DAHLBERG ME, 1991, BIOCHEMISTRY-US, V30, P4835, DOI 10.1021/bi00234a002; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DETERA SD, 1982, J BIOL CHEM, V257, P9770; Gao GX, 1997, P NATL ACAD SCI USA, V94, P407, DOI 10.1073/pnas.94.2.407; Gardner LP, 1997, BIOCHEMISTRY-US, V36, P2908, DOI 10.1021/bi962397i; GEORGIADIS MM, 1995, STRUCTURE, V3, P879, DOI 10.1016/S0969-2126(01)00223-4; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; Kaushik N, 1997, BIOCHEMISTRY-US, V36, P14430, DOI 10.1021/bi970645k; Kaushik N, 1996, BIOCHEMISTRY-US, V35, P11536, DOI 10.1021/bi960364x; Kaushik N, 1996, BIOCHEMISTRY-US, V35, P7256, DOI 10.1021/bi960537i; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; MAJUMDAR C, 1988, J BIOL CHEM, V263, P15657; MAYER AN, 1995, GENE, V153, P1, DOI 10.1016/0378-1119(94)00752-E; PANDEY VN, 1994, J BIOL CHEM, V269, P13259; Pandey VN, 1996, BIOCHEMISTRY-US, V35, P2168, DOI 10.1021/bi9516642; PANDEY VN, 1994, J BIOL CHEM, V269, P21828; POCH O, 1990, J GEN VIROL, V71, P1153, DOI 10.1099/0022-1317-71-5-1153; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARAFIANOS SG, 1995, J BIOL CHEM, V270, P19729, DOI 10.1074/jbc.270.34.19729; SARAFIANOS SG, 1995, BIOCHEMISTRY-US, V34, P7207, DOI 10.1021/bi00021a036; YADAV PNS, 1994, J BIOL CHEM, V269, P716	29	6	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					20861	20868		10.1074/jbc.274.30.20861	http://dx.doi.org/10.1074/jbc.274.30.20861			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409628	hybrid			2022-12-25	WOS:000081613100019
J	Merali, S				Merali, S			Pneumocystis carinii polyamine Catabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DL-ALPHA-DIFLUOROMETHYLORNITHINE; ANALOG-INDUCED INCREASES; RAT MODEL; SPERMIDINE; PNEUMONIA; DECARBOXYLASE; EFLORNITHINE; INHIBITOR; EFFICACY	DL-alpha-Difluoromethylornithine (DFMO) causes polyamines of the AIDS-associated opportunistic pathogen Pneumocystis carinii to diminish 15 times more rapidly than mammalian host cells. The proposed mechanism was that, unlike mammalian cells, P. carinii is unable to regulate polyamine catabolism when synthesis is blocked. To test this, the responses of the polyamine catabolic enzymes spermidine/spermine acetyltransferase (SSAT) and polyamine oxidase (PAO) were determined using a new high-performance liquid chromatography assay to measure the products of these enzymes. The specific activities in untreated Pneumocystis carinii were 1.78 +/- 0.5 pmol min-1 mg protein-1 for SSAT, similar to mammalian cells, and 6.42 +/- 0.8 pmol min-1 mg protein-1 for PAO, 19% of that of mammalian cells. DFMO treatment for 12 h caused reductions of only 11 and 4% in SSAT and PAO, respectively, despite polyamine reductions of 94, 96, and 90% for putrescine, spermidine, and spermine, respectively. The P. carinii SSAT K-m value of 25 mu M spermidine is 20% of that of mammalian cells, and the PAO K-m value of 14 nM N-1-acetylspermidine is 0.01% of that of mammalian cells. Acetylated polyamines continue to be lost from P. carinii even when exposed to DFMO. Collectively, these results support the hypothesis that P. carinii is unable to regulate polyamine catabolism.	NYU, Sch Med, Dept Med & Mol Parasitol, New York, NY 10010 USA	New York University	Merali, S (corresponding author), NYU, Sch Med, Dept Med & Mol Parasitol, 341 E 25th St, New York, NY 10010 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027685, T32AI007382, R01AI041947] Funding Source: NIH RePORTER; NIAID NIH HHS [5T32 AI07382, 1R01-AI27685, 1R01-AI41947] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARUNDEL CM, 1988, RADIAT RES, V114, P634, DOI 10.2307/3577134; BYERS TL, 1989, AM J PHYSIOL, V257, pC545, DOI 10.1152/ajpcell.1989.257.3.C545; Chin K, 1996, ANTIMICROB AGENTS CH, V40, P2318, DOI 10.1128/AAC.40.10.2318; CLARKSON AB, 1988, ANTIMICROB AGENTS CH, V32, P1158, DOI 10.1128/AAC.32.8.1158; DELLARAGIONE F, 1983, BIOCHEM J, V213, P701, DOI 10.1042/bj2130701; HOLTTA E, 1977, BIOCHEMISTRY-US, V16, P91, DOI 10.1021/bi00620a015; LIBBY PR, 1989, BIOCHEM PHARMACOL, V38, P1435, DOI 10.1016/0006-2952(89)90182-2; Merali S, 1999, P NATL ACAD SCI USA, V96, P2402, DOI 10.1073/pnas.96.5.2402; Merali S, 1996, J CHROMATOGR B, V675, P321, DOI 10.1016/0378-4347(95)00363-0; Merali S, 1996, ANTIMICROB AGENTS CH, V40, P973, DOI 10.1128/AAC.40.4.973; NAKAIKE S, 1988, JPN J CANCER RES, V79, P501, DOI 10.1111/j.1349-7006.1988.tb01619.x; PAULSON YJ, 1992, CHEST, V101, P67, DOI 10.1378/chest.101.1.67; PEGG AE, 1982, AM J PHYSIOL, V243, pC212, DOI 10.1152/ajpcell.1982.243.5.C212; PERSSON L, 1984, J BIOL CHEM, V259, P2364; PORTER CW, 1991, CANCER RES, V51, P3715; SMITH DE, 1992, AIDS, V6, P1489, DOI 10.1097/00002030-199212000-00011; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; THOMAS T, 1993, BREAST CANCER RES TR, V29, P189; VANNIEUWENHOVE S, 1992, ANN SOC BELG MED TR, V72, P39; Wallace Heather M., 1998, V79, P59; Wallace HM, 1998, BIOCHEM SOC T, V26, P571, DOI 10.1042/bst0260571; Wallace HM, 1998, BIOCHEM SOC T, V26, P569, DOI 10.1042/bst0260569; WOSTER PM, 1995, POLYAMINES REGULATIO, P171	23	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21017	21022		10.1074/jbc.274.30.21017	http://dx.doi.org/10.1074/jbc.274.30.21017			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409651	hybrid			2022-12-25	WOS:000081613100042
J	Saxena, S; Quick, MW; Tousson, A; Oh, Y; Warnock, DG				Saxena, S; Quick, MW; Tousson, A; Oh, Y; Warnock, DG			Interaction of syntaxins with the amiloride-sensitive epithelial sodium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR CHLORIDE CHANNELS; PROTEIN-KINASE-C; NA+ CHANNEL; LIDDLES SYNDROME; HUMAN HYPERTENSION; GABA TRANSPORTER; CALCIUM CHANNELS; N-TYPE; CELLS; TRAFFICKING	Amiloride-sensitive sodium channels mediate sodium entry across the apical membrane of epithelial cells in variety of tissues. The rate of Na+ entry is controlled by the regulation of the epithelial sodium channel (ENaC) complex. Insertion/retrieval of the ENaC complex into the apical membrane as well as direct kinetic effects at the single channel level are recognized mechanisms of regulation. Recent data suggest that the syntaxin family of targeting proteins interact with and functionally regulate a number of ion channels. and pumps. To evaluate the role of these proteins in regulating ENaC activity, we co-expressed rat ENaC cRNA (alpha, beta, gamma subunits) with syntaxin 1A or 3 cRNAs in Xenopus oocytes. Basal ENaC currents were inhibited by syntaxin 1A and stimulated by syntaxin 3, Both syntaxin IA and syntaxin 3 could be co-immunoprecipitated with ENaC subunit proteins, suggesting physical interaction, interestingly, immunofluorescence data suggest that with either syntaxin isoform the ENaC-associated epifluorescence on the oocyte surface is enhanced. These data indicate that (i) both syntaxin isoforms increase the net externalization of the ENaC channel complex, (ii) that the functional regulation is isoform specific, and (iii) suggest that ENaC may be regulated through mechanisms involving protein-protein interactions.	Univ Alabama Birmingham, Dept Med, Div Nephrol, Ctr Nephrol Res & Training, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Neurobiol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Saxena, S (corresponding author), Univ Alabama Birmingham, Dept Med, Div Nephrol, Ctr Nephrol Res & Training, 613 ZRB UAB Stn,703 S 19th St, Birmingham, AL 35294 USA.				NIDDK NIH HHS [DK-19407, DK-53161] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053161, R01DK019407] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abriel H, 1999, J CLIN INVEST, V103, P667, DOI 10.1172/JCI5713; Beckman ML, 1998, J NEUROSCI, V18, P6103; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENOS DJ, 1992, MEMBRANE TRANSPORT B, V5, P166; BEZPROZVANNY I, 1995, NATURE, V378, P623, DOI 10.1038/378623a0; Breton S, 1998, J AM SOC NEPHROL, V9, P155; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; HONG W, 1996, PROTEIN TRAFFICKING, P76; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LING BN, 1989, AM J PHYSIOL, V256, pF1094, DOI 10.1152/ajprenal.1989.256.6.F1094; Low SH, 1996, MOL BIOL CELL, V7, P2007, DOI 10.1091/mbc.7.12.2007; Mandon B, 1997, AM J PHYSIOL-RENAL, V273, pF718, DOI 10.1152/ajprenal.1997.273.5.F718; Mandon B, 1996, J CLIN INVEST, V98, P906, DOI 10.1172/JCI118873; Naren AP, 1998, P NATL ACAD SCI USA, V95, P10972, DOI 10.1073/pnas.95.18.10972; Naren AP, 1997, NATURE, V390, P302, DOI 10.1038/36882; Quick MW, 1997, J NEUROSCI, V17, P2967; Riento K, 1998, J CELL SCI, V111, P2681; Rossier BC, 1997, J AM SOC NEPHROL, V8, P980; SCHILD L, 1995, P NATL ACAD SCI USA, V92, P5699, DOI 10.1073/pnas.92.12.5699; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Stanley EF, 1997, NATURE, V385, P340, DOI 10.1038/385340a0; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Warnock DG, 1998, KIDNEY INT, V53, P18, DOI 10.1046/j.1523-1755.1998.00728.x; Wiser O, 1996, EMBO J, V15, P4100, DOI 10.1002/j.1460-2075.1996.tb00785.x	32	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					20812	20817		10.1074/jbc.274.30.20812	http://dx.doi.org/10.1074/jbc.274.30.20812			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409621	hybrid			2022-12-25	WOS:000081613100012
J	Jiang, WD; Ananthaswamy, HN; Muller, HK; Kripke, ML				Jiang, WD; Ananthaswamy, HN; Muller, HK; Kripke, ML			p53 protects against skin cancer induction by UV-B radiation	ONCOGENE			English	Article						sunlight; photocarcinogenesis; transgenic mice; tumor suppressor gene; mutation	SQUAMOUS-CELL CARCINOMA; P53-DEFICIENT MICE; MOUSE SKIN; MUTATIONS; TUMORS; ABNORMALITIES; SUNLIGHT	To assess the role of the p53 tumor suppressor gene in skin carcinogenesis by UV radiation, mice constitutively lacking one or both copies of the functional p53 gene were compared to wild-type mice for their susceptibility to UV carcinogenesis. Heterozygous mice showed greatly increased susceptibility to skin cancer induction, and homozygous p53 knockout mice mere even more susceptible, Accelerated tumor development in the heterozygotes was not associated with loss of the remaining wild-type allele of p53, as reported for tumors induced by other carcinogens, but in many cases was associated with UV-induced mutations in p53, Tumors arose on the ears and dorsal skin of mice of all three genotypes, and homozygous knockout mice also developed ocular tumors, mainly melanomas, Skin tumors in the p53 knockout mice were predominately squamous cell carcinomas and were associated with premalignant lesions resembling actinic keratoses, whereas those in the heterozygous and wild-type mice were mainly sarcomas, These results demonstrate the importance of p53 in protecting against UV-induced cancers, particularly in the eye and epidermis.	Univ Texas, MD Anderson Canc Ctr, Acad Programs, Dept Immunol, Houston, TX 77030 USA; Univ Tasmania, Dept Pathol, Hobart, Tas 7000, Australia	University of Texas System; UTMD Anderson Cancer Center; University of Tasmania	Kripke, ML (corresponding author), Univ Texas, MD Anderson Canc Ctr, Acad Programs, Dept Immunol, 1515 Holcombe Blvd,Box 147, Houston, TX 77030 USA.				NCI NIH HHS [R01CA46523, CA16672, P01CA68233] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, P01CA068233, R01CA046523] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ananthaswamy HN, 1998, PHOTOCHEM PHOTOBIOL, V67, P227, DOI 10.1562/0031-8655(1998)067<0227:MIHSHM>2.3.CO;2; Ananthaswamy HN, 1997, NAT MED, V3, P510, DOI 10.1038/nm0597-510; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; Cheo DL, 1996, CURR BIOL, V6, P1691, DOI 10.1016/S0960-9822(02)70794-X; DONAWHO CK, 1991, CANCER METAST REV, V10, P177, DOI 10.1007/BF00049413; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KANJILAL S, 1993, CANCER RES, V53, P2961; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KRAEMER KH, 1987, ARCH DERMATOL, V123, P241, DOI 10.1001/archderm.123.2.241; KRIPKE ML, 1977, CANCER RES, V37, P1395; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Li G, 1998, J INVEST DERMATOL, V110, P72, DOI 10.1046/j.1523-1747.1998.00090.x; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; NAKAZAWA H, 1994, P NATL ACAD SCI USA, V91, P360, DOI 10.1073/pnas.91.1.360; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	19	139	143	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 22	1999	18	29					4247	4253		10.1038/sj.onc.1202789	http://dx.doi.org/10.1038/sj.onc.1202789			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218FK	10435637				2022-12-25	WOS:000081542400008
J	Rouer, E; Brule, F; Benarous, R				Rouer, E; Brule, F; Benarous, R			A single base mutation in the 5 ' splice site of intron 7 of the lck gene is responsible for the deletion of exon 7 in lck mRNA of the JCaM1 cell line	ONCOGENE			English	Article						lck gene; alternative splicing; point mutation	TYROSINE KINASE; MESSENGER-RNA; HEMATOPOIETIC MALIGNANCIES; ANTIGEN RECEPTOR; TRANSCRIPTS; EXPRESSION; ACTIVATION; ICK; PHOSPHORYLATION; PROTEINS	The failure of signal transduction in the JCaM1 cell line was associated with the presence of an abnormal lck mRNA deleted of the exon 7 encoding for an inactive p56(lck) kinase. Our study of the Cck mRNA from various T cell lines and from peripheral blood lymphocytes of healthy donors has revealed the presence of both complete and exon 7-deleted lck transcripts. Thus the exon 7-deleted lck transcript initially described in the JCaM1 mutant cell line, arises from an alternative splicing event occurring in each cells expressing the lck gene. Genomic DNA sequencing of the lck exons 6-8 portion from both the mutant JCaM1 and its parental Jurkat cell lines revealed as the only difference, the presence of a A to G mutation within the 5' splice site of intron 7 in the JCaM1 cell line DNA. To demonstrate the role of this point mutation in the lck pre-mRNA maturation, COS cells were transfected by lck minigenes from the Jurkat and JCaM1 cell lines. In COS cells transfected with minigene from the Jurkat cell line both lck transcripts (with and without exon 7) were observed whereas only the exon 7-spliced lck transcript was observed in COS cells transfected with minigene from the JCaM1 cell line. Thus the mutation is per se responsible for the deletion of exon 7 and the absence of complete lck mRNA in the JCaM1 cell line. Presence of a restriction site (HphI) in the 5' splice site of lck intron 7 from Jurkat DNA allowed to confirm the presence of the mutation on both alleles in the JCaM1 cell line.	CHU Cochin Port Royal, ICGM, F-75014 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier	Rouer, E (corresponding author), CHU Cochin Port Royal, ICGM, 24 Rue Faubourg St Jacques,CJF97-03 Interact Mol, F-75014 Paris, France.							Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; CANCE WG, 1994, CELL GROWTH DIFFER, V5, P1347; CARRERA AC, 1993, P NATL ACAD SCI USA, V90, P442, DOI 10.1073/pnas.90.2.442; COOKE M P, 1989, New Biologist, V1, P66; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; HSI ED, 1989, J BIOL CHEM, V264, P10836; ISAKOV N, 1995, J EXP MED, V181, P375, DOI 10.1084/jem.181.1.375; JAMISON SF, 1995, NUCLEIC ACIDS RES, V23, P3260, DOI 10.1093/nar/23.16.3260; JUCKER M, 1991, LEUKEMIA, V5, P528; KRAWCZAK M, 1992, HUM GENET, V90, P41; LEVY JB, 1989, MOL CELL BIOL, V9, P3332, DOI 10.1128/MCB.9.8.3332; PERLMUTTER RM, 1988, J CELL BIOCHEM, V38, P117, DOI 10.1002/jcb.240380206; PYPER JM, 1990, MOL CELL BIOL, V10, P2035, DOI 10.1128/MCB.10.5.2035; ROUER E, 1992, ONCOGENE, V7, P2535; ROUER E, 1994, CELL GROWTH DIFFER, V5, P659; ROUER E, 1989, GENE, V84, P105, DOI 10.1016/0378-1119(89)90144-3; ROUER E, 1993, LEUKEMIA, V7, P246; STANLEY E, 1991, MOL CELL BIOL, V11, P3399, DOI 10.1128/MCB.11.7.3399; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SUDOL M, 1993, ONCOGENE, V8, P823; TAKADERA T, 1989, MOL CELL BIOL, V9, P2173, DOI 10.1128/MCB.9.5.2173; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; vanOers NSC, 1996, J EXP MED, V183, P1053, DOI 10.1084/jem.183.3.1053; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1987, ONCOGENE RES, V1, P357; VORONOVA AF, 1984, MOL CELL BIOL, V4, P2705, DOI 10.1128/MCB.4.12.2705; XU H, 1993, CELL, V74, P633, DOI 10.1016/0092-8674(93)90511-N; YAMANASHI Y, 1991, CELL REGUL, V2, P979, DOI 10.1091/mbc.2.12.979; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837	30	7	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 22	1999	18	29					4262	4268		10.1038/sj.onc.1202720	http://dx.doi.org/10.1038/sj.onc.1202720			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218FK	10435639				2022-12-25	WOS:000081542400010
J	Daulhac, L; Kowalski-Chauvel, A; Pradayrol, L; Vaysse, N; Seva, C				Daulhac, L; Kowalski-Chauvel, A; Pradayrol, L; Vaysse, N; Seva, C			Src-family tyrosine kinases in activation of ERK-1 and p85/p110-phosphatidylinositol 3-kinase by G/CCKB receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; SMOOTH-MUSCLE CELLS; FACTOR-I RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; MAP KINASE; PHOSPHOINOSITIDE-3 KINASE; PHOSPHOLIPASE C-GAMMA-1; SIGNAL-TRANSDUCTION; MEDIATED ACTIVATION; EXPRESSION CLONING	We have analyzed in Chinese hamster ovary cells the upstream mediators by which the G protein-coupled receptor, gastrin/CCKB, activates the extracellular-regulated kinases (ERKs) and p85/p110-phosphatidylinositol 3-kinase (PI 3-kinase) pathways. Overexpression of an inhibitory mutant of Shc completely blocked gastrin-stimulated Shc.Grba complex formation but partially inhibited ERK-1 activation by this peptide. Expression of Csk, which inactivates Src-family kinases, totally inhibited gastrin-induced Src-like activity detected in anti-Src and anti-She precipitates but diminished by 50% Shc phosphorylation and ERK-1 activation. We observed a rapid tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1) and an increase in Src-like kinase activity in anti-IRS-1 immunoprecipitates from gastrin-stimulated cells, suggesting that IRS-1 may be a direct substrate of Src. This hypothesis was supported by the inhibition of gastrin-induced Src IRS-1 complex formation and IRS-1 phosphorylation in Csk-transfected cells. In addition, the increase in PI 3-kinase activity measured in anti p85 or anti-IRS-1 precipitates following gastrin stimulation was abolished by Csk. Our results demonstrate the existence of two mechanisms in gastrin-mediated ERKs activation, One requires Shc phosphorylation by Src-family kinases, and the other one is independent of these two proteins. They also indicate that tyrosine phosphorylation of IRS-1 by Src-family kinases could lead to the recruitment and the activation of the p85/p110-PI 3-kinase in response to gastrin.	CHU Rangueil, Grp Rech Biol & Pathol Digest, Inst Louis Bugnard, INSERM,U151, F-31403 Toulouse, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Seva, C (corresponding author), CHU Rangueil, Grp Rech Biol & Pathol Digest, Inst Louis Bugnard, INSERM,U151, 1 Ave J Poulhes,Bat L3, F-31403 Toulouse, France.		SEVA, Catherine/O-9166-2014; Kowalski-Chauvel, Aline/O-9212-2014	SEVA, Catherine/0000-0002-4265-7372; 				Cacace AM, 1996, ONCOGENE, V13, P2517; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; CHENG GH, 1994, P NATL ACAD SCI USA, V91, P8152, DOI 10.1073/pnas.91.17.8152; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1993, DEVELOPMENT, P57; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; Hu ZW, 1996, J BIOL CHEM, V271, P8977, DOI 10.1074/jbc.271.15.8977; ITO M, 1993, J BIOL CHEM, V268, P18300; JOHNSON LR, 1977, ANNU REV PHYSIOL, V39, P135, DOI 10.1146/annurev.ph.39.030177.001031; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KOPIN AS, 1992, P NATL ACAD SCI USA, V89, P3605, DOI 10.1073/pnas.89.8.3605; KowalskiChauvel A, 1996, J BIOL CHEM, V271, P26356, DOI 10.1074/jbc.271.42.26356; Kranenburg O, 1997, EMBO J, V16, P3097, DOI 10.1093/emboj/16.11.3097; KUSYK CJ, 1986, AM J PHYSIOL, V251, P597; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MAHAJAN S, 1995, MOL CELL BIOL, V15, P5304; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Ptasznik A, 1996, J BIOL CHEM, V271, P25204, DOI 10.1074/jbc.271.41.25204; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; RAO GN, 1995, J BIOL CHEM, V270, P27871, DOI 10.1074/jbc.270.46.27871; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; Saward L, 1997, CIRC RES, V81, P249, DOI 10.1161/01.RES.81.2.249; SERGER R, 1995, FASEB J, V9, P726; SEUFFERLEIN T, 1995, CELL GROWTH DIFFER, V6, P383; SEVA C, 1994, SCIENCE, V265, P410, DOI 10.1126/science.8023165; Seva C, 1996, FEBS LETT, V378, P74, DOI 10.1016/0014-5793(95)01414-4; SEVA C, 1990, CANCER RES, V50, P5829; SINGH P, 1994, AM J PHYSIOL, V267, pG235, DOI 10.1152/ajpgi.1994.267.2.G235; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TANIGUCHI T, 1994, ONCOGENE, V9, P861; THOMASON PA, 1994, J BIOL CHEM, V269, P16525; Torres M, 1996, J BIOL CHEM, V271, P13244, DOI 10.1074/jbc.271.22.13244; Velloso LA, 1996, P NATL ACAD SCI USA, V93, P12490, DOI 10.1073/pnas.93.22.12490; VEMURI GS, 1994, BIOCHEM BIOPH RES CO, V202, P1619, DOI 10.1006/bbrc.1994.2118; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; Wan Y, 1997, J BIOL CHEM, V272, P17209, DOI 10.1074/jbc.272.27.17209; WANK SA, 1992, P NATL ACAD SCI USA, V89, P8691, DOI 10.1073/pnas.89.18.8691; WHITE MF, 1994, J BIOL CHEM, V269, P1; Yassin RR, 1998, PEPTIDES, V19, P47, DOI 10.1016/S0196-9781(97)00276-3; Zou YZ, 1998, CIRC RES, V82, P337, DOI 10.1161/01.RES.82.3.337	51	105	105	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20657	20663		10.1074/jbc.274.29.20657	http://dx.doi.org/10.1074/jbc.274.29.20657			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400698	hybrid			2022-12-25	WOS:000081438300091
J	Galande, S; Kohwi-Shigematso, T				Galande, S; Kohwi-Shigematso, T			Poly(ADP-ribose) polymerase and Ku autoantigen form a complex and synergistically bind to matrix attachment sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL LOOP ANCHORAGE; NUCLEAR MATRIX; DNA-BINDING; CELL-CYCLE; IN-VIVO; V(D)J RECOMBINATION; DEFICIENT CELLS; REPLICATION; PROTEIN; TRANSCRIPTION	Genomic sequences with a cluster of ATC sequence stretches where one strand consists exclusively of well mixed As, Ts, and Cs confer high base unpairing propensity under negative superhelical strain. Such base unpairing regions (BURs) are typically found in scaffold or matrix attachment regions (SARs/MARs) that are thought to contribute to the formation of the loop domain structure of chromatin, Several proteins, including cell type-specific proteins, have been identified that bind specifically to double-stranded BURs either in. vitro or in vivo. By using BUR-affinity chromatography to isolate BUR-binding proteins from breast cancer SK-BR-3 cells, we almost exclusively obtained a complex of poly(ADP-ribose) polymerase (PARP) and DNA-dependent protein kinase (DNA-PK), Both PARP and DNA-PK are activated by DNA strand breaks and are implicated in DNA repair, recombination, DNA replication, and transcription. In contrast to the previous notion that PARP and Ku autoantigen, the DNA-binding subunit of DNA-PK, mainly bind to free ends of DNA, here we show that both proteins individually bind BURs with high affinity and specificity in an end-independent manner using closed circular BUR-containing DNA substrates. We further demonstrate that PARR and Ku autoantigen form a molecular complex in vivo and in vitro in the absence of DNA, and as a functional consequence, their affinity to the BURs are synergistically enhanced. ADP-ribosylation of the nuclear extract abrogated the BUR binding activity of this complex. These results provide a mechanistic link toward understanding the functional overlap of PARP and DNA PK and suggest a novel role for these proteins in the regulation of chromatin structure and function.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Kohwi-Shigematso, T (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, 1 Cyclotron Rd,Mail Stop 70A-1118, Berkeley, CA 94720 USA.							BODE J, 1992, SCIENCE, V255, P195, DOI 10.1126/science.1553545; Borggrefe T, 1998, J BIOL CHEM, V273, P17025, DOI 10.1074/jbc.273.27.17025; COCKERILL PN, 1987, J BIOL CHEM, V262, P5394; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; Dantzer F, 1998, NUCLEIC ACIDS RES, V26, P1891, DOI 10.1093/nar/26.8.1891; de Belle I, 1998, J CELL BIOL, V141, P335, DOI 10.1083/jcb.141.2.335; DEMURCIA G, 1986, J BIOL CHEM, V261, P7011; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C; DICROCE PA, 1995, P NATL ACAD SCI USA, V92, P10137, DOI 10.1073/pnas.92.22.10137; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FORRESTER WC, 1994, SCIENCE, V265, P1221, DOI 10.1126/science.8066460; GASSER SM, 1987, TRENDS GENET, V3, P16, DOI 10.1016/0168-9525(87)90156-9; Gravel S, 1998, SCIENCE, V280, P741, DOI 10.1126/science.280.5364.741; GRIFFIN W, 1996, NATURE, V380, P265; HASSAN AB, 1994, J CELL SCI, V107, P425; Herrscher RF, 1995, GENE DEV, V9, P3067, DOI 10.1101/gad.9.24.3067; HOZAK P, 1994, J CELL SCI, V107, P2191; Jackson SP, 1996, CURR OPIN GENET DEV, V6, P19, DOI 10.1016/S0959-437X(96)90005-2; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; Jenuwein T, 1997, NATURE, V385, P269, DOI 10.1038/385269a0; Kirillov A, 1996, NAT GENET, V13, P435, DOI 10.1038/ng0895-435; Kohwi-Shigematsu T, 1998, METHOD CELL BIOL, V53, P323; KOHWISHIGEMATSU T, 1990, BIOCHEMISTRY-US, V29, P9551, DOI 10.1021/bi00493a009; LARGARKOVA MA, 1998, J CELL BIOCHEM, V69, P13; Laroche T, 1998, CURR BIOL, V8, P653, DOI 10.1016/S0960-9822(98)70252-0; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; Meisterernst M, 1997, P NATL ACAD SCI USA, V94, P2261, DOI 10.1073/pnas.94.6.2261; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; Morrison C, 1997, NAT GENET, V17, P479, DOI 10.1038/ng1297-479; Munoz P, 1998, MOL CELL BIOL, V18, P5797, DOI 10.1128/MCB.18.10.5797; NELSON WG, 1986, ANNU REV BIOPHYS BIO, V15, P457, DOI 10.1146/annurev.bb.15.060186.002325; Nugent CI, 1998, CURR BIOL, V8, P657, DOI 10.1016/S0960-9822(98)70253-2; Pemov A, 1998, P NATL ACAD SCI USA, V95, P14757, DOI 10.1073/pnas.95.25.14757; REEVES WH, 1989, J BIOL CHEM, V264, P5047; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; Ruscetti T, 1998, J BIOL CHEM, V273, P14461, DOI 10.1074/jbc.273.23.14461; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SHAH GM, 1995, ANAL BIOCHEM, V227, P1, DOI 10.1006/abio.1995.1245; SimbulanRosenthal CM, 1996, BIOCHEMISTRY-US, V35, P11622, DOI 10.1021/bi953010z; UMEK RM, 1988, CELL, V52, P559, DOI 10.1016/0092-8674(88)90469-2; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; Wang JS, 1998, J BIOL CHEM, V273, P31068, DOI 10.1074/jbc.273.47.31068; WANG JS, 1994, J CELL SCI, V107, P3223; Wright SC, 1996, J EXP MED, V183, P463, DOI 10.1084/jem.183.2.463; Yanagisawa J, 1996, CANCER RES, V56, P457	46	150	152	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20521	20528		10.1074/jbc.274.29.20521	http://dx.doi.org/10.1074/jbc.274.29.20521			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400681	hybrid, Green Submitted			2022-12-25	WOS:000081438300074
J	Gilon, P; Arredouani, A; Gailly, P; Gromada, J; Henquin, JC				Gilon, P; Arredouani, A; Gailly, P; Gromada, J; Henquin, JC			Uptake and release of Ca2+ by the endoplasmic reticulum contribute to the oscillations of the cytosolic Ca2+ concentration triggered by Ca2+ influx in the electrically excitable pancreatic B-cell	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; RINM5F INSULINOMA CELLS; ATP ADP RATIO; BETA-CELLS; INTRACELLULAR CA2+; CYTOPLASMIC CA2+; INTACT-CELLS; CALCIUM OSCILLATIONS; RYANODINE RECEPTOR; FREE CA-2+	The role of intracellular Ca2+ pools in oscillations of the cytosolic Ca2+ concentration ([Ca2+](c)) triggered by Ca2+ influx was investigated in mouse pancreatic B-cells. [Ca2+](c) oscillations occurring spontaneously during glucose stimulation or repetitively induced by pulses of high K+ (in the presence of diazoxide) were characterized by a descending phase in two components. A rapid decrease in [Ca2+](c) coincided with closure of voltage dependent Ca2+ channels and was followed by a slower phase independent of Ca2+ influx. Blocking the SERCA pump with thapsigargin or cyclopiazonic acid accelerated the rising phase of [Ca2+](c) oscillations and increased their amplitude, which suggests that the endoplasmic reticulum (ER) rapidly takes up Ca2+. It also suppressed the slow [Ca2+](c) recovery phase, which indicates that this phase corresponds to the slow release of Ca2+ that was taken up by the ER during the upstroke of the [Ca2+](c) transient. Glucose promoted the buffering capacity of the ER and amplified the slow [Ca2+](c) recovery phase. The slow phase induced by high KC pulses was not affected by modulators of Ca2+- or inositol 1,4,5-trisphosphate-induced Ca2+ release, did not involve a depolarization-induced Ca2+ release, and was also observed at the end of a rapid rise in [Ca2+](c) triggered from caged Ca2+. It is attributed to passive leakage of Ca2+ from the ER, We suggest that the ER displays oscillations of the Ca2+ concentration ([Ca2+](ER)) concomitant and parallel to [Ca2+](c). The observation that thapsigargin depolarizes the membrane of B-cells supports the proposal that the degree of Ca2+ filling of the ER modulates the membrane potential. Therefore, [Ca2+](ER) oscillations occurring during glucose stimulation are likely to influence the bursting behavior of B-cells and eventually [Ca2+](c) oscillations.	Univ Louvain, Fac Med, Unite Endocrinol & Metab, B-1200 Brussels, Belgium; Univ Louvain, Fac Med, Unite Physiol Gen Muscles, B-1200 Brussels, Belgium; Novo Nordisk AS, Islet Discovery Res, Dept Islet Cell Physiol, DK-2880 Bagsvaerd, Denmark	Universite Catholique Louvain; Universite Catholique Louvain; Novo Nordisk	Gilon, P (corresponding author), Univ Louvain, Fac Med, Unite Endocrinol & Metab, Av hippocrate 55, B-1200 Brussels, Belgium.		arredouani, abdelilah/Q-9650-2019	arredouani, abdelilah/0000-0002-5060-916X				AMMALA C, 1991, NATURE, V353, P849, DOI 10.1038/353849a0; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; BARKER CJ, 1994, BIOCHEM J, V297, P265, DOI 10.1042/bj2970265; BIDEN TJ, 1987, J BIOL CHEM, V262, P3567; Camello P, 1996, J PHYSIOL-LONDON, V490, P585, DOI 10.1113/jphysiol.1996.sp021169; CHATTON JY, 1995, FEBS LETT, V368, P165, DOI 10.1016/0014-5793(95)00632-J; Chay TR, 1997, BIOPHYS J, V73, P1673, DOI 10.1016/S0006-3495(97)78199-2; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CORKEY BE, 1988, J BIOL CHEM, V263, P4247; CORKEY BE, 1988, J BIOL CHEM, V263, P4254; Csordas G, 1999, EMBO J, V18, P96, DOI 10.1093/emboj/18.1.96; Detimary P, 1998, BIOCHEM J, V333, P269, DOI 10.1042/bj3330269; Dukes I. D., 1997, CURR OPIN ENDOCRINOL, V4, P262; EHRLICH BE, 1994, TRENDS PHARMACOL SCI, V15, P145, DOI 10.1016/0165-6147(94)90074-4; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; FRIEL DD, 1994, J NEUROSCI, V14, P4007; GILON P, 1992, J BIOL CHEM, V267, P20713; Golovina VA, 1997, SCIENCE, V275, P1643, DOI 10.1126/science.275.5306.1643; Gromada J, 1996, BIOCHEM J, V314, P339, DOI 10.1042/bj3140339; Hajnoczky G, 1997, EMBO J, V16, P3533, DOI 10.1093/emboj/16.12.3533; HENQUIN JC, 1984, EXPERIENTIA, V40, P1043, DOI 10.1007/BF01971450; Herrington J, 1996, NEURON, V16, P219, DOI 10.1016/S0896-6273(00)80038-0; Hofer AM, 1998, EMBO J, V17, P1986, DOI 10.1093/emboj/17.7.1986; Hofer AM, 1998, J CELL BIOL, V140, P325, DOI 10.1083/jcb.140.2.325; Hoth M, 1996, FEBS LETT, V390, P285, DOI 10.1016/0014-5793(96)00673-4; INESI G, 1994, J MEMBRANE BIOL, V141, P1; Islam MS, 1998, P NATL ACAD SCI USA, V95, P6145, DOI 10.1073/pnas.95.11.6145; Landolfi B, 1998, J CELL BIOL, V142, P1235, DOI 10.1083/jcb.142.5.1235; Liu YJ, 1996, ARCH BIOCHEM BIOPHYS, V334, P295, DOI 10.1006/abbi.1996.0458; LIU YJ, 1994, ARCH BIOCHEM BIOPHYS, V315, P387, DOI 10.1006/abbi.1994.1515; LIU YJ, 1995, CELL CALCIUM, V18, P165, DOI 10.1016/0143-4160(95)90007-1; LYTTON J, 1992, J BIOL CHEM, V267, P14483; Maechler P, 1999, J BIOL CHEM, V274, P12583, DOI 10.1074/jbc.274.18.12583; MISSIAEN L, 1991, PHARMACOL THERAPEUT, V50, P191, DOI 10.1016/0163-7258(91)90014-D; Miura Y, 1996, BIOCHEM BIOPH RES CO, V224, P67, DOI 10.1006/bbrc.1996.0985; Miura Y, 1997, J PHYSIOL-LONDON, V503, P387, DOI 10.1111/j.1469-7793.1997.387bh.x; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Mogami H, 1998, EMBO J, V17, P435, DOI 10.1093/emboj/17.2.435; NILSSON T, 1988, FEBS LETT, V229, P211, DOI 10.1016/0014-5793(88)80829-9; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; Park YB, 1996, J PHYSIOL-LONDON, V492, P329, DOI 10.1113/jphysiol.1996.sp021312; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; RIOS E, 1988, NEWS PHYSIOL SCI, V3, P223, DOI 10.1152/physiologyonline.1988.3.6.223; RIZZUTO R, 1994, J CELL BIOL, V126, P1183, DOI 10.1083/jcb.126.5.1183; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; ROE MW, 1994, AM J PHYSIOL, V266, pE852, DOI 10.1152/ajpendo.1994.266.6.E852; RORSMAN P, 1992, EMBO J, V11, P2877, DOI 10.1002/j.1460-2075.1992.tb05356.x; RUTTER GA, 1993, J BIOL CHEM, V268, P22385; SANTOS RM, 1991, PFLUG ARCH EUR J PHY, V418, P417, DOI 10.1007/BF00550880; SCHLATTERER C, 1992, EUR J CELL BIOL, V58, P172; SMITH PA, 1989, NATURE, V342, P550, DOI 10.1038/342550a0; Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027; Varadi A, 1996, BIOCHEM J, V319, P521, DOI 10.1042/bj3190521; WORLEY JF, 1994, J BIOL CHEM, V269, P14359; WORLEY JF, 1994, J BIOL CHEM, V269, P32055	57	101	101	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20197	20205		10.1074/jbc.274.29.20197	http://dx.doi.org/10.1074/jbc.274.29.20197			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400636	hybrid			2022-12-25	WOS:000081438300029
J	Kohzaki, H; Ito, K; Huang, G; Wee, HJ; Murakami, Y; Ito, Y				Kohzaki, H; Ito, K; Huang, G; Wee, HJ; Murakami, Y; Ito, Y			Block of granulocytic differentiation of 32Dcl3 cells by AML1/ETO(MTG8) but not by highly expressed Bcl-2	ONCOGENE			English	Article						AML1; AML1/ETO(MTG8); Bcl-2; 32Dcl3; granulocytic differentiation	ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; STIMULATING FACTOR-RECEPTOR; FETAL LIVER HEMATOPOIESIS; MYOSIN HEAVY-CHAIN; FUSION PROTEIN; TRANSCRIPTION FACTOR; T(8-21) TRANSLOCATION; MYELOGENOUS LEUKEMIA; FOLLICULAR LYMPHOMA	The chimeric gene, AML1/ETO (MTG8), generated in t(8;21) acute myeloid leukemia enhances the expression of Bcl-2. To evaluate whether this enhancement is the primary role of AML1/ETO in leukemogenesis, effects of over-expression of Bcl-2 in the murine myeloid precursor cell line, 32Dc13, were examined. When 32Dc13 cells expressing exogenous Bcl-2 were induced to differentiate, the onset of morphological differentiation,vas delayed. However, even the cells expressing very high levels of exogenous Bcl-2 eventually underwent differentiation without a significant decrease in the synthesis of Bcl-2. On the contrary, 32Dc13 cells stably expressing AML1/ETO mere completely resistant to differentiation and continued to grow in the presence of G-CSF. These results are consistent with the interpretation that stimulation of Bcl-2 expression is not the primary target of AML1/ETO.	Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Ito, Y (corresponding author), Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Shogoin, Kyoto 6068507, Japan.		Kohzaki, Hidetsugu/P-6151-2019; Kohzaki, Hidetsugu/D-2758-2018; Murakami, Yota/F-8850-2012	Kohzaki, Hidetsugu/0000-0003-0946-9676; 				Ahn MY, 1998, P NATL ACAD SCI USA, V95, P1812, DOI 10.1073/pnas.95.4.1812; ASOU H, 1991, BLOOD, V77, P2031; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BAKHSHI A, 1985, CELL, V41, P889; Banker DE, 1998, CLIN CANCER RES, V4, P3051; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; ERICKSON P, 1992, BLOOD, V80, P1825; Fears S, 1997, P NATL ACAD SCI USA, V94, P1949, DOI 10.1073/pnas.94.5.1949; Frank R, 1995, ONCOGENE, V11, P2667; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; Ito K, 1996, EMBO J, V15, P5636, DOI 10.1002/j.1460-2075.1996.tb00948.x; Ito Y, 1996, J CANCER RES CLIN, V122, P266, DOI 10.1007/BF01261402; ITO Y, 1997, CELL CYCLE REGULATOR, V2, P107; Kanno Y, 1998, MOL CELL BIOL, V18, P4252, DOI 10.1128/MCB.18.7.4252; KINASHI T, 1991, J EXP MED, V173, P1267, DOI 10.1084/jem.173.5.1267; Kitabayashi I, 1998, MOL CELL BIOL, V18, P846, DOI 10.1128/MCB.18.2.846; Klampfer L, 1996, P NATL ACAD SCI USA, V93, P14059, DOI 10.1073/pnas.93.24.14059; Lin EY, 1996, BLOOD, V87, P983, DOI 10.1182/blood.V87.3.983.bloodjournal873983; LIU P, 1994, COLD SPRING HARB SYM, V59, P547, DOI 10.1101/SQB.1994.059.01.061; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LU J, 1995, MOL CELL BIOL, V15, P1651; MATOZAKI S, 1995, BRIT J HAEMATOL, V89, P805; Meyers S, 1996, ONCOGENE, V13, P303; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYASHITA T, 1994, CANCER RES, V54, P3131; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; NUCIFORA G, 1995, BLOOD, V86, P1; NUNEZ G, 1990, J IMMUNOL, V144, P3602; Okada H, 1998, ONCOGENE, V17, P2287, DOI 10.1038/sj.onc.1202151; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; OSATO M, 1999, IN PRESS BLOOD; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Rhoades KL, 1996, P NATL ACAD SCI USA, V93, P11895, DOI 10.1073/pnas.93.21.11895; Rodel JE, 1996, BLOOD, V87, P858, DOI 10.1182/blood.V87.3.858.bloodjournal873858; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; ROVERA G, 1979, SCIENCE, V204, P868, DOI 10.1126/science.286421; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; Speck NA, 1995, CRIT REV EUKAR GENE, V5, P337, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.60; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; Uchida H, 1997, J IMMUNOL, V158, P2251; VALTIERI M, 1987, J IMMUNOL, V138, P3829; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WARNER NL, 1969, J NATL CANCER I, V43, P963; YANAGISAWA K, 1991, BLOOD, V78, P451	59	33	33	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	1999	18	28					4055	4062		10.1038/sj.onc.1202735	http://dx.doi.org/10.1038/sj.onc.1202735			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	216FP	10435586				2022-12-25	WOS:000081431000002
J	Liu, QJ; Grubb, JH; Huang, SS; Sly, WS; Huang, JS				Liu, QJ; Grubb, JH; Huang, SS; Sly, WS; Huang, JS			The mannose 6-phosphate/insulin-like growth factor-II receptor is a substrate of type V transforming growth factor-beta receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT RECEPTOR; TRANS-GOLGI NETWORK; 6-PHOSPHATE RECEPTOR; TGF-BETA; CYTOPLASMIC DOMAIN; PHOSPHORYLATION SITE; CELL-SURFACE; KINASE; BINDING; PROTEIN	The type V transforming growth factor beta (TGF-beta) receptor (TPR-V) is a ligand-stimulated acidotropic Ser-specific protein kinase that recognizes a motif of SXE/ S(P)/D. This motif is present in the cytoplasmic domain of the mannose 6-phosphate/insulin-like growth factor-II (Man-6-P/IGF-II) receptor. We have explored the possibility that the Man-6-P/IGF-II receptor is a substrate of T beta R-V. Purified bovine Man-6-P/IGF-II receptor was phosphorylated by purified bovine TPR-V in the presence of [gamma-P-32]ATP and MnCl2 with an apparent K-m of 130 nM. TGF-beta stimulated the phosphorylation of the Man-6-P/IGF-II receptor at 0 degrees C in mouse L cells overexpressing the Man-6-P/IGF-II receptor and in wild-type mink lung epithelial (Mv1Lu cells) metabolically labeled with [P-32]orthophosphate. The in vitro and in vivo phosphorylation of the Man-6-P/IGF-II receptor occurred at the putative phosphorylation sites as revealed by phosphopeptide mapping and amino acid sequence analysis. TGF-beta stimulated Man-6-P/IGF-II receptor-mediated uptake (similar to 2-fold after 12 h treatment) of exogenous beta-glucuronidase in Mv1Lu cells and type II TGF-beta receptor (T beta R-II)-defective mutant cells (DR26 cells) but not in type I TGF-beta receptor (T beta R-I)-defective mutant cells (R-1B cells) and human colorectal carcinoma cells (RII-37 cells) expressing T beta R-I and TPR-II but lacking T beta R-V. These results suggest the Man-6-P/IGF-II receptor serves as an in vitro and in vivo substrate of T beta R-V and that both T beta R-V and T beta R-I may play a role in mediating the TGF-beta-stimulated uptake of exogenous beta-glucuronidase.	St Louis Univ, Sch Med, Dept Biochem & Mol Biol, St Louis, MO 63104 USA	Saint Louis University	Huang, JS (corresponding author), St Louis Univ, Sch Med, Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	huangjs@wpogate.slu.edu			NATIONAL CANCER INSTITUTE [R01CA038808] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034182, R01GM034182] Funding Source: NIH RePORTER; NCI NIH HHS [CA 38808] Funding Source: Medline; NIDDK NIH HHS [DK 40163] Funding Source: Medline; NIGMS NIH HHS [GM 34182] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRAULKE T, 1992, J BIOL CHEM, V267, P17347; BROT FE, 1974, BIOCHEM BIOPH RES CO, V57, P1, DOI 10.1016/S0006-291X(74)80349-9; CHEIFETZ S, 1988, J BIOL CHEM, V263, P16984; CHEIFETZ S, 1988, J BIOL CHEM, V263, P17225; Chen HJ, 1997, J BIOL CHEM, V272, P7003, DOI 10.1074/jbc.272.11.7003; CREEK KE, 1983, BIOCHEM J, V214, P353, DOI 10.1042/bj2140353; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; FROLIK CA, 1984, J BIOL CHEM, V259, P995; GABEL CA, 1983, P NATL ACAD SCI-BIOL, V80, P775, DOI 10.1073/pnas.80.3.775; GONZALEZNORIEGA A, 1980, J CELL BIOL, V85, P839, DOI 10.1083/jcb.85.3.839; HEMER F, 1993, J BIOL CHEM, V268, P17108; HUANG SS, 1988, J BIOL CHEM, V263, P12608; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; JONES BG, 1995, EMBO J, V14, P5869, DOI 10.1002/j.1460-2075.1995.tb00275.x; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KORNFELD S, 1995, METABOLIC MOL BASES, V2, P2495; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LIU QJ, 1994, J BIOL CHEM, V269, P9221; Liu QJ, 1997, J BIOL CHEM, V272, P18891, DOI 10.1074/jbc.272.30.18891; LOBEL P, 1987, P NATL ACAD SCI USA, V84, P2233, DOI 10.1073/pnas.84.8.2233; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; MERESSE S, 1993, J CELL BIOL, V120, P67, DOI 10.1083/jcb.120.1.67; MERESSE S, 1990, J BIOL CHEM, V265, P18833; MITCHELL EJ, 1992, MOL BIOL CELL, V3, P1295, DOI 10.1091/mbc.3.11.1295; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; NOLAN CM, 1990, CELL REGUL, V1, P197, DOI 10.1091/mbc.1.2.197; NOLAN CM, 1989, METABOLIC BASIS INHE, P1589; ODA Y, 1993, J BIOL CHEM, V268, P27318; OGRADY P, 1992, J BIOL CHEM, V267, P21033; OGRADY P, 1991, BIOCHEM BIOPH RES CO, V179, P378, DOI 10.1016/0006-291X(91)91381-L; OSHIMA A, 1988, J BIOL CHEM, V263, P2553; OSHIMA A, 1987, P NATL ACAD SCI USA, V83, P8447; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PURCHIO AF, 1988, J BIOL CHEM, V263, P14211; Roberts AB, 1990, PEPTIDE GROWTH FACTO, P419; ROSORIUS O, 1993, J BIOL CHEM, V268, P21470; SATO Y, 1990, J CELL BIOL, V111, P757, DOI 10.1083/jcb.111.2.757; SEGARINI PR, 1988, J BIOL CHEM, V263, P8366; SEGARINI PR, 1992, J BIOL CHEM, V267, P1048; TAKAHASHI S, 1995, J BIOL CHEM, V270, P28397; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; WRIGHT JA, 1993, CRIT REV ONCOGENESIS, V4, P473; ZHOU M, 1995, P NATL ACAD SCI USA, V92, P9762, DOI 10.1073/pnas.92.21.9762	47	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					20002	20010		10.1074/jbc.274.28.20002	http://dx.doi.org/10.1074/jbc.274.28.20002			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391950	hybrid			2022-12-25	WOS:000081377300070
J	Klingenspor, M; Xu, P; Cohen, RD; Welch, C; Reue, K				Klingenspor, M; Xu, P; Cohen, RD; Welch, C; Reue, K			Altered gene expression pattern in the fatty liver dystrophy mouse reveals impaired insulin-mediated cytoskeleton dynamics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPRESENTATIONAL DIFFERENCE ANALYSIS; PROTEIN-KINASE-C; LIPOPROTEIN-LIPASE; FLD MUTATION; RAT ADIPOCYTES; MUTANT MOUSE; ACTIN; BINDING; CELLS; IDENTIFICATION	The mouse fatty liver dystrophy (fld) mutation is characterized by transient hypertriglyceridemia and fatty liver during the neonatal period, followed by development of a peripheral neuropathy, To uncover the metabolic pathway that is disrupted by the fld mutation, we analyzed the altered pattern of gene expression in the fatty liver of fld neonates by representational difference analysis of cDNk Differentially expressed genes detected include a novel member of the Ras superfamily of small GTP-binding proteins, a novel Ser/Thr kinase, and several actin cytoskeleton-associated proteins including actin, profilin, alpha-actinin, and myosin light chain. Because these proteins have a potential functional link in the propagation of hormone signals, we investigated cytoskeleton dynamics in fld cells in response to hormone treatment. These studies revealed that preadipocytes from fld mice exhibit impaired formation of actin membrane ruffles in response to insulin treatment, These findings suggest that the altered mRNA expression levels detected in fld tissue represent a compensatory response for the nonfunctional fld gene and that the fld gene product may be required for development of normal insulin response.	W Los Angeles Vet Affairs Med Ctr, Lipid Res Lab, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, Dept Pathol, Los Angeles, CA 90045 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Reue, K (corresponding author), W Los Angeles Vet Affairs Med Ctr, Lipid Res Lab, 11301 Wilshire Blvd,Bldg 113,Rm 312, Los Angeles, CA 90073 USA.		Klingenspor, Martin/K-5033-2019; Klingenspor, Martin/D-6930-2011	Klingenspor, Martin/0000-0002-4502-6664	NHLBI NIH HHS [HL28481] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL028481] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; BRETSCHER A, 1985, J CELL BIOL, V100, P1656, DOI 10.1083/jcb.100.5.1656; BRIQUETLAUGIER V, 1994, AM J PHYSIOL, V267, pE439, DOI 10.1152/ajpendo.1994.267.3.E439; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; Cheng HL, 1997, J CELL PHYSIOL, V171, P161; Chu CC, 1997, P NATL ACAD SCI USA, V94, P2507, DOI 10.1073/pnas.94.6.2507; Cohen RD, 1997, J CLIN INVEST, V99, P1906, DOI 10.1172/JCI119358; CONRAD PA, 1993, J CELL BIOL, V120, P1381, DOI 10.1083/jcb.120.6.1381; Dharmawardhane S, 1997, J CELL BIOL, V138, P1265, DOI 10.1083/jcb.138.6.1265; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; Edman CF, 1997, BIOCHEM J, V323, P113, DOI 10.1042/bj3230113; Gupta P. D., 1996, Cytobios, V86, P75; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LANGNER CA, 1991, J BIOL CHEM, V266, P11955; LANGNER CA, 1989, J BIOL CHEM, V264, P7994; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; LISITSYN NA, 1995, P NATL ACAD SCI USA, V92, P151, DOI 10.1073/pnas.92.1.151; Machesky Laura M., 1993, Trends in Cell Biology, V3, P381, DOI 10.1016/0962-8924(93)90087-H; MANLY KF, 1993, MAMM GENOME, V4, P303, DOI 10.1007/BF00357089; ONG JM, 1988, J BIOL CHEM, V263, P12933; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; RAYNOLDS MV, 1990, MOL ENDOCRINOL, V4, P1416, DOI 10.1210/mend-4-9-1416; Rehnmark S, 1998, J LIPID RES, V39, P2209; Reue K, 1996, J LIPID RES, V37, P1387; RIDLEY AJ, 1995, METHOD ENZYMOL, V256, P306; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rowe LB, 1996, MAMM GENOME, V7, P555, DOI 10.1007/s003359900166; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SEMENKOVICH CF, 1989, J BIOL CHEM, V264, P9030; SPRITZ N, 1975, J CLIN INVEST, V55, P1049, DOI 10.1172/JCI108005; SUNDAY ME, 1995, AM J PHYSIOL-LUNG C, V269, pL273, DOI 10.1152/ajplung.1995.269.3.L273; Tsakiridis T, 1997, SOC GEN PHY, V52, P257; Wan JS, 1996, NAT BIOTECHNOL, V14, P1685, DOI 10.1038/nbt1296-1685; Welch CL, 1996, J LIPID RES, V37, P1406; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x	39	25	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23078	23084		10.1074/jbc.274.33.23078	http://dx.doi.org/10.1074/jbc.274.33.23078			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438476	hybrid			2022-12-25	WOS:000082012800026
J	Dua, R; Levy, DL; Campbell, JL				Dua, R; Levy, DL; Campbell, JL			Analysis of the essential functions of the C-terminal protein/protein interaction domain of Saccharomyces cerevisiae pol epsilon and its unexpected ability to support growth in the absence of the DNA polymerase domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-PHASE CHECKPOINT; CHROMOSOMAL REPLICATION; CELL-CYCLE; DELTA; SUBUNIT; PATHWAY; FORM	As first observed by Wittenberg (Kesti, T., Flick, K., Keranen, S., Syvaoja, J. E., and Wittenburg, C. (1999) Mel. Cell 3, 679-685), we find that deletion mutants lacking the entire N-terminal DNA polymerase domain of yeast pol epsilon are viable. However, we now show that point mutations in DNA polymerase catalytic residues of pol epsilon are lethal. Taken together, the phenotypes of the deletion and the point mutants suggest that the polymerase of pol epsilon may normally participate in DNA replication but that another polymerase can substitute in its complete absence. Substitution is inefficient because the deletion mutants have serious defects in DNA replication. This observation raises the question of what is the essential function of the C-terminal half of pol epsilon, We show that the ability of the C-terminal half of the polymerase to support growth is disrupted by mutations in the cysteine-rich region, which disrupts both dimerization of the POL2 gene product and interaction with the essential DPB2 subunit, suggesting that this region plays an important architectural role at the replication fork even in the absence of the polymerase function. Finally, the S phase checkpoint, with respect to both induction of RNR3 transcription and cell cycle arrest, is intact in cells where replication is supported only by the C-terminal half of pol epsilon, but it is disrupted in mutants affecting the cysteine-rich region, suggesting that this domain directly affects the checkpoint rather than acting through the N-terminal polymerase active site.	CALTECH, Braun Labs 147 75, Pasadena, CA 91125 USA	California Institute of Technology	Campbell, JL (corresponding author), CALTECH, Braun Labs 147 75, Pasadena, CA 91125 USA.		Levy, Daniel/AAA-7205-2019	Levy, Daniel/0000-0002-7853-3275				Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; ARAKI H, 1995, P NATL ACAD SCI USA, V92, P11791, DOI 10.1073/pnas.92.25.11791; ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x; ARAKI H, 1991, P NATL ACAD SCI USA, V88, P4601, DOI 10.1073/pnas.88.11.4601; BUDD ME, 1993, MOL CELL BIOL, V13, P496, DOI 10.1128/MCB.13.1.496; Burgers PMJ, 1998, CHROMOSOMA, V107, P218, DOI 10.1007/s004120050300; Burgers PMJ, 1998, J BIOL CHEM, V273, P19756, DOI 10.1074/jbc.273.31.19756; CAMPBELL JL, 1993, J BIOL CHEM, V268, P25261; Desany BA, 1998, GENE DEV, V12, P2956, DOI 10.1101/gad.12.18.2956; Dua R, 1998, J BIOL CHEM, V273, P30046, DOI 10.1074/jbc.273.45.30046; DUrso G, 1997, P NATL ACAD SCI USA, V94, P12491, DOI 10.1073/pnas.94.23.12491; Gerik KJ, 1998, J BIOL CHEM, V273, P19747, DOI 10.1074/jbc.273.31.19747; HAMATAKE RK, 1990, J BIOL CHEM, V265, P4072; HENNESSY KM, 1990, GENE DEV, V4, P2252, DOI 10.1101/gad.4.12b.2252; HUANG T, 1995, J BIOL CHEM, V270, P9607, DOI 10.1074/jbc.270.16.9607; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; Kesti T, 1999, MOL CELL, V3, P679, DOI 10.1016/S1097-2765(00)80361-5; Maki S, 1998, J BIOL CHEM, V273, P21332, DOI 10.1074/jbc.273.33.21332; MORRISON A, 1991, P NATL ACAD SCI USA, V88, P9473, DOI 10.1073/pnas.88.21.9473; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; Navas TA, 1996, GENE DEV, V10, P2632, DOI 10.1101/gad.10.20.2632; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; SCHERBAKOVA PV, 1996, GENETICS, V142, P717; WAGA S, 1994, J BIOL CHEM, V269, P10923; Wang J, 1997, CELL, V89, P1087, DOI 10.1016/S0092-8674(00)80296-2; WONG SW, 1988, EMBO J, V7, P37, DOI 10.1002/j.1460-2075.1988.tb02781.x; YANG CL, 1992, NUCLEIC ACIDS RES, V20, P735, DOI 10.1093/nar/20.4.735; ZHOU Z, 1992, GENETICS, V131, P851; Zlotkin T, 1996, EMBO J, V15, P2298, DOI 10.1002/j.1460-2075.1996.tb00583.x	29	166	169	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22283	22288		10.1074/jbc.274.32.22283	http://dx.doi.org/10.1074/jbc.274.32.22283			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428796	hybrid			2022-12-25	WOS:000081868400026
J	Giblin, JP; Leaney, JL; Tinker, A				Giblin, JP; Leaney, JL; Tinker, A			The molecular assembly of ATP-sensitive potassium channels - Determinants on the pore forming subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFIER K+ CHANNEL; AFFINITY SULFONYLUREA RECEPTOR; INWARD-RECTIFIER; XENOPUS OOCYTES; C-TERMINUS; KIR6.2; BLOCK; BETA; STOICHIOMETRY; RECTIFICATION	ATP-sensitive potassium channels form a link between membrane excitability and cellular metabolism. These channels are important in physiological processes such as insulin release and they are an important site of drug action. They are an octomeric complex comprised of four sulfonylurea receptors, a member of the ATP-binding cassette family of proteins, and four Kir 6.0 subunits from the inward rectifier family of potassium channels. We have investigated the nature of the interaction between SUR1 and Kir 6.2 and the domains on the channel responsible for the biochemical and functional manifestations of coupling. The results point to the proximal C terminus determining biochemical interaction in a region that also largely governs homotypic and heterotypic interaction between different Kir family members. While this domain may be necessary for functional communication between the two proteins, it is not sufficient since relative modifications of either the N or C terminus are able to disrupt many aspects of functional coupling mediated by the sulfonylurea receptor.	Univ London Univ Coll, Rayne Inst, Dept Med, Ctr Clin Pharmacol, London WC1E 6JJ, England	University of London; King's College London; University College London	Tinker, A (corresponding author), Univ London Univ Coll, Rayne Inst, Dept Med, Ctr Clin Pharmacol, 5 Univ St, London WC1E 6JJ, England.							Aguilar-Bryan L, 1998, PHYSIOL REV, V78, P227, DOI 10.1152/physrev.1998.78.1.227; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Ammala C, 1996, J PHYSIOL-LONDON, V494, P709, DOI 10.1113/jphysiol.1996.sp021526; Ammala C, 1996, NATURE, V379, P545, DOI 10.1038/379545a0; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; Babenko AP, 1998, ANNU REV PHYSIOL, V60, P667, DOI 10.1146/annurev.physiol.60.1.667; Babenko AP, 1999, BIOCHEM BIOPH RES CO, V255, P231, DOI 10.1006/bbrc.1999.0172; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Drain P, 1998, P NATL ACAD SCI USA, V95, P13953, DOI 10.1073/pnas.95.23.13953; Gribble FM, 1997, J PHYSIOL-LONDON, V504, P35, DOI 10.1111/j.1469-7793.1997.00035.x; Gribble FM, 1997, J PHYSIOL-LONDON, V498, P87, DOI 10.1113/jphysiol.1997.sp021843; Gribble FM, 1997, EMBO J, V16, P1145, DOI 10.1093/emboj/16.6.1145; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; Hulme, 1992, RECEPTOR LIGAND INTE, V92; Inagaki N, 1997, FEBS LETT, V409, P232, DOI 10.1016/S0014-5793(97)00488-2; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; Ishida-Takahashi A, 1998, J PHYSIOL-LONDON, V508, P23, DOI 10.1111/j.1469-7793.1998.023br.x; Isomoto S, 1996, J BIOL CHEM, V271, P24321, DOI 10.1074/jbc.271.40.24321; Jan LY, 1997, ANNU REV NEUROSCI, V20, P91, DOI 10.1146/annurev.neuro.20.1.91; Koster JC, 1998, BIOPHYS J, V74, P1821, DOI 10.1016/S0006-3495(98)77892-0; Koster JC, 1999, J PHYSIOL-LONDON, V515, P19, DOI 10.1111/j.1469-7793.1999.019ad.x; LI M, 1993, ANN NY ACAD SCI, V707, P51, DOI 10.1111/j.1749-6632.1993.tb38041.x; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; Lorenz E, 1998, MOL CELL BIOL, V18, P1652, DOI 10.1128/MCB.18.3.1652; Lorenz E, 1999, J MOL CELL CARDIOL, V31, P425, DOI 10.1006/jmcc.1998.0876; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; McNicholas CM, 1996, P NATL ACAD SCI USA, V93, P8083, DOI 10.1073/pnas.93.15.8083; Minor DL, 1999, CELL, V96, P879, DOI 10.1016/S0092-8674(00)80597-8; Nelson DA, 1996, BIOCHEMISTRY-US, V35, P14793, DOI 10.1021/bi960777y; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; PHIZICKY EM, 1995, MICROBIOL REV, V59, P94, DOI 10.1128/MMBR.59.1.94-123.1995; Proks P, 1999, J PHYSIOL-LONDON, V514, P19, DOI 10.1111/j.1469-7793.1999.019af.x; Reuveny E, 1996, BIOPHYS J, V70, P754, DOI 10.1016/S0006-3495(96)79615-7; Ruknudin A, 1998, J BIOL CHEM, V273, P14165, DOI 10.1074/jbc.273.23.14165; Sakura H, 1995, FEBS LETT, V377, P338, DOI 10.1016/0014-5793(95)01369-5; Shyng SL, 1997, J GEN PHYSIOL, V110, P141, DOI 10.1085/jgp.110.2.141; Shyng SL, 1997, J GEN PHYSIOL, V110, P655, DOI 10.1085/jgp.110.6.655; Shyng SL, 1997, J GEN PHYSIOL, V110, P643, DOI 10.1085/jgp.110.6.643; STANFIELD PR, 1994, J PHYSIOL-LONDON, V478, P1; TAGLIALATELA M, 1995, EMBO J, V14, P5532, DOI 10.1002/j.1460-2075.1995.tb00240.x; Takano M, 1998, J PHYSIOL-LONDON, V512, P395, DOI 10.1111/j.1469-7793.1998.395be.x; Tinker A, 1996, CELL, V87, P857, DOI 10.1016/S0092-8674(00)81993-5; Tucker SJ, 1998, CURR OPIN NEUROBIOL, V8, P316, DOI 10.1016/S0959-4388(98)80055-X; Tucker SJ, 1998, EMBO J, V17, P3290, DOI 10.1093/emboj/17.12.3290; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; WIHLE BA, 1994, NATURE, V371, P246; Woodward R, 1997, J BIOL CHEM, V272, P10823; Xu J, 1998, METHOD ENZYMOL, V293, P3; YANG J, 1995, NEURON, V14, P1047, DOI 10.1016/0896-6273(95)90343-7; Yu WF, 1996, NEURON, V16, P441, DOI 10.1016/S0896-6273(00)80062-8	54	56	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22652	22659		10.1074/jbc.274.32.22652	http://dx.doi.org/10.1074/jbc.274.32.22652			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428846	hybrid			2022-12-25	WOS:000081868400076
J	Hon, T; Hach, A; Tamalis, D; Zhu, YH; Zhang, L				Hon, T; Hach, A; Tamalis, D; Zhu, YH; Zhang, L			The yeast heme-responsive transcriptional activator Hap1 is a preexisting dimer in the absence of heme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; DNA RECOGNITION; CELLULAR FACTOR; DIMERIZATION; PROTEIN; BINDING; RECEPTOR; SEQUENCE	In the absence of heme, Hap1 is associated with molecular chaperones such as Hsp90 and Ydj1 and forms a higher order complex termed HMC. Heme disrupts this complex and permits Hap1 to bind to DNA with high affinity, thereby activating transcription, Heme regulation of Hap1 activity is analogous to the regulation of steroid receptors by steroids, which involves molecular chaperones. Steroid receptors often exist as monomers when associated with molecular chaperones in the absence of ligand but as dimers when activated by steroids. Furthermore, previous studies indicate that dimerization might be important for heme activation of Hap1. We therefore determined whether Hap1 is a monomer or oligomer in the absence of heme. By coeluting two Hap1 size variants and by comparing DNA binding properties of the HMC and Hap1 dimer, we show that Hap1 is a preexisting dimer in the HMC. Further, increasing overexpression of Hap1 caused progressive increases in Hap1 DNA binding and transcriptional activities. Our data suggest that in the absence of heme, Hap1 exists as a dimer, and the two subunits act cooperatively in DNA binding. Hap1 repression is caused, at least in part, by inhibition of the DNA binding activity of the preexisting dimer.	NYU, Med Ctr, Dept Biochem, New York, NY 10016 USA	New York University	Zhang, L (corresponding author), NYU, Med Ctr, Dept Biochem, 550 1st Ave, New York, NY 10016 USA.	zhang102@mcrcr0.med.nyu.edu	Zhang, Li/L-5206-2013	Zhang, Li/0000-0001-9242-0763	NIGMS NIH HHS [GM53453] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053453] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOHEN SP, 1995, SCIENCE, V268, P1303, DOI 10.1126/science.7761850; CREUSOT F, 1988, J MOL BIOL, V204, P263, DOI 10.1016/0022-2836(88)90574-8; FORMAN B M, 1990, New Biologist, V2, P587; FYTLOVICH S, 1993, EMBO J, V12, P1209, DOI 10.1002/j.1460-2075.1993.tb05762.x; GARDNER KH, 1995, NAT STRUCT BIOL, V2, P898, DOI 10.1038/nsb1095-898; HALDI ML, 1995, MOL GEN GENET, V248, P229, DOI 10.1007/BF02190805; Hallstrom TC, 1998, MOL CELL BIOL, V18, P1147, DOI 10.1128/MCB.18.3.1147; Johnson J, 1996, J STEROID BIOCHEM, V56, P31, DOI 10.1016/0960-0760(95)00221-9; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KELLY PA, 1994, ACTA PAEDIATR, V83, P107, DOI 10.1111/j.1651-2227.1994.tb13301.x; King DA, 1999, NAT STRUCT BIOL, V6, P64; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LEVINE J, 1992, CURR GENET, V22, P181, DOI 10.1007/BF00351724; Lodish HF, 1995, COLD SPRING HARB SYM, V60, P93, DOI 10.1101/SQB.1995.060.01.012; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MARMORSTEIN R, 1994, GENE DEV, V8, P2504, DOI 10.1101/gad.8.20.2504; PFEIFER K, 1989, CELL, V56, P291, DOI 10.1016/0092-8674(89)90903-3; PFEIFER K, 1987, CELL, V49, P19, DOI 10.1016/0092-8674(87)90751-3; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Pratt WB, 1998, P SOC EXP BIOL MED, V217, P420; REECE RJ, 1993, SCIENCE, V261, P909, DOI 10.1126/science.8346441; Salzmann M, 1998, MOL IMMUNOL, V35, P271, DOI 10.1016/S0161-5890(98)00035-2; SIDDIQUI AH, 1989, MOL CELL BIOL, V9, P4706, DOI 10.1128/MCB.9.11.4706; SIRENKO OI, 1995, CURR GENET, V27, P509, DOI 10.1007/BF00314440; Stock J, 1996, CURR BIOL, V6, P825, DOI 10.1016/S0960-9822(02)00605-X; TURCOTTE B, 1992, GENE DEV, V6, P2001, DOI 10.1101/gad.6.10.2001; ZHANG L, 1994, J BIOL CHEM, V269, P14643; ZHANG L, 1994, GENETICS, V136, P813; ZHANG L, 1993, P NATL ACAD SCI USA, V90, P2851, DOI 10.1073/pnas.90.7.2851; Zhang L, 1996, EMBO J, V15, P4676, DOI 10.1002/j.1460-2075.1996.tb00844.x; ZHANG L, 1994, GENE DEV, V8, P2110, DOI 10.1101/gad.8.17.2110; Zhang L, 1998, MOL CELL BIOL, V18, P3819, DOI 10.1128/MCB.18.7.3819; ZITOMER RS, 1992, MICROBIOL REV, V56, P1	34	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22770	22774		10.1074/jbc.274.32.22770	http://dx.doi.org/10.1074/jbc.274.32.22770			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428861	hybrid			2022-12-25	WOS:000081868400091
J	Mak, DOD; McBride, S; Foskett, JK				Mak, DOD; McBride, S; Foskett, JK			ATP regulation of type 1 inositol 1,4,5-trisphosphate receptor channel gating by allosteric tuning of Ca2+ activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM DEPRESSION; CEREBELLAR PURKINJE-CELLS; METABOTROPIC GLUTAMATE RECEPTORS; INSULIN-SECRETING CELLS; INDUCED CALCIUM-RELEASE; SMOOTH-MUSCLE CELLS; ENDOPLASMIC-RETICULUM; ADENINE-NUCLEOTIDES; CYTOSOLIC CA2+; INTRAMITOCHONDRIAL CA2+	Inositol 1,4,5-trisphosphate (InsP(3)) mobilizes intracellular Ca2+ by binding to its receptor (InsP(3)R), an endoplasmic reticulum-localized Ca2+ release channel. Patch clamp electrophysiology of Xenopus oocyte nuclei was used to study the effects of cytoplasmic ATP concentration on the cytoplasmic Ca2+ ([Ca2+](i)) dependence of single type 1 InsP(3)R channels in native endoplasmic reticulum membrane. Cytoplasmic ATP free-acid ([ATP](i)), but not the MgATP complex, activated gating of the InsP(3)-liganded InsP(3)R, by stabilizing open channel state(s) and destabilizing the closed state(s). Activation was associated with a reduction of the half-maximal activating [Ca2+](i) from 500 +/- 50 nM in 0 [ATP](i) to 29 +/- 4 nM in 9.5 mM [ATP](i), with apparent ATP affinity = 0.27 +/- 0.04 mM, similar to in vivo concentrations. In contrast, ATP was without effect on maximum open probability or the Hill coefficient for Ca2+ activation. Thus, ATP enhances gating of the InsP(3)R by allosteric regulation of the Ca2+ sensitivity of the Ca2+ activation sites of the channel. By regulating the Ca2+-induced Ca2+ release properties of the InsP(3)R, ATP may play an important role in shaping cytoplasmic Ca2+ signals, possibly linking cell metabolic state to important Ca2+ dependent processes.	Univ Penn, Dept Physiol, Philadelphia, PA 19104 USA; Univ Penn, Inst Human Gene Therapy, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Foskett, JK (corresponding author), Univ Penn, Dept Physiol, B39 ANAT CHEM, Philadelphia, PA 19104 USA.	foskett@mail.med.upenn.edu	Foskett, Kevin/R-2549-2019	Foskett, J. Kevin/0000-0002-8854-0268				AIBA A, 1994, CELL, V79, P377, DOI 10.1016/0092-8674(94)90204-6; ALBALDAWI NF, 1993, J PHYSIOL-LONDON, V461, P633, DOI 10.1113/jphysiol.1993.sp019533; Babcock DF, 1998, CURR OPIN NEUROBIOL, V8, P398, DOI 10.1016/S0959-4388(98)80067-6; Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; BEZPROZVANNY I, 1993, NEURON, V10, P1175, DOI 10.1016/0896-6273(93)90065-Y; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BOOTMAN MD, 1994, MOL CELL ENDOCRINOL, V98, P157, DOI 10.1016/0303-7207(94)90134-1; Carter TD, 1997, J PHYSIOL-LONDON, V504, P17, DOI 10.1111/j.1469-7793.1997.00017.x; CONQUET F, 1994, NATURE, V372, P237, DOI 10.1038/372237a0; CORKEY BE, 1986, J BIOL CHEM, V261, P2567; Csordas G, 1999, EMBO J, V18, P96, DOI 10.1093/emboj/18.1.96; Dufour JF, 1997, J BIOL CHEM, V272, P2675, DOI 10.1074/jbc.272.5.2675; DUNNE MJ, 1988, J MEMBRANE BIOL, V104, P165, DOI 10.1007/BF01870928; FASOLATO C, 1991, J BIOL CHEM, V266, P20159; FERRIS CD, 1990, P NATL ACAD SCI USA, V87, P2147, DOI 10.1073/pnas.87.6.2147; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; Finch EA, 1998, NATURE, V396, P753, DOI 10.1038/25541; FLATMAN PW, 1991, ANNU REV PHYSIOL, V53, P259, DOI 10.1146/annurev.ph.53.030191.001355; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; FURUICHI T, 1995, J NEUROCHEM, V64, P953, DOI 10.1046/j.1471-4159.1995.64030953.x; GAMBERUCCI A, 1994, J BIOL CHEM, V269, P23597; GIRARD S, 1993, SCIENCE, V260, P229, DOI 10.1126/science.8385801; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; Hofer AM, 1996, FASEB J, V10, P302, DOI 10.1096/fasebj.10.2.8641563; Hsu KS, 1997, BRIT J PHARMACOL, V122, P671, DOI 10.1038/sj.bjp.0701409; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; IINO M, 1991, J GEN PHYSIOL, V98, P681, DOI 10.1085/jgp.98.4.681; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; Inoue T, 1998, J NEUROSCI, V18, P5366, DOI 10.1523/JNEUROSCI.18-14-05366.1998; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.ne.12.030189.000505; JOUAVILLE LS, 1995, NATURE, V377, P438, DOI 10.1038/377438a0; Kargacin ME, 1997, AM J PHYSIOL-CELL PH, V273, pC1416; KASAI H, 1994, TRENDS NEUROSCI, V17, P95, DOI 10.1016/0166-2236(94)90112-0; KATO N, 1993, P NATL ACAD SCI USA, V90, P3650, DOI 10.1073/pnas.90.8.3650; Khodakhah K, 1997, P NATL ACAD SCI USA, V94, P14009, DOI 10.1073/pnas.94.25.14009; KLINGENBERG M, 1980, J MEMBRANE BIOL, V56, P97, DOI 10.1007/BF01875961; Komatsu Y, 1996, J NEUROSCI, V16, P6342; KUME S, 1993, CELL, V73, P555, DOI 10.1016/0092-8674(93)90142-D; Landolfi B, 1998, J CELL BIOL, V142, P1235, DOI 10.1083/jcb.142.5.1235; LINDEN DJ, 1995, ANNU REV NEUROSCI, V18, P319, DOI 10.1146/annurev.ne.18.030195.001535; LLANO I, 1994, NEURON, V12, P663, DOI 10.1016/0896-6273(94)90221-6; LOEW LM, 1994, P NATL ACAD SCI USA, V91, P12579, DOI 10.1073/pnas.91.26.12579; Maechler P, 1998, FEBS LETT, V422, P328, DOI 10.1016/S0014-5793(97)01618-9; MAEDA N, 1991, J BIOL CHEM, V266, P1109; Mak DOD, 1998, AM J PHYSIOL-CELL PH, V275, pC179, DOI 10.1152/ajpcell.1998.275.1.C179; MAK DOD, 1994, J BIOL CHEM, V269, P29375; Mak DOD, 1997, J GEN PHYSIOL, V109, P571, DOI 10.1085/jgp.109.5.571; Mak DOD, 1998, P NATL ACAD SCI USA, V95, P15821, DOI 10.1073/pnas.95.26.15821; MARRIOTT I, 1995, AM J PHYSIOL-CELL PH, V269, pC766, DOI 10.1152/ajpcell.1995.269.3.C766; MARSHALL ICB, 1993, J BIOL CHEM, V268, P13214; MARTINEZSERRANO A, 1992, MOL BIOL CELL, V3, P235, DOI 10.1091/mbc.3.2.235; MCCORMACK JG, 1993, DEV NEUROSCI-BASEL, V15, P165, DOI 10.1159/000111332; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; MEYER T, 1988, SCIENCE, V240, P653, DOI 10.1126/science.2452482; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MIKOSHIBA K, 1993, TRENDS PHARMACOL SCI, V14, P86, DOI 10.1016/0165-6147(93)90069-V; Missiaen L, 1997, BIOCHEM J, V325, P661, DOI 10.1042/bj3250661; Missiaen L, 1998, J BIOL CHEM, V273, P8983, DOI 10.1074/jbc.273.15.8983; Miyakawa T, 1999, EMBO J, V18, P1303, DOI 10.1093/emboj/18.5.1303; NAGATA E, 1994, NEUROSCIENCE, V61, P983, DOI 10.1016/0306-4522(94)90418-9; Otani S, 1998, J PHYSIOL-LONDON, V511, P761, DOI 10.1111/j.1469-7793.1998.761bg.x; OTSU H, 1990, CELL STRUCT FUNCT, V15, P163, DOI 10.1247/csf.15.163; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1994, J CELL BIOL, V126, P1183, DOI 10.1083/jcb.126.5.1183; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; Robb-Gaspers LD, 1998, BBA-BIOENERGETICS, V1366, P17, DOI 10.1016/S0005-2728(98)00118-2; Robb-Gaspers LD, 1998, EMBO J, V17, P4987, DOI 10.1093/emboj/17.17.4987; Rutter GA, 1996, P NATL ACAD SCI USA, V93, P5489, DOI 10.1073/pnas.93.11.5489; SATOH T, 1990, J CELL BIOL, V111, P615, DOI 10.1083/jcb.111.2.615; Simpson PB, 1996, J BIOL CHEM, V271, P33493, DOI 10.1074/jbc.271.52.33493; Simpson PB, 1997, J BIOL CHEM, V272, P22654, DOI 10.1074/jbc.272.36.22654; STEHNOBITTEL L, 1995, NEURON, V14, P163, DOI 10.1016/0896-6273(95)90250-3; Takei K, 1998, SCIENCE, V282, P1705, DOI 10.1126/science.282.5394.1705; TAYLOR CW, 1995, J MEMBRANE BIOL, V145, P109; TAYLOR CW, 1991, PHARMACOL THERAPEUT, V51, P97, DOI 10.1016/0163-7258(91)90043-L; Tekkok S, 1996, J NEUROPHYSIOL, V76, P2343, DOI 10.1152/jn.1996.76.4.2343; TOESCU EC, 1995, AM J PHYSIOL-GASTR L, V269, pG173, DOI 10.1152/ajpgi.1995.269.2.G173	81	83	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22231	22237		10.1074/jbc.274.32.22231	http://dx.doi.org/10.1074/jbc.274.32.22231			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428789	hybrid			2022-12-25	WOS:000081868400019
J	Wang, Y; Knudsen, BR; Bjergbaek, L; Westergaard, O; Andersen, AH				Wang, Y; Knudsen, BR; Bjergbaek, L; Westergaard, O; Andersen, AH			Stimulated activity of human topoisomerases II alpha and II beta on RNA-containing substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA TOPOISOMERASE; MEDIATED CLEAVAGE; INTERMEDIATE; LOCALIZATION; GENE	Eukaryotic topoisomerase II is a dimeric nuclear enzyme essential for DNA metabolism and chromosome dynamics. Central to the activities of the enzyme is its ability to introduce transient double-stranded breaks in the DNA helix, where the two subunits of the, enzyme become covalently attached to the generated 5'-ends through phosphotyrosine linkages. Here, we demonstrate that human topoisomerases II alpha and II beta are able to cleave ribonucleotide-containing substrates, With suicide substrates, which are partially double-stranded molecules containing a 5'-recessed strand, cleavage of both strands was stimulated similar to 8-fold when a ribonucleotide rather than a deoxyribonucleotide was present at the scissile phosphodiester of the recessed strand. The existence of a ribonucleotide at the same position in a normal duplex substrate also enhanced topoisomerase II-mediated cleavage, although to a lesser extent. The enzyme covalently linked to the 5'-ribonucleotide in the cleavage complex efficiently performed ligation, and ligation occurred equally well to acceptor molecules terminated by either a 3'-ribo- or deoxyribonucleotide. Besides the enhanced topoisomerase II-mediated cleavage of ribonucleotide-containing substrates, cleavage of such substrates could be further stimulated by ATP or antitumor drugs. In conclusion, the observed in vitro activities of the human topoisomerase II isoforms indicate that the enzymes can operate on RNA or RNA-containing substrates and thus might possess an intrinsic RNA topoisomerase activity, as has previously been demonstrated for Escherichia coli topoisomerase III.	Aarhus Univ, Dept Biol Mol & Struct, DK-8000 Aarhus C, Denmark	Aarhus University	Andersen, AH (corresponding author), Aarhus Univ, Dept Biol Mol & Struct, CF Mollers Alle,Bldg 130, DK-8000 Aarhus C, Denmark.		Bjergbæk, Lotte/AAW-6302-2021; Andersen, Anni/O-1162-2017	Knudsen, Birgitta Ruth/0000-0002-3484-3802; Bjergbaek, Lotte/0000-0002-8233-3356; Andersen, Anni/0000-0001-7194-3258				Andersen A H, 1994, Adv Pharmacol, V29A, P83; ANDERSEN AH, 1991, J BIOL CHEM, V266, P9203; ANDERSEN AH, 1989, BIOCHEMISTRY-US, V28, P6237, DOI 10.1021/bi00441a015; Biersack H, 1996, P NATL ACAD SCI USA, V93, P8288, DOI 10.1073/pnas.93.16.8288; Burgin AB, 1997, CELL, V91, P873, DOI 10.1016/S0092-8674(00)80478-X; DIGATE RJ, 1992, J BIOL CHEM, V267, P20532; GALE KC, 1990, BIOCHEMISTRY-US, V29, P9538, DOI 10.1021/bi00493a007; JENKINS JR, 1992, NUCLEIC ACIDS RES, V20, P5587, DOI 10.1093/nar/20.21.5587; LIU LF, 1983, J BIOL CHEM, V258, P5365; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LUND K, 1990, J BIOL CHEM, V265, P13856; MAXWELL A, 1986, ADV PROTEIN CHEM, V38, P69, DOI 10.1016/S0065-3233(08)60526-4; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P4303, DOI 10.1021/bi00388a018; OSHEROFF N, 1989, PHARMACOL THERAPEUT, V41, P223, DOI 10.1016/0163-7258(89)90108-3; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; SANDER M, 1983, J BIOL CHEM, V258, P8421; SCHMIDT VK, 1994, J MOL BIOL, V241, P18, DOI 10.1006/jmbi.1994.1469; Sekiguchi J, 1997, J BIOL CHEM, V272, P15721, DOI 10.1074/jbc.272.25.15721; Sekiguchi J, 1997, MOL CELL, V1, P89, DOI 10.1016/S1097-2765(00)80010-6; SHUMAN S, 1993, J BIOL CHEM, V268, P18943; TSAIPFLUGFELDER M, 1988, P NATL ACAD SCI USA, V85, P7177, DOI 10.1073/pnas.85.19.7177; VOSBERG HP, 1985, CURR TOP MICROBIOL, V114, P19; Wang H, 1996, P NATL ACAD SCI USA, V93, P9477, DOI 10.1073/pnas.93.18.9477; WANG JC, 1987, BIOCHIM BIOPHYS ACTA, V909, P1, DOI 10.1016/0167-4781(87)90040-6; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681; Xu CJ, 1998, MOL CELL, V1, P729, DOI 10.1016/S1097-2765(00)80072-6; ZECHIEDRICH EL, 1989, BIOCHEMISTRY-US, V28, P6229, DOI 10.1021/bi00441a014	30	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22839	22846		10.1074/jbc.274.32.22839	http://dx.doi.org/10.1074/jbc.274.32.22839			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428869	hybrid			2022-12-25	WOS:000081868400099
J	Gelkop, S; Isakov, N				Gelkop, S; Isakov, N			T cell activation stimulates the association of enzymatically active tyrosine-phosphorylated ZAP-70 with the Crk adapter proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; C-CBL PROTOONCOGENE; ANTIGEN RECEPTOR; V-CRK; SH2 DOMAINS; SIGNAL-TRANSDUCTION; ZETA-CHAIN; PC12 CELLS; KINASE; COMPLEXES	Engagement of the T cell antigen receptor initiates signal transduction involving tyrosine phosphorylation of multiple effector molecules and the formation of multimolecular complexes at the receptor site. Adapter proteins that possess SH2 and SH3 protein-protein interaction domains are implicated in the assembly of cell activation-induced signaling complexes. We found that Crk adapter proteins undergo activation-induced interaction with the zeta-chain associated protein (ZAP-70) tyrosine kinase in the human T cell line, Jurkat, Incubation of various glutathione S-transferase fusion proteins with a lysate of activated Jurkat cells resulted in selective association of ZAP-70 with Crk, but not Grb2 or Nck, adapter proteins. In addition, tyrosine-phosphorylated ZAP-70 co-immunoprecipitated with Crk from a lysate of activated Jurkat cells, and ZAP-70 association with GST-Crk was observed in a lysate of activated human peripheral blood T cells. Association between the two molecules was mediated by direct physical interaction and involved the Crk-SH2 domain and phosphotyrosyl-containing sequences on ZAP-70. The association required intact Lck, considered to be an upstream regulator of ZAP-70, because it could not take place in activated JCaM1 cells, which express normal levels of ZAP-70 but are devoid of Lck. Finally, glutathione S-transferase-Crk fusion proteins were found to interact predominantly with membrane-residing tyrosine-phosphorylated ZAP-70 that exhibited autophosphorylation activity as well as phosphorylation of an exogenous substrate, CFB3. These findings suggest that Crk adapter proteins play a role in the early activation events of T lymphocytes, apparently, by direct interaction with, and regulation of, the membrane-residing ZAP-70 protein tyrosine kinase.	Ben Gurion Univ Negev, Fac Hlth Sci, Dept Microbiol & Immunol, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Canc Res Ctr, IL-84105 Beer Sheva, Israel	Ben Gurion University; Ben Gurion University	Isakov, N (corresponding author), Ben Gurion Univ Negev, Fac Hlth Sci, Dept Microbiol & Immunol, POB 653, IL-84105 Beer Sheva, Israel.	noah@bgumail.bgu.ac.il	ISAKOV, NOAH/F-1659-2012	Isakov, Noah/0000-0002-1412-0957				Altun-Gultekin ZF, 1998, MOL CELL BIOL, V18, P3044, DOI 10.1128/MCB.18.5.3044; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; Astier A, 1997, LEUKEMIA LYMPHOMA, V28, P65, DOI 10.3109/10428199709058332; BANIYASH M, 1988, J BIOL CHEM, V263, P18225; Barber DL, 1997, BLOOD, V89, P3166, DOI 10.1182/blood.V89.9.3166; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; Bocciardi R, 1997, ONCOGENE, V15, P2257, DOI 10.1038/sj.onc.1201413; BOHUSLAV J, 1993, EUR J IMMUNOL, V23, P825, DOI 10.1002/eji.1830230409; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; Evans EK, 1997, EMBO J, V16, P230, DOI 10.1093/emboj/16.2.230; Gesbert F, 1998, J BIOL CHEM, V273, P3986, DOI 10.1074/jbc.273.7.3986; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; HARIHARAN IK, 1991, CELL, V67, P717, DOI 10.1016/0092-8674(91)90066-8; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; Hock B, 1998, ONCOGENE, V17, P255, DOI 10.1038/sj.onc.1201907; Huby RDJ, 1997, J CELL BIOL, V137, P1639, DOI 10.1083/jcb.137.7.1639; Ingham RJ, 1996, J BIOL CHEM, V271, P32306, DOI 10.1074/jbc.271.50.32306; Isakov N, 1998, ADV IMMUNOL, V69, P183, DOI 10.1016/S0065-2776(08)60608-2; ISAKOV N, 1995, J EXP MED, V181, P375, DOI 10.1084/jem.181.1.375; Isakov N, 1996, J BIOL CHEM, V271, P15753, DOI 10.1074/jbc.271.26.15753; ISAKOV N, 1994, J LEUKOCYTE BIOL, V55, P265, DOI 10.1002/jlb.55.2.265; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KATZAV S, 1994, J BIOL CHEM, V269, P32579; KizakaKondoh S, 1996, P NATL ACAD SCI USA, V93, P12177, DOI 10.1073/pnas.93.22.12177; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; MADRENAS J, 1995, SCIENCE, V267, P515, DOI 10.1126/science.7824949; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Ohashi Y, 1998, J BIOL CHEM, V273, P6446, DOI 10.1074/jbc.273.11.6446; Okada S, 1998, EMBO J, V17, P2554, DOI 10.1093/emboj/17.9.2554; QIAN DP, 1993, J BIOL CHEM, V268, P4488; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; Sawasdikosol S, 1996, J IMMUNOL, V157, P110; SCHUMACHER C, 1995, J BIOL CHEM, V270, P15341, DOI 10.1074/jbc.270.25.15341; Senechal K, 1998, MOL CELL BIOL, V18, P5082, DOI 10.1128/MCB.18.9.5082; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; SloanLancaster J, 1997, J EXP MED, V186, P1713, DOI 10.1084/jem.186.10.1713; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; Smit L, 1996, ONCOGENE, V13, P381; Smit L, 1996, J BIOL CHEM, V271, P8564, DOI 10.1074/jbc.271.15.8564; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Sorokin A, 1998, ONCOGENE, V16, P2425, DOI 10.1038/sj.onc.1201781; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TENG KK, 1995, J BIOL CHEM, V270, P20677, DOI 10.1074/jbc.270.35.20677; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wang BL, 1996, ONCOGENE, V13, P1379; WANGE RL, 1995, J BIOL CHEM, V270, P18730, DOI 10.1074/jbc.270.32.18730; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Yokote K, 1998, ONCOGENE, V16, P1229, DOI 10.1038/sj.onc.1201641; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	67	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21519	21527		10.1074/jbc.274.31.21519	http://dx.doi.org/10.1074/jbc.274.31.21519			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419455	hybrid			2022-12-25	WOS:000081721100008
J	Korkotian, E; Schwarz, A; Pelled, D; Schwarzmann, G; Segal, M; Futerman, AH				Korkotian, E; Schwarz, A; Pelled, D; Schwarzmann, G; Segal, M; Futerman, AH			Elevation of intracellular glucosylceramide levels results in an increase in endoplasmic reticulum density and in functional calcium stores in cultured neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIPPOCAMPAL-NEURONS; GAUCHER DISEASE; GOLGI-APPARATUS; INOSITOL TRISPHOSPHATE; SPHINGOLIPID SYNTHESIS; DENDRITE GROWTH; CELLS; INHIBITION; CERAMIDE; INTERNALIZATION	Gaucher disease is a glycosphingolipid storage disease caused by defects in the activity of the lysosomal hydrolase, glucocerebrosidase (GlcCerase), resulting in accumulation of glucocerebroside (glucosylceramide, GlcCer) in lysosomes, The acute neuronopathic type of the disease is characterized by severe loss of neurons in the central nervous system, suggesting that a neurotoxic agent might be responsible for cellular disruption and neuronal death. We now demonstrate that upon incubation with a chemical inhibitor of GlcCerase, conduritol-B-epoxide (CBE), cultured hippocampal neurons accumulate GlcCer, Surprisingly, increased levels of tubular endoplasmic reticulum elements, an increase in [Ca2+](i) response to glutamate, and a large increase in [Ca2+](i) release from the endoplasmic reticulum in response to caffeine were detected in these cells. There was a direct relationship between these effects and GlcCer accumulation since co-incubation with CBE and an inhibitor of glycosphingolipid synthesis, fumonisin B-1, completely antagonized the effects of CBE, Similar effects on endoplasmic reticulum morphology and [Ca2+](i) stores were observed upon incubation with a short-acyl chain, nonhydrolyzable analogue of GlcCer, C-8-glucosylthioceramide. Finally, neurons with elevated GlcCer levels were much more sensitive to the neurotoxic effects of high concentrations of glutamate than control cells; moreover, this enhanced toxicity was blocked by pre-incubation with ryanodine, suggesting that [Ca2+](i) release from ryanodine-sensitive intracellular stores can induce neuronal cell death, at least in neurons with elevated GlcCer levels. These results may provide a molecular mechanism to explain neuronal dysfunction and cell death in neuronopathic forms of Gaucher disease.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; Univ Bonn, Kekule Inst Organ Chem & Biochem, D-53121 Bonn, Germany	Weizmann Institute of Science; Weizmann Institute of Science; University of Bonn	Futerman, AH (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	bmfuter@weizmann.weizmann.ac.il	Korkotian, Eduard/K-1744-2012; Korkotian, Eduard/P-4559-2019; SEGAL, MENAHEM/K-1577-2012	Korkotian, Eduard/0000-0001-5515-3387; Futerman, Anthony/0000-0003-0013-0115				ADACHI M, 1967, ARCH PATHOL, V83, P513; ADACHI M, 1977, ARCH PATHOL LAB MED, V101, P255; ALBRECHT B, 1995, CARBOHYD RES, V276, P289, DOI 10.1016/0008-6215(95)00189-Z; BARRANGER JA, 1989, GLUCOSYLCERAMIDE LIP; Betto R, 1997, BIOCHEM J, V322, P327, DOI 10.1042/bj3220327; Beutler E., 1995, METABOLIC MOL BASES, P2641; BIERBERICH E, 1999, J NEUROCHEM, V72, P1040; Boldin S, 1997, J NEUROCHEM, V68, P882; BORGES JS, 1995, EUR J OPHTHALMOL, V5, P69; DEBER CM, 1986, BIOCHEM BIOPH RES CO, V134, P731, DOI 10.1016/S0006-291X(86)80481-8; DYER CA, 1991, J NEUROSCI RES, V30, P699, DOI 10.1002/jnr.490300414; FIELDS A, 1995, BRAIN RES, V687, P94, DOI 10.1016/0006-8993(95)00475-6; Furuya S, 1996, J LIPID MEDIAT CELL, V14, P303, DOI 10.1016/0929-7855(96)00539-1; Futerman AH, 1998, BIOCHEMISTRY-MOSCOW+, V63, P74; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; Goslin K., 1998, CULTURING NERVE CELL, P339; HAREL R, 1993, J BIOL CHEM, V268, P14476; Hirschberg K, 1996, J BIOL CHEM, V271, P14876, DOI 10.1074/jbc.271.25.14876; HIRSCHBERG K, 1993, BIOCHEM J, V290, P751, DOI 10.1042/bj2900751; KAYE EM, 1986, ANN NEUROL, V20, P223, DOI 10.1002/ana.410200208; Korkotian E, 1997, J NEUROSCI, V17, P1670; Korkotian E, 1998, EUR J NEUROSCI, V10, P2076, DOI 10.1046/j.1460-9568.1998.00219.x; LEE C, 1988, CELL, V54, P37, DOI 10.1016/0092-8674(88)90177-8; Legler G, 1977, Methods Enzymol, V46, P368; MAHDIYOUN S, 1992, ARCH BIOCHEM BIOPHYS, V292, P506, DOI 10.1016/0003-9861(92)90023-P; MARTIN OC, 1994, J CELL BIOL, V125, P769, DOI 10.1083/jcb.125.4.769; MATTIE M, 1994, J BIOL CHEM, V269, P3181; MEIVARLEVY I, 1994, BIOCHEM J, V303, P377, DOI 10.1042/bj3030377; Merrill AH, 1996, TRENDS CELL BIOL, V6, P218, DOI 10.1016/0962-8924(96)10021-0; NAVARRO JC, 1990, CLIN NEUROPATHOL, V9, P310; NILSSON O, 1982, J NEUROCHEM, V39, P709, DOI 10.1111/j.1471-4159.1982.tb07950.x; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; Platt FM, 1997, SCIENCE, V276, P428, DOI 10.1126/science.276.5311.428; Prence EM, 1996, J NEUROSCI RES, V43, P365, DOI 10.1002/(SICI)1097-4547(19960201)43:3<365::AID-JNR11>3.0.CO;2-4; Samuel N, 1997, NEUROSCI LETT, V222, P179, DOI 10.1016/S0304-3940(97)13377-8; Schwarz A, 1998, DEV BRAIN RES, V108, P125, DOI 10.1016/S0165-3806(98)00041-8; SCHWARZ A, 1995, J BIOL CHEM, V270, P10990, DOI 10.1074/jbc.270.18.10990; Schwarz A, 1997, J NEUROSCI, V17, P2929; SCHWARZMANN G, 1995, J BIOL CHEM, V270, P21271, DOI 10.1074/jbc.270.36.21271; SHAYMAN JA, 1990, J BIOL CHEM, V265, P12135; Shoshan-Barmatz V, 1998, INT REV CYTOL, V183, P185, DOI 10.1016/S0074-7696(08)60145-X; Sofer A, 1996, J CELL SCI, V109, P2111; SOFER A, 1995, J BIOL CHEM, V270, P12117, DOI 10.1074/jbc.270.20.12117; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; TRINCHERA M, 1991, J BIOL CHEM, V266, P9093; Wells KM, 1998, J BIOL CHEM, V273, P5020, DOI 10.1074/jbc.273.9.5020	46	151	155	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21673	21678		10.1074/jbc.274.31.21673	http://dx.doi.org/10.1074/jbc.274.31.21673			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419477	hybrid			2022-12-25	WOS:000081721100030
J	Laufs, U; Marra, D; Node, K; Liao, JK				Laufs, U; Marra, D; Node, K; Liao, JK			3-hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing Rho GTPase-induced down-regulation of p27(Kip1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; HMG-COA REDUCTASE; CELL-CYCLE; MEVALONATE PATHWAY; S-PHASE; RAS; PROTEIN; GROWTH; G(1); PROGRESSION	The mechanism by which platelet-derived growth factor (PDGF) regulates vascular smooth muscle cell (SMC) DNA synthesis is unknown, but may involve isoprenoid intermediates of the cholesterol biosynthetic pathway. Inhibition of isoprenoid synthesis with the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor, simvastatin (Sim, 1-10 mu M), inhibited PDGF-induced SMC DNA synthesis by >95%, retinoblastoma gene product hyperphosphorylation by 90%, and cyclin-dependent kinases (cdk)-2, -4, and -6 activity by 80 +/- 5, 50 +/- 3, and 48 +/- 3%, respectively. This correlated with a 20-fold increase in p27(Kip1) without changes in p16, p21(Waf1), Or p53 levels compared with PDGF alone. Since Ras and Rho require isoprenoid modification for membrane localization and are implicated in cell cycle regulation, we investigated the effects of Sim on Ras and Rho. Up-regulation of p27(Kip1) and inhibition of Rho but not Ras membrane translocation by Sim were reversed by geranylgeranylpyrophosphate, but not farnesylpyrophosphate. In. deed, inhibition of Rho by Clostridium botulinum C3 transferase or overexpression of dominant-negative N19RhoA mutant increased p27(Kip1) and inhibited retinoblastoma hyperphosphorylation. In contrast, activation of Rho by Escherichia coli cytotoxic necrotizing factor-1 decreased p27(Kip1) and increased SMC DNA synthesis. These findings indicate that the down-regulation of p27(Kip1) by Rho GTPase mediates PDGF-induced SMC DNA synthesis and suggest a novel direct effect of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors on the vascular wall.	Harvard Univ, Brigham & Womens Hosp, Sch Med,Div Cardiovasc, Vasc Med & Atherosclerosis Unit, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Liao, JK (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med,Div Cardiovasc, Vasc Med & Atherosclerosis Unit, 221 Longwood Ave,LMRC-322, Boston, MA 02115 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052233] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-52233] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKTORIES K, 1997, J CLIN INVEST, V12, pS11; Braun-Dullaeus RC, 1998, CIRCULATION, V98, P82, DOI 10.1161/01.CIR.98.1.82; CASEY BJ, 1995, NEUROIMAGE, V2, P221, DOI 10.1006/nimg.1995.1029; CORSINI A, 1993, ATHEROSCLEROSIS, V101, P117, DOI 10.1016/0021-9150(93)90107-6; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; Gebbink MFBG, 1997, J CELL BIOL, V137, P1603, DOI 10.1083/jcb.137.7.1603; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Gosser YQ, 1997, NATURE, V387, P814, DOI 10.1038/42961; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Hirai A, 1997, J BIOL CHEM, V272, P13; HOHL RJ, 1995, J BIOL CHEM, V270, P17508, DOI 10.1074/jbc.270.29.17508; Laufs U, 1998, J BIOL CHEM, V273, P24266, DOI 10.1074/jbc.273.37.24266; Laufs U, 1998, CIRCULATION, V97, P1129, DOI 10.1161/01.CIR.97.12.1129; Lee SJ, 1998, J BIOL CHEM, V273, P10618, DOI 10.1074/jbc.273.17.10618; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lukas J, 1996, MOL CELL BIOL, V16, P6917; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; Noguchi Y, 1998, J BIOL CHEM, V273, P3649, DOI 10.1074/jbc.273.6.3649; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; PENDERGAST GC, 1995, ONCOGENE, V10, P2289; PSICKER M, 1997, J BIOL CHEM, V272, P30969; RASBAND W, 1993, NIH IMAGE PROGRAM VE; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shin WS, 1996, J BIOL CHEM, V271, P11317, DOI 10.1074/jbc.271.19.11317; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Vogt A, 1996, ONCOGENE, V13, P1991; Weber JD, 1997, J BIOL CHEM, V272, P32966, DOI 10.1074/jbc.272.52.32966; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wenke K, 1997, CIRCULATION, V96, P1398, DOI 10.1161/01.CIR.96.5.1398	35	360	375	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21926	21931		10.1074/jbc.274.31.21926	http://dx.doi.org/10.1074/jbc.274.31.21926			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419514	hybrid			2022-12-25	WOS:000081721100067
J	Nishida, Y; Knudson, CB; Nietfeld, JJ; Margulis, A; Knudson, W				Nishida, Y; Knudson, CB; Nietfeld, JJ; Margulis, A; Knudson, W			Antisense inhibition of hyaluronan synthase-2 in human articular chondrocytes inhibits proteoglycan retention and matrix assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERICELLULAR MATRICES; CARTILAGE; EXPRESSION; CLONING; CD44; IMMOBILIZATION; PROTEIN; CELLS; GENES; CDNA	In order to define the role of cell-associated hyaluronan in cartilage matrix retention, human articular chondrocytes as well as cartilage slices were treated with phosphorothioate oligonucleotides comprised of sequence antisense to the mRNA of human HA synthase-2 (HAS-2), As a prerequisite for these studies, it was necessary to determine which HA synthase (HAS), of three separate human genes capable of synthesizing HA, designated HAS-1, HAS-2, or HAS-3, is primarily responsible for HA synthesis in human articular chondrocytes, The copy number of each HAS mRNA expressed in cultured human articular chondrocytes was determined using quantitative (competitive) reverse transcription-polymerase chain reaction (RT-PCR), Only HAS-2 and HAS-3 mRNA expression was detected. The level of HAS-2 mRNA expression was 40-fold higher than that of HAS-3. Cultures of human articular chondrocytes and cartilage tissue slices were then transfected with HAS-2-specific antisense oligonucleotides. This treatment resulted in time-dependent inhibition of HAS-2 mRNA expression, as measured by quantitative RT-PCR, and a significant loss of cell-associated HA staining. Sense and reverse HAS-2 oligonucleotides showed no effect. The consequences of reduced HA levels (due to HAS-2 antisense inhibition) were a decrease in the diameter of the cell-associated matrix and a decreased capacity to retain newly synthesized proteoglycan, These results suggest that HA synthesized by HAS-2 plays a crucial role in matrix assembly and retention by human articular chondrocytes.	Rush Med Coll, Rush Presbyterian St Lukes Med Ctr, Dept Biochem, Chicago, IL 60612 USA; Univ Amsterdam, Dept Periodontol, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Dept Cell Biol, NL-1105 AZ Amsterdam, Netherlands	Rush University; University of Amsterdam; University of Amsterdam	Knudson, W (corresponding author), Rush Med Coll, Rush Presbyterian St Lukes Med Ctr, Dept Biochem, 1653 W Congress Pkwy, Chicago, IL 60612 USA.	wknudson@rush.edu	Nishida, Yoshihiro/I-7354-2014		NIAMS NIH HHS [R01 AR043384, R01-AR39507, R01-AR43384, P50-AR39239, R01 AR039507] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039507, R01AR043384, P50AR039239] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AYDELOTTE MB, 1988, CONNECT TISSUE RES, V18, P223, DOI 10.3109/03008208809016809; AYDELOTTE MB, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P237; BEHRENS F, 1989, J ORTHOPAED RES, V7, P335, DOI 10.1002/jor.1100070305; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; BUCKWALTER JA, 1982, J BIOL CHEM, V257, P9830; CELI FS, 1993, NUCLEIC ACIDS RES, V21, P1047, DOI 10.1093/nar/21.4.1047; CHOW G, 1995, J BIOL CHEM, V270, P27734, DOI 10.1074/jbc.270.46.27734; Chow G, 1998, ARTHRITIS RHEUM-US, V41, P1411, DOI 10.1002/1529-0131(199808)41:8<1411::AID-ART10>3.0.CO;2-Z; DIVIACCO S, 1992, GENE, V122, P313, DOI 10.1016/0378-1119(92)90220-J; Fulop C, 1997, ARCH BIOCHEM BIOPHYS, V337, P261, DOI 10.1006/abbi.1996.9793; Haapala J, 1996, J RHEUMATOL, V23, P1586; Hauselmann H. J., 1992, ARTICULAR CARTILAGE, P701; HAUSELMANN HJ, 1994, J CELL SCI, V107, P17; HUA Q, 1993, J CELL SCI, V106, P365; Itano N, 1996, J BIOL CHEM, V271, P9875, DOI 10.1074/jbc.271.17.9875; KNUDSON CB, 1993, J CELL BIOL, V120, P825, DOI 10.1083/jcb.120.3.825; Knudson W, 1996, EXP CELL RES, V228, P216, DOI 10.1006/excr.1996.0320; KNUDSON W, 1993, P NATL ACAD SCI USA, V90, P4003, DOI 10.1073/pnas.90.9.4003; KNUDSON W, 1991, J CELL SCI, V99, P227; KUETTNER KE, 1994, RHEUMATOLOGY; LEONETTI JP, 1991, P NATL ACAD SCI USA, V88, P2702, DOI 10.1073/pnas.88.7.2702; MANKIN HJ, 1971, J BONE JOINT SURG AM, VA 53, P523, DOI 10.2106/00004623-197153030-00009; MASUDA K, 1994, ANAL BIOCHEM, V217, P167, DOI 10.1006/abio.1994.1105; PALMOSKI M, 1979, ARTHRITIS RHEUM, V22, P508, DOI 10.1002/art.1780220511; PITA JC, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P455; PREHM P, 1984, BIOCHEM J, V220, P597, DOI 10.1042/bj2200597; Shyjan AM, 1996, J BIOL CHEM, V271, P23395, DOI 10.1074/jbc.271.38.23395; Spicer AP, 1997, GENOMICS, V41, P493, DOI 10.1006/geno.1997.4696; Spicer AP, 1998, J BIOL CHEM, V273, P1923, DOI 10.1074/jbc.273.4.1923; Spicer AP, 1997, J BIOL CHEM, V272, P8957; Sugiyama Y, 1998, J INVEST DERMATOL, V110, P116, DOI 10.1046/j.1523-1747.1998.00093.x; Tlapak-Simmons VL, 1998, J BIOL CHEM, V273, P26100, DOI 10.1074/jbc.273.40.26100; Watanabe K, 1996, J BIOL CHEM, V271, P22945, DOI 10.1074/jbc.271.38.22945; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997	34	98	109	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21893	21899		10.1074/jbc.274.31.21893	http://dx.doi.org/10.1074/jbc.274.31.21893			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419509	hybrid			2022-12-25	WOS:000081721100062
J	Tseng, M; Palaniyar, N; Zhang, WD; Evans, DH				Tseng, M; Palaniyar, N; Zhang, WD; Evans, DH			DNA binding and aggregation properties of the vaccinia virus I3L gene product	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; POXVIRUS-INFECTED CELLS; HOMOLOGOUS RECOMBINATION; BETA-PROTEIN; REPLICATION; RENATURATION; EXCHANGE; COMPLEXES; DOMAIN; ICP8	The vaccinia virus I3L gene encodes a single-stranded DNA-binding protein which may play a role in viral replication and genetic recombination. We have purified native and recombinant forms of gpI3L and characterized both the DNA-binding reaction and the structural properties of DNA-protein complexes. The purified proteins displayed anomalous electrophoretic properties in the presence of sodium dodecyl sulfate, behaving as if they were 4-kDa larger than the true mass. Agarose gel shift analysis was used to monitor the formation of complexes composed of single-stranded DNA plus gpI3L protein, These experiments detected two different DNA binding modes whose formation was dependent upon the protein density. The transition between the two binding modes occurred at a nucleotide to protein ratio of about 31 nucleotides per gpI3L monomer, S1 nuclease protection assay revealed that at saturating protein densities, each gpI3L monomer occludes 9.5 +/- 2.5 nucleotides, In the presence of magnesium, gpI3L promoted the formation of large DNA aggregates from which double-stranded DNA was excluded. Electron microscopy showed that, in the absence of magnesium and at low protein densities, gpI3L forms beaded structures on DNA. At high protein density the complexes display a smoother and less compacted morphology, In the presence of magnesium the complexes contained long fibrous and tangled arrays. These results suggest that gpI3L can form octameric complexes on DNA much like those formed by Escherichia coli single-stranded DNA protein. Moreover, the capacity to aggregate DNA may provide an environment in which hybrid DNA formation could occur during DNA replication.	Univ Guelph, Dept Mol Biol & Genet, Guelph, ON N1G 2W1, Canada	University of Guelph	Evans, DH (corresponding author), Univ Guelph, Dept Mol Biol & Genet, Guelph, ON N1G 2W1, Canada.	dhevans@uoguelph.ca	Evans, David H/M-1912-2016	Evans, David H/0000-0001-5871-299X; Palaniyar, Nades/0000-0002-2170-8548; Zhang, Wandong/0000-0001-6412-8124				ALANI E, 1992, J MOL BIOL, V227, P54, DOI 10.1016/0022-2836(92)90681-9; Alberts B.M., 1971, METHODS ENZYMOL, V21, P198; BEAUD G, 1995, J VIROL, V69, P1819, DOI 10.1128/JVI.69.3.1819-1826.1995; Bochkarev A, 1997, NATURE, V385, P176, DOI 10.1038/385176a0; BORTNER C, 1993, J MOL BIOL, V231, P241, DOI 10.1006/jmbi.1993.1279; BUJALOWSKI W, 1988, J BIOL CHEM, V263, P4629; CANTOR CR, 1980, BIOPHYSICAL CHEM 1; CHRYSOGELOS S, 1982, P NATL ACAD SCI-BIOL, V79, P5803, DOI 10.1073/pnas.79.19.5803; DAVIS RE, 1993, P NATL ACAD SCI USA, V90, P745, DOI 10.1073/pnas.90.2.745; DELANGE AM, 1986, P NATL ACAD SCI USA, V83, P614, DOI 10.1073/pnas.83.3.614; DUTCH RE, 1993, J VIROL, V67, P6945, DOI 10.1128/JVI.67.12.6945-6949.1993; DUTCH RE, 1995, J VIROL, V69, P3084, DOI 10.1128/JVI.69.5.3084-3089.1995; EVANS DH, 1984, J BIOL CHEM, V259, P252; EVANS DH, 1988, J VIROL, V62, P367, DOI 10.1128/JVI.62.2.367-375.1988; FISHER C, 1991, GENETICS, V129, P7; GRIFFITH JD, 1984, COLD SPRING HARB SYM, V49, P553, DOI 10.1101/SQB.1984.049.01.062; HEYER WD, 1988, J BIOL CHEM, V263, P15189; KMIEC E, 1981, J BIOL CHEM, V256, P2636; Kong DC, 1996, EMBO J, V15, P2010, DOI 10.1002/j.1460-2075.1996.tb00552.x; Li Z, 1998, J MOL BIOL, V276, P733, DOI 10.1006/jmbi.1997.1572; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; MERCHLINSKY M, 1989, J VIROL, V63, P2030, DOI 10.1128/JVI.63.5.2030-2035.1989; NOWAKOWSKI M, 1978, VIROLOGY, V86, P217, DOI 10.1016/0042-6822(78)90022-3; POLISKY B, 1972, VIROLOGY, V49, P168, DOI 10.1016/S0042-6822(72)80018-7; Rochester SC, 1998, J VIROL, V72, P2917, DOI 10.1128/JVI.72.4.2917-2926.1998; SAROV I, 1973, VIROLOGY, V52, P223, DOI 10.1016/0042-6822(73)90411-X; Stahl MM, 1997, GENETICS, V147, P961; TRAKTMAN P, 1990, CURR TOP MICROBIOL, V163, P93; ZHANG WD, 1995, NUCLEIC ACIDS RES, V23, P4620; ZHANG WD, 1993, J VIROL, V67, P204, DOI 10.1128/JVI.67.1.204-212.1993	31	30	32	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21637	21644		10.1074/jbc.274.31.21637	http://dx.doi.org/10.1074/jbc.274.31.21637			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419472	hybrid			2022-12-25	WOS:000081721100025
J	Bhakar, AL; Roux, PP; Lachance, C; Kryl, D; Zeindler, C; Barker, PA				Bhakar, AL; Roux, PP; Lachance, C; Kryl, D; Zeindler, C; Barker, PA			The p75 neurotrophin receptor (p75NTR) alters tumor necrosis factor-mediated NF-kappa B activity under physiological conditions, but direct p75NTR-mediated NF-kappa B activation requires cell stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; PC12 CELLS; INTRACELLULAR DOMAIN; TARGETED DISRUPTION; SIGNAL-TRANSDUCTION; NEURONAL APOPTOSIS; TRANSGENIC MICE; FACTOR-BINDING; TRK RECEPTORS; IL-1 RECEPTOR	The p75 neurotrophin receptor (p75NTR) has been linked to activation of the NF-kappa B transcriptional complex in oligodendrocytes, Schwann cells, and PCNA cells. In this report, tumor necrosis factor (TNF)- and neurotrophin-mediated NF (nuclear factor)-kappa B activation were compared in several cell lines. All cell types showed TNF-mediated activation of NF-kappa B, but direct neurotrophin-dependent activation of NF-kappa B was never observed under normal growth conditions. In PCNA cells, a modest nerve growth factor (NGF)-dependent induction of NF-kappa B was detected but only after cells were subjected to severe stress, Although NGF binding did not directly activate NF-kappa B under normal conditions, NGF consistently altered TNF-dependent NF-kappa B activation in each cell type examined, and extended exposure to NGF and TNF always increased NF-kappa B activation over that achieved with TNF alone. The increase in NF-kappa B activity mediated by NGF correlated with reduced levels of I kappa B alpha; NGF added alone had no effect on I kappa B alpha levels, but when added with TNF, NGF treatment significantly reduced I kappa B alpha levels. We propose that modulation of cytokine receptor signaling is a significant physiological function of the p75 neurotrophin receptor and that previous reports of direct NF-kappa B activation through p75NTR reflect this modulatory activity.	McGill Univ, Montreal Neurol Inst, Ctr Neuronal Survival, Montreal, PQ H3A 2B4, Canada	McGill University	Barker, PA (corresponding author), McGill Univ, Montreal Neurol Inst, Ctr Neuronal Survival, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.		Roux, Philippe P./J-3996-2012	Roux, Philippe P./0000-0002-5962-0250				Aizawa S, 1997, J BIOL CHEM, V272, P2042; Baker SJ, 1996, ONCOGENE, V12, P1; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bamji SX, 1998, J CELL BIOL, V140, P911, DOI 10.1083/jcb.140.4.911; BARKER PA, 1993, J BIOL CHEM, V268, P15150; Barker PA, 1998, CELL DEATH DIFFER, V5, P346, DOI 10.1038/sj.cdd.4400375; BARKER PA, 1994, J BIOL CHEM, V269, P30645; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; Barrett GL, 1996, J NEUROSCI RES, V45, P117, DOI 10.1002/(SICI)1097-4547(19960715)45:2<117::AID-JNR4>3.0.CO;2-D; BENEDETTI M, 1993, P NATL ACAD SCI USA, V90, P7859, DOI 10.1073/pnas.90.16.7859; Bibel M, 1999, EMBO J, V18, P616, DOI 10.1093/emboj/18.3.616; Blochl A, 1996, J BIOL CHEM, V271, P21100; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; CHANDLER CE, 1984, J BIOL CHEM, V259, P6882; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; DOBROWSKY RT, 1995, J BIOL CHEM, V270, P22135, DOI 10.1074/jbc.270.38.22135; EMFORS P, 1994, CELL, V77, P503; Frade JM, 1999, DEVELOPMENT, V126, P683; Frade JM, 1996, NATURE, V383, P166; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Guzhova IV, 1997, CELL STRESS CHAPERON, V2, P132, DOI 10.1379/1466-1268(1997)002<0132:MSPHIW>2.3.CO;2; HANTZOPOULOS PA, 1994, NEURON, V13, P187, DOI 10.1016/0896-6273(94)90469-3; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; JONES KR, 1994, CELL, V76, P989, DOI 10.1016/0092-8674(94)90377-8; Kalli K, 1998, MOL CELL BIOL, V18, P3140, DOI 10.1128/MCB.18.6.3140; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Khursigara G, 1999, J BIOL CHEM, V274, P2597, DOI 10.1074/jbc.274.5.2597; KLEIN R, 1994, NATURE, V368, P249, DOI 10.1038/368249a0; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; Ladiwala U, 1998, J NEUROSCI, V18, P1297; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; MacPhee IJ, 1997, J BIOL CHEM, V272, P23547, DOI 10.1074/jbc.272.38.23547; MAHADEO D, 1994, J BIOL CHEM, V269, P6884; Majdan M, 1997, J NEUROSCI, V17, P6988; MARANO N, 1987, J NEUROCHEM, V48, P225, DOI 10.1111/j.1471-4159.1987.tb13151.x; MCKEAN DJ, 1995, INT IMMUNOL, V7, P9, DOI 10.1093/intimm/7.1.9; MERCER EH, 1991, NEURON, V7, P703, DOI 10.1016/0896-6273(91)90274-4; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Sandberg M, 1997, J VIROL, V71, P4649, DOI 10.1128/JVI.71.6.4649-4656.1997; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; SINGH S, 1995, J BIOL CHEM, V270, P10631, DOI 10.1074/jbc.270.18.10631; SMEYNE RJ, 1994, NATURE, V368, P246, DOI 10.1038/368246a0; VERDI JM, 1994, NEURON, V12, P733, DOI 10.1016/0896-6273(94)90327-1; Yoon SO, 1998, J NEUROSCI, V18, P3273	49	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21443	21449		10.1074/jbc.274.30.21443	http://dx.doi.org/10.1074/jbc.274.30.21443			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409708	hybrid			2022-12-25	WOS:000081613100099
J	Kotani, K; Ogawa, W; Hino, Y; Kitamura, T; Ueno, H; Sano, W; Sutherland, C; Granner, DK; Kasuga, M				Kotani, K; Ogawa, W; Hino, Y; Kitamura, T; Ueno, H; Sano, W; Sutherland, C; Granner, DK; Kasuga, M			Dominant negative forms of Akt (protein kinase B) and atypical protein kinase C lambda do not prevent insulin inhibition of phosphoenolpyruvate carboxykinase gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT DIABETES-MELLITUS; GLYCOGEN-SYNTHASE KINASE-3; PHOSPHATIDYLINOSITOL 3-KINASE; GLUCOSE-TRANSPORT; PHOSPHOINOSITIDE 3-KINASE; SIGNAL-TRANSDUCTION; 3T3-L1 ADIPOCYTES; ACTIVATION; EXPRESSION; PATHWAY	Transcriptional regulation of phosphoenolpyruvate carboxykinase (PEPCK), the rate limiting enzyme in hepatic gluconeogenesis, by insulin was investigated with the use of adenovirus vectors encoding various mutant signaling proteins. Insulin inhibited transcription induced by dexamethasone and cAMP of a chloramphenicol acetyltransferase (CAT) reporter gene fused with the PEPCK promoter sequence in HL1C cells stably transfected with this construct. A dominant negative mutant of phosphoinositide (PI) 3-kinase blocked insulin inhibition of transcription of the PEPCK-CAT fusion gene, whereas a constitutively active mutant of PI 3-kinase mimicked the effect of insulin. Although a constitutively active mutant of Akt (protein kinase B) inhibited PEPCK-CAT gene transcription induced by dexamethasone and cAMP, a mutant Akt (Akt-AA) in which the phosphorylation sites targeted by insulin are replaced by alanine did not affect the ability of insulin to inhibit transcription of the fusion gene. Akt-AA almost completely inhibited insulin-induced activation of both endogenous and recombinant Abt in HL1C cells. Furthermore, neither a kinase-defective mutant protein kinase C lambda (PKC lambda), which blocked insulin-induced activation of endogenous PKC lambda, nor a dominant negative mutant of the small GTPase Pac prevented inhibition of PEPCK-CAT gene transcription by insulin. These data suggest that phosphoinositide 3-kinase is important for insulin-induced inhibition of PEPCK gene transcription and that a downstream effector of phosphoinositide 3-kinase distinct from Akt, PKC lambda, and Rac may exist for mediating the effect of insulin.	Kobe Univ, Sch Med, Dept Internal Med 2, Chuo Ku, Kobe, Hyogo 6500017, Japan; Kyushu Univ, Sch Med, Mol Cardiol Unit, Higashi Ku, Fukuoka 8128582, Japan; Vanderbilt Univ, Dept Physiol & Mol Biophys, Nashville, TN 37332 USA	Kobe University; Kyushu University; Vanderbilt University	Kotani, K (corresponding author), Kobe Univ, Sch Med, Dept Internal Med 2, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.		OGAWA, Wataru/AAQ-9586-2020	Sano, Wataru/0000-0002-1401-5591; Sutherland, Calum/0000-0003-4398-7434	NIDDK NIH HHS [DK35107] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035107, R37DK035107] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agati JM, 1998, J BIOL CHEM, V273, P18751, DOI 10.1074/jbc.273.30.18751; Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Bandyopadhyay G, 1997, J BIOL CHEM, V272, P2551; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Calera MR, 1998, J BIOL CHEM, V273, P7201, DOI 10.1074/jbc.273.13.7201; Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; FOREST CD, 1990, MOL ENDOCRINOL, V4, P1302, DOI 10.1210/mend-4-9-1302; Gabbay RA, 1996, J BIOL CHEM, V271, P1890, DOI 10.1074/jbc.271.4.1890; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HOFMANN C, 1995, METABOLISM, V44, P384, DOI 10.1016/0026-0495(95)90171-X; Holman GD, 1997, DIABETOLOGIA, V40, P991, DOI 10.1007/s001250050780; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Kitamura Y, 1997, BIOCHEM J, V322, P873, DOI 10.1042/bj3220873; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971; Kruszynska YT, 1996, J INVEST MED, V44, P413; Liao JF, 1998, J BIOL CHEM, V273, P27320, DOI 10.1074/jbc.273.42.27320; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; OBRIEN RM, 1991, BIOCHEM J, V278, P609, DOI 10.1042/bj2780609; ROSELLA G, 1995, MOL ENDOCRINOL, V9, P1396, DOI 10.1210/me.9.10.1396; Sakaue H, 1997, MOL ENDOCRINOL, V11, P1552, DOI 10.1210/me.11.10.1552; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; SUTHERLAND C, 1995, J BIOL CHEM, V270, P15501, DOI 10.1074/jbc.270.26.15501; Sutherland C, 1998, J BIOL CHEM, V273, P3198, DOI 10.1074/jbc.273.6.3198; Takata M, 1999, J BIOL CHEM, V274, P20611, DOI 10.1074/jbc.274.29.20611; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Tsakiridis T, 1996, J BIOL CHEM, V271, P19664, DOI 10.1074/jbc.271.33.19664; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; VALERA A, 1994, P NATL ACAD SCI USA, V91, P9151, DOI 10.1073/pnas.91.19.9151; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; WHITE MF, 1997, DIABETOLOGIA, V40, P2; YANG SH, 1995, BIOCHEM J, V310, P375, DOI 10.1042/bj3100375	41	95	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21305	21312		10.1074/jbc.274.30.21305	http://dx.doi.org/10.1074/jbc.274.30.21305			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409689	hybrid			2022-12-25	WOS:000081613100080
J	Kulkarni, S; Saido, TC; Suzuki, K; Fox, JEB				Kulkarni, S; Saido, TC; Suzuki, K; Fox, JEB			Calpain mediates integrin-induced signaling at a point upstream of Rho family members	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-DEPENDENT PROTEASE; PLATELET MEMBRANE SKELETON; GLYCOPROTEIN-IIB-IIIA; ACTIN STRESS FIBERS; ALPHA-KETO AMIDE; CA-2+-DEPENDENT PROTEASE; NEUTRAL PROTEASE; FOCAL ADHESIONS; CYTOSKELETAL REORGANIZATION; PROTEOLYTIC ACTIVATION	Integrin-induced adhesion leads to cytoskeletal reorganizations, cell migration, spreading, proliferation, and differentiation. The details of the signaling events that induce these changes in cell behavior are not well understood but they appear to involve activation of Rho family members which activate signaling molecules such as tyrosine kinases, serine/threonine kinases, and lipid kinases, The result is the formation of focal complexes, focal adhesions, and bundles and networks of actin filaments that allow the cell to spread. The present study shows that mu-calpain is active in adherent cells, that it cleaves proteins known to be present in focal complexes and focal adhesions, and that overexpression of mu-calpain increased the cleavage of these proteins, induced an overspread morphology and induced an increased number of stress fibers and focal adhesions. Inhibition of calpain with membrane permeable inhibitors or by expression of a dominant negative form of p-calpain resulted in an inability of cells to spread or to form focal adhesions, actin filament networks, or stress fibers. Cells expressing constitutively active Rad could still form focal complexes and actin filament networks (but not focal adhesions or stress fibers) in the presence of calpain inhibitors; cells expressing constitutively active RhoA could form focal adhesions and stress fibers. Taken together, these data indicate that calpain plays an important role in regulating the formation of focal adhesions and Rac- and Rho-induced cytoskeletal reorganizations and that it does so by acting at sites upstream of both Rad and RhoA.	Cleveland Clin Fdn, Lerner Res Inst, Joseph J Jacobs Ctr Thrombosis & Vasc Biol NB 50, Dept Mol Cardiol, Cleveland, OH 44195 USA; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Tokyo Metropolitan Inst Med Sci, Bunkyo Ku, Tokyo 113, Japan; Univ Tokyo, Bunkyo Ku, Tokyo 113, Japan	Cleveland Clinic Foundation; Case Western Reserve University; Tokyo Metropolitan Institute of Medical Science; University of Tokyo	Fox, JEB (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Joseph J Jacobs Ctr Thrombosis & Vasc Biol NB 50, Dept Mol Cardiol, 9500 Euclid Ave, Cleveland, OH 44195 USA.		Sado, Takaomi/AAN-2759-2021; Saido, Takaomi C/N-5472-2015	Sado, Takaomi/0000-0003-1970-6903; Saido, Takaomi C/0000-0003-1970-6903	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030657, R37HL030657, R23HL030657, R01HL056264] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56264, HL30657] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; AOKI K, 1986, FEBS LETT, V205, P313, DOI 10.1016/0014-5793(86)80919-X; BECKERLE MC, 1987, CELL, V51, P569, DOI 10.1016/0092-8674(87)90126-7; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOIVIN P, 1990, INT J BIOCHEM, V22, P1479, DOI 10.1016/0020-711X(90)90240-4; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; Cooray P, 1996, BIOCHEM J, V318, P41, DOI 10.1042/bj3180041; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; DU XP, 1995, J BIOL CHEM, V270, P26146, DOI 10.1074/jbc.270.44.26146; EARNEST JP, 1995, J BIOL CHEM, V270, P27259, DOI 10.1074/jbc.270.45.27259; EMORI Y, 1986, J BIOL CHEM, V261, P9465; FOX JEB, 1983, CELL MOTIL CYTOSKEL, V3, P579, DOI 10.1002/cm.970030524; FOX JEB, 1987, BLOOD, V69, P537; FOX JEB, 1983, J BIOL CHEM, V258, P9973; FOX JEB, 1985, J BIOL CHEM, V260, P1060; FOX JEB, 1993, J CELL BIOL, V120, P1501, DOI 10.1083/jcb.120.6.1501; FOX JEB, 1985, ADV EXP MED BIOL, V192, P201; FOX JEB, 1993, J BIOL CHEM, V268, P25973; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; Harada K, 1997, J NEUROCHEM, V69, P371; HARRIS AS, 1989, J BIOL CHEM, V264, P17401; HARRIS AS, 1990, P NATL ACAD SCI USA, V87, P3009, DOI 10.1073/pnas.87.8.3009; Huang C, 1997, J BIOL CHEM, V272, P19248, DOI 10.1074/jbc.272.31.19248; Huttenlocher A, 1997, J BIOL CHEM, V272, P32719, DOI 10.1074/jbc.272.52.32719; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KISHIMOTO A, 1983, J BIOL CHEM, V258, P1156; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lafrenie RM, 1996, J CELL BIOCHEM, V61, P543, DOI 10.1002/(SICI)1097-4644(19960616)61:4<543::AID-JCB7>3.0.CO;2-O; LI ZZ, 1993, J MED CHEM, V36, P3472, DOI 10.1021/jm00074a031; Li ZZ, 1996, J MED CHEM, V39, P4089, DOI 10.1021/jm950541c; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; Machesky LM, 1997, J CELL BIOL, V138, P913, DOI 10.1083/jcb.138.4.913; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; MEHDI S, 1988, BIOCHEM BIOPH RES CO, V157, P1117, DOI 10.1016/S0006-291X(88)80989-6; Mellgren RL, 1996, J BIOL CHEM, V271, P15568, DOI 10.1074/jbc.271.26.15568; Meredith JE, 1996, ENDOCR REV, V17, P207, DOI 10.1210/er.17.3.207; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; MURACHI T, 1989, BIOCHEM INT, V18, P263; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Norris FA, 1997, J BIOL CHEM, V272, P10987; POTTER DA, 1998, J CELL BIOL, V141, P1; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; SAIDO TC, 1992, J BIOCHEM, V111, P81, DOI 10.1093/oxfordjournals.jbchem.a123723; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SAKIHAMA T, 1985, P NATL ACAD SCI USA, V82, P6075, DOI 10.1073/pnas.82.18.6075; Schwartz MA, 1996, EMBO J, V15, P6525, DOI 10.1002/j.1460-2075.1996.tb01043.x; Selliah N, 1996, J IMMUNOL, V156, P3215; SHUSTER CB, 1995, J CELL BIOL, V128, P837, DOI 10.1083/jcb.128.5.837; TAPLEY PM, 1985, EUR J BIOCHEM, V151, P419, DOI 10.1111/j.1432-1033.1985.tb09118.x; TOMBIN H, 1979, P NATL ACAD SCI USA, V76, P4350; TSUJINAKA T, 1988, BIOCHEM BIOPH RES CO, V153, P1201, DOI 10.1016/S0006-291X(88)81355-X; Yuan YP, 1997, J BIOL CHEM, V272, P21847, DOI 10.1074/jbc.272.35.21847	58	106	106	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21265	21275		10.1074/jbc.274.30.21265	http://dx.doi.org/10.1074/jbc.274.30.21265			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409684	hybrid			2022-12-25	WOS:000081613100075
J	Yeliseev, AA; Kaplan, S				Yeliseev, AA; Kaplan, S			A novel mechanism for the regulation of photosynthesis gene expression by the TspO outer membrane protein of Rhodobacter sphaeroides 2.4.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL BENZODIAZEPINE RECEPTOR; COPROPORPHYRINOGEN-III OXIDASE; ESCHERICHIA-COLI; HEME-BIOSYNTHESIS; OXYGEN REGULATION; ANAEROBIC GROWTH; RHODOBACTER-SPHAEROIDES-2.4.1; CONSTRUCTION; ASSOCIATION; INVOLVEMENT	A bacterial homolog of the mammalian mitochondrial benzodiazepine receptor, the tryptophan-rich sensory protein (TspO) has been previously demonstrated to negatively affect the transcriptional expression of several photosynthesis genes of Rhodobacter sphaeroides. To identify components of the signal transduction pathway from the outer membrane-localized TspO to the DNA-active transcription factor(s), we examined the involvement of TspO in the regulation of tetrapyrrole metabolism in R. sphaeroides. By analyzing the tetrapyrrole pigments accumulated by resting cell suspensions of;R. sphaeroides we demonstrated that TspO negatively regulates the activity of coproporphyrinogen III oxidase in this bacterium. hemN, encoding one of the isoenzymes of coproporphyrinogen III oxidase of R. sphaeroides, provided in traits to the wild type strain, produced a TSPO1 mutant phenotype by abolishing the negative effect of TspO on the transcription of the photosynthesis genes, crtI and puc. It is proposed that TspO, by regulating the exit of certain tetrapyrrole intermediates of the heme/bacteriochlorophyll biosynthetic pathways in R. sphaeroides in response to the availability of molecular oxygen, causes the accumulation of a biosynthetic intermediate that serves as a corepressor for both specific pigment gene transcription and the pnc operon. The relationship between the bacterial TspO and the mitochondrial peripheral benzodiazepine receptor is discussed.	Univ Texas, Hlth Sci Ctr, Dept Microbiol & Mol Genet, Houston, TX 77225 USA	University of Texas System; University of Texas Health Science Center Houston	Kaplan, S (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Microbiol & Mol Genet, POB 20708, Houston, TX 77225 USA.		Yeliseev, Alexei A/B-3143-2009		NIGMS NIH HHS [GM15590] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKHTAR M, 1991, BIOSYNTHESIS TETRAPY, V19, P67; ARAUJO LS, 1989, COMP BIOCHEM PHYS B, V92, P297, DOI 10.1016/0305-0491(89)90281-2; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BOLLIVAR DW, 1992, BIOCHEM J, V282, P471, DOI 10.1042/bj2820471; COHENBAZIRE G, 1957, J CELL COMPAR PHYSL, V49, P25, DOI 10.1002/jcp.1030490104; DAVIS J, 1988, J BACTERIOL, V170, P320, DOI 10.1128/jb.170.1.320-329.1988; Eraso JM, 1996, J BACTERIOL, V178, P7037, DOI 10.1128/jb.178.24.7037-7046.1996; ERASO JM, 1994, J BACTERIOL, V176, P32, DOI 10.1128/JB.176.1.32-43.1994; FALK J, 1964, PORPHYRINS METALLOPR; GIBSON JD, 1962, BIOCHEM J, V84, P483; GIBSON KD, 1963, BIOCHEM J, V88, P325, DOI 10.1042/bj0880325; GIBSON LCD, 1995, P NATL ACAD SCI USA, V92, P1941, DOI 10.1073/pnas.92.6.1941; GRANICK S, 1967, BIOCHEM CHLOROP, P373; Hippler B, 1997, J BACTERIOL, V179, P7181, DOI 10.1128/jb.179.22.7181-7185.1997; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; Krueger KE, 1995, BBA-REV BIOMEMBRANES, V1241, P453, DOI 10.1016/0304-4157(95)00016-X; LACKS S, 1977, J MOL BIOL, V114, P153, DOI 10.1016/0022-2836(77)90289-3; LASCELLES J, 1956, BIOCHEM J, V62, P78, DOI 10.1042/bj0620078; LASCELLES J, 1969, J BACTERIOL, V98, P712, DOI 10.1128/JB.98.2.712-720.1969; LEE JK, 1992, J BACTERIOL, V174, P1158, DOI 10.1128/jb.174.4.1158-1171.1992; Lieb C, 1998, ARCH MICROBIOL, V169, P52; LIM CK, 1983, BIOCHEM J, V211, P435, DOI 10.1042/bj2110435; Maniatis T., 1982, MOL CLONING LAB MANU; MARTIN JP, 1987, J BACTERIOL, V169, P2516, DOI 10.1128/jb.169.6.2516-2522.1987; MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170; MOORE MD, 1989, J BACTERIOL, V171, P4385, DOI 10.1128/JB.171.8.4385-4394.1989; RATCLIFFE SL, 1995, BRIT J CANCER, V71, P300, DOI 10.1038/bjc.1995.60; Rebeiz N, 1996, ARCH BIOCHEM BIOPHYS, V333, P475, DOI 10.1006/abbi.1996.0417; Rompf A, 1998, MOL MICROBIOL, V29, P985, DOI 10.1046/j.1365-2958.1998.00980.x; Rossi E, 1986, HPLC SMALL MOL PRACT, P261; SEEHRA JS, 1983, BIOCHEM J, V209, P709, DOI 10.1042/bj2090709; ShoolinginJordan PM, 1997, METHOD ENZYMOL, V281, P309; ShoolinginJordan PM, 1997, METHOD ENZYMOL, V281, P317; Simon R., 1983, BIOTECHNOLOGY, V1, P37; Smith A., 1990, BIOSYNTHESIS HEME CH, P435; SNYDER SH, 1987, FASEB J, V1, P282, DOI 10.1096/fasebj.1.4.2820823; TAKETANI S, 1994, J BIOL CHEM, V269, P7527; TAKETANI S, 1995, J BIOCHEM-TOKYO, V117, P875, DOI 10.1093/oxfordjournals.jbchem.a124790; TROUP B, 1995, J BACTERIOL, V177, P3326, DOI 10.1128/jb.177.11.3326-3331.1995; Yeliseev AA, 1997, P NATL ACAD SCI USA, V94, P5101, DOI 10.1073/pnas.94.10.5101; YELISEEV AA, 1995, J BIOL CHEM, V270, P21167, DOI 10.1074/jbc.270.36.21167; Zeilstra-Ryalls J, 1998, J BACTERIOL, V180, P2801, DOI 10.1128/JB.180.11.2801-2809.1998; ZEILSTRARYALLS JH, 1995, J BACTERIOL, V177, P6422, DOI 10.1128/jb.177.22.6422-6431.1995	43	60	62	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21234	21243		10.1074/jbc.274.30.21234	http://dx.doi.org/10.1074/jbc.274.30.21234			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409680	hybrid			2022-12-25	WOS:000081613100071
J	Butler, GS; Hutton, M; Wattam, BA; Williamson, RA; Knauper, V; Willenbrock, F; Murphy, G				Butler, GS; Hutton, M; Wattam, BA; Williamson, RA; Knauper, V; Willenbrock, F; Murphy, G			The specificity of TIMP-2 for matrix metalloproteinases can be modified by single amino acid mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-TISSUE INHIBITOR; N-TERMINAL DOMAIN; GELATINASE-A; BIOCHEMICAL-CHARACTERIZATION; KINETIC-ANALYSIS; PROGELATINASE-A; ACTIVE DOMAIN; ACTIVATION; SITE; STROMELYSIN-1	Residues 1-127 of human TIMP-8 (N-TIMP-2), comprising three of the disulfide-bonded loops of the TIMP-8 molecule, is a discrete protein domain that folds independently of the C-terminal domain. This domain has been shown to be necessary and sufficient for metalloproteinase inhibition and contains the major sites of interaction with the catalytic N-terminal domain of active matrix metalloproteinases (MMPs), Residues identified as being involved in the interaction with MMPs by NMR chemical shift perturbation studies and TIMP/MMP crystal structures have been altered by site directed mutagenesis. We show, by measurement of association rates and apparent inhibition constants, that the specificity of these N-TIMP-2 mutants for a range of MMPs can be altered by single site mutations in either the TIMP "ridge" (Cys(1)-Cys(3) and Ser(68)-Cys(72)) Or the flexible AB loop (Ser(31)-Ile(41)). This work demonstrates that it is possible to engineer TIMPs with altered specificity and suggests that this form of protein engineering may be useful in the treatment of diseases such as arthritis and cancer where the selective inhibition of key MMPs is desirable.	Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England; Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England; Univ London Queen Mary & Westfield Coll, Dept Biochem, Lab Struct & Mechanist Enzymol, London E1 4NS, England	University of East Anglia; University of Kent; University of London; Queen Mary University London	Butler, GS (corresponding author), Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England.		Butler, Georgina/GQP-7553-2022	Butler, Georgina/0000-0003-1172-1578; Knauper, Vera/0000-0002-3965-9924				APTE SS, 1994, GENOMICS, V19, P86, DOI 10.1006/geno.1994.1016; Balbin M, 1998, J BIOL CHEM, V273, P23959, DOI 10.1074/jbc.273.37.23959; BOONE TC, 1990, P NATL ACAD SCI USA, V87, P2800, DOI 10.1073/pnas.87.7.2800; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; CRABBE T, 1992, BIOCHEMISTRY-US, V31, P8500, DOI 10.1021/bi00151a017; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; DECLERCK YA, 1993, BIOCHEM J, V289, P65, DOI 10.1042/bj2890065; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; Douglas DA, 1997, J PROTEIN CHEM, V16, P237, DOI 10.1023/A:1026348808069; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; Greene J, 1996, J BIOL CHEM, V271, P30375, DOI 10.1074/jbc.271.48.30375; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Huang W, 1997, J BIOL CHEM, V272, P22086, DOI 10.1074/jbc.272.35.22086; Hutton M, 1998, BIOCHEMISTRY-US, V37, P10094, DOI 10.1021/bi980616p; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; KOKLITIS PA, 1991, BIOCHEM J, V276, P217, DOI 10.1042/bj2760217; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Leatherbarrow R. J., 1992, GRAFIT VERSION 3 0; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; MURPHY G, 1995, METHOD ENZYMOL, V248, P496; Muskett FW, 1998, J BIOL CHEM, V273, P21736, DOI 10.1074/jbc.273.34.21736; Nagase H, 1997, BIOCHEM J, V325, P163, DOI 10.1042/bj3250163; NGUYEN Q, 1994, BIOCHEMISTRY-US, V33, P2089, DOI 10.1021/bi00174a015; OSHEA M, 1992, BIOCHEMISTRY-US, V31, P10146, DOI 10.1021/bi00157a002; Reynolds JJ, 1997, PERIODONTOL 2000, V14, P144, DOI 10.1111/j.1600-0757.1997.tb00195.x; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; WILLIAMSON RA, 1994, BIOCHEMISTRY-US, V33, P11745, DOI 10.1021/bi00205a010; WILLIAMSON RA, 1990, BIOCHEM J, V268, P267, DOI 10.1042/bj2680267; WILLIAMSON RA, 1994, PROTEIN ENG, V7, P1035, DOI 10.1093/protein/7.8.1035; Williamson RA, 1996, EUR J BIOCHEM, V241, P476, DOI 10.1111/j.1432-1033.1996.00476.x; Williamson RA, 1997, BIOCHEMISTRY-US, V36, P13882, DOI 10.1021/bi9712091; Yong VW, 1998, TRENDS NEUROSCI, V21, P75; Zhang YN, 1996, J BIOL CHEM, V271, P8015, DOI 10.1074/jbc.271.14.8015	41	66	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20391	20396		10.1074/jbc.274.29.20391	http://dx.doi.org/10.1074/jbc.274.29.20391			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400663	hybrid			2022-12-25	WOS:000081438300056
J	Morishita, R; Kawagoshi, A; Sawasaki, T; Madin, K; Ogasawara, T; Oka, T; Endo, Y				Morishita, R; Kawagoshi, A; Sawasaki, T; Madin, K; Ogasawara, T; Oka, T; Endo, Y			Ribonuclease activity of rat liver perchloric acid-soluble protein, a potent inhibitor of protein synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIDIRECTIONAL PROMOTER; CRYSTAL-STRUCTURE; RIBOSOMAL-RNA; ALPHA-SARCIN; DIFFERENTIATION; PURIFICATION; INACTIVATION; RECOGNITION; EXPRESSION	Rat liver perchloric acid-soluble protein (L-PSP) is a potent inhibitor of cell-free protein synthesis; however, its mechanism of action is not known. Here we show that the protein is a unique ribonuclease and that this activity is responsible for the inhibition of translation. The addition of perchloric acid-soluble protein to a rabbit reticulocyte cell-free system at a concentration of 6.2 mu M led to an almost complete inhibition of protein synthesis. The kinetics are unlike those of hemin-controlled inhibitor, a protein that acts at the initiation step. The inhibition appears to be due to an endoribonucleolytic activity of perchloric acid-soluble protein because L-PSP directly affects mRNA template activity and induces disaggregation of the reticulocyte polysomes into 80 S ribosomes, even in the presence of cycloheximide. These effects were observed with authentic as well as recombinant L-PSP. Analysis by thin-layer chromatography of [alpha-P-32]UTP-labeled mRNA incubated with the protein showed production of the ribonucleoside 3'-monophosphates Ap, Gp, Up, and Cp, providing direct evidence that the protein is an endoribonuclease. When either 5'- or 3'-P-32-labeled 5 S rRNA was the substrate, L-PSP cleaved phosphodiester bonds only in the single-stranded regions of the molecule.	Ehime Univ, Fac Engn, Dept Appl Chem, Matsuyama, Ehime 7908577, Japan; Kagoshima Univ, Fac Agr, Dept Vet Physiol, Kagoshima 8900065, Japan	Ehime University; Kagoshima University	Endo, Y (corresponding author), Ehime Univ, Fac Engn, Dept Appl Chem, Matsuyama, Ehime 7908577, Japan.			Sawasaki, Tatsuya/0000-0002-7952-0556				Asagi K, 1998, NEPHRON, V79, P80, DOI 10.1159/000044996; BARNARD EA, 1969, ANNU REV BIOCHEM, V38, P677, DOI 10.1146/annurev.bi.38.070169.003333; BLACKBURN P, 1977, J BIOL CHEM, V252, P5904; BOWMAN CM, 1971, P NATL ACAD SCI USA, V68, P964, DOI 10.1073/pnas.68.5.964; Ceciliani F, 1996, FEBS LETT, V393, P147, DOI 10.1016/0014-5793(96)00850-2; CHEN JJ, 1994, BIOCHIMIE, V76, P761, DOI 10.1016/0300-9084(94)90080-9; Chen SH, 1997, NUCLEIC ACIDS RES, V25, P1809, DOI 10.1093/nar/25.9.1809; ENDO Y, 1982, J BIOL CHEM, V257, P9054; ENDO Y, 1983, J BIOL CHEM, V258, P2662; ENDO Y, 1992, J BIOTECHNOL, V25, P221, DOI 10.1016/0168-1656(92)90157-5; FONTECILLACAMPS JC, 1994, J BIOL CHEM, V269, P21526; HASE M, 1982, BIOCHIM BIOPHYS ACTA, V698, P102, DOI 10.1016/0167-4781(82)90191-9; Ogawa T, 1999, SCIENCE, V283, P2097, DOI 10.1126/science.283.5410.2097; OKA T, 1995, J BIOL CHEM, V270, P30060, DOI 10.1074/jbc.270.50.30060; Oka T, 1999, CELL MOL LIFE SCI, V55, P131, DOI 10.1007/s000180050277; Samuel SJ, 1997, HEPATOLOGY, V25, P1213, DOI 10.1002/hep.510250525; Schmiedeknecht G, 1997, BIOCHEM BIOPH RES CO, V241, P59, DOI 10.1006/bbrc.1997.7772; Schmiedeknecht G, 1996, EUR J BIOCHEM, V242, P339, DOI 10.1111/j.1432-1033.1996.0339r.x; STCLAIR DK, 1987, P NATL ACAD SCI USA, V84, P8330; TOOTS I, 1981, NUCLEIC ACIDS RES, V9, P5331, DOI 10.1093/nar/9.20.5331; WOOL IG, 1992, TRENDS BIOCHEM SCI, V17, P266, DOI 10.1016/0968-0004(92)90407-Z; WRIGHT KL, 1995, J EXP MED, V181, P1459, DOI 10.1084/jem.181.4.1459; ZEGERS I, 1994, J BIOL CHEM, V269, P127	23	87	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20688	20692		10.1074/jbc.274.29.20688	http://dx.doi.org/10.1074/jbc.274.29.20688			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400702	hybrid			2022-12-25	WOS:000081438300095
J	Iwamoto, T; Uehara, A; Nakamura, TY; Imanaga, I; Shigekawa, M				Iwamoto, T; Uehara, A; Nakamura, TY; Imanaga, I; Shigekawa, M			Chimeric analysis of Na+/Ca2+ exchangers NCX1 and NCX3 reveals structural domains important for differential sensitivity to external Ni2+ or Li+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOLEMMAL NA+-CA2+ EXCHANGER; SODIUM-CALCIUM EXCHANGER; NA-CA EXCHANGE; PROTEIN-KINASE-C; DEPENDENT REGULATION; SQUID AXONS; CELLS; CATIONS; CLONING; PHOSPHORYLATION	Externally applied Ni2+, which apparently competes with Ca2+ in all three isoforms of Na+/Ca2+ exchanger, inhibits exchange activity of NCX1 or NCX2 with a 10-fold higher affinity than that of NCX3, whereas stimulation of exchange by external Li+ is significantly greater in NCX2 and NCX3 than in NCX1 (Iwamoto, T., and Shigekawa, M. (1998) Am. J. Physiol. 275, C423-C430). Here we identified structural domains in the exchanger that confer differential sensitivity to Ni2+ or Li+ by measuring intracellular Na+-dependent Ca-45(2+) uptake in CCL39 cells stably expressing NCX1/NCX3 chimeras or mutants. We found that two segments in the exchanger corresponding mostly to the internal alpha-1 and alpha-2 repeats are individually responsible for the alteration of Ni2+ sensitivity, both together accounting for similar to 80% of the difference between NCX1 and NCX3, In contrast, the segment corresponding to the alpha-2 repeat fully accounts for the differential Li+ sensitivity between the isoforms, The Ni2+ sensitivity was mimicked, respectively, by simultaneous substitution of two amino acids in the alpha-1 repeat (N125G/T127I in NCX1 and G159N/1161T in NCX3) and substitution of one amino acid in the alpha-2 repeat (V820A in NCX1 and A809V in NCX3), On the other hand, the Li+ sensitivity was mimicked by double substitution mutation in the alpha-2 repeat (V820A/Q826V in NCX1 and A809VN815Q in NCXS), Single substitution mutations at Asn(125) and Val(820) of NCX1 caused significant alterations in the interactions of the exchanger with Ca2+ and Ni2+, and Ni2+ and Li+, respectively, although the extent of alteration varied depending on the nature of side chains of substituted residues. Since the above four important residues are mostly in the putative loops of the cu repeats, these regions might form an ion interaction domain in the exchanger.	Natl Cardiovasc Ctr, Res Inst, Dept Mol Physiol, Suita, Osaka 5658565, Japan; Fukuoka Univ, Sch Med, Dept Physiol, Fukuoka 8140180, Japan	National Cerebral & Cardiovascular Center - Japan; Fukuoka University	Shigekawa, M (corresponding author), Natl Cardiovasc Ctr, Res Inst, Dept Mol Physiol, Fujishiro Dai 5, Suita, Osaka 5658565, Japan.							ALLEN TJA, 1986, J PHYSIOL-LONDON, V378, P53, DOI 10.1113/jphysiol.1986.sp016207; BEAUGE L, 1991, ANN NY ACAD SCI, V639, P147, DOI 10.1111/j.1749-6632.1991.tb17298.x; BLAUSTEIN MP, 1977, BIOPHYS J, V20, P79, DOI 10.1016/S0006-3495(77)85538-0; CONDRESCU M, 1995, J BIOL CHEM, V270, P9137, DOI 10.1074/jbc.270.16.9137; Cook O, 1998, BBA-BIOMEMBRANES, V1371, P40, DOI 10.1016/S0005-2736(97)00272-1; Doering AE, 1998, J BIOL CHEM, V273, P778, DOI 10.1074/jbc.273.2.778; EHARA T, 1989, J PHYSIOL-LONDON, V410, P227, DOI 10.1113/jphysiol.1989.sp017530; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P905, DOI 10.1085/jgp.100.6.905; HILGEMANN DW, 1996, ANN NY ACAD SCI, V779, P1; HRYSHKO LV, 1993, BIOCHIM BIOPHYS ACTA, V1151, P35, DOI 10.1016/0005-2736(93)90068-B; Iwamoto T, 1998, EUR J CELL BIOL, V76, P228, DOI 10.1016/S0171-9335(98)80038-1; Iwamoto T, 1999, FEBS LETT, V446, P264, DOI 10.1016/S0014-5793(99)00218-5; Iwamoto T, 1998, AM J PHYSIOL-CELL PH, V275, pC423, DOI 10.1152/ajpcell.1998.275.2.C423; Iwamoto T, 1998, BIOCHEMISTRY-US, V37, P17230, DOI 10.1021/bi981521q; Iwamoto T, 1996, J BIOL CHEM, V271, P13609, DOI 10.1074/jbc.271.23.13609; Kimura J, 1996, ANN NY ACAD SCI, V779, P515, DOI 10.1111/j.1749-6632.1996.tb44825.x; KIMURA J, 1986, NATURE, V319, P596, DOI 10.1038/319596a0; LI ZP, 1994, J BIOL CHEM, V269, P17434; Linck B, 1998, AM J PHYSIOL-CELL PH, V274, pC415, DOI 10.1152/ajpcell.1998.274.2.C415; MATSUOKA S, 1995, J GEN PHYSIOL, V105, P403, DOI 10.1085/jgp.105.3.403; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, P3870, DOI 10.1073/pnas.90.9.3870; MISHINA M, 1984, NATURE, V307, P604, DOI 10.1038/307604a0; Nicoll DA, 1999, J BIOL CHEM, V274, P910, DOI 10.1074/jbc.274.2.910; Nicoll DA, 1996, J BIOL CHEM, V271, P13385, DOI 10.1074/jbc.271.23.13385; Nicoll DA, 1996, J BIOL CHEM, V271, P24914, DOI 10.1074/jbc.271.40.24914; NICOLL DA, 1991, ANN NY ACAD SCI, V639, P181, DOI 10.1111/j.1749-6632.1991.tb17305.x; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; PORZIG H, 1993, AM J PHYSIOL, V265, pC748, DOI 10.1152/ajpcell.1993.265.3.C748; QUI Z, 1999, BIOPHYS J, V76, pS252; Schwarz EM, 1997, P NATL ACAD SCI USA, V94, P10249, DOI 10.1073/pnas.94.19.10249; SMITH JB, 1987, J BIOL CHEM, V262, P11988; Uehara A, 1997, PFLUG ARCH EUR J PHY, V434, P335, DOI 10.1007/s004240050405	32	38	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23094	23102		10.1074/jbc.274.33.23094	http://dx.doi.org/10.1074/jbc.274.33.23094			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438478	hybrid			2022-12-25	WOS:000082012800028
J	Etgen, GJ; Valasek, KM; Broderick, CL; Miller, AR				Etgen, GJ; Valasek, KM; Broderick, CL; Miller, AR			In vivo adenoviral delivery of recombinant human protein kinase C-zeta stimulates glucose transport activity in rat skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3T3-L1 ADIPOCYTES; PHORBOL ESTER; INSULIN; MICE; ACTIVATION; GLUT4; AKT; CONTRACTION; TRANSLOCATION; REQUIREMENT	An in vivo adenoviral gene delivery system was utilized to assess the effect of overexpressing protein kinase C (PKC)-zeta on rat skeletal muscle glucose transport activity. Female lean Zucker rats were injected with adenoviral/human PKC-zeta (hPKC-zeta) and adenoviral/LacZ in opposing tibialis anterior muscles. One week subsequent to adenoviral/gene delivery rats were subjected to hind limb perfusion. The hPKC-zeta protein was expressed at the same level (fast-twitch white) or at similar to 80% of the level (fast-twitch red) of endogenous PKC-zeta, thus approximately doubling the amount of PKC-zeta in tibialis anterior. Basal glucose transport activity was elevated similar to 3.4- and 2-fold, respectively, in fast-twitch white and red hPKC-zeta muscle relative to control. Submaximal insulin-stimulated glucose transport activity, corrected for basal transport, was similar to 90 and 40% over control values, respectively, in fast-twitch white and red hPKC-zeta muscle. The enhancement of glucose transport activity in muscle expressing hPKC-zeta occurred in the absence of any change in GLUT1 or GLUT4 protein levels, suggesting a redistribution of existing transporters to the cell surface. These results demonstrate that an adenoviral vector can be used to deliver expressible hPKC-zeta to adult rat skeletal muscle in vivo and also affirm a role for PKC-zeta in the regulation of glucose transport activity.	Eli Lilly & Co, Lilly Res Labs, Div Endocrine, Indianapolis, IN 46285 USA	Eli Lilly	Etgen, GJ (corresponding author), Eli Lilly & Co, Lilly Res Labs, Div Endocrine, DC 0545, Indianapolis, IN 46285 USA.							ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Bandyopadhyay G, 1997, J BIOL CHEM, V272, P2551; Bandyopadhyay G, 1997, ENDOCRINOLOGY, V138, P4721, DOI 10.1210/en.138.11.4721; BARBEE JL, 1993, GENE, V132, P305, DOI 10.1016/0378-1119(93)90213-M; BETT AJ, 1994, P NATL ACAD SCI USA, V91, P8802, DOI 10.1073/pnas.91.19.8802; Brozinick JT, 1998, J BIOL CHEM, V273, P14679, DOI 10.1074/jbc.273.24.14679; CONSIDINE RV, 1993, J CELL BIOCHEM, V52, P8, DOI 10.1002/jcb.240520103; ETGEN GJ, 1993, J BIOL CHEM, V268, P20164; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; GIBBS EM, 1995, J CLIN INVEST, V95, P1512, DOI 10.1172/JCI117823; GIBBS EM, 1991, BIOCHEM J, V275, P145, DOI 10.1042/bj2750145; GOULD GW, 1994, J BIOL CHEM, V269, P26622; HITT M, 1995, METH MOL G, V7, P13; KLIP A, 1988, ENDOCRINOLOGY, V123, P296, DOI 10.1210/endo-123-1-296; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LIU ML, 1993, P NATL ACAD SCI USA, V90, P11346, DOI 10.1073/pnas.90.23.11346; Mendez R, 1997, MOL CELL BIOL, V17, P5184, DOI 10.1128/MCB.17.9.5184; MERRALL NW, 1993, BIOCHIM BIOPHYS ACTA, V1177, P191, DOI 10.1016/0167-4889(93)90040-V; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; TREADWAY JL, 1994, J BIOL CHEM, V269, P29956; VIEIRA J, 1991, GENE, V100, P189, DOI 10.1016/0378-1119(91)90365-I; WHITE MF, 1994, J BIOL CHEM, V269, P1; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107	30	53	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22139	22142		10.1074/jbc.274.32.22139	http://dx.doi.org/10.1074/jbc.274.32.22139			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428775	hybrid			2022-12-25	WOS:000081868400005
J	Heikkinen, S; Pietila, M; Halmekyto, M; Suppola, S; Pirinen, E; Deeb, SS; Janne, J; Laakso, M				Heikkinen, S; Pietila, M; Halmekyto, M; Suppola, S; Pirinen, E; Deeb, SS; Janne, J; Laakso, M			Hexokinase II-deficient mice - Prenatal death of homozygotes without disturbances in glucose tolerance in heterozygotes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR SUBSTRATE-1; BETA-CELL GLUCOKINASE; TARGETED DISRUPTION; DEVELOPMENTAL EXPRESSION; DIABETES-MELLITUS; TRANSGENIC MICE; MOUSE EMBRYOS; MESSENGER-RNA; ANIMAL-MODEL; GENE	Type 2 diabetes is characterized by decreased rates of insulin-stimulated glucose uptake and utilization, reduced hexokinase II mRNA and enzyme production, and low basal levels of glucose 6-phosphate in insulin-sensitive skeletal muscle and adipose tissues. Hexokinase II is primarily expressed in muscle and adipose tissues where it catalyzes the phosphorylation of glucose to glucose 6-phosphate, a possible rate-limiting step for glucose disposal, To investigate the role of hexokinase II in insulin action and in glucose homeostasis as well as in mouse development, we generated a hexokinase II knock-out mouse. Mice homozygous for hexokinase II deficiency (HXII-/-) died at approximately 7.5 days post-fertilization, indicating that hexokinase II is vital for mouse embryogenesis after implantation and before organogenesis, HKII+/- mice were viable, fertile, and grew normally. Surprisingly, even though HKII+/- mice had significantly reduced (by 50%) hexokinase II mRNA and activity levels in skeletal muscle, heart, and adipose tissue, they did not exhibit impaired insulin action or glucose tolerance even when challenged with a high-fat diet.	Univ Kuopio, Dept Med, FIN-70211 Kuopio, Finland; Univ Kuopio, AI Virtanen Inst, FIN-70211 Kuopio, Finland; Univ Kuopio, Dept Biochem & Biotechnol, FIN-70211 Kuopio, Finland; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Genet, Seattle, WA 98195 USA	University of Eastern Finland; University of Eastern Finland; University of Eastern Finland; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Laakso, M (corresponding author), Univ Kuopio, Dept Med, POB 1777, FIN-70211 Kuopio, Finland.		Pirinen, Eija/H-9153-2015; Heikkinen, Sami P/L-1460-2013	Pirinen, Eija/0000-0003-1495-3972; Heikkinen, Sami P/0000-0002-6083-2402	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030086] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30086] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Accili D, 1996, NAT GENET, V12, P106, DOI 10.1038/ng0196-106; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BALI D, 1995, J BIOL CHEM, V270, P21464, DOI 10.1074/jbc.270.37.21464; Bruning JC, 1997, CELL, V88, P561, DOI 10.1016/S0092-8674(00)81896-6; Chang PY, 1996, J BIOL CHEM, V271, P14834, DOI 10.1074/jbc.271.25.14834; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coerver KA, 1998, HISTOCHEM CELL BIOL, V109, P75; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; EASTERBY JS, 1973, EUR J BIOCHEM, V38, P201, DOI 10.1111/j.1432-1033.1973.tb03051.x; GRIFFIN LD, 1992, BIOCHIM BIOPHYS ACTA, V1129, P309, DOI 10.1016/0167-4781(92)90508-W; GROSSBARD L, 1966, J BIOL CHEM, V241, P3546; GRUPE A, 1995, CELL, V83, P69, DOI 10.1016/0092-8674(95)90235-X; HAGER J, 1994, DIABETES, V43, P730, DOI 10.2337/diabetes.43.5.730; Hem A, 1998, LAB ANIM-UK, V32, P364, DOI 10.1258/002367798780599866; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; IYNEDJIAN PB, 1987, J BIOL CHEM, V262, P6032; Joshi RL, 1996, EMBO J, V15, P1542, DOI 10.1002/j.1460-2075.1996.tb00498.x; Joyner AL, 1993, GENE TARGETING PRACT; Kelly A, 1996, DEV DYNAM, V207, P300; Kruszynska YT, 1998, DIABETES, V47, P1107, DOI 10.2337/diabetes.47.7.1107; LAAKSO M, 1995, DIABETES, V44, P330, DOI 10.2337/diabetes.44.3.330; Lauro D, 1998, NAT GENET, V20, P294, DOI 10.1038/3112; Lombardi AM, 1997, FASEB J, V11, P1137, DOI 10.1096/fasebj.11.13.9367348; MERKLE S, 1993, BLOOD, V81, P206; MERKLE S, 1992, COMP BIOCHEM PHYS B, V101, P309, DOI 10.1016/0305-0491(92)90004-B; MOLLER DE, 1991, NEW ENGL J MED, V325, P938; MYERS MG, 1993, DIABETES, V42, P643, DOI 10.2337/diabetes.42.5.643; Pendergrass M, 1998, DIABETES, V47, P387, DOI 10.2337/diabetes.47.3.387; POSTIC C, 1994, AM J PHYSIOL, V266, pE548, DOI 10.1152/ajpendo.1994.266.4.E548; PRINTZ RL, 1993, J BIOL CHEM, V268, P5209; Saccomani MP, 1996, AM J PHYSIOL-ENDOC M, V270, pE170, DOI 10.1152/ajpendo.1996.270.1.E170; Shulman RG, 1996, DIABETES, V45, pS93, DOI 10.2337/diab.45.1.S93; STEINER DF, 1990, DIABETES CARE, V13, P600, DOI 10.2337/diacare.13.6.600; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TAYLOR SI, 1992, DIABETES, V41, P1473, DOI 10.2337/diabetes.41.11.1473; Terauchi Y, 1997, J CLIN INVEST, V99, P861, DOI 10.1172/JCI119250; Terauchi Y, 1995, J BIOL CHEM, V270, P30253, DOI 10.1074/jbc.270.51.30253; URETA T, 1982, COMP BIOCHEM PHYS B, V71, P549, DOI 10.1016/0305-0491(82)90461-8; WEST JD, 1990, GENET RES, V56, P223, DOI 10.1017/S0016672300035321; Wilson JE, 1998, DIABETES, V47, P1544, DOI 10.2337/diabetes.47.10.1544; WILSON JE, 1995, REV PHYSIOL BIOCH P, V126, P65, DOI 10.1007/BFb0049776; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; WOOD SA, 1993, NATURE, V365, P87, DOI 10.1038/365025a0; ZIEL FH, 1988, DIABETES, V37, P885, DOI 10.2337/diabetes.37.7.885	44	44	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22517	22523		10.1074/jbc.274.32.22517	http://dx.doi.org/10.1074/jbc.274.32.22517			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428828	hybrid			2022-12-25	WOS:000081868400058
J	Korman, VL; Tobacman, LS				Korman, VL; Tobacman, LS			Mutations in actin subdomain 3 that impair thin filament regulation by troponin and tropomyosin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN SUBFRAGMENT-1; YEAST ACTIN; COOPERATIVE BINDING; MUSCLE-CONTRACTION; CARDIAC TROPONIN; SKELETAL-MUSCLE; SACCHAROMYCES-CEREVISIAE; ACTOMYOSIN INTERACTIONS; GENE; ACTIVATION	Thin filament-mediated regulation of striated muscle contraction involves conformational switching among a few quaternary structures, with transitions induced by binding of Ca2+ and myosin. We establish and exploit Saccharomyces cerevisiae actin as a model system to investigate this process. Ca2+-sensitive troponin-tropomyosin binding affinities for wild type yeast actin are seen to closely resemble those for muscle actin, and these hybrid thin filaments produce Ca2+-sensitive regulation of the myosin S-1 MgATPase rate. Yeast actin filament inner domain mutant K315A/E316A depresses Ca2+ activation of the MgATPase rate, producing a 4-fold weakening of the apparent Ca2+ affinity and a 50% decrease in the MgATPase rate at saturating Ca2+ concentration. Observed destabilization of troponin-tropomyosin binding to actin in the presence of Ca2+, a 1.4-fold effect, provides a partial explanation. Despite the decrease in apparent MgATPase Ca2+ affinity, there was no detectable change in the true Ca2+ affinity of the thin filament, measured using fluorophore-labeled troponin, Another inner domain mutant, E311A/R312A, decreased the MgATPase rate but did not change the apparent Ca2+ affinity. These results suggest that charged residues on the surface of the actin inner domain are important in Ca2+- and myosin-induced thin filament activation.	Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Tobacman, LS (corresponding author), Univ Iowa, Dept Internal Med, 200 Hawkins Dr,SE610,GH, Iowa City, IA 52242 USA.				NHLBI NIH HHS [HL-38834] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038834, R29HL038834] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS S, 1993, BIOCHEMISTRY-US, V32, P5051, DOI 10.1021/bi00070a012; ANSON M, 1995, BIOPHYS J, V68, P1991, DOI 10.1016/S0006-3495(95)80376-0; Bing W, 1998, J BIOL CHEM, V273, P15016, DOI 10.1074/jbc.273.24.15016; BUTTERS CA, 1993, J BIOL CHEM, V268, P15565; Butters CA, 1997, J BIOL CHEM, V272, P13196, DOI 10.1074/jbc.272.20.13196; Cassell M, 1996, J BIOL CHEM, V271, P12867, DOI 10.1074/jbc.271.22.12867; COOK RK, 1992, J BIOL CHEM, V267, P9430; COOK RK, 1993, J BIOL CHEM, V268, P2410; DAHIYA R, 1994, J BIOL CHEM, V269, P29457; GALLWITZ D, 1980, P NATL ACAD SCI-BIOL, V77, P2546, DOI 10.1073/pnas.77.5.2546; Geeves M A, 1995, Biophys J, V68, p194S; GEEVES MA, 1994, BIOPHYS J, V67, P273, DOI 10.1016/S0006-3495(94)80478-3; Gerson Jack H., 1997, Biophysical Journal, V72, pA57; GREENE LE, 1986, J BIOL CHEM, V261, P1279; HILL LE, 1992, J BIOL CHEM, V267, P16106; Hinkle A, 1999, J BIOL CHEM, V274, P7157, DOI 10.1074/jbc.274.11.7157; HOLMES KC, 1995, BIOPHYS J S, V68, P2; JOHNSON JD, 1980, J BIOL CHEM, V255, P9635; Kim E, 1996, BIOCHEMISTRY-US, V35, P16566, DOI 10.1021/bi9623892; KRON SJ, 1992, P NATL ACAD SCI USA, V89, P4466, DOI 10.1073/pnas.89.10.4466; Landis CA, 1997, J BIOL CHEM, V272, P14051, DOI 10.1074/jbc.272.22.14051; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; LEHMAN W, 1994, NATURE, V368, P65, DOI 10.1038/368065a0; LEHMAN W, 1995, J MOL BIOL, V251, P191, DOI 10.1006/jmbi.1995.0425; Lehman W., 1996, Biophysical Journal, V70, pA15; LEVINE BA, 1988, EUR J BIOCHEM, V172, P389, DOI 10.1111/j.1432-1033.1988.tb13899.x; LORENZ M, 1995, J MOL BIOL, V246, P108, DOI 10.1006/jmbi.1994.0070; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MCKILLOP DFA, 1993, BIOPHYS J, V65, P693, DOI 10.1016/S0006-3495(93)81110-X; MILLER CJ, 1995, BIOCHEMISTRY-US, V34, P2694, DOI 10.1021/bi00008a037; Miller CJ, 1996, BIOCHEMISTRY-US, V35, P16557, DOI 10.1021/bi962388+; MOLLOY J, 1993, ADV EXP MED BIOL, V332, P165; Molloy J. E., 1995, Biophysical Journal, V68, P298; NG R, 1980, P NATL ACAD SCI-BIOL, V77, P3912, DOI 10.1073/pnas.77.7.3912; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; Saeki K, 1996, BIOCHEMISTRY-US, V35, P14465, DOI 10.1021/bi961292c; Squire JM, 1998, FASEB J, V12, P761, DOI 10.1096/fasebj.12.10.761; TOBACMAN LS, 1986, BIOCHEMISTRY-US, V25, P798, DOI 10.1021/bi00352a010; TOBACMAN LS, 1987, J BIOL CHEM, V262, P4059; TOBACMAN LS, 1987, BIOCHEMISTRY-US, V26, P492, DOI 10.1021/bi00376a022; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; TOBACMAN LS, 1990, J BIOL CHEM, V265, P931; TRYBUS KM, 1980, P NATL ACAD SCI-BIOL, V77, P7209, DOI 10.1073/pnas.77.12.7209; Vibert P, 1997, J MOL BIOL, V266, P8, DOI 10.1006/jmbi.1996.0800; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; WERTMAN KF, 1992, GENETICS, V132, P337; WILLADSEN KA, 1992, J BIOL CHEM, V267, P23746; WILLIAMS DL, 1988, BIOCHEMISTRY-US, V27, P6987, DOI 10.1021/bi00418a048; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	49	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22191	22196		10.1074/jbc.274.32.22191	http://dx.doi.org/10.1074/jbc.274.32.22191			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428784	hybrid			2022-12-25	WOS:000081868400014
J	Sanders, SA; Williams, CH; Massey, V				Sanders, SA; Williams, CH; Massey, V			The roles of two amino acid residues in the active site of L-lactate monooxygenase - Mutation of arginine 187 to methionine and histidine 240 to glutamine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINACH GLYCOLATE OXIDASE; DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; MYCOBACTERIUM-SMEGMATIS; TRANSITION-STATE; MECHANISM; SEQUENCE; FLAVOCYTOCHROME-B2; DEHYDROGENASE; EXPRESSION	Lactate monooxygenase (LMO) catalyzes the conversion of L-lactate to acetate, CO2, and water with the incorporation of molecular oxygen. Arginine 187 of LMO is highly conserved within the family of L-alpha-hydroxyacid oxidizing enzymes (LB, K. H. D., and Lederer, F. (1991) J. Biol. Chem. 266, 20877-20881). By comparison with the equivalent residue in flavocytochrome b(2) from Saccharomyces cerevisiae (Pike, A. D., Chapman, S. K, Manson, F. D. C,, Reid, G. A, Gondry, M., and Lederer, F. (1996) in Flavins and Flavoproteins (Stevenson, H. J., Massey, V., and Williams, C. Il., Jr., eds) pp. 571-574, University of Calgary Press, Calgary, AB, Canada), arginine 187 might be expected to have an important role in catalytic efficiency and substrate binding in LMO. Histidine 240 is predicted to be close to the substrate binding site of LMO, although it is not conserved within the enzyme family. Arginine 187 has been replaced with methionine (R187M), and histidine 240 has been replaced with glutamine(H240Q). L-Lactate oxidation by R187M is very slow. The binding of L-lactate to the mutant enzyme appears to be very weak, as is the binding of oxalate, a transition state analogue. The binding of pyruvate to the reduced enzyme is also very weak, resulting in complete uncoupling of enzyme turnover, with H2O2 and pyruvate as the final products. In addition, anionic forms of the flavin are unstable. The K-d for sulfite is increased nearly 400-fold by this mutation. The semiquinone form of R187M is also thermodynamically unstable, although the overall midpoint potential for the two-electron reduction of R187M is only 34 mV lower than for the wild-type enzyme. H240Q more closely resembles the wild-type enzyme. The steady-state activity of H240Q is completely coupled. The k(cat) is similar to that for the wild-type enzyme.	Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Dept Vet Affairs Med Ctr, Ann Arbor, MI 48105 USA	University of Michigan System; University of Michigan	Massey, V (corresponding author), Univ Michigan, Dept Biol Chem, 3441 Med Sci I, Ann Arbor, MI 48109 USA.				NIGMS NIH HHS [GM 11106, GM 21444] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM011106, R01GM011106] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CLARK WM, 1960, OXIDATION REDUCTION, P125; GHISLA S, 1977, J BIOL CHEM, V252, P6729; Ghisla S., 1991, CHEM BIOCH FLAVOENZY, P243; GIBSON QH, 1964, J BIOL CHEM, V239, P3927; GIEGEL DA, 1990, J BIOL CHEM, V265, P6626; HAYAISHI O, 1957, J AM CHEM SOC, V79, P4809, DOI 10.1021/ja01574a060; HUNT J, 1994, J BIOL CHEM, V269, P18904; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LE KHD, 1991, J BIOL CHEM, V266, P20877; LEDERER F, 1991, CHEM BIOCH FLAVOENZY, V2, P153; LINDQVIST Y, 1991, J BIOL CHEM, V266, P3198; LINDQVIST Y, 1989, J BIOL CHEM, V264, P3624; LOCKRIDGE O, 1972, J BIOL CHEM, V247, P8097; MAEDAYORITA K, 1995, BIOCHIMIE, V77, P631, DOI 10.1016/0300-9084(96)88178-8; MASSEY V, 1979, J BIOL CHEM, V254, P9640; MASSEY V, 1969, J BIOL CHEM, V244, P3999; MINNAERT K, 1965, BIOCHIM BIOPHYS ACTA, V110, P42, DOI 10.1016/S0926-6593(65)80093-5; Muh U, 1994, FLAVINS AND FLAVOPROTEINS 1993, P201; MUH U, 1994, J BIOL CHEM, V269, P7982; MUH U, 1994, J BIOL CHEM, V269, P7994; MUH U, 1994, J BIOL CHEM, V269, P7989; MULLER F, 1969, J BIOL CHEM, V244, P4007; PIKE AD, 1996, FLAVINS FLAVOPROTEIN, P571; SCHONBRUNN A, 1976, BIOCHEMISTRY-US, V15, P1798, DOI 10.1021/bi00654a003; SMEKAL O, 1993, BIOCHEM J, V290, P108; STANKOVICH M, 1983, BIOCHEMISTRY-US, V22, P4466, DOI 10.1021/bi00288a018; Stenberg K, 1997, PROTEIN SCI, V6, P1009, DOI 10.1002/pro.5560060506; Sun WM, 1996, J BIOL CHEM, V271, P17226, DOI 10.1074/jbc.271.29.17226; SWENSON RP, 1994, BIOCHEMISTRY-US, V33, P8505, DOI 10.1021/bi00194a015; TEGONI M, 1994, PROTEIN SCI, V3, P303; TSOU AY, 1990, BIOCHEMISTRY-US, V29, P9856, DOI 10.1021/bi00494a015; XIA ZX, 1990, J MOL BIOL, V212, P837, DOI 10.1016/0022-2836(90)90240-M; Yorita K, 1997, P NATL ACAD SCI USA, V94, P9590, DOI 10.1073/pnas.94.18.9590; Zhou ZM, 1996, BIOCHEMISTRY-US, V35, P15980, DOI 10.1021/bi962124n	34	12	12	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22289	22295		10.1074/jbc.274.32.22289	http://dx.doi.org/10.1074/jbc.274.32.22289			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428797	hybrid			2022-12-25	WOS:000081868400027
J	Williams, AB; Decourten-Myers, GM; Fischer, JE; Luo, GJ; Sun, XY; Hasselgren, PO				Williams, AB; Decourten-Myers, GM; Fischer, JE; Luo, GJ; Sun, XY; Hasselgren, PO			Sepsis stimulates release of myofilaments in skeletal muscle by a calcium-dependent mechanism	FASEB JOURNAL			English	Article						muscle catabolism; actin; myosin; ubiquitin; proteasome; calpain	END RULE PATHWAY; MYOFIBRILLAR PROTEIN BREAKDOWN; CRITICALLY-ILL PATIENTS; MESSENGER-RNA; DEGRADATION; PROTEASOME; EXERCISE; CALPAIN; INVITRO; STARVATION	Sepsis is associated with a pronounced catabolic response in skeletal muscle, mainly reflecting degradation of the myofibrillar proteins actin and myosin. Recent studies suggest that sepsis-induced muscle proteolysis may reflect ubiquitin-proteasome-dependent protein breakdown. An apparently conflicting observation is that the ubiquitin-proteasome pathway does not degrade intact myofibrils. Thus, it is possible that actin and myosin need to be released from the myofibrils before they can be ubiquitinated and degraded by the proteasome. We tested the hypothesis that sepsis results in disruption of Z-bands, increased expression of calpains, and calcium-dependent release of myofilaments in skeletal muscle. Sepsis induced in rats by cecal ligation and puncture resulted in increased gene expression of mu-calpain, m-calpain, and p94 and in Z-band disintegration in the extensor digitorum longus muscle. The release of myofilaments from myofibrillar proteins was increased in septic muscle. This response to sepsis was blocked by treating the rats with dantrolene, a substance that inhibits the release of calcium from intracellular stores to the cytoplasm. The present results provide evidence that sepsis is associated with Z-band disintegration and a calcium-dependent release of myofilaments in skeletal muscle. Release of myofilaments may be an initial and perhaps rate-limiting component of sepsis-induced muscle breakdown.	Univ Cincinnati, Coll Med, Dept Surg, Cincinnati, OH 45267 USA; Univ Cincinnati, Dept Pathol & Lab Med, Cincinnati, OH 45267 USA; Shriners Hosp Children, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Hasselgren, PO (corresponding author), Univ Cincinnati, Coll Med, Dept Surg, 231 Bethesda Ave,Mail Locat 0558, Cincinnati, OH 45267 USA.	hasselp@uc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008478] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARACOS V, 1986, AM J PHYSIOL, V250, pE702, DOI 10.1152/ajpendo.1986.250.6.E702; Belcastro A N, 1996, Can J Appl Physiol, V21, P328; Belcastro AN, 1998, MOL CELL BIOCHEM, V179, P135, DOI 10.1023/A:1006816123601; BELCASTRO AN, 1994, MOL CELL BIOCHEM, V135, P51, DOI 10.1007/BF00925960; BELCASTRO AN, 1991, MOL CELL BIOCHEM, V103, P113; BELCASTRO AN, 1993, J APPL PHYSIOL, V74, P1381, DOI 10.1152/jappl.1993.74.3.1381; BENSON DW, 1989, SURGERY, V106, P87; BHATTACHARYYA J, 1993, AM J PHYSIOL, V265, pR487, DOI 10.1152/ajpregu.1993.265.3.R487; BHATTACHARYYA J, 1991, CIRC SHOCK, V35, P117; CHAUDRY IH, 1979, SURGERY, V85, P205; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAHLMANN B, 1986, BIOCHEM J, V234, P659, DOI 10.1042/bj2340659; Diaz NL, 1998, HISTOL HISTOPATHOL, V13, P121, DOI 10.14670/HH-13.121; DOWNEY RS, 1986, SURGERY, V99, P265; DUNCAN CJ, 1987, J CELL SCI, V87, P581; ETLINGER JD, 1975, NATURE, V255, P259, DOI 10.1038/255259a0; FOSTER PS, 1991, CLIN EXP PHARMACOL P, V18, P489, DOI 10.1111/j.1440-1681.1991.tb01482.x; FRIDEN J, 1983, INT J SPORTS MED, V4, P170, DOI 10.1055/s-2008-1026030; Goldberg A L, 1975, Methods Enzymol, V39, P82; HASSELGREN O, 1990, BIOCHEM J, V267, P33; HASSELGREN PO, 1989, METABOLISM, V38, P634, DOI 10.1016/0026-0495(89)90100-5; HASSELGREN PO, 1993, PROTEIN METABOLISM S; HAUPTMANN S, 1994, VIRCHOWS ARCH, V424, P653, DOI 10.1007/BF01069747; HELLIWELL TR, 1991, J PATHOL, V164, P307, DOI 10.1002/path.1711640406; HERSCH M, 1990, SURGERY, V107, P397; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hobler SC, 1999, AM J PHYSIOL-REG I, V276, pR468, DOI 10.1152/ajpregu.1999.276.2.R468; Hobler SC, 1998, AM J PHYSIOL-REG I, V274, pR30, DOI 10.1152/ajpregu.1998.274.1.R30; HOTCHKISS RS, 1994, P NATL ACAD SCI USA, V91, P3039, DOI 10.1073/pnas.91.8.3039; KOOHMARAIE M, 1992, J ANIM SCI, V70, P3697, DOI 10.2527/1992.70123697x; Labeit S, 1997, CIRC RES, V80, P290, DOI 10.1161/01.RES.80.2.290; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWELL BB, 1986, METABOLISM, V35, P1121, DOI 10.1016/0026-0495(86)90025-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATHIEUCOSTELLO O, 1992, RESP PHYSIOL, V89, P113, DOI 10.1016/0034-5687(92)90075-8; PEDERSEN PV, 1989, SURG GYNECOL OBSTET, V168, P148; PELLEGRINO C, 1963, J CELL BIOL, V17, P327, DOI 10.1083/jcb.17.2.327; Reid WD, 1998, MOL CELL BIOCHEM, V179, P63, DOI 10.1023/A:1006803703128; Solomon V, 1998, P NATL ACAD SCI USA, V95, P12602, DOI 10.1073/pnas.95.21.12602; Solomon V, 1998, J BIOL CHEM, V273, P25216, DOI 10.1074/jbc.273.39.25216; Solomon V, 1996, J BIOL CHEM, V271, P26690, DOI 10.1074/jbc.271.43.26690; SORIMACHI H, 1989, J BIOL CHEM, V264, P20106; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; Squire JM, 1997, CURR OPIN STRUC BIOL, V7, P247, DOI 10.1016/S0959-440X(97)80033-4; STEVENS A, 1993, HISTOLOGY, P58; SUGDEN PH, 1980, BIOCHEM J, V190, P593, DOI 10.1042/bj1900593; Tiao G, 1997, J CLIN INVEST, V99, P163, DOI 10.1172/JCI119143; Tiao G, 1997, AM J PHYSIOL-REG I, V272, pR849, DOI 10.1152/ajpregu.1997.272.3.R849; TIAO G, 1994, J CLIN INVEST, V94, P2255, DOI 10.1172/JCI117588; TOMANEK RJ, 1973, J ANAT, V116, P395; VANDERWESTHUYZEN DR, 1981, J BIOL CHEM, V256, P1791; Varshavsky A, 1997, GENES CELLS, V2, P13, DOI 10.1046/j.1365-2443.1997.1020301.x; VIGOREAUX JO, 1994, J MUSCLE RES CELL M, V15, P237; WING SS, 1994, AM J PHYSIOL, V267, pE39, DOI 10.1152/ajpendo.1994.267.1.E39; WOKKE JHJ, 1988, J NEUROL SCI, V88, P95, DOI 10.1016/0022-510X(88)90208-0	55	135	140	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1999	13	11					1435	1443		10.1096/fasebj.13.11.1435	http://dx.doi.org/10.1096/fasebj.13.11.1435			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	226KL	10428767	Bronze			2022-12-25	WOS:000082019100015
J	Roth, JA; Kim, BG; Lin, WL; Cho, MI				Roth, JA; Kim, BG; Lin, WL; Cho, MI			Melatonin promotes osteoblast differentiation and bone formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALOPROTEIN GENE-TRANSCRIPTION; GLAND HORMONE MELATONIN; RETINOIC ACID RECEPTORS; NUCLEAR RECEPTOR; PINEAL-GLAND; RESPONSE ELEMENTS; X RECEPTORS; BSP GENE; RAT; IDENTIFICATION	Prior studies have demonstrated that the pineal hormone, melatonin, can stimulate chloramphenicol acetyltransferase activity in Drosophila SL-3 cells transfected with a chloramphenicol acetyltransferase reporter construct containing the response element of rat bone sialoprotein (BSP), Based on these findings, studies were performed to determine whether melatonin could similarly modulate the expression of BSP in two cell lines, the MC3T3-E1(MC3T3) pre-osteoblast and rat osteoblast-like osteosarcoma 17/2.8 cell. Initial studies demonstrated that MC3T3 cells grown in the presence of 50 nar melatonin underwent cell differentiation and mineralization by day 12 instead of the 21-day period normally required for cells grown in untreated media. Melatonin increased gene expression of BSP and the other bone marker proteins, including alkaline phosphatase (ALP); osteopontin; secreted protein, acidic and rich in cysteine; and osteocalcin in MC3T3 cells in a concentration-dependent manner. Levels of melatonin as low as 10 nM were capable of stimulating transcription of these genes when cells were grown in the presence of beta-glycerophosphate and ascorbic acid. Under these conditions, melatonin induced gene expression of the bone marker proteins; however, this does not occur until the 5th day after seeding the culture dishes. Thereafter, MC3T3 cells responded to melatonin within 2 h of treatment. The fully differentiated rat osteoblast-like osteosarcoma 17/ 2.8 cells responded rapidly to melatonin and displayed an increase in the expression of BSP, ALP, and osteocalcin genes within 1 h of exposure to the hormone. To determine whether melatonin-induced osteoblast differentiation and bone formation are mediated via the transmembrane receptor, MC3T3 cells were treated in the presence and absence of melatonin with either luzindole, a competitive inhibitor of the binding of melatonin to the transmembrane receptors, or pertussis toxin, an uncoupler of Gi from adenylate cyclase. Both luzindole and pertussis toxin were shown to reduce melatonin-induced expression of BSP and ALP, These results demonstrate, for the first time, that the pineal hormone, melatonin, is capable of promoting osteoblast differentiation and mineralization of matrix in culture and suggest that this hormone may play an essential role in regulating bone growth.	SUNY Buffalo, Sch Dent Med, Dept Oral Biol, Buffalo, NY 14214 USA; SUNY Buffalo, Sch Med & Biomed Sci, Dept Pharmacol & Toxicol, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Cho, MI (corresponding author), SUNY Buffalo, Sch Dent Med, Dept Oral Biol, B10 Foster Hall, Buffalo, NY 14214 USA.				NIDCR NIH HHS [DE4849] Funding Source: Medline; PHS HHS [R826248] Funding Source: Medline	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Baler R, 1996, BIOCHEM BIOPH RES CO, V220, P975, DOI 10.1006/bbrc.1996.0517; Batmanabane M, 1996, ANAT RECORD, V245, P519; BECKERANDRE M, 1993, BIOCHEM BIOPH RES CO, V194, P1371, DOI 10.1006/bbrc.1993.1976; BECKERANDRE M, 1994, J BIOL CHEM, V269, P28531; CARLBERG C, 1994, MOL ENDOCRINOL, V8, P757, DOI 10.1210/me.8.6.757; CASSONE VM, 1990, TRENDS NEUROSCI, V13, P457, DOI 10.1016/0166-2236(90)90099-V; CASSONE VM, 1995, PHYSIOL BEHAV, V36, P1111; CHO MI, 1992, CALCIFIED TISSUE INT, V50, P459, DOI 10.1007/BF00296778; COS S, 1995, CANCER LETT, V93, P207, DOI 10.1016/0304-3835(95)03811-A; DOLLINS AB, 1994, P NATL ACAD SCI USA, V91, P1824, DOI 10.1073/pnas.91.5.1824; DUBOCOVICH ML, 1995, TRENDS PHARMACOL SCI, V16, P50, DOI 10.1016/S0165-6147(00)88978-6; ECAROTCHARRIER B, 1989, J BIOL CHEM, V264, P20049; ESQUIFINO AI, 1987, J STEROID BIOCHEM, V27, P1089; FISHER LW, 1990, J BIOL CHEM, V265, P2347; FLORES ME, 1992, EXP CELL RES, V201, P526, DOI 10.1016/0014-4827(92)90305-R; HARADA H, 1995, ENDOCRINOLOGY, V136, P5329, DOI 10.1210/en.136.12.5329; HILL SM, 1988, CANCER RES, V48, P6121; Huether G, 1996, GERONTOLOGY, V42, P87, DOI 10.1159/000213777; HUNTER GK, 1993, P NATL ACAD SCI USA, V90, P8562, DOI 10.1073/pnas.90.18.8562; IBARAKI K, 1993, GENE, V130, P225, DOI 10.1016/0378-1119(93)90423-Z; KENNAWAY DJ, 1995, J REPROD FERTIL, P423; KIM RH, 1994, MATRIX BIOL, V14, P31, DOI 10.1016/0945-053X(94)90027-2; KRAUSE DN, 1995, EUR J PHARMACOL, V276, P207, DOI 10.1016/0014-2999(95)00028-J; Li IWS, 1996, J CELL PHYSIOL, V169, P115, DOI 10.1002/(SICI)1097-4652(199610)169:1<115::AID-JCP12>3.0.CO;2-C; LI JJ, 1993, BIOCHEM J, V289, P625, DOI 10.1042/bj2890625; Liebmann PM, 1997, INT ARCH ALLERGY IMM, V112, P203, DOI 10.1159/000237455; LYNCH HJ, 1987, ADV PINEAL RES, V2, P181; MADER S, 1993, J BIOL CHEM, V268, P591; MATSUMOTO T, 1991, BONE, V12, P27, DOI 10.1016/8756-3282(91)90051-J; MCMILLEN IC, 1995, J REPROD FERTIL, P137; MIDURA RJ, 1990, J BIOL CHEM, V265, P5285; Ogata Y, 1997, J CELL BIOCHEM, V65, P501, DOI 10.1002/(SICI)1097-4644(19970615)65:4<501::AID-JCB6>3.0.CO;2-S; OLDBERG A, 1988, J BIOL CHEM, V263, P19430; OLDBERG A, 1988, J BIOL CHEM, V263, P19433; PIERPAOLI W, 1991, ANN NY ACAD SCI, V621, P291; PIERPAOLI W, 1994, P NATL ACAD SCI USA, V91, P787, DOI 10.1073/pnas.91.2.787; REITER RJ, 1991, ENDOCR REV, V12, P151, DOI 10.1210/edrv-12-2-151; Reiter RJ, 1996, TRENDS ENDOCRIN MET, V7, P22, DOI 10.1016/1043-2760(95)00192-1; Reppert SM, 1996, TRENDS PHARMACOL SCI, V17, P100, DOI 10.1016/0165-6147(96)10005-5; Roth JA, 1997, BRAIN RES, V768, P63, DOI 10.1016/S0006-8993(97)00549-0; Schrader M, 1996, J BIOL CHEM, V271, P19732, DOI 10.1074/jbc.271.33.19732; Sodek J, 1995, CONNECT TISSUE RES, V32, P209, DOI 10.3109/03008209509013725; STEINHILBER D, 1995, J BIOL CHEM, V270, P7037, DOI 10.1074/jbc.270.13.7037; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; SUGDEN D, 1994, NEUROCHEM INT, V24, P147, DOI 10.1016/0197-0186(94)90101-5; TOWLER DA, 1995, ENDOCRINOLOGY, V136, P1089, DOI 10.1210/en.136.3.1089; Uz T, 1997, J NEUROCHEM, V69, P2220; WIESENBERG I, 1995, NUCLEIC ACIDS RES, V23, P327, DOI 10.1093/nar/23.3.327; Yang RJ, 1996, J BIOL CHEM, V271, P29839, DOI 10.1074/jbc.271.47.29839; YUNG LY, 1995, FEBS LETT, V372, P99, DOI 10.1016/0014-5793(95)00963-A; ZERNIK J, 1990, MATRIX, V10, P38, DOI 10.1016/S0934-8832(11)80136-8; ZHANG Q, 1992, EUR J BIOCHEM, V207, P649, DOI 10.1111/j.1432-1033.1992.tb17092.x; ZHUMABAYEVA BD, 1999, INT J ORAL BIOL, V23, P91	53	251	269	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					22041	22047		10.1074/jbc.274.31.22041	http://dx.doi.org/10.1074/jbc.274.31.22041			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419530	hybrid			2022-12-25	WOS:000081721100083
J	Thelen, JJ; Muszynski, MG; David, NR; Luethy, MH; Elthon, TE; Miernyk, JA; Randall, DD				Thelen, JJ; Muszynski, MG; David, NR; Luethy, MH; Elthon, TE; Miernyk, JA; Randall, DD			The dihydrolipoamide S-acetyltransferase subunit of the mitochondrial pyruvate dehydrogenase complex from maize contains a single lipoyl domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIENZYME COMPLEX; SACCHAROMYCES-CEREVISIAE; TRANSACETYLASE COMPONENT; PROTEIN-X; NUCLEOTIDE-SEQUENCE; BACILLUS-STEAROTHERMOPHILUS; PARASITIC NEMATODE; ESCHERICHIA-COLI; BINDING PROTEIN; BOVINE HEART	The dihydrolipoamide S-acetyltransferase (E2) subunit of the maize mitochondrial pyruvate dehydrogenase complex (PDC) was postulated to contain a single lipoyl domain based upon molecular mass and N-terminal protein sequence (Thelen, J. J., Miernyk, J. A., and Randall, D. D. (1998) Plant Physiol, 116, 1443-1450). This sequence was used to identify a cDNA from a maize expressed sequence tag data base. The deduced amino acid sequence of the full-length cDNA was greater than 30% identical to other E2s and contained a single lipoyl domain. Mature maize E2 was expressed in Escherichia coli and purified to a specific activity of 191 units mg(-1). The purified recombinant protein had a native mass of approximately 2.7 MDa and assembled into a 29-nm pentagonal dodecahedron as visualized by electron microscopy. Immunoanalysis of mitochondrial proteins from various plants, using a monoclonal antibody against the maize E2, revealed 50-54-kDa cross-reacting polypeptides in all samples. A larger protein (76 kDa) was also recognized in an enriched pea mitochondrial PDC preparation, indicating two distinct E2s, The presence of a single lipoyl-domain E2 in Arabidopsis thaliana was confirmed by identifying a gene encoding a hypothetical protein with 62% amino acid identity to the maize homologue, These data suggest that all plant mitochondrial PDCs contain an E2 with a single lipoyl domain. Additionally, A thaliana and other dicots possess a second E2, which contains two lipoyl domains and is only 33% identical at the amino acid level to the smaller isoform. The reason two distinct E2s exist in dicotyledon plants is uncertain, although the variability between these isoforms, particularly within the subunit-binding domain, suggests different roles in assembly and/or function of the plant mitochondrial PDC.	Univ Missouri, Dept Biochem, Columbia, MO 65211 USA; Pioneer Hi Bred Int Inc, Johnston, IA 50131 USA; Dekalb Genet, Mystic, CT 06355 USA; Univ Nebraska, Dept Biol Sci, Lincoln, NE 68588 USA; USDA ARS, Peoria, IL 61604 USA	University of Missouri System; University of Missouri Columbia; DuPont; Pioneer Hi-Bred International, Inc.; University of Nebraska System; University of Nebraska Lincoln; United States Department of Agriculture (USDA)	Randall, DD (corresponding author), Univ Missouri, Dept Biochem, 117 Schweitzer Hall, Columbia, MO 65211 USA.		Muszynski, Michael G./L-2843-2016	Muszynski, Michael G./0000-0002-0817-7594; Thelen, Jay/0000-0001-5995-1562				ALLEN AG, 1991, FEBS LETT, V287, P206, DOI 10.1016/0014-5793(91)80052-5; Allen MD, 1997, FEBS LETT, V413, P339, DOI 10.1016/S0014-5793(97)00932-0; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BEHAL RH, 1994, J BIOL CHEM, V269, P31372; BEHAL RH, 1989, P NATL ACAD SCI USA, V86, P8732, DOI 10.1073/pnas.86.22.8732; BLEILE DM, 1981, J BIOL CHEM, V256, P514; BORGES A, 1990, EUR J BIOCHEM, V194, P95, DOI 10.1111/j.1432-1033.1990.tb19432.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMP PJ, 1985, PLANT PHYSIOL, V77, P571, DOI 10.1104/pp.77.3.571; COPPEL RL, 1988, P NATL ACAD SCI USA, V85, P7317, DOI 10.1073/pnas.85.19.7317; DEMARCUCCI OL, 1995, ARCH BIOCHEM BIOPHYS, V323, P169, DOI 10.1006/abbi.1995.0023; ELTHON TE, 1989, PLANT PHYSIOL, V89, P1311, DOI 10.1104/pp.89.4.1311; FANG TK, 1987, CURR TOP PLANT BIOCH, V6, P175; GOPALAKRISHNAN S, 1989, BIOCHEM BIOPH RES CO, V160, P715, DOI 10.1016/0006-291X(89)92492-3; GUAN YH, 1995, J BIOL CHEM, V270, P5412, DOI 10.1074/jbc.270.10.5412; GUEST JR, 1987, FEMS MICROBIOL LETT, V44, P417, DOI 10.1111/j.1574-6968.1987.tb02324.x; Harris RA, 1997, J BIOL CHEM, V272, P19746, DOI 10.1074/jbc.272.32.19746; HAYES MK, 1991, PLANT PHYSIOL, V97, P1381, DOI 10.1104/pp.97.4.1381; HENDERSON CE, 1979, CELL, V17, P85, DOI 10.1016/0092-8674(79)90297-6; Klingbeil MM, 1996, J BIOL CHEM, V271, P5451, DOI 10.1074/jbc.271.10.5451; KOMUNIECKI R, 1992, ARCH BIOCHEM BIOPHYS, V296, P115, DOI 10.1016/0003-9861(92)90552-8; KRESZE GB, 1980, EUR J BIOCHEM, V112, P589; LAWSON JE, 1991, BIOCHEMISTRY-US, V30, P2834, DOI 10.1021/bi00225a015; LUETHY MH, 1995, J PLANT PHYSIOL, V145, P443, DOI 10.1016/S0176-1617(11)81768-2; Luethy MH, 1996, ALPHA KETO ACID DEHY, P71; MACHADO RS, 1992, FEMS MICROBIOL LETT, V100, P243, DOI 10.1111/j.1574-6968.1992.tb05710.x; Miernyk JA, 1998, PLANT MITOCHONDRIA: FROM GENE TO FUNCTION, P321; Millar AH, 1998, BIOCHEM J, V334, P571, DOI 10.1042/bj3340571; Mooney BP, 1999, PLANT PHYSIOL, V120, P443, DOI 10.1104/pp.120.2.443; NIU XD, 1988, P NATL ACAD SCI USA, V85, P7546, DOI 10.1073/pnas.85.20.7546; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; PERHAM RN, 1991, BIOCHEMISTRY-US, V30, P8501, DOI 10.1021/bi00099a001; POWERSGREENWOOD SL, 1989, J BIOL CHEM, V264, P3655; QUINN J, 1993, BIOCHEM J, V289, P81, DOI 10.1042/bj2890081; Randall D. D., 1996, V39, P87; Randall D. D., 1990, METHODS PLANT BIOCH, V3, P175, DOI [10.1016/B978-0-12-461013-2.50017-4, DOI 10.1016/B978-0-12-461013-2.50017-4]; REED LJ, 1990, J BIOL CHEM, V265, P8971; REED LJ, 1974, ACCOUNTS CHEM RES, V7, P40, DOI 10.1021/ar50074a002; RUBIN PM, 1977, ARCH BIOCHEM BIOPHYS, V178, P342, DOI 10.1016/0003-9861(77)90202-8; RUSSELL GC, 1992, BIOCHEM J, V287, P611, DOI 10.1042/bj2870611; SNOEP JL, 1992, EUR J BIOCHEM, V203, P245, DOI 10.1111/j.1432-1033.1992.tb19853.x; STEPHENS PE, 1983, EUR J BIOCHEM, V133, P481, DOI 10.1111/j.1432-1033.1983.tb07490.x; Stoops JK, 1997, J BIOL CHEM, V272, P5757, DOI 10.1074/jbc.272.9.5757; TAYLOR AE, 1992, PLANTA, V188, P225, DOI 10.1007/BF00216817; Thelen JJ, 1998, PLANT MITOCHONDRIA: FROM GENE TO FUNCTION, P417; Thelen JJ, 1998, PLANT PHYSIOL, V116, P1443, DOI 10.1104/pp.116.4.1443; Thelen JJ, 1999, PLANT PHYSIOL, V119, P635, DOI 10.1104/pp.119.2.635; Thelen JJ, 1998, J BIOL CHEM, V273, P26618, DOI 10.1074/jbc.273.41.26618; WAGENKNECHT T, 1991, J BIOL CHEM, V266, P24650; Wallis NG, 1996, J MOL BIOL, V263, P463, DOI 10.1006/jmbi.1996.0589; WILLIAMS M, 1979, PLANT PHYSIOL, V64, P1099, DOI 10.1104/pp.64.6.1099; Yang DQ, 1997, J BIOL CHEM, V272, P6361, DOI 10.1074/jbc.272.10.6361	52	27	28	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21769	21775		10.1074/jbc.274.31.21769	http://dx.doi.org/10.1074/jbc.274.31.21769			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419491	hybrid			2022-12-25	WOS:000081721100044
J	Weers, PMM; Narayanaswami, V; Kay, CM; Ryan, RO				Weers, PMM; Narayanaswami, V; Kay, CM; Ryan, RO			Interaction of an exchangeable apolipoprotein with phospholipid vesicles and lipoprotein particles - Role of leucines 32, 34, and 95 in Locusta migratoria apolipophorin III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; PROTEIN SECONDARY STRUCTURE; A-I; LIPID TRANSPORT; CONFORMATIONAL ADAPTATIONS; CIRCULAR-DICHROISM; MANDUCA-SEXTA; BINDING; NMR; DIMYRISTOYLPHOSPHATIDYLCHOLINE	Apolipophorin III (apoLp-III) from Locusta migratoria is an exchangeable apolipoprotein that binds reversibly to lipid surfaces. In the lipid-free state this 164-residue protein exists as a bundle of five elongated amphipathic alpha-helices, Upon lipid binding, apoLp-III undergoes a significant conformational change, resulting in exposure of its hydrophobic interior to the lipid environment. On the basis of x-ray crystallographic data (Breiter, D. R., Kanost, M. R., Benning, M. M., Wesenberg, G., Law, J. H., Wells, M. A, Rayment, I., and Holden, H. M. (1991) Biochemistry 30, 603-608), it was proposed that hydrophobic residues, present in loops that connect helices 1 and 2 (Leu-32 and Leu-34) and helices 3 and 4 (Leu-95), may function in initiation of lipid binding. To examine this hypothesis, mutant apoLp-IIIs were designed wherein the three Leu residues were replaced by Arg, individually or together. Circular dichroism spectroscopy and temperature and guanidine hydrochloride denaturation studies showed that the mutations did not cause major changes in secondary structure content or stability. In lipid binding assays, addition of apoLp-III to phospholipid vesicles caused a rapid clearance of vesicle turbidity due to transformation to discoidal complexes. L34R and L32R/L34R/L95R apoLp-IIIs displayed a much stronger interaction with lipid vesicles than wild-type apoLp-III. Furthermore, it was demonstrated that the mutant apoLp-IIIs retained their ability to bind to lipoprotein particles. However, in lipoprotein competition binding assays, the mutants displayed an impaired ability to initiate a binding interaction when compared with wild-type apoLp-III, The data indicate that the loops connecting helices 1 and 2 and helices 3 and 4 are critical regions in the protein, contributing to recognition of hydrophobic defects on lipoprotein surfaces by apoLp-III.	Univ Alberta, Heritage Med Res Ctr 328, Lipid & Lipoprot Res Grp, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Biochem, Prot Engn Network Excellence, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta	Ryan, RO (corresponding author), Univ Alberta, Heritage Med Res Ctr 328, Lipid & Lipoprot Res Grp, Edmonton, AB T6G 2S2, Canada.			Narayanaswami, Vasanthy/0000-0001-7088-4057				BLACKLOCK BJ, 1994, INSECT BIOCHEM MOLEC, V24, P855, DOI 10.1016/0965-1748(94)90015-9; Borhani DW, 1997, P NATL ACAD SCI USA, V94, P12291, DOI 10.1073/pnas.94.23.12291; BREITER DR, 1991, BIOCHEMISTRY-US, V30, P603, DOI 10.1021/bi00217a002; BROUILLETTE CG, 1984, BIOCHEMISTRY-US, V23, P359, DOI 10.1021/bi00297a027; CHEUNG MC, 1987, J LIPID RES, V28, P913; DEMEL RA, 1992, BIOCHIM BIOPHYS ACTA, V1124, P151, DOI 10.1016/0005-2760(92)90091-9; DOLPHIN PJ, 1992, STRUCTURE FUNCTION A, P295; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; Jonas A., 1992, STRUCTURE FUNCTION A, P217; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAWOOYA JK, 1986, J BIOL CHEM, V261, P3588; Kiss RS, 1999, BIOCHEMISTRY-US, V38, P4327, DOI 10.1021/bi982597p; Little C., 1981, METHOD ENZYMOL, V71, P725; LIU H, 1993, FEBS LETT, V316, P27, DOI 10.1016/0014-5793(93)81730-N; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; MANTULIN WW, 1980, J BIOL CHEM, V255, P8185; Narayanaswami V, 1996, ARCH BIOCHEM BIOPHYS, V334, P143, DOI 10.1006/abbi.1996.0439; Narayanaswami V, 1996, J BIOL CHEM, V271, P26855, DOI 10.1074/jbc.271.43.26855; Narayanaswami V, 1999, P NATL ACAD SCI USA, V96, P4366, DOI 10.1073/pnas.96.8.4366; NARAYANASWAMI V, 1995, BIOCHEMISTRY-US, V34, P11822, DOI 10.1021/bi00037a021; NOLTE RT, 1992, BIOPHYS J, V63, P1221, DOI 10.1016/S0006-3495(92)81698-3; Pace C N, 1986, Methods Enzymol, V131, P266; POWNALL HJ, 1978, BIOCHEMISTRY-US, V17, P1183, DOI 10.1021/bi00600a008; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; RAUSSENS V, 1995, J BIOL CHEM, V270, P12542, DOI 10.1074/jbc.270.21.12542; Raussens V, 1998, J BIOL CHEM, V273, P25825, DOI 10.1074/jbc.273.40.25825; REIJNGOUD DJ, 1982, BIOCHEMISTRY-US, V21, P2969, DOI 10.1021/bi00541a026; REYNOLDS JA, 1976, J BIOL CHEM, V251, P6013; Rogers DP, 1998, BIOCHEMISTRY-US, V37, P945, DOI 10.1021/bi9713512; RYAN RO, 1993, J BIOL CHEM, V268, P1525; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUMAKER VN, 1986, METHOD ENZYMOL, V128, P155; SEGREST JP, 1994, ADV PROTEIN CHEM, V45, P303; SMITH AF, 1994, J LIPID RES, V35, P1976; Soulages JL, 1998, BIOCHEMISTRY-US, V37, P10203, DOI 10.1021/bi980622l; SOULAGES JL, 1995, P NATL ACAD SCI USA, V92, P5650, DOI 10.1073/pnas.92.12.5650; SOULAGES JL, 1994, ADV PROTEIN CHEM, V45, P371; SUITS AG, 1989, P NATL ACAD SCI USA, V86, P2713, DOI 10.1073/pnas.86.8.2713; SUREWICZ WK, 1986, J BIOL CHEM, V261, P6191; VANDERHORST DJ, 1991, EUR J BIOCHEM, V196, P509; VANDERHORST DJ, 1990, BIOCHIM BIOPHYS ACTA, V1047, P195, DOI 10.1016/0005-2760(90)90518-3; Wang JJ, 1998, PROTEIN SCI, V7, P336; Wang JJ, 1997, J BIOL CHEM, V272, P17912, DOI 10.1074/jbc.272.29.17912; WANG JJ, 1995, BIOCHEMISTRY-US, V34, P6755, DOI 10.1021/bi00020a021; WANG JJ, 1992, BIOCHEMISTRY-US, V31, P8706, DOI 10.1021/bi00152a004; WEERS PMM, 1993, BIOL CHEM H-S, V374, P863, DOI 10.1515/bchm3.1993.374.7-12.863; WEERS PMM, 1994, BIOCHEMISTRY-US, V33, P3617, DOI 10.1021/bi00178a019; Weers PMM, 1998, BBA-LIPID LIPID MET, V1393, P99, DOI 10.1016/S0005-2760(98)00063-0; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WELLS MA, 1987, J BIOL CHEM, V262, P4172; WIENTZEK M, 1994, J BIOL CHEM, V269, P4605; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194	52	41	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21804	21810		10.1074/jbc.274.31.21804	http://dx.doi.org/10.1074/jbc.274.31.21804			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419496	hybrid			2022-12-25	WOS:000081721100049
J	Zeuthen, T; Klaerke, DA				Zeuthen, T; Klaerke, DA			Transport of water and glycerol in aquaporin 3 is gated by H+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KIDNEY COLLECTING DUCT; MOLECULAR-CLONING; CHANNEL; EXPRESSION; PERMEABILITY; CELLS; SELECTIVITY; MEMBRANE; OOCYTES; FAMILY	Aquaporins (AQPs) were expressed in Xenopus laevis oocytes in order to study the effects of external pH and solute structure on permeabilities. For AQP3 the osmotic water permeability, L-p, was abolished at acid pH values with a pK of 6.4 and a Hill coefficient of 3. The L-p values of AQP0, AQP1, AQP2, AQP4, and AQP5 were independent of pH, For AQP3 the glycerol permeability P-Gl, obtained from [C-14]glycerol uptake, was abolished at acid pH values with a pK of 6.1 and a Hill coefficient of 6. Consequently, AQP3 acts as a glycerol and water channel at physiological pH, but predominantly as a glycerol channel at pH values around 6.1. The pH effects were reversible. The interactions between fluxes of water and straight chain polyols were inferred from reflection coefficients to). For AQP3, water and glycerol interacted by competing for titratable site(s): sigma(Gl) was 0.15 at neutral pH but doubled at pH 6.4. The sigma values were smaller for polyols in which the -OH groups were free to form hydrogen bonds. The activation energy for the transport processes was around 5 kcal mol(-1). We suggest that water and polyols permeate AQP3 by forming successive hydrogen bonds with titratable sites.	Panum Inst, DK-2200 Copenhagen N, Denmark		Zeuthen, T (corresponding author), Panum Inst, Blegdamsvej 3C, DK-2200 Copenhagen N, Denmark.							Abrami L, 1996, PFLUG ARCH EUR J PHY, V431, P408, DOI 10.1007/BF02207279; ABRAMI L, 1995, PFLUG ARCH EUR J PHY, V430, P447, DOI 10.1007/BF00373921; Agre P, 1998, J BIOL CHEM, V273, P14659, DOI 10.1074/jbc.273.24.14659; CARLSEN A, 1976, ACTA PHYSIOL SCAND, V97, P501, DOI 10.1111/j.1748-1716.1976.tb10290.x; CREIGHTON TE, 1993, PROTEINS, P15; ECELBARGER CA, 1995, AM J PHYSIOL-RENAL, V269, pF663, DOI 10.1152/ajprenal.1995.269.5.F663; ECHEVARRIA M, 1994, P NATL ACAD SCI USA, V91, P10997, DOI 10.1073/pnas.91.23.10997; Echevarria M, 1996, J BIOL CHEM, V271, P25079, DOI 10.1074/jbc.271.41.25079; Finkelstein A., 1987, WATER MOVEMENT LIPID; FRIGERI A, 1995, P NATL ACAD SCI USA, V92, P4328, DOI 10.1073/pnas.92.10.4328; GLASSTONE S, 1941, THEORY RATE PROCESSE; Hamann S, 1998, AM J PHYSIOL-CELL PH, V274, pC1332, DOI 10.1152/ajpcell.1998.274.5.C1332; HILL AE, 1994, J MEMBRANE BIOL, V137, P197; Ishibashi K, 1997, J BIOL CHEM, V272, P20782, DOI 10.1074/jbc.272.33.20782; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6269, DOI 10.1073/pnas.91.14.6269; Katchalsky A., 1965, NONEQUILIBRIUM THERM; Kuriyama H, 1997, BIOCHEM BIOPH RES CO, V241, P53, DOI 10.1006/bbrc.1997.7769; Lagree V, 1998, J BIOL CHEM, V273, P33949, DOI 10.1074/jbc.273.51.33949; Lagree V, 1999, J BIOL CHEM, V274, P6817, DOI 10.1074/jbc.274.11.6817; MA TH, 1994, J BIOL CHEM, V269, P21845; MA TH, 1994, AM J PHYSIOL, V266, pC189, DOI 10.1152/ajpcell.1994.266.1.C189; MAUREL C, 1994, J BIOL CHEM, V269, P11869; Meinild AK, 1998, J PHYSIOL-LONDON, V508, P15, DOI 10.1111/j.1469-7793.1998.015br.x; Roudier N, 1998, J BIOL CHEM, V273, P8407, DOI 10.1074/jbc.273.14.8407; Sasaki S, 1998, ANNU REV PHYSIOL, V60, P199, DOI 10.1146/annurev.physiol.60.1.199; STEIN WD, 1962, BIOCHIM BIOPHYS ACTA, V59, P47, DOI 10.1016/0006-3002(62)90697-2; Tsukaguchi H, 1998, J BIOL CHEM, V273, P24737, DOI 10.1074/jbc.273.38.24737; ZAMPIGHI GA, 1995, J MEMBRANE BIOL, V148, P65; Zeuthen T, 1997, BIOL CELL, V89, P307, DOI 10.1016/S0248-4900(97)83383-7	30	149	151	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21631	21636		10.1074/jbc.274.31.21631	http://dx.doi.org/10.1074/jbc.274.31.21631			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419471	hybrid			2022-12-25	WOS:000081721100024
J	Boubekeur, S; Bunoust, O; Camougrand, N; Castroviejo, M; Rigoulet, M; Guerin, B				Boubekeur, S; Bunoust, O; Camougrand, N; Castroviejo, M; Rigoulet, M; Guerin, B			A mitochondrial pyruvate dehydrogenase bypass in the yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETALDEHYDE DEHYDROGENASE; CARNITINE ACETYLTRANSFERASE; BAKERS-YEAST; GENE; DECARBOXYLASE; GLUCOSE; PURIFICATION; METABOLISM; GROWTH; IDENTIFICATION	Spheroplasts of the yeast Saccharomyces cerevisiae oxidize pyruvate at a high respiratory rate, whereas isolated mitochondria do not unless malate is added. We show that a cytosolic factor, pyruvate decarboxylase, is required for the non-malate-dependent oxidation of pyruvate by mitochondria. In pyruvate decarboxylase-negative mutants, the oxidation of pyruvate by permeabilized spheroplasts was abolished. In contrast, deletion of the gene (PDA1) encoding the E1 alpha subunit of the pyruvate dehydrogenase did not affect the spheroplast respiratory rate on pyruvate but abolished the malate-dependent respiration of isolated mitochondria. Mutants disrupted for the mitochondrial acetaldehyde dehydrogenase gene (ALD7) did not oxidize pyruvate unless malate was added. We therefore propose the existence of a mitochondrial pyruvate dehydrogenase bypass different from the cytosolic one, where pyruvate is decarboxylated to acetaldehyde in the cytosol by pyruvate decarboxylase and then oxidized by mitochondrial acetaldehyde dehydrogenase. This pathway can compensate PDA1 gene deletion for lactate or respiratory glucose growth. However, the codisruption of PDA1 and ALD7 genes prevented the growth on lactate, indicating that each of these pathways contributes to the oxidative metabolism of pyruvate.	Univ Victor Segalen Bordeaux, CNRS, Inst Biochim & Genet Cellulaires, F-33077 Bordeaux, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux	Guerin, B (corresponding author), Univ Victor Segalen Bordeaux, CNRS, Inst Biochim & Genet Cellulaires, 1 Rue Camille St-Saens, F-33077 Bordeaux, France.	bernard.guerin@ibgc.u-bordeaux2.fr						Averet N, 1998, MOL CELL BIOCHEM, V184, P67, DOI 10.1023/A:1006830810440; BERGMEYER HJ, 1989, METHODS ENZYMATIC AN; BRIQUET M, 1977, BIOCHIM BIOPHYS ACTA, V459, P290, DOI 10.1016/0005-2728(77)90029-9; DECHATEAUBODEAU GA, 1976, BIOCHIMIE PARIS, V58, P601; DESTEENSMA HY, 1990, EUR J BIOCHEM, V191, P769, DOI 10.1111/j.1432-1033.1990.tb19186.x; Dickinson FM, 1996, BIOCHEM J, V315, P393, DOI 10.1042/bj3150393; FITTON V, 1994, BIOCHEMISTRY-US, V33, P9692, DOI 10.1021/bi00198a039; Flikweert MT, 1997, APPL ENVIRON MICROB, V63, P3399, DOI 10.1128/AEM.63.9.3399-3404.1997; Flikweert MT, 1996, YEAST, V12, P247, DOI 10.1002/(SICI)1097-0061(19960315)12:3<247::AID-YEA911>3.0.CO;2-I; GOUNARIS AD, 1971, J BIOL CHEM, V246, P1302; Guerin B, 1979, Methods Enzymol, V55, P149; HOHMANN S, 1990, EUR J BIOCHEM, V188, P615, DOI 10.1111/j.1432-1033.1990.tb15442.x; HOHMANN S, 1991, J BACTERIOL, V173, P7963, DOI 10.1128/jb.173.24.7963-7969.1991; JACOBSON MK, 1974, BIOCHIM BIOPHYS ACTA, V350, P277, DOI 10.1016/0005-2744(74)90502-6; KEITH AB, 1977, BIOCHEM J, V173, P787; KISPAL G, 1993, J BIOL CHEM, V268, P1824; KISPAL G, 1991, BIOCHIM BIOPHYS ACTA, V1085, P217, DOI 10.1016/0005-2760(91)90097-2; KRESZE GB, 1981, EUR J BIOCHEM, V119, P573, DOI 10.1111/j.1432-1033.1981.tb05646.x; LUTSTORF U, 1968, ARCH BIOCHEM BIOPHYS, V126, P933, DOI 10.1016/0003-9861(68)90487-6; Luttik MAH, 1998, J BIOL CHEM, V273, P24529, DOI 10.1074/jbc.273.38.24529; Meaden PG, 1997, YEAST, V13, P1319, DOI 10.1002/(SICI)1097-0061(199711)13:14<1319::AID-YEA183>3.0.CO;2-T; NALECZ MJ, 1991, BIOCHIM BIOPHYS ACTA, V1079, P87, DOI 10.1016/0167-4838(91)90028-X; PAQUIN CE, 1986, MOL CELL BIOL, V6, P70, DOI 10.1128/MCB.6.1.70; Pronk JT, 1996, YEAST, V12, P1607, DOI 10.1002/(SICI)1097-0061(199612)12:16<1607::AID-YEA70>3.0.CO;2-4; PRONK JT, 1994, MICROBIOL-SGM, V140, P601, DOI 10.1099/00221287-140-3-601; ROHDE M, 1991, ARCH BIOCHEM BIOPHYS, V290, P197, DOI 10.1016/0003-9861(91)90608-L; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Small WC, 1998, J BACTERIOL, V180, P4051, DOI 10.1128/JB.180.16.4051-4055.1998; Tessier WD, 1998, FEMS MICROBIOL LETT, V164, P29, DOI 10.1111/j.1574-6968.1998.tb13063.x; VANDENBERG MA, 1995, EUR J BIOCHEM, V231, P704; vandenBerg MA, 1996, J BIOL CHEM, V271, P28953, DOI 10.1074/jbc.271.46.28953; VANURK H, 1991, BIOCHIM BIOPHYS ACTA, V191, P769; WENZEL TJ, 1992, EUR J BIOCHEM, V209, P697, DOI 10.1111/j.1432-1033.1992.tb17338.x	33	56	59	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21044	21048		10.1074/jbc.274.30.21044	http://dx.doi.org/10.1074/jbc.274.30.21044			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409655	hybrid			2022-12-25	WOS:000081613100046
J	Nordeng, TW; Bakke, O				Nordeng, TW; Bakke, O			Overexpression of proteins containing tyrosine- or leucine-based sorting signals affects transferrin receptor trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DARBY CANINE KIDNEY; LYSOSOMAL ACID-PHOSPHATASE; LOW-DENSITY-LIPOPROTEIN; GROWTH-FACTOR RECEPTOR; COATED PIT FORMATION; ADAPTER MEDIUM CHAINS; POLARIZED MDCK CELLS; II INVARIANT CHAIN; CYTOPLASMIC DOMAIN; INTERNALIZATION SIGNAL	Targeting of many transmembrane proteins to post-Golgi compartments is dependent on cytoplasmically exposed sorting signals. The most widely used signals conform to the tyrosine- or the leucine-based motifs. Both types of signals have been implicated in protein localization to the same intracellular compartments, but previous results from both cell-free experiments and studies of transfected cell lines have indicated that the two types of signals interact with separate components of the sorting machinery. We have overexpressed several transmembrane proteins in stably transfected Madin-Darby canine kidney cells using an inducible promoter system. Overexpression of proteins containing tyrosine- or leucine-based sorting signals resulted in reduced internalization of the transferrin receptor, whereas recycling and polarized distribution was not influenced. Our results indicate that proteins with tyrosine- and leucine-based sorting signals can be transported along common saturable pathways.	Univ Oslo, Dept Biol, Div Mol Cell Biol, N-0316 Oslo, Norway	University of Oslo	Nordeng, TW (corresponding author), Univ Oslo, Dept Biol, Div Mol Cell Biol, Pb 1050 Blindern, N-0316 Oslo, Norway.			Bakke, Oddmund/0000-0003-4843-7626				Aguilar RC, 1997, J BIOL CHEM, V272, P27160, DOI 10.1074/jbc.272.43.27160; ANDERSON RGW, 1981, J CELL BIOL, V88, P441, DOI 10.1083/jcb.88.2.441; AROETI B, BIOCH BIOPHYS ACTA, V1376, P5798; BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BELTZER JP, 1991, EMBO J, V10, P3735, DOI 10.1002/j.1460-2075.1991.tb04942.x; BEROD A, 1981, J HISTOCHEM CYTOCHEM, V29, P844, DOI 10.1177/29.7.6167611; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; BOLL W, 1995, CURR BIOL, V5, P1168, DOI 10.1016/S0960-9822(95)00233-8; BREMNES B, 1994, J CELL SCI, V107, P2021; Bremnes T, 1998, J BIOL CHEM, V273, P8638, DOI 10.1074/jbc.273.15.8638; BRODSKY FM, 1985, J CELL BIOL, V101, P2047, DOI 10.1083/jcb.101.6.2047; Cao TT, 1998, J BIOL CHEM, V273, P24592, DOI 10.1074/jbc.273.38.24592; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DARGEMONT C, 1993, EMBO J, V12, P1713, DOI 10.1002/j.1460-2075.1993.tb05816.x; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; Dietrich J, 1997, J CELL BIOL, V138, P271, DOI 10.1083/jcb.138.2.271; Distel B, 1998, J BIOL CHEM, V273, P186, DOI 10.1074/jbc.273.1.186; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; Foti M, 1997, J CELL BIOL, V139, P37, DOI 10.1083/jcb.139.1.37; FULLER SD, 1986, J CELL BIOL, V103, P1767, DOI 10.1083/jcb.103.5.1767; GHOSH RN, 1994, J CELL SCI, V107, P2177; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GORVEL JP, 1995, J BIOL CHEM, V270, P2741, DOI 10.1074/jbc.270.6.2741; GUARNIERI FG, 1993, J BIOL CHEM, V268, P1941; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; HONING S, 1995, J CELL BIOL, V128, P321, DOI 10.1083/jcb.128.3.321; Honing S, 1998, EMBO J, V17, P1304, DOI 10.1093/emboj/17.5.1304; Honing S, 1996, EMBO J, V15, P5230, DOI 10.1002/j.1460-2075.1996.tb00908.x; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; IACOPETTA BJ, 1988, CELL, V54, P485, DOI 10.1016/0092-8674(88)90069-4; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; Johnson AO, 1996, J CELL BIOL, V135, P1749, DOI 10.1083/jcb.135.6.1749; JOHNSON LS, 1993, MOL BIOL CELL, V4, P1251, DOI 10.1091/mbc.4.12.1251; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; KUNDU A, 1994, J VIROL, V68, P1812, DOI 10.1128/JVI.68.3.1812-1818.1994; Le Borgne R, 1998, BBA-MOL CELL RES, V1404, P195, DOI 10.1016/S0167-4889(98)00057-3; LeBorgne R, 1996, J BIOL CHEM, V271, P2162; LeBorgne R, 1997, J CELL BIOL, V137, P335; LEHMANN LE, 1992, EMBO J, V11, P4391, DOI 10.1002/j.1460-2075.1992.tb05539.x; Lewin DA, 1998, BBA-MOL CELL RES, V1401, P129, DOI 10.1016/S0167-4889(97)00130-4; LINDMO T, 1986, METHOD ENZYMOL, V121, P678; LINDMO T, 1984, J IMMUNOL METHODS, V72, P77, DOI 10.1016/0022-1759(84)90435-6; LIPP J, 1986, CELL, V46, P1103, DOI 10.1016/0092-8674(86)90710-5; LUND KA, 1990, J BIOL CHEM, V265, P15713; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; MATTER K, 1993, CELL, V74, P1053, DOI 10.1016/0092-8674(93)90727-8; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; Maxfield FR, 1991, INTRACELLULAR TRAFFI, P157; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; MCGRAW TE, 1991, J CELL BIOL, V112, P853, DOI 10.1083/jcb.112.5.853; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; MILLER K, 1991, CELL, V65, P621, DOI 10.1016/0092-8674(91)90094-F; MOTTA A, 1995, J BIOL CHEM, V270, P27165, DOI 10.1074/jbc.270.45.27165; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Odorizzi G, 1997, J CELL BIOL, V137, P1255, DOI 10.1083/jcb.137.6.1255; Odorizzi G, 1997, J BIOL CHEM, V272, P11757, DOI 10.1074/jbc.272.18.11757; Ohno H, 1997, VIROLOGY, V238, P305, DOI 10.1006/viro.1997.8839; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; OPRESKO LK, 1987, J BIOL CHEM, V262, P4116; OPRESKO LK, 1995, J BIOL CHEM, V270, P4325, DOI 10.1074/jbc.270.9.4325; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; Presley JF, 1997, J BIOL CHEM, V272, P13929, DOI 10.1074/jbc.272.21.13929; PRILL V, 1993, EMBO J, V12, P2181, DOI 10.1002/j.1460-2075.1993.tb05866.x; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; REAVES B, 1994, FEBS LETT, V351, P448, DOI 10.1016/0014-5793(94)00813-2; ROCHE PA, 1993, P NATL ACAD SCI USA, V90, P8581, DOI 10.1073/pnas.90.18.8581; Rodionov DG, 1999, J IMMUNOL, V162, P1488; Rodionov DG, 1998, J BIOL CHEM, V273, P6005, DOI 10.1074/jbc.273.11.6005; ROMAGNOLI P, 1993, J EXP MED, V177, P583, DOI 10.1084/jem.177.3.583; Roush DL, 1998, J BIOL CHEM, V273, P26862, DOI 10.1074/jbc.273.41.26862; Salamero J, 1996, J BIOL CHEM, V271, P30318, DOI 10.1074/jbc.271.48.30318; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SANDVIG K, 1994, FEBS LETT, V346, P99, DOI 10.1016/0014-5793(94)00281-9; Santini F, 1998, MOL BIOL CELL, V9, P1177, DOI 10.1091/mbc.9.5.1177; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Simonsen A, 1997, J CELL SCI, V110, P597; Simonsen A, 1998, EUR J CELL BIOL, V76, P25, DOI 10.1016/S0171-9335(98)80014-9; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; Sorkin A, 1996, J BIOL CHEM, V271, P13377, DOI 10.1074/jbc.271.23.13377; SOSA MA, 1993, J BIOL CHEM, V268, P12537; VANDERIJN M, 1983, CYTOGENET CELL GENET, V36, P525, DOI 10.1159/000131967; Vidal M, 1997, J CELL SCI, V110, P1867; Warren RA, 1997, J BIOL CHEM, V272, P2116; Warren RA, 1998, J BIOL CHEM, V273, P17056, DOI 10.1074/jbc.273.27.17056; Weigel PH, 1998, BIOCHEM BIOPH RES CO, V246, P563, DOI 10.1006/bbrc.1998.8491; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WILDE A, 1994, J BIOL CHEM, V269, P7131; WONG SH, 1993, J BIOL CHEM, V268, P22853; WRAIGHT CJ, 1990, J BIOL CHEM, V265, P5787	97	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21139	21148		10.1074/jbc.274.30.21139	http://dx.doi.org/10.1074/jbc.274.30.21139			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409667	hybrid			2022-12-25	WOS:000081613100058
J	Bruce, JIE; Yang, XS; Ferguson, CJ; Elliott, AC; Steward, MC; Case, RM; Riccardi, D				Bruce, JIE; Yang, XS; Ferguson, CJ; Elliott, AC; Steward, MC; Case, RM; Riccardi, D			Molecular and functional identification of a Ca2+ (polyvalent cation)-sensing receptor in rat pancreas	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-SENSING RECEPTOR; EXTRACELLULAR CA2+-SENSING RECEPTOR; BOVINE PARATHYROID CELLS; ACINAR-CELLS; BETA-CELLS; HYPERCALCEMIA; METABOLISM; DUCTS; EXPRESSION; MODULATION	The balance between the concentrations of free ionized Ca2+ and bicarbonate in pancreatic juice is of critical importance in preventing the formation of calcium carbonate stones. How the pancreas regulates the ionic composition and the level of Ca2+ saturation in an alkaline environment such as the pancreatic juice is not known. Because of the tight cause-effect relationship between Ca2+ concentration and lithogenicity, and because hypercalcemia is proposed as an etiologic factor for several pancreatic diseases, we have investigated whether pancreatic tissues express a Ca2+-sensing receptor (CaR) similar to that recently identified in parathyroid tissue. Using reverse transcriptase-polymerase chain reaction and immunofluorescence microscopy, we demonstrate the presence of a CaR-like molecule in rat pancreatic acinar cells, pancreatic ducts, and islets of Langerhans, Functional studies, in which intracellular free Ca2+ concentration was measured in isolated acinar cells and interlobular ducts, show that both cell types are responsive to the CaR agonist gadolinium (Gd3+) and to changes in extracellular Ca2+ concentration. We also assessed the effects of CaR stimulation on physiological HCO3- secretion from ducts by making measurements of intracellular pH. Luminal Gd3+ is a potent stimulus for HCO3- secretion, being equally as effective as raising intracellular cAMP with forskolin, These results suggest that the CaR in the exocrine pancreas monitors the Ca2+ concentration in the pancreatic juice, and might therefore be involved in regulating the level of Ca2+ in the lumen, both under basal conditions and during hormonal stimulation. The failure of this mechanism might lead to pancreatic stone formation and even to pancreatitis.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Riccardi, D (corresponding author), Univ Manchester, Sch Biol Sci, G38 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.		Riccardi, Daniela/A-4674-2010	Riccardi, Daniela/0000-0002-7322-3163; Elliott, Austin/0000-0003-3569-9002				ARGENT BE, 1973, J PHYSIOL-LONDON, V230, P575, DOI 10.1113/jphysiol.1973.sp010205; ASHTON N, 1993, J PHYSIOL-LONDON, V471, P549, DOI 10.1113/jphysiol.1993.sp019915; Brown D, 1996, HISTOCHEM CELL BIOL, V105, P261, DOI 10.1007/BF01463929; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Case R. M., 1993, P301; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dabrowski A, 1996, J BIOL CHEM, V271, P5686, DOI 10.1074/jbc.271.10.5686; DUAN RD, 1995, AM J PHYSIOL-GASTR L, V268, pG1060, DOI 10.1152/ajpgi.1995.268.6.G1060; FRICK TW, 1994, INT J PANCREATOL, V15, P91; FRICK TW, 1990, GASTROENTEROLOGY, V98, P1675, DOI 10.1016/0016-5085(90)91106-G; Gerasimenko OV, 1996, CELL, V84, P473, DOI 10.1016/S0092-8674(00)81292-1; HAMMERLAND LG, 1995, J BONE MINER RES, V10, pS156; Ishiguro H, 1996, J PHYSIOL-LONDON, V495, P169, DOI 10.1113/jphysiol.1996.sp021582; Kato M, 1997, SURGERY, V122, P1203, DOI 10.1016/S0039-6060(97)90228-2; KATO M, 1995, GASTROENTEROLOGY, V108, pA364; Kifor O, 1998, J BIOL CHEM, V273, P21708, DOI 10.1074/jbc.273.34.21708; Layer P, 1986, Pancreas, V1, P478, DOI 10.1097/00006676-198611000-00002; Lloyd SE, 1999, AM J HUM GENET, V64, P189, DOI 10.1086/302202; MARCHE P, 1983, J PHARMACOL EXP THER, V227, P415; MARTEAU C, 1993, DIGEST DIS SCI, V38, P2090, DOI 10.1007/BF01297090; MARUYAMA Y, 1993, PFLUG ARCH EUR J PHY, V422, P476, DOI 10.1007/BF00375075; MARX SJ, 1981, MEDICINE, V60, P235; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MITHAL A, 1995, ENDOCRINOLOGY, V136, P3087, DOI 10.1210/en.136.7.3087; MITHOFER K, 1995, GASTROENTEROLOGY, V109, P239, DOI 10.1016/0016-5085(95)90290-2; NILSSON T, 1987, BIOCHEM BIOPH RES CO, V149, P152, DOI 10.1016/0006-291X(87)91617-2; Oda Y, 1998, J BIOL CHEM, V273, P23344, DOI 10.1074/jbc.273.36.23344; Pearce SHS, 1996, CLIN ENDOCRINOL, V45, P675, DOI 10.1046/j.1365-2265.1996.750891.x; Petersen OH, 1996, TRENDS NEUROSCI, V19, P411; Riccardi D, 1998, AM J PHYSIOL-RENAL, V274, pF611, DOI 10.1152/ajprenal.1998.274.3.F611; RICCARDI D, 1995, P NATL ACAD SCI USA, V92, P131, DOI 10.1073/pnas.92.1.131; Riccardi D, 1996, AM J PHYSIOL-RENAL, V271, pF951, DOI 10.1152/ajprenal.1996.271.4.F951; Sands JM, 1997, J CLIN INVEST, V99, P1399, DOI 10.1172/JCI119299; SCHREURS VVAM, 1976, BIOCHIM BIOPHYS ACTA, V436, P664, DOI 10.1016/0005-2736(76)90448-X; SILVA AM, 1994, J BIOL CHEM, V269, P17095; Speake T, 1998, J PHYSIOL-LONDON, V506, P415, DOI 10.1111/j.1469-7793.1998.415bw.x; STEWARD MC, 1998, J PHYSIOL-LONDON, V511, P23; TYSNES OB, 1988, EUR J BIOCHEM, V177, P219, DOI 10.1111/j.1432-1033.1988.tb14365.x; vandePut FHMM, 1997, J BIOL CHEM, V272, P27764, DOI 10.1074/jbc.272.44.27764; WILLEMS PHGM, 1993, CELL CALCIUM, V14, P145, DOI 10.1016/0143-4160(93)90084-J	40	130	133	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20561	20568		10.1074/jbc.274.29.20561	http://dx.doi.org/10.1074/jbc.274.29.20561			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400686	hybrid			2022-12-25	WOS:000081438300079
J	Fadel, BM; Boutet, SC; Quertermous, T				Fadel, BM; Boutet, SC; Quertermous, T			Octamer-dependent in vivo expression of the endothelial cell-specific TIE2 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; COACTIVATOR OCA-B; TRANSCRIPTION FACTOR; TRANSGENIC MICE; POU DOMAIN; VASCULAR ENDOTHELIUM; CONSERVED SEQUENCE; BINDING-PROTEINS; GROWTH-FACTOR; DNA-BINDING	The TIE2 gene, also known as TEK encodes a tyrosine kinase receptor that is required for the normal development of the vascular system during embryogenesis. TIE2 is specifically expressed in endothelial cells; however, the transcriptional mechanisms that regulate this highly restricted pattern of expression remain unknown. Here we demonstrate that a consensus octamer element located in the 5'-flanking region of TIE2 is required for normal expression in embryonic endothelial cells. Transgenic embryos carrying a TIE2/LacZ construct spanning 2.1 kilobases of upstream regulatory sequences exhibit expression of the reporter transgene specifically in endothelial cells. Site-directed mutagenesis of a consensus octamer element located in this region results in the loss of enhancer activity and significantly impairs the endothelial expression of the reporter transgene. Consistent with the in vivo data, in vitro DNA-protein binding studies show that the consensus octamer element displays an endothelial cell-specific pattern of binding, suggesting an interaction with a protein complex consisting of Oct1 and an endothelial cell-restricted cofactor. These data identify a novel role for the octamer element as an essential regulator of TIE2 expression, define the first known transcriptional pathway that mediates the expression of a developmental endothelial cell gene, and provide insights into the transcriptional mechanisms that regulate development of the vasculature during embryogenesis.	Stanford Univ, Falk Cardiovasc Res Ctr, Div Cardiovasc Med, Stanford, CA 94305 USA; Vet Affairs Med Ctr, Cardiol Sect, Palo Alto, CA 94304 USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Quertermous, T (corresponding author), Stanford Univ, Falk Cardiovasc Res Ctr, Div Cardiovasc Med, 300 Pasteur Dr, Stanford, CA 94305 USA.			Quertermous, Thomas/0000-0002-7645-9067	FDA HHS [1K08BL03978-01] Funding Source: Medline	FDA HHS		AIRD WC, 1995, P NATL ACAD SCI USA, V92, P4567, DOI 10.1073/pnas.92.10.4567; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BREIER G, 1995, DEV DYNAM, V204, P228, DOI 10.1002/aja.1002040303; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; Cepek KL, 1996, GENE DEV, V10, P2079, DOI 10.1101/gad.10.16.2079; CLARK ME, 1995, MOL CELL BIOL, V15, P6169; COENJAERTS FEJ, 1994, EMBO J, V13, P5401, DOI 10.1002/j.1460-2075.1994.tb06875.x; CORCORAN LM, 1993, GENE DEV, V7, P570, DOI 10.1101/gad.7.4.570; Corn BJ, 1991, CLIN BIOTECHNOL, V3, P15; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Fadel BM, 1998, BIOCHEM J, V330, P335; FALKNER FG, 1984, NATURE, V310, P71, DOI 10.1038/310071a0; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; HARATS D, 1995, J CLIN INVEST, V95, P1335, DOI 10.1172/JCI117784; HERR W, 1995, GENE DEV, V9, P1679, DOI 10.1101/gad.9.14.1679; Hidai C, 1998, GENE DEV, V12, P21, DOI 10.1101/gad.12.1.21; HOGAN B, 1986, MANIPULATING MOUSE E; JANSON L, 1990, P NATL ACAD SCI USA, V87, P4732, DOI 10.1073/pnas.87.12.4732; Kim MK, 1996, MOL CELL BIOL, V16, P4366; Kim U, 1996, NATURE, V383, P542, DOI 10.1038/383542a0; KORHONEN J, 1995, BLOOD, V86, P1828, DOI 10.1182/blood.V86.5.1828.bloodjournal8651828; KRISTIE TM, 1984, P NATL ACAD SCI-BIOL, V81, P4065, DOI 10.1073/pnas.81.13.4065; Lei ZM, 1997, J BIOL CHEM, V272, P14365, DOI 10.1074/jbc.272.22.14365; LUO Y, 1995, MOL CELL BIOL, V15, P4115; MURAGAKI Y, 1995, P NATL ACAD SCI USA, V92, P8763, DOI 10.1073/pnas.92.19.8763; MURPHY S, 1992, MOL CELL BIOL, V12, P3247, DOI 10.1128/MCB.12.7.3247; NODEN DM, 1989, AM REV RESPIR DIS, V140, P1097, DOI 10.1164/ajrccm/140.4.1097; OHARE P, 1988, EMBO J, V7, P4231, DOI 10.1002/j.1460-2075.1988.tb03320.x; PARDANAUD L, 1987, DEVELOPMENT, V100, P339; PARSLOW TG, 1984, P NATL ACAD SCI-BIOL, V81, P2650, DOI 10.1073/pnas.81.9.2650; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; SATO TN, 1993, P NATL ACAD SCI USA, V90, P9355, DOI 10.1073/pnas.90.20.9355; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SCHLAEGER TM, 1995, DEVELOPMENT, V121, P1089; Schlaeger TM, 1997, P NATL ACAD SCI USA, V94, P3058, DOI 10.1073/pnas.94.7.3058; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schubart DB, 1996, NATURE, V383, P538, DOI 10.1038/383538a0; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; ULLMAN KS, 1991, SCIENCE, V254, P558, DOI 10.1126/science.1683003; XIAO P, 1990, MOL CELL BIOL, V10, P4974, DOI 10.1128/MCB.10.9.4974; Xie QW, 1997, J BIOL CHEM, V272, P14867, DOI 10.1074/jbc.272.23.14867	47	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20376	20383		10.1074/jbc.274.29.20376	http://dx.doi.org/10.1074/jbc.274.29.20376			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400661	hybrid			2022-12-25	WOS:000081438300054
J	Hashimoto, A; Kurosaki, M; Gotoh, N; Shibuya, R; Kurosaki, T				Hashimoto, A; Kurosaki, M; Gotoh, N; Shibuya, R; Kurosaki, T			Shc regulates epidermal growth factor-induced activation of the JNK signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; GUANINE-NUCLEOTIDE EXCHANGE; N-TERMINAL KINASE; PROTEIN-KINASE; DEPENDENT ACTIVATION; RAS; GRB2; PHOSPHORYLATION; DOMAIN; TRANSDUCTION	Two adaptor molecules, Grb2 and Shc, have been implicated in the extracellular signal-regulated kinase (ERK) activation by receptor tyrosine kinases such as the epidermal growth factor receptor (EGFR). Here we show that the EGF-mediated ERK activation is abolished by loss of Grb2, whereas this response is not affected by loss of Shc. Conversely, the EGF-mediated c-Jun N-terminal kinase (JNK) activation is dependent on Shc, but not Grb2. These findings strongly support distinct roles for Grb2 and Shc in controlling ERK and JNK activation after EGF stimulation.	Kansai Med Univ, Inst Liver Res, Dept Mol Genet, Moriguchi, Osaka 5708506, Japan; Univ Tokyo, Inst Med Sci, Dept Genet, Minato Ku, Tokyo 1080071, Japan	Kansai Medical University; University of Tokyo	Kurosaki, T (corresponding author), Kansai Med Univ, Inst Liver Res, Dept Mol Genet, Moriguchi, Osaka 5708506, Japan.		Kurosaki, Tomohiro/D-1306-2009	Kurosaki, Tomohiro/0000-0002-6352-304X				Antonyak MA, 1998, J BIOL CHEM, V273, P2817, DOI 10.1074/jbc.273.5.2817; BAZTER AG, 1995, MOL CELL BIOL, V15, P4403; BAZTER AG, 1994, MOL CELL BIOL, V14, P5192; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; Gotoh N, 1995, ONCOGENE, V11, P2525; Hashimoto A, 1998, J EXP MED, V188, P1287, DOI 10.1084/jem.188.7.1287; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Logan SK, 1997, MOL CELL BIOL, V17, P5784, DOI 10.1128/MCB.17.10.5784; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATSUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sakaguchi K, 1998, MOL ENDOCRINOL, V12, P536, DOI 10.1210/me.12.4.536; SALCINI AE, 1994, ONCOGENE, V9, P2827; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; SOZERI O, 1992, ONCOGENE, V7, P2259; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Thomas D, 1997, J BIOL CHEM, V272, P22293, DOI 10.1074/jbc.272.35.22293; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451	33	53	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20139	20143		10.1074/jbc.274.29.20139	http://dx.doi.org/10.1074/jbc.274.29.20139			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400627	hybrid			2022-12-25	WOS:000081438300020
J	Lumb, MJ; Drake, AF; Danpure, CJ				Lumb, MJ; Drake, AF; Danpure, CJ			Effect of N-terminal alpha-helix formation on the dimerization and intracellular targeting of alanine : glyoxylate aminotransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; PRIMARY HYPEROXALURIA TYPE-1; MITOCHONDRIAL ASPARTATE-AMINOTRANSFERASE; LIVER ALDEHYDE DEHYDROGENASE; RAT-LIVER; PEROXISOMAL LOCALIZATION; STRUCTURAL FEATURES; PRECURSOR PROTEINS; MAMMALIAN-CELLS; SIGNAL PEPTIDE	The unparalleled peroxisome-to-mitochondrion mistargeting of alanine:glyoxylate aminotransferase (AGT) in the hereditary disease primary hyperoxaluria type 1 is caused by the combined presence of a common Pro(11) --> Leu polymorphism and a disease-specific Gly(170) --> Arg mutation. The Pro(11) --> Leu replacement generates a functionally weak N-terminal mitochondrial targeting sequence (MTS), the efficiency of which is increased by the additional presence of the Gly(170) --> Arg replacement. AGT dimerization is inhibited in the combined presence of both replacements but not when each is present separately. In this paper we have attempted to identify the structural determinants of AGT dimerization and mitochondrial mistargeting, Unlike most MTSs, the polymorphic MTS of AGT has little tendency to adopt an alpha-helical conformation in vitro. Nevertheless, it is able to target efficiently a monomeric green fluorescent (GFP) fusion protein, but not dimeric AGT, to mitochondria in transfected COS-1 cells. Increasing the propensity of this RIFTS to fold into an alpha-helix, by making a double Pro(11) --> Leu + Pro(10) --> Leu replacement, enabled it to target both GFP and AGT efficiently to mitochondria. The double Pro(11) --> Leu + Pro(10) --> Leu replacement retarded AGT dimerization in vitro as did the disease-causing double Pro(11) --> Leu + Gly(170) --> Arg replacement. These data suggest that N-terminal alpha-helix formation is more important for maintaining AGT in a conformation (ie. monomeric) compatible with mitochondrial import than it is for the provision of mitochondrial targeting information. The parallel effects of the Pro(10) --> Leu and Gly(170) --> Arg replacements on the dimerization and intracellular targeting of polymorphic AGT (containing the Pro(11) --> Leu replacement) raise the possibility that they might achieve their effects by the same mechanism.	UCL, MRC, Mol Cell Biol Lab, London WC1E 6BT, England; UCL, Dept Biol, London WC1E 6BT, England; Kings Coll London, Dept Pharm, London SW3 6LX, England	University of London; University College London; University of London; University College London; University of London; King's College London	Danpure, CJ (corresponding author), UCL, MRC, Mol Cell Biol Lab, Gower St, London WC1E 6BT, England.	c.danpure@ucl.ac.uk						Berks BC, 1996, MOL MICROBIOL, V22, P393, DOI 10.1046/j.1365-2958.1996.00114.x; CHEN WJ, 1987, J BIOL CHEM, V262, P15605; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; DANPURE CJ, 1994, EUR J CELL BIOL, V64, P295; DANPURE CJ, 1994, J INHERIT METAB DIS, V17, P487, DOI 10.1007/BF00711363; DANPURE CJ, 1986, FEBS LETT, V201, P20, DOI 10.1016/0014-5793(86)80563-4; DANPURE CJ, 1989, J CELL BIOL, V108, P1345, DOI 10.1083/jcb.108.4.1345; Danpure CJ., 1995, CALCIUM OXALATE BIOL, P189; DRAKE AF, 1995, BIOPOLYMERS, V4, P281; EILERS M, 1988, CELL, V52, P481, DOI 10.1016/0092-8674(88)90458-8; Endo T, 1996, J BIOL CHEM, V271, P4161; Fasman G.D., 1996, CIRCULAR DICHROISM C; Glaser E, 1998, PLANT MOL BIOL, V38, P311, DOI 10.1023/A:1006020208140; GLOVER JR, 1994, P NATL ACAD SCI USA, V91, P10541, DOI 10.1073/pnas.91.22.10541; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; HACHIYA N, 1994, EMBO J, V13, P5146, DOI 10.1002/j.1460-2075.1994.tb06844.x; HACHIYA N, 1993, EMBO J, V12, P1579, DOI 10.1002/j.1460-2075.1993.tb05802.x; Hammen PK, 1996, J BIOL CHEM, V271, P21041, DOI 10.1074/jbc.271.35.21041; Hammen PK, 1998, J EXP ZOOL, V282, P280, DOI 10.1002/(SICI)1097-010X(199809/10)282:1/2<280::AID-JEZ30>3.0.CO;2-V; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; Ishikawa K, 1996, J BIOCHEM, V119, P970; Kalish JE, 1996, EMBO J, V15, P3275, DOI 10.1002/j.1460-2075.1996.tb00692.x; Kanazawa M, 1997, BIOCHEM BIOPH RES CO, V239, P580, DOI 10.1006/bbrc.1997.7448; KARSLAKE C, 1990, BIOCHEMISTRY-US, V29, P9872, DOI 10.1021/bi00494a017; KOMIYA T, 1994, J BIOL CHEM, V269, P30893; Lain B, 1998, J BIOL CHEM, V273, P4406, DOI 10.1074/jbc.273.8.4406; LAIN B, 1994, J BIOL CHEM, V269, P15588; LAIN B, 1995, J BIOL CHEM, V270, P24732, DOI 10.1074/jbc.270.42.24732; Leiper JM, 1996, J CELL BIOL, V135, P939, DOI 10.1083/jcb.135.4.939; LEMIRE BD, 1989, J BIOL CHEM, V264, P20206; Llopis J, 1998, P NATL ACAD SCI USA, V95, P6803, DOI 10.1073/pnas.95.12.6803; MALIK KM, 1997, THESIS U LONDON LOND; MATTINGLY JR, 1993, J BIOL CHEM, V268, P26320; MCNEW JA, 1994, J CELL BIOL, V127, P1245, DOI 10.1083/jcb.127.5.1245; Mori M, 1998, BBA-MOL CELL RES, V1403, P12, DOI 10.1016/S0167-4889(98)00021-4; MOTLEY A, 1995, J CELL BIOL, V131, P95, DOI 10.1083/jcb.131.1.95; NOGUCHI T, 1979, ARCH BIOCHEM BIOPHYS, V196, P645, DOI 10.1016/0003-9861(79)90319-9; Oatey PB, 1996, EUR J BIOCHEM, V241, P374, DOI 10.1111/j.1432-1033.1996.00374.x; ODA T, 1987, EUR J BIOCHEM, V168, P537, DOI 10.1111/j.1432-1033.1987.tb13451.x; Omura T, 1998, J BIOCHEM-TOKYO, V123, P1010; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; PRENDERGAST FG, 1978, BIOCHEMISTRY-US, V17, P3448, DOI 10.1021/bi00610a004; PURDUE PE, 1991, P NATL ACAD SCI USA, V88, P10900, DOI 10.1073/pnas.88.23.10900; PURDUE PE, 1990, J CELL BIOL, V111, P2341, DOI 10.1083/jcb.111.6.2341; REYES AM, 1993, J BIOL CHEM, V268, P22281; RIZZUTO R, 1995, CURR BIOL, V5, P635, DOI 10.1016/S0960-9822(95)00128-X; ROISE D, 1988, EMBO J, V7, P649, DOI 10.1002/j.1460-2075.1988.tb02859.x; Sambrook J., 2002, MOL CLONING LAB MANU; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; THORNTON K, 1993, J BIOL CHEM, V268, P19906; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; Waltner M, 1996, J BIOL CHEM, V271, P21226, DOI 10.1074/jbc.271.35.21226; WANG Y, 1993, J BIOL CHEM, V268, P4759; WARD WW, 1982, PHOTOCHEM PHOTOBIOL, V35, P803, DOI 10.1111/j.1751-1097.1982.tb02651.x; Wiemer EAC, 1997, J CELL BIOL, V136, P71, DOI 10.1083/jcb.136.1.71; WIENHUES U, 1991, J CELL BIOL, V115, P1601, DOI 10.1083/jcb.115.6.1601; Yang F, 1996, NAT BIOTECHNOL, V14, P1246, DOI 10.1038/nbt1096-1246; Yano M, 1997, J BIOL CHEM, V272, P8459, DOI 10.1074/jbc.272.13.8459; Zhang CF, 1998, BIOCHEM BIOPH RES CO, V242, P390, DOI 10.1006/bbrc.1997.7970	59	40	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20587	20596		10.1074/jbc.274.29.20587	http://dx.doi.org/10.1074/jbc.274.29.20587			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400689	hybrid			2022-12-25	WOS:000081438300082
J	McDowell, LM; Burzio, LA; Waite, JH; Schaefer, J				McDowell, LM; Burzio, LA; Waite, JH; Schaefer, J			Rotational echo double resonance detection of cross-links formed in mussel byssus under high-flow stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMR	C-13{H-2} rotational echo double resonance NMR has been used to provide the first evidence for the formation of quinone-derived cross-links in mussel byssal plaques. Labeling of byssus was achieved by allowing mussels to filter feed from seawater containing L-[phenol-4-C-13]tyrosine and L-[ring-d(4)]tyrosine for 2 days. Plaques and threads were harvested from two groups of mussels over a period of 28 days. One group was maintained in stationary water while the other was exposed to turbulent now at 20 cm/s. The now-stressed byssal plaques exhibited significantly enhanced levels of 5, 5'-di-dihydroxyphenylalanine cross-links. The average concentration of di-dihydroxyphenylalanine cross-links in byssal plaques is 1 per 1800 total protein amino acid residues.	Washington Univ, Dept Chem, St Louis, MO 63130 USA; Univ Delaware, Coll Marine Studies, Newark, DE 19716 USA; Univ Calif Santa Barbara, Inst Marine Sci, Santa Barbara, CA 93106 USA	Washington University (WUSTL); University of Delaware; University of California System; University of California Santa Barbara	Schaefer, J (corresponding author), Washington Univ, Dept Chem, St Louis, MO 63130 USA.							ANDERSEN SO, 1992, BIOCHIM BIOPHYS ACTA, V1118, P134, DOI 10.1016/0167-4838(92)90140-9; Bell EC, 1997, MAR ECOL PROG SER, V159, P197, DOI 10.3354/meps159197; DOLMER P, 1994, OPHELIA, V40, P63, DOI 10.1080/00785326.1994.10429551; GULLION T, 1989, J MAGN RESON, V81, P196, DOI 10.1016/0022-2364(89)90280-1; HOLL SM, 1993, ARCH BIOCHEM BIOPHYS, V302, P255, DOI 10.1006/abbi.1993.1207; Klug CA, 1996, ARCH BIOCHEM BIOPHYS, V333, P221, DOI 10.1006/abbi.1996.0384; MASON HS, 1955, ADV ENZYMOL REL S BI, V16, P105; SCHAEFER J, 1987, SCIENCE, V235, P1200, DOI 10.1126/science.3823880; SCHMIDT A, 1992, J MAGN RESON, V96, P644, DOI 10.1016/0022-2364(92)90353-9; WAITE JH, 1990, COMP BIOCHEM PHYS B, V97, P19, DOI 10.1016/0305-0491(90)90172-P	10	163	169	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20293	20295		10.1074/jbc.274.29.20293	http://dx.doi.org/10.1074/jbc.274.29.20293			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400649	hybrid			2022-12-25	WOS:000081438300042
J	Mylvaganam, M; Lingwood, CA				Mylvaganam, M; Lingwood, CA			A convenient oxidation of natural glycosphingolipids to their "ceramide acids" for neoglycoconjugation - Bovine serum albumin-glycosylceramide acid conjugates as investigative probes for HIV gp120 coat protein-glycosphingolipid interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; GROWTH-FACTOR RECEPTOR; ENVELOPE GLYCOPROTEIN; GALACTOSYL CERAMIDE; GLOBOTRIAOSYL CERAMIDE; SIGNAL-TRANSDUCTION; GLYCOLIPID RECEPTOR; CHOLERA-TOXIN; CELL-ADHESION; FATTY-ACID	A new method to cleave the double bond of sphingolipids has been developed. Using limited concentrations of KMnO4 and an excess of NaIO4, in a neutral aqueous tert-butanol solvent system gave nearly quantitative yields of the oxidized product. A variety of natural glycosphingolipids (GSLs): GlcC, GalC, SGC, LC, Gb(3)C, Gb(4)C, Gg(4)C, Gb(5)C, and GM(1)C, gave the corresponding acids: 2-hydroxy-3-(N-acyl)-4-(O-glycosyl)-oxybutyric acids, i.e. "glycosyl ceramide acids" (GSL .(COOH)-C-C) in excellent yields (80-90%). Deacyl GSLs (dGSLs) were oxidized to acids containing the oligosaccharides devoid of hydrocarbon chains, i.e. "ceramide oligosaccharides" (dGSL . (NRR1COOH)-C-C, where R = R-1 = H; R = H, R-1 = CH,CO; or R = R, = Me). The efficacy of this method was demonstrated by transforming natural GSLs: GlcC, GalC, GalS, SGC, LC, Gb(3)C, and Gb(4)C into neoglycoproteins via coupling glycosyl ceramide acids (except GalS, which was coupled directly) to bovine serum albumin (BSA). Mass spectroscopic analysis of GalC-BSA conjugates, (GalC . CONH)(n)BSA and (GalS . NHCO)(n)BSA gave a value of 9 +/- 1 and 16 +/- 2 for n. Neoglycoconjugates derived from GlcC, GalC (type I and II and the behenic analog), SGC, LC, and Gb(3)C were recognized by the recombinant human immunodeficiency virus coat protein gp120 (rgp120), The GalS conjugate showed significantly reduced binding, and the Gb(4)C conjugate showed no binding. Thus, rgp120/GSL-BSA interaction requires a terminal galactose and/or glucose residue. Terminal N-acetylgalactosamine containing GSLs are not bound. The ceramide acid conjugates provide a more effective scaffold for presentation of glycone for rgp120 binding than those derived from dGSLs. The retention of receptor specificity of the glycoconjugates was validated by retention of the expected binding specificity of VT1 and VT2(e) for Gb(3)C and Gb(4)C conjugates, respectively. These studies open a new vista in the generation of glycoconjugates from GSLs and further emphasize the role of aglycone in glycolipid recognition.	Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A8, Canada; Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Lingwood, CA (corresponding author), Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052098] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK52098] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGMON V, 1991, EXP CELL RES, V196, P151, DOI 10.1016/0014-4827(91)90244-O; BERTOZZI CR, 1992, J AM CHEM SOC, V114, P10639, DOI 10.1021/ja00052a072; BHAT S, 1991, P NATL ACAD SCI USA, V88, P7131, DOI 10.1073/pnas.88.16.7131; BHAT S, 1993, AIDS RES HUM RETROV, V9, P175, DOI 10.1089/aid.1993.9.175; BORCH RF, 1971, J AM CHEM SOC, V93, P2897, DOI 10.1021/ja00741a013; BOYD B, 1989, NEPHRON, V51, P207, DOI 10.1159/000185286; BREMER EG, 1986, J BIOL CHEM, V261, P2434; DAVIS RJ, 1993, ADV LIPID RES, V25, P131; DEGRANDIS S, 1989, J BIOL CHEM, V264, P12520; Delezay O, 1996, BIOCHEMISTRY-US, V35, P15663, DOI 10.1021/bi961205g; Fantini J, 1997, J BIOL CHEM, V272, P7245, DOI 10.1074/jbc.272.11.7245; FENDERSON BA, 1990, BIOESSAYS, V12, P173, DOI 10.1002/bies.950120406; Hakomori S, 1996, CANCER RES, V56, P5309; Hakomori S, 1996, Adv Pharmacol, V36, P155, DOI 10.1016/S1054-3589(08)60581-5; HAKOMORI S, 1983, JNCI-J NATL CANCER I, V71, P231; HAKOMORI S, 1983, SPHINGOLIPID BIOCH; HAKOMORI S, 1986, SCI AM, V254, P40; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; Hammache D, 1998, J BIOL CHEM, V273, P7967, DOI 10.1074/jbc.273.14.7967; HAROUSE JM, 1991, SCIENCE, V253, P320, DOI 10.1126/science.1857969; HEAD S, 1990, INFECT IMMUN, V58, P1532, DOI 10.1128/IAI.58.6.1532-1537.1990; HOLMGREN J, 1994, PROG BRAIN RES, V101, P163; Iwabuchi K, 1998, J BIOL CHEM, V273, P9130, DOI 10.1074/jbc.273.15.9130; Jarvis WD, 1996, CLIN CANCER RES, V2, P1; KARLSSON KA, 1995, CURR OPIN STRUC BIOL, V5, P622, DOI 10.1016/0959-440X(95)80054-9; KIARASH A, 1994, J BIOL CHEM, V269, P11138; KIGUCHI K, 1993, BIOCHIM BIOPHYS ACTA, V1176, P27, DOI 10.1016/0167-4889(93)90173-M; KOJIMA N, 1991, J BIOL CHEM, V266, P17552; KUNDU SK, 1979, J LIPID RES, V20, P825; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; LAINE R, 1974, J BIOL CHEM, V14, P4460; Lee Y. C., 1994, P3; LEMIEUX RU, 1955, CAN J CHEM, V33, P1701, DOI 10.1139/v55-208; LINGWOOD C, 1991, J CELL PHYSIOL, V146, P258, DOI 10.1002/jcp.1041460210; LINGWOOD CA, 1987, J BIOL CHEM, V262, P8834; Lingwood CA, 1996, GLYCOCONJUGATE J, V13, P495, DOI 10.1007/BF00731435; Lingwood CA, 1996, TRENDS MICROBIOL, V4, P147, DOI 10.1016/0966-842X(96)10017-2; LINGWOOD CA, 1992, CURR OPIN STRUC BIOL, V2, P693; MACDONALD DL, 1980, J LIPID RES, V21, P642; March J., 1977, ADV ORGANIC CHEM, V2nd; Nyholm PG, 1996, CHEM BIOL, V3, P263, DOI 10.1016/S1074-5521(96)90106-4; PAGANO RE, 1988, BIOCHEMISTRY-US, V27, P4439, DOI 10.1021/bi00412a034; PICKING WD, 1993, BIOCHEM BIOPH RES CO, V195, P1153, DOI 10.1006/bbrc.1993.2165; Puri A, 1998, P NATL ACAD SCI USA, V95, P14435, DOI 10.1073/pnas.95.24.14435; Ragupathi G, 1997, ANGEW CHEM INT EDIT, V36, P125, DOI 10.1002/anie.199701251; Roy R, 1998, GLYCOCONJUGATE J, V15, P251, DOI 10.1023/A:1006945028547; Roy R, 1996, TRENDS GLYCOSCI GLYC, V8, P79, DOI 10.4052/tigg.8.79; ROY R, 1994, METHOD ENZYMOL, V242, P198; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SCHNAAR RL, 1994, METHOD ENZYMOL, V230, P348; Schnaar RL, 1998, ANN NY ACAD SCI, V845, P92, DOI 10.1111/j.1749-6632.1998.tb09664.x; SONNINO S, 1985, J LIPID RES, V26, P248; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; STANKER LH, 1985, J IMMUNOL METHODS, V76, P157, DOI 10.1016/0022-1759(85)90488-0; STROMBERG N, 1990, ARCH ORAL BIOL, V35, pS131, DOI 10.1016/0003-9969(90)90143-X; STULTS CLM, 1989, METHOD ENZYMOL, V179, P167; TANIGUCHI N, 1985, J BIOL CHEM, V260, P4908; Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514; YAHI N, 1992, J VIROL, V66, P4848, DOI 10.1128/JVI.66.8.4848-4854.1992; YAMAKAWA T, 1960, J BIOCHEM-TOKYO, V48, P490, DOI 10.1093/oxfordjournals.jbchem.a127197; YOUNG WW, 1979, J LIPID RES, V20, P275	61	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20725	20732		10.1074/jbc.274.29.20725	http://dx.doi.org/10.1074/jbc.274.29.20725			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400707	hybrid			2022-12-25	WOS:000081438300100
J	Balint, E; Bates, S; Vousden, KH				Balint, E; Bates, S; Vousden, KH			Mdm2 binds p73 alpha without targeting degradation	ONCOGENE			English	Article						p73; p53; Mdm2; E6; protein degradation	P53 TUMOR-SUPPRESSOR; IN-VIVO; P73; PROTEIN; GROWTH; GENE; E6; TRANSACTIVATION; ONCOPROTEINS; ACTIVATION	The function of the p53 tumor suppressor protein is regulated by interaction with Mdm2, which targets p53 for ubiquitin dependent degradation. We show here that like p53, p73 alpha forms an interaction with Mdm2, both in vitro and in cells, but this does not result in the degradation of the p73 alpha protein. The human papillomavirus E6 protein also fails to degrade p73 alpha, suggesting that the mechanisms governing p73 alpha stability are distinct from those known to regulate p53 stability. However, the interaction of Mdm2 with 73 alpha is sufficient to impede p73 alpha transcriptional function, despite the lack of degradation.	NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Vousden, KH (corresponding author), NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Bldg 560,Room 22-96,W 7th St, Frederick, MD 21702 USA.		Balint, Eva/B-8695-2008	Balint, Eva/0000-0002-1258-6892				Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; CROOK T, 1992, LANCET, V339, P1070, DOI 10.1016/0140-6736(92)90662-M; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Kubbutat MHG, 1998, MOL MED TODAY, V4, P250, DOI 10.1016/S1357-4310(98)01260-X; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; KUBBUTAT MHG, 1999, IN PRESS CELL GROWTH; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; MARSTON NJ, 1994, ONCOGENE, V9, P2707; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; Prabhu NS, 1998, INT J ONCOL, V13, P5; Roth J, 1998, J VIROL, V72, P8510, DOI 10.1128/JVI.72.11.8510-8516.1998; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Zhu JH, 1998, CANCER RES, V58, P5061	28	190	193	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 8	1999	18	27					3923	3929		10.1038/sj.onc.1202781	http://dx.doi.org/10.1038/sj.onc.1202781			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KU	10435614				2022-12-25	WOS:000081327800001
J	Brummel, KE; Butenas, S; Mann, KG				Brummel, KE; Butenas, S; Mann, KG			An integrated study of fibrinogen during blood coagulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	12th Symposium of the Protein-Society	JUL 25-29, 1998	SAN DIEGO, CA	Protein Soc			PERFORMANCE LIQUID-CHROMATOGRAPHY; ACTIVABLE FIBRINOLYSIS INHIBITOR; TISSUE FACTOR PATHWAY; FIBRINOPEPTIDE-A; CROSS-LINKING; HUMAN PLASMA; LATERAL AGGREGATION; STABILIZING FACTOR; FACTOR-XIII; THROMBIN	The rate of conversion of fibrinogen (Fg) to the insoluble product fibrin (Fn) is a key factor in hemostasis. We have developed methods to quantitate fibrinopeptides (FPs) and soluble and insoluble Fg/Fn products during the tissue factor induced clotting of whole blood. Significant FPA generation (> 50%) occurs prior to visible clotting (4 +/- 0.2 min) coincident with factor XIII activation. At this time Fg is mostly in solution along with high molecular weight cross-linked products. Cross-linking of gamma-chains is virtually complete (5 min) prior to the release of FPB, a process that does not occur until after clot formation. FPB is detected still attached to the beta-chain throughout the time course demonstrating release of only low levels of FPB from the clot. After release of FPB a carboxypeptidase-B-like enzyme removes the carboxyl-terminal arginine resulting exclusively in des-Arg FPB by the 20-min time point. This process is inhibited by epsilon-aminocaproic acid. These results demonstrate that transglutaminase and carboxypeptidase enzymes are activated simultaneously with Fn formation. The initial clot is a composite of Fn I and Bg already displaying gamma-gamma cross-linking prior to the formation of Fn II with BP-chain remaining mostly intact followed by the selective degradation of FPB to des-Arg FPB.	Univ Vermont, Coll Med, Dept Biochem, Burlington, VT 05405 USA	University of Vermont	Mann, KG (corresponding author), Univ Vermont, Coll Med, Dept Biochem, Given Bldg,Hlth Sci Complex, Burlington, VT 05405 USA.	kmann@protein.uvm.edu			NHLBI NIH HHS [T32 HL07594-13, HL 46703] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007594, P01HL046703] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; Bajzar L, 1996, BLOOD, V88, P2093, DOI 10.1182/blood.V88.6.2093.bloodjournal8862093; BELEW M, 1980, BIOCHIM BIOPHYS ACTA, V621, P169, DOI 10.1016/0005-2795(80)90169-5; BINNIE CG, 1993, BIOCHEMISTRY-US, V32, P107, DOI 10.1021/bi00052a015; BLOMBACK B, 1978, NATURE, V275, P501, DOI 10.1038/275501a0; Blomback B, 1996, THROMB RES, V83, P1, DOI 10.1016/0049-3848(96)00111-9; BLOMBACK B, 1966, BIOCHIM BIOPHYS ACTA, V115, P371, DOI 10.1016/0304-4165(66)90437-5; Boffa MB, 1998, J BIOL CHEM, V273, P2127, DOI 10.1074/jbc.273.4.2127; Broze GJ, 1996, BLOOD, V88, P3815, DOI 10.1182/blood.V88.10.3815.bloodjournal88103815; Butenas S, 1997, J BIOL CHEM, V272, P21527, DOI 10.1074/jbc.272.34.21527; Cawthern KM, 1998, BLOOD, V91, P4581, DOI 10.1182/blood.V91.12.4581.412k12_4581_4592; CHEN R, 1971, BIOCHEMISTRY-US, V10, P4486, DOI 10.1021/bi00800a021; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; EBERT RF, 1985, ANAL BIOCHEM, V148, P70, DOI 10.1016/0003-2697(85)90629-3; ECKHARDT T, 1981, J CLIN INVEST, V67, P809, DOI 10.1172/JCI110098; EMANUELE RM, 1986, SEMIN THROMB HEMOST, V12, P318, DOI 10.1055/s-2007-1003573; ERDOS EG, 1962, BIOCHEM PHARMACOL, V11, P585, DOI 10.1016/0006-2952(62)90119-3; ERDOS EG, 1970, HDB EXPERIMENTAL PHA, V25, P289; Folk J E, 1977, Adv Protein Chem, V31, P1, DOI 10.1016/S0065-3233(08)60217-X; FOLK JE, 1960, J BIOL CHEM, V235, P2272; GRON B, 1992, BLOOD COAGUL FIBRIN, V3, P731; HANTGAN R, 1983, ANN NY ACAD SCI, V408, P344, DOI 10.1111/j.1749-6632.1983.tb23256.x; HANTGAN RR, 1979, J BIOL CHEM, V254, P1272; HENDRIKS D, 1990, BIOCHIM BIOPHYS ACTA, V1034, P86, DOI 10.1016/0304-4165(90)90157-R; HERMANS J, 1982, SEMIN THROMB HEMOST, V8, P11, DOI 10.1055/s-2007-1005039; HIGGINS DL, 1983, J BIOL CHEM, V258, P9276; HOJIMA Y, 1980, THROMB RES, V20, P149, DOI 10.1016/0049-3848(80)90381-3; JONES KC, 1994, J BIOL CHEM, V269, P23367; KANAIDE H, 1975, J LAB CLIN MED, V85, P574; KOEHN JA, 1981, ANAL BIOCHEM, V116, P349, DOI 10.1016/0003-2697(81)90370-5; Kuijper PHM, 1997, BLOOD, V89, P166, DOI 10.1182/blood.V89.1.166.166_166_175; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON JH, 1993, METHOD ENZYMOL, V222, P177; LAWSON JH, 1994, J BIOL CHEM, V269, P23357; LORAND L, 1969, BIOCHEM BIOPH RES CO, V37, P219, DOI 10.1016/0006-291X(69)90722-0; LORAND L, 1993, METHOD ENZYMOL, V222, P22; Lundblad R L, 1976, Methods Enzymol, V45, P156; Mann KG, 1998, BLOOD COAGUL FIBRIN, V9, pS3; MANN KG, 1990, BLOOD, V76, P1; MANN KG, 1992, SEMIN HEMATOL, V29, P213; MARTINELLI RA, 1979, ANAL BIOCHEM, V96, P246, DOI 10.1016/0003-2697(79)90579-7; MCKEE PA, 1970, P NATL ACAD SCI USA, V66, P738, DOI 10.1073/pnas.66.3.738; MIKUNI Y, 1973, BIOCHEM BIOPH RES CO, V54, P1393, DOI 10.1016/0006-291X(73)91141-8; MORRISSEY JH, 1993, BLOOD, V81, P734; Mosesson MW, 1997, BLOOD COAGUL FIBRIN, V8, P257, DOI 10.1097/00001721-199707000-00001; MOSSESON MW, 1992, SEMIN HEMATOL, V29, P177; NG AS, 1993, METHOD ENZYMOL, V222, P341; NOSSEL HL, 1974, J CLIN INVEST, V54, P43, DOI 10.1172/JCI107749; OSTERUD B, 1977, P NATL ACAD SCI USA, V74, P5260, DOI 10.1073/pnas.74.12.5260; Rand MD, 1996, BLOOD, V88, P3432, DOI 10.1182/blood.V88.9.3432.bloodjournal8893432; RAPAPORT SI, 1995, THROMB HAEMOSTASIS, V74, P7; SCHWARTZ ML, 1971, J BIOL CHEM, V246, P5851; SEYDEWITZ HH, 1985, THROMB RES, V40, P29, DOI 10.1016/0049-3848(85)90347-0; SHAFER JA, 1988, CRIT REV CL LAB SCI, V26, P1; SHAINOFF JR, 1983, ANN NY ACAD SCI, V408, P254, DOI 10.1111/j.1749-6632.1983.tb23249.x; SOUTHAN C, 1986, THROMB RES, V43, P195, DOI 10.1016/0049-3848(86)90060-5; Spraggon G, 1997, NATURE, V389, P455, DOI 10.1038/38947; STRAUGHN W, 1966, THROMB DIATH HAEMOST, V16, P198, DOI 10.1055/s-0038-1655637; TAMAKI T, 1981, BIOCHIM BIOPHYS ACTA, V661, P280, DOI 10.1016/0005-2744(81)90016-4; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Valnickova Z, 1998, J BIOL CHEM, V273, P27220, DOI 10.1074/jbc.273.42.27220; WEISEL JW, 1986, BIOPHYS J, V50, P1079, DOI 10.1016/S0006-3495(86)83552-4; WEISEL JW, 1993, J MOL BIOL, V232, P285, DOI 10.1006/jmbi.1993.1382; WEISS HJ, 1987, ANN NY ACAD SCI, V516, P380, DOI 10.1111/j.1749-6632.1987.tb33057.x; WEITZ JI, 1988, J CLIN INVEST, V82, P1700, DOI 10.1172/JCI113783	66	103	115	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22862	22870		10.1074/jbc.274.32.22862	http://dx.doi.org/10.1074/jbc.274.32.22862			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	223YD	10428872	hybrid			2022-12-25	WOS:000081868400102
J	Cain, K; Brown, DG; Langlais, C; Cohen, GM				Cain, K; Brown, DG; Langlais, C; Cohen, GM			Caspase activation involves the formation of the aposome, a large (similar to 700 kDa) caspase-activating complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; CYTOCHROME-C; CELL-DEATH; APOPTOSIS; PROTEASES; SUBUNIT; INHIBITION; MCH2-ALPHA; CED-4; CPP32	In mammals, apoptotic protease-activating factor 1 (Apaf-1), cytochrome c, and dATP activate caspase-9, which initiates the postmitochondrial-mediated caspase cascade by proteolytic cleavage/activation of effector caspases to form active similar to 60-kDa heterotetramers. We now demonstrate that activation of caspases either in apoptotic cells or following dATP activation of cell lysates results in the formation of two large but different sized protein complexes, the "aposome" and the "microaposome". Surprisingly, most of the DEVDase activity in the lysate was present in the aposome and microaposome complexes with only small amounts of active caspase-3 present as its free similar to 60-kDa heterotetramer. The larger aposome complex (M-r = similar to 700,000) contained Apaf-1 and processed caspase-9, -3, and -7. The smaller microaposome complex (M-r = similar to 200,000-300,000) contained active caspase-3 and -7 but little if any Apaf-1 or active caspase-9. Lysates isolated from control THP.1 cells, prior to caspase activation, showed striking differences in the distribution of key apoptotic proteins. Apaf-1 and procaspase-7 may be functionally complexed as they eluted as an similar to 200-300-kDa complex, which did not have caspase cleavage (DEVDase) activity. Procaspase-3 and -9 were present as separate and smaller 60-90-kDa (dimer) complexes. During caspase activation, Apaf-1, caspase-9, and the effector caspases redistributed and formed the aposome. This resulted in the processing of the effector caspases, which were then released, possibly bound to other proteins, to form the microaposome complex.	Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England	University of Leicester	Cain, K (corresponding author), Univ Leicester, MRC, Toxicol Unit, Hodgkin Bldg,POB 138,Lancaster Rd, Leicester LE1 9HN, Leics, England.		Cohen, Gerald M/A-1687-2008					Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Chandler JM, 1998, J BIOL CHEM, V273, P10815, DOI 10.1074/jbc.273.18.10815; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Drexler HCA, 1998, APOPTOSIS, V3, P1, DOI 10.1023/A:1009604900979; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Hengartner MO, 1997, NATURE, V388, P714, DOI 10.1038/41873; HOUGH R, 1987, J BIOL CHEM, V262, P8303; LEWIS VA, 1992, NATURE, V358, P249, DOI 10.1038/358249a0; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liou AKF, 1997, EMBO J, V16, P4311, DOI 10.1093/emboj/16.14.4311; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Lupas A, 1997, TRENDS BIOCHEM SCI, V22, P399, DOI 10.1016/S0968-0004(97)01117-1; MacFarlane M, 1997, J CELL BIOL, V137, P469, DOI 10.1083/jcb.137.2.469; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; Takahashi A, 1996, CURR OPIN GENET DEV, V6, P50, DOI 10.1016/S0959-437X(96)90010-6; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	25	246	254	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22686	22692		10.1074/jbc.274.32.22686	http://dx.doi.org/10.1074/jbc.274.32.22686			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428850	hybrid			2022-12-25	WOS:000081868400080
J	Ross, TS; Gilliland, DG				Ross, TS; Gilliland, DG			Transforming properties of the Huntingtin interacting protein 1/platelet-derived growth factor beta receptor fusion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOMONOCYTIC LEUKEMIA; HEMATOPOIETIC-CELL LINES; DNA-BINDING ACTIVITY; SACCHAROMYCES-CEREVISIAE; PDGF RECEPTOR; KINASE; TEL; PHOSPHORYLATION; ACTIVATION; SIGNAL	We have previously reported that the Huntingtin interacting protein 1 (HIP1) gene is fused to the platelet-derived growth factor beta receptor (PDGF beta R) gene in a patient with chronic myelomonocytic leukemia. We now show that HIP1/PDGF beta R oligomerizes, is constitutively tyrosine-phosphorylated, and transforms the murine hematopoietic cell line, Ba/F3, to interleukin-3-independent growth. A kinase-inactive mutant is neither tyrosine-phosphorylated nor able to transform Ba/F3 cells. Oligomerization and kinase activation required the 55-amino acid carboxyl-terminal TALIN homology region but not the leucine zipper domain. Tyrosine phosphorylation of a 130-kDa protein and STAT5 correlates with transformation in cells expressing HIP1/PDGF beta R and related mutants. A deletion mutant fusion protein that contains only the TALIN homology region of HIP1 fused to PDGF beta R is incapable of transforming Ba/F3 cells and does not tyrosine-phosphorylate p130 or STAT5, although it is itself constitutively tyrosine-phosphorylated. We have also analyzed cells expressing Tyr --> Phe mutants of HIP1/PDGF beta R in the known PDGF beta R SH2 docking sites and report that none of these sites are necessary for STAT5 activation, p130 phosphorylation, or Ba/F3 transformation. The correlation of factor-independent growth of hematopoietic cells with p130 and STAT5 phosphorylation/activation in both the HIP1/ PDGF beta R Tyr --> Phe and deletion mutational variants suggests that both STAT5 and p130 are important for transformation mediated by HIP1/PDGF beta R.	Brigham & Womens Hosp, Div Hematol Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Ross, TS (corresponding author), 4 Blackfan Circle Ste 418, Boston, MA 02115 USA.	gilliland@calvin.bwh.harvard.edu		Ross, Theodora/0000-0002-9166-1802	NATIONAL CANCER INSTITUTE [K08CA076025] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007623] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050654] Funding Source: NIH RePORTER; NCI NIH HHS [K08 CA76025-01] Funding Source: Medline; NHLBI NIH HHS [T32 HL07623] Funding Source: Medline; NIDDK NIH HHS [P01DK50654] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; COURTNEIDGE SA, 1991, CELL GROWTH DIFFER, V2, P483; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; HOLTZMAN DA, 1993, J CELL BIOL, V122, P635, DOI 10.1083/jcb.122.3.635; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; Kalchman MA, 1997, NAT GENET, V16, P44, DOI 10.1038/ng0597-44; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; Okuda K, 1996, ONCOGENE, V13, P1147; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; REES DJG, 1990, NATURE, V347, P685, DOI 10.1038/347685a0; Ross TS, 1998, BLOOD, V91, P4419, DOI 10.1182/blood.V91.12.4419.412k43_4419_4426; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schwaller J, 1998, EMBO J, V17, P5321, DOI 10.1093/emboj/17.18.5321; Shuai K, 1996, ONCOGENE, V13, P247; Tomasson MH, 1999, BLOOD, V93, P1707, DOI 10.1182/blood.V93.5.1707.405k24_1707_1714; Valgeirsdottir S, 1998, ONCOGENE, V16, P505, DOI 10.1038/sj.onc.1201555; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F	25	57	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22328	22336		10.1074/jbc.274.32.22328	http://dx.doi.org/10.1074/jbc.274.32.22328			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428802	hybrid			2022-12-25	WOS:000081868400032
J	Thoden, JB; Raushel, FM; Wesenberg, G; Holden, HM				Thoden, JB; Raushel, FM; Wesenberg, G; Holden, HM			The binding of inosine monophosphate to Escherichia coli carbamoyl phosphate synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITOR; ACTIVATOR; SUBSTRATE; ANGSTROM; CRYSTAL; DOMAIN; SITES; UMP	Carbamoyl phosphate synthetase (CPS) from Escherichia coli catalyzes the formation of carbamoyl phosphate, which is subsequently employed in both the pyrimidine and arginine biosynthetic pathways. The reaction mechanism is known to proceed through at least three highly reactive intermediates: ammonia, carboxyphosphate, and carbamate, In keeping with the fact that the product of CPS is utilized in two competing metabolic pathways, the enzyme is highly regulated by a variety of effector molecules including potassium and ornithine, which function as activators, and UMP, which acts as an inhibitor. IMP is also known to bind to CPS but the actual effect of this ligand on the activity of the enzyme is dependent upon both temperature and assay conditions. Here we describe the three-dimensional architecture of CPS with bound IMP determined and refined to 2.1 Angstrom resolution. The nucleotide is situated at the C-terminal portion of a five-stranded parallel beta- sheet in the allosteric domain formed by Ser(937) to Lys(1073). Those amino acid side chains responsible for anchoring the nucleotide to the polypeptide chain include Lys(954), Thr(974), Thr(977), Lys(993), Asn(1015), and Thr(1017). A series of hydrogen bonds connect the IMP-binding pocket to the active site of the large subunit known to function in the phosphorylation of the unstable intermediate, carbamate, This structural analysis reveals, for the first time, the detailed manner in which CPS accommodates nucleotide monophosphate effector molecules within the allosteric domain.	Univ Wisconsin, Coll Agr & Life Sci, Dept Biochem, Madison, WI 53705 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA	University of Wisconsin System; University of Wisconsin Madison; Texas A&M University System; Texas A&M University College Station	Holden, HM (corresponding author), Univ Wisconsin, Coll Agr & Life Sci, Dept Biochem, 1710 Univ Ave, Madison, WI 53705 USA.		Raushel, Frank/B-7125-2015	Raushel, Frank/0000-0002-5918-3089	NIDDK NIH HHS [DK30343] Funding Source: Medline; NIGMS NIH HHS [GM55513] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK030343, R01DK030343] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON PM, 1977, BIOCHEMISTRY-US, V16, P587, DOI 10.1021/bi00623a005; BOETTCHER B, 1981, J BIOL CHEM, V256, P5977; BOETTCHER B, 1982, J BIOL CHEM, V257, P3971; BRAXTON BL, 1992, BIOCHEMISTRY-US, V31, P2309, DOI 10.1021/bi00123a015; Braxton BL, 1996, BIOCHEMISTRY-US, V35, P11918, DOI 10.1021/bi961305m; Braxton BL, 1999, BIOCHEMISTRY-US, V38, P1394, DOI 10.1021/bi982097w; Bueso J, 1999, BIOCHEMISTRY-US, V38, P3910, DOI 10.1021/bi982871f; Cervera J, 1996, BIOCHEMISTRY-US, V35, P7247, DOI 10.1021/bi952549u; CZERWINSKI RM, 1995, BIOCHEMISTRY-US, V34, P13920, DOI 10.1021/bi00042a025; Gregoriou M, 1998, PROTEIN SCI, V7, P915; KASPRZAK AA, 1988, BIOCHEMISTRY-US, V27, P8050, DOI 10.1021/bi00421a012; KOSMORSKY GS, 1995, J NEURO-OPHTHALMOL, V15, P147; LIAW SH, 1994, BIOCHEMISTRY-US, V33, P11184, DOI 10.1021/bi00203a014; MATTHEWS SL, 1972, BIOCHEMISTRY-US, V11, P1176, DOI 10.1021/bi00757a010; MIRAN SG, 1991, BIOCHEMISTRY-US, V30, P7901, DOI 10.1021/bi00246a005; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Oikonomakos NG, 1996, PROTEIN SCI, V5, P2416, DOI 10.1002/pro.5560051204; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Poland BW, 1996, J MOL BIOL, V264, P1013, DOI 10.1006/jmbi.1996.0693; Rossmann M. G., 1972, MOL REPLACEMENT METH; SCHIRMER T, 1990, NATURE, V343, P140, DOI 10.1038/343140a0; Thoden JB, 1998, BIOCHEMISTRY-US, V37, P8825, DOI 10.1021/bi9807761; Thoden JB, 1999, ACTA CRYSTALLOGR D, V55, P8, DOI 10.1107/S0907444998006234; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6305, DOI 10.1021/bi970503q; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; TROTTA PP, 1971, P NATL ACAD SCI USA, V68, P2599, DOI 10.1073/pnas.68.10.2599	27	28	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22502	22507		10.1074/jbc.274.32.22502	http://dx.doi.org/10.1074/jbc.274.32.22502			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428826	hybrid			2022-12-25	WOS:000081868400056
J	Tonini, R; Grohovaz, F; Laporta, CAM; Mazzanti, M				Tonini, R; Grohovaz, F; Laporta, CAM; Mazzanti, M			Gating mechanism of the nuclear pore complex channel in isolated neonatal and adult mouse liver nuclei	FASEB JOURNAL			English	Article						NPCs; nuclei isolation; histogram analysis; single-channel currents	IONIC PERMEABILITY; PROTEIN IMPORT; ENVELOPE; TRANSPORT; CELLS; MEMBRANE; CALCIUM; ATP; MICROSCOPY; VOLTAGE	Several types of ionic channels on the outer membrane of the nuclear envelope communicate with the nuclear cisternae. These are distinct from nucleocytoplasmic pathways, the nuclear pores that span the double membrane of the envelope and are the route for RNA and protein traffic in the nucleus. Recent data indicate that the nuclear pores may also function as ion channels. The most probable candidate for nucleocytoplasmic ion flux is a 300-400 pS pathway observed in many nuclear preparations. Morphological and functional studies of nuclear envelope suggest a tight relationship between the large conductance channel and the pore complex. However, there is no direct evidence for gating of the nuclear pore or its ability to open and close as a conventional channel. This study shows that in liver nuclei isolated from newborn mouse, there is a substantial correspondence between the number of pores and the number of channels recorded during patch-clamp. This is not the case for adult nuclei. Although pore density is comparable, some nuclear cytoskeletal components, such as actin and nonmuscle myosin, show a significant increase in the adult preparation. Previous studies demonstrate the presence of these two proteins in association with the pore complex. Here we show that by using actin filament disrupter, we were able to increase the number of active channels in adult isolated nuclei. We suggest that a functional interaction between actin filaments and the nuclear pore complex could regulate nucleocytoplasmic permeability.	Univ La Sapienza, Dipartimento Biol Cellulare & Sviluppo, I-00185 Rome, Italy; Univ Milano 1, Dipartimento Fisiol & Biochim Gen, Milan, Italy; San Raffaele Sci Inst, CNR, Ctr Farmacol Cellulare & Mol & Dibit, San Raffaele, Italy	Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Mazzanti, M (corresponding author), Univ La Sapienza, Dipartimento Biol Cellulare & Sviluppo, Piazalle A Moro 5, I-00185 Rome, Italy.		Mazzanti, Michele/A-8941-2011; Tonini, Raffaella/J-2960-2012; Grohovaz, Fabio/K-8226-2016; la porta, caterina/K-7345-2013	Grohovaz, Fabio/0000-0003-4635-259X; TONINI, Raffaella/0000-0003-1652-4709; la porta, caterina/0000-0002-3010-8966; Mazzanti, Michele/0000-0002-1819-3811				AKEY CW, 1995, J MOL BIOL, V248, P273, DOI 10.1016/S0022-2836(95)80050-6; AKEY CW, 1990, BIOPHYS J, V58, P341, DOI 10.1016/S0006-3495(90)82381-X; ALMOHANNA FA, 1994, NATURE, V367, P745, DOI 10.1038/367745a0; Assandri R, 1997, J MEMBRANE BIOL, V157, P301, DOI 10.1007/s002329900237; Badminton MN, 1998, CELL CALCIUM, V23, P79, DOI 10.1016/S0143-4160(98)90105-1; BERRIDGE MJ, 1979, J EXP BIOL, V81, P217; BERRIOS M, 1986, J CELL BIOL, V103, P711, DOI 10.1083/jcb.103.3.711; BUSTAMANTE JO, 1994, J MEMBRANE BIOL, V138, P105; BUSTAMANTE JO, 1992, PFLUG ARCH EUR J PHY, V421, P473, DOI 10.1007/BF00370259; Csermely P, 1995, BBA-REV BIOMEMBRANES, V1241, P425, DOI 10.1016/0304-4157(95)00015-1; DALE B, 1994, P ROY SOC B-BIOL SCI, V255, P119, DOI 10.1098/rspb.1994.0017; Danker T, 1997, CELL BIOL INT, V21, P747, DOI 10.1006/cbir.1997.0219; DINGWALL C, 1992, SCIENCE, V258, P942, DOI 10.1126/science.1439805; DINGWALL C, 1991, BIOESSAYS, V13, P213, DOI 10.1002/bies.950130503; Draguhn A, 1997, J MEMBRANE BIOL, V158, P159, DOI 10.1007/s002329900253; Goldberg MW, 1996, J MOL BIOL, V257, P848, DOI 10.1006/jmbi.1996.0206; GREBER UF, 1992, J CELL BIOL, V116, P15, DOI 10.1083/jcb.116.1.15; Hille B., 1992, IONIC CHANNELS EXCIT; INNOCENTI B, 1993, J MEMBRANE BIOL, V131, P137, DOI 10.1007/BF02791322; LOEWENST.WR, 1966, ANN NY ACAD SCI, V137, P708, DOI 10.1111/j.1749-6632.1966.tb50192.x; LOEWENSTEIN WR, 1963, J GEN PHYSIOL, V46, P1123, DOI 10.1085/jgp.46.6.1123; MAK DOD, 1994, J BIOL CHEM, V269, P29375; MARUYAMA Y, 1995, PFLUG ARCH EUR J PHY, V430, P148, DOI 10.1007/BF00373851; MATZKE AJM, 1992, FEBS LETT, V302, P81, DOI 10.1016/0014-5793(92)80290-W; MATZKE AJM, 1990, FEBS LETT, V271, P161, DOI 10.1016/0014-5793(90)80397-2; Mazzanti M, 1998, NEWS PHYSIOL SCI, V13, P44; MAZZANTI M, 1990, NATURE, V343, P764, DOI 10.1038/343764a0; MAZZANTI M, 1987, BIOPHYS J, V52, P95, DOI 10.1016/S0006-3495(87)83192-2; MAZZANTI M, 1994, FASEB J, V8, P231, DOI 10.1096/fasebj.8.2.7509760; Meldolesi J, 1998, NATURE, V392, P863, DOI 10.1038/31804; Nakielny S, 1997, ANNU REV NEUROSCI, V20, P269, DOI 10.1146/annurev.neuro.20.1.269; OBERLEITHNER H, 1992, CLIN INVESTIGATOR, V70, P816; OBERLEITHNER H, 1993, PFLUG ARCH EUR J PHY, V423, P88, DOI 10.1007/BF00374965; PerezTerzic C, 1996, SCIENCE, V273, P1875, DOI 10.1126/science.273.5283.1875; POWERS MA, 1994, CELL, V79, P931, DOI 10.1016/0092-8674(94)90024-8; Prat AG, 1996, AM J PHYSIOL-CELL PH, V270, pC1532, DOI 10.1152/ajpcell.1996.270.5.C1532; Rakowska A, 1998, J MEMBRANE BIOL, V163, P129, DOI 10.1007/s002329900377; Rousseau E, 1996, BIOPHYS J, V70, P703, DOI 10.1016/S0006-3495(96)79610-8; SAKMANN B, 1995, SINGLECHANNEL RECORD; SCHINDLER M, 1986, J CELL BIOL, V102, P859, DOI 10.1083/jcb.102.3.859; Schlenstedt G, 1996, FEBS LETT, V389, P75, DOI 10.1016/0014-5793(96)00583-2; TABARES L, 1991, J MEMBRANE BIOL, V123, P49, DOI 10.1007/BF01993962; UMARTH W, 1974, J MICROSC-OXFORD, V101, P103; Wiese C, 1993, CURR OPIN CELL BIOL, V5, P387, DOI 10.1016/0955-0674(93)90002-8	44	15	15	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1999	13	11					1395	1403		10.1096/fasebj.13.11.1395	http://dx.doi.org/10.1096/fasebj.13.11.1395			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	226KL	10428763				2022-12-25	WOS:000082019100011
J	Andersson, KB; Berge, T; Matre, V; Gabrielsen, OS				Andersson, KB; Berge, T; Matre, V; Gabrielsen, OS			Sequence selectivity of c-Myb in vivo - Resolution of a DNA target specificity paradox	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING DOMAIN; V-MYB; IN-VIVO; PROTOONCOGENE PRODUCT; ONCOGENE PRODUCT; GENE; CELLS; ONCOPROTEIN; RECOGNITION; PROTEINS	We have investigated the basis for the striking difference between the broad DNA sequence selectivity of the c-Myb transcription factor minimal DNA-binding domain R2R3 in vitro and the more restricted preference of a R(2)R(3)VP16 protein for Myb-specific recognition elements (MREs) in a Saccharomyces cerevisiae transactivation system. We show that sequence discrimination in yeast is highly dependent on the expression level of Myb effector protein. Full-length c-Myb and a C-terminally truncated protein (residues 1-360) were also included in the study. All of the tested Myb proteins displayed very similar DNA binding properties in electrophoretic mobility shift assays. Only minor differences between full-length c-Myb and truncated c-Myb(1-360) were observed. In transactivation studies in CV-1 cells, the MRE selectivity was highest at low expression levels of Myb effector proteins. However, the discrimination between MRE variants was rapidly lost with high input levels of effector plasmid. In c-Myb-expressing K-562 cells, the high degree of MRE selectivity was retained, thereby confirming the relevance of the results obtained in the yeast system. These data suggest that the MRE selectivity of c-Myb is an intrinsic property of only the R2R3 domain itself and that the transactivation response of a specific MRE in vivo may be highly dependent on the expression level of the Myb protein in the cell.	Univ Oslo, Dept Biochem, N-0316 Oslo 3, Norway	University of Oslo	Andersson, KB (corresponding author), Ulleval Hosp, Expt Med Res Inst, N-0407 Oslo, Norway.							BERBERICH I, 1994, J IMMUNOL, V153, P4357; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Burk O, 1997, EMBO J, V16, P1371, DOI 10.1093/emboj/16.6.1371; Deng QL, 1996, NUCLEIC ACIDS RES, V24, P766, DOI 10.1093/nar/24.4.766; DINI PW, 1993, MOL CELL BIOL, V13, P7334, DOI 10.1128/MCB.13.12.7334; GABRIELSEN OS, 1991, SCIENCE, V253, P1140, DOI 10.1126/science.1887237; Gonda TJ, 1998, INT J BIOCHEM CELL B, V30, P547, DOI 10.1016/S1357-2725(98)00003-X; HOWE KM, 1991, NUCLEIC ACIDS RES, V19, P3913, DOI 10.1093/nar/19.14.3913; JAMIN N, 1993, EUR J BIOCHEM, V216, P147, DOI 10.1111/j.1432-1033.1993.tb18126.x; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KowenzLeutz E, 1997, CELL, V91, P185, DOI 10.1016/S0092-8674(00)80401-8; KRIEG J, 1995, ONCOGENE, V10, P2221; Labastie MC, 1998, BLOOD, V92, P3624, DOI 10.1182/blood.V92.10.3624.422k17_3624_3635; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; Lyons JG, 1995, BIOCHEM J, V312, P899, DOI 10.1042/bj3120899; McIntosh PB, 1998, BIOCHEMISTRY-US, V37, P9619, DOI 10.1021/bi972861z; Miller JH., 1972, EXPT MOL GENETICS; MORSE RH, 1993, SCIENCE, V262, P1563, DOI 10.1126/science.8248805; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; MYRSET AH, 1993, EMBO J, V12, P4625, DOI 10.1002/j.1460-2075.1993.tb06151.x; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; Ness SA, 1996, BBA-REV CANCER, V1288, pF123, DOI 10.1016/S0304-419X(96)00027-3; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; Oda M, 1998, J MOL BIOL, V276, P571, DOI 10.1006/jmbi.1997.1564; OELGESCHLAGER M, 1995, MOL CELL BIOL, V15, P5966; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; Ording E, 1996, ONCOGENE, V13, P1043; ORDING E, 1994, EUR J BIOCHEM, V222, P113, DOI 10.1111/j.1432-1033.1994.tb18848.x; RAMSAY RG, 1992, J BIOL CHEM, V267, P5656; RAMSAY RG, 1991, ONCOGENE, V6, P1875; REID GA, 1982, J BIOL CHEM, V257, P3056; Rosinski JA, 1998, J MOL EVOL, V46, P74, DOI 10.1007/PL00006285; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; Tanaka Y, 1997, FEBS LETT, V413, P162, DOI 10.1016/S0014-5793(97)00900-9; TANIKAWA J, 1993, P NATL ACAD SCI USA, V90, P9320, DOI 10.1073/pnas.90.20.9320; WESTON K, 1992, NUCLEIC ACIDS RES, V20, P3043, DOI 10.1093/nar/20.12.3043; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8; Wolff L, 1996, CRIT REV ONCOGENESIS, V7, P245, DOI 10.1615/CritRevOncog.v7.i3-4.60; Worpenberg S, 1997, ONCOGENE, V15, P213, DOI 10.1038/sj.onc.1201179; ZOBEL A, 1991, ONCOGENE, V6, P1397	42	24	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21986	21994		10.1074/jbc.274.31.21986	http://dx.doi.org/10.1074/jbc.274.31.21986			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419522	hybrid			2022-12-25	WOS:000081721100075
J	Ben-Shahar, S; Komlosh, A; Nadav, E; Shaked, I; Ziv, T; Admon, A; DeMartino, GN; Reiss, Y				Ben-Shahar, S; Komlosh, A; Nadav, E; Shaked, I; Ziv, T; Admon, A; DeMartino, GN; Reiss, Y			26 S proteasome-mediated production of an authentic major histocompatibility class I-restricted epitope from an intact protein substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORNITHINE DECARBOXYLASE; MULTICATALYTIC PROTEASE; ANTIGEN PRESENTATION; INTERFERON-GAMMA; 11-S REGULATOR; ACTIVATOR PA28; CTL EPITOPE; DEGRADATION; UBIQUITIN; COMPLEX	Peptides displayed on the cell surface by major histocompatibility class I molecules (MHC class I) are generated by proteolytic processing of protein-antigens in the cytoplasm. Initially, antigens are degraded by the 26 S proteasome, most probably following ubiquitination, However, it is unclear whether this proteolysis results in the generation of MHC class I ligands or if further processing is required. To investigate the role of the 26 S proteasome in antigen presentation, we analyzed the processing of an intact antigen by purified 26 S proteasome. A recombinant ornithine decarboxylase was produced harboring the H-2K(b)-restricted peptide epitope, derived from ovalbumin SIINFEKL (termed ODC-ova), Utilizing recombinant antizyme to target the antigen to the 26 S proteasome, we found that proteolysis of ODC-ova by the 26 S proteasome resulted in the generation of the K-b-ligand. Mass spectrometry analysis indicated that in addition to SIINFEKL, the N-terminally extended ligand, HSIINFEKL, was also generated. Production of SIINFEKL was linear with time and directly proportional to the rate of ODC-ova degradation. The overall yield of SIINFEKL was approximately 5% of the amount of ODC-ova degraded. The addition of PA28, the 20 S, or the 20 S-PA28 complex to the 26 S proteasome did not significantly affect the yield of the antigenic peptide. These findings demonstrate that the 26 S proteasome can efficiently digest an intact physiological substrate and generate an authentic MHC class I-restricted epitope.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel; Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA	Tel Aviv University; Technion Israel Institute of Technology; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Reiss, Y (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel.			Ziv, Tamar/0000-0003-4299-7454; Admon, Arie/0000-0003-0504-3950				Beninga J, 1998, J BIOL CHEM, V273, P18734, DOI 10.1074/jbc.273.30.18734; Beninga J, 1998, UBIQUITIN BIOL CELL, P191; BenShahar S, 1997, J BIOL CHEM, V272, P21060, DOI 10.1074/jbc.272.34.21060; BOUCEK RJ, 1977, ARCH BIOCHEM BIOPHYS, V184, P408, DOI 10.1016/0003-9861(77)90368-X; CERUNDOLO V, 1995, EUR J IMMUNOL, V25, P554, DOI 10.1002/eji.1830250238; DEL VM, 1991, CELL, V66, P1145; DEMARTINO GN, 1994, J BIOL CHEM, V269, P20878; DICK LR, 1994, J IMMUNOL, V152, P3884; Dick TP, 1996, CELL, V86, P253, DOI 10.1016/S0092-8674(00)80097-5; DRISCOLL J, 1993, NATURE, V365, P262, DOI 10.1038/365262a0; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; GRANT EP, 1995, J IMMUNOL, V155, P3750; Groettrup M, 1996, NATURE, V381, P166, DOI 10.1038/381166a0; HAYASHI SI, 1995, BIOCHEM J, V306, P1; HEEMELS MT, 1995, ANNU REV BIOCHEM, V64, P463, DOI 10.1146/annurev.bi.64.070195.002335; Hendil KB, 1998, BIOCHEM J, V332, P749, DOI 10.1042/bj3320749; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; HOFFMAN L, 1994, J BIOL CHEM, V269, P16890; Kisselev AF, 1999, J BIOL CHEM, V274, P3363, DOI 10.1074/jbc.274.6.3363; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MA CP, 1992, J BIOL CHEM, V267, P10515; MCGUIRE MJ, 1989, BIOCHIM BIOPHYS ACTA, V995, P181, DOI 10.1016/0167-4838(89)90078-2; MOMBURG F, 1992, NATURE, V360, P174, DOI 10.1038/360174a0; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; NIEDERMANN G, 1995, IMMUNITY, V2, P289, DOI 10.1016/1074-7613(95)90053-5; Niedermann G, 1997, J EXP MED, V186, P209, DOI 10.1084/jem.186.2.209; PETERS JM, 1994, J BIOL CHEM, V269, P7709; Porgador A, 1997, IMMUNITY, V6, P715, DOI 10.1016/S1074-7613(00)80447-1; REALINI C, 1994, J BIOL CHEM, V269, P20727; RECHSTEINER M, 1998, UBIQUITIN BIOL CELL, P147; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SHASTRI N, 1995, J IMMUNOL, V155, P4339; Shimbara N, 1997, GENES CELLS, V2, P785, DOI 10.1046/j.1365-2443.1997.1610359.x; Song XL, 1997, J BIOL CHEM, V272, P27994, DOI 10.1074/jbc.272.44.27994; Tanaka K, 1998, IMMUNOL REV, V163, P161; Tobery TW, 1997, J EXP MED, V185, P909, DOI 10.1084/jem.185.5.909; TOGUNAGA F, 1994, J BIOL CHEM, V269, P17382; TOWNSEND A, 1988, J EXP MED, V168, P1211, DOI 10.1084/jem.168.4.1211; UMEZAWA H, 1982, ANNU REV MICROBIOL, V36, P75, DOI 10.1146/annurev.mi.36.100182.000451; VILLANUEVA MS, 1994, IMMUNITY, V1, P479, DOI 10.1016/1074-7613(94)90090-6; YANG Y, 1995, J BIOL CHEM, V270, P27687, DOI 10.1074/jbc.270.46.27687; YellenShaw AJ, 1997, J IMMUNOL, V158, P3227; YEWDELL J, 1994, J IMMUNOL, V152, P1163	45	46	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21963	21972		10.1074/jbc.274.31.21963	http://dx.doi.org/10.1074/jbc.274.31.21963			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419519	hybrid			2022-12-25	WOS:000081721100072
J	Kanemori, M; Yanagi, H; Yura, T				Kanemori, M; Yanagi, H; Yura, T			Marked instability of the sigma(32) heat shock transcription factor at high temperature - Implications for heat shock regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ABNORMAL PROTEINS; GENE-EXPRESSION; IN-VIVO; DNAK; DEGRADATION; INDUCTION; PROTEASE; SIGMA-32; CHAPERONE	The heat shock response in Escherichia coli depends on a transient increase in the intracellular level of sigma(32) that results from both increased synthesis and transient stabilization of normally unstable sigma(32). Although the membrane-bound ATP-dependent protease FtsH (HflB) plays an important role in degradation of sigma(32), our previous results suggested that several cytosolic ATP-dependent proteases including HslVU (ClpQY) are also involved in sigma(32) degradation (Kanemori, M,, Nishihara, K,, Yanagi, H., and Yura, T, (1997) J, Bacteriol. 179, 7219-7225), We now report on the ATP-dependent proteolysis of,sz by purified Hs1VU protease and its unusual dependence on high temperature: sigma(32) was rapidly degraded at 44 degrees C, but with much slower rates (similar to 15-fold) at 35 degrees C. FtsH-dependent degradation of sigma(32) also gave similar results. In agreement with these results in vitro, the turnover of sigma(32) in normally growing cells at high temperature (42 degrees C) was much faster than at low temperature (30 degrees C), Taken together with other evidence, these results suggest that the sigma(32) level during normal growth is primarily determined by the stability (susceptibility to proteases) and synthesis rate of sigma(32) set by ambient temperature, whereas fine adjustment such as transient stabilization of sigma(32) observed upon heat shock is brought about through monitoring changes in the cellular state of protein folding.	HSP Res Inst, Kyoto 6008813, Japan		Yura, T (corresponding author), HSP Res Inst, Kyoto Res Pk, Kyoto 6008813, Japan.	tyura@hsp.co.jp						BAHL H, 1987, GENE DEV, V1, P57, DOI 10.1101/gad.1.1.57; BLASZCZAK A, 1995, EMBO J, V14, P5085, DOI 10.1002/j.1460-2075.1995.tb00190.x; Blaszczak A, 1999, MOL MICROBIOL, V31, P157, DOI 10.1046/j.1365-2958.1999.01155.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUKAU B, 1993, MOL MICROBIOL, V9, P671, DOI 10.1111/j.1365-2958.1993.tb01727.x; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; Gamer J, 1996, EMBO J, V15, P607, DOI 10.1002/j.1460-2075.1996.tb00393.x; GOFF SA, 1985, CELL, V41, P587, DOI 10.1016/S0092-8674(85)80031-3; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; Gottesman S, 1996, ANNU REV GENET, V30, P465, DOI 10.1146/annurev.genet.30.1.465; Gross CA, 1996, ESCHERICHIA COLI SAL, P1382; HERENDEEN SL, 1979, J BACTERIOL, V139, P185, DOI 10.1128/JB.139.1.185-194.1979; Herman C, 1998, GENE DEV, V12, P1348, DOI 10.1101/gad.12.9.1348; HERMAN C, 1995, P NATL ACAD SCI USA, V92, P3516, DOI 10.1073/pnas.92.8.3516; ITO K, 1986, J BACTERIOL, V167, P201, DOI 10.1128/jb.167.1.201-204.1986; Kanemori M, 1999, J BACTERIOL, V181, P3674, DOI 10.1128/JB.181.12.3674-3680.1999; KANEMORI M, 1994, J BACTERIOL, V176, P5648, DOI 10.1128/JB.176.18.5648-5653.1994; Kanemori M, 1997, J BACTERIOL, V179, P7219, DOI 10.1128/jb.179.23.7219-7225.1997; KELLER JA, 1988, MOL MICROBIOL, V2, P31, DOI 10.1111/j.1365-2958.1988.tb00004.x; Kessel M, 1996, FEBS LETT, V398, P274, DOI 10.1016/S0014-5793(96)01261-6; KUSUKAWA N, 1988, GENE DEV, V2, P874, DOI 10.1101/gad.2.7.874; Leffers GG, 1998, J BACTERIOL, V180, P1573, DOI 10.1128/JB.180.6.1573-1577.1998; LIBEREK K, 1992, P NATL ACAD SCI USA, V89, P3516, DOI 10.1073/pnas.89.8.3516; MAURIZI MR, 1994, METHOD ENZYMOL, V244, P314; Morita M, 1999, J BACTERIOL, V181, P401, DOI 10.1128/JB.181.2.401-410.1999; Morita MT, 1999, GENE DEV, V13, P655, DOI 10.1101/gad.13.6.655; NAGAI H, 1991, P NATL ACAD SCI USA, V88, P10515, DOI 10.1073/pnas.88.23.10515; PARSELL DA, 1989, GENE DEV, V3, P1226, DOI 10.1101/gad.3.8.1226; Rohrwild M, 1997, NAT STRUCT BIOL, V4, P133, DOI 10.1038/nsb0297-133; Sambrook J., 1989, MOL CLONING LAB MANU, V2; STRAUS D, 1990, GENE DEV, V4, P2202, DOI 10.1101/gad.4.12a.2202; STRAUS DB, 1987, NATURE, V329, P348, DOI 10.1038/329348a0; STRAUS DB, 1988, GENE DEV, V2, P1851, DOI 10.1101/gad.2.12b.1851; TILLY K, 1989, J BACTERIOL, V171, P1585, DOI 10.1128/jb.171.3.1585-1589.1989; TOBE T, 1984, MOL GEN GENET, V195, P10, DOI 10.1007/BF00332716; Tomoyasu T, 1998, MOL MICROBIOL, V30, P567, DOI 10.1046/j.1365-2958.1998.01090.x; TOMOYASU T, 1995, EMBO J, V14, P2551, DOI 10.1002/j.1460-2075.1995.tb07253.x; WAWRZYNOW A, 1995, EMBO J, V14, P1867, DOI 10.1002/j.1460-2075.1995.tb07179.x; WILD J, 1993, J BACTERIOL, V175, P3992, DOI 10.1128/JB.175.13.3992-3997.1993; Wu WF, 1999, J BACTERIOL, V181, P3681, DOI 10.1128/JB.181.12.3681-3687.1999; YAMAMORI T, 1982, P NATL ACAD SCI-BIOL, V79, P860, DOI 10.1073/pnas.79.3.860; Yura T, 1996, GENES CELLS, V1, P277, DOI 10.1046/j.1365-2443.1996.28028.x; YURA T, 1993, ANNU REV MICROBIOL, V47, P321, DOI 10.1146/annurev.mi.47.100193.001541; YUZAWA H, 1993, NUCLEIC ACIDS RES, V21, P5449, DOI 10.1093/nar/21.23.5449; [No title captured]	45	36	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					22002	22007		10.1074/jbc.274.31.22002	http://dx.doi.org/10.1074/jbc.274.31.22002			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419524	hybrid			2022-12-25	WOS:000081721100077
J	Fujikawa-Adachi, K; Nishimori, I; Taguchi, T; Onishi, S				Fujikawa-Adachi, K; Nishimori, I; Taguchi, T; Onishi, S			Human mitochondrial carbonic anhydrase VB - cDNA cloning, mRNA expression, subcellular localization, and mapping to chromosome X	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE; PROTEIN; DNA; CELLS; IV; PURIFICATION; POLYPEPTIDE; DEFICIENCY; DOMAIN; GENE	A cDNA clone for a novel carbonic anhydrase (CA) isozyme was isolated from human pancreas and salivary glands. The cDNA sequence of 1182 base pairs encoded a 317-amino acid protein with a predicted mass of 36.4 kDa, The highest similarity of this cDNA and the deduced amino acid sequence is to human CAV (mitochondrial GA), hereafter referred to as GA Vk Recombinant protein expressed in COS-7 cells transfected with this cDNA clone was enriched in a mitochondrial fraction. Confocal fluorescence microscopy showed cytoplasmic granular signals in COS-7 cells expressing a fusion protein of the novel CA and green fluorescent protein. Several lines of evidence suggest that the cDNA clone presented herein encodes a novel human mitochondrial CA isozyme, designated CA VB. CA VB has a hydrophobic N-terminal mitochondrial signal sequence (33 amino acid residues). Western blot analysis showed a 36-kDa protein precursor and a 32-kDa mature protein for CA VB. Similar to CAVA, CAVE is a "low activity" enzyme with a sensitivity to acetazolamide. The CA VB gene is located on Xp22.1. Northern blot analysis in normal human tissues demonstrated expression of a 1.3-kilobase transcript in heart and skeletal muscle, and reverse transcription-polymerase chain reaction analysis showed expression of CA VB in pancreas, kidney, salivary glands, and spinal cord but not in liver, CA VA mRNA expression was observed only in liver. These findings indicate these are two genetically distinct isoforms of human CA V, designated CA VA and CA VB, which have different patterns of tissue-specific distribution, suggest different physiological roles for the two mitochondrial isozymes.	Kochi Med Sch, Dept Internal Med 1, Nanko Ku, Kochi 7838505, Japan; Kochi Med Sch, Dept Anat 1, Nanko Ku, Kochi 7838505, Japan	Kochi University; Kochi University	Nishimori, I (corresponding author), Kochi Med Sch, Dept Internal Med 1, Nanko Ku, Kochi 7838505, Japan.							BARNEA G, 1993, MOL CELL BIOL, V13, P1497, DOI 10.1128/MCB.13.3.1497; FAN YS, 1990, P NATL ACAD SCI USA, V87, P6223, DOI 10.1073/pnas.87.16.6223; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Fujikawa-Adachi K, 1999, PANCREAS, V18, P329, DOI 10.1097/00006676-199905000-00001; GAVEL Y, 1990, PROTEIN ENG, V4, P33, DOI 10.1093/protein/4.1.33; GOULD SJ, 1989, P NATL ACAD SCI USA, V86, P1934, DOI 10.1073/pnas.86.6.1934; Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226; Henry RP, 1996, ANNU REV PHYSIOL, V58, P523, DOI 10.1146/annurev.ph.58.030196.002515; KATO K, 1990, FEBS LETT, V271, P137, DOI 10.1016/0014-5793(90)80390-5; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; KRUEGER NX, 1992, P NATL ACAD SCI USA, V89, P7417, DOI 10.1073/pnas.89.16.7417; LIBERT F, 1989, SCIENCE, V244, P569, DOI 10.1126/science.2541503; MAHIEU I, 1994, BIOL CELL, V81, P131, DOI 10.1016/S0248-4900(94)80004-9; MAREN TH, 1960, J PHARMACOL EXP THER, V130, P26; MURAKAMI H, 1987, J BIOL CHEM, V262, P1382; NAGAO Y, 1993, P NATL ACAD SCI USA, V90, P7623, DOI 10.1073/pnas.90.16.7623; OKUYAMA T, 1992, P NATL ACAD SCI USA, V89, P1315, DOI 10.1073/pnas.89.4.1315; Parkkila AK, 1998, J BIOL CHEM, V273, P24620, DOI 10.1074/jbc.273.38.24620; Pastorekova S, 1997, GASTROENTEROLOGY, V112, P398, DOI 10.1053/gast.1997.v112.pm9024293; SLY WS, 1995, ANNU REV BIOCHEM, V64, P375, DOI 10.1146/annurev.bi.64.070195.002111; SUNDARAM V, 1986, AM J HUM GENET, V38, P125; Sutherlin ME, 1997, CANCER RES, V57, P4744; SUZUKI S, 1990, EMBO J, V9, P757, DOI 10.1002/j.1460-2075.1990.tb08170.x; TAGUCHI T, 1993, CYTOGENET CELL GENET, V64, P217, DOI 10.1159/000133580; TAPPER DP, 1983, METHOD ENZYMOL, V97, P426; TASHIAN RE, 1992, ADV GENET, V30, P321, DOI 10.1016/S0065-2660(08)60323-5; Tureci O, 1998, P NATL ACAD SCI USA, V95, P7608, DOI 10.1073/pnas.95.13.7608; WATAZU Y, 1990, CLIN BIOCHEM, V23, P27; ZAVADA J, 1993, INT J CANCER, V54, P268, DOI 10.1002/ijc.2910540218; ZHU XL, 1990, J BIOL CHEM, V265, P8795	30	72	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21228	21233		10.1074/jbc.274.30.21228	http://dx.doi.org/10.1074/jbc.274.30.21228			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409679	hybrid			2022-12-25	WOS:000081613100070
J	Osheroff, WP; Beard, WA; Wilson, SH; Kunkel, TK				Osheroff, WP; Beard, WA; Wilson, SH; Kunkel, TK			Base substitution specificity of DNA polymerase beta depends on interactions in the DNA minor groove	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURES; EXCISION-REPAIR; B-DNA; FIDELITY; REPLICATION; MECHANISM; PROCESSIVITY; MISMATCHES; RESOLUTION; MUTATIONS	To examine the hypothesis that interactions between a DNA polymerase and the DNA minor groove are critical for accurate DNA synthesis, we studied the fidelity of DNA polymerase beta mutants at residue Arg(283), where arginine, which interacts with the minor groove at the active site, is replaced by alanine or lysine. Alanine substitution, removing minor groove interactions, strongly reduces polymerase selectivity for all single-base mispairs examined. In contrast, the lysine substitution, which retains significant interactions with the minor groove, has wild-type-like selectivity for T.dGMP and A.dGMP mispairs but reduced selectivity for T.dCMP and A.dCMP mispairs, Examination of DNA crystal structures of these four mispairs indicates that the two mispairs excluded by the lysine mutant have an atom (N2) in an unfavorable position in the minor groove, while the two mispairs permitted by the lysine mutant do not. These results suggest that unfavorable interactions between an active site amino acid side chain and mispair-specific atoms in the minor groove contribute to DNA polymerase specificity.	NIEHS, Mol Genet Lab, Res Triangle Pk, NC 27709 USA; NIEHS, Struct Biol Lab, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Kunkel, TK (corresponding author), NIEHS, Mol Genet Lab, Res Triangle Pk, NC 27709 USA.		Wilson, Samuel H/E-6644-2019; Kunkel, Thomas A./D-5088-2019	Wilson, Samuel H/0000-0002-1702-5293; Kunkel, Thomas A./0000-0002-9900-1788	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES050158, Z01ES050158] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ahn J, 1997, BIOCHEMISTRY-US, V36, P1100, DOI 10.1021/bi961653o; Beard WA, 1996, J BIOL CHEM, V271, P12141, DOI 10.1074/jbc.271.21.12141; Beard WA, 1998, CHEM BIOL, V5, pR7, DOI 10.1016/S1074-5521(98)90081-3; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; Bebenek K, 1997, NAT STRUCT BIOL, V4, P194, DOI 10.1038/nsb0397-194; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; Boulard Y, 1997, J MOL BIOL, V268, P331, DOI 10.1006/jmbi.1997.0975; BROWN T, 1986, P NATL ACAD SCI USA, V83, P2402, DOI 10.1073/pnas.83.8.2402; Brown T., 1992, CURR OPIN STRUC BIOL, V2, P354; BRUSKOV VI, 1974, DOKL AKAD NAUK SSSR+, V219, P231; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; DREW HR, 1981, P NATL ACAD SCI-BIOL, V78, P2179, DOI 10.1073/pnas.78.4.2179; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; Holmquist GP, 1998, MUTAT RES-FUND MOL M, V400, P59, DOI 10.1016/S0027-5107(98)00051-7; HUNTER WN, 1987, J BIOL CHEM, V262, P9962; HUNTER WN, 1986, NATURE, V320, P552, DOI 10.1038/320552a0; Kennard O, 1988, STRUCTURE EXPRESSION, V2, P1; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LOEB LA, 1982, ANNU REV BIOCHEM, V52, P429; Minnick DT, 1996, J BIOL CHEM, V271, P24954, DOI 10.1074/jbc.271.40.24954; Minnick DT, 1999, J BIOL CHEM, V274, P3067, DOI 10.1074/jbc.274.5.3067; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Osheroff WP, 1999, J BIOL CHEM, V274, P3642, DOI 10.1074/jbc.274.6.3642; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12742, DOI 10.1021/bi952955d; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; Wang J, 1997, CELL, V89, P1087, DOI 10.1016/S0092-8674(00)80296-2; Werneburg BG, 1996, BIOCHEMISTRY-US, V35, P7041, DOI 10.1021/bi9527202; Wilson SH, 1998, MUTAT RES-DNA REPAIR, V407, P203, DOI 10.1016/S0921-8777(98)00002-0	32	63	63	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					20749	20752		10.1074/jbc.274.30.20749	http://dx.doi.org/10.1074/jbc.274.30.20749			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409611	hybrid			2022-12-25	WOS:000081613100002
J	Wani, MA; Wert, SE; Lingrel, JB				Wani, MA; Wert, SE; Lingrel, JB			Lung Kruppel-like factor, a zinc finger transcription factor, is essential for normal lung development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-MYC GENE; EMBRYONIC LETHALITY; BRANCHING MORPHOGENESIS; TARGETED DISRUPTION; TRANSGENIC MICE; GROWTH-FACTOR; MOUSE LUNG; BINDING PROTEIN; EXPRESSION; RECEPTOR	Lung Kruppel-like factor (LKLF) is a member of the Kruppel-like factor family of transcription factors and is highly expressed in lung with limited distribution in other tissues. Mice lacking LKLF due to inactivation of LKLF by gene targeting die in utero at midgestation around day 12.5 due to severe hemorrhage, making it difficult to study the role of this transcription factor in lung development and function, However, in vitro organ culture of lung buds removed from 11.5-day-old LKLF-/- embryos show normal tracheobronchial tree formation. To examine later stages of lung development, the embryonic lethality due to germ line LKLF null mutation was circumvented, by constructing LKLF homozygous null mouse embryonic stem cells, using a two-step gene targeting procedure, and determining whether these cells give rise to lung tissue, The targeted cells were used to produce chimeric animals, and the contribution of LKLF-deficient cells to the formation of various internal organs was analyzed, In chimeric mice that survived after birth, null embryonic stem cells contributed significantly to all of the major organs except the lungs, On the other hand, some highly chimeric animals died at birth, and histopathological examination of their lungs suggested abnormalities in their lung development, These studies show that LKLF plays an important role in normal lung development.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Childrens Hosp Med Ctr, Div Pulm Biol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center	Lingrel, JB (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, MSB ML 0524, Cincinnati, OH 45267 USA.	jenry.lingrel@uc.edu			NHLBI NIH HHS [HL 57281, HL 56387] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL056387, P50HL056387, R01HL057281] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON KP, 1995, MOL CELL BIOL, V15, P5957; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P112; CARDOSO WV, 1995, AM J PHYSIOL, V13, pL492; Chan JY, 1998, EMBO J, V17, P1779, DOI 10.1093/emboj/17.6.1779; CHARRON J, 1992, GENE DEV, V6, P2248, DOI 10.1101/gad.6.12a.2248; CHEN JZ, 1994, CURR OPIN IMMUNOL, V6, P313, DOI 10.1016/0952-7915(94)90107-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Conkright MD, 1999, NUCLEIC ACIDS RES, V27, P1263, DOI 10.1093/nar/27.5.1263; Crossley M, 1996, MOL CELL BIOL, V16, P1695; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; Ioffe E, 1996, P NATL ACAD SCI USA, V93, P11041, DOI 10.1073/pnas.93.20.11041; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; KORFHAGEN TR, 1994, J CLIN INVEST, V93, P1691, DOI 10.1172/JCI117152; Kuo CT, 1997, GENE DEV, V11, P2996, DOI 10.1101/gad.11.22.2996; Kuo CT, 1997, SCIENCE, V277, P1986, DOI 10.1126/science.277.5334.1986; LYON MF, 1990, GENETIC VARIANTS STR; Matsumoto N, 1998, J BIOL CHEM, V273, P28229, DOI 10.1074/jbc.273.43.28229; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; Minoo P, 1995, DEV BIOL, V172, P694, DOI 10.1006/dbio.1995.8080; MOENS CB, 1993, DEVELOPMENT, V119, P485; MOENS CB, 1992, GENE DEV, V6, P691, DOI 10.1101/gad.6.5.691; NESS SA, 1994, CURR OPIN GENET DEV, V4, P718, DOI 10.1016/0959-437X(94)90139-T; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; PENVY L, 1991, NATURE, V349, P257; PERKINS AC, 1995, NATURE, V375, P318; PETERS K, 1994, EMBO J, V13, P3296, DOI 10.1002/j.1460-2075.1994.tb06631.x; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; SAWAI S, 1993, DEVELOPMENT, V117, P1445; SERRA R, 1994, DEVELOPMENT, V120, P2153; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; Simonet WS, 1995, P NATL ACAD SCI USA, V92, P12461, DOI 10.1073/pnas.92.26.12461; STANTON BR, 1992, GENE DEV, V6, P2235, DOI 10.1101/gad.6.12a.2235; TENHAVEOPBROEK AAW, 1991, EXP LUNG RES, V17, P111, DOI 10.3109/01902149109064406; TENHAVEOPBROEK AAW, 1981, AM J ANAT, V162, P201, DOI 10.1002/aja.1001620303; Wani MA, 1998, TRANSGENIC RES, V7, P229, DOI 10.1023/A:1008809809843; Weinstein M, 1998, DEVELOPMENT, V125, P3615; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; WILLIAMS BO, 1994, EMBO J, V13, P4251, DOI 10.1002/j.1460-2075.1994.tb06745.x; Zeng X, 1998, DEV DYNAM, V211, P215, DOI 10.1002/(SICI)1097-0177(199803)211:3<215::AID-AJA3>3.0.CO;2-K; Zhou L, 1996, DEV BIOL, V175, P227, DOI 10.1006/dbio.1996.0110; Zhou L, 1996, J HISTOCHEM CYTOCHEM, V44, P1183, DOI 10.1177/44.10.8813084	43	102	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21180	21185		10.1074/jbc.274.30.21180	http://dx.doi.org/10.1074/jbc.274.30.21180			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409672	hybrid			2022-12-25	WOS:000081613100063
J	Aspberg, A; Adam, S; Kostka, G; Timpl, R; Heinegard, D				Aspberg, A; Adam, S; Kostka, G; Timpl, R; Heinegard, D			Fibulin-1 is a ligand for the C-type lectin domains of aggrecan and versican	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; EXTRACELLULAR-MATRIX PROTEIN; CENTRAL-NERVOUS-SYSTEM; CALCIUM-BINDING; CARTILAGE PROTEOGLYCANS; SEQUENCE-ANALYSIS; TENASCIN-R; EXPRESSION; BRAIN; MOUSE	The aggregating proteoglycans (aggrecan, versican, neurocan, and brevican) are important components of many extracellular matrices. Their N-terminal globular domain binds to hyaluronan, but the function of their C-terminal region containing a C-type lectin domain is less clear. We now report that a 90-kDa protein copurifies with recombinant lectin domains from aggrecan and versican, but not from the brain-specific neurocan and brevican. Amino acid sequencing of tryptic peptides from this protein identified it as fibulin-1. This extracellular matrix glycoprotein is strongly expressed in tissues where versican is expressed (blood vessels, skin, and developing heart), and also expressed in developing cartilage and bone. It is thus likely to interact with these proteoglycans in vivo. Surface plasmon resonance measurements confirmed that aggrecan and versican lectin domains bind fibulin-1, whereas brevican and neurocan do not. As expected for a C-type lectin, the interactions with fibulin-1 are Ca2+-dependent, with K-D values in the low nanomolar range. Using various deletion mutants, the binding site for aggrecan and versican lectin domains was mapped to the epidermal growth factor-like repeats in domain II of fibulin-1. No difference in affinity was found for deglycosylated fibulin-1, indicating that the proteoglycan C-type lectin domains bind to the protein part of fibulin-1.	Univ Lund, Dept Cell & Mol Biol, Sect Connect Tissue Biol, SE-22100 Lund, Sweden; Max Planck Inst Biochem, D-82152 Martinsried, Germany	Lund University; Max Planck Society	Aspberg, A (corresponding author), Univ Lund, Dept Cell & Mol Biol, Sect Connect Tissue Biol, POB 94, SE-22100 Lund, Sweden.			Aspberg, Anders/0000-0002-6588-6944				Adam S, 1997, J MOL BIOL, V272, P226, DOI 10.1006/jmbi.1997.1244; ARGRAVES WS, 1990, J CELL BIOL, V111, P3155, DOI 10.1083/jcb.111.6.3155; ASHER R, 1991, J NEUROSCI RES, V28, P410, DOI 10.1002/jnr.490280314; ASPBERG A, 1995, P NATL ACAD SCI USA, V92, P10590, DOI 10.1073/pnas.92.23.10590; Aspberg A, 1997, P NATL ACAD SCI USA, V94, P10116, DOI 10.1073/pnas.94.19.10116; BALBONA K, 1992, J BIOL CHEM, V267, P20120; BERNSTEIN EF, 1995, LAB INVEST, V72, P662; BIGNAMI A, 1993, J NEUROSCI RES, V34, P97, DOI 10.1002/jnr.490340110; BodeLesniewska B, 1996, J HISTOCHEM CYTOCHEM, V44, P303, DOI 10.1177/44.4.8601689; DOEGE K, 1987, J BIOL CHEM, V262, P17757; DUCROS DL, 1995, J INVEST DERMATOL, V105, P426, DOI 10.1111/1523-1747.ep12321131; Fassler R, 1996, EXP CELL RES, V222, P111, DOI 10.1006/excr.1996.0014; HEINEGARD D, 1989, FASEB J, V3, P2042, DOI 10.1096/fasebj.3.9.2663581; HEINEGARD D, 1974, J BIOL CHEM, V249, P4250; Henderson DJ, 1998, CIRC RES, V83, P523, DOI 10.1161/01.RES.83.5.523; KIMATA K, 1986, J BIOL CHEM, V261, P3517; Matsumoto N, 1998, IMMUNITY, V8, P245, DOI 10.1016/S1074-7613(00)80476-8; Matsuura R, 1996, J PATHOL, V180, P311, DOI 10.1002/(SICI)1096-9896(199611)180:3<311::AID-PATH657>3.0.CO;2-B; MAYER U, 1993, EMBO J, V12, P1879, DOI 10.1002/j.1460-2075.1993.tb05836.x; Miosge N, 1998, CELL MOL LIFE SCI, V54, P606, DOI 10.1007/s000180050188; Miosge N, 1996, HISTOCHEM J, V28, P109, DOI 10.1007/BF02331415; Mjaatvedt CH, 1998, DEV BIOL, V202, P56, DOI 10.1006/dbio.1998.9001; PAN TC, 1993, EUR J BIOCHEM, V215, P733, DOI 10.1111/j.1432-1033.1993.tb18086.x; PAN TC, 1993, J CELL BIOL, V123, P1269, DOI 10.1083/jcb.123.5.1269; PAULSSON M, 1987, BIOCHEM J, V245, P763, DOI 10.1042/bj2450763; PESHEVA P, 1989, J CELL BIOL, V109, P1765, DOI 10.1083/jcb.109.4.1765; Rauch U, 1997, CELL TISSUE RES, V290, P349, DOI 10.1007/s004410050940; RAUCH U, 1992, J BIOL CHEM, V267, P19536; RAUCH U, 1991, J BIOL CHEM, V266, P14785; Reinhardt DP, 1996, J BIOL CHEM, V271, P19489, DOI 10.1074/jbc.271.32.19489; ROARK EF, 1995, J HISTOCHEM CYTOCHEM, V43, P401, DOI 10.1177/43.4.7534784; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; Ruoslahti E, 1996, GLYCOBIOLOGY, V6, P489, DOI 10.1093/glycob/6.5.489; SAINTEMARIE G, 1962, J HISTOCHEM CYTOCHEM, V10, P250, DOI 10.1177/10.3.250; SASAKI T, 1995, J MOL BIOL, V245, P241, DOI 10.1006/jmbi.1994.0020; SCOTT PG, 1995, HISTOPATHOLOGY, V26, P423, DOI 10.1111/j.1365-2559.1995.tb00249.x; SPENCE SG, 1992, DEV BIOL, V151, P473, DOI 10.1016/0012-1606(92)90186-K; Tran H, 1997, MATRIX BIOL, V15, P479, DOI 10.1016/S0945-053X(97)90021-4; Tran H, 1997, J BIOL CHEM, V272, P22600, DOI 10.1074/jbc.272.36.22600; VERCELLI D, 1989, NATURE, V338, P649, DOI 10.1038/338649a0; YAMADA H, 1995, BIOCHEM BIOPH RES CO, V216, P957, DOI 10.1006/bbrc.1995.2713; Yamaguchi Y, 1996, PERSPECT DEV NEUROBI, V3, P307; Yamamura H, 1997, DEV BIOL, V186, P58, DOI 10.1006/dbio.1997.8559; YAO LY, 1994, MATRIX BIOL, V14, P213, DOI 10.1016/0945-053X(94)90185-6; Zhang HY, 1996, DEV DYNAM, V205, P348, DOI 10.1002/(SICI)1097-0177(199603)205:3<348::AID-AJA13>3.0.CO;2-0; ZHANG HY, 1995, DEV BIOL, V167, P18, DOI 10.1006/dbio.1995.1003; ZHANG RZ, 1994, GENOMICS, V22, P425, DOI 10.1006/geno.1994.1404; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x; ZIMMERMANN DR, 1994, J CELL BIOL, V124, P817, DOI 10.1083/jcb.124.5.817	49	173	176	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20444	20449		10.1074/jbc.274.29.20444	http://dx.doi.org/10.1074/jbc.274.29.20444			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400671	hybrid			2022-12-25	WOS:000081438300064
J	Johnson, K; Kirkpatrick, H; Comer, A; Hoffmann, FM; Laughon, A				Johnson, K; Kirkpatrick, H; Comer, A; Hoffmann, FM; Laughon, A			Interaction of Smad complexes with tripartite DNA-binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; DROSOPHILA ENDODERM INDUCTION; TUMOR-SUPPRESSOR SMAD4; MAD-RELATED PROTEIN; TRANSCRIPTIONAL ACTIVATION; SIGNAL-TRANSDUCTION; ACTS DOWNSTREAM; RECEPTOR; PROMOTER; ACTIVIN	The Smad family of transcription factors function as effecters of transforming growth factor-beta signaling pathways. Smads form heteromultimers capable of contacting DNA through the amino terminal MH1 domain. The MH1 domains of Smad3 and Smad4 have been shown to bind to the sequence 5'-GTCT-3'. Here we show that Smad3 and Smad4 complexes can contact three abutting GTCT sequences and that arrays of such sites elevate reporter expression relative to arrays of binding sites containing only two GTCTs. Smad3/4 complexes bound synergistically to probes containing two of the four possible arrangements of three GTCT sequences and showed a correlated ability to synergistically activate transcription through these sites. Purified Smad3 and Smad4 were both able to contact three abutting GTCT sequences and reporter experiments indicated that either protein could mediate contact with all three GTCTs. In contrast, the Smad4 MH1 domain was essential for reporter activation in combination with Smad1. Together, these results show that Smad complexes are flexible in their ability to interact with abutting GTCT triplets. In contrast, Smads have high affinity for only one orientation of abutting GTCT pairs. Functional Smad-binding sites within several native response elements contain degenerate GTCT triplets, suggesting that trimeric Smad-DNA interaction may be relevant in vivo.	Univ Wisconsin, Genet Lab, Madison, WI 53706 USA; Ophidian Pharmaceut, Madison, WI 53711 USA; Univ Wisconsin, Mcardle Lab Canc Res, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Laughon, A (corresponding author), Univ Wisconsin, Genet Lab, Madison, WI 53706 USA.			Hoffmann, F. Michael/0000-0002-2770-9656				Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; Brummel T, 1999, GENE DEV, V13, P98, DOI 10.1101/gad.13.1.98; Candia AF, 1997, DEVELOPMENT, V124, P4467; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chen YG, 1998, GENE DEV, V12, P2144, DOI 10.1101/gad.12.14.2144; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Eresh S, 1997, EMBO J, V16, P2014, DOI 10.1093/emboj/16.8.2014; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; HALDER G, 1998, GENE DEV, V12, P3815; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Henderson KD, 1998, BIOCHEM BIOPH RES CO, V252, P195, DOI 10.1006/bbrc.1998.9562; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Meersseman G, 1997, MECH DEVELOP, V61, P127, DOI 10.1016/S0925-4773(96)00629-6; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nakayama T, 1998, DEVELOPMENT, V125, P857; NELSON HB, 1993, ROUX ARCH DEV BIOL, V202, P341, DOI 10.1007/BF00188733; Padgett RW, 1998, BIOESSAYS, V20, P382, DOI 10.1002/(SICI)1521-1878(199805)20:5&lt;382::AID-BIES5&gt;3.0.CO;2-Q; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Song CZ, 1998, J BIOL CHEM, V273, P29287, DOI 10.1074/jbc.273.45.29287; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; Szuts D, 1998, GENE DEV, V12, P2022, DOI 10.1101/gad.12.13.2022; Tamaki K, 1998, J CELL PHYSIOL, V177, P355, DOI 10.1002/(SICI)1097-4652(199811)177:2<355::AID-JCP17>3.0.CO;2-8; Thomsen GH, 1996, DEVELOPMENT, V122, P2359; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Vindevoghel L, 1998, J BIOL CHEM, V273, P13053, DOI 10.1074/jbc.273.21.13053; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Xu X, 1998, GENE DEV, V12, P2354, DOI 10.1101/gad.12.15.2354; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	52	74	77	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20709	20716		10.1074/jbc.274.29.20709	http://dx.doi.org/10.1074/jbc.274.29.20709			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400705	hybrid			2022-12-25	WOS:000081438300098
J	Knetsch, MLW; Uyeda, TQP; Manstein, DJ				Knetsch, MLW; Uyeda, TQP; Manstein, DJ			Disturbed communication between actin- and nucleotide-binding sites in a myosin II with truncated 50/20-kDa junction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DICTYOSTELIUM-DISCOIDEUM; MOTOR DOMAIN; CHIMERIC SUBSTITUTIONS; NULL MUTANTS; HEAVY-CHAIN; SUBFRAGMENT-1; AFFINITY; LOOP; TRANSPORT; SELECTION	The kinetic and functional consequences of deleting nine residues from an actin-binding surface loop (loop 2) were examined to investigate the role of this region in myosin function. The nucleotide binding properties of myosin were not altered by the deletion. However, the deletion affected actin binding and the communication between the actin- and nucleotide-binding sites. The affinity of M765NL for actin (644 nM) was approximately 100-fold lower than that of wild-type construct M765 (5.8 nM). Despite this reduction in affinity, actin binding weakened the affinity of ADP for the motor to a similar extent for both mutant and wild-type constructs. The addition of 0.5 mu M actin decreased ADP affinity from 0.6 to 34 mu M for M765NL and from 1.6 to 39 mu M for M765. In contrast, communication between the actin- and nucleotide-binding sites appears disturbed in regard to phosphate release: thus, basal ATPase activity for M765NL (0.19 s(-1)) was 3-fold larger than for M765 (0.06 s(-1)), and the stimulation of ATPase activity by actin was 5-fold lower for M765NL. These results indicate different paths of communication between the actin- and nucleotide-binding sites, in regard to ADP and P-i release, and they confirm that loop 2 is involved in high affinity actin binding.	Max Planck Inst Med Forsch, Dept Biophys, D-69120 Heidelberg, Germany; Natl Inst Adv Interdisciplinary Res, Bion Design Grp, Ibaraki, Osaka 305, Japan	Max Planck Society; National Institute of Advanced Industrial Science & Technology (AIST)	Manstein, DJ (corresponding author), Max Planck Inst Med Forsch, Dept Biophys, Jahnstr 29, D-69120 Heidelberg, Germany.		Manstein, Dietmar J. J/M-1034-2013; Manstein, Dietmar J./AAG-2640-2019	Manstein, Dietmar J. J/0000-0003-0763-0147; Manstein, Dietmar J./0000-0003-0763-0147				CHENEY RE, 1993, CELL MOTIL CYTOSKEL, V24, P215, DOI 10.1002/cm.970240402; Coy David L., 1994, Current Opinion in Neurobiology, V4, P662, DOI 10.1016/0959-4388(94)90007-8; CRIDDLE AH, 1985, BIOCHEM J, V232, P343, DOI 10.1042/bj2320343; DAVIS JS, 1988, ANNU REV BIOPHYS BIO, V17, P217; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; EGELHOFF TT, 1990, DEV BIOL, V137, P359, DOI 10.1016/0012-1606(90)90260-P; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Furch M, 1998, BIOCHEMISTRY-US, V37, P6317, DOI 10.1021/bi972851y; Geeves M A, 1995, Biophys J, V68, p194S; GOODSON HV, 1993, P NATL ACAD SCI USA, V90, P659, DOI 10.1073/pnas.90.2.659; HASSON T, 1995, CURR OPIN CELL BIOL, V7, P587, DOI 10.1016/0955-0674(95)80017-4; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; HOLMES KC, 1997, CURR BIOL, V7, P112; KELLEY CA, 1995, BIOPHYS J, V68, pS225; Kurzawa SE, 1997, BIOCHEMISTRY-US, V36, P317, DOI 10.1021/bi962166b; Kurzawa-Goertz SE, 1998, BIOCHEMISTRY-US, V37, P7517, DOI 10.1021/bi972844+; LEHRER SS, 1972, BIOCHEMISTRY-US, V11, P1211, DOI 10.1021/bi00757a015; MANSTEIN DJ, 1995, J MUSCLE RES CELL M, V16, P325, DOI 10.1007/BF00121141; MANSTEIN DJ, 1989, SCIENCE, V246, P656, DOI 10.1126/science.2530629; MANSTEIN DJ, 1995, GENE, V162, P129, DOI 10.1016/0378-1119(95)00351-6; MANSTEIN DJ, 1989, EMBO J, V8, P923, DOI 10.1002/j.1460-2075.1989.tb03453.x; MILLAR NC, 1983, FEBS LETT, V160, P141, DOI 10.1016/0014-5793(83)80954-5; MORNET D, 1984, P NATL ACAD SCI-BIOL, V81, P736, DOI 10.1073/pnas.81.3.736; MORNET D, 1979, BIOCHEM BIOPH RES CO, V89, P925, DOI 10.1016/0006-291X(79)91867-9; PATTERSON B, 1995, GENETICS, V140, P505; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; RITCHIE MD, 1993, P NATL ACAD SCI USA, V90, P8619, DOI 10.1073/pnas.90.18.8619; Rovner AS, 1995, J BIOL CHEM, V270, P30260, DOI 10.1074/jbc.270.51.30260; RUPPEL KM, 1994, J BIOL CHEM, V269, P18773; Sambrook J., 2002, MOL CLONING LAB MANU; SCHRODER RR, 1993, NATURE, V364, P171, DOI 10.1038/364171a0; SIEMANKOWSKI RF, 1984, J BIOL CHEM, V259, P5045; Titus MA, 1997, CURR BIOL, V7, pR301, DOI 10.1016/S0960-9822(06)00143-6; Titus MA, 1993, CURR OPIN CELL BIOL, V5, P77, DOI 10.1016/S0955-0674(05)80011-0; UYEDA TQP, 1994, NATURE, V368, P567, DOI 10.1038/368567a0; Vikstrom KL, 1997, CELL STRUCT FUNCT, V22, P123, DOI 10.1247/csf.22.123; WATTS PJ, 1998, DEVELOPMENT, V103, P1; WHITE HD, 1982, METHOD ENZYMOL, V85, P698	38	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20133	20138		10.1074/jbc.274.29.20133	http://dx.doi.org/10.1074/jbc.274.29.20133			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400626	hybrid			2022-12-25	WOS:000081438300019
J	Angata, T; Nakata, D; Matsuda, T; Kitajima, K; Troy, FA				Angata, T; Nakata, D; Matsuda, T; Kitajima, K; Troy, FA			Biosynthesis of KDN (2-keto-3-deoxy-D-glycero-D-galacto-nononic acid) - Identification and characterization of a KDN-9-phosphate synthetase activity from trout testis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEAMINATED NEURAMINIC ACID; N-ACETYLNEURAMINIC ACID; LINKED GLYCAN CHAINS; BIFUNCTIONAL ENZYME CATALYZES; FIRST 2 STEPS; JELLY COAT; RAT-LIVER; RICH GLYCOPROTEIN; 3-DEOXY-D-GLYCERO-D-GALACTO-2-NONULOSONIC ACID; 2-EPIMERASE/N-ACETYLMANNOSAMINE KINASE	Although the deaminoneuraminic acid or KDN glycotope (2-keto-3-deoxy-D-glycero-D-galacto-nononic acid) is expressed in glycoconjugates that range in evolutionary diversity from bacteria to man, there is little information as to how this novel sugar is synthesized. Accordingly, biosynthetic studies were initiated in trout testis, an organ rich in KDN, to determine how this sialic acid is formed. These studies have shown that the pathway consists of the following three sequential reactions: 1) Man + ATP --> Man-6-P + ADP; 2) Man-6-P + PEP --> KDN-9-P + Pi; 3) KDN-9-P --> KDN + Pi. Reaction 1, catalyzed by a hexokinase, is the 6-O-phosphorylation of mannose to form D-mannose 6-phosphate (Man-6-P). Reaction 2, catalyzed by KDN-9-phosphate (KDN-9-P) synthetase, condenses Man-6-P and phosphoenolpyruvate (PEP) to form KDN-9-P. Reaction 3, catalyzed by a phosphatase, is the dephosphorylation of KDN-9-P to yield free KDN. It is not known if a kinase specific for Man (Reaction 1) and a phosphatase specific for KDN9-P (Reaction 3) may exist in tissues actively synthesizing KDN. In this study, the KDN-9-P synthetase, an enzyme that has not been previously described, was identified as at least one key enzyme that is specific for the KDN biosynthetic pathway. This enzyme was purified 50-fold from rainbow trout testis and characterized. The molecular weight of the enzyme was estimated to be about 80,000, and activity was maximum at neutral pH in the presence of Mn2+. N-Acetylneuraminic acid g-phosphate (Neu5Ac-9-P) synthetase, which catalyzes the condensation of N-acetyl-D-mannosamine 6-phosphate and phosphoenol-pyruvate to produce Neu5Ac-9-P, was co-purified with the KDN-9-P synthetase. Substrate competition experiments revealed, however, that syntheses of KDN-9-P and Neu5Ac-9-P were catalyzed by two separate synthetase activities. The significance of these studies takes on added importance with the recent discovery that the level of free KDN is elevated in human fetal cord but not matched adult red blood cells and in ovarian cancer cells (Inoue, S., Lin, S-L., Chang, T., Wu, S-H., Yao, C-W., Chu, T-Y., Troy, F. A., II, and Inoue, Y. (1998) J. Biol. Chem. 273, 27199-27204). This unexpected finding emphasizes the need to understand more fully the role that free KDN and KDN-glycoconjugates may play in normal hematopoiesis and malignancy.	Nagoya Univ, Grad Sch Bioagr Sci, Dept Appl Mol Biosci, Nagoya, Aichi 4648601, Japan; Univ Calif Davis, Sch Med, Dept Biol Chem, Davis, CA 95616 USA	Nagoya University; University of California System; University of California Davis	Kitajima, K (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Dept Appl Mol Biosci, Nagoya, Aichi 4648601, Japan.	kitajima@agr.nagoya-u.ac.jp		Nakata, Daisuke/0000-0001-7642-4836	NIGMS NIH HHS [GM55701] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alton G, 1998, GLYCOBIOLOGY, V8, P285, DOI 10.1093/glycob/8.3.285; Angata T, 1998, GLYCOBIOLOGY, V8, P277, DOI 10.1093/glycob/8.3.277; ANGATA T, 1994, GLYCOCONJUGATE J, V11, P493, DOI 10.1007/BF00731286; CAREY DJ, 1980, CELL, V19, P597, DOI 10.1016/S0092-8674(80)80036-5; CHEVILLARD C, 1993, BIOCHEM J, V289, P599, DOI 10.1042/bj2890599; COMB DG, 1958, BIOCHIM BIOPHYS ACTA, V29, P653, DOI 10.1016/0006-3002(58)90031-3; CORFIELD AP, 1982, SIALIC ACIDS CHEM ME, P195; DIXON M, 1964, ENZYMES, P84; Eckhardt M, 1996, P NATL ACAD SCI USA, V93, P7572, DOI 10.1073/pnas.93.15.7572; Fernley H.N., 1971, ENZYMES, V4, P417; FONTAINE MD, 1995, EUR J BIOCHEM, V231, P424, DOI 10.1111/j.1432-1033.1995.tb20715.x; GHOSH S, 1961, P NATL ACAD SCI USA, V47, P955, DOI 10.1073/pnas.47.7.955; GHOSH S, 1965, J BIOL CHEM, V240, P1531; HarduinLepers A, 1995, GLYCOBIOLOGY, V5, P741, DOI 10.1093/glycob/5.8.741; Hinderlich S, 1997, J BIOL CHEM, V272, P24313, DOI 10.1074/jbc.272.39.24313; Inoue S, 1996, J BIOL CHEM, V271, P24341, DOI 10.1074/jbc.271.40.24341; Inoue S, 1998, J BIOL CHEM, V273, P27199, DOI 10.1074/jbc.273.42.27199; INOUE S, 1988, BIOCHEM BIOPH RES CO, V153, P172, DOI 10.1016/S0006-291X(88)81204-X; IWASAKI M, 1987, BIOCHEMISTRY-US, V26, P1452, DOI 10.1021/bi00379a036; IWASAKI M, 1990, J BIOL CHEM, V265, P2596; JOURDIAN GW, 1962, BIOCHEM PREP, V9, P44; KANAMORI A, 1994, HISTOCHEMISTRY, V101, P333, DOI 10.1007/BF00268994; KANAMORI A, 1989, BIOCHEM BIOPH RES CO, V164, P744, DOI 10.1016/0006-291X(89)91522-2; KANAMORI A, 1990, J BIOL CHEM, V265, P21811; KEAN EL, 1966, J BIOL CHEM, V241, P5643; KIMURA M, 1994, J BIOL CHEM, V269, P32138; KITAJIMA K, 1994, J BIOL CHEM, V269, P21415; KNIREL YA, 1989, CARBOHYD RES, V188, P145, DOI 10.1016/0008-6215(89)84067-4; KONDO A, 1990, AGR BIOL CHEM TOKYO, V54, P2169, DOI 10.1080/00021369.1990.10870232; LAZARUS NR, 1966, BIOCHEMISTRY-US, V5, P4003, DOI 10.1021/bi00876a035; LI YT, 1994, ARCH BIOCHEM BIOPHYS, V310, P243, DOI 10.1006/abbi.1994.1163; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; MAES E, 1995, FEBS LETT, V358, P205, DOI 10.1016/0014-5793(94)01425-Z; Maes E, 1997, GLYCOCONJUGATE J, V14, P127, DOI 10.1023/A:1018577302255; MAES E, 1995, EUR J BIOCHEM, V230, P146, DOI 10.1111/j.1432-1033.1995.tb20545.x; Maru I, 1996, J BIOL CHEM, V271, P16294, DOI 10.1074/jbc.271.27.16294; MCGUIRE JE, 1976, BIOL ROLES SIALIC AC, P123; Munster AK, 1998, P NATL ACAD SCI USA, V95, P9140, DOI 10.1073/pnas.95.16.9140; NADANO D, 1986, J BIOL CHEM, V261, P1550; Panneerselvam K, 1997, J BIOL CHEM, V272, P23123, DOI 10.1074/jbc.272.37.23123; PLANCKE Y, 1995, EUR J BIOCHEM, V231, P434, DOI 10.1111/j.1432-1033.1995.tb20716.x; Qu BX, 1996, P NATL ACAD SCI USA, V93, P8995, DOI 10.1073/pnas.93.17.8995; RAHMANN H, 1976, ROUX ARCH DEV BIOL, V180, P253, DOI 10.1007/BF00848773; RAY PH, 1980, J BACTERIOL, V141, P635, DOI 10.1128/JB.141.2.635-644.1980; RODRIGUEZAPARICIO LB, 1992, J BIOL CHEM, V267, P9257; ROSEMAN S, 1961, P NATL ACAD SCI USA, V47, P958, DOI 10.1073/pnas.47.7.958; SONG Y, 1993, BIOCHEMISTRY-US, V32, P9221, DOI 10.1021/bi00086a030; SONG Y, 1995, GLYCOBIOLOGY, V5, P207, DOI 10.1093/glycob/5.2.207; SONG Y, 1991, J BIOL CHEM, V266, P21929; SRINIVASAN PR, 1959, J BIOL CHEM, V234, P716; Stasche R, 1997, J BIOL CHEM, V272, P24319, DOI 10.1074/jbc.272.39.24319; STRECKER G, 1992, BIOCHEM J, V287, P905, DOI 10.1042/bj2870905; STRECKER G, 1992, EUR J BIOCHEM, V207, P995, DOI 10.1111/j.1432-1033.1992.tb17135.x; STRECKER G, 1992, FEBS LETT, V298, P39, DOI 10.1016/0014-5793(92)80018-C; TERADA T, 1993, J BIOL CHEM, V268, P2640; TERADA T, 1993, GLYCOCONJUGATE J, V10, P331, DOI 10.1007/BF01210150; TEZUKA T, 1994, BIOCHEMISTRY-US, V33, P6495, DOI 10.1021/bi00187a016; UCHIDA Y, 1977, J BIOCHEM-TOKYO, V82, P1425, DOI 10.1093/oxfordjournals.jbchem.a131830; Vionnet J, 1999, GLYCOBIOLOGY, V9, P481, DOI 10.1093/glycob/9.5.481; WARREN L, 1962, J BIOL CHEM, V237, P1421; WARREN L, 1961, BIOCHEM BIOPH RES CO, V4, P232, DOI 10.1016/0006-291X(61)90277-7; WARREN L, 1960, BIOCHIM BIOPHYS ACTA, V44, P347, DOI 10.1016/0006-3002(60)91571-7; WATSON DR, 1966, J BIOL CHEM, V241, P5627; ZEITLER R, 1992, EUR J BIOCHEM, V204, P1165, DOI 10.1111/j.1432-1033.1992.tb16743.x; Ziak M, 1996, P NATL ACAD SCI USA, V93, P2759, DOI 10.1073/pnas.93.7.2759	65	43	43	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					22949	22956		10.1074/jbc.274.33.22949	http://dx.doi.org/10.1074/jbc.274.33.22949			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438460	hybrid			2022-12-25	WOS:000082012800010
J	Kao, CY; Tanimoto, A; Arima, N; Sasaguri, Y; Padmanabhan, R				Kao, CY; Tanimoto, A; Arima, N; Sasaguri, Y; Padmanabhan, R			Transactivation of the human cdc2 promoter by adenovirus E1A - E1A induces the expression and assembly of a heteromeric complex consisting of the CCAAT box binding factor, CBF/NF-Y, and a 110-kDa DNA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CONTROL; RETINOBLASTOMA GENE-PRODUCT; HUMAN HSP70 PROMOTER; LARGE T-ANTIGEN; NF-Y; FISSION YEAST; TRANSCRIPTIONAL REPRESSION; GROWTH SUPPRESSOR; MAMMALIAN-CELLS; NUCLEAR-PROTEIN	Cyclin-dependent kinases (CDKs) play an important role in the eukaryotic cell cycle progression. Cdc2 (CDK1) is expressed in late G(1)/S phase and required for G(2) to M phase transition in higher eukaryotes, The oncoproteins, SV40 large T antigen and adenovirus E1A, induce a 110-kDa protein which specifically recognizes the two inverted CCAAT motifs of the cdc2 promoter in cycling cells and plays an essential role in transactivation of the human cdc2 promoter. Since these CCAAT motifs also conform to the consensus binding sites for the ubiquitous heterotrimeric transcription factor, CBF/NF-Y, the role of CBF/NF-Y in the transactivation of the cdc2 promoter was examined in this study. Our results indicate that CBF/NF-Y and the 110-kDa protein interact with the CCAAT box motif to form a heteromeric complex. However, mutagenesis of the pentanucleotide CCAAT motif or in the presence of urea greater than 2.5 M, no heteromeric complex was formed. In contrast, the 110-kDa protein could still bind the mutant CCAAT motif or with the wild type motif in the presence of 2.5 M urea. Furthermore, E1A.12S induced the gene expression of all three subunits of CBF/NF-Y. Coexpression of E1A and a dominant negative mutant NF-YA subunit significantly reduced the E1A-mediated transactivation of the cdc2 promoter in a dose-dependent manner. These results support the conclusion that E1A protein mediates optimal transactivation of the human cdc2 promoter by inducing the expression and assembly of a heteromeric complex consisting of the 110-kDa protein and the CBF/NF-Y which interacts with the two CCAAT motifs of the cdc2 promoter.	Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA; Univ Occupat & Environm Hlth, Dept Pathol & Cell Biol, Kitakyushu, Fukuoka 807, Japan	University of Kansas; University of Kansas Medical Center; University of Occupational & Environmental Health - Japan	Padmanabhan, R (corresponding author), Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.							AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BECK GRJ, 1998, IN PRESS HUMAN TUMOR; Bellorini M, 1997, GENE, V193, P119, DOI 10.1016/S0378-1119(97)00109-1; Bi WM, 1997, J BIOL CHEM, V272, P26562, DOI 10.1074/jbc.272.42.26562; BRAITHWAITE AW, 1983, J VIROL, V45, P192, DOI 10.1128/JVI.45.1.192-199.1983; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; Chen HF, 1996, J BIOL CHEM, V271, P13959, DOI 10.1074/jbc.271.24.13959; CHODOSH LA, 1988, CELL, V53, P25, DOI 10.1016/0092-8674(88)90484-9; CLURMAN BE, 1995, J NATL CANCER I, V87, P1499, DOI 10.1093/jnci/87.20.1499; Corbeil HB, 1997, ONCOGENE, V15, P657, DOI 10.1038/sj.onc.1201224; Cress WD, 1996, CURR TOP MICROBIOL, V208, P63; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; Dooley KA, 1998, J BIOL CHEM, V273, P1349, DOI 10.1074/jbc.273.3.1349; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; DRAETTA G, 1988, ONCOGENE, V2, P553; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; Good LF, 1996, BIOL SIGNAL, V5, P163; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRANA X, 1995, ONCOGENE, V11, P211; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; GU W, 1997, NATURE, V387, P823; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; Kramer A, 1997, CANCER RES, V57, P5117; KREK W, 1989, EMBO J, V8, P3071, DOI 10.1002/j.1460-2075.1989.tb08458.x; KU DH, 1993, J BIOL CHEM, V268, P2255; LADOMERY M, 1995, BIOESSAYS, V17, P9, DOI 10.1002/bies.950170104; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE MG, 1988, NATURE, V333, P676, DOI 10.1038/333676a0; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LUCIBELLO FC, 1995, EMBO J, V14, P132, DOI 10.1002/j.1460-2075.1995.tb06983.x; LUM LSY, 1992, MOL CELL BIOL, V12, P2599, DOI 10.1128/MCB.12.6.2599; LUM LSY, 1990, MOL CELL BIOL, V10, P6709, DOI 10.1128/MCB.10.12.6709; MAI A, 1996, NATURE, V380, P262; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; MAITY SN, 1992, J BIOL CHEM, V267, P16574; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; MILOS PM, 1992, GENE DEV, V6, P991, DOI 10.1101/gad.6.6.991; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MURRAY AW, 1995, CURR OPIN GENET DEV, V5, P5, DOI 10.1016/S0959-437X(95)90046-2; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; OSHIMA J, 1993, ONCOGENE, V8, P2987; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PINES J, 1995, SEMIN CANCER BIOL, V6, P63, DOI 10.1006/scbi.1995.0009; PiseMasison CA, 1997, MOL CELL BIOL, V17, P1236, DOI 10.1128/MCB.17.3.1236; QUINLAN MP, 1994, ONCOGENE, V9, P2639; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; REITH W, 1994, P NATL ACAD SCI USA, V91, P554, DOI 10.1073/pnas.91.2.554; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; Sambrook J., 2002, MOL CLONING LAB MANU; Scolnick DM, 1997, CANCER RES, V57, P3693; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; Song B, 1998, J VIROL, V72, P3213, DOI 10.1128/JVI.72.4.3213-3220.1998; SUBRAMANIAN T, 1988, ONCOGENE, V2, P105; Sundseth R, 1997, MOL PHARMACOL, V51, P963, DOI 10.1124/mol.51.6.963; Tanimoto A, 1998, ONCOGENE, V17, P3103, DOI 10.1038/sj.onc.1202236; Tanimoto A, 1998, CARCINOGENESIS, V19, P1735, DOI 10.1093/carcin/19.10.1735; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WANG HGH, 1993, J VIROL, V67, P4804, DOI 10.1128/JVI.67.8.4804-4813.1993; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WILLIAMS GT, 1989, MOL CELL BIOL, V9, P2574, DOI 10.1128/MCB.9.6.2574; YU LJ, 1995, CELL GROWTH DIFFER, V6, P1505; Zerfass K, 1996, J VIROL, V70, P2637, DOI 10.1128/JVI.70.4.2637-2642.1996; Zwicker J, 1997, TRENDS GENET, V13, P3, DOI 10.1016/S0168-9525(96)30112-1; ZWICKER J, 1995, NUCLEIC ACIDS RES, V23, P3822, DOI 10.1093/nar/23.19.3822; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	91	24	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23043	23051		10.1074/jbc.274.33.23043	http://dx.doi.org/10.1074/jbc.274.33.23043			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438472	hybrid			2022-12-25	WOS:000082012800022
J	Liu, JY; Miller, PF; Willard, J; Olson, ER				Liu, JY; Miller, PF; Willard, J; Olson, ER			Functional and biochemical characterization of Escherichia coli sugar efflux transporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTRANSFERASE SYSTEM; STREPTOCOCCUS-PYOGENES; BGL OPERON; BACTERIA; PHOSPHOENOLPYRUVATE; RESISTANCE; EXPRESSION; MECHANISM; EXPULSION; ENZYME	A family of bacterial transporters, the SET (sugar efflux transporter) family, has been recently reported (Liu, J. Y., Miller, P. F., Gosink, M., and Olson, E. R. (1999) Mol. Microbiol. 31, 1845-1851), In this study, the biochemical and cell biological properties of the three Escherichia coli members (SetA, SetB, and SetC) of the family are characterized. We show that both SetA and SetB can transport lactose and glucose. In addition, SetA has broad substrate specificity, with preferences for glucosides or galactosides with alkyl or aryl substituents, Consistent with the observed in vitro substrate specificities, strains that hyperexpress SetA or SetB are desensitized to lactose analogues as measured by induction of the lac operon, In addition, strains that hyperexpress SetA are resistant to the growth inhibitory sugar analogue o-nitrophenyl-beta-D-thiogalactoside. Strains disrupted for any one or all of the set genes are viable and show no defects in lactose utilization nor increased sensitivity to inducers of the lac operon and nonmetabolizable sugar analogues. The data suggest that the set genes are either poorly expressed under normal laboratory growth conditions or are redundant with other cellular gene products.	Parke Davis Pharmaceut Res, Dept Infect Dis, Ann Arbor, MI 48106 USA	Pfizer	Olson, ER (corresponding author), Parke Davis Pharmaceut Res, Dept Infect Dis, Ann Arbor, MI 48106 USA.	Eric.Olson@wl.com						ANDREWS KJ, 1976, J BACTERIOL, V128, P510, DOI 10.1128/JB.128.1.510-513.1976; Bohn C, 1998, J BACTERIOL, V180, P6072, DOI 10.1128/JB.180.22.6072-6075.1998; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BURSTEIN C, 1965, BIOCHIM BIOPHYS ACTA, V95, P634, DOI 10.1016/0005-2787(65)90517-4; FELLAY R, 1987, GENE, V52, P147, DOI 10.1016/0378-1119(87)90041-2; FLAGG JL, 1976, J BACTERIOL, V128, P701, DOI 10.1128/JB.128.3.701-707.1976; GAMBINO L, 1993, J BACTERIOL, V175, P2888, DOI 10.1128/JB.175.10.2888-2894.1993; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HAGIHIRA H, 1963, BIOCHIM BIOPHYS ACTA, V78, P505, DOI 10.1016/0006-3002(63)90912-0; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HERZENBERG LA, 1959, BIOCHIM BIOPHYS ACTA, V31, P525, DOI 10.1016/0006-3002(59)90029-0; HILL BM, 1968, P NATL ACAD SCI USA, V59, P1259; HOFFEE P, 1964, BIOCHIM BIOPHYS ACTA, V79, P337; HUBER RE, 1980, BIOCHEM BIOPH RES CO, V96, P656, DOI 10.1016/0006-291X(80)91405-9; HUBER RE, 1984, CAN J MICROBIOL, V30, P411, DOI 10.1139/m84-060; Keyhani NO, 1997, P NATL ACAD SCI USA, V94, P14367, DOI 10.1073/pnas.94.26.14367; Khan MA, 1998, J BACTERIOL, V180, P4746, DOI 10.1128/JB.180.17.4746-4749.1998; Liu JY, 1999, MOL MICROBIOL, V31, P1845, DOI 10.1046/j.1365-2958.1999.01321.x; Miller JH., 1972, EXPT MOL GENETICS; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; Paulsen IT, 1996, MICROBIOL REV, V60, P575, DOI 10.1128/MMBR.60.4.575-608.1996; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; REIZER J, 1983, J BACTERIOL, V156, P354, DOI 10.1128/JB.156.1.354-361.1983; REIZER J, 1983, J BACTERIOL, V156, P236, DOI 10.1128/JB.156.1.236-242.1983; REIZER J, 1988, CRC CR REV MICROBIOL, V15, P297, DOI 10.3109/10408418809104461; REYNOLDS AE, 1981, NATURE, V293, P625, DOI 10.1038/293625a0; RUSSELL CB, 1989, J BACTERIOL, V171, P2609, DOI 10.1128/jb.171.5.2609-2613.1989; Sambrook J., 2002, MOL CLONING LAB MANU; Silhavy T. J., 1984, EXPT GENE FUSIONS, P107; STOCK JB, 1982, J BIOL CHEM, V257, P4543; WILSON TH, 1969, BIOCHIM BIOPHYS ACTA, V173, P501, DOI 10.1016/0005-2736(69)90014-5; WINKLER HH, 1971, J BACTERIOL, V106, P362, DOI 10.1128/JB.106.2.362-368.1971; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P4809	33	56	71	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					22977	22984		10.1074/jbc.274.33.22977	http://dx.doi.org/10.1074/jbc.274.33.22977			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438463	hybrid			2022-12-25	WOS:000082012800013
J	Skinner, MA; Wildeman, AG				Skinner, MA; Wildeman, AG			beta(1) integrin binds the 16-kDa subunit of vacuolar H+-ATPase at a site important for human papillomavirus E5 and platelet-derived growth factor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRONECTIN RECEPTOR; MOLECULAR-CLONING; FOCAL ADHESIONS; CELL-ADHESION; V-ATPASES; TYROSINE PHOSPHORYLATION; TRANSMEMBRANE DOMAINS; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; PLASMA-MEMBRANE	Integrins mediate adhesive interactions between cells and the extracellular matrix, and play a role in cell migration, proliferation, differentiation, cytoskeletal organization, and signal transduction. We have identified an interaction between the beta(1) integrin and the 16-kDa subunit of vacuolar H+-ATPase (16K), This interaction was first isolated in a yeast two-hybrid screen and confirmed by coimmunoprecipitation and in in vitro binding assays using bacterially expressed proteins. Immunofluorescent studies performed in L6 myoblasts ex pressing both native and epitope-tagged 16K demonstrate co-localization with beta(1) integrin in focal adhesions. Deletion of the fourth of four transmembrane helices in 16K results in loss of interaction with beta(1) integrin in vitro and in the two-hybrid system, and less prominent staining in focal adhesions. This helix is also required for ligand-independent activation of platelet-derived growth factor-beta receptor signaling by the human papillomavirus E5 oncoprotein. Overexpression of 16K or expression of 16K lacking this helix alters the morphology of myoblasts and fibroblasts, suggesting that the interaction of 16K with integrins could be important for cell growth control. We also discuss the possible role 16K might play in integrin movement.	Univ Guelph, Dept Genet & Mol Biol, Guelph, ON N1G 2W1, Canada	University of Guelph	Wildeman, AG (corresponding author), Univ Guelph, Dept Genet & Mol Biol, Guelph, ON N1G 2W1, Canada.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDRESSON T, 1995, J BIOL CHEM, V270, P6830, DOI 10.1074/jbc.270.12.6830; Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; Berditchevski F, 1997, J BIOL CHEM, V272, P29174, DOI 10.1074/jbc.272.46.29174; Berger LC, 1996, J VIROL, V70, P1203, DOI 10.1128/JVI.70.2.1203-1212.1996; BERGMAN M, 1995, MOL CELL BIOL, V15, P711; BIRMAN S, 1990, FEBS LETT, V261, P303, DOI 10.1016/0014-5793(90)80577-6; BRETSCHER MS, 1989, EMBO J, V8, P1341, DOI 10.1002/j.1460-2075.1989.tb03514.x; BRETSCHER MS, 1992, EMBO J, V11, P405, DOI 10.1002/j.1460-2075.1992.tb05068.x; Bretscher MS, 1996, CELL, V87, P601, DOI 10.1016/S0092-8674(00)81380-X; BROWN E, 1990, J CELL BIOL, V111, P2785, DOI 10.1083/jcb.111.6.2785; BROWN MS, 1983, CELL, V32, P663, DOI 10.1016/0092-8674(83)90052-1; Burbelo PD, 1995, J BIOL CHEM, V270, P30919, DOI 10.1074/jbc.270.52.30919; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; CLAGUE MJ, 1994, J BIOL CHEM, V269, P21; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COHEN BD, 1993, J VIROL, V67, P5303, DOI 10.1128/JVI.67.9.5303-5311.1993; DALTON SL, 1995, MOL BIOL CELL, V6, P1781, DOI 10.1091/mbc.6.12.1781; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; FATH KR, 1989, J CELL SCI, V92, P67; Felsenfeld DP, 1996, NATURE, V383, P438, DOI 10.1038/383438a0; FINBOW ME, 1994, J CELL SCI, V107, P1817; FINBOW ME, 1995, BIOESSAYS, V17, P247, DOI 10.1002/bies.950170311; FORGAC M, 1992, J EXP BIOL, V172, P155; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GLUCK SL, 1992, J EXP BIOL, V172, P219; GOLDSTEIN DJ, 1992, EMBO J, V11, P4851, DOI 10.1002/j.1460-2075.1992.tb05591.x; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; GRINNELL F, 1986, EXP CELL RES, V162, P449, DOI 10.1016/0014-4827(86)90349-6; HANADA H, 1991, BIOCHEM BIOPH RES CO, V176, P1062, DOI 10.1016/0006-291X(91)90391-J; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; HARVEY WR, 1992, J EXP BIOL, V172, P1; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; INGBER DE, 1990, J CELL BIOL, V110, P1803, DOI 10.1083/jcb.110.5.1803; JOHNSON LS, 1993, MOL BIOL CELL, V4, P1251, DOI 10.1091/mbc.4.12.1251; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; LAWSON MA, 1995, NATURE, V377, P75, DOI 10.1038/377075a0; Le Varlet B, 1991, J Dermatol Sci, V2, P287, DOI 10.1016/0923-1811(91)90053-Z; Lee BS, 1996, AM J PHYSIOL-CELL PH, V270, pC382, DOI 10.1152/ajpcell.1996.270.1.C382; LEITCH B, 1990, EXP CELL RES, V190, P218, DOI 10.1016/0014-4827(90)90189-H; MACLAREN LA, 1995, BIOL REPROD, V53, P153, DOI 10.1095/biolreprod53.1.153; MANABE T, 1993, J CELL PHYSIOL, V157, P445, DOI 10.1002/jcp.1041570303; MARQUEZSTERLING N, 1991, EUR J CELL BIOL, V56, P19; MARTINEZZAGUILAN R, 1993, AM J PHYSIOL, V265, pC1015, DOI 10.1152/ajpcell.1993.265.4.C1015; Matsuo N, 1997, BIOCHEM BIOPH RES CO, V238, P126, DOI 10.1006/bbrc.1997.7252; Merzendorfer H, 1997, J EXP BIOL, V200, P225; Mineo C, 1996, EXP CELL RES, V224, P237, DOI 10.1006/excr.1996.0133; MUELLER SC, 1989, J CELL BIOL, V109, P3455, DOI 10.1083/jcb.109.6.3455; NELSON N, 1992, J EXP BIOL, V172, P149; NEZU J, 1992, J BIOCHEM, V112, P212, DOI 10.1093/oxfordjournals.jbchem.a123879; Nomura N, 1994, DNA Res, V1, P47, DOI 10.1093/dnares/1.1.47; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; OHKUMA S, 1993, IN VITRO CELL DEV-AN, V29A, P862; Ohta T, 1996, BRIT J CANCER, V73, P1511, DOI 10.1038/bjc.1996.285; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; Pol A, 1997, BIOCHEM J, V323, P435, DOI 10.1042/bj3230435; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; RANKIN S, 1994, J BIOL CHEM, V269, P704; RAUB TJ, 1989, EXP CELL RES, V184, P407, DOI 10.1016/0014-4827(89)90340-6; REAVES B, 1994, FEBS LETT, V345, P61, DOI 10.1016/0014-5793(94)00437-4; ROSA JP, 1989, J BIOL CHEM, V264, P12596; Rubinstein E, 1997, EUR J IMMUNOL, V27, P1919, DOI 10.1002/eji.1830270815; SCHWARTZ MA, 1993, J BIOL CHEM, V268, P19931; SMITH DB, 1993, NUCLEIC ACIDS RES, V21, P359, DOI 10.1093/nar/21.2.359; SOLOWSKA J, 1991, J CELL BIOL, V114, P1079, DOI 10.1083/jcb.114.5.1079; STRAIGHT SW, 1995, J VIROL, V69, P3185, DOI 10.1128/JVI.69.5.3185-3192.1995; Sundberg C, 1996, J CELL BIOL, V132, P741, DOI 10.1083/jcb.132.4.741; SWALLOW CJ, 1990, J BIOL CHEM, V265, P7645; Tachibana I, 1997, J BIOL CHEM, V272, P29181, DOI 10.1074/jbc.272.46.29181; Turner CE, 1991, CURR OPIN CELL BIOL, V3, P849, DOI 10.1016/0955-0674(91)90059-8; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223	77	37	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23119	23127		10.1074/jbc.274.33.23119	http://dx.doi.org/10.1074/jbc.274.33.23119			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438481	hybrid			2022-12-25	WOS:000082012800031
J	Swann, PG; Odom, S; Zhou, YJ; Szallasi, Z; Blumberg, PM; Draber, P; Rivera, J				Swann, PG; Odom, S; Zhou, YJ; Szallasi, Z; Blumberg, PM; Draber, P; Rivera, J			Requirement for a negative charge at threonine 60 of the FcR gamma for complete activation of Syk	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; BASOPHILIC LEUKEMIA-CELLS; HIGH-AFFINITY RECEPTOR; IMMUNOGLOBULIN-E RECEPTOR; EPSILON-RI; MAST-CELL; IGE RECEPTOR; C-DELTA; SIGNAL-TRANSDUCTION; SH2 DOMAINS	Aggregation of Fc epsilon RI on mast cells results in the phosphorylation of the Fc epsilon RI gamma chain on tyrosine and threonine residues within the immunoreceptor tyrosine-based activation motif, In the present study we sought to identify the site of threonine phosphorylation in Fc epsilon RI gamma and investigate its functional importance. We found that threonine 60 was phosphorylated in vitro and in vivo. Expression of a mutated Fc epsilon RI gamma (T60A), in either Fc epsilon RI gamma-deficient or gamma-null mast cells, resulted in a delay of Fc epsilon RI endocytosis, inhibition of TNF-alpha mRNA production, and inhibition of degranulation but did not affect Fc epsilon RI-induced cell adhesion. Tyrosine phosphorylation of the T60A mutant gamma chain was normal, but Syk phosphorylation was dramatically reduced in these transfectents, This correlated with reduced co-immunoprecipitation of Fc epsilon RI gamma with Syk. Substitution of an aspartic residue for threonine 60 of the Fc epsilon RI gamma reconstituted complete activation of Syk and co-immunoprecipitation of Fc epsilon RI gamma with Syk. We conclude that the negative charge provided by phosphorylation of threonine 60 of the Fc epsilon RI gamma is required for the appropriate interaction and activation of Syk, This is a likely requirement for immunoreceptor tyrosine-based activation motifs involved in Syk activation.	NIAMSD, Sect Chem Immunol, NIH, Bethesda, MD 20892 USA; NIAMSD, Sect Lymphocyte Activat, NIH, Bethesda, MD 20892 USA; NCI, Cellular Carcinogenesis & Tumor Promot Lab, NIH, Bethesda, MD 20892 USA; Uniformed Serv Univ Hlth Sci, Dept Pharmacol, Bethesda, MD 20814 USA; Acad Sci Czech Republic, Inst Mol Genet, CR-14220 Prague 4, Czech Republic	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Uniformed Services University of the Health Sciences - USA; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences	Rivera, J (corresponding author), Bldg 10,Rm 9N228,10 Ctr Dr,MSC 1820, Bethesda, MD 20892 USA.	Juan_Rivera@nih.gov	Draber, Petr/G-3412-2014; Draber, Petr/E-1119-2018	Draber, Petr/0000-0002-3986-2025; Draber, Petr/0000-0002-3986-2025; Szallasi, Zoltan/0000-0001-5395-7509	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [ZIAAR041101, Z01AR041101] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AKESON AL, 1993, J IMMUNOL METHODS, V163, P181, DOI 10.1016/0022-1759(93)90121-M; ALBER G, 1992, J IMMUNOL, V149, P2428; Amoui M, 1997, EUR J IMMUNOL, V27, P321, DOI 10.1002/eji.1830270146; Anderson G J, 1994, Biomed Pept Proteins Nucleic Acids, V1, P31; Arudchandran R, 1999, J IMMUNOL METHODS, V222, P197, DOI 10.1016/S0022-1759(98)00161-6; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; BINGHAM BR, 1994, J BIOL CHEM, V269, P19300; BOCEK P, 1995, EUR J IMMUNOL, V25, P2948, DOI 10.1002/eji.1830251035; Bonnerot C, 1998, EMBO J, V17, P4606, DOI 10.1093/emboj/17.16.4606; BU JY, 1995, P NATL ACAD SCI USA, V92, P5106, DOI 10.1073/pnas.92.11.5106; CANTLEY LC, 1994, J CELL SCI, P121; Chang EY, 1997, J IMMUNOL, V159, P2624; Chen T, 1996, J BIOL CHEM, V271, P25308, DOI 10.1074/jbc.271.41.25308; Clynes R, 1998, SCIENCE, V279, P1052, DOI 10.1126/science.279.5353.1052; Costello PS, 1996, ONCOGENE, V13, P2595; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; Dombrowicz D, 1998, IMMUNITY, V8, P517, DOI 10.1016/S1074-7613(00)80556-7; DOMBROWICZ D, 1993, CELL, V75, P969, DOI 10.1016/0092-8674(93)90540-7; DRABEROVA L, 1995, EUR J IMMUNOL, V25, P2428, DOI 10.1002/eji.1830250903; Field KA, 1997, J BIOL CHEM, V272, P4276, DOI 10.1074/jbc.272.7.4276; FURUICHI K, 1984, J IMMUNOL, V133, P1513; Futterer K, 1998, J MOL BIOL, V281, P523, DOI 10.1006/jmbi.1998.1964; GERMANO P, 1994, J BIOL CHEM, V269, P23102; Gibbins JM, 1997, FEBS LETT, V413, P255, DOI 10.1016/S0014-5793(97)00926-5; HALEEMSMITH H, 1995, P NATL ACAD SCI USA, V92, P9112, DOI 10.1073/pnas.92.20.9112; HAMAWY MM, 1992, J IMMUNOL, V149, P615; HAMAWY MM, 1994, IMMUNOL TODAY, V15, P62, DOI 10.1016/0167-5699(94)90135-X; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; ISERSKY C, 1983, J IMMUNOL, V131, P388; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; Kimura T, 1996, MOL CELL BIOL, V16, P1471; Kuchtey J, 1996, J CELL PHYSIOL, V166, P643, DOI 10.1002/(SICI)1097-4652(199603)166:3<643::AID-JCP20>3.0.CO;2-6; KULCZYCKI A, 1974, J EXP MED, V139, P600, DOI 10.1084/jem.139.3.600; LIU FT, 1980, J IMMUNOL, V124, P2728; MacGlashan DW, 1997, INT ARCH ALLERGY IMM, V113, P45; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; Moriya K, 1997, P NATL ACAD SCI USA, V94, P12539, DOI 10.1073/pnas.94.23.12539; NARULA SS, 1995, STRUCTURE, V3, P1061, DOI 10.1016/S0969-2126(01)00242-8; OLAH Z, 1994, ANAL BIOCHEM, V221, P94, DOI 10.1006/abio.1994.1384; Ottinger EA, 1998, J BIOL CHEM, V273, P729, DOI 10.1074/jbc.273.2.729; PAOLINI R, 1995, J EXP MED, V181, P247, DOI 10.1084/jem.181.1.247; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; PARK JG, 1993, J CLIN INVEST, V92, P2073, DOI 10.1172/JCI116804; Pawankar R, 1997, J CLIN INVEST, V99, P1492, DOI 10.1172/JCI119311; Pelletier C, 1998, J IMMUNOL, V161, P4768; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; PRIBLUDA VS, 1994, P NATL ACAD SCI USA, V91, P11246, DOI 10.1073/pnas.91.23.11246; Pribluda VS, 1997, J BIOL CHEM, V272, P11185; QIAN DP, 1993, P NATL ACAD SCI USA, V90, P11875, DOI 10.1073/pnas.90.24.11875; RAZIN E, 1990, METHOD ENZYMOL, V187, P514; RIVERA J, 1988, MOL IMMUNOL, V25, P647, DOI 10.1016/0161-5890(88)90100-9; Song JS, 1996, J BIOL CHEM, V271, P26962, DOI 10.1074/jbc.271.43.26962; Song JS, 1998, ONCOGENE, V16, P3357, DOI 10.1038/sj.onc.1201886; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; Torigoe C, 1998, SCIENCE, V281, P568, DOI 10.1126/science.281.5376.568; TURNER H, 1995, J BIOL CHEM, V270, P9500, DOI 10.1074/jbc.270.16.9500; Yamashita T, 1998, J BIOCHEM, V123, P1199; Zhang J, 1996, J EXP MED, V184, P71, DOI 10.1084/jem.184.1.71	61	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23068	23077		10.1074/jbc.274.33.23068	http://dx.doi.org/10.1074/jbc.274.33.23068			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438475	hybrid			2022-12-25	WOS:000082012800025
J	Han, P; Werber, J; Surana, M; Fleischer, N; Michaeli, T				Han, P; Werber, J; Surana, M; Fleischer, N; Michaeli, T			The calcium/calmodulin-dependent phosphodiesterase PDE1C down-regulates glucose-induced insulin secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; CAMP-SPECIFIC PHOSPHODIESTERASE; GLUCAGON-LIKE PEPTIDE-1; PANCREATIC BETA-CELLS; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; IN-VITRO; INHIBITORS; CALMODULIN; AMP	To understand the role cAMP phosphodiesterases (PDEs) play in the regulation of insulin secretion, we analyzed cyclic nucleotide PDEs of a pancreatic beta-cell line and used family and isozyme-specific PDE inhibitors to identify the PDEs that counteract glucose-stimulated insulin secretion, We demonstrate the presence of soluble PDE1C, PDE4A and 4D, a cGMP-specific PDE, and of particulate PDES, activities in beta TC3 insulinoma cells. Selective inhibition of PDE1C, but not of PDE4, augmented glucose-stimulated insulin secretion in a dose-dependent fashion thus demonstrating that PDE1C is the major PDE counteracting glucose-dependent insulin secretion from beta TC3 cells. In pancreatic islets, inhibition of both PDE1C and PDE3 augmented glucose-dependent insulin secretion. The PDE1C of beta TC3 cells is a novel isozyme possessing a K-m, of 0.47 mu M for cAMP and 0.25 mu M for cGMP. The PDE1C isozyme of beta TC3 cells is sensitive to 8-methoxymethyl isobutylmethylxanthine and zaprinast (IC50 = 7.5 and 4.5 mu M, respectively) and resistant to vinpocetine (IC50 > 100 mu M) Increased responsiveness of PDE1C activity to calcium/calmodulin is evident upon exposure of cells to glucose. Enhanced cAMP degradation by PDE1C, due to increases in its responsiveness to calcium/calmodulin and in intracellular calcium, constitutes a glucose-dependent feedback mechanism for the control of insulin secretion.	Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Michaeli, T (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	michaeli@aecom.yu.edu			NIDDK NIH HHS [DK20541] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020541, P30DK020541] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMMALA C, 1993, NATURE, V363, P356, DOI 10.1038/363356a0; ASHCROFT SJ, 1992, INSULIN MOL BIOL PAT; Ballard SA, 1998, J UROLOGY, V159, P2164, DOI 10.1016/S0022-5347(01)63299-3; BEAVO JA, 1988, ADV SEC MESS PHOSPH, V22, P1; BEAVO JA, 1990, TRENDS PHARMACOL SCI, V11, P150, DOI 10.1016/0165-6147(90)90066-H; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BOLAFFI JL, 1990, ENDOCRINOLOGY, V126, P1750, DOI 10.1210/endo-126-3-1750; Bourguignon JJ, 1997, J MED CHEM, V40, P1768, DOI 10.1021/jm960827x; CAPITO K, 1986, ACTA ENDOCRINOL-COP, V111, P533, DOI 10.1530/acta.0.1110533; DAMBRA R, 1990, ENDOCRINOLOGY, V126, P2815, DOI 10.1210/endo-126-6-2815; EFRAT S, 1994, TRENDS BIOCHEM SCI, V19, P535, DOI 10.1016/0968-0004(94)90056-6; ElMetwally M, 1997, EUR J PHARMACOL, V324, P227, DOI 10.1016/S0014-2999(97)00076-9; Fisher DA, 1998, BIOCHEM BIOPH RES CO, V246, P570, DOI 10.1006/bbrc.1998.8684; Fisher DA, 1998, J BIOL CHEM, V273, P15559, DOI 10.1074/jbc.273.25.15559; GERMAN MS, 1993, P NATL ACAD SCI USA, V90, P1781, DOI 10.1073/pnas.90.5.1781; Giembycz MA, 1996, BRIT J PHARMACOL, V118, P1945, DOI 10.1111/j.1476-5381.1996.tb15629.x; GRODSKY GM, 1992, J CELL BIOCHEM, V48, P3, DOI 10.1002/jcb.240480103; Han P, 1997, J BIOL CHEM, V272, P16152, DOI 10.1074/jbc.272.26.16152; Hayashi M, 1998, BIOCHEM BIOPH RES CO, V250, P751, DOI 10.1006/bbrc.1998.9379; HENQUIN JC, 1984, ENDOCRINOLOGY, V115, P1125, DOI 10.1210/endo-115-3-1125; HOLZ GG, 1992, TRENDS BIOCHEM SCI, V17, P388, DOI 10.1016/0968-0004(92)90006-U; HOLZ GG, 1995, J BIOL CHEM, V270, P17749, DOI 10.1074/jbc.270.30.17749; Houslay MD, 1997, TRENDS BIOCHEM SCI, V22, P217, DOI 10.1016/S0968-0004(97)01050-5; Kajimoto Y, 1996, BIOCHEM BIOPH RES CO, V219, P941, DOI 10.1006/bbrc.1996.0327; Kilpatrick ED, 1998, DIABETES, V47, P606, DOI 10.2337/diabetes.47.4.606; LACY PE, 1967, DIABETES, V16, P35, DOI 10.2337/diab.16.1.35; LEIBOWITZ MD, 1995, DIABETES, V44, P67, DOI 10.2337/diabetes.44.1.67; Leiser M, 1996, DIABETES, V45, P1412, DOI 10.2337/diabetes.45.10.1412; Lester LB, 1997, P NATL ACAD SCI USA, V94, P14942, DOI 10.1073/pnas.94.26.14942; LIANG Y, 1994, ANNU REV NUTR, V14, P59, DOI 10.1146/annurev.nu.14.070194.000423; LIPSON LG, 1983, LIFE SCI, V32, P775, DOI 10.1016/0024-3205(83)90312-0; Loughney K, 1996, J BIOL CHEM, V271, P796, DOI 10.1074/jbc.271.2.796; MA YH, 1994, ENDOCRINOLOGY, V134, P42, DOI 10.1210/en.134.1.42; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; Parker JC, 1995, BIOCHEM BIOPH RES CO, V217, P916, DOI 10.1006/bbrc.1995.2858; Poitout V, 1996, ANNU REV MED, V47, P69; RAJAN AS, 1989, DIABETES, V38, P874, DOI 10.2337/diabetes.38.7.874; RASMUSSEN H, 1990, DIABETES CARE, V13, P655, DOI 10.2337/diacare.13.6.655; Serre V, 1998, ENDOCRINOLOGY, V139, P4448, DOI 10.1210/en.139.11.4448; SHAFIEENICK R, 1995, BRIT J PHARMACOL, V115, P1486, DOI 10.1111/j.1476-5381.1995.tb16641.x; Soderling SH, 1998, P NATL ACAD SCI USA, V95, P8991, DOI 10.1073/pnas.95.15.8991; Soderling SH, 1998, J BIOL CHEM, V273, P15553, DOI 10.1074/jbc.273.25.15553; SUGDEN MC, 1981, BIOCHEM J, V197, P459, DOI 10.1042/bj1970459; Takasawa S, 1998, J BIOL CHEM, V273, P2497, DOI 10.1074/jbc.273.5.2497; WELLS JN, 1988, METHOD ENZYMOL, V159, P489; YAN C, 1995, P NATL ACAD SCI USA, V92, P9677, DOI 10.1073/pnas.92.21.9677; Yan C, 1996, J BIOL CHEM, V271, P25699, DOI 10.1074/jbc.271.41.25699; Zhao AZ, 1998, J CLIN INVEST, V102, P869, DOI 10.1172/JCI3920; Zhao AZ, 1997, P NATL ACAD SCI USA, V94, P3223, DOI 10.1073/pnas.94.7.3223	49	72	103	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22337	22344		10.1074/jbc.274.32.22337	http://dx.doi.org/10.1074/jbc.274.32.22337			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428803	hybrid			2022-12-25	WOS:000081868400033
J	Hwang, JB; Frost, SC				Hwang, JB; Frost, SC			Effect of alternative glycosylation on insulin receptor processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; 3T3-L1 ADIPOCYTES; GLUCOSE DEPRIVATION; ALPHA-SUBUNIT; DIFFERENTIAL REGULATION; EXTRACELLULAR DOMAIN; IMPAIRS TRANSPORT; BETA-SUBUNIT; N-GLYCANASE; MUTATION	The mature insulin receptor is a cell surface heterotetrameric glycoprotein composed of two alpha- and two P-subunits. In 3T3-L1 adipocytes as in other cell types, the receptor is synthesized as a single polypeptide consisting of uncleaved alpha- and beta-subunits, migrating as a 190-kDa glycoprotein, To examine the importance of N-linked glycosylation on insulin receptor processing, we have used glucose deprivation as a tool to alter protein glycosylation, Western blot analysis shows that glucose deprivation led to a time-dependent accumulation of an alternative proreceptor of 170 kDa in a subcellular fraction consistent with endoplasmic reticulum localization, Co-precipitation assays provide evidence that the alternative proreceptor bound GRP78, an endoplasmic reticulum molecular chaperone. N-Glycosidase F treatment shows that the alternative proreceptor contained N-linked oligosaccharides. Yet, endoglycosidase H insensitivity indicates an aberrant oligosaccharide structure. Using pulse-chase methodology, we show that the synthetic rate was similar between the normal and alternative proreceptor. However, the normal proreceptor was processed into alpha- and beta-subunits (t(1/2) = 1.3 +/- 0.6 h), while the alternative proreceptor was degraded (t(1/2) = 5.1 +/- 0.6 h). Upon refeeding cells that were initially deprived of glucose, the alternative proreceptor was processed to a higher molecular weight form and gained sensitivity to endoglycosidase H. This "intermediate" form of the proreceptor was also degraded, although a small fraction escaped degradation, resulting in cleavage to the alpha- and beta-subunits, These data provide evidence for the first time that glucose deprivation leads to the accumulation of an alternative proreceptor, which can be post-translationally glycosylated with the readdition of glucose inducing both accelerated degradation and maturation.	Univ Florida, Coll Med, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida	Frost, SC (corresponding author), Univ Florida, Coll Med, Dept Biochem & Mol Biol, Box 100245, Gainesville, FL 32610 USA.				NIDDK NIH HHS [DK 45035] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACCILI D, 1992, J BIOL CHEM, V267, P586; ACCILI D, 1991, J BIOL CHEM, V266, P434; ACCILI D, 1989, EMBO J, V8, P2509, DOI 10.1002/j.1460-2075.1989.tb08388.x; ARAKAKI RF, 1987, J BIOL CHEM, V262, P11886; BASTIAN W, 1993, DIABETES, V42, P966, DOI 10.2337/diabetes.42.7.966; CARLINO A, 1992, P NATL ACAD SCI USA, V89, P2081, DOI 10.1073/pnas.89.6.2081; CARO LHP, 1994, DIABETES, V43, P240, DOI 10.2337/diabetes.43.2.240; COLLIER E, 1991, DIABETES, V40, P197, DOI 10.2337/diabetes.40.2.197; COLLIER E, 1993, BIOCHEMISTRY-US, V32, P7818, DOI 10.1021/bi00081a029; CZECH MP, 1993, J BIOL CHEM, V268, P9187; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; Fisher MD, 1996, J BIOL CHEM, V271, P11806, DOI 10.1074/jbc.271.20.11806; FREIDEN PJ, 1992, EMBO J, V11, P63, DOI 10.1002/j.1460-2075.1992.tb05028.x; FROST SC, 1985, J BIOL CHEM, V260, P2646; GOLDSTEIN BJ, 1988, J BIOL CHEM, V263, P12809; HEDO JA, 1983, J BIOL CHEM, V258, P20; HERZBERG VL, 1985, BIOCHEM BIOPH RES CO, V129, P789, DOI 10.1016/0006-291X(85)91961-8; JAMES DE, 1987, J BIOL CHEM, V262, P11817; KADOWAKI T, 1990, J CLIN INVEST, V86, P254, DOI 10.1172/JCI114693; KADOWAKI T, 1990, J BIOL CHEM, V265, P19143; Kitzman HH, 1996, MOL CELL BIOCHEM, V162, P51; KITZMAN HH, 1993, J BIOL CHEM, V268, P1320; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KNUTSON VP, 1991, FASEB J, V5, P2130, DOI 10.1096/fasebj.5.8.2022311; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LECONTE I, 1992, J BIOL CHEM, V267, P17415; LECONTE I, 1994, J BIOL CHEM, V269, P18062; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; Pahl HL, 1997, TRENDS CELL BIOL, V7, P50, DOI 10.1016/S0962-8924(96)10050-7; POUYSSEGUR J, 1977, CELL, V11, P941, DOI 10.1016/0092-8674(77)90305-1; REARICK JI, 1981, J BIOL CHEM, V256, P6255; REED BC, 1981, P NATL ACAD SCI-BIOL, V78, P2908, DOI 10.1073/pnas.78.5.2908; Romisch K, 1997, P NATL ACAD SCI USA, V94, P6730, DOI 10.1073/pnas.94.13.6730; RONNETT GV, 1984, J BIOL CHEM, V259, P4566; RONNETT GV, 1981, J BIOL CHEM, V256, P4704; Sawa T, 1996, BIOCHEM BIOPH RES CO, V218, P449, DOI 10.1006/bbrc.1996.0080; SEMPLEROWLAND SL, 1991, ELECTROPHORESIS, V12, P307, DOI 10.1002/elps.1150120414; SHIU RPC, 1977, P NATL ACAD SCI USA, V74, P3840, DOI 10.1073/pnas.74.9.3840; SUZUKI T, 1994, J BIOL CHEM, V269, P17611; Suzuki T, 1998, J BIOL CHEM, V273, P21526, DOI 10.1074/jbc.273.34.21526; Thomson MJ, 1997, J BIOL CHEM, V272, P7759, DOI 10.1074/jbc.272.12.7759; TOLEDO H, 1993, P NATL ACAD SCI USA, V90, P2505, DOI 10.1073/pnas.90.6.2505; TORDJMAN KM, 1990, BIOCHEM J, V271, P201, DOI 10.1042/bj2710201; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANPUTTEN JPM, 1985, J BIOL CHEM, V260, P7996; VanSchaftingen E, 1995, FEBS LETT, V377, P318, DOI 10.1016/0014-5793(95)01357-1; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WEI JY, 1995, J BIOL CHEM, V270, P26677, DOI 10.1074/jbc.270.44.26677; Weng S, 1997, BIOCHEM J, V322, P655, DOI 10.1042/bj3220655; WHITE MF, 1994, J BIOL CHEM, V269, P1	51	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22813	22820		10.1074/jbc.274.32.22813	http://dx.doi.org/10.1074/jbc.274.32.22813			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428866	hybrid			2022-12-25	WOS:000081868400096
J	MacKenzie, CR; Hirama, T; Buckley, JT				MacKenzie, CR; Hirama, T; Buckley, JT			Analysis of receptor binding by the channel-forming toxin aerolysin using surface plasmon resonance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN; PROTEIN; THY-1	Aerolysin is a channel-forming bacterial toxin that binds to glycosylphosphatidylinositol (GPI) anchors on host cell-surface structures. The nature of the receptors and the location of the receptor-binding sites on the toxin molecule were investigated using surface plasmon resonance. Aerolysin bound to the GPI-anchored proteins Thy-1, variant surface glycoprotein, and contactin with similar rate constants and affinities. Enzymatic removal of N-linked sugars from Thy-1 did not affect toxin binding, indicating that these sugars are not involved in the high affinity interaction with aerolysin, Aerolysin is a bilobal protein, and both lobes were shown to be required for optimal binding. The large lobe by itself bound Thy-1 with an affinity that was at least 10-fold weaker than that of the whole toxin, whereas the small lobe bound the GPI-anchored protein at least 1000-fold more weakly than the intact toxin, Mutation analyses provided further evidence that both lobes were involved in GPI anchor binding, with certain single amino acid substitutions in either domain leading to reductions in affinity of as much as 100-fold. A variant with single amino acid substitutions in both lobes of the protein was completely unable to bind the receptor. The membrane protein glycophorin, which is heavily glycosylated but not GPI-anchored, bound weakly to immobilized proaerolysin, suggesting that interactions with cell-surface carbohydrate structures other than GPI anchors may partially mediate toxin binding to host cells.	Univ Victoria, Dept Biochem & Microbiol, Victoria, BC V8W 3P6, Canada; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	University of Victoria; National Research Council Canada	Buckley, JT (corresponding author), Univ Victoria, Dept Biochem & Microbiol, POB 3055, Victoria, BC V8W 3P6, Canada.							Buckley JT, 1995, BIOCHEMISTRY-US, V34, P16450, DOI 10.1021/bi00050a028; Cowell S, 1997, MOL MICROBIOL, V25, P343, DOI 10.1046/j.1365-2958.1997.4691828.x; Diep DB, 1999, MOL MICROBIOL, V31, P785, DOI 10.1046/j.1365-2958.1999.01217.x; Diep DB, 1998, J BIOL CHEM, V273, P2355, DOI 10.1074/jbc.273.4.2355; Diep DB, 1998, MOL MICROBIOL, V30, P341, DOI 10.1046/j.1365-2958.1998.01068.x; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; EVANS SV, 1999, IN PRESS J MOL RECOG; GARLAND WJ, 1988, INFECT IMMUN, V56, P1249, DOI 10.1128/IAI.56.5.1249-1253.1988; HOWARD SP, 1982, BIOCHEMISTRY-US, V21, P1662, DOI 10.1021/bi00536a029; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; Lacy DB, 1998, CURR OPIN STRUC BIOL, V8, P778; LETARTEMUIRHEAD M, 1975, BIOCHEM J, V151, P685, DOI 10.1042/bj1510685; Mehlert A, 1998, J MOL BIOL, V277, P379, DOI 10.1006/jmbi.1997.1600; Nelson KL, 1997, J BIOL CHEM, V272, P12170, DOI 10.1074/jbc.272.18.12170; Parker MW, 1996, MOL MICROBIOL, V19, P205, DOI 10.1046/j.1365-2958.1996.355887.x; PARKER MW, 1994, NATURE, V367, P292, DOI 10.1038/367292a0; Rossjohn J, 1997, EMBO J, V16, P3426, DOI 10.1093/emboj/16.12.3426; SCHNEIDER P, 1995, METHOD ENZYMOL, V250, P614; Simanek EE, 1998, CHEM REV, V98, P833, DOI 10.1021/cr940226i; STENBERG E, 1991, J COLLOID INTERF SCI, V143, P513, DOI 10.1016/0021-9797(91)90284-F	20	58	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22604	22609		10.1074/jbc.274.32.22604	http://dx.doi.org/10.1074/jbc.274.32.22604			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428840	hybrid			2022-12-25	WOS:000081868400070
J	Newton, DT; Creuzenet, C; Mangroo, D				Newton, DT; Creuzenet, C; Mangroo, D			Formylation is not essential for initiation of protein synthesis in all eubacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA TRANSFORMYLASE; ESCHERICHIA-COLI; GENE; FORMYLTRANSFERASE; MUTANTS; GROWTH	Formylation of the initiator methionyl-tRNA, catalyzed by methionyl-tRNA formyltransferase, has long been regarded as essential for initiation of protein synthesis in eubacteria, Here, we show that this process is, in fact, dispensable in Pseudomonas aeruginosa. Disruption of the chromosomal methionyl-tRNA formyltransferase gene in P, aeruginosa resulted only in a moderate decrease in the rate of cell growth, whereas in Escherichia coli cell growth was severely impaired. The ability of the P. aeruginosa mutant strain to grow was not due to an additional copy of the methionyl-tRNA formyltransferase gene or to N-acylation of the methionyl moiety by a group other than formyl, These results indicate that P, aeruginosa can carry out formylation-independent initiation of protein synthesis, using the nonformylated methionyl-tRNA. Therefore, the dogma that eubacteria require formylation of the initiator methionyl-tRNA for initiation of protein synthesis may have been an invalid generalization of results obtained with E. coli.	Univ Guelph, Guelph Waterloo Ctr Grad Work Chem & Biochem, Dept Chem & Biochem, Guelph, ON N1G 2W1, Canada; Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada	University of Guelph; University of Waterloo; Guelph-Waterloo Centre for Graduate Work in Chemistry & Biochemistry; University of Guelph	Mangroo, D (corresponding author), Univ Guelph, Guelph Waterloo Ctr Grad Work Chem & Biochem, Dept Chem & Biochem, Guelph, ON N1G 2W1, Canada.	mangroo@chembio.uoguelph.ca						ARNOLD HH, 1977, BIOCHIM BIOPHYS ACTA, V476, P76, DOI 10.1016/0005-2787(77)90287-8; BAUMSTARK BR, 1977, J BACTERIOL, V129, P457, DOI 10.1128/JB.129.1.457-471.1977; DANCHIN A, 1973, FEBS LETT, V34, P327, DOI 10.1016/0014-5793(73)80823-3; DICKERMA.HW, 1967, J BIOL CHEM, V242, P1522; EBBOLE DJ, 1987, J BIOL CHEM, V262, P8274; GUILLON JM, 1992, J BACTERIOL, V174, P4294, DOI 10.1128/JB.174.13.4294-4301.1992; GUILLON JM, 1992, J MOL BIOL, V224, P359, DOI 10.1016/0022-2836(92)91000-F; Guillon JM, 1996, J BIOL CHEM, V271, P22321, DOI 10.1074/jbc.271.37.22321; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HARTZ D, 1989, GENE DEV, V3, P1899, DOI 10.1101/gad.3.12a.1899; HARVEY RJ, 1973, J BACTERIOL, V114, P309, DOI 10.1128/JB.114.1.309-322.1973; LAALAMI S, 1991, J MOL BIOL, V220, P335, DOI 10.1016/0022-2836(91)90017-Z; LEE CP, 1991, J BIOL CHEM, V266, P18012; MANGROO D, 1995, J BIOL CHEM, V270, P12203, DOI 10.1074/jbc.270.20.12203; MARCKER K, 1964, J MOL BIOL, V8, P835, DOI 10.1016/S0022-2836(64)80164-9; Newton DT, 1999, BIOCHEM J, V339, P63, DOI 10.1042/0264-6021:3390063; NEWTON DT, 1998, CAN SOC MICR M JUN 1, P23; SAMUEL CE, 1974, J BIOL CHEM, V249, P1198; SCHWEIZER HP, 1995, GENE, V158, P15, DOI 10.1016/0378-1119(95)00055-B; SCHWEIZER HP, 1993, BIOTECHNIQUES, V15, P831; SMITH AE, 1970, NATURE, V226, P607, DOI 10.1038/226607a0; Sprinzl M, 1996, NUCLEIC ACIDS RES, V24, P68, DOI 10.1093/nar/24.1.68; SUNDARI RM, 1976, J BIOL CHEM, V251, P3338; VARSHNEY U, 1991, J BIOL CHEM, V266, P18018; WEST SEH, 1994, GENE, V148, P81, DOI 10.1016/0378-1119(94)90237-2	25	57	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22143	22146		10.1074/jbc.274.32.22143	http://dx.doi.org/10.1074/jbc.274.32.22143			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428776	hybrid			2022-12-25	WOS:000081868400006
J	Palmieri, L; Vozza, A; Agrimi, G; De Marco, V; Runswick, MJ; Palmieri, F; Walker, JE				Palmieri, L; Vozza, A; Agrimi, G; De Marco, V; Runswick, MJ; Palmieri, F; Walker, JE			Identification of the yeast mitochondrial transporter for oxaloacetate and sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; SACCHAROMYCES-CEREVISIAE; BACTERIAL EXPRESSION; PHOSPHATE CARRIER; FUNCTIONAL RECONSTITUTION; INTERMEMBRANE SPACE; BOVINE MITOCHONDRIA; ESCHERICHIA-COLI; CHROMOSOME-XI; PROTEIN	Saccharomyces cerevisiae encodes 35 members of the mitochondrial carrier family, including the OAC protein. The transport specificities of some family members are known, but most are not, The function of the OAC has been revealed by overproduction in Escherichia coli, reconstitution into liposomes, and demonstration that the proteoliposomes transport malonate, oxaloacetate, sulfate, and thiosulfate, Reconstituted OAC catalyzes both unidirectional transport and exchange of substrates, In S. cerevisiae, OAC is in inner mitochondrial membranes, and deletion of its gene greatly reduces transport of oxaloacetate sulfate, thiosulfate, and malonate. Mitochondria from wild-type cells swelled in isoosmotic solutions of ammonium salts of oxaloacetate, sulfate, thiosulfate, and malonate, indicating that these anions are cotransported with protons. Overexpression of OAC in the deletion strain increased greatly the [S-35]sulfate/sulfate and [S-35]sulfate/oxaloacetate exchanges in proteoliposomes reconstituted with digitonin extracts of mitochondria, The main physiological role of OAC appears to be to use the proton-motive force to take up into mitochondria oxaloacetate produced from pyruvate by cytoplasmic pyruvate carboxylase.	MRC, Dunn Human Nutr Unit, Cambridge CB2 2DH, England; Univ Bari, Dept Pharmacobiol, Biochem & Mol Biol Lab, I-70125 Bari, Italy	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research; Universita degli Studi di Bari Aldo Moro	Walker, JE (corresponding author), MRC, Dunn Human Nutr Unit, Hills Rd, Cambridge CB2 2DH, England.	walker@mrc-dunn.cam.ac.uk	agrimi, gennaro/C-6020-2009; Agrimi, Gennaro/D-4001-2018	Agrimi, Gennaro/0000-0002-5219-4412; Vozza, Angelo/0000-0002-2433-465X; Walker, John/0000-0001-7929-2162				Bojunga N, 1998, MOL GEN GENET, V260, P453, DOI 10.1007/s004380050916; CHAPPELL JB, 1968, BRIT MED BULL, V24, P150, DOI 10.1093/oxfordjournals.bmb.a070618; COLLEAUX L, 1992, YEAST, V8, P325, DOI 10.1002/yea.320080410; CROMPTON M, 1974, FEBS LETT, V46, P247, DOI 10.1016/0014-5793(74)80379-0; CROMPTON M, 1974, BIOCHEM J, V142, P127, DOI 10.1042/bj1420127; DAUM G, 1982, J BIOL CHEM, V257, P3075; DIETMEIER K, 1993, J BIOL CHEM, V268, P25958; DUVE CD, 1955, BIOCHEM J, V60, P604, DOI 10.1042/bj0600604; ElMoualij B, 1997, YEAST, V13, P573, DOI 10.1002/(SICI)1097-0061(199705)13:6<573::AID-YEA107>3.0.CO;2-I; FERNANDEZ M, 1994, MOL GEN GENET, V242, P727; Fiermonte G, 1998, J BIOL CHEM, V273, P22782, DOI 10.1074/jbc.273.35.22782; Fiermonte G, 1998, J BIOL CHEM, V273, P24754, DOI 10.1074/jbc.273.38.24754; FIERMONTE G, 1993, BIOCHEM J, V294, P293, DOI 10.1042/bj2940293; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GIMPEL JA, 1973, BIOCHIM BIOPHYS ACTA, V292, P582, DOI 10.1016/0005-2728(73)90006-6; Hanning I, 1999, PLANT PHYSIOL, V119, P1025, DOI 10.1104/pp.119.3.1025; HARTL FU, 1987, CELL, V51, P1027, DOI 10.1016/0092-8674(87)90589-7; Indiveri C, 1998, BIOCHEM BIOPH RES CO, V249, P589, DOI 10.1006/bbrc.1998.9197; INDIVERI C, 1991, BIOCHIM BIOPHYS ACTA, V1069, P110, DOI 10.1016/0005-2736(91)90110-T; KAPLAN RS, 1995, J BIOL CHEM, V270, P4108, DOI 10.1074/jbc.270.8.4108; KOJ A, 1967, BIOCHEM J, V103, P791, DOI 10.1042/bj1030791; KUAN J, 1993, CRIT REV BIOCHEM MOL, V28, P209, DOI 10.3109/10409239309086795; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; Nelson DR, 1998, J MOL BIOL, V277, P285, DOI 10.1006/jmbi.1997.1594; Palmieri F, 1995, METHOD ENZYMOL, V260, P349, DOI 10.1016/0076-6879(95)60150-3; PALMIERI F, 1994, FEBS LETT, V346, P48, DOI 10.1016/0014-5793(94)00329-7; Palmieri Ferdinando, 1999, P489; Palmieri L, 1999, MOL MICROBIOL, V31, P569, DOI 10.1046/j.1365-2958.1999.01197.x; Palmieri L, 1997, FEBS LETT, V417, P114, DOI 10.1016/S0014-5793(97)01269-6; Palmieri L, 1996, FEBS LETT, V399, P299, DOI 10.1016/S0014-5793(96)01350-6; Palmieri L, 1997, FEBS LETT, V410, P447, DOI 10.1016/S0014-5793(97)00630-3; PASSARELLA S, 1977, ARCH BIOCHEM BIOPHYS, V180, P160, DOI 10.1016/0003-9861(77)90020-0; Pompon D, 1996, METHOD ENZYMOL, V272, P51, DOI 10.1016/S0076-6879(96)72008-6; Richard GF, 1997, J MOL BIOL, V268, P303, DOI 10.1006/jmbi.1997.0973; SARIS NEL, 1980, BIOCHEM J, V192, P911, DOI 10.1042/bj1920911; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIMS PJ, 1974, BIOCHEMISTRY-US, V13, P3315, DOI 10.1021/bi00713a022; Soetens O, 1998, EUR J BIOCHEM, V258, P702, DOI 10.1046/j.1432-1327.1998.2580702.x; STAPPEN R, 1993, BIOCHIM BIOPHYS ACTA, V1149, P40, DOI 10.1016/0005-2736(93)90022-R; WALKER JE, 1993, J BIOENERG BIOMEMBR, V25, P435, DOI 10.1007/BF01108401; WOHLRAB H, 1994, BIOCHEMISTRY-US, V33, P9371, DOI 10.1021/bi00198a001; Zara V, 1996, MOL CELL BIOL, V16, P6524	43	88	97	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22184	22190		10.1074/jbc.274.32.22184	http://dx.doi.org/10.1074/jbc.274.32.22184			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428783	hybrid			2022-12-25	WOS:000081868400013
J	Postel, EH				Postel, EH			Cleavage of DNA by human NM23-H2/nucleoside diphosphate kinase involves formation of a covalent protein-DNA complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYC PROMOTER; NUCLEASE-HYPERSENSITIVE ELEMENT; X-RAY STRUCTURE; 2-ANGSTROM RESOLUTION; TRANSCRIPTION FACTOR; TUMOR-METASTASIS; NM23 GENE; IN-VITRO; NUCLEOSIDE; CELLS	The NM23 gene family in humans is implicated in differentiation and cancer, but the biochemical mechanisms are unknown. Most NM23 proteins have phosphotransferase (nucleoside diphosphate kinase) activity, and the second human isoform, NM23-H2, also binds to a nuclease-hypersensitive c-MYC promoter element through which it activates c-MYC transcription. It is shown here that this DNA binding can result in double-stranded breaks, The DNA breaks occur within repeated sequence elements in the linear nuclease-hypersensitive duplex and leave staggered ends with 5-nucleotide-long 3'-extensions. The enzyme also cleaves supercoiled plasmid DNA to yield nicked circular and unit length linear products. The cleavage reaction requires only NM23-H2, DNA, Mg2+, and buffer, occurs in the absence of denaturing conditions, and can be reversed by EDTA. The cleaved DNA strands have free 3'-OH groups, and protein is attached to the 5'-phosphoryl ends. Transfer of P-32 radioactivity from DNA to NM23-H2 has been observed, and a covalent polypeptide-DNA complex has been isolated and identified by Western blotting as NM23-H2. Since covalent protein-DNA complexes are known to serve the role of breaking and rejoining DNA strands, the present findings suggest that NM23-H2 is involved in DNA structural transactions necessary for the activity of the c-MYC promoter.	Princeton Univ, Lewis Thomas Lab, Dept Biol Mol, Princeton, NJ 08540 USA	Princeton University	Postel, EH (corresponding author), Princeton Univ, Lewis Thomas Lab, Dept Biol Mol, Princeton, NJ 08540 USA.				NATIONAL CANCER INSTITUTE [R01CA076496] Funding Source: NIH RePORTER; NCI NIH HHS [CA76496] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARCINAS M, 1994, ONCOGENE, V9, P2699; BACKER JM, 1993, ONCOGENE, V8, P497; BATES AD, 1993, DNA TOPOLOGY; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BERBERICH SJ, 1995, ONCOGENE, V10, P2343; Champoux J J, 1994, Adv Pharmacol, V29A, P71; CHERFILS J, 1994, BIOCHEMISTRY-US, V33, P9062, DOI 10.1021/bi00197a006; DEAROLF CR, 1988, DEV BIOL, V129, P159, DOI 10.1016/0012-1606(88)90170-4; DELAROSA A, 1995, BIOESSAYS, V17, P53, DOI 10.1002/bies.950170111; GILLES AM, 1991, J BIOL CHEM, V266, P8784; HAILAT N, 1991, J CLIN INVEST, V88, P341, DOI 10.1172/JCI115299; HOWLETT AR, 1994, J NATL CANCER I, V86, P1838, DOI 10.1093/jnci/86.24.1838; JAYARAM M, 1994, TRENDS BIOCHEM SCI, V19, P78, DOI 10.1016/0968-0004(94)90039-6; JI L, 1995, J BIOL CHEM, V270, P13392, DOI 10.1074/jbc.270.22.13392; KANAAR R, 1990, CELL, V62, P353, DOI 10.1016/0092-8674(90)90372-L; Kraeft SK, 1996, EXP CELL RES, V227, P63, DOI 10.1006/excr.1996.0250; Kwon HJ, 1997, SCIENCE, V276, P126, DOI 10.1126/science.276.5309.126; LACOMBE ML, 1990, J BIOL CHEM, V265, P10012; LASCU I, 1996, TECHNIQUES PROTEIN C, V7, P209; Liu, 1994, ADV PHARMACOL, V29, P1; Malins DC, 1996, P NATL ACAD SCI USA, V93, P14047, DOI 10.1073/pnas.93.24.14047; MARTINEZ JA, 1995, GUT, V37, P712, DOI 10.1136/gut.37.5.712; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; Milon L, 1997, HUM GENET, V99, P550, DOI 10.1007/s004390050405; Montecino M, 1996, BIOCHEMISTRY-US, V35, P5093, DOI 10.1021/bi952489s; Morera S, 1995, STRUCTURE, V3, P1307, DOI 10.1016/S0969-2126(01)00268-4; Munier A, 1998, FEBS LETT, V434, P289, DOI 10.1016/S0014-5793(98)00996-X; OKABEKADO J, 1995, FEBS LETT, V363, P311, DOI 10.1016/0014-5793(95)00338-A; PARGELLIS CA, 1988, J BIOL CHEM, V263, P7678; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; Pinon VPB, 1999, EXP CELL RES, V246, P355, DOI 10.1006/excr.1998.4318; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; Postel EH, 1996, P NATL ACAD SCI USA, V93, P6892, DOI 10.1073/pnas.93.14.6892; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; Postel EH, 1998, INT J BIOCHEM CELL B, V30, P1291, DOI 10.1016/S1357-2725(98)00087-9; POSTEL EH, 1994, J BIOL CHEM, V269, P8627; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; SADOWSKI PD, 1993, FASEB J, V7, P760, DOI 10.1096/fasebj.7.9.8392474; Schwab M, 1996, GENE CHROMOSOME CANC, V16, P211, DOI 10.1002/(SICI)1098-2264(199608)16:4<211::AID-GCC1>3.0.CO;2-0; SHIMADA N, 1993, J BIOL CHEM, V268, P2583; STAHL JA, 1991, CANCER RES, V51, P445; STARK WM, 1992, TRENDS GENET, V8, P432, DOI 10.1016/0168-9525(92)90176-5; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; VENTURELLI D, 1995, P NATL ACAD SCI USA, V92, P7435, DOI 10.1073/pnas.92.16.7435; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WEBB PA, 1995, J MOL BIOL, V251, P574, DOI 10.1006/jmbi.1995.0457; WIGLEY DB, 1995, ANNU REV BIOPH BIOM, V24, P185, DOI 10.1146/annurev.bb.24.060195.001153; Xu J, 1996, DEV BIOL, V177, P544, DOI 10.1006/dbio.1996.0184; Yi XB, 1996, BBA-MOL CELL RES, V1310, P334, DOI 10.1016/0167-4889(95)00164-6; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	50	64	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22821	22829		10.1074/jbc.274.32.22821	http://dx.doi.org/10.1074/jbc.274.32.22821			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428867	hybrid			2022-12-25	WOS:000081868400097
J	Rossignol, M; Keriel, A; Staub, A; Egly, JM				Rossignol, M; Keriel, A; Staub, A; Egly, JM			Kinase activity and phosphorylation of the largest subunit of TFIIF transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; PROTEIN-KINASE; FUNCTIONAL-ANALYSIS; PROMOTER CLEARANCE; INITIATION-FACTOR; ESCHERICHIA-COLI; TERMINAL DOMAIN; BINDING DOMAIN; FACTOR RAP74; FACTOR RAP30	The largest subunit of the human basal transcription factor TFIIF alpha (also called RAP74) was reported previously to be the target of some phospho/dephosphorylation process. We show that TFIIF alpha possesses a serine/threonine kinase activity, allowing an autophosphorylation of the two residues at position serine 385 and threonine 389. Mutation analysis strongly suggests that autophosphorylation of both sites regulates the transcription elongation process. Moreover we also evidence three additional phosphorylation sites located at positions 207-230, 271-283, and 335-344. These sites are phosphorylated by casein kinase II-like kinases and TAF(II)250, a component of TFIID.	ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Egly, JM (corresponding author), ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, BP 163, F-67404 Illkirch, France.		Keriel, Anne/N-3753-2017	Keriel, Anne/0000-0003-3340-299X				Adamczewski JP, 1996, EMBO J, V15, P1877, DOI 10.1002/j.1460-2075.1996.tb00538.x; Archambault J, 1998, J BIOL CHEM, V273, P27593, DOI 10.1074/jbc.273.42.27593; ASO T, 1995, FASEB J, V9, P1419, DOI 10.1096/fasebj.9.14.7589983; BURTON ZF, 1988, MOL CELL BIOL, V8, P1602, DOI 10.1128/MCB.8.4.1602; CHALUT C, 1994, PROTEIN EXPRES PURIF, V5, P458, DOI 10.1006/prep.1994.1065; Chambers RS, 1996, J BIOL CHEM, V271, P24498, DOI 10.1074/jbc.271.40.24498; CHAMBERS RS, 1995, J BIOL CHEM, V270, P14962, DOI 10.1074/jbc.270.25.14962; COULOMBE B, 1994, J BIOL CHEM, V269, P19962; DEDRICK RL, 1985, BIOCHEMISTRY-US, V24, P2245, DOI 10.1021/bi00330a019; Dikstein R, 1996, CELL, V84, P781, DOI 10.1016/S0092-8674(00)81055-7; Dubrovskaya V, 1996, EMBO J, V15, P3702, DOI 10.1002/j.1460-2075.1996.tb00740.x; Fang SM, 1996, J BIOL CHEM, V271, P11703, DOI 10.1074/jbc.271.20.11703; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; GERARD M, 1991, J BIOL CHEM, V266, P20940; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HISATAKE K, 1995, P NATL ACAD SCI USA, V92, P8195, DOI 10.1073/pnas.92.18.8195; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; KEPHART DD, 1994, J BIOL CHEM, V269, P13536; KILLEEN M, 1992, J BIOL CHEM, V267, P9463; KILLEEN MT, 1992, MOL CELL BIOL, V12, P30, DOI 10.1128/MCB.12.1.30; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KITAJIMA S, 1994, J BIOL CHEM, V269, P29970; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; Lei L, 1998, MOL CELL BIOL, V18, P2130, DOI 10.1128/MCB.18.4.2130; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; MAXON ME, 1994, GENE DEV, V8, P515, DOI 10.1101/gad.8.5.515; MCCRACKEN S, 1991, SCIENCE, V253, P900, DOI 10.1126/science.1652156; O'Brien T, 1998, MOL CELL, V1, P905, DOI 10.1016/S1097-2765(00)80089-1; OHKUMA Y, 1994, NATURE, V368, P160, DOI 10.1038/368160a0; OSSIPOW V, 1995, CELL, V83, P137, DOI 10.1016/0092-8674(95)90242-2; PARVIN JD, 1994, J BIOL CHEM, V269, P18414; Rawling JM, 1997, BIOCHEM J, V324, P249, DOI 10.1042/bj3240249; Reines D, 1996, TRENDS BIOCHEM SCI, V21, P351, DOI 10.1016/0968-0004(96)10045-1; ROCHETTEEGLY C, 1995, MOL ENDOCRINOL, V9, P860, DOI 10.1210/me.9.7.860; ROY R, 1994, J BIOL CHEM, V269, P9826; RUPPERT S, 1995, GENE DEV, V9, P2747, DOI 10.1101/gad.9.22.2747; STOPA M, 1985, J BIOL CHEM, V260, P10353; TAN SY, 1994, J BIOL CHEM, V269, P25684; TAN SY, 1994, P NATL ACAD SCI USA, V91, P9808, DOI 10.1073/pnas.91.21.9808; TAN SY, 1995, P NATL ACAD SCI USA, V92, P6042, DOI 10.1073/pnas.92.13.6042; TYREE CM, 1993, GENE DEV, V7, P1254, DOI 10.1101/gad.7.7a.1254; WANG BQ, 1995, J BIOL CHEM, V270, P27035, DOI 10.1074/jbc.270.45.27035; YANKULOV K, 1995, J BIOL CHEM, V270, P23922, DOI 10.1074/jbc.270.41.23922; Yankulov KY, 1997, EMBO J, V16, P1638, DOI 10.1093/emboj/16.7.1638; Yonaha M, 1997, FEBS LETT, V410, P477, DOI 10.1016/S0014-5793(97)00642-X	47	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22387	22392		10.1074/jbc.274.32.22387	http://dx.doi.org/10.1074/jbc.274.32.22387			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428810	hybrid			2022-12-25	WOS:000081868400040
J	Silva, M; Benito, A; Sanz, C; Prosper, F; Ekhterae, D; Nunez, G; Fernandez-Luna, JL				Silva, M; Benito, A; Sanz, C; Prosper, F; Ekhterae, D; Nunez, G; Fernandez-Luna, JL			Erythropoietin can induce the expression of Bcl-x(L) through Stat5 in erythropoietin-dependent progenitor cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-X GENE; ERYTHROID PRECURSORS; TYROSINE PHOSPHORYLATION; DNA-BINDING; APOPTOSIS; ACTIVATION; PROTEINS; SURVIVAL; DEATH; DIFFERENTIATION	Erythropoietin (Epo) initiates its cellular response by binding to the Epo receptor, which triggers the activation of signal transducer and activator of transcription (Stat) 5 protein. Cell culture studies of erythroid progenitors have suggested that Epo functions as a survival factor by repressing apoptosis at least in part through Bcl-x(L), an anti-apoptotic protein of the Bcl-2 family. In this report, we examine whether Stat5 can induce transactivation of the bcl-x gene in response to Epo, Two Epo-responsive progenitor cell lines, HCD-57 and Bcl-2-transfected Ba/F3-Epo receptor (Ba/F3-EpoR-Bcl-2), were used in this study. After Epo stimulation, we observed a correlation between expression of bcl-x, and activation of Stat5 as assessed by the expression of oncostatin M, a direct target of Stat5, and the phosphorylation and nuclear translocation of Stat5, Moreover, a Stat binding element in the bcl-x promoter was found to be active in response to Epo, a finding that was further confirmed because mutagenesis of this sequence motif abrogated its promoter activity and overexpression of a dominant negative Stat5 protein blocked transactivation, When DNA-protein binding analyses were performed, we found that Stat5, not Stat1 or Stat3, was the protein bound to the bcl-x promoter in response to Epo, These data suggest that Epo-dependent activation of Stat5 is a transcriptional pathway that can be used by Epo-responsive progenitor cells to induce the expression of bcl-x(L) and consequently to inhibit apoptosis.	INSALUD, Hosp Univ Marques Valdecilla, Serv Inmunol, Santander 39008, Spain; Hosp Clin Univ, Dept Hematol & Oncol Med, Valencia 46010, Spain; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA	Hospital Universitario Marques de Valdecilla (HUMV); Hospital Clinic Universitari de Valencia; University of Michigan System; University of Michigan	Fernandez-Luna, JL (corresponding author), INSALUD, Hosp Univ Marques Valdecilla, Serv Inmunol, Santander 39008, Spain.	inmflj@humv.es	Prosper, Felipe/H-6859-2017; Nuñez, Gabriel/A-7160-2014	Prosper, Felipe/0000-0001-6115-8790; 				Benito A, 1996, BLOOD, V87, P3837, DOI 10.1182/blood.V87.9.3837.bloodjournal8793837; Berchtold S, 1997, J BIOL CHEM, V272, P30237, DOI 10.1074/jbc.272.48.30237; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHIBA T, 1993, P NATL ACAD SCI USA, V90, P11593, DOI 10.1073/pnas.90.24.11593; Damen JE, 1996, EXP HEMATOL, V24, P1455; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Fujio Y, 1997, J CLIN INVEST, V99, P2898, DOI 10.1172/JCI119484; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Grillot DAM, 1997, J IMMUNOL, V158, P4750; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; JacobsHelber SM, 1997, J BIOL CHEM, V272, P6850, DOI 10.1074/jbc.272.11.6850; KOURY MJ, 1988, J CELL PHYSIOL, V137, P65, DOI 10.1002/jcp.1041370108; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; LIBOI E, 1993, P NATL ACAD SCI USA, V90, P11351, DOI 10.1073/pnas.90.23.11351; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; Nunez Gabriel, 1994, Trends in Cell Biology, V4, P399, DOI 10.1016/0962-8924(94)90053-1; Oda A, 1998, BLOOD, V92, P443, DOI 10.1182/blood.V92.2.443.414k25_443_451; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Penta K, 1995, J BIOL CHEM, V270, P31282, DOI 10.1074/jbc.270.52.31282; Rui H, 1998, J BIOL CHEM, V273, P28, DOI 10.1074/jbc.273.1.28; SAWYER ST, 1987, J BIOL CHEM, V262, P5554; Silva M, 1996, BLOOD, V88, P1576, DOI 10.1182/blood.V88.5.1576.1576; Silva M, 1998, NEW ENGL J MED, V338, P564, DOI 10.1056/NEJM199802263380902; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Tzung SP, 1997, AM J PATHOL, V150, P1985; WEISS MJ, 1995, P NATL ACAD SCI USA, V92, P9623, DOI 10.1073/pnas.92.21.9623; WOGNUM AW, 1990, BLOOD, V76, P697; Yoshimura A, 1996, EMBO J, V15, P1055, DOI 10.1002/j.1460-2075.1996.tb00443.x; Zamorano J, 1998, J IMMUNOL, V160, P3502; ZHUANG HM, 1995, J BIOL CHEM, V270, P14500, DOI 10.1074/jbc.270.24.14500	31	229	264	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22165	22169		10.1074/jbc.274.32.22165	http://dx.doi.org/10.1074/jbc.274.32.22165			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428780	hybrid			2022-12-25	WOS:000081868400010
J	Diekman, AB; Norton, EJ; Klotz, KL; Westbrook, VA; Shibahara, H; Naaby-Hansen, S; Flickinger, CJ; Herr, JC				Diekman, AB; Norton, EJ; Klotz, KL; Westbrook, VA; Shibahara, H; Naaby-Hansen, S; Flickinger, CJ; Herr, JC			N-linked glycan of a sperm CD52 glycoform associated with human infertility	FASEB JOURNAL			English	Article						autoimmunity; isoimmunity; glycocalyx; lymphocyte; contraception	HUMAN SEMINAL PLASMA; ANTISPERM ANTIBODIES; MONOCLONAL-ANTIBODIES; HUMAN-SPERMATOZOA; MEMBRANE-GLYCOPROTEINS; EPIDIDYMAL MATURATION; SURFACE GLYCOPROTEINS; PEPTIDE BACKBONE; RAT SPERMATOZOA; CDW52 ANTIGEN	In a benchmark study, Isojima and colleagues established H6-3C4, the first successful heterohybridoma immortalized from the peripheral blood lymphocytes of an infertile woman who exhibited high sperm-immobilizing antibody titers. The present report demonstrates the identity between the glycoprotein antigens recognized by the human H6-3C4 monoclonal antibody (mAb) and the murine S19 mAb, generated in our laboratory to sperm agglutination antigen-1 (SAGA-1). Both mAb's recognize N-linked carbohydrate epitopes on the 15-25 kDa, polymorphic SAGA-I glycoprotein that is localized to all domains of the human sperm surface. Treatment with phosphatidylinositol-specific phospholipase C demonstrated that SAGA-I is anchored in the sperm plasmalemma via a GPI-lipid linkage. Immunoaffinity purification and microsequencing indicated that the core peptide of the SAGA-1 glycoprotein is identical to the sequence of CD52, a GPI-anchored lymphocyte differentiation marker implicated in signal transduction. Comparison of anti-SAGA-1 and anti-CD52 immunoreactivities revealed that the sperm form of CD52 exhibits N-linked glycan epitopes, including the epitope recognized by the infertility-associated H6-3C4 mAb, which are not detected on lymphocyte CD52. Thus, the two populations of the CD52 glycoprotein on lymphocytes and spermatozoa represent glycoforms, glycoprotein isoforms with the same core amino acid sequence but different carbohydrate structures. Furthermore, mAb's to the unique carbohydrate epitopes on sperm CD52 have multiple inhibitory effects on sperm function, including a cytotoxic effect on spermatozoa in the presence of complement. These results are the first to implicate unique carbohydrate moieties of a sperm CD52 glycoform as target epitopes in the anti-sperm immune response of an infertile woman. Furthermore, localization of CD52 on all domains of the sperm surface coupled with the multiple sperm-inhibitory effects of antibodies to its unique carbohydrate moieties suggest opportunities for immunocontraceptive development.	Univ Virginia, Hlth Sci Ctr, Dept Cell Biol, Ctr Recombinant Gamete Contracept Vaccinogens, Charlottesville, VA 22908 USA	University of Virginia	Herr, JC (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Cell Biol, Ctr Recombinant Gamete Contracept Vaccinogens, Box 439, Charlottesville, VA 22908 USA.			Westbrook, Anne/0000-0003-4570-0126	NICHD NIH HHS [U54 HD 28934, HD U54 29099] Funding Source: Medline; PHS HHS [P30 28934] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD028934] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U54HD029099] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSON DJ, 1987, J REPROD IMMUNOL, V10, P231, DOI 10.1016/0165-0378(87)90089-1; BEARER EL, 1990, J ELECTRON MICR TECH, V16, P281, DOI 10.1002/jemt.1060160403; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRONSON RA, 1990, BIOL REPROD, V43, P1019, DOI 10.1095/biolreprod43.6.1019; CINEK T, 1992, J IMMUNOL, V149, P2262; DCRUZ OJ, 1993, J IMMUNOL, V151, P1062; Deshpande PP, 1998, J AM CHEM SOC, V120, P1600, DOI 10.1021/ja9725864; Deshpande PP, 1997, NATURE, V387, P164, DOI 10.1038/387164a0; Diekman AB, 1997, BIOL REPROD, V57, P1136, DOI 10.1095/biolreprod57.5.1136; Fukuda M., 1994, MOL GLYCOBIOLOGY, P1; HALE G, 1993, J REPROD IMMUNOL, V23, P189, DOI 10.1016/0165-0378(93)90007-5; HAMILTON DW, 1986, BIOL REPROD, V34, P925, DOI 10.1095/biolreprod34.5.925; HERR JC, 1992, BIOL REPROD, V47, P11, DOI 10.1095/biolreprod47.1.11; ISOJIMA S, 1989, ARCH ANDROLOGY, V23, P185, DOI 10.3109/01485018908986841; ISOJIMA S, 1987, J REPROD IMMUNOL, V10, P67, DOI 10.1016/0165-0378(87)90051-9; ISOJIMA S, 1990, GAMETE INTERACTION P, P63; KAMEDA K, 1990, Japanese Journal of Fertility and Sterility, V35, P313; KAMEDA K, 1991, J REPROD IMMUNOL, V20, P27, DOI 10.1016/0165-0378(91)90021-H; KAMEDA K, 1992, BIOL REPROD, V46, P349, DOI 10.1095/biolreprod46.3.349; KIRCHHOFF C, 1993, MOL REPROD DEV, V34, P8, DOI 10.1002/mrd.1080340103; Kirchhoff C, 1996, MOL HUM REPROD, V2, P9, DOI 10.1093/molehr/2.1.9; Kirchhoff C, 1996, MOL HUM REPROD, V2, P177, DOI 10.1093/molehr/2.3.177; Kutteh WH, 1996, AM J REPROD IMMUNOL, V35, P429; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMANN D, 1985, J REPROD IMMUNOL, V8, P329, DOI 10.1016/0165-0378(85)90007-5; MAHONY MC, 1991, J REPROD IMMUNOL, V19, P269, DOI 10.1016/0165-0378(91)90040-W; NaabyHansen S, 1997, BIOL REPROD, V56, P771, DOI 10.1095/biolreprod56.3.771; NAABYHANSEN S, 1985, J REPROD IMMUNOL, V7, P41, DOI 10.1016/0165-0378(85)90020-8; NAZ RK, 1995, ARCH ANDROLOGY, V35, P225, DOI 10.3109/01485019508987875; NIP MMC, 1995, HUM REPROD, V10, P2564, DOI 10.1093/oxfordjournals.humrep.a135746; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OHL DA, 1995, UROLOGY, V46, P591, DOI 10.1016/S0090-4295(99)80282-9; OLSON GE, 1978, BIOL REPROD, V19, P26, DOI 10.1095/biolreprod19.1.26; PARADISI R, 1995, J REPROD IMMUNOL, V28, P61, DOI 10.1016/0165-0378(94)00911-P; PRIMAKOFF P, 1990, BIOL REPROD, V42, P929, DOI 10.1095/biolreprod42.6.929; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; ROWAN WC, 1994, INT IMMUNOL, V7, P69; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SHAI S, 1992, FERTIL STERIL, V58, P593; SNOW K, 1992, FERTIL STERIL, V58, P1011; Southgate J, 1997, HUM REPROD, V12, P65; SVENNERHOLM L, 1980, BIOCHIM BIOPHYS ACTA, V617, P97, DOI 10.1016/0005-2760(80)90227-1; TARENTINO AL, 1994, METHOD ENZYMOL, V230, P44; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TREUMANN A, 1995, J BIOL CHEM, V270, P6088, DOI 10.1074/jbc.270.11.6088; TSUJI Y, 1988, J EXP MED, V168, P343, DOI 10.1084/jem.168.1.343; WINGATE EW, 1993, J UROLOGY, V149, P1331, DOI 10.1016/S0022-5347(17)36385-1; XIA MQ, 1991, EUR J IMMUNOL, V21, P1677, DOI 10.1002/eji.1830210714; XIA MQ, 1993, BIOCHEM J, V293, P633, DOI 10.1042/bj2930633; Yeung CH, 1997, MOL HUM REPROD, V3, P1045, DOI 10.1093/molehr/3.12.1045; Yeung CH, 1997, MOL REPROD DEV, V48, P267, DOI 10.1002/(SICI)1098-2795(199710)48:2<267::AID-MRD15>3.0.CO;2-V	51	48	54	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1999	13	11					1303	1313		10.1096/fasebj.13.11.1303	http://dx.doi.org/10.1096/fasebj.13.11.1303			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	226KL	10428755				2022-12-25	WOS:000082019100003
J	Docagne, F; Nicole, O; Marti, HH; MacKenzie, ET; Buisson, A; Vivien, D				Docagne, F; Nicole, O; Marti, HH; MacKenzie, ET; Buisson, A; Vivien, D			Transforming growth factor-beta 1 as a regulator of the serpins/t-PA axis in cerebral ischemia	FASEB JOURNAL			English	Article						TGF-beta; plasminogen activator; neuroserpin; NTN	TISSUE-PLASMINOGEN-ACTIVATOR; BONE MORPHOGENETIC PROTEINS; BETA-INDUCIBLE ELEMENTS; TGF-BETA; RAT-BRAIN; DIFFERENTIAL EXPRESSION; NEUROTROPHIC FACTOR; INHIBITOR GENE; NERVOUS-SYSTEM; RECEPTORS	The tissue type plasminogen activator (t-PA) is a serine protease that is involved in neuronal plasticity and cell death induced by excitotoxins and ischemia in the brain. t-PA activity in the central nervous system is regulated through the activation of serine protease inhibitors (serpins) such as the plasminogen activator inhibitor (PAI-1), the protease nexin-1 (PN-1), and neuroserpin (NSP). Recently we demonstrated in vitro that PAI-1 produced by astrocytes mediates the neuroprotective effect of the transforming growth factor-beta 1 (TGF-beta 1) in NMDA-induced neuronal cell death. To investigate whether serpins may be involved in neuronal cell death after cerebral ischemia, we determined, by using semiquantitative RT-PCR and in situ hybridization, that focal cerebral ischemia in mice induced a dramatic overexpression of PAI-1 without any effect on PN-1, NSP, or t-PA. Then we showed that although the expression of PAI-1 is restricted to astrocytes, PN-1, NSP, and t-PA are expressed in both neurons and astrocytes. Moreover, by using semiquantitative RT-PCR and Western blotting, we observed that only the expression of PAI-1 was modulated by TGF-beta 1 treatment via a TGF-beta-inducible element contained in the PAI-I promoter (CAGA box). Finally, we compared the specificity of TGF-beta 1 action with other members of the TGF-beta family by using luciferase reporter genes. These data show that TGF-beta and activin were able to induce the overexpression of PAI-1 in astrocytes, but that bone morphogenetic proteins, glial cell line-derived neutrophic factor, and neurturin did not. These results provide new insights into the regulation of the serpins/t-PA axis and the mechanism by which TGF-beta may be neuroprotective.	Univ Caen, CNRS, UMR 6551, Neurosci Lab, F-14074 Caen, France; Max Planck Inst Physiol & Klin Forsch, D-61231 Bad Nauheim, Germany	Centre National de la Recherche Scientifique (CNRS); Universite de Caen Normandie; Max Planck Society	Vivien, D (corresponding author), Univ Caen, CNRS, UMR 6551, Neurosci Lab, IFR 47,Bd H Becquerel,BP 5229, F-14074 Caen, France.		Nicole, Olivier/AAZ-2865-2020; Docagne, Fabian/S-8308-2018; Mackenzie, Eric Thomson/L-1938-2015; buisson, alain/AAI-8218-2020	Nicole, Olivier/0000-0001-9981-1820; buisson, alain/0000-0002-4281-7911; Marti, Hugo/0000-0002-8456-334X; Docagne, Fabian/0000-0003-1745-0625; VIVIEN, DENIS/0000-0002-7636-2185; MacKenzie, Eric T/0000-0003-1057-7033				BREIER G, 1992, DEVELOPMENT, V114, P521; Buisson A, 1998, FASEB J, V12, P1683, DOI 10.1096/fasebj.12.15.1683; BUISSON A, 1995, NEUROPHARMACOLOGY, V34, P1081, DOI 10.1016/0028-3908(95)00073-F; CHAO CC, 1992, BRAIN RES, V760, P52; CONSTAM DB, 1992, J IMMUNOL, V148, P1404; CUNNINGHAM DD, 1989, J CELL BIOCHEM, V39, P55, DOI 10.1002/jcb.240390107; DALESSANDRO JS, 1994, GROWTH FACTORS, V11, P45, DOI 10.3109/08977199409015050; Datto MB, 1997, MOL CELL BIOL, V17, P2030, DOI 10.1128/MCB.17.4.2030; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; DEWULF N, 1995, ENDOCRINOLOGY, V136, P2652, DOI 10.1210/en.136.6.2652; Ebendal T, 1998, J NEUROSCI RES, V51, P139, DOI 10.1002/(SICI)1097-4547(19980115)51:2<139::AID-JNR2>3.0.CO;2-E; ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Funaba M, 1997, J NEUROENDOCRINOL, V9, P105, DOI 10.1046/j.1365-2826.1997.00558.x; GOTTI B, 1990, BRAIN RES, V522, P290, DOI 10.1016/0006-8993(90)91473-T; Gualandris A, 1996, J NEUROSCI, V16, P2220; GURWITZ D, 1988, P NATL ACAD SCI USA, V85, P3440, DOI 10.1073/pnas.85.10.3440; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; IWAHORI Y, 1995, ENDOCRINOLOGY, V136, P2652; JONES CM, 1991, DEVELOPMENT, V111, P531; KALDERON N, 1990, GLIA, V3, P413, DOI 10.1002/glia.440030513; KEETON MR, 1991, J BIOL CHEM, V266, P23048; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Kotzbauer PT, 1996, NATURE, V384, P467, DOI 10.1038/384467a0; Krueger SR, 1997, J NEUROSCI, V17, P8984; Krupinski J, 1996, STROKE, V27, P852, DOI 10.1161/01.STR.27.5.852; LEHRMANN E, 1995, EXP NEUROL, V131, P114, DOI 10.1016/0014-4886(95)90013-6; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; LOGAN A, 1992, BRAIN RES, V587, P216, DOI 10.1016/0006-8993(92)91000-5; Mabie PC, 1997, J NEUROSCI, V17, P4112; MASSAGUE J, 1996, CANC SURVEYS, V381, P620; MCNEILL H, 1994, NEUROREPORT, V5, P901, DOI 10.1097/00001756-199404000-00012; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; PREHN JHM, 1993, J CEREBR BLOOD F MET, V13, P521, DOI 10.1038/jcbfm.1993.67; Prehn JHM, 1996, NEUROPHARMACOLOGY, V35, P249, DOI 10.1016/0028-3908(96)00001-9; PREHN JHM, 1994, NEUROSCIENCE, V60, P7, DOI 10.1016/0306-4522(94)90198-8; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; RICCIO A, 1992, MOL CELL BIOL, V12, P1846, DOI 10.1128/MCB.12.4.1846; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; ROBERTS AB, 1992, MOL REPROD DEV, V32, P91, DOI 10.1002/mrd.1080320203; Rose K, 1993, IN VITRO BIOL METHOD, P46; SEEDS NW, 1995, SCIENCE, V270, P1992, DOI 10.1126/science.270.5244.1992; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Soderstrom S, 1996, CELL TISSUE RES, V286, P269, DOI 10.1007/s004410050697; SUTTON R, 1994, BLOOD COAGUL FIBRIN, V5, P167, DOI 10.1097/00001721-199404000-00002; Tsirka SE, 1997, J NEUROSCI, V17, P543; UNSICKER K, 1991, NEUROSCIENCE, V44, P613, DOI 10.1016/0306-4522(91)90082-Y; Vivien D, 1998, J NEUROCHEM, V70, P2296; VIVIEN D, 1995, J BIOL CHEM, V270, P7134, DOI 10.1074/jbc.270.13.7134; Wang YMF, 1998, NAT MED, V4, P228, DOI 10.1038/nm0298-228; WESTERHAUSEN DR, 1991, J BIOL CHEM, V266, P1092; YAMASHITA H, 1995, J CELL BIOL, V130, P217, DOI 10.1083/jcb.130.1.217; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	57	86	90	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1999	13	11					1315	1324		10.1096/fasebj.13.11.1315	http://dx.doi.org/10.1096/fasebj.13.11.1315			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	226KL	10428756	Bronze			2022-12-25	WOS:000082019100004
J	Gardin, A; Auzan, C; Clauser, E; Malherbe, T; Aunis, D; Cremel, G; Hubert, P				Gardin, A; Auzan, C; Clauser, E; Malherbe, T; Aunis, D; Cremel, G; Hubert, P			Substitution of the insulin receptor transmembrane domain with that of glycophorin A inhibits insulin action	FASEB JOURNAL			English	Article						signaling; tyrosine phosphorylation; receptor dimerization; transfection of chimeric receptors	GROWTH-FACTOR RECEPTOR-3; SIGNAL-TRANSDUCTION; POINT MUTATION; TYROSINE KINASE; CRYSTAL-STRUCTURE; A DIMERIZATION; ALPHA-HELICES; NEU ONCOGENE; BETA-SUBUNIT; ACTIVATION	To study the role of transmembrane (TM) domains interactions in the activation of the insulin receptor, we have replaced the insulin receptor TM domain with that of glycophorin A (GpA), an erythrocyte protein that spontaneously forms detergent-resistant dimers through TM-TM interactions. Insulin receptor cDNA sequences with the TM domain replaced by that of GpA were constructed and stably transfected in CHO cells, Insulin binding to cells and solubilized receptors was not modified. Electrophoresis after partial reduction of disulfide bonds revealed an altered structure for the soluble chimeric receptors, seen as an altered mobility apparently due to increased interactions between the beta subunits of the receptor. Insulin signaling was markedly decreased for cells transfected with chimeric receptors compared with cells transfected with normal receptors. A decrease in insulin-induced receptor kinase activity was observed for solubilized chimeric receptors, In conclusion, substitution by the native GpA TM domain of the insulin receptor results in structurally modified chimeric receptors that are unable to transmit the insulin signal properly. It is hypothesized that this substitution may impose structural constraints that prevent the proper changes in conformation necessary for activation of the receptor kinase. Other mutants modifying the structure or the membrane orientation of the glycophorin A TM domain are required to better understand these constraints.	INSERM, U338, F-67084 Strasbourg, France; Coll France, INSERM, U36, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France	Hubert, P (corresponding author), INSERM, U338, 5 Rue Blaise Pascal, F-67084 Strasbourg, France.		Hubert, Pierre/C-6678-2013; Dominique, Aunis/W-1419-2019	Hubert, Pierre/0000-0002-7549-8910; 				BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; Burke CL, 1997, ONCOGENE, V14, P687, DOI 10.1038/sj.onc.1200873; CADENA DL, 1992, FASEB J, V6, P2332, DOI 10.1096/fasebj.6.6.1312047; CHEATHAM B, 1993, P NATL ACAD SCI USA, V90, P7336, DOI 10.1073/pnas.90.15.7336; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; DEBANT A, 1988, P NATL ACAD SCI USA, V85, P8032, DOI 10.1073/pnas.85.21.8032; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FLORKE RR, 1990, EUR J BIOCHEM, V191, P473, DOI 10.1111/j.1432-1033.1990.tb19146.x; FRATTALI AL, 1991, J BIOL CHEM, V266, P9829; GANDERTON RH, 1992, BIOCHEM J, V288, P195, DOI 10.1042/bj2880195; Garnier N, 1997, BIOPOLYMERS, V42, P157, DOI 10.1002/(SICI)1097-0282(199708)42:2<157::AID-BIP5>3.0.CO;2-M; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; KAHN CR, 1993, RECENT PROG HORM RES, V48, P291; Kim H, 1997, J BIOL CHEM, V272, P30741, DOI 10.1074/jbc.272.49.30741; Langosch D, 1996, J MOL BIOL, V263, P525, DOI 10.1006/jmbi.1996.0595; LECONTE I, 1992, J BIOL CHEM, V267, P17415; Lee J, 1997, BIOCHEMISTRY-US, V36, P2701, DOI 10.1021/bi961815g; Lee JS, 1995, J BIOL CHEM, V270, P31136, DOI 10.1074/jbc.270.52.31136; LEMARCHANDBRUST.Y, 1988, INSULIN RECEPTORS A, P163; LEMMON MA, 1992, J BIOL CHEM, V267, P7683; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; LENWERDER K, 1997, PROTEIN SCI SU, V6, P107; LI SC, 1994, BIOCHEMISTRY-US, V33, P14333, DOI 10.1021/bi00251a047; LONGO N, 1992, J BIOL CHEM, V267, P12416; MacKenzie KR, 1998, P NATL ACAD SCI USA, V95, P3583, DOI 10.1073/pnas.95.7.3583; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MILOSO M, 1995, J BIOL CHEM, V270, P19557, DOI 10.1074/jbc.270.33.19557; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Petti LM, 1998, ONCOGENE, V16, P843, DOI 10.1038/sj.onc.1201590; ROUSSEAU F, 1994, NATURE, V371, P252, DOI 10.1038/371252a0; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; TAKAHASHI K, 1995, J BIOL CHEM, V270, P19041, DOI 10.1074/jbc.270.32.19041; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WHITTAKER J, 1994, MOL ENDOCRINOL, V8, P1521, DOI 10.1210/me.8.11.1521; Xiong QH, 1996, MOL CELL BIOL, V16, P1509; YAMAGIWA J, 1992, TOPICS PRIMATOLOGY, V2, P267	42	15	15	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1999	13	11					1347	1357		10.1096/fasebj.13.11.1347	http://dx.doi.org/10.1096/fasebj.13.11.1347			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	226KL	10428759				2022-12-25	WOS:000082019100007
J	Dunn, SE; Burns, JL; Michel, RN				Dunn, SE; Burns, JL; Michel, RN			Calcineurin is required for skeletal muscle hypertrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT TRANSCRIPTIONAL PATHWAY; CARDIAC-HYPERTROPHY; FIBER-TYPE; CYCLOSPORINE; ACTIVATION; EXPRESSION; GENE; RAT	Molecular signaling pathways linking increases in skeletal muscle usage to alterations in muscle size have not been identified. In the present study, we tested the hypothesis that calcineurin, a calcium-regulated phosphatase recently implicated in the signaling of some forms of cardiomyopathic growth, is required to induce skeletal muscle hypertrophy and muscle fiber type conversions associated with functional overload in vivo. Administration of the specific calcineurin inhibitors cyclosporin (CsA) or FK506 to mice, for which the fast plantaris muscle was overloaded for 1-4 weeks, prevented the rapid doubling of mass and individual fiber size and the 4-20-fold increase in the number of slow fibers that characterize this condition. CsA treatment influenced the expression of muscle myofibrillar protein genes in a way reflective of fiber phenotype transformations but only in the long term of the overload condition, suggesting that the control of this growth response by calcineurin is not limited to the transcriptional activation of these muscle-specific genes. Clinically, these results provide insight to the post surgical muscle wasting and weakness observed in recovering transplant recipients administered therapeutic dosages of these immunosuppressants.	Laurentian Univ, Dept Chem & Biochem, Neuromuscular Res Lab, Sudbury, ON P3E 2C6, Canada	Laurentian University	Michel, RN (corresponding author), Laurentian Univ, Dept Chem & Biochem, Neuromuscular Res Lab, Ramsey Lake Rd, Sudbury, ON P3E 2C6, Canada.							Abbott KL, 1998, MOL BIOL CELL, V9, P2905, DOI 10.1091/mbc.9.10.2905; Biring MS, 1998, J APPL PHYSIOL, V84, P1967, DOI 10.1152/jappl.1998.84.6.1967; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; CLIPSTONE NA, 1994, J BIOL CHEM, V269, P26431; CRERAR MM, 1989, MOL CELL BIOCHEM, V86, P115; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Dunn SE, 1997, AM J PHYSIOL-CELL PH, V273, pC371, DOI 10.1152/ajpcell.1997.273.2.C371; Dunn SE, 1999, FASEB J, V13, pA84; Gauthier ER, 1997, PFLUG ARCH EUR J PHY, V433, P664, DOI 10.1007/s004240050328; GOY JJ, 1989, LANCET, V1, P1446; Guerini D, 1997, BIOCHEM BIOPH RES CO, V235, P271, DOI 10.1006/bbrc.1997.6802; HONGO K, 1995, AM J PHYSIOL-CELL PH, V269, pC690, DOI 10.1152/ajpcell.1995.269.3.C690; Huey KA, 1996, AM J PHYSIOL-CELL PH, V271, pC2016, DOI 10.1152/ajpcell.1996.271.6.C2016; KANDARIAN SC, 1994, AM J PHYSIOL, V266, pC1190, DOI 10.1152/ajpcell.1994.266.5.C1190; Mende U, 1998, P NATL ACAD SCI USA, V95, P13893, DOI 10.1073/pnas.95.23.13893; MICHEL RN, 1994, J CELL BIOL, V127, P1061, DOI 10.1083/jcb.127.4.1061; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Nakayama M, 1996, MOL CELL BIOL, V16, P2408; OLHA AE, 1988, J NEUROPHYSIOL, V60, P2138, DOI 10.1152/jn.1988.60.6.2138; Phelan JN, 1997, ANAT REC, V247, P179, DOI 10.1002/(SICI)1097-0185(199702)247:2<179::AID-AR4>3.0.CO;2-T; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; SEHGAL SN, 1995, THER DRUG MONIT, V17, P660, DOI 10.1097/00007691-199512000-00019; Sussman MA, 1998, SCIENCE, V281, P1690, DOI 10.1126/science.281.5383.1690; THOMSON AW, 1989, IMMUNOL TODAY, V10, P6, DOI 10.1016/0167-5699(89)90057-1; Zhang WG, 1999, CIRC RES, V84, P722, DOI 10.1161/01.RES.84.6.722	26	218	224	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21908	21912		10.1074/jbc.274.31.21908	http://dx.doi.org/10.1074/jbc.274.31.21908			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419511	hybrid			2022-12-25	WOS:000081721100064
J	Grabner, M; Dirksen, RT; Suda, N; Beam, KG				Grabner, M; Dirksen, RT; Suda, N; Beam, KG			The II-III loop of the skeletal muscle dihydropyridine receptor is responsible for the bi-directional coupling with the ryanodine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SLOW CALCIUM CURRENT; CA2+ CHANNELS; FUNCTIONAL EXPRESSION; DYSGENIC MUSCLE; MICE LACKING; MYOTUBES; RELEASE; REGIONS; CDNAS; CELLS	The dihydropyridine receptor (DHPR) in the skeletal muscle plasmalemma functions as both voltage-gated Ca2+ channel and voltage sensor for excitation-contraction (EC) coupling. As voltage sensor, the DHPR regulates intracellular Ca2+ release via the skeletal isoform of the ryanodine receptor (RyR-1). Interaction with RyR-1 also feeds back to increase the Ca2+ current mediated by the DHPR, To identify regions of the DHPR important for receiving this signal from RyR-1, we expressed in dysgenic myotubes a chimera (SkLC) having skeletal (Sk) DHPR sequence except for a cardiac (C) II-III loop (L), Tagging with green fluorescent protein (GFP) enabled identification of expressing myotubes, Dysgenic myotubes expressing GFP-SkLC or SkLC lacked EC coupling and had very small Ca2+ currents. Introducing a short skeletal segment (alpha(1S) residues 720-765) into the cardiac II-III loop (replacing alpha(1C) residues 851-896) of GFP-SkLC restored both EC coupling and Ca2+ current densities like those of the wild type skeletal DHPR. This 46-amino acid stretch of skeletal sequence was recently shown to be capable of transferring strong, skeletal-type EC coupling to an otherwise cardiac DHPR (Nakai, J., Tanabe, T., Konno, T., Adams, B., and Beam, K.G. (1998) J. Biol. Chem, 273, 24983-24986), Thus, this segment of the skeletal II-III loop contains a motif required for both skeletal-type EC coupling and RyR-1-mediated enhancement of Ca2+ current.	Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Anat & Neurobiol, Ft Collins, CO 80523 USA	Colorado State University	Beam, KG (corresponding author), Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Anat & Neurobiol, Ft Collins, CO 80523 USA.	kbeam@lamar.colostate.edu	Tuluc, Petronel/C-2527-2011		NIAMS NIH HHS [AR 44750] Funding Source: Medline; NINDS NIH HHS [NS 24444] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR044750] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024444] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS BA, 1994, J GEN PHYSIOL, V104, P985, DOI 10.1085/jgp.104.5.985; ADAMS BA, 1989, J GEN PHYSIOL, V94, P429, DOI 10.1085/jgp.94.3.429; ADAMS BA, 1990, NATURE, V346, P569, DOI 10.1038/346569a0; ARMSTRONG CM, 1972, BIOCHIM BIOPHYS ACTA, V267, P605, DOI 10.1016/0005-2728(72)90194-6; Balog EM, 1999, AM J PHYSIOL-CELL PH, V276, pC128, DOI 10.1152/ajpcell.1999.276.1.C128; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; FELDMEYER D, 1993, PFLUG ARCH EUR J PHY, V425, P54, DOI 10.1007/BF00374503; Fleig A, 1996, J PHYSIOL-LONDON, V496, P339, DOI 10.1113/jphysiol.1996.sp021689; FLUCHER BE, 1993, J CELL BIOL, V123, P1161, DOI 10.1083/jcb.123.5.1161; Garcia J, 1997, BIOPHYS J, V72, P2515, DOI 10.1016/S0006-3495(97)78896-9; GARCIA J, 1994, J GEN PHYSIOL, V103, P107, DOI 10.1085/jgp.103.1.107; Grabner M, 1998, P NATL ACAD SCI USA, V95, P1903, DOI 10.1073/pnas.95.4.1903; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOFMANN F, 1994, ANNU REV NEUROSCI, V17, P399, DOI 10.1146/annurev.neuro.17.1.399; JURMAN ME, 1994, BIOTECHNIQUES, V17, P876; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MISHINA M, 1984, NATURE, V307, P604, DOI 10.1038/307604a0; Nakai J, 1996, NATURE, V380, P72, DOI 10.1038/380072a0; Nakai J, 1998, J BIOL CHEM, V273, P13403, DOI 10.1074/jbc.273.22.13403; NAKAI J, 1998, J BIOL CHEM, V273, P24893; O'Brien JJ, 1999, BIOPHYS J, V76, pA302; Ren DJ, 1997, J BIOL CHEM, V272, P22393, DOI 10.1074/jbc.272.36.22393; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; SUN XH, 1995, J CELL BIOL, V129, P659, DOI 10.1083/jcb.129.3.659; TAKESHIMA H, 1994, NATURE, V369, P556, DOI 10.1038/369556a0; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANABE T, 1990, NATURE, V344, P451, DOI 10.1038/344451a0; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0	29	156	158	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21913	21919		10.1074/jbc.274.31.21913	http://dx.doi.org/10.1074/jbc.274.31.21913			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419512	hybrid			2022-12-25	WOS:000081721100065
J	Haardt, M; Benharouga, M; Lechardeur, D; Kartner, N; Lukacs, GL				Haardt, M; Benharouga, M; Lechardeur, D; Kartner, N; Lukacs, GL			C-terminal truncations destabilize the cystic fibrosis transmembrane conductance regulator without impairing its biogenesis - A novel class of mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; CHLORIDE CHANNEL; CFTR; PROTEIN; GENE; MEMBRANE; CELLS; PHOSPHORYLATION; IDENTIFICATION; DEGRADATION	Defective cAMP-stimulated chloride conductance of the plasma membrane of epithelial cell is the hallmark of cystic fibrosis (CF) and results from mutations in the cystic fibrosis transmembrane conductance regulator, CFTR. In the majority of CF patients, mutations in the CFTR lead to its misfolding and premature degradation at the endoplasmic reticulum (ER), Other mutations impair the cAMP-dependent activation or the ion conductance of CFTR chloride channel. In the present work we identify a novel mechanism leading to reduced expression of CFTR at the cell surface, caused by C-terminal truncations, The phenotype of C-terminally truncated CFTR, representing naturally occurring premature termination and frameshift mutations, were examined in transient and stable heterologous expression systems. Whereas the biosynthesis, processing, and macroscopic chloride channel function of truncated CFTRs are essentially normal, the degradation rate of the mature, complex-glycosylated form is 5- to 6-fold faster than the wild type CFTR. These experiments suggest that the C terminus has a central role in maintaining the metabolic stability of the complex-glycosylated CFTR following its exit from the ER and provide a plausible explanation for the severe phenotype of CF patients harboring C-terminal truncations.	Hosp Sick Children, Res Inst, Program Cell Biol & Lung Gene Therapy, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Pharmacol, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto	Lukacs, GL (corresponding author), Hosp Sick Children, Res Inst, Program Cell Biol & Lung Gene Therapy, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.			Lechardeur, Delphine/0000-0002-5331-4607; Lukacs, Gergely/0000-0003-0900-0675				CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; Cotten JF, 1996, J BIOL CHEM, V271, P21279, DOI 10.1074/jbc.271.35.21279; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; GADSBY DC, 1994, TRENDS BIOCHEM SCI, V19, P513, DOI 10.1016/0968-0004(94)90141-4; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; KEREM B, 1989, SCIENCE, V245, P107; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; Lukacs GL, 1997, BIOCHEM J, V328, P353; LUKACS GL, 1993, J BIOL CHEM, V268, P21592; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; Mickle JE, 1998, HUM MOL GENET, V7, P729, DOI 10.1093/hmg/7.4.729; PIND S, 1994, J BIOL CHEM, V269, P12784; PRINCE LS, 1994, P NATL ACAD SCI USA, V91, P5192, DOI 10.1073/pnas.91.11.5192; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; Seibert FS, 1997, J BIOENERG BIOMEMBR, V29, P429, DOI 10.1023/A:1022478822214; Seibert FS, 1997, BIOCHEMISTRY-US, V36, P11966, DOI 10.1021/bi9712652; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; WARD CL, 1994, J BIOL CHEM, V269, P25710; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; ZIE J, 1995, J BIOL CHEM, V270, P28084; Zielenski J, 1995, ANNU REV GENET, V29, P777, DOI 10.1146/annurev.ge.29.120195.004021	31	138	142	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21873	21877		10.1074/jbc.274.31.21873	http://dx.doi.org/10.1074/jbc.274.31.21873			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419506	hybrid			2022-12-25	WOS:000081721100059
J	Kuschel, M; Zhou, YY; Cheng, HP; Zhang, SJ; Chen, Y; Lakatta, EG; Xiao, RP				Kuschel, M; Zhou, YY; Cheng, HP; Zhang, SJ; Chen, Y; Lakatta, EG; Xiao, RP			G(1) protein-mediated functional compartmentalization of cardiac beta(2)-adrenergic signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLAMBAN PHOSPHORYLATION; CALCIUM CHANNELS; HEART-CELLS; CA2+ CHANNELS; INTACT HEART; RAT-HEART; STIMULATION; MYOCYTES; CAMP; CONTRACTILITY	In contrast to beta(1)-adrenoreceptor (beta(1)-AR) signaling, beta(2)-AR stimulation in cardiomyocytes augments L-type Ca2+ current in a cAMP-dependent protein kinase (PKA)dependent manner but fails to phosphorylate phospholamban, indicating that the beta(2)-AR-induced cAMP/PKA signaling is highly localized. Here we show that inhibition of G(i) proteins with pertussis toxin (PTX) permits a full phospholamban phosphorylation and a de novo relaxant effect following beta(2)-AR stimulation, converting the localized beta(2)-AR signaling to a global signaling mode similar to that of beta(1)-AR. Thus, beta(2)-AR-mediated G(i) activation constricts the cAMP signaling to the sarcolemma. PTX treatment did not significantly affect the beta(2)-AR-stimulated PKA activation. Similar to G(i) inhibition, a protein phosphatase inhibitor, calyculin A (3 x 10(-8) M), selectively enhanced the beta(2)-AR but not beta(1)-AR-mediated contractile response. Furthermore, PTX and calyculin A treatment had a non-additive potentiating effect on the beta(2)-AR-mediated positive inotropic response. These results suggest that the interaction of the beta(2)-AR-coupled G(i), and G(s) signaling affects the local balance of protein kinase and phosphatase activities. Thus, the additional coupling of beta(2)-AR to G(i) proteins is a key factor causing the compartmentalization of beta(2)-AR-induced cAMP signaling.	NIA, Cardiovasc Sci Lab, Gerontol Res Ctr, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Xiao, RP (corresponding author), NIA, Cardiovasc Sci Lab, Gerontol Res Ctr, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	XiaoR@grc.nia.nih.gov	Xiao, Rui-Ping/AAE-2629-2019; Lakatta, Edward G/AAL-1447-2020; Yimei, Wang/AAE-4083-2019; Heping, Cheng/AAE-2680-2019	Heping, Cheng/0000-0002-9604-6702; Lakatta, Edward/0000-0002-4772-0035; Chen-Izu, Ye/0000-0003-4818-9570				ALTSCHULD RA, 1995, CIRCULATION, V92, P1612, DOI 10.1161/01.CIR.92.6.1612; BEAN BP, 1984, NATURE, V307, P371, DOI 10.1038/307371a0; CHENIZU Y, 1998, J MOL CELL CARDIOL, V30, P502; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; DRAGO GA, 1994, J BIOL CHEM, V269, P25073; ENDOH M, 1980, EUR J PHARMACOL, V65, P445, DOI 10.1016/0014-2999(80)90352-0; ENGLAND PJ, 1976, BIOCHEM J, V160, P295, DOI 10.1042/bj1600295; Gao TY, 1997, J BIOL CHEM, V272, P19401, DOI 10.1074/jbc.272.31.19401; GARVEY JL, 1988, BIOCHEM J, V249, P709, DOI 10.1042/bj2490709; Gray PC, 1998, NEURON, V20, P1017, DOI 10.1016/S0896-6273(00)80482-1; HERZIG S, 1995, PFLUG ARCH EUR J PHY, V429, P531, DOI 10.1007/BF00704158; HOHL CM, 1991, CIRC RES, V69, P1369, DOI 10.1161/01.RES.69.5.1369; HUANG XC, 1995, J NEUROCHEM, V65, P2131; Jurevicius J, 1996, P NATL ACAD SCI USA, V93, P295, DOI 10.1073/pnas.93.1.295; KAMEYAMA M, 1985, PFLUG ARCH EUR J PHY, V405, P285, DOI 10.1007/BF00582573; Kaumann A, 1999, CIRCULATION, V99, P65, DOI 10.1161/01.CIR.99.1.65; Kaumann AJ, 1996, MOL CELL BIOCHEM, V164, P113, DOI 10.1007/BF00408647; Koss KL, 1996, CIRC RES, V79, P1059, DOI 10.1161/01.RES.79.6.1059; Kuschel M, 1999, CIRCULATION, V99, P2458, DOI 10.1161/01.CIR.99.18.2458; LEVY MN, 1981, ANNU REV PHYSIOL, V43, P443, DOI 10.1146/annurev.ph.43.030181.002303; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MundinaWeilenmann C, 1996, J BIOL CHEM, V271, P33561, DOI 10.1074/jbc.271.52.33561; MURRAY KJ, 1990, BIOCHEM J, V267, P703, DOI 10.1042/bj2670703; NELSON MT, 1995, SCIENCE, V270, P633, DOI 10.1126/science.270.5236.633; NEUMANN J, 1991, CIRC RES, V69, P1450, DOI 10.1161/01.RES.69.6.1450; SPURGEON HA, 1990, AM J PHYSIOL, V258, pH574, DOI 10.1152/ajpheart.1990.258.2.H574; WEGENER AD, 1989, J BIOL CHEM, V264, P11468; XIAO RP, 1994, J BIOL CHEM, V269, P19151; Xiao RP, 1999, CIRC RES, V84, P43; XIAO RP, 1993, CIRC RES, V73, P286, DOI 10.1161/01.RES.73.2.286; XIAO RP, 1995, MOL PHARMACOL, V47, P322; Zhou YY, 1997, AM J PHYSIOL-HEART C, V273, pH1611, DOI 10.1152/ajpheart.1997.273.3.H1611	32	136	145	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					22048	22052		10.1074/jbc.274.31.22048	http://dx.doi.org/10.1074/jbc.274.31.22048			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419531	hybrid			2022-12-25	WOS:000081721100084
J	McKeehan, WL; Wu, XC; Kan, M				McKeehan, WL; Wu, XC; Kan, M			Requirement for anticoagulant heparan sulfate in the fibroblast growth factor receptor complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING; FGF-2; ACTIVATION; SEQUENCE; OLIGOSACCHARIDES; IDENTIFICATION	A divalent cation-dependent association between heparin or heparan sulfate and the ectodomain of the fibroblast growth factor (FGF) receptor kinase (FGFR) restricts FGF-independent trans-phosphorylation between self-associated FGFR and determines specificity for and mediates binding of activating FGF. Here we show that only the fraction of commercial heparin or rat liver heparan sulfate which binds to immobilized antithrombin formed an FGF-binding binary complex with the ectodomain of the FGFR kinase. Conversely, only the fraction of heparin that binds to immobilized FGFR inhibited Factor Xa in the presence of antithrombin. Only the antithrombin-bound fraction of heparin competed with SH-heparin bound to FGFR in absence of FGF, whereas both antithrombin-bound and unretained fractions competed with radiolabeled heparin bound independently to FGF-1 and FGF-2. The antithrombin-bound fraction of heparin was required to support the heparin-dependent stimulation of DNA synthesis of endothelial cells by FGF-1. The requirement for divalent cations and the antithrombin-binding motif distinguish the role of heparan sulfate as an integral subunit of the FGFR complex from the wider range of effects of heparan sulfates and homologues on FGF signaling through FGFR-independent interactions with FGF.	Texas A&M Univ, Hlth Sci Ctr, Ctr Canc Biol & Nutr, Houston, TX 77030 USA; Texas A&M Univ, Dept Biochem & Biophys, Houston, TX 77030 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston; Texas A&M University System	Kan, M (corresponding author), Texas A&M Univ, Hlth Sci Ctr, Ctr Canc Biol & Nutr, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	mkan@ibt.tamu.edu			NATIONAL CANCER INSTITUTE [R01CA059971] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040739, R01DK035310] Funding Source: NIH RePORTER; NCI NIH HHS [CA59971] Funding Source: Medline; NIDDK NIH HHS [DK35310, DK40739] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; FLAUMENHAFT R, 1990, J CELL BIOL, V111, P1651, DOI 10.1083/jcb.111.4.1651; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HERR AB, 1997, J BIOL CHEM, V272, P16385; HOSHI H, 1988, IN VITRO CELL DEV B, V24, P309; ISHIHARA M, 1994, GLYCOBIOLOGY, V4, P817, DOI 10.1093/glycob/4.6.817; ISHIHARA M, 1995, J BIOCHEM-TOKYO, V118, P1255, DOI 10.1093/oxfordjournals.jbchem.a125015; ISHIHARA M, 1993, J BIOL CHEM, V268, P4675; Kan M, 1999, J BIOL CHEM, V274, P15947, DOI 10.1074/jbc.274.22.15947; Kan M, 1996, J BIOL CHEM, V271, P26143, DOI 10.1074/jbc.271.42.26143; KAN M, 1992, IN VITRO CELL DEV-AN, V28A, P515; KAN M, 1991, METHOD ENZYMOL, V198, P158; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; Kato M, 1998, NAT MED, V4, P691, DOI 10.1038/nm0698-691; Luo YD, 1996, J BIOL CHEM, V271, P26876, DOI 10.1074/jbc.271.43.26876; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; Moy FJ, 1997, BIOCHEMISTRY-US, V36, P4782, DOI 10.1021/bi9625455; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; Pye DA, 1998, J BIOL CHEM, V273, P22936, DOI 10.1074/jbc.273.36.22936; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; Zhang LJ, 1999, J BIOL CHEM, V274, P5681, DOI 10.1074/jbc.274.9.5681	26	49	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21511	21514		10.1074/jbc.274.31.21511	http://dx.doi.org/10.1074/jbc.274.31.21511			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419453	hybrid			2022-12-25	WOS:000081721100006
J	Tsai, AL; Wu, G; Palmer, G; Bambai, B; Koehn, JA; Marshall, PJ; Kulmacz, RJ				Tsai, AL; Wu, G; Palmer, G; Bambai, B; Koehn, JA; Marshall, PJ; Kulmacz, RJ			Rapid kinetics of tyrosyl radical formation and heme redox state changes in prostaglandin H synthase-1 and-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGHER OXIDATION-STATES; MANGANO PROTOPORPHYRIN-IX; PEROXIDASE REACTION; ENZYME CATALYSIS; CYCLOOXYGENASE-2; AGENTS; SITE	Hydroperoxide-induced tyrosyl radicals are putative intermediates in cyclooxygenase catalysis by prostaglandin H synthase (PGHS)-1 and -2, Rapid-freeze EPR and stopped-flow were used to characterize tyrosyl radical kinetics in PGHS-1 and -2 reacted with ethyl hydrogen peroxide, In PGHS-1, a wide doublet tyrosyl radical (34-35 G) was formed by 4 ms, followed by transition to a wide singlet (33-34 G); changes in total radical intensity paralleled those of Intermediate II absorbance during both formation and decay phases. In PGHS-2, some wide doublet (30 G) was present at early time points, but transition to wide singlet (29 G) was complete by 50 ms. In contrast to PGHS-1, only the formation kinetics of the PGHS-2 tyrosyl radical matched the Intermediate II absorbance kinetics. Indomethacin-treated PGHS-1 and nimesulide-treated PGHS-2 rapidly formed narrow singlet EPR (25-26 G in PGHS-1; 21 G in PGHS-2), and the same line shapes persisted throughout the reactions. Radical intensity paralleled Intermediate II absorbance throughout the indomethacin-treated PGHS-1 reaction. For nimesulide-treated PGHS-2, radical formed in concert with Intermediate II, but later persisted while Intermediate II relaxed. These results substantiate the kinetic competence of a tyrosyl radical as the catalytic intermediate for both PGHS isoforms and also indicate that the heme redox state becomes uncoupled from the tyrosyl radical in PGHS-2.	Univ Texas, Hlth Sci Ctr, Div Hematol, Dept Internal Med, Houston, TX 77225 USA; Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA; Novartis Pharmaceut, Arthrit Res Dept, Summit, NJ 07901 USA	University of Texas System; University of Texas Health Science Center Houston; Rice University; Novartis	Tsai, AL (corresponding author), Univ Texas, Hlth Sci Ctr, Div Hematol, Dept Internal Med, POB 20708, Houston, TX 77225 USA.			Bambai, Bijan/0000-0002-9947-1691	NIGMS NIH HHS [GM44911, GM21337, GM52170] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021337, R01GM021337, R01GM052170] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DEGRAY JA, 1992, J BIOL CHEM, V267, P23583; DIETZ R, 1988, EUR J BIOCHEM, V171, P321, DOI 10.1111/j.1432-1033.1988.tb13793.x; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HSI LC, 1994, BIOCHEM BIOPH RES CO, V202, P1592, DOI 10.1006/bbrc.1994.2114; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; KULMACZ RJ, 1991, MOL PHARMACOL, V40, P833; KULMACZ RJ, 1990, BIOCHEMISTRY-US, V29, P8760, DOI 10.1021/bi00489a037; KULMACZ RJ, 1995, J BIOL CHEM, V270, P24019, DOI 10.1074/jbc.270.41.24019; Kulmacz RJ, 1987, PROSTAGLANDINS RELAT, P209; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; LAMBEIR AM, 1985, J BIOL CHEM, V260, P4894; LASSMANN G, 1991, J BIOL CHEM, V266, P20045; Lu GQ, 1999, J BIOL CHEM, V274, P16162, DOI 10.1074/jbc.274.23.16162; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; Stubbe J, 1998, CHEM REV, V98, P705, DOI 10.1021/cr9400875; TSAI AL, 1994, J BIOL CHEM, V269, P5085; Tsai AL, 1997, BIOCHEMISTRY-US, V36, P13085, DOI 10.1021/bi970397s; TSAI AL, 1992, J BIOL CHEM, V267, P17753; Tsai AL, 1998, J BIOL CHEM, V273, P3888, DOI 10.1074/jbc.273.7.3888; Tsai AL, 1998, ANAL BIOCHEM, V264, P165, DOI 10.1006/abio.1998.2774; Tsai AL, 1997, J BIOL CHEM, V272, P8885; TSAI AL, 1995, J BIOL CHEM, V270, P10503, DOI 10.1074/jbc.270.18.10503; Wu G, 1999, J BIOL CHEM, V274, P9231, DOI 10.1074/jbc.274.14.9231; Xiao GS, 1997, BIOCHEMISTRY-US, V36, P1836, DOI 10.1021/bi962476u	26	52	53	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21695	21700		10.1074/jbc.274.31.21695	http://dx.doi.org/10.1074/jbc.274.31.21695			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419480	hybrid			2022-12-25	WOS:000081721100033
J	Watari, H; Blanchette-Mackie, EJ; Dwyer, NK; Watari, M; Neufeld, EB; Patel, S; Pentchev, PG; Strauss, JF				Watari, H; Blanchette-Mackie, EJ; Dwyer, NK; Watari, M; Neufeld, EB; Patel, S; Pentchev, PG; Strauss, JF			Mutations in the leucine zipper motif and sterol-sensing domain inactivate the Niemann-Pick C1 glycoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTEROL HOMEOSTASIS; DISEASE; COMPLEMENTATION; ACCUMULATION; FIBROBLASTS; TRANSPORT; MUTANTS; GENE	Niemann-Pick type C (NPC) disease, characterized by accumulation of low density lipoprotein-derived free cholesterol in lysosomes, is caused by mutations in the NPC1 gene. We examined the ability of wild-type NPC1 and NPC1 mutants to correct the NPC sterol trafficking defect and their subcellular localization in CT60 cells. Cells transfected with wild-type NPC1 expressed 170- and 190-kDa proteins. Tunicamycin treatment resulted in a 140-kDa protein, the deduced size of NPC1, suggesting that NPC1 is N-glycosylated, Mutation of all four asparagines in potential N-terminal N-glycosylation sites to glutamines resulted in a 20-kDa reduction of the expressed protein. Proteins with a single N-glycosylation site mutation localized to late endosome/lysosomal compartments, as did wild-type NPC1, and each corrected the cholesterol trafficking defect. However, mutation of all four potential N-glycosylation sites reduced ability to correct the NPC phenotype commensurate with reduced expression of the protein. Mutations in the putative sterol-sensing domain resulted in inactive proteins targeted to lysosomal membranes encircling cholesterol-laden cores. N-terminal leucine zipper motif mutants could not correct the NPC defect, although they accumulated in lysosomal membranes. We conclude that NPC1 is a glycoprotein that must have an intact sterol-sensing domain and leucine zipper motif for cholesterol-mobilizing activity.	Univ Penn, Med Ctr, Dept Obstet & Gynecol, Ctr Res Reprod & Womens Hlth, Philadelphia, PA 19104 USA; Dept Vet Affairs Connecticut Healthcare Syst, Neurol Res Lab, Newington, CT 06111 USA; NIDDK, Sect Lipid Cell Biol, NIH, Newington, CT 06111 USA; NINDS, Cellular & Mol Pathophysiol Sect, Dev & Metab Neurol Branch, NIH, Bethesda, MD 20892 USA	University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Strauss, JF (corresponding author), 1354 BRBII-III,421 Curie Blvd, Philadelphia, PA 19104 USA.		Neufeld, Edward/R-3819-2019		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK060003] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034339] Funding Source: NIH RePORTER; NICHD NIH HHS [HD06274] Funding Source: Medline; NINDS NIH HHS [NS34339] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLANCHETTEMACKIE EJ, 1988, P NATL ACAD SCI USA, V85, P8022, DOI 10.1073/pnas.85.21.8022; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; COXEY RA, 1993, J LIPID RES, V34, P1165; DAHL NK, 1994, J LIPID RES, V35, P1839; Gu JZ, 1997, P NATL ACAD SCI USA, V94, P7378, DOI 10.1073/pnas.94.14.7378; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; Liscum L, 1998, CURR OPIN LIPIDOL, V9, P131, DOI 10.1097/00041433-199804000-00009; LISCUM L, 1995, J BIOL CHEM, V270, P15443, DOI 10.1074/jbc.270.26.15443; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; Neufeld EB, 1999, J BIOL CHEM, V274, P9627, DOI 10.1074/jbc.274.14.9627; Neufeld EB, 1998, INTRACELLULAR CHOLESTEROL TRAFFICKING, P93; Nohturfft A, 1998, P NATL ACAD SCI USA, V95, P12848, DOI 10.1073/pnas.95.22.12848; NORTUFFT A, 1998, J BIOL CHEM, V273, P17243; OLEANDER EH, 1992, J BIOL CHEM, V267, P4223; Patel SC, 1999, P NATL ACAD SCI USA, V96, P1657, DOI 10.1073/pnas.96.4.1657; PENTCHEV PG, 1986, J BIOL CHEM, V261, P6775; PENTSCHEV PG, 1988, P NATL ACAD SCI USA, V82, P8247; PORTE D, 1995, J BIOL CHEM, V270, P22721, DOI 10.1074/jbc.270.39.22721; RANSDALE EE, 1996, VIROLOGY, V220, P100; SPILLANE DM, 1995, BIOCHIM BIOPHYS ACTA, V124, P283; Tong Q, 1997, J BIOL CHEM, V272, P9043; Vanier MT, 1996, AM J HUM GENET, V58, P118; Watari H, 1999, P NATL ACAD SCI USA, V96, P805, DOI 10.1073/pnas.96.3.805	23	91	94	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21861	21866		10.1074/jbc.274.31.21861	http://dx.doi.org/10.1074/jbc.274.31.21861			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419504	hybrid			2022-12-25	WOS:000081721100057
J	Corbett, SA; Schwarzbauer, JE				Corbett, SA; Schwarzbauer, JE			Requirements for alpha 5 beta 1 integrin-mediated retraction of fibronectin-fibrin matrices	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; CLOT RETRACTION; EXTRACELLULAR-MATRIX; CYTOPLASMIC DOMAIN; HUMAN FIBROBLASTS; CROSS-LINKING; ALPHA(V)BETA(3); IDENTIFICATION; ALPHA(5)BETA(1); CYTOSKELETON	Retraction of the blood clot by nucleated cells contributes both to hemostasis and to tissue remodeling. Although plasma fibronectin (FN) is a key component of the clot, its role in clot retraction is unclear. In this report, we demonstrate that the incorporation of FN into fibrin matrices significantly improves clot retraction by nucleated cells expressing the integrin alpha(5)beta(1). Further, we show that FN-fibrin clots support increased cell spreading when compared with fibrin matrices. To determine the structural requirements for FN in this process, recombinant FN monomers deficient in ligand binding or fibrin cross-linking were incorporated into fibrin clots. We show that recombinant FN monomers support clot retraction by Chinese hamster ovary cells expressing the integrin alpha(5)beta(1). This process depends on both the Arg-Gly-Asp (RGD) and the synergy cell-binding sites and on covalent FN-fibrin binding, demonstrating that cross-linking within the clot is important for cell-FN interactions. These data show that alpha(5)beta(1) can bind to FN within a clot to promote clot retraction and support cell shape change. This provides strong evidence that alpha(5)beta(1)-FN interactions may contribute to the cellular events required for wound contraction.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Surg, New Brunswick, NJ 08903 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Princeton University	Corbett, SA (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Surg, New Brunswick, NJ 08903 USA.			Schwarzbauer, Jean/0000-0003-1012-7593	NATIONAL CANCER INSTITUTE [R01CA044627] Funding Source: NIH RePORTER; NCI NIH HHS [CA-44627] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGUIRRE KM, 1994, J BIOL CHEM, V269, P27863; AOTA S, 1994, J BIOL CHEM, V269, P24756; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; CHEN YP, 1995, BLOOD, V86, P2606, DOI 10.1182/blood.V86.7.2606.bloodjournal8672606; Chicurel ME, 1998, CURR OPIN CELL BIOL, V10, P232, DOI 10.1016/S0955-0674(98)80145-2; Choquet D, 1997, CELL, V88, P39, DOI 10.1016/S0092-8674(00)81856-5; Clark RAF, 1989, CURR OPIN CELL BIOL, V1, P1000, DOI 10.1016/0955-0674(89)90072-0; Clark R. A. F, 1996, MOL CELLULAR BIOL WO; Corbett SA, 1996, BLOOD, V88, P158; Corbett SA, 1997, J BIOL CHEM, V272, P24999, DOI 10.1074/jbc.272.40.24999; GARTNER TK, 1988, THROMB RES, V49, P43; Greiling D, 1997, J CELL SCI, V110, P861; GRINNELL F, 1980, CELL, V19, P517, DOI 10.1016/0092-8674(80)90526-7; Hynes R.O., 1990, FIBRONECTINS, P113, DOI DOI 10.1007/978-1-4612-3264-3_6; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KAMYKOWSKI GW, 1981, BIOPHYS CHEM, V13, P25, DOI 10.1016/0301-4622(81)80021-X; KASSNER PD, 1995, MOL BIOL CELL, V6, P661, DOI 10.1091/mbc.6.6.661; KATAGIRI Y, 1995, J BIOL CHEM, V270, P1785, DOI 10.1074/jbc.270.4.1785; KESKIOJA J, 1976, CELL, V9, P29, DOI 10.1016/0092-8674(76)90049-0; KNOX P, 1986, J CELL BIOL, V102, P2318, DOI 10.1083/jcb.102.6.2318; LEAVESLEY DI, 1993, J CELL BIOL, V121, P163, DOI 10.1083/jcb.121.1.163; Maniotis AJ, 1997, P NATL ACAD SCI USA, V94, P849, DOI 10.1073/pnas.94.3.849; MOSESSON M W, 1992, Seminars in Hematology, V29, P177; MOSHER DF, 1976, J BIOL CHEM, V16, P6614; OKADA M, 1985, J BIOL CHEM, V260, P1811; PFAFF M, 1994, J BIOL CHEM, V269, P20233; Ramos JW, 1996, J CELL BIOL, V134, P227, DOI 10.1083/jcb.134.1.227; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; Rosenfeldt H, 1998, MOL CELL BIOL, V18, P2659, DOI 10.1128/MCB.18.5.2659; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; SCHWARZBAUER JE, 1991, J CELL BIOL, V113, P1463, DOI 10.1083/jcb.113.6.1463; Sechler JL, 1996, J CELL BIOL, V134, P573, DOI 10.1083/jcb.134.2.573; Sechler JL, 1997, MOL BIOL CELL, V8, P2563, DOI 10.1091/mbc.8.12.2563; Smith RA, 1997, J BIOL CHEM, V272, P22080, DOI 10.1074/jbc.272.35.22080; Suehiro K, 1997, J BIOL CHEM, V272, P5360, DOI 10.1074/jbc.272.8.5360; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; Wennerberg K, 1996, J CELL BIOL, V132, P227, DOI 10.1083/jcb.132.1.227; Wu CY, 1996, CELL ADHES COMMUN, V4, P149, DOI 10.3109/15419069609014219; Xu JH, 1998, J CELL BIOL, V140, P709, DOI 10.1083/jcb.140.3.709; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Yang JT, 1996, MOL BIOL CELL, V7, P1737, DOI 10.1091/mbc.7.11.1737; Yee KO, 1998, CIRC RES, V83, P241, DOI 10.1161/01.RES.83.3.241	45	39	40	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					20943	20948		10.1074/jbc.274.30.20943	http://dx.doi.org/10.1074/jbc.274.30.20943			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409640	hybrid			2022-12-25	WOS:000081613100031
J	Lin, JK; Linzer, DIH				Lin, JK; Linzer, DIH			Induction of megakaryocyte differentiation by a novel pregnancy-specific hormone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILY; MOUSE; PREECLAMPSIA; EXPRESSION; PREVENTION; ACTIVATION; PROTEIN; MEMBERS; MARROW; GP130	Maturation of megakaryocytes and subsequent platelet release are normally regulated by a network of cytokines, including thrombopoietin and various interleukins, Because abnormal platelet production and activation have been implicated in gestational pathologies, additional pregnancy-specific cytokines may play important roles in the regulation of megakaryocytopoiesis, Consistent with this hypothesis, we have found that the hormone prolactin-like protein E, a placental hormone that we have recently characterized, targets megakaryocytes through a specific cell surface receptor and induces megakaryocyte differentiation through a gp130-dependent signal transduction pathway.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	Northwestern University	Linzer, DIH (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, 2153 Sheridan Rd, Evanston, IL 60208 USA.				NICHD NIH HHS [R01 HD24518, HD28048] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD028048, R01HD024518] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Baatout S, 1998, ANTICANCER RES, V18, P1871; BEAUFILS M, 1985, LANCET, V1, P840, DOI 10.1016/S0140-6736(85)92207-X; DAVISON JM, 1989, BAILLIERE CLIN ENDOC, V3, P451, DOI 10.1016/S0950-351X(89)80011-4; ELLIS MH, 1995, BLOOD REV, V9, P1, DOI 10.1016/0268-960X(95)90034-9; FAY RA, 1983, OBSTET GYNECOL, V61, P238; JACKSON CW, 1984, BLOOD, V63, P768; JACKSON CW, 1992, BLOOD, V79, P1672; JACKSON D, 1994, SCIENCE, V266, P1581, DOI 10.1126/science.7527157; KAUSHANSKY K, 1994, NATURE, V369, P568, DOI 10.1038/369568a0; Konijnenberg A, 1997, AM J OBSTET GYNECOL, V176, P461, DOI 10.1016/S0002-9378(97)70516-7; LIN J, 1998, END SOC ANN M JUN 24; Lin JD, 1997, ENDOCRINOLOGY, V138, P5535, DOI 10.1210/en.138.12.5535; MATSUMURA G, 1984, ARCH HISTOL JAPON, V47, P251, DOI 10.1679/aohc.47.251; Muller H, 1999, ENDOCRINOLOGY, V140, P2711, DOI 10.1210/en.140.6.2711; Muller H, 1998, BBA-GENE STRUCT EXPR, V1396, P251, DOI 10.1016/S0167-4781(97)00218-2; Muller H, 1998, J HISTOCHEM CYTOCHEM, V46, P737, DOI 10.1177/002215549804600606; Nakashima K, 1998, SEMIN HEMATOL, V35, P210; Nyui N, 1998, BIOCHEM BIOPH RES CO, V245, P928, DOI 10.1006/bbrc.1998.8548; Ogren L, 1988, Int Rev Cytol, V112, P1; Shavit JA, 1998, GENE DEV, V12, P2164, DOI 10.1101/gad.12.14.2164; Soares MJ, 1998, BIOL REPROD, V58, P273, DOI 10.1095/biolreprod58.2.273; Steyn DW, 1997, LANCET, V350, P1267	22	38	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21485	21489		10.1074/jbc.274.30.21485	http://dx.doi.org/10.1074/jbc.274.30.21485			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409714	hybrid			2022-12-25	WOS:000081613100105
J	Onodera, K; Shavit, JA; Motohashi, H; Katsuoka, F; Akasaka, JE; Engel, JD; Yamamoto, M				Onodera, K; Shavit, JA; Motohashi, H; Katsuoka, F; Akasaka, JE; Engel, JD; Yamamoto, M			Characterization of the murine mafF gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR NF-E2; ERYTHROLEUKEMIA CELL-DIFFERENTIATION; LEUCINE ZIPPER PROTEIN; NUCLEAR ONCOPROTEIN; UBIQUITOUS SUBUNIT; BINDING PROTEIN; V-MAF; EXPRESSION; ONCOGENE; FAMILY	Small Maf proteins are obligatory heterodimeric partner molecules of mammalian Cap'n'Collar proteins that together control a wide variety of eukaryotic genes. Although both MafK and MafG are expressed in overlapping but distinct tissue distribution patterns during embryonic development, the physiological consequences of loss-of-function mutations in either gene are modest. This suggested that compensation by the third small Maf protein, MafF, might be a major reason for such mild phenotypes and that further analysis of MafF might therefore provide important insights for understanding small Maf regulatory function(s). We therefore cloned, mapped, transcriptionally and developmentally characterized, and finally disrupted the mafF gene. We show that murine mafF is transcriptionally regulated by three different promoters and is most abundantly expressed in the lung. The lacZ gene inserted into the maF locus revealed prominent expression sites in the gut, lung, liver,outflow tract of the heart, cartilage, bone membrane, and skin but not in hematopoietic cells at any developmental stage. Homozygous maF null mutant mice were born in a normal Mendelian ratio and displayed no obvious functional deficiencies, indicating that MafF activity may be dispensable even in tissues where the expression of other small Maf proteins is quite low.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 305, Japan; Univ Tsukuba, Ctr TARA, Tsukuba, Ibaraki 305, Japan	Northwestern University; University of Tsukuba; University of Tsukuba	Engel, JD (corresponding author), Northwestern Univ, Dept Biochem, 2153 N Campus Dr, Evanston, IL 60208 USA.		Motohashi, Hozumi/AAZ-2628-2020	Katsuoka, Fumiki/0000-0003-0939-7887	NCI NIH HHS [CA80088, CA60553] Funding Source: Medline; NIGMS NIH HHS [GM08152] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA060553] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008152] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; Blank V, 1997, BLOOD, V89, P3925, DOI 10.1182/blood.V89.11.3925; Blank V, 1997, TRENDS BIOCHEM SCI, V22, P437, DOI 10.1016/S0968-0004(97)01105-5; Chan JY, 1998, EMBO J, V17, P1779, DOI 10.1093/emboj/17.6.1779; Chan KM, 1996, P NATL ACAD SCI USA, V93, P13943, DOI 10.1073/pnas.93.24.13943; Farmer SC, 1997, GENE DEV, V11, P786, DOI 10.1101/gad.11.6.786; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; GILSON UEM, 1996, GENOME RES, V6, P995; IGARASHI K, 1995, P NATL ACAD SCI USA, V92, P7445, DOI 10.1073/pnas.92.16.7445; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1993, J VIROL, V67, P2133, DOI 10.1128/JVI.67.4.2133-2141.1993; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; Kataoka K, 1996, ONCOGENE, V12, P53; KIM CG, 1992, GENE DEV, V6, P928, DOI 10.1101/gad.6.6.928; Kobayashi A, 1999, J BIOL CHEM, V274, P6443, DOI 10.1074/jbc.274.10.6443; Kotkow KJ, 1996, P NATL ACAD SCI USA, V93, P3514, DOI 10.1073/pnas.93.8.3514; MOHLER J, 1991, MECH DEVELOP, V34, P3, DOI 10.1016/0925-4773(91)90086-L; Motohashi H, 1996, GENES CELLS, V1, P223, DOI 10.1046/j.1365-2443.1996.d01-230.x; Motohashi H, 1997, NUCLEIC ACIDS RES, V25, P2953, DOI 10.1093/nar/25.15.2953; Muto A, 1998, EMBO J, V17, P5734, DOI 10.1093/emboj/17.19.5734; Nagai T, 1998, J BIOL CHEM, V273, P5358, DOI 10.1074/jbc.273.9.5358; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; Oyake T, 1996, MOL CELL BIOL, V16, P6083; PETERS LL, 1994, GENOMICS, V22, P490, DOI 10.1006/geno.1994.1418; Shavit JA, 1998, GENE DEV, V12, P2164, DOI 10.1101/gad.12.14.2164; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; Tanimoto K, 1999, NATURE, V398, P344, DOI 10.1038/18698; WOOD SA, 1993, NATURE, V365, P87, DOI 10.1038/365025a0; YAGI T, 1993, ANAL BIOCHEM, V214, P77, DOI 10.1006/abio.1993.1459	35	50	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21162	21169		10.1074/jbc.274.30.21162	http://dx.doi.org/10.1074/jbc.274.30.21162			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409670	hybrid			2022-12-25	WOS:000081613100061
J	Raychowdhury, R; Zhang, ZS; Hocker, M; Wang, TC				Raychowdhury, R; Zhang, ZS; Hocker, M; Wang, TC			Activation of human histidine decarboxylase gene promoter activity by gastrin is mediated by two distinct nuclear factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL 12-MYRISTATE 13-ACETATE; MESSENGER-RNA; CANCER CELLS; EXPRESSION; PROTEIN; RAT; PROLIFERATION; RECEPTORS; STOMACH; ELEMENT	The human histidine decarboxylase gene is regulated by gastrin through a cis-acting element known as the gastrin response element (GAS-RE) that was initially localized to a site (+2 to +24) downstream of the transcriptional start site. Electrophoretic mobility shift assays using sequentially deleted DNA probes and nuclear extracts from AGS-B gastric cancer cells showed that the GAS-RE is actually composed of two overlapping binding sites (GAS-RE1, +1 +10; and GAS-REB, +11 to +27) that bind distinct nuclear factors. Reporter gene assays demonstrated that each element alone could confer gastrin responsiveness, but the presence of both elements was required for complete gastrin response. Stimulation of AGS-B cells with gastrin for 10-20 min resulted in a >2-fold increase in factor binding. The binding was inhibited by pretreatment of AGS-B cells with cycloheximide and the MEK1 inhibitor PD98059, indicating a requirement for protein synthesis and also indicating that activation occurs through the MEK/mitogen-activated protein kinase pathway. UV cross-linking and Southwestern blot analysis showed that GAS-RE1 bound a 52-kDa protein, whereas GAS-RE2 bound a 35-kDa protein. Hence, activation of histidine decarboxylase gene promoter activity by gastrin is most likely mediated by two separate nuclear factors.	Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; Humboldt Univ, Univ Klinikum Charite, Campus Virchow Klinikum, Med Klin Schwerpunkt Hepatol & Gastroenterol, D-13353 Berlin, Germany	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Wang, TC (corresponding author), Massachusetts Gen Hosp, Gastrointestinal Unit, GRJ 724,32 Fruit St, Boston, MA 02114 USA.				NIDDK NIH HHS [DK48077] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048077] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERTRAND V, 1994, INT J CANCER, V56, P427, DOI 10.1002/ijc.2910560324; DIMALINE R, 1991, FEBS LETT, V281, P20, DOI 10.1016/0014-5793(91)80348-7; Dimaline R, 1996, J PHYSIOL-LONDON, V490, P249, DOI 10.1113/jphysiol.1996.sp021140; DIMALINE R, 1993, AM J PHYSIOL, V264, pG583, DOI 10.1152/ajpgi.1993.264.3.G583; Friis-Hansen L, 1998, AM J PHYSIOL-GASTR L, V274, pG561, DOI 10.1152/ajpgi.1998.274.3.G561; Hocker M, 1997, AM J PHYSIOL-GASTR L, V272, pG822, DOI 10.1152/ajpgi.1997.272.4.G822; Hocker M, 1997, J BIOL CHEM, V272, P27015, DOI 10.1074/jbc.272.43.27015; Hocker M, 1998, J BIOL CHEM, V273, P23046, DOI 10.1074/jbc.273.36.23046; Hocker M, 1996, AM J PHYSIOL-GASTR L, V270, pG619, DOI 10.1152/ajpgi.1996.270.4.G619; Hocker M, 1996, YALE J BIOL MED, V69, P21; Koh TJ, 1997, GASTROENTEROLOGY, V113, P1015, DOI 10.1016/S0016-5085(97)70199-9; Langhans N, 1997, GASTROENTEROLOGY, V112, P280, DOI 10.1016/S0016-5085(97)90000-7; Nagata A, 1996, P NATL ACAD SCI USA, V93, P11825, DOI 10.1073/pnas.93.21.11825; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Pyronnet S, 1998, ONCOGENE, V16, P2219, DOI 10.1038/sj.onc.1201748; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; SEVA C, 1994, REGUL PEPTIDES, V52, P31, DOI 10.1016/0167-0115(94)90018-3; TANIGUCHI T, 1994, ONCOGENE, V9, P861; TILLOTSON LG, 1994, J BIOL CHEM, V269, P2234; TODISCO A, 1995, J BIOL CHEM, V270, P28337; Zhang ZS, 1996, J BIOL CHEM, V271, P14188, DOI 10.1074/jbc.271.24.14188	21	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					20961	20969		10.1074/jbc.274.30.20961	http://dx.doi.org/10.1074/jbc.274.30.20961			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409643	hybrid			2022-12-25	WOS:000081613100034
J	Stec, DE; Davisson, RL; Haskell, RE; Davidson, BL; Sigmund, CD				Stec, DE; Davisson, RL; Haskell, RE; Davidson, BL; Sigmund, CD			Efficient liver-specific deletion of a floxed human angiotensinogen transgene by adenoviral delivery of Cre recombinase in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC RECOMBINATION; GENE-TRANSFER; HUMAN RENIN; IN-VIVO; DEFICIENT MICE; BLOOD-PRESSURE; EXPRESSION; HYPERTENSION; SYSTEM; CELLS	Tissue-specific ablation of gene function is possible in vivo by the Cre-loxP recombinase system. We generated transgenic mice containing a human angiotensinogen gene flanked by loxP sites (hAGT(flox)). To examine the physiologic consequences of tissue-specific loss of angiotensinogen gene function in vivo, we constructed an adenovirus expressing Cre recombinase. Studies were performed in several independent lines of hAGT(flox) mice before and after intravenous administration of either Adcre or Ad beta Gal as a control. Systemic administration of Adcre caused a significant decrease in circulating human angiotensinogen and markedly blunted the presser response to administration of purified recombinant human renin. Southern blot analysis of genomic DNA from various organs revealed that the Cre-mediated deletion was liver-specific. Further analysis revealed the absence of full-length human angiotensinogen mRNA and protein in the liver but not the kidney of Adcre mice, consistent with the liver being the target for adenoviruses administered intravenously, These studies demonstrate that extra-hepatic sources of ansotensinogen do not contribute significantly to the circulating pool of angiotensinogen and provide proof-of-principle that the Cre-loxP system can be used effectively to examine the contribution of the systemic and tissue renin-angiotensin system to normal and pathological regulation of blood pressure.	Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Sigmund, CD (corresponding author), Univ Iowa, Coll Med, Dept Internal Med, 2191 Med Lab, Iowa City, IA 52242 USA.		Sigmund, Curt D./W-1611-2019	Sigmund, Curt D./0000-0002-1453-0921	NHLBI NIH HHS [HL55006, HL48058] Funding Source: Medline; NIDDK NIH HHS [DK52617] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048058, P50HL055006, R37HL048058] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK052617] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABREMSKI K, 1984, J BIOL CHEM, V259, P1509; ANTON M, 1995, J VIROL, V69, P4600, DOI 10.1128/JVI.69.8.4600-4606.1995; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Beer SJ, 1998, GENE THER, V5, P740, DOI 10.1038/sj.gt.3300647; Bosch A, 1996, J CLIN INVEST, V98, P2683, DOI 10.1172/JCI119091; DAVIDSON BL, 1993, NAT GENET, V3, P219, DOI 10.1038/ng0393-219; Davisson RL, 1997, J CLIN INVEST, V99, P1258, DOI 10.1172/JCI119283; Davisson RL, 1998, CIRC RES, V83, P1047, DOI 10.1161/01.RES.83.10.1047; DAVISSON RL, 1997, IN PRESS PHYSL GENOM; Ding YM, 1997, J BIOL CHEM, V272, P28142, DOI 10.1074/jbc.272.44.28142; ENGELHARDT JF, 1993, NAT GENET, V4, P27, DOI 10.1038/ng0593-27; Ferguson AV, 1998, PROG NEUROBIOL, V54, P169, DOI 10.1016/S0301-0082(97)00065-8; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; HALL JE, 1977, AM J PHYSIOL, V232, pF538, DOI 10.1152/ajprenal.1977.232.6.F538; Harris RC, 1996, EXP NEPHROL, V4, P2; HATAE T, 1994, MOL CELL BIOCHEM, V131, P43, DOI 10.1007/BF01075723; Hilgers KF, 1997, SEMIN NEPHROL, V17, P492; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; KILBY NJ, 1993, TRENDS GENET, V9, P413, DOI 10.1016/0168-9525(93)90104-P; KREGE JH, 1995, NATURE, V375, P146, DOI 10.1038/375146a0; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0; Lee YH, 1997, MOL CELL BIOL, V17, P6014, DOI 10.1128/MCB.17.10.6014; LYNCH KR, 1991, HYPERTENSION, V17, P263, DOI 10.1161/01.HYP.17.3.263; Mckinley M.J., 1996, CLIN EXP PHARMACOL P, V3, P99; Merrill DC, 1996, J CLIN INVEST, V97, P1047, DOI 10.1172/JCI118497; MULLINS JJ, 1990, NATURE, V344, P541, DOI 10.1038/344541a0; Oliverio MI, 1998, AM J PHYSIOL-RENAL, V274, pF43, DOI 10.1152/ajprenal.1998.274.1.F43; Oliverio MI, 1997, AM J PHYSIOL-RENAL, V272, pF515, DOI 10.1152/ajprenal.1997.272.4.F515; ROWE DT, 1983, VIROLOGY, V129, P456, DOI 10.1016/0042-6822(83)90183-6; SAUER B, 1993, METHOD ENZYMOL, V225, P890; SAUER B, 1988, GENE, V70, P331, DOI 10.1016/0378-1119(88)90205-3; SMITHIES O, 1994, P NATL ACAD SCI USA, V91, P3612, DOI 10.1073/pnas.91.9.3612; Stec DE, 1998, EXP NEPHROL, V6, P568; Stein CS, 1998, GENE THER, V5, P431, DOI 10.1038/sj.gt.3300616; Tsien JZ, 1996, CELL, V87, P1317, DOI 10.1016/S0092-8674(00)81826-7; Wang Y, 1996, P NATL ACAD SCI USA, V93, P3932, DOI 10.1073/pnas.93.9.3932; Yang GY, 1998, HYPERTENSION, V31, P734, DOI 10.1161/01.HYP.31.3.734; YANG GY, 1994, J BIOL CHEM, V269, P32497; Yang GY, 1998, AM J PHYSIOL-RENAL, V274, pF932, DOI 10.1152/ajprenal.1998.274.5.F932	40	70	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21285	21290		10.1074/jbc.274.30.21285	http://dx.doi.org/10.1074/jbc.274.30.21285			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409686	hybrid			2022-12-25	WOS:000081613100077
J	De Valck, D; Jin, DY; Heyninck, K; Van de Craen, M; Contreras, R; Fiers, W; Jeang, KT; Beyaert, R				De Valck, D; Jin, DY; Heyninck, K; Van de Craen, M; Contreras, R; Fiers, W; Jeang, KT; Beyaert, R			The zinc finger protein A20 interacts with a novel anti-apoptotic protein which is cleaved by specific caspases	ONCOGENE			English	Article						A20; TNF; tax; apoptosis; caspases	TUMOR-NECROSIS-FACTOR; KAPPA-B ACTIVATION; HUMAN ENDOTHELIAL-CELLS; HTLV-I TAX; FACTOR-ALPHA; ICE/CED-3 PROTEASE; SIGNALING PROTEINS; COMMON MEDIATOR; EXPRESSION; INDUCTION	A20 is a Cys(2)/Cys(2) zinc finger protein which is induced by a variety of inflammatory stimuli and which has been characterized as an inhibitor of cell death by a yet unknown mechanism. In order to clarify its molecular mechanism of action, we used the yeast two-hybrid system to screen for proteins that interact with A20. A cDNA fragment was isolated which encoded a portion of a novel protein (TXBP151), which was recently found to be a human T-cell leukemia virus type-I (HTLV-I) Tax-binding protein. The full-length 2386bp TXBP151 mRNA encodes a protein of 86kDa, Like A20, overexpression of TXBP151 could inhibit apoptosis induced by tumour necrosis factor (TNF) in NIH3T3 cells, Moreover, transfection of antisense TXBP151 partially abolished the anti-apoptotic effect of A20, Furthermore, apoptosis induced by TNF or CD95 (Fas/ APO-1) was associated with proteolysis of TXBP151. This degradation could be inhibited by the broad-spectrum caspase inhibitor zVAD-fmk or by expression of the cowpox virus-derived inhibitor CrmA, suggesting that TXBP151 is a novel substrate for caspase family members. TXBP151 was indeed found to be specifically cleaved in vitro by members of the caspase-3-like subfamily, viz, caspase-3, caspase-6 and caspase-7, Thus TXBP151 appears to be a novel A20-binding protein which might mediate the anti-apoptotic activity of A20, and which can be processed by specific caspases.	Flanders Interuniv Inst Biotechnol, Dept Biol Mol, B-9000 Ghent, Belgium; State Univ Ghent, B-9000 Ghent, Belgium; NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA	Ghent University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Beyaert, R (corresponding author), Flanders Interuniv Inst Biotechnol, Dept Biol Mol, Ledeganckstr 35, B-9000 Ghent, Belgium.		Jeang, Kuan-Teh/A-2424-2008; Beyaert, Rudi/B-2589-2009	Beyaert, Rudi/0000-0002-5704-582X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000547, ZIAAI000547] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Cooper JT, 1996, J BIOL CHEM, V271, P18068, DOI 10.1074/jbc.271.30.18068; DeValck D, 1996, FEBS LETT, V384, P61, DOI 10.1016/0014-5793(96)00283-9; DeValck D, 1997, BIOCHEM BIOPH RES CO, V238, P590, DOI 10.1006/bbrc.1997.7343; DIXIT VM, 1990, J BIOL CHEM, V265, P2973; FEARNHEAD HO, 1995, FEBS LETT, V375, P283, DOI 10.1016/0014-5793(95)01228-7; Fujita N, 1998, ONCOGENE, V17, P1295, DOI 10.1038/sj.onc.1202065; Gachon F, 1998, J VIROL, V72, P8332, DOI 10.1128/JVI.72.10.8332-8337.1998; HENNET T, 1993, CANCER RES, V53, P1456; Heyninck K, 1999, FEBS LETT, V442, P147, DOI 10.1016/S0014-5793(98)01645-7; Jaattela M, 1996, J IMMUNOL, V156, P1166; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; Jin DY, 1997, J BIOL CHEM, V272, P25816, DOI 10.1074/jbc.272.41.25816; Jin DY, 1997, NUCLEIC ACIDS RES, V25, P379, DOI 10.1093/nar/25.2.379; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; KORIOTH F, 1995, J CELL BIOL, V130, P1, DOI 10.1083/jcb.130.1.1; LAHERTY CD, 1993, J BIOL CHEM, V268, P5032; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MAJONE F, 1993, VIROLOGY, V193, P456, DOI 10.1006/viro.1993.1145; MERTENS N, 1995, GENE, V164, P9, DOI 10.1016/0378-1119(95)00505-Z; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Natoli G, 1998, J BIOL CHEM, V273, P31262, DOI 10.1074/jbc.273.47.31262; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; OMAHONEY JV, 1994, DNA CELL BIOL, V13, P1227, DOI 10.1089/dna.1994.13.1227; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; Porter AG, 1997, BIOESSAYS, V19, P501, DOI 10.1002/bies.950190609; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; Rosin O, 1998, J BIOL CHEM, V273, P6698, DOI 10.1074/jbc.273.12.6698; RUBIN BY, 1988, CANCER RES, V48, P6006; SARMA V, 1995, J BIOL CHEM, V270, P12343, DOI 10.1074/jbc.270.21.12343; Schotte P, 1998, BIOCHEM BIOPH RES CO, V251, P379, DOI 10.1006/bbrc.1998.9425; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; SPORN SA, 1990, J IMMUNOL, V144, P4434; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Van de Craen M, 1997, FEBS LETT, V403, P61, DOI 10.1016/S0014-5793(97)00026-4; Vincenz C, 1996, J BIOL CHEM, V271, P20029, DOI 10.1074/jbc.271.33.20029; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Zen K, 1998, EXP CELL RES, V243, P425, DOI 10.1006/excr.1998.4162; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	46	118	124	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 22	1999	18	29					4182	4190		10.1038/sj.onc.1202787	http://dx.doi.org/10.1038/sj.onc.1202787			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218FK	10435631				2022-12-25	WOS:000081542400002
J	Muhlner, U; Mohle-Steinlein, U; Wizigmann-Voos, S; Christofori, G; Risau, W; Wagner, EF				Muhlner, U; Mohle-Steinlein, U; Wizigmann-Voos, S; Christofori, G; Risau, W; Wagner, EF			Formation of transformed endothelial cells in the absence of VEGFR-2/Flk-1 by Polyoma middle T oncogene	ONCOGENE			English	Article						polyoma middle T; VEGFR-2/Flk-1; angiogenesis; vascular tumors	RECEPTOR TYROSINE KINASES; EMBRYONIC STEM-CELLS; GROWTH-FACTOR VEGF; SIGNAL-TRANSDUCTION; AUTOCRINE MECHANISM; IN-VITRO; ANGIOGENESIS; EXPRESSION; MICE; DIFFERENTIATION	The middle T antigen of murine Polyomavirus (PymT) rapidly transforms endothelial cells leading to vascular malformations reminiscent of endothelial tumors or hemangiomas, Flk-1, a receptor tyrosine kinase which is activated upon binding of its ligand VEGF, is predominantly expressed in endothelial cells and essential for the formation of blood vessels since absence of Flk-1 prevents the development of mature endothelial cells in mice and in ES-cell differentiation experiments, To investigate the role of Flk-1 in PymT-induced vascular tumor formation, we studied the expression of Flk-1 and VEGF in PymT-transformed endothelial cells (Endothelioma cells, END. cells). The receptor and its ligand were both expressed in END, cells suggesting that a VEGF/Flk-1 autocrine loop might be causally involved in the formation of vascular tumors. To test this hypothesis, ES cells lacking Flk-1 were generated and the transforming potential of PymT was analysed after in vitro differentiation. Flk-1-/- END. cell lines were established which are morphologically identical to flk-1+/+ END. cells and which express several markers characteristic for endothelial cells, This result suggests that PymT functionally replaces the requirement of Flk-1 in expansion and/or survival of endothelial progenitor cells. Therefore, flk-1-/- END. cells provide a powerful tool to dissect the downstream signaling pathways of Flk-1.	Res Inst Mol Pathol, A-1030 Vienna, Austria; Max Planck Inst Physiol & Clin Res, Dept Mol & Cell Biol, D-61231 Bad Nauheim, Germany	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Max Planck Society	Wagner, EF (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.			Wagner, Erwin F/0000-0001-7872-0196				Bronson R, 1997, P NATL ACAD SCI USA, V94, P7954, DOI 10.1073/pnas.94.15.7954; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Choi K, 1998, DEVELOPMENT, V125, P725; CHRISTOFORI G, 1995, MOL ENDOCRINOL, V9, P1760, DOI 10.1210/me.9.12.1760; Dilworth Stephen M., 1995, Trends in Microbiology, V3, P31, DOI 10.1016/S0966-842X(00)88866-6; DiMaio D, 1998, ANNU REV MICROBIOL, V52, P397, DOI 10.1146/annurev.micro.52.1.397; DUBOISSTRINGFELLOW N, 1994, AM J PATHOL, V144, P796; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; GLENN GM, 1995, J VIROL, V69, P3729, DOI 10.1128/JVI.69.6.3729-3736.1995; Gotsch U, 1997, J CELL SCI, V110, P583; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; Gualandris A, 1996, CELL GROWTH DIFFER, V7, P147; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; Hashimoto M, 1995, LAB INVEST, V73, P859; Hatzopoulos AK, 1998, DEVELOPMENT, V125, P1457; HILBERG F, 1992, ONCOGENE, V7, P2371; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Jones Cindy L. A., 1996, Current Opinion in Oncology, V8, P54, DOI 10.1097/00001622-199601000-00010; Joukov V, 1996, EMBO J, V15, P290; KAIPAINEN A, 1993, J EXP MED, V178, P2077, DOI 10.1084/jem.178.6.2077; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; KELLER GM, 1995, CURR OPIN CELL BIOL, V7, P862, DOI 10.1016/0955-0674(95)80071-9; KIEFER F, 1994, ADV CANCER RES, V64, P125, DOI 10.1016/S0065-230X(08)60837-4; KIEFER F, 1994, CURR BIOL, V4, P100, DOI 10.1016/S0960-9822(94)00025-4; Korpelainen EI, 1998, CURR OPIN CELL BIOL, V10, P159, DOI 10.1016/S0955-0674(98)80137-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPUGNANI MG, 1992, J CELL BIOL, V118, P1511, DOI 10.1083/jcb.118.6.1511; Masood R, 1997, P NATL ACAD SCI USA, V94, P979, DOI 10.1073/pnas.94.3.979; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MONTESANO R, 1990, CELL, V62, P435, DOI 10.1016/0092-8674(90)90009-4; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Pepper MS, 1997, TUMOUR ANGIOGENESIS, P309; RAK J, 1995, CANCER RES, V55, P4575; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; Sabapathy KT, 1997, J CELL BIOL, V137, P953, DOI 10.1083/jcb.137.4.953; SAUER B, 1988, P NATL ACAD SCI USA, V85, P5166, DOI 10.1073/pnas.85.14.5166; Schuh AC, 1999, P NATL ACAD SCI USA, V96, P2159, DOI 10.1073/pnas.96.5.2159; SEETHARAM L, 1995, ONCOGENE, V10, P135; Seghezzi G, 1998, J CELL BIOL, V141, P1659, DOI 10.1083/jcb.141.7.1659; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; VECCHI A, 1994, EUR J CELL BIOL, V63, P247; Vittet D, 1996, BLOOD, V88, P3424, DOI 10.1182/blood.V88.9.3424.bloodjournal8893424; WAGNER EF, 1994, SEMIN CANCER BIOL, V5, P137; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WILKS AF, 1989, GENE, V85, P67, DOI 10.1016/0378-1119(89)90465-4; WIZIGMANNVOOS S, 1995, CANCER RES, V55, P1358; XIE Y, 1993, P NATL ACAD SCI USA, V90, P5569, DOI 10.1073/pnas.90.12.5569; YOUNG AT, 1995, P NATL ACAD SCI USA, V92, P11613, DOI 10.1073/pnas.92.25.11613	57	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 22	1999	18	29					4200	4210		10.1038/sj.onc.1203014	http://dx.doi.org/10.1038/sj.onc.1203014			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218FK	10435633				2022-12-25	WOS:000081542400004
J	Stacey, DW; Hitomi, M; Kanovsky, M; Gan, L; Johnson, EM				Stacey, DW; Hitomi, M; Kanovsky, M; Gan, L; Johnson, EM			Cell cycle arrest and morphological alterations following microinjection of NIH3T3 cells with Pura alpha	ONCOGENE			English	Article						Pura; cell cycle; checkpoint; microinjection; time lapse quantitative photometry	SINGLE-STRANDED-DNA; RETINOBLASTOMA GENE-PRODUCT; BINDING-PROTEIN; TRANSCRIPTION FACTOR; STIMULATES TRANSCRIPTION; MOLECULAR-CLONING; CONTROL ELEMENT; SEQUENCE; E2F; ASSOCIATION	Levels of Pur alpha, a protein implicated in control of both DNA replication and gene transcription, fluctuate during the cell cycle, being lowest in early S phase and highest just after mitosis. Here we have employed a new video time-lapse technique enabling us to determine the cell cycle position of each cell in an asynchronous culture at a given time and to ask whether introduction of Pur alpha protein at specific times can affect cell cycle progression. Approximately 80% of all NIH3T3 cells injected with Pur alpha were inhibited from passing through mitosis, Cells injected with Puree during S or G2 phases were efficiently blocked with a 4N (G2 phase) DNA level, as determined by quantitative DNA photometry of individual cells. Of the cells injected with Pur alpha. during G1 phase, 40% experienced a rapid cell death characterized by extreme cellular fragmentation. Of those G1 injected cells which remained viable, approximately equal numbers were arrested with either 2N or 4N DNA levels. Cells arrested by Pur alpha in G2 phase grew to cover a large surface area. These results link fluctuations in Pur alpha levels to aspects of cell cycle control.	Cleveland Clin Fdn, Dept Biol Mol, Lerner Res Inst, Cleveland, OH 44195 USA; CUNY Mt Sinai Sch Med, Dept Pathol, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Brookdale Ctr Mol Biol, New York, NY 10029 USA	Cleveland Clinic Foundation; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Stacey, DW (corresponding author), Cleveland Clin Fdn, Dept Biol Mol, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.				NCI NIH HHS [CA55219] Funding Source: Medline; NIGMS NIH HHS [GM52271] Funding Source: Medline; NINDS NIH HHS [NS35000] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055219, R55CA055219] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035000] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERGEMANN AD, 1992, MOL CELL BIOL, V12, P1257, DOI 10.1128/MCB.12.3.1257; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P5673, DOI 10.1128/MCB.12.12.5673; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; Chang CF, 1996, J VIROL, V70, P4150, DOI 10.1128/JVI.70.6.4150-4156.1996; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN NN, 1995, P NATL ACAD SCI USA, V92, P1087, DOI 10.1073/pnas.92.4.1087; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Chepenik LG, 1998, GENE, V210, P37, DOI 10.1016/S0378-1119(98)00033-X; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DOBROWOLSKI SF, 1994, ONCOGENE, V9, P2605; Du Q, 1997, J BIOL CHEM, V272, P14990, DOI 10.1074/jbc.272.23.14990; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; HAAS S, 1995, J CELL BIOL, V130, P1171, DOI 10.1083/jcb.130.5.1171; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HERAULT Y, 1992, NUCLEIC ACIDS RES, V20, P6377, DOI 10.1093/nar/20.23.6377; HERAULT Y, 1993, CELL MOL BIOL RES, V39, P717; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Itoh H, 1998, CELL GROWTH DIFFER, V9, P651; JOHNSON EM, 1995, J BIOL CHEM, V270, P24352, DOI 10.1074/jbc.270.41.24352; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Kelm RJ, 1997, J BIOL CHEM, V272, P26727, DOI 10.1074/jbc.272.42.26727; Krachmarov CP, 1996, P NATL ACAD SCI USA, V93, P14112, DOI 10.1073/pnas.93.24.14112; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lezon-Geyda K. A., 1997, FASEB Journal, V11, pA100; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; MA ZW, 1994, GENE, V149, P311, DOI 10.1016/0378-1119(94)90167-8; MA ZW, 1995, CYTOGENET CELL GENET, V71, P64, DOI 10.1159/000134065; MAYOL X, 1993, ONCOGENE, V8, P2561; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Nurse P, 1997, CELL, V91, P865, DOI 10.1016/S0092-8674(00)80476-6; PINES J, 1991, COLD SPRING HARB SYM, V56, P449; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; QIN XQ, 1995, MOL CELL BIOL, V15, P742; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; Zambrano N, 1997, BIOCHEM J, V328, P293, DOI 10.1042/bj3280293	41	52	53	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 22	1999	18	29					4254	4261		10.1038/sj.onc.1202795	http://dx.doi.org/10.1038/sj.onc.1202795			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218FK	10435638				2022-12-25	WOS:000081542400009
J	Fernandez, B; Czech, MP; Meisner, H				Fernandez, B; Czech, MP; Meisner, H			Role of protein kinase C in signal attenuation following T cell receptor engagement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LYMPHOCYTES-T; CBL PROTOONCOGENE PRODUCT; TYROSINE PHOSPHORYLATION; PHOSPHATIDYLINOSITOL 3-KINASE; ANTIGEN RECEPTOR; ADAPTER PROTEINS; HEMATOPOIETIC-CELLS; PHOSPHOLIPASE-C; PHORBOL ESTER; RAS PATHWAY	T lymphocyte activation through stimulation of the T cell receptor complex and co-stimulatory receptors is associated with acute tyrosine phosphorylation of intracellular proteins, which in turn mediate downstream signaling events that regulate interleukin-2 expression and cell proliferation. The extent of protein tyrosine phosphorylation is rapidly attenuated after only 1-2 min of stimulation as a means of tightly controlling the initial signaling response. Here we show that this attenuation of tyrosine phosphorylation of Shc, CrkL, and the proto-oncogene Cbl is mimicked by treatment of mouse T lymphocytes or cultured Jurkat cells with phorbol 12-myristate 13-acetate. This effect is blocked by the specific protein kinase C inhibitor GF109203X, but not by PD98059, an inhibitor of MEK1/2 kinase. Activation of protein kinase C by phorbol ester also causes rapid (t 1/2 = min) dissociation of both CrkL and p85/phosphoinositide 3-kinase from Cbl concomitant with Cbl tyrosine dephosphorylation. More important, GF109203X treatment of Jurkat cells prior to T cell receptor stimulation by anti-CD3/CD4 antibodies results in an enhanced (2-fold) peak of Cbl phosphorylation compared with that observed in control cells. Furthermore, the rate of attenuation of both Cbl tyrosine phosphorylation and its association with CrkL following stimulation with antiCD3/CD4 antibodies is much slower in Jurkat cells treated with GF109203X Taken together, these data provide strong evidence that one or more isoforms of phorbol ester-responsive protein kinase C play a key role in a feedback mechanism that attenuates tyrosine phosphorylation of proteins and reverses formation of signaling complexes in response to T cell receptor activation.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Czech, MP (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK053006] Funding Source: NIH RePORTER; NIDDK NIH HHS [1P01 DK53006-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmad S, 1997, J BIOL CHEM, V272, P29991, DOI 10.1074/jbc.272.48.29991; AlberolaIla J, 1997, ANNU REV IMMUNOL, V15, P125, DOI 10.1146/annurev.immunol.15.1.125; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Barber DL, 1997, BLOOD, V89, P3166, DOI 10.1182/blood.V89.9.3166; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; BLAKE TJ, 1991, ONCOGENE, V6, P653; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; CANTRELL DA, 1985, P NATL ACAD SCI USA, V82, P8158, DOI 10.1073/pnas.82.23.8158; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; Craddock BL, 1997, J BIOL CHEM, V272, P29281, DOI 10.1074/jbc.272.46.29281; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; DEFEA K, 1997, BIOCHEMISTRY-US, V36, P181; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; DEKKER LV, 1995, CURR OPIN STRUC BIOL, V5, P396, DOI 10.1016/0959-440X(95)80103-0; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; Dietrich J, 1998, J BIOL CHEM, V273, P24232, DOI 10.1074/jbc.273.37.24232; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; Gesbert F, 1998, J BIOL CHEM, V273, P3986, DOI 10.1074/jbc.273.7.3986; Hartley D, 1996, J BIOL CHEM, V271, P21939, DOI 10.1074/jbc.271.36.21939; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; Husson H, 1997, ONCOGENE, V14, P2331, DOI 10.1038/sj.onc.1201074; Hutchcroft JE, 1996, J BIOL CHEM, V271, P13362, DOI 10.1074/jbc.271.23.13362; Jain SK, 1997, ONCOGENE, V14, P2217, DOI 10.1038/sj.onc.1201049; Keenan C, 1997, BBA-MOL CELL RES, V1358, P113, DOI 10.1016/S0167-4889(97)00080-3; Khwaja A, 1996, ONCOGENE, V12, P2491; Kosaki A, 1998, J BIOL CHEM, V273, P940, DOI 10.1074/jbc.273.2.940; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Lauritsen JPH, 1998, J IMMUNOL, V161, P260; Liu YC, 1998, CELL SIGNAL, V10, P377, DOI 10.1016/S0898-6568(97)00179-4; Liu YC, 1997, J BIOL CHEM, V272, P168; Liu YC, 1996, J BIOL CHEM, V271, P14591, DOI 10.1074/jbc.271.24.14591; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; LUTON F, 1994, J IMMUNOL, V153, P63; Luton F, 1997, J IMMUNOL, V158, P3140; MARTH JD, 1989, J IMMUNOL, V142, P2430; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; MINAMI Y, 1987, J BIOL CHEM, V262, P13342; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Naramura M, 1998, P NATL ACAD SCI USA, V95, P15547, DOI 10.1073/pnas.95.26.15547; NEL AE, 1991, J IMMUNOL, V147, P1933; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; PARK DJ, 1992, J BIOL CHEM, V267, P1496; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; REINHERZ EL, 1982, CELL, V30, P735, DOI 10.1016/0092-8674(82)90278-1; Rellahan BL, 1997, J BIOL CHEM, V272, P30806, DOI 10.1074/jbc.272.49.30806; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RUEGG CL, 1992, J BIOL CHEM, V267, P18837; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; Sattler M, 1997, J BIOL CHEM, V272, P10248; Shi J, 1997, J IMMUNOL, V158, P4688; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Szamel M, 1998, J IMMUNOL, V160, P2207; TELERMAN A, 1987, EUR J IMMUNOL, V17, P991, DOI 10.1002/eji.1830170715; TENHOEVE J, 1993, ONCOGENE, V8, P2469; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Uddin S, 1996, BIOCHEM BIOPH RES CO, V225, P833, DOI 10.1006/bbrc.1996.1259; Ueno H, 1998, BLOOD, V91, P46, DOI 10.1182/blood.V91.1.46.46_46_53; Ueno H, 1997, J BIOL CHEM, V272, P8739, DOI 10.1074/jbc.272.13.8739; Valitutti S, 1997, J EXP MED, V185, P1859, DOI 10.1084/jem.185.10.1859; VALITUTTI S, 1995, NATURE, V375, P148, DOI 10.1038/375148a0; VEILLETTE A, 1988, ONCOGENE RES, V2, P385; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Werlen G, 1998, EMBO J, V17, P3101, DOI 10.1093/emboj/17.11.3101; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	79	12	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20244	20250		10.1074/jbc.274.29.20244	http://dx.doi.org/10.1074/jbc.274.29.20244			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400642	hybrid			2022-12-25	WOS:000081438300035
J	McCormack, T; McCormack, K; Nadal, MS; Vieira, E; Ozaita, A; Rudy, B				McCormack, T; McCormack, K; Nadal, MS; Vieira, E; Ozaita, A; Rudy, B			The effects of Shaker beta-subunits on the human lymphocyte K+ channel Kv1.3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED POTASSIUM CHANNEL; FUNCTIONAL EXPRESSION; HETEROMULTIMERIC CHANNELS; BOVINE BRAIN; PROLIFERATION	The activation of T-lymphocytes is dependent upon, and accompanied by, an increase in voltage-gated K+ conductance. Kv1.3, a Shaker family K+ channel protein, appears to play an essential role in the activation of peripheral human T cells. Although Kv1.3-mediated K+ currents increase markedly during the activation process in mice, and to a lesser degree in humans, Kv1.3 mRNA levels in these organisms do not, indicating posttranscriptional regulation. In other tissues Shaker K+ channel proteins physically associate with cytoplasmic beta-subunits (Kv beta 1-3). Recently it has been shown that Kv beta 1 and Kv beta 2 are expressed in mouse T cells and that they are up-regulated during mitogen-stimulated activation. In this study, we show that the human Kv beta subunits substantially increase K+ current amplitudes when coexpressed with their Kv1.3 counterpart, and that unlike in mouse, protein levels of human Kv beta 2 remain constant upon activation. Differences in Kv beta 2 expression between mice and humans may explain the differential K+ conductance increases which accompany T-cell proliferation in these organisms.	NYU, Sch Med, Dept Physiol & Neurosci, New York, NY 10016 USA; NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; Ventura Genet, Salt Lake City, UT 84108 USA	New York University; New York University	McCormack, T (corresponding author), Univ Arizona, Dept Mol & Cellular Biol, Life Sci S 552, Tucson, AZ 85721 USA.	yando@geocities.com	Ozaita, Andres/H-3411-2015	Ozaita, Andres/0000-0002-2239-7403; Nadal, Marcela/0000-0002-1679-4760; Rudy, Bernardo/0000-0001-5748-6900	NINDS NIH HHS [NS35215, NS30989] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035215, R01NS030989] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ATTALI B, 1992, J BIOL CHEM, V267, P8650; Autieri MV, 1997, J NEUROIMMUNOL, V77, P8, DOI 10.1016/S0165-5728(97)00050-7; CAHALAN MD, 1985, J PHYSIOL-LONDON, V358, P197, DOI 10.1113/jphysiol.1985.sp015548; CAI YC, 1992, DNA CELL BIOL, V11, P163, DOI 10.1089/dna.1992.11.163; Coetzee WA, 1999, ANN NY ACAD SCI, V868, P233, DOI 10.1111/j.1749-6632.1999.tb11293.x; DECOURSEY TE, 1984, NATURE, V307, P465, DOI 10.1038/307465a0; DECOURSEY TE, 1987, J GEN PHYSIOL, V89, P379, DOI 10.1085/jgp.89.3.379; DECOURSEY TE, 1987, J GEN PHYSIOL, V89, P405, DOI 10.1085/jgp.89.3.405; GELFAND EW, 1987, J IMMUNOL, V138, P527; HEINEMANN S, 1994, J PHYSIOL-PARIS, V88, P173, DOI 10.1016/0928-4257(94)90003-5; KITAGAWA S, 1985, J IMMUNOL, V135, P3417; Koo GC, 1997, J IMMUNOL, V158, P5120; LEE SC, 1986, J CELL BIOL, V102, P1200, DOI 10.1083/jcb.102.4.1200; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; MCCORMACK K, 1990, BIOCHEM BIOPH RES CO, V171, P1361, DOI 10.1016/0006-291X(90)90836-C; MCCORMACK K, 1995, FEBS LETT, V370, P32, DOI 10.1016/0014-5793(95)00785-8; MCKINNON D, 1986, J EXP MED, V164, P1846, DOI 10.1084/jem.164.6.1846; PAPPONE PA, 1993, AM J PHYSIOL, V264, pC1014, DOI 10.1152/ajpcell.1993.264.4.C1014; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; SCOTT VES, 1994, P NATL ACAD SCI USA, V91, P1637, DOI 10.1073/pnas.91.5.1637; Shamotienko OG, 1997, BIOCHEMISTRY-US, V36, P8195, DOI 10.1021/bi970237g; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; SUTRO JB, 1989, ADV EXP MED BIOL, V254, P113	25	49	49	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20123	20126		10.1074/jbc.274.29.20123	http://dx.doi.org/10.1074/jbc.274.29.20123			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400624	hybrid			2022-12-25	WOS:000081438300017
J	Mulero, JJ; Yeung, G; Nelken, ST; Ford, JE				Mulero, JJ; Yeung, G; Nelken, ST; Ford, JE			CD39-L4 is a secreted human apyrase, specific for the hydrolysis of nucleoside diphosphates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUDIOGENIC-SEIZURES; PLATELET-FUNCTION; CELL ACTIVATION; BREFELDIN-A; GENE; SUSCEPTIBILITY; EXPRESSION; INHIBITION; RECEPTOR; CLONING	The human ecto-apyrase gene family consists of five reported members (CD39, CD39-L1, CD39-L2, CD39-L3, and CD39-L4). The family can be subdivided into two groups by conservation of proposed structural domains. The CD39, CD39-L1, and CD39-L3 genes all encode hydrophobic portions in their carboxy and amino termini, serving as transmembrane domains for CD39 and potentially for the other two members. CD39-L2 and CD39-L4 genes encode hydrophobic portions in their amino termini, suggesting that they might encode secreted apyrases. We demonstrate that the CD39-L4 gene encodes the first reported human secreted ecto-apyrase, COS-7 cells transfected with a CD39-L4 expression construct utilizing the naturally occurring leader peptide express recombinant protein outside of the cells. This expression can be blocked by brefeldin A, a chemical that inhibits a step in mammalian secretory pathways. We also demonstrate expression of CD39-L4 message in macrophages, suggesting that the protein is present in the circulation. Furthermore, we show that CD39-L4 is an E-type apyrase, is dependent on calcium and magnesium cations, and has high degree of specificity for NDPs over NTPs as enzymatic substrates. A potential physiological role in hemostasis and platelet aggregation is presented.	Hyseq Inc, Funct Genom Dept, Sunnyvale, CA 94086 USA		Ford, JE (corresponding author), Hyseq Inc, Funct Genom Dept, 670 Almanor, Sunnyvale, CA 94086 USA.							Bonaldo MDF, 1996, GENOME RES, V6, P791, DOI 10.1101/gr.6.9.791; Brake AJ, 1996, ANNU REV CELL DEV BI, V12, P519, DOI 10.1146/annurev.cellbio.12.1.519; Chadwick BP, 1998, GENOMICS, V50, P357, DOI 10.1006/geno.1998.5317; Communi D, 1996, BIOCHEM BIOPH RES CO, V222, P303, DOI 10.1006/bbrc.1996.0739; DALY JA, 1972, CLIN CHEM, V18, P263; Gayle RB, 1998, J CLIN INVEST, V101, P1851, DOI 10.1172/JCI1753; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; MALISZEWSKI CR, 1994, J IMMUNOL, V153, P3574; Marcus AJ, 1997, J CLIN INVEST, V99, P1351, DOI 10.1172/JCI119294; MARCUS AJ, 1996, PLATELETS THEIR DISO, P79; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; NEUMANN PE, 1990, BEHAV GENET, V20, P307, DOI 10.1007/BF01067798; Nielsen H, 1997, Int J Neural Syst, V8, P581, DOI 10.1142/S0129065797000537; PLESNER L, 1995, INT REV CYTOL, V158, P1771; ROWE M, 1982, INT J CANCER, V29, P373, DOI 10.1002/ijc.2910290403; SEYFRIED TN, 1981, GENETICS, V99, P117; Somers GR, 1998, LAB INVEST, V78, P1375; Todorov LD, 1997, NATURE, V387, P76, DOI 10.1038/387076a0; VALENTINE MA, 1988, J IMMUNOL, V140, P4071; Vizi ES, 1997, NEUROSCIENCE, V79, P893, DOI 10.1016/S0306-4522(96)00658-6; Wang TF, 1996, J BIOL CHEM, V271, P9898, DOI 10.1074/jbc.271.17.9898	22	95	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20064	20067		10.1074/jbc.274.29.20064	http://dx.doi.org/10.1074/jbc.274.29.20064			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400613	hybrid			2022-12-25	WOS:000081438300006
J	van de Pas, BA; Smidt, H; Hagen, WR; van der Oost, J; Schraa, G; Stams, AJM; de Vos, WM				van de Pas, BA; Smidt, H; Hagen, WR; van der Oost, J; Schraa, G; Stams, AJM; de Vos, WM			Purification and molecular characterization of ortho-chlorophenol reductive dehalogenase, a key enzyme of halorespiration in Desulfitobacterium dehalogenans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEHALOSPIRILLUM MULTIVORANS; DEHALOBACTER-RESTRICTUS; TETRACHLOROETHENE; PROTEINS; MEMBRANE; SPECIFICITY; COFACTORS; SEQUENCES; SECRETION; CLEAVAGE	ortho-Chlorophenol reductive dehalogenase of the halorespiring Gram-positive Desulfitobacterium dehalogenans was purified 90-fold to apparent homogeneity, The purified dehalogenase catalyzed the reductive removal of a halogen atom from the ortho position of 3-chloro-4-hydroxyphenylacetate, a-chlorophenol, 2,3-dichloropenol, 2,4-dichlorophenol, 2,6-dichlorophenol, pentachlorophenol, and 2-bromo-4-chlorophenol with reduced methyl viologen as electron donor. The dechlorination of 3-chloro-4-hydroxyphenylacetate was catalyzed by the enzyme at a V-max of 28 units/mg protein and a K-m of 20 mu M. The pH and temperature optimum were 8.2 and 52 degrees C, respectively. EPR analysis indicated one [4Fe-4S] cluster (midpoint redox potential (E-m) = -440 mV), one [3Fe-4S] cluster (E-m = +70 mV), and one cobalamin per 48-kDa monomer, The Co(I)/Co(II) transition had an E-m of -370 mV, Via a reversed genetic approach based on the N-terminal sequence, the corresponding gene was isolated from a D, dehalogenans genomic library, cloned, and sequenced. This revealed the presence of two closely linked genes: (i) cprA, encoding the o-chlorophenol reductive dehalogenase, which contains a twin-arginine type signal sequence that is processed in the purified enzyme; (ii) cprB, coding for an integral membrane protein that could act as a membrane anchor of the dehalogenase, This first biochemical and molecular characterization of a chlorophenol reductive dehalogenase has revealed structural resemblance with haloalkene reductive dehalogenases.	Agr Univ Wageningen, Microbiol Lab, NL-6703 CT Wageningen, Netherlands; Agr Univ Wageningen, Biochem Lab, NL-6703 HA Wageningen, Netherlands	Wageningen University & Research; Wageningen University & Research	van de Pas, BA (corresponding author), Agr Univ Wageningen, Microbiol Lab, Hesselink van Suchtelenweg 4, NL-6703 CT Wageningen, Netherlands.		Smidt, Hauke/D-7054-2014; van+der+Oost, John/Y-2548-2019; Stams, Alfons/C-8167-2014; Hagen, Wilfred R./H-8918-2017	Smidt, Hauke/0000-0002-6138-5026; Stams, Alfons/0000-0001-7840-6500; Hagen, Wilfred R./0000-0002-1609-6671				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Berks BC, 1996, MOL MICROBIOL, V22, P393, DOI 10.1046/j.1365-2958.1996.00114.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUSCHI M, 1988, FEMS MICROBIOL LETT, V54, P155, DOI 10.1111/j.1574-6968.1988.tb02741.x; Christiansen N, 1998, FEBS LETT, V436, P159, DOI 10.1016/S0014-5793(98)01114-4; El Fantroussi S, 1998, BIOTECHNOL PROGR, V14, P167, DOI 10.1021/bp980011k; ELLIOTT JI, 1978, ARCH BIOCHEM BIOPHYS, V190, P351, DOI 10.1016/0003-9861(78)90285-0; JANDA M, 1976, ANGEW CHEM INT EDIT, V15, P443, DOI 10.1002/anie.197604431; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Loffler FE, 1996, APPL ENVIRON MICROB, V62, P3809, DOI 10.1128/AEM.62.10.3809-3813.1996; Ludwig ML, 1997, ANNU REV BIOCHEM, V66, P269, DOI 10.1146/annurev.biochem.66.1.269; Mackiewicz N, 1998, APPL ENVIRON MICROB, V64, P352; MASSEY V, 1977, J BIOL CHEM, V252, P5612; Miller E, 1998, ARCH MICROBIOL, V169, P497, DOI 10.1007/s002030050602; NEUMANN A, 1994, ARCH MICROBIOL, V162, P295, DOI 10.1007/s002030050141; Neumann A, 1998, J BACTERIOL, V180, P4140, DOI 10.1128/JB.180.16.4140-4145.1998; Neumann A, 1996, J BIOL CHEM, V271, P16515, DOI 10.1074/jbc.271.28.16515; NI SS, 1995, J BACTERIOL, V177, P5135, DOI 10.1128/jb.177.17.5135-5139.1995; PIERIK AJ, 1991, EUR J BIOCHEM, V195, P505, DOI 10.1111/j.1432-1033.1991.tb15731.x; Rabinowitz J C, 1978, Methods Enzymol, V53, P275; Sambrook J., 2002, MOL CLONING LAB MANU; SCHILTZ E, 1991, EUR J BIOCHEM, V199, P587, DOI 10.1111/j.1432-1033.1991.tb16158.x; Schumacher W, 1997, FEBS LETT, V409, P421, DOI 10.1016/S0014-5793(97)00520-6; Schumacher W, 1996, J BACTERIOL, V178, P2328, DOI 10.1128/jb.178.8.2328-2333.1996; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TRIGLIA T, 1988, NUCLEIC ACIDS RES, V16, P8186, DOI 10.1093/nar/16.16.8186; UTKIN I, 1995, APPL ENVIRON MICROB, V61, P346, DOI 10.1128/AEM.61.1.346-351.1995; UTKIN I, 1994, INT J SYST BACTERIOL, V44, P612, DOI 10.1099/00207713-44-4-612; VANASSELDONK M, 1993, MOL GEN GENET, V240, P428, DOI 10.1007/BF00280397; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; Weiner JH, 1998, CELL, V93, P93, DOI 10.1016/S0092-8674(00)81149-6	33	120	123	2	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20287	20292		10.1074/jbc.274.29.20287	http://dx.doi.org/10.1074/jbc.274.29.20287			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400648	hybrid			2022-12-25	WOS:000081438300041
J	Zubiaur, M; Guirado, M; Terhorst, C; Malavasi, F; Sancho, J				Zubiaur, M; Guirado, M; Terhorst, C; Malavasi, F; Sancho, J			The CD3-gamma delta epsilon transducing module mediates CD38-induced protein-tyrosine kinase and mitogen-activated protein kinase activation in Jurkat T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE-2; RECEPTOR ZETA-CHAIN; C-CBL PROTOONCOGENE; ANTIGEN RECEPTOR; HUMAN CD38; TCR/CD3 COMPLEX; LYMPHOCYTES-T; PHYSICAL ASSOCIATION; CALCIUM MOBILIZATION; SURFACE EXPRESSION	We have examined the ability of the CD3-gamma delta epsilon and CDS-zeta signaling modules of the T cell receptor (TCR) to couple CD38 to intracellular signaling pathways. The results demonstrated that in TCR+ T cells that express the whole set of CD3 subunits CD38 ligation led to complete tyrosine phosphorylation of both CD3-zeta and CD3-epsilon polypeptide chains. In contrast, in TCR+ cells with a defective CD3-zeta association CD38 engagement caused tyrosine phosphorylation of CD3-epsilon but not of CD3-zeta. Despite these differences, in both cell types CD38 ligation resulted in protein-tyrosine kinase and mitogen-activated protein kinase activation. However, in cells expressing chimerical CD25-zeta or CD25-epsilon receptors or in a TCR-beta(-) Jurkat T cell line, CD38 ligation did not result in tyrosine phosphorylation of the chimeric receptors, or CD3 subunits, or protein-tyrosine kinase or mitogen-activated protein kinase activation. In summary, these results support a model in which CD38 transduces activating signals inside the cell by means of CD3-epsilon and CD3-zeta tyrosine phosphorylation. Moreover, these data identify the CD3-gamma delta epsilon signaling module as a necessary and sufficient component of the TCR/CD3 complex involved in T cell activation through CD38.	CSIC, Inst Parasitol & Biomed, Granada 18001, Spain; Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Immunol, Boston, MA 02215 USA; Univ Ancona, Sch Med, Inst Biol & Genet, I-60131 Ancona, Italy	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Marche Polytechnic University	Sancho, J (corresponding author), CSIC, Inst Parasitol & Biomed, Ventanilla 11, Granada 18001, Spain.		Sancho, Jaime/K-5989-2019; Zubiaur, Mercedes/K-9390-2014; Sancho, Jaime/O-3228-2013; Zubiaur, Mercedes/AAC-5792-2021	Sancho, Jaime/0000-0003-3852-7951; Zubiaur, Mercedes/0000-0002-4127-3027; Sancho, Jaime/0000-0003-3852-7951; Zubiaur, Mercedes/0000-0002-4127-3027; Guirado Torres, Maria/0000-0002-1541-1262; MALAVASI, Fabio/0000-0002-1844-174X	Telethon [E.0662] Funding Source: Medline	Telethon(Fondazione Telethon)		ALCOVER A, 1988, EMBO J, V7, P1973, DOI 10.1002/j.1460-2075.1988.tb03035.x; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; Berthelier V, 1998, BIOCHEM J, V330, P1383, DOI 10.1042/bj3301383; BURGESS KE, 1992, P NATL ACAD SCI USA, V89, P9311, DOI 10.1073/pnas.89.19.9311; BURGESS KE, 1991, EUR J IMMUNOL, V21, P1663, DOI 10.1002/eji.1830210712; CARRERA AC, 1992, J IMMUNOL, V149, P3142; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; CHANG HC, 1989, J EXP MED, V169, P2073, DOI 10.1084/jem.169.6.2073; CHU KT, 1994, J BIOL CHEM, V269, P24095; Dave VP, 1998, INT IMMUNOL, V10, P1481, DOI 10.1093/intimm/10.10.1481; Deaglio S, 1996, J IMMUNOL, V156, P727; Deaglio S, 1998, J IMMUNOL, V160, P395; DIANZANI U, 1992, J IMMUNOL, V148, P678; DIEZOREJAS R, 1994, EMBO J, V13, P90, DOI 10.1002/j.1460-2075.1994.tb06238.x; DONNADIEU E, 1994, J BIOL CHEM, V269, P32828; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; FUNARO A, 1993, EUR J IMMUNOL, V23, P2407, DOI 10.1002/eji.1830231005; GUPTA S, 1994, J BIOL CHEM, V269, P17349; HALL CG, 1993, SCIENCE, V261, P915, DOI 10.1126/science.8346442; HERMANS MHA, 1993, EUR J IMMUNOL, V23, P2257, DOI 10.1002/eji.1830230931; Hoshino S, 1997, J IMMUNOL, V158, P741; Huby RDJ, 1995, J BIOL CHEM, V270, P30241, DOI 10.1074/jbc.270.51.30241; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; IZQUIERDO M, 1993, J EXP MED, V178, P1199, DOI 10.1084/jem.178.4.1199; IZQUIERDO M, 1994, J EXP MED, V180, P401, DOI 10.1084/jem.180.1.401; IZQUIERDO M, 1994, EUR J IMMUNOL, V24, P2462, DOI 10.1002/eji.1830241031; JACKSON DG, 1990, J IMMUNOL, V144, P2811; KAPPES DJ, 1991, P NATL ACAD SCI USA, V88, P10619, DOI 10.1073/pnas.88.23.10619; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LIU CP, 1993, EMBO J, V12, P4863, DOI 10.1002/j.1460-2075.1993.tb06176.x; LONG EO, 1991, HUM IMMUNOL, V31, P229, DOI 10.1016/0198-8859(91)90092-N; LUND FE, 1995, EUR J IMMUNOL, V25, P1338, DOI 10.1002/eji.1830250531; Lund FE, 1996, J IMMUNOL, V157, P1455; MADRENAS J, 1995, SCIENCE, V267, P515, DOI 10.1126/science.7824949; MALAVASI F, 1994, IMMUNOL TODAY, V15, P95, DOI 10.1016/0167-5699(94)90148-1; Mehta K, 1996, FASEB J, V10, P1408, DOI 10.1096/fasebj.10.12.8903511; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MOINGEON P, 1992, P NATL ACAD SCI USA, V89, P1492, DOI 10.1073/pnas.89.4.1492; Morra M, 1998, FASEB J, V12, P581, DOI 10.1096/fasebj.12.7.581; Pacheco-Castro A, 1998, J IMMUNOL, V161, P3152; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PEREZACIEGO P, 1991, J EXP MED, V174, P319, DOI 10.1084/jem.174.2.319; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RodriguezTarduchy G, 1996, J BIOL CHEM, V271, P30417, DOI 10.1074/jbc.271.48.30417; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SANCHO J, 1989, J BIOL CHEM, V264, P20760; SANCHO J, 1993, J IMMUNOL, V150, P3230; SANCHO J, 1993, EUR J IMMUNOL, V23, P1636, DOI 10.1002/eji.1830230736; SANCHO J, 1992, J BIOL CHEM, V267, P7871; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; SUZUKI S, 1992, EUR J IMMUNOL, V22, P2475, DOI 10.1002/eji.1830221002; TERHORST C, 1981, CELL, V23, P771, DOI 10.1016/0092-8674(81)90441-4; Terhorst Cox, 1995, P369; THOME M, 1995, J EXP MED, V181, P1997, DOI 10.1084/jem.181.6.1997; van Oers NSC, 1998, J IMMUNOL, V160, P163; Wardenburg JB, 1996, J BIOL CHEM, V271, P19641, DOI 10.1074/jbc.271.33.19641; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Williams S, 1997, EUR J BIOCHEM, V245, P84, DOI 10.1111/j.1432-1033.1997.00084.x; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; Zubiaur M, 1997, J IMMUNOL, V159, P193	64	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20633	20642		10.1074/jbc.274.29.20633	http://dx.doi.org/10.1074/jbc.274.29.20633			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400695	hybrid			2022-12-25	WOS:000081438300088
J	Paulus, C; Hellebrand, S; Tessmer, U; Wolf, H; Krausslich, HG; Wagner, R				Paulus, C; Hellebrand, S; Tessmer, U; Wolf, H; Krausslich, HG; Wagner, R			Competitive inhibition of human immunodeficiency virus type-1 protease by the Gag-Pol transframe protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 PROTEASE; VIRAL INFECTIVITY; RETROVIRAL PROTEASES; PARTICLE FORMATION; ASPARTIC PROTEASE; POLYPROTEIN; EXPRESSION; SEQUENCE; PRECURSOR; DIMER	The human immunodeficiency virus type-1 (HIV-1) transframe protein p6* is located between the structural and enzymatic domains of the Gag-Pol polyprotein, Banked by the nucleocapsid (NC) and the protease (PR) domain at its amino and carboxyl termini, respectively. Here, we report that recombinant highly purified HIV-1 p6* specifically inhibits mature HIV-1 PR activity. Kinetic analyses and cross-linking experiments revealed a competitive mechanism for PR inhibition by p6*. We further demonstrate that the four carboxyl-terminal residues of p6* are essential but not sufficient for p6*-mediated inhibition of PR activity. Based on these results, we suggest a role of the transframe protein p6* in regulating HIV-1 PR activity during viral replication.	Univ Regensburg, Inst Med Mikrobiol & Hyg, D-93053 Regensburg, Germany; Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany	University of Regensburg; Heinrich Pette Institute	Wagner, R (corresponding author), Univ Regensburg, Inst Med Mikrobiol & Hyg, Franz Josef Str Allee 11, D-93053 Regensburg, Germany.			Paulus, Christina/0000-0002-4123-5629				Almog N, 1996, J VIROL, V70, P7228, DOI 10.1128/JVI.70.10.7228-7232.1996; Beissinger M, 1996, EUR J BIOCHEM, V237, P383, DOI 10.1111/j.1432-1033.1996.0383k.x; DARKE PL, 1994, BIOCHEMISTRY-US, V33, P98, DOI 10.1021/bi00167a013; DARKE PL, 1989, J BIOL CHEM, V264, P2307; DUNN BM, 1994, METHOD ENZYMOL, V241, P254; Gatlin J, 1998, VIROLOGY, V244, P87, DOI 10.1006/viro.1998.9083; GELDERBLOM HR, 1991, AIDS, V5, P617, DOI 10.1097/00002030-199106000-00001; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HENDERSON LE, 1992, J VIROL, V66, P1856, DOI 10.1128/JVI.66.4.1856-1865.1992; JACKS T, 1988, NATURE, V331, P280, DOI 10.1038/331280a0; KAPLAN AH, 1991, P NATL ACAD SCI USA, V88, P4528, DOI 10.1073/pnas.88.10.4528; KARACOSTAS V, 1993, VIROLOGY, V193, P661, DOI 10.1006/viro.1993.1174; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; KONVALINKA J, 1995, J VIROL, V69, P7180, DOI 10.1128/JVI.69.11.7180-7186.1995; KRAUSSLICH HG, 1991, P NATL ACAD SCI USA, V88, P3213, DOI 10.1073/pnas.88.8.3213; KRAUSSLICH HG, 1992, J VIROL, V66, P567; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Louis JM, 1998, BIOCHEMISTRY-US, V37, P2105, DOI 10.1021/bi972059x; LOUIS JM, 1994, P NATL ACAD SCI USA, V91, P7970, DOI 10.1073/pnas.91.17.7970; MEEK TD, 1989, P NATL ACAD SCI USA, V86, P1341; MERGENER K, 1992, VIROLOGY, V186, P25, DOI 10.1016/0042-6822(92)90058-W; Misumi S, 1997, BIOCHEM BIOPH RES CO, V241, P275, DOI 10.1006/bbrc.1997.7801; PARK JS, 1991, J VIROL, V65, P5111, DOI 10.1128/JVI.65.9.5111-5117.1991; PARTIN K, 1991, P NATL ACAD SCI USA, V88, P4776, DOI 10.1073/pnas.88.11.4776; PARTIN K, 1990, J VIROL, V64, P3938, DOI 10.1128/JVI.64.8.3938-3947.1990; PEARL LH, 1987, NATURE, V329, P351, DOI 10.1038/329351a0; PETTIT SC, 1994, J VIROL, V68, P8017, DOI 10.1128/JVI.68.12.8017-8027.1994; PHYLIP LH, 1992, FEBS LETT, V314, P449, DOI 10.1016/0014-5793(92)81524-P; RICHARDS AD, 1990, J BIOL CHEM, V265, P7733; ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354; ROSE JR, 1993, J BIOL CHEM, V268, P11939; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHNEIDER J, 1988, CELL, V54, P363, DOI 10.1016/0092-8674(88)90199-7; SCHRAMM HJ, 1993, BIOCHEM BIOPH RES CO, V194, P595, DOI 10.1006/bbrc.1993.1863; STYS D, 1993, BIOCHIM BIOPHYS ACTA, V1182, P157, DOI 10.1016/0925-4439(93)90137-P; Tessmer U, 1998, J VIROL, V72, P3459, DOI 10.1128/JVI.72.4.3459-3463.1998; TOH H, 1985, NATURE, V315, P691, DOI 10.1038/315691a0; TOMASSELLI AG, 1990, BIOCHEMISTRY-US, V29, P264, DOI 10.1021/bi00453a036; VAISHNAV YN, 1991, ANNU REV BIOCHEM, V60, P577, DOI 10.1146/annurev.bi.60.070191.003045; Vogt VM, 1996, CURR TOP MICROBIOL, V214, P95; VONDERHELM K, 1989, FEBS LETT, V247, P349, DOI 10.1016/0014-5793(89)81368-7; WILLS JW, 1991, AIDS, V5, P639, DOI 10.1097/00002030-199106000-00002; WILSON W, 1988, CELL, V55, P1159, DOI 10.1016/0092-8674(88)90260-7; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279; ZYBARTH G, 1994, J VIROL, V68, P240, DOI 10.1128/JVI.68.1.240-250.1994; ZYBARTH G, 1995, J VIROL, V69, P3878, DOI 10.1128/JVI.69.6.3878-3884.1995	47	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21539	21543		10.1074/jbc.274.31.21539	http://dx.doi.org/10.1074/jbc.274.31.21539			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419458	hybrid			2022-12-25	WOS:000081721100011
J	Bianchi, A; de Lange, T				Bianchi, A; de Lange, T			Ku binds telomeric DNA in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN AUTOANTIGEN KU; STRAND BREAK REPAIR; SACCHAROMYCES-CEREVISIAE; V(D)J RECOMBINATION; YEAST KU; HOMOLOGOUS RECOMBINATION; HUMAN-CHROMOSOMES; G-TETRAPLEX; PROTEIN; END	Ku is a heterodimeric protein with high binding affinity for ends, nicks, and gaps in double-stranded DNA. Both in mammalian cells and in budding yeast, Ku plays a role in nonhomologous end joining in the double strand break repair pathway. However, Ku has a more significant role in DNA repair in mammalian cells compared with yeast, in which a homology-dependent pathway is the predominant one. Recently Ku has been shown to be a likely component of the telomeric complex in yeast, suggesting the possibility of a similar role for Ku at mammalian telomeres, However, long single-stranded G-rich overhangs are continuously present at mammalian but not at yeast telomeres. These overhangs have the potential to fold in vitro into G-G base-paired conformations, such as G-quartets, that might prevent Ku from recognizing telomeric ends and thus offer a mechanism to sequester the telomere from the prevalent double strand break repair pathway in mammals. We show here that Ku binds to mammalian telomeric DNA ends in vitro and that G-quartet conformations are unable to prevent Ku from binding with high affinity to the DNA, Our results indicate that the DNA binding characteristics of Ku are consistent with its direct interaction with telomeric DNA in mammalian cells and its proposed role as a telomere end factor.	Rockefeller Univ, New York, NY 10021 USA	Rockefeller University	de Lange, T (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.	delange@rockvax.rockefeller.edu	de Lange, Titia/B-8263-2011	de Lange, Titia/0000-0002-9267-367X; Bianchi, Alessandro/0000-0001-6583-1671	NIGMS NIH HHS [GM49046] Funding Source: Medline; CSR NIH HHS [RG0323] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049046, R37GM049046] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); CSR NIH HHS; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALAGURUMOORTHY P, 1994, J BIOL CHEM, V269, P21858; BLACKBURN EH, 1995, COLD SPRING HARBOR M; BLIER PR, 1993, J BIOL CHEM, V268, P7594; Boulton SJ, 1996, NUCLEIC ACIDS RES, V24, P4639, DOI 10.1093/nar/24.23.4639; Boulton SJ, 1996, EMBO J, V15, P5093, DOI 10.1002/j.1460-2075.1996.tb00890.x; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; Cary RB, 1997, P NATL ACAD SCI USA, V94, P4267, DOI 10.1073/pnas.94.9.4267; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dionne I, 1996, P NATL ACAD SCI USA, V93, P13902, DOI 10.1073/pnas.93.24.13902; FALZON M, 1993, J BIOL CHEM, V268, P10546; FANG GW, 1993, CELL, V74, P875, DOI 10.1016/0092-8674(93)90467-5; FELDMANN H, 1993, J BIOL CHEM, V268, P12895; Feldmann H, 1996, J BIOL CHEM, V271, P27765, DOI 10.1074/jbc.271.44.27765; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Giffin W, 1996, NATURE, V380, P265, DOI 10.1038/380265a0; GIRALDO R, 1994, EMBO J, V13, P2411, DOI 10.1002/j.1460-2075.1994.tb06526.x; Gravel S, 1998, SCIENCE, V280, P741, DOI 10.1126/science.280.5364.741; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; Grunstein M, 1997, CURR OPIN CELL BIOL, V9, P383, DOI 10.1016/S0955-0674(97)80011-7; Gu YS, 1997, P NATL ACAD SCI USA, V94, P8076, DOI 10.1073/pnas.94.15.8076; HENDERSON E, 1995, TELOMERES, P11; Jackson SP, 1996, CURR OPIN GENET DEV, V6, P19, DOI 10.1016/S0959-437X(96)90005-2; Jhappan C, 1997, NAT GENET, V17, P483, DOI 10.1038/ng1297-483; KANG C, 1992, NATURE, V356, P126, DOI 10.1038/356126a0; Laroche T, 1998, CURR BIOL, V8, P653, DOI 10.1016/S0960-9822(98)70252-0; Liang F, 1996, P NATL ACAD SCI USA, V93, P8929, DOI 10.1073/pnas.93.17.8929; Lieber MR, 1997, CURR OPIN GENET DEV, V7, P99, DOI 10.1016/S0959-437X(97)80116-5; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; McClintock B, 1942, P NATL ACAD SCI USA, V28, P458, DOI 10.1073/pnas.28.11.458; McElligott R, 1997, EMBO J, V16, P3705, DOI 10.1093/emboj/16.12.3705; Milne GT, 1996, MOL CELL BIOL, V16, P4189; MIMORI T, 1986, J BIOL CHEM, V261, P2274; MIMORI T, 1986, J BIOL CHEM, V261, P375; Muller H.J., 1938, COLLECTING NET, V13, P181; MURCHIE AIH, 1994, EMBO J, V13, P993, DOI 10.1002/j.1460-2075.1994.tb06344.x; Nugent CI, 1998, CURR BIOL, V8, P657, DOI 10.1016/S0960-9822(98)70253-2; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; Porter SE, 1996, NUCLEIC ACIDS RES, V24, P582, DOI 10.1093/nar/24.4.582; RATHMELL WK, 1994, MOL CELL BIOL, V14, P4741, DOI 10.1128/MCB.14.7.4741; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; Siede W, 1996, GENETICS, V142, P91; SMITH FW, 1993, BIOCHEMISTRY-US, V32, P8682, DOI 10.1021/bi00084a040; SMITH FW, 1992, NATURE, V356, P164, DOI 10.1038/356164a0; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; Torrance H, 1998, J BIOL CHEM, V273, P20810, DOI 10.1074/jbc.273.33.20810; Tsukamoto Y, 1997, MOL GEN GENET, V255, P543, DOI 10.1007/s004380050527; Tsukamoto Y, 1997, NATURE, V388, P900, DOI 10.1038/42288; Tsukamoto Y, 1996, NUCLEIC ACIDS RES, V24, P2067, DOI 10.1093/nar/24.11.2067; TUTEJA N, 1994, EMBO J, V13, P4991, DOI 10.1002/j.1460-2075.1994.tb06826.x; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; WANG Y, 1993, STRUCTURE, V1, P263, DOI 10.1016/0969-2126(93)90015-9; WANG Y, 1995, J MOL BIOL, V251, P76, DOI 10.1006/jmbi.1995.0417; Wellinger RJ, 1996, CELL, V85, P423, DOI 10.1016/S0092-8674(00)81120-4; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; Wright WE, 1997, GENE DEV, V11, P2801, DOI 10.1101/gad.11.21.2801; Yoo S, 1998, BIOCHEMISTRY-US, V37, P1336, DOI 10.1021/bi972100w; ZAHLER AM, 1991, NATURE, V350, P718, DOI 10.1038/350718a0; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	61	115	116	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21223	21227		10.1074/jbc.274.30.21223	http://dx.doi.org/10.1074/jbc.274.30.21223			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409678	hybrid			2022-12-25	WOS:000081613100069
J	Chazotte-Aubert, L; Oikawa, S; Gilibert, I; Bianchini, F; Kawanishi, S; Ohshima, H				Chazotte-Aubert, L; Oikawa, S; Gilibert, I; Bianchini, F; Kawanishi, S; Ohshima, H			Cytotoxicity and site-specific DNA damage induced by nitroxyl anion (NO-) in the presence of hydrogen peroxide - Implications for various pathophysiological conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; SUPEROXIDE-DISMUTASE; HYDROXYL RADICALS; PEROXYNITRITE; ANTIOXIDANT; CONVERSION; GENERATION; COPPER(II); INDUCTION; CHEMISTRY	Nitroxyl anion (NO-), the one-electron reduction product of nitric oxide (NO.), is formed under various physiological conditions. We have used four different assays (DNA strand breakage, 8-oxo-deoxyguanosine formation in calf thymus DNA, malondialdehyde generation from 2'-deoxyribose, and analysis of site-specific DNA damage using P-32-5'-end-labeled DNA fragments of the human p53 tumor suppressor gene and the c-Ha-ras-1 protooncogene) to study the effects of NO- generated from Angeli's salt on DNA damage. It was found that strong oxidants are generated from NO-, especially in the presence of H2O2 plus Fe(III)-EDTA or Cu(II), NO. released from diethylamine-NONOate had no such effect. Distinct effects of hydroxyl radical (HO.) scavengers and patterns of site-specific DNA cleavage caused by Angeli's salt alone or by Angeli's salt, H2O2, plus metal ion suggest that NO- acts as a reductant to catalyze the formation of the HO. from H2O2, plus Fe(III) and formation of Cu(I)-peroxide complexes with a reactivity similar to HO. from H2O2 and Cu(II), Angeli's salt and H2O2 exerted synergistically cytotoxic effects to MCF-7 cells, determined by lactate dehydrogenase release assay, Thus NO- may play an important role in the etiology of various pathophysiological conditions such as inflammation and neurodegenerative diseases, especially when H2O2 and transition metallic ions are present.	Int Agcy Res Canc, Unit Endogenous Canc Risk Factors, F-69372 Lyon 08, France; Mie Univ, Sch Med, Dept Hyg, Tsu, Mie 514, Japan	World Health Organization; International Agency for Research on Cancer (IARC); Mie University	Ohshima, H (corresponding author), Int Agcy Res Canc, Unit Endogenous Canc Risk Factors, 150 Cours Albert Thomas, F-69372 Lyon 08, France.		Ohshima, Hiroshi/E-8044-2010					AMELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279; BAZYLINSKI DA, 1985, INORG CHEM, V24, P4285, DOI 10.1021/ic00219a017; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CHIU SM, 1995, BIOCHEMISTRY-US, V34, P2653, DOI 10.1021/bi00008a032; DRAPER HH, 1993, FREE RADICAL BIO MED, V15, P353, DOI 10.1016/0891-5849(93)90035-S; EPE B, 1994, METHOD ENZYMOL, V234, P122; Epe B, 1996, NUCLEIC ACIDS RES, V24, P4105, DOI 10.1093/nar/24.21.4105; FariasEisner R, 1996, J BIOL CHEM, V271, P6144, DOI 10.1074/jbc.271.11.6144; Filep JG, 1997, BIOCHEM J, V321, P897, DOI 10.1042/bj3210897; FUKUTO JM, 1993, BIOCHEM BIOPH RES CO, V196, P707, DOI 10.1006/bbrc.1993.2307; GOSS SPA, 1995, CHEM RES TOXICOL, V8, P800, DOI 10.1021/tx00047a021; Gow AJ, 1998, NATURE, V391, P169, DOI 10.1038/34402; HALLIWELL B, 1987, ANAL BIOCHEM, V165, P215, DOI 10.1016/0003-2697(87)90222-3; HOBBS AJ, 1994, P NATL ACAD SCI USA, V91, P10992, DOI 10.1073/pnas.91.23.10992; HOGG N, 1992, BIOCHEM J, V281, P419, DOI 10.1042/bj2810419; Hogg N, 1996, FEBS LETT, V382, P223, DOI 10.1016/0014-5793(96)00086-5; IOANNIDIS I, 1993, BIOCHEM J, V296, P341, DOI 10.1042/bj2960341; KANNER J, 1991, ARCH BIOCHEM BIOPHYS, V289, P130, DOI 10.1016/0003-9861(91)90452-O; MASRWA M, 1988, J AM CHEM SOC, V110, P4293; Maxam A M, 1980, Methods Enzymol, V65, P499; MURPHY ME, 1991, P NATL ACAD SCI USA, V88, P10860, DOI 10.1073/pnas.88.23.10860; Nappi AJ, 1998, BBA-GEN SUBJECTS, V1380, P55, DOI 10.1016/S0304-4165(97)00125-6; Ohshima H, 1999, FREE RADICAL BIO MED, V26, P1305, DOI 10.1016/S0891-5849(98)00327-X; Ohshima H, 1998, FREE RADICAL BIO MED, V25, P1057, DOI 10.1016/S0891-5849(98)00141-5; Oikawa S, 1998, BBA-GENE STRUCT EXPR, V1399, P19, DOI 10.1016/S0167-4781(98)00092-X; Oikawa S, 1996, BIOCHEMISTRY-US, V35, P4584, DOI 10.1021/bi9527000; PACELLI R, 1995, J EXP MED, V182, P1469, DOI 10.1084/jem.182.5.1469; Pfeiffer S, 1997, FREE RADICAL BIO MED, V22, P787, DOI 10.1016/S0891-5849(96)00407-8; RODRIGUEZ H, 1995, J BIOL CHEM, V270, P17633, DOI 10.1074/jbc.270.29.17633; Rusche KM, 1998, BIOCHEMISTRY-US, V37, P15503, DOI 10.1021/bi9813936; Schmidt HHHW, 1996, P NATL ACAD SCI USA, V93, P14492, DOI 10.1073/pnas.93.25.14492; Sharpe MA, 1998, BIOCHEM J, V332, P9, DOI 10.1042/bj3320009; SLEZAK J, 1995, AM J PATHOL, V147, P772; VanUffelen BE, 1998, BIOCHEM J, V330, P719; VasquezVivar J, 1996, BIOCHEM J, V314, P869, DOI 10.1042/bj3140869; Wink DA, 1998, ARCH BIOCHEM BIOPHYS, V351, P66, DOI 10.1006/abbi.1997.0565; Wink DA, 1995, TOXICOL LETT, V82-3, P221, DOI 10.1016/0378-4274(95)03557-5; WINK DA, 1996, METHODS NITRIC OXIDE, P403; Wong PSY, 1998, BIOCHEMISTRY-US, V37, P5362, DOI 10.1021/bi973153g; Yamaguchi R, 1996, CARCINOGENESIS, V17, P2419, DOI 10.1093/carcin/17.11.2419; Yoshie Y, 1997, ARCH BIOCHEM BIOPHYS, V342, P13, DOI 10.1006/abbi.1997.0100; Yoshie Y, 1997, CHEM RES TOXICOL, V10, P1015, DOI 10.1021/tx970025k	42	70	71	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					20909	20915		10.1074/jbc.274.30.20909	http://dx.doi.org/10.1074/jbc.274.30.20909			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409635	hybrid			2022-12-25	WOS:000081613100026
J	Lamzin, VS; Morris, RJ; Dauter, Z; Wilson, KS; Teeter, MM				Lamzin, VS; Morris, RJ; Dauter, Z; Wilson, KS; Teeter, MM			Experimental observation of bonding electrons in proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAY-DIFFRACTION DATA; DENSITY PARAMETERS; ATOMIC-RESOLUTION; CRYSTAL-STRUCTURE; CRAMBIN; POLYPEPTIDES; REFINEMENT	We demonstrate with two examples the success and potential of recent developments in x-ray protein crystallography at ultra high resolution. Our preliminary structural analyses using diffraction data collected for the two proteins crambin and savinase show meaningful deviations from the conventional independent spherical atom approximation. A noise-reduction averaging technique enables bonding details of electron distributions in proteins to be revealed experimentally for the first time. We move one step closer to imaging directly the fine details of the electronic structure on which the biological function of a protein is based.	European Mol Biol Lab, D-22603 Hamburg, Germany; NCI, Upton, NY 11973 USA; Univ York, York YO1 5DD, N Yorkshire, England; Boston Coll, Dept Chem, Chestnut Hill, MA 02167 USA	European Molecular Biology Laboratory (EMBL); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of York - UK; Boston College	Lamzin, VS (corresponding author), European Mol Biol Lab, D-22603 Hamburg, Germany.			Wilson, Keith/0000-0002-3581-2194; Lamzin, Victor/0000-0002-6058-7793; Morris, Richard/0000-0003-3080-2613				Bader R. F. W., 1990, ATOMS MOL QUANTUM TH; BETZEL C, 1992, J MOL BIOL, V223, P427, DOI 10.1016/0022-2836(92)90662-4; Dauter Z, 1995, CURR OPIN STRUC BIOL, V5, P784, DOI 10.1016/0959-440X(95)80011-5; DAUTER Z, 1992, ACTA CRYSTALLOGR B, V48, P42, DOI 10.1107/S0108768191010613; JAMES RW, 1948, ACTA CRYSTALLOGR, V1, P132, DOI 10.1107/S0365110X48000351; Jelsch C, 1998, ACTA CRYSTALLOGR D, V54, P1306, DOI 10.1107/S0907444998004466; Mesecar AD, 1997, SCIENCE, V277, P202, DOI 10.1126/science.277.5323.202; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PICHONPESME V, 1995, J PHYS CHEM-US, V99, P6242, DOI 10.1021/j100016a071; PICHONPESME V, 1992, J AM CHEM SOC, V114, P2713, DOI 10.1021/ja00033a053; RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6; SCHMIDT MW, 1993, J COMPUT CHEM, V14, P1347, DOI 10.1002/jcc.540141112; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; SOUHASSOU M, 1992, J AM CHEM SOC, V114, P2371, DOI 10.1021/ja00033a012; SWANSON SM, 1988, ACTA CRYSTALLOGR A, V44, P437, DOI 10.1107/S0108767388001382; TEETER MM, 1993, J MOL BIOL, V230, P292, DOI 10.1006/jmbi.1993.1143; TEETER MM, 1981, BIOCHEMISTRY-US, V20, P5437, DOI 10.1021/bi00522a013; TEETER MM, 1979, J MOL BIOL, V127, P219, DOI 10.1016/0022-2836(79)90242-0	19	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					20753	20755		10.1074/jbc.274.30.20753	http://dx.doi.org/10.1074/jbc.274.30.20753			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409612	hybrid			2022-12-25	WOS:000081613100003
J	Muller, L; Zhu, PM; Juliano, MA; Juliano, L; Lindberg, I				Muller, L; Zhu, PM; Juliano, MA; Juliano, L; Lindberg, I			A 36-residue peptide contains all of the information required for 7B2-mediated activation of prohormone convertase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE PREDICTION; NEUROENDOCRINE POLYPEPTIDE 7B2; PROPROTEIN CONVERTASE; POSTTRANSLATIONAL MODIFICATIONS; PITUITARY POLYPEPTIDE; ENZYMATIC-ACTIVITY; PROTEIN 7B2; PC2; BIOSYNTHESIS; SEQUENCE	The prohormone convertases (PCs) are serine proteinases responsible for the processing of secretory protein precursors. PC2 is the only member of this family whose activation requires intracellular interaction with a helper protein, the neuroendocrine protein 7B2, In order to gain a better understanding of the mechanism of proPC2 activation, we have characterized the structural determinants of 7B2 required for proPC2 activation. We had already identified a proline-rich binding determinant in the 21-kDa domain, the portion of 7B2 responsible for proPC2 activation. We have now investigated the function of the weakly conserved amino-terminal portion of 21-kDa 7B2 by sequential deletions. Mutant proteins were analyzed in four assays: binding to proPC2, facilitation of proPC2 maturation, and activation of proPC2 in vivo and in vitro. We found that the aminoterminal half of 7B2 is not involved in proPC2 activation, and we identified an active 36-residue peptide that contains the previously characterized proline-rich sequence as well as an alpha-helix and the only disulfide bond of 7B2. Mutation of the cu-helix and of the cysteines demonstrated that these determinants are absolutely required for PC2 activation, Thus, the 186-residue full-length 7B2 rat protein can be functionally reduced to an internal segment of only 36 residues.	Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; Escola Paulista Med, Dept Biophys, BR-04044020 Sao Paulo, Brazil	Louisiana State University System; Universidade Federal de Sao Paulo (UNIFESP)	Lindberg, I (corresponding author), Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, 1901 Perdido St, New Orleans, LA 70112 USA.	ilindh@lsumc.edu	Lindberg, Iris/Q-3825-2019; muller, laurent/S-1990-2016; Juliano, Luiz/D-7204-2012	muller, laurent/0000-0001-9634-4323; Juliano, Luiz/0000-0002-5589-2822	NIDDK NIH HHS [DK49703, R01 DK049703] Funding Source: Medline; DRS NIH HHS [RSDA00204] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049703] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); DRS NIH HHS; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson ED, 1997, EMBO J, V16, P1508, DOI 10.1093/emboj/16.7.1508; AYOUBI TAY, 1990, J BIOL CHEM, V265, P15644; Benjannet S, 1998, FEBS LETT, V428, P37, DOI 10.1016/S0014-5793(98)00480-3; BENJANNET S, 1995, FEBS LETT, V362, P151, DOI 10.1016/0014-5793(95)00228-2; BENJANNET S, 1995, J NEUROCHEM, V64, P2303; BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; BRAKS JAM, 1994, CELL, V78, P263, DOI 10.1016/0092-8674(94)90296-8; DeBie I, 1996, J CELL BIOL, V135, P1261, DOI 10.1083/jcb.135.5.1261; Frishman D, 1996, PROTEIN ENG, V9, P133, DOI 10.1093/protein/9.2.133; GEOURJON C, 1994, PROTEIN ENG, V7, P157, DOI 10.1093/protein/7.2.157; GUEST PC, 1992, J BIOL CHEM, V267, P22401; HSI KL, 1982, FEBS LETT, V147, P261, DOI 10.1016/0014-5793(82)81055-7; KNELLER DG, 1990, J MOL BIOL, V214, P171, DOI 10.1016/0022-2836(90)90154-E; Lamango NS, 1999, ARCH BIOCHEM BIOPHYS, V362, P275, DOI 10.1006/abbi.1998.1033; Lindberg I, 1998, DNA CELL BIOL, V17, P727, DOI 10.1089/dna.1998.17.727; LINDBERG I, 1995, BIOCHEMISTRY-US, V34, P5486, DOI 10.1021/bi00016a020; LIPKIND G, 1995, J BIOL CHEM, V270, P13277, DOI 10.1074/jbc.270.22.13277; Lipkind GM, 1998, P NATL ACAD SCI USA, V95, P7310, DOI 10.1073/pnas.95.13.7310; MARTENS GJM, 1988, FEBS LETT, V234, P160, DOI 10.1016/0014-5793(88)81324-3; MARTENS GJM, 1989, EUR J BIOCHEM, V181, P75, DOI 10.1111/j.1432-1033.1989.tb14695.x; MBIKAY M, 1989, INT J PEPT PROT RES, V33, P39; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; Muller L, 1997, J CELL BIOL, V139, P625, DOI 10.1083/jcb.139.3.625; MULLER L, 1999, IN PRESS PROG NUCL A, V63; PAQUET L, 1994, J BIOL CHEM, V269, P19279; PAQUET L, 1991, FEBS LETT, V294, P23, DOI 10.1016/0014-5793(91)81334-5; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; SEIDAH NG, 1994, METHOD ENZYMOL, V244, P171; SHEN FS, 1993, J BIOL CHEM, V268, P24910; Siezen RJ, 1997, PROTEIN SCI, V6, P501; Spijker S, 1997, J BIOL CHEM, V272, P4116, DOI 10.1074/jbc.272.7.4116; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; Van Horssen AM, 1998, J NEUROCHEM, V71, P402; vandeLoo JWHP, 1997, J BIOL CHEM, V272, P27116, DOI 10.1074/jbc.272.43.27116; VANHORSSEN AM, 1995, J BIOL CHEM, V270, P14292; VEY M, 1994, J CELL BIOL, V127, P1829, DOI 10.1083/jcb.127.6.1829; WALDBIESER GC, 1991, ENDOCRINOLOGY, V128, P3228, DOI 10.1210/endo-128-6-3228; Westphal CH, 1999, CELL, V96, P689, DOI 10.1016/S0092-8674(00)80579-6; YI Z, 1993, J BIOL CHEM, V268, P5615; ZHOU A, 1994, J BIOL CHEM, V269, P17440; ZHOU A, 1993, J BIOL CHEM, V268, P1763; ZHU XR, 1995, J CELL BIOL, V129, P1641, DOI 10.1083/jcb.129.6.1641; Zhu XR, 1998, J BIOL CHEM, V273, P1158, DOI 10.1074/jbc.273.2.1158; Zhu XR, 1996, J BIOL CHEM, V271, P23582, DOI 10.1074/jbc.271.38.23582	44	25	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21471	21477		10.1074/jbc.274.30.21471	http://dx.doi.org/10.1074/jbc.274.30.21471			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409712	hybrid			2022-12-25	WOS:000081613100103
J	Hsiao, PW; Lin, DL; Nakao, R; Chang, C				Hsiao, PW; Lin, DL; Nakao, R; Chang, C			The linkage of Kennedy's neuron disease to ARA24, the first identified androgen receptor polyglutamine region-associated coactivator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BULBAR MUSCULAR-ATROPHY; CANCER DU145 CELLS; PROSTATE-CANCER; TUMOR-SUPPRESSOR; BINDING PROTEIN; CAG REPEAT; RCC1; GENE; RAN; EXPRESSION	Although the linkage of polyglutamine (poly-Q) repeat expansion in the androgen receptor (AR) to Kennedy's disease CX-linked spinal and bulbar muscular atrophy) was a major step forward, the detailed molecular mechanism of how the change in poly-Q length contributes to the disease remains unclear. Here we report the identification of a nuclear G-protein, Ras-related nuclear protein/ARA24, as the first AR coactivator that can bind differentially with different lengths of poly-Q within AR. In the yeast and mammalian reciprocal interacting assays, our data suggested the interaction of AR N-terminal domain with ARA24 diminishes as the poly-Q length increases. The coactivation of ARA24 also diminishes with the poly-Q expansion within AR. Deletion of the acidic hexapeptide (DEDDDL) at the C terminus of ARA24 further enhances its AR coactivation. Together, our data suggest that poor interaction and weaker coactivation of ARA24 to the longer poly-Q AR in the X-linked spinal and bulbar muscular atrophied AR could contribute to the weaker transactivation of AR, The con sequence of poor interaction and weak coactivation may eventually lead to the partial androgen insensitivity during the development of Kennedy's disease.	Univ Rochester, Dept Pathol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Dept Urol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Dept Radiat Oncol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Ctr Canc, Rochester, NY 14642 USA; Univ Wisconsin, Ctr Comprehens Canc, Madison, WI 53792 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester; University of Wisconsin System; University of Wisconsin Madison	Chang, C (corresponding author), Univ Rochester, Dept Pathol, George Whipple Lab Canc Res, 601 Elmwood Ave, Rochester, NY 14642 USA.	chang@pathology.rochester.edu	Hsiao, Pei-Wen/V-5653-2018	Hsiao, Pei-Wen/0000-0002-3589-6754	NATIONAL CANCER INSTITUTE [R29CA055639, R01CA055639] Funding Source: NIH RePORTER; NCI NIH HHS [CA68518, CA55639, CA71570] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BISCHOFF FR, 1991, P NATL ACAD SCI USA, V88, P10830, DOI 10.1073/pnas.88.23.10830; CHANG CS, 1992, P NATL ACAD SCI USA, V89, P5946, DOI 10.1073/pnas.89.13.5946; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; Chi NC, 1996, J CELL BIOL, V135, P559, DOI 10.1083/jcb.135.3.559; Choong CS, 1996, MOL ENDOCRINOL, V10, P1527, DOI 10.1210/me.10.12.1527; FORRESTER W, 1992, GENE DEV, V6, P1914, DOI 10.1101/gad.6.10.1914; Fujimoto N, 1999, J BIOL CHEM, V274, P8316, DOI 10.1074/jbc.274.12.8316; Giovannucci E, 1997, P NATL ACAD SCI USA, V94, P3320, DOI 10.1073/pnas.94.7.3320; Kang HY, 1999, J BIOL CHEM, V274, P8570, DOI 10.1074/jbc.274.13.8570; KAZEMIESFARJANI P, 1995, HUM MOL GENET, V4, P523, DOI 10.1093/hmg/4.4.523; KENNEDY WR, 1968, NEUROLOGY, V18, P671, DOI 10.1212/WNL.18.7.671; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; Lin DL, 1996, J BIOL CHEM, V271, P14649, DOI 10.1074/jbc.271.25.14649; MACLEAN HE, 1995, J CLIN ENDOCR METAB, V80, P508, DOI 10.1210/jc.80.2.508; Merry DE, 1998, HUM MOL GENET, V7, P693, DOI 10.1093/hmg/7.4.693; Miyamoto H, 1998, P NATL ACAD SCI USA, V95, P11083, DOI 10.1073/pnas.95.19.11083; Miyamoto H, 1998, P NATL ACAD SCI USA, V95, P7379, DOI 10.1073/pnas.95.13.7379; NAGASHIMA T, 1988, J NEUROL SCI, V87, P141, DOI 10.1016/0022-510X(88)90240-7; NISHITANI H, 1991, EMBO J, V10, P1555, DOI 10.1002/j.1460-2075.1991.tb07675.x; REN MD, 1993, J CELL BIOL, V120, P313, DOI 10.1083/jcb.120.2.313; REN MD, 1994, MOL CELL BIOL, V14, P4216, DOI 10.1128/MCB.14.6.4216; Rush MG, 1996, BIOESSAYS, V18, P103, DOI 10.1002/bies.950180206; Stanford JL, 1997, CANCER RES, V57, P1194; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458; Yeh SY, 1998, BIOCHEM BIOPH RES CO, V248, P361, DOI 10.1006/bbrc.1998.8974; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; Yeh SY, 1998, P NATL ACAD SCI USA, V95, P5527, DOI 10.1073/pnas.95.10.5527	29	185	191	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20229	20234		10.1074/jbc.274.29.20229	http://dx.doi.org/10.1074/jbc.274.29.20229			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400640	hybrid			2022-12-25	WOS:000081438300033
J	Kai, H; Hisatsune, A; Chihara, T; Uto, A; Kokusho, A; Miyata, T; Basbaum, C				Kai, H; Hisatsune, A; Chihara, T; Uto, A; Kokusho, A; Miyata, T; Basbaum, C			Myeloid ELF-1-like factor up-regulates lysozyme transcription in epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR PU.1; DOWNSTREAM ENHANCER; ETS FAMILY; GENE; EXPRESSION; BINDING; TISSUES; LOCALIZATION; MACROPHAGE; RECEPTOR	Lysozyme is an important component of innate immunity against common pathogens at mucosal surfaces. We previously cloned and characterized the bovine lysozyme 5A (lys5A) promoter with the purpose of determining cis- anal trans-acting elements controlling airway epithelial cell-specific expression. We found that such expression is controlled by protein binding to an ETS consensus sequence located approximately at -46 to -40 bp from the transcription start site. The identity of the ETS-related protein responsible for gene transactivation was unknown. In this study, we screened six ETS-related proteins by transient transfection into epithelial cells and fibroblasts. Results showed that among these factors, the myeloid Elf-1-like factor (MEF) was the most potent. Gel shift analysis of epithelial cell nuclear extracts using a lys5A probe including the ETS-binding site (-50/-31) yielded a single band with retarded mobility. This band was supershifted by an antibody directed against MEF. Supporting the possibility that MEF is responsible for functional transactivation of lysozyme in epithelial cells, we found that antisense MEF mRNA decreased lys5A promoter activity and that MEF overexpression in stably transfected cells increased lysozyme mRNA and protein expression, We conclude that MEF is required for epithelial cell transactivation of lysozyme.	Kumamoto Univ, Fac Pharmaceut Sci, Dept Pharmacol Sci, Kumamoto 862, Japan; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA	Kumamoto University; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Kai, H (corresponding author), Kumamoto Univ, Fac Pharmaceut Sci, Dept Pharmacol Sci, 5-1 Oe Honmachi, Kumamoto 862, Japan.		Chihara, Takahiro/G-7639-2019	Chihara, Takahiro/0000-0001-9989-3619	PHS HHS [P0124136, R0143762] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABE T, 1991, J CLIN INVEST, V87, P2207, DOI 10.1172/JCI115255; AHNE B, 1994, J BIOL CHEM, V269, P17794; Albagli O, 1996, MECH DEVELOP, V59, P29, DOI 10.1016/0925-4773(96)00568-0; Andreoli JM, 1997, NUCLEIC ACIDS RES, V25, P4287, DOI 10.1093/nar/25.21.4287; BOWES D, 1977, THORAX, V32, P163, DOI 10.1136/thx.32.2.163; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; Choi SG, 1998, J BIOL CHEM, V273, P110, DOI 10.1074/jbc.273.1.110; CROSS M, 1988, P NATL ACAD SCI USA, V85, P6232, DOI 10.1073/pnas.85.17.6232; DOHRMAN A, 1994, EXP LUNG RES, V20, P367, DOI 10.3109/01902149409064393; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JOHNSTON JJ, 1992, BLOOD, V79, P2998; Kai H, 1996, J CELL BIOCHEM, V61, P350, DOI 10.1002/(SICI)1097-4644(19960601)61:3<350::AID-JCB3>3.3.CO;2-4; KIM HS, 1986, J BIOL CHEM, V261, P6712; KLAGES S, 1992, NUCLEIC ACIDS RES, V20, P1925, DOI 10.1093/nar/20.8.1925; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KLOCKARS M, 1975, J HISTOCHEM CYTOCHEM, V23, P932, DOI 10.1177/23.12.1104708; KLOCKARS M, 1974, J HISTOCHEM CYTOCHEM, V22, P139, DOI 10.1177/22.3.139; LASSAR A, 1994, CURR OPIN CELL BIOL, V6, P432, DOI 10.1016/0955-0674(94)90037-X; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MASON DY, 1975, J CLIN PATHOL, V28, P124, DOI 10.1136/jcp.28.2.124; Miyazaki Y, 1996, ONCOGENE, V13, P1721; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; Nickel J, 1995, NUCLEIC ACIDS RES, V23, P4785, DOI 10.1093/nar/23.23.4785; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; Oettgen P, 1997, GENOMICS, V45, P456, DOI 10.1006/geno.1997.4974; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; Tymms MJ, 1997, ONCOGENE, V15, P2449, DOI 10.1038/sj.onc.1201427; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WURSTER AL, 1994, MOL CELL BIOL, V14, P6452, DOI 10.1128/MCB.14.10.6452; YOSHIMURA K, 1991, J BIOL CHEM, V266, P9140; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	32	30	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20098	20102		10.1074/jbc.274.29.20098	http://dx.doi.org/10.1074/jbc.274.29.20098			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400620	hybrid			2022-12-25	WOS:000081438300013
J	Salomon, RG; Sha, W; Brame, C; Kaur, K; Subbanagounder, G; O'Neil, J; Hoff, HF; Roberts, LJ				Salomon, RG; Sha, W; Brame, C; Kaur, K; Subbanagounder, G; O'Neil, J; Hoff, HF; Roberts, LJ			Protein adducts of iso[4]levuglandin E-2, a product of the isoprostane pathway, in oxidized low density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN ENDOPEROXIDES; LEVUGLANDIN E(2); HUMAN PLASMA; MACROPHAGE RECOGNITION; OXIDATIVE MODIFICATION; LIPID-PEROXIDATION; APOLIPOPROTEIN-B; FATTY-ACIDS; LDL; AGGREGATION	Levuglandin (LG) E-2, a cytotoxic seco prostanoic acid co-generated with prostaglandins by nonenzymatic rearrangements of the cyclooxygenase-derived endoperoxide, prostaglandin H-2, avidly binds to proteins. That LGE(2)-protein adducts can also be generated nonenzymatically is demonstrated by their production during free radical-induced oxidation of low density lipoprotein (LDL). Like oxidized LDL, LGE(2)-LDL, but not native LDL, undergoes receptor-mediated uptake and impaired processing by macrophage cells. Since radical-induced lipid oxidation produces isomers of prostaglandins, isoprostanes (isoPs), via endoperoxide intermediates, we postulated previously that a similar family of LG isomers, isoLGs, is cogenerated with isoPs. Now iso[4]LGE(2)-protein epitopes produced by radical-induced oxidation of arachidonic acid in the presence of protein were detected with an enzyme-linked immunosorbent assay. Iso[4]LGE(2)-protein epitopes are also generated during free radical-induced oxidation of LDL. All of the LGE(2) isomers generated upon oxidation of LDL are efficiently sequestered by covalent adduction with LDL-based amino groups. The potent electrophilic reactivity of iso-LGs can be anticipated to have biological consequences beyond their obvious potential as markers for specific arachidonate derived protein modifications that may be of value for the quantitative assessment of oxidative injury.	Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA; Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA	Case Western Reserve University; Vanderbilt University; Vanderbilt University; Cleveland Clinic Foundation	Salomon, RG (corresponding author), Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA.		Salomon, Robert G/C-3463-2008	Salomon, Robert/0000-0001-9456-3557	NIGMS NIH HHS [GM21249, GM42056, GM15431] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM015431, R01GM042056, R01GM021249, P50GM015431, R37GM042056] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; Brame CJ, 1999, J BIOL CHEM, V274, P13139, DOI 10.1074/jbc.274.19.13139; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; COREY EJ, 1984, TETRAHEDRON LETT, V25, P5013, DOI 10.1016/S0040-4039(01)91105-0; DECAPRIO AP, 1987, MOL PHARMACOL, V32, P542; DIFRANCO E, 1995, CHEM RES TOXICOL, V8, P61, DOI 10.1021/tx00043a008; EDELSTEIN C, 1986, BIOCH BIOL PLASMA LI, V11, P495; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; ESTERBAUER H, 1987, J LIPID RES, V28, P495; Fields R, 1972, Methods Enzymol, V25, P464, DOI 10.1016/S0076-6879(72)25042-X; FISHMAN RA, 1981, T AM NEUROL ASSOC, V106, P58; FOGELMAN AM, 1980, P NATL ACAD SCI-BIOL, V77, P2214, DOI 10.1073/pnas.77.4.2214; HABERLAND ME, 1982, P NATL ACAD SCI-BIOL, V79, P1712, DOI 10.1073/pnas.79.6.1712; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P345, DOI 10.1073/pnas.71.2.345; Hatch F T, 1968, Adv Lipid Res, V6, P1; HOFF HF, 1993, J LIPID RES, V34, P1919; HOFF HF, 1992, J BIOL CHEM, V267, P602; HOFT E, 1968, TETRAHEDRON LETT, P2028; Hoppe G, 1997, BBA-LIPID LIPID MET, V1344, P1, DOI 10.1016/S0005-2760(96)00160-9; IYER RS, 1994, J ORG CHEM, V59, P6038, DOI 10.1021/jo00099a039; IYER RS, 1989, PROSTAGLANDINS, V37, P471, DOI 10.1016/0090-6980(89)90096-8; JACKSON AH, 1980, COMPREHENSIVE ORGANI, V4, P275; JIROUSEK MR, 1990, PROSTAGLANDINS, V40, P611; JURGENS G, 1986, BIOCHIM BIOPHYS ACTA, V875, P103, DOI 10.1016/0005-2760(86)90016-0; Kaur K, 1997, CHEM RES TOXICOL, V10, P1387, DOI 10.1021/tx970112c; LYNCH SM, 1994, J CLIN INVEST, V93, P998, DOI 10.1172/JCI117107; MATTOCKS AR, 1968, NATURE, V217, P723, DOI 10.1038/217723a0; MILLER DB, 1990, J ORG CHEM, V55, P3164, DOI 10.1021/jo00297a036; MORROW JD, 1992, P NATL ACAD SCI USA, V89, P10721, DOI 10.1073/pnas.89.22.10721; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; MURTHI KK, 1993, BIOCHEMISTRY-US, V32, P4090, DOI 10.1021/bi00066a034; NENSETER MS, 1992, ARTERIOSCLER THROMB, V12, P369, DOI 10.1161/01.ATV.12.3.369; Nugteren D H, 1980, Adv Prostaglandin Thromboxane Res, V6, P129; NUGTEREN DH, 1973, BIOCHIM BIOPHYS ACTA, V326, P448, DOI 10.1016/0005-2760(73)90145-8; PALINSKI W, 1990, ARTERIOSCLEROSIS, V10, P325, DOI 10.1161/01.ATV.10.3.325; PARTHASARATHY S, 1992, ANNU REV MED, V43, P219, DOI 10.1146/annurev.me.43.020192.001251; PARTHASARATHY S, 1990, P NATL ACAD SCI USA, V87, P9741, DOI 10.1073/pnas.87.24.9741; PORTER NA, 1975, J ORG CHEM, V40, P3614, DOI 10.1021/jo00912a037; QUINLAN GJ, 1994, FREE RADICAL RES, V21, P95, DOI 10.3109/10715769409056561; REISFELD N, 1993, FEBS LETT, V315, P267, DOI 10.1016/0014-5793(93)81176-Z; Salomon RG, 1997, CHEM RES TOXICOL, V10, P536, DOI 10.1021/tx960157y; SALOMON RG, 1987, PROSTAGLANDINS, V34, P643, DOI 10.1016/0090-6980(87)90289-9; Salomon RG, 1997, CHEM RES TOXICOL, V10, P750, DOI 10.1021/tx970016b; SALOMON RG, 1984, J AM CHEM SOC, V106, P6049, DOI 10.1021/ja00332a049; Sayre LM, 1996, CHEM RES TOXICOL, V9, P1194, DOI 10.1021/tx960094j; SHULER KR, 1992, J IMMUNOL METHODS, V156; SIESJO BK, 1983, CEREBROVASC DIS, P251; SMITH EB, 1967, J ORG CHEM, V32, P3330, DOI 10.1021/jo01286a012; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEINBERG D, 1989, NEW ENGL J MED, V320, P916; STEINBRECHER UP, 1989, J LIPID RES, V30, P305; STEINBRECHER UP, 1987, J BIOL CHEM, V262, P3603; STROHMAIER H, 1995, J LIPID MEDIAT CELL, V11, P51, DOI 10.1016/0929-7855(94)00027-A; Subbanagounder G, 1997, J ORG CHEM, V62, P7658, DOI 10.1021/jo970858f; Taber DF, 1997, PROSTAGLANDINS, V53, P63, DOI 10.1016/S0090-6980(97)00005-1; UCHIDA K, 1995, BIOCHEM BIOPH RES CO, V212, P1068, DOI 10.1006/bbrc.1995.2078	56	49	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20271	20280		10.1074/jbc.274.29.20271	http://dx.doi.org/10.1074/jbc.274.29.20271			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400646	Green Published, hybrid			2022-12-25	WOS:000081438300039
J	Pestana, ES; Tenev, T; Gross, S; Stoyanov, B; Ogata, M; Bohmer, FD				Pestana, ES; Tenev, T; Gross, S; Stoyanov, B; Ogata, M; Bohmer, FD			The transmembrane protein tyrosine phosphatase RPTP sigma modulates signaling of the epidermal growth factor receptor in A431 cells	ONCOGENE			English	Article						EGF receptor; protein-tyrosine phosphatase; ganglioside G(M3); RPTP sigma	MESSENGER-RNA EXPRESSION; GENE-EXPRESSION; CARCINOMA-CELLS; NERVOUS-SYSTEM; INTACT-CELLS; NEU ONCOGENE; PTP-SIGMA; HUMAN LAR; KINASE; DOMAIN	Attenuation of epidermal growth factor receptor signaling by the ganglioside G(M3) has previously been found to involve activation of an unknown protein-tyrosine phosphatase (PTP). In transient expression experiments we tested different PTPs for activation towards EGF receptor by G(M3). The transmembrane PTP RPTP sigma but not RPTP alpha or the SH2-domain PTP SHP-1 exhibited elevated activity towards EGF receptor in G(M3)-treated cells. The possible relevance of RPTP sigma for regulation of EGF receptor signaling activity was further explored in stable A431 cells lines inducibly expressing RPTP sigma or RPTP sigma antisense RNA. RPTP sigma expression clearly reduced EGF receptor phosphorylation, Also, soft agar colony formation of respective cell lines was reduced upon RPTP sigma expression whereas RPTP sigma antisense RNA expression augmented both, EGF receptor phosphorylation and soft agar colony formation. In addition, RPTP sigma antisense RNA expression rendered A431 cells resistant to inhibition of EGF receptor phosphorylation by G(M3). We propose that RPTP sigma participates in EGF receptor dephosphorylation in A431 cells, becomes activated by G(M3) via an unknown mechanism and is thereby capable to mediate attenuation of EGF receptor phosphorylation by G(M3).	Klinikum Univ Jena, Res Unit Mol Cell Biol, D-07747 Jena, Germany; Osaka Univ, Sch Med, Biomed Res Ctr, Dept Oncol, Suita, Osaka 565, Japan	Friedrich Schiller University of Jena; Osaka University	Bohmer, FD (corresponding author), Klinikum Univ Jena, Res Unit Mol Cell Biol, Drackendorfer Str 1, D-07747 Jena, Germany.			Tenev, Tencho/0000-0001-8762-1069				Aicher B, 1997, J CELL BIOL, V138, P681, DOI 10.1083/jcb.138.3.681; BOHMER FD, 1993, FEBS LETT, V331, P276, DOI 10.1016/0014-5793(93)80352-U; BOHMER FD, 1995, ANAL BIOCHEM, V228, P267, DOI 10.1006/abio.1995.1349; BREMER EG, 1986, J BIOL CHEM, V261, P2434; BROWNSHIMER S, 1992, CANCER RES, V52, P478; CELLER JW, 1995, BIOCHEM BIOPH RES CO, V209, P614, DOI 10.1006/bbrc.1995.1544; Charest A, 1997, ONCOGENE, V14, P1643, DOI 10.1038/sj.onc.1201008; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; FAURE R, 1992, J BIOL CHEM, V267, P11215; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Fry DW, 1997, BIOCHEM PHARMACOL, V54, P877, DOI 10.1016/S0006-2952(97)00242-6; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gossen Manfred, 1994, Current Opinion in Biotechnology, V5, P516, DOI 10.1016/0958-1669(94)90067-1; GU M, 1996, P NATL ACAD SCI USA, V94, P12980; KAPLAN R, 1990, P NATL ACAD SCI USA, V87, P7000, DOI 10.1073/pnas.87.18.7000; Keane MM, 1996, CANCER RES, V56, P4236; Kokel M, 1998, GENE DEV, V12, P1425, DOI 10.1101/gad.12.10.1425; Kulas DT, 1996, J BIOL CHEM, V271, P748, DOI 10.1074/jbc.271.2.748; KULAS DT, 1995, J BIOL CHEM, V270, P2435, DOI 10.1074/jbc.270.6.2435; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; LEE K, 1987, EXP CELL RES, V173, P156, DOI 10.1016/0014-4827(87)90341-7; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liu F, 1997, BIOCHEM J, V327, P139, DOI 10.1042/bj3270139; LONGO FM, 1993, J BIOL CHEM, V268, P26503; Lorenz U, 1996, J EXP MED, V184, P1111, DOI 10.1084/jem.184.3.1111; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Norris K, 1997, FEBS LETT, V415, P243, DOI 10.1016/S0014-5793(97)01133-2; OGATA M, 1994, J IMMUNOL, V153, P4478; OGRADY P, 1994, J BIOL CHEM, V269, P25193; Paulson RF, 1996, NAT GENET, V13, P309, DOI 10.1038/ng0796-309; Pestana ES, 1997, BRIT J CANCER, V75, P213, DOI 10.1038/bjc.1997.36; PULIDO R, 1995, P NATL ACAD SCI USA, V92, P11686, DOI 10.1073/pnas.92.25.11686; PULIDO R, 1995, J BIOL CHEM, V270, P6722, DOI 10.1074/jbc.270.12.6722; ROTIN D, 1994, AM J PHYSIOL, V267, pL263, DOI 10.1152/ajplung.1994.267.3.L263; Schaapveld R, 1997, MOL BIOL REP, V24, P247, DOI 10.1023/A:1006870016238; Schaapveld RQJ, 1997, DEV BIOL, V188, P134, DOI 10.1006/dbio.1997.8630; Serra-Pages C, 1998, J BIOL CHEM, V273, P15611, DOI 10.1074/jbc.273.25.15611; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; SKARNES WC, 1995, P NATL ACAD SCI USA, V92, P6592, DOI 10.1073/pnas.92.14.6592; Tenev T, 1997, J BIOL CHEM, V272, P5966, DOI 10.1074/jbc.272.9.5966; TOMIC S, 1995, J BIOL CHEM, V270, P21277, DOI 10.1074/jbc.270.36.21277; Wagner J, 1996, GENOMICS, V38, P76, DOI 10.1006/geno.1996.0594; WALTON KM, 1993, NEURON, V11, P387, DOI 10.1016/0896-6273(93)90193-U; Weiss FU, 1997, CURR OPIN GENET DEV, V7, P80, DOI 10.1016/S0959-437X(97)80113-X; Weng LP, 1998, CURR BIOL, V8, P247, DOI 10.1016/S0960-9822(98)70106-X; YAN H, 1993, J BIOL CHEM, V268, P24880; ZHAI YF, 1995, MOL CARCINOGEN, V14, P103, DOI 10.1002/mc.2940140206; ZHANG JS, 1995, J CELL BIOL, V128, P415, DOI 10.1083/jcb.128.3.415; ZHANG WR, 1994, BIOCHEM J, V302, P39, DOI 10.1042/bj3020039	51	68	68	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	1999	18	28					4069	4079		10.1038/sj.onc.1202794	http://dx.doi.org/10.1038/sj.onc.1202794			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	216FP	10435588				2022-12-25	WOS:000081431000004
J	Paassilta, P; Pihlajamaa, T; Annunen, S; Brewton, RG; Wood, BM; Johnson, CC; Liu, JG; Gong, YQ; Warman, ML; Prockop, DJ; Mayne, R; Ala-Kokko, L				Paassilta, P; Pihlajamaa, T; Annunen, S; Brewton, RG; Wood, BM; Johnson, CC; Liu, JG; Gong, YQ; Warman, ML; Prockop, DJ; Mayne, R; Ala-Kokko, L			Complete sequence of the 23-kilobase human COL9A3 gene - Detection of GLY-X-Y triplet deletions that represent neutral variants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE EPIPHYSEAL DYSPLASIA; COLLAGEN TYPE-IX; CROSS-LINKING SITES; II COLLAGEN; OSTEOGENESIS IMPERFECTA; PROTEIN GENE; CARTILAGE; CHAIN; MUTATIONS; CLONING	We report the complete sequence of the human COL9A3 gene that encodes the alpha 3 chain of heterotrimeric type IX collagen, a member of the fibril-associated collagens with interrupted triple helices family of collagenous proteins. Nucleotide sequencing defined over 23,000 base pairs (bp) of the gene and about 3000 bp of the 5'-flanking sequences. The gene contains 32 exons, The domain and exon organization of the gene is almost identical to a related gene, the human COL9A2 gene. However, exon 2 of the COL9A3 gene codes for one -Gly-X-Y- triplet less than exon 2 of the COL9A2 gene. The difference is compensated by an insertion of 9 bp coding for an additional triplet in exon 4 of the COL9A3 gene. As a result, the number of -Gly-X-Y- repeats in the third collagenous domain remains the same in both genes and ensures the formation of an in-register triple helix. In the course of screening this gene for mutations, heterozygosity for separate 9-bp deletions within the COL1 domain were identified in two kindreds, In both instances, the deletions did not co-segregate with any disease phenotype, suggesting that they were neutral variants, In contrast, similar deletions in triple helical domain of type I collagen are lethal, To study whether alpha 3(IX) chains with the deletion will participate in the formation of correctly folded heterotrimeric type IX collagen, we expressed mutant alpha 3 chains together with normal alpha 1 and alpha 2 chains in insect cells, We show here that despite the deletion, mutant alpha 3 chains were secreted as heterotrimeric, triple helical molecules consisting of three alpha chains in a 1:1:1 ratio. The results suggest that the next noncollagenous domain (NC2) is capable of correcting the alignment of the alpha chains, and this ensures the formation of an in-register triple helix.							NEI NIH HHS [EY09908] Funding Source: Medline; NIAMS NIH HHS [AR30481] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009908] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR030481, R01AR030481] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALAKOKKO L, 1995, BIOCHEM J, V308, P923, DOI 10.1042/bj3080923; Ballo R, 1997, AM J MED GENET, V68, P396, DOI 10.1002/(SICI)1096-8628(19970211)68:4<396::AID-AJMG4>3.3.CO;2-R; Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOEDTKER H, 1985, ANN NY ACAD SCI, V460, P85, DOI 10.1111/j.1749-6632.1985.tb51159.x; BREWTON RG, 1995, GENOMICS, V30, P329, DOI 10.1006/geno.1995.9870; BREWTON RG, 1992, EUR J BIOCHEM, V205, P443, DOI 10.1111/j.1432-1033.1992.tb16798.x; BREWTON RG, 1994, EXTRACELLULAR MATRIX, P129; BRIGGS MD, 1994, AM J HUM GENET, V55, P678; BRIGGS MD, 1995, NAT GENET, V10, P330, DOI 10.1038/ng0795-330; BRUCKNER P, 1985, P NATL ACAD SCI USA, V82, P2608, DOI 10.1073/pnas.82.9.2608; Cohn DH, 1996, ANN NY ACAD SCI, V785, P188, DOI 10.1111/j.1749-6632.1996.tb56258.x; DALESSIO M, 1988, GENE, V67, P105, DOI 10.1016/0378-1119(88)90013-3; DEERE M, 1995, AM J HUM GENET, V56, P698; Diab M, 1996, BIOCHEM J, V314, P327, DOI 10.1042/bj3140327; ENGEL J, 1991, ANNU REV BIOPHYS BIO, V20, P137, DOI 10.1146/annurev.biophys.20.1.137; EYRE DR, 1987, FEBS LETT, V220, P337, DOI 10.1016/0014-5793(87)80842-6; FASSLER R, 1994, P NATL ACAD SCI USA, V91, P5070, DOI 10.1073/pnas.91.11.5070; GANGULY A, 1993, P NATL ACAD SCI USA, V90, P10325, DOI 10.1073/pnas.90.21.10325; Gordon MK, 1990, CURR OPIN CELL BIOL, V2, P833, DOI 10.1016/0955-0674(90)90080-X; HAREL R, 1992, J BIOL CHEM, V267, P10070; HAWKINS JR, 1991, J BIOL CHEM, V266, P22370; Krebsbach PH, 1996, J BIOL CHEM, V271, P4298, DOI 10.1074/jbc.271.8.4298; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; Mechling DE, 1996, J BIOL CHEM, V271, P13781, DOI 10.1074/jbc.271.23.13781; Muragaki Y, 1996, NAT GENET, V12, P103, DOI 10.1038/ng0196-103; NAKATA K, 1993, P NATL ACAD SCI USA, V90, P2870, DOI 10.1073/pnas.90.7.2870; NINOMIYA Y, 1990, EXTRACELLULAR MATRIX, P79; Nokelainen M, 1998, MATRIX BIOL, V16, P329, DOI 10.1016/S0945-053X(98)90004-X; PERALA M, 1994, J BIOL CHEM, V269, P5064; Pihlajamaa T, 1999, J BIOL CHEM, V274, P22464, DOI 10.1074/jbc.274.32.22464; Pihlajamaa T, 1998, MATRIX BIOL, V17, P237, DOI 10.1016/S0945-053X(98)90063-4; REESE CA, 1981, BIOCHEMISTRY-US, V20, P5443, DOI 10.1021/bi00522a014; SPRANGER J, 1992, EUR J PEDIATR, V151, P407; TAKAHARA K, 1995, GENOMICS, V29, P588, DOI 10.1006/geno.1995.9961; TOMAN D, 1995, GENE, V147, P161; Van der Rest M, 1987, STRUCTURE FUNCTION C, P195; VANDERREST M, 1988, J BIOL CHEM, V263, P1615; VASIOS G, 1988, J BIOL CHEM, V263, P2324; VAUGHAN L, 1988, J CELL BIOL, V106, P991, DOI 10.1083/jcb.106.3.991; VUORISTO MM, 1995, J BIOL CHEM, V270, P22873, DOI 10.1074/jbc.270.39.22873; WALLIS GA, 1992, J BIOL CHEM, V267, P25529; WU JJ, 1992, J BIOL CHEM, V267, P23007	43	27	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22469	22475		10.1074/jbc.274.32.22469	http://dx.doi.org/10.1074/jbc.274.32.22469			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428822	hybrid			2022-12-25	WOS:000081868400052
J	Torres, GE; Egan, TM; Voigt, MM				Torres, GE; Egan, TM; Voigt, MM			Identification of a domain involved in ATP-gated ionotropic receptor subunit assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; ION CHANNELS; P2X(2)	P2X receptors are ATP-gated ion channels found in a variety of tissues and cell types, Seven different subunits (P2X(1)-P2X(7)) have been molecularly cloned and are known to form homomeric, and in some cases heteromeric, channel complexes. However, the molecular determinants leading to the assembly of subunits into P2X receptors are unknown. To address this question we utilized a co-immunoprecipitation assay in which epitope-tagged deletion mutants and chimeric constructs were examined for their ability to co-associate with full-length P2X subunits. Deletion mutants of the P2X, receptor subunit were expressed individually and together with P2X(2) or P2X(3) receptor subunits in HEK 293 cells. Deletion of the amino terminus up to the first transmembrane domain (amino acid 28) and beyond (to amino acid 51) did not prevent subunit assembly. Analysis of the carboxyl terminus demonstrated that mutants missing the portion of the protein downstream of the second transmembrane domain could also still coassemble. However, a mutant terminating 25 amino acids before the second transmembrane domain could not assemble with other subunits or itself, implicating the missing region of the protein in assembly. This finding was supported and extended by data utilizing a chimera strategy that indicated TMD2 is a critical determinant of P2X subunit assembly.	St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA	Saint Louis University	Voigt, MM (corresponding author), St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, 1402 S Grand Blvd, St Louis, MO 63104 USA.	voigtm@slu.edu		Egan, Terrance/0000-0002-7249-3161				Barnard EA, 1998, PHARMACOL REV, V50, P291; BARNARD EA, 1992, TRENDS BIOCHEM SCI, V17, P368, DOI 10.1016/0968-0004(92)90002-Q; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; DEVILLERSTHIERY A, 1993, J MEMBRANE BIOL, V136, P97, DOI 10.1007/BF02505755; Green WN, 1999, J GEN PHYSIOL, V113, P163, DOI 10.1085/jgp.113.2.163; Keller SH, 1999, J GEN PHYSIOL, V113, P171, DOI 10.1085/jgp.113.2.171; Kim M, 1997, BIOCHEM BIOPH RES CO, V240, P618, DOI 10.1006/bbrc.1997.7713; KREIENKAMP HJ, 1995, NEURON, V14, P635, DOI 10.1016/0896-6273(95)90320-8; Le KT, 1998, J NEUROSCI, V18, P7152; LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0; Newbolt A, 1998, J BIOL CHEM, V273, P15177, DOI 10.1074/jbc.273.24.15177; Radford KM, 1997, J NEUROSCI, V17, P6529; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; SUMIKAWA K, 1992, MOL BRAIN RES, V13, P349, DOI 10.1016/0169-328X(92)90218-Z; Torres GE, 1998, FEBS LETT, V425, P19, DOI 10.1016/S0014-5793(98)00179-3; Torres GE, 1998, MOL PHARMACOL, V54, P989, DOI 10.1124/mol.54.6.989; Torres GE, 1999, J BIOL CHEM, V274, P6653, DOI 10.1074/jbc.274.10.6653; UNWIN N, 1989, NEURON, V3, P665, DOI 10.1016/0896-6273(89)90235-3; VERRALL S, 1992, CELL, V68, P23, DOI 10.1016/0092-8674(92)90203-O; YU XM, 1991, NATURE, V352, P64, DOI 10.1038/352064a0	20	65	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22359	22365		10.1074/jbc.274.32.22359	http://dx.doi.org/10.1074/jbc.274.32.22359			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428806	hybrid			2022-12-25	WOS:000081868400036
J	Funaki, M; Katagiri, H; Kanda, A; Anai, M; Nawano, R; Ogihara, T; Inukai, K; Fukushima, Y; Ono, H; Yazaki, Y; Kikuchi, M; Oka, Y; Asano, T				Funaki, M; Katagiri, H; Kanda, A; Anai, M; Nawano, R; Ogihara, T; Inukai, K; Fukushima, Y; Ono, H; Yazaki, Y; Kikuchi, M; Oka, Y; Asano, T			p85/p110-type phosphatidylinositol kinase phosphorylates not only the D-3, but also the D-4 position of the inositol ring	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR STIMULATION; GLUCOSE-TRANSPORT; 3T3-L1 ADIPOCYTES; 3-KINASE; BINDING; CELLS; 4,5-BISPHOSPHATE; ACTIN; POLYPHOSPHOINOSITIDES; IDENTIFICATION	Activation of p85/p110-type phosphatidylinositol (PI) kinase has been implicated in various cellular activities. This PI kinase phosphorylates the D-4 position with a similar or higher efficiency than the D-3 position when trichloroacetic acid-treated cell membrane is used as a substrate, although it phosphorylates almost exclusively the D-3 position of the inositol ring in phosphoinositides when purified PI is used as a substrate. Furthermore, the lipid kinase activities of p110 for both the D-3 and D-4 positions were completely abolished by introducing kinase-dead point mutations in their lipid kinase domains (Delta Kin alpha and Delta Kin beta, respectively). In addition, both PI 3- and PI 4-kinase activities of p110 alpha and p110 beta immunoprecipitates were similarly inhibited by either wortmannin or LY294002, specific inhibitors of p110, Insulin induced phosphorylation of not only the D-3 position, but also the D-4 position. Indeed, overexpression of p110 in Sf9 or 3T3-L1 cells induced marked phosphorylation of the D-4 position to a level comparable to or much greater than that of D-3, whereas inhibition of endogenous p85/p110-type PI kinase via overexpression of dominant-negative p85 alpha (Delta p85 alpha) in 3T3-L1 adipocytes abolished insulin-induced synthesis of both. Thus, p85/p110-type PI kinase phosphorylates the D-4 position of phosphoinositides more efficiently than the D-3 position in vivo, and each of the D-3- or D-4-phosphorylated phosphoinositides may transmit signals downstream.	Univ Tokyo, Fac Med, Dept Internal Med 3, Bunkyo Ku, Tokyo 113, Japan; Asahi Life Fdn, Inst Adult Dis, Shinjuku Ku, Tokyo 160, Japan; Yamaguchi Univ, Sch Med, Dept Internal Med 3, Ube, Yamaguchi 755, Japan	University of Tokyo; Asahi Life Foundation; Yamaguchi University	Asano, T (corresponding author), Univ Tokyo, Fac Med, Dept Internal Med 3, Bunkyo Ku, 7-3-1 Hongo, Tokyo 113, Japan.	asano-tky@umin.ac.jp						AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; CARPENTER G, 1992, FASEB J, V6, P3283, DOI 10.1096/fasebj.6.14.1385243; CARPENTER G, 1992, CIBA F SYMP, V164, P223; CARTER AN, 1992, J BIOL CHEM, V267, P14563; DELVECCHIO RL, 1991, J BIOL CHEM, V266, P13278; DETOMASO AW, 1993, J BIOL CHEM, V268, P1470; FRY MJ, 1993, PHILOS T ROY SOC B, V340, P337, DOI 10.1098/rstb.1993.0076; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; He H, 1998, MOL CELL BIOL, V18, P3829, DOI 10.1128/MCB.18.7.3829; HEISS SG, 1991, BIOCHEMISTRY-US, V30, P8753, DOI 10.1021/bi00100a006; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; JACKSON TR, 1992, J BIOL CHEM, V267, P16627; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; Katagiri H, 1997, AM J PHYSIOL-ENDOC M, V272, pE326, DOI 10.1152/ajpendo.1997.272.2.E326; Katagiri H, 1996, J BIOL CHEM, V271, P16987, DOI 10.1074/jbc.271.29.16987; KAZLAUSKAS A, 1994, CURR OPIN GENET DEV, V4, P5, DOI 10.1016/0959-437X(94)90085-X; Lomasney JW, 1996, J BIOL CHEM, V271, P25316, DOI 10.1074/jbc.271.41.25316; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; Ogihara T, 1997, J BIOL CHEM, V272, P12868, DOI 10.1074/jbc.272.19.12868; OKADA T, 1994, J BIOL CHEM, V269, P3568; Pawson T, 1994, Princess Takamatsu Symp, V24, P303; Rameh LE, 1997, NATURE, V390, P192, DOI 10.1038/36621; RODRIGUEZ VP, 1994, NATURE, V370, P527; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WAHL MI, 1992, J BIOL CHEM, V267, P10447; Wiedemann C, 1996, EMBO J, V15, P2094, DOI 10.1002/j.1460-2075.1996.tb00563.x	34	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					22019	22024		10.1074/jbc.274.31.22019	http://dx.doi.org/10.1074/jbc.274.31.22019			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419527	hybrid			2022-12-25	WOS:000081721100080
J	Gille, H; Downward, J				Gille, H; Downward, J			Multiple Ras effector pathways contribute to G(1) cell cycle progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; NIH 3T3 CELLS; REQUIRES PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; PHOSPHOINOSITIDE 3-KINASE; RESTRICTION POINT; ONCOGENIC RAS; GENE-PRODUCT; GROWTH; D1	The involvement of Pas in the activation of multiple early signaling pathways is well understood, but it is less clear how the various Pas effecters interact with the cell cycle machinery to cause G(1) progression. Ras-mediated activation of extracellular-regulated kinase/ mitogen-activated protein kinase has been implicated in cyclin D-1 up-regulation, but there is little extracellular-regulated kinase activity during the later stages of G(1), when cyclin D-1 expression becomes maximal, implying that other effector pathways may also be important in cyclin D-1 induction. We have addressed the involvement of Pas effecters from the phosphatidylinositol (PI) 3-kinase and Ral-GDS families in G(1) progression and compared it to that of the Raf/mitogen-activated protein kinase pathway. PI 3-kinase activity is required for the expression of endogenous cyclin D-1 and for S phase entry following serum stimulation of quiescent NM 3T3 fibroblasts, Activated PIS-kinase induces cyclin D-1 transcription and E2F activity, at least in part mediated by the serine/threonine kinase Akt/PKB, and to a lesser extent the Rho family GTPase Pac. In addition, both activated Ral-GDS-like factor and Raf stimulate cyclin D-1 transcription and E2F activity and act in synergy with PI 3-kinase. Therefore, multiple cooperating pathways mediate the effects of Pas on progression through the cell cycle.	Imperial Canc Res Fund, London WC2A 3PX, England	Cancer Research UK	Downward, J (corresponding author), Imperial Canc Res Fund, 44 Lincolns Inn Fields, London WC2A 3PX, England.			Downward, Julian/0000-0002-2331-4729				Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CHEN GM, 1998, P NATL ACAD SCI USA, V95, P1091; DEVRIESSMITS AMM, 1995, ONCOGENE, V10, P919; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DOBROWOLSKI S, 1994, MOL CELL BIOL, V14, P5441, DOI 10.1128/MCB.14.8.5441; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; Downward J, 1997, CURR BIOL, V7, P258; DUFOURNY E, 1997, J BIOL CHEM, V272, P31163; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FILMUS J, 1994, ONCOGENE, V9, P3627; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HERBER B, 1994, ONCOGENE, V9, P1295; Herman PK, 1997, EMBO J, V16, P6171, DOI 10.1093/emboj/16.20.6171; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MURTHY SCS, 1985, P NATL ACAD SCI USA, V82, P2230, DOI 10.1073/pnas.82.8.2230; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; PLEDGER WJ, 1978, P NATL ACAD SCI USA, V75, P2839, DOI 10.1073/pnas.75.6.2839; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Weber JD, 1997, J BIOL CHEM, V272, P32966, DOI 10.1074/jbc.272.52.32966; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Winston JT, 1996, ONCOGENE, V12, P127; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Yang JJ, 1998, MOL CELL BIOL, V18, P2586, DOI 10.1128/MCB.18.5.2586; Yao R, 1996, ONCOGENE, V13, P343	56	354	358	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					22033	22040		10.1074/jbc.274.31.22033	http://dx.doi.org/10.1074/jbc.274.31.22033			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419529				2022-12-25	WOS:000081721100082
J	Lowenthal, A; Levy, R				Lowenthal, A; Levy, R			Essential requirement of cytosolic phospholipase A(2) for activation of the H+ channel in phagocyte-like cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; CYTOPLASMIC PH REGULATION; NEUTROPHIL NADPH OXIDASE; NA+/H+ ANTIPORT; PLASMA-MEMBRANE; RESPIRATORY BURST; HL-60 CELLS; SUPEROXIDE GENERATION; INTERNAL PH; CONDUCTANCE	The NADPH oxidase-producing superoxide is the major mechanism by which phagocytes kill invading pathogens. We previously established a model of cytosolic phospholipase A(2) (cPLA(2))-deficient differentiated PLB-985 cells (PLB-D cells) and demonstrated that cPLA(2)-generated arachidonic acid (AA) is essential for NADPH oxidase activation (Dana, R., Leto, T., Malech, H., and Levy, R. (1998) J. Biol. Chem. 273, 441-445). In the present study, we used this model to determine the physiological role of cPLA(2) in the regulation of both the HC channel and the Na+/H+ antiporter and to study whether NADPH oxidase activation is regulated by either of these transporters. PLB-D cells and two controls: parent PLB-985 cells and PLB-985 cells transfected with the vector only (PLB cells) were differentiated using 1.25% Me2SO or 5 x 10(-8) M 1,25-dihydroxyvitamin D-3. Activation of differentiated PLB cells resulted in a Zn2+- sensitive alkalization, indicating H+ channel activity. In contrast, differentiated PLB-D cells failed to activate the H+ channel, but the addition of exogenous AA fully restored this activity, indicating the role of cPLA(2) in H+ channel activation. The presence of the H+ channel inhibitor Zn2+ caused significant inhibition of NADPH oxidase activity, suggesting a role of the H+ channel in regulating oxidase activity. Na+/H+ antiporter activity was stimulated in differentiated PLB-D cells, indicating that cPLA(2) does not participate in the regulation of this antiporter, These results establish an essential and specific physiological requirement of cPLA(2)-generated AA for activation of the H+ channel and suggest the participation of this channel in the regulation of NADPH oxidase activity.	Ben Gurion Univ Negev, Fac Hlth Sci, Dept Clin Biochem, Infect Dis Lab, IL-84105 Beer Sheva, Israel; Soroka Med Ctr, IL-84105 Beer Sheva, Israel	Ben Gurion University; Ben Gurion University; Soroka Medical Center	Levy, R (corresponding author), Ben Gurion Univ Negev, Fac Hlth Sci, Dept Clin Biochem, Infect Dis Lab, IL-84105 Beer Sheva, Israel.							ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BORON WF, 1983, J MEMBRANE BIOL, V72, P1, DOI 10.1007/BF01870311; Dana R, 1998, J BIOL CHEM, V273, P441, DOI 10.1074/jbc.273.1.441; DECOURSEY TE, 1994, J MEMBRANE BIOL, V141, P203; ENGLISH D, 1974, J IMMUNOL METHODS, V5, P249, DOI 10.1016/0022-1759(74)90109-4; Fukushima T, 1996, J CELL BIOL, V132, P1037, DOI 10.1083/jcb.132.6.1037; Gewirtz AT, 1998, J LEUKOCYTE BIOL, V64, P98, DOI 10.1002/jlb.64.1.98; GRINSTEIN S, 1984, J GEN PHYSIOL, V83, P341, DOI 10.1085/jgp.83.3.341; GRINSTEIN S, 1986, BIOCHEM BIOPH RES CO, V134, P8, DOI 10.1016/0006-291X(86)90519-X; GRINSTEIN S, 1986, J BIOL CHEM, V261, P512; GRINSTEIN S, 1986, AM J PHYSIOL, V251, pC55, DOI 10.1152/ajpcell.1986.251.1.C55; GRINSTEIN S, 1985, AM J PHYSIOL, V248, pC379, DOI 10.1152/ajpcell.1985.248.3.C379; GRINSTEIN S, 1986, AM J PHYSIOL, V250, P283; HAZAV P, 1989, CANCER RES, V49, P72; HENDERSON LM, 1987, BIOCHEM J, V246, P325, DOI 10.1042/bj2460325; HENDERSON LM, 1992, BIOCHEM J, V283, P171, DOI 10.1042/bj2830171; HENDERSON LM, 1988, BIOCHEM J, V255, P285; HENDERSON LM, 1988, BIOCHEM J, V251, P563, DOI 10.1042/bj2510563; HENDERSON LM, 1995, J BIOL CHEM, V270, P5909, DOI 10.1074/jbc.270.11.5909; Henderson LM, 1998, J BIOL CHEM, V273, P33216, DOI 10.1074/jbc.273.50.33216; Henderson LM, 1997, BIOCHEM J, V325, P701, DOI 10.1042/bj3250701; KAPUS A, 1994, J BIOL CHEM, V269, P4736; KAPUS A, 1992, BIOCHEM J, V281, P697, DOI 10.1042/bj2810697; KAPUS A, 1993, BIOCHEM J, V292, P445, DOI 10.1042/bj2920445; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KWONG CH, 1993, BIOCHEMISTRY-US, V32, P5711, DOI 10.1021/bi00072a029; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LEVY R, 1990, J IMMUNOL, V145, P2595; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; LUKACS GL, 1993, AM J PHYSIOL, V265, pC3, DOI 10.1152/ajpcell.1993.265.1.C3; MURPHY JK, 1993, AM J PHYSIOL, V264, pL523, DOI 10.1152/ajplung.1993.264.5.L523; NANDA A, 1993, P NATL ACAD SCI USA, V90, P760, DOI 10.1073/pnas.90.2.760; Nanda A, 1996, J BIOL CHEM, V271, P15963, DOI 10.1074/jbc.271.27.15963; NANDA A, 1991, P NATL ACAD SCI USA, V88, P10816, DOI 10.1073/pnas.88.23.10816; NANDA A, 1991, Cellular Physiology and Biochemistry, V1, P65, DOI 10.1159/000154595; NUNOI H, 1988, SCIENCE, V242, P1298, DOI 10.1126/science.2848319; ODONNELL VB, 1993, BIOCHEM J, V290, P41, DOI 10.1042/bj2900041; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; QU AY, 1994, AM J PHYSIOL, V266, pC1263, DOI 10.1152/ajpcell.1994.266.5.C1263; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; Susztak K, 1997, BIOCHEM J, V325, P501, DOI 10.1042/bj3250501; SWALLOW CJ, 1993, J CELL PHYSIOL, V157, P453, DOI 10.1002/jcp.1041570304; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318	44	52	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21603	21608		10.1074/jbc.274.31.21603	http://dx.doi.org/10.1074/jbc.274.31.21603			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419467	hybrid			2022-12-25	WOS:000081721100020
J	Nicke, B; Detjen, K; Logsdon, CD				Nicke, B; Detjen, K; Logsdon, CD			Muscarinic cholinergic receptors activate both inhibitory and stimulatory growth mechanisms in NIH3T3 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; INTESTINAL EPITHELIAL-CELLS; CYCLIN-DEPENDENT KINASES; 3T3 CELLS; ACETYLCHOLINE-RECEPTORS; RETINOBLASTOMA PROTEIN; DOWN-REGULATION; D1 EXPRESSION; P21; PROLIFERATION	Activation of G(q) protein-coupled receptors can either stimulate or inhibit cell growth. Previously, these opposite effects were explained by differences in the cell models. Here we show that activation of m3 muscarinic acetylcholine receptors ectopically expressed in NIH3T3 cells can cause stimulation and inhibition of growth in the same cell. A clonal cell line was selected from cells that formed foci agonist dependently (3T3/m3 cells). In quiescent 3T3/m3 cells, carbachol stimulated DNA synthesis. In contrast, when 3T3/m3 cells were growing, either due to the presence of serum or after transformation with oncogenic v-src, carbachol inhibited growth. This inhibition was not due to reduction of extracellular signal-regulated kinase activity because carbachol induced extracellular signal-regulated kinase phosphorylation in both quiescent and growing 3T3/m3 cells, Investigating the cell cycle mechanisms involved in grow th inhibition, we found that carbachol treatment decreased cyclin D1 levels, increased p21(cip1) expression, and led to hypophosphorylation of the retinoblastoma gene product (Rb), Proteasome inhibitors blocked the carbachol-induced degradation of cyclin D1, Effects on p21(cip1) were blocked by a protein kinase C inhibitor. Thus, m3 muscarinic acetylcholine receptors couple to both growth-stimulatory and -inhibitory signaling pathways in NIH3T3 cells, and the observed effects of receptor activation depend on the context of cellular growth.	Univ Michigan, Dept Physiol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Logsdon, CD (corresponding author), Univ Michigan, Dept Physiol, Box 0622,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.				NIDDK NIH HHS [DK34933, DK41225] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041225, P30DK034933] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Detjen K, 1997, GASTROENTEROLOGY, V112, P952, DOI 10.1053/gast.1997.v112.pm9041258; DETJEN K, 1995, P NATL ACAD SCI USA, V92, P10929, DOI 10.1073/pnas.92.24.10929; DEVIVO M, 1994, J BIOL CHEM, V269, P19671; Dhanasekaran N, 1998, ONCOGENE, V17, P1383, DOI 10.1038/sj.onc.1202242; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; FELDER CC, 1993, P NATL ACAD SCI USA, V90, P1706, DOI 10.1073/pnas.90.5.1706; FELDER CC, 1995, FASEB J, V9, P619, DOI 10.1096/fasebj.9.8.7768353; Frey MR, 1997, J BIOL CHEM, V272, P9424; GUTKIND JS, 1992, BIOCHEM BIOPH RES CO, V188, P155; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HARPER JW, 1993, CELL, V75, P805; Hashemolhosseini S, 1998, J BIOL CHEM, V273, P14424, DOI 10.1074/jbc.273.23.14424; Hiyama H, 1997, ONCOGENE, V14, P2533, DOI 10.1038/sj.onc.1201080; JACKSON TR, 1988, NATURE, V335, P437, DOI 10.1038/335437a0; KAHAN C, 1992, EXP CELL RES, V200, P523, DOI 10.1016/0014-4827(92)90204-L; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; Ko TC, 1998, ONCOGENE, V16, P3445, DOI 10.1038/sj.onc.1201902; LAllemain G, 1997, ONCOGENE, V14, P1981, DOI 10.1038/sj.onc.1201038; Li R, 1996, CURR BIOL, V6, P189, DOI 10.1016/S0960-9822(02)00452-9; Livneh E, 1997, EUR J BIOCHEM, V248, P1, DOI 10.1111/j.1432-1033.1997.t01-4-00001.x; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; STEPHENS EV, 1993, ONCOGENE, V8, P19; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; WU DQ, 1992, J BIOL CHEM, V267, P1811; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; XU NZ, 1994, ONCOGENE, V9, P597; YAMAMOTO T, 1988, J BIOCHEM-TOKYO, V104, P53, DOI 10.1093/oxfordjournals.jbchem.a122422; YANG J, 1993, MOL PHARMACOL, V44, P1158; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	38	33	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21701	21706		10.1074/jbc.274.31.21701	http://dx.doi.org/10.1074/jbc.274.31.21701			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419481	hybrid			2022-12-25	WOS:000081721100034
J	Pampori, N; Hato, T; Stupack, DG; Aidoudi, S; Cheresh, DA; Nemerow, GR; Shattil, SJ				Pampori, N; Hato, T; Stupack, DG; Aidoudi, S; Cheresh, DA; Nemerow, GR; Shattil, SJ			Mechanisms and consequences of affinity modulation of integrin alpha(v)beta(3) detected with a novel patch-engineered monovalent ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTION-ASSOCIATED ANTIGEN-1; OUT SIGNAL-TRANSDUCTION; GLYCOPROTEIN-IIB-IIIA; CELL-ADHESION; ALPHA-V-BETA-3 INTEGRIN; CYTOPLASMIC TAIL; VITRONECTIN RECEPTOR; VONWILLEBRAND-FACTOR; ENDOTHELIAL-CELLS; BETA-3 SUBUNIT	Integrin alpha(v)beta(3) mediates diverse responses in vascular cells, ranging from cell adhesion, migration, and proliferation to uptake of adenoviruses. However, the extent to which alpha(v)beta(3) is regulated by changes in receptor conformation (affinity), receptor diffusion/clustering (avidity), or post-receptor events is unknown. Affinity regulation of the related integrin, alpha(IIb)beta(3), has been established using a monovalent ligand-mimetic antibody, PAC1 Fab. To determine the role of affinity modulation of alpha(v)beta(3), a novel monovalent ligand-mimetic antibody (WOW-1) was created by replacing the heavy chain hypervariable region 3 of PAC1 Fab with a single alpha(v) integrin binding domain from multivalent adenovirus penton base. Both WOW-1 Fab and penton base bound selectively to activated alpha(v)beta(3), but not to alpha(IIb)beta(3), in receptor and cell binding assays. alpha(v)beta(3) affinity varied with the cell type. Unstimulated B-lymphoblastoid cells bound WORT-1 Fab poorly (apparent K-d = 2.4 mu M), but acute stimulation with phorbol 12-myristate 13-acetate increased receptor affinity >30-fold (K-d = 80 nM), With no change in receptor number. In contrast, alpha(v)beta(3) in melanoma cells was constitutively active, but ligand binding could be suppressed by overexpression of beta(3) cytoplasmic tails. Up-regulation of alpha(v)beta(3) affinity had functional consequences in that it increased cell adhesion and spreading and promoted adenovirus-mediated gene transfer. These studies establish that alpha(v)beta(3) is subject to rapid regulated changes in affinity that influence the biological functions of this integrin.	Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute	Shattil, SJ (corresponding author), Scripps Res Inst, Dept Vasc Biol, 10550 N Torrey Pines Rd,VB-5, La Jolla, CA 92037 USA.	shattil@scripps.Edu	Hato, Takaaki/AAH-8356-2021		NATIONAL EYE INSTITUTE [R01EY011431] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056595, P01HL048728] Funding Source: NIH RePORTER; NEI NIH HHS [EY11431] Funding Source: Medline; NHLBI NIH HHS [HL48728, HL56595] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMS C, 1994, J BIOL CHEM, V269, P18781; Aplin AE, 1998, PHARMACOL REV, V50, P197; Bazzoni G, 1998, TRENDS BIOCHEM SCI, V23, P30, DOI 10.1016/S0968-0004(97)01141-9; Bennett JS, 1997, J BIOL CHEM, V272, P8137, DOI 10.1074/jbc.272.13.8137; Bilato C, 1997, J CLIN INVEST, V100, P693, DOI 10.1172/JCI119582; Blystone SD, 1997, J BIOL CHEM, V272, P28757, DOI 10.1074/jbc.272.45.28757; BLYSTONE SD, 1994, J CELL BIOL, V127, P1129, DOI 10.1083/jcb.127.4.1129; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Brown E, 1996, IMMUNOL LETT, V54, P189, DOI 10.1016/S0165-2478(96)02671-5; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Byzova TV, 1998, THROMB HAEMOSTASIS, V80, P726; Byzova TV, 1997, J BIOL CHEM, V272, P27183, DOI 10.1074/jbc.272.43.27183; Byzova TV, 1998, J CELL BIOL, V143, P2081, DOI 10.1083/jcb.143.7.2081; Chellaiah M, 1996, ENDOCRINOLOGY, V137, P2432, DOI 10.1210/en.137.6.2432; CHEN YP, 1994, J BIOL CHEM, V269, P18307; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; COLLER BS, 1991, BLOOD, V77, P75; DIAMOND MS, 1994, CURR BIOL, V4, P506, DOI 10.1016/S0960-9822(00)00111-1; Dustin ML, 1998, CELL ADHES COMMUN, V6, P255, DOI 10.3109/15419069809004481; ENGLEMAN VW, 1987, J CLIN INVEST, V99, P2284; FILARDO EJ, 1995, J CELL BIOL, V130, P441, DOI 10.1083/jcb.130.2.441; Habermann BF, 1993, CURR OPIN CELL BIOL, V5, P864, DOI 10.1016/0955-0674(93)90036-P; Hato T, 1998, J CELL BIOL, V141, P1685, DOI 10.1083/jcb.141.7.1685; HELMER ME, 1998, CURR OPIN CELL BIOL, V10, P578; HU DD, 1995, J BIOL CHEM, V270, P9917, DOI 10.1074/jbc.270.17.9917; Huang S, 1997, P NATL ACAD SCI USA, V94, P8156, DOI 10.1073/pnas.94.15.8156; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 1996, DEV BIOL, V180, P402, DOI 10.1006/dbio.1996.0314; Kashiwagi H, 1997, J CELL BIOL, V137, P1433, DOI 10.1083/jcb.137.6.1433; Kucik DF, 1996, J CLIN INVEST, V97, P2139, DOI 10.1172/JCI118651; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; Leon RP, 1998, P NATL ACAD SCI USA, V95, P13159, DOI 10.1073/pnas.95.22.13159; Lin ECK, 1997, J BIOL CHEM, V272, P23912, DOI 10.1074/jbc.272.38.23912; LINDBERG FP, 1993, J CELL BIOL, V123, P485, DOI 10.1083/jcb.123.2.485; MATHIAS P, 1994, J VIROL, V68, P6811, DOI 10.1128/JVI.68.10.6811-6814.1994; Mehta RJ, 1998, BIOCHEM J, V330, P861; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; Neri D, 1996, TRENDS BIOTECHNOL, V14, P465, DOI 10.1016/S0167-7799(96)10067-6; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PELLETIER AJ, 1995, J BIOL CHEM, V270, P18133, DOI 10.1074/jbc.270.30.18133; Porter JC, 1998, TRENDS CELL BIOL, V8, P390, DOI 10.1016/S0962-8924(98)01344-0; Qi WW, 1998, J BIOL CHEM, V273, P15271, DOI 10.1074/jbc.273.24.15271; Reddy KB, 1998, J BIOL CHEM, V273, P35039, DOI 10.1074/jbc.273.52.35039; ROTHLEIN R, 1986, J EXP MED, V163, P1132, DOI 10.1084/jem.163.5.1132; Ruegg C, 1998, NAT MED, V4, P408, DOI 10.1038/nm0498-408; Sadhu C, 1998, J IMMUNOL, V160, P5622; Sampath R, 1998, J BIOL CHEM, V273, P33588, DOI 10.1074/jbc.273.50.33588; SAVAGE B, 1992, J BIOL CHEM, V267, P11300; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1066; Scatena M, 1998, J CELL BIOL, V141, P1083, DOI 10.1083/jcb.141.4.1083; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Schwartz SM, 1997, J CLIN INVEST, V99, P2814, DOI 10.1172/JCI119472; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; SHATTIL SJ, 1987, BLOOD, V70, P307; Smith G, 1998, TRENDS BIOCHEM SCI, V23, P457, DOI 10.1016/S0968-0004(98)01323-1; Stewart PL, 1997, EMBO J, V16, P1189, DOI 10.1093/emboj/16.6.1189; Stromblad S, 1996, TRENDS CELL BIOL, V6, P462, DOI 10.1016/0962-8924(96)84942-7; STUPACK DG, 1992, EXP CELL RES, V203, P443, DOI 10.1016/0014-4827(92)90019-5; SWERLICK RA, 1992, J INVEST DERMATOL, V99, P715, DOI 10.1111/1523-1747.ep12614207; vanKooyk Y, 1997, BIOCHEM SOC T, V25, P515, DOI 10.1042/bst0250515; Weerasinghe D, 1998, J CELL BIOL, V142, P595, DOI 10.1083/jcb.142.2.595; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Wickham TJ, 1995, GENE THER, V2, P750; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; Yauch RL, 1997, J EXP MED, V186, P1347, DOI 10.1084/jem.186.8.1347; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; Zhong CL, 1998, J CELL BIOL, V141, P539, DOI 10.1083/jcb.141.2.539	74	143	145	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21609	21616		10.1074/jbc.274.31.21609	http://dx.doi.org/10.1074/jbc.274.31.21609			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419468	hybrid			2022-12-25	WOS:000081721100021
J	Park, BC; Lee, YC; Strott, CA				Park, BC; Lee, YC; Strott, CA			Identification by chimera formation and site-selected mutagenesis of a key amino acid residue involved in determining stereospecificity of guinea pig 3-hydroxysteroid sulfotransferase isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; 3-ALPHA-HYDROXYSTEROID SULFOTRANSFERASE; STEROID SULFOTRANSFERASES; ESTROGEN SULFOTRANSFERASE; EXPRESSION; DISTINCT; PROTEIN; BINDING	The 3-hydroxysteroid sulfotransferases that have been isolated and cloned from humans and rodents ap pear to have broad substrate specificities. In the guinea pig, however, two 3-hydroxysteroid sulfotransferases have been isolated that function according to an innate stereospecificity: the alpha-isoform acts on steroids with a 3-hydroxyl group oriented in the alpha position, whereas the beta-isoform acts on steroids where the 3-hydroxyl group is in a beta orientation. To examine the structural basis for this remarkable stereoselectivity, chimeras of the two enzymes, which are 87% identical, were constructed. A chimera consisting of the NH2-terminal 91 amino acids of the alpha-isoform and the COOH-terminal 196 amino acids of the beta-isoform displayed activity similar to that of the alpha-isoform. Site-selected mutagenesis of this 3 alpha/beta hydroxysteroid sulfotransferase chimera involving the 12 amino acid differences that exist between the two isoforms within the 91 amino acid NH2-terminal region revealed that the amino acid residue at position 51 plays a fundamental role in determining the stereospecificity exhibited by the alpha- and beta-isoforms, i.e. if residue 51 is an asparagine, alpha activity predominates, whereas if an isoleucine is in that position, beta activity prevails.	NICHD, Sect Steriod Regulat, Endocrinol & Reprod Res Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Strott, CA (corresponding author), NICHD, Sect Steriod Regulat, Endocrinol & Reprod Res Branch, NIH, Bldg 10,Rm 6A36, Bethesda, MD 20892 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000194] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bernstein S., 1970, CHEM BIOL ASPECTS ST; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DRISCOLL WJ, 1993, J BIOL CHEM, V268, P23496; HOBKIRK R, 1985, CAN J BIOCHEM CELL B, V63, P1127, DOI 10.1139/o85-141; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; LEE YC, 1994, J BIOL CHEM, V269, P15838; LEE YC, 1990, P NATL ACAD SCI USA, V87, P2003, DOI 10.1073/pnas.87.5.2003; Luu NX, 1995, BIOCHEM BIOPH RES CO, V217, P1078, DOI 10.1006/bbrc.1995.2879; OEDA T, 1992, MOL ENDOCRINOL, V6, P1216, DOI 10.1210/me.6.8.1216; PARK BC, 1999, IN PRESS STEROIDS, V64; Roy AB, 1970, BIOCH INORGANIC COMP; Strott CA, 1996, ENDOCR REV, V17, P670, DOI 10.1210/er.17.6.670	12	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21562	21568		10.1074/jbc.274.31.21562	http://dx.doi.org/10.1074/jbc.274.31.21562			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419461	hybrid			2022-12-25	WOS:000081721100014
J	Voskoboinik, N; Strausak, D; Greenough, M; Brooks, H; Petris, M; Smith, S; Mercer, JF; Camakaris, J				Voskoboinik, N; Strausak, D; Greenough, M; Brooks, H; Petris, M; Smith, S; Mercer, JF; Camakaris, J			Functional analysis of the N-terminal CXXC metal-binding motifs in the human menkes copper-transporting p-type ATPase expressed in cultured mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; DISEASE PROTEIN; CANDIDATE GENE; INTRACELLULAR-LOCALIZATION; EFFLUX; RESISTANCE; MECHANISM; MEMBRANE; ENCODES; DOMAINS	The Menkes protein (MNK) is a copper-transporting P-type ATPase, which has six highly conserved metal-binding sites, GMTCXXC, at the N terminus. The metal-binding sites may be involved in MNK trafficking and/or copper-translocating activity. In this study, we report the detailed functional analysis in mammalian cells of recombinant human MNK and its mutants with various metal-binding sites altered by site-directed mutagenesis. The results of the study, both in vitro and in vivo, provide evidence that the metal-binding sites of MNK are not essential for the ATP-dependent copper-translocating activity of MNK. Moreover, metal-binding site mutations, which resulted in a loss of ability of MNK to traffick to the plasma membrane, produced a copper hyperaccumulating phenotype, Using an in vitro vesicle assay, we demonstrated that the apparent K-m and V-max values for the wild type MNK and its mutants were not significantly different. The results of this study suggest that copper-translocating activity of MNK and its copper-induced relocalization to the plasma membrane represent a well coordinated copper homeostasis system. It is proposed that mutations in MNK which alter either its catalytic activity or/and ability to traffick can be the cause of Menkes disease.	Univ Melbourne, Dept Genet, Parkville, Vic 3052, Australia; Deakin Univ, Sch Biol & Chem Sci, Ctr Cellular & Mol Biol, Burwood, Vic 3125, Australia; Australian Nucl Sci & Technol Org, Lucas Hts Res Labs, Radiopharmaceut Div, Lucas Hts, NSW 2234, Australia	University of Melbourne; Deakin University; Australian Nuclear Science & Technology Organisation	Camakaris, J (corresponding author), Univ Melbourne, Dept Genet, Parkville, Vic 3052, Australia.		Greenough, Mark/AAK-1615-2021; Mercer, Julian/R-8583-2019	Voskoboinik, Ilia/0000-0002-6410-009X; Greenough, Mark/0000-0001-6767-0584				[Anonymous], 1995, METABOLIC BASIS INHE; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMAKARIS J, 1995, HUM MOL GENET, V4, P2117, DOI 10.1093/hmg/4.11.2117; CHELLY J, 1993, NAT GENET, V3, P14, DOI 10.1038/ng0193-14; Dierick HA, 1997, HUM MOL GENET, V6, P409, DOI 10.1093/hmg/6.3.409; Iida M, 1998, FEBS LETT, V428, P281, DOI 10.1016/S0014-5793(98)00546-8; Kachur AV, 1997, RADIAT RES, V147, P409, DOI 10.2307/3579496; Koch KA, 1997, CHEM BIOL, V4, P549, DOI 10.1016/S1074-5521(97)90241-6; KONINGS WN, 1996, TRNASPORT PROCESSES, P3; La Fontaine S, 1998, HUM MOL GENET, V7, P1293, DOI 10.1093/hmg/7.8.1293; Lutsenko S, 1997, J BIOL CHEM, V272, P18939, DOI 10.1074/jbc.272.30.18939; MERCER JFB, 1993, NAT GENET, V3, P20, DOI 10.1038/ng0193-20; MERCER JFB, 1997, METAL IONS GENE REGU, P250; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; NUCIFORA G, 1989, P NATL ACAD SCI USA, V86, P3544, DOI 10.1073/pnas.86.10.3544; Payne AS, 1998, J BIOL CHEM, V273, P3765, DOI 10.1074/jbc.273.6.3765; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; PIPER RC, 1991, AM J PHYSIOL, V260, P570; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Sambongi Y, 1997, J BIOCHEM-TOKYO, V121, P1169, DOI 10.1093/oxfordjournals.jbchem.a021711; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SOLIOZ M, 1994, FEBS LETT, V346, P44, DOI 10.1016/0014-5793(94)00316-5; Strausak D, 1999, J BIOL CHEM, V274, P11170, DOI 10.1074/jbc.274.16.11170; Voskoboinik I, 1998, FEBS LETT, V435, P178, DOI 10.1016/S0014-5793(98)01059-X; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; VULPE C, 1997, COOPER ZINC RECEPTOR, P35; Yamaguchi Y, 1996, P NATL ACAD SCI USA, V93, P14030, DOI 10.1073/pnas.93.24.14030	27	101	102	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					22008	22012		10.1074/jbc.274.31.22008	http://dx.doi.org/10.1074/jbc.274.31.22008			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419525	hybrid			2022-12-25	WOS:000081721100078
J	Kannenberg, K; Schaerer, MT; Fuchs, K; Sieghart, W; Sigel, E				Kannenberg, K; Schaerer, MT; Fuchs, K; Sieghart, W; Sigel, E			A novel serine kinase with specificity for beta 3-subunits is tightly associated with GABA(A) receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; A RECEPTOR; PHOSPHORYLATION SITES; BENZODIAZEPINE RECEPTOR; INTRACELLULAR DOMAINS; FUNCTIONAL EXPRESSION; C PHOSPHORYLATION; RAT HIPPOCAMPUS; SUBUNITS; CAMP	Tuning of gamma-aminobutyric acid type A (GABA(A)) receptor function via phosphorylation of the receptor potentially allows neurons to modulate their inhibitory input. Several kinases, both of the serine-threonine kinase and the tyrosine kinase families, have been proposed as candidates for such a modulatory role in vivo. However, no GABA(A) receptor-phospholylating kinase physically associated with the receptor has been identified so far on a molecular level. In this study, we demonstrate a GABA(A) receptor-associated protein serine kinase phosphorylating specifically beta 3-subunits of native GABA(A) receptors. The characteristics of this novel kinase clearly distinguish it from enzymatic activities that have been shown so far to phosphorylate the GABA(A) receptor. We putatively identify this protein kinase as the previously described GTAP34 (GABA(A) receptor-tubulin complex-associated protein of molecular mass 34 kDa). Using expressed recombinant fusion proteins, we identify serine 408 as a major target of the phosphorylation reaction, whereas serine 407 is not phosphorylated. This demonstrates the high specificity of the kinase. Phosphorylation of serine 408 is known to result in a decreased receptor function. The direct association of this kinase with the receptor indicates an important physiological role.	Univ Bern, Dept Pharmacol, CH-3010 Bern, Switzerland; Univ Vienna, Psychiat Clin, Sect Biochem Psychiat, A-1090 Vienna, Austria	University of Bern; University of Vienna	Sigel, E (corresponding author), Univ Bern, Dept Pharmacol, Friedbuhlstr 49, CH-3010 Bern, Switzerland.	Erwin.Sigel@pki.unibe.ch	Sigel, Erwin/F-7736-2015; Sieghart, Werner/A-4877-2013	Sieghart, Werner/0000-0002-0443-0302				BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Brussaard AB, 1997, NEURON, V19, P1103, DOI 10.1016/S0896-6273(00)80401-8; BUREAU MH, 1995, J BIOL CHEM, V270, P26482, DOI 10.1074/jbc.270.44.26482; Connolly CN, 1996, P NATL ACAD SCI USA, V93, P9899, DOI 10.1073/pnas.93.18.9899; Essrich C, 1998, NAT NEUROSCI, V1, P563, DOI 10.1038/2798; EWERT M, 1990, J CELL BIOL, V110, P2043, DOI 10.1083/jcb.110.6.2043; HARDIE G, 1995, PROTEINKINASE FACTSB; HARING P, 1985, P NATL ACAD SCI USA, V82, P4837, DOI 10.1073/pnas.82.14.4837; HEUSCHNEIDER G, 1989, P NATL ACAD SCI USA, V86, P2938, DOI 10.1073/pnas.86.8.2938; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; Jechlinger M, 1998, J NEUROSCI, V18, P2449; Kannenberg K, 1997, J NEUROCHEM, V68, P1352; Kapur J, 1996, J NEUROPHYSIOL, V76, P2626, DOI 10.1152/jn.1996.76.4.2626; KELLENBERGER S, 1992, J BIOL CHEM, V267, P25660; KRISHEK BJ, 1994, NEURON, V12, P1081, DOI 10.1016/0896-6273(94)90316-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leidenheimer NJ, 1996, MOL BRAIN RES, V42, P131, DOI 10.1016/S0169-328X(96)00153-2; Lin YF, 1996, MOL PHARMACOL, V50, P185; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; MCDONALD BJ, 1994, J BIOL CHEM, V269, P18111; McDonald BJ, 1998, NAT NEUROSCI, V1, P23, DOI 10.1038/223; McKernan RM, 1996, TRENDS NEUROSCI, V19, P139, DOI 10.1016/S0166-2236(96)80023-3; McLean HA, 1996, J PHYSIOL-LONDON, V496, P471, DOI 10.1113/jphysiol.1996.sp021699; MICHELSON HB, 1991, SCIENCE, V253, P1420, DOI 10.1126/science.1654594; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MOSS SJ, 1995, NATURE, V377, P344, DOI 10.1038/377344a0; MOSS SJ, 1992, J BIOL CHEM, V267, P14470; MOSS SJ, 1992, SCIENCE, V257, P661, DOI 10.1126/science.1323140; MOSSIER B, 1994, J BIOL CHEM, V269, P25777; NAYEEM N, 1994, J NEUROCHEM, V62, P815; PORTER NM, 1990, NEURON, V5, P789, DOI 10.1016/0896-6273(90)90338-G; RABOW LE, 1995, SYNAPSE, V21, P189, DOI 10.1002/syn.890210302; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SHIVERS BD, 1989, NEURON, V3, P327, DOI 10.1016/0896-6273(89)90257-2; SIEGHART W, 1995, PHARMACOL REV, V47, P181; SIGEL E, 1988, P NATL ACAD SCI USA, V85, P6192, DOI 10.1073/pnas.85.16.6192; SIGEL E, 1991, FEBS LETT, V291, P150, DOI 10.1016/0014-5793(91)81124-Q; SIGEL E, 1983, J BIOL CHEM, V258, P6965; Sigel E, 1997, TRENDS PHARMACOL SCI, V18, P425, DOI 10.1016/S0165-6147(97)90675-1; SLANY A, 1995, MOL PHARMACOL, V48, P385; Smart TG, 1997, CURR OPIN NEUROBIOL, V7, P358, DOI 10.1016/S0959-4388(97)80063-3; Sperk G, 1997, NEUROSCIENCE, V80, P987, DOI 10.1016/S0306-4522(97)00146-2; SWEETNAM PM, 1988, J NEUROCHEM, V51, P1274, DOI 10.1111/j.1471-4159.1988.tb03097.x; TEHRANI MHJ, 1989, SYNAPSE, V4, P126, DOI 10.1002/syn.890040206; Todd AJ, 1996, J NEUROSCI, V16, P974; Tretter V, 1997, J NEUROSCI, V17, P2728; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; VALENZUELA CF, 1995, MOL BRAIN RES, V31, P165, DOI 10.1016/0169-328X(95)00048-W; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; YMER S, 1989, EMBO J, V8, P1665, DOI 10.1002/j.1460-2075.1989.tb03557.x	50	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21257	21264		10.1074/jbc.274.30.21257	http://dx.doi.org/10.1074/jbc.274.30.21257			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409683	hybrid			2022-12-25	WOS:000081613100074
J	Kurschat, P; Zigrino, P; Nischt, R; Breitkopf, K; Steurer, P; Klein, CE; Krieg, T; Mauch, C				Kurschat, P; Zigrino, P; Nischt, R; Breitkopf, K; Steurer, P; Klein, CE; Krieg, T; Mauch, C			Tissue inhibitor of matrix metalloproteinase-2 regulates matrix metalloproteinase-2 activation by modulation of membrane-type 1 matrix metalloproteinase activity in high and low invasive melanoma cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GELATINASE-A ACTIVATION; HUMAN BREAST-CARCINOMA; PROGELATINASE-A; IV COLLAGENASE; ENDOTHELIAL-CELLS; MESSENGER-RNA; MR 72,000; NUDE-MICE; METASTATIC PROGRESSION; CATALYTIC DOMAIN	Activation of pro-matrix metalloproteinase (MMP)-2 on the surface of malignant cells by membrane-bound MT1-MMP is believed to play a critical role during tumor progression and metastasis. In this study we present evidence that MT1-MMP plays a key role for the in vitro invasiveness of malignant melanoma. Melanoma cell lines secreted latent MMP-2 when cultured on plastic. However, when cells were grown in floating type I collagen lattices, only high invasive melanoma cells activated proMMP-2. Activation could be inhibited by antibodies against MT1-MMP, by addition of recombinant tissue inhibitor of metalloproteinases (TIMP)-2 and by inhibition of MT1-MMP cleavage. MT1-MMP protein was detected as an inactive protein in all cell lines cultured as monolayers, whereas in collagen gels, active MT1-MMP protein was detected in the membranes of both high and low invasive melanoma cells. Production of TIMP-2 was about 10-fold higher in low invasive cells as compared with high invasive melanoma cells and was further increased in the low invasive cells upon contact to collagen. Thus, in melanoma cells TIMP-2 expression levels might regulate MT1-MMP-mediated activation of proMMP-2. High invasive melanoma cells displayed increased in vitro invasiveness, which was inhibited by TIMP-8. These data indicate the importance of these enzymes for the invasion processes and support a role for MT1-MMP as an activator of proMMP-2 in malignant melanoma.	Univ Cologne, Dept Dermatol, D-50924 Cologne, Germany; Univ Wurzburg, D-97080 Wurzburg, Germany	University of Cologne; University of Wurzburg	Mauch, C (corresponding author), Univ Cologne, Dept Dermatol, D-50924 Cologne, Germany.	cornelia.mauch@uni-koeln.de		Zigrino, Paola/0000-0002-7470-0064				AZZAM HS, 1992, CANCER RES, V52, P4540; AZZAM HS, 1993, J NATL CANCER I, V85, P1758, DOI 10.1093/jnci/85.21.1758; Belien ATJ, 1999, J CELL BIOL, V144, P373, DOI 10.1083/jcb.144.2.373; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BROWN PD, 1990, CANCER RES, V50, P6184; BROWN PD, 1993, J NATL CANCER I, V85, P574, DOI 10.1093/jnci/85.7.574; BROWN PD, 1993, KIDNEY INT, V43, P163, DOI 10.1038/ki.1993.27; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Butler GS, 1997, EUR J BIOCHEM, V244, P653, DOI 10.1111/j.1432-1033.1997.t01-1-00653.x; CANETESOLER R, 1994, AM J PATHOL, V144, P518; Cao JA, 1996, J BIOL CHEM, V271, P30174, DOI 10.1074/jbc.271.47.30174; Chen WT, 1996, ENZYME PROTEIN, V49, P59, DOI 10.1159/000468616; Corcoran ML, 1996, ENZYME PROTEIN, V49, P7, DOI 10.1159/000468613; Danen EHJ, 1996, BIOCHEM BIOPH RES CO, V226, P75, DOI 10.1006/bbrc.1996.1313; Gilles C, 1997, LAB INVEST, V76, P651; Haas TL, 1998, J BIOL CHEM, V273, P3604, DOI 10.1074/jbc.273.6.3604; HERRON GS, 1986, J BIOL CHEM, V261, P2814; Kazes I, 1998, KIDNEY INT, V54, P1976, DOI 10.1046/j.1523-1755.1998.00216.x; Lehti K, 1998, BIOCHEM J, V334, P345, DOI 10.1042/bj3340345; LEVY AT, 1991, CANCER RES, V51, P439; LEWALLE JM, 1995, J CELL PHYSIOL, V165, P475, DOI 10.1002/jcp.1041650305; MACDOUGALL JR, 1995, CANCER RES, V55, P4174; Maquoi E, 1998, FEBS LETT, V424, P262, DOI 10.1016/S0014-5793(98)00187-2; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MAUCH C, 1988, EXP CELL RES, V178, P493, DOI 10.1016/0014-4827(88)90417-X; NOMURA H, 1995, CANCER RES, V55, P3263; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; Okumura Y, 1997, FEBS LETT, V402, P181, DOI 10.1016/S0014-5793(96)01523-2; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; Puente XS, 1996, CANCER RES, V56, P944; PYKE C, 1992, CANCER RES, V52, P1336; QUAX PHA, 1991, J CELL BIOL, V115, P191, DOI 10.1083/jcb.115.1.191; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1996, J BIOCHEM-TOKYO, V119, P209; Sato H, 1996, FEBS LETT, V393, P101, DOI 10.1016/0014-5793(96)00861-7; SELTZER JL, 1994, EXP CELL RES, V213, P365, DOI 10.1006/excr.1994.1211; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; STIENEKEGROBER A, 1992, EMBO J, V11, P2407, DOI 10.1002/j.1460-2075.1992.tb05305.x; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; SUDBECK BD, 1994, J BIOL CHEM, V269, P30022; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; Tanaka M, 1997, FEBS LETT, V402, P219, DOI 10.1016/S0014-5793(96)01537-2; Tomasek JJ, 1997, J BIOL CHEM, V272, P7482, DOI 10.1074/jbc.272.11.7482; Ueno H, 1997, CANCER RES, V57, P2055; Vaisanen A, 1996, J PATHOL, V180, P283; VANMUIJEN GNP, 1991, INT J CANCER, V48, P85; VANMUIJEN GNP, 1991, CLIN EXP METASTAS, V9, P259, DOI 10.1007/BF01753729; VINCENT S, 1993, NUCLEIC ACIDS RES, V21, P1498, DOI 10.1093/nar/21.6.1498; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; Yu AE, 1996, BIOCHEM CELL BIOL, V74, P823, DOI 10.1139/o96-088; Yu M, 1997, CANCER RES, V57, P5028; Zucker S, 1998, J BIOL CHEM, V273, P1216, DOI 10.1074/jbc.273.2.1216	54	142	144	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21056	21062		10.1074/jbc.274.30.21056	http://dx.doi.org/10.1074/jbc.274.30.21056			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409657	hybrid			2022-12-25	WOS:000081613100048
J	Chen, F; Demers, LM; Vallyathan, V; Ding, M; Lu, YJ; Castranova, V; Shi, XL				Chen, F; Demers, LM; Vallyathan, V; Ding, M; Lu, YJ; Castranova, V; Shi, XL			Vanadate induction of NF-kappa B involves I kappa B kinase beta and SAPK ERK kinase 1 in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARTICULATE AIR-POLLUTION; PHOSPHOTYROSINE PHOSPHATASE INHIBITORS; ALVEOLAR MACROPHAGES; IKK-ALPHA; PROTEIN PHOSPHATASES; TRANSCRIPTION FACTOR; RADICAL GENERATION; JNK PATHWAY; ACTIVATION; VANADIUM	The present studies investigated the signaling pathways of vanadate, a vanadium ion with +5 oxidation state, to activate NF-kappa B transcription factor, a pivotal regulator of inflammatory responses. Treatment of macrophages with vanadate results in the activation of both NF-kappa B and c-Jun N-terminal kinase (JNK), The activity of a recently identified cellular kinase, I kappa B kinase-beta (IKK beta), was significantly elevated concomitant with the increased degradation of I kappa B alpha and enhanced NF-kappa B activity in cells exposed to vanadate, To determine whether the IKK pathway and JNK pathway are interconnected or bifurcate upon vanadate stimulation, cells were transfected with either a kinase inactive form of IKK beta or a kinase inactive form of SAPK/ERK kinase 1 (SEK1), Inactive IKK beta was able to block vanadate-induced degradation of I kappa B alpha, yet it was unable to influence the activation of JNK by vanadate, Conversely, blockage of JNK activation by transfection of a kinase-inactive form of SEK1 resulted in partially inhibition of vanadate-induced I kappa B alpha degradation. Both vanadate-induced degradation of I kappa B alpha and activation of JNK were potently inhibited by pretreatment of cells with N-acetylcysteine or dimercaprol, These results demonstrate that early activation of stress kinases or change of cellular redox states plays a key role in vanadate-induced activation of NF-kappa B and JNK.	NIOSH, Pathol & Physiol Res Branch, Hlth Effects Lab Div, Morgantown, WV 26505 USA; Penn State Univ, Coll Med, Dept Pathol, Hershey, PA 17033 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Chen, F (corresponding author), NIOSH, Pathol & Physiol Res Branch, Hlth Effects Lab Div, 1095 Willowdale Rd, Morgantown, WV 26505 USA.		Shi, Xianglin/B-8588-2012					Abelson PH, 1997, SCIENCE, V277, P15, DOI 10.1126/science.277.5322.15; Abelson PH, 1998, SCIENCE, V281, P1609, DOI 10.1126/science.281.5383.1609; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barbeau B, 1997, J BIOL CHEM, V272, P12968, DOI 10.1074/jbc.272.20.12968; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Becker S, 1996, TOXICOL APPL PHARM, V141, P637, DOI 10.1006/taap.1996.0330; BODE HP, 1990, BIOCHIM BIOPHYS ACTA, V1022, P163, DOI 10.1016/0005-2736(90)90110-A; BRUNATI AM, 1985, BIOCHEM BIOPH RES CO, V133, P929, DOI 10.1016/0006-291X(85)91225-2; CANTLEY LC, 1979, J BIOL CHEM, V254, P1781; Chen F, 1997, ARCH BIOCHEM BIOPHYS, V342, P383, DOI 10.1006/abbi.1997.0132; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Cohen MD, 1997, J TOXICOL ENV HEALTH, V51, P591, DOI 10.1080/009841097159854; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DOCKERY DW, 1994, ANNU REV PUBL HEALTH, V15, P107, DOI 10.1146/annurev.pu.15.050194.000543; Dong WM, 1996, EXP LUNG RES, V22, P577, DOI 10.3109/01902149609046043; ELBERG G, 1994, J BIOL CHEM, V269, P9521; Eliopoulos AG, 1998, ONCOGENE, V16, P1731, DOI 10.1038/sj.onc.1201694; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; Ginn-Pease ME, 1998, FREE RADICAL BIO MED, V25, P346, DOI 10.1016/S0891-5849(98)00067-7; Good L, 1996, BIOCHEM BIOPH RES CO, V223, P123, DOI 10.1006/bbrc.1996.0856; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Kennedy T, 1998, AM J RESP CELL MOL, V19, P366, DOI 10.1165/ajrcmb.19.3.3042; Kodavanti UP, 1998, TOXICOL SCI, V43, P204, DOI 10.1093/toxsci/43.2.204; Krejsa CM, 1997, J BIOL CHEM, V272, P11541; LAU KHW, 1989, BIOCHEM J, V257, P23, DOI 10.1042/bj2570023; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LEONARD A, 1994, MUTAT RES, V317, P81, DOI 10.1016/0165-1110(94)90013-2; LIN ZG, 1996, CELL, V87, P565; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Pierce LM, 1996, TOXICOL APPL PHARM, V138, P1, DOI 10.1006/taap.1996.9999; POPE CA, 1995, INHAL TOXICOL, V7, P1, DOI 10.3109/08958379509014267; SHI XL, 1993, ARCH BIOCHEM BIOPHYS, V307, P336, DOI 10.1006/abbi.1993.1597; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; ZYCHLINSKI L, 1990, ARCH ENVIRON CON TOX, V19, P138, DOI 10.1007/BF01059822	45	53	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20307	20312		10.1074/jbc.274.29.20307	http://dx.doi.org/10.1074/jbc.274.29.20307			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400652	hybrid			2022-12-25	WOS:000081438300045
J	Chiti, F; Taddei, N; Giannoni, E; van Nuland, NAJ; Ramponi, G; Dobson, CM				Chiti, F; Taddei, N; Giannoni, E; van Nuland, NAJ; Ramponi, G; Dobson, CM			Development of enzymatic activity during protein folding - Detection of a spectroscopically silent native-like intermediate of muscle acylphosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITION-STATE; CHYMOTRYPSIN INHIBITOR-2; PROLINE ISOMERIZATION; RIBONUCLEASE-A; KINETICS; MECHANISM; DOMAIN; THERMODYNAMICS; STABILIZATION; RESIDUES	The recovery of enzymatic activity during the folding of muscle acylphosphatase and two single residue mutants (proline 54 to alanine and proline 71 to alanine) from 7 M urea has been monitored and compared with the development of intrinsic fluorescence emission. Fluorescence measurements reveal the presence in the wild-type protein of a major rapid refolding phase followed by a second low amplitude slow phase. The slow phase is absent in the fluorescence trace acquired with the proline 54 to alanine mutant, suggesting the involvement of this proline residue in the fluorescence-detected slow phase of the wild-type protein. The major kinetic phase is associated with a considerable recovery of enzymatic activity, indicating that a large fraction of molecules refolds with effective two-state behavior. The use of time-resolved enzymatic activity as a probe to follow the folding process reveals, however, the presence of another exponential slow phase arising from proline 71. This slow phase is not observable by utilizing optical probes, indicating that, unlike proline 54, the cis to trans isomerization of proline 71 can take place in an intermediate possessing a native-like fold. We suggest that, although spectroscopically silent and structurally insignificant, the cia-trans interconversion of proline residues in native-like intermediates may be crucial for the generation of enzymatic activity of functional enzymes.	Univ Oxford, New Chem Lab, Oxford Ctr Mol Sci, Oxford OX1 3QT, England; Univ Florence, Dipartimento Sci Biochim, I-50134 Florence, Italy	University of Oxford; University of Florence	Dobson, CM (corresponding author), Univ Oxford, New Chem Lab, Oxford Ctr Mol Sci, S Parks Rd, Oxford OX1 3QT, England.		Giannoni, Elisa/AAE-2092-2020	Taddei, Niccolo/0000-0003-2513-1018; Giannoni, Elisa/0000-0001-7136-1098				CAMICI G, 1976, EXPERIENTIA, V32, P535, DOI 10.1007/BF01920843; Chiti F, 1998, PROTEIN ENG, V11, P557, DOI 10.1093/protein/11.7.557; Dill KA, 1997, NAT STRUCT BIOL, V4, P10, DOI 10.1038/nsb0197-10; EVANS PA, 1989, BIOCHEMISTRY-US, V28, P362, DOI 10.1021/bi00427a050; Guijarro JI, 1998, J MOL BIOL, V276, P657, DOI 10.1006/jmbi.1997.1553; ITZHAKI LS, 1995, J MOL BIOL, V254, P260, DOI 10.1006/jmbi.1995.0616; JACKSON SE, 1991, BIOCHEMISTRY-US, V30, P10436, DOI 10.1021/bi00107a011; KIEFHABER T, 1992, PROTEIN SCI, V1, P1162, DOI 10.1002/pro.5560010910; KIEFHABER T, 1990, BIOCHEMISTRY-US, V29, P3061, DOI 10.1021/bi00464a024; KIEFHABER T, 1990, BIOCHEMISTRY-US, V29, P3053, DOI 10.1021/bi00464a023; MATOUSCHEK A, 1989, NATURE, V340, P122, DOI 10.1038/340122a0; Modesti A, 1995, PROTEIN EXPRES PURIF, V6, P799, DOI 10.1006/prep.1995.0011; PASTORE A, 1992, J MOL BIOL, V224, P427, DOI 10.1016/0022-2836(92)91005-A; Plaxco KW, 1998, BIOCHEMISTRY-US, V37, P2529, DOI 10.1021/bi972075u; Plaxco KW, 1996, CURR OPIN STRUC BIOL, V6, P630, DOI 10.1016/S0959-440X(96)80029-7; Plaxco KW, 1997, J MOL BIOL, V270, P763, DOI 10.1006/jmbi.1997.1148; RAMPONI G, 1966, EXPERIENTIA, V22, P705, DOI 10.1007/BF01901326; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SAUDEK V, 1989, EUR J BIOCHEM, V182, P85, DOI 10.1111/j.1432-1033.1989.tb14803.x; SCHMID FX, 1981, EUR J BIOCHEM, V114, P111; SCHMID FX, 1983, BIOCHEMISTRY-US, V22, P4690, DOI 10.1021/bi00289a013; Stefani M, 1995, LIFE CHEM REPORTS, V12, P271; Taddei N, 1996, BIOCHEMISTRY-US, V35, P7077, DOI 10.1021/bi952900b; Taddei N, 1997, BIOCHEMISTRY-US, V36, P7217, DOI 10.1021/bi970173+; TADDEI N, 1995, FEBS LETT, V362, P175, DOI 10.1016/0014-5793(95)00236-3; Thunnissen MMGM, 1997, STRUCTURE, V5, P69, DOI 10.1016/S0969-2126(97)00167-6; van Nuland NAJ, 1998, J MOL BIOL, V283, P883, DOI 10.1006/jmbi.1998.2009; VILLEGAS V, 1995, BIOCHEMISTRY-US, V34, P15105, DOI 10.1021/bi00046a017	28	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20151	20158		10.1074/jbc.274.29.20151	http://dx.doi.org/10.1074/jbc.274.29.20151			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400629	hybrid			2022-12-25	WOS:000081438300022
J	Miller, BA; Barber, DL; Bell, LL; Beattie, BK; Zhang, MY; Neel, BC; Yoakim, M; Rothblum, LI; Cheung, JY				Miller, BA; Barber, DL; Bell, LL; Beattie, BK; Zhang, MY; Neel, BC; Yoakim, M; Rothblum, LI; Cheung, JY			Identification of the erythropoietin receptor domain required for calcium channel activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE ERYTHROLEUKEMIA-CELLS; HUMAN ERYTHROID PRECURSORS; INTRACELLULAR-FREE CALCIUM; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOLIPASE C-GAMMA-1; PROTOONCOGENE PRODUCT; TRANSCRIPTION FACTORS; HUMAN ERYTHROBLASTS	Erythropoietin (Epo) activates a voltage-independent Ca2+ channel that is dependent on tyrosine phosphorylation, To identify the domain(s) of the Epo receptor (Epo-R) required for Epo-induced Ca2+ influx, Chinese hamster ovary (CHO) cells were transfected with wildtype or mutant Epo receptors subcloned into pTracer-cytomegalovirus vector. This vector contains an SV40 early promoter, which drives expression of the green fluorescent protein (GFP) gene, and a cytomegalovirus immediate-early Promoter driving expression of the Epo-R, Successful transfection was verified in single cells by detection of GFP, and intracellular Ca2+ ([Ca](i)) changes were simultaneously monitored with rhod-2, Transfection of CHO cells with pTracer encoding wildtype Epo-R, but not pTracer alone, resulted in an Epo-induced [Ca], increase that was abolished in cells transfected with Epo-R F8 (all eight cytoplasmic tyrosines substituted). Transfection with carboxyl-terminal deletion mutants indicated that removal of the terminal four tyrosine phosphorylation sites, but not the tyrosine at position 479, abolished Epo-induced [Ca](i) increase, suggesting that tyrosines at positions 443, 460, and/or 464 are important. In CHO cells transfected with mutant Epo-R in which phenylalanine was substituted for individual tyrosines, a significant increase in [Ca](i) was observed with mutants Epo-R Y443F and Epo-R Y464F, The rise in [Ca](i) was abolished in cells transfected with Epo-R Y460F. Results were confirmed with CHO cells transfected with plasmids expressing Epo-R mutants in which individual tyrosines were added back to Epo-R F8 and in stably transfected Ba/F3 cells. These results demonstrate a critical role for the Epo-R cytoplasmic tyrosine 460 in Epo-stimulated Ca2+ influx.	Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Pediat, Hershey, PA 17033 USA; Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Med, Hershey, PA 17033 USA; Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA; Ontario Canc Inst, Div Cellular & Mol Biol, Toronto, ON M5G 2M9, Canada; Toronto Hosp, Dept Lab Med & Pathobiol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Beth Israel Deaconess Med Ctr, Dept Med, Canc Biol Program, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Boston, MA 02215 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center	Miller, BA (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Pediat, MC-H085,POB 850, Hershey, PA 17033 USA.	bmiller1@psghs.edu		Barber, Dwayne/0000-0001-5528-8150	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR010732] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK046778, R01DK046778, F32DK009790] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR10732] Funding Source: Medline; NIDDK NIH HHS [F32 DK 09790, DK 46778] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARBER DL, 1994, MOL CELL BIOL, V14, P6506, DOI 10.1128/MCB.14.10.6506; Barber DL, 1997, BLOOD, V89, P3166, DOI 10.1182/blood.V89.9.3166; BILLESTRUP N, 1995, P NATL ACAD SCI USA, V92, P2725, DOI 10.1073/pnas.92.7.2725; Cheung JY, 1997, BLOOD, V89, P92, DOI 10.1182/blood.V89.1.92.92_92_100; CHEUNG JY, 1992, J CLIN INVEST, V90, P1850, DOI 10.1172/JCI116061; Chin H, 1996, BLOOD, V88, P4415, DOI 10.1182/blood.V88.12.4415.bloodjournal88124415; Chin H, 1998, BLOOD, V91, P3734; CONDORELLI G, 1995, BLOOD, V86, P164, DOI 10.1182/blood.V86.1.164.bloodjournal861164; CORNELIUSSEN B, 1994, NATURE, V368, P760, DOI 10.1038/368760a0; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Damen JE, 1996, EXP HEMATOL, V24, P1455; DAMEN JE, 1993, BLOOD, V81, P3204; DAMEN JE, 1995, J BIOL CHEM, V270, P23402, DOI 10.1074/jbc.270.40.23402; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; DRACHMAN JG, 1995, J BIOL CHEM, V270, P4979, DOI 10.1074/jbc.270.10.4979; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Fujitani Y, 1997, ONCOGENE, V14, P751, DOI 10.1038/sj.onc.1200907; GILLO B, 1993, BLOOD, V81, P783; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; HANAZONO Y, 1993, BLOOD, V81, P3193; HE TC, 1993, BLOOD, V82, P3530; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; HENSOLD JO, 1991, BLOOD, V77, P1362; Hilton DJ, 1996, J BIOL CHEM, V271, P4699; Huber M, 1998, P NATL ACAD SCI USA, V95, P11330, DOI 10.1073/pnas.95.19.11330; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; Klingmuller U, 1996, P NATL ACAD SCI USA, V93, P8324, DOI 10.1073/pnas.93.16.8324; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Klingmuller U, 1997, EUR J BIOCHEM, V249, P637, DOI 10.1111/j.1432-1033.1997.t01-1-00637.x; LEVENSON R, 1980, P NATL ACAD SCI-BIOL, V77, P5948, DOI 10.1073/pnas.77.10.5948; M'Rabet L, 1998, BLOOD, V92, P2133, DOI 10.1182/blood.V92.6.2133.418k19_2133_2140; MAOUCHE L, 1991, BLOOD, V78, P2557; Marrero MB, 1998, KIDNEY INT, V53, P1259, DOI 10.1046/j.1523-1755.1998.00887.x; MCMAHON G, 1984, P NATL ACAD SCI-BIOL, V81, P7461, DOI 10.1073/pnas.81.23.7461; Middleton SA, 1996, J BIOL CHEM, V271, P14045, DOI 10.1074/jbc.271.24.14045; MILLER BA, 1989, BLOOD, V73, P1188; MILLER BA, 1994, CELL CALCIUM, V16, P481, DOI 10.1016/0143-4160(94)90078-7; MILLER BA, 1988, J CLIN INVEST, V82, P309, DOI 10.1172/JCI113588; Miller BA, 1996, J CLIN INVEST, V98, P1728, DOI 10.1172/JCI118971; MILLER BA, 1991, BLOOD, V77, P486; MISITI J, 1979, J CLIN INVEST, V64, P1573, DOI 10.1172/JCI109618; MITANI A, 1994, J NEUROCHEM, V62, P626; MIURA O, 1994, BLOOD, V84, P1501; MIURA O, 1994, BLOOD, V84, P4135, DOI 10.1182/blood.V84.12.4135.bloodjournal84124135; MIURA O, 1993, ARCH BIOCHEM BIOPHYS, V306, P200, DOI 10.1006/abbi.1993.1501; MLADENOVIC J, 1988, J LAB CLIN MED, V112, P23; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; NOGUCHI CT, 1991, BLOOD, V78, P2548; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; OKAMOTO T, 1991, J BIOL CHEM, V266, P1085; REN HY, 1994, J BIOL CHEM, V269, P19633; SAWYER ST, 1984, J BIOL CHEM, V259, P2769; Schaefer A, 1996, J BIOL CHEM, V271, P13484, DOI 10.1074/jbc.271.23.13484; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; TAUCHI T, 1995, J BIOL CHEM, V270, P5631, DOI 10.1074/jbc.270.10.5631; Tauchi T, 1996, BLOOD, V87, P4495, DOI 10.1182/blood.V87.11.4495.bloodjournal87114495; TORTI M, 1992, J BIOL CHEM, V267, P8293; VACHER P, 1994, ENDOCRINOLOGY, V134, P1213, DOI 10.1210/en.134.3.1213; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YELAMARTY RV, 1990, J CLIN INVEST, V85, P1799, DOI 10.1172/JCI114638; YI TL, 1995, BLOOD, V85, P87, DOI 10.1182/blood.V85.1.87.bloodjournal85187; YOSHINO M, 1995, BRAIN RES, V695, P179, DOI 10.1016/0006-8993(95)00743-A; Zhang MY, 1997, BLOOD, V90, P2068, DOI 10.1182/blood.V90.5.2068; Zhang MY, 1998, BLOOD, V92, P1225, DOI 10.1182/blood.V92.4.1225.416k20_1225_1234; Zhang MY, 1998, BLOOD, V91, P4136, DOI 10.1182/blood.V91.11.4136.411k26_4136_4144	71	57	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20465	20472		10.1074/jbc.274.29.20465	http://dx.doi.org/10.1074/jbc.274.29.20465			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400674	hybrid			2022-12-25	WOS:000081438300067
J	Schaertl, S; Geeves, MA; Konrad, M				Schaertl, S; Geeves, MA; Konrad, M			Human nucleoside diphosphate kinase B (Nm23-82) from melanoma cells shows altered phosphoryl transfer activity due to the S122P mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-METASTASIS; DICTYOSTELIUM-DISCOIDEUM; SIGNAL-TRANSDUCTION; HEXAMERIC ENZYME; GTP SYNTHESIS; IN-VITRO; PROTEIN; GENE; NEUROBLASTOMA; STABILITY	The Se-122 --> Pro mutation in human nucleoside diphosphate kinase (NDK)-B/Nm23-H2 was recently found in melanoma cells. In comparison to the wild-type enzyme, steady state activity of NDKS122P with ATP and TDP as substrates was slowed down 5-fold. We have utilized transient kinetic techniques to analyze phosphoryl transfer between the mutant enzyme and various pairs of nucleoside triphosphates and nucleoside diphosphates. The two half-reactions of phosphorylation and dephosphorylation of the active site histidine residue (His(118)) were studied separately by making use of the intrinsic fluorescence changes which occur during these reactions. All apparent second order rate constants are drastically reduced, falling 3-fold for phosphorylation and 40-200-fold for dephosphorylation. Also, the reactivity of the mutant with pyrimidine nucleotides and deoxy nucleotides is more than 100-fold reduced compared with the wild-type. Thus, the rate-limiting step of the NDK-B-S122P-catalyzed reaction is phosphoryl transfer from the phospho enzyme intermediate to the nucleoside diphosphate and not phosphoryl transfer from the nucleoside triphosphate to the enzyme as was found for the wild-type protein. This results in a pronounced shift of the equilibrium between unphosphorylated and phosphorylated enzyme, Moreover, like the Killer-of-prune mutation in Drosophila NDK and the neuroblastoma Ser(120) --> Gly mutation in human NDK-A/Nm23-H1, the Ser(122) --> Pro substitution in NDK-B affects the stability of the protein toward heat and urea. These significantly altered properties may be relevant to the role of the mutant enzyme in various intracellular processes.	Max Planck Inst Biophys Chem, Abt Mol Genet, D-37070 Gottingen, Germany; Max Planck Inst Mol Physiol, Abt Phys Biochem, D-44026 Dortmund, Germany	Max Planck Society; Max Planck Society	Konrad, M (corresponding author), Max Planck Inst Biophys Chem, Abt Mol Genet, D-37070 Gottingen, Germany.	mkonrad@gwdg.de	Geeves, Michael/F-7583-2011	Geeves, Michael/0000-0002-9364-8898				AGARWAL RP, 1971, J BIOL CHEM, V246, P2258; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BOMINAAR AA, 1993, EMBO J, V12, P2275, DOI 10.1002/j.1460-2075.1993.tb05881.x; CHANG CL, 1994, NATURE, V370, P335, DOI 10.1038/370335a0; Chang CL, 1996, ONCOGENE, V12, P659; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; DELAROSA A, 1995, BIOESSAYS, V17, P53, DOI 10.1002/bies.950170111; DevilleBonne D, 1996, BIOCHEMISTRY-US, V35, P14643, DOI 10.1021/bi960945m; ENGEL M, 1994, BIOCHEM BIOPH RES CO, V199, P1041, DOI 10.1006/bbrc.1994.1334; Freije JMP, 1997, J BIOL CHEM, V272, P5525, DOI 10.1074/jbc.272.9.5525; GILLES AM, 1991, J BIOL CHEM, V266, P8784; GUTFREUND H, 1995, KINETICS LIFE SCI, P59; HAMBY CV, 1995, BIOCHEM BIOPH RES CO, V211, P578, DOI 10.1006/bbrc.1995.1852; HEMMERICH S, 1992, BIOCHEMISTRY-US, V31, P4580, DOI 10.1021/bi00134a007; KONRAD M, 1993, J BIOL CHEM, V268, P11326; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASCU I, 1993, J BIOL CHEM, V268, P20268; Lascu I, 1997, J BIOL CHEM, V272, P15599, DOI 10.1074/jbc.272.25.15599; LASCU I, 1992, J BIOL CHEM, V267, P12775; LEONE A, 1993, ONCOGENE, V8, P855; LIOTTA LA, 1990, J NATL CANCER I, V82, P1170, DOI 10.1093/jnci/82.14.1170; Lu Q, 1996, J BIOL CHEM, V271, P32886, DOI 10.1074/jbc.271.51.32886; MacDonald NJ, 1996, J BIOL CHEM, V271, P25107, DOI 10.1074/jbc.271.41.25107; MACDONALD NJ, 1993, J BIOL CHEM, V268, P25780; MANDAI M, 1995, BRIT J CANCER, V72, P691, DOI 10.1038/bjc.1995.395; METZ SA, 1992, J BIOL CHEM, V267, P12517; Morera S, 1995, STRUCTURE, V3, P1307, DOI 10.1016/S0969-2126(01)00268-4; Mukhopadhyay S, 1997, J BIOL CHEM, V272, P17815, DOI 10.1074/jbc.272.28.17815; Parks R.E., 1973, ENZYMES, V8, P307, DOI [10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; Postel EH, 1996, P NATL ACAD SCI USA, V93, P6892, DOI 10.1073/pnas.93.14.6892; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; Schaertl S, 1996, FEBS LETT, V394, P316, DOI 10.1016/0014-5793(96)00978-7; Schaertl S, 1998, J BIOL CHEM, V273, P5662, DOI 10.1074/jbc.273.10.5662; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; SONNEMANN J, 1995, BIOCHEM BIOPH RES CO, V209, P490, DOI 10.1006/bbrc.1995.1528; STAHL JA, 1991, CANCER RES, V51, P445; VANDECANDELAERE A, 1995, BIOCHEMISTRY-US, V34, P1332, DOI 10.1021/bi00004a028; Wagner PD, 1997, P NATL ACAD SCI USA, V94, P9000, DOI 10.1073/pnas.94.17.9000; WEBB PA, 1995, J MOL BIOL, V251, P574, DOI 10.1006/jmbi.1995.0457	41	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20159	20164		10.1074/jbc.274.29.20159	http://dx.doi.org/10.1074/jbc.274.29.20159			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400630	hybrid, Green Published			2022-12-25	WOS:000081438300023
J	Vanaman, TC; Bradshaw, RA				Vanaman, TC; Bradshaw, RA			Proteases in cellular regulation minireview series	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review									Univ Kentucky, Coll Med, Dept Biochem, Lexington, KY 40536 USA; Univ Calif Irvine, Coll Med, Dept Physiol & Biophys, Irvine, CA 92697 USA	University of Kentucky; University of California System; University of California Irvine	Vanaman, TC (corresponding author), Univ Kentucky, Coll Med, Dept Biochem, Lexington, KY 40536 USA.		Bradshaw, Ralph A/K-1515-2013					Barrett A. J., 1998, HDB PROTEOLYTIC ENZY; DEMARTINO GN, 1999, IN PRESS J BIOL CHEM, V274; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; STEINER DF, 1967, SCIENCE, V157, P697, DOI 10.1126/science.157.3789.697; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; YUAN J, 1993, CELL, V19, P641; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745	9	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20047	20047		10.1074/jbc.274.29.20047	http://dx.doi.org/10.1074/jbc.274.29.20047			1	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400608	hybrid			2022-12-25	WOS:000081438300001
J	Huang, JQ; Zhang, BT; Li, YQ; Mayer, B; Carraway, KL; Carraway, CAC				Huang, JQ; Zhang, BT; Li, YQ; Mayer, B; Carraway, KL; Carraway, CAC			c-Src association with and phosphorylation of p58(gag), a membrane- and microfilament-associated retroviral Gag-like protein in a xenotransplantable rat mammary tumor	ONCOGENE			English	Article						signal transduction; microfilaments; retroviral Gag protein; Src; SH3 domain; polyproline motif	SIGNAL-TRANSDUCTION PARTICLE; ACTIN-BINDING DOMAINS; ROUS-SARCOMA VIRUS; TYROSINE KINASE; SH3 DOMAINS; CELL MICROVILLI; ASCITES ADENOCARCINOMA; GLYCOPROTEIN COMPLEX; FOCAL ADHESIONS; IIB-IIIA	The retroviral Gag-like protein p58(gag) expressed in a highly metastatic ascites rat mammary adenocarcinoma has been implicated in cell surface changes contributing to xenotransplantability. p58(gag) is present in the cells in a plasma membrane- and microfilament-associated signal transduction particle containing Src and is phosphorylated on tyrosine. Overlay analyses and affinity chromatography with glutathione S-transferase (GST) fusion proteins of Src homology-3 (SH3) domains showed direct binding of the Src but not the Crk SH3 domain to p58(gag), This association was confirmed by coimmunoprecipitation of partially purified p58(gag) from ascites cell lysates with platelet Src, Further, a GST-p58(gag) fusion protein bound full length c-Src from either platelets or c-Src-expressing insect cells. The GST-p58(gag) fusion protein, but not GST, was phosphorylated by platelet or insect cell-expressed c-Src, but not by a kinase negative c-Src variant. The binding of GST-p58(gag) to c-Src was almost completely abolished by a 50-fold excess of the GST-SH3 domain of Src, and a parallel decrease in tyrosine phosphorylation of p58(gag) was observed. These results demonstrate that p58(gag) is tyrosine-phosphorylated as a consequence of its specific association with c-Src via its SH3 domain. These observations suggest a mechanism by which Gag proteins may contribute to retroviral maturation or pathogenesis through binding and relocalization of SH3 domain-containing proteins such as Src-like tyrosine kinases to sites of association of microfilaments with the plasma membrane.	Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA; Harvard Univ, Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA	University of Miami; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute	Carraway, CAC (corresponding author), Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA.				NATIONAL CANCER INSTITUTE [P30CA014395, R01CA072577] Funding Source: NIH RePORTER; NCI NIH HHS [CA72577-01A1, CA 14395] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altun-Gultekin ZF, 1998, MOL CELL BIOL, V18, P3044, DOI 10.1128/MCB.18.5.3044; AZIZ DC, 1989, NATURE, V338, P505, DOI 10.1038/338505a0; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; BURR JG, 1980, P NATL ACAD SCI-BIOL, V77, P3484, DOI 10.1073/pnas.77.6.3484; BURRIDGE K, 1986, Cancer Reviews, V4, P18; CARRAWAY CAC, 1983, P NATL ACAD SCI-BIOL, V80, P430, DOI 10.1073/pnas.80.2.430; CARRAWAY CAC, 1985, EXP CELL RES, V161, P150, DOI 10.1016/0014-4827(85)90499-9; CARRAWAY CAC, 1982, BIOCHIM BIOPHYS ACTA, V719, P126; CARRAWAY CAC, 1991, J BIOL CHEM, V266, P16238; CARRAWAY CAC, 1993, J BIOL CHEM, V268, P5582; CARRAWAY CAC, 1996, ROLE CELL PHYSL, V2, P207; CARRAWAY CAC, 1999, IN PRESS J BIOL CHEM; CARRAWAY CAC, 1998, GUIDEBOOK CYTOSKELET; CARRAWAY KL, 1980, NATURE, V285, P508, DOI 10.1038/285508a0; CARRAWAY KL, 1995, BIOESSAYS, V17, P171, DOI 10.1002/bies.950170212; CARRAWAY KL, 1989, BIOCHIM BIOPHYS ACTA, V988, P147, DOI 10.1016/0304-4157(89)90017-8; CARRAWAY KL, 1979, J CELL BIOL, V83, P529, DOI 10.1083/jcb.83.3.529; CARRAWAY KL, 1998, SIGNAL TRANSDUCTION; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; DAMSKY CH, 1977, J CELL BIOL, V75, P593, DOI 10.1083/jcb.75.2.593; DAVIS S, 1991, SCIENCE, V252, P712, DOI 10.1126/science.1708917; EDBAUER CA, 1984, VIROLOGY, V134, P389, DOI 10.1016/0042-6822(84)90306-4; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FOX JEB, 1993, J BIOL CHEM, V268, P25973; FOX JEB, 1994, ANN NY ACAD SCI, V714, P75, DOI 10.1111/j.1749-6632.1994.tb12032.x; GLENNEY JR, 1992, BIOCHIM BIOPHYS ACTA, V1134, P113, DOI 10.1016/0167-4889(92)90034-9; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; Higley S, 1997, CURR OPIN CELL BIOL, V9, P62, DOI 10.1016/S0955-0674(97)80153-6; HOLME TC, 1990, EUR J SURG ONCOL, V16, P161; HOWARD SC, 1982, JNCI-J NATL CANCER I, V69, P33; HUANG MJ, 1995, J VIROL, V69, P6810, DOI 10.1128/JVI.69.11.6810-6818.1995; HUGGINS JW, 1980, BIOCHIM BIOPHYS ACTA, V127, P31; JUANG SH, 1994, J BIOL CHEM, V269, P15067; Juang SH, 1996, ONCOGENE, V12, P1033; KRUEGER JG, 1983, CURR TOP MICROBIOL, V107, P51; LI Y, 1999, IN PRESS J BIOL CHEM; LIN D, 1997, TRENDS CELL BIOL, V8; LIU YC, 1989, J BIOL CHEM, V264, P1208; LO SH, 1994, J CELL BIOL, V125, P1067, DOI 10.1083/jcb.125.5.1067; LO SH, 1994, BIOESSAYS, V16, P817, DOI 10.1002/bies.950161108; MAHER PA, 1985, P NATL ACAD SCI USA, V82, P6576, DOI 10.1073/pnas.82.19.6576; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; MORSE HC, 1992, AIDS, V6, P607, DOI 10.1097/00002030-199207000-00001; NICOLSON GL, 1976, BIOCHIM BIOPHYS ACTA, V458, P1, DOI 10.1016/0304-419X(76)90014-7; Nievers MG, 1997, J CELL SCI, V110, P389; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PIWNICAWORMS H, 1990, J VIROL, V64, P61, DOI 10.1128/JVI.64.1.61-68.1990; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460-2075.1995.tb07024.x; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SHERBLOM AP, 1980, EXP CELL RES, V126, P417, DOI 10.1016/0014-4827(80)90281-5; SHRIVER K, 1981, J CELL BIOL, V89, P525, DOI 10.1083/jcb.89.3.525; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; WENG ZG, 1993, J BIOL CHEM, V268, P14956; ZHOU SY, 1995, TRENDS BIOCHEM SCI, V20, P470	62	3	3	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	1999	18	28					4099	4107		10.1038/sj.onc.1202779	http://dx.doi.org/10.1038/sj.onc.1202779			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	216FP	10435591				2022-12-25	WOS:000081431000007
J	Iizuka, M; Stillman, B				Iizuka, M; Stillman, B			Histone acetyltransferase HBO1 interacts with the ORC1 subunit of the human initiator protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORIGIN RECOGNITION COMPLEX; DNA-REPLICATION; SACCHAROMYCES-CEREVISIAE; 2-HYBRID SYSTEM; S-PHASE; HUMAN GENES; CELL-CYCLE; YEAST; XENOPUS; HOMOLOG	The origin recognition complex (ORC) is an initiator protein for DNA replication, but also effects transcriptional silencing in Saccharomyces cerevisiae and hetero chromatin function in Drosophila, It is not known, however, whether any of these functions of ORC is conserved in mammals. We report the identification of a novel protein, HBO1 (histone acetyltransferase binding to ORC), that interacts with human ORC1 protein, the largest subunit of ORC. HBO1 exists as part of a multisubunit complex that possesses histone H3 and H4 acetyltransferase activities. A fraction of the relatively abundant HBO1 protein associates with ORC1 in human cell extracts. HBO1 is a member of the MYST domain family that includes S. cerevisiae Sas2p, a protein involved in control of transcriptional silencing that also has been genetically linked to ORC function. Thus the interaction between ORC and a MYST domain acetyltransferase is widely conserved, We suggest roles for ORC-mediated acetylation of chromatin in control of both DNA replication and gene expression.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Stillman, B (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.			Stillman, Bruce/0000-0002-9453-4091	NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NCI NIH HHS [CA13106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1995, CELL, V83, P563, DOI 10.1016/0092-8674(95)90096-9; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Carpenter PB, 1998, J BIOL CHEM, V273, P24891, DOI 10.1074/jbc.273.38.24891; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; Clarke AS, 1999, MOL CELL BIOL, V19, P2515; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; Dillin A, 1997, GENETICS, V147, P1053; Dillin A, 1998, SCIENCE, V279, P1733, DOI 10.1126/science.279.5357.1733; EhrenhoferMurray AE, 1997, GENETICS, V145, P923; Eki T, 1996, GENOMICS, V36, P559, DOI 10.1006/geno.1996.0511; Eki T, 1998, CYTOGENET CELL GENET, V81, P89, DOI 10.1159/000014997; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; Fox CA, 1996, CURR OPIN CELL BIOL, V8, P354, DOI 10.1016/S0955-0674(96)80009-3; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; Fox CA, 1997, SCIENCE, V276, P1547, DOI 10.1126/science.276.5318.1547; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; Grunstein M, 1998, CELL, V93, P325, DOI 10.1016/S0092-8674(00)81160-5; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Harlow E., 1988, ANTIBODIES LAB MANUA; Hilfiker A, 1997, EMBO J, V16, P2054, DOI 10.1093/emboj/16.8.2054; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; HORIUCHI K, 1975, ANAL BIOCHEM, V69, P491, DOI 10.1016/0003-2697(75)90151-7; Huang DW, 1998, J CELL BIOL, V142, P307, DOI 10.1083/jcb.142.2.307; Ishiai M, 1997, GENOMICS, V46, P294, DOI 10.1006/geno.1997.5003; JAMES TC, 1986, MOL CELL BIOL, V6, P3862, DOI 10.1128/MCB.6.11.3862; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; Landis G, 1997, P NATL ACAD SCI USA, V94, P3888, DOI 10.1073/pnas.94.8.3888; Leatherwood J, 1996, NATURE, V379, P360, DOI 10.1038/379360a0; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; LOO S, 1995, MOL BIOL CELL, V6, P541; Luger K, 1997, J MOL BIOL, V272, P301, DOI 10.1006/jmbi.1997.1235; MuziFalconi M, 1995, P NATL ACAD SCI USA, V92, P12475, DOI 10.1073/pnas.92.26.12475; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; Pak DTS, 1997, CELL, V91, P311, DOI 10.1016/S0092-8674(00)80415-8; Parthun MR, 1996, CELL, V87, P85, DOI 10.1016/S0092-8674(00)81325-2; Quintana DG, 1997, J BIOL CHEM, V272, P28247, DOI 10.1074/jbc.272.45.28247; Reifsnyder C, 1996, NAT GENET, V14, P42, DOI 10.1038/ng0996-42; RIVIER DH, 1992, SCIENCE, V256, P659, DOI 10.1126/science.1585179; Romanowski P, 1996, CURR BIOL, V6, P1416, DOI 10.1016/S0960-9822(96)00746-4; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; SKOWRONSKI J, 1988, MOL CELL BIOL, V8, P1385, DOI 10.1128/MCB.8.4.1385; Smith ER, 1998, P NATL ACAD SCI USA, V95, P3561, DOI 10.1073/pnas.95.7.3561; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; Studitsky VM, 1996, METHOD ENZYMOL, V274, P246; Thomas J O, 1978, Methods Cell Biol, V18, P429; TRIOLO T, 1996, NATURE, V381, P351; Tugal T, 1998, J BIOL CHEM, V273, P32421, DOI 10.1074/jbc.273.49.32421; Verreault A, 1998, CURR BIOL, V8, P96, DOI 10.1016/S0960-9822(98)70040-5; Wakimoto BT, 1998, CELL, V93, P321, DOI 10.1016/S0092-8674(00)81159-9; Walter J, 1998, MOL CELL, V1, P519, DOI 10.1016/S1097-2765(00)80052-0; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595	58	246	254	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23027	23034		10.1074/jbc.274.33.23027	http://dx.doi.org/10.1074/jbc.274.33.23027			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438470	Green Accepted, hybrid			2022-12-25	WOS:000082012800020
J	Ushio-Fukai, M; Alexander, RW; Akers, M; Yin, QQ; Fujio, Y; Walsh, K; Griendling, KK				Ushio-Fukai, M; Alexander, RW; Akers, M; Yin, QQ; Fujio, Y; Walsh, K; Griendling, KK			Reactive oxygen species mediate the activation of Akt/protein kinase B by angiotensin II in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; CRITICAL COMPONENT; AKT PROTOONCOGENE; PHOSPHOLIPASE-C; HEAT-SHOCK; HYPERTROPHY; WORTMANNIN; INHIBITION	Angiotensin II, a hypertrophic/anti-apoptotic hormone, utilizes reactive oxygen species (ROS) as growth-related signaling molecules in Vascular smooth muscle cells (VSMCs). Recently, the cell survival protein kinase Akt/protein kinase B (PKB) was proposed to be involved in protein synthesis. Here we show that angiotensin II causes rapid phosphorylation of Akt/PKB (6- +/- 0.4-fold increase). Exogenous H2O2 (50-200 mu M) also stimulates Akt/PKB phosphorylation (maximal 8- +/- 0.2-fold increase), suggesting that Akt/PKB activation is redox-sensitive. Both angiotensin II and H2O2 stimulation of Akt/PKB are abrogated by the phosphatidylinositol 3-kinase (PI3-K) inhibitors wortmannin and LY294002 (2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one), suggesting that PI3-K is an upstream mediator of Akt/PKB activation in VSMCs, Furthermore, diphenylene iodonium, an inhibitor of flavin-containing oxidases, or overexpression of catalase to block angiotensin II-induced intracellular H2O2 production significantly inhibits angiotensin II-induced Akt/PKB phosphorylation, indicating a role for ROS in agonist-induced Akt/PKB activation. In VSMCs infected with dominant-negative Akt/PKB, angiotensin II-stimulated [H-3]leucine incorporation is attenuated. Thus, our studies indicate that Akt/PKB is part of the remarkable spectrum of angiotensin II signaling pathways and provide insight into the highly organized signaling mechanisms coordinated by ROS, which mediate the hypertrophic response to angiotensin II in VSMCs.	Emory Univ, Sch Med, Dept Med, Div Cardiol, Atlanta, GA 30322 USA; St Elizabeths Med Ctr, Div Cardiovasc Res, Boston, MA 02135 USA; Tufts Univ, Sch Med, Boston, MA 02135 USA	Emory University; St. Elizabeth's Medical Center; Tufts University	Ushio-Fukai, M (corresponding author), Emory Univ, Sch Med, Dept Med, Div Cardiol, 1639 Pierce Dr,Rm 319, Atlanta, GA 30322 USA.		Fujio, Yasushi/H-3421-2017	Fujio, Yasushi/0000-0003-0828-2930; Griendling, Kathy/0000-0002-9456-8582	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038206, R29HL038206, R01HL060728, R37HL038206, P01HL058000] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38206, HL58000, HL60728] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; GRIENDLING KK, 1991, J BIOL CHEM, V266, P15498; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; Konishi H, 1997, FEBS LETT, V410, P493, DOI 10.1016/S0014-5793(97)00541-3; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; OKADA T, 1994, J BIOL CHEM, V269, P3563; Pollman MJ, 1996, CIRC RES, V79, P748, DOI 10.1161/01.RES.79.4.748; PURI PL, 1995, J BIOL CHEM, V270, P22129, DOI 10.1074/jbc.270.38.22129; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; Sadoshima J, 1997, CIRC RES, V80, P228, DOI 10.1161/01.RES.80.2.228; Saward L, 1997, CIRC RES, V81, P249, DOI 10.1161/01.RES.81.2.249; Servant MJ, 1996, J BIOL CHEM, V271, P16047, DOI 10.1074/jbc.271.27.16047; Smith RC, 1997, GENE DEV, V11, P1674, DOI 10.1101/gad.11.13.1674; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; Tilton B, 1997, J BIOL CHEM, V272, P28096, DOI 10.1074/jbc.272.44.28096; Tsai JC, 1996, J BIOL CHEM, V271, P3667; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P19772, DOI 10.1074/jbc.273.31.19772; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022; UshioFukai M, 1996, J BIOL CHEM, V271, P23317, DOI 10.1074/jbc.271.38.23317; Zafari AM, 1998, HYPERTENSION, V32, P488, DOI 10.1161/01.HYP.32.3.488	38	480	490	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22699	22704		10.1074/jbc.274.32.22699	http://dx.doi.org/10.1074/jbc.274.32.22699			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428852	hybrid			2022-12-25	WOS:000081868400082
J	Wang, YL; Devereux, W; Stewart, TM; Casero, RA				Wang, YL; Devereux, W; Stewart, TM; Casero, RA			Cloning and characterization of human polyamine-modulated factor-1, a transcriptional cofactor that regulates the transcription of the spermidine/spermine N-1-acetyltransferase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; ORNITHINE DECARBOXYLASE; SPERMINE N1-ACETYLTRANSFERASE; LUNG-CANCER; CARCINOMA-CELLS; MESSENGER-RNA; HA-RAS; INDUCTION; ANALOGS; GROWTH	The increased transcription and ultimate superinduction of the spermidine/spermine N-1-acetyltransferase (SSAT) gene has been associated with the antineoplastic activity of several new antitumor polyamine analogues. In sensitive tumor cell types, the transcriptional induction appears to be regulated by the constitutive association of the transcription factor Nrf-2 with the recently discovered polyamine-responsive element. Using the yeast two-hybrid system, a new transcriptional cofactor, polyamine-modulated factor-1 (PMF-1), has been identified as a partner protein of Nrf-2 that, in combination with Nrf-2, regulates the polyamine analogue-induced transcription of SSAT, The human PMF-1 gene, located on chromosome 1 near the 1q12/1q21 border, yields an mRNA transcript of similar to 1.2 kilobases that codes for a 165-amino acid protein with a predicted molecular mass of similar to 20 kDa, The PMF-1 mRNA appears to increase in response to analogue exposure only in analogue-responsive cells, In addition to the transcriptional regulation of SSAT, PMF-1 or similar factors should be considered in the regulation of other polyamine-dependent genes.	Johns Hopkins Oncol Ctr, Res Labs, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine	Casero, RA (corresponding author), Johns Hopkins Oncol Ctr, Res Labs, 424 N Bond St, Baltimore, MD 21231 USA.	casero@welchlink.welch.jhu.edu	Stewart, Tracy Murray/B-6137-2017	Stewart, Tracy Murray/0000-0001-8679-6414; Casero, Robert/0000-0001-5653-3306	NATIONAL CANCER INSTITUTE [P50CA058184, R01CA051085] Funding Source: NIH RePORTER; NCI NIH HHS [CA51085, CA58184] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alhonen L, 1998, J BIOL CHEM, V273, P1964, DOI 10.1074/jbc.273.4.1964; Auvinen M, 1997, CANCER RES, V57, P3016; Bergeron RJ, 1997, J MED CHEM, V40, P1475, DOI 10.1021/jm960849j; Bernacki RJ, 1995, CLIN CANCER RES, V1, P847; Bryans M, 1996, BIOCHEM BIOPH RES CO, V226, P618, DOI 10.1006/bbrc.1996.1405; CASERO RA, 1992, CANCER RES, V52, P5359; CASERO RA, 1995, CANCER CHEMOTH PHARM, V36, P69; CASERO RA, 1989, CANCER RES, V49, P3829; CELANO P, 1989, J BIOL CHEM, V264, P8922; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FOGELPETROVIC M, 1993, J BIOL CHEM, V268, P19118; Giardiello FM, 1997, CANCER RES, V57, P199; Ha HC, 1997, P NATL ACAD SCI USA, V94, P11557, DOI 10.1073/pnas.94.21.11557; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Kramer DL, 1999, CANCER RES, V59, P1278; Kubota S, 1997, J NATL CANCER I, V89, P567, DOI 10.1093/jnci/89.8.567; LEI X, 1992, BIOCHEM BIOPH RES CO, V187, P1493, DOI 10.1016/0006-291X(92)90471-V; LUK GD, 1984, NEW ENGL J MED, V311, P80, DOI 10.1056/NEJM198407123110202; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; McCloskey DE, 1996, CLIN CANCER RES, V2, P441; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; PaasinenSohns A, 1997, ONCOGENE, V15, P1953, DOI 10.1038/sj.onc.1201366; Patel AR, 1997, AM J PHYSIOL-CELL PH, V273, pC1020, DOI 10.1152/ajpcell.1997.273.3.C1020; PORTER CW, 1991, CANCER RES, V51, P3715; PORTER CW, 1993, CANCER RES, V53, P581; Ray RM, 1999, AM J PHYSIOL-CELL PH, V276, pC684, DOI 10.1152/ajpcell.1999.276.3.C684; RUCKDESCHEL JC, 1986, J CLIN ONCOL, V4, P14, DOI 10.1200/JCO.1986.4.1.14; SAAB NH, 1993, J MED CHEM, V36, P2998, DOI 10.1021/jm00072a020; SCEMAMA JL, 1993, AM J PHYSIOL, V265, pG851, DOI 10.1152/ajpgi.1993.265.5.G851; Shantz LM, 1998, CANCER RES, V58, P2748; Smith MK, 1998, CARCINOGENESIS, V19, P1409, DOI 10.1093/carcin/19.8.1409; Soler AP, 1998, CANCER RES, V58, P1654; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; Tabib A, 1998, INT J BIOCHEM CELL B, V30, P135, DOI 10.1016/S1357-2725(97)00073-3; TABIB A, 1994, BIOCHEM BIOPH RES CO, V202, P720, DOI 10.1006/bbrc.1994.1990; Wang YL, 1998, J BIOL CHEM, V273, P34623, DOI 10.1074/jbc.273.51.34623; Xiao L, 1996, BIOCHEM J, V313, P691, DOI 10.1042/bj3130691	41	70	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					22095	22101		10.1074/jbc.274.31.22095	http://dx.doi.org/10.1074/jbc.274.31.22095			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419538	hybrid			2022-12-25	WOS:000081721100091
J	Gu, JJ; Dong, RP; Zhang, CH; McLaughlin, DF; Wu, MX; Schlossman, SF				Gu, JJ; Dong, RP; Zhang, CH; McLaughlin, DF; Wu, MX; Schlossman, SF			Functional interaction of DFF35 and DFF45 with caspase-activated DNA fragmentation nuclease DFF40	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; APOPTOSIS; INHIBITOR; ONCOSIS; DEGRADATION; NECROSIS	DNA fragmentation factor (DFF) functions downstream of caspase-3 and directly triggers DNA fragmentation during apoptosis, Here we described the identification and characterization of DFF35, an isoform of DFF45 comprised of 268 amino acids. Functional assays have shown that only DFF45, not DFF35, can assist in the synthesis of highly active DFF40, Using the deletion mutants, we mapped the function domains of DFF35/45 and demonstrated that the intact structure/conformation of DFF45 is essential for it to function as a chaperone and assist in the synthesis of active DFF40, Whereas the amino acid residues 101-180 of DFF35/45 mediate its binding to DFF40, the amino acid residues 23-100, which is homologous between DFF35/45 and DFF40, may function to inhibit the activity of DFF40. In contrast to DFF45, DFF35 cannot work as a chaperone, but it can bind to DFF40 more strongly than DFF45 and can inhibit its nuclease activity. These findings suggest that DFF35 may function in vivo as an important alternative mechanism to inhibit the activity of DFF40 and further, that the inhibitory effects of both DFF35 and DFF45 on DFF40 can put the death machinery under strict control.	Dana Farber Canc Inst, Div Tumor Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Schlossman, SF (corresponding author), Dana Farber Canc Inst, Div Tumor Immunol, 44 Binney St, Boston, MA 02115 USA.							Barinaga M, 1998, SCIENCE, V280, P32, DOI 10.1126/science.280.5360.32; BARRY MA, 1993, ARCH BIOCHEM BIOPHYS, V300, P440, DOI 10.1006/abbi.1993.1060; DUKE RC, 1983, P NATL ACAD SCI-BIOL, V80, P6361, DOI 10.1073/pnas.80.20.6361; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Halenbeck R, 1998, CURR BIOL, V8, P537, DOI 10.1016/S0960-9822(98)79298-X; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; MAJNO G, 1995, AM J PATHOL, V146, P3; Montague JW, 1997, J BIOL CHEM, V272, P6677, DOI 10.1074/jbc.272.10.6677; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; PEITSCH MC, 1993, EMBO J, V12, P371, DOI 10.1002/j.1460-2075.1993.tb05666.x; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Trump BF, 1997, TOXICOL PATHOL, V25, P82, DOI 10.1177/019262339702500116; Webb S J, 1997, Adv Pharmacol, V41, P1, DOI 10.1016/S1054-3589(08)61052-2; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Zhang CG, 1998, P NATL ACAD SCI USA, V95, P6290, DOI 10.1073/pnas.95.11.6290; ZHANG CH, 1995, CELL IMMUNOL, V165, P161, DOI 10.1006/cimm.1995.1201	20	73	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					20759	20762		10.1074/jbc.274.30.20759	http://dx.doi.org/10.1074/jbc.274.30.20759			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409614	hybrid			2022-12-25	WOS:000081613100005
J	Touriol, C; Morillon, A; Gensac, MC; Prats, H; Prats, AC				Touriol, C; Morillon, A; Gensac, MC; Prats, H; Prats, AC			Expression of human fibroblast growth factor 2 mRNA is post-transcriptionally controlled by a unique destabilizing element present in the 3 '-untranslated region between alternative polyadenylation sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUG-INITIATED FORMS; MESSENGER-RNA; FACTOR GENE; TRANSLATION; CELLS; CUG; GROWTH-FACTOR-2; PHENOTYPE; OOCYTES; CODONS	Fibroblast growth factor 2 (FGF-2) belongs to a family of 18 genes coding for either mitogenic differentiating factors or oncogenic proteins, the expression of which must be tightly controlled. We looked for regulatory elements in the 5823-nucleotide-long 3'-untranslated region of the FGF-2 mRNA that contains eight potential alternative polyadenylation sites. Quantitative reverse transcription-polymerase chain reaction revealed that poly(A) site utilization was cell type-dependent, with the eighth poly(A) site being used (95%) in primary human skin fibroblasts, whereas proximal sites were used in the transformed cell lines studied here. We used a cell transfection approach with synthetic reporter mRNAs to localize a destabilizing element between the first and second poly(A) sites. Although AU-rich, the FGF-2-destabilizing element had unique features: it involved a 122-nucleotide direct repeat, with both elements of the repeat being required for the destabilizing activity. These data show that short stable FGF-2 mRNAs are present in transformed cells, whereas skin fibroblasts contain mostly long unstable mRNAs, suggesting that FGF-2 mRNA stability cannot be regulated in transformed cells,The results also provide evidence of a multilevel post-transcriptional control of FGF-2 expression; such a stringent control prevents FGF-2 overexpression and permits its expression to be enhanced only in relevant physiological situations.	CHU Rangueil, Inst Louis Bugnard, INSERM, U397, F-31403 Toulouse 04, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Prats, AC (corresponding author), CHU Rangueil, Inst Louis Bugnard, INSERM, U397, Ave Jean Poulhes, F-31403 Toulouse 04, France.	pratsac@rangueil.inserm.fr	Morillon, Antonin/M-4751-2017; TOURIOL, Christian/O-8949-2014; Prats, Anne-Catherine/E-5051-2016	Morillon, Antonin/0000-0002-0575-5264; TOURIOL, Christian/0000-0003-1219-4693; Prats, Anne-Catherine/0000-0002-5282-3776; Prats, Herve/0000-0002-4861-2167				Arnaud E, 1999, MOL CELL BIOL, V19, P505; BENSAID M, 1989, EXP EYE RES, V48, P801, DOI 10.1016/0014-4835(89)90065-1; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; Brigstock DR, 1991, GROWTH FACTORS, V4, DOI 10.3109/08977199109104815; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; Claffey KP, 1998, MOL BIOL CELL, V9, P469, DOI 10.1091/mbc.9.2.469; COFFIN JD, 1995, MOL BIOL CELL, V6, P1861, DOI 10.1091/mbc.6.12.1861; COUDERC B, 1991, CELL REGUL, V2, P709, DOI 10.1091/mbc.2.9.709; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; Galy B, 1999, CANCER RES, V59, P165; Hansen WR, 1996, AM J PHYSIOL-RENAL, V271, pF126, DOI 10.1152/ajprenal.1996.271.1.F126; HENICS T, 1994, J BIOL CHEM, V269, P5377; Hoshikawa M, 1998, BIOCHEM BIOPH RES CO, V244, P187, DOI 10.1006/bbrc.1998.8239; Jarzembowski J A, 1997, Prog Mol Subcell Biol, V18, P141; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; KIMELMAN D, 1989, CELL, V59, P687, DOI 10.1016/0092-8674(89)90015-9; KNEE RS, 1994, BIOCHEM BIOPH RES CO, V205, P577, DOI 10.1006/bbrc.1994.2704; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MURPHY PR, 1994, MOL ENDOCRINOL, V8, P852, DOI 10.1210/me.8.7.852; Ohbayashi N, 1998, J BIOL CHEM, V273, P18161, DOI 10.1074/jbc.273.29.18161; PRATS AC, 1992, MOL CELL BIOL, V12, P4796, DOI 10.1128/MCB.12.10.4796; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; QUARTO N, 1991, CELL REGUL, V2, P699, DOI 10.1091/mbc.2.9.699; Rajagopalan LE, 1996, J BIOL CHEM, V271, P19871, DOI 10.1074/jbc.271.33.19871; Smallwood PM, 1996, P NATL ACAD SCI USA, V93, P9850, DOI 10.1073/pnas.93.18.9850; Vagner S, 1996, J CELL BIOL, V135, P1391, DOI 10.1083/jcb.135.5.1391; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; WAGNER JA, 1991, CURR TOP MICROBIOL, V165, P95; Wickens M, 1997, CURR OPIN GENET DEV, V7, P220, DOI 10.1016/S0959-437X(97)80132-3; YAMAGUCHI TP, 1995, CURR OPIN GENET DEV, V5, P485, DOI 10.1016/0959-437X(95)90053-J; YANAGISAWAMIWA A, 1992, SCIENCE, V257, P1401, DOI 10.1126/science.1382313	34	56	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21402	21408		10.1074/jbc.274.30.21402	http://dx.doi.org/10.1074/jbc.274.30.21402			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409702	hybrid			2022-12-25	WOS:000081613100093
J	Chiu, ML; Folcher, M; Katoh, T; Puglia, AM; Vohradsky, J; Yun, BS; Seto, H; Thompson, CJ				Chiu, ML; Folcher, M; Katoh, T; Puglia, AM; Vohradsky, J; Yun, BS; Seto, H; Thompson, CJ			Broad spectrum thiopeptide recognition specificity of the Streptomyces lividans TipAL protein and its role in regulating gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTER INDUCING ACTIVITY; THIOSTREPTON-INDUCED GENE; TRANSCRIPTIONAL ACTIVATION; ANTIBIOTIC-RESISTANCE; MULTIENZYME COMPLEXES; SP SF2741; GLUTATHIONE; SEQUENCE; BINDING; HYGROSCOPICUS	Microbial metabolites isolated in screening programs for their ability to activate transcription of the tipA promoter (ptipA) in Streptomyces lividans define a class of cyclic thiopeptide antibiotics having dehydroalanine side chains ("tails"). Here we show that such compounds of heterogeneous primary structure (representatives tested: thiostrepton, nosiheptide, berninamycin, promothiocin) are all recognized by TipAS and TipAL, two in-frame translation products of the tipA gene. The N-terminal helix-turn-helix DNA binding motif of TipAL is homologous to the MerR family of transcriptional activators, while the C terminus forms a novel ligand-binding domain. ptipA inducers formed irreversible complexes in vitro and in vivo (presumably covalent) with TipAS by reacting with the second of the two C-terminal cysteine residues. Promothiocin and thiostrepton derivatives in which the dehydroalanine side chains were removed lost the ability to modify TipAS. They were able to induce expression of ptipA as well as the tipA gene, although with reduced activity. Thus, TipA required the thiopeptide ring structure for recognition, while the tail served either as a dispensable part of the recognition domain and/or locked thiopeptides onto TipA proteins, thus leading to an irreversible transcriptional activation. Construction and analysis of a disruption mutant showed that tipA was autogenously regulated and conferred thiopeptide resistance. Thiostrepton induced the synthesis of other proteins, some of which did not require tipA.	Univ Basel, Bioctr, Dept Microbiol, CH-4056 Basel, Switzerland; Shionogi & Co Ltd, Shionogi Res Labs, Fukushima Ku, Osaka 5530002, Japan; Univ Palermo, Dipartimento Biol Cellulare & Sviluppo, Sez Genet, I-90128 Palermo, Italy; Acad Sci Czech Republic, Inst Microbiol, CZ-14220 Prague 4, Czech Republic; Korea Res Inst Biosci & Biotechnol, Taejon 305600, South Korea; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 113, Japan	University of Basel; Shionogi & Company Limited; University of Palermo; Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences; Korea Research Institute of Bioscience & Biotechnology (KRIBB); University of Tokyo	Thompson, CJ (corresponding author), Univ Basel, Bioctr, Dept Microbiol, Klingelbergstr 70, CH-4056 Basel, Switzerland.	thompson@ubaclu.unibas.ch		Chiu, Mark/0000-0001-6300-404X				AHMED M, 1994, J BIOL CHEM, V269, P28506; ANSARI AZ, 1992, NATURE, V355, P87, DOI 10.1038/355087a0; AUBELSADRON G, 1984, BIOCHIMIE, V66, P333, DOI 10.1016/0300-9084(84)90018-X; BANNISTER ER, 1966, CAN J MICROBIOL, V12, P595, DOI 10.1139/m66-085; BARDWELL JCA, 1994, MOL MICROBIOL, V14, P199, DOI 10.1111/j.1365-2958.1994.tb01281.x; BIBB MJ, 1985, MOL GEN GENET, V199, P26, DOI 10.1007/BF00327505; Broda MA, 1997, J PEPT RES, V50, P342; BUJARD H, 1987, METHOD ENZYMOL, V155, P416; CAMPBELL JL, 1978, P NATL ACAD SCI USA, V75, P2276, DOI 10.1073/pnas.75.5.2276; Chiu ML, 1996, BIOCHEMISTRY-US, V35, P2332, DOI 10.1021/bi952073e; CUNDLIFFE E, 1987, BIOCHIMIE, V69, P863, DOI 10.1016/0300-9084(87)90213-6; CUNDLIFFE E, 1980, ANTIBIOTICS PROCARYO, P555; DEMAIN AL, 1995, WHY DO MICROORGANISM, V53, P50; DRAPER DE, 1995, NUCL ACIDS S SER, V33, P5; FAHEY RC, 1978, J BACTERIOL, V133, P1126, DOI 10.1128/JB.133.3.1126-1129.1978; FAHEY RC, 1991, ADV ENZYMOL RAMB, V64, P1; GENGHOF DS, 1970, J BACTERIOL, V103, P475, DOI 10.1128/JB.103.2.475-478.1970; GEORGE JW, 1992, J BIOL CHEM, V267, P10683; Gort AS, 1998, J BACTERIOL, V180, P1402, DOI 10.1128/JB.180.6.1402-1410.1998; GUILFOILE PG, 1991, P NATL ACAD SCI USA, V88, P8553, DOI 10.1073/pnas.88.19.8553; HELMANN JD, 1990, SCIENCE, V247, P946, DOI 10.1126/science.2305262; HERNER AE, 1969, BIOCHEMISTRY-US, V8, P1335, DOI 10.1021/bi00832a006; HIDALGO E, 1994, EMBO J, V13, P138, DOI 10.1002/j.1460-2075.1994.tb06243.x; Hofs HP, 1997, ANTI-CANCER DRUG, V8, P349, DOI 10.1097/00001813-199704000-00007; HOLMES DJ, 1993, EMBO J, V12, P3183, DOI 10.1002/j.1460-2075.1993.tb05987.x; HOLMES DJ, 1993, INDUSTRIAL MICROORGANISMS: BASIC AND APPLIED MOLECULAR GENETICS, P69; Hopwood D. A., 1985, GENETIC MANIPULATION; KEPPENS L, 1979, REV AGR-BRUSSELS, V32, P159; KETTENRING J, 1991, J ANTIBIOT, V44, P702, DOI 10.7164/antibiotics.44.702; KUHSTOSS S, 1991, GENE, V103, P97, DOI 10.1016/0378-1119(91)90398-U; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAZODIER P, 1989, J BACTERIOL, V171, P3583, DOI 10.1128/jb.171.6.3583-3585.1989; MINE K, 1972, ANTIMICROB AGENTS CH, V1, P496, DOI 10.1128/AAC.1.6.496; MONRO RE, 1969, NATURE, V222, P356, DOI 10.1038/222356a0; MUIR LA, 1980, J ANIM SCI, V50, P547, DOI 10.2527/jas1980.503547x; MURAKAMI T, 1989, J BACTERIOL, V171, P1459, DOI 10.1128/jb.171.3.1459-1466.1989; MURAKAMI T, 1986, MOL GEN GENET, V205, P42, DOI 10.1007/BF02428031; NEWTON GL, 1995, EUR J BIOCHEM, V230, P821; PERHAM RN, 1991, BIOCHEMISTRY-US, V30, P8501, DOI 10.1021/bi00099a001; PETSKA S, 1969, P NATL ACAD SCI USA, V64, P709; PLATER R, 1992, GENE, V112, P117, DOI 10.1016/0378-1119(92)90312-D; PUGLIA AM, 1995, MOL MICROBIOL, V17, P737, DOI 10.1111/j.1365-2958.1995.mmi_17040737.x; REED LJ, 1974, ACCOUNTS CHEM RES, V7, P40, DOI 10.1021/ar50074a002; ROSENDAHL G, 1993, J MOL BIOL, V234, P1013, DOI 10.1006/jmbi.1993.1655; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SELVA E, 1991, J ANTIBIOT, V44, P693, DOI 10.7164/antibiotics.44.693; SMOKVINA T, 1990, GENE, V94, P53, DOI 10.1016/0378-1119(90)90467-6; SPIES HSC, 1994, EUR J BIOCHEM, V224, P203, DOI 10.1111/j.1432-1033.1994.tb20013.x; THOMAS JA, 1995, ARCH BIOCHEM BIOPHYS, V319, P1, DOI 10.1006/abbi.1995.1261; THOMPSON CJ, 1982, J BACTERIOL, V151, P678, DOI 10.1128/JB.151.2.678-685.1982; VILLAREJO MR, 1974, J BACTERIOL, V120, P466, DOI 10.1128/JB.120.1.466-474.1974; Xing YY, 1996, BIOCHEMISTRY-US, V35, P1581, DOI 10.1021/bi952132o; YUN BS, 1995, BIOSCI BIOTECH BIOCH, V59, P876, DOI 10.1271/bbb.59.876; YUN BS, 1994, J ANTIBIOT, V47, P969, DOI 10.7164/antibiotics.47.969; YUN BS, 1994, J ANTIBIOT, V47, P1541, DOI 10.7164/antibiotics.47.1541; YUN BS, 1994, J ANTIBIOT, V47, P510, DOI 10.7164/antibiotics.47.510; ZALACAIN M, 1986, NUCLEIC ACIDS RES, V14, P1565, DOI 10.1093/nar/14.4.1565; Zheleznova EE, 1999, CELL, V96, P353, DOI 10.1016/S0092-8674(00)80548-6	60	53	57	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20578	20586		10.1074/jbc.274.29.20578	http://dx.doi.org/10.1074/jbc.274.29.20578			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400688	hybrid			2022-12-25	WOS:000081438300081
J	Kato, Y; Mori, Y; Morimitsu, Y; Hiroi, S; Ishikwa, T; Osawa, T				Kato, Y; Mori, Y; Morimitsu, Y; Hiroi, S; Ishikwa, T; Osawa, T			Formation of N-epsilon-(Hexanonyl)lysine in protein exposed to lipid hydroperoxide - A plausible marker for lipid hydroperoxide-derived protein modification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-MODIFIED PROTEIN; DENSITY LIPOPROTEIN; OXIDATIVE MODIFICATION; POLYCLONAL ANTIBODY; COVALENT BINDING; OXIDIZED LDL; AMINO-ACIDS; LIPOXYGENASE-1; PRODUCTS; ESTERS	The objectives of this study were to estimate the structure of the lipid hydroperoxide-modified lysine residue and to prove the presence of the adducts in vivo. The reaction of lipid hydroperoxide toward the lysine moiety was investigated employing N-benzoyl-glycyl-L-lysine (Bz-Gly-Lys) as a model compound of Lys residues in protein and 13-hydroperoxyoctadecadienoic acid (13-HPODE) as a model of the lipid hydroperoxides. One of the products, compound X, was isolated from the reaction mixture of 13-HPODE and Bz-Gly-Lys and was then identified as N-benzoyl-glycyl-N-epsilon-(hexanonyl)lysine. To prove the formation of N-epsilon-(hexanonyl)lysine, named HEL, in protein exposed to the lipid hydroperoxide, the antibody to the synthetic hexanonyl protein was prepared and then characterized in detail. Using the anti-HEL antibody, the presence of HEL in the lipid hydroperoxide-modified proteins and oxidized LDL was confirmed. Furthermore, the positive staining by anti-HEL antibody was observed in human atherosclerotic lesions using an immunohistochemical technique. The amide-type adduct may be a useful marker for the lipid hydroperoxide-derived modification of biomolecules.	Himeji Inst Technol, Sch Humanities Environm Policy & Technol, Himeji, Hyogo 6700092, Japan; Nagoya Univ, Dept Appl Biol Sci, Nagoya, Aichi 4648601, Japan; Natl Def Med Coll, Dept Pathol, Tokorozawa, Saitama 3590042, Japan; Natl Def Med Coll, Dept Med 1, Tokuyama, Yamaguchi 3590042, Japan	University of Hyogo; Nagoya University; National Defense Medical College - Japan; National Defense Medical College - Japan	Kato, Y (corresponding author), Himeji Inst Technol, Sch Humanities Environm Policy & Technol, Himeji, Hyogo 6700092, Japan.		Kato, Yoji/W-4779-2019	Kato, Yoji/0000-0002-8295-7337				Blackburn ML, 1997, CHEM RES TOXICOL, V10, P1364, DOI 10.1021/tx970087a; Bull AW, 1996, LIFE SCI, V58, P2355, DOI 10.1016/0024-3205(96)00236-6; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; FRUEBIS J, 1992, P NATL ACAD SCI USA, V89, P10588, DOI 10.1073/pnas.89.22.10588; FUKUZAWA K, 1985, LIPIDS, V20, P854, DOI 10.1007/BF02534768; GRABAREK Z, 1990, ANAL BIOCHEM, V185, P131, DOI 10.1016/0003-2697(90)90267-D; HABERLAND ME, 1988, SCIENCE, V241, P215, DOI 10.1126/science.2455346; HIDALGO FJ, 1995, J LIPID RES, V36, P725; Kato Y, 1997, J LIPID RES, V38, P1334; Kato Y, 1996, BIOCHEM BIOPH RES CO, V226, P923, DOI 10.1006/bbrc.1996.1451; Kato Y, 1998, ARCH BIOCHEM BIOPHYS, V351, P106, DOI 10.1006/abbi.1997.0519; Kim JG, 1997, FREE RADICAL BIO MED, V23, P251, DOI 10.1016/S0891-5849(96)00615-6; KUHN H, 1991, EICOSANOIDS, V4, P9; MURAKAMI M, 1987, J BIOCHEM-TOKYO, V101, P729, DOI 10.1093/jb/101.3.729; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; SHIMASAKI H, 1982, LIPIDS, V17, P878, DOI 10.1007/BF02534582; STEINBRECHER UP, 1987, J BIOL CHEM, V262, P3603; Uchida K, 1998, P NATL ACAD SCI USA, V95, P4882, DOI 10.1073/pnas.95.9.4882; VERHAGEN J, 1977, BIOCHIM BIOPHYS ACTA, V486, P114, DOI 10.1016/0005-2760(77)90075-3; YAGI K, 1986, BIOCHEM INT, V12, P367; YAMAMOTO Y, 1989, BIOCHEM BIOPH RES CO, V165, P988, DOI 10.1016/0006-291X(89)92700-9	21	146	148	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20406	20414		10.1074/jbc.274.29.20406	http://dx.doi.org/10.1074/jbc.274.29.20406			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400665	hybrid			2022-12-25	WOS:000081438300058
J	Wisniewski, JR; Szewczuk, Z; Petry, I; Schwanbeck, R; Renner, U				Wisniewski, JR; Szewczuk, Z; Petry, I; Schwanbeck, R; Renner, U			Constitutive phosphorylation of the acidic tails of the high mobility group 1 proteins by casein kinase II alters their conformation, stability, and DNA binding specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA-MELANOGASTER; REGIONS FLANKING; BOX DOMAINS; HMG1; IDENTIFICATION; TRANSCRIPTION; CHROMATIN; MODULATE; CHMG1A; SITES	The high mobility group (HMG) 1 and 2 proteins are the most abundant non-histone components of chromosomes. Here, we report that essentially the entire pool of HMG1 proteins in Drosophila embryos and Chironomus cultured cells is phosphorylated at multiple serine residues located within acidic tails of these proteins. The phosphorylation sites match the consensus phosphorylation site of casein kinase II. Electrospray ionization mass spectroscopic analyses revealed that Drosophila HMGD and Chironomus HBG1a and HMG1b are double-phosphorylated and that Drosophila HMGZ is triple-phosphorylated. The importance of this post-translational modification was studied by comparing some properties of the native and in vitro dephosphorylated proteins. It was found that dephosphorylation affects the conformation of the proteins and decreases their conformational and metabolic stability. Moreover, it weakens binding of the proteins to four-way junction DNA by 2 orders of magnitude, whereas the strength of binding to linear DNA remains unchanged. Based on these observations, we propose that the detected phosphorylation is important for the proper function and turnover rates of these proteins. As the occurrence of acidic tails containing canonical casein kinase II phosphorylation sites is common to diverse HMG and other chromosomal proteins, our results are probably of general significance.	Univ Gottingen, Zool Inst Entwicklungsbiol 3, D-37073 Gottingen, Germany; Wroclaw B Beirut Univ, Inst Chem, PL-50383 Wroclaw, Poland	University of Gottingen; University of Wroclaw	Wisniewski, JR (corresponding author), Univ Gottingen, Zool Inst Entwicklungsbiol 3, Humboldtallee 34A, D-37073 Gottingen, Germany.	jwisnie@gwdg.de	Petry-Podgorska, Inga/I-3886-2014; Szewczuk, Zbigniew/A-2243-2013; Schwanbeck, Ralf/A-2648-2008	Schwanbeck, Ralf/0000-0003-0925-929X; Szewczuk, Zbigniew/0000-0001-5884-9363				AIZAWA S, 1994, BIOCHEMISTRY-US, V33, P14690, DOI 10.1021/bi00253a006; AlamiOuahabi N, 1996, MOL CELL BIOL, V16, P3720; BODENBACH L, 1994, EUR J BIOCHEM, V220, P263, DOI 10.1111/j.1432-1033.1994.tb18622.x; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; EISSENBERG JC, 1994, J BIOL CHEM, V269, P21315; FERRANTI P, 1992, J BIOL CHEM, V267, P22486; Frank O, 1998, J BIOL CHEM, V273, P20015, DOI 10.1074/jbc.273.32.20015; Ghidelli S, 1997, CHROMOSOMA, V105, P369, DOI 10.1007/BF02529752; Giancotti V, 1996, BIOCHEM J, V317, P865, DOI 10.1042/bj3170865; GLOVER CVC, 1983, J BIOL CHEM, V258, P3258; GLOVER CVC, 1995, PROTEIN KINASE FACTS, P243; Goodwin G, 1998, INT J BIOCHEM CELL B, V30, P761, DOI 10.1016/S1357-2725(98)00016-8; GRASSER KD, 1989, BIOCHEM BIOPH RES CO, V162, P456, DOI 10.1016/0006-291X(89)92019-6; Havel Henry A., 1996, P62; HERSHEY JC, 1995, J BIOL CHEM, V270, P25096, DOI 10.1074/jbc.270.42.25096; Heyduk E, 1997, J BIOL CHEM, V272, P19763, DOI 10.1074/jbc.272.32.19763; Hill DA, 1997, NUCLEIC ACIDS RES, V25, P3523, DOI 10.1093/nar/25.17.3523; Kulikova OG, 1996, BIOCHEMISTRY-MOSCOW+, V61, P750; MEISNER H, 1995, PROTEIN KINASE FACTS, P240; MOSEVITSKY MI, 1989, EUR J BIOCHEM, V185, P303, DOI 10.1111/j.1432-1033.1989.tb15116.x; NER SS, 1993, NUCLEIC ACIDS RES, V21, P4369, DOI 10.1093/nar/21.18.4369; NISSEN MS, 1991, J BIOL CHEM, V266, P19945; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; PALVIMO J, 1989, FEBS LETT, V257, P101, DOI 10.1016/0014-5793(89)81796-X; Payet D, 1997, J MOL BIOL, V266, P66, DOI 10.1006/jmbi.1996.0782; PEACE CN, 1989, PROTEIN STRUCTURE PR, P311; Postnikov YV, 1997, J MOL BIOL, V274, P454, DOI 10.1006/jmbi.1997.1391; RAGONE R, 1984, BIOCHEMISTRY-US, V23, P1871, DOI 10.1021/bi00303a044; REEVES R, 1991, P NATL ACAD SCI USA, V88, P1671, DOI 10.1073/pnas.88.5.1671; Ritt C, 1998, BIOCHEMISTRY-US, V37, P2673, DOI 10.1021/bi972620r; Schwanbeck R, 1997, J BIOL CHEM, V272, P27476, DOI 10.1074/jbc.272.43.27476; SHEFLIN LG, 1993, BIOCHEMISTRY-US, V32, P3238, DOI 10.1021/bi00064a005; Shirakawa H, 1997, BIOCHEMISTRY-US, V36, P5992, DOI 10.1021/bi962487n; Stros M, 1998, J BIOL CHEM, V273, P10355; STROS M, 1994, NUCLEIC ACIDS RES, V22, P1044, DOI 10.1093/nar/22.6.1044; WAGNER CR, 1992, MOL CELL BIOL, V12, P1915, DOI 10.1128/MCB.12.5.1915; WALTON GM, 1985, J BIOL CHEM, V260, P4745; Wisniewski Jacek R., 1998, Zoologica Poloniae, V43, P5; WISNIEWSKI JR, 1992, J BIOL CHEM, V267, P17170; WISNIEWSKI JR, 1994, J BIOL CHEM, V269, P10713; Wisniewski JR, 1997, EUR J BIOCHEM, V243, P151, DOI 10.1111/j.1432-1033.1997.0151a.x; WISNIEWSKI JR, 1994, J BIOL CHEM, V269, P29261; WISNIEWSKI JR, 1994, EUR J BIOCHEM, V225, P687, DOI 10.1111/j.1432-1033.1994.00687.x; Zweidler A, 1978, Methods Cell Biol, V17, P223, DOI 10.1016/S0091-679X(08)61145-0	44	70	71	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20116	20122						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400623				2022-12-25	WOS:000081438300016
J	Fujiwara, Y; Masutani, C; Mizukoshi, T; Kondo, J; Hanaoka, F; Iwai, S				Fujiwara, Y; Masutani, C; Mizukoshi, T; Kondo, J; Hanaoka, F; Iwai, S			Characterization of DNA recognition by the human UV-damaged DNA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIGMENTOSUM GROUP-E; NUCLEOTIDE EXCISION-REPAIR; RESONANCE ENERGY-TRANSFER; COMPLEMENTATION GROUP-E; GROUP-E CELLS; ANTICANCER DRUG CISPLATIN; SOLUTION-STATE STRUCTURE; GROUP-C PROTEIN; MOLECULAR-STRUCTURE; CRYSTAL-STRUCTURE	The UV-damaged DNA-binding (UV-DDB) protein is the major factor that binds DNA containing damage caused by UV radiation in mammalian cells, We have investigated the DNA recognition by this protein in vitro, using synthetic oligonucleotide duplexes and the protein purified from a HeLa cell extract. When a P-32-labeled 30-mer duplex containing the (6-4) photoproduct at a single site was used as a probe, only a single complex was detected in an electrophoretic mobility shift assay. It was demonstrated by Western blotting that both of the subunits (p48 and p127) were present in this complex. Electrophoretic mobility shift assays using various duplexes showed that the UV-DDB protein formed a specific, high affinity complex with the duplex containing an abasic site analog, in addition to the (6-4) photoproduct. By circular permutation analyses, these DNA duplexes were found to be bent at angles of 54 degrees and 57 degrees in the complexes with this protein. From the previously reported NMR studies and the fluorescence resonance energy transfer experiments in the present study, it can be concluded that the UV-DDB protein binds DNA that can be bent easily at the above angle.	Biomed Engn Res Inst, Dept Bioorgan Chem, Osaka 5650874, Japan; Inst Mol & Cellular Biol, Osaka 5650871, Japan; Mitsubishi Chem Corp, Yokohama, Kanagawa 2278502, Japan	Mitsubishi Chemical Holdings Corporation; Mitsubishi Chemical	Iwai, S (corresponding author), Biomed Engn Res Inst, Dept Bioorgan Chem, 6-2-3 Furuedai, Osaka 5650874, Japan.		Masutani, Chikahide/I-6160-2014	Masutani, Chikahide/0000-0002-8600-8227				ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; AVITAHL N, 1994, J BIOL CHEM, V269, P23553; Beger RD, 1998, J BIOL CHEM, V273, P15565, DOI 10.1074/jbc.273.25.15565; Burns JL, 1996, J BIOL CHEM, V271, P11607, DOI 10.1074/jbc.271.20.11607; CHOW CS, 1994, BIOCHEMISTRY-US, V33, P15124, DOI 10.1021/bi00254a023; CHU G, 1988, SCIENCE, V242, P564, DOI 10.1126/science.3175673; CLEGG RM, 1993, P NATL ACAD SCI USA, V90, P2994, DOI 10.1073/pnas.90.7.2994; Coppel Y, 1997, BIOCHEMISTRY-US, V36, P4817, DOI 10.1021/bi962677y; DUALAN R, 1995, GENOMICS, V29, P62, DOI 10.1006/geno.1995.1215; FELDBERG RS, 1976, BIOCHEMISTRY-US, V15, P2402, DOI 10.1021/bi00656a024; FELDBERG RS, 1982, J BIOL CHEM, V257, P6394; Gelasco A, 1998, BIOCHEMISTRY-US, V37, P9230, DOI 10.1021/bi973176v; GERVAIS V, 1995, EUR J BIOCHEM, V228, P279; GINELL SL, 1994, BIOCHEMISTRY-US, V33, P3487, DOI 10.1021/bi00178a004; GOLJER I, 1995, J BIOL CHEM, V270, P22980, DOI 10.1074/jbc.270.39.22980; Hayes S, 1998, MOL CELL BIOL, V18, P240, DOI 10.1128/MCB.18.1.240; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HIRSCHFELD S, 1990, MOL CELL BIOL, V10, P2041, DOI 10.1128/MCB.10.5.2041; Hwang BJ, 1996, MUTAT RES-DNA REPAIR, V362, P105, DOI 10.1016/0921-8777(95)00040-2; HWANG BJ, 1993, BIOCHEMISTRY-US, V32, P1657, DOI 10.1021/bi00057a033; Hwang BJ, 1998, MOL CELL BIOL, V18, P4391, DOI 10.1128/MCB.18.7.4391; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Iwai S, 1996, J AM CHEM SOC, V118, P7642, DOI 10.1021/ja9603158; KATAOKA H, 1991, BIOCHEM BIOPH RES CO, V175, P1139, DOI 10.1016/0006-291X(91)91684-5; Kazantsev A, 1996, P NATL ACAD SCI USA, V93, P5014, DOI 10.1073/pnas.93.10.5014; KEENEY S, 1994, P NATL ACAD SCI USA, V91, P4053, DOI 10.1073/pnas.91.9.4053; KEENEY S, 1993, J BIOL CHEM, V268, P21293; KEENEY S, 1992, MUTAT RES, V273, P49, DOI 10.1016/0921-8777(92)90049-9; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; KIM JK, 1995, EUR J BIOCHEM, V228, P849, DOI 10.1111/j.1432-1033.1995.0849m.x; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; MATSUDA T, 1995, J BIOL CHEM, V270, P4152, DOI 10.1074/jbc.270.8.4152; McAteer K, 1998, J MOL BIOL, V282, P1013, DOI 10.1006/jmbi.1998.2062; MURATA T, 1990, NUCLEIC ACIDS RES, V18, P7279, DOI 10.1093/nar/18.24.7279; Nichols AF, 1996, J BIOL CHEM, V271, P24317, DOI 10.1074/jbc.271.40.24317; ODA Y, 1991, NUCLEIC ACIDS RES, V19, P1407, DOI 10.1093/nar/19.7.1407; Otrin VR, 1998, MOL CELL BIOL, V18, P3182, DOI 10.1128/MCB.18.6.3182; PARKHURST KM, 1995, BIOCHEMISTRY-US, V34, P285, DOI 10.1021/bi00001a035; PAYNE A, 1994, MUTAT RES-FUND MOL M, V310, P89, DOI 10.1016/0027-5107(94)90012-4; Pfeifer GP, 1997, PHOTOCHEM PHOTOBIOL, V65, P270, DOI 10.1111/j.1751-1097.1997.tb08560.x; Plum GE, 1995, BIOCHEMISTRY-US, V34, P16148, DOI 10.1021/bi00049a030; REARDON JT, 1993, J BIOL CHEM, V268, P21301; Roll C, 1998, BIOCHEMISTRY-US, V37, P4059, DOI 10.1021/bi972377w; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SRIRAM M, 1992, EMBO J, V11, P225, DOI 10.1002/j.1460-2075.1992.tb05045.x; SRIRAM M, 1992, BIOCHEMISTRY-US, V31, P11823, DOI 10.1021/bi00162a022; Sugasawa K, 1998, MOL CELL, V2, P223, DOI 10.1016/S1097-2765(00)80132-X; Takahara PM, 1996, J AM CHEM SOC, V118, P12309, DOI 10.1021/ja9625079; TAKAO M, 1993, NUCLEIC ACIDS RES, V21, P4111, DOI 10.1093/nar/21.17.4111; TAYLOR JS, 1988, BIOPOLYMERS, V27, P1571, DOI 10.1002/bip.360271004; TAYLOR JS, 1995, PURE APPL CHEM, V67, P183, DOI 10.1351/pac199567010183; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; TREIBER DK, 1992, NUCLEIC ACIDS RES, V20, P5805, DOI 10.1093/nar/20.21.5805; VASSYLYEV DG, 1995, CELL, V83, P773, DOI 10.1016/0092-8674(95)90190-6; Watanabe T, 1999, J NEUROCHEM, V72, P549, DOI 10.1046/j.1471-4159.1999.0720549.x; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; YANG DZ, 1995, BIOCHEMISTRY-US, V34, P12912, DOI 10.1021/bi00039a054; Yang MS, 1997, METHOD ENZYMOL, V278, P417	59	142	144	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					20027	20033		10.1074/jbc.274.28.20027	http://dx.doi.org/10.1074/jbc.274.28.20027			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391953	hybrid			2022-12-25	WOS:000081377300073
J	Halleen, JM; Raisanen, S; Salo, JJ; Reddy, SV; Roodman, GD; Hentunen, TA; Lehenkari, PP; Kaija, H; Vihko, P; Vaananen, HK				Halleen, JM; Raisanen, S; Salo, JJ; Reddy, SV; Roodman, GD; Hentunen, TA; Lehenkari, PP; Kaija, H; Vihko, P; Vaananen, HK			Intracellular fragmentation of bone resorption products by reactive oxygen species generated by osteoclastic tartrate-resistant acid phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFECTED INSECT CELLS; MOLECULAR-PROPERTIES; HYDROGEN-PEROXIDE; RAT OSTEOCLASTS; PROTON PUMP; IMMUNOASSAY; RADICALS; CRYSTALLIZATION; DAMAGE	Tartrate-resistant acid phosphatase (TRAP) is highly expressed in bone-resorbing osteoclasts and activated macrophages, It has been suggested that a redox-active iron in the binuclear iron center of TRAP could have the capacity to react with hydrogen peroxide to produce highly destructive reactive oxygen species (ROS), Here we show that TRAP can generate ROS in vitro and that cells over-expressing TRAP produce higher amounts of intracellular ROS than their parent cells. We further demonstrate that these ROS can be targeted to destroy collagen and other proteins. In resorbing osteoclasts, TRAP was found in transcytotic vesicles transporting matrix degradation products through the cell, suggesting that TRAP-facilitated fragmentation of endocytosed material takes place in a specific cellular compartment. These results suggest that bone matrix degradation occurs not only extracellularly in the resorption lacunae but also intracellularly in the transcytotic vesicles. We propose that proteins containing redox-active iron could represent a novel mechanism of physiological fragmentation of organic molecules. This mechanism could be important in tissue remodeling and as a defense mechanism of phagocytosing cells.	Univ Turku, Inst Biomed, Dept Anat, FIN-20520 Turku, Finland; Univ Helsinki, Cent Hosp, Dept Orthopaed & Traumatol, FIN-02260 Helsinki, Finland; Univ Texas, Hlth Sci Ctr, Dept Med & Hematol, San Antonio, TX 78284 USA; Rayne Inst, Bone & Mineral Ctr, London WC1E 6JJ, England; Univ Oulu, Collaborating Ctr Res Reprod Hlth, FIN-90220 Oulu, Finland; Univ Oulu, Bioctr Oulu, FIN-90220 Oulu, Finland; Univ Helsinki, Dept Biosci, FIN-00014 Helsinki, Finland	University of Turku; University of Helsinki; Helsinki University Central Hospital; University of Texas System; University of Texas Health San Antonio; University of London; King's College London; University of Oulu; University of Oulu; University of Helsinki	Vaananen, HK (corresponding author), Univ Turku, Inst Biomed, Dept Anat, FIN-20520 Turku, Finland.		Nentwig, Wolfgang/A-6624-2011; Lehenkari, Petri/O-3009-2016; Salo, Jari/AAH-9112-2019	Lehenkari, Petri/0000-0002-0055-5183; 				BARON R, 1988, J CELL BIOL, V106, P1863, DOI 10.1083/jcb.106.6.1863; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; BLAIR HC, 1986, J CELL BIOL, V102, P1164, DOI 10.1083/jcb.102.4.1164; CLARK SA, 1989, J BONE MINER RES, V4, P399; DAVIES KJA, 1987, J BIOL CHEM, V262, P9908; DAVIS JC, 1982, P NATL ACAD SCI-BIOL, V79, P4623, DOI 10.1073/pnas.79.15.4623; Doi K., 1988, STRUCT BONDING BERLI, V70, P1; Garnero Patrick, 1996, P1277; Halleen J, 1996, J BONE MINER RES, V11, P1444; Halleen JM, 1998, ARCH BIOCHEM BIOPHYS, V352, P97, DOI 10.1006/abbi.1998.0600; Halleen JM, 1998, J BONE MINER RES, V13, P683, DOI 10.1359/jbmr.1998.13.4.683; HALLIWELL B, 1987, ANAL BIOCHEM, V165, P215, DOI 10.1016/0003-2697(87)90222-3; Hayman AR, 1996, DEVELOPMENT, V122, P3151; HAYMAN AR, 1994, J BIOL CHEM, V269, P1294; Henle ES, 1997, J BIOL CHEM, V272, P19095, DOI 10.1074/jbc.272.31.19095; KRAENZLIN ME, 1990, J CLIN ENDOCR METAB, V71, P442, DOI 10.1210/jcem-71-2-442; LAKKAKORPI P, 1989, J BONE MINER RES, V4, P817; Lehenkari PP, 1997, BIOCHEM BIOPH RES CO, V235, P838, DOI 10.1006/bbrc.1997.6894; MINKIN C, 1982, CALCIFIED TISSUE INT, V34, P285, DOI 10.1007/BF02411252; Nesbitt SA, 1997, SCIENCE, V276, P266, DOI 10.1126/science.276.5310.266; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; Salo J, 1997, SCIENCE, V276, P270, DOI 10.1126/science.276.5310.270; SALO J, 1996, J CELL SCI, V106, P301; SIBILLE JC, 1987, J BIOL CHEM, V262, P59; SILVERTON S, 1994, J CELL BIOCHEM, V56, P367, DOI 10.1002/jcb.240560313; TAKAGI M, 1988, J HISTOCHEM CYTOCHEM, V36, P95, DOI 10.1177/36.1.2447153; VAANANEN HK, 1990, J CELL BIOL, V111, P1305, DOI 10.1083/jcb.111.3.1305; VIHKO P, 1993, P NATL ACAD SCI USA, V90, P799, DOI 10.1073/pnas.90.3.799; YAZIJI H, 1995, AM J CLIN PATHOL, V104, P397; [No title captured]	31	192	199	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					22907	22910		10.1074/jbc.274.33.22907	http://dx.doi.org/10.1074/jbc.274.33.22907			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438453	hybrid			2022-12-25	WOS:000082012800003
J	Phillips, BW; Sharma, R; Leco, PA; Edwards, DR				Phillips, BW; Sharma, R; Leco, PA; Edwards, DR			A sequence-selective single-strand DNA-binding protein regulates basal transcription of the murine tissue inhibitor of metalloproteinases-1 (Timp-1) gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-TYPE-1 MATRIX-METALLOPROTEINASE; ERYTHROID-POTENTIATING ACTIVITY; POLYMERASE-II HOLOENZYME; ALPHA FIBRINOGEN GENE; IV COLLAGENASE; GELATINASE-A; DEVELOPMENTAL EXPRESSION; RESPONSIVE ELEMENT; MOUSE FIBROBLASTS; COACTIVATOR PC4	Tissue inhibitor of metalloproteinases-1 (TIMP-1) is important in maintaining the extracellular proteolytic balance during tissue remodeling processes. To allow homeostatic tissue turnover, the murine Timp-1 gene is expressed by most cells at a low basal level, and during acute remodeling its transcription is activated by a variety of stimuli. A non-consensus AP-1-binding site (5'-TGAGTAA-3') that is conserved in mammalian timp-1 genes is a critical element in basal and serum-stimulated transcription. We show here that each strand of this unusual AP-1 site binds a distinct single-stranded DNA-binding protein, although neither strand from a perfect consensus AP-I site from the human collagenase gene shows similar binding. One of the single-strand binding factors, which we term ssT1, binds to a second upstream Timp-1 region between nucleotides -115 and -100. Deletion analysis demonstrated that this region is important in basal but not serum-inducible transcription. The ssT1 factor was 52-54 kDa by UV cross-linking of electrophoretic mobility shift assays and Southwestern blot analysis. Its binding to DNA shows sequence selectivity rather than specificity, with 5'-CT/ATTN((4-) (6))ATC-3' as a favored motif. Multiple ssT1-like activities were found in nuclear extracts from mouse fibroblasts and rat liver and testis, suggesting that these factors may regulate basal Timp-1 transcription in a tissue-specific fashion.	Univ Calgary, Dept Med Biochem, Calgary, AB T2N 4N1, Canada	University of Calgary	Edwards, DR (corresponding author), Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England.		Edwards, Dylan R/B-4734-2009	Edwards, Dylan R/0000-0002-3292-2064				ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; Bugno M, 1995, NUCLEIC ACIDS RES, V23, P5041, DOI 10.1093/nar/23.24.5041; Butler GS, 1997, EUR J BIOCHEM, V244, P653, DOI 10.1111/j.1432-1033.1997.t01-1-00653.x; CAMPBELL CE, 1991, J BIOL CHEM, V266, P7199; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Clark IM, 1997, BIOCHEM J, V324, P611, DOI 10.1042/bj3240611; COULOMBE B, 1988, MOL CELL BIOL, V8, P3227, DOI 10.1128/MCB.8.8.3227; Cowell S, 1998, BIOCHEM J, V331, P453, DOI 10.1042/bj3310453; DECLERCK YA, 1994, GENE, V139, P185, DOI 10.1016/0378-1119(94)90753-6; DENHARDT DT, 1993, PHARMACOL THERAPEUT, V59, P329, DOI 10.1016/0163-7258(93)90074-N; DOCHERTY AJ, 1985, NATURE, V318, P3280; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; EDWARDS DR, 1992, BIOCHIM BIOPHYS ACTA, V1171, P41, DOI 10.1016/0167-4781(92)90138-P; EDWARDS DR, 1986, NUCLEIC ACIDS RES, V14, P8863, DOI 10.1093/nar/14.22.8863; EDWARDS DR, 1985, MOL CELL BIOL, V5, P3280, DOI 10.1128/MCB.5.11.3280; EDWARDS DR, 1999, IN PRESS INHIBITORS; Farrell S, 1996, GENE DEV, V10, P2359, DOI 10.1101/gad.10.18.2359; FLENNIKEN AM, 1990, GENE DEV, V4, P1094, DOI 10.1101/gad.4.7.1094; GASSON JC, 1985, NATURE, V315, P768, DOI 10.1038/315768a0; GE H, 1994, P NATL ACAD SCI USA, V91, P12691, DOI 10.1073/pnas.91.26.12691; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GEWERT DR, 1987, EMBO J, V6, P651, DOI 10.1002/j.1460-2075.1987.tb04804.x; GlucksmannKuis MA, 1996, CELL, V84, P147, DOI 10.1016/S0092-8674(00)81001-6; GOLDBERG GI, 1992, J BIOL CHEM, V267, P4583; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; ITOH Y, 1995, J BIOL CHEM, V270, P16518, DOI 10.1074/jbc.270.28.16518; Kinoshita T, 1996, CANCER RES, V56, P2535; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; Leco KJ, 1996, MOL REPROD DEV, V45, P458, DOI 10.1002/(SICI)1098-2795(199612)45:4&lt;458::AID-MRD8&gt;3.0.CO;2-Q; LIU ZY, 1995, J BIOL CHEM, V270, P7580, DOI 10.1074/jbc.270.13.7580; Liu ZY, 1997, BIOCHEMISTRY-US, V36, P14799, DOI 10.1021/bi970946u; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; Mertens PR, 1998, J BIOL CHEM, V273, P32957, DOI 10.1074/jbc.273.49.32957; Mertens PR, 1997, J BIOL CHEM, V272, P22905, DOI 10.1074/jbc.272.36.22905; Miller A, 1997, SCIENCE, V275, P1655, DOI 10.1126/science.275.5306.1655; MUKHERJEE R, 1990, NUCLEIC ACIDS RES, V18, P5713, DOI 10.1093/nar/18.19.5713; NOMURA S, 1989, DEVELOPMENT, V105, P575; Overall C., 1991, J BIOL CHEM, V266, P14061, DOI [10.1016/S0021-9258(18)92810-3, DOI 10.1016/S0021-9258(18)92810-3]; OVERALL CM, 1991, J BIOL CHEM, V266, P14064; PONTON A, 1992, GENE, V116, P187, DOI 10.1016/0378-1119(92)90515-Q; SANTORO IM, 1991, MOL CELL BIOL, V11, P1944, DOI 10.1128/MCB.11.4.1944; UCHIJIMA M, 1994, J BIOL CHEM, V269, P14946; Werten S, 1998, J MOL BIOL, V276, P367, DOI 10.1006/jmbi.1997.1534; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WILKISON WO, 1990, J BIOL CHEM, V265, P477; WITTIG B, 1992, EMBO J, V11, P4653, DOI 10.1002/j.1460-2075.1992.tb05567.x; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; Wu SY, 1998, J BIOL CHEM, V273, P12492, DOI 10.1074/jbc.273.20.12492	52	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22197	22207		10.1074/jbc.274.32.22197	http://dx.doi.org/10.1074/jbc.274.32.22197			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428785	hybrid			2022-12-25	WOS:000081868400015
J	Cheng, WH; Fu, YX; Porres, JM; Ross, DA; Lei, XG				Cheng, WH; Fu, YX; Porres, JM; Ross, DA; Lei, XG			Selenium-dependent cellular glutathione peroxidase protects mice against a pro-oxidant-induced oxidation of NADPH, NADH, lipids, and protein	FASEB JOURNAL			English	Article						F-2-isoprostanes; carbonyl; knockout; antioxidation; SOD	RADICAL-CATALYZED MECHANISM; CU/ZN-SUPEROXIDE-DISMUTASE; PARAQUAT RESISTANCE; HYDROGEN-PEROXIDE; TRANSGENIC MICE; DEFICIENT RATS; LIVER NECROSIS; VITAMIN-E; STRESS; TOXICITY	Since Our prior work indicated that Se-dependent cellular glutathione peroxidase (GPX1) was necessary for protection against paraquat lethality, the present studies were to elucidate the biochemical mechanisms related to that protection. Four groups of mice [Se-deficient or -adequate GPX1 knockout and wild-type (WT)] were injected (i.p.) with 50 mg paraquat/kg body weight and tissues were collected 0, 0.5, 1, 2, 3, or 4 h after the injection. Whereas the ratios of NADPH/NADP and NADH/NAD in lung were reduced by 50-70% only 0.5 h after the injection in all groups, these two ratios in liver of the Se-adequate WT were significantly higher than those of the three GPX1 knockout or deficient groups 2-4 h after the injection. The paraquat-induced pulmonary lipid peroxidation and hepatic protein oxidation, measured as F-2-isoprostanes and carbonyl contents, respectively, peaked at 1 h in these three groups. No such oxidative events were shown in any tissue of the Se-adequate WT throughout the time course. Whereas the F-2-isoprostane formation was accelerated by both GPX1 knockout and Se deficiency in liver, it was not significantly elevated by the paraquat treatment in brain of any group. The paraquat injection also resulted in temporal changes in lung GPX activity and GPX1 protein in the Se-adequate WT, and significant reductions in lung total SOD activity in the GPX1 knockout or deficient groups. In conclusion, GPX1 plays a critical role in maintaining the redox status of mice under acute oxidative stress, and protects against paraquat-induced oxidative destruction of lipids and protein in vivo. These protections of GPX1 seem to be inducible and coordinated with those of other antioxidant enzymes.	Cornell Univ, Dept Anim Sci, Ithaca, NY 14853 USA	Cornell University	Lei, XG (corresponding author), Cornell Univ, Dept Anim Sci, 252 Morrison Hall, Ithaca, NY 14853 USA.		FOULQUIE, JESUS MARIA PORRES/B-6442-2018	FOULQUIE, JESUS MARIA PORRES/0000-0001-5657-0764; fu, yang-xin/0000-0001-8441-6617	NIDDK NIH HHS [DK53018, R01 DK053018] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053018] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMSTAD P, 1994, J BIOL CHEM, V269, P1606; AWAD JA, 1994, J NUTR, V124, P810, DOI 10.1093/jn/124.6.810; AWAD JA, 1993, J BIOL CHEM, V268, P4161; BEHNE D, 1983, J NUTR, V113, P456, DOI 10.1093/jn/113.2.456; Benzie IFF, 1996, INT J FOOD SCI NUTR, V47, P233, DOI 10.3109/09637489609012586; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; BRAY RC, 1974, BIOCHEM J, V139, P43, DOI 10.1042/bj1390043; BURK RF, 1991, FASEB J, V5, P2274, DOI 10.1096/fasebj.5.9.1830557; BURK RF, 1980, J CLIN INVEST, V65, P1024, DOI 10.1172/JCI109754; BURK RF, 1995, HEPATOLOGY, V21, P561; BUS JS, 1974, BIOCHEM BIOPH RES CO, V58, P749, DOI 10.1016/S0006-291X(74)80481-X; CAGEN SZ, 1977, TOXICOL APPL PHARM, V40, P193, DOI 10.1016/0041-008X(77)90090-4; Cheng WH, 1998, BIOFACTORS, V7, P311, DOI 10.1002/biof.5520070403; Cheng WH, 1997, J NUTR, V127, P1445, DOI 10.1093/jn/127.8.1445; Cheng WH, 1998, J NUTR, V128, P1070, DOI 10.1093/jn/128.7.1070; COWAN DB, 1993, J BIOL CHEM, V268, P26904; Davies DS, 1977, P EUR SOC TOXICOL, V18, P21; de Haan JB, 1998, J BIOL CHEM, V273, P22528, DOI 10.1074/jbc.273.35.22528; ELROYSTEIN O, 1986, EMBO J, V5, P615, DOI 10.1002/j.1460-2075.1986.tb04255.x; FLOHE L, 1973, FEBS LETT, V32, P132, DOI 10.1016/0014-5793(73)80755-0; FRIDOVICH I, 1986, ARCH BIOCHEM BIOPHYS, V247, P1, DOI 10.1016/0003-9861(86)90526-6; Garberg P, 1996, CHEM-BIOL INTERACT, V99, P165, DOI 10.1016/0009-2797(95)03667-9; GOLDSTEIN BD, 1979, BIOCHEM PHARMACOL, V28, P27, DOI 10.1016/0006-2952(79)90265-X; GRUNE T, 1995, J BIOL CHEM, V270, P2344, DOI 10.1074/jbc.270.5.2344; Ho YS, 1997, J BIOL CHEM, V272, P16644, DOI 10.1074/jbc.272.26.16644; KALHORN TF, 1985, ANAL BIOCHEM, V151, P343, DOI 10.1016/0003-2697(85)90185-X; KEELING PL, 1982, BIOCHEM PHARMACOL, V31, P3243, DOI 10.1016/0006-2952(82)90557-3; KELNER MJ, 1990, FREE RADICAL BIO MED, V9, P149, DOI 10.1016/0891-5849(90)90118-3; KELNER MJ, 1990, J BIOL CHEM, V265, P10872; KRALL J, 1991, ARCH BIOCHEM BIOPHYS, V286, P311, DOI 10.1016/0003-9861(91)90045-K; Kunapuli P, 1997, J BIOL CHEM, V272, P27147, DOI 10.1074/jbc.272.43.27147; LAWRENCE RA, 1974, EXP EYE RES, V18, P563, DOI 10.1016/0014-4835(74)90062-1; Levander OA, 1996, J NUTR, V126, pS2427; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAIORINO M, 1990, METHOD ENZYMOL, V186, P448; MASER RL, 1994, J BIOL CHEM, V269, P27066; MERCURIO SD, 1986, J NUTR, V116, P1726, DOI 10.1093/jn/116.9.1726; MERCURIO SD, 1986, BIOCHEM PHARMACOL, V35, P4505, DOI 10.1016/0006-2952(86)90771-9; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; Morrow JD, 1996, BIOCHEM PHARMACOL, V51, P1, DOI 10.1016/0006-2952(95)02072-1; MORROW JD, 1994, METHOD ENZYMOL, V233, P163; Navarro F, 1998, FASEB J, V12, P1665, DOI 10.1096/fasebj.12.15.1665; NEUZIL J, 1993, BIOCHEM J, V293, P601; PeledKamar M, 1997, P NATL ACAD SCI USA, V94, P3883, DOI 10.1073/pnas.94.8.3883; Pratico D, 1998, FASEB J, V12, P1777, DOI 10.1096/fasebj.12.15.1777; REZNICK AZ, 1994, METHOD ENZYMOL, V233, P357; ROTRUCK JT, 1973, SCIENCE, V179, P588, DOI 10.1126/science.179.4073.588; SCHWARZ K, 1957, J AM CHEM SOC, V79, P3292, DOI 10.1021/ja01569a087; SHEN QC, 1993, J BIOL CHEM, V268, P11463; SINET PM, 1981, ARCH BIOCHEM BIOPHYS, V212, P411, DOI 10.1016/0003-9861(81)90382-9; SMITH LL, 1987, HUM TOXICOL, V6, P31, DOI 10.1177/096032718700600105; Sunde R. A., 1994, Selenium in biology and human health., P45; Ukeda H, 1997, ANAL BIOCHEM, V251, P206, DOI 10.1006/abio.1997.2273; WINTER ML, 1991, J BIOL CHEM, V266, P14446; WITSCHI H, 1977, CHEM-BIOL INTERACT, V19, P143, DOI 10.1016/0009-2797(77)90027-8	56	102	103	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1999	13	11					1467	1475		10.1096/fasebj.13.11.1467	http://dx.doi.org/10.1096/fasebj.13.11.1467			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	226KL	10428770				2022-12-25	WOS:000082019100018
J	D'Adamo, MC; Imbrici, P; Sponcichetti, F; Pessia, M				D'Adamo, MC; Imbrici, P; Sponcichetti, F; Pessia, M			Mutations in the KCNA1 gene associated with episodic ataxia type-1 syndrome impair heteromeric voltage-gated K+ channel function	FASEB JOURNAL			English	Article						potassium channel gating; hKv1.1; hKv1.2; myokymia; cerebellum	POTASSIUM-CHANNEL; MYOKYMIA SYNDROME; XENOPUS-OOCYTES; BINDING-SITE; SHAKER; KV1.1; TERMINALS; PORE; CHANNELOPATHIES; LOCALIZATION	Episodic ataxia type-1 syndrome (EA-1) is an autosomal dominant neurological disorder that manifests itself during infancy and results from point mutations in the voltage-gated potassium channel gene hKv1.1. The hallmark of the disease is continuous myokymia and episodic attacks of spastic contractions of the skeletal muscles, which cause permanent disability. Coexpression of hKv1.1 and hKv1.2 subunits produces heteromeric potassium channels with biophysical and pharmacological properties intermediate between the respective homomers. By using tandemly linked subunits, we demonstrate that hKv1.1 subunits bearing the EA-1 mutations V408A and E325D combine with hKv1.2 to produce channels with altered kinetics of activation, deactivation, C-type inactivation, and voltage dependence. Moreover, hKv1.1V408A single-channel analysis reveals a similar to threefold reduction of the mean open duration of the channel compared with the wild-type, and this mutation alters the open-state stability of both homomeric and heteromeric channels. The results demonstrate that human Kv1.2 and Kv1.1 subunits coassemble to form a novel channel with distinct gating properties that are altered profoundly by EA-1 mutations, thus uncovering novel physiopathogenetic mechanisms of episodic ataxia type-1 myokymia syndrome.	Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Pharmacol & Mol Pathol, I-66030 Santa Maria Imbaro, Chieti, Italy	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Pessia, M (corresponding author), Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Pharmacol & Mol Pathol, I-66030 Santa Maria Imbaro, Chieti, Italy.		imbrici, paola/J-6855-2018; D'Adamo, Maria Cristina/AAD-3701-2022	imbrici, paola/0000-0001-9140-5350; D'Adamo, Maria Cristina/0000-0002-6758-6064; Pessia, Mauro/0000-0002-2857-6795	Telethon [1083] Funding Source: Medline	Telethon(Fondazione Telethon)		Adelman JP, 1995, NEURON, V15, P1449, DOI 10.1016/0896-6273(95)90022-5; BECKH S, 1990, EMBO J, V9, P777, DOI 10.1002/j.1460-2075.1990.tb08173.x; BROWNE DL, 1995, HUM MOL GENET, V4, P1671, DOI 10.1093/hmg/4.9.1671; BROWNE DL, 1994, NAT GENET, V8, P136, DOI 10.1038/ng1094-136; BRUNT ERP, 1990, BRAIN, V113, P1361, DOI 10.1093/brain/113.5.1361; CHOI KL, 1993, NEURON, V10, P533, DOI 10.1016/0896-6273(93)90340-W; CHRISTIE MJ, 1990, NEURON, V2, P405; Comu S, 1996, ANN NEUROL, V40, P684, DOI 10.1002/ana.410400422; COVARRUBIAS M, 1991, NEURON, V7, P763, DOI 10.1016/0896-6273(91)90279-9; D'Adamo MC, 1998, EMBO J, V17, P1200, DOI 10.1093/emboj/17.5.1200; Gancher S T, 1986, Mov Disord, V1, P239, DOI 10.1002/mds.870010404; Gordon N, 1998, BRAIN DEV-JPN, V20, P9, DOI 10.1016/S0387-7604(97)00086-7; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; Hille B., 1992, IONIC CHANNELS EXCIT; HOPKINS WF, 1994, PFLUG ARCH EUR J PHY, V428, P382, DOI 10.1007/BF00724522; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HOSHI T, 1994, J GEN PHYSIOL, V103, P249, DOI 10.1085/jgp.103.2.249; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; KORN H, 1980, P NATL ACAD SCI-BIOL, V77, P6244, DOI 10.1073/pnas.77.10.6244; Laube G, 1996, MOL BRAIN RES, V42, P51, DOI 10.1016/S0169-328X(96)00120-9; LITT M, 1994, AM J HUM GENET, V55, P702; Liu Y, 1997, NEURON, V19, P175, DOI 10.1016/S0896-6273(00)80357-8; LOPEZ GA, 1994, NATURE, V367, P179, DOI 10.1038/367179a0; MCNAMARA NMC, 1993, NEUROSCIENCE, V57, P1039, DOI 10.1016/0306-4522(93)90047-J; Ophoff RA, 1996, CELL, V87, P543, DOI 10.1016/S0092-8674(00)81373-2; PO S, 1993, CIRC RES, V72, P1326, DOI 10.1161/01.RES.72.6.1326; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; Sanguinetti MC, 1997, NEUROPHARMACOLOGY, V36, P755, DOI 10.1016/S0028-3908(97)00029-4; Scheffer H, 1998, HUM GENET, V102, P464, DOI 10.1007/s004390050722; Smart SL, 1998, NEURON, V20, P809, DOI 10.1016/S0896-6273(00)81018-1; Southan AP, 1998, J NEUROSCI, V18, P948; VANDYKE DH, 1975, J NEUROL SCI, V25, P109, DOI 10.1016/0022-510X(75)90191-4; WANG H, 1993, NATURE, V365, P75, DOI 10.1038/365075a0; WANG H, 1994, J NEUROSCI, V14, P4588; Zerr P, 1998, FEBS LETT, V431, P461, DOI 10.1016/S0014-5793(98)00814-X; Zerr P, 1998, J NEUROSCI, V18, P2842; Zhou L, 1998, J NEUROSCI, V18, P7200	37	62	63	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1999	13	11					1335	1345		10.1096/fasebj.13.11.1335	http://dx.doi.org/10.1096/fasebj.13.11.1335			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	226KL	10428758				2022-12-25	WOS:000082019100006
J	Auge, N; Nikolova-Karakashian, M; Carpentier, S; Parthasarathy, S; Negre-Salvayre, A; Salvayre, R; Merrill, AH; Levade, T				Auge, N; Nikolova-Karakashian, M; Carpentier, S; Parthasarathy, S; Negre-Salvayre, A; Salvayre, R; Merrill, AH; Levade, T			Role of sphingosine 1-phosphate in the mitogenesis induced by oxidized low density lipoprotein in smooth muscle cells via activation of sphingomyelinase, ceramidase, and sphingosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; PROTEIN-KINASE; GROWTH-FACTOR; CELLULAR PROLIFERATION; ENDOTHELIAL-CELLS; 2ND MESSENGER; SPHINGOSINE-1-PHOSPHATE; PATHWAY; APOPTOSIS; EXPRESSION	Oxidized LDL (oxLDL) have been implicated in diverse biological events leading to the development of atherosclerotic lesions. We previously demonstrated that the proliferation of cultured vascular smooth muscle cells (SMC) induced by oxLDL is preceded by an increase in neutral sphingomyelinase activity, sphingomyelin turnover to ceramide, and stimulation of mitogen-activated protein kinases (Auge, N., Escargueil-Blanc, I., Lajoie-Mazenc, I., Sue, I., Andrieu-Abadie, N., Pieraggi, M. T., Chatelut, M., Thiers, J. C., Jaffrezou, J. P., Laurent, G., Levade, T., Negre-Salvayre, A., and Salvayre, R. (1998) J. Biol. Chem. 273, 12893-12900). Since ceramide can be converted to other bioactive metabolites, such as the well established mitogen sphingosine l-phosphate (S1P), we investigated whether additional ceramide metabolites are involved in the oxLDL-induced SMC proliferation. We report here that incubation of SMC with oxLDL increased the activities of both acidic and alkaline ceramidases as well as sphingosine kinase, and elevated cellular sphingosine and S1P. Furthermore, the mitogenic effect of oxLDL was inhibited by D-erythro-2-(N-myristoylamino)-1-phenyl-1- propanol and N,N-dimethylsphingosine which are inhibitors of ceramidase and sphingosine kinase, respectively, These findings suggest that S1P is a key mediator of the mitogenic effect of oxLDL. In agreement with this conclusion, exogenous addition of sphingosine stimulated the proliferation of cultured SMC, and this effect was abrogated by dimethylsphingosine but not by fumonisin B1, an inhibitor of the acylation of sphingosine to ceramide. Exogenous S1P also promoted SMC proliferation. Altogether, these results strongly suggest that the mitogenic effect of oxLDL in SMC involves the combined activation of sphingomyelinase(s), ceramidase(s), and sphingosine kinase, resulting in the turnover of sphingomyelin to a number of sphingolipid metabolites, of which at least S1P is critical for mitogenesis.	Univ Toulouse 3, CHU Rangueil, Inst Louis Bugnard, Lab Biochim,INSERM,U466, F-31403 Toulouse 4, France; Emory Univ, Dept Gynecol & Obstet, Atlanta, GA 30322 USA; Emory Univ, Dept Biochem, Atlanta, GA 30322 USA	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Emory University; Emory University	Levade, T (corresponding author), Univ Toulouse 3, CHU Rangueil, Inst Louis Bugnard, Lab Biochim,INSERM,U466, Bat L3,1 Ave Jean Poulhes, F-31403 Toulouse 4, France.		Parthasarathy, Sampath/AAP-3361-2020; Parthasarathy, Sampath/G-5602-2011; Levade, Thierry/O-8948-2014	Auge, Nathalie/0000-0003-2088-7211; Negre-Salvayre, Anne/0000-0003-2136-5706; Merrill, Alfred/0000-0002-6673-968X	NIGMS NIH HHS [GM 46368] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046368] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRIEU N, 1994, BIOCHEM J, V303, P341, DOI 10.1042/bj3030341; Auge N, 1996, J BIOL CHEM, V271, P19251, DOI 10.1074/jbc.271.32.19251; AUGE N, 1995, BIOCHEM J, V309, P1015, DOI 10.1042/bj3091015; Auge N, 1998, J BIOL CHEM, V273, P12893, DOI 10.1074/jbc.273.21.12893; AUTIO I, 1990, FEBS LETT, V277, P247, DOI 10.1016/0014-5793(90)80857-F; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; Bielawska A, 1996, J BIOL CHEM, V271, P12646, DOI 10.1074/jbc.271.21.12646; Bjorkerud B, 1996, ARTERIOSCL THROM VAS, V16, P416, DOI 10.1161/01.ATV.16.3.416; BORNFELDT KE, 1995, J CELL BIOL, V130, P193, DOI 10.1083/jcb.130.1.193; Chatterjee S, 1996, GLYCOBIOLOGY, V6, P303, DOI 10.1093/glycob/6.3.303; Chatterjee S, 1997, GLYCOBIOLOGY, V7, P703, DOI 10.1093/glycob/7.5.703; CHATTERJEE S, 1992, MOL CELL BIOCHEM, V111, P143; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P371; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; Edsall LC, 1998, BIOCHEMISTRY-US, V37, P12892, DOI 10.1021/bi980744d; Edsall LC, 1997, J NEUROSCI, V17, P6952; Escargueil-Blanc I, 1998, J BIOL CHEM, V273, P27389, DOI 10.1074/jbc.273.42.27389; FOLCH J, 1957, J BIOL CHEM, V226, P497; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; Harada-Shiba M, 1998, J BIOL CHEM, V273, P9681, DOI 10.1074/jbc.273.16.9681; HOLVOET P, 1994, FASEB J, V8, P1279, DOI 10.1096/fasebj.8.15.8001740; JACOBS LS, 1993, AM J PHYSIOL, V265, pC740, DOI 10.1152/ajpcell.1993.265.3.C740; Kleuser B, 1998, CANCER RES, V58, P1817; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; MALDEN LT, 1991, J BIOL CHEM, V266, P13901; Mansat V, 1997, FASEB J, V11, P695, DOI 10.1096/fasebj.11.8.9240970; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; Maziere C, 1997, FEBS LETT, V409, P351, DOI 10.1016/S0014-5793(97)00545-0; Merrill A.H., 1996, NEW COMPREHENSIVE BI, P309; NikolovaKarakashian M, 1997, J BIOL CHEM, V272, P18718, DOI 10.1074/jbc.272.30.18718; Nishio E, 1996, BIOCHEM BIOPH RES CO, V223, P413, DOI 10.1006/bbrc.1996.0907; Olivera A, 1998, Methods Mol Biol, V105, P233; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Pyne S, 1996, EUR J BIOCHEM, V237, P819, DOI 10.1111/j.1432-1033.1996.0819p.x; Rani CSS, 1997, J BIOL CHEM, V272, P10777; Riboni L, 1997, PROG LIPID RES, V36, P153, DOI 10.1016/S0163-7827(97)00008-8; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; Steinberg D, 1997, J BIOL CHEM, V272, P20963, DOI 10.1074/jbc.272.34.20963; SU Y, 1994, J BIOL CHEM, V269, P16512; Van Brocklyn JR, 1998, J LIPOSOME RES, V8, P135, DOI 10.3109/08982109809035522; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; WU J, 1995, J BIOL CHEM, V270, P11484, DOI 10.1074/jbc.270.19.11484; Xia P, 1998, P NATL ACAD SCI USA, V95, P14196, DOI 10.1073/pnas.95.24.14196; Yatomi Y, 1996, BIOCHEMISTRY-US, V35, P626, DOI 10.1021/bi9515533; ZHANG H, 1990, J BIOL CHEM, V265, P76; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155	54	145	148	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21533	21538		10.1074/jbc.274.31.21533	http://dx.doi.org/10.1074/jbc.274.31.21533			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419457	hybrid			2022-12-25	WOS:000081721100010
J	Bastie, C; Holst, D; Gaillard, D; Jehl-Pietri, C; Grimaldi, PA				Bastie, C; Holst, D; Gaillard, D; Jehl-Pietri, C; Grimaldi, PA			Expression of peroxisome proliferator-activated receptor PPAR delta promotes induction of PPAR gamma and adipocyte differentiation in 3T3C2 fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE CELL-DIFFERENTIATION; AP2 GENE-EXPRESSION; FATTY-ACIDS; OXIDIZED LDL; ADULT-RATS; ADIPOGENESIS; TRANSCRIPTION; TISSUE; LIGAND; ALPHA	Nutritional long chain fatty acids control adipose tissue mass by regulating the number and the size of adipocytes. The molecular mechanisms implicated in this action of fatty acids remain poorly understood. It has been well established that peroxisome proliferator-activated receptor (PPAR) gamma, activated by specific prostanoids, plays a central role in the control of adipocyte gene expression and terminal differentiation. Thus far, the role of PPAR delta in the control of adipose tissue mass has remained unclear. Herein, we report the effects of ectopically expressed PPAR delta on the control of adipose-related gene expression and adipogenesis of 3T3C2 fibroblasts. Treatment of PPAR delta-expressing fibroblasts with fatty acids alone did not stimulate adipogenesis, whereas exposure of cells to a combination of fatty acids and PPAR gamma activators promoted lipid accumulation and expression of a typical adipocyte program. At the molecular level, activation of PPAR delta by fatty acids induced transcription of the genes encoding fatty acid transporter, adipocyte lipid-binding protein, and PPAR gamma. Subsequent activation of PPAR gamma by specific agonists appeared to be required to promote terminal differentiation. These data demonstrate that PPAR gamma gene expression is under the control of PPAR delta activated by fatty acids and could explain, at least partially, the adipogenic action of nutritional fatty acids.	Univ Nice Sophia Antipolis, UFR Sci, INSERM,U470, Ctr Biochim, F-06108 Nice 2, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Grimaldi, PA (corresponding author), Univ Nice Sophia Antipolis, UFR Sci, INSERM,U470, Ctr Biochim, Parc Valrose, F-06108 Nice 2, France.			Bastie, Claire/0000-0001-8178-4748				AILHAUD G, 1999, IN PRESS CLIN CHIM A; AMRI EZ, 1994, J LIPID RES, V35, P930; AMRI EZ, 1991, J LIPID RES, V32, P1457; AMRI EZ, 1991, J LIPID RES, V32, P1449; AMRI EZ, 1995, J BIOL CHEM, V270, P2367, DOI 10.1074/jbc.270.5.2367; Berger J, 1999, J BIOL CHEM, V274, P6718, DOI 10.1074/jbc.274.10.6718; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798; Clarke SL, 1997, BIOCHEM BIOPH RES CO, V240, P99, DOI 10.1006/bbrc.1997.7627; Diascro DD, 1998, J BONE MINER RES, V13, P96, DOI 10.1359/jbmr.1998.13.1.96; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1575; FAUST IM, 1978, AM J PHYSIOL, V235, pE279, DOI 10.1152/ajpendo.1978.235.3.E279; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GAILLARD D, 1989, BIOCHEM J, V257, P389, DOI 10.1042/bj2570389; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GREEN S, 1994, MOL CELL ENDOCRINOL, V100, P149, DOI 10.1016/0303-7207(94)90294-1; GRIMALDI P, 1982, EMBO J, V1, P687, DOI 10.1002/j.1460-2075.1982.tb01231.x; GRIMALDI PA, 1992, P NATL ACAD SCI USA, V89, P10930, DOI 10.1073/pnas.89.22.10930; Hertz R, 1996, EUR J BIOCHEM, V235, P242, DOI 10.1111/j.1432-1033.1996.00242.x; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLYDE BJ, 1979, J LIPID RES, V20, P705; LEE SST, 1995, MOL CELL BIOL, V15, P3012; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; ROSS SR, 1990, P NATL ACAD SCI USA, V87, P9590, DOI 10.1073/pnas.87.24.9590; Sfeir Z, 1997, PROSTAG LEUKOTR ESS, V57, P17, DOI 10.1016/S0952-3278(97)90487-7; SHILLABEER G, 1994, J LIPID RES, V35, P592; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; Wu ZD, 1996, MOL CELL BIOL, V16, P4128	39	143	146	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21920	21925		10.1074/jbc.274.31.21920	http://dx.doi.org/10.1074/jbc.274.31.21920			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419513	hybrid			2022-12-25	WOS:000081721100066
J	Bortner, CD; Cidlowski, JA				Bortner, CD; Cidlowski, JA			Caspase independent/dependent regulation of K+, cell shrinkage, and mitochondrial membrane potential during lymphocyte apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNALING COMPLEX DISC; PERMEABILITY TRANSITION; CYTOCHROME-C; THYMOCYTE APOPTOSIS; FLOW-CYTOMETRY; IN-VIVO; DEATH; BCL-2; ACTIVATION; INHIBITION	The loss of cell volume is a fundamental feature of apoptosis. We have previously shown that DNA degradation and caspase activity occur only in cells which have shrunken as a result of potassium and sodium efflux (Bortner, C. D., Hughes, F. M., Jr., and Cidlowski, J. A. (1997) J. Biol Chem. 272, 32436-32442). Furthermore, maintaining a normal intracellular potassium concentration represses the cell death process by inhibiting the activity of apoptotic nucleases and suppressing the activation of effector caspases (Hughes, F, M., Jr., Bortner, C. D. Purdy, G. D., and Cidlowski, J. A. (1997) J. Biol. Chem. 272, 30567-30576). We have now investigated the relationship between cell shrinkage, ion efflux, and changes in the mitochondrial membrane potential, in addition to the role of caspases in these apoptotic events. Treatment of Jurkat cells with a series of inducers which act via distinct signal transduction pathways, resulted in all of the cell death characteristics including loss of cell viability, cell shrinkage, K+ efflux, altered mitochondrial membrane potential, and DNA fragmentation Interestingly, only cells which shrunk had a loss of mitochondrial membrane potential and the other apoptotic characteristics. Treatment of Jurkat cells with an anti-Pas antibody in the presence of the general caspase inhibitor z-VAD, abrogated these features. In contrast, when Jurkat cells were treated with either the calcium ionophore A23187 or thapsigargin, z-VAD failed to prevent cell shrinkage, K+ efflux, or changes in the mitochondrial membrane potential, while effectively inhibiting DNA degradation. Treatment of Jurkat cells with various apoptotic agents in the presence of either the caspase-3 inhibitor DEVD, or the caspase-8 inhibitor IETD also blocked DNA degradation, but failed to prevent other characteristics of apoptosis, Together these data suggest that the cell shrinkage, K+ efflux, and changes in the mitochondrial membrane potential are tightly coupled, but occur independent of DNA degradation, and can be largely caspase independent depending on the particular signal transduction pathway.	NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Cidlowski, JA (corresponding author), NIEHS, Lab Signal Transduct, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.		Cidlowski, John A/G-2548-2019	Cidlowski, John A/0000-0003-1420-0516				BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; Bilney AJ, 1998, FEBS LETT, V424, P221, DOI 10.1016/S0014-5793(98)00172-0; Bortner CD, 1996, AM J PHYSIOL-CELL PH, V271, pC950, DOI 10.1152/ajpcell.1996.271.3.C950; Bortner CD, 1997, J BIOL CHEM, V272, P32436, DOI 10.1074/jbc.272.51.32436; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; CORTESE JD, 1993, BIOCHIM BIOPHYS ACTA, V1142, P194, DOI 10.1016/0005-2728(93)90102-L; COSSARIZZA A, 1993, BIOCHEM BIOPH RES CO, V197, P40, DOI 10.1006/bbrc.1993.2438; COSSARIZZA A, 1994, EXP CELL RES, V214, P323, DOI 10.1006/excr.1994.1264; Dallaporta B, 1998, J IMMUNOL, V160, P5605; DECKWERTH TL, 1993, J CELL BIOL, V123, P1207, DOI 10.1083/jcb.123.5.1207; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hale AJ, 1996, EUR J BIOCHEM, V236, P1, DOI 10.1111/j.1432-1033.1996.00001.x; Hirsch T, 1997, ONCOGENE, V15, P1573, DOI 10.1038/sj.onc.1201324; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hughes FM, 1997, J BIOL CHEM, V272, P30567, DOI 10.1074/jbc.272.48.30567; Inai Y, 1997, CELL STRUCT FUNCT, V22, P555, DOI 10.1247/csf.22.555; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; McCarthy JV, 1997, CELL DEATH DIFFER, V4, P756, DOI 10.1038/sj.cdd.4400296; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; PETIT PX, 1995, J CELL BIOL, V130, P157, DOI 10.1083/jcb.130.1.157; Rottenberg H, 1998, BBA-MOL CELL RES, V1404, P393, DOI 10.1016/S0167-4889(98)00088-3; SCHWARTZMAN RA, 1993, ENDOCR REV, V14, P133, DOI 10.1210/er.14.2.133; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Takahashi A, 1997, ONCOGENE, V14, P2741, DOI 10.1038/sj.onc.1201131; VAYSSIERE JL, 1994, P NATL ACAD SCI USA, V91, P11752, DOI 10.1073/pnas.91.24.11752; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; WILLMAN CL, 1989, SEMIN DIAGN PATHOL, V6, P3; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yu SP, 1997, SCIENCE, V278, P114, DOI 10.1126/science.278.5335.114; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zamzami N, 1996, FEBS LETT, V384, P53, DOI 10.1016/0014-5793(96)00280-3; Zanke BW, 1998, CANCER RES, V58, P2801; Zheng TS, 1998, P NATL ACAD SCI USA, V95, P13618, DOI 10.1073/pnas.95.23.13618; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A; ZORATTI M, 1994, J BIOENERG BIOMEMBR, V26, P543, DOI 10.1007/BF00762739	50	262	270	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21953	21962		10.1074/jbc.274.31.21953	http://dx.doi.org/10.1074/jbc.274.31.21953			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419518	hybrid			2022-12-25	WOS:000081721100071
J	Broitman, S; Amosova, O; Dolinnaya, NG; Fresco, JR				Broitman, S; Amosova, O; Dolinnaya, NG; Fresco, JR			Repairing the sickle cell mutation - I. Specific covalent binding of a photoreactive third strand to the mutated base pair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIPLE-HELIX FORMATION; WATSON-CRICK; MAMMALIAN-CELLS; DNA; SEQUENCE; OLIGONUCLEOTIDE; RECOGNITION; PSORALEN; RECOMBINATION; MUTAGENESIS	A DNA third strand with a 3'-psoralen substituent was designed to form a tripler with the sequence downstream of the T.A mutant base pair of the human sickle cell beta-globin gene. Tripler-mediated psoralen modification of the mutant T residue was sought as an approach to gene repair. The 24-nucleotide purine-rich target sequence switches from one strand to the other and has four pyrimidine interruptions. Therefore, a third strand sequence favorable to two tripler motifs was used, one parallel and the other antiparallel to it. To cope with the pyrimidine interruptions, which weaken third strand binding, 5-methylcytosine and 5-propynyluracil were used in the third strand. Further, a six residue "hook" complementary to an overhang of a linear duplex target was added to the 5'-end of the third strand via a T-4 linker, In binding to the overhang by Watson-Crick pairing, the hook facilitates tripler formation. This third strand also binds specifically to the target within a supercoiled plasmid. The psoralen moiety at the 3'-end of the third strand forms photoadducts to the targeted T with high efficiency. Such monoadducts are known to preferentially trigger reversion of the mutation by DNA repair enzymes.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Fresco, JR (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.		Dolinnaya, Nina/I-8450-2012	Dolinnaya, Nina/0000-0003-1780-813X				*AM LIF SCI INC, 1994, SEQ VERS 2 0 DNA SEQ; BERRESSEM R, 1995, NUCLEIC ACIDS RES, V23, P3465, DOI 10.1093/nar/23.17.3465; BROITMAN SL, 1987, P NATL ACAD SCI USA, V84, P5120, DOI 10.1073/pnas.84.15.5120; BROSSALINA E, 1993, NUCLEIC ACIDS RES, V21, P5616, DOI 10.1093/nar/21.24.5616; Chen ZD, 1996, BIOTECHNIQUES, V21, P820; Faruqi AF, 1996, MOL CELL BIOL, V16, P6820; FOSSELLA JA, 1993, NUCLEIC ACIDS RES, V21, P4511, DOI 10.1093/nar/21.19.4511; FRANCOIS JC, 1995, BIOCHEMISTRY-US, V34, P65, DOI 10.1021/bi00001a008; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; Gamper HB, 1998, J AM CHEM SOC, V120, P2182, DOI 10.1021/ja971397i; GASPARRO FP, 1994, NUCLEIC ACIDS RES, V22, P2845, DOI 10.1093/nar/22.14.2845; Guieysse AL, 1996, NUCLEIC ACIDS RES, V24, P4210, DOI 10.1093/nar/24.21.4210; HAVRE PA, 1993, P NATL ACAD SCI USA, V90, P7879, DOI 10.1073/pnas.90.16.7879; JAYASENA SD, 1992, BIOCHEMISTRY-US, V31, P320, DOI 10.1021/bi00117a002; LETAI AG, 1988, BIOCHEMISTRY-US, V27, P9108, DOI 10.1021/bi00426a007; Maniatis T., 1982, MOL CLONING LAB MANU; MOSCHONAS N, 1982, NUCLEIC ACIDS RES, V10, P2109; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; Moses AC, 1997, J AM CHEM SOC, V119, P11591, DOI 10.1021/ja971468d; Pascolo E, 1996, J BIOL CHEM, V271, P24187, DOI 10.1074/jbc.271.39.24187; POSVIC TJ, 1989, J AM CHEM SOC, V111, P3059; Rajeev KG, 1997, NUCLEIC ACIDS RES, V25, P4187, DOI 10.1093/nar/25.21.4187; SAGE E, 1987, BIOCHEMISTRY-US, V26, P3307, DOI 10.1021/bi00386a010; SANDOR Z, 1995, BBA-GENE STRUCT EXPR, V1263, P235, DOI 10.1016/0167-4781(95)00109-T; SUN JS, 1993, CURR OPIN STRUC BIOL, V3, P345, DOI 10.1016/S0959-440X(05)80105-8; THOMAS M, 1992, BIOTECHNIQUES, V13, P533; Wang G, 1996, SCIENCE, V271, P802, DOI 10.1126/science.271.5250.802; YOON K, 1992, P NATL ACAD SCI USA, V89, P3840, DOI 10.1073/pnas.89.9.3840	28	21	21	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21763	21768		10.1074/jbc.274.31.21763	http://dx.doi.org/10.1074/jbc.274.31.21763			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419490	hybrid			2022-12-25	WOS:000081721100043
J	Martin, A; Tsui, HW; Shulman, MJ; Isenman, D; Tsui, FWL				Martin, A; Tsui, HW; Shulman, MJ; Isenman, D; Tsui, FWL			Murine SHP-1 splice variants with altered Src homology 2 (SH2) domains - Implications for the SH2-mediated intramolecular regulation of SHP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; PHOSPHOTYROSINE PHOSPHATASE; MOTH-EATEN; GENE; SEQUENCES; MUTATIONS; SH-PTP2; KINASES; LOCUS	SRP-1 is a protein-tyrosine phosphatase with two Src homology 2 (SH2) domains. These SH2 domains determine which proteins SHP-1 associates with, but they also autoregulate the activity of the catalytic domain. In this report, we find that the murine SHP-1 transcript is processed to yield a series of alternatively spliced in-frame transcripts, the majority of which exclude exons encoding one or the other SH2 domain. We have examined the corresponding protein isoforms in several ways. First, our measurements of V-max and K-m under different conditions indicate that the SH2 variants have elevated activity because of lessened autoregulation, Second, to ascertain whether regulation by the SH2 domains reflects intra- or intermolecular effects, we analyzed the state of SHP-1 by high performance liquid chromatography and sucrose density gradient centrifugation. Our results showed that SHP-1 is a monomer and, thus, is regulated in an intramolecular manner. Third, our analyses detected shape differences between SHP-1 and the active splice variant protein deleted of the amino-terminal SH2 domain; i.e. SHP-1 was globular and resistant to proteolytic digestion, while the splice variant protein was "rod-shaped" and more susceptible to proteolytic digestion.	Toronto Western Hosp, Univ Hlth Network, Toronto Hosp Res Inst, Arthrit Ctr,Res Unit, Toronto, ON M5T 2S8, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Tsui, FWL (corresponding author), Toronto Western Hosp, Univ Hlth Network, Toronto Hosp Res Inst, Arthrit Ctr,Res Unit, Mc14-417,399 Bathurst St, Toronto, ON M5T 2S8, Canada.		Martin, Alberto/B-1421-2008	Martin, Alberto/0000-0002-0795-0418				AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; BANVILLE D, 1995, GENOMICS, V27, P165, DOI 10.1006/geno.1995.1020; DECHERT U, 1994, J BIOL CHEM, V269, P5602; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; MARTIN A, 1995, FASEB J, V9, P1226, DOI 10.1096/fasebj.9.12.7672516; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PEI DH, 1993, P NATL ACAD SCI USA, V90, P1092, DOI 10.1073/pnas.90.3.1092; Pei DH, 1996, P NATL ACAD SCI USA, V93, P1141, DOI 10.1073/pnas.93.3.1141; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; Pregel MJ, 1995, PROTEIN ENG, V8, P1309, DOI 10.1093/protein/8.12.1309; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHULTZ LD, 1984, AM J PATHOL, V116, P179; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; TOWNLEY R, 1993, BIOCHEMISTRY-US, V32, P13414, DOI 10.1021/bi00212a006; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Wang J, 1997, BIOCHEMISTRY-US, V36, P2993, DOI 10.1021/bi9611873; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; ZHAO ZZ, 1993, J BIOL CHEM, V268, P2816	26	22	23	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21725	21734		10.1074/jbc.274.31.21725	http://dx.doi.org/10.1074/jbc.274.31.21725			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419485	hybrid			2022-12-25	WOS:000081721100038
J	Paz, I; Abramovitz, L; Choder, M				Paz, I; Abramovitz, L; Choder, M			Starved Saccharomyces cerevisiae cells have the capacity to support internal initiation of translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOME ENTRY SITE; RNA-POLYMERASE-II; HUMAN FIBROBLAST GROWTH-FACTOR-2; MESSENGER-RNA; STATIONARY-PHASE; ALTERNATIVE TRANSLATION; PROTEIN-SYNTHESIS; GENE-EXPRESSION; VIRUS-RNA; YEAST	Internal initiation of translation, whereby ribosomes are directed to internal AUG codon independently of the 5' end of the mRNA, has been observed rarely in higher eucaryotes and has not been demonstrated in living yeast. We report here that starved yeast cells are capable of initiating translation of a dicistronic message internally. The studied element that functions as an internal ribosome entry site (IRES) is hardly functional or not functional at all in logarithmically growing cells, Moreover, during the logarithmic growth phase, this element seems to inhibit translation reinitiation when placed as an intercistronic spacer or to inhibit translation when placed in the 5'-untranslated region of a monocistronic message. Inhibition of translation is likely due to the putative strong secondary structure of the IRES that interferes with the cap-dependent scanning process. When cells exit the logarithmic growth phase, or when artificially starved for carbon source, translation of the IRES-containing messages is substantially induced. Our findings imply that the capacity to translate internally is a characteristic of starved rather than vegetatively growing yeast cells.	Tel Aviv Univ, Dept Mol Microbiol & Biotechnol, IL-69978 Ramat Aviv, Israel	Tel Aviv University	Choder, M (corresponding author), Tel Aviv Univ, Dept Mol Microbiol & Biotechnol, IL-69978 Ramat Aviv, Israel.			Abramovitz, Lilach/0000-0001-9961-9986				ALTMANN M, 1990, GENE, V91, P127, DOI 10.1016/0378-1119(90)90173-O; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; Bernstein J, 1997, J BIOL CHEM, V272, P9356; BOUCHERIE H, 1985, J BACTERIOL, V161, P385, DOI 10.1128/JB.161.1.385-392.1985; Boy-Marcotte E, 1998, J BACTERIOL, V180, P1044, DOI 10.1128/JB.180.5.1044-1052.1998; BoyMarcotte E, 1996, MICROBIOL-UK, V142, P459, DOI 10.1099/13500872-142-3-459; CHODER M, 1993, J BACTERIOL, V175, P6358, DOI 10.1128/JB.175.19.6358-6363.1993; CHODER M, 1991, GENE DEV, V5, P2315, DOI 10.1101/gad.5.12a.2315; CHODER M, 1993, MOL CELL BIOL, V13, P6984, DOI 10.1128/MCB.13.11.6984; Costa V, 1997, MICROBIOL-UK, V143, P1649, DOI 10.1099/00221287-143-5-1649; COWARD P, 1992, J VIROL, V66, P286, DOI 10.1128/JVI.66.1.286-295.1992; EHRENFELD E, 1996, TRANSLATIONAL CONTRO, P549; ENTIAN KD, 1986, MICROBIOL SCI, V3, P366; EVSTAFIEVA AG, 1993, FEBS LETT, V335, P273, DOI 10.1016/0014-5793(93)80745-G; FUGE EK, 1994, J BACTERIOL, V176, P5802, DOI 10.1128/JB.176.18.5802-5813.1994; Gan WN, 1998, J BIOL CHEM, V273, P5006, DOI 10.1074/jbc.273.9.5006; Gan WN, 1996, J BIOL CHEM, V271, P623, DOI 10.1074/jbc.271.2.623; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; IIZUKA N, 1994, MOL CELL BIOL, V14, P7322, DOI 10.1128/MCB.14.11.7322; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; MartinezPastor MT, 1996, FEBS LETT, V390, P319, DOI 10.1016/0014-5793(96)00683-7; McCarthy JEG, 1998, MICROBIOL MOL BIOL R, V62, P1492, DOI 10.1128/MMBR.62.4.1492-1553.1998; MEUNIER JR, 1999, IN PRESS YEAST; MUNHOLLAND JM, 1990, NUCLEIC ACIDS RES, V18, P6061, DOI 10.1093/nar/18.20.6061; Nanbru C, 1997, J BIOL CHEM, V272, P32061, DOI 10.1074/jbc.272.51.32061; OH SK, 1992, GENE DEV, V6, P1643, DOI 10.1101/gad.6.9.1643; PAZ I, 1999, IN PRESS GENE; ROSE M, 1983, METHOD ENZYMOL, V101, P167; Rosenheck S, 1998, J BACTERIOL, V180, P6187; Rubbi L, 1997, BIOCHEM J, V328, P401, DOI 10.1042/bj3280401; SARNOW P, 1989, P NATL ACAD SCI USA, V86, P5795, DOI 10.1073/pnas.86.15.5795; Sheffer A, 1999, MOL CELL BIOL, V19, P2672; Vagner S, 1996, J CELL BIOL, V135, P1391, DOI 10.1083/jcb.135.5.1391; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; Vega Laso Maria R., 1993, Journal of Biological Chemistry, V268, P6453; WernerWashburne M, 1996, MOL MICROBIOL, V19, P1159, DOI 10.1111/j.1365-2958.1996.tb02461.x; WERNERWASHBURNE M, 1993, MICROBIOL REV, V57, P383, DOI 10.1128/MMBR.57.2.383-401.1993; Ye X, 1997, MOL CELL BIOL, V17, P1714, DOI 10.1128/MCB.17.3.1714	39	32	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21741	21745		10.1074/jbc.274.31.21741	http://dx.doi.org/10.1074/jbc.274.31.21741			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419487	hybrid			2022-12-25	WOS:000081721100040
J	Rizoli, SB; Rotstein, OD; Kapus, A				Rizoli, SB; Rotstein, OD; Kapus, A			Cell volume-dependent regulation of L-selectin shedding in neutrophils - A role for p38 mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; MEMBRANE-PROXIMAL CLEAVAGE; MULTIPLE ORGAN FAILURE; TYROSINE KINASE; INDUCED PHOSPHORYLATION; PHOSPHOLIPASE A(2); ADHESION MOLECULE; LUNG INFLAMMATION; DEFICIENT MICE; CROSS-LINKING	Neutrophil-mediated organ damage is a common feature of many disease states. We previously demonstrated that resuscitation with hypertonic salt solutions prevented the endotoxin-induced leukosequestration and consequent lung injury, and this effect was partially attributed to an altered surface expression of adhesion molecules, CD11b and L-selectin. In this study we investigated the mechanisms whereby osmotic stress evokes L-selectin shedding, The metalloprotease inhibitor RO 31-9790 prevented the osmotic down-regulation of L-selectin, indicating that this process was catalyzed by the same "sheddase" responsible for L-selectin cleavage induced by diverse inflammatory stimuli. The trigger for hypertonic shedding was cell shrinkage and not increased osmolarity, ionic strength, or intracellular pH. Volume reduction caused robust tyrosine phosphorylation and its inhibition by genistein and erbstatin abrogated shedding. Shrinkage stimulated tyrosine kinases Hck, Syk, and Pyk2, but prevention of their activation by the Src-family inhibitor PP1 failed to affect the L-selectin response, Hypertonicity elicited the Src family-independent activation of p38, and the inhibition of this kinase by 8B203580 strongly reduced shedding, p38 was also essential for the N-formyl-methionyl-leucyl-phenylalanine- and lipopolysaccharide-induced shedding but not the phorbol ester-induced shedding. Thus, cell volume regulates L selectin surface expression in a p38-mediated, metalloprotease dependent manner. Moreover, p38 has a central role in shedding induced by many inflammatory mediators.	Toronto Gen Hosp, Dept Surg, Toronto, ON M5G 2C4, Canada; Univ Toronto, Toronto, ON M5G 2C4, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto	Rotstein, OD (corresponding author), Toronto Gen Hosp, Dept Surg, 200 Elizabeth St,EN 9-232, Toronto, ON M5G 2C4, Canada.							Allport JR, 1997, J IMMUNOL, V158, P4365; Amoui M, 1997, EUR J IMMUNOL, V27, P1881, DOI 10.1002/eji.1830270810; Aplin AE, 1998, PHARMACOL REV, V50, P197; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; BAZIL V, 1994, J IMMUNOL, V152, P1314; BEAL AL, 1994, JAMA-J AM MED ASSOC, V271, P226, DOI 10.1001/jama.271.3.226; BENNA JE, 1996, ARCH BIOCHEM BIOPHYS, V334, P395; Bennett TA, 1996, J IMMUNOL, V156, P3093; Berton G, 1996, INT J CLIN LAB RES, V26, P160, DOI 10.1007/BF02592978; Blackwell TS, 1996, J IMMUNOL, V157, P1630; BURNS AR, 1994, J IMMUNOL, V153, P3177; CHEN AJ, 1995, J EXP MED, V182, P519, DOI 10.1084/jem.182.2.519; Crockett-Torabi E, 1998, J LEUKOCYTE BIOL, V63, P1; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Davenpeck KL, 1997, J IMMUNOL, V159, P1977; Detmers PA, 1998, J IMMUNOL, V161, P1921; Feehan C, 1996, J BIOL CHEM, V271, P7019, DOI 10.1074/jbc.271.12.7019; Frasch SC, 1998, J BIOL CHEM, V273, P8389, DOI 10.1074/jbc.273.14.8389; Frey M, 1997, J IMMUNOL, V158, P5424; Fukushima T, 1996, J CELL BIOL, V132, P1037, DOI 10.1083/jcb.132.6.1037; Gismondi A, 1997, J IMMUNOL, V159, P4729; HAMPTON MB, 1994, J INFECT DIS, V169, P839, DOI 10.1093/infdis/169.4.839; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Haribabu B, 1997, J BIOL CHEM, V272, P13961, DOI 10.1074/jbc.272.21.13961; HELLMAN P, 1994, AIDS RES HUM RETROV, V10, P391, DOI 10.1089/aid.1994.10.391; Junger WG, 1998, J CLIN INVEST, V101, P2768, DOI 10.1172/JCI1354; KAHN J, 1994, J CELL BIOL, V125, P461, DOI 10.1083/jcb.125.2.461; Kapus A, 1999, J BIOL CHEM, V274, P8093, DOI 10.1074/jbc.274.12.8093; Knall C, 1997, P NATL ACAD SCI USA, V94, P3052, DOI 10.1073/pnas.94.7.3052; Krump E, 1997, J BIOL CHEM, V272, P937, DOI 10.1074/jbc.272.2.937; Krump E, 1997, J BIOL CHEM, V272, P17303, DOI 10.1074/jbc.272.28.17303; KUCHKINA NV, 1993, EXPERIENTIA, V49, P995, DOI 10.1007/BF02125647; Lowell CA, 1996, J CELL BIOL, V133, P895, DOI 10.1083/jcb.133.4.895; Ma EA, 1997, EUR J IMMUNOL, V27, P329, DOI 10.1002/eji.1830270147; Matsuba KT, 1997, AM J PHYSIOL-HEART C, V272, pH2852, DOI 10.1152/ajpheart.1997.272.6.H2852; MCGREGOR PE, 1994, BIOCHEM BIOPH RES CO, V198, P359, DOI 10.1006/bbrc.1994.1050; Middelhoven PJ, 1997, FEBS LETT, V414, P14, DOI 10.1016/S0014-5793(97)00959-9; MIGAKI GI, 1995, J EXP MED, V182, P549, DOI 10.1084/jem.182.2.549; Mizgerd JP, 1996, J EXP MED, V184, P639, DOI 10.1084/jem.184.2.639; Mizgerd JP, 1997, J EXP MED, V186, P1357, DOI 10.1084/jem.186.8.1357; MOORE FA, 1995, SURG CLIN N AM, V75, P257, DOI 10.1016/S0039-6109(16)46587-4; MULLIGAN MS, 1994, J IMMUNOL, V152, P832; Nick JA, 1997, J CLIN INVEST, V99, P975, DOI 10.1172/JCI119263; Nick JA, 1996, J IMMUNOL, V156, P4867; PAVALKO FM, 1995, J CELL BIOL, V129, P1155, DOI 10.1083/jcb.129.4.1155; Preece G, 1996, J BIOL CHEM, V271, P11634, DOI 10.1074/jbc.271.20.11634; Qin L, 1996, J IMMUNOL, V157, P5016; Qin SF, 1997, J BIOL CHEM, V272, P2098; Qin SF, 1998, BIOCHEMISTRY-US, V37, P5481, DOI 10.1021/bi9729460; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rizoli SB, 1999, J TRAUMA, V46, P794, DOI 10.1097/00005373-199905000-00006; Rizoli SB, 1998, J IMMUNOL, V161, P6288; ROSENGREN S, 1994, AM J PHYSIOL-CELL PH, V267, pC1623, DOI 10.1152/ajpcell.1994.267.6.C1623; Steeber DA, 1997, J IMMUNOL, V159, P952; Stoddart JH, 1996, J IMMUNOL, V157, P5653; Susztak K, 1997, BIOCHEM J, V325, P501, DOI 10.1042/bj3250501; Szaszi K, 1997, J BIOL CHEM, V272, P16670, DOI 10.1074/jbc.272.26.16670; Tang MLK, 1997, J IMMUNOL, V158, P5191; Tanji-Matsuba K, 1998, CIRCULATION, V97, P91, DOI 10.1161/01.CIR.97.1.91; TEDDER TF, 1995, J EXP MED, V181, P2259, DOI 10.1084/jem.181.6.2259; Van Eeden SF, 1997, AM J PHYSIOL-HEART C, V272, pH401, DOI 10.1152/ajpheart.1997.272.1.H401; Wahl SM, 1996, J LEUKOCYTE BIOL, V59, P789, DOI 10.1002/jlb.59.6.789; Walcheck B, 1996, NATURE, V380, P720, DOI 10.1038/380720a0; Waterman WH, 1996, BIOCHEM J, V319, P17, DOI 10.1042/bj3190017; Yamamoto M, 1998, J MED CHEM, V41, P1209, DOI 10.1021/jm970404a; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; Zu YL, 1998, J IMMUNOL, V160, P1982	67	107	109	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					22072	22080		10.1074/jbc.274.31.22072	http://dx.doi.org/10.1074/jbc.274.31.22072			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419535	hybrid			2022-12-25	WOS:000081721100088
J	Kaufman, SB; Gonzalez-Lebrero, RM; Schwarzbaum, PJ; Norby, JG; Garrahan, PJ; Rossi, RC				Kaufman, SB; Gonzalez-Lebrero, RM; Schwarzbaum, PJ; Norby, JG; Garrahan, PJ; Rossi, RC			Are the states that occlude rubidium obligatory intermediates of the Na+/K+-ATPase reaction?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEADY-STATE; SODIUM-PUMP; OCCLUSION; NA,K-ATPASE; POTASSIUM; IONS; RB+; TRANSPORT; RELEASE; BINDING	In the Albers-Post model, occlusion of K+ in the E-2 conformer of the enzyme (E) is an obligatory step of Na+/K+-ATPase reaction. If this were so the ratio (Na+/ K+-ATPase activity)/(concentration of occluded species) should be equal to the rate constant for deocclusion. We tested this prediction in a partially purified Na+/K+-ATPase from pig kidney by means of rapid filtration to measure the occlusion using the K+ congener Rb+. Assuming that always two Rb+ are occluded per enzyme, the steady-state levels of occluded forms and the kinetics of deocclusion were adequately described by the Albers-Post model over a very wide range of [ATP] and [Rb+]. The same happened with the kinetics of ATP hydrolysis, However, the value of the parameters that gave best fit differed from those for occlusion in such a way that the ratio (Na+/K+-ATPase activity)/(concentration of occluded species) became much larger than the rate constant for deocclusion when [Rb+] <10 mM. This points to the presence of an extra ATP hydrolysis that is not Na+-ATPase activity and that does not involve occlusion. A possible way of explaining this is to posit that the binding of a single Rb+ increases ATP hydrolysis without occlusion.	Univ Buenos Aires, Fac Farm & Bioquim, Inst Quim & Fisicoquim Biol, RA-1113 Buenos Aires, DF, Argentina; Univ Buenos Aires, Fac Farm & Bioquim, Dept Quim Biol, RA-1113 Buenos Aires, DF, Argentina; Aarhus Univ, Inst Biophys, DK-8000 Aarhus, Denmark	University of Buenos Aires; University of Buenos Aires; Aarhus University	Rossi, RC (corresponding author), Univ Buenos Aires, Fac Farm & Bioquim, Inst Quim & Fisicoquim Biol, Junin 956, RA-1113 Buenos Aires, DF, Argentina.	rcr@mail.retina.ar		Kaufman, Sergio Benjamin/0000-0002-8763-4086; schwarzbaum, pablo/0000-0002-5176-089X; Gonzalez Lebrero, Rodolfo M./0000-0002-3832-2270				BEAUGE LA, 1979, NATURE, V280, P510, DOI 10.1038/280510a0; BLOSTEIN R, 1977, J BIOL CHEM, V252, P3035; ESMANN M, 1985, BIOCHEM BIOPH RES CO, V127, P857, DOI 10.1016/S0006-291X(85)80022-X; FORBUSH B, 1987, J BIOL CHEM, V262, P11104; Forbush B., 1988, NA PLUS K PLUS PUM A, P229; GLYNN IM, 1964, BIOCHEM J, V90, P147, DOI 10.1042/bj0900147; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; GLYNN IM, 1985, J PHYSIOL-LONDON, V368, P453, DOI 10.1113/jphysiol.1985.sp015868; GLYNN IM, 1983, CURR TOP MEMBR TRANS, V19, P625; GLYNN IM, 1982, J PHYSIOL-LONDON, V330, P17, DOI 10.1113/jphysiol.1982.sp014326; HASENAUER J, 1993, J BIOL CHEM, V268, P3289; JENSEN J, 1989, BIOCHIM BIOPHYS ACTA, V985, P248, DOI 10.1016/0005-2736(89)90409-4; JENSEN J, 1984, J PHYSIOL-LONDON, V346, P219, DOI 10.1113/jphysiol.1984.sp015018; KARLISH SJD, 1978, BIOCHIM BIOPHYS ACTA, V525, P252, DOI 10.1016/0005-2744(78)90219-X; Liu LQ, 1997, J BIOL CHEM, V272, P14380, DOI 10.1074/jbc.272.22.14380; NEUFELD AH, 1969, J BIOL CHEM, V244, P6493; OR E, 1993, J BIOL CHEM, V268, P16929; ROSSI RC, 1989, BIOCHIM BIOPHYS ACTA, V981, P105, DOI 10.1016/0005-2736(89)90087-4; Rossi RC, 1999, ANAL BIOCHEM, V270, P276, DOI 10.1006/abio.1999.4094; ROSSI RC, 1993, J BIOL CHEM, V268, P12579; Rossi RC, 1997, ANN NY ACAD SCI, V834, P327, DOI 10.1111/j.1749-6632.1997.tb52263.x; ROSSI RC, 1985, SODIUM PUMP, P443; SCHWARZBAUM PJ, 1995, BBA-BIOMEMBRANES, V1233, P33, DOI 10.1016/0005-2736(94)00229-I; SKOU JC, 1992, J BIOENERG BIOMEMBR, V24, P249; YAMAOKA K, 1978, J PHARMACOKINET BIOP, V6, P165, DOI 10.1007/BF01117450	25	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					20779	20790		10.1074/jbc.274.30.20779	http://dx.doi.org/10.1074/jbc.274.30.20779			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409617	hybrid			2022-12-25	WOS:000081613100008
J	Lee, YK; Parker, KL; Choi, HS; Moore, DD				Lee, YK; Parker, KL; Choi, HS; Moore, DD			Activation of the promoter of the orphan receptor SHP by orphan receptors that bind DNA as monomers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR HORMONE-RECEPTOR; ADRENAL HYPOPLASIA CONGENITA; STEROIDOGENIC FACTOR-I; ACID RESPONSE ELEMENT; GENE-EXPRESSION; KEY REGULATOR; FTZ-F1 GENE; BETA-GENE; DOMAIN; SUPERFAMILY	Small heterodimer partner (SHP) is an orphan nuclear receptor that lacks a conventional DNA binding domain. It interacts with several other members of the nuclear receptor superfamily and inhibits receptor transactivation, In order to characterize the regulation of SHP expression, a number of receptors and other transcription factors were tested for effects on the SHP promoter. Among these, the orphan receptor steroidogenic factor-1 (SF-1) was found to potently transactivate the SHP promoter. Detailed footprinting studies show that the SHP promoter contains at least five SF-1 binding sites, and mutagenesis studies demonstrate each of the three strongest binding sites is required for SF-1 transactivation, SHP is coexpressed with SF-1 in adrenal glands, but is also expressed in tissues that lack SF-1, including liver. However, liver expresses a close relative of SF-1, the orphan fetoprotein transcription factor (FTF), and FTF can also transactivate the SHP promoter. These results suggest that alterations in the levels or activities of SF-1 or FTF could modulate SHP expression in appropriate tissues and thereby affect a variety of receptor dependent signaling pathways.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Chonnam Natl Univ, Hormone Res Ctr, Kwangju 500757, South Korea	Baylor College of Medicine; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Chonnam National University	Moore, DD (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	moore@bcm.tmc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046546] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46546] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel FM, 1998, CURRENT PROTOCOLS MO; BAES M, 1994, MOL CELL BIOL, V14, P1544, DOI 10.1128/MCB.14.3.1544; CARTER ME, 1994, MOL CELL BIOL, V14, P4360, DOI 10.1128/MCB.14.7.4360; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; Galarneau L, 1996, MOL CELL BIOL, V16, P3853; IKEDA Y, 1993, MOL ENDOCRINOL, V7, P852, DOI 10.1210/me.7.7.852; Ikeda Y, 1996, MOL ENDOCRINOL, V10, P1261, DOI 10.1210/me.10.10.1261; Ito M, 1997, MOL CELL BIOL, V17, P1476, DOI 10.1128/MCB.17.3.1476; Johansson L, 1999, J BIOL CHEM, V274, P345, DOI 10.1074/jbc.274.1.345; Keri RA, 1996, J BIOL CHEM, V271, P10782, DOI 10.1074/jbc.271.18.10782; LALA DS, 1992, MOL ENDOCRINOL, V6, P1249, DOI 10.1210/me.6.8.1249; Lee HK, 1998, J BIOL CHEM, V273, P14398, DOI 10.1074/jbc.273.23.14398; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; LEHMANN JM, 1992, MOL CELL BIOL, V12, P2976, DOI 10.1128/MCB.12.7.2976; LEROY P, 1991, P NATL ACAD SCI USA, V88, P10138, DOI 10.1073/pnas.88.22.10138; Liu Z, 1997, MOL ENDOCRINOL, V11, P127, DOI 10.1210/me.11.2.127; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Masuda N, 1997, BBA-GENE STRUCT EXPR, V1350, P27, DOI 10.1016/S0167-4781(96)00196-0; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; Nomura M, 1996, J BIOL CHEM, V271, P8243, DOI 10.1074/jbc.271.14.8243; RICE DA, 1990, J BIOL CHEM, V265, P8052; Seel WG, 1998, MOL ENDOCRINOL, V12, P1551, DOI 10.1210/mend.12.10.0184; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336; Seol W, 1997, MOL CELL BIOL, V17, P7126, DOI 10.1128/MCB.17.12.7126; SHEN WH, 1994, CELL, V77, P651, DOI 10.1016/0092-8674(94)90050-7; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; Sugawara T, 1997, BIOCHEMISTRY-US, V36, P7249, DOI 10.1021/bi9628984; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; ZANARIA E, 1994, NATURE, V372, P635, DOI 10.1038/372635a0	32	91	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					20869	20873		10.1074/jbc.274.30.20869	http://dx.doi.org/10.1074/jbc.274.30.20869			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409629	hybrid			2022-12-25	WOS:000081613100020
J	Ressad, F; Didry, D; Egile, C; Pantaloni, D; Carlier, MF				Ressad, F; Didry, D; Egile, C; Pantaloni, D; Carlier, MF			Control of actin filament length and turnover by actin depolymerizing factor (ADF/cofilin) in the presence of capping proteins and ARP2/3 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-ACTIN; LISTERIA-MONOCYTOGENES; FACTOR COFILIN; ACANTHAMOEBA-CASTELLANII; BINDING PROTEIN; POLYMERIZATION; ACTOPHORIN; MOTILITY; PHOSPHORYLATION; DICTYOSTELIUM	The effect of Arabidopsis thaliana ADF1 and human ADF on the number of filaments in F-actin solutions has been examined using a seeded polymerization assay. ADF did not sever filaments in a catalytic fashion, but decreased the steady-state length distribution of actin filaments in correlation with its effect on actin dynamics. The increase in filament number was modest as compared with the large increase in filament turnover. ADF did not decrease the length of filaments shorter than 1 mu m. ADF promoted the rapid turnover of gelsolin-capped filaments in a manner dependent on the number of pointed ends. To explain these results, we propose that, as a consequence of the cooperative binding of ADF to F-actin, two populations of energetically different filaments coexist in solution pending a flux of subunits from one to the other. The ADF-decorated filaments depolymerize rapidly from their pointed ends, while undecorated filaments polymerize. ADF also promotes rapid turnover of gelsolin-capped filaments in the presence of the pointed end capper Arp2/3 complex. It is shown that the Arp2/3 complex steadily generates new barbed ends in solutions of gelsolin-capped filaments, which represents an important aspect of its function in actin-based motility.	CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France; Inst Pasteur, Unite Pathogenicite Microbienne Mol, Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Carlier, MF (corresponding author), CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France.							Abe H, 1996, J CELL BIOL, V132, P871, DOI 10.1083/jcb.132.5.871; Aizawa H, 1996, J CELL BIOL, V132, P335, DOI 10.1083/jcb.132.3.335; AIZAWA H, 1995, J BIOL CHEM, V270, P10923, DOI 10.1074/jbc.270.18.10923; BAMBURG JR, 1987, J CELL BIOL, V105, P2817, DOI 10.1083/jcb.105.6.2817; Blanchoin L, 1998, J BIOL CHEM, V273, P25106, DOI 10.1074/jbc.273.39.25106; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; COOPER JA, 1986, J BIOL CHEM, V261, P477; DESSEN P, 1973, EUR J BIOCHEM, V39, P157, DOI 10.1111/j.1432-1033.1973.tb03114.x; Didry D, 1998, J BIOL CHEM, V273, P25602, DOI 10.1074/jbc.273.40.25602; Du JY, 1998, BIOCHEMISTRY-US, V37, P13276, DOI 10.1021/bi981117r; GUNSALUS KC, 1995, J CELL BIOL, V131, P1243, DOI 10.1083/jcb.131.5.1243; HAWKINS M, 1993, BIOCHEMISTRY-US, V32, P9985, DOI 10.1021/bi00089a014; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; Kuhlman PA, 1997, BIOCHEMISTRY-US, V36, P13461, DOI 10.1021/bi970601b; Lappalainen P, 1997, NATURE, V388, P78, DOI 10.1038/40418; Littlefield R, 1998, ANNU REV CELL DEV BI, V14, P487, DOI 10.1146/annurev.cellbio.14.1.487; Machesky LM, 1998, NATURE, V394, P125, DOI 10.1038/28039; Machesky LM, 1997, BIOCHEM J, V328, P105; MACIVER SK, 1991, J CELL BIOL, V115, P1611, DOI 10.1083/jcb.115.6.1611; Maciver SK, 1998, EUR J BIOCHEM, V256, P388, DOI 10.1046/j.1432-1327.1998.2560388.x; MARCHAND JB, 1995, J CELL BIOL, V130, P331, DOI 10.1083/jcb.130.2.331; McGough A, 1998, CURR OPIN STRUC BIOL, V8, P166, DOI 10.1016/S0959-440X(98)80034-1; McGough A, 1997, J CELL BIOL, V138, P771, DOI 10.1083/jcb.138.4.771; MCLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18; MOON AL, 1993, J CELL BIOL, V120, P421, DOI 10.1083/jcb.120.2.421; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; NAGAOKA R, 1995, CELL MOTIL CYTOSKEL, V30, P1, DOI 10.1002/cm.970300102; NISHIDA E, 1985, BIOCHEMISTRY-US, V24, P6624, DOI 10.1021/bi00344a049; Ono S, 1999, J CELL BIOL, V145, P491, DOI 10.1083/jcb.145.3.491; Ono S, 1998, J BIOL CHEM, V273, P3778, DOI 10.1074/jbc.273.6.3778; OOSAWA F, 1975, THERMODYNAMICS POLYM, P55; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; Ressad F, 1998, J BIOL CHEM, V273, P20894, DOI 10.1074/jbc.273.33.20894; Rosenblatt J, 1997, J CELL BIOL, V136, P1323, DOI 10.1083/jcb.136.6.1323; SMALL JV, 1995, J CELL BIOL, V129, P1275, DOI 10.1083/jcb.129.5.1275; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Svitkina TM, 1997, J CELL BIOL, V139, P397, DOI 10.1083/jcb.139.2.397; WANG YL, 1985, J CELL BIOL, V101, P597, DOI 10.1083/jcb.101.2.597; WEGNER A, 1976, J MOL BIOL, V108, P139, DOI 10.1016/S0022-2836(76)80100-3; Welch MD, 1997, J CELL BIOL, V138, P375, DOI 10.1083/jcb.138.2.375; Welch MD, 1997, NATURE, V385, P265, DOI 10.1038/385265a0; Welch MD, 1998, SCIENCE, V281, P105, DOI 10.1126/science.281.5373.105; Winter D, 1997, CURR BIOL, V7, P519, DOI 10.1016/S0960-9822(06)00223-5	44	60	60	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					20970	20976		10.1074/jbc.274.30.20970	http://dx.doi.org/10.1074/jbc.274.30.20970			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409644	hybrid			2022-12-25	WOS:000081613100035
J	Chalfant, CE; Kishikawa, K; Mumby, MC; Kamibayashi, C; Bielawska, A; Hannun, YA				Chalfant, CE; Kishikawa, K; Mumby, MC; Kamibayashi, C; Bielawska, A; Hannun, YA			Long chain ceramides activate protein phosphatase-1 and protein phosphatase-2A - Activation is stereospecific and regulated by phosphatidic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DIFFERENTIATION; DOWNSTREAM TARGET; INDUCED APOPTOSIS; SPHINGOMYELIN TURNOVER; HL-60 CELLS; SPHINGOLIPIDS; STRESS; DEATH; BCL-2; SACCHAROMYCES	The search for potential targets for ceramide action led to the identification of ceramide-activated protein phosphatases, which include protein phosphatase-2A (PP2A) and protein phosphatase-1 (PP1) with roles in regulating apoptosis and cell growth. Thus far, in vitro studies on ceramide-activated protein phosphatases have been restricted to the use of short chain ceramides, limiting the extent of mechanistic insight. In this study, we show that the long chain D-erythro-C-18-ceramide activated PP2A (AB'C trimer), PP2Ac (catalytic subunit of PP2A), and PP1 gamma c and -alpha c (catalytic subunits of PP1 gamma and -1 alpha isoforms, respectively) 2-6-fold in the presence of dodecane, a lipid-solubilizing agent, with 50% maximal activation achieved at approximately 10 mu M D-erythro-C-18-ceramide. The diastereoisomers of D-erythro-C-18-ceramide, D-threo-, and L-threo-C-18-ceramide, as well as the enantiomeric L-erythro-C-18-ceramide, did not activate PP1 or PP2A, but they inhibited PP1 and PP2A activity. The addition of phosphatidic acid decreased the basal activity of PP1c but also increased the stimulation by D-erythro-C-18-ceramide from 1.8- to 2.8 fold and decreased the EC50 of D erythro-C-18-ceramide to 4.45 mu M. The addition of 150 mM KCI decreased the basal activity of PP1 and the dose of D-erythro-C-18-ceramide necessary to activate PP1c (EC50 = 6.25 mu M) and increased the ceramide responsiveness up to 10-17-fold. These studies disclose stereospecific activation of PP1 and PP2A by long chain natural ceramides under near physiologic ionic strengths in vitro. The implications of these studies for mechanisms of ceramide action are discussed.	Med Univ S Carolina, Dept Biochem & Mol Biol, Durham, NC 27710 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	Medical University of South Carolina; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, Rm 501,Basic Sci Bldg,171 Ashley Ave, Durham, NC 27710 USA.				NIGMS NIH HHS [GM43825] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BIELAWSKA A, 1992, J BIOL CHEM, V267, P18493; Cain K, 1996, BIOCHEM J, V314, P27, DOI 10.1042/bj3140027; CEGIELSKA A, 1994, MOL CELL BIOL, V14, P4616, DOI 10.1128/MCB.14.7.4616; Chu YF, 1996, J BIOL CHEM, V271, P2574, DOI 10.1074/jbc.271.5.2574; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; Dbaibo GS, 1998, J CLIN INVEST, V102, P329, DOI 10.1172/JCI1180; DBAIBO GS, 1995, P NATL ACAD SCI USA, V92, P1347, DOI 10.1073/pnas.92.5.1347; Dickson RC, 1997, J BIOL CHEM, V272, P30196, DOI 10.1074/jbc.272.48.30196; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; Gamard CJ, 1997, J BIOL CHEM, V272, P16474, DOI 10.1074/jbc.272.26.16474; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; Ito M, 1997, BIOCHEMISTRY-US, V36, P7607, DOI 10.1021/bi9702647; Jenkins GM, 1997, J BIOL CHEM, V272, P32566, DOI 10.1074/jbc.272.51.32566; JI L, 1995, FEBS LETT, V358, P211, DOI 10.1016/0014-5793(94)01428-4; KAMIBAYASHI C, 1994, J BIOL CHEM, V269, P20139; KIM MY, 1991, J BIOL CHEM, V266, P484; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; LISCOVITCH M, 1992, TRENDS BIOCHEM SCI, V17, P393, DOI 10.1016/0968-0004(92)90007-V; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; Mizushima N, 1996, FEBS LETT, V395, P267, DOI 10.1016/0014-5793(96)01050-2; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; Perry DK, 1997, J BIOL CHEM, V272, P18530, DOI 10.1074/jbc.272.30.18530; QUINTANS J, 1994, BIOCHEM BIOPH RES CO, V202, P710, DOI 10.1006/bbrc.1994.1988; Reyes JG, 1996, J BIOL CHEM, V271, P21375, DOI 10.1074/jbc.271.35.21375; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Smyth MJ, 1996, BIOCHEM J, V316, P25, DOI 10.1042/bj3160025; STRUM JC, 1994, J BIOL CHEM, V269, P15493; Voehringer DW, 1998, P NATL ACAD SCI USA, V95, P2956, DOI 10.1073/pnas.95.6.2956; WARING P, 1990, INT J IMMUNOPHARMACO, V12, P445, DOI 10.1016/0192-0561(90)90028-L; WOLFF RA, 1994, J BIOL CHEM, V269, P19605; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325	36	260	265	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20313	20317		10.1074/jbc.274.29.20313	http://dx.doi.org/10.1074/jbc.274.29.20313			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400653	hybrid			2022-12-25	WOS:000081438300046
J	Vemuri, S; Marchase, RB				Vemuri, S; Marchase, RB			The inhibition of capacitative calcium entry due to ATP depletion but not due to glucosamine is reversed by staurosporine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHAGOSOME-LYSOSOME FUSION; JURKAT T-LYMPHOCYTES; XENOPUS OOCYTES; INSULIN-RESISTANCE; INFLUX FACTOR; HEXOSAMINE BIOSYNTHESIS; PHOSPHATASE INHIBITORS; INTRACELLULAR CALCIUM; ENDOPLASMIC-RETICULUM	The capacitative Ca2+ entry pathway in J774 macrophages is rapidly inhibited by the amino sugar glucosamine. This pathway is also inhibited by treatments such as 2-deoxy-D-glucose (2dGlc) or glucose deprivation that inhibit glycolysis and lead to significant decreases in cellular ATP and other trinucleotides. We sought to determine whether glucosamine's effect on capacitative Ca2+ entry was also due to ATP depletion, as has been suggested recently for its link to insulin resistance. In contrast to brief treatments with 2dGlc, there was no significant decrease in ATP following exposure to glucosamine. In addition, the 2dGlc-mediated inhibition of capacitative Ca2+ influx was reversed by staurosporine, a microbial alkaloid that inhibits a broad range of protein kinases. Staurosporine was also able to reverse the inhibition of capacitative Ca2+ entry seen following other treatments that decreased cellular ATP levels, including cytochalasin B and iodoacetic acid. Other inhibitors of protein kinase C, including bisindolylmaleimide, K252a, H-7, and calphostin C, were unable to mimic this effect of staurosporine. However, the inhibition of capacitative Ca2+ influx in the presence of glucosamine was not reversed by staurosporine. These data indicate that the inhibitory action on capacitative Ca2+ entry of glucosamine is distinct from that caused by ATP depletion.	Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Marchase, RB (corresponding author), Univ Alabama, Dept Cell Biol, Basic Hlth Sci Bldg 690,Univ Stn, Birmingham, AL 35294 USA.							Ahnadi CE, 1996, CELL CALCIUM, V19, P509, DOI 10.1016/S0143-4160(96)90060-3; ATLAS SJ, 1980, J RECEPTOR RES, V1, P113, DOI 10.3109/10799898009044095; Barclay TS, 1998, ANN PHARMACOTHER, V32, P574, DOI 10.1345/aph.17235; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Buse MG, 1997, AM J PHYSIOL-ENDOC M, V272, pE1080, DOI 10.1152/ajpendo.1997.272.6.E1080; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CROOK ED, 1993, DIABETES, V42, P1289, DOI 10.2337/diabetes.42.9.1289; Csutora P, 1999, P NATL ACAD SCI USA, V96, P121, DOI 10.1073/pnas.96.1.121; DANIELS MC, 1993, MOL ENDOCRINOL, V7, P1041, DOI 10.1210/me.7.8.1041; Darbha S, 1996, CELL CALCIUM, V20, P361, DOI 10.1016/S0143-4160(96)90042-1; DIVIRGILIO F, 1988, J CELL BIOL, V106, P657, DOI 10.1083/jcb.106.3.657; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; FRIEDMAN SJ, 1980, P NATL ACAD SCI-BIOL, V77, P1172, DOI 10.1073/pnas.77.2.1172; GAMBERUCCI A, 1994, J BIOL CHEM, V269, P23597; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hebert LF, 1996, J CLIN INVEST, V98, P930, DOI 10.1172/JCI118876; Hresko RC, 1998, J BIOL CHEM, V273, P20658, DOI 10.1074/jbc.273.32.20658; Jaconi M, 1997, CURR BIOL, V7, P599, DOI 10.1016/S0960-9822(06)00259-4; JACONI MEE, 1990, J CELL BIOL, V110, P1555, DOI 10.1083/jcb.110.5.1555; KIM HY, 1995, J BIOL CHEM, V270, P9706, DOI 10.1074/jbc.270.17.9706; Kim YB, 1999, DIABETES, V48, P310, DOI 10.2337/diabetes.48.2.310; Kolm-Litty V, 1998, J CLIN INVEST, V101, P160, DOI 10.1172/JCI119875; Liu XB, 1998, J BIOL CHEM, V273, P33295, DOI 10.1074/jbc.273.50.33295; MARRIOTT I, 1995, AM J PHYSIOL-CELL PH, V269, pC766, DOI 10.1152/ajpcell.1995.269.3.C766; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; MEGGIO F, 1995, EUR J BIOCHEM, V234, P317, DOI 10.1111/j.1432-1033.1995.317_c.x; Mene P, 1996, J AM SOC NEPHROL, V7, P983; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; MORLEY P, 1996, EUR J ENDOCRINOL, V134, P734; PAREKH AB, 1995, P NATL ACAD SCI USA, V92, P7907, DOI 10.1073/pnas.92.17.7907; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PETERSEN CCH, 1994, J BIOL CHEM, V269, P32246; PETERSEN CCH, 1995, BIOCHEM J, V307, P663, DOI 10.1042/bj3070663; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; Qiu GX, 1998, ARZNEIMITTEL-FORSCH, V48, P469; QUASTEL JH, 1953, NATURE, V171, P252, DOI 10.1038/171252a0; RANDRIAMAMPITA C, 1995, J BIOL CHEM, V270, P29, DOI 10.1074/jbc.270.1.29; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; RAYFIELD EJ, 1982, AM J MED, V72, P439, DOI 10.1016/0002-9343(82)90511-3; ROSSETTI L, 1995, J CLIN INVEST, V96, P132, DOI 10.1172/JCI118013; SALTER DW, 1979, J BIOL CHEM, V254, P3554; Shibata K, 1996, BIOCHEM PHARMACOL, V52, P167, DOI 10.1016/0006-2952(96)00135-9; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THEODOSAKIS J, 1997, ARTHRITIS CURE; THOMAS D, 1995, J BIOL CHEM, V270, P6429, DOI 10.1074/jbc.270.12.6429; Thomas D, 1996, BIOCHEM J, V318, P649, DOI 10.1042/bj3180649; TOJYO Y, 1991, AM J PHYSIOL, V260, pC194, DOI 10.1152/ajpcell.1991.260.2.C194; Tojyo Y, 1995, JPN J PHARMACOL, V69, P381, DOI 10.1254/jjp.69.381; Wang JL, 1998, NATURE, V393, P684, DOI 10.1038/31474; Zerr KJ, 1997, ANN THORAC SURG, V63, P356; Zimmerli S, 1996, J CELL BIOL, V132, P49, DOI 10.1083/jcb.132.1.49	52	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20165	20170		10.1074/jbc.274.29.20165	http://dx.doi.org/10.1074/jbc.274.29.20165			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400631	hybrid			2022-12-25	WOS:000081438300024
J	Lakin, ND; Hann, BC; Jackson, SP				Lakin, ND; Hann, BC; Jackson, SP			The ataxia-telangiectasia related protein ATR mediates DNA-dependent phosphorylation of p53	ONCOGENE			English	Article						p53; ATR; ATM; DNA-PK; ataxia telangiectasia; DNA damage	CELL-CYCLE CHECKPOINTS; IONIZING-RADIATION; KINASE; DAMAGE; GENE; SENSITIVITY; 3-KINASE; UV	Levels of the tumour suppressor protein p53 are increased in response to a variety of DNA damaging agents. DNA damage-induced phosphorylation of p53 occurs at serine-15 in vivo. Phosphorylation of p53 at serine-15 leads to a stabilization of the polypeptide by inhibiting its interaction with Mdm2, a protein that targets p53 for ubiquitin-dependent degradation, However, the mechanisms by which DNA damage is signalled to p53 remain unclear. Here, we report the identification of a novel DNA-activated protein kinase that phosphorylates p53 on serine-15, Fractionation of HeLa nuclear extracts and biochemical analyses indicate that this kinase is distinct from the DNA-dependent protein kinase (DNA-PK) and corresponds to the human cell cycle checkpoint protein ATR. Immunoprecipitation studies of recombinant ATR reveal that catalytic activity of this polypeptide is required for DNA-stimulated phosphorylation of p53 on serine-15. These data suggest that ATR may function upstream of p53 in a signal transduction cascade initiated upon DNA damage and provide a biochemical assay system for ATR activity.	Univ Cambridge, Canc Res Campaign, Inst Canc & Dev Biol, Dept Zool, Cambridge CB2 1QR, England; Univ Cambridge, Dept Zool, Cambridge CB2 1QR, England; Univ Dundee, Dept Biochem, Canc Res Campaign Labs, Dundee DD1 4HN, Scotland	CRUK Cambridge Institute; University of Cambridge; University of Cambridge; University of Dundee	Jackson, SP (corresponding author), Univ Cambridge, Canc Res Campaign, Inst Canc & Dev Biol, Dept Zool, Tennis Court Rd, Cambridge CB2 1QR, England.		Jackson, Stephen Philip/R-4548-2019; Dry, Kate/I-2328-2014	Jackson, Stephen Philip/0000-0001-9317-7937; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARTUSO M, 1995, ONCOGENE, V11, P1427; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; DVIR A, 1993, J BIOL CHEM, V268, P10440; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; GOTTLIEB TM, 1997, BIOCHIM BIOPHYS ACTA, V1287, P77; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Hoekstra MF, 1997, CURR OPIN GENET DEV, V7, P170, DOI 10.1016/S0959-437X(97)80125-6; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jackson SP, 1996, CANCER SURV, V28, P261; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KHANNA KK, 1993, ONCOGENE, V8, P3307; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lakin ND, 1996, ONCOGENE, V13, P2707; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Longhese MP, 1998, EMBO J, V17, P5525, DOI 10.1093/emboj/17.19.5525; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; POWIS G, 1994, CANCER RES, V54, P2419; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Rotman G, 1997, CANCER SURV, V29, P285; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SMITH GCM, 1999, IN PRESS GENES DEV; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Steegenga WT, 1996, J MOL BIOL, V263, P103, DOI 10.1006/jmbi.1996.0560; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; Weinert T, 1998, CURR OPIN GENET DEV, V8, P185, DOI 10.1016/S0959-437X(98)80140-8; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; Wright JA, 1998, P NATL ACAD SCI USA, V95, P7445, DOI 10.1073/pnas.95.13.7445	34	107	110	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	1999	18	27					3989	3995		10.1038/sj.onc.1202973	http://dx.doi.org/10.1038/sj.onc.1202973			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KU	10435622				2022-12-25	WOS:000081327800009
J	Lilly, M; Sandholm, J; Cooper, JJ; Koskinen, PJ; Kraft, A				Lilly, M; Sandholm, J; Cooper, JJ; Koskinen, PJ; Kraft, A			The PIM-1 serine kinase prolongs survival and inhibits apoptosis-related mitochondrial dysfunction in part through a bcl-2-dependent pathway	ONCOGENE			English	Article						apoptosis; pim-1; bcl-2; mitochondria; IL-3; FDCP1	PROTEIN-KINASE; CELL-DEATH; HEMATOPOIETIC-CELLS; MYELOID CELLS; ANTIOXIDANT PATHWAY; SUPPRESS APOPTOSIS; BCL-2 EXPRESSION; TRANSGENIC MICE; CYTOCHROME-C; IN-VIVO	We have examined potential mechanisms by which the Pim-1 kinase acts as a hematopoietic cell survival factor. Enforced expression of the wild type 33 kd (FD/hpim33) and 44 kd (FD/mpim44) Pim-1 proteins in murine factor-dependent FDCP1 cells prolonged survival after withdrawal of IL-3, while expression of a dominant negative Pim-1 protein (FD/pimNT81) shortened survival, Following removal of IL-3 FDCP1 cells exhibited loss of mitochondrial transmembrane potential and production of reactive oxygen species, as determined by how cytometry analysis. The wild type Pim-1 proteins decreased these changes while the dominant negative protein enhanced mitochondrial dysfunction, The anti-apoptotic activity of the kinases could not be attributed to modulation of glutathione, catalase, or superoxide dismutase activities, Both the FD/hpim33 and FD/mpim44 cells maintained expression of bcl-2 mRNA following cytokine removal, while a substantial decrease was seen in FD/neo cells. To modulate Bcl-2 protein levels, a bcl-2 antisense RNA construct was coexpressed with the wild type pim-1 cDNAs, FD/hpim33 cells with low cellular Bcl-2 protein levels had shortened cytokine-independent survival compared with FD/hpim33 clones with high Bcl-2 expression. However survival of FD/mpim44 cells after IL-3 withdrawal was substantially independent of cellular Bcl-2 protein levels. The 33 kd protein delayed, and the 44 kd protein completely prevented enhanced cell death associated with enforced expression of human Bar protein however. Our results suggest that the 33 kd Pim-1 kinase may enhance cell survival through cooperation with and regulation of bcl-2, In addition the 44 kd kinase may regulate the expression or activity of other pro- and anti-apoptotic members of the bcl-2 family.	Univ Washington, Dept Med, Div Med Oncol, Seattle, WA USA; Vet Affairs Med Ctr, Seattle, WA USA; Univ Turku, Abo Akad Univ, Ctr Biotechnol, Turku, Finland; Univ Colorado, Hlth Sci Ctr, Dept Med, Div Med Oncol, Denver, CO 80262 USA	University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Abo Akademi University; University of Turku; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Lilly, M (corresponding author), Loma Linda Univ, Sch Med, Ctr Mol Biol & Gene Therapy, Loma Linda, CA 92354 USA.		Koskinen, Päivi J/G-8939-2014		NATIONAL CANCER INSTITUTE [R01CA045672, R55CA045672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044741] Funding Source: NIH RePORTER; NCI NIH HHS [CA45672] Funding Source: Medline; NIDDK NIH HHS [DK44741] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acton D, 1992, Curr Top Microbiol Immunol, V182, P293; Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Allen JD, 1996, SEMIN CANCER BIOL, V7, P299, DOI 10.1006/scbi.1996.0038; AMSON R, 1989, P NATL ACAD SCI USA, V86, P8857, DOI 10.1073/pnas.86.22.8857; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; BREUER M, 1991, CANCER RES, V51, P958; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; DOMEN J, 1993, BLOOD, V82, P1445; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; Feldman JD, 1998, J BIOL CHEM, V273, P16535, DOI 10.1074/jbc.273.26.16535; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; HEDLEY D, 1994, METHOD CELL BIOL, V42, P31; Hirsch T, 1997, BIOSCIENCE REP, V17, P67, DOI 10.1023/A:1027339418683; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KINOSHITA T, 1995, ONCOGENE, V10, P2207; Klampfer L, 1996, P NATL ACAD SCI USA, V93, P14059, DOI 10.1073/pnas.93.24.14059; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; Leverson JD, 1998, MOL CELL, V2, P417, DOI 10.1016/S1097-2765(00)80141-0; Lilly M, 1997, CANCER RES, V57, P5348; LILLY M, 1992, ONCOGENE, V7, P727; MEEKER TC, 1987, ONCOGENE RES, V1, P87; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MIYASHITA T, 1994, ONCOGENE, V9, P1799; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; NUNEZ G, 1990, J IMMUNOL, V144, P3602; Oppenheim R W, 1997, Adv Neurol, V72, P69; Ou PM, 1996, J BIOCHEM BIOPH METH, V31, P59, DOI 10.1016/0165-022X(95)00039-T; Packham G, 1996, J IMMUNOL, V156, P2792; POLOTSKAYA A, 1993, CELL GROWTH DIFFER, V4, P523; RINAUDO MS, 1995, BLOOD, V86, P80, DOI 10.1182/blood.V86.1.80.bloodjournal86180; Sakai I, 1997, J BIOL CHEM, V272, P12350, DOI 10.1074/jbc.272.19.12350; Salomoni P, 1997, P NATL ACAD SCI USA, V94, P3296, DOI 10.1073/pnas.94.7.3296; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; VANDERLUGT NMT, 1995, EMBO J, V14, P2536, DOI 10.1002/j.1460-2075.1995.tb07251.x; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wingett D, 1996, J IMMUNOL, V156, P549; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; ZAMZAMI N, 1996, J EXP MED, V183, P1293	51	143	151	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 8	1999	18	27					4022	4031		10.1038/sj.onc.1202741	http://dx.doi.org/10.1038/sj.onc.1202741			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KU	10435626	Bronze			2022-12-25	WOS:000081327800013
J	Quesnel, S; Verselis, S; Portwine, C; Garber, J; White, M; Feunteun, J; Malkin, D; Li, FP				Quesnel, S; Verselis, S; Portwine, C; Garber, J; White, M; Feunteun, J; Malkin, D; Li, FP			p53 compound heterozygosity in a severely affected child with Li-Fraumeni Syndrome	ONCOGENE			English	Article						Li-Fraumeni Syndrome; p53; germline mutations; functional assays	WILD-TYPE P53; TUMOR-SUPPRESSOR P53; CYCLIN-DEPENDENT KINASES; CANCER FAMILY SYNDROME; SOFT-TISSUE SARCOMA; GENE-MUTATIONS; CELL-LINES; GROWTH SUPPRESSION; ANTICANCER AGENTS; BREAST-CANCER	The Li-Fraumeni Syndrome (LFS) is a rare, dominantly inherited syndrome that features high risk of cancers in childhood and early adulthood. Affected families tend to develop bone and soft tissue sarcomas, breast cancers, brain tumors, leukemias, and adrenocortical carcinomas. In some kindreds, the genetic abnormality associated with this cancer phenotype is a heterozygous germline mutation in the p53 tumor suppressor gene. Recently, we identified one patient who presented in early childhood with multiple primary cancers and who harbored three germline p53 alterations (R156H and R267Q on the maternal allele and R290H on the paternal allele), To classify the biologic effects of these alterations, functional properties of each of the p53 mutants were examined using in vitro assays of cellular growth suppression and transcriptional activation. Each amino acid substitution conferred partial or complete loss of wild-type p53 function, but the child completed normal embryonic development. This observation has not been previously reported in a human, but is consistent with observations of normal embryogenesis in p53-deficient mice.	Hosp Sick Children, Div Oncol, Toronto, ON M5G 1X8, Canada; Dana Farber Canc Inst, Div Human Canc Genet, Boston, MA 02115 USA; Dana Farber Canc Inst, Div Populat Sci, Boston, MA 02115 USA; OncorMed Inc, Gaithersburg, MD 20877 USA; Inst Gustave Roussy, Mol Oncol Lab, F-75016 Villejuif, France	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; UNICANCER; Gustave Roussy	Malkin, D (corresponding author), Hosp Sick Children, Div Oncol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.		Portwine, Carol/AAS-4083-2021; Malkin, David/AAW-8715-2021; Feunteun, Jean/AAZ-1267-2020	Portwine, Carol/0000-0002-1314-8691; Feunteun, Jean/0000-0003-1212-9189				AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; Bian JH, 1997, P NATL ACAD SCI USA, V94, P14753, DOI 10.1073/pnas.94.26.14753; BIRCH JM, 1994, CANCER RES, V54, P1298; Brachmann RK, 1998, EMBO J, V17, P1847, DOI 10.1093/emboj/17.7.1847; CANNON JV, 1990, EMBO J, V9, P1595; COLES C, 1992, CANCER RES, V52, P5291; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Eeles RA, 1995, CANCER SURV, V25, P101; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; FREBOURG T, 1995, AM J HUM GENET, V56, P608; FREBOURG T, 1992, P NATL ACAD SCI USA, V89, P6413, DOI 10.1073/pnas.89.14.6413; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GARBER JE, 1990, CANCER-AM CANCER SOC, V66, P2432, DOI 10.1002/1097-0142(19901201)66:11<2432::AID-CNCR2820661132>3.0.CO;2-C; HARPER JW, 1993, CELL, V75, P805; HARTLEY AL, 1989, CANCER GENET CYTOGEN, V42, P221, DOI 10.1016/0165-4608(89)90090-3; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HU GY, 1992, BRIT J HAEMATOL, V81, P489, DOI 10.1111/j.1365-2141.1992.tb02979.x; ISHIOKA C, 1995, ONCOGENE, V10, P1485; Ishioka C, 1997, BIOCHEM BIOPH RES CO, V232, P54, DOI 10.1006/bbrc.1997.6216; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Kawamura M, 1996, ONCOGENE, V12, P2361; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kim E, 1997, ONCOGENE, V15, P857, DOI 10.1038/sj.onc.1201412; Kleihues P, 1997, AM J PATHOL, V150, P1; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANG P, 1993, INT J ONCOL, V2, P347; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; LI FP, 1969, J NATL CANCER I, V43, P1365; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1998, GENETIC BASIS HUMAN, P393; MASHIYAMA S, 1991, ONCOGENE, V6, P1313; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; OConnor PM, 1997, CANCER RES, V57, P4285; OSBORNE RJ, 1991, CANCER RES, V51, P6194; PAULES RS, 1995, CANCER RES, V55, P1763; PENG HQ, 1993, CANCER RES, V53, P3574; PROSSER J, 1992, BRIT J CANCER, V65, P527, DOI 10.1038/bjc.1992.109; PURDIE CA, 1994, ONCOGENE, V9, P603; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STRONG LC, 1987, JNCI-J NATL CANCER I, V79, P1213; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; Varley JM, 1997, CANCER RES, V57, P3245; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WILLIAMS WR, 1985, FAM CANCER, P151; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	68	25	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 8	1999	18	27					3970	3978		10.1038/sj.onc.1202783	http://dx.doi.org/10.1038/sj.onc.1202783			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KU	10435620				2022-12-25	WOS:000081327800007
J	Boulares, AH; Yakovlev, AG; Ivanova, V; Stoica, BA; Wang, GP; Iyer, S; Smulson, M				Boulares, AH; Yakovlev, AG; Ivanova, V; Stoica, BA; Wang, GP; Iyer, S; Smulson, M			Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis - Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTISENSE RNA EXPRESSION; DNA FRAGMENTATION; ICE/CED-3 PROTEASE; GENOMIC STABILITY; DEATH; DIFFERENTIATION; INHIBITION; DISEASE; DAMAGE; IDENTIFICATION	An early transient burst of poly(ADP-ribosyl)ation of nuclear proteins was recently shown to be required for apoptosis to proceed in various cell lines (Simbulan-Rosenthal, C., Rosenthal, D., Iyer, S., Boulares, H., and Smulson, M, (1998) J. Biol. Chem. 273, 13703-13712) followed by cleavage of poly(ADP-ribose) polymerase (PARP), catalyzed by caspase-3, This inactivation of PARP has been proposed to prevent depletion of NAD (a PARP substrate) and ATP, which are thought to be required for later events in apoptosis, The role of PARP cleavage in apoptosis has now been investigated in human osteosarcoma cells and PARP -/- fibroblasts stably transfected with a vector encoding a caspase-3-resistant PARP mutant. Expression of this mutant PARP increased the rate of staurosporine and tumor necrosis factor-alpha-induced apoptosis, at least in part by reducing the time interval required for the onset of caspase-3 activation and internucleosomal DNA fragmentation, as well as the generation of 50-kilobase pair DNA breaks, thought to be associated with early chromatin unfolding. Overexpression of wild-type PARP in osteosarcoma cells also accelerated the apoptotic process, although not to the same extent as that apparent in cells expressing the mutant PARP, These effects of the mutant and wild-type enzymes might be due to the early and transient poly(ADP-ribose) synthesis in response to DNA breaks, and the accompanying depletion of NAD apparent in the transfected cells. The accelerated NAD depletion did not seem to interfere with the later stages of apoptosis, These results indicate that PARP activation and subsequent cleavage have active and complex roles in apoptosis.	Georgetown Univ, Sch Med, Dept Biochem & Mol Biol, Med Ctr, Washington, DC 20007 USA	Georgetown University	Smulson, M (corresponding author), Georgetown Univ, Sch Med, Dept Biochem & Mol Biol, Med Ctr, Basic Sci Bldg,Rm 351,3900 Reservoir Rd NW, Washington, DC 20007 USA.		STOICA, BOGDAN/H-9782-2013	STOICA, BOGDAN/0000-0002-2501-6434	NCI NIH HHS [CA25344, 1P01CA74175] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA025344, P01CA074175] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; AVILA MA, 1994, YEAST, V10, P1003, DOI 10.1002/yea.320100803; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; BERGER NA, 1985, BIOCHEMISTRY-US, V24, P4352, DOI 10.1021/bi00337a015; BERGER NA, 1983, ADP RIBOSYLATION DNA, P219; Bernges F, 1997, CARCINOGENESIS, V18, P663, DOI 10.1093/carcin/18.4.663; BICKNELL GR, 1994, J CELL SCI, V107, P2483; BURSCH W, 1992, TRENDS PHARMACOL SCI, V13, P245, DOI 10.1016/0165-6147(92)90077-J; CHERNEY BW, 1985, DEV BIOL, V112, P115, DOI 10.1016/0012-1606(85)90125-3; CHERNEY BW, 1987, P NATL ACAD SCI USA, V84, P8370, DOI 10.1073/pnas.84.23.8370; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; COHEN GM, 1994, J IMMUNOL, V153, P507; Cookson MR, 1998, J NEUROCHEM, V70, P501; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; DING RC, 1994, CANCER RES, V54, P4627; DING RC, 1992, J BIOL CHEM, V267, P12804; Eldadah BA, 1996, NUCLEIC ACIDS RES, V24, P4092, DOI 10.1093/nar/24.20.4092; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Herceg Z, 1999, MOL CELL BIOL, V19, P5124; Jacobson EL, 1997, METHOD ENZYMOL, V280, P221; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; KAISER P, 1992, MOL GEN GENET, V232, P231, DOI 10.1007/BF00280001; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Le Rhun Y, 1998, BIOCHEM BIOPH RES CO, V245, P1; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; NEAMATI N, 1995, J IMMUNOL, V154, P3788; Neame SJ, 1998, J CELL BIOL, V142, P1583, DOI 10.1083/jcb.142.6.1583; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Oliver FJ, 1998, J BIOL CHEM, V273, P33533, DOI 10.1074/jbc.273.50.33533; Revillard JP, 1998, IMMUNOL TODAY, V19, P291, DOI 10.1016/S0167-5699(98)01279-1; Rosenthal DS, 1997, EXP CELL RES, V232, P313, DOI 10.1006/excr.1997.3536; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Shiokawa D, 1997, FEBS LETT, V413, P99, DOI 10.1016/S0014-5793(97)00887-9; Simbulan-Rosenthal CM, 1998, J BIOL CHEM, V273, P13703, DOI 10.1074/jbc.273.22.13703; Simbulan-Rosenthal CM, 1999, MOL CELL BIOCHEM, V193, P137, DOI 10.1023/A:1006988832729; SimbulanRosenthal CM, 1996, BIOCHEMISTRY-US, V35, P11622, DOI 10.1021/bi953010z; SMULSON ME, 1995, J BIOL CHEM, V270, P119, DOI 10.1074/jbc.270.1.119; TANAKA Y, 1984, J BIOL CHEM, V259, P6579; TANIGAWA Y, 1983, J BIOL CHEM, V258, P9184; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; VanGool L, 1997, EUR J BIOCHEM, V244, P15; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509	48	706	734	1	41	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					22932	22940		10.1074/jbc.274.33.22932	http://dx.doi.org/10.1074/jbc.274.33.22932			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438458	hybrid			2022-12-25	WOS:000082012800008
J	Asano, S; Kimura, T; Ueno, S; Kawamura, M; Takeguchi, N				Asano, S; Kimura, T; Ueno, S; Kawamura, M; Takeguchi, N			Chimeric domain analysis of the compatibility between H+,K+-ATPase and Na+,K+-ATPase beta-subunits for the functional expression of gastric H+,K+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; NA+/K+-ATPASE COMPLEXES; (NA+ + K+)-ATPASE; ALPHA-SUBUNIT; DISULFIDE BONDS; H+/K+-ATPASE; INTRACELLULAR-TRANSPORT; EXTRACELLULAR DOMAIN; PROTON PUMP; H,K-ATPASE	Gastric H+,K+-ATPase consists of alpha-subunit with 10 transmembrane domains and beta-subunit with a single transmembrane domain, We constructed cDNAs encoding chimeric beta-subunits between the gastric H+,K+ ATPase and Na+,K+-ATPase beta-subunits and co-transfected them with the H+,K+-ATPase alpha-subunit cDNA in HEK-293 cells. A chimeric beta-subunit that consists of the cytoplasmic plus transmembrane domains of Na+,K+ ATPase beta-subunit and the ectodomain of H+,K+-ATPase beta-subunit assembled with the H+,K+-ATPase alpha-subunit and expressed the K+-ATPase activity. Therefore, the whole cytoplasmic and transmembrane domains of H+,K+-ATPase beta-subunit were replaced by those of Na+,K+-ATPase beta-subunit without losing the enzyme activity. However, most parts of the ectodomain of H+,K+ ATPase beta-subunit were not replaced by the corresponding domains of Na+,K+-ATPase beta-subunit. interestingly the extracellular segment between Cys(152) and Cys(178), which contains the second disulfide bond, was exchangeable between H+,K+-ATPase and Na+,K+ ATPase, preserving the K+-ATPase activity intact. Furthermore, the K+-ATPase activity was preserved when the N-terminal first 4 amino acids ((DPYT70)-D-67) in the ectodomain of H+,K+-ATPase beta-subunit were replaced by the corresponding amino acids ((SDFE66)-S-63) of Na+,K+ ATPase beta-subunit. The ATPase activity was abolished, however, when 4 amino acids ((76)QLKS(79)) in the ectodomain of H+,K+-ATPase beta-subunit were replaced by the counterpart ((72)RVAP(75)) of Na+,K+-ATPase beta-subunit, indicating that this region is the most N-terminal one that discriminates the H+,K+-ATPase beta-subunit from that of Na+,K+-ATPase.	Toyama Med & Pharmaceut Univ, Mol Genet Res Ctr, Toyama 9300194, Japan; Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Toyama 9300194, Japan; Univ Occupat & Environm Hlth, Dept Pharmacol, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan; Univ Occupat & Environm Hlth, Dept Biol, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan	University of Toyama; University of Toyama; University of Occupational & Environmental Health - Japan; University of Occupational & Environmental Health - Japan	Asano, S (corresponding author), Toyama Med & Pharmaceut Univ, Mol Genet Res Ctr, 2630 Sugitani, Toyama 9300194, Japan.			Asano, Shinji/0000-0003-1443-8970				Asano S, 1998, AM J PHYSIOL-CELL PH, V275, pC669, DOI 10.1152/ajpcell.1998.275.3.C669; ASANO S, 1994, BIOCHEM J, V299, P59, DOI 10.1042/bj2990059; Asano S, 1997, J BIOL CHEM, V272, P17668, DOI 10.1074/jbc.272.28.17668; Asano S, 1996, J BIOL CHEM, V271, P2740, DOI 10.1074/jbc.271.5.2740; Beggah AT, 1997, J BIOL CHEM, V272, P10318; Besancon M, 1997, J BIOL CHEM, V272, P22438, DOI 10.1074/jbc.272.36.22438; CHOW DC, 1993, AM J PHYSIOL, V265, pC1562, DOI 10.1152/ajpcell.1993.265.6.C1562; CHOW DC, 1992, AM J PHYSIOL, V263, pC39, DOI 10.1152/ajpcell.1992.263.1.C39; Codina J, 1996, J BIOL CHEM, V271, P29759, DOI 10.1074/jbc.271.47.29759; Colonna TE, 1997, J BIOL CHEM, V272, P12366, DOI 10.1074/jbc.272.19.12366; EAKLE KA, 1994, J BIOL CHEM, V269, P6550; EAKLE KA, 1992, P NATL ACAD SCI USA, V89, P2834, DOI 10.1073/pnas.89.7.2834; EAKLE KA, 1995, J BIOL CHEM, V270, P13937, DOI 10.1074/jbc.270.23.13937; FARLEY RA, 1985, J BIOL CHEM, V260, P3899; HAMRICK M, 1993, J BIOL CHEM, V268, P24367; Hasler U, 1998, J BIOL CHEM, V273, P30826, DOI 10.1074/jbc.273.46.30826; Hermsen HPH, 1998, BIOCHEM J, V331, P465, DOI 10.1042/bj3310465; HORISBERGER JD, 1991, J BIOL CHEM, V266, P19131; JAISSER F, 1994, J GEN PHYSIOL, V103, P605, DOI 10.1085/jgp.103.4.605; JAUNIN P, 1993, J CELL BIOL, V123, P1751, DOI 10.1083/jcb.123.6.1751; KAWAMURA M, 1984, BIOCHIM BIOPHYS ACTA, V774, P188, DOI 10.1016/0005-2736(84)90290-6; KIRLEY TL, 1989, J BIOL CHEM, V264, P7185; KIRLEY TL, 1990, J BIOL CHEM, V265, P4227; KLAASSEN CHW, 1993, FEBS LETT, V329, P277, DOI 10.1016/0014-5793(93)80237-O; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUTSENKO S, 1994, J BIOL CHEM, V269, P4555; MATHEWS PM, 1995, AM J PHYSIOL-CELL PH, V268, pC1207, DOI 10.1152/ajpcell.1995.268.5.C1207; Melle-Milovanovic D, 1998, J BIOL CHEM, V273, P11075, DOI 10.1074/jbc.273.18.11075; MORII M, 1995, BIOCHEM PHARMACOL, V49, P1729, DOI 10.1016/0006-2952(95)00090-M; Morii M, 1996, J BIOL CHEM, V271, P4068; NOGUCHI S, 1994, FEBS LETT, V341, P233, DOI 10.1016/0014-5793(94)80463-X; NOGUCHI S, 1992, BIOCHEM BIOPH RES CO, V182, P659, DOI 10.1016/0006-291X(92)91783-M; NOGUCHI S, 1986, FEBS LETT, V196, P315, DOI 10.1016/0014-5793(86)80270-8; RENAUD KJ, 1991, J BIOL CHEM, V266, P20491; SHULL GE, 1990, J BIOL CHEM, V265, P12123; SHULL GE, 1986, J BIOL CHEM, V261, P6788; Swarts HGP, 1996, J BIOL CHEM, V271, P29764, DOI 10.1074/jbc.271.47.29764; TOH BH, 1990, P NATL ACAD SCI USA, V87, P6418, DOI 10.1073/pnas.87.16.6418; Tyagarajan K, 1997, BIOCHEMISTRY-US, V36, P10200, DOI 10.1021/bi9706125; TYAGARAJAN K, 1995, BBA-BIOMEMBRANES, V1236, P105, DOI 10.1016/0005-2736(95)00044-4; Ueno S, 1997, BBA-BIOMEMBRANES, V1330, P217, DOI 10.1016/S0005-2736(97)00167-3; UENO S, 1995, J BIOCHEM, V117, P591, DOI 10.1093/oxfordjournals.jbchem.a124749; WALDERHAUG MO, 1985, J BIOL CHEM, V260, P3852; YODA A, 1970, BIOCHEM BIOPH RES CO, V40, P880, DOI 10.1016/0006-291X(70)90985-X	44	9	10	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22257	22265		10.1074/jbc.274.32.22257	http://dx.doi.org/10.1074/jbc.274.32.22257			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428793	hybrid			2022-12-25	WOS:000081868400023
J	Hamdan, FF; Ribeiro, P				Hamdan, FF; Ribeiro, P			Characterization of a stable form of tryptophan hydroxylase from the human parasite Schistosoma mansoni	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID HYDROXYLASES; CESTODE HYMENOLEPIS-DIMINUTA; RAT TYROSINE-HYDROXYLASE; DEPENDENT PROTEIN-KINASE; PHENYLALANINE-HYDROXYLASE; MESSENGER-RNAS; FUNCTIONAL DOMAINS; CATALYTIC ACTIVITY; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI	A cDNA (Schistosoma mansoni tryptophan hydroxylase; SmTPH) encoding a protein homologous to tryptophan hydroxylase, the enzyme that catalyzes the rate-limiting step in the biosynthesis of serotonin, was cloned from the human parasite Schistosoma mansoni. Bacterial expression of SmTPH as a histidine fusion protein produced soluble active enzyme, which was purified to apparent homogeneity and a final specific activity of 0.17 mu mol/min/mg of protein. The purified enzyme was found to be a tetramer of approximately 240 kDa with a subunit size of 58 kDa. Several of the biochemical and kinetic properties of SmTPH were similar to those of mammalian tryptophan hydroxylase. Unlike the mammalian enzyme, however, SmTPH was found to be stable at 37 degrees C, its t(1/2) being nearly 23 times higher than that of a similarly expressed rabbit tryptophan hydroxylase. A semiquantitative reverse transcription polymerase chain reaction showed that the level of SmTPH mRNA in a larval stage of the parasite (cercaria) is 2.5 times higher than in adult S, mansoni, suggesting possible differences in the level of enzyme expression between the two developmental stages. This study demonstrates for the first time the presence of a functional tryptophan hydroxylase in a parasitic helminth and further suggests that the parasites are capable of synthesizing serotonin endogenously.	McGill Univ, Inst Parasitol, St Anne De Bellevue, PQ H9X 3V9, Canada	McGill University	Ribeiro, P (corresponding author), McGill Univ, Inst Parasitol, Macdonald Campus 21,111 Lakeshore Rd, St Anne De Bellevue, PQ H9X 3V9, Canada.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Banik U, 1997, J BIOL CHEM, V272, P26219, DOI 10.1074/jbc.272.42.26219; BEEVERS SJ, 1983, J NEUROCHEM, V40, P894, DOI 10.1111/j.1471-4159.1983.tb08066.x; BENNETT JL, 1973, MOL PHARMACOL, V9, P311; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BOULARAND S, 1995, J BIOL CHEM, V270, P3748, DOI 10.1074/jbc.270.8.3748; BOULARAND S, 1990, NUCLEIC ACIDS RES, V18, P4257, DOI 10.1093/nar/18.14.4257; Boularand S, 1998, J NEUROCHEM, V71, P460; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CATTO BA, 1981, EXP PARASITOL, V51, P152, DOI 10.1016/0014-4894(81)90052-7; CATTO BA, 1979, COMP BIOCH PHYSL C, V2, P235; CHAUDHURI J, 1988, INT J PARASITOL, V18, P341, DOI 10.1016/0020-7519(88)90143-9; CHO CH, 1982, PARASITOLOGY, V84, P431, DOI 10.1017/S0031182000052732; DARMON MC, 1988, J NEUROCHEM, V51, P312, DOI 10.1111/j.1471-4159.1988.tb04871.x; DAUBNER SC, 1992, J BIOL CHEM, V267, P12639; Davis Ralph E., 1995, P257, DOI 10.1016/B978-012473345-9/50015-5; DAVIS RE, 1995, J BIOL CHEM, V270, P21813, DOI 10.1074/jbc.270.37.21813; DSa CM, 1996, J NEUROCHEM, V67, P900; DSa CM, 1996, J NEUROCHEM, V67, P917; Erlandsen H, 1997, NAT STRUCT BIOL, V4, P995, DOI 10.1038/nsb1297-995; Florez JC, 1996, MOL BRAIN RES, V42, P25, DOI 10.1016/S0169-328X(96)00104-0; FRIEDMAN PA, 1972, J BIOL CHEM, V247, P4165; Goodwill KE, 1997, NAT STRUCT BIOL, V4, P578, DOI 10.1038/nsb0797-578; GREEN CB, 1994, J NEUROCHEM, V62, P2420; GRENETT HE, 1987, P NATL ACAD SCI USA, V84, P5530, DOI 10.1073/pnas.84.16.5530; Hamdan FF, 1998, J NEUROCHEM, V71, P1369; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; HUFTON SE, 1995, BIOCHEM J, V311, P353, DOI 10.1042/bj3110353; JACOBS BL, 1992, PHYSIOL REV, V72, P165, DOI 10.1152/physrev.1992.72.1.165; JENNINGS IG, 1991, P NATL ACAD SCI USA, V88, P5734, DOI 10.1073/pnas.88.13.5734; JEQUIER E, 1967, MOL PHARMACOL, V3, P274; JEQUIER E, 1969, BIOCHEM PHARMACOL, V18, P1071, DOI 10.1016/0006-2952(69)90111-7; JOH TH, 1975, P NATL ACAD SCI USA, V72, P3575, DOI 10.1073/pnas.72.9.3575; JOHANSEN PA, 1991, BIOCHEM PHARMACOL, V41, P625, DOI 10.1016/0006-2952(91)90636-J; JOHANSEN PA, 1992, BRAIN RES BULL, V29, P949, DOI 10.1016/0361-9230(92)90170-3; Kappock TJ, 1996, CHEM REV, V96, P2659, DOI 10.1021/cr9402034; KAUFMAN S, 1996, ENCY MOL BIOL, P217; KINOSHITA T, 1992, ANAL BIOCHEM, V206, P231, DOI 10.1016/0003-2697(92)90358-E; Kuhn DM, 1997, J NEUROCHEM, V68, P2220; Kuhn DM, 1998, J NEUROSCI, V18, P7111; KUHN DM, 1980, J BIOL CHEM, V255, P4137; Kumer SC, 1996, J NEUROCHEM, V67, P443; Kumer SC, 1997, J NEUROCHEM, V69, P1738; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDLEY FD, 1985, BIOCHEMISTRY-US, V24, P3389, DOI 10.1021/bi00335a001; Lindner Peter, 1992, Methods (Orlando), V4, P41, DOI 10.1016/1046-2023(92)90055-D; LIU X, 1991, NEUROCHEM INT, V18, P27, DOI 10.1016/0197-0186(91)90031-8; MANSOUR TE, 1984, ADV PARASIT, V23, P1, DOI 10.1016/S0065-308X(08)60284-5; Mei HP, 1997, EXP PARASITOL, V86, P69, DOI 10.1006/expr.1997.4150; Mockus SM, 1998, J MOL NEUROSCI, V10, P163, DOI 10.1007/BF02761772; Mockus SM, 1997, BBA-PROTEIN STRUCT M, V1342, P132, DOI 10.1016/S0167-4838(97)00069-1; Mockus SM, 1997, J MOL NEUROSCI, V9, P35, DOI 10.1007/BF02789393; Moran GR, 1998, J BIOL CHEM, V273, P12259, DOI 10.1074/jbc.273.20.12259; NAKATA H, 1982, EUR J BIOCHEM, V124, P595; NAOI M, 1994, BIOCHEM PHARMACOL, V48, P207; NECKAMEYER WS, 1992, J BIOL CHEM, V267, P4199; OKUNO S, 1985, J BIOL CHEM, V260, P2633; PARK DH, 1994, MOL CELL NEUROSCI, V5, P87, DOI 10.1006/mcne.1994.1008; RAJKOVIC A, 1990, P NATL ACAD SCI USA, V87, P8879, DOI 10.1073/pnas.87.22.8879; RIBEIRO P, 1983, MOL BIOCHEM PARASIT, V7, P53, DOI 10.1016/0166-6851(83)90116-0; RIBEIRO P, 1992, P NATL ACAD SCI USA, V89, P9593, DOI 10.1073/pnas.89.20.9593; RIBEIRO P, 1984, COMP BIOCHEM PHYS C, V79, P159, DOI 10.1016/0742-8413(84)90179-8; Sambrook J., 2002, MOL CLONING LAB MANU; STOLL J, 1990, GENOMICS, V7, P88, DOI 10.1016/0888-7543(90)90522-V; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TIPPER JP, 1994, ARCH BIOCHEM BIOPHYS, V315, P445, DOI 10.1006/abbi.1994.1523; VITTO A, 1981, J NEUROCHEM, V37, P601; VRANA KE, 1994, LIFE SCI, V55, P1045, DOI 10.1016/0024-3205(94)00639-3; VRANA SL, 1993, J NEUROSCI METH, V48, P123, DOI 10.1016/S0165-0270(05)80014-7; WEBSTER PJ, 1992, MOL BIOCHEM PARASIT, V51, P169, DOI 10.1016/0166-6851(92)90214-5; Weiger WA, 1997, BIOL REV, V72, P61, DOI 10.1017/S0006323196004975; WIDMER F, 1975, LIFE SCI, V17, P1297, DOI 10.1016/0024-3205(75)90141-1; WOOD PJ, 1986, EXP PARASITOL, V62, P114, DOI 10.1016/0014-4894(86)90014-7; YANG XJ, 1994, P NATL ACAD SCI USA, V91, P6659, DOI 10.1073/pnas.91.14.6659	74	40	46	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21746	21754		10.1074/jbc.274.31.21746	http://dx.doi.org/10.1074/jbc.274.31.21746			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419488	hybrid			2022-12-25	WOS:000081721100041
J	Muth, JN; Yamaguchi, H; Mikala, G; Grupp, IL; Lewis, W; Cheng, HP; Song, LS; Lakatta, EG; Varadi, G; Schwartz, A				Muth, JN; Yamaguchi, H; Mikala, G; Grupp, IL; Lewis, W; Cheng, HP; Song, LS; Lakatta, EG; Varadi, G; Schwartz, A			Cardiac-specific overexpression of the alpha(1) subunit of the L-type voltage-dependent Ca2+ channel in transgenic mice - Loss of isoproterenol-induced contraction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ADENYLYL-CYCLASE; CALCIUM CHANNELS; HEART; CELLS; RECEPTOR; FAILURE; ENTRY	The L-type voltage-dependent calcium channel (L-VDCC) regulates calcium influx in cardiac myocytes, Activation of the P-adrenergic receptor (PAR) pathway causes phosphorylation of the L-VDCC and that in turn increases Ca2+ influx. Targeted expression of the L-VDCC a, subunit in transgenic (Tg) mouse ventricles resulted in marked blunting of the PAR pathway. Inotropic and lusitropic responses to isoproterenol and forskolin in Tg hearts were significantly reduced. Likewise, Ca2+ current augmentation induced by isoproterenol and forskolin was markedly depressed in Tg cardiomyocytes. Despite no change in PAR number, isoproterenol-stimulated adenylyl cyclase activity was absent in Tg membranes and NaF and forskolin responses were reduced. We postulate an important pathway for regulation of the PAR by Ca2+ channels.	Univ Cincinnati, Coll Med, Inst Mol Pharmacol & Biophys, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Pathol & Lab Med, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, Cincinnati, OH 45267 USA; NIA, Cardiovasc Sci Lab, Gerontol Res Ctr, NIH, Baltimore, MD 21224 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Schwartz, A (corresponding author), Univ Cincinnati, Coll Med, Inst Mol Pharmacol & Biophys, POB 670828, Cincinnati, OH 45267 USA.		Lakatta, Edward G/AAL-1447-2020; Song, Long-Sheng/D-5899-2012; Heping, Cheng/AAE-2680-2019	Heping, Cheng/0000-0002-9604-6702; Lakatta, Edward/0000-0002-4772-0035; Song, Long-Sheng/0000-0002-6035-8106	NHLBI NIH HHS [P01 HL22619, T32 HL 07382, R01 R37HL43231] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007382, P01HL022619] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akhter SA, 1997, J BIOL CHEM, V272, P21253, DOI 10.1074/jbc.272.34.21253; Bristow MR, 1997, AM J CARDIOL, V80, pL26, DOI 10.1016/S0002-9149(97)00846-1; Carrion AM, 1999, NATURE, V398, P80, DOI 10.1038/18044; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; COLVIN RA, 1991, CELL CALCIUM, V12, P19, DOI 10.1016/0143-4160(91)90081-O; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; Fagan KA, 1998, J BIOL CHEM, V273, P9297, DOI 10.1074/jbc.273.15.9297; GREEN SA, 1994, J BIOL CHEM, V269, P26218; GRUPP IL, 1998, CARDIOVASCULAR PHYSL; GULICK J, 1991, J BIOL CHEM, V266, P9180; Gurnett CA, 1996, J BIOL CHEM, V271, P27975, DOI 10.1074/jbc.271.45.27975; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Jones WK, 1996, J CLIN INVEST, V98, P1906, DOI 10.1172/JCI118992; Maltsev VA, 1999, CIRC RES, V84, P136, DOI 10.1161/01.RES.84.2.136; MCDONALD TF, 1994, PHYSIOL REV, V74, P365, DOI 10.1152/physrev.1994.74.2.365; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Mori Y, 1996, JPN J PHARMACOL, V72, P83, DOI 10.1254/jjp.72.83; Puceat M, 1996, MOL CELL BIOCHEM, V157, P65; SCHULTZ D, 1993, P NATL ACAD SCI USA, V90, P6228, DOI 10.1073/pnas.90.13.6228; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; SULAKHE PV, 1995, MOL CELL BIOCHEM, V149, P103, DOI 10.1007/BF01076569; TOHSE N, 1992, CIRC RES, V71, P1441, DOI 10.1161/01.RES.71.6.1441; Xiao RP, 1998, J CLIN INVEST, V101, P1273, DOI 10.1172/JCI1335; YU HJ, 1993, MOL PHARMACOL, V44, P689	25	59	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21503	21506		10.1074/jbc.274.31.21503	http://dx.doi.org/10.1074/jbc.274.31.21503			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419451	hybrid			2022-12-25	WOS:000081721100004
J	Spinella, MJ; Freemantle, SJ; Sekula, D; Chang, JH; Christie, AJ; Dmitrovsky, E				Spinella, MJ; Freemantle, SJ; Sekula, D; Chang, JH; Christie, AJ; Dmitrovsky, E			Retinoic acid promotes ubiquitination and proteolysis of cyclin D1 during induced tumor cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; HEXAMETHYLENE BISACETAMIDE HMBA; BRONCHIAL EPITHELIAL-CELLS; HUMAN TERATOCARCINOMA CELL; RETINOBLASTOMA PROTEIN; PROTEASOME PATHWAY; DEPENDENT KINASES; TERMINAL DIFFERENTIATION; GROWTH SUPPRESSION; BINDING-PROTEINS	Mechanisms by which differentiation programs engage the cell cycle are poorly understood. This study demonstrates that retinoids promote ubiquitination and degradation of cyclin D1 during retinoid-induced differentiation of human embryonal carcinoma cells. In response to all-trans-retinoic acid (RA) treatment, the human embryonal carcinoma cell line NT2/D1 exhibits a progressive decline in cyclin D1 expression beginning when the cells are committed to differentiate, but before onset of terminal neuronal differentiation. The decrease in cyclin D1 protein is tightly associated with the accumulation of hypophosphorylated forms of the retinoblastoma protein and G(1) arrest. In contrast, retinoic acid receptor gamma-deficient NT2/D1-R1 cells do not growth-arrest or accumulate in G(1) and have persistent cyclin D1 overexpression despite RA treatment. Notably, stable transfection of retinoic acid receptor gamma restores RA-mediated growth suppression and differentiation to NT2/D1-R1 cells and restores the decline of cyclin D1, The proteasome inhibitor LLnL blocks this RA-mediated decline in cyclin D1. RA treatment markedly accelerates ubiquitination of wild-type cyclin D1, but not a cyclin D1 (T286A) mutant. Transient expression of cyclin D1 (T286A) in NT2/D1 cells blocks RA-mediated transcriptional decline of a differentiation-sensitive reporter plasmid and represses induction of immunophenotypic neuronal markers. Taken together, these findings strongly implicate RA-mediated degradation of cyclin D1 as a means of coupling induced differentiation and cell cycle control of human embryonal carcinoma cells.	Dartmouth Coll, Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA; Dartmouth Hitchcock Med Ctr, Dept Med, Hanover, NH 03755 USA; Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Hanover, NH 03755 USA	Dartmouth College; Dartmouth College; Dartmouth College; Norris Cotton Cancer Center	Spinella, MJ (corresponding author), Dartmouth Coll, Sch Med, Dept Pharmacol & Toxicol, 7650 Remsen, Hanover, NH 03755 USA.	michael.spinella@dartmouth.edu	Spinella, Michael/B-7210-2014		NCI NIH HHS [K01-CA75154-01, R01-CA54494-06] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA075154, R01CA054494] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn MJ, 1995, ONCOGENE, V11, P2357; ANDREWS PW, 1984, LAB INVEST, V50, P147; ANDREWS PW, 1990, DIFFERENTIATION, V43, P131, DOI 10.1111/j.1432-0436.1990.tb00439.x; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; BASELGA J, 1993, ONCOGENE, V8, P3257; BOYLE JO, 1999, JNCI-J NATL CANCER I, V91, P57; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chellappan SP, 1998, CURR TOP MICROBIOL, V227, P57; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DAILEY L, 1994, MOL CELL BIOL, V14, P7758, DOI 10.1128/MCB.14.12.7758; DESHAIES R, 1995, CURR OPIN CELL BIOL, V7, P781, DOI 10.1016/0955-0674(95)80061-1; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DOLLE P, 1990, DEVELOPMENT, V110, P1133; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Elledge SJ, 1998, BBA-REV CANCER, V1377, pM61, DOI 10.1016/S0304-419X(98)00005-5; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Gao CY, 1997, BIOESSAYS, V19, P307, DOI 10.1002/bies.950190408; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; Hershko A, 1997, CURR OPIN CELL BIOL, V9, P788, DOI 10.1016/S0955-0674(97)80079-8; Hong WK, 1997, SCIENCE, V278, P1073, DOI 10.1126/science.278.5340.1073; Jacks T, 1998, SCIENCE, V280, P1035, DOI 10.1126/science.280.5366.1035; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KURIE JM, 1993, DIFFERENTIATION, V54, P123; Langenfeld J, 1996, ONCOGENE, V13, P1983; Langenfeld J, 1997, P NATL ACAD SCI USA, V94, P12070, DOI 10.1073/pnas.94.22.12070; LEES E, 1995, CURR OPIN CELL BIOL, V7, P773, DOI 10.1016/0955-0674(95)80060-3; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; Maerz WJ, 1998, ONCOGENE, V17, P761, DOI 10.1038/sj.onc.1201992; Maki CG, 1996, CANCER RES, V56, P2649; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MILLER WH, 1994, DIFFERENTIATION, V55, P145, DOI 10.1046/j.1432-0436.1994.5520145.x; MOASSER MM, 1994, ONCOGENE, V9, P833; MOASSER MM, 1995, ONCOGENE, V10, P1537; Moasser MM, 1996, DIFFERENTIATION, V60, P251, DOI 10.1046/j.1432-0436.1996.6040251.x; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PlanasSilva MD, 1997, CURR OPIN CELL BIOL, V9, P768, DOI 10.1016/S0955-0674(97)80076-2; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Rifkind RA, 1996, PHARMACOL THERAPEUT, V69, P97, DOI 10.1016/0163-7258(95)02044-6; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Spinella MJ, 1998, ONCOGENE, V16, P3471, DOI 10.1038/sj.onc.1201876; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; Yee Amy S., 1998, Frontiers in Bioscience, V3, pD532; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635; Zavitz KH, 1997, CURR OPIN CELL BIOL, V9, P773, DOI 10.1016/S0955-0674(97)80077-4	58	147	154	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					22013	22018		10.1074/jbc.274.31.22013	http://dx.doi.org/10.1074/jbc.274.31.22013			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419526	hybrid			2022-12-25	WOS:000081721100079
J	Zelenski, NG; Rawson, RB; Brown, MS; Goldstein, JL				Zelenski, NG; Rawson, RB; Brown, MS; Goldstein, JL			Membrane topology of S2P, a protein required for intramembranous cleavage of sterol regulatory element-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOUND TRANSCRIPTION FACTOR; ACTIVATING PROTEIN; CHOLESTEROL-METABOLISM; BACILLUS-SUBTILIS; CELL-MEMBRANES; SREBPS; PROTEOLYSIS; THERMOLYSIN; RESOLUTION; PATHWAY	In sterol-depleted mammalian cells, a two-step proteolytic process releases the NH2-terminal domains of sterol regulatory element-binding proteins (SREBPs) from membranes of the endoplasmic reticulum (ER), These domains translocate into the nucleus, where they activate genes of cholesterol and fatty acid biosynthesis, The SREBPs are oriented in the membrane in a hairpin fashion, with the NH2- and COOH-terminal domains facing the cytosol and a single hydrophilic loop projecting into the lumen. The first cleavage occurs at Site-1 within the ER lumen to generate an intermediate that is subsequently released from the membrane by cleavage at Site-2, which lies within the first transmembrane domain. A membrane protein, designated S2P, a putative zinc metalloprotease, is required for this cleavage. Here, we use protease protection and glycosylation site mapping to define the topology of S2P in ER membranes. Both the NH2 and COOH termini of S2P face the cytosol, Most of S2P Is hydrophobic and appears to be buried in the membrane. All three of the long hydrophilic sequences of S2P can be glycosylated, indicating that they all project into the lumen. The HEIGH sequence of S2P, which contains two potential zinc-coordinating residues, is contained within a long hydrophobic segment. Aspartic acid 467, located similar to 300 residues away from the HEIGH sequence, appears to provide the third coordinating residue for the active site zinc. This residue, too, is located in a hydrophobic sequence. The hydrophobicity of these sequences suggests that the active site of S2P is located within the membrane in an ideal position to cleave its target, a Leu-Cys bond in the first transmembrane helix of SREBPs.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Goldstein, JL (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd,Rm L5-238, Dallas, TX 75235 USA.				NHLBI NIH HHS [HL20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; COLMAN PM, 1972, J MOL BIOL, V70, P701, DOI 10.1016/0022-2836(72)90569-4; CUTTING S, 1991, J MOL BIOL, V221, P1237; Duncan EA, 1997, J BIOL CHEM, V272, P12778, DOI 10.1074/jbc.272.19.12778; Duncan EA, 1998, J BIOL CHEM, V273, P17801, DOI 10.1074/jbc.273.28.17801; Edwards PA, 1998, CURR OPIN LIPIDOL, V9, P433, DOI 10.1097/00041433-199810000-00007; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; HASAN MT, 1994, SOMAT CELL MOLEC GEN, V20, P481, DOI 10.1007/BF02255839; HOLMES MA, 1982, J MOL BIOL, V160, P623, DOI 10.1016/0022-2836(82)90319-9; Horton JD, 1999, CURR OPIN LIPIDOL, V10, P143, DOI 10.1097/00041433-199904000-00008; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; HUA XX, 1995, J BIOL CHEM, V270, P29422, DOI 10.1074/jbc.270.49.29422; ISOLA VJ, 1989, J VIROL, V63, P2325, DOI 10.1128/JVI.63.5.2325-2334.1989; KOCH GLE, 1988, J CELL SCI, V90, P485; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lewis AP, 1999, PROTEIN SCI, V8, P439; LU S, 1995, J BACTERIOL, V177, P1082, DOI 10.1128/jb.177.4.1082-1085.1995; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Sakai J, 1998, J BIOL CHEM, V273, P5785, DOI 10.1074/jbc.273.10.5785; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Sakai J, 1997, J BIOL CHEM, V272, P20213, DOI 10.1074/jbc.272.32.20213; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	28	95	99	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21973	21980		10.1074/jbc.274.31.21973	http://dx.doi.org/10.1074/jbc.274.31.21973			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419520	hybrid			2022-12-25	WOS:000081721100073
J	Naslavsky, N; Shmeeda, H; Friedlander, G; Yanai, A; Futerman, AH; Barenholz, Y; Taraboulos, A				Naslavsky, N; Shmeeda, H; Friedlander, G; Yanai, A; Futerman, AH; Barenholz, Y; Taraboulos, A			Sphingolipid depletion increases formation of the scrapie prion protein in neuroblastoma cells infected with prions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; TRANS-GOLGI NETWORK; CULTURED-CELLS; EPITHELIAL-CELLS; CERAMIDE ANALOG; ULTRASTRUCTURAL-LOCALIZATION; DETERGENT INSOLUBILITY; ALKALINE-PHOSPHATASE; SECONDARY STRUCTURE; MEDIATED TRANSPORT	Sphingolipid-rich rafts play an essential role in the posttranslational (Borchelt, D. R., Scott, M., Taraboulos, A, Stahl, N., and Prusiner, S. B. (1990) J. Cell Biol. 110, 743-752)) formation of the scrapie prion protein PrP(Sc) from its normal conformer PrP(c) (Taraboulos, A., Scott, M., Semenov, A., Avrahami, D., Laszlo, L., Prusiner, S. B., and Avraham, D. (1995) J. Cell Biol. 129, 121-132). We investigated the importance of sphingolipids in the metabolism of the PrP isoforms in scrapie-infected ScN2a cells. The ceramide synthase inhibitor fumonisin B(1) (BB,) reduced both sphingomyelin (SM) and ganglioside GM1 in cells by up to 50%, whereas PrP(Sc) increased by 3-4-fold. Whereas FB(1) profoundly altered the cell lipid composition, the raft residents PrP(c), PrP(Sc), caveolin 1, and GM1 remained insoluble in Triton X-100. Metabolic radiolabeling demonstrated that PrP(c) production was either unchanged or slightly reduced in FB(1)-treated cells, whereas PrP(Sc) formation was augmented by 3-4-fold. To identify the sphingolipid species the decrease of which correlates with increased PrP(Sc), we used two other reagents. When cells were incubated with sphingomyelinase for 3 days, SM levels decreased, GM1 was unaltered, and PrP(Sc) increased by 3-4-fold. In contrast, the glycosphingolipid inhibitor PDMP reduced PrP(Sc) while increasing SM. Thus, PrP(Sc) seems to correlate inversely with SM levels. The effects of SM depletion contrasted with those previously obtained with the cholesterol inhibitor lovastatin, which reduced PrP(Sc) and removed it from detergent-insoluble complexes.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Mol Biol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel; Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Weizmann Institute of Science	Taraboulos, A (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Mol Biol, POB 12272, IL-91120 Jerusalem, Israel.	taraboul@cc.huji.ac.il		Friedlander, Gerard/0000-0002-6854-4261; Futerman, Anthony/0000-0003-0013-0115; Yanai, Anat/0000-0002-0792-6901				ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; Bar LK, 1997, BIOCHEMISTRY-US, V36, P2507, DOI 10.1021/bi9625004; BARBOUR S, 1992, J CELL PHYSIOL, V150, P610, DOI 10.1002/jcp.1041500322; Barenholz Y, 1996, J BIOL CHEM, V271, P3085, DOI 10.1074/jbc.271.6.3085; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BRUNING A, 1992, J BIOL CHEM, V267, P5052; BUTLER DA, 1988, J VIROL, V62, P1558, DOI 10.1128/JVI.62.5.1558-1564.1988; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; CERNEUS DP, 1993, J BIOL CHEM, V268, P3150; CHAM BE, 1976, J LIPID RES, V17, P176; CHANG WJ, 1992, J CELL BIOL, V118, P63, DOI 10.1083/jcb.118.1.63; COHEN FE, 1994, SCIENCE, V264, P530, DOI 10.1126/science.7909169; DAMMANN B, 1996, HDB NONMEDICAL APPL, V1, P85; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; FELDINGHABERMANN B, 1990, BIOCHEMISTRY-US, V29, P6314, DOI 10.1021/bi00478a028; FRA AM, 1995, FEBS LETT, V375, P11, DOI 10.1016/0014-5793(95)95228-O; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; FUTERMAN AH, 1995, TRENDS CELL BIOL, V5, P377, DOI 10.1016/S0962-8924(00)89078-9; GASSET M, 1993, P NATL ACAD SCI USA, V90, P1, DOI 10.1073/pnas.90.1.1; GASSET M, 1992, P NATL ACAD SCI USA, V89, P10940, DOI 10.1073/pnas.89.22.10940; Glick D, 1996, FEBS LETT, V394, P237, DOI 10.1016/0014-5793(96)00958-1; GORODINSKY A, 1995, J CELL BIOL, V129, P619, DOI 10.1083/jcb.129.3.619; HAGMANN J, 1982, BIOCHIM BIOPHYS ACTA, V720, P181, DOI 10.1016/0167-4889(82)90010-6; HANADA K, 1993, J BIOL CHEM, V268, P13820; HANADA K, 1995, J BIOL CHEM, V270, P6254, DOI 10.1074/jbc.270.11.6254; HARMEY JH, 1995, BIOCHEM BIOPH RES CO, V210, P753, DOI 10.1006/bbrc.1995.1723; HAY B, 1987, BIOCHEMISTRY-US, V26, P8110, DOI 10.1021/bi00399a014; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Hirschberg K, 1996, J BIOL CHEM, V271, P14876, DOI 10.1074/jbc.271.25.14876; HORVATH A, 1994, EMBO J, V13, P3687, DOI 10.1002/j.1460-2075.1994.tb06678.x; HUANG ZW, 1994, P NATL ACAD SCI USA, V91, P7139, DOI 10.1073/pnas.91.15.7139; INOKUCHI J, 1990, CANCER RES, V50, P6731; INOKUCHI JI, 1989, J CELL PHYSIOL, V141, P573, DOI 10.1002/jcp.1041410316; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P2333, DOI 10.1073/pnas.94.6.2333; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KELLINGS K, 1992, J GEN VIROL, V73, P1025, DOI 10.1099/0022-1317-73-4-1025; KURZCHALIA TV, 1994, FEBS LETT, V346, P88, DOI 10.1016/0014-5793(94)00466-8; MAYS RW, 1995, J CELL BIOL, V130, P1105, DOI 10.1083/jcb.130.5.1105; MCKINLEY MP, 1991, LAB INVEST, V65, P622; MCKINLEY MP, 1991, J VIROL, V65, P1440; MCKINLEY MP, 1983, P ELECT MICROSC SOC, V41, P802; Merrill AH, 1996, TRENDS CELL BIOL, V6, P218, DOI 10.1016/0962-8924(96)10021-0; MERZ PA, 1981, ACTA NEUROPATHOL, V54, P63, DOI 10.1007/BF00691333; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; NAKAMURA K, 1984, ANAL BIOCHEM, V142, P406, DOI 10.1016/0003-2697(84)90484-6; Naslavsky N, 1997, J BIOL CHEM, V272, P6324, DOI 10.1074/jbc.272.10.6324; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; OKADA Y, 1988, FEBS LETT, V235, P25, DOI 10.1016/0014-5793(88)81227-4; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; ROCK P, 1990, BIOCHEMISTRY-US, V29, P8484, DOI 10.1021/bi00488a040; ROGERS M, 1992, E H S NEURO, P457; ROSENWALD AG, 1992, BIOCHEMISTRY-US, V31, P3581, DOI 10.1021/bi00129a005; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; Schroeder RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/jbc.273.2.1150; SCOTT MR, 1992, PROTEIN SCI, V1, P986, DOI 10.1002/pro.5560010804; SERBAN D, 1990, NEUROLOGY, V40, P110, DOI 10.1212/WNL.40.1.110; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; SLOTTE JP, 1988, BIOCHEM J, V250, P653, DOI 10.1042/bj2500653; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; Stevens VL, 1997, J BIOL CHEM, V272, P18020, DOI 10.1074/jbc.272.29.18020; TARABOULOS A, 1990, J CELL BIOL, V110, P2117, DOI 10.1083/jcb.110.6.2117; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; TARABOULOS A, 1990, P NATL ACAD SCI USA, V87, P8262, DOI 10.1073/pnas.87.21.8262; TARABOULOS A, 1992, MOL BIOL CELL, V3, P851, DOI 10.1091/mbc.3.8.851; Taraboulos A., 1992, PRION DIS HUMANS ANI, P434; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; Zha XH, 1998, J CELL BIOL, V140, P39, DOI 10.1083/jcb.140.1.39	84	148	151	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					20763	20771		10.1074/jbc.274.30.20763	http://dx.doi.org/10.1074/jbc.274.30.20763			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409615	hybrid			2022-12-25	WOS:000081613100006
J	Brody, JR; Kadkol, SS; Mahmoud, MA; Rebel, JMJ; Pasternack, GR				Brody, JR; Kadkol, SS; Mahmoud, MA; Rebel, JMJ; Pasternack, GR			Identification of sequences required for inhibition of oncogene-mediated transformation by pp32	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR PHOSPHOPROTEIN; PROTEIN; CELLS	Oncogenic potential in prostate cancer is modulated in part by alternative use of genes of the pp32 family. This family includes the tumor suppressor pp32, expressed in normal tissue, and the pro-oncogenic genes pp32r1 and pp32r2 that are found principally in neoplastic cells. At the protein level, pp32, pp32r1, and pp32r2 are approximately 90% identical, yet they subsume opposite functions. In this study, we identify the region of pp32 associated with the ability to inhibit oncogene-mediated transformation in a rat embryo fibroblast system, an in vitro correlate of tumor-suppressive activity. Deletion and truncation analysis define a region spanning pp32 amino acids 150-174 as absolutely required for inhibition of transformed foci elicited by RAS and MYC, Comparison of pp32 with the pp32r1 sequence by moving averages of sequence identity reveals divergence over this region; pp32r2 also differs in this region through truncation after pp32 amino acid 131. The deletion experiments and the experiments of nature therefore converge to demonstrate that tumor-suppressive functions of pp32 reside in amino acids 150-174, Identification of this minimal tumor-suppressive region should help elaborate the pathways and mechanisms through which pp32 family members exert their functions.	Johns Hopkins Univ, Sch Med, Dept Pathol, Div Mol Pathol, Baltimore, MD 21205 USA	Johns Hopkins University	Pasternack, GR (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pathol, Div Mol Pathol, 512 Ross,720 Rutland Ave, Baltimore, MD 21205 USA.			Duriez, Patrick/0000-0003-1814-2552	NATIONAL CANCER INSTITUTE [R01CA054404] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 54404] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chen TH, 1996, MOL BIOL CELL, V7, P2045, DOI 10.1091/mbc.7.12.2045; Gusev Y, 1996, CELL PROLIFERAT, V29, P643, DOI 10.1111/j.1365-2184.1996.tb00978.x; Kadkol SS, 1999, NAT MED, V5, P275, DOI 10.1038/6488; Kadkol SS, 1998, PROSTATE, V34, P231, DOI 10.1002/(SICI)1097-0045(19980215)34:3<231::AID-PROS11>3.0.CO;2-F; KADKOL SS, 1996, CANC MOL BIOL, V3, P791; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Li M, 1996, BIOCHEMISTRY-US, V35, P6998, DOI 10.1021/bi960581y; MALEK SN, 1990, J BIOL CHEM, V265, P13400; WALENSKY LD, 1993, CANCER RES, V53, P4720	9	47	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20053	20055		10.1074/jbc.274.29.20053	http://dx.doi.org/10.1074/jbc.274.29.20053			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400610	hybrid			2022-12-25	WOS:000081438300003
J	Bui, DM; Gregan, J; Jarosch, E; Ragnini, A; Schweyen, RJ				Bui, DM; Gregan, J; Jarosch, E; Ragnini, A; Schweyen, RJ			The bacterial magnesium transporter CorA can functionally substitute for its putative homologue Mrs2p in the yeast inner mitochondrial membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI SHUTTLE VECTORS; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; INTERMEMBRANE SPACE; RESTRICTION SITES; CARRIER FAMILY; DEFECTS; ION; RNA; OVEREXPRESSION	The yeast nuclear gene MRS2 encodes a protein of 54 kDa, the presence of which has been shown to be essential for the splicing of group II intron RNA in mitochondria and, independently, for the maintenance of a functional respiratory system. Here we show that the MRS2 gene product (Mrs2p) is an integral protein of the inner mitochondrial membrane. It appears to be inserted into this membrane by virtue of two neighboring membrane spanning domains in its carboxyl-terminal half. A large amino-terminal and a shorter carboxyl-terminal part are likely to be exposed to the matrix space. Structural features and a short sequence motif indicate that Mrs2p may be related to the bacterial CorA Mg2+ transporter. In fact, overexpression of the CorA gene in yeast partially suppresses the pet(-) phenotype of an mrs2 disrupted yeast strain. Disruption of the MRS2 gene leads to a significant decrease in total magnesium content of mitochondria which is compensated for by the overexpression of the CorA gene. Mutants lacking or overproducing Mrs2p exhibit phenotypes consistent with the involvement of Mrs2p in mitochondrial Mg2+ homeostasis.	Univ Vienna, Inst Microbiol & Genet, Dept Genet & Microbiol, Vienna Bioctr, A-1030 Vienna, Austria	University of Vienna; Vienna Biocenter (VBC)	Schweyen, RJ (corresponding author), Univ Vienna, Inst Microbiol & Genet, Dept Genet & Microbiol, Vienna Bioctr, Dr Bohrgasse 9, A-1030 Vienna, Austria.	schweyen@gem.univie.ac.at	Gregan, Juraj/I-4161-2014; Bui Minh, Duc/H-6707-2018; Ragnini, Antonella/A-8089-2014	Gregan, Juraj/0000-0002-2989-8374; Bui Minh, Duc/0000-0002-3532-8554; Ragnini, Antonella/0000-0001-7963-7554; Jarosch, Ernst/0000-0002-5897-3492				Beeler T, 1997, BBA-BIOMEMBRANES, V1323, P310, DOI 10.1016/S0005-2736(96)00199-X; DAUM G, 1982, J BIOL CHEM, V257, P3028; Doyle JL, 1998, TRENDS GENET, V14, P92, DOI 10.1016/S0168-9525(97)01370-X; Eide DJ, 1998, ANNU REV NUTR, V18, P441, DOI 10.1146/annurev.nutr.18.1.441; FLATMAN PW, 1991, ANNU REV PHYSIOL, V53, P259, DOI 10.1146/annurev.ph.53.030191.001355; GENTZ R, 1988, J BACTERIOL, V170, P2212, DOI 10.1128/jb.170.5.2212-2220.1988; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; Jarosch E, 1996, J BIOL CHEM, V271, P17219, DOI 10.1074/jbc.271.29.17219; KANIANSKY D, 1990, J CHROMATOGR, V502, P143, DOI 10.1016/S0021-9673(01)89571-6; KOLL H, 1987, CURR GENET, V12, P503; MacDiarmid CW, 1998, J BIOL CHEM, V273, P1727, DOI 10.1074/jbc.273.3.1727; Pyle AM, 1996, MET IONS BIOL SYST, V32, P479; Quamme GA, 1997, KIDNEY INT, V52, P1180, DOI 10.1038/ki.1997.443; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; RASSOW J, 1991, FEBS LETT, V293, P85, DOI 10.1016/0014-5793(91)81157-4; SMITH RL, 1993, J BIOL CHEM, V268, P14071; Smith RL, 1998, MOL MICROBIOL, V28, P217, DOI 10.1046/j.1365-2958.1998.00810.x; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; Stuart RA, 1996, TRENDS BIOCHEM SCI, V21, P261, DOI 10.1016/S0968-0004(96)10035-9; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; VANDYCK E, 1995, MOL GEN GENET, V246, P426, DOI 10.1007/BF00290446; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WIESENBERGER G, 1991, J MOL BIOL, V217, P23, DOI 10.1016/0022-2836(91)90608-9; WIESENBERGER G, 1992, J BIOL CHEM, V267, P6963; Zhang A, 1997, CELL MOL LIFE SCI, V53, P69, DOI 10.1007/PL00000581; ZINSER E, 1995, YEAST, V11, P493, DOI 10.1002/yea.320110602	28	137	144	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20438	20443		10.1074/jbc.274.29.20438	http://dx.doi.org/10.1074/jbc.274.29.20438			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400670	hybrid			2022-12-25	WOS:000081438300063
J	Murthy, KK; Clark, K; Fortin, Y; Shen, SH; Banville, D				Murthy, KK; Clark, K; Fortin, Y; Shen, SH; Banville, D			ZRP-1, a zyxin-related protein, interacts with the second PDZ domain of the cytosolic protein tyrosine phosphatase hPTP1E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSKELETAL-ASSOCIATED PROTEINS; TUMOR-SUPPRESSOR PROTEIN; CELL-SURFACE ANTIGEN; LIM DOMAIN; SIGNALING PROTEINS; MOLECULAR-CLONING; FAS ANTIGEN; SEPTATE JUNCTIONS; BINDING DOMAIN; MESSENGER-RNA	Protein-protein interactions play an important role in the specificity of cellular signaling cascades. By using the yeast two-hybrid system, a specific interaction was identified between the second PDZ domain of the cytosolic protein tyrosine phosphatase hPTP1E and a novel protein, which was termed ZRP-1 to indicate its sequence similarity to the Zyxin protein family. The mRNA encoding this protein is distributed widely in human tissues and contains an open reading frame of 1428 base pairs, predicting a polypeptide of 476 amino acid residues. The deduced protein displays a proline-rich amino-terminal region and three double zinc finger LIM domains at its carboxyl terminus. The specific interaction of this novel protein with the second PDZ domain of hPTP1E was demonstrated both in vitro, using bacterially expressed proteins, and in vivo, by co-immunoprecipitation studies. Deletion analysis indicated that an intact carboxyl terminus is required for its interaction with the second PDZ domain of hPTP1E in the yeast two-hybrid system and suggested that other sequences, including the LIM domains, also participate in the interaction, The genomic organization of the ZRP-1 coding sequence is identical to that of the lipoma preferred partner gene, another Zyxin-related protein, suggesting that the two genes have evolved from a recent gene duplication event.	Natl Res Council Canada, Biotechnol Res Inst, Pharmaceut Biotechnol Sector, Montreal, PQ H4P 2R2, Canada	National Research Council Canada	Banville, D (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, Pharmaceut Biotechnol Sector, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.	Denis.Banville@NRC.CA						Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BANVILLE D, 1994, J BIOL CHEM, V269, P22320; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; CHAREST A, 1995, BIOCHEM J, V308, P425, DOI 10.1042/bj3080425; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Cowburn D, 1996, STRUCTURE, V4, P1005, DOI 10.1016/S0969-2126(96)00106-2; Cuppen E, 1997, J BIOL CHEM, V272, P30215, DOI 10.1074/jbc.272.48.30215; Cuppen E, 1998, MOL BIOL CELL, V9, P671, DOI 10.1091/mbc.9.3.671; DAWID IB, 1995, CR ACAD SCI III-VIE, V318, P295; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; FEUERSTEIN R, 1994, P NATL ACAD SCI USA, V91, P10655, DOI 10.1073/pnas.91.22.10655; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Gill GN, 1995, STRUCTURE, V3, P1285, DOI 10.1016/S0969-2126(01)00265-9; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; Hobert O, 1996, ONCOGENE, V12, P1577; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KIMURA K, 1994, BIOCHEM BIOPH RES CO, V198, P666, DOI 10.1006/bbrc.1994.1097; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Kurschner C, 1998, MOL CELL NEUROSCI, V11, P161, DOI 10.1006/mcne.1998.0679; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; Macalma T, 1996, J BIOL CHEM, V271, P31470, DOI 10.1074/jbc.271.49.31470; MAEKAWA K, 1994, FEBS LETT, V337, P200, DOI 10.1016/0014-5793(94)80273-4; Makalowski W, 1996, GENOME RES, V6, P846, DOI 10.1101/gr.6.9.846; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; NASMYTH KA, 1980, P NATL ACAD SCI-BIOL, V77, P2119, DOI 10.1073/pnas.77.4.2119; OEHM A, 1992, J BIOL CHEM, V267, P10709; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Petit MMR, 1996, GENOMICS, V36, P118, DOI 10.1006/geno.1996.0432; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Ranganathan R, 1997, CURR BIOL, V7, pR770, DOI 10.1016/S0960-9822(06)00401-5; Sambrook J, 1989, MOL CLONING LABORATO, V9, P16; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; Saras J, 1997, J BIOL CHEM, V272, P24333, DOI 10.1074/jbc.272.39.24333; SARAS J, 1994, J BIOL CHEM, V269, P24082; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; SONYANG Z, 1997, SCIENCE, V275, P73; Stricker NL, 1997, NAT BIOTECHNOL, V15, P336, DOI 10.1038/nbt0497-336; TAIRA M, 1995, TRENDS GENET, V11, P431, DOI 10.1016/S0168-9525(00)89139-8; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; Williams JM, 1998, MOL MICROBIOL, V27, P171, DOI 10.1046/j.1365-2958.1998.00670.x; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; WU RY, 1994, J BIOL CHEM, V269, P25085; Wu RY, 1996, J BIOL CHEM, V271, P15934, DOI 10.1074/jbc.271.27.15934; Xu XZS, 1998, J CELL BIOL, V142, P545, DOI 10.1083/jcb.142.2.545; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; Yi JS, 1998, GENOMICS, V49, P314, DOI 10.1006/geno.1998.5248; Yoo J, 1996, DNA CELL BIOL, V15, P227, DOI 10.1089/dna.1996.15.227; Zumbrunn J, 1996, EUR J BIOCHEM, V241, P657, DOI 10.1111/j.1432-1033.1996.00657.x	63	50	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20679	20687		10.1074/jbc.274.29.20679	http://dx.doi.org/10.1074/jbc.274.29.20679			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400701	hybrid			2022-12-25	WOS:000081438300094
J	Mesri, M; Altieri, DC				Mesri, M; Altieri, DC			Leukocyte microparticles stimulate endothelial cell cytokine release and tissue factor induction in a JNK1 signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-DERIVED MICROPARTICLES; ACTIVATED PROTEIN-KINASE; PROCOAGULANT ACTIVITIES; ADHESION MOLECULES; PLASMA-MEMBRANE; ATHEROSCLEROSIS; VESICULATION; EXPRESSION; MECHANISM; MONOCYTES	A role of membrane microparticles (MP) released by vascular cells in endothelial cell (EC) activation was investigated. Flow cytofluorimetric analysis of blood samples from normal volunteers revealed the presence of an heterogeneous MP population, which increased by similar to 2-fold after inflammatory stimulation with the chemotactic peptide, N-formyl-Met-Leu-Phe (2,799 +/- 360 versus 5241 +/- 640, p < 0.001), Blood-derived MP stimulated release of EC cytokines interleukin (IL)-6 (377 +/- 68 pg/ml) and MCP-1 (1, 282 +/- 79) and up-regulated de novo expression of tissue factor on the EC surface. This was associated with generation of a factor Xa-dependent procoagulant response (2.28 +/- 0.56 nM factor Xa/min/10(4) cells), in a reaction inhibited by a monoclonal antibody to tissue factor. Fluorescent labeling with antibodies to platelet GPIb alpha or leukocyte lactoferrin demonstrated that circulating MP originated from both platelets and leukocytes, However, depletion of platelet MP with an antibody to GPIb alpha did not reduce EC IL-6 release, and, similarly, MP from thrombin-stimulated platelets did not induce IL-6 release from endothelium. EC stimulation with leukocyte MP did not result in activation of the transcription factor NF-kappa B and was not associated with tyrosine phosphorylation of extracellular signal-regulated protein kinase, ERK1, In contrast, leukocyte MP stimulated a sustained, time-dependent increased tyrosine phosphorylation of similar to 46-kDa c-Jun NH2-terminal kinase (JNK1) in EC, These findings demonstrate that circulating leukocyte MP are up-regulated by inflammatory stimulation in vivo and activate a stress signaling pathway in EC, leading to increased procoagulant and proinflammatory activity, This may provide an alternative mechanism of EC activation, potentially contributing to dysregulation of endothelial functions during vascular injury.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pathol, New Haven, CT 06536 USA	Yale University	Altieri, DC (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pathol, BCMM 436B,295 Congress Ave, New Haven, CT 06536 USA.	dario.altieri@yale.edu			NHLBI NIH HHS [HL10112, R01 HL43773, HL54131] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL054131, R01HL043773, R01HL054131] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMS CS, 1990, BLOOD, V75, P128; Barry OP, 1997, J CLIN INVEST, V99, P2118, DOI 10.1172/JCI119385; Barry OP, 1998, J CLIN INVEST, V102, P136, DOI 10.1172/JCI2592; BIERHAUS A, 1995, J BIOL CHEM, V270, P26419, DOI 10.1074/jbc.270.44.26419; Bombeli T, 1997, BLOOD, V89, P2429, DOI 10.1182/blood.V89.7.2429; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CARLOS TM, 1994, BLOOD, V84, P2068; Cines DB, 1998, BLOOD, V91, P3527; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Evangelista V, 1999, BLOOD, V93, P876, DOI 10.1182/blood.V93.3.876.403k25_876_885; Fensome A, 1998, J BIOL CHEM, V273, P13157, DOI 10.1074/jbc.273.21.13157; Franchimont N, 1999, J BIOL CHEM, V274, P6783, DOI 10.1074/jbc.274.10.6783; GEORGE JN, 1982, BLOOD, V60, P834; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; JAMIESON C, 1991, J IMMUNOL, V147, P416; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEEUWENBERG JFM, 1992, IMMUNOLOGY, V77, P543; LO SK, 1995, J IMMUNOL, V154, P4768; MACKMAN N, 1990, P NATL ACAD SCI USA, V87, P2254, DOI 10.1073/pnas.87.6.2254; Mallat Z, 1999, CIRCULATION, V99, P348, DOI 10.1161/01.CIR.99.3.348; Mesri C, 1998, J IMMUNOL, V161, P4382; Napoleone E, 1997, BLOOD, V89, P541, DOI 10.1182/blood.V89.2.541; NOMURA S, 1995, ATHEROSCLEROSIS, V116, P235, DOI 10.1016/0021-9150(95)05551-7; POBER JS, 1990, PHYSIOL REV, V70, P427, DOI 10.1152/physrev.1990.70.2.427; ROBINSON RA, 1992, BLOOD, V79, P406; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; ROT A, 1992, IMMUNOL TODAY, V13, P291, DOI 10.1016/0167-5699(92)90039-A; SATTA N, 1994, J IMMUNOL, V153, P3245; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SHATTIL SJ, 1987, BLOOD, V70, P307; SIMS PJ, 1991, IMMUNOL TODAY, V12, P338, DOI 10.1016/0167-5699(91)90012-I; SIMS PJ, 1989, J BIOL CHEM, V264, P17049; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TANS G, 1991, BLOOD, V77, P2641; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Weber C, 1997, J CLIN INVEST, V100, P2085, DOI 10.1172/JCI119742; WIEDMER T, 1991, BLOOD, V78, P2880; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN MH, 1994, NATURE, V372, P798	41	288	298	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23111	23118		10.1074/jbc.274.33.23111	http://dx.doi.org/10.1074/jbc.274.33.23111			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438480	hybrid			2022-12-25	WOS:000082012800030
J	Trushin, SA; Pennington, KN; Algeciras-Schimnich, A; Paya, CV				Trushin, SA; Pennington, KN; Algeciras-Schimnich, A; Paya, CV			Protein kinase C and calcineurin synergize to activate I kappa B kinase and NF-kappa B in T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED SIGNAL TRANSDUCTION; HUMAN-IMMUNODEFICIENCY-VIRUS; RIBOSOMAL S6 KINASE; DNA-BINDING; INTERLEUKIN-2 PROMOTER; ALPHA PROTEOLYSIS; GENE-EXPRESSION; PHORBOL ESTER; PKC-THETA; PHOSPHORYLATION	The nuclear factor of kappa B (NF-kappa B) is a ubiquitous transcription factor that is key in the regulation of the immune response and inflammation. T cell receptor (TCR) cross-linking is in part required for activation of NF-kappa B, which is dependent on the phosphorylation and degradation of I kappa B alpha. By using Jurkat and primary human T lymphocytes, we demonstrate that the simultaneous activation of two second messengers of the TCR-initiated signal transduction, protein kinase C (PKC) and calcineurin, results in the synergistic activation of the I kappa B alpha kinase (IKK) complex but not of another putative I kappa B alpha kinase, p90(rsk). We also demonstrate that the IKK. complex, but not p90(rsk), is responsible for the in vivo phosphorylation of I kappa B alpha mediated by the co-activation of PKC and calcineurin, Each second messenger is necessary, as inhibition of either one reverses the activation of the IKK complex and I kappa B alpha phosphorylation in vivo, Overexpression of dominant negative forms of IKK alpha and -beta demonstrates that only IKK beta is the target for PKC and calcineurin, These results indicate that within the TCR/CD3 signal transduction pathway both PKC and calcineurin are required for the effective activation of the IKK complex and NF-kappa B in T lymphocytes.	Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Infect Dis, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Paya, CV (corresponding author), Mayo Clin & Mayo Fdn, Dept Immunol, 200 1st St SW,Guggenheim 501, Rochester, MN 55905 USA.				NCI NIH HHS [CA09127] Funding Source: Medline; NIAID NIH HHS [R01 AI36076] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036076] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Algeciras-Schimnich A, 1999, J IMMUNOL, V162, P5205; BAERBITTERLICH G, 1996, MOL CELL BIOL, V16, P1842; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAIER G, 1993, J BIOL CHEM, V268, P4997; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Boothby MR, 1997, J EXP MED, V185, P1897, DOI 10.1084/jem.185.11.1897; BRIEGEL K, 1991, NUCLEIC ACIDS RES, V19, P5929, DOI 10.1093/nar/19.21.5929; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Brown K, 1997, MOL CELL BIOL, V17, P3021, DOI 10.1128/MCB.17.6.3021; CHEN D, 1993, MOL CELL BIOL, V13, P228, DOI 10.1128/MCB.13.1.228; CHEN RH, 1991, MOL CELL BIOL, V11, P1861, DOI 10.1128/MCB.11.4.1861; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; FRANTZ B, 1994, EMBO J, V13, P861, DOI 10.1002/j.1460-2075.1994.tb06329.x; GAYNOR R, 1992, AIDS, V6, P347, DOI 10.1097/00002030-199204000-00001; Ghoda L, 1997, J BIOL CHEM, V272, P21281, DOI 10.1074/jbc.272.34.21281; Guerder S, 1995, Int Rev Immunol, V13, P135, DOI 10.3109/08830189509061743; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HOYOS B, 1989, SCIENCE, V244, P457, DOI 10.1126/science.2497518; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; IMBODEN JB, 1985, J EXP MED, V161, P446, DOI 10.1084/jem.161.3.446; JAMIESON C, 1991, J IMMUNOL, V147, P416; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KINCAID RL, 1990, J BIOL CHEM, V265, P11312; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Lin X, 1999, IMMUNITY, V10, P271, DOI 10.1016/S1074-7613(00)80027-8; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LUCAS S, 1990, FEBS LETT, V260, P53, DOI 10.1016/0014-5793(90)80064-P; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MCELHINNY JA, 1995, J VIROL, V69, P1500, DOI 10.1128/JVI.69.3.1500-1509.1995; MEICHLE A, 1990, J BIOL CHEM, V265, P8339; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; SEN J, 1995, J IMMUNOL, V154, P3213; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; Shibuya H, 1989, INT IMMUNOL, V1, P43, DOI 10.1093/intimm/1.1.43; STEFFAN NM, 1995, J IMMUNOL, V155, P4685; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRUNEH A, 1985, NATURE, V313, P318, DOI 10.1038/313318a0; Werlen G, 1998, EMBO J, V17, P3101, DOI 10.1093/emboj/17.11.3101; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhao Y, 1996, J BIOL CHEM, V271, P29773, DOI 10.1074/jbc.271.47.29773	63	154	157	4	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					22923	22931		10.1074/jbc.274.33.22923	http://dx.doi.org/10.1074/jbc.274.33.22923			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438457	hybrid			2022-12-25	WOS:000082012800007
J	Adak, S; Ghosh, S; Abu-Soud, HM; Stuehr, DJ				Adak, S; Ghosh, S; Abu-Soud, HM; Stuehr, DJ			Role of reductase domain cluster 1 acidic residues in neuronal nitric-oxide synthase - characterization of the FMN-free enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME P-450 REDUCTASE; SITE-DIRECTED MUTAGENESIS; ELECTRON-TRANSFER; FLAVOPROTEIN DOMAIN; CATALYTIC ACTIVITY; SULFITE REDUCTASE; ESCHERICHIA-COLI; BINDING DOMAIN; CALMODULIN; FLAVIN	The nNOS reductase domain is homologous to cytochrome P450 reductase, which contains two conserved clusters of acidic residues in its FMN module that play varied roles in its electron transfer reactions. To study the role of nNOS reductase domain cluster 1 acidic residues, we mutated two conserved acidic (Asp(918) and Glu(919)) and one conserved aromatic residue (Phe(892)), and investigated the effect of each mutation on flavin binding, conformational change, electron transfer reactions, calmodulin regulation, and catalytic activities. Each mutation destabilized FMN binding without significantly affecting other aspects including substrate, cofactor or calmodulin binding, or catalytic activities upon FMN reconstitution, indicating the mutational effect was restricted to the FMN module. Characterization of the FMN-depleted mutants showed that bound FMN was essential for reduction of the nNOS heme or cytochrome c, but not for ferricyanide or dichlorophenolindolphenol, and established that the electron transfer path in nNOS is NADPH to FAD to FMN to heme, Steady-state and stopped-flow kinetic analysis revealed a novel role for bound FMN in suppressing FAD reduction by NADPH, The suppression could be relieved either by FMN removal or calmodulin binding. Calmodulin binding induced a conformational change that was restricted to the FMN module. This increased the rate of FMN reduction and triggered electron transfer to the heme, We propose that the FMN module of nNOS is the key positive or negative regulator of electron transfer at all points in nNOS, This distinguishes nNOS from other related flavoproteins, and helps explain the mechanism of calmodulin regulation.	Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Stuehr, DJ (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	stuehrd@ccf.org		Ghosh, Sanjay/0000-0001-8624-1494	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051491] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51491] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUSOUD HM, 1994, J BIOL CHEM, V269, P32318; ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; ALIVERTI A, 1995, BIOCHEMISTRY-US, V34, P8371, DOI 10.1021/bi00026a019; BEATY NB, 1981, J BIOL CHEM, V256, P4611; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BURKHART BM, 1995, ACTA CRYSTALLOGR D, V51, P318, DOI 10.1107/S0907444994011716; Cho MJ, 1998, BIOCHEMISTRY-US, V37, P15593, DOI 10.1021/bi981497g; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; ESCHENBRENNER M, 1995, J BIOL CHEM, V270, P20550, DOI 10.1074/jbc.270.35.20550; Gachhui R, 1998, J BIOL CHEM, V273, P5451, DOI 10.1074/jbc.273.10.5451; Gachhui R, 1996, J BIOL CHEM, V271, P20594, DOI 10.1074/jbc.271.34.20594; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; Govindaraj S, 1997, J BIOL CHEM, V272, P7915, DOI 10.1074/jbc.272.12.7915; Huang LX, 1999, BIOCHEMISTRY-US, V38, P1912, DOI 10.1021/bi981954t; Jenkins CM, 1997, J BIOL CHEM, V272, P22509, DOI 10.1074/jbc.272.36.22509; KERWIN JF, 1995, J MED CHEM, V38, P4343, DOI 10.1021/jm00022a001; KLATT P, 1994, J BIOL CHEM, V269, P1674; KLEIN ML, 1993, J BIOL CHEM, V268, P7553; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; MAYER B, 1995, N-S ARCH PHARMACOL, V351, P453; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; Narayanasami R, 1997, NITRIC OXIDE-BIOL CH, V1, P39, DOI 10.1006/niox.1996.0103; Nishida CR, 1998, J BIOL CHEM, V273, P5566, DOI 10.1074/jbc.273.10.5566; NISIMOTO Y, 1986, J BIOL CHEM, V261, P14232; OSTROWSKI J, 1989, J BIOL CHEM, V264, P15796; PORTER TD, 1991, TRENDS BIOCHEM SCI, V16, P154, DOI 10.1016/0968-0004(91)90059-5; Richards MK, 1996, BIOCHEMISTRY-US, V35, P7772, DOI 10.1021/bi952582g; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHMIDT HHHW, 1992, BIOCHEMISTRY-US, V31, P3243, DOI 10.1021/bi00127a028; Sevrioukova I, 1996, BIOCHEMISTRY-US, V35, P7058, DOI 10.1021/bi960060a; Sevrioukova I, 1996, BIOCHEMISTRY-US, V35, P7528, DOI 10.1021/bi960330p; SEVRIOUKOVA IF, 1995, BIOCHIMIE, V77, P562, DOI 10.1016/0300-9084(96)88172-7; Sevrioukova IF, 1999, P NATL ACAD SCI USA, V96, P1863, DOI 10.1073/pnas.96.5.1863; SHEN AL, 1989, J BIOL CHEM, V264, P7584; SHEN AL, 1995, J BIOL CHEM, V270, P27475, DOI 10.1074/jbc.270.46.27475; Shen AL, 1999, J BIOL CHEM, V274, P5391, DOI 10.1074/jbc.274.9.5391; SHETA EA, 1994, J BIOL CHEM, V269, P15147; Siddhanta U, 1998, J BIOL CHEM, V273, P18950, DOI 10.1074/jbc.273.30.18950; SMITH GCM, 1994, P NATL ACAD SCI USA, V91, P8710, DOI 10.1073/pnas.91.18.8710; StevensTruss R, 1997, BIOCHEMISTRY-US, V36, P12337, DOI 10.1021/bi970973k; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; VERMILION JL, 1981, J BIOL CHEM, V256, P266; VERMILION JL, 1978, J BIOL CHEM, V253, P8812; VORHERR T, 1993, BIOCHEMISTRY-US, V32, P6081, DOI 10.1021/bi00074a020; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; Wu CQ, 1996, BIOCHEM BIOPH RES CO, V222, P439, DOI 10.1006/bbrc.1996.0763	48	82	82	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22313	22320		10.1074/jbc.274.32.22313	http://dx.doi.org/10.1074/jbc.274.32.22313			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428800	hybrid			2022-12-25	WOS:000081868400030
J	Aramli, LA; Teschke, CM				Aramli, LA; Teschke, CM			Single amino acid substitutions globally suppress the folding defects of temperature-sensitive folding mutants of phage P22 coat protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INCLUSION-BODY FORMATION; POLYMERASE CHAIN-REACTION; TAILSPIKE PROTEIN; ESCHERICHIA-COLI; IN-VITRO; AROMATIC->LEUCINE SUBSTITUTIONS; STRUCTURAL PROTEINS; MUTATIONAL ANALYSIS; CRYSTAL-STRUCTURE; GENERAL-METHOD	The amino acid sequence of a polypeptide defines both the folding pathway and the final three-dimensional structure of a protein. Eighteen amino acid substitutions have been identified in bacteriophage P22 coat protein that are defective in folding and cause their folding intermediates to be substrates for GroEL and GroES. These temperature-sensitive folding (tsf) substitutions identify amino acids that are critical for directing the folding of coat protein. Additional amino acid residues that are critical to the folding process of P22 coat protein were identified by isolating second site suppressors of the tsf coat proteins, Suppressor substitutions isolated from the phage carrying the tsf coat protein substitutions included global suppressors, which are substitutions capable of alleviating the folding defects of numerous tsf coat protein mutants. In addition, potential global and site-specific suppressors were isolated, as well as a group of same site amino acid substitutions that had a less severe phenotype than the tsf parent. The global suppressors were located at positions 163, 166, and 170 in the coat protein sequence and were 8-190 amino acid residues away from the tsf parent. Although the folding of coat proteins with tsf amino acid substitutions was improved by the global suppressor substitutions, GroEL remained necessary for folding. Therefore, we believe that the global suppressor sites identify a region that is critical to the folding of coat protein.	Univ Connecticut, Dept Mol & Cell Biol, Storrs, CT 06269 USA	University of Connecticut	Teschke, CM (corresponding author), Univ Connecticut, Dept Mol & Cell Biol, 75 N Eagleville Rd,U-3125, Storrs, CT 06269 USA.	teschke@uconnvm.uconn.edu			NIGMS NIH HHS [GM53567] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053567, R29GM053567] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BEASTY AM, 1987, PROTEIN ENG, V1, P91; Betts S, 1997, ADV PROTEIN CHEM, V50, P243, DOI 10.1016/S0065-3233(08)60323-X; BOTSTEIN D, 1972, VIROLOGY, V49, P268, DOI 10.1016/S0042-6822(72)80028-X; BOTTEMA CDK, 1993, METHOD ENZYMOL, V218, P388; BOWIE JU, 1990, SCIENCE, V247, P1306, DOI 10.1126/science.2315699; CHOTHIA C, 1984, ANNU REV BIOCHEM, V53, P537; CHRUNYK BA, 1993, J BIOL CHEM, V268, P18053; CREIGHTON TE, 1993, PROTEINS STRUCTURES, P171; EPPLER K, 1991, VIROLOGY, V183, P519, DOI 10.1016/0042-6822(91)90981-G; FANE B, 1987, GENETICS, V117, P157; FANE B, 1991, GENETICS, V127, P263; FANE B, 1991, J BIOL CHEM, V266, P11640; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; Fenton WA, 1997, PROTEIN SCI, V6, P743; FOGUEL D, 1995, BIOCHEMISTRY-US, V34, P1120, DOI 10.1021/bi00004a003; Fong DG, 1997, BIOCHEMISTRY-US, V36, P3971, DOI 10.1021/bi962188y; GALISTEO ML, 1995, J BIOL CHEM, V270, P16595, DOI 10.1074/jbc.270.28.16595; GEORGOPOULOS CP, 1973, J MOL BIOL, V76, P45, DOI 10.1016/0022-2836(73)90080-6; GOLDENBERG DP, 1981, J MOL BIOL, V145, P633, DOI 10.1016/0022-2836(81)90307-7; GOLDENBERG DP, 1988, ANNU REV BIOPHYS BIO, V17, P481; GORDON CL, 1994, J BIOL CHEM, V269, P27941; GORDON CL, 1993, J BIOL CHEM, V268, P9358; GORDON CL, 1994, GENETICS, V136, P427; GOUGH M, 1968, GENETICS, V58, P161; HAASEPETTINGELL CA, 1988, J BIOL CHEM, V263, P4977; HAN M, 1990, GENETICS, V126, P899; Huang WZ, 1997, P NATL ACAD SCI USA, V94, P8801, DOI 10.1073/pnas.94.16.8801; JARVIK J, 1975, P NATL ACAD SCI USA, V72, P2738, DOI 10.1073/pnas.72.7.2738; King J, 1996, FASEB J, V10, P57, DOI 10.1096/fasebj.10.1.8566549; KING J, 1989, PROTEIN FOLDING DECI, P225; King RD, 1996, PROTEIN SCI, V5, P2298, DOI 10.1002/pro.5560051116; KWOK S, 1990, NUCLEIC ACIDS RES, V18, P999, DOI 10.1093/nar/18.4.999; LI Y, 1981, BACTERIOPHAGE ASSEMB; LUX FG, 1991, GENETICS, V128, P549; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; McGee WA, 1998, PROTEIN SCI, V7, P1071, DOI 10.1002/pro.5560070501; MITRAKI A, 1993, J BIOL CHEM, V268, P20071; MITRAKI A, 1991, SCIENCE, V253, P54, DOI 10.1126/science.1648264; MITRAKI A, 1991, ACS SYM SER, V470, P35; MITRAKI A, 1989, BIO-TECHNOL, V7, P690, DOI 10.1038/nbt0789-690; MOIR D, 1982, GENETICS, V100, P565; Nakonechny WS, 1998, J BIOL CHEM, V273, P27236, DOI 10.1074/jbc.273.42.27236; NEAL BL, 1993, J BACTERIOL, V175, P7115, DOI 10.1128/jb.175.21.7115-7118.1993; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; PREVELIGE PE, 1993, BIOPHYS J, V64, P824, DOI 10.1016/S0006-3495(93)81443-7; Schuler B, 1998, J MOL BIOL, V281, P227, DOI 10.1006/jmbi.1998.1944; SHORTLE D, 1989, J BIOL CHEM, V264, P5315; SHORTLE D, 1985, GENETICS, V110, P539; SOMMER SS, 1992, BIOTECHNIQUES, V12, P82; STEINBACHER S, 1994, SCIENCE, V265, P383, DOI 10.1126/science.8023158; Steinbacher S, 1997, J MOL BIOL, V267, P865, DOI 10.1006/jmbi.1997.0922; SUGIHARA J, 1988, BIOCHEMISTRY-US, V27, P2872, DOI 10.1021/bi00408a031; Teschke CM, 1999, BIOCHEMISTRY-US, V38, P2873, DOI 10.1021/bi982739f; TESCHKE CM, 1995, BIOCHEMISTRY-US, V34, P6815, DOI 10.1021/bi00020a028; TESCHKE CM, 1993, BIOCHEMISTRY-US, V32, P10839, DOI 10.1021/bi00091a040; Teschke CM, 1996, BIOCHEMISTRY-US, V35, P14831, DOI 10.1021/bi960860l; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; TRUONG HTN, 1991, BIOCHEMISTRY-US, V30, P10722; TSAI AYM, 1991, J BIOL CHEM, V266, P10534; Tuma R, 1998, P NATL ACAD SCI USA, V95, P9885, DOI 10.1073/pnas.95.17.9885; Van der Schueren J, 1998, PROTEIN ENG, V11, P1211, DOI 10.1093/protein/11.12.1211; VILLAFANE R, 1994, J BACTERIOL, V176, P137, DOI 10.1128/JB.176.1.137-142.1994; Welch WJ, 1996, CELL STRESS CHAPERON, V1, P109, DOI 10.1379/1466-1268(1996)001<0109:IOMACC>2.3.CO;2; WETZEL R, 1994, TRENDS BIOTECHNOL, V12, P193, DOI 10.1016/0167-7799(94)90082-5; WINSTON F, 1979, J BACTERIOL, V137, P433, DOI 10.1128/JB.137.1.433-439.1979; ZEILSTRARYALLS J, 1993, J BACTERIOL, V175, P1134, DOI 10.1128/JB.175.4.1134-1143.1993; Zhang JX, 1997, PROTEIN SCI, V6, P1549, DOI 10.1002/pro.5560060719; Zhang JX, 1997, PROTEIN SCI, V6, P1563, DOI 10.1002/pro.5560060720	69	28	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22217	22224		10.1074/jbc.274.32.22217	http://dx.doi.org/10.1074/jbc.274.32.22217			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428787	hybrid			2022-12-25	WOS:000081868400017
J	Haas, TL; Stitelman, D; Davis, SJ; Apte, SS; Madri, JA				Haas, TL; Stitelman, D; Davis, SJ; Apte, SS; Madri, JA			Egr-1 mediates extracellular matrix-driven transcription of membrane type 1 matrix metalloproteinase in endothelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; PHENOTYPIC MODULATION; EPITHELIAL-CELLS; SKELETAL-MUSCLE; ANGIOGENESIS; ACTIVATION; MECHANISMS; GROWTH; ORGANIZATION; COLLAGENASE	Matrix metalloproteinase activity is instrumental in processes of cellular invasion. The interstitial invasion of endothelial cells during angiogenesis is accompanied by up-regulation of several matrix metalloproteinases, including membrane type 1 matrix metalloproteinase (MT1-MMP), In this study, we show that endothelial cells stimulated to undergo angiogenesis by a three-dimensional extracellular matrix environment increase production of the transcription factor Egr-1. Increased binding of Egr-1 to the MT1-MMP promoter correlates with enhanced transcriptional activity, whereas mutations in the Egr-1 binding site abrogate the increased transcription of MT1-MMP in the stimulated cells. These data identify Egr-1-mediated transcription of MT1-MMP as a mechanism by which endothelial cells can initiate an invasive phenotype in response to an alteration in extracellular matrix environment, thus functionally associating MT1-MMP with a growing number of proteins known to be up-regulated by Egr-1 in response to tissue injury or mechanical stress.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Biomed Engn, Cleveland, OH 44195 USA	Yale University; Cleveland Clinic Foundation	Madri, JA (corresponding author), Yale Univ, Sch Med, Dept Pathol, 310 Cedar St,LH 115, New Haven, CT 06520 USA.		Haas, Tara/F-6788-2013	Haas, Tara/0000-0001-8559-9574; Apte, Suneel/0000-0001-8441-1226	NHLBI NIH HHS [F23-HL09983, R01-HL5108] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009983] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKAI Y, 1994, AM J PHYSIOL, V267, pC482, DOI 10.1152/ajpcell.1994.267.2.C482; Apte SS, 1997, J BIOL CHEM, V272, P25511, DOI 10.1074/jbc.272.41.25511; AZZAM HS, 1992, CANCER RES, V52, P4540; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; Chan VT, 1998, J INVEST DERMATOL, V111, P1153, DOI 10.1046/j.1523-1747.1998.00416.x; Chicurel ME, 1998, CURR OPIN CELL BIOL, V10, P232, DOI 10.1016/S0955-0674(98)80145-2; Chiquet M, 1996, BIOCHEM CELL BIOL, V74, P737, DOI 10.1139/o96-080; Crawford HC, 1996, ENZYME PROTEIN, V49, P20, DOI 10.1159/000468614; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; DECLERCK YA, 1994, GENE, V139, P185, DOI 10.1016/0378-1119(94)90753-6; Eid MA, 1998, CANCER RES, V58, P2461; Foda HD, 1996, LAB INVEST, V74, P538; Gilles C, 1997, LAB INVEST, V76, P651; Graesser D, 1998, LAB INVEST, V78, P1445; Haas TL, 1998, J BIOL CHEM, V273, P3604, DOI 10.1074/jbc.273.6.3604; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Hudlicka O, 1998, MICROCIRCULATION, V5, P7; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Liu CT, 1996, CRIT REV ONCOGENESIS, V7, P101, DOI 10.1615/CritRevOncog.v7.i1-2.70; MADRI JA, 1983, J CELL BIOL, V97, P153, DOI 10.1083/jcb.97.1.153; MADRI JA, 1988, J CELL BIOL, V106, P1375, DOI 10.1083/jcb.106.4.1375; Mertens PR, 1997, J BIOL CHEM, V272, P22905, DOI 10.1074/jbc.272.36.22905; MICHEL JB, 1994, J CLIN INVEST, V94, P277, DOI 10.1172/JCI117318; Mignatti P, 1996, ENZYME PROTEIN, V49, P117, DOI 10.1159/000468621; MONTESANO R, 1985, CELL, V42, P469, DOI 10.1016/0092-8674(85)90104-7; Nagase H, 1998, Cell Res, V8, P179; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Pang HL, 1998, BIOCHEM J, V333, P209, DOI 10.1042/bj3330209; Pepper MS, 1997, ARTERIOSCL THROM VAS, V17, P605, DOI 10.1161/01.ATV.17.4.605; ROSKELLEY CD, 1995, CURR OPIN CELL BIOL, V7, P736, DOI 10.1016/0955-0674(95)80117-0; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1997, THROMB HAEMOSTASIS, V78, P497; Schwachtgen JL, 1998, J CLIN INVEST, V101, P2540, DOI 10.1172/JCI1404; Silverman ES, 1999, AM J PATHOL, V154, P665, DOI 10.1016/S0002-9440(10)65312-6; Tomasek JJ, 1997, J BIOL CHEM, V272, P7482, DOI 10.1074/jbc.272.11.7482; VERNON RB, 1995, AM J PATHOL, V147, P873; Vincenti MP, 1996, CRIT REV EUKAR GENE, V6, P391, DOI 10.1615/CritRevEukarGeneExpr.v6.i4.40; WOESSNER JF, 1994, ANN NY ACAD SCI, V732, P11	40	164	173	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22679	22685		10.1074/jbc.274.32.22679	http://dx.doi.org/10.1074/jbc.274.32.22679			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428849	hybrid			2022-12-25	WOS:000081868400079
J	Hao, WH; Luo, Z; Zheng, L; Prasad, K; Lafer, EM				Hao, WH; Luo, Z; Zheng, L; Prasad, K; Lafer, EM			AP180 and AP-2 interact directly in a complex that cooperatively assembles clathrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPSE-SPECIFIC PROTEIN; COATED VESICLE PROTEINS; HIGH-AFFINITY BINDING; MONOCLONAL-ANTIBODIES; PLASMA-MEMBRANE; MOLECULAR CHARACTERIZATION; F1-20 PROTEIN; BOVINE BRAIN; PHOSPHORYLATION; PURIFICATION	Clathrin-coated vesicles are involved in protein and lipid trafficking between intracellular compartments in eukaryotic cells, AP-2 and AP180 are the resident coat proteins of clathrin-coated vesicles in nerve terminals, and interactions between these proteins could be important in vesicle dynamics, AP180 and AP-2 each assemble clathrin efficiently under acidic conditions, but neither protein will assemble clathrin efficiently at physiological pH. We find that there is a direct, clathrin-independent interaction between AP180 and AP-2 and that the AP180-AP-2 complex is more efficient at assembling clathrin under physiological conditions than is either protein alone. AP180 is phosphorylated in vivo, and in crude vesicle extracts its phosphorylation is enhanced by stimulation of casein kinase II, which is known to be present in coated vesicles. We find that recombinant AP180 is a substrate for casein kinase II in vitro and that its phosphorylation weakens both the binding of AP-2 by AP180 and the cooperative clathrin assembly activity of these proteins. We have localized the binding site for AP-2 to amino acids 623-680 of AP180, The AP180/AP-2 interaction can be disrupted by a recombinant AP180 fragment containing the AP-2 binding site, and this fragment also disrupts the cooperative clathrin assembly activity of the AP180-AP-2 complex, These results indicate that AP180 and AP-2 interact directly to form a complex that assembles clathrin more efficiently than either protein alone. Phosphorylation of AP180, by modulating the affinity of AP180 for AP-2, may contribute to the regulation of clathrin assembly in vivo.	Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA	University of Texas System; University of Texas Health San Antonio	Lafer, EM (corresponding author), Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, 15355 Lambda Dr, San Antonio, TX 78245 USA.			Lafer, Eileen/0000-0002-0493-6522	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS029051, R01NS029051] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS029051, NS29051] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHLE S, 1986, EMBO J, V5, P3143, DOI 10.1002/j.1460-2075.1986.tb04621.x; AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; BARZVI D, 1988, J BIOL CHEM, V263, P4408; BARZVI D, 1986, J BIOL CHEM, V261, P9614; BECK KA, 1991, J BIOL CHEM, V266, P4442; BECK KA, 1991, J BIOL CHEM, V266, P4437; Dell'Angelica EC, 1998, SCIENCE, V280, P431, DOI 10.1126/science.280.5362.431; DellAngelica EC, 1997, J BIOL CHEM, V272, P15078, DOI 10.1074/jbc.272.24.15078; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; Dreyling MH, 1996, P NATL ACAD SCI USA, V93, P4804, DOI 10.1073/pnas.93.10.4804; Gaidarov I, 1996, J BIOL CHEM, V271, P20922, DOI 10.1074/jbc.271.34.20922; GALLUSSER A, 1993, EMBO J, V12, P5237, DOI 10.1002/j.1460-2075.1993.tb06219.x; GOUD B, 1985, J CELL BIOL, V100, P521, DOI 10.1083/jcb.100.2.521; Hao WH, 1997, J BIOL CHEM, V272, P6393, DOI 10.1074/jbc.272.10.6393; KEEN JH, 1986, J CELL BIOL, V102, P1325, DOI 10.1083/jcb.102.4.1325; KEEN JH, 1987, J CELL BIOL, V105, P1989, DOI 10.1083/jcb.105.5.1989; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; KIRCHHAUSEN T, 1989, P NATL ACAD SCI USA, V86, P2612, DOI 10.1073/pnas.86.8.2612; KOHTZ DS, 1988, J BIOL CHEM, V263, P7418; LINDNER R, 1992, J BIOL CHEM, V267, P16567; MAYCOX PR, 1992, J CELL BIOL, V118, P1379, DOI 10.1083/jcb.118.6.1379; MORRIS SA, 1990, J BIOL CHEM, V265, P3354; MORRIS SA, 1993, EMBO J, V12, P667, DOI 10.1002/j.1460-2075.1993.tb05700.x; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; MURPHY JE, 1991, J BIOL CHEM, V266, P4401; NANDI PK, 1982, BIOCHEMISTRY-US, V21, P6434, DOI 10.1021/bi00268a018; NORRIS FA, 1995, J BIOL CHEM, V270, P214, DOI 10.1074/jbc.270.1.214; Odorizzi G, 1998, TRENDS CELL BIOL, V8, P282, DOI 10.1016/S0962-8924(98)01295-1; PEARSE BMF, 1975, J MOL BIOL, V97, P93, DOI 10.1016/S0022-2836(75)80024-6; PEARSE BMF, 1984, EMBO J, V3, P1951, DOI 10.1002/j.1460-2075.1984.tb02075.x; PERRY DG, 1991, J HISTOCHEM CYTOCHEM, V39, P1461, DOI 10.1177/39.11.1918924; PERRY DG, 1992, J NEUROSCI RES, V33, P408, DOI 10.1002/jnr.490330307; PRASAD K, 1988, BIOCHEMISTRY-US, V27, P6098, DOI 10.1021/bi00416a040; PRASAD K, 1991, BIOCHEMISTRY-US, V30, P5590, DOI 10.1021/bi00236a036; PRETORIUS HT, 1981, BIOCHEMISTRY-US, V20, P2777, DOI 10.1021/bi00513a011; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; Shih W, 1995, J BIOL CHEM, V270, P31083, DOI 10.1074/jbc.270.52.31083; Simpson F, 1997, J CELL BIOL, V137, P835, DOI 10.1083/jcb.137.4.835; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; SOUSA R, 1990, NEUROSCIENCE, V34, P403, DOI 10.1016/0306-4522(90)90149-X; SOUSA R, 1992, J NEUROSCI, V12, P2130; Takei K, 1996, J CELL BIOL, V133, P1237, DOI 10.1083/jcb.133.6.1237; TIMERMAN AP, 1992, P NATL ACAD SCI USA, V89, P8976, DOI 10.1073/pnas.89.19.8976; UNGEWICKELL E, 1994, EUR J BIOCHEM, V222, P33, DOI 10.1111/j.1432-1033.1994.tb18838.x; VIGERS GPA, 1986, EMBO J, V5, P2079, DOI 10.1002/j.1460-2075.1986.tb04469.x; VOGLMAIER SM, 1992, BIOCHEM BIOPH RES CO, V187, P158, DOI 10.1016/S0006-291X(05)81473-1; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; Wilde A, 1996, J CELL BIOL, V135, P635, DOI 10.1083/jcb.135.3.635; YE W, 1995, J NEUROSCI RES, V41, P15, DOI 10.1002/jnr.490410104; YE WL, 1995, J BIOL CHEM, V270, P10933, DOI 10.1074/jbc.270.18.10933; YE WL, 1995, J BIOL CHEM, V270, P1564, DOI 10.1074/jbc.270.4.1564; ZAREMBA S, 1983, J CELL BIOL, V97, P1339, DOI 10.1083/jcb.97.5.1339; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1; ZHOU SB, 1992, J NEUROSCI, V12, P2144; ZHOU SB, 1993, J BIOL CHEM, V268, P12655	55	91	94	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22785	22794		10.1074/jbc.274.32.22785	http://dx.doi.org/10.1074/jbc.274.32.22785			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428863	hybrid			2022-12-25	WOS:000081868400093
J	Hsiao, PW; Chang, CS				Hsiao, PW; Chang, CS			Isolation and characterization of ARA160 as the first androgen receptor N-terminal-associated coactivator in human prostate cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION FUNCTION AF-2; NUCLEAR RECEPTORS; TRANSCRIPTIONAL ACTIVATION; HISTONE ACETYLTRANSFERASE; STEROID-RECEPTORS; PROTEIN; TIF2; CBP; HORMONES; ESTROGEN	The androgen receptor (AR) is a member of the steroid receptor superfamily that may require coactivators for proper or maximal transactivation, Using a purified AR N-terminal peptide as a probe to screen the human testis expression library, we identified an androgen enhanced AR N-terminal-associated protein ARA160, which consists of 1,093 amino acids with an apparent molecular mass of 160 kDa, Sequence comparison in GenBank(TM) reveals that ARA160 shares an identical sequence with a HIV-1 TATA element modulatory factor, TMF. The far-Western blotting and co-immunoprecipitation assays demonstrate that the AR can interact directly with ARA160/TMF. Affinity gel pull-down and mammalian two-hybrid assays further suggest androgen can enhance significantly the interaction between AR and ARA160. Transient transfection assays demonstrated that ARA160 might function as a coactivator for AR-mediated transactivation in human prostate cancer PC-3 cells. Our data further suggest that this AR N-terminal coactivator can function cooperatively with AR C-terminal coactivator, ARA70, in PC-3 cells. Together, our data demonstrate that ARA160 might represent the first identified androgen-enhanced N-terminal coactivator for the AR.	Univ Rochester, Dept Pathol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Dept Urol, Georgr Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Dept Radiat Oncol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Wisconsin, Ctr Comprehens Canc, Madison, WI 53792 USA	University of Rochester; University of Rochester; University of Rochester; University of Wisconsin System; University of Wisconsin Madison	Chang, CS (corresponding author), Univ Rochester, Dept Pathol, George Whipple Lab Canc Res, 601 Elmwood Ave, Rochester, NY 14642 USA.		Hsiao, Pei-Wen/V-5653-2018	Hsiao, Pei-Wen/0000-0002-3589-6754	NCI NIH HHS [CA55639, CA68518, CA71570] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA055639, R01CA055639] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; CHANG CS, 1995, CRIT REV EUKAR GENE, V5, P97, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.10; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Fujimoto N, 1999, J BIOL CHEM, V274, P8316, DOI 10.1074/jbc.274.12.8316; GARCIA JA, 1992, P NATL ACAD SCI USA, V89, P9372, DOI 10.1073/pnas.89.20.9372; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hsiao PW, 1999, J BIOL CHEM, V274, P20229, DOI 10.1074/jbc.274.29.20229; JENSTER G, 1995, J BIOL CHEM, V270, P7341, DOI 10.1074/jbc.270.13.7341; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kang HY, 1999, J BIOL CHEM, V274, P8570, DOI 10.1074/jbc.274.13.8570; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Monden T, 1997, J BIOL CHEM, V272, P29834, DOI 10.1074/jbc.272.47.29834; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; ONATE SA, 1995, SCIENCE, V270, P1354; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Yeh SY, 1998, BIOCHEM BIOPH RES CO, V248, P361, DOI 10.1006/bbrc.1998.8974; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; Yeh SY, 1998, P NATL ACAD SCI USA, V95, P5527, DOI 10.1073/pnas.95.10.5527	25	113	120	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22373	22379		10.1074/jbc.274.32.22373	http://dx.doi.org/10.1074/jbc.274.32.22373			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428808	hybrid			2022-12-25	WOS:000081868400038
J	Lefebvre, SD; Wong, ML; Morrical, SW				Lefebvre, SD; Wong, ML; Morrical, SW			Simultaneous interactions of bacteriophage T4 DNA replication proteins gp59 and gp32 with single-stranded (ss) DNA - Co-modulation of ssDNA binding activities in a DNA helicase assembly intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE 32 PROTEIN; RECA PROTEIN; RECOMBINATION; PURIFICATION; REQUIRES; FORMS	The T4 gp59 protein is the major accessory protein of the phage's replicative DNA helicase, gp41. gp59 helps load gp41 at DNA replication forks by promoting its assembly onto single-stranded (ss) DNA covered with cooperatively bound molecules of gp32, the T4 single-strand DNA binding protein (ssb). A gp59-gp32-ssDNA ternary complex is an obligatory intermediate in this helicase loading mechanism. Here, we characterize the properties of gp59-gp32-ssDNA complexes and reveal some of the biochemical interactions that occur within them. Our results indicate the following: (i) gp59 is able to co-occupy ssDNA pre-saturated with either gp32 or gp32-A (a truncated gp32 species lacking interactions with gp59); (ii) gp59 destabilizes both gp32-ssDNA and (gp32-A)-ssDNA interactions; (iii) interactions of gp59 with the A-domain of gp32 alter the ssDNA-binding properties of gp59; and (iv) gp59 organizes gp32-ssDNA versus (gp32-A)-ssDNA into morphologically distinct complexes. Our results support a model in which gp59-gp32 interactions are non-essential for the co-occupancy of both proteins on ssDNA but are essential for the formation of structures competent for helicase assembly. The data argue that specific "cross-talk" between gp59 and gp32, involving conformational changes in both, is a key feature of the gp41 helicase assembly pathway.	Univ Vermont, Coll Med, Dept Biochem, Burlington, VT 05405 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA	University of Vermont; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Morrical, SW (corresponding author), Univ Vermont, Coll Med, Dept Biochem, Burlington, VT 05405 USA.	smorrica@zoo.uvm.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM048847, R01GM048847] Funding Source: NIH RePORTER; NCI NIH HHS [CA09286] Funding Source: Medline; NIGMS NIH HHS [GM48847] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS BM, 1971, METHOD ENZYMOL, V22, P198; Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; BARRY J, 1994, J BIOL CHEM, V269, P33063; BARRY J, 1994, J BIOL CHEM, V269, P33049; Beernink HTH, 1998, BIOCHEMISTRY-US, V37, P5673, DOI 10.1021/bi9800956; CELANDER DW, 1990, BIOCHEMISTRY-US, V29, P1355, DOI 10.1021/bi00458a001; CUNNINGHAM RP, 1977, VIROLOGY, V80, P67, DOI 10.1016/0042-6822(77)90381-6; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HURLEY JM, 1993, J MOL BIOL, V229, P398, DOI 10.1006/jmbi.1993.1042; JIANG H, 1993, J BIOL CHEM, V268, P7904; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; KOWALCZYKOWSKI SC, 1990, LANDOLTBORNSTEIN NUM, P244; Kreuzer K. N., 1994, MOL BIOL BACTERIOP T, P28; KREUZER KN, 1994, MOL BIOL BACTERIOP T, V4, P89; Lefebvre SD, 1997, J MOL BIOL, V272, P312, DOI 10.1006/jmbi.1997.1264; LEFEBVRE SD, 1998, THESIS U VERMONT BUR, V4; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; MILLER H, 1987, METHOD ENZYMOL, V152, P145; MOGIG G, 1994, MOL BIOL BACTERIPH T, V4, P54; MORRICAL SW, 1994, J BIOL CHEM, V269, P33069; MORRICAL SW, 1991, J BIOL CHEM, V266, P14031; Morrical SW, 1996, J BIOL CHEM, V271, P20198, DOI 10.1074/jbc.271.33.20198; SALINAS F, 1995, CELL, V82, P111, DOI 10.1016/0092-8674(95)90057-8; SHAMOO Y, 1995, NATURE, V376, P362, DOI 10.1038/376362a0; SILVER MS, 1982, BIOCHEMISTRY-US, V21, P6066, DOI 10.1021/bi00267a007; SPACCIAPOLI P, 1994, J BIOL CHEM, V269, P447; Sweezy MA, 1997, J MOL BIOL, V266, P927, DOI 10.1006/jmbi.1996.0829; Sweezy MA, 1999, BIOCHEMISTRY-US, V38, P936, DOI 10.1021/bi9817055; TARUMI K, 1995, J BIOL CHEM, V270, P2614, DOI 10.1074/jbc.270.6.2614; TULLIUS TD, 1987, METHOD ENZYMOL, V155, P537; WILLIAMS KR, 1994, MOL BIOL BACTERIOP T, V4, P301; YAMAMOTO KR, 1970, VIROLOGY, V40, P734, DOI 10.1016/0042-6822(70)90218-7; YONESAKI T, 1994, J BIOL CHEM, V269, P1284	33	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22830	22838		10.1074/jbc.274.32.22830	http://dx.doi.org/10.1074/jbc.274.32.22830			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428868	hybrid			2022-12-25	WOS:000081868400098
J	Tagami, T; Park, Y; Jameson, JL				Tagami, T; Park, Y; Jameson, JL			Mechanisms that mediate negative regulation of the thyroid-stimulating hormone a gene by the thyroid hormone receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN HISTONE DEACETYLASE; TRANSCRIPTION FACTOR CREB; NUCLEAR-PROTEIN CBP; RETINOIC ACID; CO-REPRESSOR; ALPHA-GENE; V-ERBA; MOLECULAR-CLONING; RESPONSE ELEMENTS; CAUSE RESISTANCE	A group of transcriptional cofactors for nuclear hormone receptors, referred to as corepressors (CoRs) and coactivators (CoAs), has been shown to induce transcriptional silencing and hormone-induced activation, respectively, of genes that contain positive hormone response elements. Transcriptional silencing by CoRs involves the recruitment of histone deacetylases (HDACs), whereas ligand-dependent activation is associated with the recruitment of CoAs, which possess or recruit histone acetyltransferases (HATs), In a reciprocal manner, negatively regulated genes are stimulated by nuclear receptors in the absence of ligand and are repressed in response to ligand binding to receptors, We show here that negative regulation of the thyroid-stimulating hormone alpha (TSH alpha) promoter by the thyroid hormone receptor (TR) involves a novel mechanism in which the recruitment of CoRs by TR is associated with transcriptional stimulation and histone acetylation. Expression of excess HDAC reverses the stimulation mediated by the TR CoR complex, consistent with a pivotal role for acetylation in this event. Addition of the ligand, 3,5,3'-triiodothyronine (T3), induces transcriptional repression of the TSH alpha promoter and is associated with the loss of histone acetylation, T3-dependent repression is blocked by phosphorylation of cAMP response element binding protein, or by inhibition of HDAC, indicating that receptor action is subverted by maneuvers that stimulate histone acetylation of the target gene. We propose that negative regulation of a subset of genes by TR involves the active exchange of CoRs and CoAs with intrinsic promoter regulatory elements that normally strongly induce histone acetylation and transcriptional activation.	Northwestern Univ, Sch Med, Div Endocrinol Metab & Mol Med, Chicago, IL 60611 USA	Northwestern University	Jameson, JL (corresponding author), Northwestern Univ, Sch Med, Div Endocrinol Metab & Mol Med, Tarry 15-709,303 E Chicago Ave, Chicago, IL 60611 USA.	ljameson@nwu.edu		Jameson, James/0000-0001-9538-4059	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042144] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42144] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; ARTHUR S, 1998, CELL, V92, P475; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Barton K, 1996, NATURE, V379, P81, DOI 10.1038/379081a0; BERKOWITZ LA, 1990, P NATL ACAD SCI USA, V87, P5258, DOI 10.1073/pnas.87.14.5258; BODENNER DL, 1991, J BIOL CHEM, V266, P21666; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; CARR FE, 1992, J BIOL CHEM, V267, P18689; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHATTERJEE VKK, 1994, J CLIN ENDOCR METAB, V78, P990, DOI 10.1210/jcem.78.4.8157732; CHATTERJEE VKK, 1989, P NATL ACAD SCI USA, V86, P9114, DOI 10.1073/pnas.86.23.9114; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HOLLENBERG AN, 1995, MOL ENDOCRINOL, V9, P540, DOI 10.1210/me.9.5.540; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; JAMESON JL, 1988, J BIOL CHEM, V263, P9879; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Karin M, 1998, CELL, V93, P487, DOI 10.1016/S0092-8674(00)81177-0; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; MADISON LD, 1993, MOL CELL ENDOCRINOL, V94, P129, DOI 10.1016/0303-7207(93)90060-W; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MARGOLSKEE RF, 1993, BIOTECHNIQUES, V15, P906; MAURER RA, 1989, J BIOL CHEM, V264, P6870; NAGAYA T, 1992, J BIOL CHEM, V267, P13014; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; Pernasetti F, 1997, MOL ENDOCRINOL, V11, P986, DOI 10.1210/me.11.7.986; SAATCIOGLU F, 1993, MOL CELL BIOL, V13, P3675, DOI 10.1128/MCB.13.6.3675; SANCHEZPACHECO A, 1995, MOL CELL BIOL, V15, P6322; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; SHUPNIK MA, 1986, ENDOCRINOLOGY, V118, P367, DOI 10.1210/endo-118-1-367; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; STEVENIN B, 1995, ENDOCRINOLOGIST, V5, P286, DOI 10.1097/00019616-199507000-00008; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Tagami T, 1998, ENDOCRINOLOGY, V139, P640, DOI 10.1210/en.139.2.640; Tagami T, 1997, MOL CELL BIOL, V17, P2642, DOI 10.1128/MCB.17.5.2642; Tagami T, 1998, MOL ENDOCRINOL, V12, P1888, DOI 10.1210/me.12.12.1888; Tagami T, 1998, BIOCHEM BIOPH RES CO, V253, P358, DOI 10.1006/bbrc.1998.9799; Takeshita A, 1996, ENDOCRINOLOGY, V137, P3594, DOI 10.1210/en.137.8.3594; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WONDISFORD FE, 1993, J BIOL CHEM, V268, P2749; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YEN PM, 1994, J BIOL CHEM, V269, P903; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; ZHANG XK, 1991, MOL CELL BIOL, V11, P6016, DOI 10.1128/MCB.11.12.6016	66	93	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22345	22353		10.1074/jbc.274.32.22345	http://dx.doi.org/10.1074/jbc.274.32.22345			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428804	hybrid			2022-12-25	WOS:000081868400034
J	Lomasney, JW; Cheng, HF; Roffler, SR; King, K				Lomasney, JW; Cheng, HF; Roffler, SR; King, K			Activation of phospholipase C delta 1 through C2 domain by a Ca2+-enzyme-phosphatidylserine ternary complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; PROTEIN-KINASE-C; HIGH-AFFINITY; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; KINETIC-ANALYSIS; INOSITOL PHOSPHATES; MEMBRANE-BINDING; MIXED MICELLES; C-DELTA-1; ACID	The concentration of free Ca2+ and the composition of nonsubstrate phospholipids profoundly affect the activity of phospholipase C delta 1 (PLC delta 1), The rate of PLC delta 1 hydrolysis of phosphatidylinositol 4,5-bisphosphate was stimulated 20-fold by phosphatidylserine (PS), 4-fold by phosphatidic acid (PA), and not at all by phosphatidylethanolamine or phosphatidylcholine (PC), PS reduced the Ca2+ concentration required for half-maximal activation of PLC delta 1 from 5.4 to 0.5 mu M. In the presence of Ca2+, PLC delta 1 specifically bound to PS/PC but nob to PA/PC vesicles in a dose-dependent and saturable manner. Ca2+ also bound to PLC delta 1 and required the presence of PS/PC vesicles but not PA/PC vesicles. The free Ca2+ concentration required for half-maximal Ca2+ binding was estimated to be 8 mu M. Surface dilution kinetic analysis revealed that the K-m was reduced 20-fold by the presence of 25 mol % PS, whereas V-max and K-d were unaffected. Deletion of amino acid residues 646654 from the C2 domain of PLC delta 1 impaired Ca2+ binding and reduced its stimulation and binding by PS. Taken together, the results suggest that the formation of an enzyme-Ca2+-PS ternary complex through the C2 domain increases the affinity for substrate and consequently leads to enzyme activation.	Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan; Northwestern Univ, Sch Med, Feinberg Cardiovasc Res Inst, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Pathol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Pharmacol, Chicago, IL 60611 USA	Academia Sinica - Taiwan; Northwestern University; Northwestern University; Northwestern University	King, K (corresponding author), Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan.		Roffler, Steve R/N-7791-2018	Roffler, Steve R/0000-0003-2543-7295				CALDERONE A, 1994, HYPERTENSION, V23, P722, DOI 10.1161/01.HYP.23.6.722; CHENG HF, 1995, J BIOL CHEM, V270, P5495, DOI 10.1074/jbc.270.10.5495; CIFUENTES ME, 1993, J BIOL CHEM, V268, P11586; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; Edwards AS, 1997, BIOCHEMISTRY-US, V36, P15615, DOI 10.1021/bi9718752; Essen LO, 1997, BIOCHEMISTRY-US, V36, P2753, DOI 10.1021/bi962466t; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Feng JF, 1996, J BIOL CHEM, V271, P16451, DOI 10.1074/jbc.271.28.16451; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Gilbert GE, 1997, BIOCHEMISTRY-US, V36, P10768, DOI 10.1021/bi970537y; Grobler JA, 1998, BIOCHEMISTRY-US, V37, P5020, DOI 10.1021/bi972952w; HANNUN YA, 1990, J BIOL CHEM, V265, P2962; HENDRICKSON HS, 1984, J BIOL CHEM, V259, P5734; HENRY RA, 1995, AM J PHYSIOL-CELL PH, V269, pC349, DOI 10.1152/ajpcell.1995.269.2.C349; HOMMA Y, 1995, EMBO J, V14, P286, DOI 10.1002/j.1460-2075.1995.tb07002.x; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; JACKOWSKI S, 1989, ARCH BIOCHEM BIOPHYS, V268, P516, DOI 10.1016/0003-9861(89)90318-4; JAMES SR, 1995, J BIOL CHEM, V270, P11872, DOI 10.1074/jbc.270.20.11872; JONES GA, 1993, J BIOL CHEM, V268, P20845; KAWASAKI H, 1985, ANAL BIOCHEM, V148, P297, DOI 10.1016/0003-2697(85)90232-5; LEE MH, 1989, J BIOL CHEM, V264, P14797; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lomasney JW, 1996, J BIOL CHEM, V271, P25316, DOI 10.1074/jbc.271.41.25316; LOW MG, 1986, BIOCHEM J, V237, P139, DOI 10.1042/bj2370139; MUELLER P, 1983, BIOPHYS J, V44, P375, DOI 10.1016/S0006-3495(83)84311-2; NAKAMURA J, 1986, BIOCHIM BIOPHYS ACTA, V870, P495, DOI 10.1016/0167-4838(86)90258-X; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; NELSESTUEN GL, 1977, BIOCHEMISTRY-US, V16, P4164, DOI 10.1021/bi00638a005; NEWTON AC, 1994, BIOCHEMISTRY-US, V33, P6651, DOI 10.1021/bi00187a035; PORTIS A, 1979, BIOCHEMISTRY-US, V18, P780, DOI 10.1021/bi00572a007; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; TAYLOR SJ, 1987, BIOCHEM J, V248, P791, DOI 10.1042/bj2480791; Wang LP, 1996, J BIOL CHEM, V271, P24505, DOI 10.1074/jbc.271.40.24505; WILSON DB, 1984, J BIOL CHEM, V259, P1718; YAGISAWA H, 1994, J BIOL CHEM, V269, P20179; Yagisawa H, 1998, J BIOL CHEM, V273, P417, DOI 10.1074/jbc.273.1.417	41	66	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21995	22001		10.1074/jbc.274.31.21995	http://dx.doi.org/10.1074/jbc.274.31.21995			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419523	hybrid			2022-12-25	WOS:000081721100076
J	Barr, VA; Lane, K; Taylor, SI				Barr, VA; Lane, K; Taylor, SI			Subcellular localization and internalization of the four human leptin receptor isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCER GP130; LIGAND-INDUCED ENDOCYTOSIS; OB-R; ERYTHROPOIETIN RECEPTOR; ENDOPLASMIC-RETICULUM; EXTRACELLULAR DOMAIN; MEDIATED ENDOCYTOSIS; PROTEIN-DEGRADATION; DOWN-REGULATION; IL-6 RECEPTOR	There are four known isoforms of the human leptin receptor (HLR) with different C-terminal cytoplasmic domains (designated by the number of unique C-terminal amino acids). In cells expressing HLR-5, -15, or -274, 15-25% of the leptin binding sites were located at the plasma membrane. In contrast, in cells expressing HLR-67, only 5% of the total binding sites were at the plasma membrane. Immunofluorescent microscopy showed that all four isoforms partially co-localized with calnexin and beta-COP, markers of the endoplasmic reticulum and the Golgi, respectively. All isoforms were also detected in an unidentified punctate compartment. AU isoforms were internalized via clathrin-mediated endocytosis, but at different rates. After 20 min at 37 degrees C, 45% of a bound cohort of labeled ligand had been internalized by HLR-15, 30% by HLR-67, 25% by HLR-274, and 15% by HLR-5. Degradation of internalized leptin occurred in lysosomes. Overnight exposure to leptin down-regulated all isoforms, but to a variable extent. HLR-274 displayed the greatest down-regulation and also appeared to reach lysosomes more quickly than the other isoforms. The faster degradation of HLR-274 may help to terminate leptin signaling.	NIDDK, Diabet Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Taylor, SI (corresponding author), NIDDK, Diabet Branch, NIH, Bldg 10 9S213,10 Ctr Dr, Bethesda, MD 20892 USA.							ALLEVATO G, 1995, J BIOL CHEM, V270, P17210, DOI 10.1074/jbc.270.29.17210; Banks WA, 1996, PEPTIDES, V17, P305, DOI 10.1016/0196-9781(96)00025-3; Baskin DG, 1999, J HISTOCHEM CYTOCHEM, V47, P353, DOI 10.1177/002215549904700309; Baumann H, 1996, P NATL ACAD SCI USA, V93, P8374, DOI 10.1073/pnas.93.16.8374; Bennett BD, 1996, CURR BIOL, V6, P1170, DOI 10.1016/S0960-9822(02)70684-2; Bjorbaek C, 1997, J BIOL CHEM, V272, P32686, DOI 10.1074/jbc.272.51.32686; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; Cioffi JA, 1996, NAT MED, V2, P585, DOI 10.1038/nm0596-585; Considine RV, 1996, HORM RES, V46, P249, DOI 10.1159/000185096; Couce ME, 1997, NEUROENDOCRINOLOGY, V66, P145, DOI 10.1159/000127232; Cresswell P, 1997, CURR BIOL, V7, pR552, DOI 10.1016/S0960-9822(06)00279-X; DEITCHER DL, 1986, J CELL BIOL, V102, P911, DOI 10.1083/jcb.102.3.911; Devos R, 1997, J BIOL CHEM, V272, P18304, DOI 10.1074/jbc.272.29.18304; Diano S, 1998, J NEUROENDOCRINOL, V10, P647, DOI 10.1046/j.1365-2826.1998.00261.x; DITTRICH E, 1994, J BIOL CHEM, V269, P19014; Dittrich E, 1996, J BIOL CHEM, V271, P5487, DOI 10.1074/jbc.271.10.5487; Fei H, 1997, P NATL ACAD SCI USA, V94, P7001, DOI 10.1073/pnas.94.13.7001; FINIDORI J, 1995, J ENDOCRINOL, V147, P11, DOI 10.1677/joe.0.1470011; Fong TM, 1998, MOL PHARMACOL, V53, P234, DOI 10.1124/mol.53.2.234; Friedman J M, 1998, Nutr Rev, V56, ps38; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; GENTY N, 1994, MOL CELL ENDOCRINOL, V99, P221, DOI 10.1016/0303-7207(94)90011-6; Ghilardi N, 1997, MOL ENDOCRINOL, V11, P393, DOI 10.1210/me.11.4.393; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; Golden PL, 1997, J CLIN INVEST, V99, P14, DOI 10.1172/JCI119125; HAFT CR, 1994, J BIOL CHEM, V269, P26286; Harding PA, 1996, J BIOL CHEM, V271, P6708, DOI 10.1074/jbc.271.12.6708; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Kielar D, 1998, METABOLISM, V47, P844, DOI 10.1016/S0026-0495(98)90124-X; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Levin I, 1998, FEBS LETT, V427, P164, DOI 10.1016/S0014-5793(98)00414-1; LODISH HF, 1988, J BIOL CHEM, V263, P2107; Luoh SM, 1997, J MOL ENDOCRINOL, V18, P77, DOI 10.1677/jme.0.0180077; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Murakami T, 1997, BIOCHEM BIOPH RES CO, V231, P26, DOI 10.1006/bbrc.1996.6030; Nakashima K, 1997, FEBS LETT, V403, P79, DOI 10.1016/S0014-5793(97)00013-6; SAWYER ST, 1993, P NATL ACAD SCI USA, V90, P6849, DOI 10.1073/pnas.90.14.6849; SCHWARTZ AL, 1995, PEDIATR RES, V38, P835, DOI 10.1203/00006450-199512000-00003; Shioda S, 1998, NEUROSCI LETT, V243, P41, DOI 10.1016/S0304-3940(98)00082-2; Takahashi Y, 1996, BIOCHEM BIOPH RES CO, V228, P859, DOI 10.1006/bbrc.1996.1744; Takaya K, 1996, NAT GENET, V14, P130, DOI 10.1038/ng1096-130; Tartaglia LA, 1997, J BIOL CHEM, V272, P6093, DOI 10.1074/jbc.272.10.6093; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; White David W., 1996, Cytokine and Growth Factor Reviews, V7, P303, DOI 10.1016/S1359-6101(96)00040-8; WuPeng XS, 1997, DIABETES, V46, P513, DOI 10.2337/diabetes.46.3.513; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	54	115	121	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21416	21424		10.1074/jbc.274.30.21416	http://dx.doi.org/10.1074/jbc.274.30.21416			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409704	hybrid			2022-12-25	WOS:000081613100095
J	Bochkareva, E; Safro, M; Girshovich, A				Bochkareva, E; Safro, M; Girshovich, A			Interaction of 4,4 '-dithiodipyridine with Cys(458) triggers disassembly of GroEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL CHAPERONIN GROEL; CRYSTAL-STRUCTURE; CPN60; ATP	Chaperonin GroEL, consisting of two seven-subunit rings stacked back-to-back, is disassembled by interaction of 4,4'-dithiodipyridine (DTP) with Cys(458) located close to the intersubunit contacts within and between the rings. The thiol group of Cys(458) is inaccessible to the probe being buried into the pocket locked by segment Asn(475)-Asn(487). Flexibility of this segment is proposed to induce the "open" state of the pocket and accommodate the bulky probe inside so that the consequential irreversible shifts in the pocket constituents disassemble GroEL. This scheme is supported by the finding that DTP-induced disassembly of GroEL is facilitated by ATP, which specifically stimulates a local shift of the segment Asn(475)-Asn(487) into solution.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Girshovich, A (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.							BOCHKAREVA ES, 1994, J BIOL CHEM, V269, P44; Boisvert DC, 1996, NAT STRUCT BIOL, V3, P170, DOI 10.1038/nsb0296-170; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRAIG K, 1995, NAT STRUCT BIOL, V2, P1083, DOI 10.1038/nsb1295-1083; BROCKLEHURST K, 1982, METHOD ENZYMOL, V87, P427; ELLIS RJ, 1994, CURR OPIN STRUC BIOL, V4, P117, DOI 10.1016/S0959-440X(94)90069-8; Fenton WA, 1997, PROTEIN SCI, V6, P743; HOROVITZ A, 1993, J BIOL CHEM, V268, P9957; HOROVITZ A, 1994, J MOL BIOL, V238, P133, DOI 10.1006/jmbi.1994.1275; LUO GX, 1994, J BIOL CHEM, V269, P32151; MENDOZA JA, 1992, J PROTEIN CHEM, V11, P589, DOI 10.1007/BF01024958; SIGLER PB, 1995, PHILOS T ROY SOC B, V348, P113, DOI 10.1098/rstb.1995.0052; [No title captured]	13	8	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					20756	20758		10.1074/jbc.274.30.20756	http://dx.doi.org/10.1074/jbc.274.30.20756			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409613	hybrid			2022-12-25	WOS:000081613100004
J	de Planque, MRR; Kruijtzer, JAW; Liskamp, RMJ; Marsh, D; Greathouse, DV; Koeppe, RE; de Kruijff, B; Killian, JA				de Planque, MRR; Kruijtzer, JAW; Liskamp, RMJ; Marsh, D; Greathouse, DV; Koeppe, RE; de Kruijff, B; Killian, JA			Different membrane anchoring positions of tryptophan and lysine in synthetic transmembrane alpha-helical peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; NUCLEAR-MAGNETIC-RESONANCE; HYDROPHOBIC MISMATCH; CIRCULAR-DICHROISM; BILAYER THICKNESS; LABELED PHOSPHOLIPIDS; GRAMICIDIN CHANNEL; MODEL MEMBRANES; PROTEINS; SPECTROSCOPY	Specific interactions of membrane proteins with the membrane interfacial region potentially define protein position with respect to the lipid environment. We investigated the proposed roles of tryptophan and lysine side chains as "anchoring" residues of transmembrane proteins. Model systems were employed, consisting of phosphatidylcholine lipids and hydrophobic alpha-helical peptides, flanked either by tryptophans or lysines, Peptides were incorporated in bilayers of different thickness, and effects on lipid structure were analyzed. Induction of nonbilayer phases and also increases in bilayer thickness were observed that could be explained by a tendency of Trp as well as Lys residues to maintain interactions with the interfacial region, However, effects of the two peptides were remarkably different, indicating affinities of Trp and Lys for different sites at the interface, Our data support a model in which the Trp side chain has a specific affinity for a well defined site near the lipid carbonyl region, while the lysine side chain prefers to be located closer to the aqueous phase, near the lipid phosphate group. The information obtained in this study may further our understanding of the architecture of transmembrane proteins and may prove useful for refining prediction methods for transmembrane segments.	Univ Utrecht, Inst Biomembranes, Ctr Biomembranes & Lipid Enzymol, Dept Biochem Membranes, NL-3584 CH Utrecht, Netherlands; Univ Utrecht, Dept Med Chem, NL-3584 CA Utrecht, Netherlands; Max Planck Inst Biophys Chem, Abt Spektroskopie, D-37077 Gottingen, Germany; Univ Arkansas, Dept Chem & Biochem, Fayetteville, AR 72701 USA	Utrecht University; Utrecht University; Max Planck Society; University of Arkansas System; University of Arkansas Fayetteville	de Planque, MRR (corresponding author), Univ Utrecht, Inst Biomembranes, Ctr Biomembranes & Lipid Enzymol, Dept Biochem Membranes, Padualaan 8, NL-3584 CH Utrecht, Netherlands.	m.r.r.deplanque@chem.uu.nl	Killian, J. Antoinette/I-3001-2016; Liskamp, Rob M/I-5889-2012	Liskamp, Rob M/0000-0001-8897-8975; Killian, J. Antoinette/0000-0001-8010-3816; Koeppe, Roger/0000-0003-0676-6413; de Planque, Maurits/0000-0002-8787-0513	NIGMS NIH HHS [GM 34968] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034968] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		*APPL BIOS, 1993, APPL BIOS RES NEWS, P1; *APPL BIOS, 1993, APPL BIOS MOD 433A P; Asuncion-Punzalan E, 1998, BIOCHEMISTRY-US, V37, P4603, DOI 10.1021/bi9726234; CHAKRABARTTY A, 1993, BIOCHEMISTRY-US, V32, P5560, DOI 10.1021/bi00072a010; CULLIS PR, 1979, BIOCHIM BIOPHYS ACTA, V559, P399, DOI 10.1016/0304-4157(79)90012-1; DAVIS JH, 1976, CHEM PHYS LETT, V42, P390, DOI 10.1016/0009-2614(76)80392-2; de Planque MRR, 1998, BIOCHEMISTRY-US, V37, P9333, DOI 10.1021/bi980233r; DEJONGH HHJ, 1994, BIOCHEMISTRY-US, V33, P14521, DOI 10.1021/bi00252a019; Dieudonne D, 1998, J AM CHEM SOC, V120, P792, DOI 10.1021/ja9724046; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Gil T, 1998, BBA-REV BIOMEMBRANES, V1376, P245, DOI 10.1016/S0304-4157(98)00022-7; Goforth RL, 1999, BIOPHYS J, V76, pA217; Greathouse D V, 1999, Methods Enzymol, V294, P525; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HU W, 1993, BIOCHEMISTRY-US, V32, P7035, DOI 10.1021/bi00078a032; HUBBELL WL, 1971, J AM CHEM SOC, V93, P314; HUSCHILT JC, 1985, BIOCHEMISTRY-US, V24, P1377, DOI 10.1021/bi00327a015; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; KACHEL K, 1995, BIOCHEMISTRY-US, V34, P15475, DOI 10.1021/bi00047a012; Killian JA, 1996, BIOCHEMISTRY-US, V35, P1037, DOI 10.1021/bi9519258; Killian JA, 1998, BBA-REV BIOMEMBRANES, V1376, P401, DOI 10.1016/S0304-4157(98)00017-3; KOEPPE RE, 1994, BIOPHYS J, V66, P14, DOI 10.1016/S0006-3495(94)80748-9; LANDOLTMARTICORENA C, 1993, J MOL BIOL, V229, P602, DOI 10.1006/jmbi.1993.1066; LEWIS BA, 1983, J MOL BIOL, V166, P211, DOI 10.1016/S0022-2836(83)80007-2; Marsh D, 1998, BBA-REV BIOMEMBRANES, V1376, P267, DOI 10.1016/S0304-4157(98)00009-4; Marsh D, 1997, EUR BIOPHYS J BIOPHY, V26, P203, DOI 10.1007/s002490050072; Marsh D., 1993, PROTEIN LIPID INTERA, P41; MARSH D, 1985, PROGR PROTEIN LIPID, V1, P143; Mishra VK, 1996, BIOCHEMISTRY-US, V35, P11210, DOI 10.1021/bi960760f; MISHRA VK, 1994, J BIOL CHEM, V269, P7185; Morein S, 1997, BIOPHYS J, V73, P3078, DOI 10.1016/S0006-3495(97)78335-8; NEZIL FA, 1992, BIOPHYS J, V61, P1176, DOI 10.1016/S0006-3495(92)81926-4; Ostermeier C, 1996, CURR OPIN STRUC BIOL, V6, P460, DOI 10.1016/S0959-440X(96)80110-2; REITHMEIER RAF, 1995, CURR OPIN STRUC BIOL, V5, P491, DOI 10.1016/0959-440X(95)80034-4; Ren JH, 1997, BIOCHEMISTRY-US, V36, P10213, DOI 10.1021/bi9709295; ROUX M, 1989, BIOCHEMISTRY-US, V28, P2313, DOI 10.1021/bi00431a050; SEELIG J, 1978, BIOCHIM BIOPHYS ACTA, V515, P105, DOI 10.1016/0304-4157(78)90001-1; Subczynski WK, 1998, BIOCHEMISTRY-US, V37, P3156, DOI 10.1021/bi972148+; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; VONHEIJNE G, 1994, ANNU REV BIOPH BIOM, V23, P167; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; Wallin E, 1997, PROTEIN SCI, V6, P808; Webb RJ, 1998, BIOCHEMISTRY-US, V37, P673, DOI 10.1021/bi972441+; White SH, 1998, BBA-REV BIOMEMBRANES, V1376, P339, DOI 10.1016/S0304-4157(98)00021-5; White SH., 1994, MEMBRANE PROTEIN STR, P97, DOI [10.1007/978-1-4614-7515-6_4, DOI 10.1007/978-1-4614-7515-6_4]; WIENER MC, 1992, BIOPHYS J, V61, P434, DOI 10.1016/S0006-3495(92)81849-0; Wimley WC, 1996, NAT STRUCT BIOL, V3, P842, DOI 10.1038/nsb1096-842; Yau WM, 1998, BIOCHEMISTRY-US, V37, P14713, DOI 10.1021/bi980809c; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	50	298	300	2	671	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					20839	20846		10.1074/jbc.274.30.20839	http://dx.doi.org/10.1074/jbc.274.30.20839			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409625	hybrid			2022-12-25	WOS:000081613100016
J	Jadot, M; Lin, L; Sleat, DE; Sohar, I; Hsu, MS; Pintar, J; Dubois, F; Wattiaux-De Coninck, S; Wattiaux, R; Lobel, P				Jadot, M; Lin, L; Sleat, DE; Sohar, I; Hsu, MS; Pintar, J; Dubois, F; Wattiaux-De Coninck, S; Wattiaux, R; Lobel, P			Subcellular localization of mannose 6-phosphate glycoproteins in rat brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-II RECEPTOR; LYSOSOMAL-ENZYMES; ACID-PHOSPHATASE; TURNOVER; DEPHOSPHORYLATION; LIVER; IDENTIFICATION; MOUSE; COMPARTMENTS; MICROSOMES	The intracellular transport of soluble lysosomal enzymes relies on the post-translational modification of N-linked oligosaccharides to generate mannose 6-phosphate (Man 6-P) residues. In most cell types the Man 6-P signal is rapidly removed after targeting of the precursor proteins from the Golgi to lysosomes via interactions with Man 6-phosphate receptors, However, in brain, the steady state proportion of lysosomal enzymes containing Man 6-P is considerably higher than in other tissues. As a first step toward understanding the mechanism and biological significance of this observation, we analyzed the subcellular localization of the rat brain Man 6-P glycoproteins by combining biochemical and morphological approaches, The brain Man 6-P glycoproteins are predominantly localized in neuronal lysosomes with no evidence for a steady state localization in nonlysosomal or prelysosomal compartments. This contrasts with the clear endosome-like localization of the low steady state proportion of mannose-6-phosphorylated lysosomal enzymes. in liver. It therefore seems Likely that the observed high percentage of phosphorylated species in brain is a consequence of the accumulation of lysosomal enzymes in a neuronal lysosome that does not fully dephosphorylate the Man 6-P moieties.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Fac Univ Notre Dame Paix, Physiol Chem Lab, B-5000 Namur, Belgium; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Neurosci & Cell Biol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Namur; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Jadot, M (corresponding author), Fac Univ Notre Dame Paix, Physiol Chem Lab, B-5000 Namur, Belgium.	michel.jadot@fundp.ac.be			NIDDK NIH HHS [DK45992] Funding Source: Medline; NINDS NIH HHS [NS37918, NS21970] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045992] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037918, R01NS021970] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMARCOSTESEC A, 1974, J CELL BIOL, V61, P201, DOI 10.1083/jcb.61.1.201; BEAUFAY H, 1964, BIOCHEM J, V92, P184, DOI 10.1042/bj0920184; BRAUKER JH, 1986, EXP CELL RES, V164, P115, DOI 10.1016/0014-4827(86)90459-3; BRESCIANI R, 1992, EUR J CELL BIOL, V58, P57; Bresciani R, 1996, EUR J BIOCHEM, V238, P669, DOI 10.1111/j.1432-1033.1996.0669w.x; CHEN HJ, 1993, J BIOL CHEM, V268, P22338; DUVE CD, 1955, BIOCHEM J, V60, P604, DOI 10.1042/bj0600604; EINSTEIN R, 1989, J CELL BIOL, V109, P1037, DOI 10.1083/jcb.109.3.1037; EINSTEIN R, 1991, J CELL BIOL, V112, P81, DOI 10.1083/jcb.112.1.81; FIORILLI A, 1991, FEBS LETT, V282, P235, DOI 10.1016/0014-5793(91)80485-L; GABEL CA, 1982, J CELL BIOL, V95, P536, DOI 10.1083/jcb.95.2.536; GABEL CA, 1983, P NATL ACAD SCI-BIOL, V80, P775, DOI 10.1073/pnas.80.3.775; GABEL CA, 1993, MECH INTRACELLULAR T, P103; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; JADOT M, 1989, BIOCHEM J, V262, P981, DOI 10.1042/bj2620981; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KORNFELD S, 1986, J CLIN INVEST, V77, P1, DOI 10.1172/JCI112262; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LIMET JN, 1985, EUR J BIOCHEM, V146, P539, DOI 10.1111/j.1432-1033.1985.tb08685.x; OBRIEN DA, 1994, MOL BIOL CELL, V5, P221; PETANCESKA S, 1994, NEUROSCIENCE, V59, P729, DOI 10.1016/0306-4522(94)90190-2; ROFF CF, 1983, EXP CELL RES, V144, P333, DOI 10.1016/0014-4827(83)90412-3; SELLINGER OTTO Z., 1968, BRAIN RES, V7, P191, DOI 10.1016/0006-8993(68)90097-8; SKUDLAREK MD, 1981, J BIOL CHEM, V256, P137; Sleat DE, 1996, J BIOL CHEM, V271, P19191, DOI 10.1074/jbc.271.32.19191; SLEAT DE, 1995, CANCER RES, V55, P3424; SMITH K, 1978, J BIOL CHEM, V253, P5437; Sohar I, 1998, BIOCHEM J, V330, P903, DOI 10.1042/bj3300903; VALENZANO KJ, 1993, ANAL BIOCHEM, V209, P156, DOI 10.1006/abio.1993.1096; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WARBURTON MJ, 1976, BIOCHEM J, V158, P401, DOI 10.1042/bj1580401; WATTIAUX R, 1986, BIOCHEM BIOPH RES CO, V136, P504, DOI 10.1016/0006-291X(86)90469-9; WATTIAUX R, 1983, IODINATED DENSITY GR, P119	33	25	25	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21104	21113		10.1074/jbc.274.30.21104	http://dx.doi.org/10.1074/jbc.274.30.21104			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409663	hybrid			2022-12-25	WOS:000081613100054
J	Selmer, T; Buckel, W				Selmer, T; Buckel, W			Oxygen exchange between acetate and the catalytic glutamate residue in glutaconate CoA-transferase from Acidaminococcus fermentans - Implications for the mechanism of CoA-ester hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A-TRANSFERASE; ANAEROBIC-BACTERIA; SITE	The exchange of oxygen atoms between acetate, glutaryl-CoA, and the catalytic glutamate residue in glutaconate CoA-transferase from Acidaminococcus fermentans was analyzed using [O-18(2)]acetate together with matrix-assisted laser desorption/ionization time of flight mass spectrometry of an appropriate undecapeptide, The exchange reaction was shown to be site-specific, reversible, and required both glutaryl-CoA and [O-18(2)]acetate. The observed exchange is in agreement with the formation of a mixed anhydride intermediate between the enzyme and acetate, In contrast, with a mutant enzyme, which was converted to a thiol ester hydrolyase by replacement of the catalytic glutamate residue by aspartate, no O-18 uptake from H-2 O-18 into the carboxylate was detectable. This result is in accord with a mechanism in which the carboxylate of aspartate acts as a general base in activating a water molecule for hydrolysis of the thiol ester intermediate, This mechanism is further supported by the finding of a significant hydrolyase activity of the wild-type enzyme using acetyl-CoA as substrate, whereas glutaryl-CoA is not hydrolyzed, The small acetate molecule in the substrate binding pocket may activate a water molecule for hydrolysis of the nearby enzyme-CoA thiol ester.	Univ Marburg, Fachbereich Biol, Mikrobiol Lab, D-35032 Marburg, Germany	Philipps University Marburg	Selmer, T (corresponding author), Univ Marburg, Fachbereich Biol, Mikrobiol Lab, D-35032 Marburg, Germany.							BERGMEYER HU, 1974, METHOD ENZYMAT AN, V3, P1520; BUCKEL W, 1981, EUR J BIOCHEM, V118, P315, DOI 10.1111/j.1432-1033.1981.tb06404.x; BUCKEL W, 1974, J BACTERIOL, V117, P1248, DOI 10.1128/JB.117.3.1248-1260.1974; BUCKEL W, 1992, FEMS MICROBIOL LETT, V88, P211, DOI 10.1016/0378-1097(92)90804-W; BUCKEL W, 1986, EUR J BIOCHEM, V156, P256; Jencks W. P., 1973, ENZYMES, V9, P483; JOCOB U, 1997, STRUCTURE, V5, P415; Labahn J, 1996, CELL, V86, P321, DOI 10.1016/S0092-8674(00)80103-8; MACK M, 1995, FEBS LETT, V357, P145, DOI 10.1016/0014-5793(94)01351-Z; Mack M, 1997, FEBS LETT, V405, P209, DOI 10.1016/S0014-5793(97)00187-7; MACK M, 1994, EUR J BIOCHEM, V226, P41, DOI 10.1111/j.1432-1033.1994.tb20024.x; SCHMIDT B, 1995, CELL, V82, P271, DOI 10.1016/0092-8674(95)90314-3; SCHWEIGER G, 1987, EUR J BIOCHEM, V169, P441, DOI 10.1111/j.1432-1033.1987.tb13631.x; SIMON EJ, 1953, J AM CHEM SOC, V75, P2520, DOI 10.1021/ja01106a522; WHITE H, 1976, J BIOL CHEM, V251, P1688	15	38	39	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					20772	20778		10.1074/jbc.274.30.20772	http://dx.doi.org/10.1074/jbc.274.30.20772			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409616	hybrid			2022-12-25	WOS:000081613100007
J	Sorensen, BB; Freskgard, PO; Nielsen, LS; Rao, LVM; Ezban, M; Petersen, LC				Sorensen, BB; Freskgard, PO; Nielsen, LS; Rao, LVM; Ezban, M; Petersen, LC			Factor VIIa-induced p44/42 mitogen-activated protein kinase activation requires the proteolytic activity of factor VIIa and is independent of the tissue factor cytoplasmic domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANINE KIDNEY-CELLS; THROMBIN RECEPTOR; MOLECULAR-CLONING; FACTOR PATHWAY; CATHEPSIN-G; COAGULATION; EXPRESSION; BINDING; CA2+; INHIBITOR	Signal transduction induced by activated factor VII (FVIIa) was studied with baby hamster kidney (BHK) cells transfected with human tissue factor (TF), FVIIa induced phosphorylation of p44/42 mitogen-activated protein kinase (MAPK) in cells expressing TF, BHK(+TF), but not in wild-type BHK(-TF) cells. BHK(+TF) cells responded to FVIIa in a dose-dependent manner, with detectable phosphorylation above 10-20 nM FVIIa. BHK cells transfected with a cytoplasmic domain-deleted version of TF, (des248-263)TF, or a C245S substitution variant of TF also supported FVIIa-induced MAPK activation. Experiments with active site-inhibited FVIIa, thrombin, factor Xa, and hirudin confirmed that the catalytic activity of FVIIa was mandatory for p44/42 MAPK activation. Furthermore, a high concentration of FVIIa in complex with soluble TF induced p44/42 MAPK phosphorylation in BHK(-TF) cells. These data suggest that TF was not directly involved in FVIIa-induced p44/42 MAPK phosphorylation but rather served to localize the action of FVIIa to the cell surface, potentially to cleave a cell surface receptor. Desensitization experiments with sequential addition of proteases suggested that the p44/42 MAPK response induced by FVIIa was distinctly different from the thrombin response, possibly involving a novel member of the protease-activated receptor family.	Novo Nordisk AS, Hlth Care Discovery, Tissue Factor Factor VII Res, DK-2760 Malov, Denmark; Univ Texas, Ctr Hlth, Dept Biochem, Tyler, TX 75710 USA	Novo Nordisk; University of Texas System; University of Texas at Tyler; University of Texas-Health Sciences Center at Tyler (UTHSCT)	Petersen, LC (corresponding author), Novo Nordisk AS, Hlth Care Discovery, Tissue Factor Factor VII Res, Novo Nordisk Pk, DK-2760 Malov, Denmark.		Freskgård, Per-Ola/AAY-4194-2021					BACH R, 1988, BIOCHEMISTRY-US, V27, P4227, DOI 10.1021/bi00412a004; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Belham CL, 1996, BIOCHEM J, V320, P939, DOI 10.1042/bj3200939; BROMBERG ME, 1995, P NATL ACAD SCI USA, V92, P8205, DOI 10.1073/pnas.92.18.8205; BUSBY SJ, 1991, J BIOL CHEM, V266, P15286; Camerer E, 1996, THROMB RES, V81, P1, DOI 10.1016/0049-3848(95)00209-X; Camerer E, 1996, J BIOL CHEM, V271, P29034, DOI 10.1074/jbc.271.46.29034; Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0; Freskgard PO, 1996, PROTEIN SCI, V5, P1531, DOI 10.1002/pro.5560050809; GORMAN CM, 1985, DNA CLONING PRACTICA, V1, P142; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; Masuda M, 1996, EUR J IMMUNOL, V26, P2529, DOI 10.1002/eji.1830261037; Mody RS, 1997, BIOCHEMISTRY-US, V36, P7869, DOI 10.1021/bi9701235; MOLINO M, 1995, J BIOL CHEM, V270, P11168, DOI 10.1074/jbc.270.19.11168; Mueller BM, 1998, J CLIN INVEST, V101, P1372, DOI 10.1172/JCI930; MUELLER BM, 1992, P NATL ACAD SCI USA, V89, P11832, DOI 10.1073/pnas.89.24.11832; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; Ott I, 1998, J CELL BIOL, V140, P1241, DOI 10.1083/jcb.140.5.1241; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Parry GCN, 1998, CIRCULATION, V98, P40; Pendurthi UR, 1997, P NATL ACAD SCI USA, V94, P12598, DOI 10.1073/pnas.94.23.12598; PETERSEN LC, 1995, THROMB RES, V79, P1, DOI 10.1016/0049-3848(95)00069-4; Poulsen LK, 1998, J BIOL CHEM, V273, P6228, DOI 10.1074/jbc.273.11.6228; RAPAPORT SI, 1995, THROMB HAEMOSTASIS, V74, P7; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; Renesto P, 1997, BLOOD, V89, P1944, DOI 10.1182/blood.V89.6.1944; ROTTINGEN JA, 1995, J BIOL CHEM, V270, P4650, DOI 10.1074/jbc.270.9.4650; Semeraro N, 1997, THROMB HAEMOSTASIS, V78, P759; Shoji M, 1998, AM J PATHOL, V152, P399; Sorensen BB, 1997, J BIOL CHEM, V272, P11863, DOI 10.1074/jbc.272.18.11863; Taniguchi T, 1998, CANCER RES, V58, P4461; Taubman MB, 1997, THROMB HAEMOSTASIS, V78, P200; THIM L, 1988, BIOCHEMISTRY-US, V27, P7785, DOI 10.1021/bi00420a030; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642; ZINOCHECK TF, 1992, J BIOL CHEM, V267, P3561	37	103	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21349	21354		10.1074/jbc.274.30.21349	http://dx.doi.org/10.1074/jbc.274.30.21349			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409695	hybrid			2022-12-25	WOS:000081613100086
J	Fjeld, CC; Denu, JM				Fjeld, CC; Denu, JM			Kinetic analysis of human serine threonine protein phosphatase 2C alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FISSION YEAST; TYROSINE-PHOSPHATASE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; STRESS-RESPONSE; KINASE CASCADES; 2C; MITOGEN; PATHWAYS; P38	The PPM family of Ser/Thr protein phosphatases have recently been shown to down-regulate the stress response pathways in eukaryotes. Within the stress pathway, key signaling kinases, which are activated by protein phosphorylation, have been proposed as the in vivo substrates of PP2C, the prototypical member of the PPM family. Although it is known that these phosphatases require metal cations for activity, the molecular details of these important reactions have not been established. Therefore, here we report a detailed biochemical study to elucidate the kinetic and chemical mechanism of PP2C alpha. Steady-state kinetic and product inhibition studies revealed that PP2C alpha employs an ordered sequential mechanism, where the metal cations bind before phosphorylated substrate, and phosphate is the last product to be released. The metal-dependent activity of PP2C (as reflected in k(cat) and k(cat)/K-m), indicated that Fe2+ was 1000-fold better than Mg2+. The pH rate profiles revealed two ionizations critical for catalytic activity. An enzyme ionization with a pK(a) value of 7 must be unprotonated for catalysis, and an enzyme ionization with a pK(a) of 9 must be protonated for substrate binding. Bronsted analysis of substrate leaving group pK(a), indicated that phosphomonoester hydrolysis is rate-limiting at pH 7.0, but not at pH 8.5 where a common step independent of the nature of the substrate and alcohol product limits turnover (k(cat)). Rapid reaction kinetics between phosphomonoester and PP2C yielded exponential "bursts" of product formation, consistent with phosphate release being the slow catalytic step at pH 8.5. Dephosphorylation of synthetic phosphopeptides corresponding to several protein kinases revealed that PP2C displays a strong preference for diphosphorylated peptides in which the phosphorylated residues are in close proximity.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol L224, Portland, OR 97201 USA	Oregon Health & Science University	Denu, JM (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol L224, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	denuj@ohsu.edu						Barford D, 1996, TRENDS BIOCHEM SCI, V21, P407, DOI 10.1016/S0968-0004(96)10060-8; BROTHERUS JR, 1983, BIOCHIM BIOPHYS ACTA, V731, P290, DOI 10.1016/0005-2736(83)90021-4; Chen GJ, 1997, BIOCHEMISTRY-US, V36, P4278, DOI 10.1021/bi9618676; Das AK, 1996, EMBO J, V15, P6798, DOI 10.1002/j.1460-2075.1996.tb01071.x; Davies SP, 1995, FEBS LETT, V377, P421, DOI 10.1016/0014-5793(95)01368-7; DENU JM, 1995, J BIOL CHEM, V270, P3796, DOI 10.1074/jbc.270.8.3796; Denu JM, 1996, P NATL ACAD SCI USA, V93, P2493, DOI 10.1073/pnas.93.6.2493; Gaits F, 1997, J BIOL CHEM, V272, P17873, DOI 10.1074/jbc.272.28.17873; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Hanada M, 1998, FEBS LETT, V437, P172, DOI 10.1016/S0014-5793(98)01229-0; INGEBRITSEN TS, 1983, SCIENCE, V221, P331, DOI 10.1126/science.6306765; KING MM, 1984, J BIOL CHEM, V259, P8847; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; KYTE J, 1995, MECHANISM PROTEIN CH; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; Merkx M, 1998, BIOCHEMISTRY-US, V37, P11223, DOI 10.1021/bi980389r; Meskiene I, 1998, P NATL ACAD SCI USA, V95, P1938, DOI 10.1073/pnas.95.4.1938; PATO MD, 1991, MOL CELL BIOCHEM, V101, P31; PETERSSON L, 1980, J BIOL CHEM, V255, P6706; Pohjanjoki P, 1998, BIOCHEMISTRY-US, V37, P1754, DOI 10.1021/bi971771r; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; SHIOZAKI K, 1995, EMBO J, V14, P492, DOI 10.1002/j.1460-2075.1995.tb07025.x; Takekawa M, 1998, EMBO J, V17, P4744, DOI 10.1093/emboj/17.16.4744; Todd JL, 1999, J BIOL CHEM, V274, P13271, DOI 10.1074/jbc.274.19.13271; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; Wilson KP, 1996, J BIOL CHEM, V271, P27696, DOI 10.1074/jbc.271.44.27696; Yu L, 1997, BIOCHEMISTRY-US, V36, P10727, DOI 10.1021/bi970519g	27	64	67	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20336	20343		10.1074/jbc.274.29.20336	http://dx.doi.org/10.1074/jbc.274.29.20336			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400656	hybrid			2022-12-25	WOS:000081438300049
J	Li, NY; Erman, M; Pangborn, W; Duax, WL; Park, CM; Bruenn, J; Ghosh, D				Li, NY; Erman, M; Pangborn, W; Duax, WL; Park, CM; Bruenn, J; Ghosh, D			Structure of Ustilago maydis killer toxin KP6 alpha-subunit - A multimeric assembly with a central pore	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS-ENCODED TOXIN; CRYSTAL-STRUCTURE; 2 POLYPEPTIDES; CARDIOTOXIN; EXPRESSION; ANGSTROM; FUNGAL; GAMMA; VENOM; MODEL	Ustilago maydis is a fungal pathogen of maize, some strains of which secrete killer toxins. The toxins are encoded by double-stranded RNA viruses in the cell cytoplasm, The U. maydis killer toxin KP6 contains two polypeptide chains, alpha and beta, having 79 and 81 amino acids, respectively, both of which are necessary for its killer activity, The crystal structure of the alpha-subunit of KP6 (KP6 alpha) has been determined at 1.80-Angstrom resolution. KP6 alpha forms a single domain structure that has an overall shape of an ellipsoid with dimensions 40 Angstrom x 26 Angstrom x 21 Angstrom and belongs to the alpha/beta-sandwich family. The tertiary structure consists of a four-stranded antiparallel beta-sheet, a pair of antiparallel alpha-helices, a short strand along one edge of the sheet, and a short N-terminal helix. Although the fold is reminiscent of toxins of similar size, the topology of KP6 alpha is distinctly different in that the alpha/beta-sandwich motif has two right-handed beta alpha beta Split crossovers. Monomers of KP6 alpha assemble through crystallographic symmetries, forming a hexamer with a central pore lined by hydrophobic N-terminal helices, The central pore could play an important role in the mechanism of the killing action of the toxin.	Hauptman Woodward Med Res Inst Inc, Buffalo, NY 14203 USA; SUNY Buffalo, Dept Biol Sci, Buffalo, NY 14260 USA; Roswell Pk Canc Inst, Buffalo, NY 14263 USA	Hauptman Woodward Medical Research Institute; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Roswell Park Cancer Institute	Ghosh, D (corresponding author), Hauptman Woodward Med Res Inst Inc, 73 High St, Buffalo, NY 14203 USA.		Park, Chung-Mo/B-6175-2012	Bruenn, Jeremy/0000-0003-1480-7705				Antuch W, 1996, NAT STRUCT BIOL, V3, P662, DOI 10.1038/nsb0896-662; BHASKARAN R, 1994, J MOL BIOL, V235, P1291, DOI 10.1006/jmbi.1994.1082; BILWES A, 1994, J MOL BIOL, V239, P122, DOI 10.1006/jmbi.1994.1357; BRUNGER AT, 1992, X PLOR VERSION 3 1 U; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GU F, 1995, STRUCTURE, V3, P805, DOI 10.1016/S0969-2126(01)00215-5; HAMPEL A, 1968, SCIENCE, V162, P1384, DOI 10.1126/science.162.3860.1384; HANKIN L, 1971, PHYTOPATHOLOGY, V61, P50, DOI 10.1094/Phyto-61-50; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; Kashiwagi T, 1997, STRUCTURE, V5, P81, DOI 10.1016/S0969-2126(97)00168-8; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LI JD, 1991, NATURE, V353, P815, DOI 10.1038/353815a0; LUZZATI V, 1952, ACTA CRYSTALLOGR D, V26, P283; MILLER R, 1994, J APPL CRYSTALLOGR, V27, P613, DOI 10.1107/S0021889894000191; Minor W., 1993, XDISPLAYF PROGRAM; NAJMUDIN S, 1993, ACTA CRYSTALLOGR D, V49, P223, DOI 10.1107/S0907444992007601; ORENGO CA, 1993, STRUCTURE, V1, P105, DOI 10.1016/0969-2126(93)90026-D; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park CM, 1996, MOL MICROBIOL, V20, P957, DOI 10.1111/j.1365-2958.1996.tb02537.x; PARK CM, 1994, MOL MICROBIOL, V11, P155, DOI 10.1111/j.1365-2958.1994.tb00297.x; PARKER MW, 1989, NATURE, V337, P93, DOI 10.1038/337093a0; PEERY T, 1987, MOL CELL BIOL, V7, P470, DOI 10.1128/MCB.7.1.470; Petosa C, 1997, NATURE, V385, P833, DOI 10.1038/385833a0; PUHALLA JE, 1968, GENETICS, V60, P461; RAGHUNATHAN G, 1990, PROTEINS, V8, P213, DOI 10.1002/prot.340080304; REES B, 1987, P NATL ACAD SCI USA, V84, P3132, DOI 10.1073/pnas.84.10.3132; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; STEINLAUF R, 1988, EXP MYCOL, V12, P264, DOI 10.1016/0147-5975(88)90041-2; TAO J, 1993, MOL GEN GENET, V238, P234, DOI 10.1007/BF00279552; TAO JS, 1990, MOL CELL BIOL, V10, P1373, DOI 10.1128/MCB.10.4.1373; TERWILLINGER TC, 1995, HEAVYV4 PROGRAM	34	17	19	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20425	20431		10.1074/jbc.274.29.20425	http://dx.doi.org/10.1074/jbc.274.29.20425			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400668	hybrid			2022-12-25	WOS:000081438300061
J	Misselwitz, E; Staeck, O; Matlack, KES; Rapoport, TA				Misselwitz, E; Staeck, O; Matlack, KES; Rapoport, TA			Interaction of BiP with the J-domain of the Sec63p component of the endoplasmic reticulum protein translocation complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI DNAJ; BINDING-SPECIFICITY; CHAPERONE MACHINES; SECRETORY PROTEINS; SUBSTRATE-BINDING; PEPTIDE-BINDING; ATPASE ACTIVITY; YEAST; HSP70; IMPORT	Proteins of the Hsp70 family of ATPases interact with a conserved domain of their J-protein partners, the J-domain, to function in numerous cellular processes. We have studied the interaction of BiP, an Hsp70 family member in the lumen of the endoplasmic reticulum, with the J-domain of Sec63p, a component of the Sec complex involved in post-translational protein translocation across the endoplasmic reticulum membrane. In a real-time solid phase binding assay, BiP binds to the immobilized Sec complex or to a fusion protein of the J-domain and glutathione S-transferase in a reaction that requires ATP hydrolysis. In the final complex, BiP is bound in the ADP form with its peptide binding pocket occupied. An intact peptide binding pocket is required for this interaction. Our experiments suggest that the activation of BiP by the J-domain involves a transient contact between these components, and that in the absence of physiological substrates, J-activated BiP binds even to the J-proteins themselves.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School	Rapoport, TA (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, 240 Longwood Ave, Boston, MA 02115 USA.	tom_rapoport@hms.harvard.edu	Misselwitz, Benjamin/L-7193-2016	Misselwitz, Benjamin/0000-0002-8719-5175	NIGMS NIH HHS [GM54238-02] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054238] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Burkholder WF, 1996, P NATL ACAD SCI USA, V93, P10632, DOI 10.1073/pnas.93.20.10632; Corsi AK, 1997, J CELL BIOL, V137, P1483, DOI 10.1083/jcb.137.7.1483; Corsi AK, 1996, J BIOL CHEM, V271, P30299, DOI 10.1074/jbc.271.48.30299; CYR DM, 1992, J BIOL CHEM, V267, P20927; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Fagerstam L G, 1990, J Mol Recognit, V3, P208, DOI 10.1002/jmr.300030507; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; Gassler CS, 1998, P NATL ACAD SCI USA, V95, P15229, DOI 10.1073/pnas.95.26.15229; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GLICK BS, 1995, CELL, V80, P11, DOI 10.1016/0092-8674(95)90444-1; Greene MK, 1998, P NATL ACAD SCI USA, V95, P6108, DOI 10.1073/pnas.95.11.6108; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Holstein SEH, 1996, J CELL BIOL, V135, P925, DOI 10.1083/jcb.135.4.925; Horst M, 1997, BBA-BIOENERGETICS, V1318, P71, DOI 10.1016/S0005-2728(96)00131-4; Karzai AW, 1996, J BIOL CHEM, V271, P11236, DOI 10.1074/jbc.271.19.11236; Kelley WL, 1998, TRENDS BIOCHEM SCI, V23, P222, DOI 10.1016/S0968-0004(98)01215-8; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1995, P NATL ACAD SCI USA, V92, P6224, DOI 10.1073/pnas.92.14.6224; Matlack KES, 1998, CELL, V92, P381, DOI 10.1016/S0092-8674(00)80930-7; Matlack KES, 1997, SCIENCE, V277, P938, DOI 10.1126/science.277.5328.938; Misselwitz B, 1998, MOL CELL, V2, P593, DOI 10.1016/S1097-2765(00)80158-6; NELSON MK, 1993, GENETICS, V134, P159; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; Pierpaoli EV, 1998, J BIOL CHEM, V273, P6643, DOI 10.1074/jbc.273.12.6643; RASSOW J, 1994, J CELL BIOL, V127, P1547, DOI 10.1083/jcb.127.6.1547; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; Schneider HC, 1996, EMBO J, V15, P5796, DOI 10.1002/j.1460-2075.1996.tb00966.x; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; SCIDMORE MA, 1993, MOL BIOL CELL, V4, P1145, DOI 10.1091/mbc.4.11.1145; Suh WC, 1998, P NATL ACAD SCI USA, V95, P15223, DOI 10.1073/pnas.95.26.15223; UNGEWICKELL E, 1995, NATURE, V378, P632, DOI 10.1038/378632a0; Ungewickell E, 1997, J BIOL CHEM, V272, P19594, DOI 10.1074/jbc.272.31.19594; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WALL D, 1994, J BIOL CHEM, V269, P5446; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19300, DOI 10.1074/jbc.270.33.19300; WEI JY, 1995, J BIOL CHEM, V270, P26677, DOI 10.1074/jbc.270.44.26677; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	49	61	62	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20110	20115		10.1074/jbc.274.29.20110	http://dx.doi.org/10.1074/jbc.274.29.20110			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400622	hybrid			2022-12-25	WOS:000081438300015
J	Tani, K; Mizoguchi, T; Iwamatsu, A; Hatsuzawa, K; Tagaya, M				Tani, K; Mizoguchi, T; Iwamatsu, A; Hatsuzawa, K; Tagaya, M			P125 is a novel mammalian Sec23p-interacting protein with structural similarity to phospholipid-modifying proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; ENDOPLASMIC-RETICULUM; GOLGI-APPARATUS; TRANSPORT VESICLES; CIS-GOLGI; INTERMEDIATE COMPARTMENT; SUBUNIT INTERACTIONS; COATED VESICLES; BETA-COP; COMPLEX	COPII-coated vesicles are involved in protein transport from the endoplasmic reticulum to the Golgis apparatus. COPII consists of three parts: Sar1p and the two protein complexes, Sec23p-Sec24p and Sec13p-Sec31p. Using a glutathione S-transferase fusion protein with mouse Sec23p, we identified a novel mammalian Sec23p-interacting protein, p125, which is clearly distinct from Sec24p. The N-terminal region of p125 is rich in proline residues, and the central and C-terminal regions exhibit significant homology to phospholipid-modifying proteins, especially phosphatidic acid preferring-phospholipase A(1). We transiently expressed p125 and mouse Sec23p in mammalian cells and examined their interaction. The results showed that the N-terminal region of p125 is important for the interaction with Sec23p. We confirmed the interaction between the two proteins by a yeast two-hybrid assay. Overexpression of p125, like that of mammalian Sec23p, caused disorganization of the endoplasmic reticulum-Golgi intermediate compartment and Golgis apparatus, suggesting its role in the early secretory pathway.	Tokyo Univ Pharm & Life Sci, Sch Life Sci, Tokyo 1920392, Japan; Kirin Brewery Co Ltd, Cent Labs Key Technol, Kanagawa 2360004, Japan	Tokyo University of Pharmacy & Life Sciences; Kirin Brewery Company Limited	Tagaya, M (corresponding author), Tokyo Univ Pharm & Life Sci, Sch Life Sci, Tokyo 1920392, Japan.	tagaya@ls.toyaku.ac.jp						ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; Aridor M, 1998, J CELL BIOL, V141, P61, DOI 10.1083/jcb.141.1.61; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BARLOWE C, 1993, NATURE, V365, P347, DOI 10.1038/365347a0; Bi K, 1997, CURR BIOL, V7, P301, DOI 10.1016/S0960-9822(06)00153-9; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Campbell JL, 1997, P NATL ACAD SCI USA, V94, P837, DOI 10.1073/pnas.94.3.837; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; ESPENSHADE P, 1995, J CELL BIOL, V131, P311, DOI 10.1083/jcb.131.2.311; Gimeno RE, 1996, MOL BIOL CELL, V7, P1815, DOI 10.1091/mbc.7.11.1815; HICKE L, 1989, EMBO J, V8, P1677, DOI 10.1002/j.1460-2075.1989.tb03559.x; HIDE WA, 1992, J LIPID RES, V33, P167; Higgs HN, 1998, J BIOL CHEM, V273, P5468, DOI 10.1074/jbc.273.10.5468; HIGGS HN, 1994, P NATL ACAD SCI USA, V91, P9574, DOI 10.1073/pnas.91.20.9574; Iwamatsu A, 1996, J BIOCHEM-TOKYO, V120, P29; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; Kearns BG, 1998, TRENDS CELL BIOL, V8, P276, DOI 10.1016/S0962-8924(98)01281-1; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; KTISTAKIS NT, 1995, P NATL ACAD SCI USA, V92, P4952, DOI 10.1073/pnas.92.11.4952; Kuehn MJ, 1998, NATURE, V391, P187, DOI 10.1038/34438; KUGE O, 1994, J CELL BIOL, V125, P51, DOI 10.1083/jcb.125.1.51; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lahtinen U, 1996, J BIOL CHEM, V271, P4031; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Nomura N, 1994, DNA Res, V1, P223, DOI 10.1093/dnares/1.5.223; OPRINS A, 1993, J CELL BIOL, V121, P49, DOI 10.1083/jcb.121.1.49; ORCI L, 1991, P NATL ACAD SCI USA, V88, P8611, DOI 10.1073/pnas.88.19.8611; Paccaud JP, 1996, MOL BIOL CELL, V7, P1535, DOI 10.1091/mbc.7.10.1535; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Salama NR, 1997, MOL BIOL CELL, V8, P205, DOI 10.1091/mbc.8.2.205; SALAMA NR, 1993, EMBO J, V12, P4073, DOI 10.1002/j.1460-2075.1993.tb06091.x; SARASTE J, 1987, J CELL BIOL, V105, P2021, DOI 10.1083/jcb.105.5.2021; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SHAYWITZ DA, 1995, J CELL BIOL, V128, P769, DOI 10.1083/jcb.128.5.769; Shaywitz DA, 1997, J BIOL CHEM, V272, P25413, DOI 10.1074/jbc.272.41.25413; Siddhanta A, 1998, J BIOL CHEM, V273, P17995, DOI 10.1074/jbc.273.29.17995; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; Tagaya M, 1996, J BIOL CHEM, V271, P466, DOI 10.1074/jbc.271.1.466; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; Tang BL, 1997, MOL CELL BIOL, V17, P256, DOI 10.1128/MCB.17.1.256; Tani K, 1999, FEBS LETT, V447, P247, DOI 10.1016/S0014-5793(99)00303-8; TEAL SB, 1994, J BIOL CHEM, V269, P3135; VIHTELIC TS, 1991, GENETICS, V127, P761; Vollenweider F, 1998, J CELL BIOL, V142, P377, DOI 10.1083/jcb.142.2.377; WADHWA R, 1993, FEBS LETT, V315, P193, DOI 10.1016/0014-5793(93)81161-R; YEUNG T, 1995, METHOD ENZYMOL, V257, P145; YOSHIHISA T, 1993, SCIENCE, V259, P1466, DOI 10.1126/science.8451644	56	83	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20505	20512		10.1074/jbc.274.29.20505	http://dx.doi.org/10.1074/jbc.274.29.20505			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400679	hybrid			2022-12-25	WOS:000081438300072
J	Wu, SJ; Li, J; Tsui, P; Cook, R; Zhang, WT; Hu, Y; Canziani, G; Chaiken, I				Wu, SJ; Li, J; Tsui, P; Cook, R; Zhang, WT; Hu, Y; Canziani, G; Chaiken, I			Randomization of the receptor alpha chain recruitment epitope reveals a functional interleukin-5 with charge depletion in the CD loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOVALENT PHAGE DISPLAY; BINDING-SITES; MUTAGENESIS; PROTEIN; VARIANTS; DOMAIN; IDENTIFICATION; REPERTOIRE; LIBRARIES; SELECTION	We report the functional phage display of single chain human interleukin-5 (scIL-5) and its use for receptor-binding epitope randomization. Enzyme-linked immunosorbent assays and optical biosensor analyses verified expression of scIL-5 on the phage surface and binding of scIL-5 phage to interleukin-5 receptor Lu chain. Furthermore, an asymmetrically disabled but functional scIL-8 mutant, (wt/A5)scIL-5, was displayed on phage, (wt/A5)scIL-5 was constructed from an N-terminal half containing the original five charged residues ((EERRR92)-E-88) in the CD loop, including the Glu(89) and Arg(91) believed key in the alpha chain recognition site, combined with a C-terminal half containing a disabled CD loop sequence ((88)AAAAA(92)) missing the key recognition residues. This asymmetric variant was used as a starting point to generate an scIL-5 library in which the intact 88-92 N-terminal CD loop was randomized. From this epitope library, a receptor-binding variant of IL-5 was detected, (SLRGG/A5)scIL-5, in which the only charged residue in the CD loop is an Arg at position 90, Characterization of this variant expressed as a soluble protein in E. coli shows that the IL-5 pharmacophore for receptor alpha chain binding can function with a single positive charge in the CD loop. Charge-depleted CD loop mimetics of IL-5 suggest the importance of charge distribution in functional IL-5 receptor recruitment.	Univ Penn, Sch Med, Dept Med, Stellar Chance Labs 913,Rheumatol Div, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; SmithKline Beecham Pharmaceut, Dept Mol Immunol, King Of Prussia, PA 19406 USA	University of Pennsylvania; University of Pennsylvania; GlaxoSmithKline	Chaiken, I (corresponding author), Univ Penn, Sch Med, Dept Med, Stellar Chance Labs 913,Rheumatol Div, 422 Curie Blvd, Philadelphia, PA 19104 USA.	chaiken@mail.med.upenn.edu			NIAID NIH HHS [R01 AI/GM 40462-O1] Funding Source: Medline; NIGMS NIH HHS [R01 GM55648-03] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040462] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055648] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES RS, 1995, J IMMUNOL, V154, P6355; Baca M, 1997, J BIOL CHEM, V272, P10678; BAGLEY CJ, 1999, IL 5 MOL DRUG TARGET, P189; BASS S, 1990, PROTEINS, V8, P309, DOI 10.1002/prot.340080405; Buchli PJ, 1997, ARCH BIOCHEM BIOPHYS, V339, P79, DOI 10.1006/abbi.1996.9853; BURTON DR, 1993, IMMUNOMETHODS, V3, P155; Cabibbo A, 1995, GENE, V167, P41, DOI 10.1016/0378-1119(95)00632-X; Chaiken IM, 1999, LUNG BIOL HEALTH DIS, V125, P167; Chong LT, 1998, PROTEIN SCI, V7, P206, DOI 10.1002/pro.5560070122; CLACKSON T, 1994, TRENDS BIOTECHNOL, V12, P173, DOI 10.1016/0167-7799(94)90079-5; Dickason RR, 1996, NATURE, V379, P652, DOI 10.1038/379652a0; Edgerton MD, 1997, J BIOL CHEM, V272, P20611, DOI 10.1074/jbc.272.33.20611; GRABER P, 1995, J BIOL CHEM, V270, P15762, DOI 10.1074/jbc.270.26.15762; Jones JT, 1998, J BIOL CHEM, V273, P11667, DOI 10.1074/jbc.273.19.11667; KAY BK, 1993, GENE, V128, P59, DOI 10.1016/0378-1119(93)90153-T; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li J, 1996, J BIOL CHEM, V271, P1817, DOI 10.1074/jbc.271.4.1817; Li J, 1997, P NATL ACAD SCI USA, V94, P6694, DOI 10.1073/pnas.94.13.6694; Li J, 1996, J BIOL CHEM, V271, P31729, DOI 10.1074/jbc.271.49.31729; LOWMAN HB, 1993, J MOL BIOL, V234, P564, DOI 10.1006/jmbi.1993.1612; LOWMAN HB, 1991, J BIOL CHEM, V266, P10982; Monfardini C, 1998, J BIOL CHEM, V273, P7657, DOI 10.1074/jbc.273.13.7657; MORTON T, 1995, P NATL ACAD SCI USA, V92, P10879, DOI 10.1073/pnas.92.24.10879; Morton Thomas A., 1994, Journal of Molecular Recognition, V7, P47, DOI 10.1002/jmr.300070107; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; MURATA Y, 1992, J EXP MED, V175, P341, DOI 10.1084/jem.175.2.341; PROUDFOOT AEI, 1990, BIOCHEM J, V270, P357, DOI 10.1042/bj2700357; REIDHAAROLSON JF, 1988, SCIENCE, V241, P53, DOI 10.1126/science.3388019; SAGGIO I, 1995, EMBO J, V14, P3045, DOI 10.1002/j.1460-2075.1995.tb07307.x; Sanderson C J, 1992, Adv Pharmacol, V23, P163, DOI 10.1016/S1054-3589(08)60965-5; TAVERNIER J, 1995, P NATL ACAD SCI USA, V92, P5194, DOI 10.1073/pnas.92.11.5194; Toniatti C, 1996, EMBO J, V15, P2726, DOI 10.1002/j.1460-2075.1996.tb00633.x; Tsui P, 1996, J IMMUNOL, V157, P772; ZHONG GM, 1994, BIOTECHNIQUES, V16, P838	34	18	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20479	20488		10.1074/jbc.274.29.20479	http://dx.doi.org/10.1074/jbc.274.29.20479			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400676	hybrid			2022-12-25	WOS:000081438300069
J	Wick, W; Furnari, FB; Naumann, U; Cavenee, WK; Weller, M				Wick, W; Furnari, FB; Naumann, U; Cavenee, WK; Weller, M			PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis	ONCOGENE			English	Article						PTEN; glioma; CD95; PKB; PI 3-kinase; irradiation	TUMOR-SUPPRESSOR; PROTEIN-KINASE; PHOSPHATASE; MUTATIONS; GROWTH; CELLS; ACTIVATION; PTEN/MMAC1; 3-KINASE; SURVIVAL	The tumor suppressor gene PTEN (MMAC1, TEP1) encodes a dual-specificity phosphatase and is considered a progression-associated target of genetic alterations in human gliomas. Recently, it has been reported that the introduction of wild type PTEN into glioma cells containing endogenous mutant PTEN alleles (U87MC;, LN-308), but not in those which retain wild-type PTEN (LN-18, LN-229), causes growth suppression and inhibits cellular migration, spreading and focal adhesion. Here, we show that PTEN gene transfer has no effect on the chemosensitivity of the four cell lines. Further, a correlational analysis of the endogenous PTEN status of 12 human glioma cell lines with their sensitivity to seven different cancer chemotherapy drugs reveals no link between PTEN and chemosensitivity, In contrast, ectopic expression of wild type PTEN, but not the PTENG129R mutant, in PTEN-mutant gliomas markedly sensitizes these cells to irradiation and to CD95-ligand (CD95L)-induced apoptosis. PTEN-mediated facilitation of CD95L-induced apoptosis is associated with enhanced CD95L-evoked caspase 3 activity, Protein kinase B (PKB/Akt), previously shown to inhibit CD95L-induced apoptosis in nonglial COS7 cells, is inactivated by dephosphorylation. Interestingly, both PTEN-mutant U87MG and PTEN-wild-type LN-229 cells contain phosphorylated PKB constitutively. Wild-type PTEN gene transfer promotes dephosphorylation of PKB specifically in U87MG cells but not in LN-229 cells, Sensitization of U87NG cells to CD95L-apoptosis by wild-type PTEN is blocked by insulin-like growth factor-1 (IGF-1). The protection by IGF-1 is inhibited by the phosphoinositide 3-OH (PI 3) kinase inhibitor, wort-mannin, Although PKB is a down-stream target of PI 3 kinase, the protection by IGF-1 was not associated with the reconstitution of PKB phosphorylation. Thus, PTEN may sensitize human malignant glioma cells to CD95L-induced apoptosis in a PI 3 kinase-dependent manner that may not require PKB phosphorylation.	Univ Tubingen, Dept Neurol, D-72076 Tubingen, Germany; Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA	Eberhard Karls University of Tubingen; Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego	Weller, M (corresponding author), Univ Tubingen, Dept Neurol, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.		Wick, Wolfgang/AAA-2545-2020	Wick, Wolfgang/0000-0002-6171-634X; Weller, Michael/0000-0002-1748-174X; Furnari, Frank/0000-0003-1909-4361				BASERGA R, 1995, CANCER RES, V55, P249; Cheney IW, 1998, CANCER RES, V58, P2331; Crowder RJ, 1998, J NEUROSCI, V18, P2933; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Duerr EM, 1998, ONCOGENE, V16, P2259, DOI 10.1038/sj.onc.1201756; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Hausler P, 1998, EUR J IMMUNOL, V28, P57, DOI 10.1002/(SICI)1521-4141(199801)28:01<57::AID-IMMU57>3.0.CO;2-8; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liu WG, 1997, CANCER RES, V57, P5254; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Rhei E, 1997, CANCER RES, V57, P3657; Rieger J, 1998, FEBS LETT, V427, P124, DOI 10.1016/S0014-5793(98)00409-8; Roth W, 1997, CANCER IMMUNOL IMMUN, V44, P55, DOI 10.1007/s002620050355; Schulz JB, 1997, J NEUROCHEM, V69, P2075; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Teng DHF, 1997, CANCER RES, V57, P5221; Wang SI, 1997, CANCER RES, V57, P4183; Weller M, 1997, NEUROL RES, V19, P459; WELLER M, 1994, J CLIN INVEST, V94, P954, DOI 10.1172/JCI117462; WELLER M, 1998, INT J CANCER, V79, P1	24	97	103	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 8	1999	18	27					3936	3943		10.1038/sj.onc.1202774	http://dx.doi.org/10.1038/sj.onc.1202774			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KU	10435616				2022-12-25	WOS:000081327800003
J	Harhaj, EW; Sun, SC				Harhaj, EW; Sun, SC			IKK gamma serves as a docking subunit of the I kappa B kinase (IKK) and mediates interaction of IKK with the human T-cell leukemia virus Tax protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HTLV-I; PHOSPHATASE INHIBITORS; INDUCIBLE DEGRADATION; TYPE-1 TAX; ACTIVATION; ALPHA; BETA; PHOSPHORYLATION; INDUCTION; COMPLEX	The tax gene product of human T-cell leukemia virus type I induces activation of transcription factor NF-kappa B, which contributes to deregulated expression of various cellular genes. Tax expression triggers persistent phosphorylation and degradation of the NF-kappa B inhibitory proteins I kappa B alpha and I kappa B beta resulting in constitutive nuclear expression of NF-KB. Recent studies demonstrate that Tax activates the I kappa B kinase (IKK), although the underlying mechanism remains unclear, In this report, we show that Tax physically interacts with a regulatory component of the IKK complex, the NF-kappa B essential modulator or IKK-gamma (NEMO/IKK gamma). This molecular interaction appears to be important for recruiting Tax to the IKK catalytic subunits, IKK alpha and IKK beta. Expression of NEMO/IKK gamma greatly promotes binding of Tax to IKK alpha and IKK beta and stimulates Tax-mediated IKK activation. Interestingly, a mutant form of Tax defective in IKK activation exhibited a markedly diminished level of NEMO/IKK gamma association. These findings suggest that the physical interaction of Tax with NEMO/IKK gamma may play an important role in Tax-mediated IKK activation.	Penn State Univ, Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Sun, SC (corresponding author), Penn State Univ, Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA.				NCI NIH HHS [1 R01 CA68471] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068471] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Chu ZL, 1998, J BIOL CHEM, V273, P15891, DOI 10.1074/jbc.273.26.15891; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FEUER G, 1992, BIOCHIM BIOPHYS ACTA, V1114, P223, DOI 10.1016/0304-419X(92)90017-S; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; Gerondakis S, 1998, CURR OPIN IMMUNOL, V10, P353, DOI 10.1016/S0952-7915(98)80175-1; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Good L, 1996, BIOCHEM BIOPH RES CO, V223, P123, DOI 10.1006/bbrc.1996.0856; Good LF, 1996, J VIROL, V70, P2730, DOI 10.1128/JVI.70.5.2730-2735.1996; GREEN PL, 1990, FASEB J, V4, P169, DOI 10.1096/fasebj.4.2.2404818; GREENE WC, 1989, IMMUNOL TODAY, V10, P272, DOI 10.1016/0167-5699(89)90141-2; Karin M, 1998, CANCER J SCI AM, V4, pS92; LACOSTE J, 1995, J VIROL, V69, P564, DOI 10.1128/JVI.69.1.564-569.1995; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Siebenlist U., 1997, BIOCHIMICA BIOPHYSIC, V1332, P7; SMITH MR, 1991, J CLIN INVEST, V87, P761, DOI 10.1172/JCI115078; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; SUN SC, 1995, J BIOL CHEM, V270, P18347, DOI 10.1074/jbc.270.31.18347; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; Sun SC, 1996, MOL CELL BIOL, V16, P1058; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	37	195	200	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					22911	22914		10.1074/jbc.274.33.22911	http://dx.doi.org/10.1074/jbc.274.33.22911			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438454	hybrid			2022-12-25	WOS:000082012800004
J	Ko, JH; Miyoshi, E; Noda, K; Ekuni, A; Kang, RJ; Ikeda, Y; Taniguchi, N				Ko, JH; Miyoshi, E; Noda, K; Ekuni, A; Kang, RJ; Ikeda, Y; Taniguchi, N			Regulation of the GnT-V promoter by transcription factor Ets-1 in various cancer cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINYLTRANSFERASE-V; SIGNALING PATHWAY; MOUSE MELANOMA; GENE; EXPRESSION; INHIBITION; ENHANCER; BINDING; COLLAGENASE; TRANSFERASE	Although the precise role of oligosaccharides in metastasis is presently unknown, numerous studies suggest that the beta 1-6 branching structure of N-linked oligosaccharides plays a role in tumor metastasis, N-Acetylglucosaminyltransferase V (GnT-V), which catalyzes the formation of the beta 1-6 branch, therefore appears to play a crucial role in tumor metastasis, Recently, we demonstrated that the expression of the GnT-V gene is regulated by a transcriptional factor, Ets-l (Kang, R., Saito, H., Ihara, Y., Miyoshi, E., Koyama, N., Sheng, Y., and Taniguchi, N. (1996) J. Biol, Chem. 271, 26706-26712), In this study, we report an investigation of the general requirement for Ets-l in the expression of GnT-V in cancer cell lines. In 16 cancer cell lines, the levels of GnT-V mRNA were closely correlated with ets-l expression (r = 0.97; p < 0.0001), An increase in ets-l levels by transfection of its cDNA led to an enhancement in GnT-V expression in cells that normally expressed low levels of ets-l, In contrast, the transfection of dominant negative ets-l into cells that express high levels of ets-l resulted in a decrease in GnT-V expression, Although Ets-l cooperates with c-Jun in certain gene expressions, this was not the case in the regulation of the GnT-V gene, These results suggest that Ets-l plays a significant role in regulating the expression of GnT-V in a variety of cancers and might be involved in the potential for malignancy via the action of GnT-V.	Osaka Univ, Sch Med, Dept Biochem, Suita, Osaka 5650871, Japan	Osaka University	Taniguchi, N (corresponding author), Osaka Univ, Sch Med, Dept Biochem, Room B1,2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	proftani@biochem.med.osaka-u.ac.jp	Taniguchi, Naoyuki/I-4182-2014; Taniguchi, Naoyuki/A-7086-2016	Taniguchi, Naoyuki/0000-0001-5889-5968; 				Aperlo C, 1996, MOL CELL BIOL, V16, P6851; AUBLE DT, 1991, BIOCHEMISTRY-US, V30, P4629, DOI 10.1021/bi00232a039; Buckhaults P, 1997, J BIOL CHEM, V272, P19575, DOI 10.1074/jbc.272.31.19575; Chen ZQ, 1997, CANCER RES, V57, P2013; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DEMETRIOU M, 1995, J CELL BIOL, V130, P383, DOI 10.1083/jcb.130.2.383; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; FINNE J, 1989, INT J CANCER, V43, P300, DOI 10.1002/ijc.2910430223; GU JG, 1993, J BIOCHEM, V113, P614, DOI 10.1093/oxfordjournals.jbchem.a124091; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; Kang R, 1996, J BIOL CHEM, V271, P26706, DOI 10.1074/jbc.271.43.26706; Kaya M, 1996, ONCOGENE, V12, P221; KORCZAK B, 1993, INT J CANCER, V53, P634, DOI 10.1002/ijc.2910530418; KRAMER B, 1995, J BIOL CHEM, V270, P6577; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; Miyoshi E, 1997, INT J CANCER, V72, P1117; MIYOSHI E, 1993, CANCER RES, V53, P3899; Pierce M, 1997, GLYCOCONJUGATE J, V14, P623, DOI 10.1023/A:1018592627696; PIERCE M, 1986, J BIOL CHEM, V261, P772; PROSSER HM, 1992, P NATL ACAD SCI USA, V89, P9934, DOI 10.1073/pnas.89.20.9934; SAITO H, 1994, BIOCHEM BIOPH RES CO, V198, P318, DOI 10.1006/bbrc.1994.1045; SAITO H, 1995, EUR J BIOCHEM, V233, P18, DOI 10.1111/j.1432-1033.1995.018_1.x; SHOREIBAH M, 1993, J BIOL CHEM, V268, P15381; SUZUKI H, 1995, P NATL ACAD SCI USA, V92, P4442, DOI 10.1073/pnas.92.10.4442; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WASYLYK C, 1994, ONCOGENE, V9, P3665; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WERNERT N, 1994, CANCER RES, V54, P5683; YOSHIMURA M, 1995, P NATL ACAD SCI USA, V92, P8754, DOI 10.1073/pnas.92.19.8754	36	87	95	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					22941	22948		10.1074/jbc.274.33.22941	http://dx.doi.org/10.1074/jbc.274.33.22941			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438459	hybrid			2022-12-25	WOS:000082012800009
J	Calegari, F; Coco, S; Taverna, E; Bassetti, M; Verderio, C; Corradi, N; Matteoli, M; Rosa, P				Calegari, F; Coco, S; Taverna, E; Bassetti, M; Verderio, C; Corradi, N; Matteoli, M; Rosa, P			A regulated secretory pathway in cultured hippocampal astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROPEPTIDE-PROCESSING ENZYME; I CHROMOGRANIN-B; SECRETOGRANIN-II; CALCIUM WAVES; GLUTAMATE RELEASE; GLIAL-CELLS; CARBOXYPEPTIDASE-E; SNARE COMPLEXES; PLASMA-MEMBRANE; MESSENGER-RNA	Glial cells have been reported to express molecules originally discovered in neuronal and neuroendocrine cells, such as neuropeptides, neuropeptide processing enzymes, and ionic channels. To verify whether astrocytes may have regulated secretory vesicles, the primary cultures prepared from hippocampi of embryonic and neonatal rats were used to investigate the subcellular localization and secretory pathway followed by secretogranin II, a well known marker for dense-core granules. By indirect immunofluorescence, SgII was detected in a large number of cultured hippocampal astrocytes, Immunoreactivity for the granin was detected in the GoIgi complex and in a population of dense-core vesicles stored in the cells. Subcellular fractionation experiments revealed that SgII was stored in a vesicle population with a density identical to that of the dense-core secretory granules present in rat pheochromocytoma cells. In line with these data, biochemical results indicated that 40-50% of secretogranin II synthesized during 18-h labeling was retained intracellularly over a 4-h chase period and released after treatment with different secretagogues. The most effective stimulus appeared to be phorbol ester in combination with ionomycin in the presence of extracellular Ca2+, a treatment that was found to produce a large and sustained increase in intracellular calcium [Ca2+](i) transients, Our findings indicate that a regulated secretory pathway characterized by (i) the expression and stimulated exocytosis of a typical marker for regulated secretory granules, (ii) the presence of dense-core vesicles, and (iii) the ability to undergo [Ca2+](i) increase upon specific stimuli is present in cultured hippocampal astrocytes.	CNR, Ctr Cellular & Mol Pharmacol, Dept Med Pharmacol, I-20129 Milan, Italy	Consiglio Nazionale delle Ricerche (CNR)	Rosa, P (corresponding author), CNR, Ctr Cellular & Mol Pharmacol, Dept Med Pharmacol, Via Vanvitelli 32, I-20129 Milan, Italy.		Taverna, Elena/AFW-4935-2022; Calegari, Federico/A-2422-2009; Coco, Silvia/AAD-6719-2022; Calegari, Federico/N-7827-2019; Bassetti, Matteo/L-3081-2019; taverna, elena/O-8180-2014; Verderio, Claudia/K-4415-2016; Matteoli, Michela/K-4526-2018	taverna, elena/0000-0002-2430-4725; Verderio, Claudia/0000-0001-7216-5873; Matteoli, Michela/0000-0002-3569-7843; Rosa, Patrizia/0000-0002-2590-6955; COCO, SILVIA/0000-0002-3883-9472; calegari, federico/0000-0002-3703-2802				Advani RJ, 1998, J BIOL CHEM, V273, P10317, DOI 10.1074/jbc.273.17.10317; Bacci A, 1999, PHILOS T R SOC B, V354, P403, DOI 10.1098/rstb.1999.0393; Banker G., 1991, CULTURING NERVE CELL; Bauerfeind R, 1993, CURR OPIN CELL BIOL, V5, P628, DOI 10.1016/0955-0674(93)90132-A; Bezzi P, 1998, NATURE, V391, P281, DOI 10.1038/34651; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CHARLES AC, 1991, NEURON, V6, P983, DOI 10.1016/0896-6273(91)90238-U; Chavez RA, 1996, J CELL BIOL, V133, P1177, DOI 10.1083/jcb.133.6.1177; CHEN M, 1992, J NEUROCHEM, V58, P1691, DOI 10.1111/j.1471-4159.1992.tb10042.x; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; Corradi N, 1996, J BIOL CHEM, V271, P27116, DOI 10.1074/jbc.271.43.27116; DECAMILLI P, 1990, ANNU REV PHYSIOL, V52, P625, DOI 10.1146/annurev.ph.52.030190.003205; DITTIE AS, 1995, BIOCHEM J, V310, P777, DOI 10.1042/bj3100777; ENG LF, 1985, J NEUROIMMUNOL, V8, P203, DOI 10.1016/S0165-5728(85)80063-1; FICHERCOLBRIE R, 1993, J NEUROCHEM, V60, P2312; FINKBEINER S, 1992, NEURON, V8, P1101, DOI 10.1016/0896-6273(92)90131-V; FREDERIKSEN K, 1988, J NEUROSCI, V8, P1144; Galli T, 1998, MOL BIOL CELL, V9, P1437, DOI 10.1091/mbc.9.6.1437; Gasparri A, 1997, J BIOL CHEM, V272, P20835, DOI 10.1074/jbc.272.33.20835; Goda Y, 1997, P NATL ACAD SCI USA, V94, P769, DOI 10.1073/pnas.94.3.769; GROHOVAZ F, 1991, J CELL BIOL, V113, P1341, DOI 10.1083/jcb.113.6.1341; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HALBAN PA, 1994, BIOCHEM J, V299, P1; Hanson PI, 1997, CURR OPIN NEUROBIOL, V7, P310, DOI 10.1016/S0959-4388(97)80057-8; Hassinger TD, 1996, P NATL ACAD SCI USA, V93, P13268, DOI 10.1073/pnas.93.23.13268; HAUSER KF, 1990, BRAIN RES, V522, P347, DOI 10.1016/0006-8993(90)91482-V; HOFLEHNER J, 1995, FEBS LETT, V360, P294, DOI 10.1016/0014-5793(95)00127-U; HUTTNER WB, 1991, TRENDS BIOCHEM SCI, V16, P27, DOI 10.1016/0968-0004(91)90012-K; IACANGELO AL, 1995, REGUL PEPTIDES, V58, P65, DOI 10.1016/0167-0115(95)00069-N; Jeftinija SD, 1997, BRAIN RES, V750, P41, DOI 10.1016/S0006-8993(96)00610-5; Kahler CM, 1996, EUR J PHARMACOL, V304, P135, DOI 10.1016/0014-2999(96)00135-5; KLEIN RS, 1992, BRAIN RES, V596, P202, DOI 10.1016/0006-8993(92)91548-S; KLEIN RS, 1992, BRAIN RES, V569, P300, DOI 10.1016/0006-8993(92)90643-N; LINDBERG I, 1991, MOL ENDOCRINOL, V5, P1361, DOI 10.1210/mend-5-10-1361; MAINS RE, ANN NY ACAD SCI, V493, P278; MATSUUCHI L, 1991, J CELL BIOL, V112, P843, DOI 10.1083/jcb.112.5.843; MCAULIFFE WG, 1990, GLIA, V3, P13, DOI 10.1002/glia.440030103; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; Natori S, 1996, P NATL ACAD SCI USA, V93, P4431, DOI 10.1073/pnas.93.9.4431; NAVONE F, 1989, J CELL BIOL, V109, P3425, DOI 10.1083/jcb.109.6.3425; PARPURA V, 1995, FEBS LETT, V360, P266, DOI 10.1016/0014-5793(95)00121-O; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; Parpura V, 1995, FEBS LETT, V377, P489, DOI 10.1016/0014-5793(95)01401-2; Passafaro M, 1996, J BIOL CHEM, V271, P30096, DOI 10.1074/jbc.271.47.30096; Ravichandran V, 1996, J BIOL CHEM, V271, P13300, DOI 10.1074/jbc.271.23.13300; ROSA P, 1989, J CELL BIOL, V109, P17, DOI 10.1083/jcb.109.1.17; ROSA P, 1985, J CELL BIOL, V101, P1999, DOI 10.1083/jcb.101.5.1999; ROSA P, 1992, J HISTOCHEM CYTOCHEM, V40, P523, DOI 10.1177/40.4.1552186; ROSA P, 1992, J BIOL CHEM, V267, P12227; ROSA P, 1994, J ENDOCRINOL INVEST, V17, P207, DOI 10.1007/BF03347721; SARIA A, 1993, NEUROSCIENCE, V54, P1, DOI 10.1016/0306-4522(93)90377-R; SCAMMELL JG, 1993, TRENDS ENDOCRIN MET, V4, P14, DOI 10.1016/1043-2760(93)90058-M; SCHELLER RH, 1995, NEURON, V14, P893; SHINODA H, 1989, SCIENCE, V245, P415, DOI 10.1126/science.2569236; Sontheimer H, 1996, TRENDS NEUROSCI, V19, P325, DOI 10.1016/0166-2236(96)10039-4; SPRUCE BA, 1990, EMBO J, V9, P1787, DOI 10.1002/j.1460-2075.1990.tb08303.x; Steinhauser C, 1996, TRENDS NEUROSCI, V19, P339, DOI 10.1016/0166-2236(96)10043-6; TAGAYA M, 1995, J BIOL CHEM, V270, P15930, DOI 10.1074/jbc.270.27.15930; TOOZE SA, 1990, CELL, V60, P837, DOI 10.1016/0092-8674(90)90097-X; Verkhratsky A, 1996, TRENDS NEUROSCI, V19, P346, DOI 10.1016/0166-2236(96)10048-5; VILIJN MH, 1989, J NEUROCHEM, V53, P1487, DOI 10.1111/j.1471-4159.1989.tb08542.x; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N	65	129	134	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22539	22547		10.1074/jbc.274.32.22539	http://dx.doi.org/10.1074/jbc.274.32.22539			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428831	hybrid			2022-12-25	WOS:000081868400061
J	Cheng, D; Espenshade, PJ; Slaughter, CA; Jaen, JC; Brown, MS; Goldstein, JL				Cheng, D; Espenshade, PJ; Slaughter, CA; Jaen, JC; Brown, MS; Goldstein, JL			Secreted site-1 protease cleaves peptides corresponding to luminal loop of sterol regulatory element-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING PROTEIN; CELL-MEMBRANES; SREBPS; IDENTIFICATION; ENDOPROTEASE; FURIN	We describe a permanent line of Chinese hamster ovary cells transfected with a cDNA encoding a truncated form of Site-1 protease (S1P) that is secreted into the culture medium in an enzymatically active form. S1P, a subtilisin-like protease, normally cleaves the luminal loop of sterol regulatory element-binding proteins (SREBPs). This cleavage initiates the two-step proteolytic process by which the NH2-terminal domains of SREBPs are released from cell membranes for translocation to the nucleus, where they activate transcription of genes involved in the biosynthesis and uptake of cholesterol and fatty acids. Truncated S1P (amino acids 1-983), produced by the transfected Chinese hamster ovary cells, lacks the COOH-terminal membrane anchor. Like native S1P, this truncated protein undergoes normal autocatalytic processing after residue 137 to release an NH2-terminal propeptide, thereby generating an active form, designated S1P-B. Prior to secretion, truncated S1P-B, like native S1P-B, is cleaved further after residue 186 to generate S1P-C, which is the only form that appears in the culture medium. The secreted enzyme, designated S1P(983)-C, cleaves a synthetic peptide that terminates in a 7-amino-4-methyl-coumarin fluorochrome. This peptide, RSLK-MCA, corresponds to the internal propeptide cleavage site that generates S1P-B as described in the accompanying paper (Espenshade, P. J., Cheng, D., Goldstein, J. L., and Brown, M. S. (1999), J. Biol. Chem. 274, 22795-22804). The secreted enzyme does not cleave RSVL-MCA, a peptide corresponding to the physiologic cleavage site in SREBP-2. However, S1P(983)-C does cleave after this leucine when the RSVL sequence is contained within a 16-residue peptide corresponding to the central portion of the SREBP-2 luminal loop. The catalytic activity of S1P(983)-C differs from that of furin/prohormone convertases, two related proteases, in its more alkaline pH optimum (pH 7-8), its relative resistance to calcium chelating agents, and its ability to cleave after lysine or leucine rather than arginine. These data provide direct biochemical evidence that S1P is the protease that cleaves SREBPs and thereby functions to control lipid biosynthesis and uptake in animal cells.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Tularik Inc, S San Francisco, CA 90408 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Goldstein, JL (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd,Rm L5-238, Dallas, TX 75235 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948, F32HL009993] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 20948, HL 09993] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Duncan EA, 1997, J BIOL CHEM, V272, P12778, DOI 10.1074/jbc.272.19.12778; Duncan EA, 1998, J BIOL CHEM, V273, P17801, DOI 10.1074/jbc.273.28.17801; Espenshade PJ, 1999, J BIOL CHEM, V274, P22795, DOI 10.1074/jbc.274.32.22795; HUA XX, 1995, J BIOL CHEM, V270, P29422, DOI 10.1074/jbc.270.49.29422; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Rawson RB, 1998, J BIOL CHEM, V273, P28261, DOI 10.1074/jbc.273.43.28261; Sakai J, 1998, MOL CELL, V2, P505, DOI 10.1016/S1097-2765(00)80150-1; Sakai J, 1998, J BIOL CHEM, V273, P5785, DOI 10.1074/jbc.273.10.5785; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Sakai J, 1997, J BIOL CHEM, V272, P20213, DOI 10.1074/jbc.272.32.20213; Seidah NG, 1999, P NATL ACAD SCI USA, V96, P1321, DOI 10.1073/pnas.96.4.1321; TOLLESHAUG H, 1982, CELL, V30, P715, DOI 10.1016/0092-8674(82)90276-8; YANG JX, 1995, J BIOL CHEM, V270, P12152, DOI 10.1074/jbc.270.20.12152	15	55	57	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22805	22812		10.1074/jbc.274.32.22805	http://dx.doi.org/10.1074/jbc.274.32.22805			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428865	hybrid			2022-12-25	WOS:000081868400095
J	Hansen, NJ; Antonin, W; Edwardson, JM				Hansen, NJ; Antonin, W; Edwardson, JM			Identification of SNAREs involved in regulated exocytosis in the pancreatic acinar cell	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-GAMMA-S; MEMBRANE-PROTEIN; ZYMOGEN GRANULES; NEUROTRANSMITTER RELEASE; PLASMA-MEMBRANES; SYNTAXIN FAMILY; BINDING PROTEIN; FUSION; SYNAPTOBREVIN; SECRETION	The molecular basis of exocytotic membrane fusion in the pancreatic acinar cell was investigated using an in vitro assay that measures both zymogen granule-plasma membrane fusion and granule-granule fusion. These two fusion events were differentially sensitive to Ca2+ suggesting that they are controlled by different Ca2+-sensing mechanisms. Botulinum neurotoxin C (BoNT/C) treatment of the plasma membranes caused cleavage of syntaxin 2, the apical isoform of this Q-SNARE, but did not affect syntaxin 4, the basolateral isoform, BoNT/C also cleaved syntaxin 3, the zymogen granule isoform. BoNT/C treatment of plasma membranes abolished granule-plasma membrane fusion, whereas toxin treatment of the granules reduced granule-plasma membrane fusion and abolished granule-granule fusion, Tetanus toxin cleaved granule-associated synaptobrevin 2 but caused only a small reduction in both granule-plasma membrane fusion and granule-granule fusion. Our results indicate that syntaxin 2 is the isoform that mediates fusion between zymogen granules and the apical plasma membrane of the acinar cell, Syntaxin 3 mediates granule-granule fusion, which might be involved in compound exocytosis. In contrast, the major R-SNARE on the zymogen granule remains to be identified.	Univ Cambridge, Dept Pharmacol, Cambridge CB2 1QJ, England; Max Planck Inst Biophys Chem, Dept Neurobiol, D-37077 Gottingen, Germany	University of Cambridge; Max Planck Society	Edwardson, JM (corresponding author), Univ Cambridge, Dept Pharmacol, Tennis Court Rd, Cambridge CB2 1QJ, England.		Antonin, Wolfram/A-8656-2014; Antonin, Wolfram/P-3648-2019	Antonin, Wolfram/0000-0003-4669-379X; Antonin, Wolfram/0000-0003-4669-379X				BARNSTABLE CJ, 1985, DEV BRAIN RES, V20, P286, DOI 10.1016/0165-3806(85)90116-6; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x; Bock JB, 1997, NATURE, V387, P133, DOI 10.1038/387133a0; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; Edwardson JM, 1998, METHODS, V16, P209, DOI 10.1006/meth.1998.0669; EDWARDSON JM, 1990, BIOCHIM BIOPHYS ACTA, V1053, P32, DOI 10.1016/0167-4889(90)90022-6; Edwardson JM, 1997, CELL, V90, P325, DOI 10.1016/S0092-8674(00)80340-2; Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; FOHR KJ, 1993, METHOD ENZYMOL, V221, P149, DOI 10.1016/0076-6879(93)21014-Y; Gaisano HY, 1997, FEBS LETT, V414, P298, DOI 10.1016/S0014-5793(97)01013-2; Gaisano HY, 1996, MOL BIOL CELL, V7, P2019, DOI 10.1091/mbc.7.12.2019; GAISANO HY, 1994, J BIOL CHEM, V269, P17062; Galli T, 1998, MOL BIOL CELL, V9, P1437, DOI 10.1091/mbc.9.6.1437; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HOEKSTRA D, 1984, BIOCHEMISTRY-US, V23, P5675, DOI 10.1021/bi00319a002; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; KITAGAWA M, 1990, AM J PHYSIOL, V259, pG157, DOI 10.1152/ajpgi.1990.259.2.G157; MACLEAN CM, 1992, BIOCHEM J, V286, P747, DOI 10.1042/bj2860747; NADIN CY, 1989, J CELL BIOL, V109, P2801, DOI 10.1083/jcb.109.6.2801; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Niemann Heiner, 1994, Trends in Cell Biology, V4, P179, DOI 10.1016/0962-8924(94)90203-8; PADFIELD PJ, 1991, BIOCHEM BIOPH RES CO, V174, P536, DOI 10.1016/0006-291X(91)91450-Q; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; Patel SK, 1998, CELL, V92, P611, DOI 10.1016/S0092-8674(00)81129-0; Ravichandran V, 1996, J BIOL CHEM, V271, P13300, DOI 10.1074/jbc.271.23.13300; REGAZZI R, 1995, EMBO J, V14, P2723, DOI 10.1002/j.1460-2075.1995.tb07273.x; SCHEELE GA, 1987, GASTROENTEROLOGY, V92, P245; SCHIAVO G, 1995, J BIOL CHEM, V270, P10566, DOI 10.1074/jbc.270.18.10566; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Wong SH, 1998, MOL BIOL CELL, V9, P1549, DOI 10.1091/mbc.9.6.1549	38	91	92	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22871	22876		10.1074/jbc.274.32.22871	http://dx.doi.org/10.1074/jbc.274.32.22871			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428873	Green Published, hybrid			2022-12-25	WOS:000081868400103
J	Schulke, N; Sepuri, NBV; Gordon, DM; Saxena, S; Dancis, A; Pain, D				Schulke, N; Sepuri, NBV; Gordon, DM; Saxena, S; Dancis, A; Pain, D			A multisubunit complex of outer and inner mitochondrial membrane protein translocases stabilized in vivo by translocation intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFIED PRECURSOR PROTEIN; GENERAL IMPORT PORE; PREPROTEIN TRANSLOCATION; RECEPTOR COMPLEX; YEAST MITOCHONDRIA; SACCHAROMYCES-CEREVISIAE; DYNAMIC INTERACTION; CONTACT SITES; IDENTIFICATION; MATRIX	Translocation of nuclear encoded preproteins into the mitochondrial matrix requires the coordinated action of two translocases: one (Tom) located in the outer mitochondrial membrane and the other (Tim) located in the inner membrane. These translocases reversibly cooperate during protein import. We have previously constructed a chimeric precursor (pPGPrA) consisting of an authentic mitochondrial precursor at the N terminus (Delta(1)-pyrroline-5-carboxylate dehydrogenase, pPut) linked, through glutathione S-transferase, to protein A. When pPGPrA is expressed in yeast, it becomes irreversibly arrested during translocation across the outer and inner mitochondrial membranes. Consequently, the two membranes of mitochondria become progressively "zippered" together, forming long stretches in which they are in close contact (Schulke, N., Sepuri, N. B. V., and Pain, D. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 7314-7319), We now demonstrate that trapped PGPrA intermediates hold the import channels stably together and inhibit mitochondrial protein import and cell growth. Using IgG-Sepharose affinity chromatography of solubilized zippered membranes, we have isolated a multisub unit complex that contains all Tom and Tim components known to be essential for import of matrix-targeted proteins, namely Tom40, Tom22, Tim17, Tim23, Tim44, and matrix-localized Hsp70. Further characterization of this complex may shed light on structural features of the complete mitochondrial import machinery.	Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Pain, D (corresponding author), Univ Penn, Sch Med, Dept Physiol, D403 Richards Bldg,3700 Hamilton Walk, Philadelphia, PA 19104 USA.		Sepuri, Naresh/AAF-2704-2020		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053953, R37DK053953] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057067] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07027-24] Funding Source: Medline; NIDDK NIH HHS [DK53953-01] Funding Source: Medline; NIGMS NIH HHS [GM57067] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arnold I, 1997, FEBS LETT, V411, P195, DOI 10.1016/S0014-5793(97)00691-1; BERTHOLD J, 1995, CELL, V81, P1085, DOI 10.1016/S0092-8674(05)80013-3; BLOM J, 1993, MOL CELL BIOL, V13, P7364, DOI 10.1128/MCB.13.12.7364; Dekker PJT, 1997, EMBO J, V16, P5408, DOI 10.1093/emboj/16.17.5408; DEKKER PJT, 1993, FEBS LETT, V330, P66, DOI 10.1016/0014-5793(93)80921-G; Dekker PJT, 1998, MOL CELL BIOL, V18, P6515, DOI 10.1128/MCB.18.11.6515; Dietmeier K, 1997, NATURE, V388, P195, DOI 10.1038/40663; EILERS M, 1988, EMBO J, V7, P1139, DOI 10.1002/j.1460-2075.1988.tb02923.x; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; EMTAGE JLT, 1993, J CELL BIOL, V122, P1003, DOI 10.1083/jcb.122.5.1003; Enenkel C, 1996, P NATL ACAD SCI USA, V93, P12986, DOI 10.1073/pnas.93.23.12986; GRATZER S, 1995, J CELL BIOL, V129, P25, DOI 10.1083/jcb.129.1.25; Hill K, 1998, NATURE, V395, P516, DOI 10.1038/26780; HONLINGER A, 1995, MOL CELL BIOL, V15, P3382; Honlinger A, 1996, EMBO J, V15, P2125, DOI 10.1002/j.1460-2075.1996.tb00566.x; HORST M, 1995, EMBO J, V14, P2293, DOI 10.1002/j.1460-2075.1995.tb07223.x; JASCUR T, 1992, J BIOL CHEM, V267, P13636; KASSENBROCK CK, 1993, EMBO J, V12, P3023, DOI 10.1002/j.1460-2075.1993.tb05971.x; KIEBLER M, 1993, CELL, V74, P483, DOI 10.1016/0092-8674(93)80050-O; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; KRONIDOU NG, 1994, P NATL ACAD SCI USA, V91, P12818, DOI 10.1073/pnas.91.26.12818; Kunkele KP, 1998, CELL, V93, P1009, DOI 10.1016/S0092-8674(00)81206-4; LITHGOW T, 1994, J BIOL CHEM, V269, P15325; LITHGOW T, 1994, P NATL ACAD SCI USA, V91, P11973, DOI 10.1073/pnas.91.25.11973; MAARSE AC, 1992, EMBO J, V11, P3619, DOI 10.1002/j.1460-2075.1992.tb05446.x; MAARSE AC, 1994, FEBS LETT, V349, P215, DOI 10.1016/0014-5793(94)00669-5; MOCZKO M, 1992, FEBS LETT, V310, P265, DOI 10.1016/0014-5793(92)81345-M; MURAKAMI H, 1990, NATURE, V347, P488, DOI 10.1038/347488a0; MURAKAMI H, 1993, P NATL ACAD SCI USA, V90, P3358, DOI 10.1073/pnas.90.8.3358; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; PAIN D, 1990, NATURE, V347, P444, DOI 10.1038/347444a0; PHELPS A, 1991, BIOCHEMISTRY-US, V30, P248, DOI 10.1021/bi00215a035; RASSOW J, 1989, J CELL BIOL, V109, P1421, DOI 10.1083/jcb.109.4.1421; RASSOW J, 1994, J CELL BIOL, V127, P1547, DOI 10.1083/jcb.127.6.1547; RYAN KR, 1994, MOL BIOL CELL, V5, P529, DOI 10.1091/mbc.5.5.529; SCHERER PE, 1992, P NATL ACAD SCI USA, V89, P11930, DOI 10.1073/pnas.89.24.11930; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; Schulke N, 1997, P NATL ACAD SCI USA, V94, P7314, DOI 10.1073/pnas.94.14.7314; Sepuri NBV, 1998, J BIOL CHEM, V273, P20941, DOI 10.1074/jbc.273.33.20941; Sepuri NBV, 1998, J BIOL CHEM, V273, P1420, DOI 10.1074/jbc.273.3.1420; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; Tokatlidis K, 1996, NATURE, V384, P585, DOI 10.1038/384585a0; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; VESTWEBER D, 1988, J CELL BIOL, V107, P2037, DOI 10.1083/jcb.107.6.2037; WIENHUES U, 1991, J CELL BIOL, V115, P1601, DOI 10.1083/jcb.115.6.1601	46	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22847	22854		10.1074/jbc.274.32.22847	http://dx.doi.org/10.1074/jbc.274.32.22847			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428870	hybrid			2022-12-25	WOS:000081868400100
J	Sheng, XR; Li, X; Pan, XM				Sheng, XR; Li, X; Pan, XM			An iso-random BiBi mechanism for adenylate kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATE TRANSPHOSPHORYLASES; NUCLEAR MAGNETIC-RESONANCE; SITE-DIRECTED MUTAGENESIS; STAPHYLOCOCCAL NUCLEASE; HEMOLYTIC-ANEMIA; CRYSTALLINE RABBIT; PROLINE ISOMERISM; CALBINDIN D9K; CALF MUSCLE; X-RAY	An iso-random Bi Bi mechanism has been proposed for adenylate kinase. In this mechanism, one of the enzyme forms can bind the substrates MgATP and AMP, whereas the other form can bind the products MgADP and ADP. In a catalytic cycle, the conformational changes of the free enzyme and the ternary complexes are the rate-limiting steps. The AP(5)A inhibition equations derived from this mechanism show theoretically that AP(5)A acts as a competitive inhibitor for the forward reaction and a mixed noncompetitive inhibitor for the backward reaction.	Acad Sinica, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS	Pan, XM (corresponding author), Acad Sinica, Inst Biophys, Natl Lab Biomacromol, 15 Datun Rd, Beijing 100101, Peoples R China.							ARATA Y, 1973, ANN NY ACAD SCI, V222, P230, DOI 10.1111/j.1749-6632.1973.tb15265.x; ATKINSON DE, 1977, CELLULAR ENERGY META, P85; Boyer P.D, 1973, ENZYMES, P279; CALLAGHAN OH, 1959, BIOCHEM J, V73, P473, DOI 10.1042/bj0730473; CHA S, 1968, J BIOL CHEM, V243, P820; CHAZIN WJ, 1989, P NATL ACAD SCI USA, V86, P2195, DOI 10.1073/pnas.86.7.2195; EVANS PA, 1987, NATURE, V329, P266, DOI 10.1038/329266a0; EVANS PA, 1989, BIOCHEMISTRY-US, V28, P362, DOI 10.1021/bi00427a050; HAMADA M, 1985, J BIOL CHEM, V260, P1595; HAMADA M, 1978, ARCH BIOCHEM BIOPHYS, V190, P772, DOI 10.1016/0003-9861(78)90338-7; HAMADA M, 1979, ARCH BIOCHEM BIOPHYS, V195, P155, DOI 10.1016/0003-9861(79)90338-2; Huang C Y, 1979, Methods Enzymol, V63, P54; KHOO JC, 1970, J BIOL CHEM, V245, P4163; Kuby S.A., 1962, ENZYMES, V6, P515; KUBY SA, 1978, ARCH BIOCHEM BIOPHYS, V187, P34, DOI 10.1016/0003-9861(78)90004-8; LIENHARD GE, 1973, J BIOL CHEM, V248, P1121; MARKLEY JL, 1970, P NATL ACAD SCI USA, V65, P645, DOI 10.1073/pnas.65.3.645; MATSUURA S, 1989, J BIOL CHEM, V264, P10148; MIWA S, 1983, AM J HEMATOL, V14, P325, DOI 10.1002/ajh.2830140403; Qualtieri A, 1997, BRIT J HAEMATOL, V99, P770, DOI 10.1046/j.1365-2141.1997.4953299.x; RHOADS DG, 1968, J BIOL CHEM, V243, P3963; SCHULZ GE, 1990, J MOL BIOL, V213, P627, DOI 10.1016/S0022-2836(05)80250-5; Sheng XR, 1997, FEBS LETT, V413, P429, DOI 10.1016/S0014-5793(97)00951-4; SVENSSON LA, 1992, J MOL BIOL, V223, P601, DOI 10.1016/0022-2836(92)90976-Q; TANIUCHI H, 1966, J BIOL CHEM, V241, P4366; Thomas G, 1997, J CLIN LAB ANAL, V11, P351; TOREN A, 1994, BRIT J HAEMATOL, V87, P376, DOI 10.1111/j.1365-2141.1994.tb04925.x; TSAI MD, 1991, BIOCHEMISTRY-US, V30, P6806, DOI 10.1021/bi00242a002; TUCKER PW, 1978, MOL CELL BIOCHEM, V22, P67, DOI 10.1007/BF00496235; VONRHEIN C, 1995, STRUCTURE, V3, P483, DOI 10.1016/S0969-2126(01)00181-2; Zhang HJ, 1998, J BIOL CHEM, V273, P7448, DOI 10.1074/jbc.273.13.7448; Zhang HJ, 1997, BIOCHEM BIOPH RES CO, V238, P382, DOI 10.1006/bbrc.1997.7301; Zhang HJ, 1998, BIOCHEM J, V333, P401, DOI 10.1042/bj3330401; ZHANG YL, 1993, BIOCHIM BIOPHYS ACTA, V1164, P61, DOI 10.1016/0167-4838(93)90112-5	34	50	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22238	22242		10.1074/jbc.274.32.22238	http://dx.doi.org/10.1074/jbc.274.32.22238			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428790	hybrid			2022-12-25	WOS:000081868400020
J	Spychala, J; Zimmermann, AG; Mitchell, BS				Spychala, J; Zimmermann, AG; Mitchell, BS			Tissue-specific regulation of the ecto-5 '-nucleotidase promoter - Role of the cAMP response element site in mediating repression by the upstream regulatory region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR GENE; TRANSCRIPTION FACTOR LEF-1; CELL LEUKEMIA LYMPHOMA; ADENOSINE-DEAMINASE; ENDOTHELIAL-CELLS; BETA-CATENIN; IN-VITRO; 5'-NUCLEOTIDASE; EXPRESSION; ENHANCER	We have isolated the 5' region of the ecto-5'-nucleotidase (low K-m 5'-NT) gene and established that a 969-base pair (bp) fragment confers cell-specific expression of a CAT reporter gene that correlates with the expression of endogenous ecto-5'-NT mRNA and enzymatic activity. A 768-bp upstream negative regulatory region has been identified that conferred lymphocyte-specific negative regulation in a heterologous system with a 244-bp deoxycytidine kinase core promoter. DNase I footprinting identified several protected areas including Sp1, Sp1/AP-2, and cAMP response element (CRE) binding sites within the 201-bp core promoter region and Sp1, NRE-2a, TCF-1/LEF-1, and Sp1/NF-AT binding sites in the upstream regulatory region. Whereas the CRE site was essential in mediating the negative activity of the upstream regulatory region in Jurkat but not in HeLa cells, mutation of the Sp1/AP-2 site decreased promoter activity in both cell lines, Electrophoretic mobility shift assay analysis of proteins binding to the CRE site identified both ATF-1 and ATF-2 in Jurkat cells. Finally, phorbol 12-myristate 13-acetate increased the activity of both the core and the 969-bp promoter fragments, and this increase was abrogated by mutations at the CRE site, In summary, we have identified a tissue-specific regulatory region 5' of the ecto-5'-NT core promoter that requires the presence of a functional CRE site within the basal promoter for its suppressive activity.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Internal Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Spychala, J (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, 1106 Mary Ellen Jones Bldg, Chapel Hill, NC 27599 USA.				NCI NIH HHS [R01-CA34085] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA034085] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BELARDINELLI L, 1989, PROG CARDIOVASC DIS, V32, P73, DOI 10.1016/0033-0620(89)90015-7; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Canbolat O, 1996, BREAST CANCER RES TR, V37, P189, DOI 10.1007/BF01806500; CHEN EH, 1995, J CLIN INVEST, V95, P1660, DOI 10.1172/JCI117841; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK AR, 1993, BIOCHEM J, V296, P521, DOI 10.1042/bj2960521; Costa M, 1996, EUR J BIOCHEM, V237, P532, DOI 10.1111/j.1432-1033.1996.00532.x; Costa M, 1998, EUR J BIOCHEM, V258, P123, DOI 10.1046/j.1432-1327.1998.2580123.x; CRONSTEIN BN, 1995, J INVEST MED, V43, P50; CRONSTEIN BN, 1986, J CLIN INVEST, V78, P760, DOI 10.1172/JCI112638; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DURAK I, 1994, FREE RADICAL BIO MED, V16, P825, DOI 10.1016/0891-5849(94)90199-6; ELY SW, 1992, CIRCULATION, V85, P893, DOI 10.1161/01.CIR.85.3.893; FLOCKE K, 1991, BIOCHIM BIOPHYS ACTA, V1076, P273, DOI 10.1016/0167-4838(91)90278-8; FUKUNAGA Y, 1989, BLOOD, V74, P2486; GIESE K, 1991, GENE DEV, V5, P2567, DOI 10.1101/gad.5.12b.2567; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GUTENSOHN W, 1990, CANCER-AM CANCER SOC, V66, P1755, DOI 10.1002/1097-0142(19901015)66:8<1755::AID-CNCR2820660819>3.0.CO;2-J; HAMBOR JE, 1993, MOL CELL BIOL, V13, P7056, DOI 10.1128/MCB.13.11.7056; Hansen KR, 1995, GENE, V167, P307, DOI 10.1016/0378-1119(95)00574-9; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hernandez-Munain C, 1998, MOL CELL BIOL, V18, P3223, DOI 10.1128/MCB.18.6.3223; HOLMBERG M, 1995, EUR J BIOCHEM, V231, P466, DOI 10.1111/j.1432-1033.1995.tb20720.x; Huang S, 1997, BLOOD, V90, P1600, DOI 10.1182/blood.V90.4.1600.1600_1600_1610; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Jiang K, 1998, BIOCHEM BIOPH RES CO, V246, P192, DOI 10.1006/bbrc.1998.8591; Khoo HE, 1996, CANCER LETT, V106, P17, DOI 10.1016/0304-3835(96)04289-9; LEIDEN JM, 1994, CURR OPIN IMMUNOL, V6, P231, DOI 10.1016/0952-7915(94)90096-5; LEIDEN JM, 1993, ANNU REV IMMUNOL, V11, P539, DOI 10.1146/annurev.iy.11.040193.002543; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; MACKENZIE WM, 1994, CANCER RES, V54, P3521; Mayall TP, 1997, GENE DEV, V11, P887, DOI 10.1101/gad.11.7.887; MEININGER CJ, 1990, AM J PHYSIOL, V258, pH198, DOI 10.1152/ajpheart.1990.258.1.H198; MISUMI Y, 1990, J BIOL CHEM, V265, P2178; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Ogbourne S, 1998, BIOCHEM J, V331, P1; Oh CK, 1997, BIOCHEM J, V323, P511, DOI 10.1042/bj3230511; PRAGER MD, 1984, CANCER LETT, V24, P81, DOI 10.1016/0304-3835(84)90083-1; QUAGLIATA F, 1974, CANCER RES, V34, P3197; SALAZARGONZALEZ JF, 1985, J IMMUNOL, V135, P1778; SHERIDAN PL, 1995, GENE DEV, V9, P2090, DOI 10.1101/gad.9.17.2090; SMITH SD, 1986, BLOOD, V67, P650; SPYCHALA J, 1994, ADV EXP MED BIOL, V370, P683; Spychala J, 1997, J IMMUNOL, V158, P4947; THOMPSON LF, 1986, J IMMUNOL, V137, P2496; THOMPSON LF, 1983, J CLIN INVEST, V71, P892, DOI 10.1172/JCI110843; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; WATERMAN M L, 1990, New Biologist, V2, P621; Williams BA, 1997, BIOCHEM BIOPH RES CO, V231, P264, DOI 10.1006/bbrc.1997.6077; Zimmermann A, 1996, ADV ENZYME REGUL, V36, P75, DOI 10.1016/0065-2571(95)00012-7	52	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22705	22712		10.1074/jbc.274.32.22705	http://dx.doi.org/10.1074/jbc.274.32.22705			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428853	hybrid			2022-12-25	WOS:000081868400083
J	Folly, P; Engel, N				Folly, P; Engel, N			Chlorophyll b to chlorophyll a conversion precedes chlorophyll degradation in Hordeum vulgare L.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLORELLA-PROTOTHECOIDES; STRUCTURE ELUCIDATION; SENESCENT COTYLEDONS; A CATABOLITE; BREAKDOWN; LEAVES; RAPE; CONSTITUTION; ETIOPLASTS; PORPHYRIN	This study reveals by in vivo deuterium labeling that in higher plants chlorophyll (Chl) b is converted to Chl a before degradation. For this purpose, de-greening of excised green primary leaves of barley (Hordeum vulgare) was induced by permanent darkness in the presence of heavy water (80 atom % H-2). The resulting Chl a catabolite in the plant extract was subjected to chemical degradation by chromic acid. 3-(2-Hydroxyethyl)-4-methylmaleimide, the key fragment that originates from the Chi catabolite, was isolated. High resolution H-1-, H-2-NMR and mass spectroscopy unequivocally demonstrates that a fraction of this maleimide fragment consists of a mono-deuterated methyl group. These results suggest that Chl b is converted into Chi a before degradation. Quantification proves that the initial ratio of Chi a:Chl b in the green plant is preserved to about 60-70% in the catabolite composition isolated from yellowing leaves, The incorporation of only one deuterium atom indicates the involvement of two distinguishable redox enzymes during the conversion.	Univ Fribourg, Inst Organ Chem, CH-1700 Fribourg, Switzerland	University of Fribourg	Engel, N (corresponding author), Univ Fribourg, Inst Organ Chem, Ch Musee 9, CH-1700 Fribourg, Switzerland.	norbert.enel@unifr.ch						ALLRED AL, 1969, CHEM COMMUN, P273; [Anonymous], 1960, J AM CHEM SOC, V82, P5575; BONNETT R, 1969, CHEM IND-LONDON, P107; BRITTON G, 1977, NATURE, V268, P81, DOI 10.1038/268081a0; CLARKE AR, 1997, COMPREHENSIVE BIOL C, V3, P1; COLOWICK SP, 1966, COMPREHENSIVE BIOCH, P1; *COMM AT WEIGHTS I, 1988, PURE APPL CHEM, V70, P217; Curty C, 1997, PLANT PHYSIOL BIOCH, V35, P707; Curty C, 1996, PHYTOCHEMISTRY, V42, P1531, DOI 10.1016/0031-9422(96)00155-0; DAVIS DB, 1988, R SOC CHEM SPEC PUBL, V68, P147; DOUGHERTY RC, 1966, J AM CHEM SOC, V88, P2854, DOI 10.1021/ja00964a045; Engel N, 1996, PLANT PHYSIOL BIOCH, V34, P77; ENGEL N, 1991, FEBS LETT, V293, P131, DOI 10.1016/0014-5793(91)81168-8; Gossauer A, 1996, J PHOTOCH PHOTOBIO B, V32, P141, DOI 10.1016/1011-1344(95)07257-8; HORTENSTEINER S, 1995, NEW PHYTOL, V129, P237, DOI 10.1111/j.1469-8137.1995.tb04293.x; ITO H, 1993, ARCH BIOCHEM BIOPHYS, V306, P148, DOI 10.1006/abbi.1993.1492; Ito H, 1996, J BIOL CHEM, V271, P1475, DOI 10.1074/jbc.271.3.1475; ITURRASPE J, 1995, J ORG CHEM, V60, P6664, DOI 10.1021/jo00126a007; KATZ JJ, 1966, J AM CHEM SOC, V88, P2856, DOI 10.1021/ja00964a046; KRAUTLER B, 1991, ANGEW CHEM INT EDIT, V30, P1315, DOI 10.1002/anie.199113151; LEEPER FJ, 1991, CHLOROPHYLLS, P407; MOSS GP, 1987, PURE APPL CHEM, V59, P779, DOI 10.1351/pac198759060779; Muhlecker W, 1996, PLANT PHYSIOL BIOCH, V34, P61; MUHLECKER W, 1993, HELV CHIM ACTA, V76, P2976, DOI 10.1002/hlca.19930760822; Panico R., 1993, GUIDE IUPAC NOMENCLA, V2nd; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; Porra RJ, 1997, PHOTOCHEM PHOTOBIOL, V65, P492, DOI 10.1111/j.1751-1097.1997.tb08596.x; RUDIGER W, 1969, H-S Z PHYSIOL CHEM, V350, P1291, DOI 10.1515/bchm2.1969.350.2.1291; RUDIGER W, 1970, ANGEW CHEM INT EDIT, V9, P473, DOI 10.1002/anie.197004731; Sanders J. K. M., 1990, MODERN NMR SPECTROSC; Scheer H., 1991, CHLOROPHYLLS, P3; Scheumann V, 1998, J BIOL CHEM, V273, P35102, DOI 10.1074/jbc.273.52.35102; Scheumann V, 1996, EUR J BIOCHEM, V242, P163, DOI 10.1111/j.1432-1033.1996.0163r.x; STUBBE J, 1990, ADV ENZYMOL RAMB, V63, P349; THIELE H, 1994, 1D WIN NMR MANUAL; Valasinas A, 1998, J ORG CHEM, V63, P1239, DOI 10.1021/jo971807l; WALSH C, 1979, ENZYMATIC REACTION M, P311	37	48	54	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21811	21816		10.1074/jbc.274.31.21811	http://dx.doi.org/10.1074/jbc.274.31.21811			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419497	hybrid			2022-12-25	WOS:000081721100050
J	Fonze, E; Vermeire, M; Nguyen-Disteche, M; Brasseur, R; Charlier, P				Fonze, E; Vermeire, M; Nguyen-Disteche, M; Brasseur, R; Charlier, P			The crystal structure of a penicilloyl-serine transferase of intermediate penicillin sensitivity - The DD-transpeptidase of Streptomyces K15	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDASE-CATALYZED REACTIONS; BACILLUS-LICHENIFORMIS 749/C; BETA-LACTAM HYDROLYSIS; CARBONYL DONORS; BINDING PROTEIN; STREPTOCOCCUS-PNEUMONIAE; ANGSTROM RESOLUTION; TARGET ENZYME; ALBUS G; HYDROPHOBICITY	The serine DD-transpeptidase/penicillin-binding protein of Streptomyces K15 catalyzes peptide bond formation in a way that mimics the penicillin-sensitive peptide cross-linking reaction involved in bacterial cell wall peptidoglycan assembly. The Streptomyces K15 enzyme is peculiar in that it can be considered as an intermediate between classical penicillin-binding proteins, for which benzylpenicillin is a very efficient inactivator, and the resistant penicillin-binding proteins that have a low penicillin affinity, With its moderate penicillin sensitivity, the Streptomyces K15 DD-transpeptidase would be helpful in the understanding of the structure-activity relationship of this penicillin-recognizing protein superfamily, The structure of the Streptomyces K15 enzyme has been determined by x-ray crystallography at 2.0-Angstrom resolution and refined to an R-factor of 18.6%. The fold adopted by this 262-amino acid polypeptide generates a two-domain structure that is close to those of class A beta-lactamases. However, the Streptomyces K15 enzyme has two particular structural features. It lacks the amino-terminal alpha-helix found in the other penicilloyl-serine transferases, and it exhibits, at its surface, an additional four-stranded beta-sheet, These two characteristics might serve to anchor the enzyme in the plasma membrane. The overall topology of the catalytic pocket of the Streptomyces K15 enzyme is also comparable to that of the class A beta-lactamases, except that the Omega-loop, which bears the essential catalytic Glu(166) residue in the class A beta-lactamases, is entirely modified. This loop adopts a conformation similar to those found in the Streptomyces R61 DD-carboxypeptidase and class C beta-lactamases, with no equivalent acidic residue.	Univ Liege, Ctr Ingn Prot, Inst Chim B6, B-4000 Sart Tilman, Belgium; Univ Liege, Serv Cristallog, Inst Phys B5, B-4000 Sart Tilman, Belgium; Fac Univ Sci Agron, Ctr Biophys Mol Numer, B-5030 Gembloux, Belgium	University of Liege; University of Liege; University of Liege	Fonze, E (corresponding author), Univ Liege, Ctr Ingn Prot, Inst Chim B6, B-4000 Sart Tilman, Belgium.							AMBLER RP, 1991, BIOCHEM J, V276, P269, DOI 10.1042/bj2760269; BRASSEUR R, 1991, J BIOL CHEM, V266, P16120; BRUNGER AT, 1992, X PLOR SYSTEM CRYSTA; DIDEBERG O, 1987, BIOCHEM J, V245, P911, DOI 10.1042/bj2450911; EISENBERG D, 1984, P NATL ACAD SCI-BIOL, V81, P140, DOI 10.1073/pnas.81.1.140; ENGLEBERT S, 1994, J MOL BIOL, V241, P295, DOI 10.1006/jmbi.1994.1504; FAUCHERE JL, 1988, J MOL GRAPHICS, V6, P203, DOI 10.1016/S0263-7855(98)80004-0; FONZE E, 1995, ACTA CRYSTALLOGR D, V51, P682, DOI 10.1107/S0907444994014496; FURET P, 1988, J MOL GRAPHICS, V6, P183; FUREY W, 1992, PHASES MANUAL; GHUYSEN JM, 1991, ANNU REV MICROBIOL, V45, P37, DOI 10.1146/annurev.mi.45.100191.000345; GRANDCHAMPS J, 1995, BIOCHEM J, V307, P335, DOI 10.1042/bj3070335; HACKBARTH CJ, 1989, ANTIMICROB AGENTS CH, V33, P995, DOI 10.1128/AAC.33.7.995; HERZBERG O, 1991, J MOL BIOL, V217, P701, DOI 10.1016/0022-2836(91)90527-D; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; JACOB F, 1990, BIOCHEM J, V271, P399, DOI 10.1042/bj2710399; JACOBDUBUISSON F, 1991, PROTEIN ENG, V4, P811, DOI 10.1093/protein/4.7.811; JAMIN M, 1993, BIOCHEM J, V292, P735, DOI 10.1042/bj2920735; JELSCH C, 1993, PROTEINS, V16, P364, DOI 10.1002/prot.340160406; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KELLY JA, 1995, J MOL BIOL, V254, P223, DOI 10.1006/jmbi.1995.0613; KNOX JR, 1991, J MOL BIOL, V220, P435, DOI 10.1016/0022-2836(91)90023-Y; Knox JR, 1996, CHEM BIOL, V3, P937, DOI 10.1016/S1074-5521(96)90182-9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEPAGE S, 1995, BIOCHEM J, V309, P49, DOI 10.1042/bj3090049; LEYHBOUILLE M, 1986, BIOCHEM J, V235, P177, DOI 10.1042/bj2350177; LEYHBOUILLE M, 1987, BIOCHEM J, V241, P893, DOI 10.1042/bj2410893; LOBOVSKY E, 1993, P NATL ACAD SCI USA, V90, P11257; MOEWS PC, 1990, PROTEINS, V7, P156, DOI 10.1002/prot.340070205; NGUYENDISTECHE M, 1982, BIOCHEM J, V207, P109, DOI 10.1042/bj2070109; NGUYENDISTECHE M, 1986, BIOCHEM J, V235, P167, DOI 10.1042/bj2350167; OEFNER C, 1990, NATURE, V343, P284, DOI 10.1038/343284a0; PALOMEQUEMESSIA P, 1992, BIOCHEM J, V288, P87, DOI 10.1042/bj2880087; Pares S, 1996, NAT STRUCT BIOL, V3, P284, DOI 10.1038/nsb0396-284; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; *SIEM IND AUT INC, 1993, SAINT SOFTW REF MAN; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; Tanford Ch., 1973, HYDROPHOBIC EFFECT F; WILKIN JM, 1994, BIOCHEM J, V301, P477, DOI 10.1042/bj3010477; ZHANG KYJ, 1993, ACTA CRYSTALLOGR D, V49, P213, DOI 10.1107/S0907444992007911	40	43	44	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21853	21860		10.1074/jbc.274.31.21853	http://dx.doi.org/10.1074/jbc.274.31.21853			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419503	hybrid			2022-12-25	WOS:000081721100056
J	Mackey, ZB; Niedergang, C; Meenissier-de Murcia, J; Leppard, J; Au, K; Chen, JWQ; de Murcia, G; Tomkinson, AE				Mackey, ZB; Niedergang, C; Meenissier-de Murcia, J; Leppard, J; Au, K; Chen, JWQ; de Murcia, G; Tomkinson, AE			DNA ligase III is recruited to DNA strand breaks by a zinc finger motif homologous to that of poly(ADP-ribose) polymerase - Identification of two functionally distinct DNA binding regions within DNA ligase III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA CAPPING ENZYME; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; MAMMALIAN-CELLS; XRCC1 PROTEIN; GENE-PRODUCT; VIRUS GENE; REPAIR; DOMAIN; EXPRESSION	Mammalian DNA ligases are composed of a conserved catalytic domain flanked by unrelated sequences. At the C-terminal end of the catalytic domain, there is a 16-amino acid sequence, known as the conserved peptide, whose role in the ligation reaction is unknown. Here we show that conserved positively charged residues at the C-terminal end of this motif are required for enzyme-AMP formation. These residues probably interact with the triphosphate tail of ATP, positioning it for nucleophilic attack by the active site lysine. Amino acid residues within the sequence RFPR, which is invariant in the conserved peptide of mammalian DNA ligases, play critical roles in the subsequent nucleotidyl transfer reaction that produces the DNA-adenylate intermediate. DNA binding by the N-terminal zinc finger of DNA ligase III, which is homologous with the two zinc fingers of poly(ADP-ribose) polymerase, is not required for DNA ligase activity in vitro or in vivo. However, this zinc finger enables DNA ligase III to interact with and ligate nicked DNA at physiological salt concentrations. We suggest that in vivo the DNA ligase III zinc finger may displace poly(ADP-ribose) polymerase from DNA strand breaks, allowing repair to occur.	Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA; Ecole Super Biotechnol Strasbourg, CEA, Lab Conventionne, CNRS,UPR 9003, F-67400 Illkirch Graffenstaden, France; Glaxo Wellcome Inc, Dept Mol Genet, Res Triangle Pk, NC 27709 USA	University of Texas System; University of Texas Health San Antonio; CEA; Centre National de la Recherche Scientifique (CNRS); GlaxoSmithKline	Tomkinson, AE (corresponding author), Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, 15355 Lambda Dr, San Antonio, TX 78245 USA.			Mackey, Zachary/0000-0002-4533-0973	NIGMS NIH HHS [GM47251] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047251, R29GM047251] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUER B, 1989, DNA-J MOLEC CELL BIO, V8, P575, DOI 10.1089/dna.1989.8.575; BARNES DE, 1990, P NATL ACAD SCI USA, V87, P6679, DOI 10.1073/pnas.87.17.6679; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387; Caldecott KW, 1995, NUCLEIC ACIDS RES, V23, P4836, DOI 10.1093/nar/23.23.4836; CHATTON B, 1995, BIOTECHNIQUES, V18, P142; CHEN JW, 1995, MOL CELL BIOL, V15, P5412; COURTNEY M, 1984, P NATL ACAD SCI-BIOL, V81, P669, DOI 10.1073/pnas.81.3.669; Critchlow SE, 1997, CURR BIOL, V7, P588, DOI 10.1016/S0960-9822(06)00258-2; Decker P, 1998, ARTHRITIS RHEUM-US, V41, P918, DOI 10.1002/1529-0131(199805)41:5<918::AID-ART20>3.0.CO;2-W; GRADWOHL G, 1990, P NATL ACAD SCI USA, V87, P2990, DOI 10.1073/pnas.87.8.2990; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Hakansson K, 1997, CELL, V89, P545, DOI 10.1016/S0092-8674(00)80236-6; HAMMOND JM, 1992, NUCLEIC ACIDS RES, V20, P2667, DOI 10.1093/nar/20.11.2667; Higuchi R., 1990, RECOMBINANT PCR PCR, P177; Ho CK, 1996, J VIROL, V70, P6658, DOI 10.1128/JVI.70.10.6658-6664.1996; IKEJIMA M, 1990, J BIOL CHEM, V265, P21907; KERR SM, 1991, EMBO J, V10, P4343, DOI 10.1002/j.1460-2075.1991.tb05012.x; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leber R, 1998, J BIOL CHEM, V273, P1794, DOI 10.1074/jbc.273.3.1794; Levin DS, 1997, P NATL ACAD SCI USA, V94, P12863, DOI 10.1073/pnas.94.24.12863; Mackey ZB, 1997, MOL CELL BIOL, V17, P989, DOI 10.1128/MCB.17.2.989; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; MAZEN A, 1989, NUCLEIC ACIDS RES, V17, P4689, DOI 10.1093/nar/17.12.4689; Menissier De Murcia Josiane, 1997, Proceedings of the National Academy of Sciences of the United States of America, V94, P7303; MENISSIERDEMURCIA J, 1989, J MOL BIOL, V210, P229, DOI 10.1016/0022-2836(89)90302-1; MOLINETE M, 1993, EMBO J, V12, P2109, DOI 10.1002/j.1460-2075.1993.tb05859.x; Nash RA, 1997, BIOCHEMISTRY-US, V36, P5207, DOI 10.1021/bi962281m; SHUMAN S, 1995, MOL MICROBIOL, V17, P405, DOI 10.1111/j.1365-2958.1995.mmi_17030405.x; SIMONIN F, 1991, ANAL BIOCHEM, V195, P226, DOI 10.1016/0003-2697(91)90321-J; SMITH GL, 1989, NUCLEIC ACIDS RES, V17, P9051, DOI 10.1093/nar/17.22.9051; Subramanya HS, 1996, CELL, V85, P607, DOI 10.1016/S0092-8674(00)81260-X; THOMPSON LH, 1990, MOL CELL BIOL, V10, P6160, DOI 10.1128/MCB.10.12.6160; TOMKINSON AE, 1990, J BIOL CHEM, V265, P12611; TOMKINSON AE, 1992, BIOCHEMISTRY-US, V31, P11762, DOI 10.1021/bi00162a013; TOMKINSON AE, 1991, P NATL ACAD SCI USA, V88, P400, DOI 10.1073/pnas.88.2.400; Tomkinson AE, 1998, MUTAT RES-DNA REPAIR, V407, P1, DOI 10.1016/S0921-8777(97)00050-5; Tomkinson AE, 1997, BIOESSAYS, V19, P893, DOI 10.1002/bies.950191009; WEI YF, 1995, MOL CELL BIOL, V15, P3206	40	88	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21679	21687		10.1074/jbc.274.31.21679	http://dx.doi.org/10.1074/jbc.274.31.21679			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419478	hybrid			2022-12-25	WOS:000081721100031
J	Wang, Y; Zhou, XY; Wang, H; Wang, HY; Huq, MS; Iliakis, G				Wang, Y; Zhou, XY; Wang, H; Wang, HY; Huq, MS; Iliakis, G			Roles of replication protein a and DNA-dependent protein kinase in the regulation of DNA replication following DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN VIRUS-40 DNA; MAMMALIAN-CELLS; ATAXIA-TELANGIECTASIA; BINDING-PROTEIN; IN-VITRO; S-PHASE; INVITRO; CHECKPOINT; RADIATION; EXTRACTS	Exposure of mammalian cells to DNA damage-inducing agents (DDIA) inhibits ongoing DNA replication. The molecular mechanism of this inhibition remains to be elucidated. We employed a simian virus 40 (SV40) based in vitro DNA replication assay to study biochemical aspects of this inhibition. We report here that the reduced DNA replication activity in extracts of DDIA-treated cells is partly caused by a reduction in the amount of replication protein A (RPA). We also report that the dominant inhibitory effect is caused by the DNA-dependent protein kinase (DNA-PK) which inactivates SV40 T antigen (TAg) by phosphorylation. The results demonstrate that RPA and DNA-PK are involved in the regulation of viral DNA replication after DNA damage and suggest that analogous processes regulate cellular DNA replication with the DNA-PK targeting the functional homologues of TAg.	Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, Dept Radiat Oncol, Philadelphia, PA 19107 USA	Jefferson University	Wang, Y (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, Dept Radiat Oncol, Philadelphia, PA 19107 USA.	ya.wang@mail.tju.edu			NATIONAL CANCER INSTITUTE [P30CA056036, R01CA056706, R29CA076203] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA56036, CA56706, CA76203] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLALUNISTURNER MJ, 1993, RADIAT RES, V134, P349, DOI 10.2307/3578196; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; Brush GS, 1995, METHOD ENZYMOL, V262, P522; BRUSH GS, 1994, P NATL ACAD SCI USA, V91, P12520, DOI 10.1073/pnas.91.26.12520; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; KENNY MK, 1990, J BIOL CHEM, V265, P769; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; Kurimasa A, 1999, P NATL ACAD SCI USA, V96, P1403, DOI 10.1073/pnas.96.4.1403; LEE SH, 1995, J BIOL CHEM, V270, P12801, DOI 10.1074/jbc.270.21.12801; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAINTER RB, 1976, BIOCHIM BIOPHYS ACTA, V418, P146, DOI 10.1016/0005-2787(76)90063-0; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; PETERSON SR, 1995, P NATL ACAD SCI USA, V92, P3171, DOI 10.1073/pnas.92.8.3171; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; SEROUSSI E, 1993, J BIOL CHEM, V268, P7147; Shirahige K, 1998, NATURE, V395, P618, DOI 10.1038/27007; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; Wang Y, 1997, CANCER RES, V57, P1654; Wang Y, 1999, RADIAT RES, V151, P59, DOI 10.2307/3579747; WANG Y, 1995, RADIAT RES, V142, P169, DOI 10.2307/3579025; WATANABE I, 1974, RADIAT RES, V58, P541, DOI 10.2307/3573922; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523	35	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					22060	22064		10.1074/jbc.274.31.22060	http://dx.doi.org/10.1074/jbc.274.31.22060			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419533	hybrid			2022-12-25	WOS:000081721100086
J	Werner, F; Razzaq, TM; Ellis, V				Werner, F; Razzaq, TM; Ellis, V			Tissue plasminogen activator binds to human vascular smooth muscle cells by a novel mechanism - Evidence for a reciprocal linkage between inhibition of catalytic activity and cellular binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BOUND UROKINASE; FACTOR VIIA; MOLECULAR MECHANISM; CRYSTAL-STRUCTURE; DOMAIN; CANCER; SITE; MICE; PROLIFERATION; EXPRESSION	Human vascular smooth muscle cells (VSMC) bind tissue plasminogen activator (tPA) specifically, saturably, and with relatively high affinity (K-d 25 nM), and this binding potentiates the activation of cell-associated plasminogen (Ellis, V., and Whawell, S. A. (1997) Blood 90, 2312-2322), We have observed that this binding can be efficiently competed by DFP-inactivated tPA and S478A-tPA but not by tPA inactivated with H-D-Phe-Pro-Arg-chloromethyl ketone (PPACK), VSMC-bound tPA also exhibited a markedly reduced inhibition by PPACK, displaying biphasic kinetics with second-order rate constants of 7.5 x 10(3) M-1 s(-1) and 0.48 x 10(3) M-1 s(-1), compared with 7.2 x 10(3) M-1 s(-1) in the solution phase. By contrast, tPA binding to fibrin was competed equally well by all forms of tPA, and its inhibition was unaltered. These effects were shown to extend to the physiological tPA inhibitor, plasminogen activator inhibitor 1. tPA.plasminogen activator inhibitor 1 complex did not compete tPA binding to VSMC, and the inhibition of bound tPA was reduced by 30-fold. The behavior of the various forms of tPA bound to VSMC correlated with conformational changes in tPA detected by CD spectroscopy. These data suggest that tPA binds to its specific high affinity site on VSMC by a novel mechanism involving the serine protease domain of tPA and distinct from its binding to fibrin, Furthermore, reciprocally linked conformational changes in tPA appear to have functionally significant effects on both the interaction of tPA with its VSMC binding site and the susceptibility of bound tPA to inhibition.	Thrombosis Res Inst, London SW3 6LR, England	Thrombosis Research Institute	Ellis, V (corresponding author), Thrombosis Res Inst, Emmanuel Kaye Bldg,Manresa Rd, London SW3 6LR, England.		Ellis, Vincent/D-1860-2009	Ellis, Vincent/0000-0003-1956-073X; Werner, Finn/0000-0002-3930-3821				BAKKER AHF, 1995, J BIOL CHEM, V270, P12355, DOI 10.1074/jbc.270.21.12355; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CLOWES AW, 1990, CIRC RES, V67, P61, DOI 10.1161/01.RES.67.1.61; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; DANO K, 1994, FIBRINOLYSIS, V8, P189, DOI 10.1016/0268-9499(94)90717-X; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; Dickinson CD, 1997, J BIOL CHEM, V272, P19875, DOI 10.1074/jbc.272.32.19875; Dickinson CD, 1996, P NATL ACAD SCI USA, V93, P14379, DOI 10.1073/pnas.93.25.14379; ELLIS V, 1991, J BIOL CHEM, V266, P12752; Ellis V, 1996, J BIOL CHEM, V271, P14779, DOI 10.1074/jbc.271.25.14779; Ellis V, 1997, TRENDS CARDIOVAS MED, V7, P227, DOI 10.1016/S1050-1738(97)00084-4; ELLIS V, 1990, J BIOL CHEM, V265, P9904; Ellis V, 1997, BLOOD, V90, P2312, DOI 10.1182/blood.V90.6.2312.2312_2312_2322; GRAINGER DJ, 1994, NATURE, V370, P460, DOI 10.1038/370460a0; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; Hembrough TA, 1996, J BIOL CHEM, V271, P25684, DOI 10.1074/jbc.271.41.25684; HENNESSEY JP, 1981, BIOCHEMISTRY-US, V20, P1085, DOI 10.1021/bi00508a007; Higashi S, 1996, J BIOL CHEM, V271, P26569, DOI 10.1074/jbc.271.43.26569; HORREVOETS AJG, 1994, J BIOL CHEM, V269, P12639; KITZ R, 1962, J BIOL CHEM, V237, P3245; Krem MM, 1998, PROTEINS, V30, P34, DOI 10.1002/(SICI)1097-0134(19980101)30:1<34::AID-PROT3>3.0.CO;2-K; Lamba D, 1996, J MOL BIOL, V258, P117, DOI 10.1006/jmbi.1996.0238; LIN W, 1986, BIOCHIM BIOPHYS ACTA, V870, P185; LUPU F, 1995, ARTERIOSCL THROM VAS, V15, P1444, DOI 10.1161/01.ATV.15.9.1444; LUPU F, 1993, ARTERIOSCLER THROMB, V13, P1090, DOI 10.1161/01.ATV.13.7.1090; Markus G, 1996, FIBRINOLYSIS, V10, P75, DOI 10.1016/S0268-9499(96)80082-8; MORE RS, 1995, CARDIOVASC RES, V29, P22, DOI 10.1016/0008-6363(96)88541-5; NODAHEINY H, 1995, ARTERIOSCL THROM VAS, V15, P37, DOI 10.1161/01.ATV.15.1.37; NOVOKHATNY VV, 1991, J BIOL CHEM, V266, P12994; ORTH K, 1994, J BIOL CHEM, V269, P21117; OTTER M, 1991, J BIOL CHEM, V266, P13931; PEPPER MS, 1993, J CELL BIOL, V122, P673, DOI 10.1083/jcb.122.3.673; RAGHUNATH PN, 1995, ARTERIOSCL THROM VAS, V15, P1432, DOI 10.1161/01.ATV.15.9.1432; RAMAKRISHNAN V, 1990, J BIOL CHEM, V265, P2755; Reidy MA, 1996, CIRC RES, V78, P405, DOI 10.1161/01.RES.78.3.405; REUNING U, 1994, BLOOD, V84, P3700, DOI 10.1182/blood.V84.11.3700.bloodjournal84113700; Romer J, 1996, NAT MED, V2, P287, DOI 10.1038/nm0396-287; RUSSELL ME, 1990, J BIOL CHEM, V265, P2569; Sorensen BB, 1997, J BIOL CHEM, V272, P11863, DOI 10.1074/jbc.272.18.11863; Ueba H, 1997, ARTERIOSCL THROM VAS, V17, P1512, DOI 10.1161/01.ATV.17.8.1512; VANZONNEVELD AJ, 1986, P NATL ACAD SCI USA, V83, P4670; VERHEIJEN JH, 1986, EMBO J, V5, P3525, DOI 10.1002/j.1460-2075.1986.tb04678.x	43	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21555	21561		10.1074/jbc.274.31.21555	http://dx.doi.org/10.1074/jbc.274.31.21555			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419460	hybrid			2022-12-25	WOS:000081721100013
J	Heine, H; Delude, RL; Monks, BG; Espevik, T; Golenbock, DT				Heine, H; Delude, RL; Monks, BG; Espevik, T; Golenbock, DT			Bacterial lipopolysaccharide induces expression of the stress response genes hop and H411	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; HEAT-SHOCK PROTEINS; MARFAN-SYNDROME; EXTRACELLULAR-MATRIX; BINDING-PROTEIN; LIPID-A; INTERLEUKIN-6 PRODUCTION; HUMAN-MONOCYTES; INDUCIBLE GENE; CANDIDATE GENE	CD14-transfected Chinese hamster ovary K1 fibroblasts (CHO/CD14) respond to lipopolysaccharide (LPS) by metabolizing arachidonic acid and with translocation of NF-KB to the nucleus. Although previous experiments failed to identify the production of tumor necrosis factor-alpha and interleukin (IL)-1 beta by CHO/CD14 cells, LPS did induce the expression of IL-6 mRNA and the subsequent release of the IL-6 protein. To identify additional LPS-inducible genes, a cDNA library derived from LPS-stimulated CHO/CD14 cells was screened by subtractive hybridization. Fourteen genes were found to be expressed differentially, and two were analyzed in detail: hop (Hsp70/Hsp90-organizing protein), which is the hamster homologue of the stress-inducible yeast gene, STI1, and clone H411, which encodes a novel LPS-inducible growth factor. In response to LPS, the expression of Hop mRNA was also increased in both the murine macrophage cell line, RAW 264.7, as well as in primary hamster macrophages. This suggested that the up-regulation of Hop expression is part of the macrophage stress response to LPS. Clone H411 encodes a protein in the epidermal growth factor-like repeat protein family. Overexpression of H411 cDNA in the RAW 264.7 macrophage cell line promoted an increased growth rate, suggesting that expression of H411 is part of the proliferative cell response to LPS. Both Hop and H411 represent novel gene products not previously recognized as part of the complex biological response to endotoxin.	Boston Med Ctr, Maxwell Finland Lab Infect Dis, Boston, MA 02118 USA; Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Surg, Boston, MA 02215 USA; Norwegian Univ Sci & Technol, N-7489 Trondheim, Norway	Boston Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Norwegian University of Science & Technology (NTNU)	Heine, H (corresponding author), Boston Med Ctr, Maxwell Finland Lab Infect Dis, Boston, MA 02118 USA.		Monks, Brian/B-8362-2015; Heine, Holger/H-4552-2012	Monks, Brian/0000-0003-4008-3093; Heine, Holger/0000-0001-8128-5068	NIAID NIH HHS [AI38515] Funding Source: Medline; NIDDK NIH HHS [DK50305] Funding Source: Medline; NIGMS NIH HHS [GM 54060] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI038515] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054060, R37GM054060] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AARDEN LA, 1987, EUR J IMMUNOL, V17, P1411, DOI 10.1002/eji.1830171004; ARGRAVES WS, 1990, J CELL BIOL, V111, P3155, DOI 10.1083/jcb.111.6.3155; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BARTOLD PM, 1991, J PERIODONTAL RES, V26, P339, DOI 10.1111/j.1600-0765.1991.tb02072.x; BAYSTON KF, 1990, J MED MICROBIOL, V31, P73, DOI 10.1099/00222615-31-2-73; Blatch GL, 1997, GENE, V194, P277, DOI 10.1016/S0378-1119(97)00206-0; BONE RC, 1993, CLIN MICROBIOL REV, V6, P57, DOI 10.1128/CMR.6.1.57-68.1993; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; BURDON RH, 1986, BIOCHEM J, V240, P313, DOI 10.1042/bj2400313; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CAVAILLON JM, 1990, INFECT IMMUN, V58, P2375, DOI 10.1128/IAI.58.7.2375-2382.1990; Chang HCJ, 1997, MOL CELL BIOL, V17, P318, DOI 10.1128/MCB.17.1.318; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; Chi SH, 1996, AM J PHYSIOL-CELL PH, V270, pC1017, DOI 10.1152/ajpcell.1996.270.4.C1017; DELUDE RL, 1994, J BIOL CHEM, V269, P22253; Delude RL, 1998, J IMMUNOL, V161, P3001; DENTENER MA, 1993, J IMMUNOL, V150, P2885; DIETZ HC, 1995, HUM MOL GENET, V4, P1799, DOI 10.1093/hmg/4.suppl_1.1799; ELDADAH ZA, 1995, J CLIN INVEST, V95, P874, DOI 10.1172/JCI117737; ENGEL J, 1989, FEBS LETT, V251, P1, DOI 10.1016/0014-5793(89)81417-6; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; Feinstein DL, 1996, J BIOL CHEM, V271, P17724, DOI 10.1074/jbc.271.30.17724; FINCATO G, 1991, BLOOD, V77, P579; FREY EA, 1992, J EXP MED, V176, P1665, DOI 10.1084/jem.176.6.1665; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GOLENBOCK DT, 1993, J BIOL CHEM, V268, P22055; GRENETT HE, 1990, NUCLEIC ACIDS RES, V18, P6455, DOI 10.1093/nar/18.21.6455; Gross M, 1996, J BIOL CHEM, V271, P16833, DOI 10.1074/jbc.271.28.16833; HAMPTON RY, 1991, NATURE, V352, P342, DOI 10.1038/352342a0; HENRICSON BE, 1993, INFECT IMMUN, V61, P2325, DOI 10.1128/IAI.61.6.2325-2333.1993; HEWETT DR, 1994, J MED GENET, V31, P338, DOI 10.1136/jmg.31.4.338; HEWETT DR, 1993, HUM MOL GENET, V2, P475, DOI 10.1093/hmg/2.4.475; HONORE B, 1992, J BIOL CHEM, V267, P8485; HOTCHKISS R, 1993, AM J PHYSIOL, V265, pR1447, DOI 10.1152/ajpregu.1993.265.6.R1447; JIRIK FR, 1989, J IMMUNOL, V142, P144; Johnson BD, 1998, J BIOL CHEM, V273, P3679, DOI 10.1074/jbc.273.6.3679; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; LAWLER J, 1986, BLOOD, V67, P1197; LECKACZERNIK B, 1995, MOL CELL BIOL, V15, P120, DOI 10.1128/MCB.15.1.120; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; MANTHEY CL, 1993, INFECT IMMUN, V61, P3518, DOI 10.1128/IAI.61.8.3518-3526.1993; MARTIN GR, 1988, ADV PROTEIN CHEM, V39, P1; Martin M A, 1991, Infect Dis Clin North Am, V5, P739; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; Morrison D C, 1979, Adv Immunol, V28, P293; NICOLET CM, 1989, MOL CELL BIOL, V9, P3638, DOI 10.1128/MCB.9.9.3638; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; NORTHEMANN W, 1989, J BIOL CHEM, V264, P16072; Ozaki T, 1997, BIOCHEM BIOPH RES CO, V237, P245, DOI 10.1006/bbrc.1997.7122; Poltorak A, 1998, BLOOD CELL MOL DIS, V24, P340, DOI 10.1006/bcmd.1998.0201; RIETSCHEL ET, 1992, SCI AM, V267, P54, DOI 10.1038/scientificamerican0892-54; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHUMER W, 1976, ANN SURG, V184, P333, DOI 10.1097/00000658-197609000-00011; SKIDMORE BJ, 1975, J IMMUNOL, V114, P770; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; TAKADA H, 1991, INFECT IMMUN, V59, P295, DOI 10.1128/IAI.59.1.295-301.1991; TANNENBAUM CS, 1988, J IMMUNOL, V140, P3640; WANG MH, 1991, INFECT IMMUN, V59, P4655, DOI 10.1128/IAI.59.12.4655-4664.1991; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; Wong HR, 1996, AM J RESP CELL MOL, V15, P745, DOI 10.1165/ajrcmb.15.6.8969269; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; XING Z, 1993, AM J RESP CELL MOL, V9, P255, DOI 10.1165/ajrcmb/9.3.255; YAMAJI Y, 1995, INFECT IMMUN, V63, P3576, DOI 10.1128/IAI.63.9.3576-3581.1995; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; ZHANG YH, 1994, INFECT IMMUN, V62, P4140, DOI 10.1128/IAI.62.10.4140-4144.1994; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701	69	34	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21049	21055		10.1074/jbc.274.30.21049	http://dx.doi.org/10.1074/jbc.274.30.21049			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409656	hybrid			2022-12-25	WOS:000081613100047
J	Kawabata, H; Yang, S; Hirama, T; Vuong, PT; Kawano, S; Gombart, AF; Koeffler, HP				Kawabata, H; Yang, S; Hirama, T; Vuong, PT; Kawano, S; Gombart, AF; Koeffler, HP			Molecular cloning of transferrin receptor 2 - A new member of the transferrin receptor-like family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; MEMBRANE ANTIGEN; CHROMOSOME 7Q; INDEPENDENT UPTAKE; IRON; EXPRESSION; GENE; BINDING; RNA; HEMOCHROMATOSIS	Transferrin receptor (TfR) plays a major role in cellular iron uptake through binding and internalizing a carrier protein transferrin (Tf). We have cloned, sequenced, and mapped a human gene homologous to TfR, termed TfR2. Two transcripts were expressed from this gene: a (similar to 2.9 kilobase pairs), and beta (similar to 2.5 kilobase pairs). The predicted amino acid sequence revealed that the TfR2-alpha protein was a type II membrane protein and shared a 45% identity and 66% similarity in its extracellular domain with TfR. The TfR2-beta protein lacked the aminoterminal portion of the TfR2-alpha protein including the putative transmembrane domain. Northern blot analysis showed that the a transcript was predominantly expressed in the liver. In addition, high expression occurred in K562, an erythromegakaryocytic cell line. To analyze the function of TfR2, Chinese hamster ovary TfR-deficient cells (CHO-TRVb cells) were stably transfected with FLAG-tagged TfR2-alpha These cells showed an increase in biotinylated Tf binding to the cell surface, which was competed by nonlabeled Tf, but not by lactoferrin. Also, these cells had a marked increase in Tf-bound Fe-55 uptake. Taken together, TfR2-alpha may be a second transferrin receptor that can mediate cellular iron transport.	Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Dept Med,Div Hematol Oncol,Burns & Allen Res Inst, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Kawabata, H (corresponding author), Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Dept Med,Div Hematol Oncol,Burns & Allen Res Inst, Los Angeles, CA 90048 USA.	hkawabat@ucla.edu			NATIONAL CANCER INSTITUTE [R01CA026038] Funding Source: NIH RePORTER; NCI NIH HHS [CA26038-20] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achille A, 1996, CANCER RES, V56, P3808; Asou H, 1996, JPN J CANCER RES, V87, P269, DOI 10.1111/j.1349-7006.1996.tb00216.x; Carter RE, 1996, P NATL ACAD SCI USA, V93, P749, DOI 10.1073/pnas.93.2.749; CHAN RYY, 1992, EXP CELL RES, V202, P326, DOI 10.1016/0014-4827(92)90082-J; CHARDSON DR, 1997, BIOCHIM BIOPHYS ACTA, V1331, P1; Chumakov AM, 1997, MOL CELL BIOL, V17, P1375, DOI 10.1128/MCB.17.3.1375; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; COTNER T, 1989, BLOOD, V73, P214; ERIKSSON LC, 1986, CARCINOGENESIS, V7, P1467, DOI 10.1093/carcin/7.9.1467; Feder JN, 1998, P NATL ACAD SCI USA, V95, P1472, DOI 10.1073/pnas.95.4.1472; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; Fleming MD, 1998, P NATL ACAD SCI USA, V95, P1148, DOI 10.1073/pnas.95.3.1148; FUKUDA M, 1981, P NATL ACAD SCI-BIOL, V78, P6299, DOI 10.1073/pnas.78.10.6299; Glockner G, 1998, GENOME RES, V8, P1060; Gregorakis A K, 1998, Semin Urol Oncol, V16, P2; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; ISRAELI RS, 1993, CANCER RES, V53, P227; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; Johnson AO, 1996, J CELL BIOL, V135, P1749, DOI 10.1083/jcb.135.6.1749; Johnson E, 1997, BLOOD REV, V11, P46, DOI 10.1016/S0268-960X(97)90006-0; Kauppi B, 1996, J MOL BIOL, V262, P706, DOI 10.1006/jmbi.1996.0546; Kerr J, 1996, ONCOGENE, V13, P1815; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; Kristjansson AK, 1997, ANTICANCER RES, V17, P93; LANOTTE M, 1991, BLOOD, V77, P1080; LASH A, 1995, ANN CLIN LAB SCI, V25, P20; LEIBOLD EA, 1990, NUCLEIC ACIDS RES, V18, P1819, DOI 10.1093/nar/18.7.1819; Levy JE, 1999, NAT GENET, V21, P396, DOI 10.1038/7727; Liang H, 1998, P NATL ACAD SCI USA, V95, P3781, DOI 10.1073/pnas.95.7.3781; MCGRAW TE, 1987, J CELL BIOL, V105, P207, DOI 10.1083/jcb.105.1.207; SCHNEIDER C, 1984, NATURE, V311, P675, DOI 10.1038/311675b0; STURROCK A, 1990, J BIOL CHEM, V265, P3139; SU SL, 1995, CANCER RES, V55, P1441; TESTA U, 1993, CRIT REV ONCOGENESIS, V4, P241; Trinder D, 1996, HEPATOLOGY, V23, P1512, DOI 10.1002/hep.510230631; Weissensteiner T, 1998, NUCLEIC ACIDS RES, V26, P687; Wu KJ, 1999, SCIENCE, V283, P676, DOI 10.1126/science.283.5402.676; Yang R, 1997, CANCER RES, V57, P913	39	499	530	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					20826	20832		10.1074/jbc.274.30.20826	http://dx.doi.org/10.1074/jbc.274.30.20826			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409623	hybrid			2022-12-25	WOS:000081613100014
J	Small, K; Feng, JF; Lorenz, J; Donnelly, ET; Yu, A; Im, MJ; Dorn, GW; Liggett, SB				Small, K; Feng, JF; Lorenz, J; Donnelly, ET; Yu, A; Im, MJ; Dorn, GW; Liggett, SB			Cardiac specific overexpression of transglutaminase II (G(h)) results in a unique hypertrophy phenotype independent of phospholipase C activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG LIVER TRANSGLUTAMINASE; MYOCARDIAL-CELL HYPERTROPHY; GTP-BINDING PROTEIN; ALPHA-1-ADRENERGIC RECEPTOR; GENE-EXPRESSION; TRANSGENIC MICE; VENTRICULAR MYOCYTES; PRESSURE-OVERLOAD; SIGNAL MEDIATOR; HEART	Tissue type transglutaminase (TGII, also known as G(h)) has been considered a multifunctional protein, with both transglutaminase and GTPase activity. The role of the latter function, which is proposed as a coupling mechanism between alpha(1)-adrenergic receptors and phospholipase C (PLC), is not well defined. TGII was overexpressed in transgenic mice in a cardiac specific manner to delineated relevant signaling pathways and their consequences in the heart. Cardiac transglutaminase activity in the highest expressing line was similar to 37-fold greater than in nontransgenic lines. However, in vivo signaling to PLC, as assessed by inositol phosphate turnover in [H-3]myoinositol organ bath atrial preparations, was not increased in the TGII mice at base line or in response to alpha(1)-adrenergic receptor stimulation; nor was protein kinase C alpha (PKC alpha) or PKC epsilon activity enhanced in the TGII transgenic mice. This is in contrast to mice moderately (similar to 5-fold) overexpressing G(alpha q), where inositol phosphate turnover and PKC activity were found to be clearly enhanced. TGII overexpression resulted in a remodeling of the heart with mild hypertrophy, elevated expression of beta-myosin heavy chain and alpha-skeletal actin genes, and diffuse interstitial fibrosis. Resting ventricular function was depressed, but responsiveness to beta-agonist was not impaired, This set of pathophysiologic findings is distinct from that evoked by overexpression of G(alpha q). We conclude that TGII acts in the heart primarily as a transglutaminase, and modulation of this function results in unique pathologic sequelae, Evidence for TGII acting as a G-protein-like transducer of receptor signaling to PLC in the heart is not supported by these studies.	Univ Cincinnati, Coll Med, Dept Med, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Physiol, Cincinnati, OH 45267 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol, Cleveland, OH 44195 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Cleveland Clinic Foundation	Liggett, SB (corresponding author), Univ Cincinnati, Coll Med, Dept Med, 231 Bethesda Ave, Cincinnati, OH 45267 USA.	Stephen.Liggett@UC.edu	liggett, stephen b/E-7453-2012	Liggett, Stephen B./0000-0002-0128-3669	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL052318, P01HL022619] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045985] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52318, HL22619] Funding Source: Medline; NIGMS NIH HHS [GM45985] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHYUTHAN KE, 1987, J BIOL CHEM, V262, P1901; ACHYUTHAN KE, 1988, J BIOL CHEM, V263, P14296; Adams JW, 1996, J BIOL CHEM, V271, P1179, DOI 10.1074/jbc.271.2.1179; Adams JW, 1998, P NATL ACAD SCI USA, V95, P10140, DOI 10.1073/pnas.95.17.10140; Aeschlimann Daniel, 1996, Seminars in Thrombosis and Hemostasis, V22, P437; BAEK KJ, 1993, J BIOL CHEM, V268, P27390; BIRCKBICHLER PJ, 1981, P NATL ACAD SCI-BIOL, V78, P5005, DOI 10.1073/pnas.78.8.5005; BISHOPRIC NH, 1987, J CLIN INVEST, V80, P1194, DOI 10.1172/JCI113179; Brodde OE, 1996, BASIC RES CARDIOL, V91, P35, DOI 10.1007/BF00795360; Chen SH, 1996, J BIOL CHEM, V271, P32385, DOI 10.1074/jbc.271.50.32385; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; DAS T, 1993, J BIOL CHEM, V268, P27398; DEJONGE HW, 1995, J MOL CELL CARDIOL, V27, P93, DOI 10.1016/S0022-2828(08)80010-7; DOLYNCHUK KN, 1994, PLAST RECONSTR SURG, V93, P567, DOI 10.1097/00006534-199493030-00020; DORN GW, 1994, AM J PHYSIOL, V267, pH400, DOI 10.1152/ajpheart.1994.267.1.H400; EPAND RM, 1994, ANAL BIOCHEM, V218, P241, DOI 10.1006/abio.1994.1173; Feng JF, 1996, J BIOL CHEM, V271, P16451, DOI 10.1074/jbc.271.28.16451; Folk J E, 1977, Adv Protein Chem, V31, P1, DOI 10.1016/S0065-3233(08)60217-X; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; Hwang KC, 1996, CIRCULATION, V94, P718, DOI 10.1161/01.CIR.94.4.718; Im MJ, 1997, CELL SIGNAL, V9, P477, DOI 10.1016/S0898-6568(97)00049-1; IM MJ, 1990, J BIOL CHEM, V265, P18952; IM MJ, 1990, J BIOL CHEM, V265, P18944; IWAI N, 1995, BIOCHEM BIOPH RES CO, V209, P527, DOI 10.1006/bbrc.1995.1533; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; Jones WK, 1996, J CLIN INVEST, V98, P1906, DOI 10.1172/JCI118992; KNOWLTON KU, 1993, J BIOL CHEM, V268, P15374; KOJIMA S, 1993, J CELL BIOL, V121, P439, DOI 10.1083/jcb.121.2.439; LEE KN, 1989, BIOCHEM BIOPH RES CO, V162, P1370, DOI 10.1016/0006-291X(89)90825-5; Lorenz JN, 1997, AM J PHYSIOL-HEART C, V272, pH1137, DOI 10.1152/ajpheart.1997.272.3.H1137; Melino G, 1998, FEBS LETT, V430, P59, DOI 10.1016/S0014-5793(98)00521-3; MILANO CA, 1994, P NATL ACAD SCI USA, V91, P10109, DOI 10.1073/pnas.91.21.10109; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Park ES, 1998, BIOCHEM J, V331, P283, DOI 10.1042/bj3310283; ROCKMAN HA, 1991, P NATL ACAD SCI USA, V88, P8277, DOI 10.1073/pnas.88.18.8277; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; Sakata Y, 1998, CIRCULATION, V97, P1488; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; TERZIC A, 1993, PHARMACOL REV, V45, P147; Turki J, 1996, P NATL ACAD SCI USA, V93, P10483, DOI 10.1073/pnas.93.19.10483; VANGRONINGEN JJM, 1995, INT J CANCER, V60, P383; WANG JY, 1993, GASTROENTEROLOGY, V104, P65, DOI 10.1016/0016-5085(93)90836-2; WASPE LE, 1990, J CLIN INVEST, V85, P1206, DOI 10.1172/JCI114554; Woodcock EA, 1997, MOL CELL BIOCHEM, V172, P121, DOI 10.1023/A:1006871722652; WU DQ, 1992, J BIOL CHEM, V267, P25798	48	89	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21291	21296		10.1074/jbc.274.30.21291	http://dx.doi.org/10.1074/jbc.274.30.21291			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409687	hybrid			2022-12-25	WOS:000081613100078
J	Goruppi, S; Ruaro, E; Varnum, B; Schneider, C				Goruppi, S; Ruaro, E; Varnum, B; Schneider, C			Gas6-mediated survival in NIH3T3 cells activates stress signalling cascade and is independent of Ras	ONCOGENE			English	Article						Axl; signal transduction; apoptosis	RECEPTOR TYROSINE KINASE; ARREST-SPECIFIC GENE-6; PROTEIN-KINASE; C-JUN; PHOSPHATIDYLINOSITOL 3-KINASE; GROWTH-FACTORS; PHOSPHOINOSITIDE 3-KINASE; SELECTIVE ACTIVATION; SIGNALING PATHWAY; MAP KINASES	Gas6 isa growth factor membrane of the vitamin K-dependent family of proteins which is preferentially expressed in quiescent cells. Gas6 was identified as the ligand for Axl tyrosine kinase receptor family. Consistent with this, Gas6 was previously reported to induce cell cycle re-entry of serum-starved NIH3T3 cells and to prevent cell death after complete growth factor withdrawal, the survival effect being uncoupled from Gas6-induced mitogenesis. We have previously demonstrated that both Gas6 mitogenic and survival effects are mediated by Src and the phosphatidylinositol3-OH kinase (PI3K). Here we report that Ras is required for Gas6 mitogenesis but is dispensable for its survival effect. Gas6-induced survival requires the activity of the small GTPases of the Rho family, Rac and Rho, together with the downstream kinase Pak. Overexpression of the respective dominant negative constructs abrogates Gas6-mediated survival functions. Addition of Gas6 to serum starved cells results in the activation of AKT/PKB and in the phosphorylation of the Bcl-2 family member, Bad. By ectopic expression of a catalytically inactive form of AKT/PKB, we demonstrate that AKT/PKB is necessary for Gas6-mediated survival functions. We further show evidence that Gas6 stimulation of serum starved NIH3T3 cells results in a transient ERK, JNK/SAPK: and p38 MAPK. activation. Blocking ERK activation did not influence Gas6-induced survival, suggesting that such pathway is not involved in Gas6 protection from cell death. On the contrary we found that the late constitutive increase of p38 MAPK activity associated with cell death was downregulated in Gas6-treated NIH3T3 cells thus suggesting that Gas6 might promote survival by interfering with this pathway. Taken together the evidence here provided identity elements involved in Gas6 signalling more specifically elucidating the pathway responsible for Gas6-induced cell survival under conditions that do not allow cell proliferation.	Lab Nazl Consorzio Interuniv Biotecnol, I-34012 Trieste, Italy; Univ Udine, Dipartimento Sci Tecnol Biomed, I-33100 Udine, Italy; Amgen Inc, Thousand Oaks, CA 91320 USA	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Udine; Amgen	Schneider, C (corresponding author), Lab Nazl Consorzio Interuniv Biotecnol, AREA Sci Pk,Padriciano 99, I-34012 Trieste, Italy.				Telethon [770] Funding Source: Medline	Telethon(Fondazione Telethon)		ALESSI DR, 1995, J BIOL CHEM, V254, P1146; Avanzi GC, 1997, EXP HEMATOL, V25, P1219; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Bellosta P, 1997, ONCOGENE, V15, P2387, DOI 10.1038/sj.onc.1201419; Biscardi JS, 1996, J BIOL CHEM, V271, P29049, DOI 10.1074/jbc.271.46.29049; BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; Braunger J, 1997, ONCOGENE, V14, P2619, DOI 10.1038/sj.onc.1201123; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; BUTTKE TM, 1993, J IMMUNOL METHODS, V157, P233, DOI 10.1016/0022-1759(93)90092-L; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Chen J, 1997, ONCOGENE, V14, P2033, DOI 10.1038/sj.onc.1201039; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; FRIDKIN SK, 1995, INFECT CONT HOSP EP, V16, P135; Goruppi S, 1997, MOL CELL BIOL, V17, P4442, DOI 10.1128/MCB.17.8.4442; Goruppi S, 1996, ONCOGENE, V12, P471; GRAHAM DK, 1994, CELL GROWTH DIFFER, V5, P647; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Khwaja A, 1997, J CELL BIOL, V139, P1017, DOI 10.1083/jcb.139.4.1017; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Li RH, 1996, J NEUROSCI, V16, P2012; LING L, 1995, MOL CELL BIOL, V15, P6582; Loeser RF, 1997, ARTHRITIS RHEUM, V40, P1455, DOI 10.1002/art.1780400814; Logan SK, 1997, MOL CELL BIOL, V17, P5784, DOI 10.1128/MCB.17.10.5784; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; Mark MR, 1996, J BIOL CHEM, V271, P9785, DOI 10.1074/jbc.271.16.9785; MARK MR, 1994, J BIOL CHEM, V269, P10720; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; Nagata K, 1996, J BIOL CHEM, V271, P30022, DOI 10.1074/jbc.271.47.30022; NAKANO T, 1995, J BIOL CHEM, V270, P5702, DOI 10.1074/jbc.270.11.5702; Nakano T, 1996, FEBS LETT, V387, P78, DOI 10.1016/0014-5793(96)00395-X; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OHASHI K, 1995, J BIOL CHEM, V270, P22681, DOI 10.1074/jbc.270.39.22681; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sakata N, 1995, J BIOL CHEM, V270, P30823, DOI 10.1074/jbc.270.51.30823; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; SYMONS M, 1996, TIBS, V22, P178; Tanaka K, 1998, ENDOCRINOLOGY, V139, P852, DOI 10.1210/en.139.3.852; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAO R, 1995, SCIENCE, V2675, P2003; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	79	93	98	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 22	1999	18	29					4224	4236		10.1038/sj.onc.1202788	http://dx.doi.org/10.1038/sj.onc.1202788			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218FK	10435635				2022-12-25	WOS:000081542400006
J	Aoe, T; Huber, I; Vasudevan, C; Watkins, SC; Romero, G; Cassel, D; Hsu, VW				Aoe, T; Huber, I; Vasudevan, C; Watkins, SC; Romero, G; Cassel, D; Hsu, VW			The KDEL receptor regulates a GTPase-activating protein for ADP-ribosylation factor 1 by interacting with its non-catalytic domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-EXCHANGE; LUMINAL ER PROTEINS; GOLGI MEMBRANES; BREFELDIN-A; ENDOPLASMIC-RETICULUM; COATED VESICLES; ARF PROTEIN; COATOMER; BINDING; COMPLEX	ADP-ribosylation factor 1 (ARF1) is a key regulator of transport in the secretory system. Like all small GTPases, deactivation of ARF1 requires a GTPase-activating protein (GAP) that promotes hydrolysis of GTP to GDP on ARF1, Structure-function analysis of a GAP for ARF1 revealed that its activity in vivo requires not only a domain that catalyzes hydrolysis of GTP on ARF1 but also a non-catalytic domain. In this study, we show that the non catalytic domain of GAP is required for its recruitment from cytosol to membranes and that this domain mediates the interaction of GAP with the transmembrane KDEL receptor. Blocking its interaction with the KDEL receptor leaves the GAP cytosolic and prevents the deactivation in vivo of Golgi-localized ARF1. Thus, these findings suggest that the KDEL receptor plays a critical role in the function of GAP by regulating its recruitment from cytosol to membranes, where it can then act on its membrane-restricted target, the GTP bound form of ARF1.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA; Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel; Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Cell Biol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Ctr Biol Imaging, Pittsburgh, PA 15261 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Technion Israel Institute of Technology; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Hsu, VW (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Div Rheumatol Allergy & Immunol, Smith Bldg,Rm 538B,1 Jimmy Fund Way, Boston, MA 02115 USA.		Watkins, Simon/ABG-2590-2021	Watkins, Simon/0000-0003-4092-1552				Antonny B, 1997, J BIOL CHEM, V272, P30848, DOI 10.1074/jbc.272.49.30848; Aoe T, 1997, EMBO J, V16, P7305, DOI 10.1093/emboj/16.24.7305; Aoe T, 1998, P NATL ACAD SCI USA, V95, P1624, DOI 10.1073/pnas.95.4.1624; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Bremser M, 1999, CELL, V96, P495, DOI 10.1016/S0092-8674(00)80654-6; Brown MT, 1998, MOL CELL BIOL, V18, P7038, DOI 10.1128/MCB.18.12.7038; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; CUKIERMAN E, 1995, SCIENCE, V270, P1999, DOI 10.1126/science.270.5244.1999; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; Goldberg J, 1999, CELL, V96, P893, DOI 10.1016/S0092-8674(00)80598-X; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HSU VW, 1992, CELL, V69, P625, DOI 10.1016/0092-8674(92)90226-3; Huber I, 1998, J BIOL CHEM, V273, P24786, DOI 10.1074/jbc.273.38.24786; Klarlund JK, 1998, J BIOL CHEM, V273, P1859, DOI 10.1074/jbc.273.4.1859; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; LEWIS MJ, 1990, CELL, V61, P1359, DOI 10.1016/0092-8674(90)90699-F; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; Meacci E, 1997, P NATL ACAD SCI USA, V94, P1745, DOI 10.1073/pnas.94.5.1745; Morinaga N, 1997, P NATL ACAD SCI USA, V94, P12926, DOI 10.1073/pnas.94.24.12926; Moss J, 1998, J BIOL CHEM, V273, P21431, DOI 10.1074/jbc.273.34.21431; Orci L, 1997, CELL, V90, P335, DOI 10.1016/S0092-8674(00)80341-4; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; PELHAM HRB, 1989, EMBO J, V8, P3171, DOI 10.1002/j.1460-2075.1989.tb08475.x; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; Poon PP, 1999, EMBO J, V18, P555, DOI 10.1093/emboj/18.3.555; Premont RT, 1998, P NATL ACAD SCI USA, V95, P14082, DOI 10.1073/pnas.95.24.14082; RANDAZZO PA, 1993, J BIOL CHEM, V268, P9555; ROSSIE KM, 1992, SCAND J RHEUMATOL, V21, P109, DOI 10.3109/03009749209095080; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; TANIGAWA G, 1993, J CELL BIOL, V123, P1365, DOI 10.1083/jcb.123.6.1365; TEAL SB, 1994, J BIOL CHEM, V269, P3135; TSAI SC, 1992, P NATL ACAD SCI USA, V89, P9272, DOI 10.1073/pnas.89.19.9272; Vasudevan C, 1998, J CELL SCI, V111, P1277; Zhu YX, 1998, MOL BIOL CELL, V9, P1323, DOI 10.1091/mbc.9.6.1323	40	35	35	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20545	20549		10.1074/jbc.274.29.20545	http://dx.doi.org/10.1074/jbc.274.29.20545			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400684	hybrid			2022-12-25	WOS:000081438300077
J	Bonfils, C; Gaudet, P; Tsang, A				Bonfils, C; Gaudet, P; Tsang, A			Identification of cis-regulating elements and trans-acting factors regulating the expression of the gene encoding the small subunit of ribonucleotide reductase in Dictyostelium discoideum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRESPORE-SPECIFIC GENE; CELL-CYCLE; SEQUENCE ELEMENT; DNA-DAMAGE; PROMOTER ELEMENTS; INDUCIBLE GENE; CAMP; INDUCTION; PROTEIN; TRANSCRIPTION	We have examined the promoter of rnrB, the gene encoding the small subunit of ribonucleotide reductase of Dictyostelium discoideum, using lacZ as a reporter gene. Deletion analysis showed that expression of this gene in vegetative cells involves an AT-rich element, whereas its expression in prespore cells during development requires a region encompassing two G/C-rich elements, designated box A and box B, Removal of boxes A and B results in very low level of activity. When either box A or box B is deleted, prestalk. cells adjacent to the prespore zone also express beta-galactosidase, The behavior of these cis-regulatory elements implies that the mechanism regulating the prespore-specific expression of rnrB is different from that regulating other known prespore genes. We have used electrophoretic mobility shift assays to identify factors that interact with box A and box B, Box A interacts with a factor that is found in the nuclear fraction. While box B interacts with a factor that is present in the cytosolic fraction throughout growth and development, its presence in the nuclear fraction is developmentally regulated, Results from competition assays suggest that both box A and box B interact with transcriptional activators that have not been characterized previously.	Concordia Univ, Dept Biol, Montreal, PQ H3G 1M8, Canada; Concordia Univ, Dept Chem & Biochem, Montreal, PQ H3G 1M8, Canada; Concordia Univ, Ctr Struct & Funct Genom, Montreal, PQ H3G 1M8, Canada	Concordia University - Canada; Concordia University - Canada; Concordia University - Canada	Tsang, A (corresponding author), Concordia Univ, Dept Biol, 1455 de Maisonneuve Blvd W, Montreal, PQ H3G 1M8, Canada.							ASHWORTH JM, 1970, BIOCHEM J, V119, P175, DOI 10.1042/bj1190175; BARKLIS E, 1985, MOL CELL BIOL, V5, P1465, DOI 10.1128/MCB.5.6.1465; BJORKLUND S, 1990, BIOCHEMISTRY-US, V29, P5452; BONFILS C, 1994, MOL CELL BIOCHEM, V139, P159, DOI 10.1007/BF01081739; CECCARELLI A, 1992, DEV BIOL, V152, P188, DOI 10.1016/0012-1606(92)90169-H; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; DATTA S, 1988, GENE DEV, V2, P294, DOI 10.1101/gad.2.3.294; DATTA S, 1987, MOL CELL BIOL, V7, P149, DOI 10.1128/MCB.7.1.149; DEERING RA, 1982, J GEN MICROBIOL, V128, P2439; DINGERMANN T, 1989, GENE, V85, P353, DOI 10.1016/0378-1119(89)90428-9; DURSTON AJ, 1978, EXP CELL RES, V115, P454, DOI 10.1016/0014-4827(78)90308-7; EARLY AE, 1987, GENE, V59, P99, DOI 10.1016/0378-1119(87)90270-8; EARLY AE, 1989, NUCLEIC ACIDS RES, V17, P6473; ELLEDGE SJ, 1989, MOL CELL BIOL, V9, P4932, DOI 10.1128/MCB.9.11.4932; ELLEDGE SJ, 1990, GENE DEV, V4, P740, DOI 10.1101/gad.4.5.740; ELLEDGE SJ, 1987, MOL CELL BIOL, V7, P2783, DOI 10.1128/MCB.7.8.2783; ENGSTROM Y, 1985, J BIOL CHEM, V260, P9114; ERIKSSON S, 1984, J BIOL CHEM, V259, P1695; ESCH RK, 1992, NUCLEIC ACIDS RES, V20, P1325; ESCH RK, 1991, GENE DEV, V5, P9, DOI 10.1101/gad.5.1.9; Filatov D, 1996, J BIOL CHEM, V271, P23698, DOI 10.1074/jbc.271.39.23698; FOSNAUGH KL, 1993, DEV BIOL, V157, P38, DOI 10.1006/dbio.1993.1110; FRANKE J, 1987, DEV BIOL, V124, P504, DOI 10.1016/0012-1606(87)90503-3; Gollop R, 1997, DEVELOPMENT, V124, P3395; GRANT CE, 1990, NUCLEIC ACIDS RES, V18, P5457, DOI 10.1093/nar/18.18.5457; HABERSTROH L, 1990, GENE DEV, V4, P596, DOI 10.1101/gad.4.4.596; HABERSTROH L, 1991, DEVELOPMENT, V113, P947; HARWOOD AJ, 1990, NUCLEIC ACIDS RES, V18, P4292, DOI 10.1093/nar/18.14.4292; HJORTH AL, 1989, GENE DEV, V3, P747, DOI 10.1101/gad.3.6.747; HJORTH AL, 1990, GENE DEV, V4, P419, DOI 10.1101/gad.4.3.419; HORI R, 1994, NUCLEIC ACIDS RES, V22, P5099, DOI 10.1093/nar/22.23.5099; HURD HK, 1987, MOL CELL BIOL, V7, P3673, DOI 10.1128/MCB.7.10.3673; HURTA RAR, 1992, J BIOL CHEM, V267, P7066; Kawata T, 1997, CELL, V89, P909, DOI 10.1016/S0092-8674(00)80276-7; KIMMEL AR, 1983, NUCLEIC ACIDS RES, V11, P541, DOI 10.1093/nar/11.2.541; MANIAK M, 1990, NUCLEIC ACIDS RES, V18, P3211, DOI 10.1093/nar/18.11.3211; MCPHERSON CE, 1993, J MOL BIOL, V232, P386, DOI 10.1006/jmbi.1993.1398; PAVLOVIC J, 1989, MOL CELL BIOL, V9, P4660, DOI 10.1128/MCB.9.11.4660; PEARS CJ, 1987, EMBO J, V6, P195, DOI 10.1002/j.1460-2075.1987.tb04738.x; POWELLCOFFMAN JA, 1994, DEVELOPMENT, V120, P1601; POWELLCOFFMAN JA, 1994, MOL CELL BIOL, V14, P5840, DOI 10.1128/MCB.14.9.5840; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNITZLER GR, 1994, GENE DEV, V8, P502, DOI 10.1101/gad.8.4.502; SHAULSKY G, 1995, P NATL ACAD SCI USA, V92, P5660, DOI 10.1073/pnas.92.12.5660; Sussman M., 1966, METHOD CELL PHYSIOL, V2, P397; Szekeres T, 1997, CRIT REV CL LAB SCI, V34, P503, DOI 10.3109/10408369709006424; THELANDER L, 1980, J BIOL CHEM, V255, P7426; Tsang A, 1996, BBA-GENE STRUCT EXPR, V1309, P100, DOI 10.1016/S0167-4781(96)00109-1; VAUTI F, 1990, MOL CELL BIOL, V10, P4080, DOI 10.1128/MCB.10.8.4080; ZADAHAMES IM, 1978, DEV BIOL, V63, P307, DOI 10.1016/0012-1606(78)90136-7; ZIMMERMAN W, 1993, DEV BIOL, V160, P178, DOI 10.1006/dbio.1993.1296	52	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20384	20390		10.1074/jbc.274.29.20384	http://dx.doi.org/10.1074/jbc.274.29.20384			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400662	hybrid			2022-12-25	WOS:000081438300055
J	Nadkarni, V; Gabbay, KH; Bohren, KM; Sheikh-Hamad, D				Nadkarni, V; Gabbay, KH; Bohren, KM; Sheikh-Hamad, D			Osmotic response element enhancer activity - Regulation through p38 kinase and mitogen-activated extracellular signal-regulated kinase kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDOSE REDUCTASE GENE; AMINO-TERMINAL KINASES; CANINE KIDNEY-CELLS; PROTEIN-KINASE; MOLECULAR-CLONING; HYPERTONIC STRESS; MAMMALIAN-CELLS; TRANSPORTER; BETAINE; CDNA	Hypertonicity induces a group of genes that are responsible for the intracellular accumulation of protective organic osmolytes such as sorbitol and betaine. Two representative genes are the aldose reductase enzyme (AR, EC 1.1.1.21), which is responsible for the conversion of glucose to sorbitol, and the betaine transporter (BGT1), which mediates Na+-coupled betaine uptake in response to osmotic stress. We recently reported that the induction of BGT1 mRNA in the renal epithelial Madin-Darby canine kidney cell line is inhibited by SB203580, a specific p38 kinase inhibitor. In these studies we report that the hypertonic induction of aldose reductase mRNA in HepG2 cells as well as the osmotic response element (ORE) driven reporter gene expression in transfected HepG2 cells are both inhibited by SB203580, suggesting that p38 kinase mediates the activation and/or binding of the transcription factor(s) to the ORE. Electrophoretic gel mobility shift assays with cell extracts prepared from SB203580-treated, hypertonically stressed HepG2 cells further show that the binding of trans-acting factors to the ORE is prevented and is thus also dependent on the activity of p38 kinase. Similarly, treatment of hypertonically stressed cells with PD098059, a mitogen-activated extracellular regulated kinase kinase (MEK1) inhibitor, results in inhibition of the hypertonic induction of aldose reductase mRNA ORE- driven reporter gene expression, and the binding of trans-acting factors to the ORE. ORE-driven reporter gene expression was not affected by p38 kinase inhibition or MEK1 inhibition in cells incubated in isoosmotic media, These data indicate that p38 kinase and MEK1 are involved in the regulation of the hyperosmotic stress response.	Baylor Coll Med, Dept Med, Div Renal, Houston, TX 77030 USA; Baylor Coll Med, Harry B & Aileen Gordon Diabet Res Lab, Mol Diabet & Metab Sect, Dept Pediat, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Sheikh-Hamad, D (corresponding author), Baylor Coll Med, Dept Med, Div Renal, Houston, TX 77030 USA.			Bohren, Kurt/0000-0002-3183-4118	NATIONAL EYE INSTITUTE [R01EY011018] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055137] Funding Source: NIH RePORTER; NEI NIH HHS [EY11018] Funding Source: Medline; NIDDK NIH HHS [DK55137] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERTYN J, 1994, MOL CELL BIOL, V14, P4135, DOI 10.1128/MCB.14.6.4135; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BOHREN KM, 1989, J BIOL CHEM, V264, P9547; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Denkert C, 1998, ARCH BIOCHEM BIOPHYS, V354, P172, DOI 10.1006/abbi.1998.0661; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Ferraris JD, 1996, J BIOL CHEM, V271, P18318, DOI 10.1074/jbc.271.31.18318; GABBAY KH, 1973, NEW ENGL J MED, V288, P831, DOI 10.1056/NEJM197304192881609; GARCIAPEREZ A, 1989, J BIOL CHEM, V264, P16815; GARCIAPEREZ A, 1991, PHYSIOL REV, V71, P1081, DOI 10.1152/physrev.1991.71.4.1081; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; ITOH T, 1994, J CLIN INVEST, V93, P2387, DOI 10.1172/JCI117245; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Ko BCB, 1997, J BIOL CHEM, V272, P16431, DOI 10.1074/jbc.272.26.16431; Kultz D, 1997, J BIOL CHEM, V272, P13165, DOI 10.1074/jbc.272.20.13165; KWON HM, 1992, J BIOL CHEM, V267, P6297; KWON HM, 1995, BIOCHEM BIOPH RES CO, V213, P975, DOI 10.1006/bbrc.1995.2224; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; Miyakawa H, 1999, P NATL ACAD SCI USA, V96, P2538, DOI 10.1073/pnas.96.5.2538; MORIGUCHI T, 1995, J BIOL CHEM, V270, P12969, DOI 10.1074/jbc.270.22.12969; MORIYAMA T, 1989, J BIOL CHEM, V264, P16810; POMBO CM, 1994, J BIOL CHEM, V269, P26546; Ruepp B, 1996, P NATL ACAD SCI USA, V93, P8624, DOI 10.1073/pnas.93.16.8624; Sheikh-Hamad D, 1998, J BIOL CHEM, V273, P1832, DOI 10.1074/jbc.273.3.1832; Taha C, 1997, AM J PHYSIOL-ENDOC M, V273, pE68, DOI 10.1152/ajpendo.1997.273.1.E68; TAKENAKA M, 1994, J BIOL CHEM, V269, P29379; UCHIDA S, 1992, P NATL ACAD SCI USA, V89, P8230, DOI 10.1073/pnas.89.17.8230; WANG K, 1993, J BIOL CHEM, V268, P16052; Wolfe SA, 1997, NATURE, V385, P172, DOI 10.1038/385172a0; YAMAUCHI A, 1992, J BIOL CHEM, V267, P649; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124	33	78	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20185	20190		10.1074/jbc.274.29.20185	http://dx.doi.org/10.1074/jbc.274.29.20185			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400634	hybrid			2022-12-25	WOS:000081438300027
J	Gaschet, J; Hsu, VW				Gaschet, J; Hsu, VW			Distribution of ARF6 between membrane and cytosol is regulated by its GTPase cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; RECEPTOR-MEDIATED ENDOCYTOSIS; NUCLEOTIDE-EXCHANGE PROTEIN; GOLGI MEMBRANES; GUANINE-NUCLEOTIDE; ACTIVATING PROTEIN; BREFELDIN-A; BINDING PROTEIN; RAC1-INTERACTING PROTEIN; TRANSPORT VESICLES	The ADP-ribosylation factor (ARF) subfamily of small GTPases regulates intracellular transport. Although much is known about how ARF1 regulates transport in the secretory pathways, regulation of the endocytic pathways by ARF6 remains less understood. In particular, whereas cycling of ARF1 between membrane and cytosol represents a major mechanism of regulating its function, this regulation has been questioned for ARF6, In this study, we found that ARF6 is distributed both on membranes and in the cytosol, Cytosolic ARF6 is recruited to membranes in a GTP-dependent manner that is fundamentally similar to ARF1. However, unlike ARF1, release of membrane-bound ARF6 to the cytosol requires hydrolysis of GTP that is sensitive to the level of magnesium, These findings suggest that the GTPase cycle of ARF6 also regulates its distribution between membrane and cytosol and that this form of regulation will also likely be important for the function of ARF6. Moreover, as ARF6 has little intrinsic ability to hydrolyze GTP, magnesium concentration most likely affects the release of membrane-bound ARF6 by altering the activity of its GTPase-activating protein.	Harvard Univ, Dept Med, Div Rheumatol Allergy & Immunol, Brigham & Womens Hosp,Med Sch, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Hsu, VW (corresponding author), Harvard Univ, Dept Med, Div Rheumatol Allergy & Immunol, Brigham & Womens Hosp,Med Sch, Smith 538B,1 Jimmy Fund Way, Boston, MA 02115 USA.		Gaschet, Joelle/F-6761-2013	Gaschet, Joelle/0000-0003-2154-1255				BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Cavenagh MM, 1996, J BIOL CHEM, V271, P21767, DOI 10.1074/jbc.271.36.21767; CUKIERMAN E, 1995, SCIENCE, V270, P1999, DOI 10.1126/science.270.5244.1999; D'Souza-Schorey C, 1997, EMBO J, V16, P5445, DOI 10.1093/emboj/16.17.5445; D'Souza-Schorey C, 1998, J CELL BIOL, V140, P603, DOI 10.1083/jcb.140.3.603; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; DASCHER C, 1994, J BIOL CHEM, V269, P1437; Ding M, 1996, J BIOL CHEM, V271, P24005, DOI 10.1074/jbc.271.39.24005; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FRANCO M, 1995, J BIOL CHEM, V270, P1337, DOI 10.1074/jbc.270.3.1337; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; Meacci E, 1997, P NATL ACAD SCI USA, V94, P1745, DOI 10.1073/pnas.94.5.1745; Morinaga N, 1997, P NATL ACAD SCI USA, V94, P12926, DOI 10.1073/pnas.94.24.12926; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Ooi CE, 1998, J CELL BIOL, V142, P391, DOI 10.1083/jcb.142.2.391; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; Peyroche A, 1996, NATURE, V384, P479, DOI 10.1038/384479a0; Premont RT, 1998, P NATL ACAD SCI USA, V95, P14082, DOI 10.1073/pnas.95.24.14082; Radhakrishna H, 1996, J CELL BIOL, V134, P935, DOI 10.1083/jcb.134.4.935; Randazzo PA, 1997, BIOCHEM J, V324, P413, DOI 10.1042/bj3240413; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; RANDAZZO PA, 1993, J BIOL CHEM, V268, P9555; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Sanchez-Madrid F, 1999, EMBO J, V18, P501, DOI 10.1093/emboj/18.3.501; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Song J, 1998, J CELL SCI, V111, P2257; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; TANIGAWA G, 1993, J CELL BIOL, V123, P1365, DOI 10.1083/jcb.123.6.1365; TEAL SB, 1994, J BIOL CHEM, V269, P3135; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; TSAI SC, 1992, P NATL ACAD SCI USA, V89, P9272, DOI 10.1073/pnas.89.19.9272; VanAelst L, 1996, EMBO J, V15, P3778, DOI 10.1002/j.1460-2075.1996.tb00751.x; WELSH CF, 1994, J BIOL CHEM, V269, P15583; West MA, 1997, J CELL BIOL, V138, P1239, DOI 10.1083/jcb.138.6.1239; Yang CZ, 1998, J BIOL CHEM, V273, P4006, DOI 10.1074/jbc.273.7.4006	43	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					20040	20045		10.1074/jbc.274.28.20040	http://dx.doi.org/10.1074/jbc.274.28.20040			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391955	hybrid			2022-12-25	WOS:000081377300075
J	Kodama, A; Takaishi, K; Nakano, K; Nishioka, H; Takai, Y				Kodama, A; Takaishi, K; Nakano, K; Nishioka, H; Takai, Y			Involvement of Cdc42 small G protein in cell-cell adhesion, migration and morphology of MDCK cells	ONCOGENE			English	Article						Cdc42Hs; G25K; cadherin; cell adhesion; cell migration; cell morphology	FILAMENT-BINDING PROTEIN; RAC1 SMALL GTPASES; ADHERENS-TYPE JUNCTIONS; FOCAL ADHESIONS; TIGHT JUNCTIONS; ACTIN-CYTOSKELETON; MOLECULAR CHARACTERIZATION; CA2+-DEPENDENT EXOCYTOSIS; SACCHAROMYCES-CEREVISIAE; CYTOPLASMIC DOMAIN	The Rho small G protein family consists of the Rho, Rac, and Cdc42 subfamilies and regulates various cell functions through reorganization of the actin cytoskeleton. We previously showed that the Rho subfamily regulates the formation of stress fibers and focal adhesions whereas the Rac subfamily regulates the E-cadherin-based cell-cell adhesion in MDCK cells, We studied here tbe function of the Cdc42 subfamily, consisting of two members, Cdc42Hs and G25k, in cell adhesion, migration, and morphology of MDCK cells. For this purpose, we made and used MDCK cell lines stably expressing each of dominant active mutants of Cdc42Hs (sMDCK-Cdc42HsDA)and G25K (sMDCK-G25KDA). Actin filaments at the cell-cell adhesion sites increased in both sMDCK-Cdc42HsDA and -G25KDA cells. Both E-cadherin and beta-catenin, adherens junctional proteins, at the cell-cell adhesion sites also increased in both sMDCK-Cdc42HsDA and -G25KDA cells. Electron microscopic analysis revealed that sMDCK-Cdc42NsDA cells tightly contacted with each other throughout the lateral membranes. Moreover, both the HGF- and TPA-induced disruption of the cadherin-based cell-cell adhesion and the subsequent cell migration were inhibited in both sMDCK-Cdc42HsDA and -G25KDA cells. Go-expression of the dominant negative mutant of Rad, a member of the Rac subfamily, with the dominant active mutant of Cdc42Hs did not inhibit the increased accumulation of actin filaments at the cell-cell adhesion sites. These results suggest that the Cdc42 subfamily is involved in the cadherin-based cell-cell adhesion in a manner independent of the Rac subfamily. Furthermore, the cells were frequently enveloped by the large multinuclear cells in both sMDCK-Gdc42HsDA and -G25KDA cells. Video microscopic analysis revealed that the cells were engulfed by the large cells during cytokinesis.	Osaka Univ, Sch Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan; JCR Pharmaceut Co Ltd, Japan Sci & Technol Corp, ERATO, Takai Biotimer Project,Nishi Ku, Kobe, Hyogo 6512241, Japan	Osaka University; Japan Science & Technology Agency (JST)	Takai, Y (corresponding author), Osaka Univ, Sch Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.							ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; Allen WE, 1998, J CELL BIOL, V141, P1147, DOI 10.1083/jcb.141.5.1147; ANDERSON JM, 1995, AM J PHYSIOL, V269, P467; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; CITI S, 1988, NATURE, V333, P272, DOI 10.1038/333272a0; DRECHSEL DN, 1996, CURR BIOL, V7, P12; Dutartre H, 1996, J CELL SCI, V109, P367; EATON S, 1995, J CELL BIOL, V131, P151, DOI 10.1083/jcb.131.1.151; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; GEIGER B, 1991, CELL MOTIL CYTOSKEL, V20, P1, DOI 10.1002/cm.970200102; GUMBINER BM, 1993, J CELL BIOL, V123, P1631, DOI 10.1083/jcb.123.6.1631; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; Imamura H, 1998, MOL BIOL CELL, V9, P2561, DOI 10.1091/mbc.9.9.2561; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; JOCKUSCH BM, 1995, REV CELL DEV BIOL, V11, P379; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; Jou TS, 1998, J CELL BIOL, V142, P101, DOI 10.1083/jcb.142.1.101; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Keon BH, 1996, J CELL BIOL, V134, P1003, DOI 10.1083/jcb.134.4.1003; Komuro R, 1996, GENES CELLS, V1, P943, DOI 10.1046/j.1365-2443.1996.760276.x; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kuroda S, 1997, BIOCHEM BIOPH RES CO, V240, P430, DOI 10.1006/bbrc.1997.7675; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Nakanishi H, 1997, J CELL BIOL, V139, P951, DOI 10.1083/jcb.139.4.951; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; NUSRAT A, 1995, P NATL ACAD SCI USA, V92, P10629, DOI 10.1073/pnas.92.23.10629; Ohtsuka T, 1998, J CELL BIOL, V143, P1227, DOI 10.1083/jcb.143.5.1227; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; PEYRIERAS N, 1985, P NATL ACAD SCI USA, V82, P8067, DOI 10.1073/pnas.82.23.8067; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schneeberger EE, 1992, AM J PHYSIOL, V262, P647; SHIBAMOTO S, 1995, J CELL BIOL, V128, P949, DOI 10.1083/jcb.128.5.949; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Stoffler HE, 1998, J CELL SCI, V111, P2779; STOKER M, 1991, BIOCHIM BIOPHYS ACTA, V1072, P81, DOI 10.1016/0304-419X(91)90008-9; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; Takai Y, 1996, GENES CELLS, V1, P615, DOI 10.1046/j.1365-2443.1996.00257.x; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1995, ONCOGENE, V11, P39; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; VESTWEBER D, 1984, CELL DIFFER DEV, V15, P269, DOI 10.1016/0045-6039(84)90084-8; WILKINS JA, 1986, J CELL BIOL, V103, P1483, DOI 10.1083/jcb.103.4.1483; WOODS DF, 1993, MECH DEVELOP, V44, P85, DOI 10.1016/0925-4773(93)90059-7; ZAHRAOUI A, 1994, J CELL BIOL, V124, P101, DOI 10.1083/jcb.124.1.101; ZHONG Y, 1993, J CELL BIOL, V120, P477, DOI 10.1083/jcb.120.2.477	64	85	85	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 8	1999	18	27					3996	4006		10.1038/sj.onc.1202773	http://dx.doi.org/10.1038/sj.onc.1202773			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KU	10435623				2022-12-25	WOS:000081327800010
J	Brocke, L; Chiang, LW; Wagner, PD; Schulman, H				Brocke, L; Chiang, LW; Wagner, PD; Schulman, H			Functional implications of the subunit composition of neuronal CaM kinase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; ALTERNATIVELY SPLICED ISOFORMS; HAMSTER OVARY CELLS; MOLECULAR-CLONING; CALCIUM SIGNALS; BETA-SUBUNIT; CALMODULIN; EXPRESSION; AUTOPHOSPHORYLATION; BRAIN	The assembly of 6-12 subunits of Ca2+/calmodulin-dependent kinase II (CaM kinase II) into holoenzymes is an important structural feature of the enzyme and its postulated role as a molecular detector of Ca2+ oscillations. Using single cell reverse transcriptase-polymerase chain reaction, we show that alpha- and beta-CaM kinase II mRNAs are simultaneously present in the majority of hippocampal neurons examined and that co-assembly of their protein products into heteromers is therefore possible. The subunit composition of CaM kinase II holoenzymes was analyzed by immunoprecipitation with subunit-specific monoclonal antibodies. Rat forebrain CaM kinase II consists of heteromers composed of alpha and beta subunits at a ratio of 2:1 and homomers composed of only alpha subunits, We examined the functional effect of the heteromeric assembly by analyzing the calmodulin dependence of autophosphorylation, Recombinant homomers of alpha- or beta-CaM kinase II, as well as of alternatively spliced beta isoforms, have distinct calmodulin dependences for autophosphorylation based on differences in their calmodulin affinities. Half-maximal autophosphorylation of alpha is achieved at 130 nM calmodulin, while that for beta occurs at 15 nM calmodulin, In CaM kinase II isolated from rat forebrain, however, the calmodulin dependence for autophosphorylation of the beta subunits is shifted toward that of alpha homomers, This suggests that Thr(287) in beta subunits is phosphorylated by a subunits present in the same holoenzyme, Once autophosphorylated, beta-CaM kinase II traps calmodulin by reducing the rate of calmodulin dissociation.	Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA; NCI, Biochem Lab, NIH, Bethesda, MD 20892 USA	Stanford University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Schulman, H (corresponding author), Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA.	schulman@cmgm.stanford.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030179, R37GM030179] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH048108] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30179] Funding Source: Medline; NIMH NIH HHS [MH48108] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ADELSTEIN RS, 1981, J BIOL CHEM, V256, P7501; BAITINGER C, 1990, J CELL BIOL, V111, P1763, DOI 10.1083/jcb.111.5.1763; Bayer KU, 1998, EMBO J, V17, P5598, DOI 10.1093/emboj/17.19.5598; Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; BENNETT MK, 1983, J BIOL CHEM, V258, P2735; BENSON DL, 1992, NEUROSCIENCE, V46, P851, DOI 10.1016/0306-4522(92)90189-9; BROCKE L, 1995, J NEUROSCI, V15, P6797; CHIANG LW, 1994, MOL BRAIN RES, V27, P183, DOI 10.1016/0169-328X(94)90202-X; Cho YH, 1998, SCIENCE, V279, P867, DOI 10.1126/science.279.5352.867; Edlund M, 1996, J BIOL CHEM, V271, P1393, DOI 10.1074/jbc.271.3.1393; EDMAN CF, 1994, BIOCHIM BIOPHYS ACTA, V1221, P90; FEIG S, 1993, J NEUROSCI, V13, P1010; Giese KP, 1998, SCIENCE, V279, P870, DOI 10.1126/science.279.5352.870; GuptaRoy B, 1996, J BIOL CHEM, V271, P19846, DOI 10.1074/jbc.271.33.19846; GuptaRoy B, 1996, J NEUROCHEM, V66, P1282; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; HANSON PI, 1992, J BIOL CHEM, V267, P17216; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; KANASEKI T, 1991, J CELL BIOL, V115, P1049, DOI 10.1083/jcb.115.4.1049; KARLS U, 1992, MOL CELL BIOL, V12, P3644, DOI 10.1128/MCB.12.8.3644; Kolb SJ, 1998, J BIOL CHEM, V273, P31555, DOI 10.1074/jbc.273.47.31555; KURET J, 1985, J BIOL CHEM, V260, P6427; Leonard AS, 1999, P NATL ACAD SCI USA, V96, P3239, DOI 10.1073/pnas.96.6.3239; LIN CR, 1987, P NATL ACAD SCI USA, V84, P5962, DOI 10.1073/pnas.84.16.5962; LIU N, 1994, J MOL NEUROSCI, V5, P193, DOI 10.1007/BF02736733; LOU LL, 1986, P NATL ACAD SCI USA, V83, P9497, DOI 10.1073/pnas.83.24.9497; LUBYPHELPS K, 1995, J BIOL CHEM, V270, P21532, DOI 10.1074/jbc.270.37.21532; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MILLER SG, 1988, NEURON, V1, P593, DOI 10.1016/0896-6273(88)90109-2; MILLER SG, 1985, J BIOL CHEM, V260, P9039; MUKHERJI S, 1994, J BIOL CHEM, V269, P13744; NGHIEM P, 1993, J BIOL CHEM, V268, P5471; Ouyang Y, 1997, J NEUROSCI, V17, P5416; RICH D P, 1990, Molecular and Cellular Neuroscience, V1, P107; Rich RC, 1998, J BIOL CHEM, V273, P28424, DOI 10.1074/jbc.273.43.28424; SCHULMAN H, 1984, J CELL BIOL, V99, P11, DOI 10.1083/jcb.99.1.11; SCHULMAN H, 1992, CELL CALCIUM, V13, P401, DOI 10.1016/0143-4160(92)90053-U; Shen K, 1998, NEURON, V21, P593, DOI 10.1016/S0896-6273(00)80569-3; Shen K, 1999, SCIENCE, V284, P162, DOI 10.1126/science.284.5411.162; SKENE JHP, 1990, NEUROSCI RES       S, V13, pS12; SPRENGEL R, 1993, FEBS LETT, V325, P90, DOI 10.1016/0014-5793(93)81420-5; SRINIVASAN M, 1994, J CELL BIOL, V126, P839, DOI 10.1083/jcb.126.4.839; Strack S, 1998, J BIOL CHEM, V273, P20689, DOI 10.1074/jbc.273.33.20689; THOMAS KL, 1994, NEURON, V13, P737, DOI 10.1016/0896-6273(94)90040-X; TOBIMATSU T, 1989, J BIOL CHEM, V264, P17907; TOBIMATSU T, 1988, J BIOL CHEM, V263, P16082; Tombes RM, 1997, BBA-MOL CELL RES, V1355, P281, DOI 10.1016/S0167-4889(96)00141-3; Waxham MN, 1998, J BIOL CHEM, V273, P17579, DOI 10.1074/jbc.273.28.17579; YAMAUCHI T, 1990, FEBS LETT, V266, P55, DOI 10.1016/0014-5793(90)81505-I; YAMAUCHI T, 1989, J BIOL CHEM, V264, P19108	51	119	121	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22713	22722		10.1074/jbc.274.32.22713	http://dx.doi.org/10.1074/jbc.274.32.22713			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428854	hybrid			2022-12-25	WOS:000081868400084
J	Rogatsky, I; Trowbridge, JM; Garabedian, MJ				Rogatsky, I; Trowbridge, JM; Garabedian, MJ			Potentiation of human estrogen receptor alpha transcriptional activation through phosphorylation of serines 104 and 106 by the cyclin A-CDK2 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGESTERONE-RECEPTOR; FACTOR GATA-1; CELL-LINE; GENE; BINDING; KINASE; ENHANCEMENT; D1; DIFFERENTIATION; IDENTIFICATION	Both estradiol binding and phosphorylation regulate transcriptional activation by the human estrogen receptor alpha (ER). We have previously shown that activation of the cyclin A-CDK2 complex by overexpression of cyclin A leads to enhanced ER-dependent transcriptional activation and that the cyclin A-CDK2 complex phosphorylates the ER N-terminal activation function-1 (AF-1) between residues 82 and 121. Within ER AF-1, serines 104, 106, and 118 represent potential CDK phosphorylation sites, and in this current study, we ascertain their importance in mediating cyclin A-CDK2-dependent enhancement of ER transcriptional activity. Cyclin A overexpression does not enhance transcriptional activation by an ER derivative bearing serine-to alanine changes at residues 104, 106, and 118. Likewise, the cyclin A-CDK2 complex does not phosphorylate this triple-mutated derivative in vitro. Individual serine-to-alanine mutations at residues 104 and 106, but not 118, decrease ER-dependent transcriptional enhancement in response to cyclin A. The same relationship holds for ER phosphorylation by cyclin A-CDK2 in vitro. Finally, enhancement of ER transcriptional activation by cyclin A is evident in the absence and presence of estradiol, as well as in the presence of tamoxifen, suggesting that the effect of the cyclin A-CDK2 on ER transcriptional activation is AF-a-independent. These results indicate that the enhancement of ER transcriptional activation by the cyclin A-CDK2 complex is mediated via the AF-1 domain by phosphorylation of serines 104 and 106. We propose that these residues control ER AF-1 activity in response to signals that affect cyclin A-CDK2 function.	NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA; NYU, Sch Med, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA	New York University; New York University	Garabedian, MJ (corresponding author), NYU, Sch Med, Dept Microbiol, 550 1st Ave, New York, NY 10016 USA.	garabm0l@mcrcr.med.nyu.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007180] Funding Source: NIH RePORTER; NIAID NIH HHS [5T32AI07180-17] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALAM J, 1990, ANAL BIOCHEM, V188, P245, DOI 10.1016/0003-2697(90)90601-5; ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; AUSUBEL FM, 1996, CURRENT PROTOCOLS MO, V1; BLOBEL GA, 1995, MOL CELL BIOL, V15, P3147; Blobel GA, 1996, MOL CELL BIOL, V16, P1687, DOI 10.1128/mcb.16.4.1687; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Cariou S, 1998, BREAST CANCER RES TR, V52, P29, DOI 10.1023/A:1006154900130; Collecchi P, 1999, INT J CANCER, V84, P139, DOI 10.1002/(SICI)1097-0215(19990420)84:2<139::AID-IJC8>3.0.CO;2-Y; Garabedian Michael J., 1998, P237; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; Holmes JK, 1996, J BIOL CHEM, V271, P25240, DOI 10.1074/jbc.271.41.25240; Joel PB, 1998, MOL CELL BIOL, V18, P1978, DOI 10.1128/MCB.18.4.1978; KANEKO KJ, 1993, BIOCHEMISTRY-US, V32, P8348, DOI 10.1021/bi00083a039; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kraus WL, 1995, P NATL ACAD SCI USA, V92, P12314, DOI 10.1073/pnas.92.26.12314; Krstic MD, 1997, MOL CELL BIOL, V17, P3947, DOI 10.1128/MCB.17.7.3947; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; MA ZQ, 1993, P NATL ACAD SCI USA, V90, P3740, DOI 10.1073/pnas.90.8.3740; McInerney EM, 1996, J BIOL CHEM, V271, P24172, DOI 10.1074/jbc.271.39.24172; McInerney EM, 1996, P NATL ACAD SCI USA, V93, P10069, DOI 10.1073/pnas.93.19.10069; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; Schulman BA, 1998, P NATL ACAD SCI USA, V95, P10453, DOI 10.1073/pnas.95.18.10453; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Sweeney K J, 1996, Cancer Treat Res, V83, P141; Trowbridge JM, 1997, P NATL ACAD SCI USA, V94, P10132, DOI 10.1073/pnas.94.19.10132; Tsihlias J, 1999, ANNU REV MED, V50, P401; Tzeng DZ, 1996, BIOCHEM BIOPH RES CO, V223, P554, DOI 10.1006/bbrc.1996.0933; von Lindern M, 1998, MOL ENDOCRINOL, V12, P263, DOI 10.1210/me.12.2.263; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; WEISZ A, 1990, MOL ENDOCRINOL, V4, P1041, DOI 10.1210/mend-4-7-1041; WEISZ A, 1990, NUCLEIC ACIDS RES, V18, P5097, DOI 10.1093/nar/18.17.5097; Zhang YX, 1997, MOL ENDOCRINOL, V11, P823, DOI 10.1210/me.11.6.823; Zhu XL, 1998, MODERN PATHOL, V11, P1082; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6; Zwijsen RML, 1998, GENE DEV, V12, P3488, DOI 10.1101/gad.12.22.3488	37	144	148	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22296	22302		10.1074/jbc.274.32.22296	http://dx.doi.org/10.1074/jbc.274.32.22296			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428798	hybrid			2022-12-25	WOS:000081868400028
J	Ball, T; Fuchs, T; Sperr, WR; Valent, P; Vangelista, L; Kraft, D; Valenta, R				Ball, T; Fuchs, T; Sperr, WR; Valent, P; Vangelista, L; Kraft, D; Valenta, R			B cell epitopes of the major timothy grass pollen allergen, Phl p 1, revealed by gene fragmentation as candidates for immunotherapy	FASEB JOURNAL			English	Article						type I allergy; allergen gene fragmentation; immunotherapy; blocking antibodies	GROUP-I ALLERGENS; SITE-DIRECTED MUTAGENESIS; IGG BLOCKING ANTIBODIES; DUST MITE ALLERGEN; IMMUNOLOGICAL CHARACTERIZATION; IMMUNOGLOBULIN-E; RYE-GRASS; INTERLEUKIN-4 PRODUCTION; POTENTIAL USE; SKIN-TEST	Group I grass pollen allergens are recognized by IgE antibodies of almost 40% of allergic individuals and therefore belong to the most important elicitors of Type I allergy worldwide. We have previously isolated the cDNA coding for the group 1 allergen from timothy grass, Phl p 1, and demonstrated that recombinant Phl p 1 contains most of the B cell as well as T cell epitopes of group 1 allergens from a variety of grass and corn species. Here we determine continuous B cell epitopes of Phl p 1 by gene fragmentation. IgE antibodies of grass pollen allergic patients identified five continuous epitope-containing areas that on an average bound 40% of Phl p 1-specific ISE antibodies and were stably recognized in the course of disease. in contrast to untreated patients, patients undergoing grass pollen immunotherapy started to mount IgG, antibodies to the recombinant IgE-defined fragments in the course of immunotherapy. The protective role of these IgG, antibodies is demonstrated by observations that 1) increases in rPhl p 1 fragment-specific IgG, were in parallel with decreases in Phl p 1-specific IgE, and 2) preincubation of rPhl p 1 with patients sera containing rPhl p 1 fragment-specific IgG, blocked histamine release from basophils of an untreated grass pollen allergic patient, We propose to use recombinant Phl p 1 fragments for active immunotherapy in order to induce protective IgG responses against IgE epitopes in grass pollen allergic patients. This concept may be applied for the development of allergy vaccines whenever the primary sequence or structure of an allergen is available.	Univ Vienna, AKH, Dept Gen & Expt Pathol, Div Immunopathol,Mol Immunopathol Grp, A-1090 Vienna, Austria; Univ Gottingen, Dept Dermatol, D-3400 Gottingen, Germany; Univ Vienna, AKH, Dept Internal Med 1, Div Hematol & Hemostaseol, A-1010 Vienna, Austria; EMBL, Struct Biol Programme, Heidelberg, Germany	University of Vienna; University of Gottingen; University of Vienna; European Molecular Biology Laboratory (EMBL)	Valenta, R (corresponding author), Univ Vienna, AKH, Dept Gen & Expt Pathol, Div Immunopathol,Mol Immunopathol Grp, Waehringer Guertel 18-20, A-1090 Vienna, Austria.		Test, PV/U-9451-2019; Test, Test/Y-7921-2019; Sperr, Mast/V-4767-2019; Valent, Peter/B-8533-2016; Gamperl, Susi/V-2715-2019	Sperr, Mast/0000-0002-7778-5219; Valent, Peter/0000-0003-0456-5095; Gamperl, Susi/0000-0003-0456-5095; Vangelista, Luca/0000-0003-0764-5031; Sperr, Wolfgang/0000-0003-3288-8027; Valenta, Rudolf/0000-0001-5944-3365				AALBERSE RC, 1983, J IMMUNOL, V130, P722; ADKINSON NF, 1979, J IMMUNOL, V122, P965; Akdis CA, 1998, EUR J IMMUNOL, V28, P914, DOI 10.1002/(SICI)1521-4141(199803)28:03<914::AID-IMMU914>3.0.CO;2-C; BALL T, 1994, J BIOL CHEM, V269, P28323; BIRKNER T, 1990, ALLERGY, V45, P418, DOI 10.1111/j.1398-9995.1990.tb01092.x; BROADWATER AH, 1993, GENE, V131, P227, DOI 10.1016/0378-1119(93)90297-G; Casolaro V, 1996, CURR OPIN IMMUNOL, V8, P796, DOI 10.1016/S0952-7915(96)80007-0; Cooke RA, 1935, J EXP MED, V62, P733, DOI 10.1084/jem.62.6.733; Cosgrove DJ, 1997, P NATL ACAD SCI USA, V94, P6559, DOI 10.1073/pnas.94.12.6559; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; ESCH RE, 1989, MOL IMMUNOL, V26, P557, DOI 10.1016/0161-5890(89)90007-2; Ferreira F, 1998, FASEB J, V12, P231, DOI 10.1096/fasebj.12.2.231; Ferreira F, 1996, J EXP MED, V183, P599, DOI 10.1084/jem.183.2.599; FREIDHOFF LR, 1986, J ALLERGY CLIN IMMUN, V78, P1190, DOI 10.1016/0091-6749(86)90271-X; GLEICH GJ, 1981, J IMMUNOL, V126, P575; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P261, DOI 10.1016/0091-6749(82)90062-8; GRIFFITH IJ, 1991, FEBS LETT, V279, P210, DOI 10.1016/0014-5793(91)80151-R; GROTE M, 1994, J HISTOCHEM CYTOCHEM, V42, P427, DOI 10.1177/42.3.8308259; Heiss S, 1996, J ALLERGY CLIN IMMUN, V98, P938, DOI 10.1016/S0091-6749(96)80010-8; Hiller KM, 1997, J ALLERGY CLIN IMMUN, V100, P335, DOI 10.1016/S0091-6749(97)70246-X; JOHNSON P, 1965, NATURE, V206, P935, DOI 10.1038/206935b0; Kay A.B., 1997, ALLERGY ALLERGIC DIS; Kobayashi I, 1996, J ALLERGY CLIN IMMUN, V97, P638, DOI 10.1016/S0091-6749(96)70309-3; KOLBE L, 1991, INT ARCH ALLER A IMM, V95, P202, DOI 10.1159/000235430; LAFFER S, 1994, J ALLERGY CLIN IMMUN, V94, P689, DOI 10.1016/0091-6749(94)90176-7; Laffer S, 1996, MOL IMMUNOL, V33, P417, DOI 10.1016/0161-5890(95)00152-2; LAFFER S, 1996, J ALLERGY CLIN IMMUN, V98, P625; LICHTENSTEIN LM, 1968, J IMMUNOL, V101, P317; Loveless MH, 1943, J IMMUNOL, V47, P165; Loveless MH, 1940, J IMMUNOL, V38, P25; Menz G, 1996, CLIN EXP ALLERGY, V26, P50, DOI 10.1111/j.1365-2222.1996.tb00056.x; Niederberger V, 1998, J ALLERGY CLIN IMMUN, V101, P258, DOI 10.1016/S0091-6749(98)70391-4; OBrien RM, 1997, CLIN EXP ALLERGY, V27, P46, DOI 10.1046/j.1365-2222.1997.d01-424.x; PEREZ M, 1990, J BIOL CHEM, V265, P16210; REST B, 1994, PROTEINS, V20, P216; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schenk S, 1995, J ALLERGY CLIN IMMUN, V96, P986, DOI 10.1016/S0091-6749(95)70237-7; Schreihofer AM, 1997, FASEB J, V11, P99; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; SECRIST H, 1995, J EXP MED, V181, P1081, DOI 10.1084/jem.181.3.1081; SEGAL DM, 1977, P NATL ACAD SCI USA, V41, P457; SHCHERBAN TY, 1995, P NATL ACAD SCI USA, V92, P9245, DOI 10.1073/pnas.92.20.9245; Smith AM, 1996, MOL IMMUNOL, V33, P399, DOI 10.1016/0161-5890(95)00150-6; Smith PM, 1996, J ALLERGY CLIN IMMUN, V98, P331, DOI 10.1016/S0091-6749(96)70158-6; SMITH PM, 1994, MOL IMMUNOL, V31, P491, DOI 10.1016/0161-5890(94)90068-X; SOBOTKA AK, 1976, J IMMUNOL, V117, P84; SUPHIOGLU C, 1995, CLIN EXP ALLERGY, V25, P853, DOI 10.1111/j.1365-2222.1995.tb00028.x; Takai T, 1997, NAT BIOTECHNOL, V15, P754, DOI 10.1038/nbt0897-754; Tame A, 1996, CLIN EXP ALLERGY, V26, P43, DOI 10.1111/j.1365-2222.1996.tb00055.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; URBANEK R, 1986, CLIN ALLERGY, V16, P317, DOI 10.1111/j.1365-2222.1986.tb01963.x; VALENT P, 1989, P NATL ACAD SCI USA, V86, P5542, DOI 10.1073/pnas.86.14.5542; Valenta R, 1998, INT ARCH ALLERGY IMM, V116, P167, DOI 10.1159/000023942; VALENTA R, 1992, INT ARCH ALLERGY, V26, P50; Valenta R, 1997, IGE REGULATION MOL M, P225; Vanderlugt CJ, 1996, CURR OPIN IMMUNOL, V8, P831, DOI 10.1016/S0952-7915(96)80012-4; Vercelli D, 1998, INT ARCH ALLERGY IMM, V116, P1, DOI 10.1159/000023918; Vrtala S, 1998, J IMMUNOL, V160, P6137; Vrtala S, 1997, J CLIN INVEST, V99, P1673, DOI 10.1172/JCI119330; VRTALA S, 1993, INT ARCH ALLERGY IMM, V102, P160, DOI 10.1159/000236567; Vrtala S, 1996, J ALLERGY CLIN IMMUN, V97, P781, DOI 10.1016/S0091-6749(96)80156-4; XU HL, 1995, GENE, V164, P255, DOI 10.1016/0378-1119(95)00527-D	65	67	69	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1999	13	11					1277	1290		10.1096/fasebj.13.11.1277	http://dx.doi.org/10.1096/fasebj.13.11.1277			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	226KL	10428753				2022-12-25	WOS:000082019100001
J	Weitkamp, B; Cullen, P; Plenz, G; Robenek, H; Rauterberg, J				Weitkamp, B; Cullen, P; Plenz, G; Robenek, H; Rauterberg, J			Human macrophages synthesize type VIII collagen in vitro and in the atherosclerotic plaque	FASEB JOURNAL			English	Article						double in situ hybridization; atherosclerosis; matrix metalloproteinase; fluorescence staining	MONOCYTE-DERIVED MACROPHAGES; SMOOTH-MUSCLE CELLS; X COLLAGEN; MATRIX METALLOPROTEINASES; GENE-EXPRESSION; DIFFERENTIAL EXPRESSION; ARTICULAR-CARTILAGE; ENDOTHELIAL-CELLS; MESSENGER-RNA; MAST-CELLS	Type VIII collagen is a short-chain collagen that is present in increased amounts in atherosclerotic lesions. Although the physiological function of this matrix protein is unclear, recent data suggest an important role in tissue remodeling. Type VIII collagen in the atherosclerotic lesion is mainly derived from smooth muscle cells. We now show that macrophages in the atherosclerotic vessel wall and monocytes in adjacent mural thrombi also express type VIII collagen. We demonstrated this using a novel combined fluorescence technique that simultaneously stains, within the same tissue section, specific RNAs by in situ hybridization and proteins by indirect immunofluorescence. In culture, human monocyte/macrophages expressed type VIII collagen at all time points from 1 h to 3 wk after isolation. Western blotting and immunoprecipitation also revealed secretion of type VIII collagen into the medium of 14-day-old macrophages. Because this is the first report of secretion of a collagen by macrophages, we tested the effect of lipopolysaccharide (LPS) and interferon gamma, substances that stimulate macrophages to secrete lyric enzymes, on macrophage expression of type VIII collagen. LPS and interferon gamma decreased expression of type VIII collagen. By contrast, secretion of matrix metalloproteinase 1 (MMP 1) was increased, indicating a switch from a collagen-producing to a degradative phenotype. Double in situ hybridization studies of expression of type VIII collagen and MMP 1 in human coronary arteries showed that in regions important for plaque stability, the ratio of MMP 1 RNA to macrophage type VIII collagen RNA varies widely, indicating that the transition from one phenotype to the other that we observed in vitro may also occur in vivo.	Inst Arterioskleroseforsch, D-48149 Munster, Germany		Rauterberg, J (corresponding author), Inst Arterioskleroseforsch, Domagkstr 3, D-48149 Munster, Germany.							ADACHI K, 1988, AM J PATHOL, V133, P193; AIGNER T, 1993, VIRCHOWS ARCH B, V63, P205, DOI 10.1007/BF02899263; BARNES JL, 1994, AM J PATHOL, V145, P585; Bendeck MP, 1996, CIRC RES, V79, P524, DOI 10.1161/01.RES.79.3.524; BHARDWAJ RS, 1992, EUR J IMMUNOL, V22, P1891, DOI 10.1002/eji.1830220732; Bjerrum OJ., 1986, ELECTROPHORESIS 86, P315; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; DING GH, 1993, AM J PHYSIOL, V264, pF577, DOI 10.1152/ajprenal.1993.264.4.F577; GALIS ZS, 1995, ANN NY ACAD SCI, V748, P501; GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619; GALIS ZS, 1995, P NATL ACAD SCI USA, V92, P402, DOI 10.1073/pnas.92.2.402; Halpert I, 1996, P NATL ACAD SCI USA, V93, P9748, DOI 10.1073/pnas.93.18.9748; HIROTA S, 1993, AM J PATHOL, V143, P1003; KAPOOR R, 1988, J CELL BIOL, V107, P721, DOI 10.1083/jcb.107.2.721; KATSUDA S, 1994, AM J PATHOL, V145, P1208; KIRSCH T, 1990, BIOCHEM J, V265, P453, DOI 10.1042/bj2650453; KITTELBERGER R, 1990, CONNECT TISSUE RES, V24, P303, DOI 10.3109/03008209009152157; KWAN APL, 1991, J CELL BIOL, V114, P597, DOI 10.1083/jcb.114.3.597; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee RT, 1996, ARTERIOSCL THROM VAS, V16, P1070, DOI 10.1161/01.ATV.16.8.1070; LERAT H, 1993, BLOOD, V82, P1480; LEVITT D, 1983, J CELL BIOL, V97, P351, DOI 10.1083/jcb.97.2.351; Libby P, 1996, CURR OPIN LIPIDOL, V7, P330, DOI 10.1097/00041433-199610000-00012; LIPTAY MJ, 1993, J CLIN INVEST, V91, P588, DOI 10.1172/JCI116238; Loffler JA, 1995, EUR ARCH OTO-RHINO-L, V252, P475, DOI 10.1007/BF02114754; MacBeath JRE, 1996, BIOCHEM J, V319, P993, DOI 10.1042/bj3190993; MURAGAKI Y, 1992, EUR J BIOCHEM, V207, P895, DOI 10.1111/j.1432-1033.1992.tb17122.x; MURRAY HW, 1988, ANN INTERN MED, V108, P595, DOI 10.7326/0003-4819-108-4-595; NERLICH AG, 1992, HISTOCHEMISTRY, V98, P275, DOI 10.1007/BF00270010; Nikkari ST, 1996, AM J PATHOL, V149, P1427; OBRIEN ER, 1994, ARTERIOSCLER THROMB, V14, P1648, DOI 10.1161/01.ATV.14.10.1648; PAULUS W, 1991, BRIT J CANCER, V63, P367, DOI 10.1038/bjc.1991.87; PLENZ G, 1994, HUM GENET, V93, P575; PLENZ G, 1993, CELL TISSUE RES, V273, P381, DOI 10.1007/BF00312841; RAINES EW, 1996, ATHEROSCLEROSIS CORO, P539; RUGER B, 1994, INT J EXP PATHOL, V75, P397; Ruger BM, 1996, DIABETOLOGIA, V39, P1215, DOI 10.1007/BF02658509; SAGE H, 1980, BIOCHEMISTRY-US, V19, P5747, DOI 10.1021/bi00566a013; SAWADA H, 1990, J CELL BIOL, V110, P219, DOI 10.1083/jcb.110.1.219; SCHLESINGER L, 1984, J EXP MED, V159, P1289, DOI 10.1084/jem.159.4.1289; SCHMITZ G, 1990, ARTERIOSCLEROSIS, V10, P1010, DOI 10.1161/01.ATV.10.6.1010; SHAH PK, 1995, CIRCULATION, V92, P1565; Sibinga NES, 1997, CIRC RES, V80, P532, DOI 10.1161/01.RES.80.4.532; STARY HC, 1994, ARTERIOSCLER THROMB, V14, P840, DOI 10.1161/01.ATV.14.5.840; Sukhova GK, 1996, CIRCULATION, V94, P98; VANDERREST M, 1993, CURR OPIN STRUC BIOL, V3, P430, DOI 10.1016/S0959-440X(05)80117-4; VONDERMARK K, 1992, ARTHRITIS RHEUM-US, V35, P806, DOI 10.1002/art.1780350715; WICHA MS, 1983, EXP CELL RES, V143, P475, DOI 10.1016/0014-4827(83)90077-0; ZUCKERMAN SH, 1979, IMMUNOLOGY, V38, P401; ZWADLO G, 1985, J IMMUNOL, V134, P1487	51	56	57	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1999	13	11					1445	1457		10.1096/fasebj.13.11.1445	http://dx.doi.org/10.1096/fasebj.13.11.1445			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	226KL	10428768				2022-12-25	WOS:000082019100016
J	Magert, HJ; Standker, L; Kreutzmann, P; Zucht, HD; Reinecke, M; Sommerhoff, CP; Fritz, H; Forssmann, WG				Magert, HJ; Standker, L; Kreutzmann, P; Zucht, HD; Reinecke, M; Sommerhoff, CP; Fritz, H; Forssmann, WG			LEKTI, a novel 15-domain type of human serine proteinase inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE STRUCTURE; EXPRESSION; ELASTASE; PATTERN; AGRIN	Proteinase inhibitors are important negative regulators of proteinase action in vivo. We have succeeded in isolating two previously unknown polypeptides (HF6478 and HF7665) from human blood filtrate that are parts of a larger precursor protein containing two typical Kazal-type serine proteinase inhibitor motifs. The entire precursor protein, as deduced from the nucleotide sequence of the cloned cDNA, exhibits 15 potential inhibitory domains, including the Kazal-type domains, HF6478, HF7665, and 11 additional similar domains, An inhibitory effect of HF7665 on trypsin activity is demonstrated. Because all of the 13 HF6478- and HF7665-related domains share partial homology to the typical Kazal-type domain but lack one of the three conserved disulfide bonds, they may represent a novel type of serine proteinase inhibitor. The gene encoding the multidomain proteinase inhibitor, which we have termed LEKTI, was localized on human chromosome 5q31-32, As shown by reverse transcriptase-polymerase chain reaction and Northern blot analysis, it is expressed in the thymus, vaginal epithelium, Bartholin's glands, oral mucosa, tonsils, and the parathyroid glands. From these results, we assume that LEKTI may play a role in antiinflammatory and/or antimicrobial protection of mucous epithelia.	Lower Saxony Inst Peptide Res, D-30625 Hannover, Germany; Univ Zurich, Dept Anat, CH-8057 Zurich, Switzerland; Univ Munich, Klinikum Innenstadt, Dept Clin Chem & Clin Biochem, D-80336 Munich, Germany	University of Zurich; University of Munich	Magert, HJ (corresponding author), Lower Saxony Inst Peptide Res, Feodor Lynen Str 31, D-30625 Hannover, Germany.							BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; BIROC SL, 1993, DEV BRAIN RES, V75, P119, DOI 10.1016/0165-3806(93)90071-H; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; FUCHS R, 1991, COMPUT APPL BIOSCI, V7, P105; GREENE LJ, 1969, J BIOL CHEM, V244, P2646; Hautamaki RD, 1997, SCIENCE, V277, P2002, DOI 10.1126/science.277.5334.2002; Hiemstra PS, 1996, INFECT IMMUN, V64, P4520, DOI 10.1128/IAI.64.11.4520-4524.1996; KAZAL LA, 1948, J AM CHEM SOC, V70, P3034, DOI 10.1021/ja01189a060; Kleiman RJ, 1996, CELL, V85, P461, DOI 10.1016/S0092-8674(00)81245-3; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; Magert HJ, 1998, REGUL PEPTIDES, V73, P165, DOI 10.1016/S0167-0115(97)01078-1; Magert HJ, 1999, J BIOL CHEM, V274, P444, DOI 10.1074/jbc.274.1.444; MILLER F, 1969, AM J MED, V46, P615, DOI 10.1016/0002-9343(69)90080-1; NEURATH H, 1984, SCIENCE, V224, P350, DOI 10.1126/science.6369538; OHLSSON K, 1980, EUR J CLIN INVEST, V10, P373, DOI 10.1111/j.1365-2362.1980.tb00048.x; Pardigol A, 1998, P NATL ACAD SCI USA, V95, P6308, DOI 10.1073/pnas.95.11.6308; Richter R, 1999, J CHROMATOGR B, V726, P25, DOI 10.1016/S0378-4347(99)00012-2; Roberts RM, 1995, CRIT REV EUKAR GENE, V5, P385, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.80; Sambrook J., 2002, MOL CLONING LAB MANU; Schulz-Knappe P, 1996, Eur J Med Res, V1, P223; SCOTT MJ, 1987, J BIOL CHEM, V262, P5899; Seife C, 1997, SCIENCE, V277, P1602, DOI 10.1126/science.277.5332.1602; Standker L, 1996, EUR J BIOCHEM, V241, P557, DOI 10.1111/j.1432-1033.1996.00557.x; Wahl SM, 1997, ORAL DIS S1, V3, pS64; WALTER MA, 1994, NAT GENET, V7, P22, DOI 10.1038/ng0594-22; YAMAMOTO T, 1985, BIOCHEM BIOPH RES CO, V132, P605, DOI 10.1016/0006-291X(85)91176-3	26	207	219	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21499	21502		10.1074/jbc.274.31.21499	http://dx.doi.org/10.1074/jbc.274.31.21499			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419450	hybrid			2022-12-25	WOS:000081721100003
J	LeBlanc, AJ; Yermovsky-Kammerer, AE; Hajduk, SL				LeBlanc, AJ; Yermovsky-Kammerer, AE; Hajduk, SL			A nuclear encoded and mitochondrial imported dicistronic tRNA precursor in Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA GENES; LEISHMANIA-MITOCHONDRIA; ORGANIZATION; SEQUENCE; DNA; TRANSCRIPTION; EXPRESSION; GENOME; OCCURS	The mitochondrial tRNAs of Trypanosoma brucei are nuclear encoded and imported into the mitochondrion, A heterogeneous population of RNAs having characteristics of precursor tRNAs have previously been identified within the mitochondrion of T. brucei, suggesting that import occurs via a precursor molecule. In order to identify nuclear genes encoding tRNAs targeted to the mitochondrion, individual mitochondrial tRNAs were separated using two-dimensional gel electrophoresis and enzymatically sequenced. A 1.1-kilobase pair genomic DNA fragment was cloned containing three tRNA genes, tRNA(1)(Ser), tRNA(Leu), and tRNA(2)(Ser). Dicistronic precursors containing the tRNA(1)(Ser) and tRNA(Leu) transcripts with a 59-nucleotide intergenic sequence were identified by reverse transcriptase and polymerase chain reactions and the 5' end of the precursors determined. The dicistronic precursor tRNA is present both in the cytosol and the mitochondrion supporting a model for tRNA import involving precursor tRNA transcripts.	Univ Alabama, Sch Med, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; Univ Alabama, Sch Dent, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Hajduk, SL (corresponding author), Univ Alabama, Sch Med, Dept Biochem & Mol Genet, 1918 Univ Blvd, Birmingham, AL 35294 USA.				PHS HHS [A121401] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Adhya S, 1997, J BIOL CHEM, V272, P21396, DOI 10.1074/jbc.272.34.21396; Aphasizhev R, 1998, MOL BIOCHEM PARASIT, V93, P73, DOI 10.1016/S0166-6851(98)00022-X; BURGER G, 1995, J MOL BIOL, V245, P522, DOI 10.1006/jmbi.1994.0043; CAMPBELL DA, 1989, MOL BIOCHEM PARASIT, V37, P257, DOI 10.1016/0166-6851(89)90157-6; CAMPBELL DA, 1989, NUCLEIC ACIDS RES, V17, P9479, DOI 10.1093/nar/17.22.9479; CHEN DHT, 1994, MOL BIOCHEM PARASIT, V64, P121, DOI 10.1016/0166-6851(94)90140-6; CUNNINGHAM I, 1977, J PROTOZOOL, V24, P325, DOI 10.1111/j.1550-7408.1977.tb00987.x; CURNOW AW, 1994, BIOCHIMIE, V76, P1183, DOI 10.1016/0300-9084(94)90048-5; Fan H, 1998, MOL CELL BIOL, V18, P3201, DOI 10.1128/MCB.18.6.3201; GRAY MW, 1988, PHILOS T R SOC B, V319, P135, DOI 10.1098/rstb.1988.0038; HANCOCK K, 1992, J BIOL CHEM, V267, P23963; HANCOCK K, 1992, NUCLEIC ACIDS RES, V20, P2602, DOI 10.1093/nar/20.10.2602; HANCOCK K, 1990, J BIOL CHEM, V265, P19208; HARRIS ME, 1990, J BIOL CHEM, V265, P11368; HAUSER R, 1995, EMBO J, V14, P4212, DOI 10.1002/j.1460-2075.1995.tb00095.x; JOYCE PBM, 1989, NUCLEIC ACIDS RES, V17, P5461, DOI 10.1093/nar/17.14.5461; MAHAPATRA S, 1994, NUCLEIC ACIDS RES, V22, P3381, DOI 10.1093/nar/22.16.3381; Mahapatra S, 1996, J BIOL CHEM, V271, P20432, DOI 10.1074/jbc.271.34.20432; MARECHALDROUARD L, 1988, NUCLEIC ACIDS RES, V16, P4777, DOI 10.1093/nar/16.11.4777; MARECHALDROUARD L, 1990, NUCLEIC ACIDS RES, V18, P3689, DOI 10.1093/nar/18.13.3689; MOTTRAM JC, 1991, NUCLEIC ACIDS RES, V19, P3995, DOI 10.1093/nar/19.14.3995; MOTTRAM JC, 1991, J BIOL CHEM, V266, P18313; PRITCHARD AE, 1990, NUCLEIC ACIDS RES, V18, P173, DOI 10.1093/nar/18.1.173; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNEIDER A, 1994, NUCLEIC ACIDS RES, V22, P3699, DOI 10.1093/nar/22.18.3699; SHARP SJ, 1985, CRC CR REV BIOCH MOL, V19, P107, DOI 10.3109/10409238509082541; SIMPSON AM, 1989, NUCLEIC ACIDS RES, V17, P5427, DOI 10.1093/nar/17.14.5427; SUYAMA Y, 1967, BIOCHEMISTRY-US, V6, P2829, DOI 10.1021/bi00861a025; SUYAMA Y, 1978, ARCH BIOCHEM BIOPHYS, V191, P437, DOI 10.1016/0003-9861(78)90382-X; SUYAMA Y, 1986, CURR GENET, V10, P411, DOI 10.1007/BF00418415; TARASSOV I, 1995, EMBO J, V14, P3461, DOI 10.1002/j.1460-2075.1995.tb07352.x	31	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21071	21077		10.1074/jbc.274.30.21071	http://dx.doi.org/10.1074/jbc.274.30.21071			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409659	hybrid			2022-12-25	WOS:000081613100050
J	Grallert, H; Buchner, J				Grallert, H; Buchner, J			Analysis of GroE-assisted folding under nonpermissive conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAPERONIN ATPASE CYCLE; CITRATE SYNTHASE; ESCHERICHIA-COLI; HEAT-SHOCK; IN-VIVO; PROTEIN; MECHANISM; BINDING; POLYPEPTIDE; SUBSTRATE	The molecular chaperones GroEL and GroES facilitate protein folding in an ATP-dependent manner under conditions where no spontaneous folding occurs. It has remained unknown whether GroE achieves this by a passive sequestration of protein inside the GroE cavity or by changing the folding pathway of a protein. Here we used citrate synthase, a well studied model substrate, to discriminate between these possibilities. We demonstrate that GroE maintains unfolding intermediates in a state that allows productive folding under nonpermissive conditions. During encapsulation of non-native protein inside GroEL GroES complexes, a folding reaction takes place, generating association competent monomeric intermediates that are no longer recognized by GroEL. Thus, GroE shifts folding intermediates to a productive folding pathway under heat shock conditions where even the native protein unfolds in the absence of GroE.	Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Garching, Germany	Technical University of Munich	Buchner, J (corresponding author), Tech Univ Munich, Inst Organ Chem & Biochem, Lichtenbergstr 4, D-85747 Garching, Germany.		Buchner, Johannes/A-2651-2010	Buchner, Johannes/0000-0003-1282-7737				Boisvert DC, 1996, NAT STRUCT BIOL, V3, P170, DOI 10.1038/nsb0296-170; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; Buchner J, 1998, METHOD ENZYMOL, V290, P323, DOI 10.1016/S0076-6879(98)90029-5; Buckle AM, 1997, P NATL ACAD SCI USA, V94, P3571, DOI 10.1073/pnas.94.8.3571; BURSTON SG, 1995, J MOL BIOL, V249, P138, DOI 10.1006/jmbi.1995.0285; BURSTON SG, 1992, ANN NY ACAD SCI, V672, P1; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; Ewalt KL, 1997, CELL, V90, P491, DOI 10.1016/S0092-8674(00)80509-7; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; Fedorov AN, 1997, J MOL BIOL, V268, P712, DOI 10.1006/jmbi.1997.1007; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; FISHER MT, 1994, J BIOL CHEM, V269, P29598; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Goloubinoff P, 1997, FEBS LETT, V407, P215, DOI 10.1016/S0014-5793(97)00348-7; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; Grallert H, 1998, J BIOL CHEM, V273, P33305, DOI 10.1074/jbc.273.50.33305; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOLLNEUGEBAUER B, 1991, BIOCHEMISTRY-US, V30, P58; Hoshino M, 1996, J MOL BIOL, V262, P575, DOI 10.1006/jmbi.1996.0536; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2553; Lorimer G, 1997, NATURE, V388, P720, DOI 10.1038/41892; Lorimer GH, 1996, FASEB J, V10, P5, DOI 10.1096/fasebj.10.1.8566548; MARTIN J, 1992, SCIENCE, V258, P995, DOI 10.1126/science.1359644; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MENDOZA JA, 1992, J BIOL CHEM, V267, P17631; PAJOT P, 1976, EUR J BIOCHEM, V63, P263, DOI 10.1111/j.1432-1033.1976.tb10228.x; Perrett S, 1997, J MOL BIOL, V269, P892, DOI 10.1006/jmbi.1997.1081; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SCHMIDT M, 1994, J BIOL CHEM, V269, P27964; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; Shtilerman M, 1999, SCIENCE, V284, P822, DOI 10.1126/science.284.5415.822; Sparrer H, 1996, J MOL BIOL, V258, P74, DOI 10.1006/jmbi.1996.0235; Sparrer H, 1997, P NATL ACAD SCI USA, V94, P1096, DOI 10.1073/pnas.94.4.1096; SRERE PA, 1966, J BIOL CHEM, V241, P2157; STANIFORTH RA, 1994, BIOCHEM J, V300, P651, DOI 10.1042/bj3000651; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; Todd MJ, 1996, P NATL ACAD SCI USA, V93, P4030, DOI 10.1073/pnas.93.9.4030; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; ZAHN R, 1994, J MOL BIOL, V242, P150, DOI 10.1006/jmbi.1994.1566	44	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20171	20177		10.1074/jbc.274.29.20171	http://dx.doi.org/10.1074/jbc.274.29.20171			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400632	hybrid			2022-12-25	WOS:000081438300025
J	Kim, E; Lowenson, JD; Clarke, S; Young, SG				Kim, E; Lowenson, JD; Clarke, S; Young, SG			Phenotypic analysis of seizure-prone mice lacking L-isoaspartate (D-aspartate) O-methyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN CARBOXYL METHYLTRANSFERASE; N-ACETYLASPARTYLGLUTAMATE; REPAIR HYPOTHESIS; DAMAGED PROTEINS; RESIDUES; GLUTAMATE; PEPTIDES; DEAMIDATION; SUCCINIMIDE; DEGRADATION	Within proteins and peptides, both L-asparaginyl and L-aspartyl residues spontaneously degrade, generating isomerized and racemized aspartyl residues. The enzyme protein L-isoaspartate (D-aspartate) O-methyltransferase (E.C. 2.1.1.77) initiates the conversion of L-isoaspartyl and D-aspartyl residues to normal L-aspartyl residues, This "repair" reaction helps to maintain proper protein conformation by preventing the accumulation of damaged proteins containing abnormal amino acid residues. Pcmt1-/- mice manifest two key phenotypes: a fatal seizure disorder and retarded growth. In this study, we characterized both phenotypes and demonstrated that they are linked. Continuous electroencephalogram monitoring of Pcmt1-/- mice revealed that abnormal cortical activity for similar to 50% of each 24-h period, even in mice that had no visible evidence of convulsions. The fatal seizure disorder in Pcmt1-/- mice can be mitigated but not eliminated by antiepileptic drugs. Interestingly, antiepileptic therapy normalized the growth of Pcmt1-/- mice, suggesting that the growth retardation is due to seizures rather than a global disturbance in growth at the cellular level. Consistent with this concept, the growth rate of Pcmt1-/- fibroblasts was indistinguishable from that of wild-type fibroblasts.	Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Kim, E (corresponding author), Gladstone Inst Cardiovasc Dis, POB 419100, San Francisco, CA 94141 USA.		Lowenson, Jonathan/AAN-6768-2020	Young, Stephen/0000-0001-7270-3176	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047660] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026020, R01GM026020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015451] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47660] Funding Source: Medline; NIA NIH HHS [AG15451-01] Funding Source: Medline; NIGMS NIH HHS [GM26020] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRENNAN TV, 1994, J BIOL CHEM, V269, P24586; Brovia V, 1996, J NEUROCHEM, V67, P382; CAPASSO S, 1991, Peptide Research, V4, P234; Catanzano F, 1997, PROTEIN SCI, V6, P1682, DOI 10.1002/pro.5560060808; Coyle JT, 1997, NEUROBIOL DIS, V4, P231, DOI 10.1006/nbdi.1997.0153; FUJII N, 1994, J BIOCHEM-TOKYO, V116, P663, DOI 10.1093/oxfordjournals.jbchem.a124577; GALLETTI P, 1988, BIOCHEMISTRY-US, V27, P1752, DOI 10.1021/bi00405a055; GEIGER T, 1987, J BIOL CHEM, V262, P785; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Ichikawa JK, 1998, ARCH BIOCHEM BIOPHYS, V358, P222, DOI 10.1006/abbi.1998.0830; JOHNSON BA, 1987, J BIOL CHEM, V262, P12283; JOHNSON BA, 1987, J BIOL CHEM, V262, P5622; KAGAN RM, 1995, BIOCHEMISTRY-US, V34, P10794, DOI 10.1021/bi00034a012; Kagan RM, 1997, COMP BIOCHEM PHYS B, V117, P379, DOI 10.1016/S0305-0491(96)00333-1; Kim E, 1997, P NATL ACAD SCI USA, V94, P6132, DOI 10.1073/pnas.94.12.6132; KOENIG ML, 1994, NEUROREPORT, V5, P1063, DOI 10.1097/00001756-199405000-00012; Lowenson J. D., 1995, DEAMIDATION ISOASPAR, P47; LOWENSON JD, 1991, J BIOL CHEM, V266, P19396; LOWENSON JD, 1992, J BIOL CHEM, V267, P5985; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Luthi-Carter R, 1998, BRAIN RES, V795, P341, DOI 10.1016/S0006-8993(98)00244-3; MACLAREN DC, 1992, GENOMICS, V14, P852, DOI 10.1016/S0888-7543(05)80104-1; MACLAREN DC, 1995, PROTEIN EXPRES PURIF, V6, P99, DOI 10.1006/prep.1995.1013; MCFADDEN PN, 1987, P NATL ACAD SCI USA, V84, P2595, DOI 10.1073/pnas.84.9.2595; MOLINARRODE R, 1992, EXP BRAIN RES, V89, P40; Noguchi S, 1998, J MOL BIOL, V278, P231, DOI 10.1006/jmbi.1998.1674; OLIYAI C, 1994, PHARMACEUT RES, V11, P751, DOI 10.1023/A:1018944800691; Sainz J, 1997, AM J HUM GENET, V61, P1205, DOI 10.1086/301596; SERVAL V, 1990, J NEUROCHEM, V55, P39, DOI 10.1111/j.1471-4159.1990.tb08818.x; STEPHENSON RC, 1989, J BIOL CHEM, V264, P6164; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TYLERCROSS R, 1991, J BIOL CHEM, V266, P22549; VALIVULLAH HM, 1994, J NEUROCHEM, V63, P1714; VISICK JE, 1995, MOL MICROBIOL, V16, P835, DOI 10.1111/j.1365-2958.1995.tb02311.x; WASSARMAN PM, 1993, GUIDE TECHNIQUES MOU, pR35; Yamamoto A, 1998, J NEUROSCI, V18, P2063; ZACZEK R, 1983, P NATL ACAD SCI-BIOL, V80, P1116, DOI 10.1073/pnas.80.4.1116	38	56	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20671	20678		10.1074/jbc.274.29.20671	http://dx.doi.org/10.1074/jbc.274.29.20671			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400700	hybrid			2022-12-25	WOS:000081438300093
J	Ma, TH; Song, YL; Gillespie, A; Carlson, EJ; Epstein, CJ; Verkman, AS				Ma, TH; Song, YL; Gillespie, A; Carlson, EJ; Epstein, CJ; Verkman, AS			Defective secretion of saliva in transgenic mice lacking aquaporin-5 water channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOME LOCUS 12Q13; FLUID SECRETION; GLANDS; MOUSE; CDNA; LOCALIZATION; EXPRESSION; HOMOLOGS; TISSUES; CLONING	Aquaporin-6 (AQP5) is a water selective transporting protein expressed in epithelial cells of serous acini in salivary gland. We generated AQP5 null mice by targeted gene disruption. The genotype distribution from intercross of founder AQP5 heterozygous mice was 70: 69:29 wild-type:heterozygote:knockout, indicating impaired prenatal survival of the null mice. The knockout mice had grossly normal appearance, but grew similar to 20% slower than litter-matched wild-type mice when placed on solid food after weaning. Pilocarpine-stimulated saliva production was reduced by more than 60% in AQP5 knockout mice. Compared with the saliva from wild-type mice, the saliva from knockout mice was hypertonic (420 mosM) and dramatically more viscous. Amylase and protein secretion, functions of salivary mucous cells, were not affected by AQP5 deletion. Water channels AQP1 and AQP4 have also been localized to salivary gland; however, pilocarpine stimulation studies showed no defect in the volume or composition of saliva in AQP1 and AQP4 knockout mice. These results implicate a key role for AQP5 in saliva fluid secretion and provide direct evidence that high epithelial cell membrane water permeability is required for active, near-isosmolar fluid transport.	Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Dept Pediat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Verkman, AS (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, 1246 Hlth Sci E Tower, San Francisco, CA 94143 USA.	verkman@itsa.ucsf.edu		Ma, Tonghui/0000-0001-9338-1030	NHLBI NIH HHS [HL59198, HL60288] Funding Source: Medline; NIDDK NIH HHS [DK35124] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL060288, R01HL059198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035124, R01DK035124] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bai CX, 1999, J CLIN INVEST, V103, P555, DOI 10.1172/JCI4138; Chou CL, 1999, J CLIN INVEST, V103, P491, DOI 10.1172/JCI5704; COOK DI, 1989, HDB PHYSL, P1; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; Delporte C, 1998, BIOCHEM BIOPH RES CO, V246, P584, DOI 10.1006/bbrc.1998.8668; Delporte C, 1997, P NATL ACAD SCI USA, V94, P3268, DOI 10.1073/pnas.94.7.3268; FRIGERI A, 1995, J CELL SCI, V108, P2993; Funaki H, 1998, AM J PHYSIOL-CELL PH, V275, pC1151, DOI 10.1152/ajpcell.1998.275.4.C1151; Hamann S, 1998, AM J PHYSIOL-CELL PH, V274, pC1332, DOI 10.1152/ajpcell.1998.274.5.C1332; Ishida N, 1997, BIOCHEM BIOPH RES CO, V238, P891, DOI 10.1006/bbrc.1997.7396; Lee MD, 1996, J BIOL CHEM, V271, P8599, DOI 10.1074/jbc.271.15.8599; LI J, 1994, PFLUG ARCH EUR J PHY, V428, P455, DOI 10.1007/BF00374565; Ma TH, 1998, J BIOL CHEM, V273, P4296, DOI 10.1074/jbc.273.8.4296; Ma TH, 1996, GENOMICS, V35, P543, DOI 10.1006/geno.1996.0396; Ma TH, 1997, GENOMICS, V43, P387, DOI 10.1006/geno.1997.4836; Ma TH, 1997, J CLIN INVEST, V100, P957, DOI 10.1172/JCI231; MARMARY Y, 1987, COMP BIOCHEM PHYS A, V88, P307, DOI 10.1016/0300-9629(87)90488-9; Matsuzaki T, 1999, CELL TISSUE RES, V295, P513, DOI 10.1007/s004410051257; NAUNTOFTE B, 1992, AM J PHYSIOL, V263, pG823, DOI 10.1152/ajpgi.1992.263.6.G823; Nielsen S, 1997, AM J PHYSIOL-CELL PH, V273, pC1549, DOI 10.1152/ajpcell.1997.273.5.C1549; RAINA S, 1995, J BIOL CHEM, V270, P1908, DOI 10.1074/jbc.270.4.1908; Schnermann J, 1998, P NATL ACAD SCI USA, V95, P9660, DOI 10.1073/pnas.95.16.9660; Spring KR, 1998, ANNU REV PHYSIOL, V60, P105, DOI 10.1146/annurev.physiol.60.1.105; Wolff A, 1997, J DENT RES, V76, P1782, DOI 10.1177/00220345970760111001; Yang BX, 1999, GENOMICS, V57, P79, DOI 10.1006/geno.1999.5759; Yang BX, 1997, J BIOL CHEM, V272, P16140, DOI 10.1074/jbc.272.26.16140	26	430	467	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20071	20074		10.1074/jbc.274.29.20071	http://dx.doi.org/10.1074/jbc.274.29.20071			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400615	hybrid			2022-12-25	WOS:000081438300008
J	Mace, G; Blanpied, C; Emorine, LJ; Druet, P; Dietrich, G				Mace, G; Blanpied, C; Emorine, LJ; Druet, P; Dietrich, G			Morphine-like activity of natural human IgG autoantibodies is because of binding to the first and third extracellular loops of the mu-opioid receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE; ACTIVATION; RHODOPSIN; PEPTIDES	We have previously demonstrated that randomly selected healthy individuals express anti-human mu-opioid receptor antibodies which behave as agonist in vitro. In this study, we show that the activity of these antibodies was not affected by the deletion of the amino-terminal region of the receptor. Using agarose-bound peptide columns, we affinity-purified IgG specifically directed toward each extracellular loop. Whatever its specificity, each anti-human mu-opioid receptor (hMOR) extracellular loop peptide IgG preparation was unable, when examined individually, to reduce adenylate cyclase activity. Activation of the hMOR was, however, achieved by the simultaneous binding of IgG to the first and third extracellular loops of the receptor. Our results suggest that the simultaneous binding of IgG antibodies to these two loops mimics morphine-induced receptor activation by triggering a coordinated shift of the third and sixth transmembrane helices.	INSERM, U28, F-31059 Toulouse, France; Univ Toulouse 3, Hop Purpan, F-31059 Toulouse, France; Univ Toulouse 3, Inst Pharmacol & Biol Struct, CNRS, UPR 9062, F-31077 Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Dietrich, G (corresponding author), INSERM, U28, Pl Dr Baylac, F-31059 Toulouse, France.		Dietrich, Gilles/AAC-2119-2020	Dietrich, Gilles/0000-0002-2232-1716				ALVAREZ R, 1990, ANAL BIOCHEM, V187, P98, DOI 10.1016/0003-2697(90)90423-7; AVRAMEAS S, 1995, RES IMMUNOL, V146, P235, DOI 10.1016/0923-2494(96)80259-8; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; BORDA E, 1984, CLIN EXP IMMUNOL, V57, P679; Dietrich G, 1998, J NEUROCHEM, V70, P2106; Druet E, 1998, EUR J IMMUNOL, V28, P183, DOI 10.1002/(SICI)1521-4141(199801)28:01<183::AID-IMMU183>3.0.CO;2-O; Dunham TD, 1999, J BIOL CHEM, V274, P1683, DOI 10.1074/jbc.274.3.1683; ELLING CE, 1995, NATURE, V374, P74, DOI 10.1038/374074a0; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; FU MLX, 1994, LANCET, V344, P1660, DOI 10.1016/S0140-6736(94)90456-1; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; Mace G, 1999, EUR J IMMUNOL, V29, P997, DOI 10.1002/(SICI)1521-4141(199903)29:03<997::AID-IMMU997>3.0.CO;2-1; MAGNUSSON Y, 1994, CIRCULATION, V89, P2760, DOI 10.1161/01.CIR.89.6.2760; Mansour A, 1997, J NEUROCHEM, V68, P344, DOI 10.1046/j.1471-4159.1997.68010344.x; MORRIS JC, 1994, AUTOIMMUNITY, V17, P287, DOI 10.3109/08916939409010669; NAGAYAMA Y, 1991, J CLIN INVEST, V88, P336, DOI 10.1172/JCI115297; Okayama H, 1992, Biotechnology, V24, P270; Pogozheva ID, 1998, BIOPHYS J, V75, P612, DOI 10.1016/S0006-3495(98)77552-6; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; TOTA MR, 1990, J BIOL CHEM, V265, P16891; Wallukat G, 1999, J CLIN INVEST, V103, P945, DOI 10.1172/JCI4106; WANG JB, 1993, P NATL ACAD SCI USA, V90, P10230, DOI 10.1073/pnas.90.21.10230; Wang WW, 1995, P NATL ACAD SCI USA, V92, P12436, DOI 10.1073/pnas.92.26.12436	24	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20079	20082		10.1074/jbc.274.29.20079	http://dx.doi.org/10.1074/jbc.274.29.20079			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400617	hybrid			2022-12-25	WOS:000081438300010
J	Nicieza, RG; Huergo, J; Connolly, BA; Sanchez, J				Nicieza, RG; Huergo, J; Connolly, BA; Sanchez, J			Purification, characterization, and role of nucleases and serine proteases in Streptomyces differentiation - Analogies with the biochemical processes described in late steps of eukaryotic apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; RECOMBINANT CYCLOPHILIN-A; CIS-TRANS-ISOMERASE; EXOCYTOPLASMIC ENDONUCLEASE; RESTRICTION FUNCTION; DNA-DEGRADATION; RAT THYMOCYTES; DEOXYRIBONUCLEASE; IDENTIFICATION; ANTIBIOTICUS	Two exocellular nucleases with molecular masses of 18 and 34 kDa, which are nutritionally regulated and reach their maximum activity during aerial mycelium formation and sporulation, have been detected in Streptomyces antibioticus. Their function appears to be DNA degradation in the substrate mycelium, and in agreement with this proposed role the two nucleases cooperate efficiently with a periplasmic nuclease previously described in Streptomyces antibioticus to completely hydrolyze DNA. The nucleases cut DNA nonspecifically, leaving 5'-phosphate mononucleotides as the predominant products. Both proteins require Mg2+, and the additional presence of Ca2+ notably stimulates their activities. The two nucleases are inhibited by Zn2+ and aurin tricarboxylic acid. The 18-kDa nuclease from Streptomyces is reminiscent of NUC-18, a thymocyte nuclease proposed to have a key role in glucocorticoid-stimulated apoptosis. The 18-kDa nuclease was shown, by aminoterminal protein sequencing, to be a member of the cyclophilin family and also to possess peptidylprolyl cis-trans-isomerase activity. NUC-18 has also been shown to be a cyclophilin, and "native" cyclophilins are capable of DNA degradation. The S. antibioticus 18-kDa nuclease is produced by a proteolytic processing from a less active protein precursor. The protease responsible has been identified as a serine protease that is inhibited by N-alpha-p-tosyl-L-lysine chloromethyl ketone and leupeptin. Inhibition of both of the nucleases or the protease impairs aerial mycelium development in S. antibioticus. The biochemical features of cellular DNA degradation during Streptomyces development show significant analogies with the late steps of apoptosis of eukaryotic cells.	Univ Oviedo, Dept Biol Func, E-33006 Oviedo, Spain; Univ Oviedo, Inst Univ Biotecnol Asturias, E-33006 Oviedo, Spain; Univ Newcastle Upon Tyne, Dept Biochem & Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	University of Oviedo; University of Oviedo; Newcastle University - UK	Sanchez, J (corresponding author), Univ Oviedo, Dept Biol Func, E-33006 Oviedo, Spain.							Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Ameisen JC, 1996, SCIENCE, V272, P1278, DOI 10.1126/science.272.5266.1278; Anderson P, 1997, MICROBIOL MOL BIOL R, V61, P33, DOI 10.1128/.61.1.33-46.1997; APARICIO JF, 1991, APPL MICROBIOL BIOT, V36, P153, DOI 10.1007/BF00164411; APARICIO JF, 1988, J GEN MICROBIOL, V134, P2345; APARICIO JF, 1992, BIOCHEM J, V281, P231, DOI 10.1042/bj2810231; APARICIO JF, 1992, EUR J BIOCHEM, V205, P695, DOI 10.1111/j.1432-1033.1992.tb16831.x; Aravind L, 1999, TRENDS BIOCHEM SCI, V24, P47, DOI 10.1016/S0968-0004(98)01341-3; BARRY MA, 1993, ARCH BIOCHEM BIOPHYS, V300, P440, DOI 10.1006/abbi.1993.1060; CAL S, 1995, BIOCHEM J, V306, P93, DOI 10.1042/bj3060093; Cal S, 1996, BIOCHEMISTRY-US, V35, P10828, DOI 10.1021/bi960616u; CHATER KF, 1989, GENETICS BACTERIAL D, P129; Chaudhary D, 1998, J BIOL CHEM, V273, P17708, DOI 10.1074/jbc.273.28.17708; Chinnaiyan AM, 1997, NATURE, V388, P728, DOI 10.1038/41913; COMPTON MM, 1987, J BIOL CHEM, V262, P8288; CORNILLON S, 1994, J CELL SCI, V107, P2691; DELOSREYESGAVIL.CG, 1991, J GEN MICROBIOL, V136, P299; DELOSREYESGAVILAN CG, 1988, J BACTERIOL, V170, P1339, DOI 10.1128/jb.170.3.1339-1345.1988; DELOSREYESGAVILAN CG, 1988, FEMS MICROBIOL LETT, V56, P301, DOI 10.1016/0378-1097(88)90078-X; DOHERTY AJ, 1991, NUCLEIC ACIDS RES, V19, P6129, DOI 10.1093/nar/19.22.6129; DREW HR, 1984, CELL, V37, P491, DOI 10.1016/0092-8674(84)90379-9; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; Fraser M J, 1980, Methods Enzymol, V65, P255; FRASER MJ, 1993, NUCLEASES, P171; GAIDO ML, 1991, J BIOL CHEM, V266, P18580; GIBB GD, 1988, CAN J MICROBIOL, V34, P187, DOI 10.1139/m88-034; Greenberg JT, 1996, P NATL ACAD SCI USA, V93, P12094, DOI 10.1073/pnas.93.22.12094; Hale AJ, 1996, EUR J BIOCHEM, V236, P1, DOI 10.1111/j.1432-1033.1996.00001.x; Hochman A, 1997, CRIT REV MICROBIOL, V23, P207, DOI 10.3109/10408419709115136; Kang SG, 1995, MICROBIOL-UK, V141, P3095, DOI 10.1099/13500872-141-12-3095; Kim IS, 1996, MICROBIOL-UK, V142, P1797, DOI 10.1099/13500872-142-7-1797; KIM S, 1995, MICROBIOLOGY, V141, P1017; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MENDEZ C, 1985, CAN J MICROBIOL, V31, P446, DOI 10.1139/m85-083; Montague JW, 1996, EXPERIENTIA, V52, P957, DOI 10.1007/BF01920104; MONTAGUE JW, 1994, J BIOL CHEM, V269, P18877; Montague JW, 1997, J BIOL CHEM, V272, P6677, DOI 10.1074/jbc.272.10.6677; NATSUME M, 1989, J ANBIBIOT, V42, P441; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; OMURA S, 1986, BACTERIA, V9, pR17; Osborne BA, 1996, TRENDS GENET, V12, P489, DOI 10.1016/S0168-9525(96)30108-X; Pandey S, 1997, BIOCHEMISTRY-US, V36, P711, DOI 10.1021/bi962387h; Peitsch Manuel C., 1994, Trends in Cell Biology, V4, P37, DOI 10.1016/0962-8924(94)90002-7; PEITSCH MC, 1993, EMBO J, V12, P371, DOI 10.1002/j.1460-2075.1993.tb05666.x; Rao MB, 1998, MICROBIOL MOL BIOL R, V62, P597, DOI 10.1128/MMBR.62.3.597-635.1998; ROSENTHAL AL, 1977, ANAL BIOCHEM, V80, P76, DOI 10.1016/0003-2697(77)90627-3; SHAPIRO S, 1989, REGULATION SECONDARY, P149; Shiokawa D, 1998, BIOCHEM J, V332, P713, DOI 10.1042/bj3320713; SMYTH MJ, 1994, CLIN EXP PHARMACOL P, V21, P67, DOI 10.1111/j.1440-1681.1994.tb02438.x; Solary E, 1998, CELL BIOL TOXICOL, V14, P121, DOI 10.1023/A:1007481921502; SUN XM, 1994, J BIOL CHEM, V269, P14857; Uren AG, 1998, TRENDS BIOCHEM SCI, V23, P159, DOI 10.1016/S0968-0004(98)01198-0; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; VUKELIC B, 1995, APPL MICROBIOL BIOT, V43, P1056, DOI 10.1007/BF00166925; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WILDERMUTH H, 1970, J GEN MICROBIOL, V60, P43, DOI 10.1099/00221287-60-1-43; YANAGIDA T, 1980, J ANTIBIOT, V33, P1206, DOI 10.7164/antibiotics.33.1206; ZANG C, 1996, MOL MICROBIOL, V20, P9	61	59	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20366	20375		10.1074/jbc.274.29.20366	http://dx.doi.org/10.1074/jbc.274.29.20366			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400660	hybrid			2022-12-25	WOS:000081438300053
J	Takahashi, E; Abe, J; Gallis, B; Aebersold, R; Spring, DJ; Krebs, EG; Berk, BC				Takahashi, E; Abe, J; Gallis, B; Aebersold, R; Spring, DJ; Krebs, EG; Berk, BC			p90(RSK) is a serum-stimulated Na+/H+ exchanger isoform-1 kinase - Regulatory phosphorylation of serine 703 of Na+/H+ exchanger isoform-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; ACTIVATED PROTEIN-KINASE; SPONTANEOUSLY HYPERTENSIVE RATS; EPIDERMAL GROWTH-FACTOR; WISTAR-KYOTO RATS; NA-H EXCHANGE; S6 KINASE; INDUCE PHOSPHORYLATION; UBIQUITOUS ISOFORM; MASS-SPECTROMETRY	The Na+/H+ exchanger isoform-1 (NHE-1) is the key member of a family of exchangers that regulates intracellular pH and cell volume. Activation of NHE-1 by growth factors is rapid, correlates with increased NHE-1 phosphorylation and cell alkalinization, and plays a role in cell cycle progression. By two-dimensional tryptic peptide mapping of immunoprecipitated NHE-1, we identify serine 703 as the major serum-stimulated amino acid, Mutation of serine 703 to alanine had no effect on acid-stimulated Na+/H+ exchange but completely prevented the growth factor-mediated increase in NHE-1 affinity for HC. In addition, we show that p90 ribosomal S6 kinase (p90(RSK)) is a key NHE-1 kinase since p90(RSK) phosphorylates NHE-1 serine 703 stoichiometrically in vitro, and transfection with kinase inactive p90(RSK) inhibits serum-induced phosphorylation of NHE-1 serine 703 in transfected 293 cells. These findings establish p90(RSK) as a serum-stimulated NHE-1 kinase and a mediator of increased Na+/H+ exchange in vivo.	Univ Rochester, Cardiovasc Res Ctr, Rochester, NY 14642 USA; Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA	University of Rochester; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Berk, BC (corresponding author), Univ Rochester, Cardiovasc Res Ctr, Box 679, Rochester, NY 14642 USA.			Berk, Bradford/0000-0002-2767-4115				Aharonovitz O, 1996, J BIOL CHEM, V271, P16494, DOI 10.1074/jbc.271.28.16494; BERK BC, 1989, J CLIN INVEST, V83, P822, DOI 10.1172/JCI113964; BERK BC, 1987, J BIOL CHEM, V262, P5057; BERTRAND B, 1994, J BIOL CHEM, V269, P13703; Bianchini L, 1997, J BIOL CHEM, V272, P271; CHAMBARD JC, 1986, EXP CELL RES, V164, P282, DOI 10.1016/0014-4827(86)90029-7; Cox GA, 1997, CELL, V91, P139, DOI 10.1016/S0092-8674(01)80016-7; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ERIKSON E, 1986, J BIOL CHEM, V261, P350; ERIKSON E, 1988, 2ND MESSENGERS PHOSP, V12, P135; FAFOURNOUX P, 1991, BIOCHEMISTRY-US, V30, P9510, DOI 10.1021/bi00103a018; Figeys D, 1998, ELECTROPHORESIS, V19, P1811, DOI 10.1002/elps.1150191045; FLIEGEL L, 1992, BIOCHEM J, V282, P139, DOI 10.1042/bj2820139; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; Goss G, 1996, AM J PHYSIOL-CELL PH, V270, pC1493, DOI 10.1152/ajpcell.1996.270.5.C1493; GOSS GG, 1994, J BIOL CHEM, V269, P8741; GRINSTEIN S, 1992, J BIOL CHEM, V267, P23823; GROVE JR, 1993, BIOCHEMISTRY-US, V32, P7727, DOI 10.1021/bi00081a018; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Kelly MP, 1997, CIRC RES, V80, P853; Kusuhara M, 1998, CIRC RES, V83, P824, DOI 10.1161/01.RES.83.8.824; Lin X, 1996, P NATL ACAD SCI USA, V93, P12631, DOI 10.1073/pnas.93.22.12631; LUCCHESI PA, 1994, HYPERTENSION, V24, P734, DOI 10.1161/01.HYP.24.6.734; MCSWINE RL, 1994, J CELL PHYSIOL, V161, P351, DOI 10.1002/jcp.1041610220; MITSUKA M, 1991, AM J PHYSIOL, V260, pC562, DOI 10.1152/ajpcell.1991.260.3.C562; MOOLENAAR WH, 1983, NATURE, V304, P645, DOI 10.1038/304645a0; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; NOEL J, 1995, AM J PHYSIOL-CELL PH, V268, pC283, DOI 10.1152/ajpcell.1995.268.2.C283; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; PARIS S, 1984, J BIOL CHEM, V259, P989; Phan VN, 1997, HYPERTENSION, V29, P1265, DOI 10.1161/01.HYP.29.6.1265; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; Robertson MA, 1997, J BIOL CHEM, V272, P287; SABRI A, 1997, CIRCULATION, V96, P46; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SARDET C, 1991, J BIOL CHEM, V266, P19166; SICZKOWSKI M, 1995, CIRC RES, V76, P825, DOI 10.1161/01.RES.76.5.825; SICZKOWSKI M, 1994, J HYPERTENS, V12, P775; SIFFERT W, 1995, HYPERTENSION, V26, P649, DOI 10.1161/01.HYP.26.4.649; Spring DJ, 1999, MOL CELL BIOL, V19, P317; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; Takahashi E, 1997, CIRC RES, V81, P268, DOI 10.1161/01.RES.81.2.268; TOMINAGA, 1998, EMBO J, V17, P4712; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P13710; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P5583; Wang H, 1997, BIOCHEMISTRY-US, V36, P9151, DOI 10.1021/bi970802f; WATTS JD, 1994, J BIOL CHEM, V269, P29520; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903	51	212	213	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20206	20214		10.1074/jbc.274.29.20206	http://dx.doi.org/10.1074/jbc.274.29.20206			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400637	hybrid			2022-12-25	WOS:000081438300030
J	Xie, ZJ; Bikle, DD				Xie, ZJ; Bikle, DD			Phospholipase C-gamma 1 is required for calcium-induced keratinocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED MURINE KERATINOCYTES; INOSITOL PHOSPHATE FORMATION; INTRACELLULAR FREE CALCIUM; HUMAN INVOLUCRIN PROMOTER; MOUSE EPIDERMAL-CELLS; TERMINAL DIFFERENTIATION; SIGNAL TRANSDUCTION; METABOLISM; GROWTH; EXPRESSION	Phospholipase C-gamma 1 is the most abundant member of the phospholipase C family in keratinocytes and is induced by calcium. Phospholipase C-gamma 1, therefore, may be involved in the signal transduction system leading to calcium regulation of keratinocyte differentiation. To test this hypothesis, expression of phospholipase C-gamma 1 in human keratinocytes was blocked by transfecting cells with the antisense human phospholipase C-gamma 1 cDNA construct. These cells demonstrated a dramatic reduction in phospholipase C-gamma 1 protein level compared with the empty vector-transfected cells and a marked reduction in the mRNA and protein levels of the differentiation markers involucrin and transglutaminase following administration of calcium. Similarly, cotransfection of antisense phospholipase C-gamma 1 constructs with a luciferase reporter vector containing involucrin or transglutaminase promoters led to a substantial reduction in calcium-stimulated involucrin and transglutaminase promoter activities. Similar results were seen following treatment with a specific phospholipase C inhibitor U73122. To determine whether phospholipase C-gamma 1 regulated differentiation by controlling intracellular calcium, we examined the ability of antisense phospholipase C-gamma 1 to block the calcium-induced rise in intracellular calcium and found that it could. These findings indicate that phospholipase C-gamma 1 is a critical component of the signaling pathway mediating calcium regulation of keratinocyte differentiation via its mobilization of intracellular calcium.	Univ Calif San Francisco, Vet Affairs Med Ctr, Endocrine Unit, San Francisco, CA 94121 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Xie, ZJ (corresponding author), Univ Calif San Francisco, Vet Affairs Med Ctr, Endocrine Unit, 4150 Clement St,111N, San Francisco, CA 94121 USA.	zjxie@itsa.ucsf.edu	xie, zhongjian/K-7858-2016	xie, zhongjian/0000-0002-4328-1303				BALA GA, 1990, BIOL REPROD, V43, P704, DOI 10.1095/biolreprod43.4.704; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BLEASDALE JE, 1990, J PHARMACOL EXP THER, V255, P756; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARROLL JM, 1993, P NATL ACAD SCI USA, V90, P10270, DOI 10.1073/pnas.90.21.10270; CARROLL JM, 1992, J CELL SCI, V103, P925; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; Goo Rhee Sue, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P35; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Haase I, 1997, J INVEST DERMATOL, V108, P748, DOI 10.1111/1523-1747.ep12292135; Haase I, 1996, Exp Dermatol, V5, P84, DOI 10.1111/j.1600-0625.1996.tb00099.x; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HENNINGS H, 1983, J CELL PHYSIOL, V116, P265, DOI 10.1002/jcp.1041160303; IZANT JG, 1985, SCIENCE, V229, P345, DOI 10.1126/science.2990048; JAKEN S, 1988, CARCINOGENESIS, V9, P1033, DOI 10.1093/carcin/9.6.1033; JIANG CK, 1991, J INVEST DERMATOL, V97, P969, DOI 10.1111/1523-1747.ep12491889; KRUSZEWSKI FH, 1991, AM J PHYSIOL, V261, pC767, DOI 10.1152/ajpcell.1991.261.5.C767; LEE E, 1991, CARCINOGENESIS, V12, P1651, DOI 10.1093/carcin/12.9.1651; LU S, 1995, J BIOL CHEM, V270, P9748, DOI 10.1074/jbc.270.17.9748; MACLAUGHLIN JA, 1990, J NUTR BIOCHEM, V1, P81, DOI 10.1016/0955-2863(90)90054-O; MAJERUS PW, 1986, SCIENCE, V234, P1519, DOI 10.1126/science.3024320; Mariniello L, 1995, J BIOL CHEM, V270, P31358, DOI 10.1074/jbc.270.52.31358; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Ng Dean C., 1996, Frontiers in Bioscience (online), V1, pA16; PILLAI S, 1988, J CELL PHYSIOL, V134, P229, DOI 10.1002/jcp.1041340208; PILLAI S, 1988, J BIOL CHEM, V263, P5390; PILLAI S, 1990, J CELL PHYSIOL, V143, P294, DOI 10.1002/jcp.1041430213; PUNNONEN K, 1993, J INVEST DERMATOL, V101, P719, DOI 10.1111/1523-1747.ep12371682; PUNNONEN K, 1994, MOL CARCINOGEN, V10, P216, DOI 10.1002/mc.2940100406; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; ROSENBACH T, 1991, J INVEST DERMATOL, V96, P116, DOI 10.1111/1523-1747.ep12515929; ROSENBACH T, 1993, ARCH DERMATOL RES, V285, P393, DOI 10.1007/BF00372131; SMITH RJ, 1990, J PHARMACOL EXP THER, V253, P688; SREEKUMAR P, 1995, J CLIN INVEST, V96, P602, DOI 10.1172/JCI118075; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; TALWAR HS, 1989, J INVEST DERMATOL, V93, P241, DOI 10.1111/1523-1747.ep12277581; TANG W, 1988, J INVEST DERMATOL, V90, P37, DOI 10.1111/1523-1747.ep12462536; ZIBOH VA, 1984, BIOCHEM BIOPH RES CO, V122, P1234, DOI 10.1016/0006-291X(84)91224-5	39	67	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20421	20424		10.1074/jbc.274.29.20421	http://dx.doi.org/10.1074/jbc.274.29.20421			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400667	hybrid			2022-12-25	WOS:000081438300060
J	Zhang, XM; Verdine, GL				Zhang, XM; Verdine, GL			A small region in HMGI I(Y) is critical for cooperation with NF-kappa B on DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IFN-BETA GENE; GROUP PROTEIN HMG-I(Y); TRANSCRIPTIONAL ACTIVATION; CHROMOSOMAL-PROTEINS; VIRUS INDUCTION; BINDING DOMAIN; I PROTEINS; T-CELLS; EXPRESSION; PROMOTER	The high mobility group HMG I(Y) protein has been reported to promote the expression of several NF-kappa B-dependent genes by enhancing the binding of NF-kappa B to DNA. The molecular origins of cooperativity in the binding of NF-kappa B and HMG I(Y) to DNA are not well understood. Here we have examined the determinants of specificity in the binding of HMG I(Y), both alone and in cooperation with NF-kappa B, to two different DNA elements, PRDII from the interferon-beta enhancer and Ig kappa B from the immunoglobulin kappa light chain enhancer. Of particular interest was the influence of a flanking AT-rich sequence on binding by HMG I(Y). Utilizing yeast one-hybrid screening assays together with alanine-scanning mutagenesis, we have identified mutations of residues in HMG: I(Y) that decrease cooperative binding of NF-kappa B to PRDII and Ig kappa B sites. These same mutations similarly decreased the binding of HMG: I(Y) alone to DNA, and paradoxically, decreased the strength of protein-protein interactions between HMG I(Y) and NF-kappa B. Of the three tandemly repeated basic regions that represent putative DNA-binding motifs in HMG; I(Y), the residues within the second repeat are most important for recognition of core NF-kappa B sites, whereas the second and third repeats both appear to be involved in binding to sites that are flanked by AT-rich sequences. Overall, the second repeat of HMG I(Y) is primarily responsible for the stimulatory effect of this protein on the binding of NF-kappa B to PRDII and Ig kappa B elements.	Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University; Harvard University	Verdine, GL (corresponding author), Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA.							Arlotta P, 1997, J BIOL CHEM, V272, P29904, DOI 10.1074/jbc.272.47.29904; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chytil M, 1998, P NATL ACAD SCI USA, V95, P14076, DOI 10.1073/pnas.95.24.14076; Chytil M, 1996, CURR OPIN STRUC BIOL, V6, P91, DOI 10.1016/S0959-440X(96)80100-X; Cramer P, 1997, EMBO J, V16, P7078, DOI 10.1093/emboj/16.23.7078; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DU W, 1992, P NATL ACAD SCI USA, V89, P2150, DOI 10.1073/pnas.89.6.2150; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; Farnet CM, 1997, CELL, V88, P483, DOI 10.1016/S0092-8674(00)81888-7; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; Himes SR, 1996, IMMUNITY, V5, P479, DOI 10.1016/S1074-7613(00)80503-8; Huth JR, 1997, NAT STRUCT BIOL, V4, P657, DOI 10.1038/nsb0897-657; JOHN S, 1995, MOL CELL BIOL, V15, P1786; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; JOHNSON KR, 1988, J BIOL CHEM, V263, P18338; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; KleinHessling S, 1996, P NATL ACAD SCI USA, V93, P15311, DOI 10.1073/pnas.93.26.15311; LANDSMAN D, 1991, MOL CELL BIOL, V11, P4483, DOI 10.1128/MCB.11.9.4483; LEGER H, 1995, MOL CELL BIOL, V15, P3738; LEWIS H, 1994, MOL CELL BIOL, V14, P5701, DOI 10.1128/MCB.14.9.5701; Maher JF, 1996, P NATL ACAD SCI USA, V93, P6716, DOI 10.1073/pnas.93.13.6716; Maniatis T, 1998, COLD SPRING HARB SYM, V63, P609, DOI 10.1101/sqb.1998.63.609; Mantovani F, 1998, NUCLEIC ACIDS RES, V26, P1433, DOI 10.1093/nar/26.6.1433; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; MOORE PA, 1993, MOL CELL BIOL, V13, P1666, DOI 10.1128/MCB.13.3.1666; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; NOURBAKHSH M, 1993, EMBO J, V12, P451, DOI 10.1002/j.1460-2075.1993.tb05677.x; Peterson BR, 1996, P NATL ACAD SCI USA, V93, P13671, DOI 10.1073/pnas.93.24.13671; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; REEVES R, 1990, J BIOL CHEM, V265, P8573; SODEOKA M, 1993, BIOORG MED CHEM LETT, V3, P1089, DOI 10.1016/S0960-894X(00)80293-0; Sun LJ, 1997, P NATL ACAD SCI USA, V94, P4919, DOI 10.1073/pnas.94.10.4919; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TJADEN G, 1994, PLANT CELL, V6, P107, DOI 10.1105/tpc.6.1.107; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; VASHEE S, 1995, P NATL ACAD SCI USA, V92, P10683, DOI 10.1073/pnas.92.23.10683; VISVANATHAN KV, 1989, EMBO J, V8, P1129, DOI 10.1002/j.1460-2075.1989.tb03483.x; WOOD LD, 1995, NUCLEIC ACIDS RES, V23, P4210, DOI 10.1093/nar/23.20.4210; Yang SW, 1995, EMBO J, V14, P6292, DOI 10.1002/j.1460-2075.1995.tb00319.x; Yie JM, 1997, MOL CELL BIOL, V17, P3649, DOI 10.1128/MCB.17.7.3649	45	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20235	20243		10.1074/jbc.274.29.20235	http://dx.doi.org/10.1074/jbc.274.29.20235			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400641	hybrid			2022-12-25	WOS:000081438300034
J	Hagiyama, H; Adachi, T; Yoshida, T; Nomura, T; Miyasaka, N; Honjo, T; Tsubata, T				Hagiyama, H; Adachi, T; Yoshida, T; Nomura, T; Miyasaka, N; Honjo, T; Tsubata, T			Signaling through the antigen receptor of B lymphocytes activates a p53-independent pathway of c-Myc-induced apoptosis	ONCOGENE			English	Article						apoptosis; B lymphocyte; c-Myc; p53	CELL-CYCLE ARREST; DNA-BINDING SITE; TRANSGENIC MICE; LYMPHOMA-CELLS; MEDIATED APOPTOSIS; GROWTH ARREST; P53; EXPRESSION; INDUCTION; PROTEIN	Deregulated expression of c-Myc has been shown to induce or enhance apoptosis in various different cell types, c-Myc requires p53 for apoptosis in some but not all the cell types, indicating heterogeneous mechanisms for c-Myc-induced apoptosis, In B lymphoma line WEHI-231, stable expression of c-Myc has been demonstrated to protect cells from BCR-mediated apoptosis. However, stable expression of c-Myc carrying pro-apoptotic functions may generate variant cells resistant to apoptosis. By utilizing an inducible system for c-Myc, me demonstrated here that deregulated expression of c-Myc induced apoptosis of WEHI-231 by itself, indicating that c-Myc induces apoptosis in WEHI-231 as is the case for other cell types. When transactivation of p53 was inactivated, WEHI-231 cells overexpressing c-Myc no longer underwent apoptosis in the absence of other stimuli, but showed markedly enhanced apoptosis in the presence of BCR ligation. These results indicate that deregulated c-Myc expression enhances apoptosis by a p53-independent pathway in the presence of BCR signaling but requires p53 for apoptosis in the absece of BCR crosslinking in WEHI-231, BCR ligation may thus activate a p53-independent pathway of Myc-induced apoptosis.	Tokyo Med & Dent Univ, Inst Med Res, Dept Immunol, Bunkyo Ku, Tokyo 1138510, Japan; Tokyo Med & Dent Univ, Fac Med, Dept Internal Med 1, Bunkyo Ku, Tokyo 1138519, Japan; Kyoto Univ, Grad Sch Med, Dept Med Chem, Kyoto 6068501, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Kyoto University	Tsubata, T (corresponding author), Tokyo Med & Dent Univ, Inst Med Res, Dept Immunol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.		Honjo, Tasuku/N-4470-2016; Yoshida, Tsutomu/H-9046-2013; Tsubata, Takeshi/AAI-7489-2021; Yoshida, Tsutomu/A-7486-2012	Tsubata, Takeshi/0000-0003-0760-1258; 				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ASKEW DS, 1991, ONCOGENE, V6, P1915; BENHAMOU LE, 1990, EUR J IMMUNOL, V20, P1405, DOI 10.1002/eji.1830200630; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHEN CH, 1994, RADIAT RES, V139, P307, DOI 10.2307/3578828; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; Dong JA, 1997, ONCOGENE, V15, P639, DOI 10.1038/sj.onc.1201237; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; ELIYAHU D, 1988, ONCOGENE, V3, P313; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FISCHER G, 1994, J EXP MED, V179, P221, DOI 10.1084/jem.179.1.221; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GOODNOW CC, 1992, ANNU REV IMMUNOL, V10, P489, DOI 10.1146/annurev.iy.10.040192.002421; HASBOLD J, 1990, EUR J IMMUNOL, V20, P1685, DOI 10.1002/eji.1830200810; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Klefstrom J, 1997, EMBO J, V16, P7382, DOI 10.1093/emboj/16.24.7382; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Lenahan MK, 1996, ONCOGENE, V12, P1847; MCCORMACK JE, 1984, P NATL ACAD SCI-BIOL, V81, P5546, DOI 10.1073/pnas.81.17.5546; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; Sakamuro D, 1995, ONCOGENE, V11, P2411; Scott DW, 1996, INT IMMUNOL, V8, P1375, DOI 10.1093/intimm/8.9.1375; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Trudel M, 1997, J EXP MED, V186, P1873, DOI 10.1084/jem.186.11.1873; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Wang KS, 1996, EXPERT SYST APPL, V10, P1, DOI 10.1016/0957-4174(95)00029-1; WANG Y, 1995, MOL CELL BIOL, V15, P2157; WARNER GL, 1992, CELL GROWTH DIFFER, V3, P175; WU C, 1984, NATURE, V311, P81, DOI 10.1038/311081a0; Wu M, 1996, MOL CELL BIOL, V16, P5015; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Yi AK, 1996, J IMMUNOL, V157, P4918	37	20	20	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	1999	18	28					4091	4098		10.1038/sj.onc.1202772	http://dx.doi.org/10.1038/sj.onc.1202772			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	216FP	10435590				2022-12-25	WOS:000081431000006
J	Shinbo, T; Matsuki, A; Matsumoto, Y; Kosugi, S; Takahashi, Y; Niwa, O; Kominami, R				Shinbo, T; Matsuki, A; Matsumoto, Y; Kosugi, S; Takahashi, Y; Niwa, O; Kominami, R			Allelic loss mapping and physical delineation of a region harboring a putative thymic lymphoma suppressor gene on mouse chromosome 12	ONCOGENE			English	Article						tumor suppressor gene; physical mapping; allelic loss (or LOH) analysis; gamma-ray induced thymic lymphoma	ALLELOTYPE ANALYSIS; FREQUENT LOSS; HETEROZYGOSITY; CANCER; LOCI; MICE; CARCINOMAS; GENOME	Our previous allelic loss analasis of gamma-ray induced thymic lymphomas in F-1 hybrid and backcross mice between BALB/c and MSM strains mapped the Tlsr4 region exhibiting a high frequency of allelic loss (62%) to a 2.9 cM interval between the markers D12Mit53 and D12Mit279 on mouse chromosome 12, To narrow further the interval harboring a putative tumor suppressor gene, a high-density scan has been carried out for informative 361 thymic lymphomas, Construction of a physical map of Tlsr4 with 3 YAC and 15 BAC clones and isolation of YAC- and BAC-derived polymorphic probes lead to fine allelic loss mapping. Three successive pola morphic sites within one BAC exhibit the retention of both alleles in seven, one and four lymphomas, suggesting that a common region of allelic loss for Tlsr4 exists within the BAC region. Pulsed-field gel electrophoresis of NotI digests of this and other clones determines that the commonly lost region is a 35 kb interval with a NotI site. NotI sites are frequently associated with coding regions, and our preliminary sequencing has identified ESTs in the region. Thus, the present study facilitates the identification of genes in the Tlsr4 region that mould lead to isolation of a novel tumor suppressor gene.	Niigata Univ, Sch Med, Dept Biochem, Niigata 9518122, Japan; Niigata Univ, Sch Med, Dept Med 2, Niigata 9518122, Japan; Kyoto Univ, Ctr Radiat Biol, Sakyou Ku, Kyoto 6068315, Japan	Niigata University; Niigata University; Kyoto University	Kominami, R (corresponding author), Niigata Univ, Sch Med, Dept Biochem, Asahimachi 1-757, Niigata 9518122, Japan.		Kosugi, S./K-5142-2019	Kosugi, Shin-ichi/0000-0002-6602-7412				ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; Bandera CA, 1997, CANCER RES, V57, P513; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BONHOMME F, 1989, GENETIC VARIANTS STR, P658; Brown MA, 1997, TRENDS GENET, V13, P202, DOI 10.1016/S0168-9525(97)01132-3; CHANG WYH, 1995, CANCER RES, V55, P3246; DIETRICH WF, 1994, P NATL ACAD SCI USA, V91, P9451, DOI 10.1073/pnas.91.20.9451; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; HAYASHI T, 1993, GENOMICS, V17, P490, DOI 10.1006/geno.1993.1352; HEGI ME, 1994, CANCER RES, V54, P6257; Jacks T, 1996, ANNU REV GENET, V30, P603, DOI 10.1146/annurev.genet.30.1.603; KEMP CJ, 1993, CANCER RES, V53, P6022; KNUDSON AG, 1985, CANCER RES, V45, P1437; Matsumoto Y, 1998, ONCOGENE, V16, P2747, DOI 10.1038/sj.onc.1201810; OKAMOTO M, 1995, CARCINOGENESIS, V16, P2659, DOI 10.1093/carcin/16.11.2659; Radany EH, 1997, P NATL ACAD SCI USA, V94, P8664, DOI 10.1073/pnas.94.16.8664; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; Santos J, 1998, ONCOGENE, V17, P925, DOI 10.1038/sj.onc.1202009; Santos J, 1996, ONCOGENE, V12, P669; SUZUKI T, 1989, CANCER RES, V49, P1095; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; YOUNG J, 1993, ONCOGENE, V8, P671; Zhuang SM, 1996, CANCER RES, V56, P3338	24	27	29	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	1999	18	28					4131	4136		10.1038/sj.onc.1202767	http://dx.doi.org/10.1038/sj.onc.1202767			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	216FP	10435594				2022-12-25	WOS:000081431000010
J	Still, IH; Hamilton, M; Vince, P; Wolfman, A; Cowell, JK				Still, IH; Hamilton, M; Vince, P; Wolfman, A; Cowell, JK			Cloning of TACC1, an embryonically expressed, potentially transforming coiled coil containing gene, from the 8p11 breast cancer amplicon	ONCOGENE			English	Article						TACC1; embryonic; transforming; breast cancer	AMPLIFICATION; REGION; RECEPTORS; CARCINOMA; DOMAINS	Amplification of several chromosomal regions have been observed in human breast carcinomas. One such region, 8p11, is amplified in 10-15% of tumor samples, Although the FGFR1 gene is located close to this region, and is often included within the amplicon, the observation that tumors exhibiting 8p11 amplification do not always overexpress FGFR1 suggests that another gene located close to FGFR1 is involved in the tumorigenic process. We now report the precise location of four expressed sequence tags (ESTs) within this region and the cloning of a novel gene, designated TACC1 (transforming acidic coiled coil gene 1), which encodes an 8 kb transcript and which is expressed at high levels during early embryogenesis. Constitutive expression of this gene under the control of the cytomegalovirus (CMV) promoter in mouse fibroblasts, results in cellular transformation and anchorage independent growth, suggesting that inappropriate expression can impart a proliferative advantage. This observation raises the possibility that amplification of TACC1 could promotemalignant growth, thereby making TACC1 an attractive candidate for the gene promoting tumorigenicity as a result of the 8p11 amplification in human breast cancers.	Cleveland Clin Fdn, Lerner Res Inst, Ctr Mol Genet, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Still, IH (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Ctr Mol Genet, 9500 Euclid Ave, Cleveland, OH 44195 USA.			Cowell, John/0000-0002-2079-5950	NIGMS NIH HHS [GM49652] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM049652, R01GM049652] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adelaide J, 1998, GENE CHROMOSOME CANC, V22, P186, DOI 10.1002/(SICI)1098-2264(199807)22:3<186::AID-GCC4>3.0.CO;2-S; ADNANE J, 1991, ONCOGENE, V6, P659; Courjal F, 1997, CANCER RES, V57, P4360; DIB A, 1995, ONCOGENE, V10, P995; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; Hawthorn L, 1995, GENOMICS, V30, P425, DOI 10.1006/geno.1995.1260; MCLESKEY SW, 1994, CANCER RES, V54, P523; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; SCLESSINGER U, 1992, NEURON, V9, P383; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; THEILLET C, 1990, ONCOGENE, V5, P147; THEILLET C, 1993, GENE CHROMOSOME CANC, V7, P219, DOI 10.1002/gcc.2870070407; Weskamp G, 1996, J CELL BIOL, V132, P717, DOI 10.1083/jcb.132.4.717; WEYMAN CM, 1996, ADVANCES IN ONCOBIOL, V1, P159	16	99	105	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 8	1999	18	27					4032	4038		10.1038/sj.onc.1202801	http://dx.doi.org/10.1038/sj.onc.1202801			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KU	10435627				2022-12-25	WOS:000081327800014
J	Moor, AN; Fliegel, L				Moor, AN; Fliegel, L			Protein kinase-mediated regulation of the Na+/H+ exchanger in the rat myocardium by mitogen-activated protein kinase-dependent pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; NA-H EXCHANGE; PHOSPHORYLATION; NHE1; P90(RSK)	We examined regulation of the Na+/H+ exchanger isoform 1 by phosphorylation in the rat myocardium. We utilized cell extracts from adult rat hearts, adult rat extracts fractionated by fast performance liquid chromatography, and extracts from cultured neonatal cardiac myocytes. The carboxyl-terminal 178 amino acids of the Na+/H+ exchanger were expressed in Escherichia coli fused with glutathione S-transferase. The purified protein was used as a substrate for in vitro phosphorylation and in-gel kinase assays. Unfractionated extracts from neonatal myocytes or adult hearts phosphorylated the COOH-terminal domain of the antiporter. Western blot analysis revealed that mitogen-activated protein (MAP) kinase (44 and 42 kDa) and p90(rsk) (90 kDa) were present in specific fractions of cardiac extracts that phosphorylated the COOH-terminal protein, In-gel kinase assays confirmed that protein kinases of approximately 44 and 90 kDa could phosphorylate this domain. MAP kinase and p90(rsk)-dependent phosphorylation of the antiporter could be demonstrated by immunoprecipitation of these kinases from extracts of neonatal cardiac myocytes. PD98059, a mitogen-activated protein kinase kinase inhibitor, decreased MAP kinase and p90(rsk) phosphorylation of the antiporter and abolished serum and endothelin 1-stimulated increases in steady-state pH(i). These results confirm the presence of MAP kinase-dependent phosphorylation in the regulation of the Na+/H+ exchanger in the rat myocardium and suggest an important role for p90(rsk) phosphorylation in regulation of the protein by endothelin-mediated stimulation of the antiporter.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada	University of Alberta	Fliegel, L (corresponding author), Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada.	lfliegel@gpu.srv.ualberta.ca						Besson P, 1998, AM J PHYSIOL-CELL PH, V274, pC831, DOI 10.1152/ajpcell.1998.274.3.C831; Bianchini L, 1997, J BIOL CHEM, V272, P271; BJORBAEK C, 1995, J BIOL CHEM, V270, P18848, DOI 10.1074/jbc.270.32.18848; CHAILLET JR, 1985, J GEN PHYSIOL, V86, P765, DOI 10.1085/jgp.86.6.765; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DYCK JRB, 1995, CARDIOVASC RES, V29, P203, DOI 10.1016/S0008-6363(96)88571-3; Fliegel L, 1997, J MOL CELL CARDIOL, V29, P1991, DOI 10.1006/jmcc.1997.0479; Fliegel L, 1996, NAPLUS HPLUS EXCHANG, P1; HASSARD TH, 1991, UNDERSTANDING BIOSTA, P263; HAWORTH R, 1998, J MOL CELL CARDIOL, V30, P337; HAWORTH RS, 1993, BIOCHEM J, V289, P637, DOI 10.1042/bj2890637; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; Karmazyn M., 1996, NAPLUS HPLUS EXCHANG, P189; KRAMER BK, 1991, CIRC RES, V68, P269, DOI 10.1161/01.RES.68.1.269; Lin X, 1996, P NATL ACAD SCI USA, V93, P12631, DOI 10.1073/pnas.93.22.12631; Lucchesi PA, 1996, CIRC RES, V78, P962, DOI 10.1161/01.RES.78.6.962; MICHALAK M, 1990, J BIOL CHEM, V265, P5869; MOE OW, 1995, J CLIN INVEST, V96, P2187, DOI 10.1172/JCI118273; Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3; Numata M, 1998, J BIOL CHEM, V273, P6951, DOI 10.1074/jbc.273.12.6951; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; Orlowski J., 1996, NAPLUS HPLUS EXCHANG, P123; Phan VN, 1997, HYPERTENSION, V29, P1265, DOI 10.1161/01.HYP.29.6.1265; SICZKOWSKI M, 1995, CIRC RES, V76, P825, DOI 10.1161/01.RES.76.5.825; SILVA NLCL, 1995, BIOCHEMISTRY-US, V34, P10412, DOI 10.1021/bi00033a013; Takahashi E, 1997, CIRC RES, V81, P268, DOI 10.1161/01.RES.81.2.268; Tominaga T, 1998, EMBO J, V17, P4712, DOI 10.1093/emboj/17.16.4712; Wakabayashi S, 1997, BIOCHEMISTRY-US, V36, P12854, DOI 10.1021/bi9715472; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P5583; Wang H, 1997, BIOCHEMISTRY-US, V36, P9151, DOI 10.1021/bi970802f	30	130	134	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					22985	22992		10.1074/jbc.274.33.22985	http://dx.doi.org/10.1074/jbc.274.33.22985			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438464	hybrid			2022-12-25	WOS:000082012800014
J	Alpert, D; Schwenger, P; Han, JH; Vilcek, J				Alpert, D; Schwenger, P; Han, JH; Vilcek, J			Cell stress and MKK6b-mediated p38 MAP kinase activation inhibit tumor necrosis factor-induced I kappa B phosphorylation and NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; SIGNAL-REGULATED KINASE; JUN NH2-TERMINAL KINASE; PROTEIN-KINASE; SODIUM-SALICYLATE; TRANSCRIPTION FACTOR; INDUCED APOPTOSIS; GENE-EXPRESSION; TERMINAL KINASE; ALPHA PHOSPHORYLATION	Tumor necrosis factor (TNF) exerts many actions through activation of the transcription factor NF-kappa B. NF-kappa B is sequestered in the cytosol by an inhibitory subunit I kappa B, which is inducibly phosphorylated by an I kappa B kinase complex and subsequently degraded. Sodium salicylate (NaSal) can block NF-kappa B activation by inhibiting I kappa B alpha phosphorylation. Recently, we used the specific p38 mitogen-activated protein (MAP) kinase inhibitor SB203580 to demonstrate that inhibition of TNF-induced I kappa B alpha phosphorylation requires NaSal-induced p38 activation. We demonstrate that NaSal similarly inhibits TNF-induced I kappa beta beta degradation in a p38-dependent manner. To further examine the role of p38, we determined whether other agents that activate p38 can block TNF-induced I kappa B phosphorylation and degradation. Sorbitol, H2O2, and arsenite each blocked I kappa B alpha phosphorylation induced by TNF, and SB203580 reversed the inhibitory effects of sorbitol and H2O2, but not arsenite. In addition, sorbitol and H2O2 blocked TNF-induced but not interleukin-1-induced I kappa B alpha phosphorylation, whereas arsenite inhibited I kappa B alpha phosphorylation induced by TNF and interleukin-1. Transient expression of MAP kinase kinase (MKK) 6b(E), a constitutive activator of p38, reduced both TNF-induced phosphorylation of I kappa B alpha and NF-kappa B-dependent reporter activity. However, MKK7(D), a constitutive activator of c-Jun N-terminal kinases, failed to inhibit these TNF actions. Thus, sustained p38 activation by various stimuli inhibits TNF-induced I kappa B phosphorylation and NF-kappa B activation.	NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA; Scripps Res Inst, La Jolla, CA 92037 USA	New York University; Scripps Research Institute	Vilcek, J (corresponding author), NYU, Sch Med, Dept Microbiol, 550 1st Ave, New York, NY 10016 USA.	jan.vilcek@med.nyu.edu	Han, J/G-4671-2010		NATIONAL CANCER INSTITUTE [R35CA049731, R01CA075071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007308] Funding Source: NIH RePORTER; NCI NIH HHS [R35-CA49731, R01-CA75071] Funding Source: Medline; NIGMS NIH HHS [5T32-GM07308] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Auron PE, 1998, CYTOKINE GROWTH F R, V9, P221, DOI 10.1016/S1359-6101(98)00018-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beauparlant P, 1996, J VIROL, V70, P5777, DOI 10.1128/JVI.70.9.5777-5785.1996; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Bitko V, 1997, VIROLOGY, V232, P369, DOI 10.1006/viro.1997.8582; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Darnay BG, 1997, J LEUKOCYTE BIOL, V61, P559, DOI 10.1002/jlb.61.5.559; Demarchi F, 1996, J VIROL, V70, P4427, DOI 10.1128/JVI.70.7.4427-4437.1996; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Frasch SC, 1998, J BIOL CHEM, V273, P8389, DOI 10.1074/jbc.273.14.8389; GAUTAM SC, 1995, BLOOD, V86, P2541; Graves JD, 1996, P NATL ACAD SCI USA, V93, P13814, DOI 10.1073/pnas.93.24.13814; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Huang S, 1997, IMMUNITY, V6, P739, DOI 10.1016/S1074-7613(00)80449-5; Johnson DR, 1996, J BIOL CHEM, V271, P16317, DOI 10.1074/jbc.271.27.16317; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Lahdenpohja N, 1998, J IMMUNOL, V160, P1354; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lee SY, 1997, J EXP MED, V185, P1275, DOI 10.1084/jem.185.7.1275; Li YC, 1997, J BIOL CHEM, V272, P20646, DOI 10.1074/jbc.272.33.20646; Li Z, 1997, MOL CELL BIOL, V17, P6184, DOI 10.1128/MCB.17.10.6184; Lin RT, 1996, MOL CELL BIOL, V16, P1401; Liu YS, 1996, FREE RADICAL BIO MED, V21, P771, DOI 10.1016/0891-5849(96)00176-1; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Milligan SA, 1998, ARCH BIOCHEM BIOPHYS, V352, P255, DOI 10.1006/abbi.1998.0603; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; Moriguchi T, 1996, J BIOL CHEM, V271, P26981, DOI 10.1074/jbc.271.43.26981; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; New L, 1998, EMBO J, V17, P3372, DOI 10.1093/emboj/17.12.3372; New LG, 1998, TRENDS CARDIOVAS MED, V8, P220, DOI 10.1016/S1050-1738(98)00012-7; OETH P, 1995, BLOOD, V86, P4144, DOI 10.1182/blood.V86.11.4144.bloodjournal86114144; Pierce JW, 1996, J IMMUNOL, V156, P3961; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; Schwenger P, 1999, J CELL PHYSIOL, V179, P109, DOI 10.1002/(SICI)1097-4652(199904)179:1<109::AID-JCP13>3.0.CO;2-W; Schwenger P, 1996, J BIOL CHEM, V271, P8089, DOI 10.1074/jbc.271.14.8089; Schwenger P, 1998, MOL CELL BIOL, V18, P78, DOI 10.1128/MCB.18.1.78; Schwenger P, 1997, P NATL ACAD SCI USA, V94, P2869, DOI 10.1073/pnas.94.7.2869; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; Shumilla JA, 1998, ARCH BIOCHEM BIOPHYS, V349, P356, DOI 10.1006/abbi.1997.0470; SNOW ET, 1992, PHARMACOL THERAPEUT, V53, P31, DOI 10.1016/0163-7258(92)90043-Y; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Wallach D, 1997, TRENDS BIOCHEM SCI, V22, P107, DOI 10.1016/S0968-0004(97)01015-3; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang XM, 1998, J BIOL CHEM, V273, P9373, DOI 10.1074/jbc.273.16.9373; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Weil R, 1997, J BIOL CHEM, V272, P9942; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu ZG, 1997, MOL CELL BIOL, V17, P7407, DOI 10.1128/MCB.17.12.7407; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang JH, 1998, GENE, V212, P95, DOI 10.1016/S0378-1119(98)00158-9; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; Zechner D, 1998, J BIOL CHEM, V273, P8232, DOI 10.1074/jbc.273.14.8232	79	96	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22176	22183		10.1074/jbc.274.32.22176	http://dx.doi.org/10.1074/jbc.274.32.22176			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428782	hybrid			2022-12-25	WOS:000081868400012
J	Erickson, RW; Langel-Peveri, P; Traynor-Kaplan, AE; Heyworth, PG; Curnutte, JT				Erickson, RW; Langel-Peveri, P; Traynor-Kaplan, AE; Heyworth, PG; Curnutte, JT			Activation of human neutrophil NADPH oxidase by phosphatidic acid or diacylglycerol in a cell-free system - Activity of diacylglycerol is dependent on its conversion to phosphatidic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; PROTEIN-KINASE-C; CHRONIC GRANULOMATOUS-DISEASE; STIMULATED HUMAN-NEUTROPHILS; ELECTROPERMEABILIZED HUMAN NEUTROPHILS; ADENINE-DINUCLEOTIDE PHOSPHATE; FULLY SOLUBLE SYSTEM; PHOSPHOLIPASE-D; SUPEROXIDE PRODUCTION; PLASMA-MEMBRANE	The superoxide-generating neutrophil NADPH oxidase can be activated in cell-free reconstitution systems by several agonists, most notably arachidonic acid and the detergent sodium dodecyl sulfate. In this study, we show that both phosphatidic acids and diacylglycerols can serve separately as potent, physiologic activators of NADPH oxidase in a cell-free system. Stimulation of superoxide generation by these lipids was dependent upon both Mg2+ and agonist concentration. Activation of NADPH oxidase by phosphatidic acids did not appear to require their conversion to corresponding diacylglycerols by phosphatidate phosphohydrolase, since diacylglycerols were much slower than phosphatidic acids to activate the system and required the presence of ATP. Stimulation of the oxidase by dioctanoylglycerol proved to be by a means other than the activation of protein kinase C. Instead, dioctanoylglycerol was converted to dioctanoylphosphatidic acid by an endogenous diacylglycerol kinase present in the cell-free reaction system. This conversion was sensitive to the diacylglycerol kinase inhibitor R59949 and explains the markedly slower kinetics of activation and the novel ATP requirement seen with dioctanoylglycerol. The level of dioctanoylphosphatidic acid formed was suboptimal for NADPH oxidase activation but could synergize with the unmetabolized dioctanoylglycerol to activate superoxide generation.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Genentech Inc, Dept Immunol, S San Francisco, CA 94080 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92037 USA	Scripps Research Institute; Roche Holding; Genentech; University of California System; University of California San Diego	Heyworth, PG (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, MEM-241,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NCI NIH HHS [CA68276] Funding Source: Medline; NIAID NIH HHS [AI24838] Funding Source: Medline; NIDDK NIH HHS [DK47240] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA068276, R01CA068276] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024838] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047240] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; AGWU DE, 1989, BIOCHEM BIOPH RES CO, V159, P79, DOI 10.1016/0006-291X(89)92407-8; AGWU DE, 1991, J CLIN INVEST, V88, P531, DOI 10.1172/JCI115336; AGWU DE, 1989, J BIOL CHEM, V264, P1405; BABIOR BM, 1988, J BIOL CHEM, V263, P1713; BADWEY JA, 1989, J BIOL CHEM, V264, P20676; BELLAVITE P, 1988, J BIOL CHEM, V263, P8210; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; BURNHAM DN, 1990, J BIOL CHEM, V265, P17550; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; COCKCROFT S, 1984, BIOCHEM J, V222, P557, DOI 10.1042/bj2220557; CURNUTTE J T, 1992, Immunodeficiency Reviews, V3, P149; CURNUTTE JT, 1989, P NATL ACAD SCI USA, V86, P825, DOI 10.1073/pnas.86.3.825; CURNUTTE JT, 1984, J BIOL CHEM, V259, P1851; CURNUTTE JT, 1987, J BIOL CHEM, V262, P5563; CURNUTTE JT, 1989, J CLIN INVEST, V83, P1236, DOI 10.1172/JCI114006; CURNUTTE JT, 1987, J BIOL CHEM, V262, P6450; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; DANA R, 1994, BIOCHEM J, V297, P217, DOI 10.1042/bj2970217; Dana R, 1998, J BIOL CHEM, V273, P441, DOI 10.1074/jbc.273.1.441; DECOURCELLES DD, 1989, J BIOL CHEM, V264, P3274; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677, DOI 10.1002/jlb.60.6.677; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; DINAUER MC, 1987, NATURE, V327, P717, DOI 10.1038/327717a0; ElBenna J, 1996, J BIOL CHEM, V271, P6374; ELY EW, 1995, BBA-LIPID LIPID MET, V1258, P135; ENGLISH D, 1991, BIOCHEM BIOPH RES CO, V175, P423, DOI 10.1016/0006-291X(91)91581-V; English D, 1996, CELL SIGNAL, V8, P341, DOI 10.1016/0898-6568(95)00076-3; GELAS P, 1989, FEBS LETT, V251, P213, DOI 10.1016/0014-5793(89)81457-7; HENDERSON LM, 1993, EUR J BIOCHEM, V211, P157, DOI 10.1111/j.1432-1033.1993.tb19882.x; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HEYNEMAN RA, 1984, J LEUKOCYTE BIOL, V36, P751, DOI 10.1002/jlb.36.6.751; HEYWORTH PG, 1990, J BIOENERG BIOMEMBR, V22, P1, DOI 10.1007/BF00762842; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; HEYWORTH PG, 1992, CELLULAR MOL MECHANI, V4, P43; ISHITOYA J, 1987, BIOCHEM BIOPH RES CO, V144, P1025, DOI 10.1016/S0006-291X(87)80066-9; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KOSHKIN V, 1994, FEBS LETT, V338, P285, DOI 10.1016/0014-5793(94)80285-8; KOUL O, 1987, ARCH BIOCHEM BIOPHYS, V253, P453, DOI 10.1016/0003-9861(87)90199-8; LAMBETH JD, 1988, J BIOENERG BIOMEMBR, V20, P709, DOI 10.1007/BF00762549; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; MARTIN TW, 1988, BIOCHIM BIOPHYS ACTA, V962, P282, DOI 10.1016/0005-2760(88)90258-5; MAYO LA, 1990, METHOD ENZYMOL, V186, P567; MCPHAIL LC, 1985, J CLIN INVEST, V75, P1735, DOI 10.1172/JCI111884; MCPHAIL LC, 1995, P NATL ACAD SCI USA, V92, P7931, DOI 10.1073/pnas.92.17.7931; MITSUYAMA T, 1993, FEBS LETT, V328, P67, DOI 10.1016/0014-5793(93)80967-Y; OLSON SC, 1990, FEBS LETT, V272, P19, DOI 10.1016/0014-5793(90)80439-P; PAI JK, 1988, J BIOL CHEM, V263, P12472; PARK JW, 1992, J BIOL CHEM, V267, P17327; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; PERRY DK, 1992, J IMMUNOL, V149, P2749; PEVERI P, 1992, P NATL ACAD SCI USA, V89, P2494, DOI 10.1073/pnas.89.6.2494; QUALLIOTINEMANN D, 1993, J BIOL CHEM, V268, P23843; Rais S, 1998, CELL SIGNAL, V10, P121, DOI 10.1016/S0898-6568(97)00116-2; RIDER LG, 1987, J BIOL CHEM, V262, P5603; ROSSI F, 1990, BIOCHEM BIOPH RES CO, V168, P320, DOI 10.1016/0006-291X(90)91711-Z; SEGAL AW, 1987, NATURE, V326, P88, DOI 10.1038/326088a0; SERHAN CN, 1982, BIOCHEM BIOPH RES CO, V107, P951, DOI 10.1016/0006-291X(82)90615-5; SMITH CD, 1985, J BIOL CHEM, V260, P5875; TAKENAWA T, 1985, BIOCHEM PHARMACOL, V34, P1931; TAMURA M, 1993, ARCH BIOCHEM BIOPHYS, V305, P477, DOI 10.1006/abbi.1993.1450; TAYLOR GS, 1993, BIOCHIM BIOPHYS ACTA, V1175, P219, DOI 10.1016/0167-4889(93)90026-L; Tokumura A, 1997, BBA-LIPID LIPID MET, V1344, P87, DOI 10.1016/S0005-2760(96)00130-0; TRAYNOR AE, 1989, BLOOD, V73, P296; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; TSUNAWAKI S, 1986, J BIOL CHEM, V261, P1563; UHLINGER DJ, 1991, J BIOL CHEM, V266, P20990; VOLPI M, 1983, BIOCHEM BIOPH RES CO, V112, P957, DOI 10.1016/0006-291X(83)91711-4; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; Waite KA, 1997, J BIOL CHEM, V272, P15569, DOI 10.1074/jbc.272.24.15569; WIENTJES FB, 1993, BIOCHEM J, V296, P557, DOI 10.1042/bj2960557; ZHANG L, 1991, J IMMUNOL, V146, P2730	76	56	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22243	22250		10.1074/jbc.274.32.22243	http://dx.doi.org/10.1074/jbc.274.32.22243			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428791	hybrid			2022-12-25	WOS:000081868400021
J	Huck, S; Deveaud, E; Namane, A; Zouali, M				Huck, S; Deveaud, E; Namane, A; Zouali, M			Abnormal DNA methylation and deoxycytosine-deoxyguanine content in nucleosomes from lymphocytes undergoing apoptosis	FASEB JOURNAL			English	Article						autoimmunity; SLE; GC%; C2-ceramide	SYSTEMIC LUPUS-ERYTHEMATOSUS; ALU FAMILY MEMBERS; B-CELLS; IMMUNE-COMPLEXES; CIRCULATING DNA; ANTIBODIES; ANTIGEN; EXPRESSION; FRAGMENTS; SUBSET	Systemic lupus erythematosus (SLE) is characterized by an accelerated apoptosis of peripheral lymphocytes and an impairment of the clearance of apoptotic cells, Since changes in DNA methylation and in deoxycytosine and deoxyguanine (GC) content have been shown to enhance the potential of DNA to activate murine and human B lymphocytes, we tested the capacity of lymphocytes undergoing apoptosis (under conditions that mimic the deletion of self-reactive cells after antigen receptor engagement) to generate nucleosomes with a particular base composition. Using two cell culture systems and four apoptosis triggers, we found an increase of deoxymethylcytosine in fragmented chromosomal DNA of apoptotic B and T lymphocytes. However, this increase was not associated with modulation of DNA (cytosine-5) methyltransferase, the enzyme that methylates eukaryotic DNA, which suggests that the changes in DNA methylation patterns are not linked to the process of de novo DNA methylation during cell death. In addition, we could not detect a unique methylation pattern in highly repetitive Alu sequences present in the human genome of SLE subjects, as compared with controls, However, the abnormal DNA methylation of apoptotic nucleosomes was associated with an unusual pattern of nuclease-resistant, GC-rich regions in these DNA fragments. We propose that the combination of an accelerated apoptosis with a defect in the clearance of apoptotic cells results in release of increased amounts of nucleosomes with abnormally methylated, GC-rich DNA and provides an autologous stimulation that could bypass tolerance to self in systemic autoimmune diseases. These findings support the concept that the structure and dynamics of nucleosomes are critical in determining their immunogenicity in SLE.	Inst Pasteur, Dept Immunol, F-75015 Paris, France; Inst Pasteur, Unite Immunochim Analyt, F-75015 Paris, France; Inst Pasteur, Lab Chim Struturale Macromol, F-75015 Paris, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Zouali, M (corresponding author), Inst Pasteur, Dept Immunol, 28 Rue Dr Roux, F-75015 Paris, France.		Namane, Abdelkader/O-1857-2013	Namane, Abdelkader/0000-0001-7180-7619; Zouali, Moncef/0000-0002-8225-456X				AMASAKI Y, 1995, CLIN EXP IMMUNOL, V99, P245; BATZER MA, 1990, NUCLEIC ACIDS RES, V18, P6793, DOI 10.1093/nar/18.23.6793; BATZER MA, 1991, NUCLEIC ACIDS RES, V19, P3619, DOI 10.1093/nar/19.13.3619; BELL DA, 1990, J CLIN INVEST, V85, P1487, DOI 10.1172/JCI114595; BENHAMOU LE, 1990, EUR J IMMUNOL, V20, P1405, DOI 10.1002/eji.1830200630; Bertino L, 1996, DEV BRAIN RES, V95, P38, DOI 10.1016/0165-3806(96)00059-4; BESTOR TH, 1994, CURR OPIN CELL BIOL, V6, P380, DOI 10.1016/0955-0674(94)90030-2; Botto M, 1998, NAT GENET, V19, P56, DOI 10.1038/ng0598-56; Cabrespines A, 1998, J AUTOIMMUN, V11, P19, DOI 10.1006/jaut.1997.0172; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; CORVETTA A, 1991, J CHROMATOGR-BIOMED, V566, P481, DOI 10.1016/0378-4347(91)80265-E; EMLEN W, 1994, J IMMUNOL, V152, P3685; FOURNIE GJ, 1988, KIDNEY INT, V33, P487, DOI 10.1038/ki.1988.25; Hahn BH, 1998, NEW ENGL J MED, V338, P1359, DOI 10.1056/NEJM199805073381906; HASBOLD J, 1990, EUR J IMMUNOL, V20, P1685, DOI 10.1002/eji.1830200810; HELLMANNBLUMBERG U, 1993, MOL CELL BIOL, V13, P4523, DOI 10.1128/MCB.13.8.4523; HERRMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506, DOI 10.1093/nar/22.24.5506; HESS EV, 1993, SYSTEMIC LUPUS ERYTH, P893; Hossain MM, 1997, EXP TOXICOL PATHOL, V49, P201, DOI 10.1016/S0940-2993(97)80008-5; Huck S, 1998, J AUTOIMMUN, V11, P449, DOI 10.1006/jaut.1998.0226; Huck S, 1996, CLIN IMMUNOL IMMUNOP, V80, P1, DOI 10.1006/clin.1996.0087; KOLESNICK R, 1995, J EXP MED, V181, P1949, DOI 10.1084/jem.181.6.1949; KRAPF F, 1989, CLIN EXP IMMUNOL, V75, P336; KRIEG AM, 1995, J CLIN IMMUNOL, V15, P284, DOI 10.1007/BF01541318; LI JZ, 1989, ARTHRITIS RHEUM-US, V32, P726, DOI 10.1002/anr.1780320610; Liang H, 1996, J CLIN INVEST, V98, P1119, DOI 10.1172/JCI118894; MATERA AG, 1990, NUCLEIC ACIDS RES, V18, P6019, DOI 10.1093/nar/18.20.6019; Miniou P, 1997, HUM GENET, V99, P738, DOI 10.1007/s004390050441; Mizugaki M, 1997, CLIN EXP IMMUNOL, V110, P265; MYSLER E, 1994, J CLIN INVEST, V93, P1029, DOI 10.1172/JCI117051; Pisetsky DS, 1996, IMMUNITY, V5, P303, DOI 10.1016/S1074-7613(00)80256-3; RICHARDSON B, 1990, ARTHRITIS RHEUM, V33, P1665, DOI 10.1002/art.1780331109; RICHARDSON BC, 1992, ARTHRITIS RHEUM, V35, P647, DOI 10.1002/art.1780350608; ROSEN A, 1995, J EXP MED, V181, P1557, DOI 10.1084/jem.181.4.1557; RUMORE PM, 1990, J CLIN INVEST, V86, P69, DOI 10.1172/JCI114716; Saitoh F, 1995, ANTICANCER RES, V15, P2137; SANO H, 1982, J IMMUNOL, V128, P1341; SANO H, 1989, SCAND J IMMUNOL, V30, P51, DOI 10.1111/j.1365-3083.1989.tb01188.x; SANO H, 1985, J CLIN INVEST, V76, P1314, DOI 10.1172/JCI112105; SANO H, 1983, J IMMUNOL, V130, P187; SCHMID CW, 1991, NUCLEIC ACIDS RES, V19, P5613, DOI 10.1093/nar/19.20.5613; STOLLAR BD, 1994, FASEB J, V8, P337, DOI 10.1096/fasebj.8.3.7511550; Sun SQ, 1997, J IMMUNOL, V159, P3119; TERADA K, 1991, CLIN EXP IMMUNOL, V85, P66; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Utz PJ, 1997, J EXP MED, V185, P843, DOI 10.1084/jem.185.5.843; YOSHIDA H, 1990, EUR J IMMUNOL, V20, P1989, DOI 10.1002/eji.1830200917; YUNG RL, 1994, RHEUM DIS CLIN N AM, V20, P61; ZOUALI M, 1989, EUR J IMMUNOL, V19, P1757, DOI 10.1002/eji.1830190934	49	48	57	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1999	13	11					1415	1422		10.1096/fasebj.13.11.1415	http://dx.doi.org/10.1096/fasebj.13.11.1415			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	226KL	10428765				2022-12-25	WOS:000082019100013
J	Schendel, SL; Azimov, R; Pawlowski, K; Godzik, A; Kagan, BL; Reed, JC				Schendel, SL; Azimov, R; Pawlowski, K; Godzik, A; Kagan, BL; Reed, JC			Ion channel activity of the BH3 only Bcl-2 family member, BID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; APOPTOSIS; MITOCHONDRIA; PROTEIN; BAX; DEATH; BCL-X(L); PEPTIDE; RELEASE; PATHWAY	BID is a member of the BH3-only subgroup of Bcl-2 family proteins that displays pro-apoptotic activity. The NH2-terminal region of BID contains a caspase-8 (Casp-8) cleavage site and the cleaved form of BID translocates to mitochondrial membranes where it is a potent inducer of cytochrome c release. Secondary structure and fold predictions suggest that BID has a high degree of ct-helical content and structural similarity to Bcl-X-L, which itself is highly similar to bacterial pore-forming toxins. Moreover, circular dichroism analysis confirmed a high alpha-helical content of BID. Amino-terminal truncated BID Delta 1-55, mimicking the Casp-8-cleaved molecule, formed channels in planar bilayers at neutral pH and in liposomes at acidic pH. In contrast, full-length BID displayed channel activity only at nonphysiological pH 4.0 (but not at neutral pH) in planar bilayers and failed to form channels in liposomes even under acidic conditions. On a single channel level, BID Delta 1-55 channels were voltage-gated and exhibited multiconductance behavior at neutral pH. When full-length BID was cleaved by Casp-8, it too demonstrated channel activity similar to that seen with BID Delta 1-55. Thus, BID appears to share structural and functional similarity with other Bcl-2 family proteins known to have channel-forming activity, but its activity exhibits a novel form of activation: proteolytic cleavage.	Burnham Inst, La Jolla, CA 92307 USA; Univ Calif Los Angeles, W Los Angeles Vet Affairs Med Ctr, Sch Med, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Inst Neuropsychiat, Los Angeles, CA 90024 USA	Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center; University of California System; University of California Los Angeles	Reed, JC (corresponding author), Burnham Inst, La Jolla, CA 92307 USA.		Godzik, Adam/A-7279-2009; Pawlowski, Krzysztof/E-3262-2012; Pawłowski, Krzysztof/C-2949-2013; Godzik, Adam/AAW-1467-2020; Kagan, Bruce/ABD-7389-2020	Godzik, Adam/0000-0002-2425-852X; Pawłowski, Krzysztof/0000-0002-5367-0935; Godzik, Adam/0000-0002-2425-852X; Schendel, Sharon/0000-0002-5062-7261	NIGMS NIH HHS [GM-60049] Funding Source: Medline; NIMH NIH HHS [MH 01174] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060049] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K02MH001174] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; CONGDON RW, 1993, ANAL BIOCHEM, V213, P407, DOI 10.1006/abio.1993.1439; CRAMER WA, 1995, ANNU REV BIOPH BIOM, V24, P611, DOI 10.1146/annurev.biophys.24.1.611; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Jaroszewski L, 1998, PROTEIN SCI, V7, P1431; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Mirzabekov T A, 1999, Methods Enzymol, V294, P661; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schendel SL, 1998, CELL DEATH DIFFER, V5, P372, DOI 10.1038/sj.cdd.4400365; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281	29	157	164	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21932	21936		10.1074/jbc.274.31.21932	http://dx.doi.org/10.1074/jbc.274.31.21932			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419515	hybrid			2022-12-25	WOS:000081721100068
J	Symmank, H; Saenger, W; Bernhard, F				Symmank, H; Saenger, W; Bernhard, F			Analysis of engineered multifunctional peptide synthetases - Enzymatic characterization of surfactin synthetase domains in hybrid bimodular systems	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS; MOLECULAR CHARACTERIZATION; SUBSTRATE-SPECIFICITY; BIOSYNTHESIS; GENES; ANTIBIOTICS; EXPRESSION; PROTEINS; MODULE	The combinatorial reorganization of distinct modules of multimodular peptide synthetases is of increasing interest for the generation of new peptides with optimized bioactive properties. Each module is at least composed of enzymatic domains responsible for the adenylation, thioester formation, and condensation of an amino acid residue of the final peptide product. We analyzed various possible fusion sites for the recombination of peptide synthetases and evaluated the impact of different recombination strategies on the amino acid adenylation and acyl-thioester formation activities of peptide synthetase modules. Hybrid bimodular peptide synthetases were generated by recombination of the corresponding reading frames encoding for L-glutamic acid- and L-leucine-specific modules of surfactin synthetase SrfA-A at presumed inner- and intradomainic regions. We demonstrate that fusions at a previously postulated hinge region, dividing the amino acid adenylating domains of peptide synthetase modules into two subdomains, and at the highly conserved 4'-phosphopantetheine binding motif in acyl-thioester forming domains resulted in enzymatically active hybrid domains. By contrast, most manipulations in condensation domains Like deletions, the complete exchange or the construction of chimeric domains considerably reduced or completely abolished the amino acid adenylation and thioester formation activity of the hybrid module.	Free Univ Berlin, Inst Kristallog, D-14195 Berlin, Germany	Free University of Berlin	Bernhard, F (corresponding author), Free Univ Berlin, Inst Kristallog, Takustr 6, D-14195 Berlin, Germany.			Bernhard, Frank/0000-0002-4860-1783				ARIMA K, 1968, BIOCHEM BIOPH RES CO, V31, P488, DOI 10.1016/0006-291X(68)90503-2; BAUMGART F, 1991, BIOCHEM BIOPH RES CO, V177, P998, DOI 10.1016/0006-291X(91)90637-M; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cane DE, 1998, SCIENCE, V282, P63, DOI 10.1126/science.282.5386.63; Cole PA, 1996, STRUCTURE, V4, P239, DOI 10.1016/S0969-2126(96)00028-7; Conti E, 1997, EMBO J, V16, P4174, DOI 10.1093/emboj/16.14.4174; Conti E, 1996, STRUCTURE, V4, P287, DOI 10.1016/S0969-2126(96)00033-0; COSMINA P, 1993, MOL MICROBIOL, V8, P821, DOI 10.1111/j.1365-2958.1993.tb01629.x; DIEZ B, 1989, MOL GEN GENET, V218, P572, DOI 10.1007/BF00332426; Elsner A, 1997, J BIOL CHEM, V272, P4814, DOI 10.1074/jbc.272.8.4814; Georgiou G, 1996, CURR OPIN BIOTECH, V7, P190, DOI 10.1016/S0958-1669(96)80012-7; GUTIERREZ S, 1991, J BACTERIOL, V173, P2354; HAESE A, 1993, MOL MICROBIOL, V7, P905, DOI 10.1111/j.1365-2958.1993.tb01181.x; KANDA M, 1978, J BIOCHEM, V84, P435, DOI 10.1093/oxfordjournals.jbchem.a132144; KANDA M, 1989, J BIOCHEM-TOKYO, V105, P653, DOI 10.1093/oxfordjournals.jbchem.a122720; KLEINKAUF H, 1990, EUR J BIOCHEM, V192, P1, DOI 10.1111/j.1432-1033.1990.tb19188.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACCABE AP, 1991, J BIOL CHEM, V266, P12646; MENKHAUS M, 1993, J BIOL CHEM, V268, P7678; PEYPOUX F, 1991, EUR J BIOCHEM, V202, P101, DOI 10.1111/j.1432-1033.1991.tb16349.x; Quadri LEN, 1998, BIOCHEMISTRY-US, V37, P1585, DOI 10.1021/bi9719861; Sambrook J., 2002, MOL CLONING LAB MANU; Schneider A, 1998, MOL GEN GENET, V257, P308, DOI 10.1007/s004380050652; STACHELHAUS T, 1995, FEMS MICROBIOL LETT, V125, P3, DOI 10.1016/0378-1097(94)00459-5; STACHELHAUS T, 1995, SCIENCE, V269, P69, DOI 10.1126/science.7604280; ULLRICH C, 1991, BIOCHEMISTRY-US, V30, P6503, DOI 10.1021/bi00240a022; WEBER G, 1994, CURR GENET, V26, P120, DOI 10.1007/BF00313798; Weinreb PH, 1998, BIOCHEMISTRY-US, V37, P1575, DOI 10.1021/bi9719859; YAMADA M, 1969, J BIOCHEM, V66, P529, DOI 10.1093/oxfordjournals.jbchem.a129178	29	21	26	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21581	21588		10.1074/jbc.274.31.21581	http://dx.doi.org/10.1074/jbc.274.31.21581			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419464	hybrid			2022-12-25	WOS:000081721100017
J	Dumon, S; Santos, SCR; Debierre-Grockiego, F; Gouilleux-Gruart, V; Cocault, L; Boucheron, C; Mollat, P; Gisselbrecht, S; Gouilleux, F				Dumon, S; Santos, SCR; Debierre-Grockiego, F; Gouilleux-Gruart, V; Cocault, L; Boucheron, C; Mollat, P; Gisselbrecht, S; Gouilleux, F			IL-3 dependent regulation of Bcl-x(L) gene expression by STAT5 in a bone marrow derived cell line	ONCOGENE			English	Article						apoptosis; STAT5; Bcl-x(L); transcription	COLONY-STIMULATING FACTOR; RECEPTOR-BETA-CHAIN; BCL-X GENE; DNA-BINDING; HEMATOPOIETIC-CELLS; GROWTH-HORMONE; TRANSCRIPTIONAL ACTIVATION; ERYTHROID-DIFFERENTIATION; INDUCED PROLIFERATION; SIGNAL-TRANSDUCTION	Activation of the Jak/STAT pathway by cytokines has been shown to regulate differentiation, proliferation or apoptosis in hematopoeitic cells. Among the Stat proteins, STAT5 is activated by a broad range of cytokines. In order to study the role of STAT5 in hematopoietic cells, we stably expressed a dominant negative form of STAT5 (STAT5A Delta 749) in the IL-3 dependent bone marrow derived Ba/F3 cell line. Ba/F3 cells expressing STAT5A Delta 749 were found to be more sensitive to apoptosis than parental or control Ba/F3 cells after IL-3 withdrawal. Analysis of the expression of the cell death regulators, Bcl-2 and Bcl-x, revealed that the level of Bcl-x was lower in Ba/F3 cells expressing STAT5A Delta 749 than in control cells. IL-3 regulation of Bcl-x expression at protein and mRNA levels was impaired in these cells while that of Bcl-2 expression was unaffected. We further demonstrated that the Bcl-x gene promoter contained a proximal STAT consensus sequence that bound STAT5. Transactivation of a Bcl-x gene promoter reporter construct by STAT5 was observed in Ba/F3 cells. Introduction of a mutation in the STAT binding site abolished this transactivation. These data indicate that Bcl-x is probably a STAT5 target gene. They also support the involvement of STAT5 in hematopoietic cell survival.	Inst Cochin Genet Mol, INSERM U363, F-75014 Paris, France; CHU Amiens, Immunol Lab, F-80054 Amiens, France; Hoescht Marion Roussel, Romainville, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Picardie Universites; Universite de Picardie Jules Verne (UPJV); CHU Amiens	Gouilleux, F (corresponding author), Inst Cochin Genet Mol, INSERM U363, 27 Rue Fbg St Jacques, F-75014 Paris, France.		Santos, Susana/AAM-8902-2021; Debierre-Grockiego, Francoise/AAD-4322-2021	Constantino Rosa Santos, Susana/0000-0002-5711-1292; PETIT, Laurence/0000-0002-2475-9367; Gouilleux, Fabrice/0000-0001-6047-1718				Ahmed M, 1998, ONCOGENE, V16, P489, DOI 10.1038/sj.onc.1201556; Amarante-Mendes GP, 1998, ONCOGENE, V16, P1383, DOI 10.1038/sj.onc.1201664; Azam M, 1997, IMMUNITY, V6, P691, DOI 10.1016/S1074-7613(00)80445-8; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BROOME HE, 1995, J IMMUNOL, V155, P2311; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Chai SK, 1997, J IMMUNOL, V159, P4720; Chen Q, 1997, ONCOGENE, V15, P2249, DOI 10.1038/sj.onc.1201371; Chretien S, 1996, EMBO J, V15, P4174, DOI 10.1002/j.1460-2075.1996.tb00792.x; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; delPeso L, 1997, SCIENCE, V278, P687; Feldman GM, 1997, BLOOD, V90, P1768, DOI 10.1182/blood.V90.5.1768; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Friedman MC, 1996, P NATL ACAD SCI USA, V93, P2077, DOI 10.1073/pnas.93.5.2077; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; Fujio Y, 1997, J CLIN INVEST, V99, P2898, DOI 10.1172/JCI119484; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; GouilleuxGruart V, 1996, BLOOD, V87, P1692; Grillot DAM, 1997, J IMMUNOL, V158, P4750; HELM MH, 1995, SCIENCE, V267, P1347; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Iwatsuki K, 1997, J BIOL CHEM, V272, P8149, DOI 10.1074/jbc.272.13.8149; KANZANSKY AV, 1995, MOL ENDOCRINOL, V9, P1598; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KINOSHITA T, 1995, ONCOGENE, V10, P2207; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Lecine P, 1996, MOL CELL BIOL, V16, P6829; Leverrier Y, 1997, ONCOGENE, V14, P425, DOI 10.1038/sj.onc.1200845; LEVERRIER Y, 1999, IN PRESS CELL DEATH; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Meyer J, 1998, BLOOD, V91, P1901, DOI 10.1182/blood.V91.6.1901.1901_1901_1908; Moriggl R, 1997, MOL CELL BIOL, V17, P3663, DOI 10.1128/MCB.17.7.3663; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; PALLARD C, 1995, J BIOL CHEM, V270, P15942, DOI 10.1074/jbc.270.27.15942; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; Park J R, 1996, Curr Opin Hematol, V3, P191; Pircher TJ, 1997, MOL CELL ENDOCRINOL, V133, P169, DOI 10.1016/S0303-7207(97)00164-0; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; Rui H, 1998, J BIOL CHEM, V273, P28, DOI 10.1074/jbc.273.1.28; Schaefer TS, 1997, MOL CELL BIOL, V17, P5307, DOI 10.1128/MCB.17.9.5307; Schindler C, 1998, TRENDS CELL BIOL, V8, P97, DOI 10.1016/S0962-8924(98)01233-1; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Thomas J, 1998, ONCOGENE, V16, P1399, DOI 10.1038/sj.onc.1201672; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Verdier F, 1998, MOL CELL BIOL, V18, P5852, DOI 10.1128/MCB.18.10.5852; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; WAKAO H, 1995, EMBO J, V14, P854, DOI 10.1002/j.1460-2075.1995.tb07064.x; Wang DM, 1996, MOL CELL BIOL, V16, P6141; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WOOD TJJ, 1995, J BIOL CHEM, V270, P9448, DOI 10.1074/jbc.270.16.9448; Yoshimura A, 1996, EMBO J, V15, P1055, DOI 10.1002/j.1460-2075.1996.tb00443.x; Zamorano J, 1998, J IMMUNOL, V160, P3502	68	134	137	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 22	1999	18	29					4191	4199		10.1038/sj.onc.1202796	http://dx.doi.org/10.1038/sj.onc.1202796			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218FK	10435632	Green Published			2022-12-25	WOS:000081542400003
J	Chen, W; Pawelek, TR; Kulmacz, RJ				Chen, W; Pawelek, TR; Kulmacz, RJ			Hydroperoxide dependence and cooperative cyclooxygenase kinetics in prostaglandin H synthase-1 and-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANGANESE PROTOPORPHYRIN-IX; HIGHER OXIDATION-STATE; ENDOPEROXIDE SYNTHASE; SELECTIVE-INHIBITION; PEROXIDASE REACTION; REACTION-MECHANISMS; ARACHIDONIC-ACID; BIOSYNTHESIS; REQUIREMENTS	Prostaglandin H synthase isoform-1 (PGHS-1) cyclooxygenase activity has a cooperative response to arachidonate concentration, whereas the second isoform, PGHS-2, exhibits saturable kinetics. The basis for the cooperative PGHS-1 behavior and for the difference in cooperativity between the isoforms was unclear. The two cyclooxygenase activities have different efficiencies of feedback activation by hydroperoxide. To determine whether the cooperative kinetics were governed by the feedback activation characteristics, we examined the cyclooxygenase activities under conditions where feedback activation was either assisted (by exogenous peroxide) or impaired (by replacement of heme with mangano protoporphyrin IX to form MnPGHS-1 and -2). Heme replacement increased PGHS-1 cyclooxygenase cooperativity and changed PGHS-2 cyclooxygenase kinetics from saturable to cooperative. Peroxide addition decreased or abolished cyclooxygenase cooperativity in PGHS-1, MnPGHS-1, and MnPGHS-2, Kinetic simulations predicted that cyclooxygenase cooperativity depends on the hydroperoxide activator requirement and initial peroxide concentration, consistent with observed behavior. The results indicate that PGHS-1 cyclooxygenase cooperativity originates in the feedback activation kinetics and that the cooperativity difference between the isoforms can be explained by the difference in feedback activation loop efficiency. This linkage between activation efficiency and cyclooxygenase cooperativity indicates an interdependence between fatty acid and hydroperoxide levels in controlling the synthesis of potent prostanoid mediators.	Univ Texas, Hlth Sci Ctr, Dept Internal Med, Div Hematol, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston	Kulmacz, RJ (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Internal Med, Div Hematol, 6431 Fannin St, Houston, TX 77030 USA.	kulmacz@heart.med.uth.tmc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052170] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52170] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARNETT J, 1994, BBA-PROTEIN STRUCT M, V1209, P130, DOI 10.1016/0167-4838(94)90148-1; CAPDEVILA JH, 1995, BIOCHEMISTRY-US, V34, P3325, DOI 10.1021/bi00010a023; COOK HW, 1979, ANAL BIOCHEM, V96, P341, DOI 10.1016/0003-2697(79)90591-8; DIETZ R, 1988, EUR J BIOCHEM, V171, P321, DOI 10.1111/j.1432-1033.1988.tb13793.x; Dixon M., 1979, ENZYMES, P400; HEMLER ME, 1979, ARCH BIOCHEM BIOPHYS, V193, P340, DOI 10.1016/0003-9861(79)90038-9; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; JIANG ZY, 1991, LIPIDS, V26, P853, DOI 10.1007/BF02536169; KULMACZ RJ, 1994, BIOCHEMISTRY-US, V33, P5428, DOI 10.1021/bi00184a011; KULMACZ RJ, 1983, PROSTAGLANDINS, V25, P531, DOI 10.1016/0090-6980(83)90025-4; KULMACZ RJ, 1991, DEV ONCOL, V67, P205; KULMACZ RJ, 1995, J BIOL CHEM, V270, P24019, DOI 10.1074/jbc.270.41.24019; Kulmacz RJ, 1987, PROSTAGLANDINS RELAT, P209; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; MARSHALL PJ, 1987, J BIOL CHEM, V262, P3510; MOFFAT K, 1974, J AM CHEM SOC, V96, P5259, DOI 10.1021/ja00823a046; ODENWALLER R, 1992, J BIOL CHEM, V267, P13863; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; SAMUELSSON B, 1978, ANNU REV BIOCHEM, V47, P997, DOI 10.1146/annurev.bi.47.070178.005025; SMITH WL, 1972, BIOCHEMISTRY-US, V11, P3276, DOI 10.1021/bi00767a024; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; So OY, 1998, J BIOL CHEM, V273, P5801, DOI 10.1074/jbc.273.10.5801; STRIEDER S, 1992, J BIOL CHEM, V267, P13870; Swinney DC, 1997, J BIOL CHEM, V272, P12393, DOI 10.1074/jbc.272.19.12393; Tsai AL, 1997, BIOCHEMISTRY-US, V36, P13085, DOI 10.1021/bi970397s; Tsai AL, 1998, J BIOL CHEM, V273, P3888, DOI 10.1074/jbc.273.7.3888; Tsai AL, 1997, J BIOL CHEM, V272, P8885; TSAI AL, 1995, J BIOL CHEM, V270, P10503, DOI 10.1074/jbc.270.18.10503; WEI CH, 1995, BIOCHEMISTRY-US, V34, P8499, DOI 10.1021/bi00026a034	30	62	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20301	20306		10.1074/jbc.274.29.20301	http://dx.doi.org/10.1074/jbc.274.29.20301			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400651	hybrid			2022-12-25	WOS:000081438300044
J	Hartley, DK; Hurley, TR; Hardwick, JS; Lund, TC; Medveczky, PG; Sefton, BM				Hartley, DK; Hurley, TR; Hardwick, JS; Lund, TC; Medveczky, PG; Sefton, BM			Activation of the Lck tyrosine-protein kinase by the binding of the tip protein of herpesvirus Saimiri in the absence of regulatory tyrosine phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; OPEN READING FRAME; T-CELLS; INTERLEUKIN-2 INDEPENDENCE; CRYSTAL-STRUCTURE; SH3 DOMAINS; SRC; P56(LCK); TRANSFORMATION; MUTATION	The Tip protein of herpesvirus saimiri 484 binds to the Lck tyrosine-protein kinase at two sites and activates it dramatically. Lck has been shown previously to be activated by either phosphorylation of Tyr(394) or dephosphorylation of Tyr(505). We examined here whether a change in the phosphorylation of either site was required for the activation of Lck by Tip. Remarkably, mutation of both regulatory sites of tyrosine phosphorylation did not prevent activation of Lck by Tip either in vivo or in a cell free in vitro system. Tip therefore appears to be able to activate Lck through an induced conformational change that does not necessarily involve altered phosphorylation of the kinase. Tip may represent the prototype of a novel type of regulator of tyrosine-protein kinases.	Salk Inst Biol Studies, Mol Biol & Virol Lab, La Jolla, CA 92037 USA; Univ S Florida, Dept Med Microbiol, Tampa, FL 33612 USA	Salk Institute; State University System of Florida; University of South Florida	Sefton, BM (corresponding author), Salk Inst Biol Studies, Mol Biol & Virol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Medveczky, Peter/A-6846-2012	Medveczky, Peter/0000-0002-1798-2595	NATIONAL CANCER INSTITUTE [P30CA014195, R01CA042350] Funding Source: NIH RePORTER; NCI NIH HHS [CA14195, CA42350, CA42364] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; BIESINGER B, 1995, J BIOL CHEM, V270, P4729, DOI 10.1074/jbc.270.9.4729; BIESINGER B, 1992, P NATL ACAD SCI USA, V89, P3116, DOI 10.1073/pnas.89.7.3116; Briggs SD, 1997, J BIOL CHEM, V272, P17899, DOI 10.1074/jbc.272.29.17899; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; CEREDIG R, 1983, J EXP MED, V158, P1654, DOI 10.1084/jem.158.5.1654; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; DESROSIERS RC, 1985, SCIENCE, V228, P184, DOI 10.1126/science.2983431; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; Dunant NM, 1996, J VIROL, V70, P1323, DOI 10.1128/JVI.70.3.1323-1330.1996; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; Gonfloni S, 1997, EMBO J, V16, P7261, DOI 10.1093/emboj/16.24.7261; HARDWICK JS, 1995, P NATL ACAD SCI USA, V92, P4527, DOI 10.1073/pnas.92.10.4527; HARRISON T, 1977, VIROLOGY, V77, P319, DOI 10.1016/0042-6822(77)90428-7; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; HURLEY TR, 1989, ONCOGENE, V4, P265; HURLEY TR, 1989, SCIENCE, V245, P407, DOI 10.1126/science.2787934; HYMAN R, 1980, IMMUNOGENETICS, V10, P261, DOI 10.1007/BF01561574; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; JUNG JU, 1995, J BIOL CHEM, V270, P20660, DOI 10.1074/jbc.270.35.20660; JUNG JU, 1995, MOL CELL BIOL, V15, P6506; KAMPS MP, 1988, ONCOGENE, V2, P305; KOOMEY JM, 1984, J VIROL, V50, P662, DOI 10.1128/JVI.50.2.662-665.1984; LUND T, 1995, J VIROL, V69, P4495, DOI 10.1128/JVI.69.7.4495-4499.1995; Lund T, 1997, J VIROL, V71, P378, DOI 10.1128/JVI.71.1.378-382.1997; Lund T, 1996, J VIROL, V70, P600, DOI 10.1128/JVI.70.1.600-606.1996; Lund TC, 1999, J VIROL, V73, P1689, DOI 10.1128/JVI.73.2.1689-1694.1999; LUO K, 1990, ONCOGENE, V5, P921; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MEDVECZKY MM, 1993, VIROLOGY, V196, P402, DOI 10.1006/viro.1993.1495; MELENDEZ LV, 1971, SCIENCE, V171, P1161, DOI 10.1126/science.171.3976.1161; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MURTHY SCS, 1989, J VIROL, V63, P3307, DOI 10.1128/JVI.63.8.3307-3314.1989; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; REINHERZ EL, 1979, P NATL ACAD SCI USA, V76, P4061, DOI 10.1073/pnas.76.8.4061; REYNOLDS PJ, 1992, ONCOGENE, V7, P1949; SEFTON BM, 1991, ANNU REV CELL BIOL, V7, P257, DOI 10.1146/annurev.cellbio.7.1.257; SEFTON BM, 1980, J VIROL, V33, P220, DOI 10.1128/JVI.33.1.220-229.1980; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WEIL R, 1994, J BIOL CHEM, V269, P22830; Wiese N, 1996, J BIOL CHEM, V271, P847, DOI 10.1074/jbc.271.2.847; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; WRIGHT DD, 1994, MOL CELL BIOL, V14, P2429, DOI 10.1128/MCB.14.4.2429; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	50	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20056	20059		10.1074/jbc.274.29.20056	http://dx.doi.org/10.1074/jbc.274.29.20056			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400611	hybrid			2022-12-25	WOS:000081438300004
J	Hirotani, M; Zhang, YK; Fujita, N; Naito, M; Tsuruo, T				Hirotani, M; Zhang, YK; Fujita, N; Naito, M; Tsuruo, T			NH2-terminal BH4 domain of Bcl-2 is functional for heterodimerization with Bax and inhibition of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; PROTEIN; FAMILY; DIMERIZATION; MEMBERS; MITOCHONDRIA; PROTEASES; BCL-X(L); CASPASES; DISTINCT	The Bcl-2 family proteins comprise pro-apoptotic as well as anti-apoptotic members. Heterodimerization between members of the Bcl-2 family proteins is a key event in the regulation of apoptosis. We report here that Bcl-2 protein was selectively cleaved by active caspase-3-like proteases in CTLL-2 cell apoptosis in response to interleukin-a deprivation. Structural and functional analyses of the cleaved fragment revealed that the NH2-terminal region of Bcl-2 (1-34 amid acids) was required for its anti-apoptotic activity and heterodimerization with pro-apoptotic Bax protein. Site directed mutagenesis of the NH2 terminal region showed that substitutions of hydrophobic residues of BH4 domain resulted in the loss of ability to form a heterodimer with Bax. Particularly instructive was that the V15E mutant of Bcl-2, which completely lost the ability to form a heterodimer with Bax, failed to inhibit Bax- and staurosporine-induced apoptosis. Our results suggest that the BH4 domain of Bcl-2 is critical for its heterodimerization with Bax and for exhibiting anti-apoptotic activity. Therefore, agents interferring with the critical residues of the BH4 domain may provide a new strategy in cancer therapy by impairing Bcl-2 function.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Toshima Ku, Tokyo 1708455, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Tsuruo, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.		Fujita, Naoya/A-7349-2010	Fujita, Naoya/0000-0002-9631-9264				Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Diaz JL, 1997, J BIOL CHEM, V272, P11350; Farrow SN, 1996, CURR OPIN GENET DEV, V6, P45, DOI 10.1016/S0959-437X(96)90009-X; Fujita N, 1998, ONCOGENE, V17, P1295, DOI 10.1038/sj.onc.1202065; Grandgirard D, 1998, EMBO J, V17, P1268, DOI 10.1093/emboj/17.5.1268; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Huang DCS, 1998, EMBO J, V17, P1029, DOI 10.1093/emboj/17.4.1029; Hunter JJ, 1996, J BIOL CHEM, V271, P8521, DOI 10.1074/jbc.271.15.8521; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; Kaipia A, 1997, ENDOCRINOLOGY, V138, P5497, DOI 10.1210/en.138.12.5497; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Lee LC, 1996, J BIOL CHEM, V271, P23284, DOI 10.1074/jbc.271.38.23284; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wang K, 1998, MOL CELL BIOL, V18, P6083, DOI 10.1128/MCB.18.10.6083; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440	34	74	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20415	20420		10.1074/jbc.274.29.20415	http://dx.doi.org/10.1074/jbc.274.29.20415			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400666	hybrid			2022-12-25	WOS:000081438300059
J	Sambrano, GR; Coughlin, SR				Sambrano, GR; Coughlin, SR			The carboxyl tail of protease-activated receptor-1 is required for chemotaxis - Correlation of signal termination and directional migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET THROMBIN RECEPTOR; CHEMOATTRACTANT RECEPTORS; PROTEOLYTIC MECHANISM; DIRECTED MIGRATION; INTERNALIZATION; PHOSPHORYLATION; CHEMOKINE; RESPONSES; CELLS; DESENSITIZATION	The G protein-coupled thrombin receptor, protease-activated receptor 1 (PAR1), mediates many of the actions of thrombin on cells including chemotaxis. In contrast to the reversible agonist binding that regulates signaling by most G protein-coupled receptors (GPCRs), PAR1 is activated by an irreversible proteolytic mechanism. Although activated PAR1 is phosphorylated, uncoupled, and internalized like typical GPCRs, signal termination is additionally dependent on lysosomal degradation of cleaved and activated receptors. In the present study we exploit two PAR1 mutants to examine the link between chemotaxis and receptor shutoff. One, a carboxyl tail deletion mutant (Y397Z), is defective in phosphorylation and internalization. The other, a carboxyl tail chimeric receptor (P/S), is phosphorylated and internalized upon activation but recycles to the plasma membrane like reversibly activated GPCRs. Expression of these receptors in a hematopoietic cell line disrupted cell migration along thrombin gradients. Thrombin activation of cells expressing P/S or Y397Z resulted in persistent signaling independent of the continued presence of thrombin. Signaling in response to the soluble agonist peptide SFLLRN was reversible for P/S but persisted for Y397Z. Strikingly, cells expressing P/S responded chemokinetically to thrombin but chemotactically to SFLLRN. In contrast, Y397Z-mediated migration was largely chemokinetic to both agonists. These studies suggest that termination of PAR1 signaling at the level of the receptor is necessary for gradient detection and directional migration.	Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Coughlin, SR (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, HSE-1300,505 Parnassus Ave, San Francisco, CA 94143 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044907] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44907] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arai H, 1997, J BIOL CHEM, V272, P25037, DOI 10.1074/jbc.272.40.25037; Arai H, 1997, P NATL ACAD SCI USA, V94, P14495, DOI 10.1073/pnas.94.26.14495; Campbell JJ, 1996, J CELL BIOL, V134, P255, DOI 10.1083/jcb.134.1.255; CHEN J, 1994, J BIOL CHEM, V269, P16041; DApuzzo M, 1997, EUR J IMMUNOL, V27, P1788, DOI 10.1002/eji.1830270729; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cb.04.110188.003245; DUNN GA, 1990, BIOL CHEMOTACTIC RES, P1; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; Hsu MH, 1997, J BIOL CHEM, V272, P29426, DOI 10.1074/jbc.272.47.29426; HUNG DT, 1992, J CELL BIOL, V116, P827, DOI 10.1083/jcb.116.3.827; HUNG DT, 1992, J CLIN INVEST, V89, P1350, DOI 10.1172/JCI115721; ISHII K, 1993, J BIOL CHEM, V269, P27719; Kim JY, 1997, J BIOL CHEM, V272, P27313, DOI 10.1074/jbc.272.43.27313; Neptune ER, 1997, P NATL ACAD SCI USA, V94, P14489, DOI 10.1073/pnas.94.26.14489; Prossnitz ER, 1997, J BIOL CHEM, V272, P15213, DOI 10.1074/jbc.272.24.15213; RAIFPREMINGER M, 1995, BBA-MOL CELL RES, V1265, P49; Shapiro MJ, 1996, J BIOL CHEM, V271, P32874, DOI 10.1074/jbc.271.51.32874; Sklar L A, 1990, Semin Cell Biol, V1, P115; TRANQUILLO RT, 1988, J CELL BIOL, V106, P303, DOI 10.1083/jcb.106.2.303; TRANQUILLO RT, 1990, BIOL CHEMOTACTIC RES, P35; Trejo J, 1999, J BIOL CHEM, V274, P2216, DOI 10.1074/jbc.274.4.2216; Trejo J, 1998, P NATL ACAD SCI USA, V95, P13698, DOI 10.1073/pnas.95.23.13698; Trejo J, 1996, J BIOL CHEM, V271, P21536, DOI 10.1074/jbc.271.35.21536; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WILKINSON P C, 1990, FEMS (Federation of European Microbiological Societies) Microbiology Immunology, V64, P303, DOI 10.1016/0378-1097(90)90502-H; ZIGMOND SH, 1979, J CELL BIOL, V82, P517, DOI 10.1083/jcb.82.2.517	26	29	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20178	20184		10.1074/jbc.274.29.20178	http://dx.doi.org/10.1074/jbc.274.29.20178			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400633	hybrid			2022-12-25	WOS:000081438300026
J	Baymann, F; Zito, F; Kuras, R; Minai, L; Nitschke, W; Wollman, FA				Baymann, F; Zito, F; Kuras, R; Minai, L; Nitschke, W; Wollman, FA			Functional characterization of Chlamydomonas mutants defective in cytochrome f maturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYLAKOID MEMBRANE POLYPEPTIDES; SITE-DIRECTED MUTAGENESIS; COLI LEADER PEPTIDASE; ELECTRON-TRANSFER; HEME ATTACHMENT; PHOTOSYSTEM-I; REINHARDTII; CHLOROPLAST; PROTEIN; TRANSFORMATION	We have altered the N terminus of cytochrome f by site-directed mutagenesis of the chloroplast petA gene in Chlamydomonas reinhardtii, We have replaced the tyrosine residue, Tyr(32), located immediately downstream of the processing site Ala(29)-Gln(30)-Ala(31) by a proline. Tyr(32) in the N terminus of the mature protein and serves as the sixth axial ligand to the heme iron. This mutant, F32P, accumulated different forms of holocytochrome f and assembled them into the cytochrome b(6)f complex. The strain was able to grow phototrophically. Our results therefore contradict a previous report (Zhou, J., Fernandez-Velasco, J. G., and Malkin, R. (1996) J, Biol. Chem, 271, 1-8) that a mutation, considered to be identical to the mutation described here, prevented cytochrome b(6)f assembly. A comparative functional characterization of F32P with F29L-31L, a site-directed processing mutant in which we had replaced the processing site by a Leu(29)-Gln(30)-Leu(31) sequence (2), revealed that both mutants accumulate high spin cytochrome f, with an unusual orientation of the heme and low spin cytochrome f with an Lu-band peak at 552 nm, Both hemes have significantly lower redox potentials than wild type cytochrome f, We attribute the high spin form to uncleaved pre-holocytochrome f and the low spin form to misprocessed forms of cytochrome f that were cleaved at a position different from the regular Ala(29)-Gln-Ala(31) motif, In contrast to F29L-31L, F32P displayed a small population of functional cytochrome f; presumably cleaved at Ala(29), with characteristics close to those of wild type cytochrome f, The latter form would account for cytochrome b(6)f turnover and photosynthetic electron transfer that sustain phototrophic growth of F32P.	Inst Biol Physicochim, CNRS, UPR 1261, F-75005 Paris, France; Hebrew Univ Jerusalem, IL-91904 Jerusalem, Israel; CNRS, Inst Biol Struct & Microbiol, BIP, UPR 9036, F-13402 Marseille, France	Centre National de la Recherche Scientifique (CNRS); Hebrew University of Jerusalem; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Wollman, FA (corresponding author), Inst Biol Physicochim, CNRS, UPR 1261, 13 Rue Pierre & Marie Curie, F-75005 Paris, France.		Nitschke, Wolfgang/C-4812-2012	Zito, Francesca/0000-0003-1783-5090; Nitschke, Wolfgang/0000-0003-2084-3032				ATTEIA A, 1992, J BIOL CHEM, V267, P226; BARKOCYGALLAGHER GA, 1992, J BIOL CHEM, V267, P1231; BAYMANN F, 1991, ANAL BIOCHEM, V199, P269, DOI 10.1016/0003-2697(91)90100-8; BENNOUN P, 1970, BIOCHIM BIOPHYS ACTA, V216, P357, DOI 10.1016/0005-2728(70)90227-6; BERGSTROM J, 1982, BIOCHIM BIOPHYS ACTA, V682, P452, DOI 10.1016/0005-2728(82)90060-3; BOYNTON JE, 1988, SCIENCE, V240, P1534, DOI 10.1126/science.2897716; BULTE L, 1990, BIOCHIM BIOPHYS ACTA, V1020, P72, DOI 10.1016/0005-2728(90)90095-L; CAMMACK E, 1979, BIOCHIM BIOPHYS ACTA, V548, P267; CHUA NH, 1975, P NATL ACAD SCI USA, V72, P2175, DOI 10.1073/pnas.72.6.2175; Crofts A.R., 1999, PHOTOTROPHIC PROKARY, P229; DELEPELAIRE P, 1983, PHOTOBIOCH PHOTOBIOP, V6, P279; DUTTON PL, 1971, FEBS LETT, V65, P117; GIRARDBASCOU J, 1992, CURR GENET, V22, P47, DOI 10.1007/BF00351741; GOLDSCHMIDTCLERMONT M, 1991, NUCLEIC ACIDS RES, V19, P4083, DOI 10.1093/nar/19.15.4083; GRZYBEK S, 1993, FIFTH INTERNATIONAL CONFERENCE ON THE SPECTROSCOPY OF BIOLOGICAL MOLECULES, P25; HALPIN C, 1989, EMBO J, V8, P3917, DOI 10.1002/j.1460-2075.1989.tb08572.x; HOWE G, 1994, J BIOL CHEM, V269, P5824; HOWE G, 1995, MOL GEN GENET, V246, P156, DOI 10.1007/BF00294678; HOWE G, 1992, EMBO J, V11, P2789, DOI 10.1002/j.1460-2075.1992.tb05346.x; JOLIOT P, 1994, P NATL ACAD SCI USA, V91, P1034, DOI 10.1073/pnas.91.3.1034; JOLIOT P, 1974, BIOCHIM BIOPHYS ACTA, V357, P267, DOI 10.1016/0005-2728(74)90066-8; JOLIOT P, 1980, J CHIM PHYS PCB, V77, P209, DOI 10.1051/jcp/1980770209; Karamyshev AL, 1998, J MOL BIOL, V277, P859, DOI 10.1006/jmbi.1997.1617; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KURAS R, 1995, BIOCHEMISTRY-US, V34, P7468, DOI 10.1021/bi00022a021; KURAS R, 1995, J BIOL CHEM, V270, P27797, DOI 10.1074/jbc.270.46.27797; KURAS R, 1994, EMBO J, V13, P1019, DOI 10.1002/j.1460-2075.1994.tb06350.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTINEZ SE, 1994, STRUCTURE, V2, P95, DOI 10.1016/S0969-2126(00)00012-5; Minai L, 1996, P NATL ACAD SCI USA, V93, P6338, DOI 10.1073/pnas.93.13.6338; NILSSON I, 1992, FEBS LETT, V299, P243, DOI 10.1016/0014-5793(92)80124-Y; NUGENT JHA, 1981, BIOCHIM BIOPHYS ACTA, V635, P488, DOI 10.1016/0005-2728(81)90108-0; Pierre Y, 1997, J BIOL CHEM, V272, P21901, DOI 10.1074/jbc.272.35.21901; PIERRE Y, 1995, J BIOL CHEM, V270, P29342, DOI 10.1074/jbc.270.49.29342; RIEDEL A, 1991, J BIOL CHEM, V266, P17838; RUTHERFORD AW, 1990, BIOCHIM BIOPHYS ACTA, V1019, P128, DOI 10.1016/0005-2728(90)90133-O; SHEN LM, 1991, BIOCHEMISTRY-US, V30, P11775, DOI 10.1021/bi00115a006; SMITH TA, 1994, J CELL BIOL, V126, P365, DOI 10.1083/jcb.126.2.365; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; Vener AV, 1997, P NATL ACAD SCI USA, V94, P1585, DOI 10.1073/pnas.94.4.1585; WILLEY DL, 1988, PHOTOSYNTH RES, V17, P126; Wollman FA, 1999, BBA-BIOENERGETICS, V1411, P21, DOI 10.1016/S0005-2728(99)00043-2; WOLLMAN FA, 1984, J CELL BIOL, V98, P1, DOI 10.1083/jcb.98.1.1; Xie ZY, 1998, BBA-BIOENERGETICS, V1365, P309, DOI 10.1016/S0005-2728(98)00085-1; Xie ZY, 1998, GENETICS, V148, P681; Zhou JH, 1996, J BIOL CHEM, V271, P6225, DOI 10.1074/jbc.271.11.6225; Zito F, 1999, EMBO J, V18, P2961, DOI 10.1093/emboj/18.11.2961; Zito F, 1998, BIOCHEMISTRY-US, V37, P10395, DOI 10.1021/bi980238o	48	14	16	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					22957	22967		10.1074/jbc.274.33.22957	http://dx.doi.org/10.1074/jbc.274.33.22957			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438461	hybrid			2022-12-25	WOS:000082012800011
J	Baumgartner, U; Hamilton, B; Piskacek, M; Ruis, H; Rottensteiner, H				Baumgartner, U; Hamilton, B; Piskacek, M; Ruis, H; Rottensteiner, H			Functional analysis of the Zn(2)Cys(6) transcription factors Oaf1p and Pip2p - Different roles in fatty acid induction of beta-oxidation in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENCODING PEROXISOMAL PROTEINS; GLUCOSE REPRESSION; GAL4P-ACTIVATED GENES; BINDING PROTEIN; CARBON SOURCE; YEAST; PROLIFERATION; DOMAIN; ACTIVATION; KINASE	Fatty acid induction of the peroxisomal beta-oxidation machinery in Saccharomyces cerevisiae involves transcriptional control of genes regulated by the oleate response element (ORE), Glucose as the preferred carbon source antagonizes this effect. Induction is dependent on the Zn,Cys, family members Oaf1p and Pip2p, which bind to this element as a heterodimer, We show here by ectopically expressing both components and LexA fusion derivatives that this transcription factor complex is only active in the presence of oleate, In contrast to Pip2p, Oaf1p is responsive to oleate activation in the absence of the other component of the heterodimer, Therefore, it is the exclusive receptor of the oleate signal. Pip2p is active also under noninducing conditions but is effectively inhibited when complexed with Oaf1p in the absence of inducer. It contributes to the transactivation properties of the Oaf1p-Pip2p heterodimer and is required for efficient binding of Oaf1p to OREs in vivo. Repression of ORE-dependent transcription by glucose occurs via both Oaf1p and Pip2p, By dissecting functional domains of both proteins, we identified a region required for regulated activity of the C-terminal activation domain. These findings allow us to postulate a model for carbon source-regulated transcription of peroxisomal protein genes.	Univ Vienna, Vienna Bioctr, Inst Biochem & Mol Zellbiol, A-1030 Vienna, Austria; Univ Vienna, Ludwig Boltzmann Forschungsstelle Biochem, A-1030 Vienna, Austria	University of Vienna; Vienna Biocenter (VBC); Ludwig Boltzmann Institute; University of Vienna	Rottensteiner, H (corresponding author), Univ Vienna, Vienna Bioctr, Inst Biochem & Mol Zellbiol, Dr Bohrgasse 9, A-1030 Vienna, Austria.	hr@abc.univie.ac.at	Piskacek, Martin/I-4280-2016	Piskacek, Martin/0000-0002-6283-1542				Blank TE, 1997, MOL CELL BIOL, V17, P2566, DOI 10.1128/MCB.17.5.2566; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carlson M, 1998, CURR OPIN GENET DEV, V8, P560, DOI 10.1016/S0959-437X(98)80011-7; Carvajal E, 1997, MOL GEN GENET, V256, P406, DOI 10.1007/s004380050584; CHASMAN DI, 1990, MOL CELL BIOL, V10, P2916, DOI 10.1128/MCB.10.6.2916; COOK WJ, 1994, MOL CELL BIOL, V14, P629, DOI 10.1128/MCB.14.1.629; desEtages SAG, 1996, GENETICS, V142, P1069; Dombek KM, 1997, MOL CELL BIOL, V17, P1450, DOI 10.1128/MCB.17.3.1450; EINERHAND AWC, 1993, EUR J BIOCHEM, V214, P323, DOI 10.1111/j.1432-1033.1993.tb17927.x; EINERHAND AWC, 1995, MOL CELL BIOL, V15, P3405; FILIPITS M, 1993, GENE, V132, P49, DOI 10.1016/0378-1119(93)90513-3; Gancedo JM, 1998, MICROBIOL MOL BIOL R, V62, P334, DOI 10.1128/MMBR.62.2.334-361.1998; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Gorner W, 1998, GENE DEV, V12, P586, DOI 10.1101/gad.12.4.586; Gray WM, 1996, MOL CELL BIOL, V16, P347; Gurvitz A, 1997, MOL MICROBIOL, V26, P675, DOI 10.1046/j.1365-2958.1997.5931969.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Johnston M, 1999, TRENDS GENET, V15, P29, DOI 10.1016/S0168-9525(98)01637-0; JONES EW, 1977, GENETICS, V85, P23; Karpichev IV, 1997, MOL CELL BIOL, V17, P69, DOI 10.1128/MCB.17.1.69; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lesage P, 1996, MOL CELL BIOL, V16, P1921, DOI 10.1128/mcb.16.5.1921; Luo Y, 1996, J BIOL CHEM, V271, P12068, DOI 10.1074/jbc.271.20.12068; Nourani A, 1997, MOL GEN GENET, V256, P397, DOI 10.1007/s004380050583; Poch O, 1997, GENE, V184, P229, DOI 10.1016/S0378-1119(96)00602-6; Rahner A, 1996, NUCLEIC ACIDS RES, V24, P2331, DOI 10.1093/nar/24.12.2331; RandezGil F, 1997, MOL CELL BIOL, V17, P2502, DOI 10.1128/MCB.17.5.2502; RONNE H, 1995, TRENDS GENET, V11, P12, DOI 10.1016/S0168-9525(00)88980-5; Rottensteiner H, 1997, EUR J BIOCHEM, V247, P776, DOI 10.1111/j.1432-1033.1997.00776.x; Rottensteiner H, 1996, EMBO J, V15, P2924, DOI 10.1002/j.1460-2075.1996.tb00655.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schjerling P, 1996, NUCLEIC ACIDS RES, V24, P4599, DOI 10.1093/nar/24.23.4599; SIMON M, 1991, MOL CELL BIOL, V11, P699, DOI 10.1128/MCB.11.2.699; STANWAY CA, 1995, CURR GENET, V27, P404, DOI 10.1007/BF00311208; STONE G, 1993, EMBO J, V12, P1375, DOI 10.1002/j.1460-2075.1993.tb05782.x; VEENHUIS M, 1987, YEAST, V3, P77, DOI 10.1002/yea.320030204; Wang D, 1997, J BIOL CHEM, V272, P19383, DOI 10.1074/jbc.272.31.19383; Yano KI, 1997, P NATL ACAD SCI USA, V94, P1721, DOI 10.1073/pnas.94.5.1721	40	50	54	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22208	22216		10.1074/jbc.274.32.22208	http://dx.doi.org/10.1074/jbc.274.32.22208			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428786	hybrid			2022-12-25	WOS:000081868400016
J	Moreland, RJ; Tirode, F; Yan, Q; Conaway, W; Egly, JM; Conaway, RC				Moreland, RJ; Tirode, F; Yan, Q; Conaway, W; Egly, JM; Conaway, RC			A role for the TFIIH XPB DNB helicase in promoter escape by RNA polymerase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR IIH; GENERAL INITIATION-FACTORS; ABORTIVE INITIATION; COMPLEX-FORMATION; BASAL FACTORS; RAT-LIVER; ATP; REQUIREMENT; YEAST; PURIFICATION	TFIIH is an RNA polymerase II transcription factor that performs ATP-dependent functions in both transcription initiation, where it catalyzes formation of the open complex, and in promoter escape, where it suppresses arrest of the early elongation complex at promoter-proximal sites. TFIIH possesses three known ATP-dependent activities: a 3' -->5' DNA helicase catalyzed by its XPB subunit, a 5' --> 3' DNA helicase catalyzed by its XPD subunit, and a carboxyl-terminal domain (CTD) kinase activity catalyzed by its CDK7 subunit. In this report, we exploit TFIIH mutants to investigate the contributions of TFIIH DNA helicase and CTD kinase activities to efficient promoter escape by RNA polymerase II in a minimal transcription system reconstituted with purified polymerase and general initiation factors. Our findings argue that the TFIIH XPB DNA helicase is primarily responsible for preventing premature arrest of early elongation intermediates during exit of polymerase from the promoter.	Oklahoma Med Res Fdn, Program Mol & Cell Biol, Oklahoma City, OK 73104 USA; Univ Strasbourg 1, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, Illkirch Graffenstaden, de Strasbour, France; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA; Oklahoma Med Res Fdn, Howard Hughes Med Inst, Oklahoma City, OK 73104 USA	Oklahoma Medical Research Foundation; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Oklahoma System; University of Oklahoma Health Sciences Center; Howard Hughes Medical Institute; Oklahoma Medical Research Foundation	Conaway, RC (corresponding author), Oklahoma Med Res Fdn, Program Mol & Cell Biol, 825 NE 13th St, Oklahoma City, OK 73104 USA.		TIRODE, Franck/HHS-7070-2022; Yan, Qin/E-8893-2012; Tirode, Franck/B-4586-2009	Yan, Qin/0000-0003-4077-453X; Tirode, Franck/0000-0003-4731-7817; Conaway, Joan/0000-0002-2786-0663	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041628, R37GM041628] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41628] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Coin F, 1999, EMBO J, V18, P1357, DOI 10.1093/emboj/18.5.1357; CONAWAY JW, 1991, J BIOL CHEM, V266, P7804; Conaway JW, 1998, COLD SPRING HARB SYM, V63, P357, DOI 10.1101/sqb.1998.63.357; Conaway RC, 1996, METHOD ENZYMOL, V273, P194; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; Drapkin R, 1996, P NATL ACAD SCI USA, V93, P6488, DOI 10.1073/pnas.93.13.6488; Dvir A, 1996, J BIOL CHEM, V271, P23352, DOI 10.1074/jbc.271.38.23352; Dvir A, 1997, P NATL ACAD SCI USA, V94, P9006, DOI 10.1073/pnas.94.17.9006; Dvir A, 1996, J BIOL CHEM, V271, P7245, DOI 10.1074/jbc.271.13.7245; GERARD M, 1991, J BIOL CHEM, V266, P20940; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; GUZDER SN, 1994, NATURE, V369, P578, DOI 10.1038/369578a0; Holstege FCP, 1997, EMBO J, V16, P7468, DOI 10.1093/emboj/16.24.7468; Holstege FCP, 1996, EMBO J, V15, P1666, DOI 10.1002/j.1460-2075.1996.tb00512.x; HOLSTEGE FCP, 1995, EMBO J, V14, P810, DOI 10.1002/j.1460-2075.1995.tb07059.x; JIANG Y, 1995, J BIOL CHEM, V270, P27332, DOI 10.1074/jbc.270.45.27332; JIANG Y, 1993, J BIOL CHEM, V268, P6535; Keene RG, 1999, J BIOL CHEM, V274, P11526, DOI 10.1074/jbc.274.17.11526; Kugel JF, 1998, P NATL ACAD SCI USA, V95, P9232, DOI 10.1073/pnas.95.16.9232; Kumar KP, 1998, P NATL ACAD SCI USA, V95, P9767, DOI 10.1073/pnas.95.17.9767; LUSE DS, 1987, J BIOL CHEM, V262, P14990; PAN GH, 1994, J BIOL CHEM, V269, P30101; PARVIN JD, 1994, J BIOL CHEM, V269, P18414; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PETERSON MG, 1991, NATURE, V354, P369; Reardon JT, 1996, P NATL ACAD SCI USA, V93, P6482, DOI 10.1073/pnas.93.13.6482; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Rossignol M, 1997, EMBO J, V16, P1628, DOI 10.1093/emboj/16.7.1628; SAMUELS M, 1984, J BIOL CHEM, V259, P2517; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; SVEJSTRUP JQ, 1994, J BIOL CHEM, V269, P28044; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; TAN SY, 1994, BIOTECHNIQUES, V16, P824; TANTIN D, 1994, J BIOL CHEM, V269, P17397; Tirode F, 1999, MOL CELL, V3, P87, DOI 10.1016/S1097-2765(00)80177-X; TSUBOI A, 1992, NUCLEIC ACIDS RES, V20, P3250, DOI 10.1093/nar/20.12.3250; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; Yan M, 1997, EMBO J, V16, P7457, DOI 10.1093/emboj/16.24.7457	41	76	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22127	22130		10.1074/jbc.274.32.22127	http://dx.doi.org/10.1074/jbc.274.32.22127			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428772	hybrid			2022-12-25	WOS:000081868400002
J	Sorensen, O; Bratt, T; Johnsen, AH; Madsen, MT; Borregaard, N				Sorensen, O; Bratt, T; Johnsen, AH; Madsen, MT; Borregaard, N			The human antibacterial cathelicidin, hCAP-18, is bound to lipoproteins in plasma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE LL-37; HUMAN NEUTROPHILS; DEFENSIN; PROTEINS; BINDING; IDENTIFICATION; CHOLESTEROL; LEUKOCYTES; GRANULES; CLEAVAGE	Cathelicidins are a family of antibacterial and lipopolysaccharide-binding proteins. hCAP-18, the only human cathelicidin, is a major protein of the specific granules of human neutrophils, The plasma level of hCAP-18 is >20-fold higher than that of other specific granule proteins relative to their levels within circulating neutrophils, The aim of this study was to elucidate the background for this high plasma level of hCAP-18. Plasma was subjected to molecular sieve chromatography, and hCAP-18 was found in distinct high molecular mass fractions that coeluted with apolipoproteins A-I and B, respectively. The association of hCAP-18 with lipoproteins was validated by the cofractionation of hCAP-18 with lipoproteins using two different methods for isolation of lipoproteins from plasma. Furthermore, the level of hCAP-18 in delipidated plasma was <1% of that in normal plasma. Immunoprecipitation of very low, low, and high density lipoprotein particles with anti-apolipoprotein antibodies resulted in coprecipitation of hCAP-18, The binding of hCAP-18 to lipoproteins was mediated by the antibacterial C-terminal part of the protein. The binding of hCAP-18 to lipoproteins suggests that lipoproteins may play an important role as a reservoir of this antimicrobial protein.	Natl Univ Hosp, Dept Biochem, Ctr Lab Med & Pathol, DK-2100 Copenhagen O, Denmark; Natl Univ Hosp, Finsen Ctr, Dept Hematol, Granulocyte Res Lab, DK-2100 Copenhagen O, Denmark		Sorensen, O (corresponding author), Rigshosp, Dept Hematol L9322, Granulocyte Res Lab, 9 Blegdamsvej, DK-2100 Copenhagen, Denmark.	olesoeren@rh.dk	Eckhardt, Erik/G-1567-2010	Sorensen, Ole E./0000-0001-8681-6921				AGERBERTH B, 1995, P NATL ACAD SCI USA, V92, P195, DOI 10.1073/pnas.92.1.195; AHMAD I, 1995, BBA-BIOMEMBRANES, V1237, P109, DOI 10.1016/0005-2736(95)00087-J; Arnljots K, 1998, LEUKEMIA, V12, P1789, DOI 10.1038/sj.leu.2401202; Bals R, 1998, P NATL ACAD SCI USA, V95, P9541, DOI 10.1073/pnas.95.16.9541; Barnathan ES, 1997, AM J PATHOL, V150, P1009; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BRONZERT TJ, 1977, CLIN CHEM, V23, P2089; COWLAND JB, 1995, FEBS LETT, V368, P173, DOI 10.1016/0014-5793(95)00634-L; FINLEY PR, 1978, CLIN CHEM, V24, P931; Frohm M, 1997, J BIOL CHEM, V272, P15258, DOI 10.1074/jbc.272.24.15258; Gudmundsson GH, 1996, EUR J BIOCHEM, V238, P325, DOI 10.1111/j.1432-1033.1996.0325z.x; Higazi AAR, 1997, BLOOD, V89, P4290, DOI 10.1182/blood.V89.12.4290; Johansson J, 1998, J BIOL CHEM, V273, P3718, DOI 10.1074/jbc.273.6.3718; KJELDSEN L, 1994, BLOOD, V83, P1640, DOI 10.1182/blood.V83.6.1640.bloodjournal8361640; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARRICK JW, 1995, INFECT IMMUN, V63, P1291, DOI 10.1128/IAI.63.4.1291-1297.1995; LOLLIKE K, 1995, LEUKEMIA, V9, P159; MATSUDAIRA PT, 1989, PRACTICAL GUIDE PROT, P20; Nilsson MF, 1999, INFECT IMMUN, V67, P2561, DOI 10.1128/IAI.67.5.2561-2566.1999; OUCHTERLONY O, 1986, HDB EXPT IMMUNOLOGY, V6; Panyutich A, 1997, INFECT IMMUN, V65, P978, DOI 10.1128/IAI.65.3.978-985.1997; PANYUTICH AV, 1995, AM J RESP CELL MOL, V12, P351, DOI 10.1165/ajrcmb.12.3.7873202; PANYUTICH AV, 1993, J LAB CLIN MED, V122, P202; PANYUTICH AV, 1994, FEBS LETT, V356, P169, DOI 10.1016/0014-5793(94)01261-X; PANYUTICH AV, 1991, AM J RESP CELL MOL B, V12, P351; PECKMILLER KA, 1993, CANCER CHEMOTH PHARM, V32, P109, DOI 10.1007/BF00685612; RITONJA A, 1989, FEBS LETT, V255, P211, DOI 10.1016/0014-5793(89)81093-2; SCOCCHI M, 1992, EUR J BIOCHEM, V209, P589, DOI 10.1111/j.1432-1033.1992.tb17324.x; Sorensen O, 1997, BLOOD, V90, P2796; Sorensen O, 1997, J IMMUNOL METHODS, V206, P53, DOI 10.1016/S0022-1759(97)00084-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Turner J, 1998, ANTIMICROB AGENTS CH, V42, P2206, DOI 10.1128/AAC.42.9.2206; Wang YQ, 1998, J BIOL CHEM, V273, P33115, DOI 10.1074/jbc.273.50.33115; ZANETTI M, 1991, J IMMUNOL, V146, P4295; ZANETTI M, 1995, FEBS LETT, V374, P1, DOI 10.1016/0014-5793(95)01050-O	35	94	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22445	22451		10.1074/jbc.274.32.22445	http://dx.doi.org/10.1074/jbc.274.32.22445			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428818	hybrid			2022-12-25	WOS:000081868400048
J	Brazzolotto, X; Gaillard, J; Pantopoulos, K; Hentze, MW; Moulis, JM				Brazzolotto, X; Gaillard, J; Pantopoulos, K; Hentze, MW; Moulis, JM			Human cytoplasmic aconitase (iron regulatory protein 1) is converted into its [3Fe-4S] form by hydrogen peroxide in vitro but is not activated for iron-responsive element binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FE-S CLUSTER; NITRIC-OXIDE; OXIDATIVE STRESS; MESSENGER-RNA; ESCHERICHIA-COLI; SULFUR CLUSTERS; 2<4FE-4S> FERREDOXIN; DNA-DAMAGE; IN-VITRO; SUPEROXIDE	Iron regulatory protein 1 (IRP1) regulates the synthesis of proteins involved in iron homeostasis by binding to iron-responsive elements (IREs) of messenger RNA. IRP1 is a cytoplasmic aconitase when it contains a [4Fe-4S] cluster and an RNA-binding protein after complete removal of the metal center by an unknown mechanism. Human IRP1, obtained as the pure recombinant [4Fe-4S] form, is an enzyme as efficient toward cis-aconitate as the homologous mitochondrial aconitase, The aconitase activity of IRP1 is rapidly lost by reaction with hydrogen peroxide as the [4Fe-4S] cluster is quantitatively converted into the [3Fe-4S] form with release of a single ferrous ion per molecule. The IRE binding capacity of IRP1 is not elicited with H2O2. Ferrous sulfate (but not other more tightly coordinated ferrous ions, such as the complex with ethylenediamine tetraacetic acid) counteracts the inhibitory action of hydrogen peroxide on cytoplasmic aconitase, probably by replenishing iron at the active site. These results cast doubt on the ability of reactive oxygen species to directly increase IRP1 binding to IRE and support a signaling role for hydrogen peroxide in the posttranscriptional control of proteins involved in iron homeostasis in vivo.	CEA, Dept Biol Mol & Struct, Lab Metalloprot, F-38054 Grenoble 9, France; CEA, Dept Rech Fondamentale Mat Condensee, F-38054 Grenoble 9, France; European Mol Biol Lab, D-69117 Heidelberg, Germany	CEA; CEA; European Molecular Biology Laboratory (EMBL)	Moulis, JM (corresponding author), CEA, Dept Biol Mol & Struct, Lab Metalloprot, 17 Rue Martyrs, F-38054 Grenoble 9, France.	jean-marc.moulis@cea.fr	Pantopoulos, Kostas/A-9668-2008; Hentze, Matthias W/V-3980-2017; Brazzolotto, Xavier/GXG-3805-2022	Pantopoulos, Kostas/0000-0002-2305-0057; Hentze, Matthias W/0000-0002-4023-7876; Brazzolotto, Xavier/0000-0001-9219-1032; Moulis, Jean-Marc/0000-0001-5615-9852				Aspinwall R, 1997, P NATL ACAD SCI USA, V94, P109, DOI 10.1073/pnas.94.1.109; BABBS CF, 1990, METHOD ENZYMOL, V186, P137; BASILION JP, 1994, ARCH BIOCHEM BIOPHYS, V311, P517, DOI 10.1006/abbi.1994.1270; Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; Beinert H, 1996, CHEM REV, V96, P2335, DOI 10.1021/cr950040z; Bouton C, 1996, J BIOL CHEM, V271, P2300, DOI 10.1074/jbc.271.4.2300; Bouton C, 1997, J BIOL CHEM, V272, P19969, DOI 10.1074/jbc.272.32.19969; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cairo G, 1996, FASEB J, V10, P1326, DOI 10.1096/fasebj.10.11.8836047; CASTRO L, 1994, J BIOL CHEM, V269, P29409; Castro LA, 1998, ARCH BIOCHEM BIOPHYS, V359, P215, DOI 10.1006/abbi.1998.0898; DAILEY HA, 1994, BIOCHEMISTRY-US, V33, P403, DOI 10.1021/bi00168a003; Dandekar T, 1998, BIOINFORMATICS, V14, P271, DOI 10.1093/bioinformatics/14.3.271; Degli Esposti M, 1998, FEBS LETT, V430, P338, DOI 10.1016/S0014-5793(98)00688-7; EMERYGOODMAN A, 1993, NUCLEIC ACIDS RES, V21, P1457, DOI 10.1093/nar/21.6.1457; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; FLINT DH, 1993, J BIOL CHEM, V268, P22369; FREJAVILLE C, 1995, J MED CHEM, V38, P258, DOI 10.1021/jm00002a007; Frishman D, 1996, EUR J BIOCHEM, V239, P197, DOI 10.1111/j.1432-1033.1996.0197u.x; GARDNER PR, 1995, J BIOL CHEM, V270, P13399, DOI 10.1074/jbc.270.22.13399; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; Gehring NH, 1999, J BIOL CHEM, V274, P6219, DOI 10.1074/jbc.274.10.6219; Goldenberg HA, 1997, CRIT REV CL LAB SCI, V34, P529, DOI 10.3109/10408369709006425; Gray MW, 1999, SCIENCE, V283, P1476, DOI 10.1126/science.283.5407.1476; GRAY NK, 1993, EUR J BIOCHEM, V218, P657, DOI 10.1111/j.1432-1033.1993.tb18420.x; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P11735, DOI 10.1073/pnas.89.24.11735; HALLIWELL B, 1992, FEBS LETT, V307, P108, DOI 10.1016/0014-5793(92)80911-Y; Hanson ES, 1998, J BIOL CHEM, V273, P7588, DOI 10.1074/jbc.273.13.7588; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; Henle ES, 1997, J BIOL CHEM, V272, P19095, DOI 10.1074/jbc.272.31.19095; HENSON CP, 1967, J BIOL CHEM, V242, P3833; Hentze MW, 1996, TRENDS BIOCHEM SCI, V21, P282, DOI 10.1016/S0968-0004(96)20019-2; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; HIRLING H, 1992, NUCLEIC ACIDS RES, V20, P33, DOI 10.1093/nar/20.1.33; Kennedy MC, 1997, J BIOL CHEM, V272, P20340, DOI 10.1074/jbc.272.33.20340; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; Keyer K, 1996, P NATL ACAD SCI USA, V93, P13635, DOI 10.1073/pnas.93.24.13635; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTINS EAL, 1995, ARCH BIOCHEM BIOPHYS, V316, P128, DOI 10.1006/abbi.1995.1019; MOULIS JM, 1994, BIOMETALS, V7, P272, DOI 10.1007/BF00144121; Pantopoulos K, 1998, P NATL ACAD SCI USA, V95, P10559, DOI 10.1073/pnas.95.18.10559; PANTOPOULOS K, 1995, P NATL ACAD SCI USA, V92, P1267, DOI 10.1073/pnas.92.5.1267; PANTOPOULOS K, 1995, EMBO J, V14, P2917, DOI 10.1002/j.1460-2075.1995.tb07291.x; Pantopoulos K, 1996, MOL CELL BIOL, V16, P3781; Pantopoulos K, 1997, J BIOL CHEM, V272, P9802; Phillips JD, 1996, BIOCHEMISTRY-US, V35, P15704, DOI 10.1021/bi960653l; PHILPOTT CC, 1991, NUCLEIC ACIDS RES, V19, P6333, DOI 10.1093/nar/19.22.6333; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; QUINKAL I, 1994, PROTEIN ENG, V7, P681, DOI 10.1093/protein/7.5.681; ROSE IA, 1967, J BIOL CHEM, V242, P1870; Rouault TA, 1996, TRENDS BIOCHEM SCI, V21, P174, DOI 10.1016/0968-0004(96)10024-4; Schalinske KL, 1997, BIOCHEMISTRY-US, V36, P3950, DOI 10.1021/bi9624447; TABOR S, 1990, CURRENT PROTOCOLS MO; THEIL EC, 1994, BIOCHEM J, V304, P1; Toth I, 1999, J BIOL CHEM, V274, P4467, DOI 10.1074/jbc.274.7.4467; Wardman P, 1996, RADIAT RES, V145, P523, DOI 10.2307/3579270	60	92	95	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21625	21630		10.1074/jbc.274.31.21625	http://dx.doi.org/10.1074/jbc.274.31.21625			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419470	hybrid			2022-12-25	WOS:000081721100023
J	Pellegrini, L; Passer, BJ; Tabaton, M; Ganjei, JK; D'Adamio, L				Pellegrini, L; Passer, BJ; Tabaton, M; Ganjei, JK; D'Adamio, L			Alternative, non-secretase processing of Alzheimer's beta-amyloid precursor protein during apoptosis by caspase-6 and-8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MISSENSE MUTATIONS; FAMILY PROTEASES; CELL-DEATH; DISEASE; GENE; CLEAVAGE; PEPTIDE; MUTANT; PRESENILIN-1; INVOLVEMENT	Alzheimer's disease (AD) is a progressive neurodegenerative disorder. Although the pathogenesis of AD is unknown, it is widely accepted that AD is caused by extracellular accumulation of a neurotoxic peptide, known as A beta, Mutations in the beta-amyloid precursor protein (APP), from which A beta arises by proteolysis, are associated with some forms of familial AD (FAD) and result in increased A beta production. Two other FAD genes, presenilin-1 and -2, have also been shown to regulate A beta production; however, studies examining the biological role of these FAD genes suggest an alternative theory for the pathogenesis of AD. In fact, all three genes have been shown to regulate programmed cell death, hinting at the possibility that dysregulation of apoptosis plays a primary role in causing neuronal loss in AD. In an attempt to reconcile these two hypotheses, we investigated APP processing during apoptosis and found that APP is processed by the cell death proteases caspase-6 and -8. APP is cleaved by caspases in the intracellular portion of the protein, in a site distinct from those processed by secretases. Moreover, it represents a general effect of apoptosis, because it occurs during cell death induced by several stimuli both in T cells and in neuronal cells.	NIAID, T Cell Apoptopsis Unit, Cellular & Mol Immunol Lab, NIH, Bethesda, MD 20892 USA; Univ Genoa, Ist Anat Umana, I-16132 Genoa, Italy; Univ Genoa, Dipartimento Neurosci, I-16132 Genoa, Italy	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Genoa; University of Genoa	D'Adamio, L (corresponding author), NIAID, T Cell Apoptopsis Unit, Cellular & Mol Immunol Lab, NIH, Bldg 4-431, Bethesda, MD 20892 USA.			D'Adamio, Luciano/0000-0002-2204-9441; D'Adamio, Luciano/0000-0002-9820-4882; Pellegrini, Luca/0000-0002-4235-7708				Barnes NY, 1998, J NEUROSCI, V18, P5869; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Galli C, 1998, P NATL ACAD SCI USA, V95, P1247, DOI 10.1073/pnas.95.3.1247; Giambarella U, 1997, EMBO J, V16, P4897, DOI 10.1093/emboj/16.16.4897; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; Guenette SY, 1996, P NATL ACAD SCI USA, V93, P10832, DOI 10.1073/pnas.93.20.10832; Guo Q, 1996, NEUROREPORT, V8, P379, DOI 10.1097/00001756-199612200-00074; Guo Q, 1997, J NEUROSCI, V17, P4212; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LeBlanc A, 1995, J NEUROSCI, V15, P7837; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Loetscher H, 1997, J BIOL CHEM, V272, P20655, DOI 10.1074/jbc.272.33.20655; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; PODLISNY MB, 1991, AM J PATHOL, V138, P1423; Price DL, 1998, ANNU REV NEUROSCI, V21, P479, DOI 10.1146/annurev.neuro.21.1.479; Rano TA, 1997, CHEM BIOL, V4, P149, DOI 10.1016/S1074-5521(97)90258-1; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; SturchlerPierrat C, 1997, P NATL ACAD SCI USA, V94, P13287, DOI 10.1073/pnas.94.24.13287; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Vito P, 1997, J BIOL CHEM, V272, P28315, DOI 10.1074/jbc.272.45.28315; Vito P, 1996, J BIOL CHEM, V271, P31025, DOI 10.1074/jbc.271.49.31025; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; Weidemann A, 1999, J BIOL CHEM, V274, P5823, DOI 10.1074/jbc.274.9.5823; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Yamatsuji T, 1996, EMBO J, V15, P498, DOI 10.1002/j.1460-2075.1996.tb00382.x	45	138	147	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21011	21016		10.1074/jbc.274.30.21011	http://dx.doi.org/10.1074/jbc.274.30.21011			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409650	hybrid			2022-12-25	WOS:000081613100041
J	Sanbe, A; Fewell, JG; Gulick, J; Osinska, H; Lorenz, J; Hall, DG; Murray, LA; Kimball, TR; Witt, SA; Robbins, J				Sanbe, A; Fewell, JG; Gulick, J; Osinska, H; Lorenz, J; Hall, DG; Murray, LA; Kimball, TR; Witt, SA; Robbins, J			Abnormal cardiac structure and function in mice expressing nonphosphorylatable cardiac regulatory myosin light chain 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE FIBERS; PROTEIN-KINASE-C; MYOCARDIAL-INFARCTION; TRANSGENIC MICE; STRIATED-MUSCLE; MAMMALIAN HEART; SMOOTH-MUSCLE; PHOSPHORYLATION; TENSION; POTENTIATION	A role for myosin phosphorylation in modulating normal cardiac function has long been suspected, and we hypothesized that changing the phosphorylation status of a cardiac myosin light chain might alter cardiac function in the whole animal. To test this directly, transgenic mice were created in which three potentially phosphorylatable serines in the ventricular isoform of the regulatory myosin light chain were mutated to alanines. Lines were obtained in which replacement of the endogenous species in the ventricle with the nonphosphorylatable, transgenically encoded protein was essentially complete. The mice show a spectrum of cardiovascular changes. As previously observed in skeletal muscle, Ca2+ sensitivity of force development was dependent upon the phosphorylation status of the regulatory light chain. Structural abnormalities were detected by both gross histology and transmission electron microscopic analyses. Mature animals showed both atrial hypertrophy and dilatation. Echocardiographic analysis revealed that as a result of chamber enlargement, severe tricuspid valve insufficiency resulted in a detectable regurgitation jet. We conclude that regulated phosphorylation of the regulatory myosin light chains appears to play an important role in maintaining normal cardiac function over the lifetime of the animal.	Childrens Hosp Res Fdn, Div Mol Cardiovasc Biol, Dept Pediat, Cincinnati, OH 45229 USA; Childrens Hosp Res Fdn, Dept Pediat, Div Cardiol, Cincinnati, OH 45229 USA; Univ Georgia, Coll Vet Med, Dept Pathol, Athens, GA 30603 USA; Univ Cincinnati, Dept Mol & Cellular Physiol, Cincinnati, OH 45267 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Georgia; University of Georgia; University System of Ohio; University of Cincinnati	Robbins, J (corresponding author), Childrens Hosp Res Fdn, Div Mol Cardiovasc Biol, Dept Pediat, Cincinnati, OH 45229 USA.				NHLBI NIH HHS [HL56620, HL56370, HL41496] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041496, R01HL056620, R01HL056370] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adhikari BB, 1999, BIOCHEMISTRY-US, V38, P3127, DOI 10.1021/bi982553g; Akiyama K, 1997, J MOL CELL CARDIOL, V29, P2641, DOI 10.1006/jmcc.1997.0493; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Colbert MC, 1997, J CLIN INVEST, V100, P1958, DOI 10.1172/JCI119727; Dickinson MH, 1997, BIOPHYS J, V73, P3122, DOI 10.1016/S0006-3495(97)78338-3; Fewell JG, 1997, AM J PHYSIOL-HEART C, V273, pH1595, DOI 10.1152/ajpheart.1997.273.3.H1595; Fewell JG, 1998, J CLIN INVEST, V101, P2630, DOI 10.1172/JCI2825; FITZSIMONS DP, 1989, J APPL PHYSIOL, V67, P2447, DOI 10.1152/jappl.1989.67.6.2447; FITZSIMONS DP, 1990, J APPL PHYSIOL, V68, P2426, DOI 10.1152/jappl.1990.68.6.2426; HERRING BP, 1992, J BIOL CHEM, V267, P25945; HOIT BD, 1995, CIRC RES, V77, P632, DOI 10.1161/01.RES.77.3.632; IKEBE M, 1986, J BIOL CHEM, V261, P36; Jones WK, 1996, J CLIN INVEST, V98, P1906, DOI 10.1172/JCI118992; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; KIRSCHBAUM BJ, 1989, EUR J BIOCHEM, V179, P23, DOI 10.1111/j.1432-1033.1989.tb14516.x; LEVINE RJC, 1995, BIOPHYS J, V68, pS224; LIU XL, 1995, J MOL CELL CARDIOL, V27, P2613, DOI 10.1006/jmcc.1995.0048; Lorenz JN, 1997, AM J PHYSIOL-HEART C, V272, pH1137, DOI 10.1152/ajpheart.1997.272.3.H1137; METZGER JM, 1989, J GEN PHYSIOL, V93, P855, DOI 10.1085/jgp.93.5.855; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; MOORE RL, 1990, J CELL PHYSIOL, V143, P257, DOI 10.1002/jcp.1041430209; MORANO I, 1992, BASIC RES CARDIOL, V87, P129; MORANO I, 1985, FEBS LETT, V189, P221, DOI 10.1016/0014-5793(85)81027-9; NOLAND TA, 1993, BIOCHEM BIOPH RES CO, V193, P254, DOI 10.1006/bbrc.1993.1617; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Palermo J, 1995, CELL MOL BIOL RES, V41, P501; Palermo J, 1996, CIRC RES, V78, P504, DOI 10.1161/01.RES.78.3.504; Patel JR, 1996, BIOPHYS J, V70, P2333, DOI 10.1016/S0006-3495(96)79799-0; Periasamy M, 1999, J BIOL CHEM, V274, P2556, DOI 10.1074/jbc.274.4.2556; PERRIE WT, 1973, BIOCHEM J, V135, P151, DOI 10.1042/bj1350151; ROBBINS J, 1995, ANN NY ACAD SCI, V752, P492, DOI 10.1111/j.1749-6632.1995.tb17458.x; STULL JT, 1980, ADV CYCL NUCL RES, V13, P40; SWEENEY HL, 1986, AM J PHYSIOL, V250, pC657, DOI 10.1152/ajpcell.1986.250.4.C657; SWEENEY HL, 1994, P NATL ACAD SCI USA, V91, P1490, DOI 10.1073/pnas.91.4.1490; SWEENEY HL, 1990, P NATL ACAD SCI USA, V87, P414, DOI 10.1073/pnas.87.1.414; SWEENEY HL, 1993, AM J PHYSIOL, V264, pC1085, DOI 10.1152/ajpcell.1993.264.5.C1085; TOHTONG R, 1995, NATURE, V374, P650, DOI 10.1038/374650a0; TUAZON PT, 1982, EUR J BIOCHEM, V129, P205, DOI 10.1111/j.1432-1033.1982.tb07041.x; VANDENBOOM R, 1995, AM J PHYSIOL-CELL PH, V268, pC596, DOI 10.1152/ajpcell.1995.268.3.C596; VENEMA RC, 1993, BIOCHEM J, V294, P401, DOI 10.1042/bj2940401	40	100	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21085	21094		10.1074/jbc.274.30.21085	http://dx.doi.org/10.1074/jbc.274.30.21085			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409661	hybrid			2022-12-25	WOS:000081613100052
J	Cote, JF; Turner, CE; Tremblay, ML				Cote, JF; Turner, CE; Tremblay, ML			Intact LIM 3 and LIM 4 domains of paxillin are required for the association to a novel polyproline region (Pro 2) of protein-tyrosine phosphatase-PEST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; PTP-PEST; SH3 DOMAIN; SIGNAL-TRANSDUCTION; SUBSTRATE; BINDING; PHOSPHORYLATION; IDENTIFICATION; P130(CAS); LOCALIZATION	The focal adhesion protein p130(Cas) was identified as a substrate for the protein-tyrosine phosphatase (PTP)-PEST, and the specificity of this interaction is mediated by a dual mechanism involving a Src homology 3 domain-mediated binding and PTP domain recognition. Recently, paxillin was also demonstrated to interact with PTP-PEST (Shen, Y., Schneider, G., Cloutier, J. F., Veillette, A., and Schaller, M. D. (1998) J. Biol. Chem. 273, 6474-6481). In the present study, we show that amino acids 344-397 of PTP-PEST are sufficient for the binding to paxillin. We demonstrate that a proline-rich segment of PTP-PEST (Pro 2), (355)PPEPHPVPPILTPSPPSAFP(374), is essential for this interaction in vivo, Furthermore, mutation of proline residues within the Pro 2 motif reveal that proline 362 is critical for the binding of paxillin. Conversely, using deletion and point mutants of paxillin, LIM 3 and 4 domains were both found to be necessary for binding of PTP-PEST. Finally, using a "substrate trapping" approach, we demonstrate that, unlike p130(Cas), paxillin is not a substrate for PTP-PEST. In conclusion, we show that a novel proline-rich motif found in PTP-PEST serves as a ligand for the LIM domains of paxillin. Interestingly, the focal adhesion targeting of paxillin is mediated by LIM 3. Thus, we propose that PTP-PEST, by a competition with the ligand of paxillin in the focal adhesion complex, could contribute to the removal of paxillin from the adhesion sites and consequently promote focal adhesion turnover.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; SUNY Hlth Sci Ctr, Dept Anat & Cell Biol, Cell & Mol Biol Program, Syracuse, NY 13210 USA	McGill University; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Tremblay, ML (corresponding author), McGill Univ, Dept Biochem, 3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.				NIGMS NIH HHS [GM47607, R01 GM047607] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047607, R29GM047607] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; Bellis SL, 1997, BIOCHEM J, V325, P375, DOI 10.1042/bj3250375; BELLIS SL, 1995, J BIOL CHEM, V270, P17437, DOI 10.1074/jbc.270.29.17437; Brown MC, 1998, NAT STRUCT BIOL, V5, P677, DOI 10.1038/1370; Brown MC, 1998, MOL BIOL CELL, V9, P1803, DOI 10.1091/mbc.9.7.1803; Brown MC, 1996, J CELL BIOL, V135, P1109, DOI 10.1083/jcb.135.4.1109; Charest A, 1996, J BIOL CHEM, V271, P8424, DOI 10.1074/jbc.271.14.8424; CHAREST A, 1995, BIOCHEM J, V308, P425, DOI 10.1042/bj3080425; Charest A, 1997, ONCOGENE, V14, P1643, DOI 10.1038/sj.onc.1201008; Chen HI, 1997, J BIOL CHEM, V272, P17070, DOI 10.1074/jbc.272.27.17070; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Cote JF, 1998, BIOCHEMISTRY-US, V37, P13128, DOI 10.1021/bi981259l; Davidson D, 1997, J BIOL CHEM, V272, P23455, DOI 10.1074/jbc.272.37.23455; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Garton AJ, 1999, J BIOL CHEM, V274, P3811, DOI 10.1074/jbc.274.6.3811; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; Garton AJ, 1997, ONCOGENE, V15, P877, DOI 10.1038/sj.onc.1201279; HABIB T, 1994, J BIOL CHEM, V269, P25243; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lipsky BP, 1998, J BIOL CHEM, V273, P11709, DOI 10.1074/jbc.273.19.11709; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; Nakamoto T, 1997, MOL CELL BIOL, V17, P3884, DOI 10.1128/MCB.17.7.3884; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Nishiya N, 1999, J BIOL CHEM, V274, P9847, DOI 10.1074/jbc.274.14.9847; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; Shen Y, 1998, J BIOL CHEM, V273, P6474, DOI 10.1074/jbc.273.11.6474; Shibanuma M, 1997, MOL CELL BIOL, V17, P1224, DOI 10.1128/MCB.17.3.1224; Spencer S, 1997, J CELL BIOL, V138, P845, DOI 10.1083/jcb.138.4.845; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Tachibana K, 1997, J BIOL CHEM, V272, P29083, DOI 10.1074/jbc.272.46.29083; Tiganis T, 1998, MOL CELL BIOL, V18, P1622, DOI 10.1128/MCB.18.3.1622; Timms JF, 1998, MOL CELL BIOL, V18, P3838, DOI 10.1128/MCB.18.7.3838; TURNER CE, 1994, J CELL SCI, V107, P1583; Wu RY, 1996, J BIOL CHEM, V271, P15934, DOI 10.1074/jbc.271.27.15934	38	73	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20550	20560		10.1074/jbc.274.29.20550	http://dx.doi.org/10.1074/jbc.274.29.20550			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400685	hybrid			2022-12-25	WOS:000081438300078
J	Gigoux, V; Escrieut, C; Fehrentz, JA; Poirot, S; Maigret, B; Moroder, L; Gully, D; Martinez, J; Vaysse, N; Fourmy, D				Gigoux, V; Escrieut, C; Fehrentz, JA; Poirot, S; Maigret, B; Moroder, L; Gully, D; Martinez, J; Vaysse, N; Fourmy, D			Arginine 336 and asparagine 333 of the human cholecystokinin-A receptor binding site interact with the penultimate aspartic acid and the C-terminal amide of cholecystokinin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; PARTIAL AGONIST ACTIVITY; RAT PANCREATIC ACINI; NEUROKININ-1 RECEPTOR; FUNCTIONAL EXPRESSION; NONPEPTIDE ANTAGONIST; TRANSMEMBRANE DOMAINS; EXTRACELLULAR DOMAIN; BIOLOGICAL-ACTIVITY; MOLECULAR-CLONING	The cholecystokinin-A receptor (CCK-AR) is a G protein-coupled receptor that mediates important central and peripheral cholecystokinin actions. Residues of the CCK-AR binding site that interact with the C-terminal part of CCK that is endowed with biological activity are still unknown. Here we report on the identification of Arg-336 and Asn-333 of CCK-AR, which interact with the Asp-8 carboxylate and the C-terminal amide of CCK-9, respectively. Identification of the two amino acids was achieved by dynamics-based docking of CCK in a refined three-dimensional model of CCK-AR using, as constraints, previous results that demonstrated that Trp-39/Gln-40 and Met-195/Arg-197 interact with the N terminus and the sulfated tyrosine of CCK, respectively. Arg-336-Asp-8 and Asn-333-amide interactions were pharmacologically assessed by mutational exchange of Arg-336 and Asn-333 in the receptor or reciprocal elimination of the partner chemical functions in CCK, This study also allowed us to demonstrate that (i) the identified interactions are crucial for stabilizing the high affinity phospholipase C-coupled state of the CCK-AR CCK complex, (ii) Arg-336 and Asn-333 are directly involved in interactions with nonpeptide antagonists SR-27,897 and L-364,718, and (iii) Arg-336 but not Asn-333 is directly involved in the binding of the peptide antagonist JMV 179 and the peptide partial agonist JMV 180, These data will be used to obtain an integrated dynamic view of the molecular processes that link agonist binding to receptor activation.	CHU Rangueil, Inst Louis Bugnard, INSERM, U151, F-31403 Toulouse 4, France; Univ Nancy 1, Chim Theor Lab, F-54506 Vandoeuvre Nancy, France; Fac Pharm Montpellier, CNRS, UMR 5810, F-34060 Montpellier, France; Max Planck Inst Biochem, D-82143 Martinsried, Germany; Sanofi Rech, F-31036 Toulouse, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lorraine; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Max Planck Society; Sanofi-Aventis; Sanofi France	Fourmy, D (corresponding author), CHU Rangueil, Inst Louis Bugnard, INSERM, U151, Bat L3, F-31403 Toulouse 4, France.		Poirot, Sandrine/D-5448-2017; Martinez, Jean/R-9421-2019; Fourmy, Daniel/AAE-3703-2019; Gigoux, Véronique/AAE-6090-2020	Martinez, Jean/0000-0002-9267-4621; Fourmy, Daniel/0000-0001-9910-4827; Gigoux, Véronique/0000-0003-1408-5335; Moroder, Luis/0000-0001-9570-5713				Beinfeld MC, 1997, LIFE SCI, V61, P2359, DOI 10.1016/S0024-3205(97)00644-9; Blaker M, 1998, MOL PHARMACOL, V54, P857, DOI 10.1124/mol.54.5.857; CAMPAGNE F, 1999, IN PRESS COMPUT AIDE; DEWEERTH A, 1993, BIOCHEM BIOPH RES CO, V194, P811, DOI 10.1006/bbrc.1993.1894; Di Paolo E, 1998, FEBS LETT, V424, P207, DOI 10.1016/S0014-5793(98)00175-6; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; FENG YH, 1995, J BIOL CHEM, V270, P12846, DOI 10.1074/jbc.270.21.12846; FONG TM, 1992, J BIOL CHEM, V267, P25664; FONG TM, 1992, BIOCHEMISTRY-US, V31, P11806, DOI 10.1021/bi00162a019; FONG TM, 1994, MED RES REV, V14, P387, DOI 10.1002/med.2610140402; FONG TM, 1992, BIOPHYS J, V62, P59, DOI 10.1016/S0006-3495(92)81778-2; FOURMY D, 1989, EUR J BIOCHEM, V185, P397, DOI 10.1111/j.1432-1033.1989.tb15128.x; FREIDINGER RM, 1989, MED RES REV, V9, P271, DOI 10.1002/med.2610090303; GALAS MC, 1988, AM J PHYSIOL, V254, pG176, DOI 10.1152/ajpgi.1988.254.2.G176; GARDNER JD, 1984, AM J PHYSIOL, V246, pG292, DOI 10.1152/ajpgi.1984.246.3.G292; GARDNER JD, 1975, J CLIN INVEST, V56, P366, DOI 10.1172/JCI108101; GETHER U, 1994, J BIOL CHEM, V269, P23959; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; Gigoux V, 1998, J BIOL CHEM, V273, P14380, DOI 10.1074/jbc.273.23.14380; Gigoux V., 1998, Digestive Diseases and Sciences, V43, P1884; GULLY D, 1993, EUR J PHARMACOL, V232, P13, DOI 10.1016/0014-2999(93)90722-T; HOWARD JM, 1984, AM J PHYSIOL, V247, pG261, DOI 10.1152/ajpgi.1984.247.3.G261; HUANG RRC, 1994, BIOCHEMISTRY-US, V33, P3007, DOI 10.1021/bi00176a033; Inoue H, 1997, GENOMICS, V42, P331, DOI 10.1006/geno.1997.4749; JENSEN RT, 1982, J BIOL CHEM, V257, P5554; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; KENNEDY K, 1995, BIOCHEM BIOPH RES CO, V213, P845, DOI 10.1006/bbrc.1995.2206; Kennedy K, 1997, J BIOL CHEM, V272, P2920, DOI 10.1074/jbc.272.5.2920; KOPIN AS, 1995, J BIOL CHEM, V270, P5019, DOI 10.1074/jbc.270.10.5019; LIGNON MF, 1990, CELL SIGNAL, V2, P339, DOI 10.1016/0898-6568(90)90063-G; LIGNON MF, 1987, J BIOL CHEM, V262, P7226; MATOZAKI T, 1990, J BIOL CHEM, V265, P6247; NODA K, 1995, J BIOL CHEM, V270, P28511, DOI 10.1074/jbc.270.48.28511; ONDETTI MA, 1970, AM J DIG DIS, V15, P149, DOI 10.1007/BF02235646; PAN GZ, 1981, BIOCHIM BIOPHYS ACTA, V678, P352, DOI 10.1016/0304-4165(81)90114-8; POIROT SS, 1994, MOL PHARMACOL, V45, P599; REHFELD JF, 1994, ADV CANCER RES, V63, P295, DOI 10.1016/S0065-230X(08)60403-0; ROLLAND M, 1991, INT J PEPT PROT RES, V38, P181; Schwartz TW, 1996, TRENDS PHARMACOL SCI, V17, P213, DOI 10.1016/0165-6147(96)10017-1; Silvente-Poirot S, 1998, MOL PHARMACOL, V54, P364, DOI 10.1124/mol.54.2.364; SILVENTE-POIROT S, 1993, EUR J BIOCHEM, V212, P529, DOI 10.1111/j.1432-1033.1993.tb17690.x; SILVENTE-POIROT S, 1993, EUR J BIOCHEM, V215, P513, DOI 10.1111/j.1432-1033.1993.tb18061.x; Smeets RLL, 1997, EUR J PHARMACOL, V325, P93, DOI 10.1016/S0014-2999(97)00106-4; ULRICH CD, 1993, BIOCHEM BIOPH RES CO, V193, P204, DOI 10.1006/bbrc.1993.1610; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; Wank SA, 1998, AM J PHYSIOL-GASTR L, V274, pG607, DOI 10.1152/ajpgi.1998.274.4.G607; WILLIAMS JA, 1993, PHYSIOL REV, V73, P701, DOI 10.1152/physrev.1993.73.4.701	48	70	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20457	20464		10.1074/jbc.274.29.20457	http://dx.doi.org/10.1074/jbc.274.29.20457			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400673	hybrid			2022-12-25	WOS:000081438300066
J	Greller, G; Horlacher, R; DiRuggiero, J; Boos, W				Greller, G; Horlacher, R; DiRuggiero, J; Boos, W			Molecular and biochemical analysis of MalK, the ATP-hydrolyzing subunit of the trehalose maltose transport system of the hyperthermophilic archaeon Thermococcus litoralis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; ABC TRANSPORTER; BINDING; PROTEIN; GENE; SEQUENCES; IDENTIFICATION; LIPOPROTEIN; METABOLISM	We report the cloning, sequencing, and expression of malK encoding the ATP-hydrolyzing subunit of the maltose/trehalose transport system of the hyperthermophilic archaeon Thermococcus Litoralis. According to the deduced amino acid sequence, MalK consists of 372 amino acids with a calculated molecular weight of 41,787. It shows 47% identity with the MalK protein of Escherichia coli and high sequence conservation in important regions. C-terminal His-tagged MalK was purified. The soluble protein appeared monomeric by molecular sieve chromatography and showed ATPase activity. Enzymatic activity was highest at 80 degrees C with a K-m of 150 mu M and a V-max of 0.55 mu mol of ATP hydrolyzed/min/mg of protein. ADP was not a substrate but a;competitive inhibitor (K-i 230 mu M). GTP and CTP were also hydrolyzed, ATPase activity was inhibited by N-ethylmaleimide but not by vanadate. The strong homology found between the components of this archaeal transport system and the bacterial systems is evidence for the evolutionary conservation of the ABC transporters in these two phylogenetic branches.	Univ Konstanz, Dept Biol, D-78457 Constance, Germany; Univ Maryland, Ctr Marine Biotechnol, Baltimore, MD 21202 USA	University of Konstanz; University System of Maryland; University of Maryland Baltimore	Boos, W (corresponding author), Univ Konstanz, Dept Biol, D-78457 Constance, Germany.							Aravind L, 1998, TRENDS GENET, V14, P442, DOI 10.1016/S0168-9525(98)01553-4; BANEYX F, 1991, J BACTERIOL, V173, P2696, DOI 10.1128/jb.173.8.2696-2703.1991; Boos W, 1998, MICROBIOL MOL BIOL R, V62, P204, DOI 10.1128/MMBR.62.1.204-229.1998; BOOS W, 1996, ESCHERICHIA COLI SAL, V1, P1175; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN RGW, 1990, APPL OPTICS, V29, P4159, DOI 10.1364/AO.29.004159; CHAN KM, 1986, ANAL BIOCHEM, V157, P375, DOI 10.1016/0003-2697(86)90640-8; DAHL MK, 1989, MOL GEN GENET, V218, P199, DOI 10.1007/BF00331269; GILSON E, 1982, NUCLEIC ACIDS RES, V10, P7449, DOI 10.1093/nar/10.22.7449; Gupta RS, 1998, MICROBIOL MOL BIOL R, V62, P1435, DOI 10.1128/MMBR.62.4.1435-1491.1998; Harlow E., 1988, ANTIBODIES LAB MANUA; Herrmann A, 1996, RES MICROBIOL, V147, P733, DOI 10.1016/S0923-2508(97)85120-0; Hess D, 1996, GENE, V172, P121, DOI 10.1016/0378-1119(96)00176-X; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; Horlacher R, 1998, J BACTERIOL, V180, P680, DOI 10.1128/JB.180.3.680-689.1998; Kawarabayasi Y, 1998, DNA Res, V5, P55, DOI 10.1093/dnares/5.2.55; KUHNAU S, 1991, J BACTERIOL, V173, P2180; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liebl W, 1997, J BACTERIOL, V179, P941, DOI 10.1128/jb.179.3.941-948.1997; Linton KJ, 1998, MOL MICROBIOL, V28, P5, DOI 10.1046/j.1365-2958.1998.00764.x; MORBACH S, 1993, J BIOL CHEM, V268, P18617; OVERDUIN P, 1988, MOL MICROBIOL, V2, P767, DOI 10.1111/j.1365-2958.1988.tb00088.x; OWEN RJ, 1987, NUCLEIC ACIDS RES, V15, P3631, DOI 10.1093/nar/15.8.3631; Pajatsch M, 1998, J BACTERIOL, V180, P2630, DOI 10.1128/JB.180.10.2630-2635.1998; Panagiotidis CH, 1998, MOL MICROBIOL, V30, P535, DOI 10.1046/j.1365-2958.1998.01084.x; POLSON A, 1980, IMMUNOL COMMUN, V9, P475, DOI 10.3109/08820138009066010; REYES M, 1988, J BACTERIOL, V170, P4598, DOI 10.1128/jb.170.10.4598-4602.1988; RUSSELL RRB, 1992, J BIOL CHEM, V267, P4631; Sahm K, 1996, J BACTERIOL, V178, P1039, DOI 10.1128/jb.178.4.1039-1046.1996; Saito K, 1998, APPL MICROBIOL BIOT, V50, P193, DOI 10.1007/s002530051276; SCHNEIDER E, 1994, J BIOL CHEM, V269, P20456; Schneider E, 1998, FEMS MICROBIOL REV, V22, P1; SHUMAN HA, 1981, J BIOL CHEM, V256, P560; Thomm M, 1996, FEMS MICROBIOL REV, V18, P159; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vetriani C, 1998, P NATL ACAD SCI USA, V95, P12300, DOI 10.1073/pnas.95.21.12300; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Xavier KB, 1996, J BACTERIOL, V178, P4773, DOI 10.1128/jb.178.16.4773-4777.1996; Yoshida K, 1996, MICROBIOL-UK, V142, P3113, DOI 10.1099/13500872-142-11-3113	39	56	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20259	20264		10.1074/jbc.274.29.20259	http://dx.doi.org/10.1074/jbc.274.29.20259			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400644	hybrid			2022-12-25	WOS:000081438300037
J	Kobayashi, S; Millhorn, DE				Kobayashi, S; Millhorn, DE			Stimulation of expression for the adenosine A2A receptor gene by hypoxia in PC12 cells - A potential role in cell protection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CENTRAL-NERVOUS-SYSTEM; ENDOTHELIAL GROWTH-FACTOR; MESSENGER-RNA EXPRESSION; TYROSINE-HYDROXYLASE; RAT-BRAIN; CALMODULIN INHIBITORS; CYCLIC-AMP; ACTIVATION; MECHANISMS	The purpose of this study was to examine the regulation of adenosine A2A receptor (A2AR) gene expression during hypoxia in pheochromocytoma (PC12) cells. Northern blot analysis revealed that the A2AR mRNA level was substantially increased after a 3-h exposure to hypoxia (5% O-2), which reached a peak at 12 h. Immunoblot analysis showed that the A2AR protein level was also increased during hypoxia. Inhibition of de novo protein synthesis blocked A2AR induction by hypoxia. In addition, removal of extracellular free Ca2+, chelation of intracellular free Ca2+, and pretreatment with protein kinase C inhibitors prevented A2AR induction by hypoxia, Moreover, depletion of protein kinase C activity by prolonged treatment with phorbol la-myristate 13-acetate significantly inhibited the hypoxic induction of A2AR. A2AR antagonists led to a significant enhancement of A2AR mRNA levels during hypoxia, whereas A2AR agonists caused down-regulation of A2AR expression during hypoxia. This suggests that A2AR regulates its own expression during hypoxia by feedback mechanisms. We further found that activation of A2AR enhances cell viability during hypoxia and also inhibits vascular endothelial growth factor expression in PC12 cells. Thus, increased expression of A2AR during hypoxia might protect cells against hypoxia and may act to inhibit hypoxia-induced angiogenic activity mediated by vascular endothelial growth factor.	Univ Cincinnati, Dept Mol & Cellular Physiol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Millhorn, DE (corresponding author), Univ Cincinnati, Dept Mol & Cellular Physiol, 231 Bethesda Ave,POB 670576, Cincinnati, OH 45267 USA.	David.Millhorn@UC.Edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL033831, R01HL059945] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 59945, R37 HL 33831] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADEN U, 1994, MOL BRAIN RES, V23, P354, DOI 10.1016/0169-328X(94)90247-X; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Beitner-Johnson D, 1998, BIOCHEM BIOPH RES CO, V242, P61, DOI 10.1006/bbrc.1997.7907; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; Brundege J M, 1997, Adv Pharmacol, V39, P353, DOI 10.1016/S1054-3589(08)60076-9; BRUNS RF, 1990, ANN NY ACAD SCI, V603, P211; Chu YY, 1996, DNA CELL BIOL, V15, P329, DOI 10.1089/dna.1996.15.329; CONN G, 1990, P NATL ACAD SCI USA, V87, P2628, DOI 10.1073/pnas.87.7.2628; DAVIS PD, 1992, J MED CHEM, V35, P994, DOI 10.1021/jm00084a004; ERNY RE, 1981, J BIOL CHEM, V256, P1335; FANDREY J, 1995, RESP PHYSIOL, V101, P1, DOI 10.1016/0034-5687(95)00013-4; FARAGO A, 1990, FEBS LETT, V268, P350, DOI 10.1016/0014-5793(90)81284-U; FINK JS, 1992, MOL BRAIN RES, V14, P186, DOI 10.1016/0169-328X(92)90173-9; FISHER S, 1995, BRAIN RES MOL BRAIN, V28, P141; FREDHOLM BB, 1995, PHARMACOL TOXICOL, V76, P228, DOI 10.1111/j.1600-0773.1995.tb00135.x; GAO Y, 1994, LIFE SCI, V55, pPL61, DOI 10.1016/0024-3205(94)00889-2; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GINTY DD, 1991, J BIOL CHEM, V266, P15325; Ginty DD, 1997, NEURON, V18, P183, DOI 10.1016/S0896-6273(00)80258-5; Green S. H., 1995, Methods (Orlando), V7, P222, DOI 10.1006/meth.1995.1028; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HELFMAN T, 1993, AM J MED SCI, V306, P37, DOI 10.1097/00000441-199307000-00010; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HIGGINS MJ, 1994, PHARM WORLD SCI, V16, P62, DOI 10.1007/BF01880657; Hochachka PW, 1996, P NATL ACAD SCI USA, V93, P9493, DOI 10.1073/pnas.93.18.9493; HUANG FL, 1989, J BIOL CHEM, V264, P4238; JOHANSSON B, 1995, NEUROPHARMACOLOGY, V34, P393, DOI 10.1016/0028-3908(95)00009-U; Kacimi R, 1995, AM J PHYSIOL-HEART C, V269, pH1865, DOI 10.1152/ajpheart.1995.269.6.H1865; Kobayashi S, 1998, J PHYSIOL-LONDON, V508, P95, DOI 10.1111/j.1469-7793.1998.095br.x; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Li HT, 1996, CIRCULATION, V94, P3303, DOI 10.1161/01.CIR.94.12.3303; LI HT, 1995, CIRCULATION, V92, P918, DOI 10.1161/01.CIR.92.4.918; LUPICA CR, 1992, J NEUROSCI, V12, P3753; MACNICOL M, 1992, J BIOL CHEM, V267, P12197; Mishra RR, 1998, MOL BRAIN RES, V59, P74, DOI 10.1016/S0169-328X(98)00139-9; NAKAZAWA K, 1993, BRIT J PHARMACOL, V109, P137, DOI 10.1111/j.1476-5381.1993.tb13543.x; NISHIZUKA Y, 1989, JAMA-J AM MED ASSOC, V262, P1826, DOI 10.1001/jama.262.13.1826; NORRIS ML, 1995, J BIOL CHEM, V270, P23774, DOI 10.1074/jbc.270.40.23774; OHTANI K, 1995, J NEUROCHEM, V65, P605; OLAH ME, 1995, ANNU REV PHARMACOL, V35, P581, DOI 10.1146/annurev.pa.35.040195.003053; PASSEGUE E, 1995, MOL CELL ENDOCRINOL, V107, P29, DOI 10.1016/0303-7207(94)03417-R; Peterfreund RA, 1997, EUR J PHARMACOL, V336, P71, DOI 10.1016/S0014-2999(97)01194-1; Raymond R, 1997, KIDNEY INT, V51, P536, DOI 10.1038/ki.1997.74; ROSKOSKI R, 1987, J NEUROCHEM, V48, P236, DOI 10.1111/j.1471-4159.1987.tb13153.x; SAITOH O, 1994, NEUROREPORT, V5, P1317, DOI 10.1097/00001756-199406000-00005; SCANZIANI M, 1992, NEURON, V9, P919, DOI 10.1016/0896-6273(92)90244-8; SILVER PJ, 1986, BIOCHEM PHARMACOL, V35, P2545, DOI 10.1016/0006-2952(86)90052-3; SMELLIE FW, 1979, LIFE SCI, V24, P2475, DOI 10.1016/0024-3205(79)90458-2; Takagi H, 1996, INVEST OPHTH VIS SCI, V37, P2165; TAMM I, 1978, ADV VIRUS RES, V22, P188; Tymianski M, 1996, NEUROSURGERY, V38, P1176; VonLubitz DKJE, 1995, EUR J PHARMACOL, V287, P295, DOI 10.1016/0014-2999(95)00498-X; WANG GL, 1993, J BIOL CHEM, V268, P21513; WILLIAMS M, 1987, J NEUROCHEM, V48, P498, DOI 10.1111/j.1471-4159.1987.tb04120.x; WINN HR, 1981, AM J PHYSIOL, V241, pH235, DOI 10.1152/ajpheart.1981.241.2.H235; ZETTERSTROM T, 1982, NEUROSCI LETT, V29, P111, DOI 10.1016/0304-3940(82)90338-X; Zhu WH, 1997, AM J PHYSIOL-CELL PH, V273, pC1143, DOI 10.1152/ajpcell.1997.273.4.C1143; ZHU WH, 1996, AM J PHYSIOL, V271, pC657	60	91	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20358	20365		10.1074/jbc.274.29.20358	http://dx.doi.org/10.1074/jbc.274.29.20358			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400659	hybrid			2022-12-25	WOS:000081438300052
J	Bilanges, B; Varrault, A; Basyuk, E; Rodriguez, C; Mazumdar, A; Pantaloni, C; Bockaert, J; Theillet, C; Spengler, D; Journot, L				Bilanges, B; Varrault, A; Basyuk, E; Rodriguez, C; Mazumdar, A; Pantaloni, C; Bockaert, J; Theillet, C; Spengler, D; Journot, L			Loss of expression of the candidate tumor suppressor gene ZAC in breast cancer cell lines and primary tumors	ONCOGENE			English	Article						ZAC; breast tumors; tumor suppressor gene; methylation; 6q25	ZINC-FINGER PROTEIN; MAMMARY EPITHELIAL-CELLS; ESTROGEN-RECEPTOR GENE; DNA METHYLATION; CHROMOSOME 6Q; E-CADHERIN; FAMILIAL MELANOMA; GROWTH INHIBITOR; CPG METHYLATION; SOLID TUMORS	Loss of chromosome 6q21-qter is the second most frequent loss of chromosomal material in sporadic breast neoplasms suggesting the presence of at least one tumor suppressor gene on 6q, We recently isolated a cDNA encoding a new Zinc finger protein which we named ZAC according to its functional properties, namely induction of apoptosis and control of cell cycle progression. ZAC is expressed in normal mammary gland and maps to 6q24-q25, a recognized breast cancer hot spot on 6q, In the present report, we investigated the possible inactivation of ZAC in breast cancer cell lines and primary tumors, We detected no mutation in ZAC coding region in a panel of 45 breast tumors with allelic imbalance of 6q24-q25, However, a survey of eight breast cancer cell lines showed a deeply reduced (three cell lines) or complete loss of (five cell lines) ZAC expression. Treatment of three of these cell lines with the methylation-interfering agent 5-azacytidine induced ZAC re-expression, In addition, Northern blot and RNase protection assay analysis of ZAC expression in 23 unselected primary breast tumors showed a reduced expression in several samples. Together with its functional properties and chromosomal localization, these findings substantiate ZAC as a good candidate for the tumor suppressor gene on 6q24-q25.	CCIPE, CNRS, UPR 9023, F-34094 Montpellier 05, France; Ctr Rech CRLC Val Aurelle Paul Lamarque, CNRS, UMR 5535, Equipe Genome & Canc, F-34098 Montpellier 05, France; Max Planck Inst Psychiat, D-80804 Munich, Germany	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Max Planck Society	Journot, L (corresponding author), CCIPE, CNRS, UPR 9023, 141 Rue Cardonille, F-34094 Montpellier 05, France.		Journot, Laurent/T-9652-2018; Bilanges, Benoit/AAP-6078-2020; Theillet, Charles/O-7634-2018	Journot, Laurent/0000-0003-3499-8887; Theillet, Charles/0000-0001-5555-2759; Basyuk, Eugenia/0000-0001-9768-4557; Bilanges, Benoit/0000-0003-4400-3716				Abdollahi A, 1997, CANCER RES, V57, P2029; Abdollahi A, 1997, ONCOGENE, V14, P1973, DOI 10.1038/sj.onc.1201034; Astrom AK, 1999, CANCER RES, V59, P918; Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; Bose S, 1998, ONCOGENE, V17, P123, DOI 10.1038/sj.onc.1201940; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; Chappell SA, 1997, BRIT J CANCER, V75, P1324, DOI 10.1038/bjc.1997.224; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; DEVILEE P, 1991, ONCOGENE, V6, P1705; Dhingra K, 1996, SEMIN ONCOL, V23, P436; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Dobrovic A, 1997, CANCER RES, V57, P3347; Ellisen LW, 1998, ANNU REV MED, V49, P425; FERGUSON AT, 1995, CANCER RES, V55, P2279; FitzGerald MG, 1996, P NATL ACAD SCI USA, V93, P8541, DOI 10.1073/pnas.93.16.8541; Fujii H, 1996, GENE CHROMOSOME CANC, V16, P35, DOI 10.1002/(SICI)1098-2264(199605)16:1<35::AID-GCC5>3.0.CO;2-4; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GRAFF JR, 1995, CANCER RES, V55, P5195; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hankins GR, 1996, ONCOGENE, V12, P2003; HENDERSON BE, 1988, CANCER RES, V48, P246; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Huang RP, 1997, INT J CANCER, V72, P102, DOI 10.1002/(SICI)1097-0215(19970703)72:1<102::AID-IJC15>3.0.CO;2-L; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; Huynh H, 1996, CANCER RES, V56, P4865; HUYNH HT, 1995, CANCER RES, V55, P2225; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kas K, 1998, J BIOL CHEM, V273, P23026, DOI 10.1074/jbc.273.36.23026; Kas K, 1997, NAT GENET, V15, P170, DOI 10.1038/ng0297-170; KNUDSON AG, 1985, CANCER RES, V45, P1437; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; Malzahn K, 1998, VIRCHOWS ARCH, V433, P119, DOI 10.1007/s004280050226; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Mertens F, 1997, CANCER RES, V57, P2765; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Nagase T, 1996, DNA Res, V3, P17, DOI 10.1093/dnares/3.1.17; NEGRINI M, 1994, CANCER RES, V54, P1331; Nishizaki T, 1997, GENE CHROMOSOME CANC, V19, P267, DOI 10.1002/(SICI)1098-2264(199708)19:4<267::AID-GCC9>3.0.CO;2-V; Noviello C, 1996, CLIN CANCER RES, V2, P1601; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; ORPHANOS V, 1995, BRIT J CANCER, V71, P290, DOI 10.1038/bjc.1995.58; OTTAVIANO YL, 1994, CANCER RES, V54, P2552; Pagotto U, 1999, ENDOCRINOLOGY, V140, P987, DOI 10.1210/en.140.2.987; PETRANGELI E, 1995, BRIT J CANCER, V72, P973, DOI 10.1038/bjc.1995.444; Rejthar A, 1997, NEOPLASMA, V44, P370; Rhei E, 1997, CANCER RES, V57, P3657; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Sheng ZM, 1996, BRIT J CANCER, V73, P144, DOI 10.1038/bjc.1996.27; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; Spengler D, 1997, EMBO J, V16, P2814, DOI 10.1093/emboj/16.10.2814; Stirzaker C, 1997, CANCER RES, V57, P2229; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TAYLORPAPADIMITRIOU J, 1989, J CELL SCI, V94, P403; Teng DHF, 1997, CANCER RES, V57, P5221; Theile M, 1996, ONCOGENE, V13, P677; Varrault A, 1998, P NATL ACAD SCI USA, V95, P8835, DOI 10.1073/pnas.95.15.8835; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Voz ML, 1998, ONCOGENE, V16, P1409, DOI 10.1038/sj.onc.1201660; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	69	86	89	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	1999	18	27					3979	3988		10.1038/sj.onc.1202933	http://dx.doi.org/10.1038/sj.onc.1202933			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KU	10435621				2022-12-25	WOS:000081327800008
J	Prunier, C; Mazars, A; Noe, V; Bruyneel, E; Mareel, M; Gespach, C; Atfi, A				Prunier, C; Mazars, A; Noe, V; Bruyneel, E; Mareel, M; Gespach, C; Atfi, A			Evidence that Smad2 is a tumor suppressor implicated in the control of cellular invasion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAD-RELATED PROTEIN; GROWTH-FACTOR-BETA; SIGNALING PATHWAY; ACTIVATION; RECEPTORS; KINASE; PHOSPHORYLATION; CARCINOMA; SER(465); MUTANT	The Smad2 protein plays an essential role in the transforming growth factor-beta (TGF-beta) signaling pathway. This pathway mediates growth inhibitory signals from the cell surface to the nucleus. Although Smad2 protein is significantly mutated in human cancers, there is no definitive evidence implicating Smad2 as a tumor-suppressor gene. Here we show that overexpression of the tumor-derived missense mutation Smad2.D450E, an unphosphorylable form of Smad2 found in colorectal and lung cancers, did not abolish the TGF-beta-mediated growth arrest, suggesting that resistance to the growth-inhibiting effects of TGF-beta exhibited by human tumors cannot be linked to the inactivation of Smad2 protein. In contrast, overexpression of Smad2.D450E induces cellular invasion, and this effect was enhanced by TGF-beta. A similar invasive phenotype was obtained in cells expressing another inactivating mutation in Smad2 (Smad2.P445H) found in colorectal cancer. These findings indicate that genetic defects in Smad2 are sufficient to confer the invasion-promoting effect of TGF-beta and reveal that TGF-beta acts through Smad2 to induce cellular invasion by a novel mechanism that is independent of Smad2 phosphorylation by the activated TGF-beta type I receptor.	Hop St Antoine, INSERM, U482, F-75571 Paris 12, France; State Univ Ghent Hosp, Expt Cancerol Lab, B-9000 Ghent, Belgium	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Ghent University; Ghent University Hospital	Atfi, A (corresponding author), Hop St Antoine, INSERM, U482, 184 Rue Faubourg St Antoine, F-75571 Paris 12, France.		Frottier, Celine Prunier/G-8259-2017	Frottier, Celine Prunier/0000-0002-7784-0273				Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; Atfi A, 1995, P NATL ACAD SCI USA, V92, P12110, DOI 10.1073/pnas.92.26.12110; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Goto D, 1998, FEBS LETT, V430, P201, DOI 10.1016/S0014-5793(98)00658-9; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Lo RS, 1998, EMBO J, V17, P996, DOI 10.1093/emboj/17.4.996; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; Uchida K, 1996, CANCER RES, V56, P5583; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Waldrip WR, 1998, CELL, V92, P797, DOI 10.1016/S0092-8674(00)81407-5; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	25	46	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					22919	22922		10.1074/jbc.274.33.22919	http://dx.doi.org/10.1074/jbc.274.33.22919			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438456	hybrid			2022-12-25	WOS:000082012800006
J	Hegde, P; Gu, GG; Chen, D; Free, SJ; Singh, S				Hegde, P; Gu, GG; Chen, D; Free, SJ; Singh, S			Mutational analysis of the Shab-encoded delayed rectifier K+ channels in Drosophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED POTASSIUM CHANNELS; LARVAL MUSCLE-FIBERS; CHARGED RESIDUES; CALCIUM CHANNELS; GENE; SHAKER; FAMILY; PORE; MELANOGASTER; CURRENTS	K+ currents in Drosophila muscles have been resolved into two voltage-activated currents (I-A and I-K) and two Ca2+-activated currents (I-CF and I-CS). Mutations that affect I-A (Shaker) and I-CF (slowpoke) have helped greatly in the analysis of these currents and their role in membrane excitability, Lack of mutations that specifically affect channels for the delayed rectifier current (I-K) has made their genetic and functional identity difficult to elucidate. With the help of mutations in the Shab K+ channel gene, we show that this gene encodes the delayed rectifier K+ channels in Drosophila, Three mutant alleles with a temperature-sensitive paralytic phenotype were analyzed. Analysis of the ionic currents from mutant larval body wall muscles showed a specific effect on delayed rectifier K+ current (I-K). Two of the mutant alleles contain missense mutations, one in the aminoterminal region of the channel protein and the other in the pore region of the channel. The third allele contains two deletions in the amino-terminal region and is a null allele. These observations identity the channels that carry the delayed rectifier current and provide an in vivo physiological role for the Shab-encoded K+ channels in Drosophila. The availability of mutations that affect I-K opens up possibilities for studying I-K and its role in larval muscle excitability.	SUNY Buffalo, Dept Biochem Pharmacol, Buffalo, NY 14260 USA; SUNY Buffalo, Dept Biol Sci, Buffalo, NY 14260 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Singh, S (corresponding author), SUNY Buffalo, Dept Biochem Pharmacol, 308 Hochstetter Hall, Buffalo, NY 14260 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050779] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-50779] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADELMAN JP, 1992, NEURON, V9, P209, DOI 10.1016/0896-6273(92)90160-F; Armstrong CM, 1998, NEURON, V20, P371, DOI 10.1016/S0896-6273(00)80981-2; Ashburner M., 1989, DROSOPHILA LAB HDB; ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; BABILA T, 1994, NEURON, V12, P615, DOI 10.1016/0896-6273(94)90217-8; BATE M, 1990, DEVELOPMENT, V110, P791; BELTZER JP, 1991, J BIOL CHEM, V266, P973; BRITTNACHER JG, 1983, GENETICS, V103, P659; Bulman DE, 1997, HUM MOL GENET, V6, P1679, DOI 10.1093/hmg/6.10.1679; BUTLER A, 1989, SCIENCE, V243, P943, DOI 10.1126/science.2493160; Charlier C, 1998, NAT GENET, V18, P53, DOI 10.1038/ng0198-53; CHOPRA M, 1994, J NEUROBIOL, V25, P119, DOI 10.1002/neu.480250204; CHOPRA M, 1994, THESIS GND U AMRISTS; CHOVNICK A, 1970, GENETICS, V66, P315; COVARRUBIAS M, 1991, NEURON, V7, P763, DOI 10.1016/0896-6273(91)90279-9; Crossley AC, 1978, GENETICS BIOL DROS B, V2, P499; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Gafvelin G, 1997, J BIOL CHEM, V272, P6119, DOI 10.1074/jbc.272.10.6119; GHO M, 1986, PFLUG ARCH EUR J PHY, V407, P526, DOI 10.1007/BF00657511; GIELOW ML, 1995, J NEUROSCI, V15, P6085; Gross A, 1996, NEURON, V16, P399, DOI 10.1016/S0896-6273(00)80057-4; Gu GG, 1997, J NEUROBIOL, V33, P265, DOI 10.1002/(SICI)1097-4695(199709)33:3<265::AID-NEU5>3.0.CO;2-#; Hille B., 1992, IONIC CHANNELS EXCIT; HOLM DG, 1976, GENETICS BIOL DROS B, V1, P529; Jan LY, 1997, ANNU REV NEUROSCI, V20, P91, DOI 10.1146/annurev.neuro.20.1.91; KAMB A, 1987, CELL, V50, P405, DOI 10.1016/0092-8674(87)90494-6; Kraliz D, 1997, J NEUROBIOL, V32, P1; Kraliz D, 1998, J NEUROGENET, V12, P25, DOI 10.3109/01677069809108553; Kubo Y, 1996, RECEPTOR CHANNEL, V4, P73; MACKINNON R, 1990, NEURON, V5, P767, DOI 10.1016/0896-6273(90)90335-D; MACKINNON R, 1998, SCIENCE, V17, P1200; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; PARKS GD, 1993, J BIOL CHEM, V268, P19101; PONGS O, 1988, EMBO J, V7, P1087, DOI 10.1002/j.1460-2075.1988.tb02917.x; SALKOFF L, 1992, TRENDS NEUROSCI, V15, P161, DOI 10.1016/0166-2236(92)90165-5; Singh NA, 1998, NAT GENET, V18, P25, DOI 10.1038/ng0198-25; SINGH S, 1989, NEURON, V2, P1325, DOI 10.1016/0896-6273(89)90070-6; SINGH S, 1987, MOL GEN GENET, V208, P226, DOI 10.1007/BF00330446; STEWART BA, 1994, J COMP PHYSIOL A, V175, P179, DOI 10.1007/BF00215114; TSUNODA S, 1995, J NEUROSCI, V15, P5209; Tu LW, 1996, J BIOL CHEM, V271, P18904, DOI 10.1074/jbc.271.31.18904; Tyson J, 1997, HUM MOL GENET, V6, P2179, DOI 10.1093/hmg/6.12.2179; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; WARMKE J, 1991, SCIENCE, V252, P1560, DOI 10.1126/science.1840699; WEI A, 1990, SCIENCE, V248, P599, DOI 10.1126/science.2333511; WILLIAMSON R, 1977, DROSOPHILA INFORMATI, V51, P150; Wu C F, 1992, Ion Channels, V3, P261; WU CF, 1985, J NEUROSCI, V5, P2626; XU J, 1995, J BIOL CHEM, V270, P24761, DOI 10.1074/jbc.270.42.24761; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0	50	20	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					22109	22113		10.1074/jbc.274.31.22109	http://dx.doi.org/10.1074/jbc.274.31.22109			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419540	hybrid			2022-12-25	WOS:000081721100093
J	Nishiyama, A; Matsui, M; Iwata, S; Hirota, K; Masutani, H; Nakamura, H; Takagi, Y; Sono, H; Gon, Y; Yodoi, J				Nishiyama, A; Matsui, M; Iwata, S; Hirota, K; Masutani, H; Nakamura, H; Takagi, Y; Sono, H; Gon, Y; Yodoi, J			Identification of thioredoxin-binding protein-2/vitamin D-3 up-regulated protein 1 as a negative regulator of thioredoxin function and expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-DERIVED FACTOR; REDOX REGULATION; GENE-EXPRESSION; VITAMIN-D; ESCHERICHIA-COLI; HORMONE ACTION; CELL-GROWTH; RECEPTOR; DNA; REDUCTION	Recent works have shown the importance of reduction/oxidation (redox) regulation in various biological phenomena. Thioredoxin (TRX) is one of the major components of the thiol reducing system and plays multiple roles in cellular processes such as proliferation, apoptosis, and gene expression. To investigate the molecular mechanism of TRX action, we used a yeast two-hybrid system to identify TRX-binding proteins. One of the candidates, designated as thioredoxin-binding protein-2 (TBP-2), was identical to vitamin D-3 up-regulated protein 1 (VDUP1). The association of TRX with TBP-2/ VDUP1 was observed in vitro and in vivo, TBP-2/VDUP1 bound to reduced TRX but not to oxidized TRX nor to mutant TRX, in which two redox active cysteine residues are substituted by serine, Thus, the catalytic center of TRX seems to be important for the interaction. Insulin reducing activity of TRX was inhibited by the addition of recombinant TBP-2/VDUP1 protein in vitro. In COS-7 and HEK293 cells transiently transfected with TBP-2/VDUP1 expression vector, decrease of insulin reducing activity of TRX and diminishment of TRX expression was observed. These results suggested that TBP-2/VDUP1 serves as a negative regulator of the biological function and expression of TRX, Treatment of HL-60 cells with la,25-dihydroxyvitamin D-3 caused an increase of TBP-2/VDUP1 expression and down-regulation of the expression and the reducing activity of TRX. Therefore, the TRX-TBP-2/VDUP1 interaction may be an important redox regulatory mechanism in cellular processes, including differentiation of myeloid and macrophage lineages.	Kyoto Univ, Inst Virus Res, Dept Biol Responses, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Yodoi, J (corresponding author), Kyoto Univ, Inst Virus Res, Dept Biol Responses, Sakyo Ku, 53 Shogoin Kawahara Cho, Kyoto 6068507, Japan.		Iwata, Satoshi/A-8819-2011; Masutani, Hiroshi/B-5114-2014; Hirota, Kiichi/E-9181-2010	Hirota, Kiichi/0000-0003-1110-0827; Masutani, Hiroshi/0000-0001-7633-2827				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; CHEN KS, 1994, BBA-GENE STRUCT EXPR, V1219, P26, DOI 10.1016/0167-4781(94)90242-9; Darwish Hisham, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P89; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; DOKOH S, 1984, CANCER RES, V44, P2103; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; FRAMPTON RJ, 1983, CANCER RES, V43, P4443; FUJII S, 1991, CANCER, V68, P1583, DOI 10.1002/1097-0142(19911001)68:7<1583::AID-CNCR2820680720>3.0.CO;2-N; Gallegos A, 1996, CANCER RES, V56, P5765; GASDASKA JR, 1995, CELL GROWTH DIFFER, V6, P1643; Harlow E., 1988, ANTIBODIES LAB MANUA; Hayashi S, 1997, NUCLEIC ACIDS RES, V25, P4035, DOI 10.1093/nar/25.20.4035; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1995, STRUCTURE, V3, P239, DOI 10.1016/S0969-2126(01)00153-8; HOLMGREN A, 1979, J BIOL CHEM, V254, P9113; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Kagoshima H, 1996, J BIOL CHEM, V271, P33074, DOI 10.1074/jbc.271.51.33074; KALLIS GB, 1980, J BIOL CHEM, V255, P261; Kogaki H, 1996, J CLIN LAB ANAL, V10, P257, DOI 10.1002/(SICI)1098-2825(1996)10:5<257::AID-JCLA5>3.3.CO;2-#; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; LAURENT TC, 1964, J BIOL CHEM, V239, P3436; Makino Y, 1996, J CLIN INVEST, V98, P2469, DOI 10.1172/JCI119065; MANGELSDORF DJ, 1984, J CELL BIOL, V98, P391, DOI 10.1083/jcb.98.2.391; MARK DF, 1976, P NATL ACAD SCI USA, V73, P780, DOI 10.1073/pnas.73.3.780; Maruyama T, 1997, MOL HUM REPROD, V3, P989, DOI 10.1093/molehr/3.11.989; Matsui M, 1996, DEV BIOL, V178, P179, DOI 10.1006/dbio.1996.0208; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; MCCLELLAND M, 1994, NUCLEIC ACIDS RES, V22, P4419, DOI 10.1093/nar/22.21.4419; MITSUI A, 1992, BIOCHEM BIOPH RES CO, V186, P1220, DOI 10.1016/S0006-291X(05)81536-0; MIYAURA C, 1981, BIOCHEM BIOPH RES CO, V102, P937, DOI 10.1016/0006-291X(81)91628-4; MULLER EGD, 1991, J BIOL CHEM, V266, P9194; NAKAMURA H, 1992, CANCER-AM CANCER SOC, V69, P2091, DOI 10.1002/1097-0142(19920415)69:8<2091::AID-CNCR2820690814>3.0.CO;2-X; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; Nishiyama A, 1999, IMMUNOL LETT, V68, P155, DOI 10.1016/S0165-2478(99)00045-0; PAHL HL, 1994, BIOESSAYS, V16, P497, DOI 10.1002/bies.950160709; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; SALZ HK, 1994, GENETICS, V136, P1075; Sambrook J., 2002, MOL CLONING LAB MANU; Sasada T, 1996, J CLIN INVEST, V97, P2268, DOI 10.1172/JCI118668; SATO N, 1995, J IMMUNOL, V154, P3194; SUDA T, 1990, ANNU REV NUTR, V10, P195, DOI 10.1146/annurev.nu.10.070190.001211; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; Ueda S, 1998, J IMMUNOL, V161, P6689; WAKASUGI N, 1990, P NATL ACAD SCI USA, V87, P8282, DOI 10.1073/pnas.87.21.8282; Weichsel A, 1996, STRUCTURE, V4, P735, DOI 10.1016/S0969-2126(96)00079-2; WOLLMAN EE, 1988, J BIOL CHEM, V263, P15506; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; Yang XQ, 1998, BREAST CANCER RES TR, V48, P33, DOI 10.1023/A:1005929714900; YODOI J, 1992, IMMUNOL TODAY, V13, P405, DOI 10.1016/0167-5699(92)90091-K; Young LH, 1996, MOL CARCINOGEN, V15, P251, DOI 10.1002/(SICI)1098-2744(199604)15:4<251::AID-MC2>3.0.CO;2-J	54	567	608	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21645	21650		10.1074/jbc.274.31.21645	http://dx.doi.org/10.1074/jbc.274.31.21645			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419473	hybrid			2022-12-25	WOS:000081721100026
J	Makinen, T; Olofsson, B; Karpanen, T; Hellman, U; Soker, S; Klagsbrun, M; Eriksson, U; Alitalo, K				Makinen, T; Olofsson, B; Karpanen, T; Hellman, U; Soker, S; Klagsbrun, M; Eriksson, U; Alitalo, K			Differential binding of vascular endothelial growth factor B splice and proteolytic isoforms to neuropilin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVOUS-SYSTEM; SEMAPHORIN-III; VEGF-B; RECEPTOR; PLACENTA; PROTEIN; CELLS; ANGIOGENESIS; SPECIFICITY; EXPRESSION	Vascular endothelial growth factor B (VEGF-B) is expressed in various tissues, especially strongly in the heart, and binds selectively to one of the VEGF receptors, VEGFR-1. The two splice isoforms, VEGF-B(167) and VEGF-B(186), have identical NH(2)-terminal cystine knot growth factor domains but differ in their COOH-terminal domains which give these forms their distinct biochemical properties. In this study, we show that both splice isoforms of VEGF-B bind specifically to Neuropilin-1 (NRP1), a receptor for collapsins/semaphorins and for the VEGFB(165) isoform. The NRP1 binding of VEGF-B could be competed by an excess of VEGF(165). The binding of VEGF-B(167) was mediated by the heparin binding domain, whereas the binding of VEGF-B(186) to NRP1 was regulated by exposure of a short COOH-terminal proline-rich peptide upon its proteolytic processing. In immunohistochemistry, NRP1 distribution was found to be overlapping or adjacent to known sites of VEGF-B expression in several tissues, in particular in the developing heart, suggesting the involvement of VEGF-B in NRP1-mediated signaling.	Univ Helsinki, Haartman Ins, Mol Canc Biol Lab, FIN-00014 Helsinki, Finland; Ludwig Inst Canc Res, Stockholm Branch, SE-17177 Stockholm, Sweden; Ludwig Inst Canc Res, Uppsala Branch, SE-75124 Uppsala, Sweden; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	University of Helsinki; Ludwig Institute for Cancer Research; Ludwig Institute for Cancer Research; Harvard University; Harvard Medical School	Alitalo, K (corresponding author), Univ Helsinki, Haartman Ins, Mol Canc Biol Lab, POB 21,Haartmaninkatu 3, FIN-00014 Helsinki, Finland.	Kari.Alitalo@Helsinki.FI	Alitalo, Kari K/J-5013-2014; Makinen, Taija/C-5765-2014; Makinen, Taija/CAI-2233-2022	Alitalo, Kari K/0000-0002-7331-0902; Makinen, Taija/0000-0002-9338-1257; Makinen, Taija/0000-0002-9338-1257; Karpanen, Terhi/0000-0002-2803-083X				Aase K, 1999, DEV DYNAM, V215, P12, DOI 10.1002/(SICI)1097-0177(199905)215:1<12::AID-DVDY3>3.0.CO;2-N; Chen H, 1998, NEURON, V21, P1283, DOI 10.1016/S0896-6273(00)80648-0; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; Feiner L, 1997, NEURON, V19, P539, DOI 10.1016/S0896-6273(00)80370-0; Ferrara N, 1998, NAT MED, V4, P336, DOI 10.1038/nm0398-336; Fujisawa H, 1997, CELL TISSUE RES, V290, P465, DOI 10.1007/s004410050954; Giger RJ, 1998, NEURON, V21, P1079, DOI 10.1016/S0896-6273(00)80625-X; HAUSER S, 1993, GROWTH FACTORS, V9, P259, DOI 10.3109/08977199308991586; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; HELDIN CH, 1993, GROWTH FACTORS, V8, P245, DOI 10.3109/08977199308991570; Hellman U, 1997, SPRING LAB MAN, P97; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Kawakami A, 1996, J NEUROBIOL, V29, P1, DOI 10.1002/(SICI)1097-4695(199601)29:1<1::AID-NEU1>3.0.CO;2-F; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; Kitsukawa T, 1995, DEVELOPMENT, V121, P4309; Klagsbrun Michael, 1996, Cytokine and Growth Factor Reviews, V7, P259, DOI 10.1016/S1359-6101(96)00027-5; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; Korpelainen EI, 1998, CURR OPIN CELL BIOL, V10, P159, DOI 10.1016/S0955-0674(98)80137-3; MAGLIONE D, 1993, ONCOGENE, V8, P925; Migdal M, 1998, J BIOL CHEM, V273, P22272, DOI 10.1074/jbc.273.35.22272; Nakamura F, 1998, NEURON, V21, P1093, DOI 10.1016/S0896-6273(00)80626-1; Olofsson B, 1996, J BIOL CHEM, V271, P19310, DOI 10.1074/jbc.271.32.19310; Olofsson B, 1998, P NATL ACAD SCI USA, V95, P11709, DOI 10.1073/pnas.95.20.11709; Persico MG, 1999, CURR TOP MICROBIOL, V237, P31; Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; TAKAGI S, 1995, DEV BIOL, V170, P207, DOI 10.1006/dbio.1995.1208; TISCHER E, 1991, J BIOL CHEM, V266, P11947	30	214	234	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21217	21222		10.1074/jbc.274.30.21217	http://dx.doi.org/10.1074/jbc.274.30.21217			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409677	hybrid			2022-12-25	WOS:000081613100068
J	Dhamija, S; Liu, Y; Yamada, Y; Snead, ML; Krebsbach, PH				Dhamija, S; Liu, Y; Yamada, Y; Snead, ML; Krebsbach, PH			Cloning and characterization of the murine ameloblastin promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENTIN PHOSPHOPROTEIN; PROTEIN INTERACTIONS; TOOTH DEVELOPMENT; CULTURED-CELLS; RAT INCISORS; EXPRESSION; GENES; DIFFERENTIATION; AMELOGENIN; MATRIX	The molecular mechanisms directing the highly restricted expression pattern of murine ameloblastin were characterized by cloning and functional analysis of the ameloblastin promoter. The transcription start site, mapped by primer extension, was located 19 base pairs (bp) 5' of the published cDNA. The promoter was analyzed in a mouse ameloblast-like cell line (LS8) and was compared with promoter activity in primary gingival fibroblasts and pulp fibroblasts. Sequential 5'-deletion mutants encompassing DNA sequences from -1616 to -781 bp exhibited high promoter activity in LS8 cells, whereas the promoter activity decreased to 50% of the full-length construct in the -781- and -477-bp regions. The -217-bp promoter region regained promoter activity that approached the activity of the full-length promoter construct, suggesting that both positive and negative cis-acting regions may be involved in ameloblastin transcriptional regulation. Activity of the ameloblastin promoter in gingival and pulp fibroblasts was minimal and ranged from 8 to 30% of the activity in ameloblast-like cells. Several DNA-protein complexes were formed between functionally important promoter fragments and nuclear extracts from LS8 cells. The inactivity of promoter constructs in pulp and gingival fibroblasts as well as the absence of similar DNA-protein complexes from these cells suggest that regulatory regions of the murine ameloblastin promoter may function in a cell-specific manner.	Univ Michigan, Sch Dent, Dept Oral Med Pathol & Oncol, Ann Arbor, MI 48109 USA; NIDCR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA; Univ So Calif, Sch Dent, Ctr Craniofacial Mol Biol, Los Angeles, CA 90033 USA	University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of Southern California	Krebsbach, PH (corresponding author), Univ Michigan, Sch Dent, Dept Oral Med Pathol & Oncol, Rm 4207, Ann Arbor, MI 48109 USA.		Krebsbach, Paul H./AAC-4765-2021		NIDCR NIH HHS [K02 DE00426, R29 DE12502] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [K02DE000426, R29DE012502] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aberg T, 1997, DEV DYNAM, V210, P383, DOI 10.1002/(SICI)1097-0177(199712)210:4<383::AID-AJA3>3.0.CO;2-C; Begue-Kirn C, 1998, EUR J ORAL SCI, V106, P963, DOI 10.1046/j.0909-8836.1998.eos106510.x; Chen E, 1998, GENE, V216, P131, DOI 10.1016/S0378-1119(98)00300-X; CHEN LS, 1992, ARCH ORAL BIOL, V37, P771, DOI 10.1016/0003-9969(92)90110-T; DENTE L, 1988, GENE DEV, V2, P259, DOI 10.1101/gad.2.2.259; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Feng JQ, 1998, J BIOL CHEM, V273, P9457, DOI 10.1074/jbc.273.16.9457; Fong CD, 1998, EUR J ORAL SCI, V106, P324, DOI 10.1111/j.1600-0722.1998.tb02193.x; Kettunen P, 1998, DEV DYNAM, V211, P256, DOI 10.1002/(SICI)1097-0177(199803)211:3<256::AID-AJA7>3.0.CO;2-G; KREBSBACH PH, 1993, MOL CELL BIOL, V13, P5168, DOI 10.1128/MCB.13.9.5168; Krebsbach PH, 1996, J BIOL CHEM, V271, P4431; Lee SK, 1996, INT J DEV BIOL, V40, P1141; Maas R, 1997, CRIT REV ORAL BIOL M, V8, P4, DOI 10.1177/10454411970080010101; MacDougall M, 1997, GENOMICS, V41, P115, DOI 10.1006/geno.1997.4643; Nanci A, 1998, J HISTOCHEM CYTOCHEM, V46, P911, DOI 10.1177/002215549804600806; Paine ML, 1998, J DENT RES, V77, P496, DOI 10.1177/00220345980770030901; Paine ML, 1997, J BONE MINER RES, V12, P221, DOI 10.1359/jbmr.1997.12.2.221; Sambrook J., 2002, MOL CLONING LAB MANU; SATOKATA I, 1994, NAT GENET, V6, P348, DOI 10.1038/ng0494-348; SAUER F, 1991, NATURE, V353, P563, DOI 10.1038/353563a0; SHEA MJ, 1990, GENE DEV, V4, P1128, DOI 10.1101/gad.4.7.1128; SIMMER JP, 1995, CRIT REV ORAL BIOL M, V6, P84, DOI 10.1177/10454411950060020701; Snead ML, 1996, CONNECT TISSUE RES, V35, P41, DOI 10.3109/03008209609029173; Thomas BL, 1997, DEVELOPMENT, V124, P4811; Uchida T, 1997, J HISTOCHEM CYTOCHEM, V45, P1329, DOI 10.1177/002215549704501002	26	28	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20738	20743		10.1074/jbc.274.29.20738	http://dx.doi.org/10.1074/jbc.274.29.20738			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400709	hybrid			2022-12-25	WOS:000081438300102
J	Tabor, DE; Kim, JB; Spiegelman, BN; Edwards, PA				Tabor, DE; Kim, JB; Spiegelman, BN; Edwards, PA			Identification of conserved cis-elements and transcription factors required for sterol-regulated transcription of stearoyl-CoA desaturase 1 and 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FARNESYL DIPHOSPHATE SYNTHASE; POLYUNSATURATED FATTY-ACIDS; LIPOPROTEIN RECEPTOR GENE; BINDING PROTEIN; DIFFERENTIATION FACTOR-1; 3T3-L1 PREADIPOCYTES; NF-Y; EXPRESSION; PROMOTER; LIVER	We previously identified stearoyl-CoA desaturase 2 (SCD2) as a new member of the family of genes that are transcriptionally regulated in response to changing levels of nuclear sterol regulatory element binding proteins (SREBPs) or adipocyte determination and differentiation factor 1 (ADD1). A novel sterol regulatory element (SRE) (5'-AGCAGATTGTG-3') identified in the proximal promoter of the mouse SCD2 gene is required for induction of SCD2 promoter-reporter genes in response to cellular sterol depletion (Tabor, D. E,, Kim, J. B., Spiegelman, B. M., and Edwards, P. A. (1998) J, Biol, Chem. 273, 22052-22058). In this report, we demonstrate that this novel SRE is both present in the promoter of the SCD1 gene and is critical for the sterol-dependent transcription of SCD1 promoter-reporter genes. Two conserved cis elements (5'-CCAAT-3') lie 5 and 48 base pairs 3' of the novel SREs in the promoters of both the SCD1 and SCDB murine genes. Mutation of either of these putative NF-Y binding sites attenuates the transcriptional activation of SCD1 or SCD2 promoter-reporter genes in response to cellular sterol deprivation, Induction of both reporter genes is also attenuated when cells are cotransfected with dominant-negative forms of either NF-Y or SREBP. In addition, we demonstrate that the induction of SCD1 and SCD2 mRNAs that occurs during the differentiation of 3T3-L1 preadipocytes to adipocytes is paralleled by an increase in the levels of ADD1/SREBP-1c and that the SCD1 and SCD2 mRNAs are induced to even higher levels in response to ectopic expression of ADD 1/SREBP-1c. We conclude that transcription of both SCD1 and SCD2 genes is responsive to cellular sterol levels and to the levels of nuclear SREBP/ADD1 and that transcriptional induction requires three spatially conserved cis elements, that bind SREBP and NF-Y. Additional studies demonstrate that maximal transcriptional repression of SCD2 reporter genes in response to an exogenous polyunsaturated fatty acid is dependent upon the SRE and the adjacent CCAAT motif.	Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	Edwards, PA (corresponding author), Univ Calif Los Angeles, Dept Biol Chem, CHS 33-257, Los Angeles, CA 90095 USA.			KIM, Jae Bum/0000-0003-2337-6935	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 30568] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Casimir DA, 1996, J BIOL CHEM, V271, P29847, DOI 10.1074/jbc.271.47.29847; CLARKE SD, 1990, J NUTR, V120, P225, DOI 10.1093/jn/120.2.225; CLARKE SD, 1993, PROG LIPID RES, V32, P139, DOI 10.1016/0163-7827(93)90013-M; Dooley KA, 1998, J BIOL CHEM, V273, P1349, DOI 10.1074/jbc.273.3.1349; EDWARDS PA, 1999, IN PRESS ANN REV BIO; Ericsson J, 1998, J BIOL CHEM, V273, P17865, DOI 10.1074/jbc.273.28.17865; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; Ericsson J, 1997, J BIOL CHEM, V272, P7298, DOI 10.1074/jbc.272.11.7298; Ericsson J, 1996, J BIOL CHEM, V271, P24359, DOI 10.1074/jbc.271.40.24359; Guan GM, 1997, J BIOL CHEM, V272, P10295; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; JACKSON SM, 1995, J BIOL CHEM, V270, P21445, DOI 10.1074/jbc.270.37.21445; Jackson SM, 1996, J LIPID RES, V37, P1712; KAESTNER KH, 1989, J BIOL CHEM, V264, P14755; KASTURI I, 1982, J BIOL CHEM, V257, P12224; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Kim JB, 1998, P NATL ACAD SCI USA, V95, P4333, DOI 10.1073/pnas.95.8.4333; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; Korn BS, 1998, J CLIN INVEST, V102, P2050, DOI 10.1172/JCI5341; Magana MM, 1997, J LIPID RES, V38, P1630; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; Miller CW, 1996, P NATL ACAD SCI USA, V93, P9443, DOI 10.1073/pnas.93.18.9443; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NTAMBI JM, 1988, J BIOL CHEM, V263, P17291; NTAMBI JM, 1995, PROG LIPID RES, V34, P139, DOI 10.1016/0163-7827(94)00010-J; Oliner JD, 1996, GENE DEV, V10, P2903, DOI 10.1101/gad.10.22.2903; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Sakai J, 1998, J BIOL CHEM, V273, P5785, DOI 10.1074/jbc.273.10.5785; Sambrook J., 2002, MOL CLONING LAB MANU; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; Sato R, 1996, J BIOL CHEM, V271, P26461, DOI 10.1074/jbc.271.43.26461; Sessler AM, 1996, J BIOL CHEM, V271, P29854, DOI 10.1074/jbc.271.47.29854; Shimomura I, 1998, J BIOL CHEM, V273, P35299, DOI 10.1074/jbc.273.52.35299; SMITH JR, 1990, J BIOL CHEM, V265, P2306; SPEAR DH, 1992, J BIOL CHEM, V267, P14462; Tabor DE, 1998, J BIOL CHEM, V273, P22052, DOI 10.1074/jbc.273.34.22052; Tabor DE, 1998, MAMM GENOME, V9, P341, DOI 10.1007/s003359900765; Thewke DP, 1998, J BIOL CHEM, V273, P21402, DOI 10.1074/jbc.273.33.21402; Waters KM, 1997, BBA-LIPID LIPID MET, V1349, P33, DOI 10.1016/S0005-2760(97)00069-6; WATERS KM, 1996, LIPIDS, V31, P33; Worgall TS, 1998, J BIOL CHEM, V273, P25537, DOI 10.1074/jbc.273.40.25537	44	186	199	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20603	20610		10.1074/jbc.274.29.20603	http://dx.doi.org/10.1074/jbc.274.29.20603			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400691	hybrid, Green Published			2022-12-25	WOS:000081438300084
J	Wu, XD; Clack, BA; Zhi, G; Stull, JT; Cremo, CR				Wu, XD; Clack, BA; Zhi, G; Stull, JT; Cremo, CR			Phosphorylation-dependent structural changes in the regulatory light chain domain of smooth muscle heavy meromyosin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYMATIC-ACTIVITY; 2-HEADED STRUCTURE; ATPASE ACTIVITY; GIZZARD MYOSIN; SCALLOP MYOSIN; TAIL JUNCTION; 2 HEADS; MOTOR; CONFORMATION; ACTIN	Smooth muscle heavy meromyosin, a double-headed proteolytic fragment of myosin lacking the COOH-terminal two-thirds of the tail, has been shown previously to be regulate by phosphorylation, To examine phosphorylation-dependent structural changes near the head-tail junction, we prepared five well regulated heavy meromyosins containing single-cysteine mutants of the human smooth muscle regulatory light chain labeled with the photocross-linking reagent, benzophenone-iodoacetamide, For those mutants that generated cross-links, only one type of cross-linked species was observed, a regulatory light chain dimer, Irradiated mutants fell into two classes. First, for Q15C, A23C, and wild type (Cys-108), a regulatory light chain dimer was formed for dephosphorylated but not thiophosphorylated heavy meromyosin. These data provide direct chemical evidence that in the dephosphorylated state, Gln-15, Ala-BS, and Cys-108 on one head are positioned near (within 8.9 Angstrom) the regulatory light chain of the partner head and that thiophosphorylation abolishes proximity, This behavior was also observed for the Q15C mutant on a truncated heavy meromyosin lacking both catalytic domains. For the actin-heavy meromyosin complex, cross-links were formed in both de- and thiophosphorylated states. S59C and T134C mutants were in a second mutant class, where regulatory light chain dimers were not detected in dephosphorylated or thiophosphorylated heavy meromyosin, suggesting positions outside the region of interaction of the regulatory light chains.	Washington State Univ, Dept Biochem & Biophys, Pullman, WA 99164 USA; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA	Washington State University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Cremo, CR (corresponding author), Washington State Univ, Dept Biochem & Biophys, POB 644660, Pullman, WA 99164 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL026043, R01HL026043] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR040917, R01AR040917] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL26043] Funding Source: Medline; NIAMS NIH HHS [AR40917] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADELSTEIN RS, 1982, METHOD ENZYMOL, V85, P298; COLE DG, 1990, J BIOL CHEM, V265, P22537; CREMO CR, 1995, J BIOL CHEM, V270, P2171, DOI 10.1074/jbc.270.5.2171; DORMAN G, 1994, BIOCHEMISTRY-US, V33, P5661, DOI 10.1021/bi00185a001; FACEMYER KC, 1992, BIOCONJUGATE CHEM, V3, P408, DOI 10.1021/bc00017a009; FLICKER PF, 1983, J MOL BIOL, V169, P723, DOI 10.1016/S0022-2836(83)80167-3; FRADO LLY, 1992, J MUSCLE RES CELL MO, V13; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, V2, P423; Ikebe M, 1998, BIOCHEMISTRY-US, V37, P13285, DOI 10.1021/bi981130b; IKEBE M, 1994, J BIOL CHEM, V269, P28173; IKEBE M, 1994, P NATL ACAD SCI USA, V91, P9096, DOI 10.1073/pnas.91.19.9096; IKEBE M, 1984, J BIOL CHEM, V259, P1639; IKEBE M, 1985, J BIOL CHEM, V260, P3146; Ikebe M, 1998, J BIOL CHEM, V273, P17702, DOI 10.1074/jbc.273.28.17702; IKEBE M, 1985, BIOCHEMISTRY-US, V24, P2380, DOI 10.1021/bi00330a038; MATSUURA M, 1995, FEBS LETT, V363, P246, DOI 10.1016/0014-5793(95)00326-5; MORITA JI, 1991, BIOCHEMISTRY-US, V30, P9539, DOI 10.1021/bi00103a022; Offer G, 1996, J MOL BIOL, V256, P407, DOI 10.1006/jmbi.1996.0096; Olney JJ, 1996, J BIOL CHEM, V271, P20375, DOI 10.1074/jbc.271.34.20375; ONISHI H, 1990, J BIOL CHEM, V265, P19362; PERSECHINI A, 1986, J BIOL CHEM, V261, P6293; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P1; Rosenfeld SS, 1998, J BIOL CHEM, V273, P28682, DOI 10.1074/jbc.273.44.28682; Rovner AS, 1995, J BIOL CHEM, V270, P30260, DOI 10.1074/jbc.270.51.30260; ROWE T, 1993, EMBO J, V12, P4877, DOI 10.1002/j.1460-2075.1993.tb06177.x; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sambrook J., 2002, MOL CLONING LAB MANU; Sata M, 1997, P NATL ACAD SCI USA, V94, P91, DOI 10.1073/pnas.94.1.91; Sata M, 1996, BIOCHEMISTRY-US, V35, P11113, DOI 10.1021/bi960435s; SEIDEL JC, 1980, J BIOL CHEM, V255, P4355; Sellers JR, 1991, CURR OPIN CELL BIOL, V3, P98, DOI 10.1016/0955-0674(91)90171-T; SELLERS JR, 1995, PROTEIN PROFILE, V2, P1323; SELLERS JR, 1985, J BIOL CHEM, V260, P5815; SUZUKI H, 1985, J BIOL CHEM, V260, P4810; TRYBUS KM, 1993, J BIOL CHEM, V268, P4412; Trybus KM, 1998, J BIOL CHEM, V273, P18423, DOI 10.1074/jbc.273.29.18423; Trybus KM, 1997, P NATL ACAD SCI USA, V94, P48, DOI 10.1073/pnas.94.1.48; TRYBUS KM, 1994, J BIOL CHEM, V269, P20819; WHITE HD, 1985, J BIOL CHEM, V260, P982; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0; Zhang YY, 1997, BIOPHYS J, V72, P1308, DOI 10.1016/S0006-3495(97)78777-0	42	34	34	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20328	20335		10.1074/jbc.274.29.20328	http://dx.doi.org/10.1074/jbc.274.29.20328			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400655	hybrid			2022-12-25	WOS:000081438300048
J	Chaturvedi, P; Eng, WK; Zhu, Y; Mattern, MR; Mishra, R; Hurle, MR; Zhang, XL; Annan, RS; Lu, Q; Faucette, LF; Scott, GF; Li, XT; Carr, SA; Johnson, RK; Winkler, JD; Zhou, BBS				Chaturvedi, P; Eng, WK; Zhu, Y; Mattern, MR; Mishra, R; Hurle, MR; Zhang, XL; Annan, RS; Lu, Q; Faucette, LF; Scott, GF; Li, XT; Carr, SA; Johnson, RK; Winkler, JD; Zhou, BBS			Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway	ONCOGENE			English	Article						Chk2; ATM; cdc25C; gamma-radiation; hydroxyurea; topotecan	ATAXIA-TELANGIECTASIA; PROTEIN-KINASE; FISSION YEAST; S-PHASE; SCHIZOSACCHAROMYCES-POMBE; REPLICATION; GENE; PHOSPHORYLATION; TRANSCRIPTION; CDS1	In response to DNA damage and replication blocks, cells activate pathways that arrest the cell cycle and induce the transcription of genes that facilitate repair. In mammals, ATM (ataxia telangiectasia mutated) kinase together with other checkpoint kinases are important components in this response. We have cloned the rat and human homologs of Saccharomyces cerevisiae Rad 53 and Schizosaccharomyces pombe Cds1, called checkpoint kinase 2 (chk2). Complementation studies suggest that Chk2 can partially replace the function of the defective checkpoint kinase in the Cds1 deficient yeast strain. Chk2 was phosphorylated and activated in response to DNA damage in an ATM dependent manner. Its activation in response to replication blocks by hydroxyurea (HU) treatment, however, was independent of ATM, Using mass spectrometry, me found that, similar to Chk1, Chk2 can phosphorylate serine 216 in Cdc25C, a site known to be involved in negative regulation of Cdc25C, These results suggest that Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Activation of Chk2 might not only delay mitotic entry, but also increase the capacity of cultured cells to survive after treatment with gamma-radiation or with the topoisomerase-I inhibitor topotecan.	SmithKline Beecham Pharmaceut, Dept Oncol Res, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Mol Biol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Bioinformat, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Phys & Struct Chem, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Gene Express Sci, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Prot Biochem, King Of Prussia, PA 19406 USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Zhou, BBS (corresponding author), SmithKline Beecham Pharmaceut, Dept Oncol Res, 709 Swedeland Rd, King Of Prussia, PA 19406 USA.		Carr, Steven A./AAH-8366-2019		NCI NIH HHS [CA-50771-09] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA050771, U19CA050771] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; BIEMANN K, 1990, METHOD ENZYMOL, V193, P886, DOI 10.1016/0076-6879(90)93460-3; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Boddy MN, 1998, SCIENCE, V280, P909, DOI 10.1126/science.280.5365.909; Carr SA, 1996, ANAL BIOCHEM, V239, P180, DOI 10.1006/abio.1996.0313; Cimprich KA, 1996, P NATL ACAD SCI USA, V93, P2850, DOI 10.1073/pnas.93.7.2850; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HOFMANN K, 1995, TRENDS BIOCHEM SCI, V20, P347, DOI 10.1016/S0968-0004(00)89072-6; Huang MX, 1998, CELL, V94, P595, DOI 10.1016/S0092-8674(00)81601-3; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; KINGSBURY WD, 1991, J MED CHEM, V34, P98, DOI 10.1021/jm00105a017; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; MURRAY AW, 1995, CURR OPIN GENET DEV, V5, P5, DOI 10.1016/S0959-437X(95)90046-2; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; RYAN AJ, 1994, CARCINOGENESIS, V15, P823, DOI 10.1093/carcin/15.5.823; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SCUDIERO DA, 1988, CANCER RES, V48, P4827; Shirahige K, 1998, NATURE, V395, P618, DOI 10.1038/27007; Sun ZX, 1996, GENE DEV, V10, P395, DOI 10.1101/gad.10.4.395; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; WEICHSELBAUM RR, 1978, NATURE, V271, P261, DOI 10.1038/271261a0; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766; Zhang XL, 1998, ANAL CHEM, V70, P2050, DOI 10.1021/ac971207m; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	39	356	365	0	19	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	1999	18	28					4047	4054		10.1038/sj.onc.1202925	http://dx.doi.org/10.1038/sj.onc.1202925			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	216FP	10435585				2022-12-25	WOS:000081431000001
J	Brar, SS; Kennedy, TP; Whorton, AR; Murphy, TM; Chitano, P; Hoidal, JR				Brar, SS; Kennedy, TP; Whorton, AR; Murphy, TM; Chitano, P; Hoidal, JR			Requirement for reactive oxygen species in serum-induced and platelet-derived growth factor-induced growth of airway smooth muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING PROTEIN; CHRONIC GRANULOMATOUS-DISEASE; DEPENDENT H2O2 GENERATION; NECROSIS-FACTOR-ALPHA; C-FOS; ANGIOTENSIN-II; MESSENGER-RNA; CELL-PROLIFERATION; NADPH-OXIDASE; TRANSFORMING GROWTH-FACTOR-BETA-1	Reactive oxygen species have been recently identified as important mediators of mitogenic signaling in a number of cell types. We therefore explored their role in mediating mitogenesis of airway smooth muscle. The antioxidants catalase, N-acetylcysteine, and probucol significantly reduced proliferation in primary cultures of rat tracheal smooth muscle stimulated with fetal bovine serum or platelet-derived growth factor, without affecting cell viability or inducing apoptosis. N-Acetylcysteine also significantly reduced serum-stimulated elevation of c-Fos but did not prevent the normal mitogen-induced increase in c-fos mRNA. Fractionation of ribosomes by sucrose density centrifugation and subsequent dot-blot Northern analysis revealed that antioxidants reduced incorporation of c-fos mRNA into the heaviest polyribosomes, suggesting redox regulation of c-fos mRNA translation. Serum treatment of monolayers produced a small but reproducibly significant rise in superoxide dismutase-inhibitable reduction of ferricytochrome c by myocyte monolayers. Serum-induced ferricytochrome c reduction, cellular proliferation, and c-Fos elevation were decreased by the flavoprotein-dependent enzyme inhibitor dipheyleneiodonium. Growth responses to fetal bovine serum and superoxide dismutase-inhibitable reduction of ferricytochrome c were not different between cultured tracheal myocytes from wild-type versus gp91 phagocyte oxidase null mice. These results suggest that mitogen stimulation of airway smooth muscle induces signal transduction of cell proliferation that is in part dependent on generation of partially reduced oxygen species, generated by an NADH or NADPH oxidoreductase that is different from the oxidase in phagocytic cells.	Carolinas Med Ctr, Dept Internal Med, Charlotte, NC 28232 USA; Duke Univ, Med Ctr, Dept Pharmacol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA; Univ Utah, Dept Internal Med, Div Resp Crit Care & Occupat Pulm Med, Salt Lake City, UT 84132 USA	Carolinas Medical Center; Duke University; Duke University; Utah System of Higher Education; University of Utah	Kennedy, TP (corresponding author), Carolinas Med Ctr, Dept Internal Med, POB 32861, Charlotte, NC 28232 USA.							ABE MK, 1994, AM J RESP CELL MOL, V11, P577, DOI 10.1165/ajrcmb.11.5.7946386; Abe MK, 1998, AM J RESP CELL MOL, V18, P562, DOI 10.1165/ajrcmb.18.4.2958; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Backman KS, 1997, CHEST, V112, P1234, DOI 10.1378/chest.112.5.1234; BASHFORD CL, 1987, SPECTROPHOTOMETRY SP, P1; Bhunia AK, 1997, J BIOL CHEM, V272, P15642, DOI 10.1074/jbc.272.25.15642; BOUCHER RC, 1979, J ALLERGY CLIN IMMUN, V64, P197, DOI 10.1016/0091-6749(79)90095-2; BRAMLEY AM, 1994, EUR RESPIR J, V7, P337, DOI 10.1183/09031936.94.07020337; BRISSEAU GF, 1995, BLOOD, V85, P1025, DOI 10.1182/blood.V85.4.1025.bloodjournal8541025; Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609; CASSCELLS W, 1992, CIRCULATION, V86, P723, DOI 10.1161/01.CIR.86.3.723; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOPRA DP, 1992, ANAT REC, V233, P261, DOI 10.1002/ar.1092330209; Chu E, 1996, BIOESSAYS, V18, P191, DOI 10.1002/bies.950180306; CLERCH LB, 1992, J BIOL CHEM, V267, P2853; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CURRAN T, 1987, ONCOGENE, V2, P79; Dashtaki R, 1998, J PHARMACOL EXP THER, V285, P876; DEMOLY P, 1995, RESP MED, V89, P329, DOI 10.1016/0954-6111(95)90003-9; DEMOLY P, 1992, AM J RESP CELL MOL, V7, P128, DOI 10.1165/ajrcmb/7.2.128; DINAUER MC, 1993, CRIT REV CL LAB SCI, V30, P329, DOI 10.3109/10408369309082591; FAZZONE H, 1993, J CLIN INVEST, V92, P1278, DOI 10.1172/JCI116700; FENG L, 1995, J CLIN INVEST, V95, P1669, DOI 10.1172/JCI117842; FICK RB, 1987, J APPL PHYSIOL, V63, P1147, DOI 10.1152/jappl.1987.63.3.1147; Fridovich I, 1985, HDB METHODS OXYGEN R, P121; Fryer A, 1997, J PHARMACOL EXP THER, V282, P208; GLASSBERG MK, 1994, AM J RESP CELL MOL, V10, P316, DOI 10.1165/ajrcmb.10.3.7509612; GonzalezEspinosa C, 1996, BBA-MOL CELL RES, V1310, P217, DOI 10.1016/0167-4889(95)00168-9; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; Herbert JM, 1996, FEBS LETT, V395, P43, DOI 10.1016/0014-5793(96)00998-2; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Hirst SJ, 1996, AM J PHYSIOL-LUNG C, V270, pL415, DOI 10.1152/ajplung.1996.270.3.L415; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; JUNIPER EF, 1990, AM REV RESPIR DIS, V142, P832, DOI 10.1164/ajrccm/142.4.832; Karpova AY, 1997, AM J PHYSIOL-LUNG C, V272, pL558, DOI 10.1152/ajplung.1997.272.3.L558; Kennedy T, 1998, AM J RESP CELL MOL, V19, P366, DOI 10.1165/ajrcmb.19.3.3042; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KRIEGERBRAUER HI, 1995, BIOCHEM J, V307, P549, DOI 10.1042/bj3070549; KRIEGERBRAUER HI, 1992, J CLIN INVEST, V89, P1006, DOI 10.1172/JCI115641; KriegerBrauer HI, 1997, J BIOL CHEM, V272, P10135; KU G, 1988, AM J CARDIOL, V62, pB77, DOI 10.1016/S0002-9149(88)80057-2; LAM S, 1987, J ALLERGY CLIN IMMUN, V80, P44, DOI 10.1016/S0091-6749(87)80189-6; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LEDWITH BJ, 1990, MOL CELL BIOL, V10, P1545, DOI 10.1128/MCB.10.4.1545; Marshall C, 1996, AM J RESP CELL MOL, V15, P633, DOI 10.1165/ajrcmb.15.5.8918370; McKay S, 1998, AM J RESP CELL MOL, V18, P823, DOI 10.1165/ajrcmb.18.6.2924; *MERR DOW PHARM IN, 1990, PHYS DESK REF, P1469; Mohazzab HKM, 1994, AM J PHYSIOL, V266, P2568; MohazzabH KM, 1996, AM J PHYSIOL-HEART C, V270, pH1044, DOI 10.1152/ajpheart.1996.270.3.H1044; PAGANO PJ, 1995, AM J PHYSIOL-HEART C, V268, pH2274, DOI 10.1152/ajpheart.1995.268.6.H2274; PANETTIERI RA, 1990, AM J PHYSIOL, V259, pL365, DOI 10.1152/ajplung.1990.259.6.L365; PARE PD, 1991, AM REV RESPIR DIS, V143, P1189, DOI 10.1164/ajrccm/143.5_Pt_1.1189; PARTHASARATHY S, 1986, J CLIN INVEST, V77, P641, DOI 10.1172/JCI112349; PERSSON CGA, 1986, LANCET, V2, P1126; PICK E, 1981, J IMMUNOL METHODS, V46, P211, DOI 10.1016/0022-1759(81)90138-1; POLLOCK JD, 1995, NAT GENET, V9, P202, DOI 10.1038/ng0295-202; RADEKE HH, 1991, J BIOL CHEM, V266, P21025; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; RONDON IJ, 1995, FEBS LETT, V359, P267, DOI 10.1016/0014-5793(95)00066-I; SAMBROOK J, 1989, MOL CLONING LABORATO, V7, P53; SATRIANO JA, 1993, J CLIN INVEST, V92, P1564, DOI 10.1172/JCI116737; Sylvester AM, 1998, J CLIN INVEST, V101, P940, DOI 10.1172/JCI1630; Tardif JC, 1997, NEW ENGL J MED, V337, P365, DOI 10.1056/NEJM199708073370601; THANNICKAL VJ, 1993, AM J PHYSIOL, V265, pL622, DOI 10.1152/ajplung.1993.265.6.L622; Thannickal VJ, 1995, J BIOL CHEM, V270, P30334, DOI 10.1074/jbc.270.51.30334; Tsai JC, 1996, J BIOL CHEM, V271, P3667; UshioFukai M, 1996, J BIOL CHEM, V271, P23317, DOI 10.1074/jbc.271.38.23317; Winyard P G, 1997, Adv Pharmacol, V38, P403; Zhan SX, 1996, BLOOD, V88, P2714, DOI 10.1182/blood.V88.7.2714.bloodjournal8872714	74	82	84	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					20017	20026		10.1074/jbc.274.28.20017	http://dx.doi.org/10.1074/jbc.274.28.20017			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391952	hybrid			2022-12-25	WOS:000081377300072
J	Pelicano, L; Brumpt, C; Pitha, PM; Chelbi-Alix, MK				Pelicano, L; Brumpt, C; Pitha, PM; Chelbi-Alix, MK			Retinoic acid resistance in NB4 APL cells is associated with lack of interferon alpha synthesis Stat1 and p48 induction	ONCOGENE			English	Article						IRF-1; IRF-3; cAMP; Sp100; differentiation	ACUTE PROMYELOCYTIC LEUKEMIA; PML-RAR-ALPHA; TRANSCRIPTION FACTOR; GENE-EXPRESSION; IFN-ALPHA; SIGNAL TRANSDUCER; GENOMIC STRUCTURE; T(15-17); ELEMENT; GAMMA	In the t(15;17) acute promyelocytic leukaemia (APL), all trans-retinoic (RA) treatment induces maturation leading to clinically complete but not durable remission, as RA resistance develops in the treated patients as well as lit vitro. RA and interferons (IFNs) are known inhibitors of proliferation in various cells including those from APL, In this report, we show that they can act cooperatively to inhibit growth and to induce differentiation of NB4 cells but not of two RA-resistant NB4 derived cell lines, NB4-R1 and NB4-R2, However, the resistant cell lines respond to IFN, In NB4 cells, RA increases the expression of Stat1, p48 and IRF-1, three transcription factors playing a central role in the IFN response and induces the synthesis and the secretion of IFN alpha, RA-induced IFN alpha seems to play a role in inhibition of NB4 cell growth but not in their differentiation, In the resistant cells, NB4-R1 and NB4-R2, both the induction of IFN and the increase of Stat1 and p48 expression by RA are completely blocked, In contrast, IRF-1 mRNA and protein expressions are induced in the three cell lines. This suggests that increase of IRF-1 expression is not sufficient for IFN induction. Our results identify some defects linked to RA-resistance in APL and support the hypothesis that RA-induced Stat1 expression and IFN secretion may be one of the mechanisms mediating growth inhibition by RA.	Hop St Louis, CNRS, UPR 9051, F-75475 Paris 10, France; Johns Hopkins Univ, Ctr Oncol, Baltimore, MD 21231 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Johns Hopkins University; Johns Hopkins Medicine	Chelbi-Alix, MK (corresponding author), Hop St Louis, CNRS, UPR 9051, 1 Ave Vellefaux, F-75475 Paris 10, France.							ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; CASTAIGNE S, 1990, BLOOD, V76, P1704; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; ChelbiAlix MK, 1995, LEUKEMIA, V9, P2027; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; DEGOS L, 1995, BLOOD, V85, P2643, DOI 10.1182/blood.V85.10.2643.bloodjournal85102643; Demaeyer E., 1988, INTERFERONS OTHER RE; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Duprez E, 1996, ONCOGENE, V12, P2451; Duprez E, 1996, ONCOGENE, V12, P2443; DUPREZ E, 1992, LEUKEMIA, V6, P1281; EISENHAUER EA, 1994, LEUKEMIA, V8, P1622; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; Giandomenico V, 1997, CELL GROWTH DIFFER, V8, P91; Gianni M, 1997, BLOOD, V89, P1001, DOI 10.1182/blood.V89.3.1001; Gianni M, 1998, BLOOD, V91, P4300, DOI 10.1182/blood.V91.11.4300.411k41_4300_4310; Gupta S, 1996, EMBO J, V15, P1075, DOI 10.1002/j.1460-2075.1996.tb00445.x; Handa H, 1997, LEUKEMIA RES, V21, P1087, DOI 10.1016/S0145-2126(97)00090-8; Harada H, 1996, GENES CELLS, V1, P995, DOI 10.1046/j.1365-2443.1996.870287.x; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KANNO Y, 1993, MOL CELL BIOL, V13, P3951, DOI 10.1128/MCB.13.7.3951; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; Kizaki M, 1997, LEUKEMIA LYMPHOMA, V25, P427, DOI 10.3109/10428199709039029; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Kolla V, 1996, J BIOL CHEM, V271, P10508, DOI 10.1074/jbc.271.18.10508; KUMAR R, 1995, ANTICANCER RES, V15, P353; LANCILLOTTI F, 1995, CANCER RES, V55, P3158; LANOTTE M, 1991, BLOOD, V77, P1080; Lehtonen A, 1997, J IMMUNOL, V159, P794; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARUYAMA M, 1989, NUCLEIC ACIDS RES, V17, P3292, DOI 10.1093/nar/17.8.3292; Matikainen S, 1997, CELL GROWTH DIFFER, V8, P687; Matikainen S, 1996, BLOOD, V88, P114; MILLER WH, 1995, BLOOD, V85, P3021, DOI 10.1182/blood.V85.11.3021.bloodjournal85113021; NasonBurchenal K, 1996, BLOOD, V88, P3926, DOI 10.1182/blood.V88.10.3926.bloodjournal88103926; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Ohmori Y, 1997, J BIOL CHEM, V272, P14899, DOI 10.1074/jbc.272.23.14899; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; Pelicano L, 1997, ONCOGENE, V15, P2349, DOI 10.1038/sj.onc.1201410; Pelicano L, 1998, B CANCER, V85, P313; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; Pellegrini S, 1997, EUR J BIOCHEM, V248, P615, DOI 10.1111/j.1432-1033.1997.00615.x; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; Pfeffer LM, 1998, CANCER RES, V58, P2489; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; Pine R, 1997, NUCLEIC ACIDS RES, V25, P4346, DOI 10.1093/nar/25.21.4346; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; ROBERTSON KA, 1992, BLOOD, V80, P1885; RUCHAUD S, 1994, P NATL ACAD SCI USA, V91, P8428, DOI 10.1073/pnas.91.18.8428; Schafer SL, 1998, J BIOL CHEM, V273, P2714, DOI 10.1074/jbc.273.5.2714; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SEN GC, 1993, ADV VIRUS RES, V42, P57, DOI 10.1016/S0065-3527(08)60083-4; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; Stadler M, 1995, ONCOGENE, V11, P2565; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; Weihua Xiao, 1997, Journal of Biological Chemistry, V272, P9742; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; YAN RQ, 1995, NUCLEIC ACIDS RES, V23, P459, DOI 10.1093/nar/23.3.459; Yoshida H, 1996, CANCER RES, V56, P2945	62	30	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 8	1999	18	27					3944	3953		10.1038/sj.onc.1202802	http://dx.doi.org/10.1038/sj.onc.1202802			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KU	10435617				2022-12-25	WOS:000081327800004
J	Golovanevsky, V; Kanner, BI				Golovanevsky, V; Kanner, BI			The reactivity of the gamma-aminobutyric acid transporter GAT-1 toward sulfhydryl reagents is conformationally sensitive - Identification of a major target residue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GABA TRANSPORTER; RAT-BRAIN; SEROTONIN TRANSPORTER; DOPAMINE TRANSPORTER; TRANSMEMBRANE TOPOLOGY; XENOPUS OOCYTES; ION-BINDING; EXPRESSION; SODIUM; SITE	The gamma-aminobutyric acid (GABA) transporter GAT-1 is a prototype of neurotransmitter transporters that maintain low synaptic levels of the transmitter. Transport by GAT-1 is sensitive to the polar sulfhydryl reagent a-aminoethyl methanethiosulfonate. Following replacement of endogenous cysteines to other residues by site-directed mutagenesis, we have identified cysteine 399 as the major determinant of the sensitivity of the transporter to sulfhydryl modification, Cysteine-399 is located in the intracellular loop connecting putative transmembrane domains eight and nine. Binding of both sodium and chloride leads to a reduced sensitivity to sulfhydryl reagents, whereas subsequent binding of GABA increases it. Strikingly binding of the nontransportable GABA analogue SKF100330A gives rise to a marked protection against sulfhydryl modification. These effects were not observed in C399S transporters. Under standard conditions GAT-1 is almost insensitive to ward the impermeant 2-(trimethylammonium)ethyl methanethiosulfonate. However, in a chloride-free medium, addition of SKF100330A renders wild type GAT-1, but not C399S, very sensitive to this impermeant reagent. These observations indicate that the accessibility of cysteine 399 is highly dependent on the conformation of GAT-1, Consequently, topological assignments based on accessibility of endogeneous or engineered cysteines to small polar sulfhydryl reagents need to be interpreted with extreme caution.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Kanner, BI (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, POB 12272, IL-91120 Jerusalem, Israel.				NINDS NIH HHS [NS16708] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS016708, R01NS016708] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKABAS MH, 1994, J BIOL CHEM, V269, P14865; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; ALI FE, 1985, J MED CHEM, V28, P653, DOI 10.1021/jm50001a020; Bennett ER, 1997, J BIOL CHEM, V272, P1203, DOI 10.1074/jbc.272.2.1203; BEYREUTHER K, 1981, METHODS PROTEIN SEQU, P139; Bismuth Y, 1997, J BIOL CHEM, V272, P16096, DOI 10.1074/jbc.272.26.16096; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen JG, 1997, BIOCHEMISTRY-US, V36, P1479, DOI 10.1021/bi962256g; Chen JG, 1997, J BIOL CHEM, V272, P28321, DOI 10.1074/jbc.272.45.28321; Chen JG, 1998, J BIOL CHEM, V273, P12675, DOI 10.1074/jbc.273.20.12675; Clark JA, 1997, J BIOL CHEM, V272, P14695, DOI 10.1074/jbc.272.23.14695; Ferrer JV, 1998, P NATL ACAD SCI USA, V95, P9238, DOI 10.1073/pnas.95.16.9238; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HU LA, 1991, BIOCHEM J, V330, P771; JUNG H, 1994, BIOCHEMISTRY-US, V33, P12166; KAVANAUGH MP, 1992, J BIOL CHEM, V267, P22007; KESHET GI, 1995, FEBS LETT, V371, P39, DOI 10.1016/0014-5793(95)00859-8; KEYNAN S, 1988, BIOCHEMISTRY-US, V27, P12, DOI 10.1021/bi00401a003; KEYNAN S, 1992, BIOCHEMISTRY-US, V31, P1974, DOI 10.1021/bi00122a011; KLEINBERGERDORON N, 1994, J BIOL CHEM, V269, P3063; Kuner T, 1996, NEURON, V17, P343, DOI 10.1016/S0896-6273(00)80165-8; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MABJEESH NJ, 1993, BIOCHEMISTRY-US, V32, P8540, DOI 10.1021/bi00084a021; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; MAGER S, 1996, J NEUROSCI, V16, P5404; MELIKIAN HE, 1994, J BIOL CHEM, V269, P12290; Olivares L, 1997, J BIOL CHEM, V272, P1211, DOI 10.1074/jbc.272.2.1211; PANTANOWITZ S, 1993, J BIOL CHEM, V268, P3222; RADIAN R, 1986, J BIOL CHEM, V261, P5437; UHL GR, 1992, TRENDS NEUROSCI, V15, P265, DOI 10.1016/0166-2236(92)90068-J; WANG JB, 1995, J NEUROCHEM, V64, P1416; Yu N, 1998, FEBS LETT, V426, P174, DOI 10.1016/S0014-5793(98)00333-0; Zarbiv R, 1998, J BIOL CHEM, V273, P14231, DOI 10.1074/jbc.273.23.14231	35	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23020	23026		10.1074/jbc.274.33.23020	http://dx.doi.org/10.1074/jbc.274.33.23020			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438469	hybrid			2022-12-25	WOS:000082012800019
J	Nisimoto, Y; Motalebi, S; Han, CH; Lambeth, JD				Nisimoto, Y; Motalebi, S; Han, CH; Lambeth, JD			The p67(phox) activation domain regulates electron flow from NADPH to flavin in flavocytochrome b(558)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; CHRONIC GRANULOMATOUS-DISEASE; CELL-FREE SYSTEM; NEUTROPHIL CYTOCHROME-B; IN-VITRO; EFFECTOR REGION; INSERT REGION; BINDING SITE; RAC-BINDING; COMPLEX	An activation domain in p67(phox) (residues within 199-210) is essential for cytochrome b(558)-dependent activation of NADPH superoxide (O-2(.-)) generation in a cell-free system (Han, C.-H., Freeman, J. L. R., Lee, T., Motalebi, S. A., and Lambeth, J. D. (1998) J. Biol. Chem. 273, 16663-16668). To determine the steady state reduction flavin in the presence of highly absorbing hemes, 8-nor-8-S-thioacetamido-FAD ("thioacetamido-FAD") was reconstituted into the flavocytochrome, and the fluorescence of its oxidized form was monitored. Thioacetamido-FAD-reconstituted cytochrome showed lower activity (7% versus 100%) and increased steady state flavin reduction (28 versus <5%) compared with the enzyme reconstituted with native FAD, Omission of p67(phox) decreased the percent steady state reduction of the flavin to 4%, but omission of p47(phox) had little effect. The activation domain on p67(phox) was critical for regulating flavin reduction, since mutations in this region that decreased O-2(.-) generation also decreased the steady state reduction of flavin, Thus, the activation domain on p67(phox) regulates the reductive half-reaction for FAD, This reaction is comprised of the binding of NADPH followed by hydride transfer to the flavin, Kinetic deuterium isotope effects along with K-m values permitted calculation of the K-d for NADPH, (R)-NADPD but not (S)-NADPD showed kinetic deuterium isotope effects on V and V/K of about 1.9 and 1.5, respectively, demonstrating stereospecificity for the R hydride transfer. The calculated K-d for NADPH was 40 mu M in the presence of wild type p67(phox) and was similar to 55 mu M using the weakly activating p67(phox)(V205A), Thus, the activation domain of p67(phox) regulates the reduction of FAD but has only a small effect on NADPH binding, consistent with a dominant effect on hydride/electron transfer from NADPH to FAD.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Aichi Med Univ, Dept Biochem, Nagakute, Aichi 4801195, Japan	Emory University; Aichi Medical University	Lambeth, JD (corresponding author), Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022809] Funding Source: NIH RePORTER; NIAID NIH HHS [AI22809] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ABRAMS CS, 1995, J BIOL CHEM, V270, P23317, DOI 10.1074/jbc.270.40.23317; Ahmed S, 1998, J BIOL CHEM, V273, P15693, DOI 10.1074/jbc.273.25.15693; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNHAM DN, 1990, J BIOL CHEM, V265, P17550; CLELAND WW, 1982, CRC CR REV BIOCH MOL, V13, P385; COLOWICK SP, 1957, METHOD ENZYMOL, V3, P840; CORNFORTH J. W., 1965, PROC ROY SCI SER B BIOL SCI, V163, P436; CROSS AR, 1982, BIOCHEM J, V204, P479, DOI 10.1042/bj2040479; CROSS AR, 1995, J BIOL CHEM, V270, P6543, DOI 10.1074/jbc.270.12.6543; CROSS AR, 1995, J BIOL CHEM, V270, P17075, DOI 10.1074/jbc.270.29.17075; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677, DOI 10.1002/jlb.60.6.677; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; DINAUER MC, 1987, NATURE, V327, P717, DOI 10.1038/327717a0; DORSEUIL O, 1995, J LEUKOCYTE BIOL, V58, P108, DOI 10.1002/jlb.58.1.108; Dorseuil O, 1996, J BIOL CHEM, V271, P83, DOI 10.1074/jbc.271.1.83; Dusi S, 1996, BIOCHEM J, V314, P409, DOI 10.1042/bj3140409; Freeman JL, 1996, J BIOL CHEM, V271, P22578, DOI 10.1074/jbc.271.37.22578; Freeman JL, 1996, J BIOL CHEM, V271, P19794, DOI 10.1074/jbc.271.33.19794; FREEMAN JLR, 1994, BIOCHEMISTRY-US, V33, P13431, DOI 10.1021/bi00249a031; Han CH, 1998, J BIOL CHEM, V273, P16663, DOI 10.1074/jbc.273.27.16663; HEYWORTH PG, 1994, J BIOL CHEM, V269, P30749; IMAJOHOHMI S, 1992, J BIOL CHEM, V267, P180; JEONG SS, 1994, ANAL BIOCHEM, V221, P273, DOI 10.1006/abio.1994.1411; KLEINBERG ME, 1994, BIOCHEMISTRY-US, V33, P2490, DOI 10.1021/bi00175a018; KLINMAN JP, 1985, J AM CHEM SOC, V107, P1058, DOI 10.1021/ja00290a052; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; Koshkin V, 1996, J BIOL CHEM, V271, P30326, DOI 10.1074/jbc.271.48.30326; Koshkin V, 1997, BBA-BIOENERGETICS, V1319, P139, DOI 10.1016/S0005-2728(96)00154-5; KRECK ML, 1994, J BIOL CHEM, V269, P4161; Kreck ML, 1996, BIOCHEMISTRY-US, V35, P15683, DOI 10.1021/bi962064l; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; MASSEY V, 1979, J BIOL CHEM, V254, P9640; Nisimoto Y, 1997, J BIOL CHEM, V272, P18834, DOI 10.1074/jbc.272.30.18834; NISIMOTO Y, 1995, J BIOL CHEM, V270, P16428, DOI 10.1074/jbc.270.27.16428; ORR GA, 1984, ANAL BIOCHEM, V142, P232, DOI 10.1016/0003-2697(84)90544-X; PARK JW, 1992, J BIOL CHEM, V267, P17327; PARKOS CA, 1988, P NATL ACAD SCI USA, V85, P3319, DOI 10.1073/pnas.85.10.3319; PEMBER SO, 1983, BLOOD, V61, P1105; QUINN MT, 1993, J BIOL CHEM, V268, P20983; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; SCHOPFER LM, 1981, J BIOL CHEM, V256, P7329; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SEGAL AW, 1978, NATURE, V276, P515, DOI 10.1038/276515a0; SEYAMA Y, 1977, J BIOCHEM-TOKYO, V81, P1167, DOI 10.1093/oxfordjournals.jbchem.a131543; SUMIMOTO H, 1992, BIOCHEM BIOPH RES CO, V186, P1368, DOI 10.1016/S0006-291X(05)81557-8; TAYLOR WR, 1993, PROTEIN SCI, V2, P1675, DOI 10.1002/pro.5560021013; UHLINGER DJ, 1992, BIOCHEM BIOPH RES CO, V186, P509, DOI 10.1016/S0006-291X(05)80837-X; UHLINGER DJ, 1994, J BIOL CHEM, V269, P22095; UHLINGER DJ, 1993, J BIOL CHEM, V268, P8624; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318; Yu LX, 1998, P NATL ACAD SCI USA, V95, P7993, DOI 10.1073/pnas.95.14.7993	53	145	148	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					22999	23005		10.1074/jbc.274.33.22999	http://dx.doi.org/10.1074/jbc.274.33.22999			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438466	hybrid			2022-12-25	WOS:000082012800016
J	Huby, RDJ; Dearman, RJ; Kimber, I				Huby, RDJ; Dearman, RJ; Kimber, I			Intracellular phosphotyrosine induction by major histocompatibility complex class II requires co-aggregation with membrane rafts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-II; GPI-ANCHORED PROTEINS; T-CELL ACTIVATION; MEDIATED SIGNAL-TRANSDUCTION; NECROSIS-FACTOR-ALPHA; HUMAN B-CELLS; CROSS-LINKING; STRUCTURAL COMPARTMENTALIZATION; CYTOPLASMIC DOMAIN; EPITHELIAL-CELLS	Cross-linking MHC class II molecules human leukocyte antigen (HLA-DR) on the surface of THP-1 cells was found to induce their entry into the glycolipid-enriched membrane fraction of the plasma membrane. At the cellular level, this resulted in the synergistic co-aggregation of class II with cholera toxin, a marker of membrane rafts. The accompanying induction of intracellular protein tyrosine phosphorylation could be inhibited by treating cells with methyl-beta-cyclodextrin, a drug that chelates membrane cholesterol and thereby disperses membrane rafts. Signaling could also be inhibited by treating cells with the Src-family kinase inhibitor PP1. Together, these results show that the induced association of class II molecules with membrane rafts can contribute to their aggregation on the cell surface and mediate an association with intracellular protein-tyrosine kinases.	Zeneca Cent Toxicol Lab, Macclesfield SK10 4TJ, Cheshire, England		Huby, RDJ (corresponding author), Zeneca Cent Toxicol Lab, Alderley Pk, Macclesfield SK10 4TJ, Cheshire, England.							Ahsmann EJM, 1997, EUR J IMMUNOL, V27, P2688, DOI 10.1002/eji.1830271031; ALTOMONTE M, 1993, J IMMUNOL, V151, P5115; ANDRE P, 1994, J EXP MED, V179, P763, DOI 10.1084/jem.179.2.763; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CAMBIER JC, 1989, J EXP MED, V170, P877, DOI 10.1084/jem.170.3.877; CHATILA T, 1993, IMMUNOL REV, V131, P43, DOI 10.1111/j.1600-065X.1993.tb01529.x; CHIA CP, 1994, J IMMUNOL, V153, P3398; CORLEY RB, 1985, P NATL ACAD SCI USA, V82, P516, DOI 10.1073/pnas.82.2.516; Deckert M, 1996, J CELL BIOL, V133, P791, DOI 10.1083/jcb.133.4.791; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; Dustin ML, 1999, SCIENCE, V283, P649, DOI 10.1126/science.283.5402.649; EDIDIN M, 1991, J CELL BIOL, V112, P1143, DOI 10.1083/jcb.112.6.1143; FIEDLER K, 1993, BIOCHEMISTRY-US, V32, P6365, DOI 10.1021/bi00076a009; FIELD KA, 1995, P NATL ACAD SCI USA, V92, P9201, DOI 10.1073/pnas.92.20.9201; Field KA, 1997, J BIOL CHEM, V272, P4276, DOI 10.1074/jbc.272.7.4276; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; FRA AM, 1994, J BIOL CHEM, V269, P30745; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; HARTON JA, 1993, J IMMUNOL, V151, P5282; HARTON JA, 1995, IMMUNITY, V3, P349, DOI 10.1016/1074-7613(95)90119-1; Kabouridis PS, 1997, EMBO J, V16, P4983, DOI 10.1093/emboj/16.16.4983; KANSAS GS, 1991, J IMMUNOL, V147, P4094; Keller P, 1998, J CELL BIOL, V140, P1357, DOI 10.1083/jcb.140.6.1357; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; MEHINDATE K, 1995, J EXP MED, V182, P1573, DOI 10.1084/jem.182.5.1573; MERRITT EA, 1994, PROTEIN SCI, V3, P166; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; MOONEY N, 1989, J IMMUNOGENET, V16, P273; MOURAD W, 1990, J EXP MED, V172, P1513, DOI 10.1084/jem.172.5.1513; NABAVI N, 1992, NATURE, V360, P266, DOI 10.1038/360266a0; NEWELL MK, 1993, P NATL ACAD SCI USA, V90, P10459, DOI 10.1073/pnas.90.22.10459; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; Reich Z, 1997, NATURE, V387, P617, DOI 10.1038/42500; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; Rodgers W, 1996, J CELL BIOL, V135, P1515, DOI 10.1083/jcb.135.6.1515; Romagnoli P, 1997, J IMMUNOL, V158, P5757; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; STAHL A, 1995, J CELL BIOL, V129, P335, DOI 10.1083/jcb.129.2.335; Stauffer TP, 1997, J CELL BIOL, V139, P1447, DOI 10.1083/jcb.139.6.1447; Stulnig TM, 1997, J BIOL CHEM, V272, P19242, DOI 10.1074/jbc.272.31.19242; TREDE NS, 1991, J IMMUNOL, V146, P2310; Truman JP, 1996, EXP HEMATOL, V24, P1409; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; WADE WF, 1993, IMMUNOL TODAY, V14, P539, DOI 10.1016/0167-5699(93)90184-M; Wilson KM, 1996, J CELL SCI, V109, P2101; Wulfing C, 1998, SCIENCE, V282, P2266, DOI 10.1126/science.282.5397.2266; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8	53	107	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22591	22596		10.1074/jbc.274.32.22591	http://dx.doi.org/10.1074/jbc.274.32.22591			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428838	hybrid			2022-12-25	WOS:000081868400068
J	Honda, Y; Honda, S				Honda, Y; Honda, S			The daf-2 gene network for longevity regulates oxidative stress resistance and Mn-superoxide dismutase gene expression in Caenorhabditis elegans	FASEB JOURNAL			English	Article						life extension mutant; Mn-SOD; C. elegans; nematode	FREE-RADICAL THEORY; LIFE-SPAN; DAUER FORMATION; INSULIN-RESISTANCE; METHYL VIOLOGEN; FAMILY MEMBER; NEMATODE; GLUCOSE; OXYGEN; AGE-1	Longevity is regulated by the daf-2 gene network in Caenorhabditis elegans, Mutations in the daf-2 gene, which encodes a member of the insulin receptor family, confer the life extension (Age) phenotype and the constitutive dauer (a growth-arrested larval form specialized for dispersal) formation phenotype, The Age phenotype is mutually potentiated by two life extension mutations in the daf-2 gene and the clk-1 gene, a homologue of yeast CAT5/COQ7 known to regulate ubiquinone biosynthesis, Zn this study, we demonstrated that the daf-2 mutation also conferred an oxidative stress resistance (Oxr) phenotype, which was also enhanced by the clk-1 mutation, Similar to the Age phenotype, the Oxr phenotype was regulated by the genetic pathway of insulin-like signaling from daf-2 to the daf-16 gene, a homologue of the HNF-3/forkhead transcription factor, These findings led us to examine whether the insulin-like signaling pathway regulates the gene expression of antioxidant defense enzymes. We found that the mRNA level of the sod-3 gene, which encodes Mn-superoxide dismutase (SOD), was much higher in daf-2 mutants than in the wild type. Moreover, the increased sod-3 gene expression phenotype is regulated by the insulin-like signaling pathway. Although the clk-1 mutant itself did not display Oxr and the increased sod-3 expression phenotypes, the clk-1 mutation enhanced them in the daf-2 mutant, suggesting that clk-1 is involved in longevity in two ways: clk-1 composes the original clk-1 longevity program and the daf-2 longevity program. These observations suggest that the daf-2 gene network controls longevity by regulating the MnSOD-associated antioxidant defense system, This system appears to play a role in efficient life maintenance at the dauer stage.	Tokyo Metropolitan Inst Gerontol, Itabashi Ku, Tokyo 1730015, Japan	Tokyo Metropolitan Institute of Gerontology	Honda, S (corresponding author), Tokyo Metropolitan Inst Gerontol, Itabashi Ku, 35-2 Sakaecho, Tokyo 1730015, Japan.	hondas@center.tmig.or.jp	HONDA, Yoko/F-4558-2018	HONDA, Yoko/0000-0002-9978-8672				ANDERSON GL, 1982, CAN J ZOOL, V60, P288, DOI 10.1139/z82-038; Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; BRENNER S, 1974, GENETICS, V77, P71; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Croteau DL, 1997, J BIOL CHEM, V272, P25409, DOI 10.1074/jbc.272.41.25409; DARR D, 1995, FREE RADICAL BIO MED, V18, P195, DOI 10.1016/0891-5849(94)00118-4; DORMAN JB, 1995, GENETICS, V141, P1399; Ewbank JJ, 1997, SCIENCE, V275, P980, DOI 10.1126/science.275.5302.980; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; FRIEDMAN DB, 1988, GENETICS, V118, P75; GIGLIO MP, 1994, BIOCHEM MOL BIOL INT, V33, P37; GOTTLIEB S, 1994, GENETICS, V137, P107; HARMAN D, 1994, ANN NY ACAD SCI, V717, P1, DOI 10.1111/j.1749-6632.1994.tb12069.x; HARTMAN P, 1995, J GERONTOL A-BIOL, V50, pB322, DOI 10.1093/gerona/50A.6.B322; HASSAN HM, 1978, J BIOL CHEM, V253, P8143; HAYFLICK L, 1987, MODERN BIOL THEORIES, P21; Ho YS, 1996, AM J PHYSIOL-LUNG C, V270, pL810, DOI 10.1152/ajplung.1996.270.5.L810; HONDA S, 1993, J GERONTOL, V48, pB57, DOI 10.1093/geronj/48.2.B57; HONDA S, 1992, MECH AGEING DEV, V63, P235, DOI 10.1016/0047-6374(92)90002-U; Hunter T, 1997, J BIOL CHEM, V272, P28652, DOI 10.1074/jbc.272.45.28652; ISHII N, 1990, MUTAT RES, V237, P165, DOI 10.1016/0921-8734(90)90022-J; Ishii N, 1998, NATURE, V394, P694, DOI 10.1038/29331; Jonassen T, 1998, J BIOL CHEM, V273, P3351, DOI 10.1074/jbc.273.6.3351; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; KENYON C, 1997, C ELEGANS, V2, P791; KIM H, 1992, DIABETOLOGIA, V35, P261, DOI 10.1007/BF00400927; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; KLASS M, 1976, NATURE, V260, P523, DOI 10.1038/260523a0; Lakowski B, 1996, SCIENCE, V272, P1010, DOI 10.1126/science.272.5264.1010; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; LARSEN PL, 1995, GENETICS, V139, P1567; Lee YJ, 1998, J BIOL CHEM, V273, P5294, DOI 10.1074/jbc.273.9.5294; Lewis JA, 1995, METHOD CELL BIOL, V48, P3; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Malone EA, 1996, GENETICS, V143, P1193; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; Murakami S, 1996, GENETICS, V143, P1207; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; Papadopoulos MC, 1997, BRAIN RES, V748, P151, DOI 10.1016/S0006-8993(96)01293-0; Parkes TL, 1998, NAT GENET, V19, P171, DOI 10.1038/534; RAMIREZ R, 1995, MOL CELL BIOCHEM, V142, P43, DOI 10.1007/BF00928912; RandezGil F, 1997, MOL CELL BIOL, V17, P2502, DOI 10.1128/MCB.17.5.2502; Riddle DL, 1997, C ELEGANS, P739; Sacher G. A., 1978, The genetics of aging., P151; Sambrook J., 1989, MOL CLONING LAB MANU, V2; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; Suzuki N, 1996, DNA Res, V3, P171, DOI 10.1093/dnares/3.3.171; SWANSON MM, 1981, DEV BIOL, V84, P27, DOI 10.1016/0012-1606(81)90367-5; TAKESHIGE K, 1979, BIOCHEM J, V180, P129, DOI 10.1042/bj1800129; THOR H, 1982, J BIOL CHEM, V257, P2419; Tissenbaum HA, 1998, GENETICS, V148, P703; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; VANFLETEREN JR, 1995, FASEB J, V9, P1355, DOI 10.1096/fasebj.9.13.7557026; VANFLETEREN JR, 1993, BIOCHEM J, V292, P605, DOI 10.1042/bj2920605; VANVOORHIES WA, 1992, NATURE, V360, P456, DOI 10.1038/360456a0; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888; VOWELS JJ, 1992, GENETICS, V130, P105; WHITE MF, 1994, JOSLINS DIABETES MEL, P139; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703	61	566	592	4	71	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1999	13	11					1385	1393		10.1096/fasebj.13.11.1385	http://dx.doi.org/10.1096/fasebj.13.11.1385			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	226KL	10428762				2022-12-25	WOS:000082019100010
J	Mason, CAE; Chang, P; Fallery, C; Rabinovitch, M				Mason, CAE; Chang, P; Fallery, C; Rabinovitch, M			Nitric oxide mediates LC-3-dependent regulation of fibronectin in ductus arteriosus intimal cushion formation	FASEB JOURNAL			English	Article						extracellular matrix; cell migration; microtubule; atherosclerosis	SMOOTH-MUSCLE CELLS; ENDOTHELIAL GROWTH-FACTOR; RNA-BINDING PROTEIN; MICROTUBULE-ASSOCIATED PROTEIN-1; ACTIVATED PROTEIN-KINASE-1 BMK1; MESSENGER-RNA; IN-VIVO; POSTTRANSCRIPTIONAL REGULATION; TRANSPLANT ARTERIOSCLEROSIS; 3'-UNTRANSLATED REGION	Ductus arteriosus intimal cushion formation is characterized by fibronectin-dependent smooth muscle cell (SMC) migration. Enhanced fibronectin synthesis in ductus SMC is regulated by the interaction of LC-3, a microtubule-associated protein, with an AU-rich element (ARE) in the 3'-untranslated region of fibronectin mRNA, facilitating its recruitment to polyribosomes for translation. Since nitric oxide (NO) is implicated in posttranscriptional gene regulation and is produced in the ductus, we investigated its mechanistic role in LC-3-mediated fibronectin synthesis, NO production was sevenfold higher in ductus vs. aortic SMC (P<0.005) associated with increased neuronal NO synthase (nNOS) expression. The NOS inhibitor L-NMMA decreased fibronectin synthesis by similar to 45-50% (P<0.05), whereas the NO donor, SNAP, increased ductus fibronectin synthesis similar to onefold (P<0.05); neither agent altered fibronectin mRNA levels. Immunoblotting revealed that SNAP increased and GNMMA reduced a membrane-associated phosphorylated form of LC-3. RNA gel mobility shift assays confirmed that NO enhanced LC-3 binding to the fibronectin mRNA ARE. Our studies indicate a tissue-specific program in the ductus arteriosus whereby elevated nNOS expression and NO production regulate the posttranscriptional increase in fibronectin synthesis required for SMC motility.	Hosp Sick Children, Res Inst, Div Cardiovasc Res, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Pediat, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Pathol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Med, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto	Rabinovitch, M (corresponding author), Hosp Sick Children, Res Inst, Div Cardiovasc Res, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	MR@sickkids.on.ca						Abe J, 1997, J BIOL CHEM, V272, P20389, DOI 10.1074/jbc.272.33.20389; Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; ABMAN SH, 1990, AM J PHYSIOL, V259, pH1921, DOI 10.1152/ajpheart.1990.259.6.H1921; Akyurek LM, 1996, AM J PATHOL, V149, P1981; Arthur JF, 1997, ARTERIOSCL THROM VAS, V17, P737, DOI 10.1161/01.ATV.17.4.737; BORNFELDT KE, 1994, J CLIN INVEST, V93, P1266, DOI 10.1172/JCI117081; BOUDREAU N, 1991, DEV BIOL, V143, P235, DOI 10.1016/0012-1606(91)90074-D; BOUDREAU N, 1992, LAB INVEST, V67, P350; BOUDREAU N, 1991, LAB INVEST, V64, P187; Brown C, 1998, FASEB J, V12, pA704; BRUGG B, 1993, NEUROSCIENCE, V52, P489, DOI 10.1016/0306-4522(93)90401-Z; CALVERT R, 1985, EMBO J, V4, P1171, DOI 10.1002/j.1460-2075.1985.tb03756.x; CLAUSELL N, 1994, CIRCULATION, V89, P2768, DOI 10.1161/01.CIR.89.6.2768; CLAUSELL N, 1995, BRIT HEART J, V73, P534; Clyman RI, 1998, PEDIATR RES, V43, P633, DOI 10.1203/00006450-199805000-00012; COCEANI F, 1994, CAN J PHYSIOL PHARM, V72, P82, DOI 10.1139/y94-013; CORNFIELD DN, 1992, AM J PHYSIOL, V262, pH1474, DOI 10.1152/ajpheart.1992.262.5.H1474; Farhadian F, 1996, CARDIOVASC RES, V32, P433, DOI 10.1016/S0008-6363(96)00119-8; Fox JJ, 1996, AM J PHYSIOL-HEART C, V271, pH2638, DOI 10.1152/ajpheart.1996.271.6.H2638; GITTENBERGERDEGROOT AC, 1985, J AM COLL CARDIOL, V6, P394, DOI 10.1016/S0735-1097(85)80178-9; Graf K, 1997, HYPERTENSION, V29, P334, DOI 10.1161/01.HYP.29.1.334; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; HAN JR, 1995, P NATL ACAD SCI USA, V92, P9550, DOI 10.1073/pnas.92.21.9550; Hartsfield CL, 1997, AM J PHYSIOL-LUNG C, V273, pL980; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; Hynes RO, 1990, FIBRONECTINS; Janssen YMW, 1997, AM J PHYSIOL-LUNG C, V273, pL789, DOI 10.1152/ajplung.1997.273.4.L789; Kuroki M, 1996, J CLIN INVEST, V98, P1667, DOI 10.1172/JCI118962; KWON YK, 1993, MOL CELL BIOL, V13, P6547, DOI 10.1128/MCB.13.10.6547; Lau YT, 1996, BIOCHEM BIOPH RES CO, V221, P670, DOI 10.1006/bbrc.1996.0654; LEE KH, 1994, J BIOL CHEM, V269, P14371; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; LITMAN P, 1993, NEURON, V10, P627, DOI 10.1016/0896-6273(93)90165-N; LopezFigueroa MO, 1996, NEUROENDOCRINOLOGY, V63, P384, DOI 10.1159/000126979; Luoma JS, 1998, ARTERIOSCL THROM VAS, V18, P157, DOI 10.1161/01.ATV.18.2.157; MALTER JS, 1991, J BIOL CHEM, V266, P3167; Mann SS, 1996, J NEUROSCI RES, V43, P535, DOI 10.1002/(SICI)1097-4547(19960301)43:5<535::AID-JNR3>3.0.CO;2-J; MANN SS, 1994, J BIOL CHEM, V269, P11492; Mason CAE, 1999, NAT MED, V5, P176, DOI 10.1038/5538; MASSON D, 1995, J CELL BIOL, V131, P1015, DOI 10.1083/jcb.131.4.1015; Mayer B, 1997, TRENDS BIOCHEM SCI, V22, P477, DOI 10.1016/S0968-0004(97)01147-X; McGary EC, 1997, J BIOL CHEM, V272, P8628, DOI 10.1074/jbc.272.13.8628; MOLOSSI S, 1995, J CELL PHYSIOL, V163, P19, DOI 10.1002/jcp.1041630104; MONCADA S, 1991, EUR J CLIN INVEST, V21, P361, DOI 10.1111/j.1365-2362.1991.tb01383.x; MORRIS BJ, 1995, J BIOL CHEM, V270, P24740; Nelson PR, 1998, J VASC SURG, V27, P117, DOI 10.1016/S0741-5214(98)70298-8; Noiri E, 1997, J BIOL CHEM, V272, P1747, DOI 10.1074/jbc.272.3.1747; PANTOPOULOS K, 1995, P NATL ACAD SCI USA, V92, P1267, DOI 10.1073/pnas.92.5.1267; Parenti A, 1998, J BIOL CHEM, V273, P4220, DOI 10.1074/jbc.273.7.4220; PAYNE JM, 1993, J BIOL CHEM, V268, P80; Poppa V, 1998, ARTERIOSCL THROM VAS, V18, P1312, DOI 10.1161/01.ATV.18.8.1312; RABINOVITCH M, 1988, DEV BIOL, V130, P250, DOI 10.1016/0012-1606(88)90431-9; Rairigh RL, 1998, J CLIN INVEST, V101, P15, DOI 10.1172/JCI1228; Ravalli S, 1997, TRANSPLANT P, V29, P2579, DOI 10.1016/S0041-1345(97)00516-2; RONDON IJ, 1995, FEBS LETT, V359, P267, DOI 10.1016/0014-5793(95)00066-I; ROSS R, 1971, J CELL BIOL, V50, P172, DOI 10.1083/jcb.50.1.172; RUSSELL ME, 1995, CIRCULATION, V92, P457, DOI 10.1161/01.CIR.92.3.457; Sarkar R, 1996, CIRC RES, V78, P225, DOI 10.1161/01.RES.78.2.225; SCHOENFELD TA, 1989, J NEUROSCI, V9, P1712; Silvagno F, 1996, J BIOL CHEM, V271, P11204, DOI 10.1074/jbc.271.19.11204; SMITH GCS, 1993, CARDIOVASC RES, V27, P2205, DOI 10.1093/cvr/27.12.2205; STANDART N, 1990, GENE DEV, V4, P2157, DOI 10.1101/gad.4.12a.2157; STUEHR DJ, 1991, FASEB J, V5, P98, DOI 10.1096/fasebj.5.1.1703974; TALEGHANY N, 1992, J NEUROSCI RES, V33, P257, DOI 10.1002/jnr.490330209; URSELL PC, 1995, INT J CARDIOL, V50, P217, DOI 10.1016/0167-5273(95)02380-F; VONDERLEYEN HE, 1995, P NATL ACAD SCI USA, V92, P1137, DOI 10.1073/pnas.92.4.1137; Walker J, 1996, DEV BIOL, V173, P292, DOI 10.1006/dbio.1996.0024; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; WHITE CR, 1994, P NATL ACAD SCI USA, V91, P1044, DOI 10.1073/pnas.91.3.1044; Wilcox JN, 1997, ARTERIOSCL THROM VAS, V17, P2479, DOI 10.1161/01.ATV.17.11.2479; ZAIDI SHE, 1995, J BIOL CHEM, V270, P17292, DOI 10.1074/jbc.270.29.17292; Zhou B, 1997, J CLIN INVEST, V100, P3070, DOI 10.1172/JCI119862; Zhou B, 1998, CIRC RES, V83, P481, DOI 10.1161/01.RES.83.5.481; ZHU L, 1993, LAB INVEST, V68, P321; ZICHE M, 1994, J CLIN INVEST, V94, P2036, DOI 10.1172/JCI117557	77	21	21	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1999	13	11					1423	1434		10.1096/fasebj.13.11.1423	http://dx.doi.org/10.1096/fasebj.13.11.1423			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	226KL	10428766				2022-12-25	WOS:000082019100014
J	Kania, AM; Reichenberger, E; Baur, ST; Karimbux, NY; Taylor, RW; Olsen, BR; Nishimura, I				Kania, AM; Reichenberger, E; Baur, ST; Karimbux, NY; Taylor, RW; Olsen, BR; Nishimura, I			Structural variation of type XII collagen at its carboxyl-terminal NC1 domain generated by tissue-specific alternative splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IX COLLAGEN; EMBRYONIC-DEVELOPMENT; II COLLAGEN; IN-VITRO; EXPRESSION; VARIANTS; CARTILAGE; LOCALIZATION; MOLECULE; LIGAMENT	This paper reports the identification of two structural variations in the NC1 domain of rat and mouse type XII: collagen. The long NC1 domain encoding 74 amino acids showed homology to chicken type XII and XIV collagens. The short NC1 domain was composed of 19 amino acids. Through genomic DNA analyses, two alternative exons were identified, each of which contained the variable NC1 sequence. With the amino-terminal NC3 splicing alternatives, we propose here a new descriptive nomenclature: types XIIA-1 and XIIB-1 which include a long NC1 sequence encoded by exon 1 (from the 3'-end), and types XIIA-2 and XIIB-2 which include a short NCI sequence encoded by exon 2, Types XIIA-1 and XIIB-1, the predominant transcripts in 15-day old mouse embryos, showed decreased expression in 17-day old embryos when type XIIB-2 expression was sustained at constant levels. In adult mice, type XIIB-1 associates with ligament and tendon, whereas type XIIB-2 is expressed in various other tissues. The long NC1 domain contains an extended acidic region (pI = 3.4) followed by a terminal basic region (pI = 13.8). Because the short NC1 domain lacks these features, structural variations in the type XII collagen NC1 domain suggests different functional roles in a tissue-specific fashion.	Univ Calif Los Angeles, Sch Dent, Jane & Jerry Weintraub Ctr Reconstruct Biotechnol, Div Adv Prosthodont Biomat & Hosp Dent, Los Angeles, CA 90095 USA; Harvard Univ, Sch Dent Med, Dept Periodontol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Univ Alabama, Sch Dent, Dept Orthodont, Birmingham, AL 35213 USA	University of California System; University of California Los Angeles; Harvard University; Harvard School of Dental Medicine; Harvard University; Harvard Medical School; University of Alabama System; University of Alabama Birmingham	Nishimura, I (corresponding author), Univ Calif Los Angeles, Sch Dent, Jane & Jerry Weintraub Ctr Reconstruct Biotechnol, Div Adv Prosthodont Biomat & Hosp Dent, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.				NIAMS NIH HHS [AR36820] Funding Source: Medline; NIDCR NIH HHS [DE00351, DE07010] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR036820, R01AR036820] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BOHME K, 1995, DEV DYNAM, V204, P432; DIAB M, 1996, BIOCH J, V314; EYRE DR, 1987, FEBS LETT, V220, P337, DOI 10.1016/0014-5793(87)80842-6; FONT B, 1993, J BIOL CHEM, V268, P25015; Font B, 1996, MATRIX BIOL, V15, P341, DOI 10.1016/S0945-053X(96)90137-7; GORDON MK, 1989, J BIOL CHEM, V264, P19772; GORDON MK, 1987, P NATL ACAD SCI USA, V84, P6040, DOI 10.1073/pnas.84.17.6040; Innis MA, 1990, PCR PROTOCOLS GUIDE; INOGUCHI K, 1995, J BIOCHEM-TOKYO, V117, P137, DOI 10.1093/oxfordjournals.jbchem.a124700; KARIMBUX NY, 1992, J DENT RES, V71, P1355, DOI 10.1177/00220345920710070201; KEENE DR, 1991, J CELL BIOL, V113, P971, DOI 10.1083/jcb.113.4.971; KOCH M, 1995, J CELL BIOL, V130, P1005, DOI 10.1083/jcb.130.4.1005; LUNGSTRUM GP, 1991, J CELL BIOL, V113, P963; Mechling DE, 1996, J BIOL CHEM, V271, P13781, DOI 10.1074/jbc.271.23.13781; NISHIYAMA T, 1994, J BIOL CHEM, V269, P28193; Niyibizi C, 1995, MATRIX BIOL, V14, P743, DOI 10.1016/S0945-053X(05)80017-4; OH SP, 1993, DEV DYNAM, V196, P37, DOI 10.1002/aja.1001960105; Sambrook J., 2002, MOL CLONING LAB MANU; SHAW LM, 1991, TRENDS BIOCHEM SCI, V16, P191, DOI 10.1016/0968-0004(91)90074-6; SUGRUE SP, 1989, J CELL BIOL, V109, P939, DOI 10.1083/jcb.109.2.939; TRUEB J, 1992, BIOCHIM BIOPHYS ACTA, V1171, P97, DOI 10.1016/0167-4781(92)90145-P; VANDERREST M, 1988, J BIOL CHEM, V263, P1615; WALCHLI C, 1994, J CELL SCI, V107, P669; WATT SL, 1992, J BIOL CHEM, V267, P20093; WU JJ, 1992, BIOCHEM J, V314, P327; YAMAGATA M, 1991, J CELL BIOL, V115, P209, DOI 10.1083/jcb.115.1.209; ZHAN Q, 1995, EXP EYE RES, V60, P551, DOI 10.1016/S0014-4835(05)80070-3	27	30	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					22053	22059		10.1074/jbc.274.31.22053	http://dx.doi.org/10.1074/jbc.274.31.22053			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419532	hybrid			2022-12-25	WOS:000081721100085
J	Seiler-Tuyns, A; Dufour, N; Spertini, F				Seiler-Tuyns, A; Dufour, N; Spertini, F			Human tumor necrosis factor-alpha gene 3 ' untranslated region confers inducible toxin responsiveness to homologous promoter in monocytic THP-1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-II LIGANDS; MESSENGER-RNA; TNF-ALPHA; TRANSCRIPTIONAL ACTIVATION; 3'-UNTRANSLATED REGION; NUCLEOTIDE-SEQUENCE; PRIMARY MACROPHAGES; LIPOPOLYSACCHARIDE; EXPRESSION; CACHECTIN	To better define the role of 3' untranslated region (3'UTR) on transcriptional regulation of the human tumor necrosis factor (TNF)-alpha gene, monocytic human THP-1 cells were transfected with two TNF-alpha promoter constructs spanning base pairs -1897/-1 and -1214/-1, respectively, and linked to the rabbit beta-globin gene. Quantitative globin gene expression of chimerae was measured by reverse transcription-polymerase chain reaction. A construct linking the chicken beta-actin promoter and a deleted portion of the beta-globin gene was cotransfected and used as internal standard. Unexpectedly, when THP-1 cells were stimulated with lipopolysaccharide or toxic shock syndrome toxin-1, gene regulation was hardly detected. In contrast, endogenous TNF-alpha gene regulation measured by the same reverse transcription-polymerase chain reaction procedure was vigorous. Remarkably, ligation of 3'UTR to chimeric constructs led to a drastic drop in the basal level of chimeric gene expression, resulting in a 15- to 40-fold induction of the reporter gene. Consistently, when the TNF-alpha promoter was replaced by the cytomegalovirus early immediate promoter, gene expression was also uniformly reduced but was no longer up-regulated upon stimulation with lipopolysaccharide and toxic shock syndrome toxin-1. These data provide the first line of evidence that, in addition to its role in TNF-alpha transcript stability and translation, human TNF-alpha 3'UTR also participates in modulating gene expression at the transcriptional level.	CHU Vaudois, Dept Med, Div Immunol & Allergy, CH-1011 Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Spertini, F (corresponding author), CHU Vaudois, Dept Med, Div Immunol & Allergy, CH-1011 Lausanne, Switzerland.							BECKER L, 1995, PEDIATR RES, V37, P165, DOI 10.1203/00006450-199502000-00007; BEUTLER B, 1988, BIOCHEMISTRY-US, V27, P7575, DOI 10.1021/bi00420a001; BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BEUTLER B, 1991, J CLIN INVEST, V87, P1336, DOI 10.1172/JCI115137; BEUTLER B, 1992, TUMOR NECROSIS FACTO, P561; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DROUET C, 1991, J IMMUNOL, V147, P1694; Espel E, 1996, EUR J IMMUNOL, V26, P2417, DOI 10.1002/eji.1830261023; Estoppey O, 1996, EUR J IMMUNOL, V26, P1475, DOI 10.1002/eji.1830260711; GOLDFELD AE, 1990, P NATL ACAD SCI USA, V87, P9769, DOI 10.1073/pnas.87.24.9769; HAN J, 1991, J IMMUNOL, V146, P1843; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; HAN JH, 1991, BIOCHIM BIOPHYS ACTA, V1090, P22, DOI 10.1016/0167-4781(91)90032-H; Jacob CO, 1996, J IMMUNOL, V156, P3043; KOST TA, 1983, NUCLEIC ACIDS RES, V11, P8287, DOI 10.1093/nar/11.23.8287; KRUYS V, 1992, P NATL ACAD SCI USA, V89, P673, DOI 10.1073/pnas.89.2.673; LATTION AL, 1992, MOL CELL BIOL, V12, P5217, DOI 10.1128/MCB.12.11.5217; LE JM, 1987, LAB INVEST, V56, P234; NEDOSPASOV SA, 1986, COLD SPRING HARB SYM, V51, P611, DOI 10.1101/SQB.1986.051.01.073; NEDWIN GE, 1985, NUCLEIC ACIDS RES, V13, P6361, DOI 10.1093/nar/13.17.6361; OLD LJ, 1985, SCIENCE, V230, P630, DOI 10.1126/science.2413547; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; Sperisen P, 1992, PCR Methods Appl, V1, P164; TAKASHIBA S, 1995, INFECT IMMUN, V63, P1529, DOI 10.1128/IAI.63.4.1529-1534.1995; TREDE NS, 1991, J IMMUNOL, V146, P2310; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717	28	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21714	21718		10.1074/jbc.274.31.21714	http://dx.doi.org/10.1074/jbc.274.31.21714			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419483	hybrid			2022-12-25	WOS:000081721100036
J	Ashton, AW; Watanabe, G; Albanese, C; Harrington, EO; Ware, JA; Pestell, RG				Ashton, AW; Watanabe, G; Albanese, C; Harrington, EO; Ware, JA; Pestell, RG			Protein kinase c delta inhibition of S-phase transition in capillary endothelial cells involves the cyclin-dependent kinase inhibitor p27(Kip1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; RETINOBLASTOMA PROTEIN; CDK INHIBITORS; TYROSINE PHOSPHORYLATION; ANGIOGENESIS INVITRO; PROMOTER ACTIVITY; PHORBOL ESTER; DNA-SYNTHESIS; CHO CELLS; PROLIFERATION	Distinct protein kinase C (PKC) isoforms differentially regulate cellular proliferation in rat microvascular endothelial cells (EC), Overexpression of PKC alpha has little effect on proliferation, whereas PKC delta slows endothelial cell proliferation and induces S-phase arrest. Analyses were performed on EC overexpressing PKC alpha (PKC alpha EC) or PKC delta (PKC delta EC) to determine the role of specific cell cycle regulatory proteins in the PKC delta-induced cell cycle arrest, Serum-induced stimulation of cyclins D1, E, and A-associated kinase activity was delayed by 12 h in the PKC delta EC line in association with S-phase arrest. However, the protein levels for cyclins D1, E, and A were similar. Nuclear accumulation of cyclin D1 protein in response to serum was also delayed in PKC delta EC. In the PKC delta EC line, serum induced p27(Kip1) hut not p15(Ink4a) or p21(Cip1). Serum did not affect p27(Kip1) levels in the control vascular endothelial cell line. Immunoprecipitation-Western blotting analysis of p27(Kip1) showed serum stimulation of the vascular endothelial cell line resulted in increased amounts of cyclin D1 bound to p27(Kip1). In the PKC delta EC line, serum did not increase the amount of cyclin D1 bound to p27(Kip1). Transfection of full-length p27(Kip1) antisense into the PCK delta EC line reversed the S-phase arrest and resulted in normal cell cycle progression, suggesting a critical role for p27(Kip1) in the PKC delta-mediated S-phase arrest.	Albert Einstein Coll Med, Div Cardiovasc, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Ashton, AW (corresponding author), Albert Einstein Coll Med, Div Cardiovasc, Jack & Pearl Resnick Campus,1300 Morris Pk Ave, Bronx, NY 10461 USA.	ashton@aecom.yu.edu	Ware, Joseph/AAC-2843-2022	Harrington, Elizabeth/0000-0002-3207-5301	NCI NIH HHS [CA75503, CA70897] Funding Source: Medline; NHLBI NIH HHS [HL47032] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070897, R55CA075503, R01CA075503] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047032] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGRAWAL D, 1995, CELL GROWTH DIFFER, V6, P1199; AUSPRUNK DH, 1977, MICROVASC RES, V14, P53, DOI 10.1016/0026-2862(77)90141-8; Byeon IJL, 1998, MOL CELL, V1, P421, DOI 10.1016/S1097-2765(00)80042-8; CACERES A, 1984, J NEUROSCI, V4, P394; Chen DH, 1997, J CLIN INVEST, V99, P2334, DOI 10.1172/JCI119414; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; COPPOCK DL, 1993, CELL GROWTH DIFFER, V4, P483; DAVIET I, 1990, FEBS LETT, V259, P315, DOI 10.1016/0014-5793(90)80035-H; DENNING MF, 1993, J BIOL CHEM, V268, P26079; Diehl JA, 1997, MOL CELL BIOL, V17, P7362, DOI 10.1128/MCB.17.12.7362; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; Frey MR, 1997, J BIOL CHEM, V272, P9424; GRUBER JR, 1992, J BIOL CHEM, V267, P13356; GSCHWENDT M, 1994, FEBS LETT, V347, P85, DOI 10.1016/0014-5793(94)00514-1; Hamada K, 1996, BBA-MOL CELL RES, V1310, P149, DOI 10.1016/0167-4889(95)00148-4; Harrington EO, 1997, J BIOL CHEM, V272, P7390, DOI 10.1074/jbc.272.11.7390; HIRAI S, 1994, EMBO J, V13, P2331, DOI 10.1002/j.1460-2075.1994.tb06517.x; HU DE, 1995, INFLAMMATION, V19, P39, DOI 10.1007/BF01534379; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KINDREGAN HC, 1994, J BIOL CHEM, V269, P27756; KOSAKA C, 1996, AM J PHYSIOL, V39, pC170; Koyama H, 1996, CELL, V87, P1069, DOI 10.1016/S0092-8674(00)81801-2; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LEE RJ, 1999, METHODS MOL MED FIBR; Livneh E, 1996, ONCOGENE, V12, P1545; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Luo Y, 1996, MOL CELL BIOL, V16, P6744; Lybarger L, 1996, CYTOMETRY, V25, P211, DOI 10.1002/(SICI)1097-0320(19961101)25:3<211::AID-CYTO2>3.0.CO;2-I; MILTENYI S, 1990, CYTOMETRY, V11, P231, DOI 10.1002/cyto.990110203; MITTNACHT S, 1994, EMBO J, V13, P118, DOI 10.1002/j.1460-2075.1994.tb06241.x; MONTESANO R, 1985, CELL, V42, P469, DOI 10.1016/0092-8674(85)90104-7; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; Paulus W, 1996, J VIROL, V70, P62, DOI 10.1128/JVI.70.1.62-67.1996; PESTELL RG, 1999, IN PRESS ENDOCR REV; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PRESTA M, 1991, CELL REGUL, V2, P719, DOI 10.1091/mbc.2.9.719; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; SASAGURI T, 1993, EXP CELL RES, V208, P311, DOI 10.1006/excr.1993.1251; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shiyanov P, 1997, MOL BIOL CELL, V8, P1815, DOI 10.1091/mbc.8.9.1815; SIEBENKOTTEN G, 1998, CELL SEPARATION METH, P271; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212; Watanabe G, 1996, J BIOL CHEM, V271, P22570, DOI 10.1074/jbc.271.37.22570; Watanabe G, 1998, DEV BRAIN RES, V108, P77, DOI 10.1016/S0165-3806(98)00032-7; Watanabe G, 1997, J BIOL CHEM, V272, P20063, DOI 10.1074/jbc.272.32.20063; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Winston J, 1996, J BIOL CHEM, V271, P11253, DOI 10.1074/jbc.271.19.11253; WRIGHT PS, 1992, J CELL PHYSIOL, V152, P448, DOI 10.1002/jcp.1041520303; Xiong W, 1997, AM J PHYSIOL-LUNG C, V272, pL1205, DOI 10.1152/ajplung.1997.272.6.L1205; YAMAGUCHI K, 1995, BIOCHEM BIOPH RES CO, V210, P639, DOI 10.1006/bbrc.1995.1708; Yancopoulos GD, 1998, CELL, V93, P661, DOI 10.1016/S0092-8674(00)81426-9; YANG EY, 1990, J CELL BIOL, V111, P731, DOI 10.1083/jcb.111.2.731; Zang Q, 1997, J BIOL CHEM, V272, P13275, DOI 10.1074/jbc.272.20.13275; Zhao JY, 1998, GENE DEV, V12, P456, DOI 10.1101/gad.12.4.456; ZHOU W, 1993, J BIOL CHEM, V268, P23041	68	73	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					20805	20811		10.1074/jbc.274.30.20805	http://dx.doi.org/10.1074/jbc.274.30.20805			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409620	hybrid			2022-12-25	WOS:000081613100011
J	Bobkova, EV; Habib, N; Alexander, G; Hall, BD				Bobkova, EV; Habib, N; Alexander, G; Hall, BD			Mutational analysis of the hydrolytic activity of yeast RNA polymerase III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACILITATED TRANSCRIPT CLEAVAGE; TERNARY COMPLEXES; TERMINATION; ELONGATION; SEQUENCES; GENE	For 25 mutant alleles of ret1, encoding the second largest subunit of yeast RNA polymerase III, we have studied the polymerase III nuclease activity, measuring both the total yield and dinucleotide product composition. Mutations affecting amino acids 309-325 gave slightly elevated nuclease activity. In region 367-376, two mutations gave 12-15-fold increased nuclease activity. Our results do not support the catalytic role in nuclease activity proposed for the conserved DDRD motif in this region (Shirai, T., and Go, M. (1991) Proc. Natl. Acad., Sci. U. S. A. 88, 9056-9060), Mutations centered on a basic region front amino acids 480 to 490, which aligns with Escherichia coli beta-subunit sequences between Rif(r) clusters I and II, produce changes in the relative yields of A- and G-containing dinucleotides, Four such mutant polymerases pause during elongation at GPy sequences and, in addition, have a reduced frequency of termination at T-5 terminator sequences. We propose that the side chains of these mutationally altered amino acids are in direct contact with bases in the RNA-DNA hybrid very near the growing S'-end, Two mutations in domain I near the C terminus produced very large increases in exonuclease activity and strongly increased termination, suggesting that this region also contacts the nascent RNA in the hybrid region.	Univ Washington, Dept Genet, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Hall, BD (corresponding author), Univ Washington, Dept Genet, POB 357360, Seattle, WA 98195 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM011895] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM11895] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON DS, 1985, EMBO J, V4, P2657, DOI 10.1002/j.1460-2075.1985.tb03984.x; BAKER RE, 1986, J BIOL CHEM, V261, P5275; Bobkova EV, 1997, J BIOL CHEM, V272, P22832, DOI 10.1074/jbc.272.36.22832; BOGENHAGEN DF, 1981, CELL, V24, P261, DOI 10.1016/0092-8674(81)90522-5; Chedin S, 1998, GENE DEV, V12, P3857, DOI 10.1101/gad.12.24.3857; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; JAMES P, 1990, GENETICS, V125, P293; JIN DJ, 1992, P NATL ACAD SCI USA, V89, P1453, DOI 10.1073/pnas.89.4.1453; JIN DJ, 1988, J MOL BIOL, V202, P45, DOI 10.1016/0022-2836(88)90517-7; KOSKI RA, 1980, CELL, V22, P415, DOI 10.1016/0092-8674(80)90352-9; MATSUZAKI H, 1994, J MOL BIOL, V235, P1173, DOI 10.1006/jmbi.1994.1072; REINES D, 1992, J BIOL CHEM, V267, P3795; ROSENBERG M, 1979, ANNU REV GENET, V13, P319, DOI 10.1146/annurev.ge.13.120179.001535; Sambrook J., 2002, MOL CLONING LAB MANU; SHAABAN SA, 1995, MOL CELL BIOL, V15, P1467; Shaaban SA, 1996, MOL CELL BIOL, V16, P6468; SHAABAN SA, 1993, THESIS U WASHINGTON; SHIRAI T, 1991, P NATL ACAD SCI USA, V88, P9056, DOI 10.1073/pnas.88.20.9056; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; VONHIPPEL PH, 1992, SCIENCE, V255, P809, DOI 10.1126/science.1536005; WHITEHALL SK, 1994, J BIOL CHEM, V269, P2299	22	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21342	21348		10.1074/jbc.274.30.21342	http://dx.doi.org/10.1074/jbc.274.30.21342			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409694	hybrid			2022-12-25	WOS:000081613100085
J	Li, RX; Blanchette-Mackie, EJ; Ladisch, S				Li, RX; Blanchette-Mackie, EJ; Ladisch, S			Induction of endocytic vesicles by exogenous C-6-ceramide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLGI-APPARATUS; CERAMIDE ANALOG; PATHWAY; PROTEIN; STRESS; CELLS; DIFFERENTIATION; ARREST; KINASE; CYCLE	Ceramide is a newly discovered second messenger that has been shown to cause cell growth arrest and apoptosis, Here, we present evidence that exogenously added C-6-ceramide induces enlargement of late endosomes and lysosomes, 10 mu M C-6-ceramide caused the formation of numerous vesicles of varying sizes (2-10 mu m) in fibroblasts (3T3-L1 and 3T3-F442A), without toxic effects. Vesicle formation induced by C-6-ceramide was time- and dose-dependent, rapid, and reversible. Numerous small vesicles appeared within 8 h of treatment with 10 mu M C-6-ceramide, They enlarged with time, with large vesicles found in the perinuclear region and small ones observed at the cell periphery. Within 24 h of treatment, similar to 30% of the cells exhibited these vesicles. Removal of ceramide from the culture medium caused disappearance of the vesicles, which reappeared upon readdition of ceramide, Confocal immunofluorescence microscopic analysis using an anti-lysosome-associated membrane protein antibody identified the enlarged vesicles as late endosomes/lysosomes. The fluorescent C-6-NBD-ceramide, a vital stain for the Golgi apparatus, did not stain these vesicles. The effect on vesicle formation was influenced by ceramide structure; D-erythro-C-6-ceramide was the most active ceramide analogue tested. Short chain ceramide metabolites, such as sphingosine, sphingosine 1-phosphate, N-hexanoyl-sphingosylphosphorylcholine, N-acetylpsychosine, and C-2-ceramide G(M3), (G(M3), N-acetylneuraminosyl-alpha(2,3)-galactosyl-beta (1,4)-glucosylceramide), were inactive in causing vesicle formation when added exogenously, Together, these studies demonstrate that exogenous C-6-ceramide induces endocytic vesicle formation and causes enlarged late endosomes and lysosomes in mouse fibroblasts.	Childrens Res Inst, Ctr Canc & Transplant Biol, Glycobiol Program, Washington, DC 20010 USA; George Washington Univ, Sch Med, Dept Pediat, Washington, DC 20052 USA; George Washington Univ, Sch Med, Dept Biochem Mol Biol, Washington, DC 20052 USA; NIDDK, Lipid Cell Biol Sect, NIH, Bethesda, MD 20892 USA	George Washington University; George Washington University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Li, RX (corresponding author), Childrens Res Inst, Ctr Canc & Transplant Biol, Glycobiol Program, 111 Michigan Ave NW, Washington, DC 20010 USA.				NCI NIH HHS [CA61010] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061010] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK060003] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERTS B, 1994, MOL BIOL CELL, P612; BLANCHETTEMACKIE EJ, 1995, J LIPID RES, V36, P1211; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; CHEN CS, 1995, J BIOL CHEM, V270, P13291, DOI 10.1074/jbc.270.22.13291; CHEN JW, 1985, J CELL BIOL, V101, P85, DOI 10.1083/jcb.101.1.85; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DBAIBO GS, 1995, P NATL ACAD SCI USA, V92, P1347, DOI 10.1073/pnas.92.5.1347; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HAUSER JM, 1994, J BIOL CHEM, P6803; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; JOHNSON GD, 1981, J IMMUNOL METHODS, V43, P349, DOI 10.1016/0022-1759(81)90183-6; KOMORI H, 1995, FEBS LETT, V374, P299, DOI 10.1016/0014-5793(95)01137-4; Li GP, 1997, J BIOL CHEM, V272, P10337; LIPSKY NG, 1983, P NATL ACAD SCI-BIOL, V80, P2608, DOI 10.1073/pnas.80.9.2608; LIPSKY NG, 1985, SCIENCE, V228, P745, DOI 10.1126/science.2581316; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; MARTIN OC, 1993, P NATL ACAD SCI USA, V90, P2661, DOI 10.1073/pnas.90.7.2661; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Murphy C, 1996, NATURE, V384, P427, DOI 10.1038/384427a0; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; ROSENWALD AG, 1993, J BIOL CHEM, V268, P4577; Schimmoller F, 1998, J BIOL CHEM, V273, P22161, DOI 10.1074/jbc.273.35.22161; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; YOUNES A, 1992, J BIOL CHEM, V267, P842; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X	29	51	51	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21121	21127		10.1074/jbc.274.30.21121	http://dx.doi.org/10.1074/jbc.274.30.21121			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409665	hybrid			2022-12-25	WOS:000081613100056
J	Nijenhuis, M; Zalm, R; Burbach, JPH				Nijenhuis, M; Zalm, R; Burbach, JPH			Mutations in the vasopressin prohormone involved in diabetes insipidus impair endoplasmic reticulum export but not sorting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROPHYSIN-II GENE; BIOSYNTHETIC PRECURSOR; CRYSTAL-STRUCTURE; CODING REGION; PC12 CELLS; PROTEIN; PEPTIDE; IDENTIFICATION; HORMONE; KINDREDS	Familial neurohypophysial diabetes insipidus is characterized by vasopressin deficiency caused by heterozygous expression of a mutated vasopressin prohormone gene. To elucidate the mechanism of this disease, we stably expressed five vasopressin prohormones with a mutation in the neurophysin moiety (NP14G-->R, NP47E-->G, NP47 Delta E, NP57G-->S, and NP65G-->V) in the neuroendocrine cell lines Neuro-2A and PC12/PC2, Metabolic labeling demonstrated that processing and secretion of all five mutants was impaired, albeit to different extents (NP65G-->V greater than or equal to NP14G-->R > NP47 Delta E greater than or equal to NP47E-->G > NP57G-->S), Persisting endoglycosidase H sensitivity revealed these defects to be due to retention of mutant prohormone in the endoplasmic reticulum. Mutant prohormones that partially passed the endoplasmic reticulum were normally targeted to the regulated secretory pathway. Surprisingly, this also included mutants with mutations in residues involved in binding of vasopressin to neurophysin, a process implicated in targeting of the prohormone. To mimick the high expression in vasopressin-producing neurons, mutant vasopressin prohormones were transiently expressed in Neuro-2A cells. Immunofluorescence displayed formation of large accumulations of mutant prohormone in the endoplasmic reticulum, accompanied by redistribution of an endoplasmic reticulum marker. Our data suggest that prolonged perturbation of the endoplasmic reticulum eventually leads to degeneration of neurons expressing mutant vasopressin prohormones, explaining the dominant nature of the disease.	Univ Utrecht, Rudolf Magnus Inst Neurosci, NL-3508 TA Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center	Nijenhuis, M (corresponding author), Univ Utrecht, Rudolf Magnus Inst Neurosci, Univ Weg 100,POB 80040, NL-3508 TA Utrecht, Netherlands.	M.Nijenhuis@med.uu.nl						AARTS LHJ, 1995, NEUROREPORT, V6, P969, DOI 10.1097/00001756-199505090-00005; ANDO S, 1987, J BIOL CHEM, V262, P12962; Arvan P, 1998, BIOCHEM J, V332, P593, DOI 10.1042/bj3320593; BERGERON C, 1991, ACTA NEUROPATHOL, V81, P345, DOI 10.1007/BF00305879; BIRCH NP, 1994, NEUROPEPTIDES, V27, P307, DOI 10.1016/0143-4179(94)90057-4; Bottger G, 1996, J BIOL CHEM, V271, P29191, DOI 10.1074/jbc.271.46.29191; BRAVERMAN LE, 1965, ANN INTERN MED, V63, P503, DOI 10.7326/0003-4819-63-3-503; BRESLOW E, 1990, ADV ENZYMOL RAMB, V63, P1; BURGOYNE RD, 1993, BIOCHEM J, V293, P305, DOI 10.1042/bj2930305; Calvo B, 1998, J CLIN ENDOCR METAB, V83, P995, DOI 10.1210/jc.83.3.995; CHEN LQ, 1991, P NATL ACAD SCI USA, V88, P4240, DOI 10.1073/pnas.88.10.4240; de Bree FM, 1998, CELL MOL NEUROBIOL, V18, P173, DOI 10.1023/A:1022564803093; DEBREE FM, 1994, BIOCHIMIE, V76, P315, DOI 10.1016/0300-9084(94)90165-1; DITTIE AS, 1995, BIOCHEM J, V310, P777, DOI 10.1042/bj3100777; FASSINA G, 1988, J BIOL CHEM, V263, P13539; FUJIWARA TM, 1995, ANNU REV MED, V46, P331; Gagliardi PC, 1997, J CLIN ENDOCR METAB, V82, P3643, DOI 10.1210/jc.82.11.3643; Gainer H., 1988, P2265; Grant FD, 1998, J CLIN ENDOCR METAB, V83, P3958, DOI 10.1210/jc.83.11.3958; GREEN JR, 1967, BRAIN, V90, P707, DOI 10.1093/brain/90.3.707; Greidanus TBV, 1996, NEUROPEPTIDES, V30, P452, DOI 10.1016/S0143-4179(96)90009-8; Heppner C, 1998, J CLIN ENDOCR METAB, V83, P693, DOI 10.1210/jc.83.2.693; Ito M, 1997, J CLIN INVEST, V99, P1897, DOI 10.1172/JCI119357; KANMERA T, 1985, J BIOL CHEM, V260, P8474; KLEBE RJ, 1969, J CELL BIOL, V43, pA69; Lang T, 1997, NEURON, V18, P857, DOI 10.1016/S0896-6273(00)80325-6; LIU B, 1987, PEPTIDES, V8, P7, DOI 10.1016/0196-9781(87)90156-2; MA YH, 1995, ENDOCRINOLOGY, V136, P2622, DOI 10.1210/en.136.6.2622; MERCKEN M, 1992, J NEUROBIOL, V23, P309, DOI 10.1002/neu.480230310; Morris JF, 1995, ADV EXP MED BIOL, V395, P49; NAGAI I, 1984, ACTA ENDOCRINOL-COP, V105, P318, DOI 10.1530/acta.0.1050318; Nijenhuis M, 1996, J IMMUNOL, V157, P5467; NORTH WG, 1983, J ENDOCRINOL, V96, P373, DOI 10.1677/joe.0.0960373; NORTH WG, 1995, BREAST CANCER RES TR, V34, P229, DOI 10.1007/BF00689714; Olias G, 1996, DNA CELL BIOL, V15, P929, DOI 10.1089/dna.1996.15.929; POW DV, 1992, NEUROSCIENCE, V50, P503, DOI 10.1016/0306-4522(92)90442-5; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; Rauch F, 1996, CLIN ENDOCRINOL, V44, P45, DOI 10.1046/j.1365-2265.1996.628449.x; Repaske DR, 1996, J CLIN ENDOCR METAB, V81, P2328, DOI 10.1210/jc.81.6.2328; Repaske DR, 1997, J CLIN ENDOCR METAB, V82, P51, DOI 10.1210/jc.82.1.51; Rittig S, 1996, J INVEST MED, V44, pA387; Rittig S, 1996, AM J HUM GENET, V58, P107; Robertson G, 1995, INT CONGR SER, V1098, P593; ROBINSON ICAF, 1976, ACTA ENDOCRINOL-COP, V83, P36, DOI 10.1530/acta.0.0830036; Rose JP, 1996, NAT STRUCT BIOL, V3, P163, DOI 10.1038/nsb0296-163; SAUSVILLE E, 1985, J BIOL CHEM, V260, P236; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; Ueta Y, 1996, J CLIN ENDOCR METAB, V81, P1787, DOI 10.1210/jc.81.5.1787; van der Eb A J, 1980, Methods Enzymol, V65, P826; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; Verhage M, 1995, EUR J PHARM-MOLEC PH, V291, P387, DOI 10.1016/0922-4106(95)90081-0	54	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21200	21208		10.1074/jbc.274.30.21200	http://dx.doi.org/10.1074/jbc.274.30.21200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409675	hybrid			2022-12-25	WOS:000081613100066
J	Xu, ZJ; Hirasawa, A; Shinoura, H; Tsujimoto, G				Xu, ZJ; Hirasawa, A; Shinoura, H; Tsujimoto, G			Interaction of the alpha(1B)-adrenergic receptor with gC1q-R, a multifunctional protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BETA-2-ADRENERGIC RECEPTOR; COUPLED RECEPTORS; BETA(2)-ADRENERGIC RECEPTOR; BINDING-PROTEIN; FUNCTIONAL EXPRESSION; ADRENERGIC-RECEPTORS; CARBOXYL-TERMINUS; CELLULAR PROTEIN; DOWN-REGULATION; GLOBULAR HEADS	gC1q-R, a multifunctional protein, was found to bind with the carboxyl-terminal cytoplasmic domain of the alpha(1B)-adrenergic receptor (173 amino acids, amino acids 344-516) in a yeast two-hybrid screen of a cDNA library prepared from the rat liver. In a series of studies with deletion mutants in this region, the ten arginine-rich amino acids (amino acids 369-378) were identified as the site of interaction. The interaction was confirmed by specific co-immunoprecipitation of gC1q-R with full-length alpha(1B)-adrenergic receptors expressed on transfected COS-7 cells, as well as by fluorescence confocal laser scanning microscopy, which showed co-localization of these proteins in intact cells. Interestingly, the alpha(1B)-adrenergic receptors were exclusively localized to the region of the plasma membrane in COS-7 cells that expressed the alpha(1B)-adrenergic receptor alone, whereas gC1q-R was localized in the cytoplasm in COS-7 cells that expressed gC1q-R alone; however, in cells that coexpressed alpha(1B)-adrenergic receptors and gC1q-R, most of the alpha(1B)-adrenergic receptors were co-localized with gC1q-R in the intracellular region, and a remarkable down-regulation of receptor expression was observed. These observations suggest a new role for the previously identified complement regulatory molecule, gC1q-R, in regulating the cellular localization and expression of the alpha(1B)-adrenergic receptors.	Natl Childrens Med Res Ctr, Dept Mol Cell Pharmacol, Setagaya Ku, Tokyo 1541809, Japan	National Center for Child Health & Development - Japan	Tsujimoto, G (corresponding author), Natl Childrens Med Res Ctr, Dept Mol Cell Pharmacol, Setagaya Ku, Taishido 3-35-31, Tokyo 1541809, Japan.							Awaji T, 1998, MOL ENDOCRINOL, V12, P1099, DOI 10.1210/me.12.8.1099; CAMPBELL PT, 1991, MOL PHARMACOL, V39, P192; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRASER CM, 1994, PROG NUCLEIC ACID RE, V49, P113; Ghebrehiwet B, 1998, IMMUNOBIOLOGY, V199, P225, DOI 10.1016/S0171-2985(98)80029-6; GHEBREHIWET B, 1994, J EXP MED, V179, P1809, DOI 10.1084/jem.179.6.1809; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; HEIN L, 1995, NEUROPHARMACOLOGY, V34, P357, DOI 10.1016/0028-3908(95)00018-2; Herwald H, 1996, J BIOL CHEM, V271, P13040, DOI 10.1074/jbc.271.22.13040; Hirasawa A, 1996, FEBS LETT, V386, P141, DOI 10.1016/0014-5793(96)00388-2; Hirasawa A, 1997, MOL PHARMACOL, V52, P764, DOI 10.1124/mol.52.5.764; Klein U, 1997, J BIOL CHEM, V272, P19099, DOI 10.1074/jbc.272.31.19099; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; Krueger KM, 1997, J BIOL CHEM, V272, P5; LATTION AL, 1994, J BIOL CHEM, V269, P22887; Lim BL, 1996, J BIOL CHEM, V271, P26739, DOI 10.1074/jbc.271.43.26739; PARKER EM, 1995, J BIOL CHEM, V270, P6482, DOI 10.1074/jbc.270.12.6482; Schulein R, 1998, MOL PHARMACOL, V54, P525, DOI 10.1124/mol.54.3.525; SOHLEMANN P, 1995, EUR J BIOCHEM, V232, P464, DOI 10.1111/j.1432-1033.1995.tb20832.x; SterneMarr R, 1995, VITAM HORM, V51, P193, DOI 10.1016/S0083-6729(08)61039-0; VALIQUETTE M, 1990, P NATL ACAD SCI USA, V87, P5089, DOI 10.1073/pnas.87.13.5089; YU L, 1995, J VIROL, V69, P3007, DOI 10.1128/JVI.69.5.3007-3016.1995	26	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21149	21154		10.1074/jbc.274.30.21149	http://dx.doi.org/10.1074/jbc.274.30.21149			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409668	hybrid			2022-12-25	WOS:000081613100059
J	Durkin, JT; Murthy, S; Husten, EJ; Trusko, SP; Savage, MJ; Rotella, DP; Greenberg, BD; Siman, R				Durkin, JT; Murthy, S; Husten, EJ; Trusko, SP; Savage, MJ; Rotella, DP; Greenberg, BD; Siman, R			Rank-order of potencies for inhibition of the secretion of A beta 40 and A beta 42 suggests that both are generated by a single gamma-secretase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; BETA-PROTEIN; INTRACELLULAR PRODUCTION; TRANSMEMBRANE DOMAIN; PEPTIDE; SPECIFICITY; CELLS; ACCUMULATION; COMPARTMENT	The Alzheimer's disease amyloid peptide A beta has a heterogeneous COOH terminus, as variants 40 and 42 residues long are found in neuritic plaques and are secreted constitutively by cultured cells, The proteolytic activity that liberates the A beta COOH terminus from the beta-amyloid precursor protein is called gamma-secretase. It could be one protease with dual specificity or two distinct enzymes. By using enzyme-linked immunosorbent assays selective for A beta 40 or A beta 42, we have measured A beta secretion by a HeLa cell line, and we have examined the dose responses for a panel of five structurally diverse gamma-secretase inhibitors. The inhibitors lowered A beta and p3 secretion and increased levels of the COOH-terminal 99-residue beta-amyloid precursor protein derivative that is the precursor for A beta but did not alter secretion of beta-amyloid precursor protein derivatives generated by other secretases, indicating that the inhibitors blocked the gamma-secretase processing step. The dose dependent inhibition of A beta 42 was unusual, as the compounds elevated A beta 42 secretion at sub-inhibitory doses and then inhibited secretion at higher doses. A compound was identified that elevated A beta 42 secretion at a low concentration without inhibiting A beta 42 or A beta 40 at high concentrations, demonstrating that these phenomena are separable pharmacologically, Using either of two methods, IC50 values for inhibition of A beta 42 and A beta 40 were found to have the same rank order and fall on a trend line with near-unit slope. These results favor the hypothesis that A beta variants ending at residue 40 or 42 are generated by a single gamma-seeretase.	Cephalon Inc, W Chester, PA 19380 USA	Teva Pharmaceutical Industries; Cephalon Inc.	Durkin, JT (corresponding author), Cephalon Inc, 145 Brandywine Pkwy, W Chester, PA 19380 USA.							Burdick D, 1997, BRAIN RES, V746, P275, DOI 10.1016/S0006-8993(96)01262-0; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; Citron M, 1996, P NATL ACAD SCI USA, V93, P13170, DOI 10.1073/pnas.93.23.13170; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; DOHERTY AM, 1992, J MED CHEM, V35, P2, DOI 10.1021/jm00079a001; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; FULLER SJ, 1995, BIOCHEMISTRY-US, V34, P8091, DOI 10.1021/bi00025a015; HAASS C, 1993, J BIOL CHEM, V268, P3021; HAASS C, 1995, NAT MED, V1, P1291, DOI 10.1038/nm1295-1291; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; HIGAKI J, 1995, NEURON, V14, P651, DOI 10.1016/0896-6273(95)90322-4; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; Klafki HW, 1996, J BIOL CHEM, V271, P28655, DOI 10.1074/jbc.271.45.28655; Kuentzel SL, 1996, AMYLOID, V3, P86, DOI 10.3109/13506129609014360; Lichtenthaler SF, 1997, BIOCHEMISTRY-US, V36, P15396, DOI 10.1021/bi971071m; MAK K, 1994, BRAIN RES, V667, P138, DOI 10.1016/0006-8993(94)91725-6; Mann DMA, 1996, ANN NEUROL, V40, P149, DOI 10.1002/ana.410400205; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; Perez RG, 1996, J BIOL CHEM, V271, P9100, DOI 10.1074/jbc.271.15.9100; RAO CM, 1993, J MED CHEM, V36, P2614, DOI 10.1021/jm00070a004; Reaume AG, 1996, J BIOL CHEM, V271, P23380, DOI 10.1074/jbc.271.38.23380; Savage MJ, 1995, AMYLOID, V2, P234, DOI 10.3109/13506129508999005; Savage MJ, 1998, J NEUROSCI, V18, P1743; SAVAGE MJ, 1994, NEUROSCIENCE, V60, P607, DOI 10.1016/0306-4522(94)90490-1; SCHENK DB, 1995, J MED CHEM, V38, P4141, DOI 10.1021/jm00021a001; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHIOSAKI K, 1993, J MED CHEM, V36, P468, DOI 10.1021/jm00056a007; SIMAN R, 1993, J BIOL CHEM, V268, P16602; Siman R, 1996, CURR OPIN BIOTECH, V7, P601, DOI 10.1016/S0958-1669(96)80070-X; SIMAN R, 1995, RESEARCH ADVANCES IN ALZHEIMER'S DISEASE AND RELATED DISORDERS, P675; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Tienari PJ, 1997, P NATL ACAD SCI USA, V94, P4125, DOI 10.1073/pnas.94.8.4125; Tischer E, 1996, J BIOL CHEM, V271, P21914, DOI 10.1074/jbc.271.36.21914; TSUJINAKA T, 1988, BIOCHEM BIOPH RES CO, V153, P1201, DOI 10.1016/S0006-291X(88)81355-X; WERTKIN AM, 1993, P NATL ACAD SCI USA, V90, P9513, DOI 10.1073/pnas.90.20.9513; Wolfe MS, 1998, J MED CHEM, V41, P6, DOI 10.1021/jm970621b; Yamazaki T, 1997, BIOCHEMISTRY-US, V36, P8377, DOI 10.1021/bi970209y; YOUNKIN SG, 1995, ANN NEUROL, V37, P287, DOI 10.1002/ana.410370303	41	43	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20499	20504		10.1074/jbc.274.29.20499	http://dx.doi.org/10.1074/jbc.274.29.20499			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400678	hybrid			2022-12-25	WOS:000081438300071
J	Valles, S; Tsoi, C; Huang, WY; Wyllie, D; Carlotti, F; Askari, JA; Humphries, MJ; Dower, SK; Qwarnstrom, EE				Valles, S; Tsoi, C; Huang, WY; Wyllie, D; Carlotti, F; Askari, JA; Humphries, MJ; Dower, SK; Qwarnstrom, EE			Recruitment of a heparan sulfate subunit to the interleukin-1 receptor complex - Regulation by fibronectin attachment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; PROTEOGLYCAN CYTOPLASMIC DOMAIN; PROTEIN-KINASE-C; MURINE B-CELL; NF-KAPPA-B; MOLECULAR-CLONING; IL-1 RECEPTOR; DORSOVENTRAL SIGNAL; STABLE EXPRESSION; DROSOPHILA EMBRYO	In this study, we identified an adhesion-regulated subunit of the interleukin-1 (IL-1) receptor complex. Transfection of fibroblasts with an IL-1 receptor-EGFP construct showed that the fusion protein was located at focal adhesions in cells attaching to fibronectin. Fibronectin attachment caused enhancement in endogenous IL-1 type I receptor levels from on average 2500 to 4300 receptors/cell. In addition, matrix attachment resulted in a decrease in binding affinity (K-a) from 1.0 x 10(9) (M-1) to 5.6 x 10(8) (M-1), due to a 2-fold reduction in association rate constant. The adhesion-mediated effects were reversed by soluble heparin. Cross-linking experiments showed that in cells attached to fibronectin, 50-70% of the radiolabeled IL-1 was associated with a heparinase sensitive, high molecular mass component of about 300 kDa, with a core protein of 80-90 kDa, Formation of the complex was dependent on cell interaction with the heparin binding region in fibronectin and required IL-1/type I IL-1 receptor binding. This report demonstrates the recruitment of a heparan sulfate to the IL-1 receptor complex, following attachment to fibronectin, which correlates with alterations in receptor function. The data suggest that the heparan sulfate constitutes an attachment regulated component of the IL-1 receptor complex with the role of mediating matrix regulation of IL-1 responses.	Royal Hallamshire Hosp, Div Mol & Genet Med, Funct Genom Grp, Sheffield S10 2JF, S Yorkshire, England; Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England	University of Sheffield; University of Washington; University of Washington Seattle; University of Manchester	Qwarnstrom, EE (corresponding author), Royal Hallamshire Hosp, Div Mol & Genet Med, Funct Genom Grp, Glossop Rd, Sheffield S10 2JF, S Yorkshire, England.		Valles, Soraya L./H-9320-2019	Valles, Soraya L./0000-0003-4861-4266; dower, steve/0000-0002-4675-4225; Humphries, Martin/0000-0002-4331-6967; Qwarnstrom, Eva/0000-0003-4417-8663	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011251, R01DE010363] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE-10363, DE-11251] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aviezer D, 1997, MOL CELL BIOL, V17, P1938, DOI 10.1128/MCB.17.4.1938; BOMSZTYK K, 1989, P NATL ACAD SCI USA, V86, P8034, DOI 10.1073/pnas.86.20.8034; BOMSZTYK K, 1990, J BIOL CHEM, V265, P9413; BonnehBarkay D, 1997, J BIOL CHEM, V272, P12415, DOI 10.1074/jbc.272.19.12415; BROWN PJ, 1985, SCIENCE, V228, P1448, DOI 10.1126/science.4012302; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; CAREY DJ, 1990, J CELL BIOL, V111, P2053, DOI 10.1083/jcb.111.5.2053; CHIEFETZ S, 1988, J BIOL CHEM, V263, P16984; CHIZZONITE R, 1989, P NATL ACAD SCI USA, V86, P8029, DOI 10.1073/pnas.86.20.8029; COSMAN D, 1986, MOL IMMUNOL, V23, P935, DOI 10.1016/0161-5890(86)90123-9; DAVID G, 1990, J CELL BIOL, V111, P3165, DOI 10.1083/jcb.111.6.3165; DAVID G, 1992, J CELL BIOL, V118, P961, DOI 10.1083/jcb.118.4.961; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; DOWER SK, 1985, J EXP MED, V162, P501, DOI 10.1084/jem.162.2.501; DOWER SK, 1986, NATURE, V324, P266, DOI 10.1038/324266a0; DOWER SK, 1990, J INVEST DERMATOL, V94, pS68, DOI 10.1111/1523-1747.ep12875154; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Feyzi E, 1997, J BIOL CHEM, V272, P5518, DOI 10.1074/jbc.272.9.5518; Filla MS, 1998, J CELL PHYSIOL, V174, P310, DOI 10.1002/(SICI)1097-4652(199803)174:3<310::AID-JCP5>3.0.CO;2-R; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GALINDO RL, 1995, DEVELOPMENT, V121, P2209; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; GROSSHANS J, 1994, NATURE, V372, P563, DOI 10.1038/372563a0; Horowitz A, 1998, J BIOL CHEM, V273, P10914, DOI 10.1074/jbc.273.18.10914; HORUK R, 1987, J BIOL CHEM, V262, P16275; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETSOU A, 1993, EMBO J, V12, P3449, DOI 10.1002/j.1460-2075.1993.tb06019.x; LINDAHL U, 1978, ANNU REV BIOCHEM, V47, P385, DOI 10.1146/annurev.bi.47.070178.002125; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; Lortat-Jacob H, 1997, CYTOKINE, V9, P101, DOI 10.1006/cyto.1996.0142; MAKAREM R, 1994, J BIOL CHEM, V269, P4005; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; Mitcham JL, 1996, J BIOL CHEM, V271, P5777, DOI 10.1074/jbc.271.10.5777; MITCHAM JL, 1995, CYTOKINE, V7, P595; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Norris JL, 1996, GENE DEV, V10, P862, DOI 10.1101/gad.10.7.862; Oh ES, 1997, ARCH BIOCHEM BIOPHYS, V344, P67, DOI 10.1006/abbi.1997.0180; Oh ES, 1998, J BIOL CHEM, V273, P10624, DOI 10.1074/jbc.273.17.10624; Oh ES, 1997, J BIOL CHEM, V272, P8133, DOI 10.1074/jbc.272.13.8133; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; OSTBERG CO, 1995, FEBS LETT, V367, P93, DOI 10.1016/0014-5793(95)00509-8; PARK LS, 1987, J EXP MED, V166, P476, DOI 10.1084/jem.166.2.476; QWARNSTROM EE, 1988, J BIOL CHEM, V263, P8261; QWARNSTROM EE, 1993, BIOCHEM J, V294, P613, DOI 10.1042/bj2940613; QWARNSTROM EE, 1991, P NATL ACAD SCI USA, V88, P1232, DOI 10.1073/pnas.88.4.1232; QWARNSTROM EE, 1994, J BIOL CHEM, V269, P30765; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; Sharma B, 1998, J BIOL CHEM, V273, P4642, DOI 10.1074/jbc.273.8.4642; SIMS JE, 1989, P NATL ACAD SCI USA, V86, P8946, DOI 10.1073/pnas.86.22.8946; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SLACK J, 1993, J BIOL CHEM, V268, P2513; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; SPRIGGS MK, 1990, J BIOL CHEM, V265, P22499; SUDHALTER J, 1989, J BIOL CHEM, V264, P6892; Tiedemann K, 1997, MATRIX BIOL, V15, P469, DOI 10.1016/S0945-053X(97)90020-2; URDAL DL, 1988, J BIOL CHEM, V263, P2870; Volpe F, 1997, FEBS LETT, V419, P41, DOI 10.1016/S0014-5793(97)01426-9; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Wight Thomas N., 1992, Current Opinion in Cell Biology, V4, P793, DOI 10.1016/0955-0674(92)90102-I; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Zhu P, 1998, BIOCHEM J, V330, P975, DOI 10.1042/bj3300975; ZHU XT, 1993, STRUCTURE, V1, P27, DOI 10.1016/0969-2126(93)90006-3	69	18	18	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20103	20109		10.1074/jbc.274.29.20103	http://dx.doi.org/10.1074/jbc.274.29.20103			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400621	hybrid			2022-12-25	WOS:000081438300014
J	Vo, QD; Gruol, DJ				Vo, QD; Gruol, DJ			Identification of P-glycoprotein mutations causing a loss of steroid recognition and transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREDICTED TRANSMEMBRANE DOMAIN-11; MULTIDRUG-RESISTANCE PROTEIN; DRUG-BINDING SITE; SUBSTRATE-SPECIFICITY; FUNCTIONAL CONSEQUENCES; MDR GENE; INDUCED APOPTOSIS; CELLS; PROGESTERONE; RESIDUES	P-glycoproteins transport a wide variety of hydrophobic compounds out of cells, While the diversity of transported molecules suggests a mechanism involving broad specificity, there is evidence of significant discrimination within given classes of molecules. One example of this behavior is transport of corticosteroids by the murine mdr1 P-glycoprotein, The presence of hydroxyl groups, associated with specific steroid carbon atoms, regulates the ability of corticosteroids to be transported. This specificity is demonstrated here by experiments measuring the ability of steroids to inhibit drug transport. The results indicate that a keto oxygen associated with the 3- and 20-carbon atoms, as well as a 17-carbon hydroxyl group, each acts to enhance steroidal P-glycoprotein inhibitory activity. Moreover, inhibitory steroids can be used for directed selection of variant cells, expressing mutated P-glycoproteins with a severely impaired ability to transport dexamethasone. The five mutations, reported here, are located within transmembrane domains 4-6, proximal to the cytoplasmic interface. The altered P-glycoproteins exhibit reduced capacity to be inhibited by specific steroids, suggesting decreased capacity to bind these molecules avidly. Studies comparing the relative inhibitory activity of a series of steroids indicate that these mutations alter recognition of the 17 alpha-hydroxyl group and the 20-keto oxygen atom.	Sidney Kimmel Canc Ctr, San Diego, CA 92121 USA		Gruol, DJ (corresponding author), Sidney Kimmel Canc Ctr, 10835 Altman Row, San Diego, CA 92121 USA.				NIDDK NIH HHS [DK51107] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051107] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bakos E, 1997, BIOCHEM J, V323, P777, DOI 10.1042/bj3230777; Barnes KM, 1996, BIOCHEMISTRY-US, V35, P4820, DOI 10.1021/bi952380k; Beaudet L, 1998, BIOCHEMISTRY-US, V37, P9073, DOI 10.1021/bi972656j; BOURGEOIS S, 1993, MOL ENDOCRINOL, V7, P840, DOI 10.1210/me.7.7.840; BRUGGEMANN EP, 1989, J BIOL CHEM, V264, P15483; BRUGGEMANN EP, 1992, J BIOL CHEM, V267, P21020; Chen G, 1997, J BIOL CHEM, V272, P5974, DOI 10.1074/jbc.272.9.5974; CHOI K, 1988, CELL, V53, P519, DOI 10.1016/0092-8674(88)90568-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CURRIER SJ, 1992, J BIOL CHEM, V267, P25153; CURRIER SJ, 1989, J BIOL CHEM, V264, P14376; Demmer A, 1997, J BIOL CHEM, V272, P20913, DOI 10.1074/jbc.272.33.20913; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; DEVINE SE, 1992, P NATL ACAD SCI USA, V89, P4564, DOI 10.1073/pnas.89.10.4564; DHIR R, 1993, BIOCHEMISTRY-US, V32, P9492, DOI 10.1021/bi00087a030; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; Gottesman MM, 1995, ANNU REV GENET, V29, P607, DOI 10.1146/annurev.ge.29.120195.003135; GREENBERGER LM, 1990, J BIOL CHEM, V265, P4394; GREENBERGER LM, 1993, J BIOL CHEM, V268, P11417; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; GRUOL D, 1999, IN PRESS BIOCH PHARM; GRUOL DJ, 1994, BIOCHEM CELL BIOL, V72, P561, DOI 10.1139/o94-075; GRUOL DJ, 1994, CANCER RES, V54, P3088; GRUOL DJ, 1984, J CELL PHYSIOL, V119, P107, DOI 10.1002/jcp.1041190118; GRUOL DJ, 1989, MOL ENDOCRINOL, V3, P2119, DOI 10.1210/mend-3-12-2119; Gruol DJ, 1997, CANCER RES, V57, P720; Hafkemeyer P, 1998, BIOCHEMISTRY-US, V37, P16400, DOI 10.1021/bi980871+; Hanna M, 1996, BIOCHEMISTRY-US, V35, P3625, DOI 10.1021/bi951333p; HARRIS AW, 1973, J IMMUNOL, V110, P431; JOHNSON DM, 1984, CANCER RES, V44, P2435; KAJIJI S, 1993, BIOCHEMISTRY-US, V32, P4185, DOI 10.1021/bi00067a005; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; Kwan T, 1998, BIOCHEMISTRY-US, V37, P3337, DOI 10.1021/bi972680x; LEPAGE P, 1993, MOL CELL BIOL, V13, P7380, DOI 10.1128/MCB.13.12.7380; LOO TW, 1993, J BIOL CHEM, V268, P3143; Loo TW, 1997, J BIOL CHEM, V272, P31945, DOI 10.1074/jbc.272.51.31945; LOO TW, 1994, J BIOL CHEM, V269, P7243; LOO TW, 1994, BIOCHEMISTRY-US, V33, P14049, DOI 10.1021/bi00251a013; Loo TW, 1996, J BIOL CHEM, V271, P15414, DOI 10.1074/jbc.271.26.15414; LOO TW, 1993, J BIOL CHEM, V268, P19965; Loo TW, 1998, METHOD ENZYMOL, V292, P480; MORRIS DI, 1994, MOL PHARMACOL, V46, P329; Muller M, 1996, J BIOL CHEM, V271, P1877; QIAN XD, 1990, J BIOL CHEM, V265, P18753; SAFA AR, 1990, P NATL ACAD SCI USA, V87, P7225, DOI 10.1073/pnas.87.18.7225; Taguchi Y, 1997, BIOCHEMISTRY-US, V36, P8883, DOI 10.1021/bi970553v; Urbatsch IL, 1998, BIOCHEMISTRY-US, V37, P4592, DOI 10.1021/bi9728001; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; Wu Q, 1998, BIOCHEMISTRY-US, V37, P11272, DOI 10.1021/bi980598b; YANG CPH, 1989, J BIOL CHEM, V264, P782; YANG CPH, 1990, J BIOL CHEM, V265, P10282; ZHANG XP, 1995, J BIOL CHEM, V270, P5441, DOI 10.1074/jbc.270.10.5441; [No title captured]	54	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20318	20327		10.1074/jbc.274.29.20318	http://dx.doi.org/10.1074/jbc.274.29.20318			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400654	hybrid			2022-12-25	WOS:000081438300047
J	Smith, JS; Alderete, B; Minn, Y; Borell, TJ; Perry, A; Mohapatra, G; Hosek, SM; Kimmel, D; O'Fallon, J; Yates, A; Feuerstein, BG; Burger, PC; Scheithauer, BW; Jenkins, RB				Smith, JS; Alderete, B; Minn, Y; Borell, TJ; Perry, A; Mohapatra, G; Hosek, SM; Kimmel, D; O'Fallon, J; Yates, A; Feuerstein, BG; Burger, PC; Scheithauer, BW; Jenkins, RB			Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype	ONCOGENE			English	Article						diffuse glioma; tumor suppressor gene; loss of heterozygosity; fluorescence in situ hybridization; comparative genomic hybridization; chromosome 1; chromosome 19	COMPARATIVE GENOMIC HYBRIDIZATION; IN-SITU HYBRIDIZATION; OLIGODENDROGLIAL TUMORS; CYTOGENETIC ANALYSIS; PCV CHEMOTHERAPY; GENETIC-ANALYSIS; CELL-LINES; HETEROZYGOSITY; OLIGOASTROCYTOMAS; ASTROCYTOMAS	Allelic alterations of chromosomes 1 and 19 are frequent events in human diffuse gliomas and have recently proven to be strong predictors of chemotherapeutic response and prolonged survival in oligodendrogliomas (Cairncross ct al., 1998; Smith et al,, submitted), Using 115 human diffuse gliomas, we localized regions of common allelic loss on chromosomes 1 and 19 and assessed the association of these deletion intervals with glioma histological subtypes. Further, we evaluated the capacity of multiple modalities to detect these alterations, including loss of heterozygosity (LOH), fluorescence in situ hybridization (FISH), and comparative genomic hybridization (CGH), The correlation coefficients for detection of 1p and 19q alterations, respectively, between modalities were: 0.98 and 0.87 for LOH and FISH, 0.79 and 0.60 for LOH and CGH, and 0.79 and 0.53 for FISH and CGH, Minimal deletion regions were defined on 19q13.3 (D19S412-D19S596) and 1p (D1S468-D1S1612), Loss of the 1p36 region was found in 18% of astrocytomas (10/55) and in 73% (24/33) of oligodendrogliomas (P < 0.0001), and loss of the 19q13.3 region was found in 38% (21/55) of astrocytomas and 73% (24/33) of oligodendrogliomas (P = 0.0017), Loss of both regions was found in 11% (6/55) of astrocytomas and in 63% (21/33) of oligodendrogliomas (P < 0.0001). All gliomas with LOH on either 1p or 19q demonstrated loss of the corresponding FISH probe, 1p36 or 19q13.3, suggesting not only locations of putative tumor suppressor genes, but also a simple assay for assessment of 1p and 19q alterations as diagnostic and prognostic markers.	Mayo Clin & Mayo Fdn, Div Lab Genet, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Anat Pathol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Neurol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biostat, Rochester, MN 55905 USA; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94115 USA; Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94115 USA; Univ Calif San Francisco, Brain Tumor Res Ctr, San Francisco, CA 94115 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21287 USA; Ohio State Univ, Div Neuropathol, Columbus, OH 43210 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Johns Hopkins University; University System of Ohio; Ohio State University	Jenkins, RB (corresponding author), Mayo Clin & Mayo Fdn, Div Lab Genet, 200 1st St SW, Rochester, MN 55905 USA.		Feuerstein, Burt G/A-5186-2015	Feuerstein, Burt G/0000-0001-7276-8842; Perry, Arie/0000-0002-8300-7261	NATIONAL CANCER INSTITUTE [U01CA050905, U01CA064898, U01CA050910] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASHWORTH LK, 1995, NAT GENET, V11, P422, DOI 10.1038/ng1295-422; BAER R, 1993, SEMIN CANCER BIOL, V4, P341; BELLO MJ, 1995, INT J CANCER, V64, P207; BELLO MJ, 1994, INT J CANCER, V57, P172, DOI 10.1002/ijc.2910570207; CAIRNCROSS G, 1994, J CLIN ONCOL, V12, P2013, DOI 10.1200/JCO.1994.12.10.2013; Cairncross JG, 1998, J NATL CANCER I, V90, P1473, DOI 10.1093/jnci/90.19.1473; CAIRNCROSS JG, 1988, ANN NEUROL, V23, P360, DOI 10.1002/ana.410230408; CHUNG R, 1991, GENE CHROMOSOME CANC, V3, P323, DOI 10.1002/gcc.2870030502; CLIBY W, 1993, CANCER RES, V53, P2393; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; COLLINS A, 1992, P NATL ACAD SCI USA, V89, P4598, DOI 10.1073/pnas.89.10.4598; FRANKEL RH, 1992, CANCER RES, V52, P1427; FULTS D, 1992, CANCER RES, V52, P674; *GDB TM, HUM GEN DAT; GLASS J, 1992, J NEUROSURG, V76, P741, DOI 10.3171/jns.1992.76.5.0741; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; KIM DH, 1995, INT J CANCER, V60, P812, DOI 10.1002/ijc.2910600615; Kim L, 1996, J NEUROSURG, V85, P602, DOI 10.3171/jns.1996.85.4.0602; KLEIHUES P, 1992, HISTOLOGICAL TYPING; KRAUS JA, 1995, J NEUROPATH EXP NEUR, V54, P91, DOI 10.1097/00005072-199501000-00011; LEVIN VA, 1993, CANC PRINCIPLES PRAC, P1679; LINDBLOM A, 1993, CANCER RES, V53, P4356; Louis DN, 1997, BRAIN PATHOL, V7, P755, DOI 10.1111/j.1750-3639.1997.tb01062.x; LOUIS DN, 1995, TRENDS GENET, V11, P412, DOI 10.1016/S0168-9525(00)89125-8; Maintz D, 1997, J NEUROPATH EXP NEUR, V56, P1098, DOI 10.1097/00005072-199710000-00003; Mason WP, 1996, NEUROLOGY, V46, P203, DOI 10.1212/WNL.46.1.203; Mohapatra G, 1998, GENE CHROMOSOME CANC, V21, P195, DOI 10.1002/(SICI)1098-2264(199803)21:3<195::AID-GCC3>3.3.CO;2-A; MOHAPATRA G, 1995, GENE CHROMOSOME CANC, V13, P86, DOI 10.1002/gcc.2870130203; Muliokandov MR, 1996, CANCER RES, V56, P197; MURRAY JC, 1994, SCIENCE, V265, P2049, DOI 10.1126/science.8091227; Nunnally J.C., 1994, PSYCHOMETRIC THEORY, DOI DOI 10.1037/018882; Perry A, 1997, J NEUROPATH EXP NEUR, V56, P999, DOI 10.1097/00005072-199709000-00005; PIPER J, 1995, CYTOMETRY, V19, P10, DOI 10.1002/cyto.990190104; QIAN JQ, 1995, CANCER RES, V55, P5408; RANSOM DT, 1992, GENE CHROMOSOME CANC, V5, P357, DOI 10.1002/gcc.2870050412; REIFENBERGER J, 1994, AM J PATHOL, V145, P1175; RITLAND SR, 1995, GENE CHROMOSOME CANC, V12, P277, DOI 10.1002/gcc.2870120407; Rosenberg JE, 1996, ONCOGENE, V13, P2483; SALTMAN DL, 1990, GENE CHROMOSOME CANC, V2, P259, DOI 10.1002/gcc.2870020402; Schwab M, 1996, GENE CHROMOSOME CANC, V16, P211, DOI 10.1002/(SICI)1098-2264(199608)16:4<211::AID-GCC1>3.0.CO;2-0; SEIZINGER BR, 1991, CYTOGENET CELL GENET, V58, P1080, DOI 10.1159/000133722; Smith J. C., UNPUB; Smith MAJ, 1997, PROBAB ENG INFORM SC, V11, P451, DOI 10.1017/S0269964800004976; TESTA JR, 1994, GENE CHROMOSOME CANC, V11, P178, DOI 10.1002/gcc.2870110307; Weber RG, 1996, ONCOGENE, V13, P983	45	287	299	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	1999	18	28					4144	4152		10.1038/sj.onc.1202759	http://dx.doi.org/10.1038/sj.onc.1202759			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	216FP	10435596				2022-12-25	WOS:000081431000012
J	Fournier, N; Raj, K; Saudan, P; Utzig, S; Sahli, R; Simanis, V; Beard, P				Fournier, N; Raj, K; Saudan, P; Utzig, S; Sahli, R; Simanis, V; Beard, P			Expression of human papillomavirus 16 E2 protein in Schizosaccharomyces pombe delays the initiation of mitosis	ONCOGENE			English	Article						HPV16; mitosis; cdc2 kinase; yeast; cell cycle	FISSION YEAST; CELL-CYCLE; GENETIC-ANALYSIS; CERVICAL-CANCER; S-PHASE; TYPE-16; KINASE; DOMAINS; CLONING; DNA	Infection by some types of human papillomavirus (HPV) is associated with the development of cervical cancer. Analysis of viral DNA from cervical tumours shows that the E2 gene is frequently disrupted during integration into the host cell's DNA, It has therefore been suggested that loss of E2p is an important step in malignant transformation. Expression of E2p in the fission yeast Schizosaccharomyces pombe retards the G2-M transition, by delaying activation of Cdc2p kinase, In contrast, S phase progression, and commitment to cell division in late G1 are not affected. The delay is independent of the transcriptional trans-activation function of E2p, and does not result from E2p DNA binding mimicking DNA damage. Increased expression of E2p also delays mitotic initiation in mammalian cells, S, pombe may thus provide a simple model for the analysis of E2p function.	Swiss Inst Expt Canc Res, Cell Cycle Control Lab, CH-1066 Epalinges, Switzerland; Swiss Inst Expt Canc Res, Dept Virol, CH-1066 Epalinges, Switzerland; CHU Vaudois, Dept Microbiol, CH-1011 Lausanne, Switzerland	Swiss Institute Experimental Cancer Research; Swiss Institute Experimental Cancer Research; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Simanis, V (corresponding author), Swiss Inst Expt Canc Res, Cell Cycle Control Lab, Chemin Boveresses 155, CH-1066 Epalinges, Switzerland.		Sahli, Roland/K-6479-2017	Sahli, Roland/0000-0001-7513-1142				ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ANDROPHY EJ, 1987, NATURE, V325, P70, DOI 10.1038/325070a0; BENSON JD, 1995, J VIROL, V69, P4364, DOI 10.1128/JVI.69.7.4364-4372.1995; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; CHIANG CM, 1992, P NATL ACAD SCI USA, V89, P5799, DOI 10.1073/pnas.89.13.5799; CORREABORDES J, 1995, CELL, V83, P1001, DOI 10.1016/0092-8674(95)90215-5; COSTELLO G, 1986, CURR GENET, V11, P119, DOI 10.1007/BF00378203; Creanor J, 1996, J CELL SCI, V109, P1647; CULLEN AP, 1991, J VIROL, V65, P606, DOI 10.1128/JVI.65.2.606-612.1991; Daniel B, 1997, J GEN VIROL, V78, P1095, DOI 10.1099/0022-1317-78-5-1095; Desaintes C, 1997, EMBO J, V16, P504, DOI 10.1093/emboj/16.3.504; DOWHANICK JJ, 1995, J VIROL, V69, P7791, DOI 10.1128/JVI.69.12.7791-7799.1995; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FANKHAUSER C, 1994, EMBO J, V13, P3011, DOI 10.1002/j.1460-2075.1994.tb06600.x; Frattini MG, 1997, EMBO J, V16, P318, DOI 10.1093/emboj/16.2.318; GIRI I, 1988, EMBO J, V7, P2823, DOI 10.1002/j.1460-2075.1988.tb03138.x; HAGAN I, 1988, J CELL SCI, V91, P587; Harlow E., 1988, ANTIBODIES LAB MANUA; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HIBMA MH, 1995, EUR J BIOCHEM, V229, P517, DOI 10.1111/j.1432-1033.1995.tb20493.x; Hitt M. M., 1994, CELL BIOL LAB HDB, V1, P479; MACNEILL SA, 1991, MOL GEN GENET, V229, P109, DOI 10.1007/BF00264219; MATSUKURA T, 1995, INT J CANCER, V61, P13, DOI 10.1002/ijc.2910610104; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; NASIM A, 1975, GENETICS, V79, P573; NURSE P, 1980, GENETICS, V96, P627; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; NURSE P, 1975, NATURE, V256, P547, DOI 10.1038/256547a0; OKAZAKI K, 1990, NUCLEIC ACIDS RES, V18, P6485, DOI 10.1093/nar/18.22.6485; REYMOND A, 1992, MOL GEN GENET, V234, P449, DOI 10.1007/BF00538705; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; Sakai H, 1996, J VIROL, V70, P1602, DOI 10.1128/JVI.70.3.1602-1611.1996; SALZMAN NP, 1987, PAPOVIRIDEAE, V2; Sambrook J, 1989, MOL CLONING; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Shiozaki K, 1997, MOL BIOL CELL, V8, P409, DOI 10.1091/mbc.8.3.409; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; Steger G, 1997, J VIROL, V71, P50, DOI 10.1128/JVI.71.1.50-58.1997; Stern B, 1996, TRENDS GENET, V12, P345; TAN SH, 1994, J VIROL, V68, P6411, DOI 10.1128/JVI.68.10.6411-6420.1994; THURIAUX P, 1980, J GEN MICROBIOL, V116, P525; USHIKAI M, 1994, J VIROL, V68, P6655, DOI 10.1128/JVI.68.10.6655-6666.1994; Vernon SD, 1997, INT J CANCER, V74, P50, DOI 10.1002/(SICI)1097-0215(19970220)74:1<50::AID-IJC9>3.3.CO;2-P	48	24	24	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	1999	18	27					4015	4021		10.1038/sj.onc.1202775	http://dx.doi.org/10.1038/sj.onc.1202775			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KU	10435625				2022-12-25	WOS:000081327800012
J	Magdinier, F; Dalla Venezia, N; Lenoir, GM; Frappart, L; Dante, R				Magdinier, F; Dalla Venezia, N; Lenoir, GM; Frappart, L; Dante, R			BRCA1 expression during prenatal development of the human mammary gland	ONCOGENE			English	Article						BRCA1; mRNA; protein; prenatal development; human mammary gland	SPORADIC BREAST-CANCER; OVARIAN-CANCER; SUBCELLULAR-LOCALIZATION; MEIOTIC CELLS; DNA-DAMAGE; GENE; DIFFERENTIATION; MUTATIONS; PROTEIN; TISSUES	Germ-line alterations of BRCA1 are associated with elevated risk of breast cancer. Evidence for the involvement of Brca1 in cellular differentiation and morphogenesis has been obtained in mouse models during embryogenesis, Although the presence of well-conserved functional domains might suggest a similar function for both human and mouse genes, very few data on BRCA1 expression in human fetal tissues are available. We have, therefore, investigated the expression of BRCA1 in the mammary gland from human female fetuses aged between 15 and 33 weeks, Quantification of BRCA1 transcripts, using a competitive reverse transcriptase PCR method, indicates a progressive decrease in BRCA1 expression with increasing fetal age between the 15th and 30th week of gestation. Subsequently, the amount of BRCA1 transcripts becomes similar to that found in adult mammary gland. Analysis of BRCA1 protein revealed, in fetal samples, a 220 kDa band corresponding to the 220 kDa BRCA1 protein described in human cell lines. These later experiments confirm that the relative level of the 220 kDa BRCA1 protein is highest in the early stages of mammary gland development. The temporal patterns of BRCA1 expression in human fetuses suggest a role for BRCA1 in the morphogenesis and differentiation of the human mammary gland.	UCBL1, CNRS, UMR 5641, Genet Lab, F-69373 Lyon 08, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Dante, R (corresponding author), UCBL1, CNRS, UMR 5641, Genet Lab, 8 Ave Rockefeller, F-69373 Lyon 08, France.		Magdinier, Frederique/I-4735-2016; VENEZIA, Nicole DALLA/C-6542-2017	Magdinier, Frederique/0000-0002-0159-9559; VENEZIA, Nicole DALLA/0000-0002-4553-3535				Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Bertwistle D, 1998, CURR OPIN GENET DEV, V8, P14, DOI 10.1016/S0959-437X(98)80056-7; Blackshear PE, 1998, ONCOGENE, V16, P61, DOI 10.1038/sj.onc.1201506; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dawson E K, 1934, Edinb Med J, V41, P653; Easton D, 1997, NAT GENET, V16, P210, DOI 10.1038/ng0797-210; Ellisen LW, 1998, ANNU REV MED, V49, P425; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GIROD C, 1970, COURS BIOL REPROD; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Lu ML, 1996, CANCER RES, V56, P4578; Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248; Marks JR, 1997, ONCOGENE, V14, P115, DOI 10.1038/sj.onc.1200808; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; NEUHAUSEN SL, 1994, CANCER RES, V54, P6069; Rajan JV, 1997, DEV BIOL, V184, P385, DOI 10.1006/dbio.1997.8526; Ribieras S, 1997, INT J CANCER, V73, P715, DOI 10.1002/(SICI)1097-0215(19971127)73:5<715::AID-IJC17>3.0.CO;2-4; Russo J., 1987, The mammary gland. Development, regulation, and function., P67; Saka Y, 1997, GENE DEV, V11, P3387, DOI 10.1101/gad.11.24.3387; Sakakura T., 1987, The mammary gland. Development, regulation, and function., P37; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; Spillman MA, 1996, ONCOGENE, V13, P1639; Tanner JM, 1962, GROWTH ADOLESCENCE, V2nd, P28; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994	38	20	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	1999	18	27					4039	4043		10.1038/sj.onc.1202780	http://dx.doi.org/10.1038/sj.onc.1202780			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KU	10435628	Green Published			2022-12-25	WOS:000081327800015
J	Pihlajamaa, T; Perala, M; Vuoristo, MM; Nokelainen, M; Bodo, M; Schulthess, T; Vuorio, E; Timpl, R; Engel, J; Ala-Kokko, L				Pihlajamaa, T; Perala, M; Vuoristo, MM; Nokelainen, M; Bodo, M; Schulthess, T; Vuorio, E; Timpl, R; Engel, J; Ala-Kokko, L			Characterization of recombinant human type IX collagen - Association of alpha chains into homotrimeric and heterotrimeric molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIPLE-HELICAL DOMAINS; CROSS-LINKING SITES; CARTILAGE; PROCOLLAGEN; IDENTIFICATION; EXPRESSION; CONTAINS; SEQUENCE; CLONING; PROTEIN	As type IX collagen is a minor cartilage component, it is difficult to purify sufficient amounts of it from tissues or cultured cells to study its structure and function. Also, the conventional pepsin digestion used for fibrillar collagens cannot be utilized for purifying type IX collagen, because it contains several interruptions in its collagenous triple helix. A baculovirus expression system was used here to produce recombinant human type IX collagen by coinfecting insect cells with three viruses containing full-length cDNAs for the alpha 1(IX), alpha 2(IX), and alpha 3(IX) collagen chains together with a double promoter virus for the alpha and beta subunits of human prolyl 4-hydroxylase, Correctly folded recombinant type IX collagen was secreted, consisting of the three alpha chains in a 1:1:1 ratio and showing the expected biphasic thermal melting profile. When the individual alpha chains were expressed, disulfide-bonded homotrimers and homodimers of the alpha chains were observed, When the cells were coinfected with the viruses for all three alpha chains, heterotrimers of alpha 1(IX), alpha 2(IX), and alpha 3(IX) were detected in cell culture medium, and the other possible combinations were less prominent. When any two of the alpha chains were co-expressed, in addition to the homodimers and homotrimers, only alpha 1(IX) and alpha 3(IX) chains were disulfide-bonded. The results thus suggest that the most favored molecular species is an alpha 1(IX)alpha 2(IX)alpha 3(IX) heterotrimer, but the chains are also able to form disulfide-bonded heterotrimers of (alpha 1(IX) and alpha 3(IX) chains and (alpha 1(IX))(3), (alpha 2(IX))(3), and (alpha 3(IX))(3) homotrimers.	Oulu Univ, Bioctr, Collagen Res Unit, FIN-90220 Oulu, Finland; Oulu Univ, Dept Biochem Med, FIN-90220 Oulu, Finland; Univ Turku, Dept Med Biochem & Mol Biol, FIN-20520 Turku, Finland; FibroGen Inc, San Francisco, CA 94080 USA; Univ Basel, Bioctr, Dept Biophys Chem, CH-4056 Basel, Switzerland; Max Planck Inst Biochem, D-82152 Martinsried, Germany	University of Oulu; University of Oulu; University of Turku; FibroGen; University of Basel; Max Planck Society	Ala-Kokko, L (corresponding author), Oulu Univ, Bioctr, Collagen Res Unit, Kajaanintie 52A, FIN-90220 Oulu, Finland.	Leena.Ala-Kokko@oulu.fi		Vuorio, Eero/0000-0003-3404-2439				BLOMBACK B, 1967, METHOD ENZYMOL, V11, P398; BREWTON RG, 1995, GENOMICS, V30, P329, DOI 10.1006/geno.1995.9870; BREWTON RG, 1994, EXTRACELLULAR MATRIX, P129; BRUCKNER P, 1985, P NATL ACAD SCI USA, V82, P2608, DOI 10.1073/pnas.82.9.2608; Bulleid NJ, 1997, EMBO J, V16, P6694, DOI 10.1093/emboj/16.22.6694; Diab M, 1996, BIOCHEM J, V314, P327, DOI 10.1042/bj3140327; DUANCE VC, 1984, BIOCHEM J, V221, P885, DOI 10.1042/bj2210885; EYRE DR, 1987, FEBS LETT, V220, P337, DOI 10.1016/0014-5793(87)80842-6; FASSLER R, 1994, P NATL ACAD SCI USA, V91, P5070, DOI 10.1073/pnas.91.11.5070; GAILL F, 1991, J MOL BIOL, V221, P209, DOI 10.1016/0022-2836(91)80215-G; GRUENWALD S, 1993, BACULOVIRUS EXPRESSI, P51; Hagg R, 1997, J BIOL CHEM, V272, P20650, DOI 10.1074/jbc.272.33.20650; LABOURDETTE L, 1993, FEBS LETT, V320, P211, DOI 10.1016/0014-5793(93)80588-L; Lamberg A, 1996, J BIOL CHEM, V271, P11988, DOI 10.1074/jbc.271.20.11988; Lees JF, 1997, EMBO J, V16, P908, DOI 10.1093/emboj/16.5.908; Mechling DE, 1996, J BIOL CHEM, V271, P13781, DOI 10.1074/jbc.271.23.13781; Miles CA, 1998, J MOL BIOL, V277, P135, DOI 10.1006/jmbi.1997.1603; MORRIS NP, 1987, J BIOL CHEM, V262, P11345; MURAGAKI Y, 1990, EUR J BIOCHEM, V192, P703, DOI 10.1111/j.1432-1033.1990.tb19279.x; Myllyharju J, 1997, J BIOL CHEM, V272, P21824, DOI 10.1074/jbc.272.35.21824; NINOMIYA Y, 1990, EXTRACELLULAR MATRIX, P79; Nokelainen M, 1998, MATRIX BIOL, V16, P329, DOI 10.1016/S0945-053X(98)90004-X; PERALA M, 1993, FEBS LETT, V319, P177, DOI 10.1016/0014-5793(93)80062-Y; Pihlajamaa T, 1998, MATRIX BIOL, V17, P237, DOI 10.1016/S0945-053X(98)90063-4; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; REESE CA, 1981, BIOCHEMISTRY-US, V20, P5443, DOI 10.1021/bi00522a014; ROKOS I, 1994, MATRIX BIOL, V14, P1, DOI 10.1016/0945-053X(94)90024-8; Van der Rest M, 1987, STRUCTURE FUNCTION C, P195; VASIOS G, 1988, J BIOL CHEM, V263, P2324; VAUGHAN L, 1988, J CELL BIOL, V106, P991, DOI 10.1083/jcb.106.3.991; WU JJ, 1992, J BIOL CHEM, V267, P23007	31	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22464	22468		10.1074/jbc.274.32.22464	http://dx.doi.org/10.1074/jbc.274.32.22464			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428821	hybrid			2022-12-25	WOS:000081868400051
J	Chyan, YJ; Poeggeler, B; Omar, RA; Chain, DG; Frangione, B; Ghiso, J; Pappolla, MA				Chyan, YJ; Poeggeler, B; Omar, RA; Chain, DG; Frangione, B; Ghiso, J; Pappolla, MA			Potent neuroprotective properties against the Alzheimer beta-amyloid by an endogenous melatonin-related indole structure, indole-3-propionic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE DAMAGE; HIPPOCAMPAL-NEURONS; LIPID-PEROXIDATION; MITOCHONDRIAL-DNA; PROTEIN TOXICITY; CORTICAL-NEURONS; CELL-DEATH; IN-VITRO; DISEASE; STRESS	Widespread cerebral deposition of a 40-43-amino acid peptide called the amyloid beta-protein (A beta) in the form of amyloid fibrils is one of the most prominent neuropathologic features of Alzheimer's disease. Numerous studies suggest that A beta is toxic to neurons by free radical-mediated mechanisms, We have previously reported that melatonin prevents oxidative stress and death of neurons exposed to A beta, In the process of screening indole compounds for neuroprotection against A beta, potent neuroprotective properties were uncovered for an endogenous related species, indole-3-propionic acid (IPA), This compound has previously been identified in the plasma and cerebrospinal fluid of humans, but its functions are not known. IPA completely protected primary neurons and neuroblastoma cells against oxidative damage acid death caused by exposure to A beta, by inhibition of superoxide dismutase, or by treatment with hydrogen peroxide, In kinetic competition experiments using free radical-trapping agents, the capacity of IPA to scavenge hydroxyl radicals exceeded that of melatonin, an indoleamine considered to be the most potent naturally occurring scavenger of free radicals. In contrast with other antioxidants, IPA was not converted to reactive intermediates with pro-oxidant activity. These findings may have therapeutic applications in a broad range of clinical situations.	Univ S Alabama, Coll Med, Dept Pathol, Mobile, AL 36617 USA; Univ S Alabama, Coll Med, Dept Neurol, Mobile, AL 36617 USA; Univ Louisville, Dept Pathol, Louisville, KY 40206 USA; NYU, Dept Pathol, New York, NY 10016 USA; Mindset Ltd, Jerusalem, Israel	University of South Alabama; University of South Alabama; University of Louisville; New York University	Pappolla, MA (corresponding author), Univ S Alabama, Coll Med, Dept Pathol, Mobile, AL 36617 USA.		Pappolla, Miguel/ABE-4966-2021		NIA NIH HHS [R55 AG14381, R01 AG11130, R01 AG05891] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG011130, R55AG014381, R01AG005891] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aksenov MY, 1998, J MOL NEUROSCI, V10, P181, DOI 10.1007/BF02761773; BEHL C, 1992, BIOCHEM BIOPH RES CO, V186, P944, DOI 10.1016/0006-291X(92)90837-B; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BORS W, 1985, CRC HDB METHODS OXYG, P181; Bozner P, 1997, J NEUROPATH EXP NEUR, V56, P1356, DOI 10.1097/00005072-199712000-00010; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Calingasan NY, 1999, J NEUROCHEM, V72, P751, DOI 10.1046/j.1471-4159.1999.0720751.x; CANDEIAS LP, 1995, FREE RADICAL RES, V23, P403, DOI 10.3109/10715769509065262; CANDEIAS LP, 1993, FREE RADICAL BIO MED, V15, P385, DOI 10.1016/0891-5849(93)90038-V; Chan TY, 1996, J PINEAL RES, V20, P187, DOI 10.1111/j.1600-079X.1996.tb00257.x; FRANK L, 1987, BIOCHEM PHARMACOL, V27, P251; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOODMAN Y, 1994, EXP NEUROL, V128, P1, DOI 10.1006/exnr.1994.1107; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HYMAN BT, 1995, RESEARCH ADVANCES IN ALZHEIMER'S DISEASE AND RELATED DISORDERS, P453; JELLET JJ, 1980, CAN J MICROBIOL, V26, P448, DOI 10.1139/m80-074; Lyras L, 1997, J NEUROCHEM, V68, P2061; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; MATTSON MP, 1997, ALZHEIMERS DIS REV, V2, P1; Matuszak Z, 1997, FREE RADICAL BIO MED, V23, P367, DOI 10.1016/S0891-5849(96)00614-4; McCabe DR, 1997, J CHROMATOGR B, V691, P23, DOI 10.1016/S0378-4347(96)00416-1; MECOCCI P, 1994, ANN NEUROL, V36, P747, DOI 10.1002/ana.410360510; Moosmann B, 1997, FEBS LETT, V413, P467, DOI 10.1016/S0014-5793(97)00961-7; MORITA I, 1992, J CHROMATOGR-BIOMED, V576, P334, DOI 10.1016/0378-4347(92)80208-8; Nappi AJ, 1997, BBA-GEN SUBJECTS, V1336, P295, DOI 10.1016/S0304-4165(97)00039-1; OMAR RA, 1987, CANCER RES, V47, P3473; Pappolla M, 1998, J BIOL CHEM, V273, P7185, DOI 10.1074/jbc.273.13.7185; PAPPOLLA MA, 1992, AM J PATHOL, V140, P621; Pappolla MA, 1997, J NEUROSCI, V17, P1683; Pappolla MA, 1998, AM J PATHOL, V152, P871; POEGGELER B, 1993, J PINEAL RES, V14, P151, DOI 10.1111/j.1600-079X.1993.tb00498.x; Poeggeler B, 1996, REDOX REP, V2, P179, DOI 10.1080/13510002.1996.11747046; POEGGELER B, 1998, REACTIVE OXYGEN SPEC, P421; Reiter RJ, 1998, PROG NEUROBIOL, V56, P359, DOI 10.1016/S0301-0082(98)00052-5; Sayre LM, 1997, J NEUROCHEM, V68, P2092; SMITH CD, 1991, P NATL ACAD SCI USA, V88, P10540, DOI 10.1073/pnas.88.23.10540; Smith MA, 1998, J NEUROCHEM, V70, P2212, DOI 10.1046/j.1471-4159.1998.70052212.x; SMITH MA, 1994, AM J PATHOL, V145, P42; Tan DX, 1993, ENDOCR J, V1, P57; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; WHITTEMORE ER, 1994, NEUROREPORT, V5, P1485, DOI 10.1097/00001756-199407000-00019; YOUNG SN, 1980, J NEUROCHEM, V34, P1087, DOI 10.1111/j.1471-4159.1980.tb09944.x	43	280	298	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21937	21942		10.1074/jbc.274.31.21937	http://dx.doi.org/10.1074/jbc.274.31.21937			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419516	hybrid			2022-12-25	WOS:000081721100069
J	Ganesan, AK; Vincent, TS; Olson, JC; Barbieri, JT				Ganesan, AK; Vincent, TS; Olson, JC; Barbieri, JT			Pseudomonas aeruginosa exoenzyme S disrupts Ras-mediated signal transduction by inhibiting guanine nucleotide exchange factor-catalyzed nucleotide exchange	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLTRANSFERASE ACTIVITY; RHO-PROTEINS; EUKARYOTIC CELLS; ACTIVATION; EFFECTORS; SOS; GLUCOSYLATION; RIBOSYLATES; INFECTIONS; EXPRESSION	Pseudomonas aeruginosa exoenzyme S double ADP-ribosylates Ras at Arg(41) and Arg(128). Since Arg(41) is adjacent to the switch 1 region of Ras, ADP-ribosylation could interfere with Ras-mediated signal transduction via several mechanisms, including interaction with Raf, or guanine nucleotide exchange factor-stimulated or intrinsic nucleotide exchange. Initial experiments showed that ADP-ribosylated Ras (ADP-r-Ras) and unmodified Ras (Ras) interacted with Raf with equal efficiencies, indicating that ADP-ribosylation did not interfere with Ras-Raf interactions, While ADP-r-Ras and Ras possessed equivalent intrinsic nucleotide exchange rates, guanine nucleotide exchange factor (Cdc25) stimulated the nucleotide exchange of ADP-r-Ras at a 3-fold slower rate than Ras. ADP-r-Ras did not affect the nucleotide exchange of Ras, indicating that the ADP-ribosylation of pas was not a dominant negative phenotype. Ras-R41K and ADP-r-Ras R41K possessed similar exchange rates as Ras, indicating that ADP-ribosylation at Arg(128) did not inhibit Cdc25-stimulated nucleotide exchange, Consistent with the slower nucleotide exchange rate of ADP-r-Ras as compared with Ras, ADP-r-Ras bound its guanine nucleotide exchange factor (Cdc25) less efficiently than Ras in direct binding experiments. Together, these data indicate that ADP-ribosylation of Ras at Arg(41) disrupts Ras-Cdc25 interactions, which inhibits the rate-limiting step in Ras signal transduction, the activation of Ras by its guanine nucleotide exchange factor.	Med Coll Wisconsin, Milwaukee, WI 53226 USA; Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA	Medical College of Wisconsin; Medical University of South Carolina	Barbieri, JT (corresponding author), Med Coll Wisconsin, Milwaukee, WI 53226 USA.	toxin@mew.edu						BJORN MJ, 1979, INFECT IMMUN, V24, P837, DOI 10.1128/IAI.24.3.837-842.1979; BODEY GP, 1983, REV INFECT DIS, V5, P279; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; CANTRELL D, 1994, CURR OPIN IMMUNOL, V6, P380, DOI 10.1016/0952-7915(94)90116-3; Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717; COBURN J, 1989, INFECT IMMUN, V57, P996, DOI 10.1128/IAI.57.3.996-998.1989; COBURN J, 1989, J BIOL CHEM, V264, P9004; COBURN J, 1991, J BIOL CHEM, V266, P6438; Corbalan-Garcia S, 1998, MOL CELL BIOL, V18, P880, DOI 10.1128/MCB.18.2.880; CorbalanGarcia S, 1996, ONCOGENE, V12, P1063; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Ferrell JE, 1997, J BIOL CHEM, V272, P19008, DOI 10.1074/jbc.272.30.19008; Foschi M, 1997, EMBO J, V16, P6439, DOI 10.1093/emboj/16.21.6439; FOX PL, 1994, ONCOGENE, V9, P3519; FRECH M, 1994, BIOCHEMISTRY-US, V33, P3237, DOI 10.1021/bi00177a014; Ganesan AK, 1998, J BIOL CHEM, V273, P7332, DOI 10.1074/jbc.273.13.7332; Ganesan AK, 1999, J BIOL CHEM, V274, P9503, DOI 10.1074/jbc.274.14.9503; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; Just I, 1996, J BIOL CHEM, V271, P10149, DOI 10.1074/jbc.271.17.10149; JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; KNIGHT DA, 1995, INFECT IMMUN, V63, P3182, DOI 10.1128/IAI.63.8.3182-3186.1995; Knight DA, 1997, INFECT IMMUN, V65, P3304, DOI 10.1128/IAI.65.8.3304-3309.1997; KULICH SM, 1995, INFECT IMMUN, V63, P1; KULICH SM, 1994, J BIOL CHEM, V269, P10431; LENZEN C, 1995, METHOD ENZYMOL, V255, P95; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; McGuffie EM, 1998, INFECT IMMUN, V66, P2607, DOI 10.1128/IAI.66.6.2607-2613.1998; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Olson JC, 1997, INFECT IMMUN, V65, P248, DOI 10.1128/IAI.65.1.248-256.1997; OPPENHEIMER NJ, 1978, J BIOL CHEM, V253, P4907; PEDERSON K, 1998, IN PRESS MOL MICROBI; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; Santos MF, 1997, J CLIN INVEST, V100, P216, DOI 10.1172/JCI119515; Schmidt G, 1998, J BIOL CHEM, V273, P13669, DOI 10.1074/jbc.273.22.13669; SHIROUZU M, 1994, ONCOGENE, V9, P2153; TONG L, 1991, J MOL BIOL, V217, P503, DOI 10.1016/0022-2836(91)90753-S; Wittinghofer A, 1996, TRENDS BIOCHEM SCI, V21, P488, DOI 10.1016/S0968-0004(96)10064-5; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P382, DOI 10.1016/0968-0004(91)90156-P; Yahr TL, 1996, MOL MICROBIOL, V22, P991, DOI 10.1046/j.1365-2958.1996.01554.x; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	42	70	73	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21823	21829		10.1074/jbc.274.31.21823	http://dx.doi.org/10.1074/jbc.274.31.21823			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419499	hybrid			2022-12-25	WOS:000081721100052
J	Le, XF; Groner, Y; Kornblau, SM; Gu, Y; Hittelman, WN; Levanon, D; Mehta, K; Arlinghaus, RB; Chang, KS				Le, XF; Groner, Y; Kornblau, SM; Gu, Y; Hittelman, WN; Levanon, D; Mehta, K; Arlinghaus, RB; Chang, KS			Regulation of AML2/CBFA3 in hematopoietic cells through the retinoic acid receptor alpha-dependent signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; DROSOPHILA SEGMENTATION GENE; ACUTE PROMYELOCYTIC LEUKEMIA; TRANSCRIPTION FACTOR FAMILY; RUNT HOMOLOGY DOMAIN; OSTEOBLAST DIFFERENTIATION; DNA-BINDING; DEFINITIVE HEMATOPOIESIS; CLEIDOCRANIAL DYSPLASIA	AML2 is a member of the acute myelogenous leukemia, AML family of transcription factors, The biologic functions of AML1 and AML3 have been well characterized; however, the functional role of AML2 remains unknown. In this study, we found that AML2 protein expressed predominantly in cells of hematopoietic origin is a nuclear serine phosphoprotein associated with the nuclear matrix, and its expression is not cell cycle-related. In HL-60 cells AML2 expression can be induced by all three natural retinoids, all-trans-retinoic acid (RA), 13-cis-RA, and 9-cis-RA in a dose-dependent manner. A synthetic retinoic acid derivative, 4HPR, which neither activates RA receptor (RAR) alpha nor retinoic X receptor alpha was unable to induce the expression of AML2. A RAR-selective activator,TTNPB, induced AML2 expression similar to RA, Our study further showed that AGN193109, a potent RAR alpha antagonist, suppressed AML2 expression induced by RA and that a retinoic X receptor pan agonist AGN194204 had no effect on its expression, Taken together, these studies conclusively demonstrated that the expression of AML2 in HL-60 cells is regulated through the RAR alpha-specific signaling pathway, Our study further showed that after all-trans-retinoic acid priming, AML2 expression could be augmented by vitamin D-3. Based on these studies we hypothesize that AML2 expression is normally regulated by retinoid/vitamin D nuclear receptors mainly through the RAR alpha-dependent signaling pathway and that it may play a role in hematopoietic cell differentiation.	Univ Texas, MD Anderson Canc Ctr, Dept Lab Med, Div Pathol & Lab Med, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Hematol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Clin Invest, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Weizmann Institute of Science	Chang, KS (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Lab Med, Div Pathol & Lab Med, Box 072,1515 Holcombe Blvd, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA-16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM KB, 1995, GENOMICS, V25, P603; Agarwal C, 1996, CELL GROWTH DIFFER, V7, P521; BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1995, GENE, V159, P245, DOI 10.1016/0378-1119(95)00060-J; Banerjee C, 1997, J CELL BIOCHEM, V66, P1, DOI 10.1002/(SICI)1097-4644(19970701)66:1<1::AID-JCB1>3.0.CO;2-V; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHANG KS, 1995, BLOOD, V85, P3646, DOI 10.1182/blood.V85.12.3646.bloodjournal85123646; Clarke S, 1998, J LEUKOCYTE BIOL, V63, P153, DOI 10.1002/jlb.63.2.153; COLLINS SJ, 1979, J EXP MED, V149, P969, DOI 10.1084/jem.149.4.969; COLLINS SJ, 1987, BLOOD, V70, P1233; Corsetti MT, 1997, BLOOD, V89, P2359, DOI 10.1182/blood.V89.7.2359; DAGA A, 1992, NATURE, V356, P484, DOI 10.1038/356484b0; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; ERICKSON P, 1992, BLOOD, V80, P1825; Erickson PF, 1996, BLOOD, V88, P1813; Fanjul AN, 1996, J BIOL CHEM, V271, P22441, DOI 10.1074/jbc.271.37.22441; FURUKAWA K, 1990, CELL GROWTH DIFFER, V1, P135; GAO JZ, 1991, P NATL ACAD SCI USA, V88, P4882, DOI 10.1073/pnas.88.11.4882; Ghozi MC, 1996, P NATL ACAD SCI USA, V93, P1935, DOI 10.1073/pnas.93.5.1935; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; Ito Y, 1996, J CANCER RES CLIN, V122, P266, DOI 10.1007/BF01261402; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kornblau SM, 1997, BLOOD, V90, P309; Kurokawa M, 1996, ONCOGENE, V12, P883; Le XF, 1998, ONCOGENE, V16, P1839, DOI 10.1038/sj.onc.1201705; Le XF, 1996, J BIOL CHEM, V271, P130, DOI 10.1074/jbc.271.1.130; Le XF, 1998, EUR J HAEMATOL, V60, P217; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LU J, 1995, MOL CELL BIOL, V15, P1651; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MERRIMAN HL, 1995, BIOCHEMISTRY-US, V34, P13125, DOI 10.1021/bi00040a025; Meyers S, 1996, ONCOGENE, V13, P303; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; NAGY L, 1995, MOL CELL BIOL, V15, P3540; NUCIFORA G, 1995, BLOOD, V86, P1; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; OLSSON IL, 1982, CANCER RES, V42, P3924; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; PANDITA TK, 1992, RADIAT RES, V130, P94, DOI 10.2307/3578485; PIETTE J, 1987, EMBO J, V6, P1331, DOI 10.1002/j.1460-2075.1987.tb02372.x; ROBERTSON KA, 1992, BLOOD, V80, P1885; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; SCHRADER M, 1993, J BIOL CHEM, V268, P17830; SIMEONE A, 1995, DEV DYNAM, V203, P61, DOI 10.1002/aja.1002030107; SPECK NA, 1987, MOL CELL BIOL, V7, P1101, DOI 10.1128/MCB.7.3.1101; Speck NA, 1995, CRIT REV EUKAR GENE, V5, P337, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.60; TANAKA K, 1995, BIOCHEM BIOPH RES CO, V211, P1023, DOI 10.1006/bbrc.1995.1913; Tanaka T, 1996, MOL CELL BIOL, V16, P3967; Teng M, 1997, J MED CHEM, V40, P2445, DOI 10.1021/jm9703911; Tsuji K, 1998, BONE, V22, P87, DOI 10.1016/S8756-3282(97)00267-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WIJMENGA C, 1995, GENOMICS, V26, P611, DOI 10.1016/0888-7543(95)80185-O; Zhang YW, 1997, ONCOGENE, V15, P367, DOI 10.1038/sj.onc.1201352	66	52	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21651	21658		10.1074/jbc.274.31.21651	http://dx.doi.org/10.1074/jbc.274.31.21651			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419474	hybrid			2022-12-25	WOS:000081721100027
J	Napper, S; Delbaere, LTJ; Waygood, EB				Napper, S; Delbaere, LTJ; Waygood, EB			The aspartyl replacement of the active site histidine in histidine-containing protein, HPr, of the Escherichia coli phosphoenolpyruvate: Sugar phosphotransferase system can accept and donate a phosphoryl group - Spontaneous dephosphorylation of acyl-phosphate autocatalyzes an internal cyclization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESTRAINED MOLECULAR-DYNAMICS; NUCLEAR-MAGNETIC-RESONANCE; HIGH-RESOLUTION STRUCTURE; PHOSPHOCARRIER PROTEIN; SALMONELLA-TYPHIMURIUM; BACILLUS-SUBTILIS; NMR-SPECTROSCOPY; ACETATE KINASE; ENZYME-I; TRANSPORT	The active site residue, His(15), in histidine-containing protein, HPr, can be replaced by aspartate and still act as a phosphoacceptor and phosphodonor with enzyme I and enzyme IIAgglucose, respectively. Other substitutions, including cysteine, glutamate, serine, threonine, and tyrosine, failed to show any activity. Enzyme I K-m for His(15) --> Asp HPr is increased 10-fold and V-max is decreased 1000-fold compared with wild type HPr, The phosphorylation of Asp(15) led to a spontaneous internal rearrangement involving the loss of the phosphoryl group and a water molecule, which was confirmed by mass spectrometry, The protein species formed had a higher pi than His(15) --> Asp HPr, which could arise from the formation of a succinimide or an isoimide, Hydrolysis of the isolated high pi form gave only aspartic acid at residue 15, and no isoaspartic acid was detected. This indicates that an isoimide rather than a succinimide is formed. In the absence of phosphorylation, no formation of the high pi form could be found, indicating that phosphorylation catalyzed the formation of the cyclization. The possible involvement of Asn(12) in an internal cyclization with Asp(15) was eliminated by the Asn(12) --> Ala mutation in His(15) --> AspHPr. Asn(12) substitutions of alanine, aspartate, serine, and threonine in wild type HPr indicated a general requirement for residues capable of forming a hydrogen bond with the N epsilon(2) atom of His(15), but elimination of the hydrogen bond has only a 4-fold decrease in k(cat)/K-m.	Univ Saskatchewan, Dept Biochem, Saskatoon, SK S7N 5E5, Canada	University of Saskatchewan	Waygood, EB (corresponding author), Univ Saskatchewan, Dept Biochem, 107 Wiggins Rd,Hlth Sci Bldg, Saskatoon, SK S7N 5E5, Canada.	bruce.waygood@usask.ca						ANDERSON B, 1971, J BIOL CHEM, V246, P7023; ANDERSON JW, 1991, BIOCHEMISTRY-US, V30, P9601, DOI 10.1021/bi00104a006; ANDERSON JW, 1993, J BIOL CHEM, V268, P12325; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRENNAN TV, 1994, J BIOL CHEM, V269, P24586; Brunger A. T, 1993, XPLOR MANUAL VERSION; CLARKE S, 1987, INT J PEPT PROT RES, V30, P808, DOI 10.1111/j.1399-3011.1987.tb03390.x; CLARKE S, 1992, STABILITY PROTEIN PH, P1; ERNI B, 1989, J BIOL CHEM, V264, P18733; FOX DK, 1986, J BIOL CHEM, V261, P3487; FOX DK, 1986, J BIOL CHEM, V261, P3498; GEIGER T, 1987, J BIOL CHEM, V262, P785; HERZBERG O, 1994, CURR OPIN STRUC BIOL, V4, P814, DOI 10.1016/0959-440X(94)90262-3; HERZBERG O, 1992, P NATL ACAD SCI USA, V89, P2499, DOI 10.1073/pnas.89.6.2499; HESS JF, 1988, NATURE, V336, P139, DOI 10.1038/336139a0; JIA ZC, 1994, BIOCHEM CELL BIOL, V72, P202, DOI 10.1139/o94-030; JIA ZC, 1993, J BIOL CHEM, V268, P22490; Jones BE, 1997, PROTEIN SCI, V6, P2107; KALBITZER HR, 1993, EUR J BIOCHEM, V216, P205, DOI 10.1111/j.1432-1033.1993.tb18134.x; KLEVIT RE, 1986, BIOCHEMISTRY-US, V25, P7774, DOI 10.1021/bi00371a073; KUNDIG W, 1964, P NATL ACAD SCI USA, V52, P1067, DOI 10.1073/pnas.52.4.1067; LEE LG, 1982, FEBS LETT, V149, P288, DOI 10.1016/0014-5793(82)81119-8; LENGELER JW, 1996, HDB BIOL PHYS, V2, P573; MATTOO RL, 1983, ANAL BIOCHEM, V128, P245, DOI 10.1016/0003-2697(83)90372-X; MCFADDEN PN, 1982, P NATL ACAD SCI-BIOL, V79, P2460, DOI 10.1073/pnas.79.8.2460; MEADOW ND, 1982, J BIOL CHEM, V257, P4526; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; Napper S, 1996, BIOCHEMISTRY-US, V35, P11260, DOI 10.1021/bi9603480; Noguchi S, 1998, J MOL BIOL, V278, P231, DOI 10.1006/jmbi.1998.1674; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; POSTMA PW, 1996, ESCHERICHIA COLI SAL; Prasad L, 1998, J MOL BIOL, V280, P829, DOI 10.1006/jmbi.1998.1888; ROBERTSON AJ, 1994, PLANT PHYSIOL, V105, P181, DOI 10.1104/pp.105.1.181; RUSSELL CB, 1989, J BACTERIOL, V171, P2609, DOI 10.1128/jb.171.5.2609-2613.1989; SANDERS DA, 1989, J BIOL CHEM, V264, P21770; SHARMA S, 1993, J BIOL CHEM, V268, P17695; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THALLER C, 1981, J MOL BIOL, V147, P465, DOI 10.1016/0022-2836(81)90496-4; VANDIJK AA, 1990, BIOCHEMISTRY-US, V29, P8164, DOI 10.1021/bi00487a026; VANNULAND NAJ, 1995, J MOL BIOL, V246, P180, DOI 10.1006/jmbi.1994.0075; VANNULAND NAJ, 1994, J MOL BIOL, V237, P544, DOI 10.1006/jmbi.1994.1254; VANNULAND NAJ, 1992, EUR J BIOCHEM, V210, P881; VANNULAND NAJ, 1992, EUR J BIOCHEM, V203, P483; VIOLAND BN, 1992, PROTEIN SCI, V1, P1634, DOI 10.1002/pro.5560011211; WAYGOOD EB, 1987, J BACTERIOL, V169, P2810, DOI 10.1128/jb.169.6.2810-2818.1987; Waygood EB, 1998, BIOCHEM CELL BIOL, V76, P359, DOI 10.1139/bcb-76-2-3-359; WAYGOOD EB, 1985, BIOCHEMISTRY-US, V24, P6938, DOI 10.1021/bi00345a028; WAYGOOD EB, 1984, J CELL BIOCHEM, V25, P139, DOI 10.1002/jcb.240250304; WAYGOOD EB, 1979, ANAL BIOCHEM, V95, P293, DOI 10.1016/0003-2697(79)90219-7; WEIGEL N, 1982, J BIOL CHEM, V257, P4477; WITTEKIND M, 1990, BIOCHEMISTRY-US, V29, P7191, DOI 10.1021/bi00483a006; WITTEKIND M, 1992, PROTEIN SCI, V1, P1363, DOI 10.1002/pro.5560011016; WRIGHT HT, 1991, CRIT REV BIOCHEM MOL, V26, P1, DOI 10.1080/10409230490440532	54	18	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21776	21782		10.1074/jbc.274.31.21776	http://dx.doi.org/10.1074/jbc.274.31.21776			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419492	hybrid			2022-12-25	WOS:000081721100045
J	Wu, WJ; Vrhovski, B; Weiss, AS				Wu, WJ; Vrhovski, B; Weiss, AS			Glycosaminoglycans mediate the coacervation of human tropoelastin through dominant charge interactions involving lysine side chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELASTIN-BINDING PROTEIN; EXTRACELLULAR-MATRIX; DUCTUS-ARTERIOSUS; HEPARIN-BINDING; LYSYL OXIDASE; FIBER; DOMAINS; SULFATE	Following cellular secretion into the extracellular matrix, tropoelastin is transported, deposited, and crosslinked to make elastin, Assembly by coacervation was examined for an isoform of tropoelastin that lacks the hydrophilic domain encoded by exon 26A It is equivalent to a naturally secreted form of tropoelastin and shows similar coacervation performance to its partner containing 26A, thereby generalizing the concept that splice form variants are able to coacervate under comparable conditions. This is optimal under physiological conditions of temperature, salt concentration, and pH, The proteins were examined for their ability to interact with extracellular matrix glycosaminoglycans. These negatively charged molecules interacted with positively charged lysine residues and promoted coacervation of tropoelastin in a temperature- and concentration-dependent manner. A testable model for elastin-glycosaminoglycan interactions is proposed, where tropoelastin deposition during elastogenesis is encouraged by local exposure to matrix glycosaminoglycans. Unmodified proteins are retained at similar to 3 mu M dissociation constant. Following lysyl oxidase modification of tropoelastin lysine residues, they are released from glycosaminoglycan interactions, thereby permitting those residues to contribute to elastin cross-links.	Univ Sydney, Dept Biochem G08, Sydney, NSW 2006, Australia	University of Sydney	Weiss, AS (corresponding author), Univ Sydney, Dept Biochem G08, Sydney, NSW 2006, Australia.		Weiss, Anthony S/GYV-0157-2022; Weiss, Anthony S/F-8103-2010	Weiss, Anthony S/0000-0002-8106-4836				BACCARANICONTRI M, 1990, EUR J CELL BIOL, V53, P305; BEDELLHOGAN D, 1993, J BIOL CHEM, V268, P10345; Bisaccia F, 1998, BIOCHEMISTRY-US, V37, P11128, DOI 10.1021/bi9802566; BROWNAUGSBURGER P, 1994, J BIOL CHEM, V269, P28443; BrownAugsburger P, 1996, BIOCHEM J, V318, P149, DOI 10.1042/bj3180149; FORNIERI C, 1987, J CELL BIOL, V105, P1463, DOI 10.1083/jcb.105.3.1463; GRODZINSKY AJ, 1983, CRIT REV BIOMED ENG, V9, P133; HINEK A, 1991, J CLIN INVEST, V88, P2083, DOI 10.1172/JCI115538; HINEK A, 1994, J CELL BIOL, V126, P563, DOI 10.1083/jcb.126.2.563; Hinek A, 1995, CIBA F SYMP, V192, P185; INDIK Z, 1987, P NATL ACAD SCI USA, V84, P5680, DOI 10.1073/pnas.84.16.5680; Lamme EN, 1996, J HISTOCHEM CYTOCHEM, V44, P1311, DOI 10.1177/44.11.8918906; LEE MK, 1991, P NATL ACAD SCI USA, V88, P2768, DOI 10.1073/pnas.88.7.2768; MARTIN SL, 1995, GENE, V154, P159, DOI 10.1016/0378-1119(94)00848-M; MCGOWAN SE, 1993, ARCH BIOCHEM BIOPHYS, V302, P322, DOI 10.1006/abbi.1993.1218; PasqualiRonchetti I, 1997, MICROSC RES TECHNIQ, V38, P428, DOI 10.1002/(SICI)1097-0029(19970815)38:4<428::AID-JEMT10>3.0.CO;2-L; Rabinovitch M, 1996, SEMIN PERINATOL, V20, P531, DOI 10.1016/S0146-0005(96)80067-X; SCOTT JE, 1995, J ANAT, V187, P259; Sherratt MJ, 1997, INT J BIOCHEM CELL B, V29, P1063, DOI 10.1016/S1357-2725(97)00028-9; Sweeney SM, 1998, P NATL ACAD SCI USA, V95, P7275, DOI 10.1073/pnas.95.13.7275; URRY DW, 1969, NATURE, V222, P795, DOI 10.1038/222795a0; URRY DW, 1995, BIOCHEM BIOPH RES CO, V210, P1031, DOI 10.1006/bbrc.1995.1760; VELEBNY V, 1981, CONNECT TISSUE RES, V9, P63, DOI 10.3109/03008208109160241; Vrhovski B, 1997, EUR J BIOCHEM, V250, P92, DOI 10.1111/j.1432-1033.1997.00092.x; Wallon UM, 1997, J BIOL CHEM, V272, P7473, DOI 10.1074/jbc.272.11.7473; WALSH RL, 1991, CLIN SCI, V81, P341, DOI 10.1042/cs0810341; Xu WY, 1997, ARCH BIOCHEM BIOPHYS, V341, P273, DOI 10.1006/abbi.1997.9954	27	119	125	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21719	21724		10.1074/jbc.274.31.21719	http://dx.doi.org/10.1074/jbc.274.31.21719			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419484	hybrid			2022-12-25	WOS:000081721100037
J	Kirsch, DG; Doseff, A; Chau, BN; Lim, DS; de Souza-Pinto, NC; Hansford, R; Kastan, MB; Lazebnik, YA; Hardwick, JM				Kirsch, DG; Doseff, A; Chau, BN; Lim, DS; de Souza-Pinto, NC; Hansford, R; Kastan, MB; Lazebnik, YA; Hardwick, JM			Caspase-3-dependent cleavage of Bcl-2 promotes release of cytochrome c	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DRUG-INDUCED APOPTOSIS; CELL-DEATH; MORPHOLOGICAL-CHANGES; DNA FRAGMENTATION; CASPASE FAMILY; PROTEIN; BAX; ACTIVATION; PATHWAY; MITOCHONDRIA	Caspases are cysteine proteases that mediate apoptosis by proteolysis of specific substrates, Although many caspase substrates have been identified, for most substrates the physiologic caspase(s) required for cleavage is unknown. The Bcl-2 protein, which inhibits apoptosis, is cleaved at Asp-34 by caspases during apoptosis and by recombinant caspase-3 in vitro. In the present study, we show that endogenous caspase-3 is a physiologic caspase for Bcl-2, Apoptotic extracts from 293 cells cleave Bcl-2 but not Bax, even though Bax is cleaved to an 18-kDa fragment in SK-NSH cells treated with ionizing radiation. In contrast to Bcl-2, cleavage of Bax was only partially blocked by caspase inhibitors. Inhibitor profiles indicate that Bax may be cleaved by more than one type of noncaspase protease, Immunodepletion of caspase-3 from 293 extracts abolished cleavage of Bcl-2 and caspase-7, whereas immunodepletion of caspase-7 had no effect on Bcl-2 cleavage. Furthermore, MCF-7 cells, which lack caspase-3 expression, do not cleave Bcl-2 following staurosporine-induced cell death. However, transient transfection of caspase-3 into MCF-7 cells restores Bcl-2 cleavage after staurosporine treatment. These results demonstrate that in these models of apoptosis, specific cleavage of Bcl-2 requires activation of caspase-3, When the pro-apoptotic caspase cleavage fragment of Bcl-2 is transfected into baby hamster kidney cells, it localizes to mitochondria and causes the release of cytochrome c into the cytosol. Therefore, caspase-3-dependent cleavage of Bcl-2 appears to promote further caspase activation as part of a positive feedback loop for executing the cell.	Johns Hopkins Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; Johns Hopkins Sch Publ Hlth, Ctr Oncol, Baltimore, MD 21205 USA; Johns Hopkins Sch Publ Hlth, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Johns Hopkins Sch Publ Hlth, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Sch Med, Ctr Oncol, Baltimore, MD 21205 USA; Johns Hopkins Sch Med, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; Johns Hopkins Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Johns Hopkins Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; NIA, NIH, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Cold Spring Harbor Laboratory; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Hardwick, JM (corresponding author), Johns Hopkins Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA.		Lim, Dae-Sik/C-1599-2011; Souza-Pinto, Nadja C./C-3462-2013; Doseff, Andrea/E-2991-2011; Souza-Pinto, Nadja/T-3050-2019	Lim, Dae-Sik/0000-0003-2356-7555; Souza-Pinto, Nadja C./0000-0003-4206-964X; Souza-Pinto, Nadja/0000-0003-4206-964X	NCI NIH HHS [CA77715] Funding Source: Medline; NIEHS NIH HHS [ES05777] Funding Source: Medline; NIGMS NIH HHS [GM07309] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077715] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005777, R37ES005777] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cheng EHY, 1997, P NATL ACAD SCI USA, V94, P690, DOI 10.1073/pnas.94.2.690; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Fearnhead HO, 1997, GENE DEV, V11, P1266, DOI 10.1101/gad.11.10.1266; Goldman SC, 1996, AM J PATHOL, V148, P1381; Grandgirard D, 1998, EMBO J, V17, P1268, DOI 10.1093/emboj/17.5.1268; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; Huang DCS, 1998, EMBO J, V17, P1029, DOI 10.1093/emboj/17.4.1029; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; LI P, 1997, CELL, V91, P497; Lim DS, 1998, P NATL ACAD SCI USA, V95, P10146, DOI 10.1073/pnas.95.17.10146; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Maravei DV, 1997, CELL DEATH DIFFER, V4, P707, DOI 10.1038/sj.cdd.4400311; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; Talanian RV, 1997, J BIOL CHEM, V272, P9677; TANAKA S, 1992, BLOOD, V79, P229; Thomas A, 1996, ONCOGENE, V12, P1055; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhivotovsky B, 1997, BIOCHEM BIOPH RES CO, V230, P481, DOI 10.1006/bbrc.1996.6016	46	406	436	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21155	21161		10.1074/jbc.274.30.21155	http://dx.doi.org/10.1074/jbc.274.30.21155			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409669	hybrid			2022-12-25	WOS:000081613100060
J	Steveson, TC; Keutmann, HT; Mains, RE; Eipper, BA				Steveson, TC; Keutmann, HT; Mains, RE; Eipper, BA			Phosphorylation of cytosolic domain Ser(937) affects both biosynthetic and endocytic trafficking of peptidylglycine alpha-amidating monooxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; TRANS-GOLGI NETWORK; CASEIN KINASE-II; PEPTIDE-PROCESSING ENZYME; GRANULE-ASSOCIATED PROTEINS; CYTOPLASMIC DOMAIN; SECRETORY GRANULES; INTRACELLULAR TRAFFICKING; ROUTING DETERMINANTS; NEUROENDOCRINE CELLS	Peptidylglycine alpha-amidating monooxygenase (PARI), a bifunctional enzyme, catalyzes the COOH-terminal amidation of bioactive peptides. In test tube assays, PAM is phosphorylated by protein kinase C at Ser(937). The roles of phosphorylation and dephosphorylation of Ser(937) in the biosynthetic and endocytic trafficking of integral membrane PAM were examined using an antiserum specific for the phosphorylation of Ser(937) and using AtT-20 cells expressing membrane PAM in which Ser(937) was mutated to Ala or Asp. Although phosphorylation at Ser(937) can occur while PAM is in the endoplasmic reticulum,, early steps in the biosynthetic trafficking of membrane PAM were not affected by Ser(937) phosphorylation. The inability to phosphorylate PAM/S937A increased its intracellular degradation and decreased secretion of the soluble monooxygenase portion of PAM. In contrast, the biosynthetic trafficking of PAM/S937A was indistinguishable from wild-type PAM. Despite the fact that Ser(937) is adjacent to the only Tyr-based internalization motif in PARZ internalization and trafficking through early endosomes were unaffected by phosphorylation, However, PAM antibody internalized by wild-type PAM acquired a perinuclear localization, while antibody internalized by PAM/S937A was routed to lysosomes, and antibody bound to PAM/S937D maintained a dispersed, punctate pattern. In cells stimulated with phorbol ester, phosphorylation of Ser(937) increased and phosphorylated PAM accumulated in large vesicular structures. Therefore, phosphorylation of PAM-1 at Ser(937) directs newly synthesized and internalized protein away from lysosomes, while dephosphorylation is needed for a different step in the late endocytic pathway.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA	Johns Hopkins University; Harvard University; Massachusetts General Hospital	Eipper, BA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, WSB 907,725 N Wolfe St, Baltimore, MD 21205 USA.				NIDDK NIH HHS [DK-09520, DK-32949] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032949, R37DK032949, R56DK032949, F32DK009520] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alam MR, 1997, J BIOL CHEM, V272, P12667, DOI 10.1074/jbc.272.19.12667; Alam MR, 1996, J BIOL CHEM, V271, P28636, DOI 10.1074/jbc.271.45.28636; Alconada A, 1996, EMBO J, V15, P6096, DOI 10.1002/j.1460-2075.1996.tb00998.x; BRADBURY AF, 1991, TRENDS BIOCHEM SCI, V16, P112, DOI 10.1016/0968-0004(91)90044-V; BREITFELD PP, 1990, J BIOL CHEM, V265, P13750; Breuer P, 1997, MOL BIOL CELL, V8, P567, DOI 10.1091/mbc.8.4.567; Denzer K, 1997, BIOCHEM J, V326, P497, DOI 10.1042/bj3260497; DINTZIS SM, 1994, J BIOL CHEM, V269, P12159; Dittie AS, 1997, EMBO J, V16, P4859, DOI 10.1093/emboj/16.16.4859; EIPPER BA, 1992, J BIOL CHEM, V267, P4008; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; EIPPER BA, 1991, J BIOL CHEM, V266, P7827; EIPPER BA, 1993, PROTEIN SCI, V2, P489; FUTTER CE, 1989, J CELL SCI, V94, P685; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; HUGHES EN, 1981, J BIOL CHEM, V256, P664; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; HUSTEN EJ, 1991, J BIOL CHEM, V266, P17004; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; JONES BG, 1995, EMBO J, V14, P5869, DOI 10.1002/j.1460-2075.1995.tb00275.x; KAIN SR, 1993, J BIOL CHEM, V268, P19640; KLUMPERMAN J, 1993, J CELL BIOL, V121, P997, DOI 10.1083/jcb.121.5.997; KORNER C, 1994, J BIOL CHEM, V269, P16529; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBORGNE R, 1993, J BIOL CHEM, V268, P22552; Leger J, 1997, J BIOL CHEM, V272, P8441, DOI 10.1074/jbc.272.13.8441; MAINS RE, 1990, FRONT NEUROENDOCRIN, V11, P52; MALTESE JY, 1993, ENDOCRINOLOGY, V133, P2579, DOI 10.1210/en.133.6.2579; MALTESE JY, 1995, NUCLEIC ACIDS RES, V23, P1146, DOI 10.1093/nar/23.7.1146; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; MERESSE S, 1993, J CELL BIOL, V120, P67, DOI 10.1083/jcb.120.1.67; MERESSE S, 1990, J BIOL CHEM, V265, P18833; MERKLER DJ, 1994, ENZYME MICROB TECH, V16, P450, DOI 10.1016/0141-0229(94)90014-0; Milgram SL, 1996, J BIOL CHEM, V271, P17526, DOI 10.1074/jbc.271.29.17526; Milgram SL, 1996, MOL ENDOCRINOL, V10, P837, DOI 10.1210/me.10.7.837; MILGRAM SL, 1994, J CELL BIOL, V124, P33, DOI 10.1083/jcb.124.1.33; MILGRAM SL, 1992, J CELL BIOL, V117, P717, DOI 10.1083/jcb.117.4.717; Milgram SL, 1997, J CELL SCI, V110, P695; MILGRAM SL, 1994, J CELL SCI, V107, P737; MILGRAM SL, 1993, J CELL BIOL, V121, P23, DOI 10.1083/jcb.121.1.23; Norcott JP, 1996, J CELL BIOL, V134, P1229, DOI 10.1083/jcb.134.5.1229; OKAMOTO CT, 1992, J BIOL CHEM, V267, P9925; OKAMOTO CT, 1994, J BIOL CHEM, V269, P15676; PERKINS SN, 1990, BIOCHEM BIOPH RES CO, V171, P926, DOI 10.1016/0006-291X(90)90772-F; ROHRER J, 1995, J CELL BIOL, V130, P1297, DOI 10.1083/jcb.130.6.1297; SCHAFER W, 1995, EMBO J, V14, P2424, DOI 10.1002/j.1460-2075.1995.tb07240.x; SCHNABEL E, 1989, MOL ENDOCRINOL, V3, P1223, DOI 10.1210/mend-3-8-1223; SEIDAH NG, 1993, BIOCHEM SOC T, V21, P685, DOI 10.1042/bst0210685; SHIELDS D, 1991, PEPTIDE BIOSYNTHESIS, P37; SMEEKENS SP, 1993, BIO-TECHNOL, V11, P182, DOI 10.1038/nbt0293-182; SONG LX, 1995, J NEUROCHEM, V65, P444; SOSSIN WS, 1989, NEURON, V2, P1407, DOI 10.1016/0896-6273(89)90186-4; SOSSIN WS, 1990, J CELL BIOL, V110, P1, DOI 10.1083/jcb.110.1.1; Steiner D. F., 1991, PEPTIDE BIOSYNTHESIS, P1; STOFFERS DA, 1989, P NATL ACAD SCI USA, V86, P735, DOI 10.1073/pnas.86.2.735; TAKAHASHI K, 1990, BIOCHEM BIOPH RES CO, V169, P524, DOI 10.1016/0006-291X(90)90362-Q; TAUSK FA, 1992, MOL ENDOCRINOL, V6, P2185, DOI 10.1210/me.6.12.2185; Wan L, 1998, CELL, V94, P205, DOI 10.1016/S0092-8674(00)81420-8; West AE, 1997, J NEUROSCI, V17, P6038; YUN HY, 1993, ARCH BIOCHEM BIOPHYS, V301, P77, DOI 10.1006/abbi.1993.1117; YUN HY, 1994, J BIOL CHEM, V269, P10946; YUN HY, 1995, J BIOL CHEM, V270, P30075	62	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21128	21138		10.1074/jbc.274.30.21128	http://dx.doi.org/10.1074/jbc.274.30.21128			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409666	hybrid			2022-12-25	WOS:000081613100057
J	Aikawa, Y; Kuraoka, A; Kondo, H; Kawabuchi, M; Watanabe, T				Aikawa, Y; Kuraoka, A; Kondo, H; Kawabuchi, M; Watanabe, T			Involvement of PITPnm, a mammalian homologue of Drosophila rdgB, in phosphoinositide synthesis on Golgi membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL TRANSFER PROTEIN; RETINAL-DEGENERATION-B; CDP-DIACYLGLYCEROL SYNTHASE; INOSITOL TRISPHOSPHATE; ENDOPLASMIC-RETICULUM; GENETIC DISSECTION; CLONING; KINASE; EXPRESSION; GROWTH	Phosphatidylinositol transfer protein (PITP) is involved in phospholipase C-mediated signaling and membrane trafficking. We previously reported cloning and characterization of a gene encoding for membrane-bound PITP, named PITPnm, that is a mammalian homologue of the Drosophila retinal degeneration B (rdgB) gene (Aikawa, Y., Hara, H., and Watanabe, T. (1997) Biochem. Biophys. Res. Commun, 236, 559-564). Here we report the subcellular localization of PITPnm protein and provide evidence for its involvement in phosphatidylinositol 4-phosphate (PtdIns 4-P) synthesis. PITPnm is an integral membrane protein that largely localized in close association with membranes of Golgi vacuoles and the endoplasmic reticulum (ER). The amino terminus region of PITPnm was exposed to cytoplasmic side. Interaction with various phosphoinositides was observed in the amino terminus region spanning from 196 amino acids to 257 amino acids of PITPnm. At the amino terminus regions of 1-372 amino acids, PITPnm formed a complex with type III PtdIns 4-kinase. The transmembrane and carboxyl-terminal portions (residues 418-1242) functioned to retain the PITPnm in the Golgi vacuole. These results suggest that PITPnm plays a role in phosphoinositide synthesis on the Golgi vacuoles and possibly in the PtdIns signaling pathway in mammalian cells.	Kyushu Univ, Fac Med, Med Inst Bioregulat, Dept Mol Immunol,Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Fac Med, Dept Anat, Higashi Ku, Fukuoka 8128582, Japan; Tohoku Univ, Sch Med, Dept Anat, Sendai, Miyagi 9808575, Japan	Kyushu University; Kyushu University; Tohoku University	Watanabe, T (corresponding author), Kyushu Univ, Fac Med, Med Inst Bioregulat, Dept Mol Immunol,Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.							Aikawa Y, 1997, BIOCHEM BIOPH RES CO, V236, P559, DOI 10.1006/bbrc.1997.7009; AITKEN JF, 1990, J BIOL CHEM, V265, P4711; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; BROWN JE, 1984, NATURE, V311, P160, DOI 10.1038/311160a0; Chang JHT, 1997, J NEUROSCI, V17, P5881; CUNNINGHAM E, 1995, CURR BIOL, V5, P775, DOI 10.1016/S0960-9822(95)00154-0; DEVARY O, 1987, P NATL ACAD SCI USA, V84, P6939, DOI 10.1073/pnas.84.19.6939; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; Fraser IDC, 1998, EMBO J, V17, P2261, DOI 10.1093/emboj/17.8.2261; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; FUJIKI Y, 1982, J CELL BIOL, V93, P103, DOI 10.1083/jcb.93.1.103; Fukami K, 1996, J BIOL CHEM, V271, P2646, DOI 10.1074/jbc.271.5.2646; Hamilton BA, 1997, NEURON, V18, P711, DOI 10.1016/S0896-6273(00)80312-8; Hara S, 1997, J BIOL CHEM, V272, P14908, DOI 10.1074/jbc.272.23.14908; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HARRIS WA, 1977, J GEN PHYSIOL, V69, P261, DOI 10.1085/jgp.69.3.261; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HOTTA Y, 1970, P NATL ACAD SCI USA, V67, P1156, DOI 10.1073/pnas.67.3.1156; IMAI A, 1987, NATURE, V325, P726, DOI 10.1038/325726a0; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; Ji QS, 1997, P NATL ACAD SCI USA, V94, P2999, DOI 10.1073/pnas.94.7.2999; Jones SM, 1998, J BIOL CHEM, V273, P10349, DOI 10.1074/jbc.273.17.10349; KAUFFMANNZEH A, 1995, SCIENCE, V268, P1188, DOI 10.1126/science.7761838; Kearns BG, 1997, NATURE, V387, P101, DOI 10.1038/387101a0; Kearns MA, 1998, EMBO J, V17, P4004, DOI 10.1093/emboj/17.14.4004; MASAI I, 1993, P NATL ACAD SCI USA, V90, P11157, DOI 10.1073/pnas.90.23.11157; Milligan SC, 1997, J CELL BIOL, V139, P351, DOI 10.1083/jcb.139.2.351; Nakagawa T, 1996, J BIOL CHEM, V271, P12088, DOI 10.1074/jbc.271.20.12088; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHASHI M, 1995, NATURE, V377, P544, DOI 10.1038/377544a0; Saito S, 1997, J BIOL CHEM, V272, P9503; SKINNER HB, 1993, EMBO J, V12, P4775, DOI 10.1002/j.1460-2075.1993.tb06166.x; STARK WS, 1983, J INSECT PHYSIOL, V29, P123, DOI 10.1016/0022-1910(83)90135-X; SUZUKI E, 1991, J ELECTRON MICROSC, V40, P187; Takeuchi H, 1998, BIOCHEM J, V334, P211, DOI 10.1042/bj3340211; THOMAS GMH, 1993, CELL, V74, P919, DOI 10.1016/0092-8674(93)90471-2; VANPARIDON PA, 1988, BIOCHIM BIOPHYS ACTA, V943, P76, DOI 10.1016/0005-2736(88)90348-3; VIHTELIC TS, 1993, J CELL BIOL, V122, P1013, DOI 10.1083/jcb.122.5.1013; WIRTZ KWA, 1991, ANNU REV BIOCHEM, V60, P73, DOI 10.1146/annurev.biochem.60.1.73; WOODARD C, 1992, J NEUROGENET, V8, P17, DOI 10.3109/01677069209167269; WU L, 1995, NATURE, V373, P216, DOI 10.1038/373216a0; Zuker Charles S., 1992, Current Opinion in Neurobiology, V2, P622, DOI 10.1016/0959-4388(92)90029-K	43	29	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20569	20577		10.1074/jbc.274.29.20569	http://dx.doi.org/10.1074/jbc.274.29.20569			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400687	hybrid			2022-12-25	WOS:000081438300080
J	Barthel, A; Okino, ST; Liao, JF; Nakatani, K; Li, JP; Whitlock, JP; Roth, RA				Barthel, A; Okino, ST; Liao, JF; Nakatani, K; Li, JP; Whitlock, JP; Roth, RA			Regulation of GLUT1 gene transcription by the serine threonine kinase Akt1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE; ACTIVATED PROTEIN-KINASE; L6 MUSCLE-CELLS; TRANSPORTER GENE; PHOSPHATIDYLINOSITOL 3-KINASE; GLUCOSE-TRANSPORT; 3T3-L1 ADIPOCYTES; SIGNALING PATHWAY; SKELETAL-MUSCLE; GROWTH-FACTOR	We used mouse hepatoma (Hepa1c1c7) cells to study the role of the serine/threonine kinase Akt in the induction of GLUT1 gene expression. In order to selectively turn on the Akt kinase cascade, we expressed a hydroxytamoxifen-regulatable form of Akt (myristoylated Akt1 estrogen receptor chimera (MER-Akt1)) in the Hepa1c1c7 cells; we verified that hydroxytamoxifen stimulates MER-Akt1 activity to a similar extent as the activation of endogenous Akt by insulin. Our studies reveal that stimulation of MER-Akt1 by hydroxytamoxifen induces GLUT1 mRNA and protein accumulation to levels comparable to that induced by insulin; therefore, activation of the Akt cascade suffices to induce GLUT1 gene expression in this cell system. Furthermore, expression of a kinase-inactive Akt mutant partially inhibits the response of the GLUT1 gene to insulin. Additional studies reveal that the induction of GLUT1 mRNA by Akt and by insulin reflects increased mRNA synthesis and not decreased mRNA degradation. Our findings imply that the GLUT1 gene responds to insulin at the transcriptional level and that Akt mediates a step in the activation of GLUT1 gene expression in this system.	Stanford Univ, Med Ctr, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA	Stanford University	Roth, RA (corresponding author), Stanford Univ, Med Ctr, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA.			Nakatani, Kaname/0000-0001-6709-541X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034926, R37DK034926] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008655] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 34926] Funding Source: Medline; NIEHS NIH HHS [ES08655] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Agati JM, 1998, J BIOL CHEM, V273, P18751, DOI 10.1074/jbc.273.30.18751; BASHAN N, 1992, AM J PHYSIOL, V262, pC682, DOI 10.1152/ajpcell.1992.262.3.C682; Behrooz A, 1997, J BIOL CHEM, V272, P5555, DOI 10.1074/jbc.272.9.5555; BIRNBAUM MJ, 1987, SCIENCE, V235, P1495, DOI 10.1126/science.3029870; Calera MR, 1998, J BIOL CHEM, V273, P7201, DOI 10.1074/jbc.273.13.7201; Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482; Coffer PJ, 1998, BIOCHEM J, V335, P1; DEHERREROS AG, 1989, J BIOL CHEM, V264, P19994; Dickens M, 1998, J BIOL CHEM, V273, P20144, DOI 10.1074/jbc.273.32.20144; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217; Hajduch E, 1998, DIABETES, V47, P1006, DOI 10.2337/diabetes.47.7.1006; HAUSDORFF SF, 1994, J BIOL CHEM, V269, P21391; HIRAKI Y, 1989, P NATL ACAD SCI USA, V86, P8252, DOI 10.1073/pnas.86.21.8252; HOLMAN GD, 1994, BIOESSAYS, V16, P753, DOI 10.1002/bies.950161010; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; Kozlovsky N, 1997, J BIOL CHEM, V272, P33367, DOI 10.1074/jbc.272.52.33367; Krook A, 1997, DIABETES, V46, P2110, DOI 10.2337/diabetes.46.12.2110; LEE WH, 1993, ENDOCRINOLOGY, V133, P2540, DOI 10.1210/en.133.6.2540; Liao JF, 1998, J BIOL CHEM, V273, P27320, DOI 10.1074/jbc.273.42.27320; Liu AX, 1998, CANCER RES, V58, P2973; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; Mueckler M, 1997, BIOCHEM SOC T, V25, P951, DOI 10.1042/bst0250951; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; Olson AL, 1996, ANNU REV NUTR, V16, P235, DOI 10.1146/annurev.nu.16.070196.001315; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Somwar R, 1998, AM J PHYSIOL-ENDOC M, V275, pE618, DOI 10.1152/ajpendo.1998.275.4.E618; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; TAHA C, 1995, J BIOL CHEM, V270, P24678, DOI 10.1074/jbc.270.42.24678; TODAKA M, 1994, J BIOL CHEM, V269, P29265; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Walker KS, 1998, BIOCHEM J, V331, P299, DOI 10.1042/bj3310299; WALKER PS, 1989, J BIOL CHEM, V264, P6587; Wang D, 1998, J BIOL CHEM, V273, P25420, DOI 10.1074/jbc.273.39.25420; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085	40	245	251	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20281	20286		10.1074/jbc.274.29.20281	http://dx.doi.org/10.1074/jbc.274.29.20281			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400647	hybrid			2022-12-25	WOS:000081438300040
J	Yang, AJ; Chandswangbhuvana, D; Shu, T; Henschen, A; Glabe, CG				Yang, AJ; Chandswangbhuvana, D; Shu, T; Henschen, A; Glabe, CG			Intracellular accumulation of insoluble, newly synthesized A beta n-42 in amyloid precursor protein-transfected cells that have been treated with A beta 1-42	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; BETA-PROTEIN; SECRETASE CLEAVAGE; SENILE PLAQUES; NT2N CELLS; PEPTIDE; AGGREGATION; RESISTANCE; DEPOSITS; INTERNALIZATION	Our early study indicates that intracellular A beta 1-42 aggregates are resistant to degradation and accumulate as an insoluble residue in lysosomes, where they alter the normal catabolism of amyloid precursor protein (APP) to cause the accumulation of insoluble APP and amyloidogenic fragments. In this study, we examined whether the addition of exogenous A beta 1-42 also leads to the accumulation of newly synthesized intracellular A beta. Here we describe that newly synthesized A beta, especially A beta n-42, is generated from metabolically labeled APP and accumulates in the insoluble fraction of cell lysates after A beta 1-42 treatment. These results suggest that intracellular A beta may derive from a solid phase, intracellular pathway. In contrast to the pathway that primarily produces secreted A beta 1-40, the solid-phase intracellular pathway preferentially produces A beta n-42 with ragged amino termini. Biochemical studies and amino acid sequencing analyses indicate that these intracellular A beta also share the same types of A beta structures that accumulate in the brain of Alzheimer's disease patients, suggesting that a significant fraction of the amyloid deposits in Alzheimer's disease may arise by this solid-phase pathway.	Nathan S Kline Inst Psychiat Res, Dementia Res Program, Orangeburg, NY 10962 USA; Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92717 USA	Nathan Kline Institute for Psychiatric Research; University of California System; University of California Irvine	Yang, AJ (corresponding author), Nathan S Kline Inst Psychiat Res, Dementia Res Program, 140 Old Orangeburg Rd,Bldg 39, Orangeburg, NY 10962 USA.				NATIONAL INSTITUTE ON AGING [P01AG000538] Funding Source: NIH RePORTER; NIA NIH HHS [AG00538] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; BURDICK D, 1992, J BIOL CHEM, V267, P546; Burdick D, 1997, BRAIN RES, V746, P275, DOI 10.1016/S0006-8993(96)01262-0; CATALDO AM, 1990, BRAIN RES, V513, P181, DOI 10.1016/0006-8993(90)90456-L; Cataldo AM, 1996, J NEUROPATH EXP NEUR, V55, P704, DOI 10.1097/00005072-199606000-00004; CATALDO AM, 1990, P NATL ACAD SCI USA, V87, P3861, DOI 10.1073/pnas.87.10.3861; CHLOUPEK RC, 1994, J CHROMATOGR A, V686, P45, DOI 10.1016/S0021-9673(94)89009-9; Chyung ASC, 1997, J CELL BIOL, V138, P671, DOI 10.1083/jcb.138.3.671; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; CUMMINGS BJ, 1992, NEUROSCIENCE, V48, P763, DOI 10.1016/0306-4522(92)90265-4; DAVISSALINAS J, 1995, J NEUROCHEM, V65, P931; FRACKOWIAK J, 1992, ACTA NEUROPATHOL, V84, P225; FRASER PE, 1991, BIOPHYS J, V60, P1190, DOI 10.1016/S0006-3495(91)82154-3; GREGORI L, 1994, BIOCHEM BIOPH RES CO, V203, P1731, DOI 10.1006/bbrc.1994.2386; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; JOACHIM C, 1991, AM J PATHOL, V138, P373; KNAUER MF, 1992, P NATL ACAD SCI USA, V89, P7437, DOI 10.1073/pnas.89.16.7437; KOO EH, 1994, J BIOL CHEM, V269, P17386; MILLER DL, 1993, ARCH BIOCHEM BIOPHYS, V301, P41, DOI 10.1006/abbi.1993.1112; NASLUND J, 1994, P NATL ACAD SCI USA, V91, P8378, DOI 10.1073/pnas.91.18.8378; Naslund J, 1996, J NEUROCHEM, V67, P294; NORDSTEDT C, 1994, J BIOL CHEM, V269, P30773; Perry G, 1989, Prog Clin Biol Res, V317, P1021; PRUSINER SB, 1987, LAB INVEST, V56, P349; REFOLO LM, 1995, J NEUROSCI RES, V40, P694, DOI 10.1002/jnr.490400515; ROHER AE, 1993, P NATL ACAD SCI USA, V90, P10836, DOI 10.1073/pnas.90.22.10836; ROHER AE, 1993, J BIOL CHEM, V268, P3072; Saido TC, 1996, NEUROSCI LETT, V215, P173, DOI 10.1016/0304-3940(96)12970-0; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; Skovronsky DM, 1998, J CELL BIOL, V141, P1031, DOI 10.1083/jcb.141.4.1031; SOREGHAN B, 1994, J BIOL CHEM, V269, P28551; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TABATON M, 1991, P NATL ACAD SCI USA, V88, P2098, DOI 10.1073/pnas.88.6.2098; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390; TSUZUKI K, 1994, NEUROSCI LETT, V182, P151, DOI 10.1016/0304-3940(94)90785-4; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; Xu HX, 1997, P NATL ACAD SCI USA, V94, P3748, DOI 10.1073/pnas.94.8.3748; YANG AJ, 1995, J BIOL CHEM, V270, P14786, DOI 10.1074/jbc.270.24.14786; YOUNKIN SG, 1994, TOHOKU J EXP MED, V174, P217, DOI 10.1620/tjem.174.217	40	96	100	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20650	20656		10.1074/jbc.274.29.20650	http://dx.doi.org/10.1074/jbc.274.29.20650			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400697	hybrid			2022-12-25	WOS:000081438300090
J	Heger, P; Rosorius, O; Hauber, J; Stauber, RH				Heger, P; Rosorius, O; Hauber, J; Stauber, RH			Titration of cellular export factors, but not heteromultimerization, is the molecular mechanism of trans-dominant HTLV-1 Rex mutants	ONCOGENE			English	Article						HTLV-1 Rex; nucleo-cytoplasmic trafficking; trans-dominance; GFP	VIRUS TYPE-I; VIRAL MESSENGER-RNA; LEUKEMIA-VIRUS; NUCLEAR EXPORT; GENE-EXPRESSION; NEGATIVE MUTANTS; TRANSCRIPTIONAL ACTIVATOR; NUCLEOLAR LOCALIZATION; SEQUENCE REQUIREMENTS; REGULATORY PROTEINS	The HTLV-1 Rex protein is an essential shuttle protein required for nuclear export of unspliced and incompletely-spliced viral RNAs. Several trans-dominant (TD) mutant Rex proteins have been reported, however, the mechanism of trans-dominance is not known. We compared TD Rex mutants and found that a natural occurring Rex mutant, Rexp21, lacking the RNA. binding domain, was highly TD and inhibited also HIV-1 Rev function. Using fusions to the green fluorescent protein (GFP) we observed that Rexp21-GFP displayed a cytoplasmic localization but was actively shuttling between the nucleus and the cytoplasm in live human cells. The presence of Rexp21-GFP inhibited the nuclear export of Res and HIV-1 Rev as assayed by cotransfection and microinjection experiments, However, Rex-GFP or Rexp21-GFP did not form heteromultimers with nuclear Res mutants in Fire. In contrast, shuttling was essential for tr ans-dominance. Thus, we propose that TD Res mutants do not function by retaining WT Res in the nucleus by protein-protein interactions, as demonstrated for Rev, but to titrate factors essential for Rex/Rev export, Our findings demonstrate differences between the regulatory proteins Res and Rev and implicate a novel strategy to generate highly TD Res mutants also applicable to other proteins.	Univ Erlangen Nurnberg, Inst Med & Clin Virol, D-91054 Erlangen, Germany	University of Erlangen Nuremberg	Stauber, RH (corresponding author), Univ Erlangen Nurnberg, Inst Med & Clin Virol, Schlossgarten 4, D-91054 Erlangen, Germany.			Heger, Peter/0000-0003-2583-2981; Stauber, Roland/0000-0002-1341-4523				ADACHI Y, 1992, J BIOL CHEM, V267, P21977; Bakker A, 1996, J VIROL, V70, P5511, DOI 10.1128/JVI.70.8.5511-5518.1996; BERNEMAN ZN, 1992, P NATL ACAD SCI USA, V89, P3005, DOI 10.1073/pnas.89.7.3005; BHAT NK, 1993, VIROLOGY, V196, P15, DOI 10.1006/viro.1993.1450; BLACK AC, 1991, VIROLOGY, V181, P433, DOI 10.1016/0042-6822(91)90875-C; BLACK AC, 1994, VIROLOGY, V200, P29, DOI 10.1006/viro.1994.1159; BOGERD H, 1993, J VIROL, V67, P2496, DOI 10.1128/JVI.67.5.2496-2502.1993; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Bogerd HP, 1998, J VIROL, V72, P8627, DOI 10.1128/JVI.72.11.8627-8635.1998; BOGERD HP, 1991, P NATL ACAD SCI USA, V88, P5704, DOI 10.1073/pnas.88.13.5704; BOHNLEIN E, 1991, J VIROL, V65, P7051; BOHNLEIN S, 1991, J VIROL, V65, P81; CANN AJ, 1985, NATURE, V318, P571, DOI 10.1038/318571a0; Ciminale V, 1997, J VIROL, V71, P2810, DOI 10.1128/JVI.71.4.2810-2818.1997; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; DETHE G, 1993, AIDS RES HUM RETROV, V9, P381, DOI 10.1089/aid.1993.9.381; ESSEX M, 1995, LEUKEMIA, V9, pS71; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FELBER BK, 1997, MRNA METABOLISM POST, P323; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; FURUTA RA, 1995, J VIROL, V69, P1591, DOI 10.1128/JVI.69.3.1591-1599.1995; GESSAIN A, 1985, LANCET, V2, P407; GITLIN SD, 1993, MOL BIOL HUMAN T CEL; Gorlich D, 1997, CURR OPIN CELL BIOL, V9, P412, DOI 10.1016/S0955-0674(97)80015-4; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; GRASSMANN R, 1991, J VIROL, V65, P3721, DOI 10.1128/JVI.65.7.3721-3727.1991; Grone M, 1996, VIROLOGY, V218, P316, DOI 10.1006/viro.1996.0200; Hakata Y, 1998, J VIROL, V72, P6602, DOI 10.1128/JVI.72.8.6602-6607.1998; Hammarskjold ML, 1997, SEMIN CELL DEV BIOL, V8, P83, DOI 10.1006/scdb.1996.0127; HAMMES SR, 1993, VIROLOGY, V193, P41, DOI 10.1006/viro.1993.1101; Heger P, 1998, J VIROL, V72, P8659, DOI 10.1128/JVI.72.11.8659-8668.1998; Henderson BR, 1997, J MOL BIOL, V274, P693, DOI 10.1006/jmbi.1997.1420; HIDAKA M, 1988, EMBO J, V7, P519, DOI 10.1002/j.1460-2075.1988.tb02840.x; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HOFER L, 1991, J VIROL, V65, P3379, DOI 10.1128/JVI.65.6.3379-3383.1991; HOPE TJ, 1992, J VIROL, V66, P1849, DOI 10.1128/JVI.66.4.1849-1855.1992; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; KANAMORI H, 1990, EMBO J, V9, P4161, DOI 10.1002/j.1460-2075.1990.tb07639.x; KATAHIRA J, 1995, J VIROL, V69, P3125, DOI 10.1128/JVI.69.5.3125-3133.1995; Kim FJ, 1996, MOL CELL BIOL, V16, P5147; King JA, 1998, ONCOGENE, V16, P3309, DOI 10.1038/sj.onc.1201884; KIYOKAWA T, 1985, P NATL ACAD SCI USA, V82, P8359, DOI 10.1073/pnas.82.24.8359; KUBOTA S, 1992, J VIROL, V66, P2510, DOI 10.1128/JVI.66.4.2510-2513.1992; Kubota S, 1996, VIROLOGY, V220, P502, DOI 10.1006/viro.1996.0339; KUBOTA S, 1991, J VIROL, V65, P2452, DOI 10.1128/JVI.65.5.2452-2456.1991; LAGRENADE L, 1990, LANCET, V336, P1345; MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MCGUIRE KL, 1993, J VIROL, V67, P1590, DOI 10.1128/JVI.67.3.1590-1599.1993; MORGAN OS, 1989, LANCET, V2, P1184; MURAI K, 1990, J ACQ IMMUN DEF SYND, V3, P1006; Nakielny S, 1996, J CELL BIOL, V134, P1365, DOI 10.1083/jcb.134.6.1365; NOSAKA T, 1989, P NATL ACAD SCI USA, V86, P9798, DOI 10.1073/pnas.86.24.9798; ORITA S, 1991, FEBS LETT, V295, P127, DOI 10.1016/0014-5793(91)81402-T; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Palmeri D, 1996, J VIROL, V70, P6442, DOI 10.1128/JVI.70.9.6442-6445.1996; PARK MH, 1993, TRENDS BIOCHEM SCI, V18, P475, DOI 10.1016/0968-0004(93)90010-K; PARK MH, 1993, BIOFACTORS, V4, P95; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POLLARD VW, 1998, IN PRESS ANN REV MIC; RIMSKY L, 1989, NATURE, V341, P453, DOI 10.1038/341453a0; ROSORIUS O, 1998, UNPUB; SCHMIDTZACHMANN MS, 1993, CELL, V74, P493, DOI 10.1016/0092-8674(93)80051-F; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; SMITH MR, 1991, J CLIN INVEST, V87, P761, DOI 10.1172/JCI115078; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; STAUBER R, 1995, VIROLOGY, V213, P439, DOI 10.1006/viro.1995.0016; Stauber RH, 1998, VIROLOGY, V252, P126, DOI 10.1006/viro.1998.9400; Stauber RH, 1998, BIOTECHNIQUES, V24, P462, DOI 10.2144/98243rr01; Stauber RH, 1998, VIROLOGY, V251, P38, DOI 10.1006/viro.1998.9295; SZILVAY AM, 1995, J VIROL, V69, P3315, DOI 10.1128/JVI.69.6.3315-3323.1995; Thomas SL, 1998, J VIROL, V72, P2935, DOI 10.1128/JVI.72.4.2935-2944.1998; Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15; WEICHSELBRAUN I, 1992, J VIROL, V66, P4540, DOI 10.1128/JVI.66.7.4540-4545.1992; WEICHSELBRAUN I, 1992, J VIROL, V66, P2583, DOI 10.1128/JVI.66.4.2583-2587.1992; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; YOSHIDA M, 1996, J ACQ IMMUN DEF SYND, V13, P63; Zolotukhin AS, 1999, J VIROL, V73, P120, DOI 10.1128/JVI.73.1.120-127.1999	83	29	29	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	1999	18	28					4080	4090		10.1038/sj.onc.1202762	http://dx.doi.org/10.1038/sj.onc.1202762			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	216FP	10435589				2022-12-25	WOS:000081431000005
J	de Rudder, KEE; Sohlenkamp, C; Geiger, O				de Rudder, KEE; Sohlenkamp, C; Geiger, O			Plant-exuded choline is used for rhizobial membrane lipid biosynthesis by phosphatidylcholine synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; N-METHYLTRANSFERASE; ENZYMATIC-SYNTHESIS; GLYCINE BETAINE; GENE; MELILOTI; PHOSPHATIDYLETHANOLAMINE; EXPRESSION; LEGUMINOSARUM	Phosphatidylcholine is a major lipid of eukaryotic membranes, but found in only few prokaryotes, Enzymatic methylation of phosphatidylethanolamine by phospholipid N-methyltransferase was thought to be the only biosynthetic pathway to yield phosphatidylcholine in bacteria. However, mutants of the microsymbiotic soil bacterium Sinorhizobium (Rhizobium) meliloti, defective in phospholipid N-methyltransferase, form phosphatidylcholine in wild type amounts when choline is provided in the growth medium. Here we describe a second bacterial pathway for phosphatidylcholine biosynthesis involving the novel enzymatic activity, phosphatidylcholine synthase, that forms phosphatidylcholine directly from choline and CDP-diacylglycerol in cell-free extracts of S, meliloti, We further demonstrate that roots of host plants of S, meliloti exude choline and that the amounts of exuded choline are sufficient to allow for maximal phosphatidylcholine biosynthesis in S. meliloti via the novel pathway.	Tech Univ Berlin, Inst Biotechnol, FG Tech Biochem, D-13353 Berlin, Germany	Technical University of Berlin	Geiger, O (corresponding author), Tech Univ Berlin, Inst Biotechnol, FG Tech Biochem, Sekr GG1,Seestr 13, D-13353 Berlin, Germany.		Sohlenkamp, Christian/C-6219-2018; Geiger, Otto/F-6356-2019	Sohlenkamp, Christian/0000-0002-9962-2859; Geiger, Otto/0000-0002-7794-1568				ARONDEL V, 1993, J BIOL CHEM, V268, P16002; BELISLE JT, 1994, J BACTERIOL, V176, P2151, DOI 10.1128/JB.176.8.2151-2157.1994; BERINGER JE, 1974, J GEN MICROBIOL, V84, P188; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Breedveld MW., 1998, RHIZOBIACEAE, P81, DOI [10.1007/978-94-011-5060-6_5, DOI 10.1007/978-94-011-5060-6_5]; CARMAN GM, 1983, CAN J MICROBIOL, V29, P1452, DOI 10.1139/m83-222; DECHAVIGNY A, 1991, J BIOL CHEM, V266, P5323; deRudder KEE, 1997, J BACTERIOL, V179, P6921, DOI 10.1128/jb.179.22.6921-6928.1997; EATON BR, 1976, ARCH BIOCHEM BIOPHYS, V176, P604, DOI 10.1016/0003-9861(76)90204-6; HEACOCK PN, 1989, J BIOL CHEM, V264, P14972; HOSAKA K, 1989, J BIOL CHEM, V264, P2053; KANFER J, 1964, J BIOL CHEM, V239, P1720; KANFER JN, 1980, CAN J BIOCHEM CELL B, V58, P1370, DOI 10.1139/o80-186; KENNEDY EP, 1989, PHOSPHATIDYLCHOLINE, P1; LANDS WEM, 1960, J BIOL CHEM, V235, P2233; MAIZEL JV, 1956, PLANT PHYSIOL, V31, P407, DOI 10.1104/pp.31.5.407; MCCAMAN RE, 1985, METHOD ENZYMAT AN, V8, P462; NACHIAPPAN V, 1994, ANAL BIOCHEM, V222, P283, DOI 10.1006/abio.1994.1487; Osteras M, 1998, P NATL ACAD SCI USA, V95, P11394, DOI 10.1073/pnas.95.19.11394; POCARD JA, 1989, J BACTERIOL, V171, P531, DOI 10.1128/jb.171.1.531-537.1989; RHODES D, 1993, ANNU REV PLANT PHYS, V44, P357, DOI 10.1146/annurev.pp.44.060193.002041; Rock C. O., 1996, NEW COMPREHENSIVE BI, V31, P35; SHEARD NF, 1986, AM J CLIN NUTR, V43, P219, DOI 10.1093/ajcn/43.2.219; SHERR SI, 1965, J BIOL CHEM, V240, P7711; SMITH LT, 1988, J BACTERIOL, V170, P3142, DOI 10.1128/jb.170.7.3142-3149.1988; TAHARA Y, 1994, J GEN APPL MICROBIOL, V40, P389, DOI 10.2323/jgam.40.389; THIELE OW, 1968, EUR J BIOCHEM, V5, P513, DOI 10.1111/j.1432-1033.1968.tb00400.x; TSUKAGOSHI Y, 1991, J BACTERIOL, V173, P2134, DOI 10.1128/jb.173.6.2134-2136.1991; VANBRUSSEL AAN, 1986, J BACTERIOL, V165, P517, DOI 10.1128/jb.165.2.517-522.1986; VINCENT JM, 1970, IBP HDB, V15, P75; Zhao M, 1998, ANAL BIOCHEM, V258, P48, DOI 10.1006/abio.1997.2559	31	76	81	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					20011	20016		10.1074/jbc.274.28.20011	http://dx.doi.org/10.1074/jbc.274.28.20011			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391951	hybrid			2022-12-25	WOS:000081377300071
J	Sipes, JM; Krutzsch, HC; Lawler, J; Roberts, DD				Sipes, JM; Krutzsch, HC; Lawler, J; Roberts, DD			Cooperation between thrombospondin-1 type 1 repeat peptides and alpha(v)beta(3) integrin ligands to promote melanoma cell spreading and focal adhesion kinase phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FALCIPARUM-INFECTED ERYTHROCYTES; HEPARIN-BINDING PEPTIDES; ENDOTHELIAL-CELLS; I REPEATS; ALPHA-2-BETA-1 INTEGRIN; TERMINAL DOMAIN; PROTEIN; RECEPTOR; MOTILITY; GROWTH	CD47-binding sequences from the carboxyl-terminal domain of thrombospondin-1 (TSP1) are known to regulate activity of the alpha(v)beta(3) integrin (Gao, G., Lindberg, F. P., Dimitry, J. M., Brown, E. J., and Frazier, W. A. (1996) J. Cell Biol. 135, 533-544). Here we show that peptides from the type 1 repeats of TSP1 also stimulate alpha(v)beta(3) integrin function in melanoma cells. Addition of soluble peptide 246 (KRFKQDGGWSHWSPWSS) enhances spreading of A2058 melanoma cells on several gp, integrin ligands, including vitronectin, recombinant TSP1 fragments containing the Arg-Gly-Asp sequence, and native TSP1. This activity requires the Trp residues and is independent of CD36-binding sequences in the type 1 repeats. Recombinant type 1 repeats expressed as a glutathione S-transferase fusion protein also enhance spreading on vitronectin and TSP1, Activation of alpha(v)beta(3) integrin by the soluble peptide 246 stimulates organization of F-actin and increases tyrosine phosphorylation of focal adhesion kinase, In contrast, direct adhesion of melanoma cells on immobilized peptide 246 inhibits tyrosine phosphorylation of focal adhesion kinase, Stimulation of alpha(v)beta(3) integrin function by the type 1 repeat peptide differs from that induced by CD47-binding TSP1 peptides in that heparan sulfate proteoglycans are required and pertussis toxin does not inhibit the former activity. Thus, the type I repeats contain a second sequence of TSP1 that can enhance alpha(v)beta(3) integrin signaling, and these two sequences stimulate recognition of both vitronectin and TSP1 by the alpha(v)beta(3) integrin.	NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Roberts, DD (corresponding author), NCI, Pathol Lab, NIH, Bldg 10,Rm 2A33,10 Ctr Dr,MSC 1500, Bethesda, MD 20892 USA.	droberts@helix.nih.gov	Roberts, David D./A-9699-2008; Lawler, Jack/AAJ-1379-2020	Roberts, David D./0000-0002-2481-2981; 	NHLBI NIH HHS [HL28749] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028749] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams JC, 1997, MOL BIOL CELL, V8, P2345, DOI 10.1091/mbc.8.11.2345; AKIYAMA SK, 1985, J BIOL CHEM, V260, P4492; AOTA S, 1994, J BIOL CHEM, V269, P24756; ASCH AS, 1992, BIOCHEM BIOPH RES CO, V182, P1208, DOI 10.1016/0006-291X(92)91860-S; Aznavoorian S, 1996, J BIOL CHEM, V271, P3247, DOI 10.1074/jbc.271.6.3247; BARNWELL JW, 1985, J IMMUNOL, V135, P3494; Bondinell W E, 1994, Bioorg Med Chem, V2, P897, DOI 10.1016/S0968-0896(00)82039-8; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; Chung J, 1997, J BIOL CHEM, V272, P14740, DOI 10.1074/jbc.272.23.14740; Clezardin P, 1997, BIOCHEM J, V321, P819, DOI 10.1042/bj3210819; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; Gao AG, 1996, J BIOL CHEM, V271, P21, DOI 10.1074/jbc.271.1.21; Gao AG, 1996, J CELL BIOL, V135, P533, DOI 10.1083/jcb.135.2.533; Guo NH, 1998, CANCER RES, V58, P3154; GUO NH, 1992, J BIOL CHEM, V267, P19349; Guo NH, 1997, J PEPT RES, V50, P210; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; Guo NH, 1997, CANCER RES, V57, P1735; GUO NH, 1992, J BIOL CHEM, V267, P17743; HAYASHI K, 1992, J CELL BIOL, V119, P945, DOI 10.1083/jcb.119.4.945; HOGG PJ, 1994, THROMB HAEMOSTASIS, V72, P787; IIDA J, 1995, CANCER RES, V55, P2177; Iida J, 1998, J BIOL CHEM, V273, P5955, DOI 10.1074/jbc.273.10.5955; Iida J, 1996, SEMIN CANCER BIOL, V7, P155, DOI 10.1006/scbi.1996.0021; Keenan RM, 1997, J MED CHEM, V40, P2289, DOI 10.1021/jm970205r; Knutson JR, 1996, MOL BIOL CELL, V7, P383, DOI 10.1091/mbc.7.3.383; Kolanus W, 1997, CURR OPIN CELL BIOL, V9, P725, DOI 10.1016/S0955-0674(97)80127-5; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LEGRAND C, 1992, BLOOD, V79, P1995; LI WX, 1993, J BIOL CHEM, V268, P16179; MAKABE T, 1990, J BIOL CHEM, V265, P14270; MURPHYULLRICH JE, 1993, J BIOL CHEM, V268, P26784; Oh ES, 1997, J BIOL CHEM, V272, P8133, DOI 10.1074/jbc.272.13.8133; PANTON LJ, 1987, INFECT IMMUN, V55, P2754, DOI 10.1128/IAI.55.11.2754-2758.1987; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; Qian XH, 1997, EXP CELL RES, V235, P403, DOI 10.1006/excr.1997.3681; Roberts David D., 1994, Journal of Tissue Culture Methods, V16, P217, DOI 10.1007/BF01540654; ROBERTS DD, 1988, CANCER RES, V48, P6785; Roberts DD, 1996, FASEB J, V10, P1183, DOI 10.1096/fasebj.10.10.8751720; SCHULTZCHERRY S, 1995, J BIOL CHEM, V270, P7304, DOI 10.1074/jbc.270.13.7304; SCHULTZCHERRY S, 1993, J CELL BIOL, V122, P923, DOI 10.1083/jcb.122.4.923; SUN XJ, 1989, J BIOL CHEM, V264, P11288; TARABOLETTI G, 1990, J CELL BIOL, V111, P765, DOI 10.1083/jcb.111.2.765; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; TUSZYNSKI GP, 1987, CANCER RES, V47, P4130; VOGEL T, 1993, J CELL BIOCHEM, V53, P74, DOI 10.1002/jcb.240530109; Wang XQ, 1998, MOL BIOL CELL, V9, P865, DOI 10.1091/mbc.9.4.865; YAMAGATA M, 1989, J BIOL CHEM, V264, P8012; Yoshida T, 1998, J BIOL CHEM, V273, P1583, DOI 10.1074/jbc.273.3.1583; ZABRENETZKY V, 1994, INT J CANCER, V59, P191, DOI 10.1002/ijc.2910590209	50	54	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22755	22762		10.1074/jbc.274.32.22755	http://dx.doi.org/10.1074/jbc.274.32.22755			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428859	hybrid			2022-12-25	WOS:000081868400089
J	Zhang, Y; Chen, QA				Zhang, Y; Chen, QA			The noncollagenous domain 1 of type X collagen - A novel motif for trimer and higher order multimer formation without a triple helix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHMID METAPHYSEAL CHONDRODYSPLASIA; CARTILAGE MATRIX; IN-VITRO; FIBRIL ASSOCIATION; ALPHA-1(X) NC1; COILED-COIL; PROTEIN; GENE; EXPRESSION; MUTATIONS	In this study, we test the hypothesis that the carboxyl noncollagenous (NC1) domain of collagen X is sufficient to direct multimer formation without a triple helix. Two peptides containing the NC1 domain of avian collagen X have been synthesized using a bacterial expression system and their properties characterized. One peptide consists only of the NC1 domain, and the other is a chimeric molecule with a noncollagenous A domain of matrilin-1 fused to the N terminus of NC1. The NC1 peptide alone forms a 45-kDa trimer under native conditions, suggesting that NC1 contains all the information for trimerization without any triple helical residues. This trimeric association is highly thermostable without intermolecular disulfide bonds. This indicates that the NC1 domain contributes to the remarkable structural stability of collagen X. Chemical cross-linking of the NC1 trimer results in a series of varying sized multimers, the smallest of which is a trimer, Therefore the NCI trimer is sufficient to form higher order multimers. The chimeric A-NC1 peptide forms a homotrimer by itself, and a series of heterotrimers with the NC1 peptide via the NC1 domain. Thus the NC1(X) domain directs multimer formation, even in a noncollagenous molecule.	Penn State Univ, Coll Med, Dept Cell & Mol Physiol, Musculoskeletal Res Lab, Hershey, PA 17033 USA; Penn State Univ, Coll Med, Dept Orthopaed & Rehabil, Musculoskeletal Res Lab, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Chen, QA (corresponding author), Penn State Univ, Coll Med, Dept Cell & Mol Physiol, Musculoskeletal Res Lab, Hershey, PA 17033 USA.		Chen, Qian/C-4354-2011	Chen, Qian/0000-0003-4406-5618	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM104937] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R29AG014399, R01AG014399] Funding Source: NIH RePORTER; NIA NIH HHS [AG000811, AG14399] Funding Source: Medline; NIGMS NIH HHS [P20 GM104937] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHAN D, 1995, J BIOL CHEM, V270, P4558, DOI 10.1074/jbc.270.9.4558; Chan D, 1996, J BIOL CHEM, V271, P13566, DOI 10.1074/jbc.271.23.13566; Chan D, 1998, J CLIN INVEST, V101, P1490, DOI 10.1172/JCI1976; CHEN Q, 1995, MOL BIOL CELL, V6, P1743, DOI 10.1091/mbc.6.12.1743; CHEN Q, 1990, P NATL ACAD SCI USA, V87, P8046, DOI 10.1073/pnas.87.20.8046; CHEN Q, 1992, J CELL BIOL, V117, P687, DOI 10.1083/jcb.117.3.687; DAVIS JG, 1995, SCIENCE, V267, P1031, DOI 10.1126/science.7863331; ENGEL J, 1991, ANNU REV BIOPHYS BIO, V20, P137, DOI 10.1146/annurev.biophys.20.1.137; GERSTENFELD LC, 1991, J CELL BIOL, V112, P501, DOI 10.1083/jcb.112.3.501; GIBSON GJ, 1985, J CELL BIOL, V101, P277, DOI 10.1083/jcb.101.1.277; HAUDENSCHILD DR, 1995, J BIOL CHEM, V270, P23150, DOI 10.1074/jbc.270.39.23150; Hayward CPM, 1997, CLIN INVEST MED, V20, P176; HAYWARD CPM, 1995, J BIOL CHEM, V270, P18246, DOI 10.1074/jbc.270.31.18246; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; KAVETY B, 1994, MOL BRAIN RES, V27, P152, DOI 10.1016/0169-328X(94)90196-1; KWAN APL, 1991, J CELL BIOL, V114, P597, DOI 10.1083/jcb.114.3.597; Kwan KM, 1997, J CELL BIOL, V136, P459, DOI 10.1083/jcb.136.2.459; LUVALLE P, 1988, J BIOL CHEM, V263, P18378; MAZZORANA M, 1993, J BIOL CHEM, V268, P3029; MCINTOSH I, 1995, HUM MUTAT, V5, P121, DOI 10.1002/humu.1380050204; McLaughlin SH, 1998, BIOCHEM J, V331, P793, DOI 10.1042/bj3310793; Mechling DE, 1996, J BIOL CHEM, V271, P13781, DOI 10.1074/jbc.271.23.13781; NINOMIYA Y, 1986, J BIOL CHEM, V261, P5041; REICHENBERGER E, 1991, DEV BIOL, V148, P562, DOI 10.1016/0012-1606(91)90274-7; REID KBM, 1983, BIOCHEM SOC T, V11, P1; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; SCHMID TM, 1984, J ULTRA MOL STRUCT R, V86, P186, DOI 10.1016/S0022-5320(84)80057-X; SCHMID TM, 1985, DEV BIOL, V107, P373, DOI 10.1016/0012-1606(85)90319-7; SCHMID TM, 1990, DEV BIOL, V138, P53, DOI 10.1016/0012-1606(90)90176-J; SCHMID TM, 1989, CONNECT TISSUE RES, V20, P215, DOI 10.3109/03008208909023890; SCHMID TM, 1984, BIOCHEMISTRY-US, V23, P553, DOI 10.1021/bi00298a024; SCHMID TM, 1983, J BIOL CHEM, V258, P9504; TAKAMATSU N, 1993, MOL CELL BIOL, V13, P1516, DOI 10.1128/MCB.13.3.1516; WARMAN ML, 1993, NAT GENET, V5, P79, DOI 10.1038/ng0993-79; YAMAGUCHI N, 1991, J BIOL CHEM, V266, P4508	35	30	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22409	22413		10.1074/jbc.274.32.22409	http://dx.doi.org/10.1074/jbc.274.32.22409			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428813	hybrid			2022-12-25	WOS:000081868400043
J	Jordan, JD; Carey, KD; Stork, PJS; Iyengar, R				Jordan, JD; Carey, KD; Stork, PJS; Iyengar, R			Modulation of rap activity by direct interaction of G alpha(o) with Rap1 GTPase-activating protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEINS; GAMMA-SUBUNIT; ALPHA-SUBUNIT; CYCLIC-AMP; MAP KINASE; INHIBITION; BRAIN; PHOSPHORYLATION; PATHWAY; CLONING	We used the yeast two-hybrid system to identify proteins that interact directly with G alpha(o). Mutant-activated G alpha(o) was used as the bait to screen a cDNA library from chick dorsal root ganglion neurons. We found that G alpha(o) interacted with several proteins including Gz-GTPase-activating protein (Gz-GAP), a new RGS protein (RGS-17), a novel protein of unknown function (IP6), and Rap1GAP. This study focuses on Rap1GAP, which selectively interacts with G alpha(o) and G alpha(i) but not with G alpha(s) or G alpha(q). Rap1GAP interacts more avidly with the unactivated G alpha(o) as compared with the mutant (Q205L)-activated G alpha(o). When expressed in HEK-293 cells, unactivated G alpha(o) co-immunoprecipitates with the Rap1GAP. Expression of chick Rap1GAP in PC-12 cells inhibited activation of Rap1 by forskolin, When unactivated G alpha(o) was expressed, the amount of activated Rap1 was greatly increased. This effect was not observed with the Q205L-G alpha(o). Expression of unactivated G alpha(o) stimulated MAP-kinase (MAPK1/2) activity in a Rap1GAP-dependent manner. These results identify a novel function of G alpha(o), which in its resting state can sequester Rap1GAP thereby regulating Rap1 activity and consequently gating signal flow from Rap1 to MAPK1/2. Thus, activation of G(o) could modulate the Rap1 effects on a variety of cellular functions.	CUNY Mt Sinai Sch Med, Dept Pharmacol, New York, NY 10029 USA; Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Oregon Health & Science University	Jordan, JD (corresponding author), CUNY Mt Sinai Sch Med, Dept Pharmacol, Box 1215,1 Gustave Levy Pl, New York, NY 10029 USA.			Jordan, Dedrick/0000-0002-0706-9583	NCI NIH HHS [CA-72971] Funding Source: Medline; NIDDK NIH HHS [DK-38671] Funding Source: Medline; NIGMS NIH HHS [GM-54508] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072971] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054508] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; DIVERSEPIERLUISSI M, 1995, NEURON, V14, P191, DOI 10.1016/0896-6273(95)90254-6; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; Glick JL, 1998, J BIOL CHEM, V273, P26008, DOI 10.1074/jbc.273.40.26008; HILDEBRANDT JD, 1983, NATURE, V302, P706, DOI 10.1038/302706a0; Impey S, 1999, NEURON, V23, P11, DOI 10.1016/S0896-6273(00)80747-3; Iyengar R, 1996, SCIENCE, V271, P461, DOI 10.1126/science.271.5248.461; Jordan JD, 1998, BIOCHEM PHARMACOL, V55, P1347; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; Luo Y, 1999, J BIOL CHEM, V274, P10685, DOI 10.1074/jbc.274.16.10685; Mochizuki N, 1996, GENE, V181, P39, DOI 10.1016/S0378-1119(96)00456-8; MOISES HC, 1994, J NEUROSCI, V14, P3842; Morris AJ, 1997, BIOCHEM PHARMACOL, V54, P429, DOI 10.1016/S0006-2952(97)00032-4; NEER EJ, 1984, J BIOL CHEM, V259, P4222; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Smit Martine J., 1998, V32, P1; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STRITTMATTER SM, 1994, J NEUROSCI, V14, P2327; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; VIDAL M, 1997, YEAST 2 HYBRID SYSTE, P109; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wang J, 1998, J BIOL CHEM, V273, P26014, DOI 10.1074/jbc.273.40.26014; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451	26	130	136	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21507	21510		10.1074/jbc.274.31.21507	http://dx.doi.org/10.1074/jbc.274.31.21507			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419452	hybrid			2022-12-25	WOS:000081721100005
J	Ronnstrand, L; Siegbahn, A; Rorsman, C; Johnell, M; Hansen, K; Heldin, CH				Ronnstrand, L; Siegbahn, A; Rorsman, C; Johnell, M; Hansen, K; Heldin, CH			Overactivation of phospholipase C-gamma 1 renders platelet-derived growth factor beta-receptor-expressing cells independent of the phosphatidylinositol 3-kinase pathway for chemotaxis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SIGNAL-TRANSDUCTION; TYROSINE KINASES; SRC-FAMILY; GAMMA; PHOSPHORYLATION; PLC-GAMMA-1; ACTIVATION; DOMAIN; MITOGENESIS	We have previously shown that porcine aortic endothelial cells expressing the Y934F platelet-derived growth factor (PDGF) beta-receptor mutant respond to PDGF-BB in a chemotaxis assay at about 100-fold lower concentration than do wild-type PDGF beta-receptor-expressing cells (Hansen, K., Johnell, M., Siegbahn, A., Rorsman, C., Engstrom, U., Wernstedt, C., Heldin, C.-H., and Ronnstrand, L. (1996) EMBO J. 15, 5299-5913). Here we show that the increased chemotaxis correlates with increased activation of phospholipase C-gamma 1 (PLC-gamma 1), measured as inositol-1,4,5-trisphosphate release. By two-dimensional phosphopeptide mapping, the increase in phosphorylation of PLC-gamma 1 was shown not to be selective for any site, rather a general increase in phosphorylation of PLC-gamma 1 was seen. Specific inhibitors of protein kinase C, bisindolylmaleimide (GF109203X), and phosphatidylinositol 3-kinase (PI3-kinase), LY294002, did not affect the activation of PLC-gamma 1. To assess whether increased activation of PLC-gamma 1 is the cause of the hyperchemotaetic behavior of the Y934F mutant cell line, we constructed cell lines expressing either wildtype or a catalytically compromised version of PLC-gamma 1 under a tetracycline-inducible promoter. Overexpression and concomitant increased activation of wild-type PLC-gamma 1 in response to PDGF-BB led to a hyperchemotactic behavior of the cells, while the catalytically compromised PLC-gamma 1 mutant had no effect on PDGF-BB-induced chemotaxis. Furthermore, in cells expressing normal levels of PLC-gamma 1, chemotaxis was inhibited by LY294002. In contrast, the increase in chemotactic response seen upon overexpression of PLC-gamma 1 was not inhibited by the PI3-kinase inhibitor LY294002. These observations suggest the existence of two different pathways which mediate PDGF-induced chemotaxis; depending on the cellular context, the PI3-kinase pathway or the PLC-gamma 1 pathway may dominate.	Biomed Ctr, Ludwig Inst Canc Res, S-75124 Uppsala, Sweden; Univ Uppsala Hosp, Dept Clin Chem, S-75185 Uppsala, Sweden	Ludwig Institute for Cancer Research; Uppsala University; Uppsala University Hospital	Ronnstrand, L (corresponding author), Biomed Ctr, Ludwig Inst Canc Res, Box 595, S-75124 Uppsala, Sweden.	Lars.Ronnstrand@LICR.uu.se	Ronnstrand, Lars/A-2429-2011	Ronnstrand, Lars/0000-0003-1275-5809; Hansen, Klaus/0000-0001-9657-8816				ARTEAGA CL, 1991, P NATL ACAD SCI USA, V88, P10435, DOI 10.1073/pnas.88.23.10435; Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; BLUMEJENSEN P, 1995, J BIOL CHEM, V270, P14192, DOI 10.1074/jbc.270.23.14192; BOONEN GJJC, 1993, BIOCHIM BIOPHYS ACTA, V1178, P97, DOI 10.1016/0167-4889(93)90114-5; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; Derman MP, 1997, J BIOL CHEM, V272, P6465, DOI 10.1074/jbc.272.10.6465; ERIKSSON A, 1995, J BIOL CHEM, V270, P7773, DOI 10.1074/jbc.270.13.7773; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Hansen K, 1996, EMBO J, V15, P5299, DOI 10.1002/j.1460-2075.1996.tb00915.x; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Heldin CH, 1998, BBA-REV CANCER, V1378, pF79, DOI 10.1016/S0304-419X(98)00015-8; Higaki M, 1996, J BIOL CHEM, V271, P29342, DOI 10.1074/jbc.271.46.29342; HUANG PS, 1995, FEBS LETT, V358, P287, DOI 10.1016/0014-5793(94)01453-8; Ji QS, 1997, P NATL ACAD SCI USA, V94, P2999, DOI 10.1073/pnas.94.7.2999; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KUNDRA V, 1994, ONCOGENE, V9, P1429; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LIAO F, 1993, BIOCHEM BIOPH RES CO, V191, P1028, DOI 10.1006/bbrc.1993.1320; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; NAKANISHI O, 1993, J BIOL CHEM, V268, P10754; OZAWA K, 1993, J BIOL CHEM, V268, P2280; Rameh LE, 1998, J BIOL CHEM, V273, P23750, DOI 10.1074/jbc.273.37.23750; SIEGBAHN A, 1990, J CLIN INVEST, V85, P916, DOI 10.1172/JCI114519; Smith MR, 1996, BIOCHEM BIOPH RES CO, V222, P186, DOI 10.1006/bbrc.1996.0719; Wang ZX, 1998, MOL CELL BIOL, V18, P590, DOI 10.1128/MCB.18.1.590; WENNSTROM S, 1994, ONCOGENE, V9, P651; WRIGHT TM, 1988, P NATL ACAD SCI USA, V85, P1869, DOI 10.1073/pnas.85.6.1869	32	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					22089	22094		10.1074/jbc.274.31.22089	http://dx.doi.org/10.1074/jbc.274.31.22089			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419537	hybrid			2022-12-25	WOS:000081721100090
J	Watson, K; Gooderham, NJ; Davies, DS; Edwards, RJ				Watson, K; Gooderham, NJ; Davies, DS; Edwards, RJ			Nucleosomes bind to cell surface proteoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; ANTI-DNA ANTIBODIES; CULTURED T-CELLS; HEPARAN-SULFATE; PLASMA-MEMBRANE; HISTONES; CHROMATIN; RECEPTOR; PROTEINS; LUPUS	Material on the surface of activated T-cells was displaced following incubation with a sulfated polysaccharide, dextrin 2-sulfate (D2S), and purified by anion-exchange chromatography, This revealed a complex comprising histones H2A, H2B, H3, and H4 and DNA fragmented into 180-base pair units characteristic of mono-, di-, tri, and polynucleosomes, a pattern of fragmentation similar to that found in apoptotic cells. An antibody raised against the purified nucleosome preparation bound to the plasma membrane of activated Tcells confirming the surface location of nucleosomes. The interaction of sulfated polysaccharides with nucleosomes was investigated using a biotinylated derivative of D2S, It was found that sulfated polysaccharides bound to nucleosomes via the N termini of histones, especially H2A and H2B. Treatment of T-cells with either heparinase or heparitinase abolished nucleosome binding to plasma membranes. This suggests that nucleosomes are anchored to the surface of T-cells by heparan sulfate proteoglycans through an ionic interaction with the basic N-terminal residues in the histones, Furthermore, nucleosomes bound to the cell surface in this manner are then able to bind other sulfated polysaccharides, such as D2S, heparin, or dextran sulfate, through unoccupied histone N termini forming a complex comprising cell surface heparan sulfate proteoglycans, nucleosomes, and sulfated polysaccharides.	Hammersmith Hosp, Imperial Coll, Sch Med, Clin Pharmacol Sect, London W12 0NN, England	Imperial College London	Watson, K (corresponding author), Hammersmith Hosp, Imperial Coll, Sch Med, Clin Pharmacol Sect, DuCane Rd, London W12 0NN, England.	kwatson@rpms.ac.uk		Gooderham, Nigel/0000-0001-7645-8219				AMOURA Z, 1994, ARTHRITIS RHEUM, V37, P1684, DOI 10.1002/art.1780371118; BELL DA, 1991, CLIN IMMUNOL IMMUNOP, V60, P13, DOI 10.1016/0090-1229(91)90108-M; BELL DA, 1990, J CLIN INVEST, V85, P1487, DOI 10.1172/JCI114595; BENNETT RM, 1991, CLIN EXP IMMUNOL, V86, P374; BENNETT RM, 1985, J CLIN INVEST, V76, P2182, DOI 10.1172/JCI112226; BILOZUR ME, 1990, J BIOL CHEM, V265, P19697; BLAIR IA, 1981, BRIT J PHARMACOL, V72, P435, DOI 10.1111/j.1476-5381.1981.tb10994.x; BOHM L, 1984, BIOSCIENCE REP, V4, P365, DOI 10.1007/BF01122502; BURLINGAME RW, 1994, J CLIN INVEST, V94, P184, DOI 10.1172/JCI117305; CORITSIDIS GN, 1995, KIDNEY INT, V47, P1258, DOI 10.1038/ki.1995.180; DUKE RC, 1983, P NATL ACAD SCI-BIOL, V80, P6361, DOI 10.1073/pnas.80.20.6361; EDWARDS RJ, 1988, BIOCHEM PHARMACOL, V37, P3735, DOI 10.1016/0006-2952(88)90408-X; EMLEN W, 1992, J IMMUNOL, V148, P3042; GASPARRO FP, 1990, PHOTOCHEM PHOTOBIOL, V52, P315, DOI 10.1111/j.1751-1097.1990.tb04187.x; GORDON MY, 1987, NATURE, V326, P403, DOI 10.1038/326403a0; HEFENEIDER SH, 1992, CLIN IMMUNOL IMMUNOP, V63, P245, DOI 10.1016/0090-1229(92)90229-H; HEFENEIDER SH, 1993, AUTOIMMUNITY, V15, P187, DOI 10.3109/08916939309019926; JACOB L, 1989, P NATL ACAD SCI USA, V86, P4669, DOI 10.1073/pnas.86.12.4669; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KORNBERG RD, 1989, METHOD ENZYMOL, V170, P3; Koutouzov S, 1996, EUR J IMMUNOL, V26, P472; KUBOTA T, 1990, IMMUNOL LETT, V23, P187, DOI 10.1016/0165-2478(90)90190-2; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MECHERI S, 1993, MOL IMMUNOL, V30, P549, DOI 10.1016/0161-5890(93)90029-B; MOHAN C, 1993, J EXP MED, V177, P1367, DOI 10.1084/jem.177.5.1367; MORIKAWA S, 1978, INT J CANCER, V21, P166, DOI 10.1002/ijc.2910210207; OJCIUS DM, 1991, IMMUNOL LETT, V28, P101; RAZ E, 1993, EUR J IMMUNOL, V23, P383, DOI 10.1002/eji.1830230213; REKVIG OP, 1987, IMMUNOL INVEST, V16, P535, DOI 10.3109/08820138709087100; RIECKMANN P, 1991, J IMMUNOL, V146, P3462; ROBERTS R, 1988, NATURE, V332, P376, DOI 10.1038/332376a0; SEARLE J, 1982, PATHOL ANNU, V17, P229; SHAUNAK S, 1994, BRIT J PHARMACOL, V113, P151, DOI 10.1111/j.1476-5381.1994.tb16187.x; TERMAAT RM, 1992, KIDNEY INT, V42, P1363, DOI 10.1038/ki.1992.428; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; TURNBULL JE, 1991, BIOCHEM J, V273, P553, DOI 10.1042/bj2730553; vanBruggen MCJ, 1997, EUR J IMMUNOL, V27, P1564, DOI 10.1002/eji.1830270636; VILLEPONTEAU B, 1992, BIOCHEM J, V288, P953, DOI 10.1042/bj2880953; Watson K, 1999, BIOCHEM PHARMACOL, V57, P775, DOI 10.1016/S0006-2952(98)00352-9; WATSON K, 1995, BIOCHEM PHARMACOL, V50, P299, DOI 10.1016/0006-2952(95)00142-M; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	43	74	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21707	21713		10.1074/jbc.274.31.21707	http://dx.doi.org/10.1074/jbc.274.31.21707			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419482	hybrid			2022-12-25	WOS:000081721100035
J	Wilson, T; Guerrette, S; Fishel, R				Wilson, T; Guerrette, S; Fishel, R			Dissociation of mismatch recognition and ATPase activity by hMSH2-hMSH3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MICROSATELLITE INSTABILITY; DNA-MISMATCH; GENETIC-RECOMBINATION; REPAIR PROTEINS; TUMOR-CELLS; BINDING; CANCER; SEQUENCES; ALPHA	MSH2-MSH3 directs the repair of insertion/deletion loops of up to 13 nucleotides in vivo and in vitro, To examine the biochemical basis of this repair specificity, we characterized the mispair binding and ATPase activity of hMSH2-hMSH3. The ATPase was found to be regulated by a mismatch-stimulated ADP --> ATP exchange, which induces a conformational transition by the protein complex. We demonstrated strong binding of hMSH2-hMSH3 to an insertion/deletion loop containing 24 nucleotides that is incapable of provoking ADP --> ATP exchange, suggesting that mismatch recognition appears to be necessary but not sufficient to induce the intrinsic ATPase. These studies support the idea that hMSH2-hMSH3 functions as an adenosine nucleotide-regulated molecular switch that must be activated by mismatched nucleotides for classical mismatch repair to occur.	Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Genet & Mol Biol Program, Philadelphia, PA 19107 USA	Jefferson University	Fishel, R (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Genet & Mol Biol Program, 233 S 10th St, Philadelphia, PA 19107 USA.	rfishel@hendrix.jci.tju.edu			NCI NIH HHS [CA67007, F32 CA73134, CA56542, R01 CA067007] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA073134, R01CA056542, R01CA067007] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; ALANI E, 1994, GENETICS, V137, P19; Alani E, 1997, MOL CELL BIOL, V17, P2436, DOI 10.1128/MCB.17.5.2436; Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; Blackwell LJ, 1998, J BIOL CHEM, V273, P32049, DOI 10.1074/jbc.273.48.32049; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; CHI NW, 1994, J BIOL CHEM, V269, P29984; DEMEREC M, 1957, CARNEGIE I WASH YB, V370, P390; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Fishel R, 1998, GENE DEV, V12, P2096, DOI 10.1101/gad.12.14.2096; FISHEL R, 1994, SCIENCE, V266, P1403, DOI 10.1126/science.7973733; FISHEL R, 1995, CURR OPIN GENET DEV, V5, P382, DOI 10.1016/0959-437X(95)80055-7; Fishel R, 1997, CURR OPIN GENET DEV, V7, P105, DOI 10.1016/S0959-437X(97)80117-7; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; HABER LT, 1991, EMBO J, V10, P2707, DOI 10.1002/j.1460-2075.1991.tb07815.x; Habraken Y, 1996, CURR BIOL, V6, P1185, DOI 10.1016/S0960-9822(02)70686-6; HILL RF, 1970, MUTAT RES, V9, P341, DOI 10.1016/0027-5107(70)90135-1; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; Kirkpatrick DT, 1997, NATURE, V387, P929, DOI 10.1038/43225; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; KOLODNER RD, 1995, TRENDS BIOCHEM SCI, V20, P397, DOI 10.1016/S0968-0004(00)89087-8; KUNKEL TA, 1993, NATURE, V365, P207, DOI 10.1038/365207a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOEB LA, 1994, CANCER RES, V54, P5059; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; MIYAKE T, 1960, GENETICS, V45, P755; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; PARKER BO, 1992, P NATL ACAD SCI USA, V89, P1730, DOI 10.1073/pnas.89.5.1730; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PAULING C, 1965, P NATL ACAD SCI USA, V54, P1728, DOI 10.1073/pnas.54.6.1728; PELTOMAKI P, 1993, CANCER RES, V53, P5853; Sia EA, 1997, MOL CELL BIOL, V17, P2851, DOI 10.1128/MCB.17.5.2851; SIEGEL EC, 1967, J BACTERIOL, V94, P38, DOI 10.1128/JB.94.1.38-47.1967; SIEGEL EC, 1970, J BACTERIOL, V104, P604, DOI 10.1128/JB.104.1.604-605.1970; Sugawara N, 1997, P NATL ACAD SCI USA, V94, P9214, DOI 10.1073/pnas.94.17.9214; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; Tran HT, 1996, GENETICS, V143, P1579; Umar A, 1998, GENETICS, V148, P1637; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WITKIN EM, 1964, J MOL BIOL, V8, P610, DOI 10.1016/S0022-2836(64)80017-6	44	81	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21659	21664		10.1074/jbc.274.31.21659	http://dx.doi.org/10.1074/jbc.274.31.21659			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419475	hybrid			2022-12-25	WOS:000081721100028
J	Hasegawa, H; Fujita, H; Katoh, H; Aoki, J; Nakamura, K; Ichikawa, A; Negishi, M				Hasegawa, H; Fujita, H; Katoh, H; Aoki, J; Nakamura, K; Ichikawa, A; Negishi, M			Opposite regulation of transepithelial electrical resistance and paracellular permeability by Rho in Madin-Darby canine kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIGHT JUNCTION PERMEABILITY; STRESS FIBER FORMATION; BINDING PROTEIN-RHO; SMALL GTPASE-RHO; NEURITE RETRACTION; ADENYLATE-CYCLASE; ENDOTHELIAL-CELLS; ADP-RIBOSYLTRANSFERASE; LYSOPHOSPHATIDIC ACID; CONSTITUTIVE ACTIVITY	Small GTPase Rho has been thought to be important for the formation and the maintenance of tight junction in epithelial cells, but the role of Rho in the regulation of barrier function of tight junction is not web understood. We here examined whether Rho was involved in the barrier function of tight junction in Madin-Darby canine kidney (MDCK) cells. The activation of prostaglandin EP3 beta receptor, coupled to a Rho activation pathway, induced the increase in transepithelial electrical resistance (TER) but the increase in paracellular flux of mannitol in the preformed monolayer of the MDCK cells expressing the EP3 beta receptor. This effect of the EP3 receptor was mimicked by the expression of constitutively active RhoA but not by active Rad in MDCK cells, using an isopropyl-beta-D-thiogalactoside-inducible expression system. On the other hand, the activation of EP3 beta receptor suppressed the elevation of TER and the decrease in paracellular mannitol flux during Ca2+ switch-induced tight junction formation, whereas the expression of active RhoA or Rad did not apparently affect the TER development in the Ca2+ switch. These results demonstrate that the EP3 receptor and active RhoA regulate permeabilities of ionic and nonionic molecules in opposite directions in the preformed monolayer, and the EP3 receptor suppresses the elevation of TER during the tight junction formation.	Kyoto Univ, Fac Pharmaceut Sci, Dept Mol Neurobiol, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Fac Pharmaceut Sci, Dept Physiol Chem, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University; Kyoto University	Negishi, M (corresponding author), Kyoto Univ, Fac Pharmaceut Sci, Dept Mol Neurobiol, Sakyo Ku, Kyoto 6068501, Japan.		Nakamura, Kazuhiro/A-5431-2008	Nakamura, Kazuhiro/0000-0002-6095-8996				AKTORIES K, 1987, FEBS LETT, V212, P109, DOI 10.1016/0014-5793(87)81566-1; BALDA MS, 1991, J MEMBRANE BIOL, V122, P193, DOI 10.1007/BF01871420; Balda MS, 1996, J CELL BIOL, V134, P1031, DOI 10.1083/jcb.134.4.1031; Balda MS, 1998, J CELL SCI, V111, P541; BUSE P, 1995, J BIOL CHEM, V270, P28223; Chang CW, 1997, J NEUROCHEM, V69, P859; CHEN MCY, 1988, GASTROENTEROLOGY, V94, P1121, DOI 10.1016/0016-5085(88)90002-9; CITI S, 1988, NATURE, V333, P272, DOI 10.1038/333272a0; COLEMAN RA, 1994, PROSTAGLANDINS, V47, P151, DOI 10.1016/0090-6980(94)90084-1; COLEMAN RA, 1990, COMPREHENSIVE MED CH, V3, P643; DEALMEIDA JB, 1994, J CELL SCI, V107, P507; Denker BM, 1996, J BIOL CHEM, V271, P25750, DOI 10.1074/jbc.271.42.25750; Dodane V, 1996, J MEMBRANE BIOL, V149, P199, DOI 10.1007/s002329900020; Furuse M, 1998, J CELL BIOL, V143, P391, DOI 10.1083/jcb.143.2.391; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; Gardner TW, 1996, BIOCHEM J, V320, P717, DOI 10.1042/bj3200717; GONZALEZMARISCAL L, 1989, J MEMBRANE BIOL, V107, P43, DOI 10.1007/BF01871082; GUMBINER B, 1991, P NATL ACAD SCI USA, V88, P3460, DOI 10.1073/pnas.88.8.3460; GUMBINER B, 1987, AM J PHYSIOL, V253, P749; GUMBINER BM, 1993, J CELL BIOL, V123, P1631, DOI 10.1083/jcb.123.6.1631; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Hamilton SE, 1997, BIOCHEM BIOPH RES CO, V234, P1, DOI 10.1006/bbrc.1997.6569; Hasegawa H, 1996, J BIOL CHEM, V271, P1857, DOI 10.1074/jbc.271.4.1857; Hasegawa H, 1997, BIOCHEM BIOPH RES CO, V234, P631, DOI 10.1006/bbrc.1997.6655; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hirase T, 1997, J CELL SCI, V110, P1603; ITO W, 1991, GENE, V102, P67, DOI 10.1016/0378-1119(91)90539-N; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; Jou TS, 1998, J CELL BIOL, V142, P101, DOI 10.1083/jcb.142.1.101; Katoh H, 1996, J BIOL CHEM, V271, P29780, DOI 10.1074/jbc.271.47.29780; Katoh H, 1998, J BIOL CHEM, V273, P2489, DOI 10.1074/jbc.273.5.2489; Keon BH, 1996, J CELL BIOL, V134, P1003, DOI 10.1083/jcb.134.4.1003; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; KRALL JF, 1984, J ENDOCRINOL, V102, P329, DOI 10.1677/joe.0.1020329; Langford AM, 1996, HUM EXP TOXICOL, V15, P619, DOI 10.1177/096032719601500804; McCarthy KM, 1996, J CELL SCI, V109, P2287; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; NEGISHI M, 1989, J BIOL CHEM, V264, P3916; NEGISHI M, 1995, BBA-LIPID LIPID MET, V1259, P109, DOI 10.1016/0005-2760(95)00146-4; NUSRAT A, 1995, P NATL ACAD SCI USA, V92, P10629, DOI 10.1073/pnas.92.23.10629; OHIA SE, 1990, J PHARMACOL EXP THER, V255, P11; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Saha C, 1998, J BIOL CHEM, V273, P21629, DOI 10.1074/jbc.273.34.21629; Schulze C, 1997, J NEUROCHEM, V68, P991; SEKINE A, 1989, J BIOL CHEM, V264, P8602; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; SUGIMOTO Y, 1992, J BIOL CHEM, V267, P6463; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Wong V, 1997, J CELL BIOL, V136, P399, DOI 10.1083/jcb.136.2.399; ZHONG Y, 1993, J CELL BIOL, V120, P477, DOI 10.1083/jcb.120.2.477	59	55	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					20982	20988		10.1074/jbc.274.30.20982	http://dx.doi.org/10.1074/jbc.274.30.20982			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409646	hybrid			2022-12-25	WOS:000081613100037
J	Kishikawa, K; Chalfant, CE; Perry, DK; Bielawska, A; Hannun, YA				Kishikawa, K; Chalfant, CE; Perry, DK; Bielawska, A; Hannun, YA			Phosphatidic acid is a potent and selective inhibitor of protein phosphatase 1 and an inhibitor of ceramide-mediated responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-D ACTIVITY; HUMAN MESANGIAL CELLS; CANINE KIDNEY-CELLS; KINASE C-ALPHA; DOWNSTREAM TARGET; HUMAN-NEUTROPHILS; INDUCED APOPTOSIS; ACTIVATION; PATHWAY; BCL-2	In the present study, we report that phosphatidic acid (PA) functions as a novel, potent, and selective inhibitor of protein phosphatase 1 (PP1). The catalytic subunit of PP1 alpha was inhibited by PA dose-dependently in a noncompetitive manner with a K-i value of 80 nM. The inhibition by PA was specific to PP1 as PA failed to inhibit protein phosphatase 2A (PP2A) or PP2B. Furthermore, PA was the most effective and potent inhibitor of PP1 compared with other phospholipids. Because we recently showed that ceramides activated PP1, we next examined the effects of PA on ceramide stimulation of PP1. PA inhibited both basal and ceramide-stimulated PP1 activities, and ceramide showed potent and stereoselective activation of PP1 in the presence of PA. Next, the effects of PA on ceramide-induced responses were examined. Molt-4 cells took up PA dose- and time-dependently such that by 1 and 3 h, uptake of PA was 0.37 and 0.65% of total PA added, respectively. PA at 30 mu M and calyculin A at 10 nM (an inhibitor of PP1 and PP2A at low concentrations), but not okadaic acid at 10 nM (a PP2A inhibitor at low concentrations) prevented poly(ADP-ribose) polymerase proteolysis induced by C-6-ceramide. Moreover, the combination of PA with okadaic acid prevented retinoblastoma gene product dephosphorylation induced by C-6-ceramide. These data suggest that PA functions as a specific regulator of PP1 and may reverse or counteract those effects of ceramide that are mediated by PP1, such as apoptosis and retinoblastoma gene product dephosphorylation.	Med Univ S Carolina, Dept Biochem, Charleston, SC 29425 USA	Medical University of South Carolina	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem, 171 Ashley Ave, Charleston, SC 29425 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-43825] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BILLAH MM, 1989, J BIOL CHEM, V264, P9069; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; BURSTEN SL, 1994, AM J PHYSIOL, V266, pC1093, DOI 10.1152/ajpcell.1994.266.4.C1093; BURSTEN SL, 1991, J BIOL CHEM, V266, P20732; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Cohen PTW, 1997, TRENDS BIOCHEM SCI, V22, P245, DOI 10.1016/S0968-0004(97)01060-8; Cui Y, 1997, CELL SIGNAL, V9, P257, DOI 10.1016/S0898-6568(96)00177-5; DBAIBO GS, 1995, P NATL ACAD SCI USA, V92, P1347, DOI 10.1073/pnas.92.5.1347; ElBawab S, 1997, EUR J BIOCHEM, V247, P1151, DOI 10.1111/j.1432-1033.1997.01151.x; ENDO S, 1997, BIOCHEMISTRY-US, V36, P986; English D, 1996, CHEM PHYS LIPIDS, V80, P117, DOI 10.1016/0009-3084(96)02549-2; English D, 1996, CELL SIGNAL, V8, P341, DOI 10.1016/0898-6568(95)00076-3; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; GOMEZMUNOZ A, 1994, J BIOL CHEM, V269, P8937; HANNUN YA, 1996, SCIENCE, V274, P1885; Heitman Joseph, 1993, Methods (Orlando), V5, P176, DOI 10.1006/meth.1993.1022; HUANG CF, 1992, J BIOL CHEM, V267, P16859; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; Ito M, 1997, BIOCHEMISTRY-US, V36, P7607, DOI 10.1021/bi9702647; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; JONES GA, 1993, J BIOL CHEM, V268, P20845; JONES MJ, 1995, J BIOL CHEM, V270, P5007, DOI 10.1074/jbc.270.10.5007; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; MARTIN SJ, 1995, CELL DEATH DIFFER, V2, P253; NAKAMURA T, 1994, J BIOL CHEM, V269, P18384; Perry DK, 1997, J BIOL CHEM, V272, P18530, DOI 10.1074/jbc.272.30.18530; Smyth MJ, 1996, BIOCHEM J, V316, P25, DOI 10.1042/bj3160025; VENABLE ME, 1994, J BIOL CHEM, V269, P26040; Venable ME, 1996, J BIOL CHEM, V271, P24800, DOI 10.1074/jbc.271.40.24800; WONG K, 1995, J BIOL CHEM, V270, P3056, DOI 10.1074/jbc.270.7.3056; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325	36	92	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21335	21341		10.1074/jbc.274.30.21335	http://dx.doi.org/10.1074/jbc.274.30.21335			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409693	hybrid			2022-12-25	WOS:000081613100084
J	Lebreton, S; Gontero, B				Lebreton, S; Gontero, B			Memory and imprinting in multienzyme complexes - Evidence for information transfer from glyceraldehyde-3-phosphate dehydrogenase to phosphoribulokinase under reduced state in Chlamydomonas reinhardtii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALVIN CYCLE ACTIVITY; CHLOROPLAST ENZYMES; SPINACH-CHLOROPLASTS; KINETIC-PROPERTIES; LIGHT REGULATION; HIGHER-PLANTS; LIVING CELL; THIOREDOXIN; MODULATION; ACTIVATION	The phosphoribulokinase, when it is in a reduced state in a bi-enzyme complex, is more active than when it is oxidized. This complex dissociates upon dilution to give a metastable reduced form of phosphoribulokinase, which differs from the stable form isolated beside the complex. The kinetic parameters of the reduced stable phosphoribulokinase and those of the complex are very similar, unlike those of the metastable form, Although the kinetic mechanism of the reduced stable form is ordered, with ribulose-5-phosphate binding first, ATP binds first to the phosphoribulokinase in the complex and to the metastable form. Therefore, phosphoribulokinase bears an imprint from glyceraldehyde-3-phosphate dehydrogenase after disruption of the complex. Dissociation of phosphoribulokinase from the complex also enhances its flexibility. The imprinting and greater flexibility result in the catalytic constant of dissociated phosphoribulokinase being 10-fold higher than that of the enzyme in the complex. Imprinting corresponds to stabilization-destabilization energies resulting from conformation changes generated by protein-protein interactions. The energy stored within the metastable phosphoribulokinase is mainly used to decrease the energy barrier to catalysis.	Univ Paris 06, CNRS, Inst Jacques Monod, F-75251 Paris 05, France; Univ Paris 07, CNRS, Inst Jacques Monod, F-75251 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Gontero, B (corresponding author), Univ Paris 06, CNRS, Inst Jacques Monod, 2 Pl Jussieu, F-75251 Paris 05, France.			lebreton, Sandrine/0000-0003-4772-9467				ANDERSON LE, 1995, PLANTA, V196, P245; Avilan L, 1997, EUR J BIOCHEM, V246, P78, DOI 10.1111/j.1432-1033.1997.00078.x; Avilan L, 1997, EUR J BIOCHEM, V250, P296, DOI 10.1111/j.1432-1033.1997.0296a.x; Bowyer JR, 1997, PLANT BIOCH, DOI [10.1016/B978-0-12-214674-9.X5000-0, 10.1016/B978-012214674-9/50003-5.49-p.4, DOI 10.1016/B978-0-12-214674-9.X5000-0]; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brandes HK, 1996, J BIOL CHEM, V271, P3333; BUCHANAN BB, 1980, ANNU REV PLANT PHYS, V31, P341, DOI 10.1146/annurev.pp.31.060180.002013; CADET F, 1988, BIOCHEM J, V253, P249, DOI 10.1042/bj2530249; DALZIEL K, 1957, ACTA CHEM SCAND, V11, P1706, DOI 10.3891/acta.chem.scand.11-1706; Droux M, 1998, EUR J BIOCHEM, V255, P235, DOI 10.1046/j.1432-1327.1998.2550235.x; FASKE M, 1995, BBA-PROTEIN STRUCT M, V1247, P135, DOI 10.1016/0167-4838(94)00203-S; FULTON AB, 1982, CELL, V30, P345, DOI 10.1016/0092-8674(82)90231-8; GARDEMANN A, 1983, BIOCHIM BIOPHYS ACTA, V722, P51, DOI 10.1016/0005-2728(83)90156-1; GONTERO B, 1993, EUR J BIOCHEM, V217, P1075, DOI 10.1111/j.1432-1033.1993.tb18339.x; GONTERO B, 1988, EUR J BIOCHEM, V173, P437, DOI 10.1111/j.1432-1033.1988.tb14018.x; GOODSELL DS, 1991, TRENDS BIOCHEM SCI, V16, P203, DOI 10.1016/0968-0004(91)90083-8; Harris EH, 1989, CHLAMYDOMONAS SOURCE, P25, DOI [DOI 10.1016/B978-0-12-326880-8.50007-9, DOI 10.1126/SCIENCE.246.4936.1503-A]; HELDT HW, 1973, BIOCHIM BIOPHYS ACTA, V314, P224, DOI 10.1016/0005-2728(73)90137-0; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; Jacquot JP, 1997, NEW PHYTOL, V136, P543, DOI 10.1046/j.1469-8137.1997.00784.x; Lebreton S, 1997, EUR J BIOCHEM, V246, P85, DOI 10.1111/j.1432-1033.1997.t01-2-00085.x; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MCDONALD FD, 1987, PHOTOSYNTHESIS, P175; MINTON AP, 1981, BIOPOLYMERS, V20, P2093, DOI 10.1002/bip.1981.360201006; Neet K E, 1980, Methods Enzymol, V64, P192; NELDER JA, 1965, COMPUT J, V7, P308, DOI 10.1093/comjnl/7.4.308; NICHOLSON S, 1987, EUR J BIOCHEM, V162, P423, DOI 10.1111/j.1432-1033.1987.tb10619.x; PORTER MA, 1988, J BIOL CHEM, V263, P123; PRADEL J, 1981, EUR J BIOCHEM, V113, P507, DOI 10.1111/j.1432-1033.1981.tb05092.x; RAULT M, 1991, EUR J BIOCHEM, V197, P791, DOI 10.1111/j.1432-1033.1991.tb15973.x; RICARD J, 1972, EUR J BIOCHEM, V31, P14, DOI 10.1111/j.1432-1033.1972.tb02494.x; Ricard J, 1998, CELL MOL LIFE SCI, V54, P1231, DOI 10.1007/s000180050250; ROESLER KR, 1990, PLANT PHYSIOL, V93, P188, DOI 10.1104/pp.93.1.188; Runquist JA, 1998, BIOCHEMISTRY-US, V37, P1221, DOI 10.1021/bi972052f; SCHEIBE R, 1991, PLANT PHYSIOL, V96, P1, DOI 10.1104/pp.96.1.1; SCHURMANN P, 1995, METHOD ENZYMOL, V252, P274; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; SRERE PA, 1982, TRENDS BIOCHEM SCI, V7, P373; SUSS KH, 1995, PLANT PHYSIOL, V107, P1387, DOI 10.1104/pp.107.4.1387; TABITA FR, 1988, MICROBIOL REV, V52, P155, DOI 10.1128/MMBR.52.2.155-189.1988; Wedel N, 1997, P NATL ACAD SCI USA, V94, P10479, DOI 10.1073/pnas.94.19.10479; Wedel N, 1998, P NATL ACAD SCI USA, V95, P9699, DOI 10.1073/pnas.95.16.9699; WOLOSIUK RA, 1993, FASEB J, V7, P622, DOI 10.1096/fasebj.7.8.8500687	43	25	28	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					20879	20884		10.1074/jbc.274.30.20879	http://dx.doi.org/10.1074/jbc.274.30.20879			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409631	hybrid			2022-12-25	WOS:000081613100022
J	Tessier, F; Obrenovich, M; Monnier, VM				Tessier, F; Obrenovich, M; Monnier, VM			Structure and mechanism of formation of human lens fluorophore LM-1 - Relationship to vesperlysine A and the advanced Maillard reaction in aging, diabetes, and cataractogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKS; GLYCATION; PROTEINS; METHYLGLYOXAL; ASCORBATE; INCREASE; LYSINE; GLYCOSYLATION; CRYSTALLINS; PENTOSIDINE	Human lens crystallins become progressively yellow-brown pigmented with age. Both fluorescent and nonfluorescent protein adducts and cross-links are formed, many of which result from the advanced Maillard reaction. One of them, LM-1, is a blue fluorophore that was earlier tentatively identified as a cross-link involving lysine residues (1), A two-step chromatographic system was used to unequivocally identify and quantitatively prepare a synthetic fluorescent cross-link with lysine residues that had identical UV, fluorescent, and chromatographic properties with both acetylated and nonacetylated LM-1. Proton,(13)C NMR, and molecular mass of the synthetic compound were identical with vesperlysine A, a fluorescent cross-link discovered by Nakamura ct at (2), The fragmentation patterns of vesperlysine A and LM-1 were identical as determined by NMR/ mass spectrometry, Lenticular levels of vesperlysine A increase curvilinearly with age and reach 20 pmol/mg at 90 years. Levels correlate with degree of lens crystallin pigmentation and fluorescence and are increased in diabetes, in contrast to N(epsilon)-(carboxymethyl)lysine and pentosidine, Ascorbate, D-pentoses, and D-threose, but neither D-glucose under oxidative conditions, DL-glyceraldehyde, methylglyoxal, glyoxal, nor glycolaldehyde, are precursors, However, addition of C-2 compounds greatly catalyzes vesperlysine A formation from ribose, Thus, vesperlysine A/LM-1 is a novel product of the advanced Maillard reaction in vivo and a specific marker of a diabetic process in the lens that is different from glyco- and lipoxidation.	Case Western Reserve Univ, Sch Med, Inst Pathol, Cleveland, OH 44106 USA	Case Western Reserve University	Monnier, VM (corresponding author), Case Western Reserve Univ, Sch Med, Inst Pathol, Cleveland, OH 44106 USA.	vmm3@po.cwru.edu	Monnier, Vincent M/B-1371-2009; Tessier, Frederic J/G-3729-2018	Tessier, Frederic J/0000-0001-8096-5715	NEI NIH HHS [EY07099, P-30 EY11373] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007099, P30EY011373] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ahmed MU, 1997, BIOCHEM J, V324, P565, DOI 10.1042/bj3240565; DUNN JA, 1990, BIOCHEMISTRY-US, V29, P10964, DOI 10.1021/bi00501a014; Frye EB, 1998, J BIOL CHEM, V273, P18714, DOI 10.1074/jbc.273.30.18714; Graham L., 1996, Investigative Ophthalmology and Visual Science, V37, pS886; LO TWC, 1994, J BIOL CHEM, V269, P32299; LYONS TJ, 1991, DIABETES, V40, P1010, DOI 10.2337/diabetes.40.8.1010; NAGARAJ RH, 1992, BIOCHIM BIOPHYS ACTA, V1116, P34, DOI 10.1016/0304-4165(92)90125-E; Nagaraj RH, 1996, DIABETES, V45, P587, DOI 10.2337/diabetes.45.5.587; Nagaraj RH, 1996, J BIOL CHEM, V271, P19338, DOI 10.1074/jbc.271.32.19338; NAGARAJ RH, 1991, P NATL ACAD SCI USA, V88, P10257, DOI 10.1073/pnas.88.22.10257; NAKAMURA K, 1990, ADV LIF SCI, P461; Nakamura K, 1997, BIOCHEM BIOPH RES CO, V232, P227, DOI 10.1006/bbrc.1997.6262; Ortwerth BJ, 1997, PHOTOCHEM PHOTOBIOL, V65, P666, DOI 10.1111/j.1751-1097.1997.tb01909.x; ORTWERTH BJ, 1994, EXP EYE RES, V58, P665, DOI 10.1006/exer.1994.1064; PATRICK JS, 1990, J GERONTOL, V45, pB18, DOI 10.1093/geronj/45.1.B18; PRIE A, 1965, INVEST OPHTHALMOL, V4, P629; Saxena P, 1996, EXP EYE RES, V63, P535, DOI 10.1006/exer.1996.0144; Shipanova IN, 1997, ARCH BIOCHEM BIOPHYS, V344, P29, DOI 10.1006/abbi.1997.0195; WELLSKNECHT KJ, 1995, BIOCHEMISTRY-US, V34, P3702, DOI 10.1021/bi00011a027	19	156	158	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					20796	20804		10.1074/jbc.274.30.20796	http://dx.doi.org/10.1074/jbc.274.30.20796			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409619	hybrid			2022-12-25	WOS:000081613100010
J	Patel, RC; Vestal, DJ; Xu, Z; Bandyopadhyay, S; Guo, WD; Erme, SM; Williams, BRG; Sen, GC				Patel, RC; Vestal, DJ; Xu, Z; Bandyopadhyay, S; Guo, WD; Erme, SM; Williams, BRG; Sen, GC			DRBP76, a double-stranded RNA-binding nuclear protein, is phosphorylated by the interferon-induced protein kinase, PKR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINUS; DOMAIN; IDENTIFICATION; EXPRESSION; CLONING; PURIFICATION; SYNTHETASES; APOPTOSIS; RESIDUES; NF45	The interferon-induced double-stranded RNA-activated protein kinase PKR is the prototype of a class of double-stranded (dsRNA)-binding proteins (DRBPs) which share a dsRNA-binding motif conserved from Drosophila to humans. Here we report the purification of DRBP76, a new human member of this class of proteins. Sequence from the amino terminus of DRBP76 matched that of the M phase-specific protein, MPP4. DRBP76 was also cloned by the yeast two-hybrid screening of a cDNA library using a mutant PKR as bait. Analysis of the cDNA sequence revealed that it is the full-length version of MPP4, has a bipartite nuclear localization signal, two motifs that can mediate interactions with both dsRNA and PKR, five epitopes for potential M phase-specific phosphorylation, two potential sites for phosphorylation by cyclin-dependent kinases, a RG2 motif present in many RNA-binding proteins and predicts a protein of 76 kDa, DsRNA and PKR interactions of DRBP76 were confirmed by analysis of in vitro translated and purified native proteins. Cellular expression of an epitope-tagged DRBP76 demonstrated its nuclear localization, and its co-immunoprecipitation with PKR demonstrated that the two proteins interact in vivo. Finally, purified DRBP76 was shown to be a substrate of PHR in vitro, indicating that this protein's cellular activities may be regulated by PKR-mediated phosphorylation.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA; Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Sen, GC (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	seng@ccf.org	Patel, Rekha/M-7123-2015; Williams, Bryan R. G./A-5021-2009	Patel, Rekha/0000-0001-9434-4880; Williams, Bryan R. G./0000-0002-4969-1151	NATIONAL CANCER INSTITUTE [P01CA062220, R01CA068782] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034039, R21AI034039] Funding Source: NIH RePORTER; NCI NIH HHS [CA-68782, CA-62220] Funding Source: Medline; NIAID NIH HHS [AI-34039] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BASS BL, 1994, CURR BIOL, V4, P301, DOI 10.1016/S0960-9822(00)00069-5; Cai RR, 1998, J BIOL CHEM, V273, P11274, DOI 10.1074/jbc.273.18.11274; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; Gale M, 1998, MOL CELL BIOL, V18, P5208, DOI 10.1128/MCB.18.9.5208; GHISOLFI L, 1992, J BIOL CHEM, V267, P2955; Ghosh A, 1997, J BIOL CHEM, V272, P15452, DOI 10.1074/jbc.272.24.15452; GHOSH SK, 1991, J BIOL CHEM, V266, P15293; JUDWARE R, 1991, MOL CELL BIOL, V11, P3259, DOI 10.1128/MCB.11.6.3259; KAO PN, 1994, J BIOL CHEM, V269, P20691; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; Lee K, 1996, MOL CELL BIOL, V16, P3023; LEE SB, 1994, VIROLOGY, V199, P491, DOI 10.1006/viro.1994.1151; Liao HJ, 1998, P NATL ACAD SCI USA, V95, P8514, DOI 10.1073/pnas.95.15.8514; MatsumotoTaniura N, 1996, MOL BIOL CELL, V7, P1455, DOI 10.1091/mbc.7.9.1455; PATEL RC, 1992, J BIOL CHEM, V267, P7671; PATEL RC, 1994, CELL MOL BIOL RES, V40, P671; PATEL RC, 1995, P NATL ACAD SCI USA, V92, P8283, DOI 10.1073/pnas.92.18.8283; Patel RC, 1998, MOL CELL BIOL, V18, P7009, DOI 10.1128/MCB.18.12.7009; Patel RC, 1996, J BIOL CHEM, V271, P25657, DOI 10.1074/jbc.271.41.25657; Patel RC, 1998, EMBO J, V17, P4379, DOI 10.1093/emboj/17.15.4379; PINES J, 1990, New Biologist, V2, P389; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; Sarkar SN, 1998, METHODS, V15, P233, DOI 10.1006/meth.1998.0627; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; Ting NSY, 1998, J BIOL CHEM, V273, P2136, DOI 10.1074/jbc.273.4.2136; WILLIAMS BRG, 1995, SEMIN VIROL, V6, P191, DOI 10.1006/smvy.1995.0024; Zamanian-Daryoush M, 1999, ONCOGENE, V18, P315, DOI 10.1038/sj.onc.1202293	31	112	114	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20432	20437		10.1074/jbc.274.29.20432	http://dx.doi.org/10.1074/jbc.274.29.20432			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400669	hybrid			2022-12-25	WOS:000081438300062
J	Rodrigueza, WV; Thuahnai, ST; Temel, RE; Lund-Katz, S; Phillips, MC; Williams, DL				Rodrigueza, WV; Thuahnai, ST; Temel, RE; Lund-Katz, S; Phillips, MC; Williams, DL			Mechanism of scavenger receptor class B type I-mediated selective uptake of cholesteryl esters from high density lipoprotein to adrenal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; SR-BI; CELLULAR CHOLESTEROL; STEROIDOGENIC CELLS; HEPATOMA-CELLS; RAT; METABOLISM; GLAND; KINETICS; HDL	Despite extensive studies and characterizations of the high density lipoprotein-cholesteryl ester (HDL-CE)-selective uptake pathway, the mechanisms by which the hydrophobic CE molecules are transferred from the HDL particle to the plasma membrane have remained elusive, until the discovery that scavenger receptor BI (SR-BI) plays an important role. To elucidate the molecular mechanism, we examined the quantitative relationships between the binding of HDL and the selective uptake of its CE in the murine adrenal Y1-BS1 cell line. A comparison of concentration dependences shows that half-maximal high affinity cell association of HDL occurs at 8.7 +/- 4.7 mu g/ml and the K-m of HDL-CE-selective uptake is 4.5 +/- 1.5 mu g/ml. These values are similar, and there is a very high correlation between these two processes (r(2) = 0.98), suggesting that they are Linked. An examination of lipid uptake from reconstituted HDL particles of defined composition and size shows that there is a non-stoichiometric uptake of HDL lipid components, with CE being preferred over the major HDL phospholipids, phosphatidylcholine and sphingomyelin, Comparison of the rates of selective uptake of different classes of phospholipid in this system gives the ranking: phosphatidylserine > phosphatidylcholine approximate to phosphatidylinositol > sphingomyelin. The rate of CE-selective uptake from donor particles is proportional to the amount of CE initially present in the particles, suggesting a mechanism in which CE moves down its concentration gradient from HDL particles docked on SR-BI into the cell plasma membrane. The activation energy for CE uptake from either HDL3 or reconstituted HDL is about 9 kcal/mol, indicating that HDL CE uptake occurs via a non-aqueous pathway. HDL binding to SR-BI allows access of CE molecules to a "channel" formed by the receptor from which water is excluded and along which HDL-CE molecules move down their concentration gradient into the cell plasma membrane.	MCP Hahnemann Univ, Dept Biochem, Philadelphia, PA 19129 USA; SUNY Stony Brook, Dept Pharmacol Sci, Univ Med Ctr, Stony Brook, NY 11794 USA	Drexel University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Stony Brook University Hospital	Phillips, MC (corresponding author), MCP Hahnemann Univ, Dept Biochem, 2900 Queen Ln, Philadelphia, PA 19129 USA.		Eckhardt, Erik/G-1567-2010	Phillips, Michael/0000-0002-7147-8007	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032868, P01HL022633, T32HL007443] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07443, HL22633, HL32868] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ANDERSEN JM, 1978, J BIOL CHEM, V253, P9024; Barter PJ, 1996, CURR OPIN LIPIDOL, V7, P82, DOI 10.1097/00041433-199604000-00006; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Connelly MA, 1999, J BIOL CHEM, V274, P41, DOI 10.1074/jbc.274.1.41; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GLASS C, 1985, J BIOL CHEM, V260, P744; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Gu XJ, 1998, J BIOL CHEM, V273, P35388, DOI 10.1074/jbc.273.41.26338; GWYNNE JT, 1976, P NATL ACAD SCI USA, V73, P4329, DOI 10.1073/pnas.73.12.4329; GWYNNE JT, 1989, J BIOL CHEM, V264, P8141; GWYNNE JT, 1980, J BIOL CHEM, V255, P875; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; KOVANEN PT, 1979, J BIOL CHEM, V254, P5498; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; Krieger M, 1998, P NATL ACAD SCI USA, V95, P4077, DOI 10.1073/pnas.95.8.4077; Landschulz KT, 1996, J CLIN INVEST, V98, P984, DOI 10.1172/JCI118883; LUNDKATZ S, 1986, BIOCHEMISTRY-US, V25, P1562, DOI 10.1021/bi00355a016; LUNDKATZ S, 1982, BIOCHEMISTRY-US, V21, P2964, DOI 10.1021/bi00541a025; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MASSEY JB, 1982, J BIOL CHEM, V257, P5444; MENDEL CM, 1985, BIOCHEM J, V228, P269, DOI 10.1042/bj2280269; MORRISON JR, 1994, J BIOL CHEM, V269, P13911; Murao K, 1997, J BIOL CHEM, V272, P17551, DOI 10.1074/jbc.272.28.17551; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; PITTMAN RC, 1984, J LIPID RES, V25, P1577; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; PITTMAN RC, 1987, J BIOL CHEM, V262, P2435; Plump AS, 1996, J CLIN INVEST, V97, P2660, DOI 10.1172/JCI118716; POWNALL HJ, 1982, BIOCHIM BIOPHYS ACTA, V712, P169, DOI 10.1016/0005-2760(82)90099-6; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Rigotti A, 1996, J BIOL CHEM, V271, P33545, DOI 10.1074/jbc.271.52.33545; Rigotti A, 1997, CURR OPIN LIPIDOL, V8, P181, DOI 10.1097/00041433-199706000-00009; RINNINGER F, 1993, BIOCHIM BIOPHYS ACTA, V1166, P275, DOI 10.1016/0005-2760(93)90108-L; RINNINGER F, 1988, J LIPID RES, V29, P1179; RINNINGER F, 1987, J LIPID RES, V28, P1313; Rodrigueza WV, 1997, ARTERIOSCL THROM VAS, V17, P383, DOI 10.1161/01.ATV.17.2.383; SHEN BW, 1977, P NATL ACAD SCI USA, V74, P837, DOI 10.1073/pnas.74.3.837; SPARKS DL, 1992, J LIPID RES, V33, P123; SPARROW CP, 1990, BIOCHIM BIOPHYS ACTA, V1043, P203, DOI 10.1016/0005-2760(90)90297-B; STEIN Y, 1983, BIOCHIM BIOPHYS ACTA, V752, P98, DOI 10.1016/0005-2760(83)90237-0; Temel RE, 1997, P NATL ACAD SCI USA, V94, P13600, DOI 10.1073/pnas.94.25.13600; TERPSTRA AHM, 1989, J LIPID RES, V30, P1663; Wang N, 1996, J BIOL CHEM, V271, P21001, DOI 10.1074/jbc.271.35.21001	44	164	166	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20344	20350		10.1074/jbc.274.29.20344	http://dx.doi.org/10.1074/jbc.274.29.20344			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400657	hybrid			2022-12-25	WOS:000081438300050
J	Ryan, MT; Muller, H; Pfanner, N				Ryan, MT; Muller, H; Pfanner, N			Functional staging of ADP ATP carrier translocation across the outer mitochondrial membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE NATIVE ELECTROPHORESIS; PROTEIN IMPORT RECEPTOR; SACCHAROMYCES-CEREVISIAE; INTERMEMBRANE SPACE; YEAST MITOCHONDRIA; PRECURSOR PROTEINS; INNER-MEMBRANE; PREPROTEIN TRANSLOCASE; ADP/ATP CARRIER; CONTACT SITES	The ADP/ATP carrier (AAC) is the major representative of the inner membrane carrier proteins of mitochondria that are synthesized without cleavable presequences. The characterization of the import pathway of AAC into mitochondria has mainly depended on an operational staging system. Here, we introduce two approaches for analyzing the import of AAC, blue native electrophoresis and folding-induced translocation arrest, that allow a functional staging of AAC transport across the outer membrane. (i) Blue native electrophoresis permits a direct monitoring of the receptor stage of AAC and its chase into mitochondria. Binding to this stage requires the receptor protein Tom70 but not Tom37 or Tom20, (ii) A fusion protein between AAC and dihydrofolate reductase can be selectively arrested in the general import pore complex of the outer membrane by ligand induced folding of the passenger protein. Cross-linking demonstrates that the arrested preprotein is in close contact not only with several receptors and Tim10 but also with the channel protein Tom40, providing the first direct evidence that cleavable preproteins and carrier preproteins interact with the same outer membrane channel. The staging system presented here permits a molecular dissection of AAC transport across the outer mitochondrial membrane, relates it to functional units of the translocases, and indicates a coordinated and successive cooperation of distinct translocase subcomplexes during transfer of the preprotein.	Univ Freiburg, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany	University of Freiburg	Pfanner, N (corresponding author), Univ Freiburg, Inst Biochem & Mol Biol, Hermann Herder Str 7, D-79104 Freiburg, Germany.		Ryan, Michael T/C-6673-2011; Ryan, Michael/X-2152-2019; Pfanner, Nikolaus/AAV-7878-2021	Ryan, Michael T/0000-0003-2586-8829; Ryan, Michael/0000-0003-2586-8829; 				Adam A, 1999, EMBO J, V18, P313, DOI 10.1093/emboj/18.2.313; Alconada A, 1995, METHOD ENZYMOL, V260, P263, DOI 10.1016/0076-6879(95)60144-9; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BLOM J, 1995, EUR J BIOCHEM, V232, P309, DOI 10.1111/j.1432-1033.1995.tb20813.x; Brix J, 1997, J BIOL CHEM, V272, P20730, DOI 10.1074/jbc.272.33.20730; DAUM G, 1982, J BIOL CHEM, V257, P3028; Dekker PJT, 1997, EMBO J, V16, P5408, DOI 10.1093/emboj/16.17.5408; Dekker PJT, 1998, MOL CELL BIOL, V18, P6515, DOI 10.1128/MCB.18.11.6515; Dekker PJT, 1996, BIOL CHEM, V377, P535; Dietmeier K, 1997, NATURE, V388, P195, DOI 10.1038/40663; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; FUJIKI Y, 1982, J CELL BIOL, V93, P103, DOI 10.1083/jcb.93.1.103; GAMBILL BD, 1993, J CELL BIOL, V123, P109, DOI 10.1083/jcb.123.1.109; Glick BS, 1995, METHOD ENZYMOL, V260, P224, DOI 10.1016/0076-6879(95)60140-6; GRATZER S, 1995, J CELL BIOL, V129, P25, DOI 10.1083/jcb.129.1.25; Guthrie C, 1991, METHODS ENZYMOLOGY, V194; HACHIYA N, 1995, NATURE, V376, P705, DOI 10.1038/376705a0; Harlow E, 1988, ANTIBODIES LABORATOR, P471; HARTL FU, 1987, CELL, V51, P1027, DOI 10.1016/0092-8674(87)90589-7; Hill K, 1998, NATURE, V395, P516, DOI 10.1038/26780; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; HONLINGER A, 1995, MOL CELL BIOL, V15, P3382; Honlinger A, 1996, EMBO J, V15, P2125, DOI 10.1002/j.1460-2075.1996.tb00566.x; HORST M, 1995, EMBO J, V14, P2293, DOI 10.1002/j.1460-2075.1995.tb07223.x; KEIL P, 1993, FEBS LETT, V321, P197, DOI 10.1016/0014-5793(93)80107-6; Kerscher O, 1997, J CELL BIOL, V139, P1663, DOI 10.1083/jcb.139.7.1663; KIEBLER M, 1993, CELL, V74, P483, DOI 10.1016/0092-8674(93)80050-O; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; Koehler CM, 1998, EMBO J, V17, P6477, DOI 10.1093/emboj/17.22.6477; Koehler CM, 1998, SCIENCE, V279, P369, DOI 10.1126/science.279.5349.369; Komiya T, 1998, EMBO J, V17, P3886, DOI 10.1093/emboj/17.14.3886; Komiya T, 1997, EMBO J, V16, P4267, DOI 10.1093/emboj/16.14.4267; Kubrich M, 1998, J BIOL CHEM, V273, P16374, DOI 10.1074/jbc.273.26.16374; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON JE, 1988, J BIOL CHEM, V263, P14812; LITHGOW T, 1994, P NATL ACAD SCI USA, V91, P11973, DOI 10.1073/pnas.91.25.11973; LITHGOW T, 1995, TRENDS BIOCHEM SCI, V20, P98, DOI 10.1016/S0968-0004(00)88972-0; MAYER A, 1995, EMBO J, V14, P4204, DOI 10.1002/j.1460-2075.1995.tb00094.x; MOCZKO M, 1993, FEBS LETT, V326, P251, DOI 10.1016/0014-5793(93)81801-6; MOCZKO M, 1994, J BIOL CHEM, V269, P9045; NARGANG FE, 1995, EMBO J, V14, P1099, DOI 10.1002/j.1460-2075.1995.tb07093.x; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Palmisano A, 1998, BIOCHEM J, V333, P151, DOI 10.1042/bj3330151; PFALLER R, 1988, J CELL BIOL, V107, P2483, DOI 10.1083/jcb.107.6.2483; Pfanner N, 1997, CURR BIOL, V7, pR100, DOI 10.1016/S0960-9822(06)00048-0; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; PFANNER N, 1987, J BIOL CHEM, V262, P7528; Pfanner N, 1998, CURR BIOL, V8, pR262, DOI 10.1016/S0960-9822(98)70168-X; Pfanner N, 1997, ANNU REV CELL DEV BI, V13, P25, DOI 10.1146/annurev.cellbio.13.1.25; RAMAGE L, 1993, EMBO J, V12, P4115, DOI 10.1002/j.1460-2075.1993.tb06095.x; RASSOW J, 1991, FEBS LETT, V293, P85, DOI 10.1016/0014-5793(91)81157-4; RASSOW J, 1989, J CELL BIOL, V109, P1421, DOI 10.1083/jcb.109.4.1421; RYAN KR, 1995, CELL, V83, P517, DOI 10.1016/0092-8674(95)90089-6; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SCHLEYER M, 1984, J BIOL CHEM, V259, P3487; SIKORSKI RS, 1989, GENETICS, V122, P19; Sirrenberg C, 1998, NATURE, V391, P912, DOI 10.1038/36136; Sirrenberg C, 1996, NATURE, V384, P582, DOI 10.1038/384582a0; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; SOLLNER T, 1991, METHOD CELL BIOL, V34, P345; STEGER HF, 1990, J CELL BIOL, V111, P2353, DOI 10.1083/jcb.111.6.2353; TAMURA T, 1983, CELL, V34, P587, DOI 10.1016/0092-8674(83)90391-4; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; ZIMMERMANN R, 1980, EUR J BIOCHEM, V109, P217, DOI 10.1111/j.1432-1033.1980.tb04787.x	70	147	149	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20619	20627		10.1074/jbc.274.29.20619	http://dx.doi.org/10.1074/jbc.274.29.20619			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400693	hybrid			2022-12-25	WOS:000081438300086
J	Verschueren, K; Remacle, JE; Collart, C; Kraft, H; Baker, BS; Tylzanowski, P; Nelles, L; Wuytens, G; Su, MT; Bodmer, R; Smith, JC; Huylebroeck, D				Verschueren, K; Remacle, JE; Collart, C; Kraft, H; Baker, BS; Tylzanowski, P; Nelles, L; Wuytens, G; Su, MT; Bodmer, R; Smith, JC; Huylebroeck, D			SIP1, a novel zinc finger homeodomain repressor, interacts with Smad proteins and binds to 5 '-CACCT sequences in candidate target genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-INDUCED TRANSCRIPTION; FAMILY MEDIATOR SMAD1; GROWTH-FACTOR-BETA; TGF-BETA; DNA-BINDING; TUMOR-SUPPRESSOR; SIGNALING PATHWAYS; XENOPUS HOMOLOG; ACTIVIN; ACTIVATION	Activation of transforming growth factor beta receptors causes the phosphorylation and nuclear translocation of Smad proteins, which then participate in the regulation of expression of target genes. We describe a novel Smad-interacting protein, SIP1, which was identified using the yeast two-hybrid system. Although SIP1 interacts with the MH2 domain of receptor-regulated Smads in yeast and in vitro, its interaction with full length Smads in mammalian cells requires receptor-mediated Smad activation. SIP1 is a new member of the delta EF1/Zfh-1 family of two-handed zinc finger/homeodomain proteins. Like delta EF1, SIP1 binds to 5'-CACCT sequences in different promoters, including the Xenopus brachyury promoter. Overexpression of either full-length SIP1 or its C-terminal zinc finger cluster, which bind to the Xbra2 promoter in vitro, prevented expression of the endogenous Xbra gene in early Xenopus embryos. Therefore, SIP1, like delta EF1, is likely to be a transcriptional repressor, which may be involved in the regulation of at least one immediate response gene for activin-depend ent signal transduction pathways. The identification of this Smad-interacting protein opens new routes to investigate the mechanisms by which transforming growth factor beta members exert their effects on expression of target genes in responsive cells and in the vertebrate embryo.	Flanders Interuniv Inst Biotechnol, Dept Cell Growth Differentiat & Dev VIB07, B-3000 Louvain, Belgium; Catholic Univ Louvain, Lab Mol Biol CELGEN, B-3000 Louvain, Belgium; Natl Inst Med Res, Div Dev Biol, London NW7 1AA, England; Univ Michigan, Dept Biol, Ann Arbor, MI 48109 USA	Universite Catholique Louvain; MRC National Institute for Medical Research; University of Michigan System; University of Michigan	Huylebroeck, D (corresponding author), Flanders Interuniv Inst Biotechnol, Dept Cell Growth Differentiat & Dev VIB07, Herestr 49, B-3000 Louvain, Belgium.		Tylzanowski, Przemko/G-8881-2013	Huylebroeck, Danny/0000-0003-4862-1079; Smith, Jim/0000-0003-2413-9392; Tylzanowski, Przemko/0000-0003-0769-559X				Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; DUBOULE D, 1994, GUIDEBOOK HOMEOBOX G, P27; FORTINI ME, 1991, MECH DEVELOP, V34, P113, DOI 10.1016/0925-4773(91)90048-B; FRANKLIN AJ, 1994, MOL CELL BIOL, V14, P6773, DOI 10.1128/MCB.14.10.6773; Genetta T, 1996, GENE, V169, P289, DOI 10.1016/0378-1119(95)00824-1; GENETTA T, 1994, MOL CELL BIOL, V14, P6153, DOI 10.1128/MCB.14.9.6153; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HARLAND RM, 1991, METHOD CELL BIOL, V36, P675; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Higashi Y, 1997, J EXP MED, V185, P1467, DOI 10.1084/jem.185.8.1467; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; IKEDA K, 1995, EUR J BIOCHEM, V233, P73, DOI 10.1111/j.1432-1033.1995.073_1.x; Ikeda K, 1998, MOL CELL BIOL, V18, P10, DOI 10.1128/MCB.18.1.10; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; KISPERT A, 1993, EMBO J, V12, P3211, DOI 10.1002/j.1460-2075.1993.tb05990.x; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; LAI ZC, 1993, P NATL ACAD SCI USA, V90, P4122, DOI 10.1073/pnas.90.9.4122; Latinkic BV, 1997, GENE DEV, V11, P3265, DOI 10.1101/gad.11.23.3265; LEE ME, 1991, J BIOL CHEM, V266, P16188; LeSuer JA, 1999, DEVELOPMENT, V126, P137; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Lo RS, 1998, EMBO J, V17, P996, DOI 10.1093/emboj/17.4.996; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Meersseman G, 1997, MECH DEVELOP, V61, P127, DOI 10.1016/S0925-4773(96)00629-6; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; Nishimura R, 1998, J BIOL CHEM, V273, P1872, DOI 10.1074/jbc.273.4.1872; PANNESE M, 1995, DEVELOPMENT, V121, P707; Postigo AA, 1997, EMBO J, V16, P3924, DOI 10.1093/emboj/16.13.3924; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; SEKELSKY JJ, 1995, GENETICS, V139, P1347; Sekido R, 1996, GENE, V173, P227, DOI 10.1016/0378-1119(96)00185-0; SEKIDO R, 1994, MOL CELL BIOL, V14, P5692, DOI 10.1128/MCB.14.9.5692; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shimizu A, 1998, GENES CELLS, V3, P125, DOI 10.1046/j.1365-2443.1998.00174.x; SLACK JMW, 1984, J EMBRYOL EXP MORPH, V80, P289; SMITH JC, 1983, J EMBRYOL EXP MORPH, V78, P299; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH JC, 1993, CELLULAR INTERACTION, P181; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; Suzuki A, 1997, DEV BIOL, V184, P402, DOI 10.1006/dbio.1997.8548; Takagi T, 1998, DEVELOPMENT, V125, P21; VERSCHUEREN K, 1995, MECH DEVELOP, V52, P109, DOI 10.1016/0925-4773(95)00395-H; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; WILLIAMS TM, 1991, SCIENCE, V254, P1791, DOI 10.1126/science.1840704; Xu X, 1998, GENE DEV, V12, P2354, DOI 10.1101/gad.12.15.2354; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	61	397	410	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20489	20498		10.1074/jbc.274.29.20489	http://dx.doi.org/10.1074/jbc.274.29.20489			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400677	hybrid			2022-12-25	WOS:000081438300070
J	Ricci, JE; Maulon, L; Luciano, F; Guerin, S; Livolsi, A; Mari, B; Breittmayer, JP; Peyron, JF; Auberger, P				Ricci, JE; Maulon, L; Luciano, F; Guerin, S; Livolsi, A; Mari, B; Breittmayer, JP; Peyron, JF; Auberger, P			Cleavage and relocation of the tyrosine kinase P59FYN during Fas-mediated apoptosis in T lymphocytes	ONCOGENE			English	Article						Fas; apoptosis; caspases; p59Fyn	PROGRAMMED CELL-DEATH; NF-KAPPA-B; ICE/CED-3 PROTEASE; ICE-LIKE; POLY(ADP-RIBOSE) POLYMERASE; CAENORHABDITIS-ELEGANS; CYSTEINE PROTEASE; ACTIVATION; SRC; PHOSPHORYLATION	Ligation of Fas with its natural ligand or with anti-Fas antibodies induces an apoptotic program in Fas sensitive cells. We report here the identification of the tyrosine kinase p59Fyn as a substrate for CPP32-like proteinases and more particularly caspase 3 during Fas-mediated apoptosis in Jurkat T cells. Inhibition of CPP32-like proteinases by Ac-Asp-Glu-Val-Asp-aldehyde but not by Ac-Tyr-Val-Ala-Asp-aldehyde prevents CPP32, PARP and p59Fyn cleavage indicating that CPP32 or CPP32-like proteinases are responsible for the cleavage of p59Fyn, Cleavage occurs in the N-terminal domain of p59Fyn between Asp19 and Gly20 and is accompanied by relocation of an active p57Fyn kinase to cytoplasm of Fas-stimulated Jurkat cells as judged by both biochemical and confocal microscopy experiments. Thus, p59Fyn relocation and activity may play an important role during Fas-mediated cell death in human T lymphocytes.	Fac Med Nice, CJF Activat Cellules Hematopoiet 96 05, F-06107 Nice 02, France; Hop de lArchet, INSERM, U343, Nice, France	UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Auberger, P (corresponding author), Fac Med Nice, CJF Activat Cellules Hematopoiet 96 05, Ave de Valombrose, F-06107 Nice 02, France.		Ricci, Jean Ehrland/I-7117-2016; AUBERGER, Patrick/G-1491-2013; luciano, frederic/P-6264-2016; RICCI, Jean Ehrland/AAS-4379-2020; Mari, Bernard P/D-7445-2015; Mari, Bernard P/GVS-3100-2022; Mari, Bernard P/F-8960-2013; Mari, Bernard/Q-5832-2019; Jean-Francois, Peyron/AAA-9496-2022; Peyron, Jean-Francois/M-5682-2016	Ricci, Jean Ehrland/0000-0003-1585-8117; AUBERGER, Patrick/0000-0002-2481-8275; luciano, frederic/0000-0001-9253-4998; RICCI, Jean Ehrland/0000-0003-1585-8117; Mari, Bernard P/0000-0002-0422-9182; Mari, Bernard P/0000-0002-0422-9182; Mari, Bernard P/0000-0002-0422-9182; Mari, Bernard/0000-0002-0422-9182; Jean-Francois, Peyron/0000-0001-6113-916X; Peyron, Jean-Francois/0000-0001-6113-916X				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; Atkinson EA, 1996, J BIOL CHEM, V271, P5968, DOI 10.1074/jbc.271.11.5968; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Campbell KS, 1998, J IMMUNOL, V161, P1728; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; COHEN JJ, 1991, ADV IMMUNOL, V50, P55; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; Dubrez L, 1996, EMBO J, V15, P5504, DOI 10.1002/j.1460-2075.1996.tb00935.x; EISCHEN CM, 1994, J IMMUNOL, V153, P1947; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LEY SC, 1994, J CELL BIOL, V125, P639, DOI 10.1083/jcb.125.3.639; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; Mari B, 1997, FASEB J, V11, P869, DOI 10.1096/fasebj.11.11.9285485; MARI B, 1992, EMBO J, V11, P3875, DOI 10.1002/j.1460-2075.1992.tb05480.x; Mari B, 1996, FASEB J, V10, P309, DOI 10.1096/fasebj.10.2.8641564; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SCUDIERO DA, 1988, CANCER RES, V48, P4827; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Simon HU, 1998, BLOOD, V92, P547, DOI 10.1182/blood.V92.2.547.414k02_547_557; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Wolven A, 1997, MOL BIOL CELL, V8, P1159, DOI 10.1091/mbc.8.6.1159; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073	38	29	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	1999	18	27					3963	3969		10.1038/sj.onc.1202782	http://dx.doi.org/10.1038/sj.onc.1202782			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KU	10435619				2022-12-25	WOS:000081327800006
J	Prescott, SM				Prescott, SM			A thematic series on oxidation of lipids as a source of messengers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review									Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	Prescott, SM (corresponding author), Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.							DONLEAVY JP, 1968, GINGER MAN, P80	1	2	4	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					22901	22901		10.1074/jbc.274.33.22901	http://dx.doi.org/10.1074/jbc.274.33.22901			1	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438451	hybrid			2022-12-25	WOS:000082012800001
J	Kazansky, AV; Kabotyanski, EB; Wyszomierski, SL; Mancini, MA; Rosen, JM				Kazansky, AV; Kabotyanski, EB; Wyszomierski, SL; Mancini, MA; Rosen, JM			Differential effects of prolactin and src/abl kinases on the nuclear translocation of STAT5B and STAT5A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; EPIDERMAL GROWTH-FACTOR; DNA-BINDING ACTIVITY; COLONY-STIMULATING FACTOR; SRC FAMILY KINASES; C-SRC; CONSTITUTIVE ACTIVATION; GENE PROMOTER; BETA-CASEIN; CELL-LINES	In this study, DNA binding and tyrosine phosphorylation of STAT5A and STAT5B were compared with their subcellular localization determined using indirect immunofluorescence microscopy. Following prolactin activation, both STAT5A and STAT5B were rapidly translocated into the nucleus and displayed a detergent-resistant, punctate nuclear staining pattern. Similar to prolactin induction, src activation resulted in tyrosine phosphorylation and DNA binding of both STAT5A and STAT5B. However, nuclear translocation of only STAT5B but not STAT5A was observed. This selective nuclear translocation appears to be mediated via the carboxyl-terminal sequences in STAT5B. Furthermore, overexpression of a dominant negative kinase-inactive mutant of JAK2 prevented prolactin-induced tyrosine phosphorylation and nuclear translocation of STAT5A and STAT5B but did not block src kinase activation and nuclear translocation of STAT5B. In co-transfection assays, prolactin-mediated activation but not src kinase-mediated activation of STAT5B resulted in the induction of a beta-casein promoter-driven reporter construct. These results suggest that STATE activation by src may occur by a mechanism distinct from that employed in cytokine activation of the JAK/STAT pathway, resulting in the selective nuclear translocation of STAT5B.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	Baylor College of Medicine	Rosen, JM (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	jrosen@bcm.tmc.edu			NCI NIH HHS [CA16303] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA016303, R01CA016303] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI S, 1992, MOL ENDOCRINOL, V6, P1242, DOI 10.1210/me.6.8.1242; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; BELKIN AM, 1995, EXP CELL RES, V221, P132, DOI 10.1006/excr.1995.1360; BERLANGA JJ, 1995, MOL ENDOCRINOL, V9, P1461, DOI 10.1210/me.9.11.1461; Boucheron C, 1998, J BIOL CHEM, V273, P33936, DOI 10.1074/jbc.273.51.33936; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Campbell GS, 1997, J BIOL CHEM, V272, P2591, DOI 10.1074/jbc.272.5.2591; CAMPBELL GS, 1994, P NATL ACAD SCI USA, V91, P5232, DOI 10.1073/pnas.91.12.5232; Cao XM, 1996, MOL CELL BIOL, V16, P1595; CAPCO DG, 1982, CELL, V29, P847, DOI 10.1016/0092-8674(82)90446-9; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; Chin H, 1998, BLOOD, V91, P3734; CLEVENGER CV, 1994, MOL ENDOCRINOL, V8, P674, DOI 10.1210/me.8.6.674; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DaSilva L, 1996, MOL CELL ENDOCRINOL, V117, P131, DOI 10.1016/0303-7207(95)03738-1; DOPPLER W, 1989, P NATL ACAD SCI USA, V86, P104, DOI 10.1073/pnas.86.1.104; DUSANTERFOURT I, 1994, EMBO J, V13, P2583, DOI 10.1002/j.1460-2075.1994.tb06548.x; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; ERWIN RA, 1995, ENDOCRINOLOGY, V136, P3512, DOI 10.1210/en.136.8.3512; Frank DA, 1996, LEUKEMIA, V10, P1724; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; GOUILLEUX F, 1995, ENDOCRINOLOGY, V136, P5700, DOI 10.1210/en.136.12.5700; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; Han YL, 1997, MOL ENDOCRINOL, V11, P1180, DOI 10.1210/me.11.8.1180; HAPP B, 1993, CELL GROWTH DIFFER, V4, P9; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; Herrington J, 1999, J BIOL CHEM, V274, P5138, DOI 10.1074/jbc.274.8.5138; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Johnson HM, 1998, P SOC EXP BIOL MED, V218, P149; Johnson HM, 1998, BIOCHEM BIOPH RES CO, V244, P607, DOI 10.1006/bbrc.1998.8254; KAZANSKY AV, 1995, MOL ENDOCRINOL, V9, P1598, DOI 10.1210/me.9.11.1598; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LANDGREN E, 1995, ONCOGENE, V10, P2027; LI S, 1995, MOL CELL BIOL, V15, P2063; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; Liu XW, 1996, MOL ENDOCRINOL, V10, P1496, DOI 10.1210/me.10.12.1496; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Lund TC, 1997, J VIROL, V71, P6677, DOI 10.1128/JVI.71.9.6677-6682.1997; Luo GY, 1997, J BIOL CHEM, V272, P26841, DOI 10.1074/jbc.272.43.26841; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MAA MC, 1992, ONCOGENE, V7, P2429; Mao WG, 1997, ONCOGENE, V15, P3083, DOI 10.1038/sj.onc.1201496; Meinke A, 1996, MOL CELL BIOL, V16, P6937; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; Nelson KL, 1998, J BIOL CHEM, V273, P7072, DOI 10.1074/jbc.273.12.7072; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; Pendergast AM, 1996, CURR OPIN CELL BIOL, V8, P174, DOI 10.1016/S0955-0674(96)80063-9; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; RAUGHT B, 1994, MOL CELL BIOL, V14, P1752, DOI 10.1128/MCB.14.3.1752; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; Rosen JM, 1998, BIOCHEM SOC SYMP, P101; ROSEN N, 1986, J BIOL CHEM, V261, P3754; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; RUI H, 1994, J BIOL CHEM, V269, P5364; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHMITT-NEY M, 1992, P NATL ACAD SCI USA, V89, P3130, DOI 10.1073/pnas.89.7.3130; SCHMITT-NEY M, 1991, MOL CELL BIOL, V11, P3745, DOI 10.1128/MCB.11.7.3745; Sekimoto T, 1997, EMBO J, V16, P7067, DOI 10.1093/emboj/16.23.7067; Sekimoto T, 1996, J BIOL CHEM, V271, P31017, DOI 10.1074/jbc.271.49.31017; Strehlow I, 1998, J BIOL CHEM, V273, P28049, DOI 10.1074/jbc.273.43.28049; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; TWAMLEY GM, 1992, ONCOGENE, V7, P1893; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; Verdier F, 1998, MOL CELL BIOL, V18, P5852, DOI 10.1128/MCB.18.10.5852; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WeberNordt RM, 1996, BLOOD, V88, P809; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHAN X, 1994, J BIOL CHEM, V269, P20221; ZHUANG HM, 1994, J BIOL CHEM, V269, P21411	86	98	101	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22484	22492		10.1074/jbc.274.32.22484	http://dx.doi.org/10.1074/jbc.274.32.22484			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428824	hybrid			2022-12-25	WOS:000081868400054
J	Lehman, K; Schwer, B; Ho, CK; Rouzankina, I; Shuman, S				Lehman, K; Schwer, B; Ho, CK; Rouzankina, I; Shuman, S			A conserved domain of yeast RNA triphosphatase flanking the catalytic core regulates self-association and interaction with the guanylyltransferase component of the mRNA capping apparatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXY-TERMINAL DOMAIN; MESSENGER-RNA; POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; NUCLEOSIDE TRIPHOSPHATASE; MUTATIONAL ANALYSIS; 5'-CAPPING ENZYME; 5'-TRIPHOSPHATASE; SUBUNIT; GENE	The 549-amino acid yeast RNA triphosphatase Cet1p catalyzes the first step in mRNA cap formation. Cet1p consists of three domains as follows: (i) a 230-amino acid N-terminal segment that is dispensable for catalysis in vitro and for Cet1p function in vivo; (ii) a protease-sensitive segment from residues 230 to 275 that is dispensable for catalysis but essential for Cet1p function in vitro; and (iii) a catalytic domain from residues 275 to 539. Sedimentation analysis indicates that purified Cet1(231-549)p is a homodimer. Cet1(231-549)p binds in vitro to the yeast RNA guanylyltransferase Ceg1p to form a 7.1 S complex that we surmise to be a trimer consisting of two molecules of Cet1(231-549)p and one molecule of Ceg1p. The more extensively truncated protein Cet1(276-549)p, which cannot support cell growth, sediments as a monomer and does not interact with Ceg1p. An intermediate deletion protein Cet1(246-549)p, which supports cell growth only when overexpressed, sediments principally as a discrete salt-stable 11.5 S homo-oligomeric complex. These data implicate the segment of Ceg1p from residues 230 to 275 in regulating self-association and in binding to Ceg1p. Genetic data support the existence of a Ceg1p-binding domain flanking the catalytic domain of Cet1p, to wit: (i) the ts growth phenotype of 2 mu CETI (246-549) is suppressed by overexpression of Ceg1p; (ii) a ts alanine cluster mutation CETI (201-549)/K250A-W251A is suppressed by overexpression of Ceg1p; and (iii) 15 other cet-ts alleles with missense changes mapping elsewhere in the protein are not suppressed by Ceg1p overexpression. Finally, we show that the in vivo function of Cet1(275-549)p is completely restored by fusion to the guanylyltransferase domain of the mouse capping enzyme. We hypothesize that the need for Ceg1p binding by yeast RNA triphosphatase can by bypassed when the triphosphatase catalytic domain is delivered to the RNA polymerase II elongation complex by linkage in cis to the mammalian guanylyltransferase.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.		Ho, KIong/GPP-6051-2022					Cho EJ, 1998, GENE DEV, V12, P3482, DOI 10.1101/gad.12.22.3482; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; Gross CH, 1998, J VIROL, V72, P10020, DOI 10.1128/JVI.72.12.10020-10028.1998; Ho CK, 1998, J BIOL CHEM, V273, P34151, DOI 10.1074/jbc.273.51.34151; Ho CK, 1998, MOL CELL BIOL, V18, P5189, DOI 10.1128/MCB.18.9.5189; Ho CK, 1998, J BIOL CHEM, V273, P9577, DOI 10.1074/jbc.273.16.9577; Ho CK, 1999, MOL CELL, V3, P405, DOI 10.1016/S1097-2765(00)80468-2; ITOH N, 1987, J BIOL CHEM, V262, P1989; ITOH N, 1984, J BIOL CHEM, V259, P3923; Janbon G, 1997, YEAST, V13, P985, DOI 10.1002/(SICI)1097-0061(199708)13:10<985::AID-YEA153>3.0.CO;2-T; Jin JP, 1998, J VIROL, V72, P10011, DOI 10.1128/JVI.72.12.10011-10019.1998; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; SCHWER B, 1994, P NATL ACAD SCI USA, V91, P4328, DOI 10.1073/pnas.91.10.4328; Sekiguchi J, 1997, NUCLEIC ACIDS RES, V25, P727, DOI 10.1093/nar/25.4.727; SHIBAGAKI Y, 1992, J BIOL CHEM, V267, P9521; Tsukamoto T, 1998, BIOCHEM BIOPH RES CO, V243, P101, DOI 10.1006/bbrc.1997.8038; Tsukamoto T, 1997, BIOCHEM BIOPH RES CO, V239, P116, DOI 10.1006/bbrc.1997.7439; Yamada-Okabe T, 1998, NUCLEIC ACIDS RES, V26, P1700, DOI 10.1093/nar/26.7.1700; Yamada-Okabe T, 1998, FEBS LETT, V435, P49, DOI 10.1016/S0014-5793(98)01037-0; Yu L, 1996, J VIROL, V70, P6162, DOI 10.1128/JVI.70.9.6162-6168.1996; Yu L, 1997, J VIROL, V71, P9837, DOI 10.1128/JVI.71.12.9837-9843.1997; Yue ZY, 1997, P NATL ACAD SCI USA, V94, P12898, DOI 10.1073/pnas.94.24.12898	22	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22668	22678		10.1074/jbc.274.32.22668	http://dx.doi.org/10.1074/jbc.274.32.22668			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428848	hybrid			2022-12-25	WOS:000081868400078
J	Leo, E; Welsh, K; Matsuzawa, S; Zapata, JM; Kitada, S; Mitchell, RS; Ely, KR; Reed, JC				Leo, E; Welsh, K; Matsuzawa, S; Zapata, JM; Kitada, S; Mitchell, RS; Ely, KR; Reed, JC			Differential requirements for tumor necrosis factor receptor-associated factor family proteins in CD40 mediated induction of NF-kappa B and Jun N-terminal kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCING PROTEINS; LYMPHOTOXIN-BETA RECEPTOR; CELL-DEATH; BINDING-SITES; JNK/SAPK ACTIVATION; CYTOPLASMIC REGION; ENDOTHELIAL-CELLS; TRAF FAMILY; EXPRESSION; DOMAIN	CD40 is a member of the tumor necrosis factor receptor family that mediates a number of important signaling events in B-lymphocytes and some other types of cells through interaction of its cytoplasmic let) domain with tumor necrosis factor receptor-associated factor (TRAF) proteins. Alanine substitution and truncation mutants of the human CD40ct domain were generated, revealing residues critical for binding TRAF2, TRAF3, or both of these proteins. In contrast to TRAF2 and TRAF3, direct binding of TRAF1, TRAF4, TRAF5, or TRAF6 to CD40 was not detected. However, TRAF5 could be recruited to wild-type CD40 in a TRAF3-dependent manner but not to a CD40 mutant (Q263A) that selectively fails to bind TRAF3. CD40 mutants with impaired binding to TRAF2, TRAF3, or both of these proteins completely retained the ability to activate NF-kappa B and Jun N-terminal kinase (JNK), implying that CD40 can stimulate TRAF2- and TRAF3-independent pathways for NF-kappa B and JNK activation. A carboxyl-truncation mutant of CD40 lacking the last 32 amino acids required for TRAF2 and TRAF3 binding, CD40(Delta 32), mediated NF-kappa B induction through a mechanism that was suppressible by co-expression of TRAF6(Delta N), a dominant-negative version of TRAF6, but not by TRAF2(Delta N), implying that while TRAF6 does not directly bind CD40, it can participate in CD40 signaling. In contrast, TRAF Delta(Delta N) did not impair JNK activation by CD40(Delta 32). Taken together, these findings reveal redundancy in the involvement of TRAF family proteins in CD40-mediated NF-kappa B induction and suggest that the membrane-proximal region of CD40 may stimulate the JNK pathway through a TRAF-independent mechanism.	Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Reed, JC (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jreed@burnham-inst.org	Zapata, Juan M/J-6304-2014	Zapata, Juan M/0000-0002-0110-0009	NCI NIH HHS [CA-69381] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA069381] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; Boucher LM, 1997, BIOCHEM BIOPH RES CO, V233, P592, DOI 10.1006/bbrc.1997.6509; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; Clark LB, 1996, ADV IMMUNOL, V63, P43; Colas P, 1996, NATURE, V380, P548, DOI 10.1038/380548a0; Devergne O, 1996, MOL CELL BIOL, V16, P7098; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Eliopoulos AG, 1996, ONCOGENE, V13, P2243; GALANG CK, 1994, ONCOGENE, V9, P2913; Gedrich RW, 1996, J BIOL CHEM, V271, P12852, DOI 10.1074/jbc.271.22.12852; Grammer AC, 1998, J IMMUNOL, V161, P1183; Hanissian SH, 1997, IMMUNITY, V6, P379, DOI 10.1016/S1074-7613(00)80281-2; Hara T, 1997, BIOCHEM BIOPH RES CO, V233, P187, DOI 10.1006/bbrc.1997.6343; Henn V, 1998, NATURE, V391, P591, DOI 10.1038/35393; Hess S, 1996, J EXP MED, V183, P159, DOI 10.1084/jem.183.1.159; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hornung M, 1998, EUR J IMMUNOL, V28, P3812, DOI 10.1002/(SICI)1521-4141(199811)28:11<3812::AID-IMMU3812>3.3.CO;2-E; Hsing Y, 1997, J IMMUNOL, V159, P4898; HU HM, 1994, J BIOL CHEM, V269, P30069; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; KARMANN K, 1995, P NATL ACAD SCI USA, V92, P4342, DOI 10.1073/pnas.92.10.4342; Kashiwada M, 1998, J EXP MED, V187, P237, DOI 10.1084/jem.187.2.237; Krajewska M, 1998, AM J PATHOL, V152, P1549; Krajewski S, 1997, J IMMUNOL, V159, P5841; Lee HH, 1999, P NATL ACAD SCI USA, V96, P1421, DOI 10.1073/pnas.96.4.1421; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Lin SC, 1996, MOL CELL BIOL, V16, P4591; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; MIYASHITA T, 1995, CELL, V80, P293; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Park YC, 1999, NATURE, V398, P533, DOI 10.1038/19110; Pullen SS, 1998, BIOCHEMISTRY-US, V37, P11836, DOI 10.1021/bi981067q; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Sandberg M, 1997, J VIROL, V71, P4649, DOI 10.1128/JVI.71.6.4649-4656.1997; SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; Shi CS, 1997, J BIOL CHEM, V272, P32102, DOI 10.1074/jbc.272.51.32102; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Tsukamoto N, 1999, P NATL ACAD SCI USA, V96, P1234, DOI 10.1073/pnas.96.4.1234; VanArsdale TL, 1997, P NATL ACAD SCI USA, V94, P2460, DOI 10.1073/pnas.94.6.2460; Yamamoto H, 1998, J IMMUNOL, V161, P4753; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Zhang Y, 1998, J IMMUNOL, V160, P1053	56	80	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22414	22422		10.1074/jbc.274.32.22414	http://dx.doi.org/10.1074/jbc.274.32.22414			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428814	hybrid			2022-12-25	WOS:000081868400044
J	Martinez-Botas, J; Suarez, Y; Ferruelo, AJ; Gomez-Coronado, D; Lasuncion, MA				Martinez-Botas, J; Suarez, Y; Ferruelo, AJ; Gomez-Coronado, D; Lasuncion, MA			Cholesterol starvation decreases P34(cdc2) kinase activity and arrests the cell cycle at G2	FASEB JOURNAL			English	Article						SKF 104976; cholesterol synthesis; cell proliferation; low density lipoprotein; caffeine	DENSITY-LIPOPROTEIN RECEPTOR; SMOOTH-MUSCLE CELLS; DIPHOSPHATE SYNTHASE GENE; CDC2 PROTEIN-KINASE; HMG-COA REDUCTASE; LYMPHOCYTE-PROLIFERATION; S-PHASE; MEVALONATE PATHWAY; MOLECULAR-CLONING; STEROL SYNTHESIS	As a major component of mammalian cell plasma membranes, cholesterol is essential for cell growth. Accordingly, the restriction of cholesterol provision has been Shown to result in cell proliferation inhibition. We explored the potential regulatory role of cholesterol on cell cycle progression. MOLT-4 and HL-60 cell lines were cultured in a cholesterol-deficient medium and simultaneously exposed to SKF 104976, which is a specific inhibitor of lanosterol 14-alpha demethylase. Through HPLC analyses with on-line radioactivity detection, we found that SKF 104976 efficiently blocked the [C-14]-acetate incorporation into cholesterol, resulting in an accumulation of lanosterol and dihydrolanosterol, without affecting the synthesis of mevalonic acid. The inhibitor also produced a rapid and intense inhibition of cell proliferation (IC50 = 0.1 mu M), as assessed by both [H-3]-thymidine incorporation into DNA and cell counting. Flow cytometry and morphological examination showed that treatment with SKF 104976 for 48 h or longer resulted in the accumulation of cells specifically at G2 phase, whereas both the GI traversal and the transition through S were unaffected. The G2 arrest was accompanied by an increase in the hyperphosphorylated form of p34(cdc2) and a reduction of its activity, as determined by assaying the H1 histone phosphorylating activity of p34(cdc2) immunoprecipitates. The persistent deficiency of cholesterol induced apoptosis. However, supplementing the medium with cholesterol, either in the form of LDL or free cholesterol dissolved in ethanol, completely abolished these effects, whereas mevalonate was ineffective. Caffeine, which abrogates the G2 checkpoint by preventing p34(cdc2) phosphorylation, reduced the accumulation in G2 when added to cultures containing cells on transit to G2, but was ineffective in cells arrested at G2 by sustained cholesterol starvation. Cells arrested in G2, however, were still viable and responded to cholesterol provision by activating p34(cdc2) and resuming the cell cycle. We conclude that in both lymphoblastoid and promyelocytic cells, cholesterol availability governs the G2 traversal, probably by affecting p34(cdc2) activity.	Hosp Ramon & Cajal, Serv Bioquim Invest, E-28034 Madrid, Spain; Univ Alcala de Henares, Dept Bioquim & Biol Mol, Alcala De Henares 99775, Spain	Hospital Universitario Ramon y Cajal; Universidad de Alcala	Lasuncion, MA (corresponding author), Hosp Ramon & Cajal, Serv Bioquim Invest, Ctra Colmenar,Km 9, E-28034 Madrid, Spain.	miguel.a.lasuncion@hrs.es	Martinez-Botas, Javier/AAD-8733-2021; Lasunción, Miguel A./K-6167-2014	Martinez-Botas, Javier/0000-0002-5190-3619; Lasunción, Miguel A./0000-0003-0299-9391; Ferruelo, Antonio/0000-0001-9840-3569; Suarez, Yajaira/0000-0003-4549-2953				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BROWN MS, 1974, J BIOL CHEM, V249, P7306; BUTTKE TM, 1992, J BIOL CHEM, V267, P8819; BUTTKE TM, 1980, J BACTERIOL, V144, P124, DOI 10.1128/JB.144.1.124-130.1980; Carrero P, 1998, BIOCHEM PHARMACOL, V55, P1125, DOI 10.1016/S0006-2952(97)00635-7; CHAKRABARTI R, 1991, J BIOL CHEM, V266, P12216; CHEN HW, 1975, P NATL ACAD SCI USA, V72, P1950, DOI 10.1073/pnas.72.5.1950; CHEN HW, 1974, NATURE, V251, P419, DOI 10.1038/251419a0; CHEN HY, 1988, ULTRASOUND MED BIOL, V14, P263, DOI 10.1016/0301-5629(88)90091-9; CHUNG BH, 1986, METHOD ENZYMOL, V128, P181; CORSINI A, 1993, ATHEROSCLEROSIS, V101, P117, DOI 10.1016/0021-9150(93)90107-6; Crick DC, 1997, EXP CELL RES, V231, P302, DOI 10.1006/excr.1997.3480; CUTHBERT JA, 1990, J BIOL CHEM, V265, P18568; DAHL C, 1987, P NATL ACAD SCI USA, V84, P4012, DOI 10.1073/pnas.84.12.4012; DAHL JS, 1983, P NATL ACAD SCI-BIOL, V80, P692, DOI 10.1073/pnas.80.3.692; DAHL JS, 1980, BIOCHEMISTRY-US, V19, P1467, DOI 10.1021/bi00548a032; DEMARCQ C, 1994, CELL GROWTH DIFFER, V5, P983; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; FAUST JR, 1991, J BIOL CHEM, V266, P9961; FOLCH J, 1957, J BIOL CHEM, V226, P497; FORGULAFITTE ME, 1992, CANCER RES, V52, P6827; GRANA X, 1995, ONCOGENE, V11, P211; GrayBablin J, 1997, CANCER RES, V57, P604; GUAN GM, 1995, J BIOL CHEM, V270, P21958, DOI 10.1074/jbc.270.37.21958; HAEFFNER EW, 1984, CANCER RES, V44, P2668; HAIN J, 1993, CANCER RES, V53, P1507; JAKOBISIAK M, 1991, P NATL ACAD SCI USA, V88, P3628, DOI 10.1073/pnas.88.9.3628; KEYOMARSI K, 1991, CANCER RES, V51, P3602; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; LANGAN TJ, 1991, J CELL PHYSIOL, V149, P284, DOI 10.1002/jcp.1041490215; Lew DJ, 1996, CURR OPIN CELL BIOL, V8, P795, DOI 10.1016/S0955-0674(96)80080-9; LLOYD DB, 1995, J BIOL CHEM, V270, P25812, DOI 10.1074/jbc.270.43.25812; LOCK RB, 1994, CANCER RES, V54, P4933; MAYER RJ, 1991, J BIOL CHEM, V266, P20070; OCONNELL MJ, 1994, CURR OPIN CELL BIOL, V6, P867, DOI 10.1016/0955-0674(94)90058-2; OSBORNE TF, 1985, CELL, V42, P203, DOI 10.1016/S0092-8674(85)80116-1; PALACIN M, 1988, J LIPID RES, V29, P26; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; QUESNEYHUNEEUS V, 1979, P NATL ACAD SCI USA, V76, P5056, DOI 10.1073/pnas.76.10.5056; Raiteri M, 1997, J PHARMACOL EXP THER, V281, P1144; RAMGOPAL M, 1983, P NATL ACAD SCI-BIOL, V80, P712, DOI 10.1073/pnas.80.3.712; RODRIGUEZ RJ, 1982, BIOCHEM BIOPH RES CO, V106, P435, DOI 10.1016/0006-291X(82)91129-9; Rogler G, 1995, BASIC RES CARDIOL, V90, P443, DOI 10.1007/BF00788536; RUJANAVECH C, 1986, J BIOL CHEM, V261, P7196; RUSSELL DW, 1983, P NATL ACAD SCI-BIOL, V80, P7501, DOI 10.1073/pnas.80.24.7501; SAWAMURA M, 1993, CLIN EXP PHARMACOL P, V20, P509, DOI 10.1111/j.1440-1681.1993.tb01733.x; SCHULZ S, 1994, EUR J IMMUNOL, V24, P301, DOI 10.1002/eji.1830240204; SCHULZ S, 1992, CANCER RES, V52, P1372; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sindermann J, 1997, J IMMUNOL METHODS, V202, P205, DOI 10.1016/S0022-1759(97)00007-0; SINENSKY M, 1990, J BIOL CHEM, V265, P19937; SMITH JR, 1988, J BIOL CHEM, V263, P18480; SMYTHE C, 1992, CELL, V68, P787, DOI 10.1016/0092-8674(92)90153-4; SPEAR DH, 1992, J BIOL CHEM, V267, P14462; TABACIK C, 1989, BIOCHIM BIOPHYS ACTA, V1011, P149, DOI 10.1016/0167-4889(89)90202-4; VITOLS S, 1994, BLOOD, V84, P2689; Vogt A, 1996, ONCOGENE, V13, P1991; WEJDE J, 1993, J CELL PHYSIOL, V155, P539, DOI 10.1002/jcp.1041550312; Yao SL, 1996, NAT MED, V2, P1140, DOI 10.1038/nm1096-1140	62	64	64	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1999	13	11					1359	1370		10.1096/fasebj.13.11.1359	http://dx.doi.org/10.1096/fasebj.13.11.1359			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	226KL	10428760				2022-12-25	WOS:000082019100008
J	Leiter, H; Mucha, J; Staudacher, E; Grimm, R; Glossl, J; Altmann, F				Leiter, H; Mucha, J; Staudacher, E; Grimm, R; Glossl, J; Altmann, F			Purification, cDNA cloning, and expression of GDP-L-Fuc : Asn-linked GlcNAc alpha 1,3-fucosyltransferase from mung beans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOUND N-ACETYLGLUCOSAMINE; LEPIDOPTERAN CELL-LINES; FUCOSYL-TRANSFERASES; GLYCANS; OLIGOSACCHARIDES; GLYCOPROTEINS; IDENTIFICATION; PROTEINS; EPITOPE; SPECIFICITY	Substitution of the asparagine-linked GlcNAc by alpha 1,3-linked fucose is a widespread feature of plant as well as of insect glycoproteins, which renders the N-glycan immunogenic. We have purified from mung bean seedlings the GDP-L-Fuc:Asn-linked GlcNAc alpha 1,3-fucosyltransferase (core alpha 1,3-fucosyltransferase) that is responsible for the synthesis of this linkage. The major isoform had an apparent mass of 54 kDa and isoelectric points ranging from 6.8 to 8.2. From that protein, four tryptic peptides were isolated and sequenced. Based on an approach involving reverse transcriptase-polymerase chain reaction with degenerate primers and rapid amplification of cDNA ends, core alpha 1,3-fucosyltransferase cDNA was cloned from mung bean mRNA. The 2200-base pair cDNA contained an open reading frame of 1530 base pairs that encoded a 510-amino acid protein with a predicted molecular mass of 56.8 kDa. Analysis of cDNA derived from genomic DNA revealed the presence of three introns within the open reading frame. Remarkably, from the four exons, only exon II exhibited significant homology to animal and bacterial alpha 1,3/4-fucosyltransferases which, though, are responsible for the biosynthesis of Lewis determinants. The recombinant fucosyltransferase was expressed in Sf21 insect cells using a baculovirus vector. The enzyme acted on glycopeptides having the glycan structures GlcNAc beta 1-2Man alpha 1-3(GlcNAc beta 1-2Man alpha 1-6)Man beta 1-4GlcNAc beta 1-4GlcNAc beta 1-Asn, GlcNAc beta 1-2Man alpha 1-3(GlcNAc beta 1-2Man alpha 1-6)Man beta-1-4GlcNAc beta 1-4(Fuc alpha 1-6)GlcNAc beta 1-Asn, and GlcNAc beta-1-2Man alpha 1-3[Man alpha 1-3(Man alpha 1-6)Man alpha 1-6]Man beta 1-4-GlcNAc beta 1-4GlcNAc beta 1-Asn but not on, e.g. N-acetyllactosamine. The structure of the core alpha 1,3-fucosylated product was verified by high performance liquid chromatography of the pyridylaminated glycan and by its insensitivity to N-glycosidase F as revealed by matrix-assisted laser desorption/ionization time of flight mass spectrometry.	Agr Univ Vienna, Inst Chem, A-1190 Vienna, Austria; Agr Univ Vienna, Ctr Appl Genet, A-1190 Vienna, Austria; Hewlett Packard Co, Waldbronn, Germany	University of Natural Resources & Life Sciences, Vienna; University of Natural Resources & Life Sciences, Vienna; Hewlett-Packard	Altmann, F (corresponding author), Agr Univ Vienna, Inst Chem, Muthgasse 18, A-1190 Vienna, Austria.		Glössl, Josef/H-8208-2013	Glössl, Josef/0000-0002-5042-8828; Staudacher, Erika/0000-0001-8282-1424; Altmann, Friedrich/0000-0002-0112-7877				Aalberse RC, 1998, ALLERGY, V53, P54, DOI 10.1111/j.1398-9995.1998.tb04940.x; Aalberse RC, 1997, CLIN REV ALLERG IMMU, V15, P375, DOI 10.1007/BF02737733; ALTMANN F, 1995, J BIOL CHEM, V270, P17344, DOI 10.1074/jbc.270.29.17344; ALTMANN F, 1992, ANAL BIOCHEM, V204, P215, DOI 10.1016/0003-2697(92)90164-3; Altmann F, 1999, GLYCOCONJUGATE J, V16, P109, DOI 10.1023/A:1026488408951; ALTMANN F, 1995, GLYCOCONJUGATE J, V12, P84, DOI 10.1007/BF00731873; Breton C, 1998, GLYCOBIOLOGY, V8, P87, DOI 10.1093/glycob/8.1.87; Costache M, 1997, TRANSFUS CLIN BIOL, V4, P367, DOI 10.1016/S1246-7820(97)80042-0; DeBose-Boyd RA, 1998, GLYCOBIOLOGY, V8, P905, DOI 10.1093/glycob/8.9.905; Edbrooke MR, 1997, BIOCHEM SOC T, V25, P880, DOI 10.1042/bst0250880; FAYE L, 1993, ANAL BIOCHEM, V209, P104, DOI 10.1006/abio.1993.1088; FAYE L, 1988, GLYCOCONJUGATE J, V5, P245, DOI 10.1007/BF01049085; Fitchette-Laine AC, 1997, PLANT J, V12, P1411, DOI 10.1046/j.1365-313x.1997.12061411.x; GarciaCasado G, 1996, GLYCOBIOLOGY, V6, P471, DOI 10.1093/glycob/6.4.471; GOMEZ L, 1994, P NATL ACAD SCI USA, V91, P1829, DOI 10.1073/pnas.91.5.1829; GORG A, 1988, ELECTROPHORESIS, V9, P681, DOI 10.1002/elps.1150091103; HASE S, 1984, J BIOCHEM-TOKYO, V95, P197, DOI 10.1093/oxfordjournals.jbchem.a134585; Hebsgaard SM, 1996, NUCLEIC ACIDS RES, V24, P3439, DOI 10.1093/nar/24.17.3439; HOLMES EH, 1995, J BIOL CHEM, V270, P8145, DOI 10.1074/jbc.270.14.8145; JANKIEWICZ A, 1998, ALLERGO J, V7, P87; JOZIASSE DH, 1992, GLYCOBIOLOGY, V2, P271, DOI 10.1093/glycob/2.4.271; KUBELKA V, 1994, ARCH BIOCHEM BIOPHYS, V308, P148, DOI 10.1006/abbi.1994.1021; KUBELKA V, 1993, EUR J BIOCHEM, V213, P1193, DOI 10.1111/j.1432-1033.1993.tb17870.x; KUROSAKA A, 1991, J BIOL CHEM, V266, P4168; LEE YC, 1990, ANAL BIOCHEM, V188, P259, DOI 10.1016/0003-2697(90)90603-7; Lerouge P, 1998, PLANT MOL BIOL, V38, P31, DOI 10.1023/A:1006012005654; MCMANUS MT, 1988, PLANTA, V175, P506, DOI 10.1007/BF00393072; Melo NS, 1997, FEBS LETT, V415, P186, DOI 10.1016/S0014-5793(97)01121-6; Oriol R, 1999, GLYCOBIOLOGY, V9, P323, DOI 10.1093/glycob/9.4.323; Palacpac NQ, 1999, P NATL ACAD SCI USA, V96, P4692, DOI 10.1073/pnas.96.8.4692; Petersen A, 1996, J ALLERGY CLIN IMMUN, V98, P805, DOI 10.1016/S0091-6749(96)70130-6; PRENNER C, 1992, BIOCHEM J, V284, P377, DOI 10.1042/bj2840377; RYAN OC, 1998, J EXP BOT, V49, P1463; Sherwood AL, 1998, J BIOL CHEM, V273, P25256, DOI 10.1074/jbc.273.39.25256; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Smith PL, 1996, J BIOL CHEM, V271, P8250, DOI 10.1074/jbc.271.14.8250; Staudacher E, 1998, GLYCOCONJUGATE J, V15, P355, DOI 10.1023/A:1006969701231; STAUDACHER E, 1991, EUR J BIOCHEM, V199, P745, DOI 10.1111/j.1432-1033.1991.tb16179.x; STAUDACHER E, 1995, GLYCOCONJUGATE J, V12, P780, DOI 10.1007/BF00731239; Staudacher E, 1996, TRENDS GLYCOSCI GLYC, V8, P391, DOI 10.4052/tigg.8.391; STAUDACHER E, 1992, EUR J BIOCHEM, V207, P987, DOI 10.1111/j.1432-1033.1992.tb17134.x; STRASSER R, 1999, IN PRESS GLYCOBIOLOG; TRETTER V, 1993, INT ARCH ALLERGY IMM, V102, P259, DOI 10.1159/000236534; Uozumi N, 1996, J BIOL CHEM, V271, P27810, DOI 10.1074/jbc.271.44.27810; WANG X, 1994, INSECT BIOCHEM MOLEC, V24, P233, DOI 10.1016/0965-1748(94)90002-7; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; Wilson IBH, 1998, GLYCOBIOLOGY, V8, P651, DOI 10.1093/glycob/8.7.651; Wilson IBH, 1998, GLYCOCONJUGATE J, V15, P1055, DOI 10.1023/A:1006960401562; Yanagidani S, 1997, J BIOCHEM-TOKYO, V121, P626; Zeleny R, 1997, ANAL BIOCHEM, V246, P96, DOI 10.1006/abio.1996.9973; Zeng YC, 1997, J BIOL CHEM, V272, P31340, DOI 10.1074/jbc.272.50.31340; [No title captured]	52	81	97	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21830	21839		10.1074/jbc.274.31.21830	http://dx.doi.org/10.1074/jbc.274.31.21830			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419500	hybrid			2022-12-25	WOS:000081721100053
J	Yamamoto, K; Dang, QN; Kennedy, SP; Osathanondh, R; Kelly, RA; Lee, RT				Yamamoto, K; Dang, QN; Kennedy, SP; Osathanondh, R; Kelly, RA; Lee, RT			Induction of tenascin-C in cardiac myocytes by mechanical deformation - Role of reactive oxygen species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ACTIVATED PROTEIN-KINASES; STIMULATES SUPEROXIDE PRODUCTION; RENIN-ANGIOTENSIN SYSTEM; SMOOTH-MUSCLE CELLS; GENE-EXPRESSION; TRANSCRIPTION FACTOR; ENDOTHELIAL-CELLS; IN-VITRO; MYOCARDIAL-ISCHEMIA	Mechanical overload may change cardiac structure through angiotensin II-dependent and angiotensin II-independent mechanisms. We investigated the effects of mechanical strain on the gene expression of tenascin-C, a prominent extracellular molecule in actively remodeling tissues, in neonatal rat cardiac myocytes, Mechanical strain induced tenascin-C mRNA (3.9 +/- 0.5-fold, p < 0.01, n = 13) and tenascin-C protein in an amplitude-dependent manner but did not induce secreted protein acidic and rich in cysteine nor fibronectin, RNase protection assay demonstrated that mechanical strain induced all three alternatively spliced isoforms of tenascin-C, An angiotensin II receptor type 1 antagonist inhibited mechanical induction of brain natriuretic peptide but not tenascin-C. Antioxidants such as N-acetyl-L-cysteine, catalase, and 1,2-dihydroxy-benzene-3,5-disulfonate significantly inhibited induction of tenascin-C. Truncated tenascin-C promoter-reporter assays using dominant negative mutants of I kappa B alpha and I kappa B kinase beta and electrophoretic mobility shift assays indicated that mechanical strain increases tenascin-C gene transcription by activating nuclear factor-kappa B through reactive oxygen species. Our findings demonstrate that mechanical strain induces tenascin-C in cardiac myocytes through a nuclear factor-kappa B dependent and angiotensin II-independent mechanism. These data also suggest that reactive oxygen species may participate in mechanically induced left ventricular remodeling.	Harvard Univ, Brigham & Womens Hosp, Sch Med,Dept Med, Div Cardiovasc, Boston, MA 02115 USA; Pfizer Inc, Dept Mol Sci, Div Cent Res, Groton, CT 06340 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Pfizer	Lee, RT (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med,Dept Med, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA.				NHLBI NIH HHS [HL-54759] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL054759, R01HL054759] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARROYO CM, 1987, FEBS LETT, V221, P101, DOI 10.1016/0014-5793(87)80360-5; BAKER KM, 1992, ANNU REV PHYSIOL, V54, P227, DOI 10.1146/annurev.physiol.54.1.227; BAKER KM, 1990, AM J PHYSIOL, V259, P324; BOLLI R, 1988, J CLIN INVEST, V82, P476, DOI 10.1172/JCI113621; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; CAREY RA, 1980, J MOL CELL CARDIOL, V12, P929, DOI 10.1016/0022-2828(80)90060-7; Cheng GC, 1997, CIRC RES, V80, P28, DOI 10.1161/01.RES.80.1.28; CHENG W, 1995, J CLIN INVEST, V96, P2247, DOI 10.1172/JCI118280; Chiquet-Ehrismann R, 1991, CURR OPIN CELL BIOL, V3, P800, DOI 10.1016/0955-0674(91)90053-2; CHIQUETEHRISMANN R, 1994, J CELL BIOL, V127, P2093, DOI 10.1083/jcb.127.6.2093; CHIQUETEHRISMANN R, 1991, CELL REGUL, V2, P927, DOI 10.1091/mbc.2.11.927; CHIQUETEHRISMANN R, 1995, EXPERIENTIA, V51, P853, DOI 10.1007/BF01921736; CHIQUETEHRISMANN R, 1995, BIOESSAYS, V17, P873, DOI 10.1002/bies.950171009; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNG CY, 1994, J CELL BIOL, V126, P539, DOI 10.1083/jcb.126.2.539; CROSSIN KL, 1986, J CELL BIOL, V102, P1917, DOI 10.1083/jcb.102.5.1917; DellItalia LJ, 1997, AM J PHYSIOL-HEART C, V273, pH961, DOI 10.1152/ajpheart.1997.273.2.H961; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Ferrari R, 1998, EUR HEART J, V19, pB2; Force T, 1996, CIRC RES, V78, P947, DOI 10.1161/01.RES.78.6.947; GARLICK PB, 1987, CIRC RES, V61, P757, DOI 10.1161/01.RES.61.5.757; GHERZI R, 1995, J BIOL CHEM, V270, P3429, DOI 10.1074/jbc.270.7.3429; Harada K, 1998, CIRCULATION, V97, P1952, DOI 10.1161/01.CIR.97.19.1952; Harada K, 1998, CIRC RES, V82, P779, DOI 10.1161/01.RES.82.7.779; HEDIN U, 1991, AM J PATHOL, V139, P649; Hishikawa K, 1997, CIRC RES, V81, P797; Hishikawa K, 1997, CIRCULATION, V96, P3610; Howard AB, 1997, AM J PHYSIOL-CELL PH, V272, pC421, DOI 10.1152/ajpcell.1997.272.2.C421; Hsieh HJ, 1998, J CELL PHYSIOL, V175, P156, DOI 10.1002/(SICI)1097-4652(199805)175:2<156::AID-JCP5>3.0.CO;2-N; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Jones PL, 1996, CIRC RES, V79, P1131, DOI 10.1161/01.RES.79.6.1131; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; KOJIMA M, 1994, CIRCULATION, V89, P2204, DOI 10.1161/01.CIR.89.5.2204; KOMURO I, 1991, J BIOL CHEM, V266, P1265; Komuro I, 1996, FASEB J, V10, P631, DOI 10.1096/fasebj.10.5.8621062; LAFLEUR DW, 1994, J BIOL CHEM, V269, P20757; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LI Y, 1994, EUR J BIOCHEM, V226, P31, DOI 10.1111/j.1432-1033.1994.tb20023.x; Liang FQ, 1998, J BIOL CHEM, V273, P14612, DOI 10.1074/jbc.273.23.14612; LIGHTNER VA, 1989, J CELL BIOL, V108, P2483, DOI 10.1083/jcb.108.6.2483; LINDPAINTNER K, 1991, CIRC RES, V68, P905, DOI 10.1161/01.RES.68.4.905; Mettouchi A, 1997, MOL CELL BIOL, V17, P3202, DOI 10.1128/MCB.17.6.3202; Nakamura K, 1998, CIRCULATION, V98, P794, DOI 10.1161/01.CIR.98.8.794; Norman DAM, 1998, CARDIOVASC RES, V39, P434, DOI 10.1016/S0008-6363(98)00118-7; PENG M, 1995, CELL MOL BIOL RES, V41, P189; PRIETO AL, 1993, P NATL ACAD SCI USA, V90, P10154, DOI 10.1073/pnas.90.21.10154; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Schwachtgen JL, 1998, J CLIN INVEST, V101, P2540, DOI 10.1172/JCI1404; SPRINGHORN JP, 1989, BIOCHEM J, V258, P73, DOI 10.1042/bj2580073; Sylla BS, 1998, P NATL ACAD SCI USA, V95, P10106, DOI 10.1073/pnas.95.17.10106; Thienelt CD, 1997, CIRCULATION, V95, P2677, DOI 10.1161/01.CIR.95.12.2677; Tran K, 1997, MOL CELL BIOL, V17, P5386, DOI 10.1128/MCB.17.9.5386; Wung BS, 1997, CIRC RES, V81, P1, DOI 10.1161/01.RES.81.1.1; YAMAMOTO K, 1993, J CLIN INVEST, V92, P1889, DOI 10.1172/JCI116781; YAMAZAKI T, 1995, J CLIN INVEST, V96, P438, DOI 10.1172/JCI118054; YAMAZAKI T, 1993, J BIOL CHEM, V268, P12069; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; ZISCH AH, 1992, J CELL BIOL, V119, P203, DOI 10.1083/jcb.119.1.203	62	97	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21840	21846		10.1074/jbc.274.31.21840	http://dx.doi.org/10.1074/jbc.274.31.21840			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419501	hybrid			2022-12-25	WOS:000081721100054
J	Christmas, P; Ursino, SR; Fox, JW; Soberman, RJ				Christmas, P; Ursino, SR; Fox, JW; Soberman, RJ			Expression of the CYP4F3 gene - Tissue-specific splicing and alternative promoters generate high and low K-m forms of leukotriene B-4 omega-hydroxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; TRACT BINDING-PROTEIN; FUNCTIONAL-CHARACTERIZATION; MESSENGER-RNA; CDNA CLONING; EXON; IDENTIFICATION; 20-HYDROXYLASE; INFLAMMATION; LIVER	Cytochrome P450 4F3 (CYP4F3) catalyzes the inactivation of leukotriene Bq by omega-oxidation in human neutrophils, To understand the regulation of CYP4F3 expression, we analyzed the CYP4F3 gene and cloned a novel isoform (CYP4F3B) that is expressed in fetal and adult liver, but not in neutrophils, The CYP4F3 gene contains 14 exons and 13 introns, The cDNAs for CYP4F3A (the neutrophil isoform) and CYP4F3B have identical coding regions, except that they contain exons 4 and 3, respectively. Both exons code for amino acids 66-114 but share only 27% identity. When expressed in COS-7 cells, the K-m of CYP4F3B was determined to be 26-fold higher than the K-m of CYP4F3A using leukotriene B-4 as a substrate. 5'-Rapid amplification of cDNA end studies reveal that the CYP4F3A and CYP4F3B transcripts have 5'-termini derived from different parts of the gene and are initiated from distinct transcription start sites located 519 and 71 base pairs (bp), respectively, from the ATG initiation codon, A consensus TATA box is located 27 bp upstream of the CYP4F3B transcription start site, and a TATA box-like sequence is located 23 bp upstream of the CYP4F3A transcription start site. The data indicate that the tissue-specific expression of functionally distinct CYP4F3 isoforms is regulated by alternative promoter usage and mutually exclusive exon splicing.	Massachusetts Gen Hosp, Dept Med, Arthrit Unit, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University	Soberman, RJ (corresponding author), Massachusetts Gen Hosp E, Dept Med, Arthritis Unit, 149 Navy Yard,13th St, Charlestown, MA 02129 USA.				NIEHS NIH HHS [ES50859] Funding Source: Medline	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ashiya M, 1997, RNA, V3, P996; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Chan RCC, 1997, MOL CELL BIOL, V17, P4667, DOI 10.1128/MCB.17.8.4667; CHEN LP, 1993, ARCH BIOCHEM BIOPHYS, V300, P18, DOI 10.1006/abbi.1993.1003; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; FORDHUTCHINSON AW, 1990, CRIT REV IMMUNOL, V10, P1; Gooding C, 1998, RNA, V4, P85; Grabowski PJ, 1998, CELL, V92, P709, DOI 10.1016/S0092-8674(00)81399-9; HENDERSON WR, 1994, ANN INTERN MED, V121, P684, DOI 10.7326/0003-4819-121-9-199411010-00010; Kawashima H, 1995, BIOCHEM BIOPH RES CO, V217, P1137, DOI 10.1006/bbrc.1995.2887; KIKUTA Y, 1994, FEBS LETT, V348, P70, DOI 10.1016/0014-5793(94)00587-7; Kikuta Y, 1998, DNA CELL BIOL, V17, P221, DOI 10.1089/dna.1998.17.221; Kikuta Y, 1998, ARCH BIOCHEM BIOPHYS, V355, P201, DOI 10.1006/abbi.1998.0724; KIKUTA Y, 1993, J BIOL CHEM, V268, P9376; LEWIS RA, 1981, J EXP MED, V154, P1243, DOI 10.1084/jem.154.4.1243; LIBRI D, 1990, MOL CELL BIOL, V10, P5036, DOI 10.1128/MCB.10.10.5036; Lou H, 1999, MOL CELL BIOL, V19, P78; MERRYMANSIMPSON AE, 1996, GEN PHARMACOL, V28, P351; MIGLIORISI G, 1987, AM J PATHOL, V127, P156; MULLICK J, 1995, BIOCHEMISTRY-US, V34, P13729, DOI 10.1021/bi00042a003; MULLIGAN GJ, 1992, J BIOL CHEM, V267, P25480; PALMER RMJ, 1980, PROSTAGLANDINS, V20, P411, DOI 10.1016/S0090-6980(80)80058-X; Perez I, 1997, RNA, V3, P764; POWELL WS, 1984, J BIOL CHEM, V259, P3082; ROSENBACH T, 1987, CLIN EXP IMMUNOL, V69, P221; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SHAK S, 1985, J CLIN INVEST, V76, P1218, DOI 10.1172/JCI112077; SHAK S, 1984, J BIOL CHEM, V259, P181; Sharma S, 1997, MED ONCOL, V14, P99, DOI 10.1007/BF02990954; Simpson ER, 1997, FASEB J, V11, P29, DOI 10.1096/fasebj.11.1.9034163; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; Slayton  WB, 1998, PEDIATR RES, V43, P774, DOI 10.1203/00006450-199806000-00010; SOBERMAN RJ, 1987, J BIOL CHEM, V262, P12421; SOBERMAN RJ, 1985, P NATL ACAD SCI USA, V82, P2292, DOI 10.1073/pnas.82.8.2292; TAVASSOLI M, 1991, BLOOD CELLS, V1, P269; TERNOWITZ T, 1987, ACTA PATH MICRO IM C, V95, P47; Valcarcel J, 1997, CURR BIOL, V7, pR705, DOI 10.1016/S0960-9822(06)00361-7; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	39	61	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21191	21199		10.1074/jbc.274.30.21191	http://dx.doi.org/10.1074/jbc.274.30.21191			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409674	hybrid			2022-12-25	WOS:000081613100065
J	Chu, GC; Katakura, K; Zhang, XH; Yoshida, T; Ikeda-Saito, M				Chu, GC; Katakura, K; Zhang, XH; Yoshida, T; Ikeda-Saito, M			Heme degradation as catalyzed by a recombinant bacterial heme oxygenase (Hmu O) from Corynebacterium diphtheriae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISTAL WATER LIGAND; CARBON-MONOXIDE; YERSINIA-ENTEROCOLITICA; TRANSPORT-SYSTEM; IRON TRANSPORT; COMPLEX; EXPRESSION; SITE; ACQUISITION; MECHANISM	Hmu O, a heme degradation enzyme in the pathogen Corynebacterium diphtheriae, catalyzes the oxygen-dependent conversion of hemin to biliverdin, carbon monoxide, and free iron. A bacterial expression system using a synthetic gene coding for the 215-amino acid, full-length Hmu O has been constructed. Expressed at very high levels in Escherichia coli BL21, the enzyme binds hemin stoichiometrically to form a hexacoordinate high spin hemin-Hmu O complex. When ascorbic acid is used as the electron donor, Hmu O converts hemin to biliverdin with alpha-hydroxyhemin and verdoheme as intermediates. The overall conversion rate to biliverdin is approximately 4-fold slower than that by rat heme oxygenase (HO) isoform 1. Reaction of the hemin-Hmu O complex with hydrogen peroxide yields a verdoheme species, the recovery of which is much less compared with rat HO-1. Reaction of the hemin complex with meta-chloroperbenzoic acid generates a ferryl oxo species. Thus, the catalytic intermediate species and the nature of the active form in the first oxygenation step of Hmu O appear to be similar to those of the mammalian HO. However, the considerably slow catalytic rate and low level of verdoheme recovery in the hydrogen peroxide reaction suggest that the active-site structure of Hmu O is different from that of its mammalian counterpart.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Yamagata Univ, Sch Med, Dept Biochem, Yamagata 9909585, Japan	Case Western Reserve University; Yamagata University	Chu, GC (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA.		Ikeda-Saito, Masao/A-5992-2008; Ikeda-Saito, Masao/K-2703-2015		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057272] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 57272] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEERS RF, 1952, J BIOL CHEM, V195, P133; Braun V, 1997, BIOL CHEM, V378, P779; De Montellano PRO, 1998, ACCOUNTS CHEM RES, V31, P543; DOCHERTY JC, 1984, J BIOL CHEM, V259, P3066; Fujii H, 1998, J AM CHEM SOC, V120, P8251, DOI 10.1021/ja973925w; FUJII H, 1990, THESIS KYOTO U; Ikeda-Saito M, 1998, KEIO UNIV SYMP LIFE, V1, P304; ISHIKAWA K, 1995, J BIOL CHEM, V270, P6345, DOI 10.1074/jbc.270.11.6345; LEE BC, 1995, MOL MICROBIOL, V18, P383, DOI 10.1111/j.1365-2958.1995.mmi_18030383.x; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; Matera KM, 1996, J BIOL CHEM, V271, P6618, DOI 10.1074/jbc.271.12.6618; Matera KM, 1997, BIOCHEMISTRY-US, V36, P4909, DOI 10.1021/bi962321m; Migita CT, 1998, J BIOL CHEM, V273, P945, DOI 10.1074/jbc.273.2.945; MILLS M, 1995, J BACTERIOL, V177, P3004, DOI 10.1128/jb.177.11.3004-3009.1995; NATHANSON JA, 1995, NEURON, V14, P781, DOI 10.1016/0896-6273(95)90222-8; PAUL KG, 1953, ACTA CHEM SCAND, V7, P1284, DOI 10.3891/acta.chem.scand.07-1284; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10919, DOI 10.1073/pnas.94.20.10919; SAITO S, 1986, J CHEM SOC PERK T 1, P1, DOI 10.1039/p19860000001; Sambrook J., 2002, MOL CLONING LAB MANU; SCHACTER BA, 1972, J BIOL CHEM, V247, P3601; SCHMITT MP, 1994, J BACTERIOL, V176, P1141, DOI 10.1128/JB.176.4.1141-1149.1994; Schmitt MP, 1997, J BACTERIOL, V179, P838, DOI 10.1128/jb.179.3.838-845.1997; Sono M, 1996, CHEM REV, V96, P2841, DOI 10.1021/cr9500500; STAYTON PS, 1989, MET IONS BIOL SYST, V25, P417; STOJILJKOVIC I, 1994, MOL MICROBIOL, V13, P719, DOI 10.1111/j.1365-2958.1994.tb00465.x; STOJILJKOVIC I, 1992, EMBO J, V11, P4359, DOI 10.1002/j.1460-2075.1992.tb05535.x; Takahashi S, 1997, BIOCHEMISTRY-US, V36, P1402, DOI 10.1021/bi962361q; TAKAHASHI S, 1994, J BIOL CHEM, V269, P1010; TAO X, 1994, MOL MICROBIOL, V14, P191, DOI 10.1111/j.1365-2958.1994.tb01280.x; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; Wilks A, 1996, BIOCHEMISTRY-US, V35, P930, DOI 10.1021/bi952405f; Wilks A, 1998, J BIOL CHEM, V273, P837, DOI 10.1074/jbc.273.2.837; WILKS A, 1993, J BIOL CHEM, V268, P22357; YOSHIDA T, 1978, J BIOL CHEM, V253, P4230; YOSHIDA T, 1980, J BIOL CHEM, V255, P4418; YOSHIDA T, 1978, J BIOL CHEM, V253, P4224; YOSHIDA T, 1980, J BIOCHEM-TOKYO, V88, P557, DOI 10.1093/oxfordjournals.jbchem.a133003; Zakhary R, 1996, P NATL ACAD SCI USA, V93, P795, DOI 10.1073/pnas.93.2.795	39	65	66	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21319	21325		10.1074/jbc.274.30.21319	http://dx.doi.org/10.1074/jbc.274.30.21319			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409691	hybrid			2022-12-25	WOS:000081613100082
J	Gao, XD; Kaigorodov, V; Jigami, Y				Gao, XD; Kaigorodov, V; Jigami, Y			YND1, a homologue of GDA1, encodes membrane-bound apyrase required for Golgi N- and O-glycosylation in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANOSINE DIPHOSPHATASE; NUCLEOTIDE SULFATE; PROTEIN GLYCOSYLATION; APPARATUS MEMBRANE; ESCHERICHIA-COLI; GDP-MANNOSE; GENE FAMILY; VRG4 GENE; MNN4 GENE; YEAST	The gene for the open reading frame YER005w that is homologous to yeast Golgi GDPase encoded by the GDA1 gene was cloned and named YND1. It encodes a 630-amino acid protein that contains a single transmembrane region near the carboxyl terminus. The overexpression of the YND1 gene in the gda1 null mutant caused a significant increase in microsomal membrane-bound nucleoside phosphatase activity with a luminal orientation,The activity was equally high toward ADP/ ATP, GDP/GTP, and UDP/UTP and similar to 50% less toward CDP/CTP and thiamine. pyrophosphate, but there was no activity toward GMP, indicating that the Ynd1 protein belongs to the apyrase family, This substrate specificity is different from that of yeast GDPase, but similar to that of human Golgi UDPase, The Delta ynd1 mutant cells were defective in O- and N-linked glycosylation in the Golgi compartments. The overexpression of the YND1 gene complemented some glycosylation defects in Delta gda1 disruptants, suggesting a partially redundant function of yeast apyrase and GDPase. From these results and the phenotype of the Delta ynd1 Delta gda1 double deletion showing a synthetic effect, we conclude that yeast apyrase is required for Golgi glycosylation and cell wall integrity, providing the first direct evidence for the in vivo function of intracellular apyrase in eukaryotic cells.	Natl Inst Biosci & Human Technol, Dept Mol Biol, Tsukuba, Ibaraki 3058566, Japan	National Institute of Advanced Industrial Science & Technology (AIST)	Jigami, Y (corresponding author), Natl Inst Biosci & Human Technol, Dept Mol Biol, 1-1 Higashi, Tsukuba, Ibaraki 3058566, Japan.	jigami@nibh.go.jp						ABEIJON C, 1993, J CELL BIOL, V122, P307, DOI 10.1083/jcb.122.2.307; Abeijon C, 1997, TRENDS BIOCHEM SCI, V22, P203, DOI 10.1016/S0968-0004(97)01053-0; BALLOU CE, 1990, METHOD ENZYMOL, V185, P440; BALLOU L, 1991, P NATL ACAD SCI USA, V88, P3209, DOI 10.1073/pnas.88.8.3209; BERNINSONE P, 1994, J BIOL CHEM, V269, P207; CAPASSO JM, 1984, P NATL ACAD SCI-BIOL, V81, P7051, DOI 10.1073/pnas.81.22.7051; Dean N, 1997, J BIOL CHEM, V272, P31908, DOI 10.1074/jbc.272.50.31908; DEAN N, 1995, P NATL ACAD SCI USA, V92, P1287, DOI 10.1073/pnas.92.5.1287; Dietrich FS, 1997, NATURE, V387, P78, DOI 10.1038/387s078; EDWARDS FA, 1993, FEBS LETT, V325, P86, DOI 10.1016/0014-5793(93)81419-Z; FANTA N, 1988, ARCH BIOL MED EXP, V21, P129; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Gentzsch M, 1996, EMBO J, V15, P5752, DOI 10.1002/j.1460-2075.1996.tb00961.x; GIROLOMONI G, 1993, J INVEST DERMATOL, V100, P282, DOI 10.1111/1523-1747.ep12469769; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P290; Handa M, 1996, BIOCHEM BIOPH RES CO, V218, P916, DOI 10.1006/bbrc.1996.0162; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HILL K, 1992, GENETICS, V130, P273; Hirschberg CB, 1997, GLYCOBIOLOGY, V7, P169, DOI 10.1093/glycob/7.2.169; HIRSCHBERG CB, 1996, TRANSPORTER NUCLEOTI, P105; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; Komoszynski M, 1996, BBA-MOL CELL RES, V1310, P233, DOI 10.1016/0167-4889(95)00135-2; KURANDA MJ, 1991, J BIOL CHEM, V266, P19758; Leberer E, 1996, MOL GEN GENET, V252, P608, DOI 10.1007/s004380050268; Lussier M, 1997, J BIOL CHEM, V272, P15527, DOI 10.1074/jbc.272.24.15527; Lussier M, 1997, GENETICS, V147, P435; MARCUS AJ, 1993, FASEB J, V7, P516, DOI 10.1096/fasebj.7.6.8472890; NAKAJIMA T, 1975, P NATL ACAD SCI USA, V72, P3912, DOI 10.1073/pnas.72.10.3912; Odani T, 1996, GLYCOBIOLOGY, V6, P805, DOI 10.1093/glycob/6.8.805; Odani T, 1997, FEBS LETT, V420, P186, DOI 10.1016/S0014-5793(97)01513-5; PLESNER L, 1995, INT REV CYTOL, V158, P141; Poster JB, 1996, J BIOL CHEM, V271, P3837; ROEMER T, 1993, MOL CELL BIOL, V13, P4039, DOI 10.1128/MCB.13.7.4039; Roy SK, 1998, J BIOL CHEM, V273, P2583, DOI 10.1074/jbc.273.5.2583; SHAILUBHAI K, 1991, J BIOL CHEM, V266, P16587; SHERMAN F, 1991, METHOD ENZYMOL, V194, P21; Shimma Y, 1997, MOL GEN GENET, V256, P469, DOI 10.1007/s004380050591; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; VERCESI AE, 1991, J BIOL CHEM, V266, P14431; Wang TF, 1998, J BIOL CHEM, V273, P11392, DOI 10.1074/jbc.273.18.11392; YANAGISAWA K, 1990, J BIOL CHEM, V265, P19351; YIP CL, 1994, P NATL ACAD SCI USA, V91, P2723, DOI 10.1073/pnas.91.7.2723	43	76	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21450	21456		10.1074/jbc.274.30.21450	http://dx.doi.org/10.1074/jbc.274.30.21450			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409709	hybrid			2022-12-25	WOS:000081613100100
J	Gonzalez, DS; Karaveg, K; Vandersall-Nairn, AS; Lal, A; Moremen, KW				Gonzalez, DS; Karaveg, K; Vandersall-Nairn, AS; Lal, A; Moremen, KW			Identification, expression, and characterization of a cDNA encoding human endoplasmic reticulum mannosidase I, the enzyme that catalyzes the first mannose trimming step in mammalian Asn-linked oligosaccharide biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROCESSING ALPHA-MANNOSIDASE; SEQUENCE-BASED CLASSIFICATION; OUTER CHAIN SYNTHESIS; GDP-L-FUCOSE; SACCHAROMYCES-CEREVISIAE; RAT-LIVER; GLYCOPROTEIN-BIOSYNTHESIS; DETERMINES EXPRESSION; EXON AMPLIFICATION; MOLECULAR-CLONING	We have isolated a full-length cDNA clone encoding a human alpha 1,2-mannosidase that catalyzes the first mannose trimming step in the processing of mammalian Asn-linked oligosaccharides. This enzyme has been proposed to regulate the timing of quality control glycoprotein degradation in the endoplasmic reticulum (ER) of eukaryotic cells. Human expressed sequence tag clones were identified by sequence similarity to mammalian and yeast oligosaccharide-processing mannosidases, and the full-length coding region of the putative mannosidase homolog was isolated by a combination of 5'-rapid amplification of cDNA ends and direct polymerase chain reaction from human placental cDNA. The open reading frame predicted a 663-amino acid type II transmembrane polypeptide with a short cytoplasmic tail (47 amino acids), a single transmembrane domain (22 amino acids), and a large COOH-terminal catalytic domain (594 amino acids). Northern blots detected a transcript of similar to 2.8 kilobase pairs that was ubiquitously expressed in human tissues. Expression of an epitope-tagged full-length form of the human mannosidase homolog in normal rat kidney cells resulted in an ER pattern of localization, When a recombinant protein, consisting of protein A fused to the COOH-terminal luminal domain of the human mannosidase homolog, was expressed in COS cells, the fusion protein was found to cleave only a single alpha 1,2-mannose residue from Man(9)GlcNAc(2) to produce a unique Man(8)GlcNAc(2) isomer (Man8B). The mannose cleavage reaction required divalent cations as indicated by inhibition with EDTA or EGTA and reversal of the inhibition by the addition of Ca2+. The enzyme was also sensitive to inhibition by deoxymannojirimycin and kifunensine, but not swainsonine. The results on the localization, substrate specificity, and inhibitor profiles indicate that the cDNA reported here encodes an enzyme previously designated ER mannosidase I. Enzyme reactions using a combination of human ER mannosidase I and recombinant Golgi mannosidase IA indicated that that these two enzymes are complementary in their cleavage of Man(9)GlcNAc(2) oligosaccharides to Man(5)GlcNAc(2).	Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA; Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Moremen, KW (corresponding author), Univ Georgia, Dept Biochem & Mol Biol, Life Sci Bldg, Athens, GA 30602 USA.	moremen@arches.uga.edu	Moremen, Kelley/AAD-4661-2019	Nairn, Alison/0000-0002-4453-7593	NCRR NIH HHS [RR05351] Funding Source: Medline; NIGMS NIH HHS [GM47533] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047533] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKINSON PH, 1984, J CELL BIOL, V98, P2245, DOI 10.1083/jcb.98.6.2245; BISCHOFF J, 1990, J BIOL CHEM, V265, P17110; BISCHOFF J, 1983, J BIOL CHEM, V258, P7907; BISCHOFF J, 1986, J BIOL CHEM, V261, P4766; BISCHOFF J, 1984, BIOCHEM BIOPH RES CO, V125, P324, DOI 10.1016/S0006-291X(84)80371-X; BISCHOFF J, 1986, J BIOL CHEM, V261, P4758; BROWN PH, 1986, J BIOL CHEM, V261, P2575; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; Burke J, 1996, EUR J CELL BIOL, V70, P298; CAMIRAND A, 1991, J BIOL CHEM, V266, P15120; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; DANIEL PF, 1994, GLYCOBIOLOGY, V4, P551, DOI 10.1093/glycob/4.5.551; Dole K, 1997, J STRUCT BIOL, V120, P69, DOI 10.1006/jsbi.1997.3903; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GODELAINE D, 1981, J BIOL CHEM, V256, P161; GRONDIN B, 1992, GLYCOBIOLOGY, V2, P369, DOI 10.1093/glycob/2.4.369; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; Henrissat B, 1998, BIOCHEM SOC T, V26, P153, DOI 10.1042/bst0260153; HERSCOVICS A, 1994, J BIOL CHEM, V269, P9864; Herscovics A, 1999, BBA-GEN SUBJECTS, V1426, P275, DOI 10.1016/S0304-4165(98)00129-9; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; HICKMAN S, 1984, J CELL BIOL, V98, P407, DOI 10.1083/jcb.98.2.407; Howard S, 1997, BIOCHEM BIOPH RES CO, V238, P896, DOI 10.1006/bbrc.1997.7148; Jakob CA, 1998, J CELL BIOL, V142, P1223, DOI 10.1083/jcb.142.5.1223; JELINEKKELLY S, 1985, J BIOL CHEM, V260, P2253; Knop M, 1996, YEAST, V12, P1229, DOI 10.1002/(SICI)1097-0061(19960930)12:12<1229::AID-YEA15>3.0.CO;2-H; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAHTINEN U, 1992, J CELL SCI, V103, P321; LAL A, 1994, J BIOL CHEM, V269, P9872; Lal A, 1998, GLYCOBIOLOGY, V8, P981, DOI 10.1093/glycob/8.10.981; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; LARSEN RD, 1989, P NATL ACAD SCI USA, V86, P8227, DOI 10.1073/pnas.86.21.8227; Liao YF, 1996, J BIOL CHEM, V271, P28348, DOI 10.1074/jbc.271.45.28348; LIPARI F, 1995, BIOCHEM BIOPH RES CO, V209, P322, DOI 10.1006/bbrc.1995.1506; Lipari F, 1999, BIOCHEMISTRY-US, V38, P1111, DOI 10.1021/bi981643i; LIPARI F, 1994, GLYCOBIOLOGY, V4, P697, DOI 10.1093/glycob/4.5.697; Lipari F, 1996, J BIOL CHEM, V271, P27615, DOI 10.1074/jbc.271.44.27615; Liu Y, 1999, J BIOL CHEM, V274, P5861, DOI 10.1074/jbc.274.9.5861; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; LOWE JB, 1991, J BIOL CHEM, V266, P17467; LUBAS WA, 1987, J BIOL CHEM, V262, P3775; LUBAS WA, 1988, J BIOL CHEM, V263, P3990; Merkle RK, 1997, BBA-GEN SUBJECTS, V1336, P132, DOI 10.1016/S0304-4165(97)00023-8; MOREMEN KW, 1991, J CELL BIOL, V115, P1521, DOI 10.1083/jcb.115.6.1521; MOREMEN KW, 1991, J BIOL CHEM, V266, P16876; MOREMEN KW, 1994, GLYCOBIOLOGY, V4, P113, DOI 10.1093/glycob/4.2.113; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PUCCIA R, 1993, BIOCHEM J, V290, P21, DOI 10.1042/bj2900021; RAJAN VP, 1989, J BIOL CHEM, V264, P11158; RIZZOLO LJ, 1988, J BIOL CHEM, V263, P9520; ROMERO PA, 1994, GLYCOBIOLOGY, V4, P135, DOI 10.1093/glycob/4.2.135; ROSENFELD MG, 1984, J CELL BIOL, V99, P1076, DOI 10.1083/jcb.99.3.1076; SANCHEZLOPEZ R, 1988, J BIOL CHEM, V263, P11892; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMID RW, 1957, ANAL CHEM, V29, P264, DOI 10.1021/ac60122a026; SCHNEIKERT J, 1995, J BIOL CHEM, V270, P17736, DOI 10.1074/jbc.270.30.17736; SCHNEIKERT J, 1994, GLYCOBIOLOGY, V4, P445, DOI 10.1093/glycob/4.4.445; SCHUTZBACH JS, 1990, J BIOL CHEM, V265, P2546; SHAPER NL, 1988, J BIOL CHEM, V263, P10420; SHOUP VA, 1976, J BIOL CHEM, V251, P3845; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vallee F, 1999, ACTA CRYSTALLOGR D, V55, P571, DOI 10.1107/S090744499801244X; Vandersall-Nairn AS, 1998, GLYCOBIOLOGY, V8, P1183, DOI 10.1093/glycob/8.12.1183; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; Weng S, 1996, GLYCOBIOLOGY, V6, P861, DOI 10.1093/glycob/6.8.861; Weng SA, 1996, ARCH BIOCHEM BIOPHYS, V325, P113, DOI 10.1006/abbi.1996.0014; WENG SA, 1993, J BIOL CHEM, V268, P25656; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; Yang M, 1998, J EXP MED, V187, P835, DOI 10.1084/jem.187.6.835; ZIEGLER F D, 1991, Glycobiology, V1, P605, DOI 10.1093/glycob/1.6.605; ZIEGLER FD, 1994, J BIOL CHEM, V269, P12527	76	118	129	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21375	21386		10.1074/jbc.274.30.21375	http://dx.doi.org/10.1074/jbc.274.30.21375			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409699	hybrid			2022-12-25	WOS:000081613100090
J	Gonzalo, S; Greentree, WK; Linder, ME				Gonzalo, S; Greentree, WK; Linder, ME			SNAP-25 is targeted to the plasma membrane through a novel membrane-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC SNARE COMPLEX; T-SNARE; PROTEIN; PALMITOYLATION; MYRISTOYLATION; IDENTIFICATION; LOCALIZATION; SUFFICIENT; EXOCYTOSIS; TRANSPORT	SNAP-25, syntaxin, and synaptobrevin are SNARE proteins that mediate fusion of synaptic vesicles with the plasma membrane. Membrane attachment of syntaxin and synaptobrevin is achieved through a C-terminal hydrophobic tail, whereas SNAP-25 association with membranes appears to depend upon palmitoylation of cysteine residues located in the center of the molecule. This process requires an intact secretory pathway and is inhibited by brefeldin A. Here we show that the minimal plasma membrane-targeting domain of SNAP-25 maps to residues 85-120, This sequence is both necessary and sufficient to target a heterologous protein to the plasma membrane. Palmitoylation of this domain is sensitive to brefeldin A, suggesting that it uses the same membrane-targeting mechanism as the full-length protein. As expected, the palmitoylated cysteine cluster is present within this domain, but surprisingly membrane anchoring requires an additional five-amino acid sequence that is highly conserved among SNAP-25 family members. Significantly, the membrane-targeting module coincides with the protease-sensitive stretch (residues 83-120) that connects the two alpha-helices that SNAP-25 contributes to the four-helix bundle of the synaptic SNARE complex. Our results demonstrate that residues 85-120 of SNAP-25 represent a protein module that is physically and functionally separable from the SNARE complex-forming domains.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Linder, ME (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave,POB 8228, St Louis, MO 63110 USA.		Linder, Maurine/AAU-9999-2021; Gonzalo, Susana/T-8275-2019	Linder, Maurine/0000-0003-2202-9712; Gonzalo, Susana/0000-0001-9631-1206	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051466] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51466] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARK IC, 1994, P NATL ACAD SCI USA, V91, P4621, DOI 10.1073/pnas.91.11.4621; BARK IC, 1993, J MOL BIOL, V233, P67, DOI 10.1006/jmbi.1993.1485; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; DEGTYAREV MY, 1994, J BIOL CHEM, V269, P30898; DiPaolo G, 1997, J BIOL CHEM, V272, P5175, DOI 10.1074/jbc.272.8.5175; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; Fasshauer D, 1998, BIOCHEMISTRY-US, V37, P10354, DOI 10.1021/bi980542h; Gonzalo S, 1998, MOL BIOL CELL, V9, P585, DOI 10.1091/mbc.9.3.585; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HESS DT, 1992, J NEUROSCI, V12, P4634; Katz L, 1998, EMBO J, V17, P6200, DOI 10.1093/emboj/17.21.6200; Koticha DK, 1999, J BIOL CHEM, V274, P9053, DOI 10.1074/jbc.274.13.9053; Lane SR, 1997, J NEUROCHEM, V69, P1864; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; LIU YC, 1993, BIOCHEMISTRY-US, V32, P10714, DOI 10.1021/bi00091a023; Morales J, 1998, MOL BIOL CELL, V9, P1, DOI 10.1091/mbc.9.1.1; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; OYLER GA, 1992, DEV BRAIN RES, V65, P133, DOI 10.1016/0165-3806(92)90172-S; Poirier MA, 1998, J BIOL CHEM, V273, P11370, DOI 10.1074/jbc.273.18.11370; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; Ravichandran V, 1996, J BIOL CHEM, V271, P13300, DOI 10.1074/jbc.271.23.13300; Rossi G, 1997, J BIOL CHEM, V272, P16610, DOI 10.1074/jbc.272.26.16610; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sambrook J., 2002, MOL CLONING LAB MANU; SHAHINIAN S, 1995, BIOCHEMISTRY-US, V34, P3813, DOI 10.1021/bi00011a039; Steegmaier M, 1998, J BIOL CHEM, V273, P34171, DOI 10.1074/jbc.273.51.34171; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Ungermann C, 1998, NATURE, V396, P543, DOI 10.1038/25069; vantHof W, 1997, J CELL BIOL, V136, P1023, DOI 10.1083/jcb.136.5.1023; Veit M, 1996, FEBS LETT, V385, P119, DOI 10.1016/0014-5793(96)00362-6; Wang GY, 1997, J CELL SCI, V110, P505; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Wolven A, 1997, MOL BIOL CELL, V8, P1159, DOI 10.1091/mbc.8.6.1159; Zlatkine P, 1997, J CELL SCI, V110, P673	36	92	95	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21313	21318		10.1074/jbc.274.30.21313	http://dx.doi.org/10.1074/jbc.274.30.21313			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409690	hybrid			2022-12-25	WOS:000081613100081
J	Han, ZS; Ip, YT				Han, ZS; Ip, YT			Interaction and specificity of Rel-related proteins in regulating Drosophila immunity gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INSECT IMMUNITY; RECEPTOR FAMILY; NUCLEAR IMPORT; HOST-DEFENSE; DORSAL; TOLL; SEQUENCE; INDUCTION; CECROPIN	NF-kappa B/Rel family proteins regulate genes that are critical for many cellular processes including apoptosis, inflammation, immune response, and development. NF-kappa B/Rel proteins function as homodimers or heterodimers, which recognize specific DNA sequences within target promoters. We examined the activity of different Drosophila Rel-related proteins in modulating Drosophila immunity genes by expressing the Rel proteins in stably transfected cell lines. We also compared how different combinations of these transcriptional regulators control the activity of various immunity genes. The results show that Rel proteins are directly involved in regulating the Drosophila antimicrobial response. Furthermore, the drosomycin and defensin expression is best induced by the Relish/Dif and the Relish/Dorsal heterodimers, respectively, whereas the attacin activity can be efficiently up-regulated by the Relish homodimer and heterodimers, These results illustrate how the formation of Rel protein dimers differentially regulate target gene expression.	Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Program Mol Med, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Ip, YT (corresponding author), Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Program Mol Med, 373 Plantat St, Worcester, MA 01605 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053269] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53269] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASLING B, 1995, INSECT BIOCHEM MOLEC, V25, P511, DOI 10.1016/0965-1748(94)00091-C; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; DIMARCQ JL, 1994, EUR J BIOCHEM, V221, P201, DOI 10.1111/j.1432-1033.1994.tb18730.x; Dushay MS, 1998, AM J HUM GENET, V62, P10, DOI 10.1086/301694; Dushay MS, 1996, P NATL ACAD SCI USA, V93, P10343, DOI 10.1073/pnas.93.19.10343; ENGSTROM Y, 1993, J MOL BIOL, V232, P327, DOI 10.1006/jmbi.1993.1392; FEHLBAUM P, 1994, J BIOL CHEM, V269, P33159; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gross I, 1996, NUCLEIC ACIDS RES, V24, P1238, DOI 10.1093/nar/24.7.1238; Han ZQS, 1998, MOL CELL BIOL, V18, P3527, DOI 10.1128/MCB.18.6.3527; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HULTMARK D, 1994, BIOCHEM BIOPH RES CO, V199, P144, DOI 10.1006/bbrc.1994.1206; HULTMARK D, 1993, TRENDS GENET, V9, P178, DOI 10.1016/0168-9525(93)90165-E; IP YT, 1994, CURR OPIN GENET DEV, V4, P672, DOI 10.1016/0959-437X(94)90133-N; IP YT, 1993, CELL, V75, P753, DOI 10.1016/0092-8674(93)90495-C; Kadalayil L, 1997, NUCLEIC ACIDS RES, V25, P1233, DOI 10.1093/nar/25.6.1233; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; KYLSTEN P, 1990, EMBO J, V9, P217, DOI 10.1002/j.1460-2075.1990.tb08098.x; LEMAITRE B, 1995, EMBO J, V14, P536, DOI 10.1002/j.1460-2075.1995.tb07029.x; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Lemaitre B, 1997, P NATL ACAD SCI USA, V94, P14614, DOI 10.1073/pnas.94.26.14614; LORD KA, 1990, ONCOGENE, V5, P1095; MARTIN GB, 1993, SCIENCE, V262, P1432, DOI 10.1126/science.7902614; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Meng XJ, 1999, GENE DEV, V13, P792, DOI 10.1101/gad.13.7.792; O'Neill LAJ, 1998, J LEUKOCYTE BIOL, V63, P650, DOI 10.1002/jlb.63.6.650; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; PETERSEN UM, 1995, EMBO J, V14, P3146, DOI 10.1002/j.1460-2075.1995.tb07317.x; REICHHART JM, 1993, CR ACAD SCI III-VIE, V316, P1218; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Shen BH, 1998, DEVELOPMENT, V125, P4719; SUN SC, 1992, EUR J BIOCHEM, V204, P885, DOI 10.1111/j.1432-1033.1992.tb16708.x; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Vulsteke V, 1993, Insect Mol Biol, V2, P195, DOI 10.1111/j.1365-2583.1994.tb00139.x; WHITHAM S, 1994, CELL, V78, P1101, DOI 10.1016/0092-8674(94)90283-6; WICKER C, 1990, J BIOL CHEM, V265, P22493; Williams MJ, 1997, EMBO J, V16, P6120, DOI 10.1093/emboj/16.20.6120; Wu LP, 1998, NATURE, V392, P93, DOI 10.1038/32195; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239	43	92	93	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21355	21361		10.1074/jbc.274.30.21355	http://dx.doi.org/10.1074/jbc.274.30.21355			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409696	hybrid, Green Published			2022-12-25	WOS:000081613100087
J	Tamura, K; Liu, HT; Takahashi, H				Tamura, K; Liu, HT; Takahashi, H			Auxin induction of cell cycle regulated activity of tobacco telomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REVERSE-TRANSCRIPTASE; ARABIDOPSIS-THALIANA; IMMORTAL CELLS; KINASE-C; PROTEIN; EXPRESSION; ACTIVATION; DIFFERENTIATION; CULTURE; PLANTS	Telomerase activity was measured at each phase of the cell cycle in synchronized tobacco (Nicotiana tabacum) BY-2 cells in suspension culture with the use of the telomeric repeat amplification protocol assay. The activity was low or undetectable at most phases of the cell cycle but showed a marked increase at early S phase. The induction of telomerase activity was not affected by the S phase blockers aphidicolin (which inhibits DNA polymerase alpha) or hydroxyurea (which inhibits ribonucleotide reductase), but it was prevented by olomoucine, an inhibitor of Cdc2/Cdk2 kinases that blocks G(1)-S cell cycle transition. These results suggest that the induction of telomerase activity is not directly coupled to DNA replication by conventional DNA polymerases, but rather is triggered by the entry of cells into S phase. Various analogs of the plant hormone auxin, including indole-3-acetic acid, alpha-naphthaleneacetic acid, and 2,3-dichlorophenoxyacetic acid, potentiated the increase in telomerase activity at early S phase; the growth-inactive analog 2,3-dichlorophenoxyacetic acid, however, had no such effect. Potentiation by indole-3-acetic acid of the induction of telomerase activity was dose dependent. Together, these data indicate that telomerase activity in tobacco cells is regulated in a cell cycle-dependent manner, and that the increase in activity at S phase is specifically inducible by auxin.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan	University of Tokyo	Takahashi, H (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.							Abel S, 1996, PLANT PHYSIOL, V111, P9, DOI 10.1104/pp.111.1.9; ABEL S, 1995, J BIOL CHEM, V270, P19093, DOI 10.1074/jbc.270.32.19093; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BLATT MR, 1994, PLANT J, V5, P55, DOI 10.1046/j.1365-313X.1994.5010055.x; Bodnar AG, 1996, EXP CELL RES, V228, P58, DOI 10.1006/excr.1996.0299; Buchkovich K J, 1996, Prog Cell Cycle Res, V2, P187; Buchkovich KJ, 1996, MOL BIOL CELL, V7, P1443, DOI 10.1091/mbc.7.9.1443; Chapon C, 1997, RNA, V3, P1337; Engelhardt M, 1997, BLOOD, V90, P182; FAJKUS J, 1995, MOL GEN GENET, V247, P633, DOI 10.1007/BF00290355; Fajkus J, 1996, FEBS LETT, V391, P307, DOI 10.1016/0014-5793(96)00757-0; Fan XQ, 1997, MOL BIOL CELL, V8, P2145, DOI 10.1091/mbc.8.11.2145; FERREIRA PCG, 1994, PLANT CELL, V6, P1763, DOI 10.1105/tpc.6.12.1763; Fitzgerald MS, 1996, P NATL ACAD SCI USA, V93, P14422, DOI 10.1073/pnas.93.25.14422; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; Heller K, 1996, MOL GEN GENET, V252, P342, DOI 10.1007/BF02173780; HERMERLY AS, 1993, PLANT CELL, V5, P1711; Hicks C, 1998, BBA-BIOMEMBRANES, V1375, P1, DOI 10.1016/S0005-2736(98)00114-X; HIRT H, 1991, P NATL ACAD SCI USA, V88, P1636, DOI 10.1073/pnas.88.5.1636; Igarashi H, 1996, BIOCHEM BIOPH RES CO, V219, P649, DOI 10.1006/bbrc.1996.0288; KILIAN A, 1995, P NATL ACAD SCI USA, V92, P9555, DOI 10.1073/pnas.92.21.9555; Killan A, 1998, PLANT MOL BIOL, V37, P621, DOI 10.1023/A:1005994629814; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kruk PA, 1997, BIOCHEM BIOPH RES CO, V233, P717, DOI 10.1006/bbrc.1997.6549; Ku WC, 1997, BIOCHEM BIOPH RES CO, V241, P730, DOI 10.1006/bbrc.1997.7874; Kunimura C, 1998, ONCOGENE, V17, P187, DOI 10.1038/sj.onc.1201916; Leyser O, 1998, CURR BIOL, V8, pR305, DOI 10.1016/S0960-9822(98)70193-9; Lingner J, 1998, CURR OPIN GENET DEV, V8, P226, DOI 10.1016/S0959-437X(98)80145-7; MANTELL LL, 1994, EMBO J, V13, P3211, DOI 10.1002/j.1460-2075.1994.tb06620.x; MARTINEZ MC, 1992, P NATL ACAD SCI USA, V89, P7360, DOI 10.1073/pnas.89.16.7360; MIAO GH, 1993, P NATL ACAD SCI USA, V90, P943, DOI 10.1073/pnas.90.3.943; Mitsui H, 1996, PLANT MOL BIOL, V30, P177, DOI 10.1007/BF00017812; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; Qian DQ, 1996, PLANT CELL, V8, P2381, DOI 10.1105/tpc.8.12.2381; Ramakrishnan S, 1998, CANCER RES, V58, P622; RICHARDS EJ, 1988, CELL, V53, P127, DOI 10.1016/0092-8674(88)90494-1; Riha K, 1998, PLANT CELL, V10, P1691, DOI 10.1105/tpc.10.10.1691; Savoysky E, 1996, BIOCHEM BIOPH RES CO, V226, P329, DOI 10.1006/bbrc.1996.1356; Sharma HW, 1995, P NATL ACAD SCI USA, V92, P12343, DOI 10.1073/pnas.92.26.12343; Shimada Y, 1997, BIOCHEM BIOPH RES CO, V232, P492, DOI 10.1006/bbrc.1997.6327; Ulaner GA, 1998, CANCER RES, V58, P4168; VANRENTERGHEM B, 1994, J BIOL CHEM, V269, P24666; Weng NP, 1996, J EXP MED, V183, P2471, DOI 10.1084/jem.183.6.2471; Weng NP, 1997, P NATL ACAD SCI USA, V94, P10827, DOI 10.1073/pnas.94.20.10827; Yamada O, 1996, BBA-MOL CELL RES, V1314, P260, DOI 10.1016/S0167-4889(96)00104-8; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601; ZHOU W, 1994, BIOCHEM BIOPH RES CO, V199, P191, DOI 10.1006/bbrc.1994.1213; Zhu XL, 1996, P NATL ACAD SCI USA, V93, P6091, DOI 10.1073/pnas.93.12.6091	49	41	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					20997	21002		10.1074/jbc.274.30.20997	http://dx.doi.org/10.1074/jbc.274.30.20997			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409648	hybrid			2022-12-25	WOS:000081613100039
J	Lu, SY; Deng, PC; Liu, XC; Luo, JX; Han, RS; Gu, XC; Liang, SP; Wang, XC; Li, F; Lozanov, V; Patthy, A; Pongor, S				Lu, SY; Deng, PC; Liu, XC; Luo, JX; Han, RS; Gu, XC; Liang, SP; Wang, XC; Li, F; Lozanov, V; Patthy, A; Pongor, S			Solution structure of the major alpha-amylase inhibitor of the crop plant amaranth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OMEGA-CONOTOXIN GVIA; AMINO-ACID-SEQUENCE; NUCLEAR-MAGNETIC-RESONANCE; SPIDER SELENOCOSMIA-HUWENA; INDIAN FINGER MILLET; REESEI CELLOBIOHYDROLASE-I; ELEUSINE-CORACANA GAERTN; TRICHODERMA-REESEI; HUWENTOXIN-I; TRYPSIN-INHIBITOR	alpha-Amylase inhibitor (AAI), a 32-residue miniprotein from the Mexican crop plant amaranth (Amaranthus hypochondriacus), is the smallest known alpha-amylase inhibitor and is specific for insect alpha-amylases (Chagolla-Lopez, A., Blanco Labra, A., Patthy, A., Sanchez, R., and Pongor, S, (1994) J. Biol. Chem. 269, 23675-23680), Its disulfide topology was confirmed by Edman degradation, and its three-dimensional solution structure was determined:by two-dimensional H-1 NMR spectroscopy at 500 MHz, Structural constraints (consisting of 348 nuclear Overhauser effect interproton distances, 8 backbone dihedral constraints, and 9 disulfide distance constraints) were used as an input to the X-PLOR program for simulated annealing and energy minimization calculations, The final set of 10 structures had a mean pairwise root mean square deviation of 0.32 Angstrom for the backbone atoms and 1.04 Angstrom for all heavy atoms. The structure of AAI consists of a short triple-stranded beta-sheet stabilized by three disulfide bonds, forming a typical knottin or inhibitor cystine knot fold found in miniproteins, which binds various macromolecular ligands, When the first intercystine segment of AAI (sequence IPKWNR) was inserted into a homologous position of the spider toxin Huwentoxin I, the resulting chimera showed a significant inhibitory activity, suggesting that this segment takes part in enzyme binding.	Peking Univ, Beijing 100871, Peoples R China; Cathay Biotech Co, Beijing 10080, Peoples R China; Hunan Normal Univ, Changsha, Peoples R China; Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; Agr Biotechnol Ctr, H-2102 Godollo, Hungary	Peking University; Hunan Normal University; International Center for Genetic Engineering & Biotechnology (ICGEB)	Gu, XC (corresponding author), Peking Univ, Beijing 100871, Peoples R China.		Li, Feng/F-2256-2010; Li, Feng/J-1678-2019	Li, Feng/0000-0002-5819-734X; Lozanov, Valentin/0000-0003-0465-3714				BARBOSA PJB, 1999, IN PRESS STRUCTURE; BERNFELD P, 1955, METHOD ENZYMOL, V1, P149, DOI 10.1016/0076-6879(55)01021-5; BLOCH C, 1991, FEBS LETT, V279, P101, DOI 10.1016/0014-5793(91)80261-Z; BODE W, 1989, FEBS LETT, V242, P285, DOI 10.1016/0014-5793(89)80486-7; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CAMPOS FAP, 1984, FEBS LETT, V167, P221, DOI 10.1016/0014-5793(84)80130-1; CAMPOS FAP, 1983, FEBS LETT, V152, P300, DOI 10.1016/0014-5793(83)80400-1; CHANG JY, 1994, J BIOL CHEM, V269, P22087; CHICHE L, 1989, PROTEINS, V6, P405, DOI 10.1002/prot.340060407; DAVIS JH, 1993, BIOCHEMISTRY-US, V32, P7396, DOI 10.1021/bi00080a009; Drakopoulou E, 1996, J BIOL CHEM, V271, P11979, DOI 10.1074/jbc.271.20.11979; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; IVENGAR RB, 1979, EUR J BIOCHEM, V96, P193; KIM JI, 1994, J BIOL CHEM, V269, P23876; KRAULIS PJ, 1989, BIOCHEMISTRY-US, V28, P7241, DOI 10.1021/bi00444a016; KURIHARA Y, 1992, CRIT REV FOOD SCI, V32, P231, DOI 10.1080/10408399209527598; LAMPE RA, 1993, BIOCHEMISTRY-US, V32, P3255, DOI 10.1021/bi00064a007; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LENGUYEN D, 1990, BIOCHIMIE, V72, P431, DOI 10.1016/0300-9084(90)90067-Q; Liang SP, 1997, SCI CHINA SER C, V40, P449, DOI 10.1007/BF03183581; LINDER M, 1995, PROTEIN SCI, V4, P1056, DOI 10.1002/pro.5560040604; LIS H, 1986, ANNU REV BIOCHEM, V55, P33; Lozanov V, 1997, J PEPT RES, V50, P65; MAEDA K, 1986, BIOCHIM BIOPHYS ACTA, V871, P250, DOI 10.1016/0167-4838(86)90206-2; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MORENO J, 1989, P NATL ACAD SCI USA, V86, P7885, DOI 10.1073/pnas.86.20.7885; NISHIUCHI Y, 1986, BIOPOLYMERS, V25, P61; OHTSUBO KI, 1992, FEBS LETT, V309, P68, DOI 10.1016/0014-5793(92)80741-X; OLMEDO FG, 1989, OXF SURV PLANT MOL C, V6, P31; PALLAGHY PK, 1994, PROTEIN SCI, V3, P1833, DOI 10.1002/pro.5560031022; PARK CS, 1992, BIOCHEMISTRY-US, V31, P7749, DOI 10.1021/bi00149a002; PIERPOINT WS, 1987, PHYSIOL MOL PLANT P, V31, P291, DOI 10.1016/0885-5765(87)90072-5; QU YX, 1995, J PROTEIN CHEM, V14, P549, DOI 10.1007/BF01886881; Qu YX, 1997, J PROTEIN CHEM, V16, P565, DOI 10.1023/A:1026314722607; REINIKAINEN T, 1992, PROTEINS, V14, P475, DOI 10.1002/prot.340140408; REINIKAINEN T, 1995, PROTEINS, V22, P392, DOI 10.1002/prot.340220409; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RICHARDSON M, 1987, NATURE, V327, P432, DOI 10.1038/327432a0; RICHARDSON M, 1990, METHODS PLANT BIOCH, V5, P261; RYAN CA, 1989, BIOESSAYS, V10, P20, DOI 10.1002/bies.950100106; SATO K, 1993, BIOCHEM BIOPH RES CO, V194, P1292, DOI 10.1006/bbrc.1993.1964; SINGH NK, 1989, PLANT PHYSIOL, V90, P1096, DOI 10.1104/pp.90.3.1096; Smith GP, 1998, J MOL BIOL, V277, P317, DOI 10.1006/jmbi.1997.1621; SVENSSON B, 1986, CARLSBERG RES COMMUN, V51, P493, DOI 10.1007/BF02906891; Vita C, 1998, BIOPOLYMERS, V47, P93, DOI 10.1002/(SICI)1097-0282(1998)47:1<93::AID-BIP10>3.3.CO;2-B; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479; Wuthrich K, 1986, NMR PROTEINS NUCL AC; YU HT, 1993, BIOCHEMISTRY-US, V32, P13123, DOI 10.1021/bi00211a022; ZHANG DG, 1993, J PROTEIN CHEM, V12, P735, DOI 10.1007/BF01024931	49	32	38	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20473	20478		10.1074/jbc.274.29.20473	http://dx.doi.org/10.1074/jbc.274.29.20473			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400675	hybrid			2022-12-25	WOS:000081438300068
J	Russell, LC; Whitt, SR; Chen, MS; Chinkers, M				Russell, LC; Whitt, SR; Chen, MS; Chinkers, M			Identification of conserved residues required for the binding of a tetratricopeptide repeat domain to heat shock protein 90	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; SERINE/THREONINE PHOSPHATASE; HSP90; RECEPTOR; TPR; CHAPERONES; INTERACTS; FAMILY; IMMUNOPHILIN; ACTIVATION	The sequential binding of heat shock protein 90 (hsp90) to a series of tetratricopeptide repeat (TPR) proteins is critical to its function as a molecular chaperone. We have used site-directed mutagenesis to clarify the structural basis for the binding of hsp90 to the TPR domain of phosphoprotein phosphatase 5 (PP5). This TPR domain was chosen for study because its three-dimensional structure is known. We examined co-immunoprecipitation of hsp90 with wild type and mutant TPR constructs from transfected cells. Only mutations located on one face of the TPR domain affected hsp90 binding. This allowed the identification of a binding groove. Three basic residues that are highly conserved in hsp90-binding TPR proteins extend prominently into this groove. Lys-97 and Arg-101 were absolutely required for hsp90 binding, while mutation of Arg-74 diminished, but did not abrogate, hsp90 binding. Mutation of Lys-32, another conserved basic residue in the binding groove, also blocked hsp90 binding. The TPR domain of PP5 bound specifically to a 12-kDa C-terminal fragment of hsp90. This binding was reduced by mutation of acidic residues in the hsp90 fragment. These data suggest conservation, among hsp90-binding TPR proteins, of a binding groove containing basic residues that interact with acidic residues near the C terminus of hsp90.	Univ S Alabama, Dept Pharmacol, Mobile, AL 36688 USA	University of South Alabama	Chinkers, M (corresponding author), Univ S Alabama, Dept Pharmacol, Mobile, AL 36688 USA.	michaelc@jaguar1.usouthal.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047063] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055877] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 47063] Funding Source: Medline; NIDDK NIH HHS [DK 55877] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BECKER W, 1994, J BIOL CHEM, V269, P22586; Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; Callahan MA, 1998, J VIROL, V72, P5189, DOI 10.1128/JVI.72.6.5189-5197.1998; Carrello A, 1999, J BIOL CHEM, V274, P2682, DOI 10.1074/jbc.274.5.2682; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; Chen CF, 1996, MOL CELL BIOL, V16, P4691; Chen MS, 1996, J BIOL CHEM, V271, P32315, DOI 10.1074/jbc.271.50.32315; CHEN MX, 1994, EMBO J, V13, P4278, DOI 10.1002/j.1460-2075.1994.tb06748.x; Chen MX, 1997, FEBS LETT, V400, P136, DOI 10.1016/S0014-5793(96)01427-5; Chen SY, 1998, CELL STRESS CHAPERON, V3, P118, DOI 10.1379/1466-1268(1998)003<0118:DIOPAT>2.3.CO;2; CHINKERS M, 1994, P NATL ACAD SCI USA, V91, P11075, DOI 10.1073/pnas.91.23.11075; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; Cziepluch C, 1998, J VIROL, V72, P4149, DOI 10.1128/JVI.72.5.4149-4156.1998; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; Dolinski KJ, 1998, MOL CELL BIOL, V18, P7344, DOI 10.1128/MCB.18.12.7344; Duina AA, 1998, J BIOL CHEM, V273, P10819, DOI 10.1074/jbc.273.18.10819; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; Frydman J, 1997, TRENDS BIOCHEM SCI, V22, P87, DOI 10.1016/S0968-0004(97)01005-0; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; HIRANO T, 1990, CELL, V60, P319, DOI 10.1016/0092-8674(90)90746-2; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; Marsh JA, 1998, MOL CELL BIOL, V18, P7353, DOI 10.1128/MCB.18.12.7353; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Pratt WB, 1998, P SOC EXP BIOL MED, V217, P420; Prodromou C, 1999, EMBO J, V18, P754, DOI 10.1093/emboj/18.3.754; Reynolds PD, 1999, J CLIN ENDOCR METAB, V84, P663, DOI 10.1210/jc.84.2.663; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; Scheibel T, 1998, BIOCHEM PHARMACOL, V56, P675, DOI 10.1016/S0006-2952(98)00120-8; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; Silverstein AM, 1997, J BIOL CHEM, V272, P16224, DOI 10.1074/jbc.272.26.16224; Smith DF, 1998, PHARMACOL REV, V50, P493; Whitesell L, 1998, MOL CELL BIOL, V18, P1517, DOI 10.1128/MCB.18.3.1517; Young JC, 1997, FEBS LETT, V418, P139, DOI 10.1016/S0014-5793(97)01363-X; Young JC, 1998, J BIOL CHEM, V273, P18007, DOI 10.1074/jbc.273.29.18007	36	138	142	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20060	20063		10.1074/jbc.274.29.20060	http://dx.doi.org/10.1074/jbc.274.29.20060			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400612	hybrid			2022-12-25	WOS:000081438300005
J	Cho, MC; Rapacciuolo, A; Koch, WJ; Kobayashi, Y; Jones, LR; Rockman, HA				Cho, MC; Rapacciuolo, A; Koch, WJ; Kobayashi, Y; Jones, LR; Rockman, HA			Defective beta-adrenergic receptor signaling precedes the development of dilated cardiomyopathy in transgenic mice with calsequestrin overexpression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC-SPECIFIC OVEREXPRESSION; FAILING HUMAN HEART; SARCOPLASMIC-RETICULUM; HYPERTROPHY; FAILURE; EXPRESSION; KINASE; INHIBITOR; ALPHA	Calsequestrin is a high capacity Ca2+-binding protein in the junctional sarcoplasmic reticulum that forms a quaternary complex with junctin, triadin, and the ryanodine receptor. Transgenic mice with cardiac-targeted calsequestrin overexpression show marked suppression of Ca2+-induced Ca2+ release, myocyte hypertrophy, and premature death by 16 weeks of age (Jones, L. R., Suzuki, Y. J., Wang, W., Kobayashi, Y. M., Ramesh, V., Franzini-Armstrong, C., Cleemann, L., and Morad, M. (1998) J, Clin. Invest. 101, 1385-1393), To investigate whether alterations in intracellular Ca2+ trigger changes in the beta-adrenergic receptor pathway, we studied calsequestrin overexpressing transgenic mice at 7 and 14 weeks of age. As assessed by echocardiography, calsequestrin mice at 7 weeks showed mild left ventricular enlargement, mild decreased fractional shortening with increased wall thickness. By 14 weeks, the phenotype progressed to marked left ventricular enlargement and severely depressed systolic function. Cardiac catheterization in calsequestrin mice revealed markedly impaired beta-adrenergic receptor responsiveness in both 7- and 14- week mice. Biochemical analysis in 7- and 14-week mice showed a significant decrease in total beta-adrenergic receptor density, adenylyl cyclase activity, and the percent high affinity agonist binding, which was associated with increased beta-adrenergic receptor kinase 1 levels. Taken together, these data indicate that alterations in beta-adrenergic receptor signaling precede the development of overt heart failure in this mouse model of progressive cardiomyopathy.	Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Duke Univ, Dept Surg, Durham, NC 27710 USA; Indiana Univ, Sch Med, Krannert Inst Cardiol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA	University of North Carolina; University of North Carolina Chapel Hill; Duke University; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Rockman, HA (corresponding author), Duke Univ, Med Ctr, Dept Med, Box 3104, Durham, NC 27710 USA.	rockm001@mc.duke.edu	Rapacciuolo, Antonio/AAR-8012-2020	Rapacciuolo, Antonio/0000-0002-4739-7004	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028556, R01HL056687] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56687, HL03041, HL28556] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; Bristow MR, 1998, LANCET, V352, P8; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; Cho MC, 1999, CIRCULATION, V99, P2702, DOI 10.1161/01.CIR.99.20.2702; Choi DJ, 1997, J BIOL CHEM, V272, P17223, DOI 10.1074/jbc.272.27.17223; Eichhorn EJ, 1996, CIRCULATION, V94, P2285, DOI 10.1161/01.CIR.94.9.2285; Fentzke RC, 1998, J CLIN INVEST, V101, P2415, DOI 10.1172/JCI2950; Force T, 1998, HYPERTENSION, V31, P152, DOI 10.1161/01.HYP.31.1.152; Gomez AM, 1997, SCIENCE, V276, P800, DOI 10.1126/science.276.5313.800; GROSSMAN W, 1975, J CLIN INVEST, V56, P56, DOI 10.1172/JCI108079; Jones LR, 1998, J CLIN INVEST, V101, P1385, DOI 10.1172/JCI1362; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; Kubota T, 1997, CIRC RES, V81, P627, DOI 10.1161/01.RES.81.4.627; Lorell BH, 1997, CIRCULATION, V96, P3824; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Phillips RM, 1998, CARDIOVASC RES, V37, P346, DOI 10.1016/S0008-6363(97)00260-5; Rockman HA, 1998, P NATL ACAD SCI USA, V95, P7000, DOI 10.1073/pnas.95.12.7000; ROCKMAN HA, 1991, P NATL ACAD SCI USA, V88, P8277, DOI 10.1073/pnas.88.18.8277; Sakata Y, 1998, CIRCULATION, V97, P1488; Sato Y, 1998, J BIOL CHEM, V273, P28470, DOI 10.1074/jbc.273.43.28470; UNGERER M, 1993, CIRCULATION, V87, P454, DOI 10.1161/01.CIR.87.2.454; UNGERER M, 1994, CIRC RES, V74, P206, DOI 10.1161/01.RES.74.2.206; Wakasaki H, 1997, P NATL ACAD SCI USA, V94, P9320, DOI 10.1073/pnas.94.17.9320; Zhang L, 1997, J BIOL CHEM, V272, P23389, DOI 10.1074/jbc.272.37.23389	25	101	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22251	22256		10.1074/jbc.274.32.22251	http://dx.doi.org/10.1074/jbc.274.32.22251			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428792	Green Published, hybrid			2022-12-25	WOS:000081868400022
J	Yoshida, M; Meksuriyen, D; Kashiwagi, K; Kawai, G; Igarashi, K				Yoshida, M; Meksuriyen, D; Kashiwagi, K; Kawai, G; Igarashi, K			Polyamine stimulation of the synthesis of oligopeptide-binding protein (OppA) - Involvement of a structural change of the Shine-Dalgarno sequence and the initiation codon AUG in OppA mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							30-S RIBOSOMAL-SUBUNITS; TRANSFER-RNA FORMATION; ESCHERICHIA-COLI; MESSENGER-RNA; RAT-LIVER; TRANSLATION INITIATION; BOVINE LYMPHOCYTES; METHYLATION; SPERMINE; REGION	We previously suggested that the degree of polyamine stimulation of oligopeptide-binding protein (OppA) synthesis is dependent on the secondary structure and position of the Shine-Dalgarno (SD) sequence of OppA mRNA. To study the structural change of OppA mRNA induced by polyamines and polyamine stimulation of initiation complex formation, four different 130-mer OppA mRNAs containing the initiation region were synthesized in vitro. The structural change of these mRNAs induced by polyamines was examined by measuring their sensitivity to RNase T-1, specific for single-stranded RNA, and RNase V-1, which recognizes double-stranded or stacked RNA. In parallel, the effect of spermidine on mRNA-dependent fMet-tRNA binding to ribosomes was examined. Our results indicate that the secondary structure of the SD sequence and initiation codon AUG is important for the efficiency of initiation complex formation and that spermidine relaxes the structure of the SD sequence and the initiation codon AUG. The existence of a GC-rich double-stranded region close to the SD sequence is important for spermidine stimulation of fMet-tRNA binding to ribosomes, Spermidine apparently binds to this GC-rich stem and causes a structural change of the SD sequence and the initiation codon, facilitating an interaction with 30 S ribosomal subunits.	Chiba Univ, Fac Pharmaceut Sci, Inage Ku, Chiba 2638522, Japan; Chiba Inst Technol, Fac Engn, Dept Ind Chem, Narashino, Chiba 2758588, Japan	Chiba University; Chiba Institute of Technology	Igarashi, K (corresponding author), Chiba Univ, Fac Pharmaceut Sci, Inage Ku, Yayoi Cho 1-33, Chiba 2638522, Japan.	iga16077@p.chiba-u.ac.jp		Igarashi, Kazuei/0000-0003-3751-3187				CALOGERO RA, 1988, P NATL ACAD SCI USA, V85, P6427, DOI 10.1073/pnas.85.17.6427; Cohen S A, 1998, Guttmacher Rep Public Policy, V1, P1; DONISKELLER H, 1977, NUCLEIC ACIDS RES, V4, P2527, DOI 10.1093/nar/4.8.2527; ECHANDI G, 1975, BIOCHEM BIOPH RES CO, V67, P1185, DOI 10.1016/0006-291X(75)90798-6; EHRESMANN C, 1987, NUCLEIC ACIDS RES, V15, P9109, DOI 10.1093/nar/15.22.9109; FAVAUDON V, 1976, BIOCHEMISTRY-US, V15, P3903, DOI 10.1021/bi00663a001; HARTZ D, 1991, J MOL BIOL, V218, P83, DOI 10.1016/0022-2836(91)90875-7; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IGARASHI K, 1981, EUR J BIOCHEM, V113, P587, DOI 10.1111/j.1432-1033.1981.tb05103.x; IGARASHI K, 1984, CANCER RES, V44, P5332; Igarashi K, 1997, J BIOL CHEM, V272, P4058, DOI 10.1074/jbc.272.7.4058; IGARASHI K, 1979, EUR J BIOCHEM, V93, P345, DOI 10.1111/j.1432-1033.1979.tb12829.x; IGARASHI K, 1978, EUR J BIOCHEM, V82, P301, DOI 10.1111/j.1432-1033.1978.tb12024.x; ITO K, 1990, J BIOL CHEM, V265, P13036; KASHIWAGI K, 1990, J BIOL CHEM, V265, P8387; MITSUI K, 1984, BIOCHEMISTRY-US, V23, P2679, DOI 10.1021/bi00307a022; MIYAMOTO S, 1993, ARCH BIOCHEM BIOPHYS, V300, P63, DOI 10.1006/abbi.1993.1009; OGASAWARA T, 1989, J BIOCHEM-TOKYO, V105, P164, DOI 10.1093/oxfordjournals.jbchem.a122633; PENG ZH, 1990, ARCH BIOCHEM BIOPHYS, V279, P138, DOI 10.1016/0003-9861(90)90473-C; QUIGLEY GJ, 1978, P NATL ACAD SCI USA, V75, P64, DOI 10.1073/pnas.75.1.64; ROSANO CL, 1977, J BIOL CHEM, V252, P652; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TURNER DH, 1988, ANNU REV BIOPHYS BIO, V17, P167; WATANABE S, 1991, J BIOL CHEM, V266, P20803; WATANABE Y, 1981, BIOCHIM BIOPHYS ACTA, V656, P134, DOI 10.1016/0005-2787(81)90078-2; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	27	58	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22723	22728		10.1074/jbc.274.32.22723	http://dx.doi.org/10.1074/jbc.274.32.22723			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428855	hybrid			2022-12-25	WOS:000081868400085
J	Kooby, DA; Carew, JF; Halterman, MW; Mack, JE; Bertino, JR; Blumgart, LH; Federoff, HJ; Fong, YM				Kooby, DA; Carew, JF; Halterman, MW; Mack, JE; Bertino, JR; Blumgart, LH; Federoff, HJ; Fong, YM			Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207)	FASEB JOURNAL			English	Article						attenuated virus; gene therapy; hepatobiliary tumors; replication; competent	RIBONUCLEOTIDE REDUCTASE; COLONIC-CARCINOMA; THYMIDINE KINASE; DELETION MUTANT; INVIVO BEHAVIOR; DNA-SYNTHESIS; GENE-THERAPY; REPLICATION; CELLS; GROWTH	G207 is a multi-mutated, replication-competent type-1 herpes simplex virus designed to target, infect, and lyse neurological tumors. This study examines the feasibility of using G207 in the treatment of human colorectal cancer and defines the biological determinants of its antitumor efficacy. This virus was tested on five human colorectal cancer cell lines in vitro to determine efficacy of infection and tumor cell kill. These results were correlated to measures of tumor cell proliferation. In vivo testing was performed through direct injections of G207 into xenografts of human colorectal cancer tumors grown in flanks of athymic rats. To evaluate an alternate method of administration, hepatic portal vein infusion of G207 was performed in a syngeneic model of liver metastases in Buffalo rats. Among the five cell lines tested, infection rates ranged between 10% and 90%, which correlated directly with S-phase fraction (8.6%-36.6%) and was proportional to response to G207 therapy in vitro (1%-93%). Direct injection of G207 into nude rat flank tumors suppressed tumor growth significantly vs. control (0.58 +/- 0.60 cm(3) vs. 9.16 +/- 3.70 cm(3), P<0. 0001). In vivo tumor suppression correlated with in vitro effect. In the syngeneic liver tumor model, portal infusion resulted in significant reduction in number of liver nodules (13 +/- 10 nodules in G207-treated livers vs. 80 +/- 30 nodules in control livers, P<0.05). G207 infects and kills human colorectal cancer cells efficiently. In vitro cytotoxicity assay and tumor S-phase fraction can be used to predict response to treatment in vivo. This antineoplastic agent can be delivered effectively by both direct tumor injection and regional vascular infusion. G207 should be investigated further as therapy for colorectal cancer and liver metastases.	Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Mol Pharmacol, New York, NY 10021 USA; Univ Rochester, Med Ctr, Dept Microbiol & Immunol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Neurosci, Rochester, NY 14642 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Rochester; University of Rochester	Fong, YM (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Surg, 1275 York Ave, New York, NY 10021 USA.	fongy@mskcc.org			NCI NIH HHS [T32 CA 09685, T32 CA 09501, CA 76416] Funding Source: Medline; NIMH NIH HHS [F30 MH012305, F30 MH012305-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009685, T32CA009501] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [F30MH012305] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Advani SJ, 1998, GENE THER, V5, P160, DOI 10.1038/sj.gt.3300546; AUGUST DA, 1984, CANCER METAST REV, V3, P303, DOI 10.1007/BF00051457; Carroll NM, 1996, ANN SURG, V224, P323, DOI 10.1097/00000658-199609000-00008; CARUSO M, 1993, P NATL ACAD SCI USA, V90, P7024, DOI 10.1073/pnas.90.15.7024; CHEN SH, 1995, P NATL ACAD SCI USA, V92, P2577, DOI 10.1073/pnas.92.7.2577; CHOU J, 1990, SCIENCE, V250, P1262, DOI 10.1126/science.2173860; CHOU J, 1992, P NATL ACAD SCI USA, V89, P3266, DOI 10.1073/pnas.89.8.3266; DEBRAUW LM, 1987, J SURG ONCOL, V34, P81, DOI 10.1002/jso.2930340204; Fong Y, 1996, SEMIN SURG ONCOL, V12, P219, DOI 10.1002/(SICI)1098-2388(199607/08)12:4<219::AID-SSU3>3.0.CO;2-8; Fong YM, 1997, J CLIN ONCOL, V15, P938, DOI 10.1200/JCO.1997.15.3.938; GELLER AI, 1988, SCIENCE, V241, P1667, DOI 10.1126/science.2843986; GOLDSTEIN DJ, 1988, J VIROL, V62, P2970, DOI 10.1128/JVI.62.8.2970-2977.1988; GOLDSTEIN DJ, 1988, VIROLOGY, V166, P41, DOI 10.1016/0042-6822(88)90144-4; GOLDSTEIN DJ, 1988, J VIROL, V62, P196, DOI 10.1128/JVI.62.1.196-205.1988; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; JACOBSON JG, 1989, VIROLOGY, V173, P276, DOI 10.1016/0042-6822(89)90244-4; JIA WWG, 1994, J NATL CANCER I, V86, P1209, DOI 10.1093/jnci/86.16.1209; Karpoff HM, 1997, J CLIN INVEST, V99, P799, DOI 10.1172/JCI119226; KENNEY S, 1994, J NATL CANCER I, V86, P1185, DOI 10.1093/jnci/86.16.1185; Kucharczuk JC, 1997, CANCER RES, V57, P466; LAFRENIERE R, 1986, J NATL CANCER I, V76, P309; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; Luoh SM, 1997, J MOL ENDOCRINOL, V18, P77, DOI 10.1677/jme.0.0180077; MEIGNIER B, 1990, J INFECT DIS, V162, P313, DOI 10.1093/infdis/162.2.313; MEIGNIER B, 1988, J INFECT DIS, V158, P602, DOI 10.1093/infdis/158.3.602; MINETA T, 1995, NAT MED, V1, P938, DOI 10.1038/nm0995-938; Miyatake SI, 1997, CANCER GENE THER, V4, P222; PANIS Y, 1992, BRIT J SURG, V79, P221, DOI 10.1002/bjs.1800790309; Roizman B, 1996, P NATL ACAD SCI USA, V93, P11307, DOI 10.1073/pnas.93.21.11307; Roizman B, 1997, J NEUROVIROL, V3, pS1; Toda M, 1998, HUM GENE THER, V9, P2177, DOI 10.1089/hum.1998.9.15-2177; Toda M, 1998, J IMMUNOL, V160, P4457; Tung C, 1996, HUM GENE THER, V7, P2217, DOI 10.1089/hum.1996.7.18-2217; WEISS L, 1986, J PATHOL, V150, P195, DOI 10.1002/path.1711500308; Whitley RJ, 1998, CLIN INFECT DIS, V26, P541, DOI 10.1086/514600; WILLETT CG, 1984, ANN SURG, V200, P685, DOI 10.1097/00000658-198412000-00001; Wood C B, 1976, Clin Oncol, V2, P285; YAZAKI T, 1995, CANCER RES, V55, P4752	38	151	153	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1999	13	11					1325	1334		10.1096/fasebj.13.11.1325	http://dx.doi.org/10.1096/fasebj.13.11.1325			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	226KL	10428757				2022-12-25	WOS:000082019100005
J	Jordan, DB; Bacot, KO; Carlson, TJ; Kessel, M; Viitanen, PV				Jordan, DB; Bacot, KO; Carlson, TJ; Kessel, M; Viitanen, PV			Plant riboflavin biosynthesis - Cloning, chloroplast localization expression, purification, and partial characterization of spinach lumazine synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE ANALYSIS; GTP CYCLOHYDROLASE-II; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; CLONED DNA; GENE; SUBUNIT; INTEGRATION; RESOLUTION	Lumazine synthase, which catalyzes the penultimate step of riboflavin biosynthesis, has been cloned from three higher plants (spinach, tobacco, and arabidopsis) through functional complementation of an Escherichia coli auxotroph. Whereas the three plant proteins exhibit some structural similarities to known microbial homologs, they uniquely possess N-terminal polypeptide extensions that resemble typical chloroplast transit peptides. In vitro protein import assays with intact chloroplasts and immunolocalization experiments verify that higher plant lumazine synthase is synthesized in the cytosol as a larger molecular weight precursor protein, which is post-translationally imported into chloroplasts where it is proteolytically cleaved to its mature size. The authentic spinach enzyme is estimated to constitute <0.02% of the total chloroplast protein. Recombinant "mature" spinach lumazine synthase is expressed in E. coli at levels exceeding 30% of the total soluble protein and is readily purified to homogeneity using a simple two-step procedure. Apparent V-max and K-m values obtained with the purified plant protein are similar to those reported for microbial lumazine synthases. Electron microscopy and hydrodynamic studies reveal that native plant lumazine synthase is a hollow capsid-like structure comprised of 60 identical 16.5-kDa subunits, resembling its icosahedral counterparts in E. coli and Bacillus subtilis.	Dupont Co, Life Sci, Expt Stn, Wilmington, DE 19880 USA; Dupont Co, Agr Prod, Stine Haskell Res Ctr, Newark, DE 19714 USA; Dupont Co, Agr Prod, Expt Stn, Wilmington, DE 19880 USA; NIH, Struct Biol Lab, Bethesda, MD 20892 USA	DuPont; DuPont; DuPont; National Institutes of Health (NIH) - USA	Viitanen, PV (corresponding author), Dupont Co, Life Sci, Expt Stn, Wilmington, DE 19880 USA.							BACHER A, 1980, J BIOL CHEM, V255, P632; Bacher A, 1996, BIOCHEM SOC T, V24, P89, DOI 10.1042/bst0240089; Bacher A., 1991, CHEM BIOCH FLAVOPROT, P215; BALBAS P, 1993, GENE, V136, P211, DOI 10.1016/0378-1119(93)90466-G; Balbas P, 1996, GENE, V172, P65, DOI 10.1016/0378-1119(96)00028-5; CAMPBELL JL, 1978, P NATL ACAD SCI USA, V75, P2276, DOI 10.1073/pnas.75.5.2276; CLINE K, 1985, J BIOL CHEM, V260, P3691; COHEN EJ, 1943, PROTEINS AMINO ACIDS, P374; DICKSON R, 1994, J BIOL CHEM, V269, P26858; FULLER TE, 1995, J BACTERIOL, V177, P7265, DOI 10.1128/jb.177.24.7265-7270.1995; GARCIARAMIREZ JJ, 1995, J BIOL CHEM, V270, P23801, DOI 10.1074/jbc.270.40.23801; GAVEL Y, 1990, FEBS LETT, V261, P455, DOI 10.1016/0014-5793(90)80614-O; Goldbaum FA, 1998, J STRUCT BIOL, V123, P175, DOI 10.1006/jsbi.1998.4022; HARVEY RA, 1966, J BIOL CHEM, V241, P2120; KIS K, 1995, J BIOL CHEM, V270, P16788, DOI 10.1074/jbc.270.28.16788; KOBAYASHI M, 1995, GENE, V160, P303, DOI 10.1016/0378-1119(95)00246-3; LADENSTEIN R, 1988, J MOL BIOL, V203, P1045, DOI 10.1016/0022-2836(88)90128-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CY, 1994, J BACTERIOL, V176, P2100, DOI 10.1128/jb.176.7.2100-2104.1994; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAZUR BJ, 1985, NUCLEIC ACIDS RES, V13, P2373, DOI 10.1093/nar/13.7.2373; Miller JH, 1972, EXPT MOL GENETICS, P201; MIRONOV VN, 1989, DOKL AKAD NAUK SSSR+, V305, P482; MITSUDA H, 1971, METHOD ENZYMOL, V18, P539; MOODY MF, 1981, J MOL BIOL, V150, P217, DOI 10.1016/0022-2836(81)90450-2; Mortl S, 1996, J BIOL CHEM, V271, P33201, DOI 10.1074/jbc.271.52.33201; Ochman H., 1990, PCR PROTOCOLS GUIDE, P219; Plaut GWE, 1971, METHODS ENZYMOL B, V18, P515; RICHTER G, 1993, J BACTERIOL, V175, P4045, DOI 10.1128/JB.175.13.4045-4051.1993; RICHTER G, 1992, J BACTERIOL, V174, P4050, DOI 10.1128/jb.174.12.4050-4056.1992; RITSERT K, 1995, J MOL BIOL, V253, P151, DOI 10.1006/jmbi.1995.0542; SANTOS MA, 1995, J BIOL CHEM, V270, P437, DOI 10.1074/jbc.270.1.437; SCHOTT K, 1990, J BIOL CHEM, V265, P4204; TAURA T, 1992, MOL GEN GENET, V234, P429, DOI 10.1007/BF00538702; VIITANEN PV, 1988, J BIOL CHEM, V263, P15000; WYMAN AR, 1985, P NATL ACAD SCI USA, V82, P2880, DOI 10.1073/pnas.82.9.2880	36	57	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					22114	22121		10.1074/jbc.274.31.22114	http://dx.doi.org/10.1074/jbc.274.31.22114			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419541	hybrid			2022-12-25	WOS:000081721100094
J	Shao, RP; Hu, MCT; Zhou, BHP; Lin, SY; Chiao, PJ; von Lindern, RH; Spohn, B; Hung, MC				Shao, RP; Hu, MCT; Zhou, BHP; Lin, SY; Chiao, PJ; von Lindern, RH; Spohn, B; Hung, MC			E1A sensitizes cells to tumor necrosis factor-induced apoptosis through inhibition of I kappa B kinases and nuclear factor kappa B activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER; SUPPRESSION; ACTIVATION; ALPHA; INDUCTION	The adenovirus E1A protein has been implicated in increasing cellular susceptibility to apoptosis induced by tumor necrosis factor (TNF); however, its mechanism of action is still unknown. Since activation of nuclear factor kappa B (NF-kappa B) has been shown to play an anti-apoptotic role in TNF-induced apoptosis, we examined apoptotic susceptibility and NF-kappa B activation induced by TNF in the E1A transfectants and their parental cells. Here, we reported that E1A inhibited activation of NF-kappa B and rendered cells more sensitive to TNF-induced apoptosis. We further showed that this inhibition was through suppression of I kappa B kinase (IKK) activity and I kappa B phosphorylation. Moreover, deletion of the p300 and Rb binding domains of E1A abolished its function in blocking IKK activity and I kappa B phosphorylation, suggesting that these domains are essential for the E1A function in down-regulating IKK activity and NF-kappa B signaling. However, the role of E1A in inhibiting IKK activity might be indirect. Nevertheless, our results suggest that inhibition of IKK activity by E1A is an important mechanism for the E1A-mediated sensitization of TNF-induced apoptosis.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Sect Mol Cell Biol,Breast Canc Basic Res Program, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Hung, MC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Sect Mol Cell Biol,Breast Canc Basic Res Program, Box 108,1515 Holcombe Blvd, Houston, TX 77030 USA.	mhung@notes.mdacc.tmc.edu	Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	NCI NIH HHS [R01-CA58880, CA16672, R01-CA77858] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA058880, R01CA077858] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARROYO M, 1992, NUCLEIC ACIDS RES, V20, P5947, DOI 10.1093/nar/20.22.5947; Bakker TR, 1999, INT J CANCER, V80, P320; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Boeckman FA, 1996, J PHARMACOL EXP THER, V279, P515; Chang JY, 1996, ONCOGENE, V13, P1405; Chang JY, 1997, ONCOGENE, V14, P561, DOI 10.1038/sj.onc.1200861; Chiou SK, 1997, J VIROL, V71, P3515, DOI 10.1128/JVI.71.5.3515-3525.1997; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Deng J, 1998, ONCOGENE, V17, P2167, DOI 10.1038/sj.onc.1202148; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; RULEY HE, 1990, CANCER CELL-MON REV, V2, P258; Scheidereit C, 1998, NATURE, V395, P225, DOI 10.1038/26121; Shao RP, 1997, J BIOL CHEM, V272, P32739, DOI 10.1074/jbc.272.52.32739; Shisler J, 1996, J VIROL, V70, P68, DOI 10.1128/JVI.70.1.68-77.1996; Simeonidis S, 1999, P NATL ACAD SCI USA, V96, P49, DOI 10.1073/pnas.96.1.49; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; YU DH, 1993, CANCER RES, V53, P891; Yu DH, 1998, CANCER METAST REV, V17, P195, DOI 10.1023/A:1006054421970	25	90	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21495	21498		10.1074/jbc.274.31.21495	http://dx.doi.org/10.1074/jbc.274.31.21495			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419449	hybrid			2022-12-25	WOS:000081721100002
J	Abe, J; Berk, BC				Abe, J; Berk, BC			Fyn and JAK2 mediate Ras activation by reactive oxygen species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; SIGNAL-REGULATED KINASES; ANGIOTENSIN-II; PROTEIN-KINASE; GROWTH-FACTOR; PROTEIN-KINASE-1 BMK1; TYROSINE KINASES; FREE-RADICALS; C-SRC; P21(RAS)	Reactive oxygen species (ROS) activate Ras and the extracellular signal-regulated kinase (ERK) cascade. Because JAK2 is a critical mediator for Ras/Raf/ERK activation by several hormones, we examined the role of JAK2 in ROS signal events. H2O2 stimulated JAK2 activity in fibroblasts with peak at 2-5 min. To determine the specific role of Src and Fyn as mediators of JAK2 activation and its downstream events, we used fibroblasts derived from transgenic mice deficient in Src (Src-/-) or Fyn (Fyn-/-). H2O2-stimulated JAK2 activity was completely inhibited in Fyn-/- cells. Shc tyrosine phosphorylation and Ras activation by H2O2 were also significantly reduced in Fyn-/- cells, but not altered in Src-/- cells. Activation of JAK2 was restored when Fyn-/- cells were transfected with B-Fyn but not with Src. Inhibiting JAK2 activity with the specific inhibitor AG-490 prevented H2O2 stimulated Shc and Ras activation. H2O2-mediated ERK1/2 activation in Fyn-/- cells and AG-490 treated cells was completely inhibited at an early time (5 min), but not at late times (20-40 min) after stimulation. These results define a new redox-sensitive pathway for Ras activation and rapid ERK1/2 activation, which is mediated by Fyn and JAK2.	Univ Rochester, Sch Med & Dent, Cardiol Unit, Cardiovasc Res Ctr, Rochester, NY 14642 USA	University of Rochester	Berk, BC (corresponding author), Univ Rochester, Sch Med & Dent, Cardiol Unit, Cardiovasc Res Ctr, Box 679,601 Elmwood Ave, Rochester, NY 14642 USA.			Berk, Bradford/0000-0002-2767-4115	NHLBI NIH HHS [HL49192, HL44721] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044721, R01HL049192] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe J, 1998, TRENDS CARDIOVAS MED, V8, P59, DOI 10.1016/S1050-1738(97)00133-3; Abe J, 1997, J BIOL CHEM, V272, P20389, DOI 10.1074/jbc.272.33.20389; Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; AUCHSCHWELK W, 1992, J CARDIOVASC PHARM S, V9, P62; BAAS AS, 1995, CIRC RES, V77, P29, DOI 10.1161/01.RES.77.1.29; Campbell GS, 1997, J BIOL CHEM, V272, P2591, DOI 10.1074/jbc.272.5.2591; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Foschi M, 1997, EMBO J, V16, P6439, DOI 10.1093/emboj/16.21.6439; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HALLIWELL B, 1989, BRIT J EXP PATHOL, V70, P737; Han YL, 1996, J BIOL CHEM, V271, P5947, DOI 10.1074/jbc.271.10.5947; HE TC, 1995, J BIOL CHEM, V270, P11055, DOI 10.1074/jbc.270.19.11055; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Ishida M, 1998, CIRC RES, V82, P7; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; Liao DF, 1997, J BIOL CHEM, V272, P6146, DOI 10.1074/jbc.272.10.6146; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; Marrero MB, 1997, J BIOL CHEM, V272, P24684, DOI 10.1074/jbc.272.39.24684; McKenzie FR, 1996, J BIOL CHEM, V271, P13476, DOI 10.1074/jbc.271.23.13476; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Rao GN, 1996, ONCOGENE, V13, P713; Schieffer B, 1996, J BIOL CHEM, V271, P10329, DOI 10.1074/jbc.271.17.10329; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; Uddin S, 1997, BIOCHEM BIOPH RES CO, V235, P83, DOI 10.1006/bbrc.1997.6741; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451	30	174	180	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21003	21010		10.1074/jbc.274.30.21003	http://dx.doi.org/10.1074/jbc.274.30.21003			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409649	hybrid			2022-12-25	WOS:000081613100040
J	Bioukar, EB; Marricco, NC; Zuo, DM; Larose, L				Bioukar, EB; Marricco, NC; Zuo, DM; Larose, L			Serine phosphorylation of the ligand-activated beta-platelet-derived growth factor receptor by casein kinase I-gamma 2 inhibits the receptor's autophosphorylating activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR; TYROSINE KINASE; SIGNALING MOLECULES; DNA-SYNTHESIS; PDGF; PROTEIN; SITE; NCK; BINDING; DOMAIN	Platelet-derived growth factor (PDGF) receptors (PDGFRs) are membrane protein-tyrosine kinases that, upon activation, become tyrosine-phosphorylated and associate with numerous SH2 domain-containing molecules involved in mediating signal transduction. In Rat-2 fibroblasts, we have characterized the phosphorylation of the beta-PDGFR following its activation by PDGF, In contrast to tyrosine phosphorylation, which was transient and returned to near basal levels by 30 min, PDGF-stimulated Ser/Thr phosphorylation of the beta-PDGFR was increased by 5 min and remained elevated after 30 min. In vivo, after 5 min of PDGF stimulation, serine phosphorylation of the beta-PDGFR was greatly reduced by CKI-7, a specific inhibitor of casein kinase I (CKI), In vitro, recombinant CKI-gamma 2 phosphorylated the ligand-activated beta-PDGFR on serine residues in a CKI-7-sensitive manner and resulted in a marked inhibition of the receptor's autophosphorylating activity. Furthermore, in Rat-2 fibroblasts, expression of hemagglutinin epitope-tagged active CKI-gamma 2 resulted in a dramatic decrease in the tyrosine phosphorylation state of the beta-PDGFR in response to PDGF, consistent with receptor inactivation. Our data suggest that upon PDGF stimulation, CKI-gamma 2 is activated and/or translocated in proximity to the beta-PDGFR, whereby it phosphorylates the beta-PDGFR on serine residues and negatively regulates its tyrosine kinase activity, leading to receptor inactivation.	McGill Univ, Polypeptide Lab, Dept Expt Med, Montreal, PQ H3A 2B2, Canada	McGill University	Bioukar, EB (corresponding author), McGill Univ, Polypeptide Lab, Dept Expt Med, Strathcona Bldg,3640 Univ St,Rm W315, Montreal, PQ H3A 2B2, Canada.							AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Baxter RM, 1998, J BIOL CHEM, V273, P17050, DOI 10.1074/jbc.273.27.17050; BEYAERT R, 1995, J BIOL CHEM, V270, P23293, DOI 10.1074/jbc.270.40.23293; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; CHIJIWA T, 1989, J BIOL CHEM, V264, P4924; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; COUNTAWAY JL, 1990, J BIOL CHEM, V265, P3407; Di Guglielmo GM, 1998, MOL CELL BIOCHEM, V182, P59, DOI 10.1023/A:1006883311233; FANTL WJ, 1989, MOL CELL BIOL, V9, P4473, DOI 10.1128/MCB.9.10.4473; Ferguson SSG, 1998, LIFE SCI, V62, P1561, DOI 10.1016/S0024-3205(98)00107-6; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; GARDNER DP, 1994, J CELL PHYSIOL, V158, P245, DOI 10.1002/jcp.1041580206; GAZIT A, 1984, CELL, V39, P89, DOI 10.1016/0092-8674(84)90194-6; GRANDE J, 1988, FEBS LETT, V232, P130, DOI 10.1016/0014-5793(88)80401-0; Hansen K, 1996, EMBO J, V15, P5299, DOI 10.1002/j.1460-2075.1996.tb00915.x; Heldin CH, 1997, FEBS LETT, V410, P17, DOI 10.1016/S0014-5793(97)00318-9; HOEKSTRA MF, 1994, MOL BIOL CELL, V5, P877, DOI 10.1091/mbc.5.8.877; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KAZLAUSKAS A, 1994, CURR OPIN GENET DEV, V4, P5, DOI 10.1016/0959-437X(94)90085-X; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; Kiyokawa N, 1997, J BIOL CHEM, V272, P18656, DOI 10.1074/jbc.272.30.18656; KLINGHOFFER RA, 1995, J BIOL CHEM, V270, P22208, DOI 10.1074/jbc.270.38.22208; LEWIS RE, 1994, J BIOL CHEM, V269, P26259; Lussier G, 1997, J BIOL CHEM, V272, P2688, DOI 10.1074/jbc.272.5.2688; MacPhee IJ, 1997, J BIOL CHEM, V272, P23547, DOI 10.1074/jbc.272.38.23547; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; Montmayeur JP, 1997, J BIOL CHEM, V272, P32670, DOI 10.1074/jbc.272.51.32670; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; Quijano VJ, 1998, J BIOL CHEM, V273, P1200, DOI 10.1074/jbc.273.2.1200; Quilliam LA, 1996, J BIOL CHEM, V271, P28772, DOI 10.1074/jbc.271.46.28772; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; ROSE R, 1986, CELL, V46, P155; Ross R, 1988, Adv Exp Med Biol, V234, P9; ROTH RA, 1987, DIABETES, V36, P123, DOI 10.2337/diabetes.36.1.123; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; TAKAYAMA S, 1988, J BIOL CHEM, V263, P3440; THEROUX SJ, 1992, J BIOL CHEM, V267, P16620; Tobin AB, 1997, J BIOL CHEM, V272, P20844, DOI 10.1074/jbc.272.33.20844; TUAZON PT, 1985, J CELL BIOCHEM, V28, P159, DOI 10.1002/jcb.240280208; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WILLIAMS LT, 1991, COLD SH Q B, V56, P243; Yokote K, 1996, J BIOL CHEM, V271, P30942, DOI 10.1074/jbc.271.48.30942; ZHAI LM, 1995, J BIOL CHEM, V270, P12717, DOI 10.1074/jbc.270.21.12717	47	29	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21457	21463		10.1074/jbc.274.30.21457	http://dx.doi.org/10.1074/jbc.274.30.21457			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409710	hybrid			2022-12-25	WOS:000081613100101
J	Hershey, PEC; McWhirter, SM; Gross, JD; Wagner, G; Alber, T; Sachs, AB				Hershey, PEC; McWhirter, SM; Gross, JD; Wagner, G; Alber, T; Sachs, AB			The cap-binding protein eIF4E promotes folding of a functional domain of yeast translation initiation factor eIF4G1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA 5'-CAP; FACTOR 4G EIF4G; SACCHAROMYCES-CEREVISIAE; FACTOR EIF-4E; DEPENDENT TRANSLATION; FACTOR 4E; COMPLEX; CELL; P20; CLEAVAGE	The association of eucaryotic translation initiation factor eLF4G with the cap-binding protein eIF4E establishes a critical link between the mRNA and the ribosome during translation initiation. This association requires a conserved seven amino acid peptide within eIF4G that binds to eIF4E, Here we report that a 98-amino acid fragment of S. cerevisiae eIF4G1 that contains this eIF4E binding peptide undergoes an unfolded to folded transition upon binding to eIF4E. The folding of the eIF4G1 domain was evidenced by the eIF4E-dependent changes in its protease sensitivity and H-1-N-15 HSQC NMR spectrum. Analysis of a series of charge-to-alanine mutations throughout the essential 55.4-kDa core of yeast eIF4G1 also revealed substitutions within this 98-amino acid region that led to reduced eIF4E binding in vivo and in vitro. These data suggest that the association of yeast eIF4E with eIF4G1 leads to the formation of a structured domain within eIF4G1 that could serve as a specific site for interactions with other components of the translational apparatus. They also suggest that the stability of the native eIF4E-eIF4G complex is determined by amino acid residues outside of the conserved seven-residue consensus sequence.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	University of California System; University of California Berkeley; Harvard University; Harvard Medical School	Sachs, AB (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 401 Barker Hall, Berkeley, CA 94720 USA.				PHS HHS [50308] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Altmann M, 1997, EMBO J, V16, P1114, DOI 10.1093/emboj/16.5.1114; ALTMANN M, 1989, MOL CELL BIOL, V9, P4467, DOI 10.1128/MCB.9.10.4467; BARETTINO D, 1994, NUCLEIC ACIDS RES, V22, P541, DOI 10.1093/nar/22.3.541; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BRENNER C, 1988, MOL CELL BIOL, V8, P3556, DOI 10.1128/MCB.8.8.3556; CRUZ J, 1997, P NATL ACAD SCI USA, V94, P5201; EDERY I, 1988, GENE, V74, P517, DOI 10.1016/0378-1119(88)90184-9; Feigenblum D, 1996, MOL CELL BIOL, V16, P5450; Fletcher CM, 1998, BIOCHEMISTRY-US, V37, P9, DOI 10.1021/bi972494r; GOYER C, 1989, J BIOL CHEM, V264, P7603; GOYER C, 1993, MOL CELL BIOL, V13, P4860, DOI 10.1128/MCB.13.8.4860; GUTHRIE C, 1991, GUIDE YEAST GENETICS, V194, P14; Haghighat A, 1997, J BIOL CHEM, V272, P21677, DOI 10.1074/jbc.272.35.21677; Haghighat A, 1996, J VIROL, V70, P8444, DOI 10.1128/JVI.70.12.8444-8450.1996; Imataka H, 1997, MOL CELL BIOL, V17, P6940, DOI 10.1128/MCB.17.12.6940; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; LANG V, 1994, J BIOL CHEM, V269, P6117; MADER S, 1995, MOL CELL BIOL, V15, P4990; MATHEWS MB, 1996, COLD SPRING HARBOR M, V30, P1; Merrick W.C., 1996, COLD SPRING HARBOR M, V30, P31; Morley SJ, 1997, RNA, V3, P1085; Ohlmann T, 1997, EMBO J, V16, P844, DOI 10.1093/emboj/16.4.844; Ptushkina M, 1998, EMBO J, V17, P4798, DOI 10.1093/emboj/17.16.4798; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; SHATKIN AJ, 1976, CELL, V9, P645, DOI 10.1016/0092-8674(76)90128-8; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; Tarun SZ, 1997, MOL CELL BIOL, V17, P6876, DOI 10.1128/MCB.17.12.6876; Tarun SZ, 1997, P NATL ACAD SCI USA, V94, P9046, DOI 10.1073/pnas.94.17.9046; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; TARUN SZ, 1995, GENE DEV, V9, P2997, DOI 10.1101/gad.9.23.2997; Vasilescu S, 1996, J BIOL CHEM, V271, P7030, DOI 10.1074/jbc.271.12.7030; ZANCHIN NIT, 1995, J BIOL CHEM, V270, P26505, DOI 10.1074/jbc.270.44.26505	32	76	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21297	21304		10.1074/jbc.274.30.21297	http://dx.doi.org/10.1074/jbc.274.30.21297			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409688	hybrid			2022-12-25	WOS:000081613100079
J	Monroe, WT; McQuain, MM; Chang, MS; Alexander, JS; Haselton, FR				Monroe, WT; McQuain, MM; Chang, MS; Alexander, JS; Haselton, FR			Targeting expression with light using caged DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; TRANSGENIC MICE; MAMMALIAN-CELLS; RESPONSIVE PROMOTER; TRANSFECTION; ULTRAVIOLET; METHYLATION; PHOTOLYSIS; LINE; RNA	In this report, we describe the inactivation and site-specific light induction of plasmid expression using a photosensitive caging compound. Plasmids coding for luciferase were caged with 1-(4,5- dimethoxy-2-nitrophenyl)diazoethane (DMNPE) and transfected into similar to 1-cm diameter sites of the skin of rats with particle bombardment. Skin sites transfected with caged plasmids did not express luciferase, However, subsequent exposure of transfected skin sites to 355-nm laser light induced luciferase expression in proportion to the amount of light. Liposome transfection of HeLa cells with DMNPE-caged green fluorescent protein (GFP) plasmids showed similar results. Caging DNA with DMNPE blocks expression at the level of transcription, since in vitro production of mRNA from linearized GFP plasmid was also blocked by caging and subsequently restored by exposure to light. Under the reaction conditions of these experiments, our absorbance data indicate that each DMNPE-caged GFP plasmid contains similar to 270 caging groups, In addition to inhibition and subsequent restoration of plasmid bioactivity, the presence and photocleavage of this relatively small number of cage groups also alters electrophoretic mobility of plasmids and optical absorption characteristics. This light-induced expression strategy provides a new means to target the expression of genetic material with spatial and temporal specificity.	Vanderbilt Univ, Dept Biomed Engn, Nashville, TN 37235 USA; Vanderbilt Univ, Dept Ophthalmol, Nashville, TN 37235 USA	Vanderbilt University; Vanderbilt University	Haselton, FR (corresponding author), Vanderbilt Univ, Dept Biomed Engn, Box 1510B, Nashville, TN 37235 USA.	haselton@vuse.vanderbilt.edu			NATIONAL EYE INSTITUTE [R01EY010086] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR041943] Funding Source: NIH RePORTER; NEI NIH HHS [EY10086] Funding Source: Medline; NIAMS NIH HHS [AR41943] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAMS SR, 1993, ANNU REV PHYSIOL, V55, P755, DOI 10.1146/annurev.ph.55.030193.003543; ANDRES AC, 1987, P NATL ACAD SCI USA, V84, P1299, DOI 10.1073/pnas.84.5.1299; Benn SI, 1996, J CLIN INVEST, V98, P2894, DOI 10.1172/JCI119118; BRULS WAG, 1984, PHOTOCHEM PHOTOBIOL, V40, P485, DOI 10.1111/j.1751-1097.1984.tb04622.x; CHANG MS, 1997, INVEST OPHTH VIS SCI, V4, pS441; Chaulk SG, 1998, NUCLEIC ACIDS RES, V26, P3173, DOI 10.1093/nar/26.13.3173; Dantzig J A, 1998, Methods Enzymol, V291, P307; EDEN S, 1994, CURR OPIN GENET DEV, V4, P255, DOI 10.1016/S0959-437X(05)80052-8; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Hart LR, 1996, SEMIN ONCOL, V23, P154; HASELTON FR, 1997, INVEST OPHTH VIS SCI, V4, pS441; HYNES NE, 1981, P NATL ACAD SCI-BIOL, V78, P2038, DOI 10.1073/pnas.78.4.2038; JOHNSON PH, 1977, BIOCHEMISTRY-US, V16, P4217, DOI 10.1021/bi00638a014; KAPLAN JH, 1978, BIOCHEMISTRY-US, V17, P1929, DOI 10.1021/bi00603a020; MAYO KE, 1982, CELL, V29, P99, DOI 10.1016/0092-8674(82)90094-0; MCCRAY JA, 1980, P NATL ACAD SCI-BIOL, V77, P7237, DOI 10.1073/pnas.77.12.7237; MCCRAY JA, 1989, ANNU REV BIOPHYS BIO, V18, P239, DOI 10.1146/annurev.biophys.18.1.239; McGall G, 1996, P NATL ACAD SCI USA, V93, P13555, DOI 10.1073/pnas.93.24.13555; *MOL PROB, 1997, PHOT CAG PROB PROD I; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Ramsahoye BH, 1996, BLOOD REV, V10, P249, DOI 10.1016/S0268-960X(96)90009-0; Robert C, 1996, J INVEST DERMATOL, V106, P721, DOI 10.1111/1523-1747.ep12345616; Schindl A, 1998, J PHOTOCH PHOTOBIO B, V44, P97, DOI 10.1016/S1011-1344(98)00127-4; SEARLE PF, 1985, MOL CELL BIOL, V5, P1480, DOI 10.1128/MCB.5.6.1480; Stein GS, 1996, J CELL BIOCHEM, V62, P198, DOI 10.1002/(SICI)1097-4644(199608)62:2<198::AID-JCB8>3.3.CO;2-3; Tseng WC, 1997, J BIOL CHEM, V272, P25641, DOI 10.1074/jbc.272.41.25641; WALKER JW, 1988, J AM CHEM SOC, V110, P7170, DOI 10.1021/ja00229a036; WEINTRAUB H, 1986, CELL, V46, P115, DOI 10.1016/0092-8674(86)90865-2; Werstuck G, 1998, SCIENCE, V282, P296, DOI 10.1126/science.282.5387.296; Yarranton Geoffrey T., 1992, Current Opinion in Biotechnology, V3, P506, DOI 10.1016/0958-1669(92)90078-W	31	139	145	0	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					20895	20900		10.1074/jbc.274.30.20895	http://dx.doi.org/10.1074/jbc.274.30.20895			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409633	hybrid			2022-12-25	WOS:000081613100024
J	Rouleau, M; Marsolais, F; Richard, M; Nicolle, L; Voigt, B; Adam, G; Varin, L				Rouleau, M; Marsolais, F; Richard, M; Nicolle, L; Voigt, B; Adam, G; Varin, L			Inactivation of brassinosteroid biological activity by a salicylate-inducible steroid sulfotransferase from Brassica napus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SUSPENSION CULTURES; PLANT-GROWTH; FLAVONOL 3-SULFOTRANSFERASE; ARABIDOPSIS; BIOSYNTHESIS; CYTOCHROME-P450; GENE; IDENTIFICATION; BRASSINOLIDE; METABOLISM	Recent discoveries from brassinosteroid-deficient mutants led to the recognition that plants, like animals, use steroids to regulate their growth and development. We describe the characterization of one member of a Brassica napus sulfotransferase gene family coding for an enzyme that catalyzes the O-sulfonation of brassinosteroids and of mammalian estrogenic steroids. The enzyme is specific for the hydroxyl group at position 22 of brassinosteroids with a preference for 24-epicathasterone, an intermediate in the biosynthesis of 24-epibrassinolide. Enzymatic sulfonation of 24-epibrassinolide abolishes its biological activity in the bean second internode bioassay. This mechanism of hormone inactivation by sulfonation is similar to the modulation of estrogen biological activity observed in mammals. Furthermore, the expression of the B. napus steroid sulfotransferase genes was found to be induced by salicylic acid, a signal molecule in the plant defense response. This pattern of expression suggests that, in addition to an increased synthesis of proteins having antimicrobial properties, plants respond to pathogen infection by modulating steroid-dependent growth and developmental processes.	Concordia Univ, Dept Biol, Montreal, PQ H3G 1M8, Canada; Univ Laval, Dept Biol, Ste Foy, PQ G1K 7P4, Canada; Inst Plant Biochem, Dept Nat Prod, D-06018 Halle, Germany	Concordia University - Canada; Laval University; Leibniz Institut fur Pflanzenbiochemie	Varin, L (corresponding author), Concordia Univ, Dept Biol, 1455 De Maisonneuve Blvd W, Montreal, PQ H3G 1M8, Canada.	varin1@clone.concordia.ca		Marsolais, Frederic/0000-0003-3914-141X				Banoglu E, 1997, DRUG METAB DISPOS, V25, P1304; BRINDLE PA, 1988, PHYTOCHEMISTRY, V27, P133, DOI 10.1016/0031-9422(88)80603-4; CASHMORE AR, 1982, METHODS CHLOROPLAST, P387; Choe SW, 1998, PLANT CELL, V10, P231, DOI 10.1105/tpc.10.2.231; Clouse SD, 1997, PHYSIOL PLANTARUM, V100, P702, DOI 10.1034/j.1399-3054.1997.1000334.x; Clouse SD, 1998, ANNU REV PLANT PHYS, V49, P427, DOI 10.1146/annurev.arplant.49.1.427; Cutler HG, 1991, ACS SYM SER, V474, P312, DOI [10.1021/BK-1991-0474, DOI 10.1021/BK-1991-0474]; FUJIOKA S, 1995, BIOSCI BIOTECH BIOCH, V59, P1973, DOI 10.1271/bbb.59.1973; GEUNS JMC, 1978, PHYTOCHEMISTRY, V17, P1, DOI 10.1016/S0031-9422(00)89671-5; GROVE MD, 1979, NATURE, V281, P216, DOI 10.1038/281216a0; HAUDENSCHILD C, 1995, PHYTOCHEMISTRY, V40, P1117, DOI 10.1016/0031-9422(95)00434-9; HOBKIRK R, 1993, TRENDS ENDOCRIN MET, V4, P69, DOI 10.1016/S1043-2760(05)80018-9; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; Kauschmann A, 1996, PLANT J, V9, P701, DOI 10.1046/j.1365-313X.1996.9050701.x; Lacomme C, 1996, PLANT MOL BIOL, V30, P995, DOI 10.1007/BF00020810; Li JM, 1997, CELL, V90, P929, DOI 10.1016/S0092-8674(00)80357-8; Li JM, 1996, SCIENCE, V272, P398, DOI 10.1126/science.272.5260.398; Marsolais F, 1995, J BIOL CHEM, V270, P30458, DOI 10.1074/jbc.270.51.30458; Marsolais F, 1997, EUR J BIOCHEM, V247, P1056, DOI 10.1111/j.1432-1033.1997.01056.x; Mathur J, 1998, PLANT J, V14, P593, DOI 10.1046/j.1365-313X.1998.00158.x; MCMORRIS TC, 1993, J ORG CHEM, V58, P2338, DOI 10.1021/jo00060a063; MCMORRIS TC, 1994, PHYTOCHEMISTRY, V36, P585, DOI 10.1016/S0031-9422(00)89779-4; MITCHELL JW, 1968, AGR HDB USDA, V336; ROTH JA, 1986, TRENDS PHARMACOL SCI, V7, P404, DOI 10.1016/0165-6147(86)90402-5; Sambrook J., 2002, MOL CLONING LAB MANU; Shi JR, 1996, J BIOL CHEM, V271, P9384, DOI 10.1074/jbc.271.16.9384; SIMONS RG, 1989, CAN J BOT, V67, P288, DOI 10.1139/b89-042; SPENGLER B, 1995, PHYTOCHEMISTRY, V40, P907, DOI 10.1016/0031-9422(95)98170-L; Strott CA, 1996, ENDOCR REV, V17, P670, DOI 10.1210/er.17.6.670; Szekeres M, 1996, CELL, V85, P171, DOI 10.1016/S0092-8674(00)81094-6; TAKATSUTO S, 1994, J CHROMATOGR A, V658, P3, DOI 10.1016/0021-9673(94)85202-2; VANDERHEIJDEN R, 1989, PHYTOCHEMISTRY, V28, P2981, DOI 10.1016/0031-9422(89)80264-X; VARIN L, 1995, J BIOL CHEM, V270, P12498, DOI 10.1074/jbc.270.21.12498; VARIN L, 1987, ANAL BIOCHEM, V161, P176, DOI 10.1016/0003-2697(87)90669-5; VISSER TJ, 1994, CHEM-BIOL INTERACT, V92, P293, DOI 10.1016/0009-2797(94)90071-X; VOGELI U, 1988, PLANT PHYSIOL, V88, P1291, DOI 10.1104/pp.88.4.1291; Voigt B, 1996, TETRAHEDRON, V52, P1997, DOI 10.1016/0040-4020(95)01042-4; Voigt B, 1997, TETRAHEDRON, V53, P17039, DOI 10.1016/S0040-4020(97)10146-6; WARD ER, 1991, PLANT CELL, V3, P1085, DOI 10.1105/tpc.3.10.1085; Weinshilboum RM, 1997, FASEB J, V11, P3, DOI 10.1096/fasebj.11.1.9034160; YOKOTA T, 1992, CURR PLANT SCI BIOT, V13, P298; [No title captured]	42	84	96	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					20925	20930		10.1074/jbc.274.30.20925	http://dx.doi.org/10.1074/jbc.274.30.20925			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409637	hybrid			2022-12-25	WOS:000081613100028
J	Tuininga, JE; Verhees, CH; van der Oost, J; Kengen, SWM; Stams, AJM; de Vos, WM				Tuininga, JE; Verhees, CH; van der Oost, J; Kengen, SWM; Stams, AJM; de Vos, WM			Molecular and biochemical characterization of the ADP-dependent phosphofructokinase from the hyperthermophilic archaeon Pyrococcus furiosus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBDEN-MEYERHOF PATHWAY; SUGAR FERMENTATION; PURIFICATION; GLYCERALDEHYDE-3-PHOSPHATE; GLUCOKINASE; EVOLUTION; OPERATION; PROTEIN; ENZYME	Pyrococcus furiosus uses a modified Embden-Meyerhof pathway involving two ADP-dependent kinases. Using the N-terminal amino acid sequence of the previously purified ADP-dependent glucokinase, the corresponding gene as well as a related open reading frame were detected in the genome of P. furiosus. Both genes were successfully cloned and expressed in Escherichia coli, yielding highly thermoactive ADP-dependent glucokinase and phosphofructokinase. The deduced amino acid sequences of both kinases were 21.1% identical but did not reveal significant homology with those of other known sugar kinases. The ADP-dependent phosphofructokinase was purified and characterized. The oxygen-stable protein had a native molecular mass of approximately 180 kDa and was composed of four identical 52-kDa subunits. It had a specific activity of 88 units/mg at 50 degrees C and a pH optimum of 6.5. As phosphoryl group donor, ADP could be replaced by GDP, ATP, and GTP to a limited extent. The K-m values for fructose 6-phosphate and ADP were 2.3 and 0.11 mM, respectively. The phosphofructokinase did not catalyze the reverse reaction, nor was it regulated by any of the known allosteric modulators of ATP dependent phosphofructokinases. ATP and AMP were identified as competitive inhibitors of the phosphofructokinase, raising the K-m for ADP to 0.34 and 0.41 mM, respectively.	Wageningen Univ Agr, Dept Biomol Sci, Microbiol Lab, NL-6703 CT Wageningen, Netherlands	Wageningen University & Research	Tuininga, JE (corresponding author), Wageningen Univ Agr, Dept Biomol Sci, Microbiol Lab, Hesselink Van Suchtelenweg 4, NL-6703 CT Wageningen, Netherlands.	Judith.Tuininga@algemeen.micr.wau.nl	van+der+Oost, John/Y-2548-2019; Stams, Alfons/C-8167-2014	Kengen, Serve/0000-0001-6139-8946; Stams, Alfons/0000-0001-7840-6500				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; de Vos WM, 1998, EXTREMOPHILES, V2, P201, DOI 10.1007/s007920050061; FOTHERGILLGILMORE LA, 1993, PROG BIOPHYS MOL BIO, V59, P105, DOI 10.1016/0079-6107(93)90001-Z; HEDRICK JL, 1968, ARCH BIOCHEM BIOPHYS, V126, P155, DOI 10.1016/0003-9861(68)90569-9; HONDMANN DHA, 1990, J CHROMATOGR, V510, P155, DOI 10.1016/S0021-9673(01)93749-5; Kengen SWM, 1996, FEMS MICROBIOL REV, V18, P119; KENGEN SWM, 1994, J BIOL CHEM, V269, P17537; KENGEN SWM, 1993, EUR J BIOCHEM, V213, P305, DOI 10.1111/j.1432-1033.1993.tb17763.x; Kengen SWM, 1995, J BIOL CHEM, V270, P30453, DOI 10.1074/jbc.270.51.30453; MUKUND S, 1995, J BIOL CHEM, V270, P8389, DOI 10.1074/jbc.270.15.8389; PHILLIPS NFB, 1993, ARCH BIOCHEM BIOPHYS, V300, P309, DOI 10.1006/abbi.1993.1043; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAFER T, 1992, ARCH MICROBIOL, V158, P188, DOI 10.1007/BF00290815; SCHAFER T, 1993, ARCH MICROBIOL, V159, P354, DOI 10.1007/BF00290918; Selig M, 1997, ARCH MICROBIOL, V167, P217, DOI 10.1007/BF03356097; Siebers B, 1998, J BACTERIOL, V180, P2137, DOI 10.1128/JB.180.8.2137-2143.1998; van der Oost J, 1998, J BIOL CHEM, V273, P28149, DOI 10.1074/jbc.273.43.28149	17	82	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21023	21028		10.1074/jbc.274.30.21023	http://dx.doi.org/10.1074/jbc.274.30.21023			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409652	hybrid			2022-12-25	WOS:000081613100043
J	Hook, SS; Kemp, BE; Means, AR				Hook, SS; Kemp, BE; Means, AR			Peptide specificity determinants at P-7 and P-6 enhance the catalytic efficiency of Ca2+/calmodulin-dependent protein kinase I in the absence of activation loop phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; MUSCLE MYOSIN KINASE; MAP KINASE; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; REQUIRES PHOSPHORYLATION; PERMISSIVE ACTIVATION; NEUTRON-SCATTERING; TYROSINE KINASE; BASIC RESIDUES	Phosphorylation of Ca2+/calmodulin-dependent protein kinase I (CaM KI) at Thr-177 by recombinant rat Ca2+/calmodulin-dependent kinase kinase B (CaM KKB) modulates the kinetics of synapsin-(4-13) peptide phosphorylation by reducing the K-m 44-fold and decreasing the K-CaM 4-fold. There is also a slight decrease in K-m for ATP and increase in enzyme V-max. A synthetic peptide substrate from the yeast transcription factor, ADR1-(222-234)G233 is a 15-fold better substrate for the Thr-177 dephospho-form of CaM KI than synapsin-(4-13). The Thr-177 dephospho-enzyme has a K-m and V-max for ADR1-(222-234)G233 similar to the values with synapsin-(4-13) using the Thr-177 phosphorylated enzyme. Likewise, with ADR1-(222-234)G233 as substrate, phosphorylation of Thr-177 or substitution of T177A had very little effect on the kinetic values. Using chimeric peptides between synapsin-(4-13) and ADR1-(222-234)G233 we found that N-terminal basic residues at P-7 and P-6 positions were sufficient to allow efficient phosphorylation by the Thr-177 dephospho-form of CaM KI. Phosphorylation of Thr-177 expands the substrate specificity of CaM KI and is not merely an "on-off" switch for kinase activity.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia	Duke University; St. Vincent's Institute of Medical Research	Means, AR (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, POB 3813, Durham, NC 27710 USA.	means001@mc.duke.edu	Kemp, Bruce E/L-2633-2014; Kemp, Bruce/G-9602-2019	Kemp, Bruce E/0000-0001-6735-5082; Kemp, Bruce/0000-0001-6735-5082	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033976] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-33976] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS JA, 1995, BIOCHEMISTRY-US, V34, P2447, DOI 10.1021/bi00008a007; ALESSANDRINI A, 1992, P NATL ACAD SCI USA, V89, P8200, DOI 10.1073/pnas.89.17.8200; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; Aletta JM, 1996, J BIOL CHEM, V271, P20930, DOI 10.1074/jbc.271.34.20930; Anderson KA, 1998, J BIOL CHEM, V273, P31880, DOI 10.1074/jbc.273.48.31880; CASNELLIE JE, 1991, METHOD ENZYMOL, V200, P115; CAZAUBON S, 1994, BIOCHEM J, V301, P443, DOI 10.1042/bj3010443; CAZAUBON SM, 1993, J BIOL CHEM, V268, P17559; Chatila T, 1996, J BIOL CHEM, V271, P21542, DOI 10.1074/jbc.271.35.21542; Cheng XD, 1998, P NATL ACAD SCI USA, V95, P9849, DOI 10.1073/pnas.95.17.9849; Chin D, 1997, J BIOL CHEM, V272, P31235, DOI 10.1074/jbc.272.50.31235; CONTI MA, 1981, J BIOL CHEM, V256, P3178; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; Cunningham ME, 1997, J BIOL CHEM, V272, P10957; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DENIS CL, 1992, MOL CELL BIOL, V12, P1507, DOI 10.1128/MCB.12.4.1507; DEREMER MF, 1992, J BIOL CHEM, V267, P13466; Edelman AM, 1996, J BIOL CHEM, V271, P10806, DOI 10.1074/jbc.271.18.10806; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; Feng J, 1997, MOL CELL BIOL, V17, P2497, DOI 10.1128/MCB.17.5.2497; Gauzzi MC, 1996, J BIOL CHEM, V271, P20494, DOI 10.1074/jbc.271.34.20494; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; GUITON M, 1994, J BIOL CHEM, V269, P30370; Hardwick JS, 1997, J BIOL CHEM, V272, P25429, DOI 10.1074/jbc.272.41.25429; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; HER JH, 1993, BIOCHEM J, V296, P25, DOI 10.1042/bj2960025; Ho N, 1996, J EXP MED, V184, P101, DOI 10.1084/jem.184.1.101; INOUE S, 1995, BIOCHEM BIOPH RES CO, V215, P861, DOI 10.1006/bbrc.1995.2543; KEMP BE, 1985, J BIOL CHEM, V260, P3355; KEMP BE, 1976, P NATL ACAD SCI USA, V73, P1038, DOI 10.1073/pnas.73.4.1038; KEMP BE, 1991, METHOD ENZYMOL, V201, P287; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; Kitani T, 1997, J BIOCHEM-TOKYO, V122, P243; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Krueger JK, 1998, BIOCHEMISTRY-US, V37, P13997, DOI 10.1021/bi981311d; Krueger JK, 1997, BIOCHEMISTRY-US, V36, P6017, DOI 10.1021/bi9702703; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LEE JC, 1995, BIOCHEM BIOPH RES CO, V210, P631, DOI 10.1006/bbrc.1995.1705; LEE JC, 1994, P NATL ACAD SCI USA, V91, P6413, DOI 10.1073/pnas.91.14.6413; LEE JSC, 1994, J BIOL CHEM, V269, P2158; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Liu KD, 1997, CURR BIOL, V7, P817, DOI 10.1016/S0960-9822(06)00369-1; McCarty JH, 1998, ONCOGENE, V16, P1691, DOI 10.1038/sj.onc.1201688; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MICHNOFF CH, 1986, J BIOL CHEM, V261, P8320; Millward TA, 1998, EMBO J, V17, P5913, DOI 10.1093/emboj/17.20.5913; MITRA G, 1991, ONCOGENE, V6, P2237; ORR JW, 1994, J BIOL CHEM, V269, P27715; Park IK, 1995, J BIOL CHEM, V270, P30464, DOI 10.1074/jbc.270.51.30464; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PEARSON RB, 1986, J BIOL CHEM, V261, P25; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PICCIOTTO MR, 1995, SYNAPSE, V20, P75, DOI 10.1002/syn.890200111; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; STEINBERG RA, 1993, MOL CELL BIOL, V13, P2332, DOI 10.1128/MCB.13.4.2332; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; WALSH D A, 1992, Current Opinion in Cell Biology, V4, P241, DOI 10.1016/0955-0674(92)90039-F; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0	63	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20215	20222		10.1074/jbc.274.29.20215	http://dx.doi.org/10.1074/jbc.274.29.20215			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400638	hybrid			2022-12-25	WOS:000081438300031
J	Moreno-Manzano, V; Ishikawa, Y; Lucio-Cazana, J; Kitamura, M				Moreno-Manzano, V; Ishikawa, Y; Lucio-Cazana, J; Kitamura, M			Suppression of apoptosis by all-trans-retinoic acid - Dual intervention in the c-Jun N-terminal kinase-AP-1 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-INDUCED APOPTOSIS; SMOOTH-MUSCLE CELLS; OXIDANT-INITIATED APOPTOSIS; KAPPA-B; MESANGIAL CELLS; MESSENGER-RNA; GROWTH-FACTOR; IN-VIVO; MATRIX METALLOPROTEINASE-1; ULTRAVIOLET-RADIATION	Retinoic acid induces apoptosis of various cells, whereas little is known about its anti-apoptotic potential. In this report, we describe an anti-apoptotic property of all-trans-retinoic acid (t-RA) in mammalian cells. Mesangial cells exposed to hydrogen peroxide (H2O2) exhibited shrinkage of the cytoplasm, membrane blebbing, condensation of nuclei, and DNA fragmentation. Pretreatment with t-RA attenuated the morphologic and biochemical hallmarks of apoptosis. t-RA also inhibited apoptosis of mesangial cells triggered by pyrrolidine dithiocarbamate, whereas it did not prevent tumor necrosis factor-cu-induced apoptosis. The anti-apoptotic effect against H2O2 was similarly observed in NRK49F fibroblasts, but not in Madin-Darby canine kidney epithelial cells and ECV304 endothelial cells. Mesangial cells exposed to H2O2 undergo apoptosis via the activator protein 1 (AP-1)-dependent pathway. We found that t-RA abrogated the H2O2-induced expression of c-fos/c-jun and activation of AP-1. Furthermore, t-RA inhibited H2O2-triggered activation of c-Jun N-terminal kinase (JNK), and dominant-negative inhibition of JNK attenuated the H2O2-induced apoptosis. These data disclosed the novel potential of retinoic acid as an inhibitor of apoptosis. The anti-apoptotic action of t-RA was ascribed, at least in part, to dual suppression of the cell death pathway mediated by JNK and AP-1.	UCL, Sch Med, Rayne Inst, Dept Med,Glomerular Bioengn Unit, London WC1E 6JJ, England; Univ Alcala de Henares, Dept Physiol & Pharmacol, E-28871 Alcala De Henares, Spain	University of London; King's College London; University College London; UCL Medical School; Universidad de Alcala	Kitamura, M (corresponding author), UCL, Sch Med, Rayne Inst, Dept Med,Glomerular Bioengn Unit, 5 Univ St, London WC1E 6JJ, England.	m.kitamura@medicine.ucl.ac.uk	Moreno, Victoria/B-4175-2014; Lucio-Cazana, Francisco-Javier/B-8149-2009	Moreno, Victoria/0000-0002-6035-9491; Lucio-Cazana, Francisco-Javier/0000-0001-9249-8501				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Burkitt MJ, 1998, ARCH BIOCHEM BIOPHYS, V353, P73, DOI 10.1006/abbi.1998.0618; BUSAM KJ, 1993, ONCOGENE, V8, P2267; Butterfield L, 1997, J BIOL CHEM, V272, P10110; Chadwick CC, 1998, EXP CELL RES, V239, P423, DOI 10.1006/excr.1997.3913; Chen SC, 1998, J CLIN INVEST, V102, P653, DOI 10.1172/JCI3483; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COSSARIZZA A, 1995, EXP CELL RES, V220, P232, DOI 10.1006/excr.1995.1311; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DAS NP, 1989, J NEUROCHEM, V52, P585, DOI 10.1111/j.1471-4159.1989.tb09159.x; DAVIS BH, 1993, BIOCHEM J, V294, P785, DOI 10.1042/bj2940785; DE LUCA LM, 1991, FASEB J, V5, P2924; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P1585, DOI 10.1093/nar/19.7.1585; DeMeester SL, 1998, SHOCK, V10, P1, DOI 10.1097/00024382-199807000-00001; Desai SH, 1997, J BIOL CHEM, V272, P12809, DOI 10.1074/jbc.272.19.12809; Fisher GJ, 1998, J CLIN INVEST, V101, P1432, DOI 10.1172/JCI2153; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HARRISON DJ, 1988, HISTOPATHOLOGY, V12, P679, DOI 10.1111/j.1365-2559.1988.tb01995.x; Hofer G, 1996, J BIOL CHEM, V271, P28306, DOI 10.1074/jbc.271.45.28306; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ishikawa Y, 1997, BIOCHEM BIOPH RES CO, V240, P496, DOI 10.1006/bbrc.1997.7665; Ishikakawa Yoshihisa, 1998, Journal of the American Society of Nephrology, V9, p497A; IWATA M, 1992, J IMMUNOL, V149, P3302; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Kang JX, 1997, P NATL ACAD SCI USA, V94, P13671, DOI 10.1073/pnas.94.25.13671; Ketley NJ, 1997, BLOOD, V90, P4578, DOI 10.1182/blood.V90.11.4578.4578_4578_4587; Kitamura M, 1996, P NATL ACAD SCI USA, V93, P7387, DOI 10.1073/pnas.93.14.7387; KITAMURA M, 1994, J CLIN INVEST, V94, P497, DOI 10.1172/JCI117361; Kitamura M, 1997, J IMMUNOL, V159, P1404; Lee HY, 1998, J BIOL CHEM, V273, P7066, DOI 10.1074/jbc.273.12.7066; Liu ZH, 1996, AM J PHYSIOL-CELL PH, V270, pC1595, DOI 10.1152/ajpcell.1996.270.6.C1595; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; LOVE JM, 1994, CURR OPIN CELL BIOL, V6, P825, DOI 10.1016/0955-0674(94)90051-5; MCDONNELL SE, 1990, MOL CELL BIOL, V10, P4284, DOI 10.1128/MCB.10.8.4284; Miano JM, 1996, CIRCULATION, V93, P1886, DOI 10.1161/01.CIR.93.10.1886; Mooney A, 1997, J IMMUNOL, V159, P3949; Moreno Manzano V., 1999, Journal of Pharmacology and Experimental Therapeutics, V289, P123; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NAGPAL S, 1995, J BIOL CHEM, V270, P923, DOI 10.1074/jbc.270.2.923; Oeth P, 1998, BLOOD, V91, P2857, DOI 10.1182/blood.V91.8.2857.2857_2857_2865; PACKER L, 1991, METHOD ENZYMOL, V190, P3; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; SAMOKYSZYN VM, 1990, FREE RADICAL BIO MED, V8, P491, DOI 10.1016/0891-5849(90)90063-O; Sandau K, 1997, J IMMUNOL, V158, P4938; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; Schroen DJ, 1996, J CELL PHYSIOL, V169, P320, DOI 10.1002/(SICI)1097-4652(199611)169:2<320::AID-JCP11>3.3.CO;2-Z; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SHAH SV, 1995, ANNU REV PHYSIOL, V57, P245; Shimizu A, 1996, LAB INVEST, V74, P941; SIMONSON MS, 1994, AM J PHYSIOL-RENAL, V267, pF805, DOI 10.1152/ajprenal.1994.267.5.F805; Singh I, 1998, J BIOL CHEM, V273, P20354, DOI 10.1074/jbc.273.32.20354; SIUSS HK, 1994, MOL CELL BIOL, V14, P8376; Sonenshein GE, 1997, SEMIN CANCER BIOL, V8, P113, DOI 10.1006/scbi.1997.0062; Studzinski GP, 1995, CELL GROWTH APOPTOSI; Sugiyama H, 1999, J BIOL CHEM, V274, P19532, DOI 10.1074/jbc.274.28.19532; Sugiyama H, 1996, J AM SOC NEPHROL, V7, P2357; Sugiyama H, 1996, KIDNEY INT, V49, P103, DOI 10.1038/ki.1996.14; TAKEMURA T, 1995, KIDNEY INT, V48, P1886, DOI 10.1038/ki.1995.487; TALLEY AK, 1995, MOL CELL BIOL, V15, P2359; Tsai JC, 1996, J BIOL CHEM, V271, P3667; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Vincenti MP, 1996, CRIT REV EUKAR GENE, V6, P391, DOI 10.1615/CritRevEukarGeneExpr.v6.i4.40; Wan HS, 1997, ONCOGENE, V15, P2109, DOI 10.1038/sj.onc.1201381; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; YANG Y, 1995, J BIOL CHEM, V270, P18672, DOI 10.1074/jbc.270.31.18672; YANG YL, 1993, P NATL ACAD SCI USA, V90, P6170, DOI 10.1073/pnas.90.13.6170; Yokoo T, 1997, J IMMUNOL, V159, P2886; Yokoo T, 1996, AM J PHYSIOL-RENAL, V270, pF806, DOI 10.1152/ajprenal.1996.270.5.F806; Yokoo T, 1997, AM J PHYSIOL-RENAL, V273, pF206, DOI 10.1152/ajprenal.1997.273.2.F206; ZAULI G, 1995, BRIT J HAEMATOL, V90, P274, DOI 10.1111/j.1365-2141.1995.tb05147.x	75	87	91	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20251	20258		10.1074/jbc.274.29.20251	http://dx.doi.org/10.1074/jbc.274.29.20251			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400643	hybrid			2022-12-25	WOS:000081438300036
J	Curry, HA; Clemens, RA; Shah, S; Bradbury, CM; Botero, A; Goswami, P; Gius, D				Curry, HA; Clemens, RA; Shah, S; Bradbury, CM; Botero, A; Goswami, P; Gius, D			Heat shock inhibits radiation-induced activation of NF-kappa B via inhibition of I-kappa B kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IONIZING-RADIATION; STRESS-RESPONSE; C-JUN; ALPHA; PHOSPHORYLATION; PROTEIN; EXPRESSION; SIGNAL; TRANSCRIPTION; FIBROBLASTS	Radiation stimulates signaling cascades that result in the activation of several transcription factors that are believed to play a central role in protective response(s) to ionizing radiation (IR). It is also well established that heat shock alters the regulation of signaling cascades and transcription factors and is a potent radiosensitizing agent. To explore the hypothesis that heat disrupts or alters the regulation of signaling factors activated by IR, the effect of heat shock on IR-induced activation of NF-kappa B was determined. Irradiated HeLa cells demonstrated transient increases in NF-kappa B DNA binding activity and NF-kappa B protein nuclear localization. In addition, irradiated cells demonstrated increased I-kappa B phosphorylation and decreased I-kappa B alpha cytoplasmic protein levels, corresponding temporally with the increase of NF-kappa B DNA binding. Heat shock prior to IR inhibited the increase in NF-kappa B DNA binding activity, nuclear localization of NF-kappa B, and the phosphorylation and subsequent degradation of I-kappa B. I-kappa B kinase (IKK) immunoprecipitation assays demonstrated an increase in IKK catalytic activity in response to IR that was inhibited by pretreatment with heat. Kinetic experiments determined that heat-induced inhibition of NF-kappa B activation in response to LR decayed within 5 h after heating. Furthermore, pretreatment with cycloheximide, to block de novo protein synthesis, did not alter heat shock inhibition of IR induction of NF-kappa B, These experiments demonstrate that heat shock transiently inhibits IR induction of NF-kappa B DNA binding activity by preventing IKK activation and suggests a mechanism independent of protein synthesis.	Washington Univ, Sch Med, Edward Mallinckrodt Inst Radiol, Radiat Oncol Ctr,Sect Canc Biol, St Louis, MO 63110 USA	Washington University (WUSTL)	Gius, D (corresponding author), Washington Univ, Sch Med, Edward Mallinckrodt Inst Radiol, Radiat Oncol Ctr,Sect Canc Biol, 510 S Kingshighway, St Louis, MO 63110 USA.	davidg@radonc.wustl.edu		Goswami, Prabhat/0000-0002-5700-2096; Clemens, Regina/0000-0001-6932-3893	NCI NIH HHS [1 K08 CA72602-01, P01 CA75556, R29 CA69593] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA069593, P01CA075556, K08CA072602] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Besancon F, 1998, P NATL ACAD SCI USA, V95, P8081, DOI 10.1073/pnas.95.14.8081; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CONNOR WG, 1977, RADIOLOGY, V123, P497, DOI 10.1148/123.2.497; DATTA R, 1992, BIOCHEMISTRY-US, V31, P8300, DOI 10.1021/bi00150a025; DAVIDSON JF, 1996, P NATL ACAD SCI USA, V93, P5516; Dewey W.C., 1980, RAD BIOL CANCER RES, P589; DEWEY WC, 1994, INT J HYPERTHER, V10, P457, DOI 10.3109/02656739409009351; Diamond DA, 1999, J BIOL CHEM, V274, P16959, DOI 10.1074/jbc.274.24.16959; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DIGNAM JD, 1990, METHOD ENZYMOL, V182, P194; DUBOIS MF, 1993, FEBS LETT, V324, P191, DOI 10.1016/0014-5793(93)81391-C; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; Guyton KZ, 1996, FREE RADICAL BIO MED, V20, P735, DOI 10.1016/0891-5849(95)02151-5; HALLAHAN DE, 1993, J BIOL CHEM, V268, P4903; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; ILIAKIS G, 1990, INT J HYPERTHER, V6, P813, DOI 10.3109/02656739009140828; JUNG M, 1995, SCIENCE, V268, P1619, DOI 10.1126/science.7777860; JURIVICH DA, 1992, SCIENCE, V255, P1243, DOI 10.1126/science.1546322; JURIVICH DA, 1995, J BIOL CHEM, V270, P24489, DOI 10.1074/jbc.270.41.24489; KAL HB, 1975, RADIOLOGY, V117, P215, DOI 10.1148/117.1.215; KAMADA Y, 1995, GENE DEV, V9, P1559, DOI 10.1101/gad.9.13.1559; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Lindquist S, 1996, P NATL ACAD SCI USA, V93, P5301, DOI 10.1073/pnas.93.11.5301; Liu L, 1998, MOL CELL BIOL, V18, P4221, DOI 10.1128/MCB.18.7.4221; Luque I, 1998, MOL CELL BIOL, V18, P1213, DOI 10.1128/MCB.18.3.1213; Maity A, 1997, INT J RADIAT ONCOL, V37, P639, DOI 10.1016/S0360-3016(96)00598-6; Morimoto RI, 1997, ESSAYS BIOCHEM, V32, P17; Polla BS, 1996, P NATL ACAD SCI USA, V93, P6458, DOI 10.1073/pnas.93.13.6458; RITZ MF, 1993, RECEPTOR, V3, P311; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SPITZ DR, 1988, RADIAT RES, V114, P114, DOI 10.2307/3577149; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WEICHSELBAUM RR, 1994, INT J RADIAT ONCOL, V30, P229, DOI 10.1016/0360-3016(94)90539-8; WOOTEN MW, 1991, EXP CELL RES, V193, P274, DOI 10.1016/0014-4827(91)90096-D; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	48	94	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23061	23067		10.1074/jbc.274.33.23061	http://dx.doi.org/10.1074/jbc.274.33.23061			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438474	hybrid			2022-12-25	WOS:000082012800024
J	Gersappe, A; Burger, L; Pintel, DJ				Gersappe, A; Burger, L; Pintel, DJ			A premature termination codon in either exon of minute virus of mice P4 promoter-generated pre-mRNA can inhibit nuclear splicing of the intervening intron in an open reading frame-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; AUTONOMOUS PARVOVIRUS; NONSENSE MUTATIONS; SITE SELECTION; PROTEIN; CELLS; INITIATION; EXCISION	How premature translation termination codons (PTCs) mediate effects on nuclear RNA processing is unclear. Here we show that a PTC at nucleotide (nt) 385 in the NS1/2 shared exon of P4-generated pre-mRNAs of the autonomous parvovirus minute virus of mice caused a decrease in the accumulated levels of doubly spliced R2 relative to singly spliced R1, although the total accumulated levels of R1 plus R2 remained the same. The effect of this PTC was evident within nuclear RNA, was mediated by a PTC and not a missense transversion mutation at this position, and could be suppressed by improvement of the large intron splice sites and by mutation of the AUG that initiated translation of R1 and R2, In contrast to the PTC at nt 385, the reading frame-dependent effect of the PTC at nt 2018 depended neither on the initiating AUG nor the normal termination codon for NS2; however, it could be suppressed by a single nucleotide deletion mutation in the upstream NS1/2 common exon that shifted the 2018 PTC out of the NS2 open reading frame. This suggested that there was recognition and communication of reading frame between exons on a pre-mRNA in the nucleus prior to or concomitant with splicing.	Univ Missouri, Sch Med, Dept Mol Microbiol & Immunol, Columbia, MO 65212 USA	University of Missouri System; University of Missouri Columbia	Pintel, DJ (corresponding author), Univ Missouri, Sch Med, Dept Mol Microbiol & Immunol, Columbia, MO 65212 USA.							ASTELL CR, 1986, J VIROL, V57, P656, DOI 10.1128/JVI.57.2.656-669.1986; Carter MS, 1996, EMBO J, V15, P5965, DOI 10.1002/j.1460-2075.1996.tb00983.x; CLEMENS KE, 1987, VIROLOGY, V160, P511, DOI 10.1016/0042-6822(87)90028-6; CLEMENS KE, 1990, J VIROL, V64, P3967, DOI 10.1128/JVI.64.8.3967-3973.1990; COTMORE SF, 1987, ADV VIRUS RES, V33, P91, DOI 10.1016/S0065-3527(08)60317-6; COTMORE SF, 1986, J VIROL, V58, P724, DOI 10.1128/JVI.58.3.724-732.1986; DIETZ HC, 1994, NAT GENET, V8, P183, DOI 10.1038/ng1094-183; Fabrizio P, 1997, EMBO J, V16, P4092, DOI 10.1093/emboj/16.13.4092; Gersappe A, 1999, MOL CELL BIOL, V19, P1640; Gersappe A, 1999, MOL CELL BIOL, V19, P364; Haut DD, 1998, J VIROL, V72, P1834, DOI 10.1128/JVI.72.3.1834-1843.1998; JONGENEEL CV, 1986, J VIROL, V59, P564, DOI 10.1128/JVI.59.3.564-573.1986; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEJBKOWICZ F, 1992, P NATL ACAD SCI USA, V89, P9612, DOI 10.1073/pnas.89.20.9612; Lund E, 1998, SCIENCE, V282, P2082, DOI 10.1126/science.282.5396.2082; Maquat LE, 1996, AM J HUM GENET, V59, P279; MAQUAT LE, 1995, RNA, V1, P453; MIRIAMI E, 1994, NUCLEIC ACIDS RES, V22, P3084, DOI 10.1093/nar/22.15.3084; NAEGER LK, 1992, GENE DEV, V6, P1107, DOI 10.1101/gad.6.6.1107; NILSEN TW, 1994, CELL, V78, P1, DOI 10.1016/0092-8674(94)90563-0; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PINTEL D, 1983, NUCLEIC ACIDS RES, V11, P1019, DOI 10.1093/nar/11.4.1019; PINTEL DJ, 1995, SEMIN VIROL, V6, P283, DOI 10.1006/smvy.1995.0034; SCHOBORG RV, 1991, VIROLOGY, V181, P22, DOI 10.1016/0042-6822(91)90466-O; TEIGELKAMP S, 1995, EMBO J, V14, P2602, DOI 10.1002/j.1460-2075.1995.tb07258.x; URLAUB G, 1989, MOL CELL BIOL, V9, P2868, DOI 10.1128/MCB.9.7.2868; Zhang J, 1997, EMBO J, V16, P826, DOI 10.1093/emboj/16.4.826; ZHAO QH, 1995, J VIROL, V69, P6170, DOI 10.1128/JVI.69.10.6170-6179.1995	28	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22452	22458		10.1074/jbc.274.32.22452	http://dx.doi.org/10.1074/jbc.274.32.22452			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428819	hybrid			2022-12-25	WOS:000081868400049
J	Kassam, A; Capone, JP; Rachubinski, RA				Kassam, A; Capone, JP; Rachubinski, RA			Orphan nuclear hormone receptor RevErb alpha modulates expression from the promoter of the hydratase-dehydrogenase gene by inhibiting peroxisome proliferator-activated receptor alpha-dependent transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-BINDING PROTEIN; THYROID-HORMONE; ERBA-ALPHA; RESPONSIVE ELEMENT; FATTY-ACIDS; ADIPOCYTE DIFFERENTIATION; CO-REPRESSOR; DNA-BINDING; CROSS-TALK; INDUCTION	Peroxisome proliferator-activated receptor alpha (PPAR alpha) heterodimerizes with the 9-cis-retinoic acid receptor (RXR alpha) to bind to peroxisome proliferator-response elements (PPRE) present in the upstream regions of a number of genes involved in metabolic homeostasis. Among these genes are those encoding fatty acyl-CoA oxidase (AOx) and enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase (HD), the first two enzymes of the peroxisomal beta-oxidation pathway. Here we demonstrate that the orphan nuclear hormone receptor, RevErb alpha, modulates PPAR alpha/RXR alpha-dependent transactivation in a response element specific manner. In vitro binding analysis showed that RevErb alpha bound the HD-PPRE but not the AOx-PPRE. Determinants within the HD-PPRE required for RevErb alpha binding were distinct from those required for PPAR alpha/RXR alpha binding. In transient transfections, RevErb alpha antagonized transactivation by PPAR alpha/RXR alpha from an HD-PPRE luciferase reporter construct, whereas no effects were observed with an AOx-PPRE reporter construct. These data identify the HD gene as a target for RevErb alpha and illustrate cross-talk between the RevErb alpha and PPAR alpha signaling pathways on the HD-PPRE. Our results suggest a novel role for RevErb alpha in regulating peroxisomal beta-oxidation.	Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2H7, Canada; McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada	University of Alberta; McMaster University	Rachubinski, RA (corresponding author), Univ Alberta, Dept Cell Biol, Med Sci Bldg 5-14, Edmonton, AB T6G 2H7, Canada.	rick.rachubinski@ualberta.ca						Adelmant G, 1996, P NATL ACAD SCI USA, V93, P3553, DOI 10.1073/pnas.93.8.3553; BESNARD P, 1993, FEBS LETT, V327, P219, DOI 10.1016/0014-5793(93)80173-R; BOGAZZI F, 1994, J BIOL CHEM, V269, P11683; CASTELEIN H, 1994, J BIOL CHEM, V269, P26754; CHAWLA A, 1993, J BIOL CHEM, V268, P16265; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHU RY, 1995, J BIOL CHEM, V270, P29636; DiRenzo J, 1997, MOL CELL BIOL, V17, P2166, DOI 10.1128/MCB.17.4.2166; Dowell P, 1997, J BIOL CHEM, V272, P33435, DOI 10.1074/jbc.272.52.33435; DOWNES M, 1995, MOL ENDOCRINOL, V9, P1666, DOI 10.1210/me.9.12.1666; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; Forman BM, 1998, NATURE, V395, P612, DOI 10.1038/26996; FORMAN BM, 1994, MOL ENDOCRINOL, V8, P1253, DOI 10.1210/me.8.9.1253; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Gervois P, 1999, MOL ENDOCRINOL, V13, P400, DOI 10.1210/me.13.3.400; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; HARDING HP, 1993, MOL CELL BIOL, V13, P3113, DOI 10.1128/MCB.13.5.3113; HARDING HP, 1995, MOL CELL BIOL, V15, P4791; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hsu MH, 1998, J BIOL CHEM, V273, P27988, DOI 10.1074/jbc.273.43.27988; Hunter J, 1996, MOL CELL ENDOCRINOL, V116, P213, DOI 10.1016/0303-7207(95)03717-9; IKEDA Y, 1993, MOL ENDOCRINOL, V7, P852, DOI 10.1210/me.7.7.852; JugeAubry C, 1997, J BIOL CHEM, V272, P25252, DOI 10.1074/jbc.272.40.25252; KAIKAUS RM, 1993, J BIOL CHEM, V268, P9593; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Lambe KG, 1996, EUR J BIOCHEM, V239, P1, DOI 10.1111/j.1432-1033.1996.0001u.x; Latruffe N, 1997, BIOCHIMIE, V79, P81, DOI 10.1016/S0300-9084(97)81496-4; LAZAR MA, 1990, DNA CELL BIOL, V9, P77, DOI 10.1089/dna.1990.9.77; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LOCK EA, 1989, ANNU REV PHARMACOL, V29, P145; MARCUS SL, 1993, P NATL ACAD SCI USA, V90, P5723, DOI 10.1073/pnas.90.12.5723; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; MIYAJIMA N, 1989, CELL, V57, P31, DOI 10.1016/0092-8674(89)90169-4; Miyata KS, 1996, J BIOL CHEM, V271, P9189, DOI 10.1074/jbc.271.16.9189; MIYATA KS, 1993, J BIOL CHEM, V268, P19169; RETNAKARAN R, 1994, MOL ENDOCRINOL, V8, P1234, DOI 10.1210/me.8.9.1234; RODRIGUEZ JC, 1994, J BIOL CHEM, V269, P18767; SCEARCE LM, 1993, J BIOL CHEM, V268, P8855; SPANJAARD RA, 1994, MOL ENDOCRINOL, V8, P286, DOI 10.1210/me.8.3.286; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; Vu-Dac N, 1998, J BIOL CHEM, V273, P25713, DOI 10.1074/jbc.273.40.25713; Winrow Christopher J., 1994, Gene Expression, V4, P53; Winrow CJ, 1998, J BIOL CHEM, V273, P31442, DOI 10.1074/jbc.273.47.31442; Zamir I, 1996, MOL CELL BIOL, V16, P5458; ZHANG BW, 1993, J BIOL CHEM, V268, P12939; ZHANG BW, 1992, P NATL ACAD SCI USA, V89, P7541, DOI 10.1073/pnas.89.16.7541	48	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22895	22900		10.1074/jbc.274.32.22895	http://dx.doi.org/10.1074/jbc.274.32.22895			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428876	hybrid			2022-12-25	WOS:000081868400106
J	Grone, HJ; Weber, C; Weber, KSC; Grone, EF; Rabelink, T; Klier, CM; Wells, TNC; Proudfoot, AE; Schlondorff, D; Nelson, PJ				Grone, HJ; Weber, C; Weber, KSC; Grone, EF; Rabelink, T; Klier, CM; Wells, TNC; Proudfoot, AE; Schlondorff, D; Nelson, PJ			Met-RANTES reduces vascular and tubular damage during acute renal transplant rejection: blocking monocyte arrest and recruitment	FASEB JOURNAL			English	Article						chemokine receptors; inflammation; monocyte; endothelium	PLATELET-ACTIVATING-FACTOR; ALLOGRAFT-REJECTION; CHEMOKINE EXPRESSION; ENDOTHELIAL-CELLS; ADHESION; ANTAGONIST; INFLAMMATION; LYMPHOCYTES; KIDNEY; FLOW	Chemokines are thought to contribute to the cellular infiltrate characteristic of renal transplant rejection. We show that Met-RANTES, a chemokine receptor antagonist, suppresses recruitment of inflammatory cells into renal allografts. In a renal transplant model (Fisher RT1v1 rat kidney into Lewis RT1 rat) where no additional immune suppressant was used, Met-RANTES-treated animals showed a significant reduction in vascular injury score (16.10 +/- 5.20 vs. 62.67 +/- 18.64) and tubular damage score (15.70 +/- 5.22 vs. 33.00 +/- 6.44) relative to untreated animals. In a more severe rejection model (Brown-Norway RT1v1 rat kidney into Lewis RT1(1) rat), Met-RANTES significantly augmented low-dose cyclosporin A treatment to reduce all aspects of renal injury including interstitial inflammation (score 71.00 +/- 6.10 vs. 157.30 +/- 21.30). The majority of infiltrating cells in these models (60-70%) consisted of monocytes. Potential mechanisms of action of Met-RANTES were tested using monocyte attachment assays on microvascular endothelium under physiological flow conditions. Preexposure of microvascular endothelium to RANTES resulted in RANTES immobilization and RANTES-induced firm adhesion of monocytes only after prestimulation of the endothelium with IL-1 beta. Met-RANTES completely inhibited this RANTES-mediated arrest. Thus, Met-RANTES may counter acute rejection by blocking leukocyte firm adhesion to inflamed endothelium.	Univ Munich, Med Poliklin, AG Klin Biochem, D-80336 Munich, Germany; German Canc Res Ctr, Dept Expt Pathol, Heidelberg, Germany; Univ Utrecht, NL-3508 TC Utrecht, Netherlands; Univ Munich, Inst Prophylaxis & Epidemiol, D-80539 Munich, Germany; Serono Pharmaceut Inst, Geneva, Switzerland	University of Munich; Helmholtz Association; German Cancer Research Center (DKFZ); Utrecht University; University of Munich	Nelson, PJ (corresponding author), Univ Munich, Med Poliklin, AG Klin Biochem, Schillerstr 42, D-80336 Munich, Germany.	nelson@medpoli.med.uni-muenchen.de	Rabelink, Ton J./A-5316-2008; Weber, Christian/AAW-2153-2020	Rabelink, Ton J./0000-0001-6780-5186; Weber, Christian/0000-0003-4610-8714; Wells, Timothy/0000-0001-9796-847X				ALMOND PS, 1993, TRANSPLANTATION, V55, P752, DOI 10.1097/00007890-199304000-00013; ALPERS CE, 1993, KIDNEY INT, V44, P805, DOI 10.1038/ki.1993.315; BASADONNA GP, 1993, TRANSPLANTATION, V55, P993, DOI 10.1097/00007890-199305000-00007; Bennett William M., 1996, P587; BISHOP GA, 1986, KIDNEY INT, V29, P708, DOI 10.1038/ki.1986.56; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; Castro M C, 1998, Transpl Int, V11 Suppl 1, pS15; DEVERGNE O, 1994, J EXP MED, V179, P1689, DOI 10.1084/jem.179.5.1689; Elsner J, 1997, EUR J IMMUNOL, V27, P2892, DOI 10.1002/eji.1830271122; ERL W, 1995, ATHEROSCLEROSIS, V113, P99, DOI 10.1016/0021-9150(94)05434-K; FISHER B, 1965, SURGERY, V58, P904; Gibbs P, 1993, Transpl Immunol, V1, P109, DOI 10.1016/0966-3274(93)90003-Q; Gong JH, 1996, J BIOL CHEM, V271, P10521, DOI 10.1074/jbc.271.18.10521; GRONE HJ, 1996, DIALYSIS TRANSPLANT, V11, P1916; HEAF JG, 1998, TRANSPL INT, V1, pS26; KAMEYOSHI Y, 1994, INT ARCH ALLERGY IMM, V104, P49, DOI 10.1159/000236751; KAMEYOSHI Y, 1992, J EXP MED, V176, P587, DOI 10.1084/jem.176.2.587; Kitayama J, 1998, J CLIN INVEST, V101, P2017, DOI 10.1172/JCI2688; KooijmansCoutinho MF, 1996, TRANSPLANTATION, V61, P1338, DOI 10.1097/00007890-199605150-00009; Kukreti S, 1997, BLOOD, V89, P4104, DOI 10.1182/blood.V89.11.4104; Lloyd CM, 1997, J LEUKOCYTE BIOL, V62, P676, DOI 10.1002/jlb.62.5.676; Lloyd GM, 1997, J EXP MED, V185, P1371, DOI 10.1084/jem.185.7.1371; Lukacs NW, 1996, J LEUKOCYTE BIOL, V59, P13, DOI 10.1002/jlb.59.1.13; LUSCINSKAS FW, 1994, J IMMUNOL, V156, P326; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Mantovani A, 1997, IMMUNOL TODAY, V18, P231, DOI 10.1016/S0167-5699(97)81662-3; MANTOVANI A, 1992, FASEB J, V6, P2591, DOI 10.1096/fasebj.6.8.1592209; MOREL D, 1993, TRANSPLANTATION, V55, P773, DOI 10.1097/00007890-199304000-00017; NADEAU KC, 1995, P NATL ACAD SCI USA, V92, P8729, DOI 10.1073/pnas.92.19.8729; Nagano H, 1997, TRANSPLANTATION, V63, P1101, DOI 10.1097/00007890-199704270-00009; Nelson PJ, 1998, CURR OPIN IMMUNOL, V10, P265, DOI 10.1016/S0952-7915(98)80164-7; Nelson PJ, 1998, CYTOKINES, P433, DOI 10.1016/B978-012498340-3/50030-0; Nibbs RJB, 1997, J BIOL CHEM, V272, P32078, DOI 10.1074/jbc.272.51.32078; Nickerson P, 1997, TRANSPLANTATION, V63, P489, DOI 10.1097/00007890-199702270-00001; Oppenheim Joost J., 1996, P187; PATTISON J, 1994, LANCET, V343, P209, DOI 10.1016/S0140-6736(94)90992-X; Piali L, 1998, EUR J IMMUNOL, V28, P961, DOI 10.1002/(SICI)1521-4141(199803)28:03<961::AID-IMMU961>3.0.CO;2-4; PlaterZyberk C, 1997, IMMUNOL LETT, V57, P117, DOI 10.1016/S0165-2478(97)00075-8; Pober Jordan S., 1996, P127; Proudfoot AEI, 1996, J BIOL CHEM, V271, P2599, DOI 10.1074/jbc.271.5.2599; ROT A, 1992, IMMUNOL TODAY, V13, P291, DOI 10.1016/0167-5699(92)90039-A; Schlondorff D, 1997, KIDNEY INT, V51, P610, DOI 10.1038/ki.1997.90; SCHMEELK J, 1995, KLUW T MATH, V10, P1; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; SIMON M, 1995, AM J PHYSIOL-RENAL, V268, pF240, DOI 10.1152/ajprenal.1995.268.2.F240; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Stojanovic T, 1996, LAB INVEST, V74, P496; Strom TB, 1996, CURR OPIN IMMUNOL, V8, P688, DOI 10.1016/S0952-7915(96)80087-2; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; Teixeira MM, 1997, J CLIN INVEST, V100, P1657, DOI 10.1172/JCI119690; Valente JF, 1998, SURG CLIN N AM, V78, P1, DOI 10.1016/S0039-6109(05)70631-9; vonLuettichau I, 1996, CYTOKINE, V8, P89, DOI 10.1006/cyto.1996.0012; WEBER C, 1993, EUR J IMMUNOL, V23, P852, DOI 10.1002/eji.1830230413; WEBER C, 1995, J IMMUNOL, V155, P445; Weber C, 1997, J CLIN INVEST, V100, P2085, DOI 10.1172/JCI119742; WEBER KSC, 1999, IN PRESS ARTERIOSCL; WIEDERMANN CJ, 1993, CURR BIOL, V3, P735, DOI 10.1016/0960-9822(93)90020-O; ZIEGLERHEITBROCK HWL, 1988, INT J CANCER, V41, P456, DOI 10.1002/ijc.2910410324	59	200	214	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1999	13	11					1371	1383		10.1096/fasebj.13.11.1371	http://dx.doi.org/10.1096/fasebj.13.11.1371			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	226KL	10428761	Bronze			2022-12-25	WOS:000082019100009
J	Lee, JH; Baker, TJ; Mahal, LK; Zabner, J; Bertozzi, CR; Wiemer, DF; Welsh, MJ				Lee, JH; Baker, TJ; Mahal, LK; Zabner, J; Bertozzi, CR; Wiemer, DF; Welsh, MJ			Engineering novel cell surface receptors for virus-mediated gene transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALIC-ACID; IN-VIVO; ADENOVIRUS; BIOSYNTHESIS; EFFICIENCY; INHIBITION; DELIVERY; VECTORS; PATHWAY	The absence of viral receptors is a major barrier to efficient gene transfer in many cells. To overcome this barrier, we developed an artificial receptor based on expression of a novel sugar, We fed cells an unnatural monosaccharide, a modified mannosamine that replaced the acetyl group with a levulinate group (ManLev), ManLev was metabolized and incorporated into cell-surface glycoconjugates. The synthetic sugar decorated the cell surface with a unique ketone group that served as a foundation on which we built an adenovirus receptor by covalently binding biotin hydrazide to the ketone. The artificial receptor enhanced adenoviral vector binding and gene transfer to cells that are relatively resistant to adenovirus infection. These data are the first to suggest the feasibility of a strategy that improves the efficiency of gene transfer by using the biosynthetic machinery of the cell to engineer novel sugars on the cell surface.	Univ Iowa, Coll Med, Howard Hughes Med Inst, Iowa City, IA 52242 USA; Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Univ Iowa, Dept Chem, Iowa City, IA 52242 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Ctr Adv Mat, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of Iowa; University of Iowa; University of Iowa; University of Iowa; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Welsh, MJ (corresponding author), Univ Iowa, Coll Med, Howard Hughes Med Inst, 500 EMRB, Iowa City, IA 52242 USA.		Baker, Tracy/AAM-2917-2020; Mahal, Lara/GRY-7287-2022	Baker, Tracy/0000-0003-4508-3471; Mahal, Lara/0000-0003-4791-8524; Zabner, Joseph/0000-0002-9606-1339; Welsh, Michael/0000-0002-1646-6206	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK25295] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; CORFIELD AP, 1982, SIALIC ACIDS CHEM ME; Fasbender A, 1997, J BIOL CHEM, V272, P6479, DOI 10.1074/jbc.272.10.6479; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KASAHARA N, 1994, SCIENCE, V266, P1373, DOI 10.1126/science.7973726; KAYSER H, 1992, J BIOL CHEM, V267, P16934; KEPPLER OT, 1995, J BIOL CHEM, V270, P1308, DOI 10.1074/jbc.270.3.1308; Krasnykh V, 1998, J VIROL, V72, P1844, DOI 10.1128/JVI.72.3.1844-1852.1998; Leopold PL, 1998, HUM GENE THER, V9, P367, DOI 10.1089/hum.1998.9.3-367; Mahal LK, 1997, SCIENCE, V276, P1125, DOI 10.1126/science.276.5315.1125; Qiu CB, 1998, HUM GENE THER, V9, P507, DOI 10.1089/hum.1998.9.4-507; SARKAR AK, 1995, P NATL ACAD SCI USA, V92, P3323, DOI 10.1073/pnas.92.8.3323; SETH P, 1994, J VIROL, V68, P933, DOI 10.1128/JVI.68.2.933-940.1994; VARKI A, 1991, FASEB J, V5, P226, DOI 10.1096/fasebj.5.2.2004668; Warren L., 1994, BOUND CARBOHYDRATES; Wickham TJ, 1996, NAT BIOTECHNOL, V14, P1570, DOI 10.1038/nbt1196-1570; Wickham TJ, 1995, GENE THER, V2, P750; Wieser JR, 1996, FEBS LETT, V395, P170, DOI 10.1016/0014-5793(96)01029-0; Yarema KJ, 1998, J BIOL CHEM, V273, P31168, DOI 10.1074/jbc.273.47.31168; Zabner J, 1996, J VIROL, V70, P6994, DOI 10.1128/JVI.70.10.6994-7003.1996	20	76	79	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21878	21884		10.1074/jbc.274.31.21878	http://dx.doi.org/10.1074/jbc.274.31.21878			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419507	hybrid			2022-12-25	WOS:000081721100060
J	Poon, WW; Barkovich, RJ; Hsu, AY; Frankel, A; Lee, PT; Shepherd, JN; Myles, DC; Clarke, CF				Poon, WW; Barkovich, RJ; Hsu, AY; Frankel, A; Lee, PT; Shepherd, JN; Myles, DC; Clarke, CF			Yeast and rat Coq3 and Escherichia coli UbiG polypeptides catalyze both O-methyltransferase steps in coenzyme Q biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYUNSATURATED FATTY-ACIDS; UBIQUINONE BIOSYNTHESIS; SACCHAROMYCES-CEREVISIAE; PROTEIN IMPORT; MITOCHONDRIAL PROTEIN; ENDOPLASMIC-RETICULUM; STRUCTURAL GENE; PARA-HYDROXYBENZOATE; C-METHYLTRANSFERASE; NUCLEOTIDE-SEQUENCE	Ubiquinone (coenzyme Q or Q) is a lipid that functions in the electron transport chain in the inner mitochondrial membrane of eukaryotes and the plasma membrane of prokaryotes. Q-deficient mutants of Saccharomyces cerevisiae harbor defects in one of eight COQ genes (coq1-coq8) and are unable to grow on nonfermentable carbon sources. The biosynthesis of Q involves two separate O-methylation steps. In yeast, the first O-methylation utilizes 3,4-dihydroxy-5-hexaprenylbenzoic acid as a substrate and is thought to be catalyzed by Coq3p, a 32.7-kDa protein that is 40% identical to the Escherichia coli O-methyltransferase, UbiG. In this study, farnesylated analogs corresponding to the second O-methylation step, demethyl-Q(3) and Q(3), have been chemically synthesized and used to study Q biosynthesis in yeast mitochondria in vitro, Both yeast and rat Coq3p recognize the demethyl-Q(3) precursor as a substrate. In addition, E. coli UbiGp was purified and found to catalyze both O-methylation steps. Futhermore, antibodies to yeast Coq3p were used to determine that the Coq3 polypeptide is peripherally associated with the matrix-side of the inner membrane of yeast mitochondria. The results indicate that one O-methyltransferase catalyzes both steps in Q biosynthesis in eukaryotes and prokaryotes and that Q biosynthesis is carried out within the matrix compartment of yeast mitochondria.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Clarke, CF (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, 607 Charles E Young Dr E, Los Angeles, CA 90095 USA.	cathy@mbi.ucla.edu		Poon, Wayne/0000-0003-0625-3968	NIGMS NIH HHS [GM07185, GM45952] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045952] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS A, 1997, METHODS YEAST GENETI, P145; ALAM SS, 1975, ARCH BIOCHEM BIOPHYS, V171, P183, DOI 10.1016/0003-9861(75)90022-3; ASHBY MN, 1992, J BIOL CHEM, V267, P4128; ASHBY MN, 1990, J BIOL CHEM, V265, P13157; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; Avelange-Macherel MH, 1998, PLANT J, V14, P203, DOI 10.1046/j.1365-313X.1998.00109.x; Baker W, 1941, J CHEM SOC, P670, DOI 10.1039/jr9410000670; Barkovich RJ, 1997, J BIOL CHEM, V272, P9182; BOWRY VW, 1995, J BIOL CHEM, V270, P5756, DOI 10.1074/jbc.270.11.5756; BRANDT U, 1994, CRIT REV BIOCHEM MOL, V29, P165, DOI 10.3109/10409239409086800; CASEY J, 1978, BIOCHIM BIOPHYS ACTA, V530, P487, DOI 10.1016/0005-2760(78)90168-6; CHEN WJ, 1987, CELL, V49, P651, DOI 10.1016/0092-8674(87)90541-1; CLARKE CF, 1991, J BIOL CHEM, V266, P16636; COQUE JJR, 1995, J BACTERIOL, V177, P2230, DOI 10.1128/jb.177.8.2230-2235.1995; COX GB, 1969, J BACTERIOL, V99, P450, DOI 10.1128/JB.99.2.450-458.1969; Dawson RMC, 1986, DATA BIOCH RES, P2; Dibrov E, 1997, J BIOL CHEM, V272, P9175; Do TQ, 1996, P NATL ACAD SCI USA, V93, P7534, DOI 10.1073/pnas.93.15.7534; Ernster L., 1993, CLIN INVESTIGATOR, V71, P60; Ewbank JJ, 1997, SCIENCE, V275, P980, DOI 10.1126/science.275.5302.980; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GARFIN DE, 1990, METHOD ENZYMOL, V182, P425; GIBSON F, 1973, Biochemical Society Transactions, V1, P317; Gibson F, 1978, Methods Enzymol, V53, P600; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; GOEWERT RR, 1981, BIOCHEMISTRY-US, V20, P5611, DOI 10.1021/bi00522a040; GOEWERT RR, 1981, BIOCHEMISTRY-US, V20, P4217, DOI 10.1021/bi00517a041; Harlow E., 1988, ANTIBODIES LAB MANUA; HARRINGTON MG, 1990, METHOD ENZYMOL, V182, P488; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HOUSER RM, 1977, J BIOL CHEM, V252, P4017; Hsu AY, 1996, BIOCHEMISTRY-US, V35, P9797, DOI 10.1021/bi9602932; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Jarosch E, 1996, J BIOL CHEM, V271, P17219, DOI 10.1074/jbc.271.29.17219; Jonassen T, 1996, ARCH BIOCHEM BIOPHYS, V330, P285, DOI 10.1006/abbi.1996.0255; Jonassen T, 1998, J BIOL CHEM, V273, P3351, DOI 10.1074/jbc.273.6.3351; KAAKKOLA S, 1994, GEN PHARMACOL-VASC S, V25, P813, DOI 10.1016/0306-3623(94)90082-5; KAGAN RM, 1994, ARCH BIOCHEM BIOPHYS, V310, P417, DOI 10.1006/abbi.1994.1187; KAGAN V, 1990, BIOCHEM BIOPH RES CO, V169, P851, DOI 10.1016/0006-291X(90)91971-T; KALEN A, 1990, J BIOL CHEM, V265, P1158; KALEN A, 1987, BIOCHIM BIOPHYS ACTA, V926, P70, DOI 10.1016/0304-4165(87)90183-8; Knox C, 1998, J BIOL CHEM, V273, P25587, DOI 10.1074/jbc.273.40.25587; Kobayashi T, 1997, P NATL ACAD SCI USA, V94, P11857, DOI 10.1073/pnas.94.22.11857; Koehler CM, 1998, EMBO J, V17, P6477, DOI 10.1093/emboj/17.22.6477; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee PT, 1997, J BACTERIOL, V179, P1748, DOI 10.1128/jb.179.5.1748-1754.1997; LEPPIK RA, 1976, BIOCHIM BIOPHYS ACTA, V428, P146, DOI 10.1016/0304-4165(76)90116-1; MARBOIS BN, 1994, GENE, V138, P213; Marbois BN, 1996, J BIOL CHEM, V271, P2995, DOI 10.1074/jbc.271.6.2995; MCEWEN JE, 1986, J BIOL CHEM, V261, P1872; MEGANATHAN G, 1996, ESCHERICHIA COLI SAL, V1, P642; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; MOMOSE K, 1972, J BIOL CHEM, V247, P3930; MOORE HW, 1966, J AM CHEM SOC, V88, P564, DOI 10.1021/ja00955a031; NAKAHIGASHI K, 1992, J BACTERIOL, V174, P7352, DOI 10.1128/jb.174.22.7352-7359.1992; NAMBUDIRI AMD, 1977, BIOCHEM BIOPH RES CO, V76, P282, DOI 10.1016/0006-291X(77)90723-9; NARUTA Y, 1980, J ORG CHEM, V45, P4097, DOI 10.1021/jo01309a006; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; OHASHI A, 1982, J BIOL CHEM, V257, P3042; Okada K, 1998, FEBS LETT, V431, P241, DOI 10.1016/S0014-5793(98)00753-4; Okada K, 1997, J BACTERIOL, V179, P3058, DOI 10.1128/jb.179.9.3058-3060.1997; OLSON RE, 1983, VITAM HORM, V40, P1, DOI 10.1016/S0083-6729(08)60431-8; POON WW, 1995, ARCH BIOCHEM BIOPHYS, V320, P305, DOI 10.1016/0003-9861(95)90014-4; Poon WW, 1997, MOL ASPECTS MED, V18, pS121; READING DS, 1989, NATURE, V337, P655, DOI 10.1038/337655a0; REPETTO B, 1989, MOL CELL BIOL, V9, P2695, DOI 10.1128/MCB.9.6.2695; Santos-Ocana C, 1998, J BIOENERG BIOMEMBR, V30, P465, DOI 10.1023/A:1020542230308; Santos-Ocana C, 1998, J BIOL CHEM, V273, P8099, DOI 10.1074/jbc.273.14.8099; Shepherd JA, 1996, TETRAHEDRON LETT, V37, P2395, DOI 10.1016/0040-4039(96)00324-3; SHEPHERD JA, 1995, THESIS U CALIFORNIA; SHUNK CH, 1966, J ORG CHEM, V31, P1638, DOI 10.1021/jo01343a505; SIEBERT M, 1994, MICROBIOL-SGM, V140, P897, DOI 10.1099/00221287-140-4-897; STROOBAN.P, 1972, J BACTERIOL, V109, P134, DOI 10.1128/JB.109.1.134-139.1972; TECLEBRHAN H, 1995, BBA-LIPID LIPID MET, V1256, P157, DOI 10.1016/0005-2760(95)00016-6; TRUMPOWER BL, 1974, J BIOL CHEM, V249, P3041; VAJO Z, 1999, IN PRESS MAMM GENOME; VIDGREN J, 1994, NATURE, V368, P354, DOI 10.1038/368354a0; WU GH, 1992, J GEN MICROBIOL, V138, P2101, DOI 10.1099/00221287-138-10-2101; WU GH, 1993, J GEN MICROBIOL, V139, P1795, DOI 10.1099/00221287-139-8-1795; YAFFE MP, 1991, METHOD ENZYMOL, V194, P627; Zeng H, 1998, J BACTERIOL, V180, P3681, DOI 10.1128/JB.180.14.3681-3685.1998	81	92	98	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21665	21672		10.1074/jbc.274.31.21665	http://dx.doi.org/10.1074/jbc.274.31.21665			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419476	hybrid			2022-12-25	WOS:000081721100029
J	Inada, A; Someya, Y; Yamada, Y; Ihara, Y; Kubota, A; Ban, N; Watanabe, R; Tsuda, K; Seino, Y				Inada, A; Someya, Y; Yamada, Y; Ihara, Y; Kubota, A; Ban, N; Watanabe, R; Tsuda, K; Seino, Y			The cyclic AMP response element modulator family regulates the insulin gene transcription by interacting with transcription factor IID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE ZIPPER STRUCTURE; BINDING-PROTEIN CREB; HUMAN TFIID COMPLEX; CLONAL CELL-LINE; MOLECULAR-CLONING; CDNA CLONES; B-CELLS; EXPRESSION; DNA; ACTIVATOR	We analyzed a mechanism of transcriptional regulation of the human insulin gene by cyclic AMP response element modulator (CREM) through four cyclic AMP response elements (CREs). We isolated two novel CREM isoforms (CREM Delta Q1 and CREM Delta Q2), which lack one of the glutamine-rich domains, Q1 and Q2 respectively, and six known isoforms (CREM tau alpha, CREM alpha, inducible cyclic AMP early repressor (ICER) I, ICER I gamma, CREM-17X, and CREM-17) from rat pancreatic islets and the RINm5F pancreatic beta-cell line. CREM isoforms functioned as efficient transcriptional activators or repressors to modulate insulin promoter activity by binding to all of the insulin CREs. The binding activity of repressors is higher than that of activators and suppressed not only basal activity but also activator-induced activities. Furthermore, CREM activator interacted directly with the transcription factor IID components hTAF(II)130 and TATA box-binding protein (TBP). These results suggest that the activation of the insulin gene transcription by CREM activator is mediated by not only direct binding to the CREs but also by recruiting transcription factor IID to the insulin promoter via its interaction with hTAF(II)130 and TBP. On the other hand, the CREM repressor ICER competitively interrupts the binding of the activators to CREs and does not interact with either TBP or hTAF(II)130; therefore, it might fail to stabilize the basal transcriptional machinery and repress transactivation.	Kyoto Univ, Grad Sch Med, Dept Metab & Clin Nutr, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Fac Integrated Human Stud, Kyoto 6068501, Japan	Kyoto University; Kyoto University	Seino, Y (corresponding author), Kyoto Univ, Grad Sch Med, Dept Metab & Clin Nutr, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan.							ASHCROFT SJH, 1986, DIABETOLOGIA, V29, P727, DOI 10.1007/BF00870283; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; DEADOUETS C, 1995, MOL CELL BIOL, V15, P3301; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; DEGROOT RP, 1993, MOL ENDOCRINOL, V7, P1495, DOI 10.1210/me.7.11.1495; DELMAS V, 1993, MOL ENDOCRINOL, V7, P1502, DOI 10.1210/me.7.11.1502; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; Fitzgerald LR, 1996, J NEUROCHEM, V67, P490; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; Foulkes NS, 1996, P NATL ACAD SCI USA, V93, P14140, DOI 10.1073/pnas.93.24.14140; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; Gellersen B, 1997, MOL ENDOCRINOL, V11, P97, DOI 10.1210/me.11.1.97; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; GOTOH M, 1985, TRANSPLANTATION, V40, P437, DOI 10.1097/00007890-198510000-00018; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HAMMONDS P, 1987, FEBS LETT, V213, P149, DOI 10.1016/0014-5793(87)81481-3; HAMMONDS P, 1987, FEBS LETT, V223, P131, DOI 10.1016/0014-5793(87)80523-9; HISATAKE K, 1995, P NATL ACAD SCI USA, V92, P8195, DOI 10.1073/pnas.92.18.8195; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HSU SM, 1981, AM J CLIN PATHOL, V75, P734, DOI 10.1093/ajcp/75.5.734; Inada A, 1998, BIOCHEM BIOPH RES CO, V253, P712, DOI 10.1006/bbrc.1998.9833; INAGAKI N, 1992, P NATL ACAD SCI USA, V89, P1045, DOI 10.1073/pnas.89.3.1045; KLEMM RD, 1995, P NATL ACAD SCI USA, V92, P5788, DOI 10.1073/pnas.92.13.5788; LAOIDE BM, 1993, EMBO J, V12, P1179, DOI 10.1002/j.1460-2075.1993.tb05759.x; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MEYER TE, 1992, NUCLEIC ACIDS RES, V20, P6106, DOI 10.1093/nar/20.22.6106; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MONACO L, 1995, P NATL ACAD SCI USA, V92, P10673, DOI 10.1073/pnas.92.23.10673; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; Nantel F, 1996, NATURE, V380, P159, DOI 10.1038/380159a0; OIE HK, 1983, ENDOCRINOLOGY, V112, P1070, DOI 10.1210/endo-112-3-1070; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; Sander M, 1997, J MOL MED, V75, P327, DOI 10.1007/s001090050118; SASSONECORSI P, 1994, EMBO J, V13, P4717, DOI 10.1002/j.1460-2075.1994.tb06797.x; STEHLE JH, 1993, NATURE, V365, P314, DOI 10.1038/365314a0; Struhl K, 1996, CELL, V84, P179, DOI 10.1016/S0092-8674(00)80970-8; Tanese N, 1996, P NATL ACAD SCI USA, V93, P13611, DOI 10.1073/pnas.93.24.13611; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; Tao Y, 1997, J BIOL CHEM, V272, P6714, DOI 10.1074/jbc.272.10.6714; TJIAN R, 1995, SCI AM, V272, P54, DOI 10.1038/scientificamerican0295-54; WAEBER G, 1991, MOL ENDOCRINOL, V5, P1431, DOI 10.1210/mend-5-10-1431; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x	52	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21095	21103		10.1074/jbc.274.30.21095	http://dx.doi.org/10.1074/jbc.274.30.21095			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409662	hybrid			2022-12-25	WOS:000081613100053
J	Raab, M; Kang, H; da Silva, A; Zhu, XC; Rudd, CE				Raab, M; Kang, H; da Silva, A; Zhu, XC; Rudd, CE			FYN-T-FYB-SLP-76 interactions define a T-cell receptor zeta/CD3-mediated tyrosine phosphorylation pathway that up-regulates interleukin 2 transcription in T-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADAPTER PROTEIN SLP-76; C-CBL PROTOONCOGENE; ANTIGEN-RECEPTOR; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; MICE LACKING; INTRACELLULAR-LOCALIZATION; GENETIC-EVIDENCE; ZAP-70 KINASE; ZETA-CHAIN	Protein-tyrosine kinases p56(Lck), SYK, and ZAP-70 and downstream adaptors LAT and SLP-76 have been implicated as essential components in T-cell activation. Another lymphoid-specific adaptor FYB/SLAP has also been identified as a predominant binding partner of SLP-76 and the Src kinase FYN-T, although its role in the activation process has been unclear. Inthis study, we demonstrate that FYN-T selectively phosphorylates FYB providing a template for the recruitment of FYN-T and SLP-76 SH2 domain binding. This interaction is unusual in its distinct cytoplasmic localization and its long term stable kinetics of phosphorylation. Furthermore, we demonstrate for the first time that the co-expression of all three components of the FYN-T-FYB-SLP-76 matrix can synergistically up-regulate T-cell receptor-driven interleukin 2 transcription activity. These findings document the existence of a T-cell receptor-regulated FYN-T-FYB pathway that interfaces with the adaptor SLP-76 and cap-regulates lymphokine production in T-cells.	Harvard Med Sch, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Div Tumor Immunol, Boston, MA 02115 USA; Harvard Med Sch, Dept Med, Boston, MA 02115 USA; Harvard Med Sch, Dept Pathol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Rudd, CE (corresponding author), Harvard Med Sch, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Div Tumor Immunol, Boston, MA 02115 USA.		Rudd, Christopher E/ABF-7259-2021; Rudd, Christopher E/GOH-2021-2022	Rudd, Christopher E/0000-0001-5295-9019				APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; Boussiotis VA, 1996, J EXP MED, V184, P365, DOI 10.1084/jem.184.2.365; BROWN M, 1977, J GEN VIROL, V36, P361, DOI 10.1099/0022-1317-36-2-361; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; Clements JL, 1998, SCIENCE, V281, P416, DOI 10.1126/science.281.5375.416; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; daSilva AJ, 1997, J IMMUNOL, V158, P2007; DASILVA AJ, 1992, MOL IMMUNOL, V29, P1417, DOI 10.1016/0161-5890(92)90215-J; DaSilva AJ, 1997, P NATL ACAD SCI USA, V94, P7493, DOI 10.1073/pnas.94.14.7493; DASILVA AJ, 1993, J EXP MED, V178, P2107, DOI 10.1084/jem.178.6.2107; DAVIDSON D, 1994, MOL CELL BIOL, V14, P4554, DOI 10.1128/MCB.14.7.4554; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; DUPLAY P, 1994, J EXP MED, V179, P1163, DOI 10.1084/jem.179.4.1163; Fang N, 1996, J IMMUNOL, V157, P3769; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; Gauen LKT, 1996, J CELL BIOL, V133, P1007, DOI 10.1083/jcb.133.5.1007; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; Groves T, 1996, IMMUNITY, V5, P417, DOI 10.1016/S1074-7613(00)80498-7; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEY SC, 1994, J CELL BIOL, V125, P639, DOI 10.1083/jcb.125.3.639; LUO KX, 1992, MOL CELL BIOL, V12, P4724, DOI 10.1128/MCB.12.10.4724; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; Musci MA, 1997, J BIOL CHEM, V272, P11674, DOI 10.1074/jbc.272.18.11674; MUSTELIN T, 1994, IMMUNITY, V1, P351, DOI 10.1016/1074-7613(94)90065-5; Onodera H, 1996, J BIOL CHEM, V271, P22225, DOI 10.1074/jbc.271.36.22225; Peterson EJ, 1998, CURR OPIN IMMUNOL, V10, P337, DOI 10.1016/S0952-7915(98)80173-8; Pivniouk V, 1998, CELL, V94, P229, DOI 10.1016/S0092-8674(00)81422-1; Qian DP, 1997, J EXP MED, V185, P1253, DOI 10.1084/jem.185.7.1253; QUILL H, 1992, J IMMUNOL, V149, P2887; Raab M, 1996, BIOCHEM BIOPH RES CO, V222, P50, DOI 10.1006/bbrc.1996.0696; Raab M, 1997, IMMUNITY, V6, P155, DOI 10.1016/S1074-7613(00)80422-7; Rudd CE, 1999, CELL, V96, P5, DOI 10.1016/S0092-8674(00)80953-8; RUDD CE, 1994, IMMUNOL TODAY, V15, P225, DOI 10.1016/0167-5699(94)90248-8; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAROSI GA, 1992, INT IMMUNOL, V4, P1211, DOI 10.1093/intimm/4.11.1211; SloanLancaster J, 1997, J EXP MED, V186, P1713, DOI 10.1084/jem.186.10.1713; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TAICHMAN RS, 1992, CYTOKINE, V4, P441, DOI 10.1016/1043-4666(92)90004-B; TRAUB LM, 1995, J BIOL CHEM, V270, P4933, DOI 10.1074/jbc.270.9.4933; TSYGANKOV AY, 1994, J BIOL CHEM, V269, P7792; vanOers NSC, 1996, IMMUNITY, V5, P429, DOI 10.1016/S1074-7613(00)80499-9; WANGE RL, 1995, J BIOL CHEM, V270, P18730, DOI 10.1074/jbc.270.32.18730; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; Wardenburg JB, 1996, J BIOL CHEM, V271, P19641, DOI 10.1074/jbc.271.33.19641; Wardenburg JB, 1998, IMMUNITY, V9, P607, DOI 10.1016/S1074-7613(00)80658-5; Weber JR, 1998, J EXP MED, V187, P1157, DOI 10.1084/jem.187.7.1157; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	60	87	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21170	21179		10.1074/jbc.274.30.21170	http://dx.doi.org/10.1074/jbc.274.30.21170			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409671	hybrid			2022-12-25	WOS:000081613100062
J	Cristobal, S; Scotti, P; Luirink, J; von Heijne, G; de Gier, JWL				Cristobal, S; Scotti, P; Luirink, J; von Heijne, G; de Gier, JWL			The signal recognition particle-targeting pathway does not necessarily deliver proteins to the Sec-translocase in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNER MEMBRANE-PROTEIN; HIGH-LEVEL EXPRESSION; N-TERMINAL TAIL; INDEPENDENT TRANSLOCATION; CYTOPLASMIC MEMBRANE; ESSENTIAL COMPONENT; EXPORT; MITOCHONDRIA; MACHINERY; RNA	ProW is an Escherichia coli inner membrane protein that consists of a 100-residue-long periplasmic N-terminal tail (N-tail) followed by seven closely spaced transmembrane segments. N-tail translocation presumably proceeds in a C-to-N-terminal direction and represents a poorly understood aspect of membrane protein biogenesis. Here, using an in vivo depletion approach, we show that N-tail translocation in a ProW derivative comprising the N-tail and the first transmembrane segment fused to the globular P2 domain of leader peptidase depends both on the bacterial signal recognition particle (SRP) and the Sec-translocase. Surprisingly, however, a deletion construct with only one transmembrane segment downstream of the N-tail can assemble properly even under severe depletion of SecE, a central component of the Sec-translocase, but not under SRP-depletion conditions. To our knowledge, this is the first demonstration that the SRP-targeting pathway does not necessarily deliver SRP-dependent inner membrane proteins to the Sec-translocase. The data further suggest that N-tail translocation can proceed in the absence of a functional Sec-translocase.	Univ Stockholm, Arrhenius Lab, Dept Biochem, S-10691 Stockholm, Sweden; Biocentrum Amsterdam, Dept Microbiol, NL-1081 HV Amsterdam, Netherlands	Stockholm University; University of Amsterdam	de Gier, JWL (corresponding author), Univ Stockholm, Arrhenius Lab, Dept Biochem, S-10691 Stockholm, Sweden.	degier@biokemi.su.se	von Heijne, Gunnar/AAH-9389-2019; Luirink, Joen/AAB-8658-2021; von Heijne, Gunnar/F-5576-2011	von Heijne, Gunnar/0000-0002-4490-8569; Luirink, J./0000-0001-8431-0804; Cristobal, Susana/0000-0002-3894-2218; SCOTTI, Pier-Arnaldo/0000-0003-4427-3695				Akiyama Y, 1996, J BIOL CHEM, V271, P31196, DOI 10.1074/jbc.271.49.31196; Bernstein HD, 1998, P NATL ACAD SCI USA, V95, P14587, DOI 10.1073/pnas.95.25.14587; Bogsch EG, 1998, J BIOL CHEM, V273, P18003, DOI 10.1074/jbc.273.29.18003; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CSONKA LN, 1991, ANNU REV MICROBIOL, V45, P569, DOI 10.1146/annurev.mi.45.100191.003033; DALBEY RE, 1995, TRENDS CELL BIOL, V5, P380, DOI 10.1016/S0962-8924(00)89079-0; Dalbey RE, 1999, TRENDS BIOCHEM SCI, V24, P17, DOI 10.1016/S0968-0004(98)01333-4; de Gier JWL, 1998, P NATL ACAD SCI USA, V95, P14646, DOI 10.1073/pnas.95.25.14646; deGier JWL, 1996, FEBS LETT, V399, P307, DOI 10.1016/S0014-5793(96)01354-3; GOWRISHANKAR J, 1989, J BACTERIOL, V171, P1923, DOI 10.1128/jb.171.4.1923-1931.1989; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; He SC, 1997, MOL BIOL CELL, V8, P1449, DOI 10.1091/mbc.8.8.1449; Hell K, 1998, P NATL ACAD SCI USA, V95, P2250, DOI 10.1073/pnas.95.5.2250; JOHNSTON S, 1985, GENE, V34, P137, DOI 10.1016/0378-1119(85)90121-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; McMurry JL, 1999, J BIOL CHEM, V274, P6776, DOI 10.1074/jbc.274.10.6776; Mitsopoulos C, 1997, FEBS LETT, V419, P18, DOI 10.1016/S0014-5793(97)01413-0; POGLIANO JA, 1994, EMBO J, V13, P554, DOI 10.1002/j.1460-2075.1994.tb06293.x; Qi HY, 1999, J BIOL CHEM, V274, P8993, DOI 10.1074/jbc.274.13.8993; RIBES V, 1990, CELL, V63, P591, DOI 10.1016/0092-8674(90)90454-M; Saaf A, 1998, J BIOL CHEM, V273, P30415, DOI 10.1074/jbc.273.46.30415; Settles AM, 1998, TRENDS CELL BIOL, V8, P494, DOI 10.1016/S0962-8924(98)01387-7; Traxler B, 1996, J BIOL CHEM, V271, P12394, DOI 10.1074/jbc.271.21.12394; Valent QA, 1998, EMBO J, V17, P2504, DOI 10.1093/emboj/17.9.2504; WHITLEY P, 1995, J BIOL CHEM, V270, P29831; WHITLEY P, 1994, EMBO J, V13, P4653, DOI 10.1002/j.1460-2075.1994.tb06788.x; Yang YB, 1997, J BIOL CHEM, V272, P13660, DOI 10.1074/jbc.272.21.13660	27	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20068	20070		10.1074/jbc.274.29.20068	http://dx.doi.org/10.1074/jbc.274.29.20068			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400614	Green Published, hybrid			2022-12-25	WOS:000081438300007
J	Hayashi, Y; Nishio, M; Naito, Y; Yokokura, H; Nimura, Y; Hidaka, H; Watanabe, Y				Hayashi, Y; Nishio, M; Naito, Y; Yokokura, H; Nimura, Y; Hidaka, H; Watanabe, Y			Regulation of neuronal nitric-oxide synthase by calmodulin kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; ELECTROPHORETIC TRANSFER; POLYACRYLAMIDE GELS; PHOSPHORYLATION; BINDING; IDENTIFICATION; NITROCELLULOSE; DOMAINS	Phosphorylation of neuronal nitric-oxide synthase (nNOS) by Ca2+/calmodulin (CaM)-dependent protein kinases (CaM kinases) including CaM kinase I alpha (CaM-K I alpha), CaM kinase II alpha (CaM-K II alpha), and CaM kinase IV (CaM-K IV), was studied. It was found that purified recombinant nNOS was phosphorylated by CaM-K I alpha, CaM-K II alpha, and CaM-K IV at Ser(847) in vitro. Replacement of Ser(847) with Ala (S847A) prevented phosphorylation by CaM kinases, Phosphorylated recombinant wild-type nNOS at Ser(847) (approximate to 0.5 mol of phosphate incorporation into nNOS) exhibited a 30% decrease of V-max with little change of both the K-m for L-arginine and K-act for CaM relative to unphosphorylated enzyme. The activity of mutant S847D was decreased to a level 50-60% as much as the wild-type enzyme. The decreased NOS enzyme activity of phosphorylated nNOS at Ser(847) and mutant S847D was partially due to suppression of CaM binding, but not to impairment of dimer formation which is thought to be essential for enzyme activation. Inactive nNOS lacking CaM-binding ability was generated by mutation of Lys(732)-Lys-Leu to Asp(732)-Asp-Glu (Watanabe, Y., Hu, Y., and Hidaka, H. (1997) FEBS Lett. 403, 75-78). It was phosphorylated by CaM kinases, as was the wild-type enzyme, indicating that CaM-nNOS binding was not required for the phosphorylation reaction. We developed antibody NP847, which specifically recognize nNOS in its phosphorylated state at Ser(847). Using the antibody NP847, we obtained evidence that nNOS is phosphorylated at Ser(847) in rat brain. Thus, our results suggest that CaM kinase-induced phosphorylation of nNOS at Ser(847) alters the activity control of this enzyme.	Nagoya Univ, Sch Med, Dept Pharmacol, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Surg 1, Showa Ku, Nagoya, Aichi 4668550, Japan	Nagoya University; Nagoya University	Watanabe, Y (corresponding author), Nagoya Univ, Sch Med, Dept Pharmacol, Showa Ku, Nagoya, Aichi 4668550, Japan.			Watanabe, Yasuo/0000-0003-2232-0091				ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1992, J BIOL CHEM, V267, P10976; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Brenman JE, 1996, J NEUROSCI, V16, P7407; BRICKEY DA, 1994, J BIOL CHEM, V269, P29047; BRUNE B, 1991, BIOCHEM BIOPH RES CO, V181, P921, DOI 10.1016/0006-291X(91)91279-L; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Colbran R J, 1990, Curr Top Cell Regul, V31, P181; DINERMAN JL, 1994, NEUROPHARMACOLOGY, V33, P1245, DOI 10.1016/0028-3908(94)90023-X; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; Jaffrey SR, 1998, NEURON, V20, P115, DOI 10.1016/S0896-6273(00)80439-0; Kantor DB, 1996, SCIENCE, V274, P1744, DOI 10.1126/science.274.5293.1744; KLATT P, 1992, J BIOL CHEM, V267, P11374; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; NAIRN AC, 1994, SEMIN CANCER BIOL, V5, P295; NAKANE M, 1991, BIOCHEM BIOPH RES CO, V180, P1396, DOI 10.1016/S0006-291X(05)81351-8; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NISHIZAWA K, 1991, J BIOL CHEM, V266, P3074; RICHARDS MK, 1994, BIOCHEMISTRY-US, V33, P14723, DOI 10.1021/bi00253a010; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; Soderling TR, 1996, BBA-PROTEIN STRUCT M, V1297, P131, DOI 10.1016/S0167-4838(96)00105-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Watanabe Y, 1997, FEBS LETT, V403, P75, DOI 10.1016/S0014-5793(97)00012-4; YOKOKURA H, 1995, J BIOL CHEM, V270, P23851, DOI 10.1074/jbc.270.40.23851	31	156	156	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20597	20602		10.1074/jbc.274.29.20597	http://dx.doi.org/10.1074/jbc.274.29.20597			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400690	hybrid			2022-12-25	WOS:000081438300083
J	O'Donnell, VB; Taylor, KB; Parthasarathy, S; Kuhn, H; Koesling, D; Friebe, A; Bloodsworth, A; Darley-Usmar, VM; Freeman, BA				O'Donnell, VB; Taylor, KB; Parthasarathy, S; Kuhn, H; Koesling, D; Friebe, A; Bloodsworth, A; Darley-Usmar, VM; Freeman, BA			15-lipoxygenase catalytically consumes nitric oxide and impairs activation of guanylate cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; DIET-INDUCED ATHEROSCLEROSIS; OXIDIZED LIPID DERIVATIVES; RELAXING FACTOR; HYPERCHOLESTEROLEMIC RABBITS; SOYBEAN LIPOXYGENASE-1; OXIDATIVE MODIFICATION; MEDIATED OXIDATION; METHYL LINOLEATE; PEROXYL RADICALS	Analysis of purified soybean and rabbit reticulocyte 15-lipoxygenase (15-LOX) and PA317 cells transfected with human 15-LOX revealed a rapid rate of linoleate-dependent nitric oxide ((NO)-N-.) uptake that coincided with reversible inhibition of product ((13S)-hydroperoxyoctadecadienoic acid, or (13S)-HPODE) formation. No reaction of (NO)-N-. (up to 2 mu M) with either native (E-red) or ferric LOXs (0.2 mu M) metal centers to form nitrosyl complexes occurred at these (NO)-N-. concentrations. During HPODE-dependent activation of 15-LOX, there was consumption of 2 mol of (NO)-N-./mol of 15-LOX. Stopped flow fluorescence spectroscopy showed that (NO)-N-. (2.2 mu M) did not alter the rate or extent of (13S)-HPODE-induced tryptophan fluorescence quenching associated with 15-LOX activation. Additionally, (NO)-N-. does not inhibit the anaerobic peroxidase activity of 15-LOX, inferring that the inhibitory actions of (NO)-N-. are due to reaction with the enzyme-bound lipid peroxyl radical, rather than impairment of (13S)-HPODE-dependent enzyme activation. From this, a mechanism of 15-LOX inhibition by (NO)-N-. is proposed whereby reaction of (NO)-N-. with EredLOO. generates E-red and LOONO, which hydrolyzes to (13S)-HPODE and nitrite (NO2-). Reactivation of E-red, considerably slower than dioxygenase activity, is then required to complete the catalytic cycle and leads to a net inhibition of rates of (13S)-HPODE formation. This reaction of (NO)-N-. with 15-LOX inhibited (NO)-N-.-dependent activation of soluble guanylate cyclase and consequent cGMP production. Since accelerated (NO)-N-. production, enhanced 15-LOX gene expression, and 15-LOX product formation occurs in diverse inflammatory conditions, these observations indicate that reactions of (NO)-N-. with lipoxygenase peroxyl radical intermediates will result in modulation of both (NO)-N-. bioavailability and rates of production of lipid signaling mediators.	Univ Alabama, Dept Anesthesiol, Birmingham, AL 35233 USA; Univ Alabama, Dept Biochem & Mol Biol, Birmingham, AL 35233 USA; Univ Alabama, Dept Pathol, Birmingham, AL 35233 USA; Univ Alabama, Ctr Free Radical Biol, Birmingham, AL 35233 USA; Emory Univ, Dept Obstet & Gynecol, Atlanta, GA 30322 USA; Humboldt Univ, Inst Biochem, Berlin, Germany; Free Univ Berlin, Inst Pharmacol, D-1000 Berlin, Germany	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Emory University; Humboldt University of Berlin; Free University of Berlin	Freeman, BA (corresponding author), Univ Alabama, Dept Anesthesiol, 946 THT,619 19th St S, Birmingham, AL 35233 USA.		Darley-Usmar, Victor/F-7656-2010; Freeman, Bruce A/H-9342-2012; Parthasarathy, Sampath/G-5602-2011; O'Donnell, Valerie/C-6948-2012; Parthasarathy, Sampath/AAP-3361-2020	/0000-0003-4089-8460; Darley-Usmar, Victor/0000-0001-8921-7086	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL058418, R01HL051245] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL51245, P60-HL58418, P01-HL40456] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUERBACH BJ, 1992, ANAL BIOCHEM, V201, P375, DOI 10.1016/0003-2697(92)90354-A; BELKNER J, 1993, EUR J BIOCHEM, V213, P251, DOI 10.1111/j.1432-1033.1993.tb17755.x; Belkner J, 1998, J BIOL CHEM, V273, P23225, DOI 10.1074/jbc.273.36.23225; BENZ DJ, 1995, J BIOL CHEM, V270, P5191, DOI 10.1074/jbc.270.10.5191; Brovkovych V, 1999, J PHARMACEUT BIOMED, V19, P135, DOI 10.1016/S0731-7085(98)00090-9; CAYATTE AJ, 1994, ARTERIOSCLER THROMB, V14, P753, DOI 10.1161/01.ATV.14.5.753; COOKE JP, 1994, ARTERIOSCLER THROMB, V14, P653, DOI 10.1161/01.ATV.14.5.653; DAVIES MG, 1995, J SURG RES, V59, P35, DOI 10.1006/jsre.1995.1129; EGMOND MR, 1977, EUR J BIOCHEM, V76, P469, DOI 10.1111/j.1432-1033.1977.tb11617.x; EGMOND MR, 1975, BIOCHIM BIOPHYS ACTA, V397, P43, DOI 10.1016/0005-2744(75)90177-1; FINAZZIAGRO A, 1973, BIOCHIM BIOPHYS ACTA, V326, P462, DOI 10.1016/0005-2760(73)90146-X; FOLCIK VA, 1995, J CLIN INVEST, V96, P504, DOI 10.1172/JCI118062; GALLON AA, 1993, LIPIDS, V28, P125, DOI 10.1007/BF02535776; GALLON AA, 1994, LIPIDS, V29, P171, DOI 10.1007/BF02536725; GALPIN JR, 1978, BIOCHIM BIOPHYS ACTA, V536, P356, DOI 10.1016/0005-2795(78)90494-4; GOSS SPA, 1995, CHEM RES TOXICOL, V8, P800, DOI 10.1021/tx00047a021; GRYGLEWSKI RJ, 1986, NATURE, V320, P454, DOI 10.1038/320454a0; HAMBERG M, 1967, J BIOL CHEM, V242, P5329; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P3400, DOI 10.1073/pnas.71.9.3400; Harats D, 1997, ATHEROSCLEROSIS, V134, P279, DOI 10.1016/S0021-9150(97)89459-2; HAYASHI K, 1995, FEBS LETT, V370, P37, DOI 10.1016/0014-5793(95)00786-9; HOGG N, 1993, FEBS LETT, V334, P170, DOI 10.1016/0014-5793(93)81706-6; Holzhutter HG, 1997, EUR J BIOCHEM, V245, P608, DOI 10.1111/j.1432-1033.1997.00608.x; IGNARRO LJ, 1988, J PHARMACOL EXP THER, V246, P218; IGNARRO LJ, 1993, P NATL ACAD SCI USA, V90, P8103, DOI 10.1073/pnas.90.17.8103; ISHIROPOOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V289, P446; JESSUP W, 1992, BIOCHIM BIOPHYS ACTA, V1180, P73, DOI 10.1016/0925-4439(92)90029-M; KANNER J, 1992, LIPIDS, V27, P46, DOI 10.1007/BF02537058; Kuban RJ, 1998, BIOCHEM J, V332, P237, DOI 10.1042/bj3320237; Kuhn H, 1996, PROG LIPID RES, V35, P203, DOI 10.1016/S0163-7827(96)00008-2; KUHN H, 1994, J EXP MED, V179, P1903, DOI 10.1084/jem.179.6.1903; LEFER AM, 1993, ARTERIOSCLER THROMB, V13, P771, DOI 10.1161/01.ATV.13.6.771; LEWIS RS, 1995, J BIOL CHEM, V270, P29350, DOI 10.1074/jbc.270.49.29350; Liu XP, 1998, J BIOL CHEM, V273, P18709, DOI 10.1074/jbc.273.30.18709; Liu XP, 1998, P NATL ACAD SCI USA, V95, P2175, DOI 10.1073/pnas.95.5.2175; LUDWIG P, 1987, EUR J BIOCHEM, V168, P325, DOI 10.1111/j.1432-1033.1987.tb13424.x; MALORANTA U, 1994, FEBS LETT, V337, P179, DOI 10.1016/0014-5793(94)80269-6; MINOR RL, 1990, J CLIN INVEST, V86, P2109, DOI 10.1172/JCI114949; MIYANOHARA A, 1988, P NATL ACAD SCI USA, V85, P6538, DOI 10.1073/pnas.85.17.6538; NELSON MJ, 1987, J BIOL CHEM, V262, P12137; O'Donnell VB, 1999, CHEM RES TOXICOL, V12, P83, DOI 10.1021/tx980207u; ODonnell VB, 1997, BIOCHEMISTRY-US, V36, P15216, DOI 10.1021/bi971891z; OLeary VJ, 1996, FREE RADICAL BIO MED, V20, P525, DOI 10.1016/0891-5849(95)02084-5; PADMAJA S, 1993, BIOCHEM BIOPH RES CO, V195, P539, DOI 10.1006/bbrc.1993.2079; PARTHASARATHY S, 1989, P NATL ACAD SCI USA, V86, P1046, DOI 10.1073/pnas.86.3.1046; RANKIN SM, 1991, J LIPID RES, V32, P449; RAPOPORT SM, 1990, BLOOD CELL BIOCH, V1, P151; RUBBO H, 1994, J BIOL CHEM, V269, P26066; Rubbo H, 1995, ARCH BIOCHEM BIOPHYS, V324, P15, DOI 10.1006/abbi.1995.9935; SALERNO JC, 1979, BIOCHIM BIOPHYS ACTA, V579, P246, DOI 10.1016/0005-2795(79)90104-1; SCHEWE T, 1987, PROSTAGLANDINS RELAT, P229; Schultz G., 1984, METHOD ENZYMAT AN, P379; Sendobry SM, 1997, BRIT J PHARMACOL, V120, P1199, DOI 10.1038/sj.bjp.0701007; SHEN J, 1998, J CLIN INVEST, V98, P2201; STONE JR, 1996, BIOCHEMISTRY-US, V35, P1094; VERBEUREN TJ, 1990, EUR J PHARMACOL, V191, P173, DOI 10.1016/0014-2999(90)94145-N; WALLINGTON TJ, 1992, CHEM REV, V92, P667, DOI 10.1021/cr00012a008; WEISNER R, 1996, FEBS LETT, V389, P229; White CR, 1996, P NATL ACAD SCI USA, V93, P8745, DOI 10.1073/pnas.93.16.8745; YAMOMOTO S, 1995, J LIPID MEDIAT CELL, V12, P195; YATES MT, 1992, FEBS LETT, V309, P135, DOI 10.1016/0014-5793(92)81081-V; YLAHERTTUALA S, 1991, J CLIN INVEST, V87, P1146, DOI 10.1172/JCI115111; YLAHERTTUALA S, 1995, J CLIN INVEST, V95, P2692, DOI 10.1172/JCI117971; YOKOYAMA C, 1986, J BIOL CHEM, V261, P6714	64	67	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20083	20091		10.1074/jbc.274.29.20083	http://dx.doi.org/10.1074/jbc.274.29.20083			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400618	hybrid			2022-12-25	WOS:000081438300011
J	Sharma, N; Crane, A; Clement, JP; Gonzalez, G; Babenko, AP; Bryan, J; Aguilar-Bryan, L				Sharma, N; Crane, A; Clement, JP; Gonzalez, G; Babenko, AP; Bryan, J; Aguilar-Bryan, L			The c terminus of SUR1 is required for trafficking of KKATP channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DI-LEUCINE MOTIF; K-ATP CHANNELS; SULFONYLUREA RECEPTOR; CYTOPLASMIC DOMAIN; CARBOXYL-TERMINUS; DOWN-REGULATION; TRANSPORT; MEMBRANE; ENDOCYTOSIS; RESIDUES	In beta cells from the pancreas, ATP-sensitive potassium channels, or K-ATP channels, are composed of two subunits, SUR1 and K(IR)6.2, assembled in a (SUR1/ K(IR)6.2)(4) stoichiometry. The correct stoichiometry of channels at the cell surface is tightly regulated by the presence of novel endoplasmic reticulum (ER) retention signals in SUR1 and K(IR)6.2; incompletely assembled K-ATP channels fail to exit the ER/cis-Golgi compartments. In addition to these retrograde signals, we show that the C terminus of SUR1 has an anterograde signal, composed in part of a dileucine motif and downstream phenylalanine, which is required for K-ATP channels to exit the ER/cis-Golgi compartments and transit to the cell surface. Deletion of as few as seven amino acids, including the phenylalanine, from SUR1 markedly reduces surface expression of K-ATP channels. Mutations leading to truncation of the C terminus of SUR1 are one cause of a severe, recessive form of persistent hyperinsulinemic hypoglycemia of infancy. We propose that the complete loss of beta cell K-ATP channel activity seen in this form of hyperinsulinism is a failure of K-ATP channels to traffic to the plasma membrane.	Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Aguilar-Bryan, L (corresponding author), Baylor Coll Med, Dept Med, 537E,1 Baylor Plaza, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052771, R01DK044311] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44311, DK52771] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguilar-Bryan L, 1999, ENDOCR REV, V20, P101, DOI 10.1210/er.20.2.101; Aguilar-Bryan L, 1998, METHOD ENZYMOL, V292, P732; Aguilar-Bryan L, 1998, PHYSIOL REV, V78, P227, DOI 10.1152/physrev.1998.78.1.227; Aguilar-Bryan L, 1996, DIABETES REV, V4, P336; AGUILARBRYAN L, 1990, J BIOL CHEM, V265, P8218; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Babenko AP, 1999, FEBS LETT, V445, P131, DOI 10.1016/S0014-5793(99)00102-7; Babenko AP, 1998, CIRC RES, V83, P1132, DOI 10.1161/01.RES.83.11.1132; Bannykh SI, 1998, TRENDS CELL BIOL, V8, P21, DOI 10.1016/S0962-8924(97)01184-7; Barlowe C, 1998, BBA-MOL CELL RES, V1404, P67, DOI 10.1016/S0167-4889(98)00047-0; BREMNES B, 1994, J CELL SCI, V107, P2021; Bryan J, 1997, CURR OPIN CELL BIOL, V9, P553, DOI 10.1016/S0955-0674(97)80033-6; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; DIETRICH J, 1994, EMBO J, V13, P2156, DOI 10.1002/j.1460-2075.1994.tb06492.x; Dittrich E, 1996, J BIOL CHEM, V271, P5487, DOI 10.1074/jbc.271.10.5487; Drain P, 1998, P NATL ACAD SCI USA, V95, P13953, DOI 10.1073/pnas.95.23.13953; Dunne MJ, 1997, NEW ENGL J MED, V336, P703, DOI 10.1056/NEJM199703063361005; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; Geisler C, 1998, J BIOL CHEM, V273, P21316, DOI 10.1074/jbc.273.33.21316; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; Kreis TE, 1995, ANNU REV CELL DEV BI, V11, P677, DOI 10.1146/annurev.cb.11.110195.003333; Kuehn MJ, 1997, CURR OPIN CELL BIOL, V9, P477, DOI 10.1016/S0955-0674(97)80022-1; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; Nickel W, 1998, HISTOCHEM CELL BIOL, V109, P477, DOI 10.1007/s004180050249; OGATA S, 1994, J BIOL CHEM, V269, P5210; PERMUTT MA, 1996, DIABETES REV, V4, P347; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; Schulein R, 1998, MOL PHARMACOL, V54, P525, DOI 10.1124/mol.54.3.525; Schwanstecher M, 1999, Methods Enzymol, V294, P445; SHIN JY, 1991, J BIOL CHEM, V266, P10658; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Warren G, 1998, CURR OPIN CELL BIOL, V10, P493, DOI 10.1016/S0955-0674(98)80064-1; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	34	128	131	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20628	20632		10.1074/jbc.274.29.20628	http://dx.doi.org/10.1074/jbc.274.29.20628			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400694	hybrid			2022-12-25	WOS:000081438300087
J	Steffgen, J; Burckhardt, BC; Langenberg, C; Kuhne, L; Muller, GA; Burckhardt, G; Wolff, NA				Steffgen, J; Burckhardt, BC; Langenberg, C; Kuhne, L; Muller, GA; Burckhardt, G; Wolff, NA			Expression cloning and characterization of a novel sodium dicarboxylate cotransporter from winter flounder kidney	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOLATERAL MEMBRANE-VESICLES; BRUSH-BORDER MEMBRANES; ORGANIC ANION; NA+/DICARBOXYLATE COTRANSPORTER; PROXIMAL CONVOLUTION; STRUCTURE PREDICTION; RAT-KIDNEY; TRANSPORT; SECRETION; SEQUENCE	A cDNA coding for a Na+-dicarboxylate cotransporter, fNaDC-3, from winter flounder (Pseudopleuronectes americanus) kidney was isolated by functional expression in Xenopus laevis oocytes, The fNaDC-3 cDNA is 2384 nucleotides long and encodes a protein of 601 amino acids with a calculated molecular mass of 66.4 kDa, Secondary structure analysis predicts at least eight membrane-spanning domains. Transport of succinate by fNaDC-3 was sodium dependent, could be inhibited by lithium, and evoked an inward current. The apparent affinity constant (K-m) of fNaDC-3 for succinate of 30 mu M resembles that of Na+-dicarboxylate transport in the basolateral membrane of mammalian renal proximal tubules. The substrates specific for the basolateral transporter, 2,3-dimethylsuccinate and cis-aconitate, not only inhibited succinate uptake but also evoked inward currents, proving that they are transported by fNaDC-3. Succinate transport via fNaDC-3 decreased by lowering pH, as did citrate transport, although much more moderately. These characteristics suggest that fNaDC-3 is a new type of Na+-dicarboxylate transporter that most likely corresponds to the Na+-dicarboxylate cotransporter in the basolateral membrane of mammalian renal proximal tubules.	Univ Gottingen, Abt Nephrol & Rheumatol, D-37075 Gottingen, Germany; Univ Gottingen, Abt Vegetat Physiol & Pathophysiol, D-37073 Gottingen, Germany	University of Gottingen; University of Gottingen	Steffgen, J (corresponding author), Univ Gottingen, Abt Nephrol & Rheumatol, Robert Koch Str 40, D-37075 Gottingen, Germany.							Bai LQ, 1997, AM J PHYSIOL-GASTR L, V273, pG267, DOI 10.1152/ajpgi.1997.273.2.G267; BURCKHARDT G, 1989, KIDNEY INT, V36, P370, DOI 10.1038/ki.1989.205; BURCKHARDT G, 1984, PFLUG ARCH EUR J PHY, V401, P254, DOI 10.1007/BF00582592; Chen XZ, 1998, J BIOL CHEM, V273, P20972, DOI 10.1074/jbc.273.33.20972; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; Edwards RM, 1997, J PHARMACOL EXP THER, V281, P1059; FUKUHARA Y, 1983, AM J PHYSIOL, V245, pF374, DOI 10.1152/ajprenal.1983.245.3.F374; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; HUANG XQ, 1994, COMPUT APPL BIOSCI, V10, P227; JORGENSEN KE, 1983, AM J PHYSIOL, V244, pF686, DOI 10.1152/ajprenal.1983.244.6.F686; Khatri IA, 1996, BBA-GENE STRUCT EXPR, V1309, P58, DOI 10.1016/S0167-4781(96)00138-8; KINTER WB, 1975, FORTSCHR ZOOL, V23, P223; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MARKOVICH D, 1993, P NATL ACAD SCI USA, V90, P8073, DOI 10.1073/pnas.90.17.8073; MILLER DS, 1991, AM J PHYSIOL, V261, pR1470, DOI 10.1152/ajpregu.1991.261.6.R1470; Pajor AM, 1998, J BIOL CHEM, V273, P18923, DOI 10.1074/jbc.273.30.18923; Pajor AM, 1996, AM J PHYSIOL-RENAL, V270, pF642, DOI 10.1152/ajprenal.1996.270.4.F642; Pajor AM, 1996, AM J PHYSIOL-CELL PH, V271, pC1808, DOI 10.1152/ajpcell.1996.271.6.C1808; PAJOR AM, 1995, J BIOL CHEM, V270, P5779, DOI 10.1074/jbc.270.11.5779; PRITCHARD JB, 1993, PHYSIOL REV, V73, P765, DOI 10.1152/physrev.1993.73.4.765; Sekine T, 1998, AM J PHYSIOL-RENAL, V275, pF298, DOI 10.1152/ajprenal.1998.275.2.F298; SHERIDAN E, 1983, PFLUG ARCH EUR J PHY, V399, P18, DOI 10.1007/BF00652517; SIMPSON D, 1983, AM J PHYSIOL, V244, P223; STEFFGEN J, 1994, BIOCHEM J, V297, P35, DOI 10.1042/bj2970035; Turk E, 1996, J BIOL CHEM, V271, P1925, DOI 10.1074/jbc.271.4.1925; ULLRICH KJ, 1989, KIDNEY INT, V36, P78, DOI 10.1038/ki.1989.164; ULLRICH KJ, 1984, PFLUG ARCH EUR J PHY, V400, P241, DOI 10.1007/BF00581554; ULLRICH KJ, 1994, BBA-REV BIOMEMBRANES, V1197, P45, DOI 10.1016/0304-4157(94)90018-3; Ullrich KJ, 1997, J MEMBRANE BIOL, V158, P95, DOI 10.1007/s002329900247; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; WERNER A, 1994, AM J PHYSIOL, V267, pF311, DOI 10.1152/ajprenal.1994.267.2.F311; Wolff NA, 1997, FEBS LETT, V417, P287, DOI 10.1016/S0014-5793(97)01304-5; WRIGHT SH, 1982, BIOCHIM BIOPHYS ACTA, V684, P287, DOI 10.1016/0005-2736(82)90019-0; WRIGHT SH, 1987, AM J PHYSIOL, V253, pF432, DOI 10.1152/ajprenal.1987.253.3.F432; [No title captured]	36	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20191	20196		10.1074/jbc.274.29.20191	http://dx.doi.org/10.1074/jbc.274.29.20191			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400635	hybrid			2022-12-25	WOS:000081438300028
J	Suzuki, T; Uchida-Toita, M; Yoshida, M				Suzuki, T; Uchida-Toita, M; Yoshida, M			Tax protein of HTLV-1 inhibits CBP/p300-mediated transcription by interfering with recruitment of CBP/p300 onto DNA element of E-box or p53 binding site	ONCOGENE			English	Article						HTLV-1; Tax; trans-repression; CBP/p300	T-CELL LEUKEMIA; VIRUS TYPE-1 TAX; ACUTE MYELOID-LEUKEMIA; NF-KAPPA-B; CREB BINDING; GENE-EXPRESSION; HISTONE ACETYLTRANSFERASE; TRANSACTIVATOR TAX; ONCOPROTEIN TAX; COACTIVATOR CBP	Tax protein of human T-cell leukemia virus type 1 (HTLV-1) is a potent transcriptional regulator which can activate or repress specific cellular genes and has been proposed to contribute to leukemogenic processes in adult T-cell leukemia, The molecular mechanism of Tax-mediated trans-activation has been well investigated. However, trans-repression by Tax remains to be studied in detail, although it is known to require a specific DIVA element such as E-box or p53 binding site. Examining possible mechanisms of trans-repression, we found that co-expression of E47 and p300 activated E-box dependent transcription and this activation was efficiently repressed by Tax. In this system, Tax bound to p300 and decreased the level of p300 complexed on the E-box element. Similarly, Tax inhibited transcription directed by p53 and CBP, reducing the level of CBP on the p53 binding site. These results indicate that Tax interferes with recruitment of CBP/p300 into protein complexes on E-box and p53 binding site through its binding to CBP/p300. In contrast to these findings, we observed that Tax increased the level of CBP on the viral 21-bp enhancer which is trans-activated by Tax. From these observations, we propose a universal mechanism for Tax-mediated trans-repression and trans-activation of transcription in which Tax binds to CBP/p300 and determines the accessibility of CBP/p300 to protein complexes on specific DNA element.	Univ Tokyo, Inst Med Sci, Dept Cellular & Mol Biol, Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Yoshida, M (corresponding author), Univ Tokyo, Inst Med Sci, Dept Cellular & Mol Biol, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.							Akagi T, 1997, FEBS LETT, V406, P263, DOI 10.1016/S0014-5793(97)00280-9; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bex F, 1998, MOL CELL BIOL, V18, P2392, DOI 10.1128/MCB.18.4.2392; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Brauweiler A, 1997, VIROLOGY, V231, P135, DOI 10.1006/viro.1997.8509; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Colgin MA, 1998, J VIROL, V72, P9396, DOI 10.1128/JVI.72.11.9396-9399.1998; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Lemasson I, 1997, J VIROL, V71, P1975, DOI 10.1128/JVI.71.3.1975-1983.1997; Lenzmeier BA, 1998, MOL CELL BIOL, V18, P721, DOI 10.1128/MCB.18.2.721; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Mulloy JC, 1998, J VIROL, V72, P8852, DOI 10.1128/JVI.72.11.8852-8860.1998; Muraoka M, 1996, ONCOGENE, V12, P1565; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; POEISZ BJ, 1980, P NATL ACAD SCI USA, V77, P7415; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; SUZUKI T, 1994, ONCOGENE, V9, P3099; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; UITTENBOGAARD MN, 1994, J BIOL CHEM, V269, P22466; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yoshida M, 1993, Trends Microbiol, V1, P131, DOI 10.1016/0966-842X(93)90127-D; YOSHIDA M, 1995, CURR TOP MICROBIOL, V193, P79; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	42	83	84	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	1999	18	28					4137	4143		10.1038/sj.onc.1202766	http://dx.doi.org/10.1038/sj.onc.1202766			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	216FP	10435595				2022-12-25	WOS:000081431000011
J	Moro, O; Wakita, K; Ohnuma, M; Denda, S; Lerner, EA; Tajima, M				Moro, O; Wakita, K; Ohnuma, M; Denda, S; Lerner, EA; Tajima, M			Functional characterization of structural alterations in the sequence of the vasodilatory peptide maxadilan yields a pituitary adenylate cyclase-activating peptide type 1 receptor-specific antagonist	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLY LUTZOMYIA-LONGIPALPIS; SALIVARY-GLANDS; I RECEPTOR; POLYPEPTIDE; EXPRESSION; SECONDARY; MEMBRANES; CLONING; TISSUE; CELLS	Maxadilan is a vasodilatory peptide derived from sand flies that is an agonist at the pituitary adenylate cyclase-activating peptide (PACAP) type 1 receptor. Surprisingly, maxadilan does not share significant sequence homology with PACAP, To examine the relationship between structure and activity of maxadilan, several amino acid substitutions and deletions were made in the peptide. These peptides were examined in vitro for binding to crude membranes derived from rabbit brain, a tissue that expresses PACAP type 1 receptors; and induction of cAMP was determined in PC12 cells, a line that expresses these receptors, The peptides were examined in vivo for their ability to induce erythema in rabbit skin. Substitution of the individual cysteines at positions 1 and 5 or deletion of this ring structure had little effect on activity. Substitution of either cysteine at position 14 or 51 eliminated activity. Deletion of the 19 amino acids between positions 24 and 42 resulted in a peptide with binding, but no functional activity. The capacity of this deletion mutant to interact with COS cells transfected with the PACAP type 1 receptor revealed that this peptide was a specific antagonist to the PACAP type 1 receptor.	Shiseido Basic Res Ctr, Kohoku Ku, Yokohama, Kanagawa 2238553, Japan; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA	Shiseido Company, Limited; Harvard University; Massachusetts General Hospital	Tajima, M (corresponding author), Shiseido Basic Res Ctr, Kohoku Ku, 1050 Nippa, Yokohama, Kanagawa 2238553, Japan.	tajima_masahiro@po.shiseido.co.jp	Denda, Sumiko/J-1898-2019		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042005] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR42005] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ando E, 1996, Biomed Pept Proteins Nucleic Acids, V2, P41; CHIBA T, 1989, AM J PHYSIOL, V256, pE331, DOI 10.1152/ajpendo.1989.256.2.E331; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; GOURLET P, 1991, EUR J BIOCHEM, V195, P535, DOI 10.1111/j.1432-1033.1991.tb15734.x; INAGAKI N, 1994, P NATL ACAD SCI USA, V91, P2679, DOI 10.1073/pnas.91.7.2679; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; LAU SYM, 1984, J BIOL CHEM, V259, P3253; LERNER EA, 1991, J BIOL CHEM, V266, P11234; MIMEAULT M, 1992, J MED CHEM, V35, P2163, DOI 10.1021/jm00090a003; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; Moro O, 1997, J BIOL CHEM, V272, P966, DOI 10.1074/jbc.272.2.966; MORO O, 1995, BIOCHEM BIOPH RES CO, V216, P234, DOI 10.1006/bbrc.1995.2615; OHNUMA M, 1994, PEPTIDE CH, P145; PISEGNA JR, 1993, P NATL ACAD SCI USA, V90, P6345, DOI 10.1073/pnas.90.13.6345; RIBEIRO JMC, 1989, SCIENCE, V243, P212, DOI 10.1126/science.2783496; VANDERMEERS A, 1992, EUR J BIOCHEM, V208, P815, DOI 10.1111/j.1432-1033.1992.tb17252.x; WRAY V, 1993, BIOCHEMISTRY-US, V32, P5832, DOI 10.1021/bi00073a016; Yoshida S, 1996, RAPID COMMUN MASS SP, V10, P641, DOI 10.1002/(SICI)1097-0231(199604)10:6<641::AID-RCM548>3.0.CO;2-E	18	63	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23103	23110		10.1074/jbc.274.33.23103	http://dx.doi.org/10.1074/jbc.274.33.23103			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438479	hybrid			2022-12-25	WOS:000082012800029
J	Okajima, T; Yoshida, K; Kondo, T; Furukawa, K				Okajima, T; Yoshida, K; Kondo, T; Furukawa, K			Human homolog of Caenorhabditis elegans sqv-3 gene is galactosyltransferase I involved in the biosynthesis of the glycosaminoglycan-protein linkage region of proteoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE; MOLECULAR-CLONING; FIBROBLAST GROWTH; UDP-GALACTOSE; EXPRESSION; BETA-1,4-GALACTOSYLTRANSFERASE; FAMILY; CELLS; GLYCOSYLTRANSFERASES; PURIFICATION	A cDNA encoding a novel galactosyltransferase was identified based on BLAST analysis of expressed sequence tags, and the cDNA clones were isolated from a human melanoma line library. The new cDNA sequence encoded a type II membrane protein with 327 amino acid sequence and showed 38% homology to the Cae norhabditis elegans sqv-3 gene involved in the vulval invagination and oocyte development. Extracts from L cells transfected with the galactosyltransferase cDNA in an expression vector and a fusion protein with protein A exhibited marked galactosyltransferase activity specific for p-nitrophenyl-beta-D-xylopyranoside. Moreover, transfection with the cloned cDNA restored glycosaminoglycan synthesis of galactosyltransferase I-deficient Chinese hamster ovary mutant pgsB-761 cells. Analysis of the enzyme product by beta-galactosidase digestion, mass spectroscopy, and NMR spectroscopy revealed that the reaction product was formed via beta-1,4 linkage, indicating that the enzyme is galactosyltransferase I (UDP-galactose:O-beta-D-xylosylprotein 4-beta-D-galactosyltransferase, EC 2.4.1.133) involved in the synthesis of the glycosaminoglycan-protein linkage region of proteoglycans.	Nagoya Univ, Sch Med, Dept Biochem 2, Nagoya, Aichi 4660065, Japan; Sugiyama Jogakuen Univ, Sch Life Studies, Nagoya, Aichi 4640802, Japan; Nagoya Univ, Chem Instrument Ctr, Nagoya, Aichi 4648602, Japan	Nagoya University; Nagoya University	Furukawa, K (corresponding author), Nagoya Univ, Sch Med, Dept Biochem 2, Nagoya, Aichi 4660065, Japan.		Okajima, Tetsuya/I-7332-2014	Okajima, Tetsuya/0000-0002-3677-648X				Almeida R, 1997, J BIOL CHEM, V272, P31979, DOI 10.1074/jbc.272.51.31979; ASHIKARI S, 1995, J BIOL CHEM, V270, P29586, DOI 10.1074/jbc.270.49.29586; BAME KJ, 1989, J BIOL CHEM, V264, P8059; ESKO JD, 1987, J BIOL CHEM, V262, P12189; HELTING T, 1969, J BIOL CHEM, V244, P2790; Herman T, 1999, P NATL ACAD SCI USA, V96, P968, DOI 10.1073/pnas.96.3.968; Herman T, 1999, P NATL ACAD SCI USA, V96, P974, DOI 10.1073/pnas.96.3.974; Kitagawa H, 1998, J BIOL CHEM, V273, P6615, DOI 10.1074/jbc.273.12.6615; Kitagawa H, 1999, J BIOL CHEM, V274, P13933, DOI 10.1074/jbc.274.20.13933; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lind T, 1998, J BIOL CHEM, V273, P26265, DOI 10.1074/jbc.273.41.26265; Lo NW, 1998, GLYCOBIOLOGY, V8, P517, DOI 10.1093/glycob/8.5.517; Lugemwa FN, 1996, J BIOL CHEM, V271, P19159, DOI 10.1074/jbc.271.32.19159; MASRI KA, 1988, BIOCHEM BIOPH RES CO, V157, P657, DOI 10.1016/S0006-291X(88)80300-0; NAGATA Y, 1992, J BIOL CHEM, V267, P12082; Nomura T, 1998, J BIOL CHEM, V273, P13570, DOI 10.1074/jbc.273.22.13570; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; QUENTIN E, 1990, P NATL ACAD SCI USA, V87, P1342, DOI 10.1073/pnas.87.4.1342; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; Rostand KS, 1997, INFECT IMMUN, V65, P1; Sato T, 1998, P NATL ACAD SCI USA, V95, P472, DOI 10.1073/pnas.95.2.472; SCHWARTZ NB, 1975, J BIOL CHEM, V250, P5200; Schwientek T, 1998, J BIOL CHEM, V273, P29331, DOI 10.1074/jbc.273.45.29331; THAMPOE IJ, 1989, CANCER RES, V49, P6258; Vetere A, 1997, EUR J BIOCHEM, V247, P1083, DOI 10.1111/j.1432-1033.1997.01083.x; Wei G, 1999, J BIOL CHEM, V274, P7857, DOI 10.1074/jbc.274.12.7857; Wight Thomas N., 1992, Current Opinion in Cell Biology, V4, P793, DOI 10.1016/0955-0674(92)90102-I; YAMASHIRO S, 1995, J BIOL CHEM, V270, P6149, DOI 10.1074/jbc.270.11.6149; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	31	120	124	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					22915	22918		10.1074/jbc.274.33.22915	http://dx.doi.org/10.1074/jbc.274.33.22915			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438455	hybrid			2022-12-25	WOS:000082012800005
J	Barth, A				Barth, A			Phosphoenzyme conversion of the sarcoplasmic reticulum Ca2+-ATPase - Molecular interpretation of infrared difference spectra	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CAGED-ATP; ADENOSINE 5'-TRIPHOSPHATE; MECHANISTIC IMPLICATIONS; STRUCTURAL-CHANGES; CATALYTIC CYCLE; CALCIUM ATPASE; FTIR-SPECTRA; CA2+ BINDING; SPECTROSCOPY	Time-resolved Fourier transform infrared difference spectra of the phosphoenzyme conversion and Ca2+ release reaction (Ca2E1-P --> E-2-P) of the sarcoplasmic reticulum Ca2+-ATPase were recorded at pH 7 and 1 degrees C in H2O and (H2O)-H-2. In the amide I spectral region, the spectra indicate backbone conformational changes preserving conformational changes of the preceding phosphorylation step. beta-sheet or turn structures (band at 1685 cm(-1)) and alpha-helical structures (band at 1653 cm(-1)) seem to be involved. Spectra of the model compound EDTA for Ca2+ chelation indicate the assignment of bands at 1570, 1554, 1411 and 1399 cm(-1) to Ca2+ chelating Asp and Glu carboxylate groups partially shielded from the aqueous environment. In addition, an E-2-P band at 1638 cm(-1) has been tentatively assigned to a carboxylate group in a special environment. A Tyr residue seems to be involved in the reaction (band at 1517 cm(-1) in H2O and 1515 cm(-1) in (H2O)-H-2). A band at 1192 cm(-1) was shown by isotopic replacement in the gamma-phosphate of ATP to originate from the E-2-P phosphate group. This is a clear indication that the immediate environment of the phosphoenzyme phosphate group changes in the conversion reaction, altering phosphate geometry and/or electron distribution.	Univ Frankfurt, Inst Biophys, D-60590 Frankfurt, Germany	Goethe University Frankfurt	Barth, A (corresponding author), Univ Frankfurt, Inst Biophys, Theodor Stern Kai 7,Haus 74, D-60590 Frankfurt, Germany.		Barth, Andreas/N-8872-2013	Barth, Andreas/0000-0001-5784-7673				ADAMS SR, 1993, ANNU REV PHYSIOL, V55, P755, DOI 10.1146/annurev.ph.55.030193.003543; ANDERSEN JP, 1989, BIOCHIM BIOPHYS ACTA, V988, P47, DOI 10.1016/0304-4157(89)90003-8; Andersen JP, 1995, BIOSCIENCE REP, V15, P243, DOI 10.1007/BF01788358; BARTH A, 1994, BBA-BIOMEMBRANES, V1194, P75, DOI 10.1016/0005-2736(94)90205-4; Barth A, 1998, BIOPHYS J, V75, P538, DOI 10.1016/S0006-3495(98)77543-5; Barth A, 1996, J BIOL CHEM, V271, P30637, DOI 10.1074/jbc.271.48.30637; BARTH A, 1991, BIOCHIM BIOPHYS ACTA, V1057, P115, DOI 10.1016/S0005-2728(05)80091-X; Barth A, 1997, J BIOL CHEM, V272, P25507, DOI 10.1074/jbc.272.41.25507; Barth A, 1997, J AM CHEM SOC, V119, P4149, DOI 10.1021/ja964430u; BARTH A, 1995, J AM CHEM SOC, V117, P10311, DOI 10.1021/ja00146a015; BARTH A, 1990, FEBS LETT, V277, P147, DOI 10.1016/0014-5793(90)80830-C; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BUCHET R, 1992, BIOCHIM BIOPHYS ACTA, V1104, P207, DOI 10.1016/0005-2736(92)90152-C; BUCHET R, 1991, BIOCHIM BIOPHYS ACTA, V1069, P209, DOI 10.1016/0005-2736(91)90126-S; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; Cepus V, 1998, Methods Enzymol, V291, P223; Corrie J. E. T., 1993, BIOORGANIC PHOTOCHEM, P243; DEACON GB, 1980, COORDIN CHEM REV, V33, P227, DOI 10.1016/S0010-8545(00)80455-5; DEMEIS L, 1988, FEBS LETT, V232, P73, DOI 10.1016/0014-5793(88)80389-2; DOYLE BB, 1971, BIOCHEMISTRY-US, V10, P3052; DUPONT Y, 1983, FEBS LETT, V156, P93, DOI 10.1016/0014-5793(83)80255-5; GEORG H, 1994, BBA-BIOENERGETICS, V1188, P139, DOI 10.1016/0005-2728(94)90032-9; Goormaghtigh E, 1994, Subcell Biochem, V23, P329; GREEN NM, 1986, CIBA F SYMP, V122, P93; Haris P I, 1994, Methods Mol Biol, V22, P183; Hienerwadel R, 1997, BIOCHEMISTRY-US, V36, P14712, DOI 10.1021/bi971521a; HIGHSMITH S, 1986, BIOCHEMISTRY-US, V25, P1049, DOI 10.1021/bi00353a015; Inesi G, 1995, BIOSCIENCE REP, V15, P327, DOI 10.1007/BF01788365; INESI G, 1985, ENZYMES BIOL MEMBR, V3, P157; KAPLAN JH, 1990, ANNU REV PHYSIOL, V52, P897; LAUTIE A, 1980, SPECTROCHIM ACTA A, V36, P85, DOI 10.1016/0584-8539(80)80062-6; MCCRAY JA, 1989, ANNU REV BIOPHYS BIO, V18, P239, DOI 10.1146/annurev.biophys.18.1.239; Mintz E, 1997, BBA-BIOENERGETICS, V1318, P52, DOI 10.1016/S0005-2728(96)00132-6; Mintz E, 1995, BIOSCIENCE REP, V15, P377, DOI 10.1007/BF01788369; NAKAMOTO K, 1963, J AM CHEM SOC, V85, P309, DOI 10.1021/ja00886a014; NAKAMOTO RK, 1984, J BIOL CHEM, V259, P2961; PINCHAS S, 1971, INFRARED SPECTRA LAB, P133; SAWYER DT, 1963, J AM CHEM SOC, V85, P314, DOI 10.1021/ja00886a015; SUSI H, 1967, J BIOL CHEM, V242, P5460; TACKETT JE, 1989, APPL SPECTROSC, V43, P483, DOI 10.1366/0003702894202931; TAKEUCHI H, 1988, J AM CHEM SOC, V110, P392, DOI 10.1021/ja00210a013; TAKEUCHI H, 1986, SPECTROCHIM ACTA A, V42, P1069, DOI 10.1016/0584-8539(86)80021-6; Troullier A, 1996, BIOPHYS J, V71, P2970, DOI 10.1016/S0006-3495(96)79537-1; VENYAMINOV SY, 1990, BIOPOLYMERS, V30, P1243, DOI 10.1002/bip.360301309	44	31	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22170	22175		10.1074/jbc.274.32.22170	http://dx.doi.org/10.1074/jbc.274.32.22170			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428781	hybrid			2022-12-25	WOS:000081868400011
J	Hoober, KL; Sheasley, SL; Gilbert, HF; Thorpe, C				Hoober, KL; Sheasley, SL; Gilbert, HF; Thorpe, C			Sulfhydryl oxidase from egg white - A facile catalyst for disulfide bond formation in proteins and peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; ISOMERASE; RIBONUCLEASE; PURIFICATION; GLUTATHIONE	Both metalloprotein and flavin-linked sulfhydryl oxidases catalyze the oxidation of thiols to disulfides with the reduction of oxygen to hydrogen peroxide, Despite earlier suggestions for a role in protein disulfide bond formation, these enzymes have received comparatively little general attention. Chicken egg white sulfhydryl oxidase utilizes an internal redox-active cystine bridge and a FAD moiety in the oxidation of a range of small molecular weight thiols such as glutathione, cysteine, and dithiothreitol, The oxidase is shown here to exhibit a high catalytic activity toward a range of reduced peptides and proteins including insulin A and B chains, lysozyme, ovalbumin, riboflavin-binding protein, and RNase, Catalytic efficiencies are up to 100-fold higher than for reduced glutathione, with typical K-m values of about 110-330 mu M/protein thiol, compared with 20 mM for glutathione. RNase activity is not significantly recovered when the cysteine residues are rapidly oxidized by sulfhydryl oxidase, but activity is efficiently restored when protein disulfide isomerase is also present. Sulfhydryl oxidase can also oxidize reduced protein disulfide isomerase directly. These data show that sulfhydryl oxidase and protein disulfide isomerase can cooperate in vitro in the generation and rearrangement of native disulfide pairings. A possible role for the oxidase in the protein secretory pathway in vivo is discussed.	Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA; Baylor Coll Med, Dept Biochem, Houston, TX 77030 USA	University of Delaware; Baylor College of Medicine	Thorpe, C (corresponding author), Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA.				NIGMS NIH HHS [GM40379, GM26643] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026643, R01GM040379] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARDWELL JCA, 1993, CELL, V74, P769, DOI 10.1016/0092-8674(93)90455-Y; BERGMAN LW, 1979, J BIOL CHEM, V254, P8869; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; CHEN W, 1995, P NATL ACAD SCI USA, V92, P6229, DOI 10.1073/pnas.92.14.6229; CLARE DA, 1988, ARCH BIOCHEM BIOPHYS, V265, P351, DOI 10.1016/0003-9861(88)90138-5; DELAMOTTE RS, 1987, BIOCHEMISTRY-US, V26, P7363, DOI 10.1021/bi00397a025; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; Freedman RB, 1998, CURR BIOL, V8, pR468, DOI 10.1016/S0960-9822(98)70295-7; FREEDMAN RB, 1989, BIOCHEM SOC SYMP, V55, P167; Gilbert HF, 1998, METHOD ENZYMOL, V290, P26, DOI 10.1016/S0076-6879(98)90005-2; Gilbert HF, 1997, J BIOL CHEM, V272, P29399, DOI 10.1074/jbc.272.47.29399; GOLDSMITH LA, 1987, METHOD ENZYMOL, V143, P510; HAWKINS HC, 1991, BIOCHEM J, V275, P335, DOI 10.1042/bj2750335; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; Hoober KL, 1999, BIOCHEMISTRY-US, V38, P3211, DOI 10.1021/bi9820816; Hoober KL, 1996, J BIOL CHEM, V271, P30510, DOI 10.1074/jbc.271.48.30510; Huppa JB, 1998, CELL, V92, P145, DOI 10.1016/S0092-8674(00)80907-1; HUTH JR, 1993, J BIOL CHEM, V268, P16472; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; JANOLINO VG, 1987, ARCH BIOCHEM BIOPHYS, V258, P265, DOI 10.1016/0003-9861(87)90344-4; JANOLINO VG, 1975, J BIOL CHEM, V250, P2532; KUSAKABE H, 1982, AGR BIOL CHEM TOKYO, V46, P2057, DOI 10.1080/00021369.1982.10865382; LASH LH, 1984, BIOCHIM BIOPHYS ACTA, V779, P191, DOI 10.1016/0304-4157(84)90008-X; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; OSTROWSKI MC, 1980, BIOCHEMISTRY-US, V19, P2639, DOI 10.1021/bi00553a016; PETERS T, 1982, J BIOL CHEM, V257, P8847; Pollard MG, 1998, MOL CELL, V1, P171, DOI 10.1016/S1097-2765(00)80018-0; Raina S, 1997, ANNU REV MICROBIOL, V51, P179, DOI 10.1146/annurev.micro.51.1.179; Rietsch A, 1998, ANNU REV GENET, V32, P163, DOI 10.1146/annurev.genet.32.1.163; SCHMELZER CH, 1982, BIOCHEM BIOPH RES CO, V107, P196, DOI 10.1016/0006-291X(82)91688-6; SOUTE BAM, 1992, BIOCHEM J, V281, P255, DOI 10.1042/bj2810255; Suh JK, 1999, P NATL ACAD SCI USA, V96, P2687, DOI 10.1073/pnas.96.6.2687; TAKAMORI K, 1980, BIOCHIM BIOPHYS ACTA, V615, P309, DOI 10.1016/0005-2744(80)90499-4; Walker KW, 1996, BIOCHEMISTRY-US, V35, P1972, DOI 10.1021/bi952157n; ZIEGLER DM, 1977, TRENDS BIOCHEM SCI, V2, P79, DOI 10.1016/0968-0004(77)90042-1	35	98	102	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22147	22150		10.1074/jbc.274.32.22147	http://dx.doi.org/10.1074/jbc.274.32.22147			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428777	hybrid			2022-12-25	WOS:000081868400007
J	Sowa, G; Liu, JW; Papapetropoulos, A; Rex-Haffner, M; Hughes, TE; Sessa, WC				Sowa, G; Liu, JW; Papapetropoulos, A; Rex-Haffner, M; Hughes, TE; Sessa, WC			Trafficking of endothelial nitric-oxide synthase in living cells - Quantitative evidence supporting the role of palmitoylation as a kinetic trapping mechanism limiting membrane diffusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; GOLGI-APPARATUS; BINDING DOMAIN; CAVEOLAE; ASSOCIATION; EXPRESSION; ACYLATION; COMPLEX; LOCALIZATION; INHIBITION	To examine endothelial nitric-oxide synthase (eNOS) trafficking in living endothelial cells, the eNOS deficient endothelial cell Line ECV304 was stably transfected with an eNOS-green fluorescent protein (GFP) fusion construct and characterized by functional, biochemical, and microscopic analysis. eNOS-GFP was co localized with Golgi and plasma membrane markers and produced NO in response to agonist challenge. Localization in the plasma membrane was dependent on the palmitoylation state, since the palmitoylation mutant of eNOS (C15S/C26S eNOS-GFP) was excluded from the plasma membrane and was concentrated in a diffuse perinuclear pattern. Fluorescence recovery after photobleaching (FRAP) revealed eNOS-GFP in the perinuclear region moving 3 times faster than the plasmalemmal pool, suggesting that protein-lipid or protein-protein interactions are different in these two cellular domains. FRAP of the palmitoylation mutant was two times faster than that of wild-type eNOS-GFP, indicating that palmitoylation was influencing the rate of trafficking, Interestingly, FRAP of C15S/C26S eNOS-GFP but not wild-type eNOS-GFP fit a model of protein diffusion in a lipid bilayer, These data suggest that the regulation of eNOS trafficking within the plasma membrane and Golgi are probably different mechanisms and not due to simple diffusion of the protein in a lipid bilayer.	Yale Univ, Sch Med, Boyer Ctr Mol Med,Mol Cardiobiol Program, Dept Ophthalmol & Visual Sci, New Haven, CT 06536 USA; Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06536 USA	Yale University; Yale University	Sessa, WC (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med,Mol Cardiobiol Program, Dept Ophthalmol & Visual Sci, Rm 436D,295 Congress Ave, New Haven, CT 06536 USA.	william.sessa@yale.edu	Andreas, Papapetropoulos/AAJ-3089-2020; Sessa, William C/B-6844-2011	Sessa, William C/0000-0001-5759-1938; Papapetropoulos, Andreas/0000-0002-4253-5930; Hughes, Thomas/0000-0002-8430-070X; Sowa, Grzegorz/0000-0001-8150-1525; Hughes, Thomas/0000-0001-5880-9951	NATIONAL EYE INSTITUTE [R01EY008362] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL051948] Funding Source: NIH RePORTER; NEI NIH HHS [EY08362] Funding Source: Medline; NHLBI NIH HHS [HL51948, HL50974] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aberle S, 1997, NITRIC OXIDE-BIOL CH, V1, P226, DOI 10.1006/niox.1997.0129; Andries LJ, 1998, CIRC RES, V82, P195; AXELROD D, 1976, P NATL ACAD SCI USA, V73, P4594, DOI 10.1073/pnas.73.12.4594; Chuang JZ, 1998, J CELL BIOL, V142, P1245, DOI 10.1083/jcb.142.5.1245; Cole NB, 1996, SCIENCE, V273, P797, DOI 10.1126/science.273.5276.797; CONRAD PA, 1995, J CELL BIOL, V131, P1421, DOI 10.1083/jcb.131.6.1421; DiPaolo G, 1997, J BIOL CHEM, V272, P5175, DOI 10.1074/jbc.272.8.5175; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; Haller C, 1998, EUR J CELL BIOL, V75, P353, DOI 10.1016/S0171-9335(98)80068-X; Howl J, 1998, ENDOTHELIUM-J ENDOTH, V6, P23, DOI 10.3109/10623329809053402; Kantor DB, 1996, SCIENCE, V274, P1744, DOI 10.1126/science.274.5293.1744; Liu JW, 1997, J CELL BIOL, V137, P1525, DOI 10.1083/jcb.137.7.1525; Liu JW, 1996, BIOCHEMISTRY-US, V35, P13277, DOI 10.1021/bi961720e; LIU YC, 1994, J NEUROSCI, V14, P5807; Miggin SM, 1998, BBA-GEN SUBJECTS, V1425, P543, DOI 10.1016/S0304-4165(98)00109-3; OBRIEN AJ, 1995, HISTOCHEM CELL BIOL, V103, P221, DOI 10.1007/BF01454027; Papapetropoulos A, 1996, J CELL PHYSIOL, V167, P213, DOI 10.1002/(SICI)1097-4652(199605)167:2<213::AID-JCP4>3.0.CO;2-S; PAPAPETROPOULOS A, 1994, HYPERTENSION, V23, P476, DOI 10.1161/01.HYP.23.4.476; Partikian A, 1998, J CELL BIOL, V140, P821, DOI 10.1083/jcb.140.4.821; Resh MD, 1996, CELL SIGNAL, V8, P403, DOI 10.1016/S0898-6568(96)00088-5; Rizzo V, 1998, J BIOL CHEM, V273, P34724, DOI 10.1074/jbc.273.52.34724; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; SESSA WC, 1995, J BIOL CHEM, V270, P17641, DOI 10.1074/jbc.270.30.17641; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; STANBOLI A, 1994, NEUROSCI LETT, V171, P209, DOI 10.1016/0304-3940(94)90641-6; Subramanian K, 1997, CELL, V89, P963, DOI 10.1016/S0092-8674(00)80281-0; TAKAHASHI K, 1990, IN VITRO CELL DEV B, V26, P265; TERRY BR, 1995, BIOCHEM BIOPH RES CO, V217, P21, DOI 10.1006/bbrc.1995.2740; Uittenbogaard A, 1998, J BIOL CHEM, V273, P6525, DOI 10.1074/jbc.273.11.6525; van Meer G, 1998, TRENDS CELL BIOL, V8, P29, DOI 10.1016/S0962-8924(97)01196-3; Vasudevan C, 1998, J CELL SCI, V111, P1277; VENEMA RC, 1995, J BIOL CHEM, V270, P14705, DOI 10.1074/jbc.270.24.14705; Venema VJ, 1997, BIOCHEM BIOPH RES CO, V236, P155, DOI 10.1006/bbrc.1997.6921; Wedegaertner PB, 1998, BIOL SIGNAL RECEPT, V7, P125; Yokoe E, 1996, NAT BIOTECHNOL, V14, P1252, DOI 10.1038/nbt1096-1252; Zolotukhin S, 1996, J VIROL, V70, P4646, DOI 10.1128/JVI.70.7.4646-4654.1996	42	97	100	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22524	22531		10.1074/jbc.274.32.22524	http://dx.doi.org/10.1074/jbc.274.32.22524			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428829	hybrid			2022-12-25	WOS:000081868400059
J	Page, K; Li, D; Hodge, JA; Liu, PT; Vanden Hoek, TL; Becker, LB; Pestell, RG; Rosner, MR; Hershenson, MB				Page, K; Li, D; Hodge, JA; Liu, PT; Vanden Hoek, TL; Becker, LB; Pestell, RG; Rosner, MR; Hershenson, MB			Characterization of a rac1 signaling pathway to cyclin D-1 expression in airway smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ACTIVATED PROTEIN-KINASE; NEUTROPHIL NADPH OXIDASE; GROWTH-FACTOR; MAP KINASE; INDEPENDENT PATHWAYS; TRACHEAL MYOCYTES; ANGIOTENSIN-II; BINDING; RHO	We examined the importance of the Rho family GTPase Rad for cyclin D-1 promoter transcriptional activation in bovine tracheal myocytes. Overexpression of active Rad induced transcription from the cyclin D-1 promoter, whereas platelet-derived growth factor (PDGF)-induced transcription was inhibited by a dominant-negative allele of Rad, suggesting that Rad functions as an upstream activator of cyclin D-1 in this system. Rad forms part of the NADPH oxidase complex that generates reactive oxygen species such as H2O2. PDGF stimulated a substantial increase in intracellular reactive oxygen species, as measured by the fluorescence of dichlorofluorescein-loaded cells, and this was blocked by the glutathione peroxidase mimetic ebselen. Pretreatment with ebselen, catalase, and the flavoprotein inhibitor diphenylene iodonium each attenuated PDGF- and Rac1-mediated cyclin D-1 promoter activation, while having no effect on the induction of cyclin D-1 by mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) kinase-1 (MEK1), the upstream activator of ERKs. Antioxidant treatment also inhibited PDGF-induced cyclin D-1 protein expression and DNA synthesis. Overexpression of an N-terminal fragment of p67(phox), a component of NADPH oxidase which interacts with Rad, attenuated PDGF-indueed cyclin D-1 promoter activity, whereas overexpression of the wild-type p67 did not. Finally, Rad was neither required nor sufficient for ERK activation. Taken together, these data suggest a model by which two distinct signaling pathways, the ERK and Rad pathways, positively regulate cyclin D-1 and smooth muscle growth.	Univ Chicago, Dept Pediat, Chicago, IL 60637 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Dept Pharmacol & Physiol Sci, Chicago, IL 60637 USA; Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA; Albert Einstein Coll Med, Dept Med & Dev & Mol Biol, Albert Einstein Canc Ctr, Bronx, NY 10461 USA	University of Chicago; University of Chicago; University of Chicago; University of Chicago; Yeshiva University; Albert Einstein College of Medicine	Vanden Hoek, TL (corresponding author), Univ Chicago, Childrens Hosp, 5841 S Maryland Ave,MC 4064, Chicago, IL 60637 USA.				NHLBI NIH HHS [HL07605, HL03459, HL03779] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003459] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABE MK, 1994, AM J RESP CELL MOL, V11, P577, DOI 10.1165/ajrcmb.11.5.7946386; ABO A, 1992, J BIOL CHEM, V267, P16767; ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; Ahmed S, 1998, J BIOL CHEM, V273, P15693, DOI 10.1074/jbc.273.25.15693; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; Auer KL, 1998, MOL BIOL CELL, V9, P561, DOI 10.1091/mbc.9.3.561; Bachmann S, 1997, KIDNEY INT, V51, P479, DOI 10.1038/ki.1997.66; Creedon DJ, 1996, J BIOL CHEM, V271, P20713, DOI 10.1074/jbc.271.34.20713; EBINA M, 1993, AM REV RESPIR DIS, V148, P720, DOI 10.1164/ajrccm/148.3.720; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HERSHENSON MB, 1995, J BIOL CHEM, V270, P19908, DOI 10.1074/jbc.270.34.19908; Hippenstiel S, 1998, BIOCHEM BIOPH RES CO, V245, P830, DOI 10.1006/bbrc.1998.8525; HUANG TS, 1995, P NATL ACAD SCI USA, V92, P4793, DOI 10.1073/pnas.92.11.4793; JONES SA, 1994, FEBS LETT, V355, P178, DOI 10.1016/0014-5793(94)01201-6; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; Karpova AY, 1997, AM J PHYSIOL-LUNG C, V272, pL558, DOI 10.1152/ajplung.1997.272.3.L558; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; McGuire TF, 1996, J BIOL CHEM, V271, P27402, DOI 10.1074/jbc.271.44.27402; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MOROOKA H, 1995, J BIOL CHEM, V270, P30084; OLASHAW NE, 1992, MOL BIOL CELL, V3, P1131, DOI 10.1091/mbc.3.10.1131; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Pagano PJ, 1997, P NATL ACAD SCI USA, V94, P14483, DOI 10.1073/pnas.94.26.14483; PARMACEK MS, 1992, MOL CELL BIOL, V12, P1967, DOI 10.1128/MCB.12.5.1967; Popoff MR, 1996, J BIOL CHEM, V271, P10217, DOI 10.1074/jbc.271.17.10217; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Ramakrishnan M, 1998, AM J RESP CELL MOL, V18, P736, DOI 10.1165/ajrcmb.18.6.3152; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SIES H, 1993, FREE RADICAL BIO MED, V14, P313, DOI 10.1016/0891-5849(93)90028-S; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Vanden Hoek TL, 1998, J BIOL CHEM, V273, P18092, DOI 10.1074/jbc.273.29.18092; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Whelchel A, 1997, AM J RESP CELL MOL, V16, P589, DOI 10.1165/ajrcmb.16.5.9160841; Xiong W, 1997, AM J PHYSIOL-LUNG C, V272, pL1205, DOI 10.1152/ajplung.1997.272.6.L1205; YAN MH, 1994, J BIOL CHEM, V269, P19067; Zohn IE, 1998, MOL CELL BIOL, V18, P1225, DOI 10.1128/MCB.18.3.1225	50	116	121	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					22065	22071		10.1074/jbc.274.31.22065	http://dx.doi.org/10.1074/jbc.274.31.22065			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419534	hybrid			2022-12-25	WOS:000081721100087
J	Atanasova, E; Chiappa, S; Wieben, E; Brimijoin, S				Atanasova, E; Chiappa, S; Wieben, E; Brimijoin, S			Novel messenger RNA and alternative promoter for murine acetylcholinesterase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; MOUSE ACETYLCHOLINESTERASE; TRANSCRIPTION FACTOR; SINGLE GENE; MAMMALIAN ACETYLCHOLINESTERASE; CDNA SEQUENCES; ELEMENTS; CHOLINESTERASES; MUSCLE; FORMS	A portion of the 5'-flanking region of murine acetylcholinesterase was cloned from genomic DNA by 5'-rapid amplification of genomic ends, identified in a mouse genomic library, and sequenced. Multiple potential binding sites for universal and tissue-specific transcription factors were suggestive of a promoter region within this DNA sequence. Potential promoter activity was confirmed by coupling the new sequence to the open reading frame of a luciferase reporter gene in transient expression experiments with nerve and muscle cells. 5'-Rapid amplification of cDNA ends with templates from multiple sources revealed a novel transcription start site (at position -626, relative to translation start), located 32 bases downstream from a TATAA sequence. This start site appeared to mark a novel exon (1a) comprising 291 base pairs between positions -335 and -626, relative to the translation start. Supporting this conclusion, polymerase chain reactions with cDNA from mouse brain, heart, and other tissues, consistently amplified a transcript containing the exon 1a sequence fused to the invariant sequence beginning at position -22 in exon 2, but lacking exon I. Northern blot analyses confirmed the in vivo expression of exon 1a-containing transcripts, especially in heart, brain, liver, and kidney. These results indicate that the murine acetylcholinesterase gene has a functioning alternative promoter that may influence expression of acetylcholinesterase in certain tissues.	Mayo Clin & Mayo Fdn, Dept Pharmacol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Brimijoin, S (corresponding author), Mayo Clin & Mayo Fdn, Dept Pharmacol, 200 1St St Sw, Rochester, MN 55905 USA.							AUSUBEL RM, 1997, CURRENT PROTOCOLS MO; Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; BERGERON D, 1995, CELL MOL BIOL RES, V41, P155; BIGGIN MD, 1989, TRENDS GENET, V5, P377, DOI 10.1016/0168-9525(89)90173-X; Boulikas Teni, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P117; Brank M, 1998, EUR J BIOCHEM, V251, P374, DOI 10.1046/j.1432-1327.1998.2510374.x; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CAO XM, 1993, J BIOL CHEM, V268, P16949; Chan R. Y. Y., 1995, Society for Neuroscience Abstracts, V21, P800; CRESNAR B, 1994, J NEUROSCI RES, V38, P294, DOI 10.1002/jnr.490380307; EKSTROM TJ, 1993, DNA CELL BIOL, V12, P63, DOI 10.1089/dna.1993.12.63; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; GETMAN DK, 1992, AM J HUM GENET, V51, P170; GETMAN DK, 1995, J BIOL CHEM, V270, P23511, DOI 10.1074/jbc.270.40.23511; HAHN SL, 1993, J NEUROCHEM, V60, P1058, DOI 10.1111/j.1471-4159.1993.tb03254.x; HALL LMC, 1986, EMBO J, V5, P2949, DOI 10.1002/j.1460-2075.1986.tb04591.x; HASEL KW, 1990, NUCLEIC ACIDS RES, V18, P4019, DOI 10.1093/nar/18.13.4019; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; LEGAY C, 1993, J NEUROCHEM, V60, P337, DOI 10.1111/j.1471-4159.1993.tb05856.x; LI Y, 1993, J BIOL CHEM, V268, P3563; LI Y, 1993, J BIOL CHEM, V268, P5790; LI Y, 1991, J BIOL CHEM, V266, P23083; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; MAULET Y, 1990, NEURON, V4, P289, DOI 10.1016/0896-6273(90)90103-M; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MIZOBUCHI M, 1993, BIOTECHNIQUES, V15, P215; MUTERO A, 1995, J BIOL CHEM, V270, P1866, DOI 10.1074/jbc.270.40.23511; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; RACHINSKY TL, 1992, GENOMICS, V14, P511, DOI 10.1016/S0888-7543(05)80255-1; RACHINSKY TL, 1990, NEURON, V5, P317, DOI 10.1016/0896-6273(90)90168-F; ROTUNDO RL, 1988, P NATL ACAD SCI USA, V85, P7805, DOI 10.1073/pnas.85.20.7805; SCHIBLER U, 1987, ANNU REV GENET, V21, P237, DOI 10.1146/annurev.ge.21.120187.001321; SCHUMACHER M, 1988, J BIOL CHEM, V263, P18979; SIKORAV JL, 1988, EMBO J, V7, P2983, DOI 10.1002/j.1460-2075.1988.tb03161.x; SIKORAV JL, 1987, EMBO J, V6, P1865, DOI 10.1002/j.1460-2075.1987.tb02445.x; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; TAYLOR P, 1991, J BIOL CHEM, V266, P4025; TAYLOR P, 1994, ANNU REV PHARMACOL, V34, P281, DOI 10.1146/annurev.pa.34.040194.001433; TIMMUSK T, 1995, J CELL BIOL, V128, P185, DOI 10.1083/jcb.128.1.185; TOUTANT JP, 1988, HDB EXP PHARM, V86, P225; TRIVEDI RA, 1995, J NEUROCHEM, V64, P2230; WOOD KV, 1991, BIOLUMINESCENCE AND CHEMILUMINESCENCE, P543; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	49	27	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21078	21084		10.1074/jbc.274.30.21078	http://dx.doi.org/10.1074/jbc.274.30.21078			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409660	hybrid			2022-12-25	WOS:000081613100051
J	Chevet, E; Lemaitre, G; Janjic, N; Barritault, D; Bikfalvi, A; Katinka, MD				Chevet, E; Lemaitre, G; Janjic, N; Barritault, D; Bikfalvi, A; Katinka, MD			Fibroblast growth factor receptors participate in the control of mitogen-activated protein kinase activity during nerve growth factor-induced neuronal differentiation of PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHEOCHROMOCYTOMA CELLS; SIGNAL-TRANSDUCTION; NEUROTROPHIC FACTOR; FGF-RECEPTOR; BINDING-SITES; SH2 DOMAIN; EXPRESSION; PHOSPHORYLATION; TRANSFORMATION; CASCADE	The current paradigm for the role of nerve growth factor (NGF) or FGF-2 in the differentiation of neuronal cells implies their binding to specific receptors and activation of kinase cascades leading to the expression of differentiation specific genes. We examined herein the hypothesis that FGF receptors (FGFRs) are involved in NGF-induced neuritogenesis of pheochromocytoma-derived PC12 cells. We demonstrate that in PC12 cells, FGFR expression and activity are modulated upon NGF treatment and that a dominant negative FGFR-2 reduces NGF-induced neuritogenesis. Moreover, FGF-2 expression is modulated by NGF, and FGF-2 is detected at the cell surface. Oligonucleotides that specifically inhibit FGF-2 binding to its receptors are able to significantly reduce NGF-induced neurite outgrowth. Finally, the duration of mitogen-activated protein kinase (MAPK) activity upon FGF or NGF stimulation is shortened in FGFR-2 dominant negative cells through inactivation of signaling from the receptor to the Ras/MAPK pathway. In conclusion, these results demonstrate that FGFR activation is involved in neuritogenesis induced by NGF where it contributes to a sustained MAPK activity in response to NGF.	Univ Bordeaux 1, Growth Factor & Cell Differentiat Lab, F-33405 Talence, France; Univ Paris 12, Lab CRRET, F-94010 Creteil, France; NexStar Pharmaceut Inc, Boulder, CO 80301 USA	UDICE-French Research Universities; Universite de Bordeaux; Universite Paris-Est-Creteil-Val-de-Marne (UPEC)	Bikfalvi, A (corresponding author), Univ Bordeaux 1, Growth Factor & Cell Differentiat Lab, Ave Fac, F-33405 Talence, France.		chevet, eric/E-4992-2016; Lemaître, Gilles/AAL-5889-2021	chevet, eric/0000-0001-5855-4522; 				Baird Andrew, 1994, Current Opinion in Neurobiology, V4, P78, DOI 10.1016/0959-4388(94)90035-3; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; Campochiaro PA, 1996, J NEUROSCI, V16, P1679; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; CHIU IM, 1989, MOL CHEM NEUROPATHOL, V10, P37, DOI 10.1007/BF02969485; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; DOHERTY P, 1995, NEURON, V14, P57, DOI 10.1016/0896-6273(95)90240-6; Dono R, 1998, EMBO J, V17, P4213, DOI 10.1093/emboj/17.15.4213; Foehr ED, 1998, IMMUNOL CELL BIOL, V76, P406, DOI 10.1046/j.1440-1711.1998.00775.x; GREEN LS, 1995, CHEM BIOL, V2, P683, DOI 10.1016/1074-5521(95)90032-2; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; HEUER JG, 1990, NEURON, V5, P283, DOI 10.1016/0896-6273(90)90165-C; HUANG JT, 1995, J BIOL CHEM, V270, P5065, DOI 10.1074/jbc.270.10.5065; ISHII H, 1995, MOL CELL BIOL, V15, P3664; Iwasaki S, 1996, J BIOL CHEM, V271, P17360, DOI 10.1074/jbc.271.29.17360; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; JELLINEK D, 1995, BIOCHEMISTRY-US, V34, P11363, DOI 10.1021/bi00036a009; KATOHSEMBA R, 1992, J NEUROCHEM, V59, P282, DOI 10.1111/j.1471-4159.1992.tb08902.x; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; LEONARD DGB, 1987, MOL CELL BIOL, V7, P3156, DOI 10.1128/MCB.7.9.3156; LI Y, 1994, MOL CELL BIOL, V14, P7660, DOI 10.1128/MCB.14.11.7660; LIPTON SA, 1988, P NATL ACAD SCI USA, V85, P2388, DOI 10.1073/pnas.85.7.2388; MCKEEHAN WL, 1994, MOL REPROD DEV, V39, P69, DOI 10.1002/mrd.1080390112; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; MORRISON RS, 1986, P NATL ACAD SCI USA, V83, P7537, DOI 10.1073/pnas.83.19.7537; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; NEUFELD G, 1987, J CELL PHYSIOL, V131, P131, DOI 10.1002/jcp.1041310119; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; Ong SH, 1996, BIOCHEM BIOPH RES CO, V225, P1021, DOI 10.1006/bbrc.1996.1288; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Ortega S, 1998, P NATL ACAD SCI USA, V95, P5672, DOI 10.1073/pnas.95.10.5672; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; Renaud F, 1996, J BIOL CHEM, V271, P2801, DOI 10.1074/jbc.271.5.2801; Saffell JL, 1997, NEURON, V18, P231, DOI 10.1016/S0896-6273(00)80264-0; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCIMECA JC, 1992, J BIOL CHEM, V267, P17369; SPIVAKKROIZMAN T, 1994, J BIOL CHEM, V269, P14419; TAIJI M, 1992, MOL CELL BIOL, V12, P2193, DOI 10.1128/MCB.12.5.2193; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; Torres M, 1996, ONCOGENE, V12, P77; UENO H, 1992, J BIOL CHEM, V267, P1470; VAILLANCOURT RR, 1995, MOL CELL BIOL, V15, P3644; Wang JK, 1996, ONCOGENE, V13, P721; YAN GC, 1993, BIOCHEM BIOPH RES CO, V194, P512, DOI 10.1006/bbrc.1993.1849; YAYON A, 1990, P NATL ACAD SCI USA, V87, P5346, DOI 10.1073/pnas.87.14.5346	51	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					20901	20908		10.1074/jbc.274.30.20901	http://dx.doi.org/10.1074/jbc.274.30.20901			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409634	hybrid			2022-12-25	WOS:000081613100025
J	Orchansky, PL; Kwan, R; Lee, F; Schrader, JW				Orchansky, PL; Kwan, R; Lee, F; Schrader, JW			Characterization of the cytoplasmic domain of interleukin-13 receptor-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMMON GAMMA-CHAIN; HUMAN B-CELLS; SIGNAL-TRANSDUCTION; STIMULATING FACTOR; MOLECULAR-CLONING; BINDING SUBUNIT; CSF RECEPTOR; GM-CSF; EXPRESSION; ACTIVATION	Interleukin (IL)-13 and IL-4 are pleiotropic immunoregulatory cytokines that share many overlapping biological properties reflecting the fact that both can utilize a receptor complex composed of the IL-4 receptor-alpha (IL-4R alpha) chain and the IL-13R alpha chain. The cytoplasmic domain of the IL-13R alpha is 60 amino acids long and is essential for IL-13-dependent growth. it contains a Pro-rich domain in the membrane-proximal region and two Tyr residues. Here we show that a truncated H-13R alpha, lacking the 38 carboxyl-terminal residues but retaining the Pro-rich region, can support IL-13-dependent proliferation, although with reduced efficiency. A Y402F mutant of the cytoplasmic domain of IL-13R alpha supported normal IL-13-induced growth. However, tyrosine phosphorylation of signal transducer and activator of transcription 3 (STAT3), which we show is induced by IL-13 and IL-4 in cells that express the IL-13R alpha, was significantly reduced. The cytoplasmic domain of IL-13R alpha was constitutively associated with STAT3, Tyk2, and Janus kinase 1 (JAK1). IL-13-induced tyrosine phosphorylation of IL-13R alpha in vivo could not be detected using anti-Tyr(P) antibodies. A glutathione S-transferase fusion protein of the cytoplasmic domain of IL-13R alpha was phosphorylated on tyrosine in vitro by JAK1, JAK3, and Tyk2, although the tyrosine phosphorylation events mediated by Tyk2 and JAK3 were not detectable using anti-phosphotyrosine antibodies. These data, together with the demonstration that IL-13R alpha associates constitutively with Tyk2 and that Tyr-402 is involved in IL-13-induced phosphorylation of STAT3, suggest that the latter is mediated by Tyk2. Tyrosine phosphorylation of STAT3, which was not necessary for IL-13-induced proliferation, may account for some of the effects of IL-4 and IL-13 on the function of their targets.	Univ British Columbia, Biomed Res Ctr, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Orchansky, PL (corresponding author), Univ British Columbia, Biomed Res Ctr, 2222 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.							Aman MJ, 1996, J BIOL CHEM, V271, P29265, DOI 10.1074/jbc.271.46.29265; Caput D, 1996, J BIOL CHEM, V271, P16921, DOI 10.1074/jbc.271.28.16921; Chen M, 1997, P NATL ACAD SCI USA, V94, P6910, DOI 10.1073/pnas.94.13.6910; DeFife KM, 1997, J IMMUNOL, V158, P3385; DEFRANCE T, 1994, J EXP MED, V179, P135, DOI 10.1084/jem.179.1.135; Donaldson DD, 1998, J IMMUNOL, V161, P2317; Doyle SE, 1998, BLOOD, V92, P867; Endo T, 1996, J IMMUNOL, V156, P2240; Fujitani Y, 1997, ONCOGENE, V14, P751, DOI 10.1038/sj.onc.1200907; GLINIAK BC, 1990, CELL, V63, P1073, DOI 10.1016/0092-8674(90)90510-L; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Hilton DJ, 1996, P NATL ACAD SCI USA, V93, P497, DOI 10.1073/pnas.93.1.497; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KEEGAN AD, 1995, P NATL ACAD SCI USA, V92, P7681, DOI 10.1073/pnas.92.17.7681; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levings MK, 1999, J IMMUNOL, V162, P5224; Malabarba MG, 1996, BIOCHEM J, V319, P865, DOI 10.1042/bj3190865; MALEFYT RD, 1993, RES IMMUNOL, V144, P629, DOI 10.1016/S0923-2494(05)80016-1; Matsuguchi T, 1997, J BIOL CHEM, V272, P17450, DOI 10.1074/jbc.272.28.17450; MCKENZIE ANJ, 1993, P NATL ACAD SCI USA, V90, P3735, DOI 10.1073/pnas.90.8.3735; McKenzie GJ, 1998, IMMUNITY, V9, P423, DOI 10.1016/S1074-7613(00)80625-1; Miloux B, 1997, FEBS LETT, V401, P163, DOI 10.1016/S0014-5793(96)01462-7; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Moriggl R, 1998, EUR J BIOCHEM, V251, P25, DOI 10.1046/j.1432-1327.1998.2510025.x; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; Oakes SA, 1996, IMMUNITY, V5, P605, DOI 10.1016/S1074-7613(00)80274-5; OBIRI NI, 1995, J BIOL CHEM, V270, P8797, DOI 10.1074/jbc.270.15.8797; Obiri NI, 1996, CLIN CANCER RES, V2, P1743; Ogata N, 1998, BLOOD, V91, P2264, DOI 10.1182/blood.V91.7.2264.2264_2264_2271; Orchansky PL, 1997, J BIOL CHEM, V272, P22940, DOI 10.1074/jbc.272.36.22940; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; PERNIS A, 1995, P NATL ACAD SCI USA, V92, P7971, DOI 10.1073/pnas.92.17.7971; Pfeffer LM, 1997, J BIOL CHEM, V272, P11002; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; Rolling C, 1996, FEBS LETT, V393, P53, DOI 10.1016/0014-5793(96)00835-6; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SHIMADA A, 1995, METHOD MOL BIOL, V57, P157; SMERZBERTLING C, 1995, J BIOL CHEM, V270, P966, DOI 10.1074/jbc.270.2.966; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VITA N, 1995, J BIOL CHEM, V270, P3512, DOI 10.1074/jbc.270.8.3512; WELHAM MJ, 1995, J BIOL CHEM, V270, P12286, DOI 10.1074/jbc.270.20.12286; Wright K, 1997, J BIOL CHEM, V272, P12626, DOI 10.1074/jbc.272.19.12626; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; Zhu YX, 1997, J BIOL CHEM, V272, P21334, DOI 10.1074/jbc.272.34.21334; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x; ZURAWSKI SM, 1995, J BIOL CHEM, V270, P13869, DOI 10.1074/jbc.270.23.13869	52	39	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					20818	20825		10.1074/jbc.274.30.20818	http://dx.doi.org/10.1074/jbc.274.30.20818			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409622	hybrid			2022-12-25	WOS:000081613100013
J	Sakikawa, C; Taguchi, H; Makino, Y; Yoshida, M				Sakikawa, C; Taguchi, H; Makino, Y; Yoshida, M			On the maximum size of proteins to stay and fold in the cavity of GroEL underneath GroES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; CHAPERONIN ATPASE CYCLE; CRYSTAL-STRUCTURE; CO-CHAPERONIN; MECHANISM; BINDING; BACTERIOPHAGE-T4; 2.8-ANGSTROM; INTERMEDIATE; POLYPEPTIDE	GroEL encapsulates non-native protein in a folding cage underneath GroES (cis-cavity). Here we report the maximum size of the non-native protein to stay and fold in the cis-cavity, Using total soluble proteins of Escherichia coli in denatured state as binding substrates and protease resistance as the measure of polypeptide held in the cis-cavity, it was estimated that the cis-cavity can accommodate up to similar to 57-kDa non-native proteins. To know if a protein with nearly the maximum size can complete folding in the cis-cavity, we made a 54-kDa protein in which green fluorescent protein (GFP) and its blue fluorescent variant were fused tandem. This fusion protein was captured in the cis-cavity, and folding occurred there. Fluorescence resonance energy transfer proved that both GFP and blue fluorescent protein moieties of the same fused protein were able to fold into native structures in the cis-cavity, Consistently, simulated packing of crystal structures shows that two native GFPs just fit in the cis-cavity, A fusion protein of three GFPs (82 kDa) was also attempted, but, as expected, it was not captured in the cis-cavity.	Tokyo Inst Technol, Resources Utilizat Res Lab, Yokohama, Kanagawa 2268503, Japan	Tokyo Institute of Technology	Yoshida, M (corresponding author), Tokyo Inst Technol, Resources Utilizat Res Lab, 4259 Nagatsuta, Yokohama, Kanagawa 2268503, Japan.	myoshida@res.titech.ac.jp	Taguchi, Hideki/B-6946-2009; taguchi, hideki/AAM-2663-2021	Taguchi, Hideki/0000-0002-6612-9339; taguchi, hideki/0000-0002-6612-9339				BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; Dubaquie Y, 1998, EMBO J, V17, P5868, DOI 10.1093/emboj/17.20.5868; Ewalt KL, 1997, CELL, V90, P491, DOI 10.1016/S0092-8674(00)80509-7; Fenton WA, 1997, PROTEIN SCI, V6, P743; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GORDON CL, 1994, J BIOL CHEM, V269, P27941; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HayerHartl MK, 1996, EMBO J, V15, P6111, DOI 10.1002/j.1460-2075.1996.tb00999.x; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; Hunt JF, 1997, CELL, V90, P361, DOI 10.1016/S0092-8674(00)80343-8; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; Li XQ, 1997, J BIOL CHEM, V272, P28545, DOI 10.1074/jbc.272.45.28545; Makino Y, 1997, J BIOL CHEM, V272, P12468, DOI 10.1074/jbc.272.19.12468; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; Netzer WJ, 1997, NATURE, V388, P343, DOI 10.1038/41024; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; Sigler PB, 1998, ANNU REV BIOCHEM, V67, P581, DOI 10.1146/annurev.biochem.67.1.581; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; Yang F, 1996, NAT BIOTECHNOL, V14, P1246, DOI 10.1038/nbt1096-1246	36	92	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21251	21256		10.1074/jbc.274.30.21251	http://dx.doi.org/10.1074/jbc.274.30.21251			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409682	hybrid			2022-12-25	WOS:000081613100073
J	Zech, B; Wilm, M; van Eldik, R; Brune, B				Zech, B; Wilm, M; van Eldik, R; Brune, B			Mass spectrometric analysis of nitric oxide-modified caspase-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-NITROSYLATION; APOPTOSIS; PROTEASES; ENZYME; CELLS; NO	Caspases are a family of cysteine proteases activated during apoptosis, Modification of caspases by nitric oxide and its relevance during apoptosis is currently a controversial subject. In this study we analyzed the S-nitrosated form of caspase-3 at a molecular level. By using electrospray ionization-mass spectrometry, we detected poly-S-nitrosation of caspase-3 with an average of about 2 molecules of NO bound per enzyme. Although NO treatment completely inhibited enzyme activity, S-nitrosation was not restricted to the active site cysteine. Rather, we detected multiple relative mass increases of 30 +/- 1 Da in both the p12 and p17 subunits of caspase-3, corresponding to single to triple S-nitrosation, The stability of these S-nitrosations differed in physiologically relevant concentrations of 5 mM glutathione. Whereas all S-nitroso bonds in the p12 subunit were cleaved with release of NO and partial formation of protein-mixed disulfides with glutathione, a single S-nitrosation in the p17 subunit remained stable. Since this S-nitrosation was not observed in a mutant form of caspase-3 lacking the active site cysteine, we conclude that NO nitrosates the active site cysteine of caspase-3 and that this modification is notably inert to fast trans-nitrosation with glutathione. Furthermore, we provide evidence that treatment of caspase-3 with NO can lead to mixed disulfide formation with glutathione, demonstrating the oxidative character of NO.	Univ Erlangen Nurnberg, Fac Med, Dept Med 4, Expt Div, D-91054 Erlangen, Germany; Univ Erlangen Nurnberg, Inst Inorgan Chem, D-91058 Erlangen, Germany; European Mol Biol Lab, Prot & Peptide Grp, D-69117 Heidelberg, Germany	University of Erlangen Nuremberg; University of Erlangen Nuremberg; European Molecular Biology Laboratory (EMBL)	Brune, B (corresponding author), Univ Erlangen Nurnberg, Fac Med, Dept Med 4, Expt Div, Loschgestr 8, D-91054 Erlangen, Germany.			Wilm, Matthias/0000-0002-5461-6834				Becker K, 1998, NAT STRUCT BIOL, V5, P267, DOI 10.1038/nsb0498-267; Brune B, 1998, EUR J PHARMACOL, V351, P261, DOI 10.1016/S0014-2999(98)00274-X; Chlichlia K, 1998, BLOOD, V91, P4311, DOI 10.1182/blood.V91.11.4311.411k07_4311_4320; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; CRAIG WS, 1988, METHOD ENZYMOL, V156, P333; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Hampton MB, 1997, FEBS LETT, V414, P552, DOI 10.1016/S0014-5793(97)01068-5; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; Li JR, 1997, BIOCHEM BIOPH RES CO, V240, P419, DOI 10.1006/bbrc.1997.7672; Liang H, 1997, J MOL BIOL, V274, P291, DOI 10.1006/jmbi.1997.1415; MANN M, 1995, TRENDS BIOCHEM SCI, V20, P219, DOI 10.1016/S0968-0004(00)89019-2; Mannick JB, 1997, J BIOL CHEM, V272, P24125, DOI 10.1074/jbc.272.39.24125; Mohr S, 1997, BIOCHEM BIOPH RES CO, V238, P387, DOI 10.1006/bbrc.1997.7304; Nathan C, 1997, J CLIN INVEST, V100, P2417, DOI 10.1172/JCI119782; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; Stamler JS, 1998, NAT STRUCT BIOL, V5, P247, DOI 10.1038/nsb0498-247; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P8087, DOI 10.1073/pnas.89.17.8087; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Stennicke HR, 1997, J BIOL CHEM, V272, P25719, DOI 10.1074/jbc.272.41.25719; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519	24	91	95	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					20931	20936		10.1074/jbc.274.30.20931	http://dx.doi.org/10.1074/jbc.274.30.20931			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409638	hybrid			2022-12-25	WOS:000081613100029
J	Ducray, C; Pommier, JP; Martins, L; Boussin, FD; Sabatier, L				Ducray, C; Pommier, JP; Martins, L; Boussin, FD; Sabatier, L			Telomere dynamics, end-to-end fusions and telomerase activation during the human fibroblast immortalization process	ONCOGENE			English	Article						telomere; chromosomal instability; telamerase	CELLULAR SENESCENCE; TERMINAL TRANSFERASE; LIFE-SPAN; CELLS; LENGTH; TRF2; INSTABILITY; TETRAHYMENA; PROTEINS; CANCER	Loss of telomeric repeats during cell proliferation could play a role in senescence, It has been generally assumed that activation of telomerase prevents further telomere shortening and is essential for cell immortalization, In this study, we performed a detailed cytogenetic and molecular characterization of four SV40 transformed human fibroblastic cell lines by regularly monitoring the size distribution of terminal restriction fragments, telomerase activity and the associated chromosomal instability throughout immortalization, The mean TRF lengths progressively decreased in pre-crisis cells during the lifespan of the cultures, At crisis, telomeres reached a critical size, different among the cell lines, contributing to the peak of dicentric chromosomes, which resulted mostly from telomeric associations. We observed a direct correlation between short telomere length at crisis and chromosomal instability. In two immortal cell lines, although telomerase was detected, mean telomere length still continued to decrease whereas the number of dicentric chromosomes associated was stabilized. Thus telomerase could protect specifically telomeres which have reached a critical size against end-to-end dicentrics, while long telomeres continue to decrease, although at a slower rate as before crisis. This suggests a balance between elongation by telomerase and telomere shortening, towards a stabilized 'optimal' length.	CEA, DSV, DRR, Lab Radiobiol & Oncol, F-92265 Fontenay Aux Roses, France	CEA; UDICE-French Research Universities; Universite Paris Saclay	Sabatier, L (corresponding author), CEA, DSV, DRR, Lab Radiobiol & Oncol, BP6, F-92265 Fontenay Aux Roses, France.			Sabatier, Laure/0000-0003-0552-6549; Boussin, francois/0000-0003-3778-4403				ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; BENN PA, 1976, AM J HUM GENET, V28, P465; Bilaud T, 1997, NAT GENET, V17, P236, DOI 10.1038/ng1097-236; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; Dutrillaux B, 1981, PRATIQUE ANAL CHROMO; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Filatov L, 1998, ONCOGENE, V16, P1825, DOI 10.1038/sj.onc.1201711; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREIDER CW, 1991, CELL, V67, P645, DOI 10.1016/0092-8674(91)90058-7; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Holt SE, 1996, MOL CELL BIOL, V16, P2932; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; Jones CJ, 1998, EXP CELL RES, V240, P333, DOI 10.1006/excr.1998.3944; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; Lansdorp PM, 1996, HUM MOL GENET, V5, P685, DOI 10.1093/hmg/5.5.685; LINGNER J, 1995, SCIENCE, V269, P1533, DOI 10.1126/science.7545310; McClintock B, 1939, P NATL ACAD SCI USA, V25, P405, DOI 10.1073/pnas.25.8.405; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; OERTER KE, 1990, ANAL BIOCHEM, V189, P235, DOI 10.1016/0003-2697(90)90114-O; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; RHYU MS, 1995, J NATL CANCER I, V87, P884, DOI 10.1093/jnci/87.12.884; Rubin H, 1998, NAT BIOTECHNOL, V16, P396, DOI 10.1038/nbt0598-396; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; Shen MH, 1997, P NATL ACAD SCI USA, V94, P13618, DOI 10.1073/pnas.94.25.13618; SPRUNG CN, 1998, IN PRESS EXP CELL RE; TOMMERUP H, 1994, MOL CELL BIOL, V14, P5777, DOI 10.1128/MCB.14.9.5777; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Wan TSK, 1999, GENE CHROMOSOME CANC, V24, P83, DOI 10.1002/(SICI)1098-2264(199901)24:1<83::AID-GCC12>3.0.CO;2-C; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WRIGHT WE, 1992, EXP GERONTOL, V27, P383, DOI 10.1016/0531-5565(92)90069-C; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088	44	114	119	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 22	1999	18	29					4211	4223		10.1038/sj.onc.1202797	http://dx.doi.org/10.1038/sj.onc.1202797			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218FK	10435634				2022-12-25	WOS:000081542400005
J	Costanzo, A; Guiet, C; Vito, P				Costanzo, A; Guiet, C; Vito, P			c-E10 is a caspase-recruiting domain-containing protein that interacts with components of death receptors signaling pathway and activates nuclear factor-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CELL-DEATH; NECROSIS-FACTOR RECEPTOR-1; FADD-DEPENDENT APOPTOSIS; TRAIL-INDUCED APOPTOSIS; TNF RECEPTOR-1; KINASE; MEMBER; FAMILY; SEQUENCE; CD95	Members of the tumor necrosis factor receptor superfamily induce apoptosis via interaction with FADD and regulate cell growth and differentiation through TRADD and TRAFs molecules. While screening for molecules involved in the regulation of death receptor signaling, we identified a novel protein, c-E10. c-E10 contains an amino-terminal caspase-recruiting domain (CARD) and shares a sequence homologous with E10, a viral CARD-containing protein that binds to c-E10. In transfection experiments c-E10 oligomerizes, binds to the cytoplasmic portion of TRAIL receptor 1 (DR4) and coprecipitates with TRADD. Expression of c-E10 under the control of a doxycycline-dependent transcriptional transactivator results in NF-kappa B activation, which is inhibited by dominant negative forms of TRAF2 and NIK kinase. Thus, our results suggest that c-E10 is an adapter protein that activates NF-kappa B through a molecular pathway involved in death receptor signaling.	Basel Inst Immunol, CH-4005 Basel, Switzerland; Fdn A Cesalpino, Med Clin 1, I-00161 Rome, Italy		Vito, P (corresponding author), Basel Inst Immunol, Grenzacherstr 487, CH-4005 Basel, Switzerland.		vito, pasquale/ABF-5505-2020; Costanzo, Antonio/GZG-2433-2022; Costanzo, Antonio/D-3896-2012	Costanzo, Antonio/0000-0001-9697-2557; vito, pasquale/0000-0002-5721-7716				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bodmer JL, 1997, IMMUNITY, V6, P79, DOI 10.1016/S1074-7613(00)80244-7; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chou JJ, 1998, CELL, V94, P171, DOI 10.1016/S0092-8674(00)81417-8; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Griffith TS, 1998, J IMMUNOL, V161, P2833; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; Inohara N, 1998, J BIOL CHEM, V273, P12296, DOI 10.1074/jbc.273.20.12296; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; Koseki T, 1998, P NATL ACAD SCI USA, V95, P5156, DOI 10.1073/pnas.95.9.5156; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mariani SM, 1997, J CELL BIOL, V137, P221, DOI 10.1083/jcb.137.1.221; Marsters SA, 1996, CURR BIOL, V6, P1669, DOI 10.1016/S0960-9822(02)70791-4; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Natoli G, 1998, J BIOL CHEM, V273, P31262, DOI 10.1074/jbc.273.47.31262; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Ponton A, 1996, J BIOL CHEM, V271, P8991, DOI 10.1074/jbc.271.15.8991; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TELFORD EAR, 1995, J MOL BIOL, V249, P520, DOI 10.1006/jmbi.1995.0314; Thome M, 1998, CURR BIOL, V8, P885, DOI 10.1016/S0960-9822(07)00352-1; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X	45	69	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20127	20132		10.1074/jbc.274.29.20127	http://dx.doi.org/10.1074/jbc.274.29.20127			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400625	hybrid			2022-12-25	WOS:000081438300018
J	Kristiansen, M; Kozyraki, R; Jacobsen, C; Nexo, E; Verroust, PJ; Moestrup, SK				Kristiansen, M; Kozyraki, R; Jacobsen, C; Nexo, E; Verroust, PJ; Moestrup, SK			Molecular dissection of the intrinsic factor-vitamin B-12 receptor, cubilin, discloses regions important for membrane association and ligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CUB DOMAIN ARCHITECTURE; COBALAMIN MALABSORPTION; LIPOPROTEIN RECEPTOR; BRUSH-BORDER; PROTEIN; EXPRESSION; ANTIBODIES; FAMILY; GENE	Cubilin, the receptor for intrinsic factor-vitamin B-12, is a novel type of high molecular weight receptor consisting of a 27 CUB ((c) under bar omplement components C1r/C1s, (U) under bar egf, and (b) under bar one morphogenic protein-1) domain cluster preceded by 8 epidermal growth factor repeats and a short N-terminal sequence, In addition to binding the vitamin B-12-carrier complex, cubilin also binds receptor-associated protein. To delineate the structures for membrane association and ligand binding we established a panel of stable transfected Chinese hamster ovary cells expressing overlapping segments of rat cubilin, Analysis of conditioned media and cell extracts of transfected cells revealed that the N-terminal cubilin region conveys membrane association, Helical plotting of this region demonstrated a conserved amphipathic helix pattern (Lys(74)-Glu(109)) aS a candidate site for hydrophobic interactions. Ligand affinity chromatography and surface plasmon resonance analysis of the secreted cubilin fragments showed ligand binding in the CUB domain region. Further dissection of binding-active fragments localized the binding site for intrinsic factor-vitamin B-12 to CUB domains 5-8 and a receptor-associated protein-binding site to CUB domains 13-14. In conclusion, the N-terminal cubilin region seems crucial for membrane association, whereas the CUB domain cluster harbors distinct sites for ligand binding.	Aarhus Univ, Dept Med Biochem, DK-8000 Aarhus C, Denmark; Aarhus Univ Hosp, AKH, Dept Clin Biochem, DK-8000 Aarhus, Denmark; Hop Tenon, INSERM 489, F-75020 Paris, France	Aarhus University; Aarhus University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Moestrup, SK (corresponding author), Aarhus Univ, Dept Med Biochem, Ole Worms Alle Blgn 170, DK-8000 Aarhus C, Denmark.		Moestrup, Søren Kragh/A-1403-2014; Moestrup, Søren Kragh/AAD-1735-2019; Kozyraki, Renata/G-5321-2017	Moestrup, Søren Kragh/0000-0003-3862-2107; Nexo, Ebba/0000-0001-9406-9081; Madsen, Mette/0000-0001-7241-6505; Kozyraki, Renata/0000-0001-9779-5898				Aminoff M, 1999, NAT GENET, V21, P309, DOI 10.1038/6831; Birn H, 1997, J BIOL CHEM, V272, P26497, DOI 10.1074/jbc.272.42.26497; Cheng H, 1996, ANAT REC, V244, P327; Dias JM, 1997, PROTEIN SCI, V6, P725; FYFE JC, 1991, J BIOL CHEM, V266, P4489; Gliemann J, 1998, BIOL CHEM, V379, P951; GRASBECK R, 1960, ACTA MED SCAND, V167, P289; GUEANT JL, 1995, GASTROENTEROLOGY, V108, P1622, DOI 10.1016/0016-5085(95)90122-1; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; IMERSLUND O, 1960, Acta Paediatr Suppl, V49(Suppl 119), P1; Kozyraki R, 1998, BLOOD, V91, P3593; Lindblom A, 1999, J BIOL CHEM, V274, P6374, DOI 10.1074/jbc.274.10.6374; Moestrup SK, 1998, J BIOL CHEM, V273, P5235, DOI 10.1074/jbc.273.9.5235; MOESTRUP SK, VITAMIN B12 B12 PROT, P477; NEXO E, 1976, BIOCHIM BIOPHYS ACTA, V446, P143, DOI 10.1016/0005-2795(76)90106-9; NEXO E, 1998, VITAMIN B12 B12 PROT, P461, DOI DOI 10.1002/9783527612192.CH30; SAHALI D, 1988, J EXP MED, V167, P213, DOI 10.1084/jem.167.1.213; SEETHARAM B, 1994, ADV T ADDISONS DIS, V2, P393; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; TANG LH, 1992, J BIOL CHEM, V267, P22982; Varela PF, 1997, J MOL BIOL, V274, P635, DOI 10.1006/jmbi.1997.1424; WILLNOW TE, 1995, P NATL ACAD SCI USA, V92, P4537, DOI 10.1073/pnas.92.10.4537; YANG Y, 1985, J CLIN INVEST, V76, P2057, DOI 10.1172/JCI112208	23	102	110	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20540	20544		10.1074/jbc.274.29.20540	http://dx.doi.org/10.1074/jbc.274.29.20540			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400683	hybrid			2022-12-25	WOS:000081438300076
J	Ogata, M; Takada, T; Mori, Y; Uchida, Y; Miki, T; Okuyama, A; Kosugi, A; Sawada, M; Oh-hora, M; Hamaoka, T				Ogata, M; Takada, T; Mori, Y; Uchida, Y; Miki, T; Okuyama, A; Kosugi, A; Sawada, M; Oh-hora, M; Hamaoka, T			Regulation of phosphorylation level and distribution of PTP36, a putative protein tyrosine phosphatase, by cell-substrate adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSKELETAL-ASSOCIATED PROTEINS; SEQUENCE HOMOLOGY; BAND-4.1 FAMILY; FOCAL ADHESIONS; CDNA CLONING; DOMAIN; IDENTIFICATION; EXPRESSION; KINASE; EZRIN	Recently we have cloned a putative protein tyrosine phosphatase, PTP36/PTPD2/pez, which possesses a domain homologous to the N-terminal half of band 4.1 protein. In mouse fibroblasts adhered to substrates, PTP36 was phosphorylated on serine residues, PTP36 was found to make complexes with serine/threonine kinase(s), which phosphorylated PTP36 in vitro. PTP36 was dephosphorylated rapidly when the cell-substrate adhesion was disrupted and it was phosphorylated again along with the reattachment of the cells to fibronectin. Rephosphorylation of PTP36 seemed to depend on actin polymerization since it was inhibited by cytochalasin D. The cell detachment also induced the translocation of PTP36 into the membrane-associated cytoskeletal fraction. Staurosporine and ML-9, which inhibited the phosphorylation of PTP36 in vivo, induced the translocation of PTP36 too. On the contrary, when the dephosphorylation of PTP36 was inhibited by okadaic acid, no translocation of PTP36 was induced by the cell detachment. These results demonstrate that the cell-substrate adhesion and cell spreading regulates the intracellular localization of PTP36 most likely through its phosphorylation and therefore, PTP36 may play important roles in the signal transduction pathway of cell-adhesion.	Osaka Univ, Sch Med, Biomed Res Ctr, Dept Oncol, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Urol, Osaka 5650871, Japan; Osaka Univ, Fac Med, Sch Allied Hlth Sci, Osaka 5650871, Japan	Osaka University; Osaka University; Osaka University	Ogata, M (corresponding author), Osaka Univ, Sch Med, Biomed Res Ctr, Dept Oncol, 2-2 Yamadaoka, Osaka 5650871, Japan.							ARAI M, 1994, J NEUROSCI RES, V38; Arregui CO, 1998, J CELL BIOL, V143, P861, DOI 10.1083/jcb.143.3.861; Balsamo J, 1998, J CELL BIOL, V143, P523, DOI 10.1083/jcb.143.2.523; BANIYASH M, 1988, J BIOL CHEM, V263, P18225; BANVILLE D, 1994, J BIOL CHEM, V269, P22320; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Denu JM, 1996, CELL, V87, P361, DOI 10.1016/S0092-8674(00)81356-2; FERRELL JE, 1990, MOL CELL BIOL, V10, P3020, DOI 10.1128/MCB.10.6.3020; Gu MX, 1996, J BIOL CHEM, V271, P27751, DOI 10.1074/jbc.271.44.27751; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; Gu MX, 1996, P NATL ACAD SCI USA, V93, P12980, DOI 10.1073/pnas.93.23.12980; HIGASHITSUJI H, 1995, ONCOGENE, V10, P407; LABBE D, 1994, FEBS LETT, V356, P351, DOI 10.1016/0014-5793(94)01305-5; LAMB NJC, 1988, J CELL BIOL, V106, P1955, DOI 10.1083/jcb.106.6.1955; MAEKAWA K, 1994, FEBS LETT, V337, P200, DOI 10.1016/0014-5793(94)80273-4; MAHER PA, 1993, P NATL ACAD SCI USA, V90, P11177, DOI 10.1073/pnas.90.23.11177; MOLLER NPH, 1994, P NATL ACAD SCI USA, V91, P7477, DOI 10.1073/pnas.91.16.7477; Ogata M, 1999, J BIOL CHEM, V274, P12905, DOI 10.1074/jbc.274.18.12905; OGATA M, 1995, J BIOL CHEM, V270, P2337, DOI 10.1074/jbc.270.25.15076; Persson C, 1997, EMBO J, V16, P2307, DOI 10.1093/emboj/16.9.2307; Saras J, 1997, J BIOL CHEM, V272, P24333, DOI 10.1074/jbc.272.39.24333; Saras J, 1997, J BIOL CHEM, V272, P20979, DOI 10.1074/jbc.272.34.20979; SARAS J, 1994, J BIOL CHEM, V269, P24082; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SAWADA M, 1994, BIOCHEM BIOPH RES CO, V203, P479, DOI 10.1006/bbrc.1994.2207; Sevinsky JR, 1996, J CELL BIOL, V133, P293, DOI 10.1083/jcb.133.2.293; Shi XP, 1996, EXP CELL RES, V225, P348, DOI 10.1006/excr.1996.0185; SIEGEL JN, 1992, CURRENT PROTOCOLS IM; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SMITH AL, 1995, BIOCHEM BIOPH RES CO, V209, P959, DOI 10.1006/bbrc.1995.1591; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TAKEUCHI K, 1994, J CELL SCI, V107, P1921; Tonks N K, 1996, Adv Pharmacol, V36, P91, DOI 10.1016/S1054-3589(08)60578-5; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; ZHANG SH, 1995, J BIOL CHEM, V270, P20067, DOI 10.1074/jbc.270.34.20067; Zhang SH, 1997, J BIOL CHEM, V272, P27281, DOI 10.1074/jbc.272.43.27281	37	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20717	20724		10.1074/jbc.274.29.20717	http://dx.doi.org/10.1074/jbc.274.29.20717			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400706	hybrid			2022-12-25	WOS:000081438300099
J	Rubin, DA; Hellman, P; Zon, LI; Lobb, CJ; Bergwitz, C; Juppner, H				Rubin, DA; Hellman, P; Zon, LI; Lobb, CJ; Bergwitz, C; Juppner, H			A G protein-coupled receptor from zebrafish is activated by human parathyroid hormone and not by human or teleost parathyroid hormone-related peptide - Implications for the evolutionary conservation of calcium-regulating peptide hormones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PTH-RELATED PEPTIDE; CALCITONIN-RECEPTOR; METAPHYSEAL CHONDRODYSPLASIA; FUNCTIONAL-CHARACTERIZATION; PTH/PTHRP RECEPTOR; GROWTH-HORMONE; GENE; EXPRESSION; CLONING; ISOFORMS	Genomic and cDNA clones encoding portions of a putative catfish parathyroid hormone (PTH) 2 receptor (PTH2R) led to the isolation of a cDNA encoding a full-length zebrafish PTH2R (zPTH2R), The zPTH2R shared 63 and 60% amino acid sequence identity with human and rat PTH2Rs, respectively, 47-52% identity with mammalian and frog PTH/PTHrP receptors (PTH1R), and less than 37% with other members of this family of G protein-coupled receptors, COS-7 cells expressing zPTH2R(43), a 5' splice variant that lacked 17 amino acids in the amino-terminal extracellular domain, showed cAMP accumulation when challenged with [Tyr(34)]hPTH(1-34)-amide (hPTH) (EC50, 1.64 +/- 0.95 nM) and [Ile(5),Trp(23),Tyr(36)]hPTHrP-(1-36)-amide ([Ile5, Trp23]hPTKrP) (EC50, 46.8 +/- 12.1 nM) but not when stimulated with [Tyr(36)]hPTHrP-(1-36)-amide (hPTHrP), [Trp(23),Tyr(36)]hPTHrP-(1-36)-amide ([Trp(23)]hPTHrP), or [Ala(29),Glu(30), Ala(34), Glu(35), Tyr(36)]fugufish PTHrP-(1-36)-amide (fuguPTHrP), FuguPTHrP also failed to activate the human PTH2R but had similar efficiency and efficacy as hPTH and hPTHrP when tested with cells expressing the human PTH1R. Agonist-dependent activation of zPTH2R was less efficient than that of zPTH2R(43), and both receptor variants showed no cAMP accumulation when stimulated with either secretin, growth hormone-releasing hormone, or calcitonin. The zPTH2R thus has ligand specificity similar to that of the human homolog, which raises the possibility that a PTH-like molecule exists in zebrafish, species which lack parathyroid glands.	Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Serv Pediat, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Sch Med, Boston, MA 02115 USA; Univ Mississippi, Med Ctr, Dept Microbiol, Jackson, MS 39216 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Harvard Medical School; University of Mississippi; University of Mississippi Medical Center	Juppner, H (corresponding author), Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.	jueppner@helix.mgh.harvard.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009500, P01DK011794] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-11794, DK 09500, F32 DK09500] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bergwitz C, 1997, J BIOL CHEM, V272, P28861, DOI 10.1074/jbc.272.46.28861; Bergwitz C, 1998, ENDOCRINOLOGY, V139, P723, DOI 10.1210/en.139.2.723; Bettoun JD, 1998, J CLIN INVEST, V102, P958, DOI 10.1172/JCI3678; Bettoun JD, 1997, J CLIN ENDOCR METAB, V82, P1031, DOI 10.1210/jc.82.4.1031; BOND CE, 1998, BIOL FISHES; Chalmers DT, 1996, TRENDS PHARMACOL SCI, V17, P166, DOI 10.1016/0165-6147(96)81594-X; Chow BKC, 1997, GEN COMP ENDOCR, V105, P176, DOI 10.1006/gcen.1996.6818; DETRICH HW, 1995, P NATL ACAD SCI USA, V92, P10713, DOI 10.1073/pnas.92.23.10713; Devlin AJ, 1996, GEN COMP ENDOCR, V101, P83, DOI 10.1006/gcen.1996.0010; Dores RM, 1996, GEN COMP ENDOCR, V103, P1, DOI 10.1006/gcen.1996.0088; Drezner Marc K., 1996, P263; FELSENSTEIN J, 1993, SYST BIOL, V42, P193, DOI 10.2307/2992541; Gardella TJ, 1996, J BIOL CHEM, V271, P19888, DOI 10.1074/jbc.271.33.19888; Gardella TJ, 1996, J BIOL CHEM, V271, P12820, DOI 10.1074/jbc.271.22.12820; *GCG, 1994, GCG PROGR MAN WISC P; HARVEY S, 1987, GEN COMP ENDOCR, V68, P136, DOI 10.1016/0016-6480(87)90069-4; HEDGES SB, 1992, MOL BIOL EVOL, V9, P366; HELLMAN P, 1993, THESIS UPPSALA U UPP; INGLETON PM, 1995, GEN COMP ENDOCR, V98, P211, DOI 10.1006/gcen.1995.1062; Jobert AS, 1996, MOL ENDOCRINOL, V10, P1066, DOI 10.1210/me.10.9.1066; Joun H, 1997, ENDOCRINOLOGY, V138, P1742, DOI 10.1210/en.138.4.1742; KANEKO T, 1993, J EXP BIOL, V184, P31; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; Karaplis AC, 1998, ENDOCRINOLOGY, V139, P5255, DOI 10.1210/en.139.12.5255; KONG XF, 1994, BIOCHEM BIOPH RES CO, V200, P1290, DOI 10.1006/bbrc.1994.1591; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; LEE CW, 1994, ENDOCRINOLOGY, V135, P1488, DOI 10.1210/en.135.4.1488; MADDISON WP, 1992, MACCLADE ANAL PHYLOG; MCCUAIG KA, 1995, NUCLEIC ACIDS RES, V23, P1948, DOI 10.1093/nar/23.11.1948; MCCUAIG KA, 1994, P NATL ACAD SCI USA, V91, P5051, DOI 10.1073/pnas.91.11.5051; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Nelson JS, 1994, FISHES WORLD, DOI 10.1002/9781119174844; NUSSENZVEIG DR, 1995, ENDOCRINOLOGY, V136, P2047, DOI 10.1210/en.136.5.2047; Philbrick WM, 1998, P NATL ACAD SCI USA, V95, P11846, DOI 10.1073/pnas.95.20.11846; POTTS JT, 1997, METABOLIC BONE DIS, P51; Pough FH, 1989, VERTEBRATE LIFE; ROSENBERG J, 1991, J BONE MINER RES  S1, V6, P379; Rubin DA, 1996, J MOL ENDOCRINOL, V16, P73, DOI 10.1677/jme.0.0160073; RUBIN DA, 1995, MOL PHYLOGENET EVOL, V4, P129, DOI 10.1006/mpev.1995.1013; RUBIN DA, 1994, GEN COMP ENDOCR, V95, P71, DOI 10.1006/gcen.1994.1103; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; SCHIPANI E, 1995, J CLIN ENDOCR METAB, V80, P1611, DOI 10.1210/jc.80.5.1611; Schipani E, 1997, P NATL ACAD SCI USA, V94, P13689, DOI 10.1073/pnas.94.25.13689; Schipani E, 1996, NEW ENGL J MED, V335, P708, DOI 10.1056/NEJM199609053351004; SCHNEIDER H, 1993, EUR J PHARM-MOLEC PH, V246, P149, DOI 10.1016/0922-4106(93)90092-N; SCHOWALTER DB, 1989, ANAL BIOCHEM, V177, P90, DOI 10.1016/0003-2697(89)90019-5; Segre Gino V., 1996, P377; SEXTON PM, 1993, MOL ENDOCRINOL, V7, P815, DOI 10.1210/me.7.6.815; Shyu JF, 1996, J BIOL CHEM, V271, P31127, DOI 10.1074/jbc.271.49.31127; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; Stock DW, 1996, P NATL ACAD SCI USA, V93, P10858, DOI 10.1073/pnas.93.20.10858; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; Swofford D.L., 1993, PHYLOGENETIC ANAL US; Swofford David L., 1990, P411; Usdin TB, 1997, ENDOCRINOLOGY, V138, P831, DOI 10.1210/en.138.2.831; USDIN TB, 1995, J BIOL CHEM, V270, P15455, DOI 10.1074/jbc.270.26.15455; Usdin TB, 1996, ENDOCRINOLOGY, V137, P4285, DOI 10.1210/en.137.10.4285; Wysolmerski JJ, 1998, DEVELOPMENT, V125, P1285; WYSOLMERSKI JJ, 1995, DEVELOPMENT, V121, P3539; WYSOLMERSKI JJ, 1994, P NATL ACAD SCI USA, V91, P1133, DOI 10.1073/pnas.91.3.1133; Yang Kai H., 1996, P347; Zhang P, 1998, J CLIN ENDOCR METAB, V83, P3365, DOI 10.1210/jc.83.9.3373	62	50	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23035	23042		10.1074/jbc.274.33.23035	http://dx.doi.org/10.1074/jbc.274.33.23035			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438471	hybrid			2022-12-25	WOS:000082012800021
J	Dale, H; Krebs, MP				Dale, H; Krebs, MP			Membrane insertion kinetics of a protein domain in vivo - The bacterioopsin N terminus inserts co-translationally	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; SIGNAL-RECOGNITION PARTICLE; ESCHERICHIA-COLI; CYTOPLASMIC MEMBRANE; HALOBACTERIUM-HALOBIUM; SECRETORY PROTEINS; CONDUCTING CHANNEL; CYSTEINE RESIDUES; PURPLE MEMBRANE; P-GLYCOPROTEIN	The pathway by which segments of a polytopic membrane protein are inserted into the membrane has not been resolved in vivo. We have developed an in vivo kinetic assay to examine the insertion pathway of the polytopic protein bacterioopsin, the apoprotein of Halobacterium salinarum. bacteriorhodopsin. Strains were constructed that express the bacteriorhodopsin mutants I4C:H-6 and T5C:H-6, which carry a unique Cys in the N-terminal extracellular domain and a polyhistidine tag at the C terminus. Translocation of the N-terminal domain was detected using a membrane-impermeant gel shift reagent to derivatize the Cys residue of nascent radiolabeled molecules. Derivatization was assessed by gel electrophoresis of the fully elongated radiolabeled population. The time required to translocate and fully derivatize the Cys residues of I4C:H-6 and T5C:H-6 is 46 +/- 9 and 61 +/- 6 s, respectively. This is significantly shorter than the elongation times of the proteins, which are 114 +/- 26 and 169 +/- 16 s, respectively. These results establish that translocation of the bacterioopsin N terminus and insertion of the first transmembrane segment occur co translationally and confirm the use of the assay to monitor the kinetics of polytopic membrane protein insertion in vivo.	Univ Wisconsin, Sch Med, Dept Biomol Chem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Krebs, MP (corresponding author), Univ Wisconsin, Sch Med, Dept Biomol Chem, Madison, WI 53706 USA.			Krebs, Mark/0000-0001-9017-6066				Bibi E, 1998, TRENDS BIOCHEM SCI, V23, P51, DOI 10.1016/S0968-0004(97)01134-1; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; Bochkareva E, 1996, J BIOL CHEM, V271, P22256, DOI 10.1074/jbc.271.36.22256; Borel AC, 1996, BIOCHEMISTRY-US, V35, P10587, DOI 10.1021/bi960950q; Borel AC, 1996, CELL, V85, P379, DOI 10.1016/S0092-8674(00)81116-2; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; Bremer H., 1996, E COLI SALMONELLA CE, V2, P1553; Brown JR, 1997, MICROBIOL MOL BIOL R, V61, P456, DOI 10.1128/.61.4.456-502.1997; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; Grigorieff N, 1996, J MOL BIOL, V259, P393, DOI 10.1006/jmbi.1996.0328; GROPP R, 1992, P NATL ACAD SCI USA, V89, P1204, DOI 10.1073/pnas.89.4.1204; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; HARTMANN E, 1994, NATURE, V367, P654, DOI 10.1038/367654a0; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; Jander G, 1996, J BACTERIOL, V178, P3049, DOI 10.1128/jb.178.11.3049-3058.1996; Johnson AE, 1997, TRENDS CELL BIOL, V7, P90, DOI 10.1016/S0962-8924(97)01029-5; Joly JC, 1997, BIOCHEMISTRY-US, V36, P10067, DOI 10.1021/bi9707739; Krebs MP, 1997, J MOL BIOL, V267, P172, DOI 10.1006/jmbi.1996.0848; KREBS MP, 1991, P NATL ACAD SCI USA, V88, P859, DOI 10.1073/pnas.88.3.859; KREBS MP, 1993, P NATL ACAD SCI USA, V90, P1987, DOI 10.1073/pnas.90.5.1987; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lanyi JK, 1997, J BIOL CHEM, V272, P31209, DOI 10.1074/jbc.272.50.31209; Long JC, 1998, J BIOL CHEM, V273, P16235, DOI 10.1074/jbc.273.26.16235; Luneberg J, 1998, J BIOL CHEM, V273, P28822, DOI 10.1074/jbc.273.44.28822; Lutsenko S, 1997, J BIOL CHEM, V272, P5249, DOI 10.1074/jbc.272.8.5249; MACFARLANE J, 1995, EUR J BIOCHEM, V233, P766, DOI 10.1111/j.1432-1033.1995.766_3.x; MARTOGLIO B, 1995, CELL, V81, P207, DOI 10.1016/0092-8674(95)90330-5; MATLACK KES, 1995, J BIOL CHEM, V270, P6170, DOI 10.1074/jbc.270.11.6170; Moss K, 1998, MOL BIOL CELL, V9, P2681, DOI 10.1091/mbc.9.9.2681; Mothes W, 1997, CELL, V89, P523, DOI 10.1016/S0092-8674(00)80234-2; MUECKLER M, 1986, CELL, V44, P629, DOI 10.1016/0092-8674(86)90272-2; Newitt JA, 1998, J BIOL CHEM, V273, P12451, DOI 10.1074/jbc.273.20.12451; Oesterhelt D, 1974, Methods Enzymol, V31, P667; Ota K, 1998, MOL CELL, V2, P495, DOI 10.1016/S1097-2765(00)80149-5; Pohlschroder M, 1997, CELL, V91, P563, DOI 10.1016/S0092-8674(00)80443-2; RANDALL LL, 1983, CELL, V33, P231, DOI 10.1016/0092-8674(83)90352-5; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; SEEHRA JS, 1984, J BIOL CHEM, V259, P4187; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SINGER SJ, 1987, P NATL ACAD SCI USA, V84, P1960, DOI 10.1073/pnas.84.7.1960; SKACH WR, 1993, J BIOL CHEM, V268, P23552; SORENSEN MA, 1989, J MOL BIOL, V207, P365, DOI 10.1016/0022-2836(89)90260-X; Spannagel C, 1998, BIOCHEMISTRY-US, V37, P615, DOI 10.1021/bi9714971; SUMPER M, 1978, EUR J BIOCHEM, V89, P229, DOI 10.1111/j.1432-1033.1978.tb20917.x; TRAXLER B, 1992, J BIOL CHEM, V267, P5339; Uchida K, 1995, J BIOL CHEM, V270, P30862, DOI 10.1074/jbc.270.52.30862; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; Valent QA, 1998, EMBO J, V17, P2504, DOI 10.1093/emboj/17.9.2504; VONHEIJNE G, 1995, BIOESSAYS, V17, P25, DOI 10.1002/bies.950170107; WESSELS HP, 1988, CELL, V55, P61, DOI 10.1016/0092-8674(88)90009-8; Wickner W, 1996, J BIOL CHEM, V271, P29514, DOI 10.1074/jbc.271.47.29514; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938	53	42	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22693	22698		10.1074/jbc.274.32.22693	http://dx.doi.org/10.1074/jbc.274.32.22693			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428851	hybrid			2022-12-25	WOS:000081868400081
J	Mamula, MJ; Gee, RJ; Elliott, JI; Sette, A; Southwood, S; Jones, PJ; Blier, PR				Mamula, MJ; Gee, RJ; Elliott, JI; Sette, A; Southwood, S; Jones, PJ; Blier, PR			Isoaspartyl post-translational modification triggers autoimmune responses to self-proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTOREACTIVE T-CELLS; LPR-LPR MICE; B-CELLS; PHOSPHOCARRIER PROTEIN; O-METHYLTRANSFERASE; LUPUS AUTOIMMUNITY; ANTI-SM; PEPTIDE; REPAIR; METHYLATION	The normal functioning immune system is programmed to attack foreign pathogens and other foreign proteins while maintaining tolerance to self-proteins. The mechanisms by which tolerance is broken in the initiation of autoimmunity are not completely understood, In the present study, mice immunized with the murine cytochrome c peptide 90-104 showed no response by the B or T cell compartments, However, immunization with the isoaspartyl form of this peptide, where the linkage of Asp(93) to Leu(94) occurs through the beta-carboxyl group, resulted in strong B and T cell autoimmune responses. Antibodies elicited by immunization with the isoaspartyl form of self-peptide were cross-reactive in binding to both isoforms of cytochrome c peptide and to native cytochrome c self-protein, In a similar manner, immunization of mice with the isoaspartyl form of a peptide autoantigen of human systemic lupus erythematosus (SLE) resulted in strong B and T cell responses while mice maintained tolerance to the normal aspartyl form of self-antigen, Isoaspartyl linkages within proteins are enhanced in aging and stressed cells and arise under physiological conditions, These posttranslationally modified peptides may serve as an early immunologic stimulus in autoimmune disease.	Yale Univ, Sch Med, Rheumatol Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Epimmune Inc, San Diego, CA 92121 USA; Boehringer Ingelheim Pharmaceut Inc, Dept Analyt Sci & Immunol Dis, Ridgefield, CT 06877 USA	Yale University; Yale University; Boehringer Ingelheim	Mamula, MJ (corresponding author), Yale Univ, Sch Med, Rheumatol Sect, 333 Cedar St,LCI 610,POB 208031, New Haven, CT 06520 USA.	mark.mamula@yale.edu	Sette, Alessandro/AFO-8916-2022		NIAID NIH HHS [AI36529] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI036529] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASWAD DW, 1995, DEAMIDATION ISOASPAR, P31; BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; BLOOM DD, 1993, J IMMUNOL, V150, P1579; BOCKENSTEDT LK, 1995, J IMMUNOL, V154, P3516; BRENNAN TV, 1994, J BIOL CHEM, V269, P24586; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; BRINGMANN P, 1983, EMBO J, V2, P1129, DOI 10.1002/j.1460-2075.1983.tb01557.x; BUUS S, 1987, SCIENCE, V235, P1353, DOI 10.1126/science.2435001; CHAZIN WJ, 1989, BIOCHEMISTRY-US, V28, P8646, DOI 10.1021/bi00447a055; CLARKE S, 1985, ANNU REV BIOCHEM, V54, P479, DOI 10.1146/annurev.bi.54.070185.002403; DeVry CG, 1996, ARCH BIOCHEM BIOPHYS, V335, P321, DOI 10.1006/abbi.1996.0513; FATENEJAD S, 1994, J IMMUNOL, V152, P5523; GALLETTI P, 1995, BIOCHEM J, V306, P313, DOI 10.1042/bj3060313; Garza KM, 1997, IMMUNITY, V6, P89, DOI 10.1016/S1074-7613(00)80245-9; GORGA JC, 1987, J BIOL CHEM, V262, P16087; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; JEVNIKAR AM, 1994, J EXP MED, V179, P1137, DOI 10.1084/jem.179.4.1137; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAUFMAN DL, 1993, NATURE, V366, P69, DOI 10.1038/366069a0; Kim E, 1997, P NATL ACAD SCI USA, V94, P6132, DOI 10.1073/pnas.94.12.6132; KOREN E, 1995, J IMMUNOL, V154, P4857; LADINO CA, 1992, J CELL PHYSIOL, V153, P297, DOI 10.1002/jcp.1041530209; LEHMANN PV, 1992, NATURE, V358, P155, DOI 10.1038/358155a0; LOU YH, 1993, J IMMUNOL, V151, P5790; LURA R, 1988, BIOCHEMISTRY-US, V27, P7671, DOI 10.1021/bi00420a015; MAMULA MJ, 1995, IMMUNOL REV, V144, P301, DOI 10.1111/j.1600-065X.1995.tb00074.x; MAMULA MJ, 1993, J EXP MED, V177, P567, DOI 10.1084/jem.177.2.567; MAMULA MJ, 1993, IMMUNOL TODAY, V14, P151, DOI 10.1016/0167-5699(93)90274-O; MAMULA MJ, 1994, J IMMUNOL, V152, P1453; Meadows L, 1997, IMMUNITY, V6, P273, DOI 10.1016/S1074-7613(00)80330-1; Molberg O, 1998, NAT MED, V4, P713, DOI 10.1038/nm0698-713; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; Najbauer J, 1996, BIOCHEMISTRY-US, V35, P5183, DOI 10.1021/bi953063g; ROHER AE, 1993, J BIOL CHEM, V268, P3072; ROMANIK EA, 1989, J BIOL CHEM, V264, P14050; Roth R, 1996, J IMMUNOL, V157, P2924; SANTORO TJ, 1988, J EXP MED, V167, P1713, DOI 10.1084/jem.167.5.1713; SCHILD H, 1990, SCIENCE, V247, P1587, DOI 10.1126/science.2321019; SETTE A, 1989, J IMMUNOL, V142, P35; SETTE A, 1992, J IMMUNOL, V148, P844; SHARMA S, 1993, J BIOL CHEM, V268, P17695; SHLOMCHIK MJ, 1987, NATURE, V328, P805, DOI 10.1038/328805a0; Skipper JCA, 1996, J EXP MED, V183, P527, DOI 10.1084/jem.183.2.527; STEINBERG AD, 1980, J IMMUNOL, V125, P871; TAN EM, 1989, ADV IMMUNOL, V44, P93, DOI 10.1016/S0065-2776(08)60641-0; TSAI W, 1994, BIOCHEM BIOPH RES CO, V203, P491, DOI 10.1006/bbrc.1994.2209; VOORTER CEM, 1988, J BIOL CHEM, V263, P19020; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; Wood P, 1998, J EXP MED, V188, P773, DOI 10.1084/jem.188.4.773	49	169	174	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22321	22327		10.1074/jbc.274.32.22321	http://dx.doi.org/10.1074/jbc.274.32.22321			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428801	hybrid			2022-12-25	WOS:000081868400031
J	Wang, DX; Sadee, W; Quillan, JM				Wang, DX; Sadee, W; Quillan, JM			Calmodulin binding to G protein-coupling domain of opioid receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; PHARMACOLOGICAL CHARACTERIZATION; FUNCTIONAL EXPRESSION; RAT-BRAIN; ACTIVATION; MODULATION; CLONING; OPIATE; KINASE; CELLS	The ubiquitous intracellular Ca2+ sensor calmodulin (CaM) regulates numerous proteins involved in cellular signaling of G protein-coupled receptors, but most known interactions between GPCRs and CaM occur downstream of the receptor. Using a sequence-based motif search, we have identified the third intracellular loop of the opioid receptor family as a possible direct contact point for interaction with CaM, in addition to its established role in G protein activation. Peptides derived from the third intracellular loop of the mu-opioid (OP3) receptor strongly bound CaM and were able to reduce binding interactions observed between CaM and immunopurified OP3 receptor. Functionally, CaM reduced basal and agonist-stimulated S-35-labeled guanosine 5'-3-O-(thio)triphosphate incorporation, a measure of G protein activation, in membranes containing recombinant OP3 receptor. Changes in CaM membrane levels as a result of overexpression or antisense CaM suppression inversely affected basal and agonist-induced G protein activation. The ability of CaM to abolish high affinity binding sites of an agonist at OP3 further supports the hypothesis of a direct interaction between CaM and opioid receptors, An OP3 receptor mutant with a Lys(273) --> Ala substitution (K273A-OP3), an amino acid predicted to play a critical role in CaM binding based on motif structure, was found to be unaffected by changes in CaM levels but coupled more efficiently to G proteins than the wild-type receptor, Stimulation of both the OP1 (delta-opioid) and OP3 wild-type receptors, but not the K273A-OP3 mutant, induced release of CaM from the plasma membrane. These results suggest that CaM directly competes with G proteins for binding to opioid receptors and that CaM may itself serve as an independent second messenger molecule that is released upon receptor stimulation.	Univ Calif San Francisco, Sch Pharm, Dept Biopharmaceut Sci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Neurobiol Drug Addict, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Sadee, W (corresponding author), Univ Calif San Francisco, Sch Pharm, Dept Biopharmaceut Sci, San Francisco, CA 94143 USA.		Wang, Danxin/I-5810-2019	Wang, Danxin/0000-0002-7134-3065	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004166] Funding Source: NIH RePORTER; NIDA NIH HHS [DA04166] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ARDEN JR, 1995, J NEUROCHEM, V65, P1636; BARAM D, 1983, J NEUROCHEM, V40, P55, DOI 10.1111/j.1471-4159.1983.tb12652.x; Burford NT, 1998, EUR J PHARMACOL, V342, P123, DOI 10.1016/S0014-2999(97)01556-2; CHEN Y, 1993, MOL PHARMACOL, V44, P8; CHEUNG WY, 1970, BIOCHEM BIOPH RES CO, V38, P533, DOI 10.1016/0006-291X(70)90747-3; CHEUNG WY, 1971, J BIOL CHEM, V246, P2859; COSTA T, 1989, P NATL ACAD SCI USA, V86, P7321, DOI 10.1073/pnas.86.19.7321; COSTA T, 1988, MOL PHARMACOL, V34, P744; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DSOUZA M, 1997, TRENDS GENET, V13, P487; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; EVANS T, 1984, MOL PHARMACOL, V26, P395; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; HANBAUER I, 1979, NEUROPHARMACOLOGY, V18, P859, DOI 10.1016/0028-3908(79)90082-0; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; KAKIUCHI S, 1970, BIOCHEM BIOPH RES CO, V41, P1104, DOI 10.1016/0006-291X(70)90199-3; KAKIUCHI S, 1972, ADV CYCL NUCL RES<D>, V1, P455; KATAOKA M, 1989, P NATL ACAD SCI USA, V86, P6944, DOI 10.1073/pnas.86.18.6944; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; KINCAID RL, 1982, J BIOL CHEM, V257, P638; LAW PY, 1993, MOL PHARMACOL, V43, P684; Lin KD, 1999, BIOTECHNIQUES, V26, P318, DOI 10.2144/99262rr02; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; Liu MY, 1997, J BIOL CHEM, V272, P18801, DOI 10.1074/jbc.272.30.18801; MALENCIK DA, 1983, BIOCHEM BIOPH RES CO, V114, P50, DOI 10.1016/0006-291X(83)91592-9; MESTEK A, 1995, J NEUROSCI, V15, P2396, DOI 10.1523/JNEUROSCI.15-03-02396.1995; Minakami R, 1997, J BIOL CHEM, V272, P20291, DOI 10.1074/jbc.272.32.20291; NEHMAD R, 1982, MOL PHARMACOL, V22, P389; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PAYNE ME, 1988, J BIOL CHEM, V263, P7190; PUTKEY JA, 1983, J BIOL CHEM, V258, P1864; SCHULMAN H, 1992, CELL CALCIUM, V13, P401, DOI 10.1016/0143-4160(92)90053-U; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311; VANELDICK LJ, 1998, CALMODULIN SIGNAL TR; Wade SM, 1996, MOL PHARMACOL, V50, P351; WANG JB, 1994, FEBS LETT, V338, P217, DOI 10.1016/0014-5793(94)80368-4; WANG Z, 1994, LIFE SCI, V54, P339	39	102	111	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					22081	22088		10.1074/jbc.274.31.22081	http://dx.doi.org/10.1074/jbc.274.31.22081			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419536	hybrid			2022-12-25	WOS:000081721100089
J	Abe, H; Iehara, N; Utsunomiya, K; Kita, T; Doi, T				Abe, H; Iehara, N; Utsunomiya, K; Kita, T; Doi, T			A vitamin D analog regulates mesangial cell smooth muscle phenotypes in a transforming growth factor-beta type II receptor-mediated manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; ACTIN EXPRESSION; DIFFERENTIATION; INVITRO; CLONING; MICE; RNA; GROWTH-FACTOR-BETA-1; HYPERCALCEMIA; COLLAGEN	Mesangial cells share features with contractile smooth muscle cells and mechanically support the capillary wall. The role of vitamin D compounds and the transforming growth factor-beta (TGF-beta) type II receptor in modulating the smooth muscle phenotype of cultured mesangial cells was examined. Cell proliferation was significantly inhibited by the vitamin D analog 22-oxa-1,25-dihydroxyvitamin D-3 (22-oxacalcitriol; OCT) rather than by 1,25-dihydroxyvitamin D-3 (1,25(OH)(2)D-3) in a dose-dependent manner. OCT-treated early passage mesangial cells (MC-E cells) had increased expression levels of type IV collagen and smooth muscle alpha actin mRNA, but 1,25(OH)(2)D-3-treated MC-E cells did not. The addition of a TGF-beta(1)-neutralizing antibody to the OCT-treated MC-E cells blocked this inhibitory effect for cell proliferation and attenuated the up-regulated mRNA levels. However, after exposure to 1,25(OH),D, or OCT, there was no significant difference in the secretion of active TGF-beta. We next investigated whether TGF-beta type II receptor (RII) was involved in this regulation. OCT treatment significantly increased the expression of the RII mRNA in MC-E cells. These results suggest that the vitamin D analog OCT induces smooth muscle phenotypic alterations and that this phenomenon was mediated through the induction of RII in cultured mesangial cells.	Kyoto Univ, Fac Med, Dept Clin Bioregulatory Sci, Div Mol Med Adult & Geriatr Dis, Kyoto 6068397, Japan; Kyoto Univ, Fac Med, Div Artificial Kidneys, Kyoto 6068397, Japan	Kyoto University; Kyoto University	Doi, T (corresponding author), Kyoto Univ, Fac Med, Div Artificial Kidneys, Sakyo Ku, 54 Shogoin Kawaharacho, Kyoto 6068507, Japan.	doitoshi@kuhp.kyoto-u.ac.jp						ABE E, 1981, P NATL ACAD SCI-BIOL, V78, P4990, DOI 10.1073/pnas.78.8.4990; ABE J, 1987, FEBS LETT, V226, P58, DOI 10.1016/0014-5793(87)80550-1; ABE J, 1991, ENDOCRINOLOGY, V129, P832, DOI 10.1210/endo-129-2-832; ABE J, 1990, J NUTR SCI VITAMINOL, V36, P21, DOI 10.3177/jnsv.36.21; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BJORKERUD S, 1991, ARTERIOSCLER THROMB, V11, P892, DOI 10.1161/01.ATV.11.4.892; BURBELO PD, 1991, J BIOL CHEM, V266, P22297; DAVIES M, 1994, KIDNEY INT, V45, P320, DOI 10.1038/ki.1994.41; DESMOULIERE A, 1993, J CELL BIOL, V122, P103, DOI 10.1083/jcb.122.1.103; DOI T, 1992, P NATL ACAD SCI USA, V89, P2873, DOI 10.1073/pnas.89.7.2873; DOI T, 1989, AM J PATHOL, V134, P395; DOI T, 1991, J EXP MED, V173, P1287, DOI 10.1084/jem.173.5.1287; FLOEGE J, 1991, KIDNEY INT, V40, P477, DOI 10.1038/ki.1991.235; FLOEGE J, 1994, KIDNEY INT, V45, P360, DOI 10.1038/ki.1994.46; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Iehara N, 1996, KIDNEY INT, V49, P1330, DOI 10.1038/ki.1996.189; JOHNSON RJ, 1992, J AM SOC NEPHROL, V2, pS190; Koizumi H, 1997, J DERMATOL SCI, V15, P207, DOI 10.1016/S0923-1811(97)00609-9; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACKAY K, 1988, KIDNEY INT, V33, P677, DOI 10.1038/ki.1988.53; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MURAYAMA E, 1986, CHEM PHARM BULL, V34, P4410; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; OBERBAUMER I, 1985, EUR J BIOCHEM, V147, P217, DOI 10.1111/j.1432-1033.1985.tb08739.x; OKUDA S, 1990, J CLIN INVEST, V86, P453, DOI 10.1172/JCI114731; OWENS GK, 1995, PHYSIOL REV, V75, P487; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SCHENBORN ET, 1985, NUCLEIC ACIDS RES, V13, P6223, DOI 10.1093/nar/13.17.6223; STRIKER GE, 1985, LAB INVEST, V53, P122; SUZUKI A, 1994, FEBS LETT, V355, P19, DOI 10.1016/0014-5793(94)01156-7; VENKATACHALAM MA, 1985, AM J PHYSIOL, V249, pC48, DOI 10.1152/ajpcell.1985.249.1.C48; VERBEEK MM, 1994, AM J PATHOL, V144, P372; WEINREICH T, 1991, AM J KIDNEY DIS, V18, P359, DOI 10.1016/S0272-6386(12)80096-5; Wu GF, 1998, J BIOL CHEM, V273, P7749, DOI 10.1074/jbc.273.13.7749; YAMAMOTO T, 1994, KIDNEY INT, V45, P916, DOI 10.1038/ki.1994.122; YAMAMOTO T, 1993, P NATL ACAD SCI USA, V90, P1814, DOI 10.1073/pnas.90.5.1814; Yamamoto T, 1996, KIDNEY INT, V49, P461, DOI 10.1038/ki.1996.65; ZENTELLA A, 1992, P NATL ACAD SCI USA, V89, P5176, DOI 10.1073/pnas.89.11.5176	40	31	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					20874	20878		10.1074/jbc.274.30.20874	http://dx.doi.org/10.1074/jbc.274.30.20874			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409630	Green Submitted, hybrid			2022-12-25	WOS:000081613100021
J	Haslam, SM; Houston, KM; Harnett, W; Reason, AJ; Morris, HR; Dell, A				Haslam, SM; Houston, KM; Harnett, W; Reason, AJ; Morris, HR; Dell, A			Structural studies of N-glycans of filarial parasites - Conservation of phosphorylcholine-substituted glycans among species and discovery of novel chito-oligomers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCRETORY-SECRETORY PRODUCT; ACANTHOCHEILONEMA-VITEAE; ONCHOCERCA-GIBSONI; LINKED OLIGOSACCHARIDES; MASS-SPECTROMETRY; PROTEIN; GLYCOPROTEIN; ACTIVATION; ATTACHMENT	N-Type glycans containing phosphorylcholine (PC-glycans), unusual structures found in the important human pathogens filarial nematodes, represent a novel target for chemotherapy. Previous work in our laboratories produced compositional information on the PC-glycan of ES-62, a secreted protein of the rodent parasite Acanthocheilonema viteae. In particular, we established using fast atom bombardment mass spectrometry (MS) analysis that PC was attached to a glycan with a trimannosyl core, with and without core fucosylation, carrying between one and four additional N-acetylglucosamine residues. In the present study, we demonstrate that this structure is conserved among filarial nematodes, including the parasite of humans, Onchocerca volvulus, for which new drugs are most urgently sought. Furthermore, by employing a variety of procedures, including collision-activated dissociation MS MS analysis and matrix-assisted laser desorption MS analysis, we reveal that surprisingly, filarial nematodes also contain N-linked glycans, the antennae of which are composed of chito-oligomers. To our knowledge, this is the first report of such structures in a eukaryotic glycoprotein.	Imperial Coll, Dept Biochem, London SW7 2AY, England; Univ Strathclyde, Dept Immunol, Glasgow G4 0NR, Lanark, Scotland; M Scan Ltd, Ascot SL5 7PZ, Berks, England	Imperial College London; University of Strathclyde	Dell, A (corresponding author), Imperial Coll, Dept Biochem, London SW7 2AY, England.							ALBERSHEIM PETER, 1967, CARBOHYD RES, V5, P340, DOI 10.1016/S0008-6215(00)80510-8; Bakkers J, 1997, P NATL ACAD SCI USA, V94, P7982, DOI 10.1073/pnas.94.15.7982; COPEMAN DB, 1979, TROPENMED PARASITOL, V30, P469; COPEMAN DB, 1993, ACTA TROP, V53, P307, DOI 10.1016/0001-706X(93)90036-B; Deehan MR, 1997, J IMMUNOL, V159, P6105; Deehan MR, 1998, J IMMUNOL, V160, P2692; DELL A, 1994, METHOD ENZYMOL, V230, P108; DELL A, 1987, ADV CARBOHYD CHEM BI, V45, P19, DOI 10.1016/S0065-2318(08)60136-5; EGGE H, 1987, MASS SPECTROM REV, V6, P331, DOI 10.1002/mas.1280060302; GEREMIA RA, 1994, P NATL ACAD SCI USA, V91, P2669, DOI 10.1073/pnas.91.7.2669; Harnett MM, 1998, PARASITE IMMUNOL, V20, P551, DOI 10.1046/j.1365-3024.1998.00181.x; HARNETT W, 1994, INT J PARASITOL, V24, P543, DOI 10.1016/0020-7519(94)90146-5; HARNETT W, 1989, PARASITOLOGY, V99, P229, DOI 10.1017/S0031182000058686; HARNETT W, 1993, EXP PARASITOL, V77, P498, DOI 10.1006/expr.1993.1113; HARNETT W, 1993, J IMMUNOL, V151, P4829; HARNETT W, 1995, PERSPECTIVES NEMATOD, P207; Haslam SM, 1996, J BIOL CHEM, V271, P30561, DOI 10.1074/jbc.271.48.30561; Haslam SM, 1997, MOL BIOCHEM PARASIT, V85, P53, DOI 10.1016/S0166-6851(96)02807-1; Houston KM, 1996, J PARASITOL, V82, P320, DOI 10.2307/3284169; Houston KM, 1997, J BIOL CHEM, V272, P1527, DOI 10.1074/jbc.272.3.1527; LAL RB, 1990, AM J TROP MED HYG, V42, P56, DOI 10.4269/ajtmh.1990.42.56; LOCHNIT G, 1995, EUR J BIOCHEM, V228, P805, DOI 10.1111/j.1432-1033.1995.tb20326.x; Macdonald M, 1996, INT J PARASITOL, V26, P1075, DOI 10.1016/S0020-7519(96)00097-5; SEMINO CE, 1995, P NATL ACAD SCI USA, V92, P3498, DOI 10.1073/pnas.92.8.3498; *WHO, 1997, TROPICAL DIS RES PRO, P86; WORMS MJ, 1961, J PARASITOL, V47, P963, DOI 10.2307/3275034	26	89	90	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					20953	20960		10.1074/jbc.274.30.20953	http://dx.doi.org/10.1074/jbc.274.30.20953			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409642	hybrid			2022-12-25	WOS:000081613100033
J	McBride, HJ; Yu, YX; Stillman, DJ				McBride, HJ; Yu, YX; Stillman, DJ			Distinct regions of the Swi5 and Ace2 transcription factors are required for specific gene activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COOPERATIVE DNA-BINDING; CELL-CYCLE REGULATION; YEAST HO GENE; SACCHAROMYCES-CEREVISIAE; ZINC-FINGER; PROMOTER; EXPRESSION; SW15; PROTEIN; G(1)	Swi5 and Ace2 are cell cycle-regulated transcription factors that activate expression of early G(1)-specific genes in Saccharomyces cerevisiae. Swi5 and Ace2 have zinc finger DNA-binding domains that are highly conserved, and the two proteins bind to the same DNA sequences in vitro. Despite this similarity in DNA binding, Swi5 and Ace2 activate different genes in vivo, with Swi5 activating the HO gene and Ace2 activating CTS1 expression. In this report we have used chimeric fusions between Swi5 and Ace2 to determine what regions of these proteins are necessary for promoter-specific activation of HO and CTS1. We have identified specific regions of Swi5 and Ace2 that are required for activation of HO and CTS1, respectively. The Swi5 protein binds HO promoter DNA cooperatively with the Phoa homeodomain protein, and the HO specificity region of Swi5 identified in the chimeric analysis coincides with the region of Swi5 previously identified that interacts with PhoB in vitro. Swi5 and Ace2 also activate expression of a number of other genes expressed in G(1) phase of the cell cycle, including ASH1, CDC6, EGT2, PCL2, PCL9, RME1, and SIC1. Analysis of the Swi5/Ace2 chimeras shows that distinct regions of Swi5 and Ace2 contribute to the transcriptional activation of some of these other G(1)-regulated genes.	Univ Utah, Hlth Sci Ctr, Huntsman Canc Inst, Dept Oncol Sci,Div Mol Biol & Genet, Salt Lake City, UT 84132 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	Stillman, DJ (corresponding author), Univ Utah, Hlth Sci Ctr, Huntsman Canc Inst, Dept Oncol Sci,Div Mol Biol & Genet, 50 N Med Dr,Rm 5C334 SOM, Salt Lake City, UT 84132 USA.			Stillman, David/0000-0002-5268-2416; McBride, Helen/0000-0003-3428-2846	NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048624, R01GM039067] Funding Source: NIH RePORTER; NCI NIH HHS [5 P30 CA42014] Funding Source: Medline; NIGMS NIH HHS [GM48624, GM39067] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aerne BL, 1998, MOL BIOL CELL, V9, P945, DOI 10.1091/mbc.9.4.945; Bhoite LT, 1998, MOL CELL BIOL, V18, P6436, DOI 10.1128/MCB.18.11.6436; Bobola N, 1996, CELL, V84, P699, DOI 10.1016/S0092-8674(00)81048-X; BRAZAS RM, 1993, P NATL ACAD SCI USA, V90, P11237, DOI 10.1073/pnas.90.23.11237; BRAZAS RM, 1995, J BIOL CHEM, V270, P29151, DOI 10.1074/jbc.270.49.29151; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; DOHRMANN PR, 1992, GENE DEV, V6, P93, DOI 10.1101/gad.6.1.93; Dohrmann PR, 1996, MOL CELL BIOL, V16, P1746; DOHRMANN PR, 1994, THESIS U UTAH SALT L; Dutnall RN, 1996, STRUCTURE, V4, P599, DOI 10.1016/S0969-2126(96)00064-0; Iyer V, 1996, P NATL ACAD SCI USA, V93, P5208, DOI 10.1073/pnas.93.11.5208; JIANG YW, 1995, GENETICS, V140, P103; Knapp D, 1996, MOL CELL BIOL, V16, P5701; Kovacech B, 1996, MOL CELL BIOL, V16, P3264; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; McBride HJ, 1997, MOL CELL BIOL, V17, P2669, DOI 10.1128/MCB.17.5.2669; McInerny CJ, 1997, GENE DEV, V11, P1277, DOI 10.1101/gad.11.10.1277; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; NASMYTH K, 1987, CELL, V49, P549, DOI 10.1016/0092-8674(87)90457-0; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; NASMYTH K, 1987, EMBO J, V6, P243, DOI 10.1002/j.1460-2075.1987.tb04745.x; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; STILLMAN DJ, 1994, GENETICS, V136, P781; STILLMAN DJ, 1988, EMBO J, V7, P485, DOI 10.1002/j.1460-2075.1988.tb02836.x; Tennyson CN, 1998, MOL MICROBIOL, V28, P69, DOI 10.1046/j.1365-2958.1998.00773.x; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; TOONE WM, 1995, EMBO J, V14, P5824, DOI 10.1002/j.1460-2075.1995.tb00270.x; TOYN JH, 1996, GENETICS, V145, P85; YU Y, 1998, UNPUB	30	67	69	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21029	21036		10.1074/jbc.274.30.21029	http://dx.doi.org/10.1074/jbc.274.30.21029			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409653	Green Accepted, Green Submitted, hybrid			2022-12-25	WOS:000081613100044
J	Shi, WX; Schramm, VL; Almo, SC				Shi, WX; Schramm, VL; Almo, SC			Nucleoside hydrolase from leishmania major - Cloning, expression, catalytic properties, transition state inhibitors, and the 2.5-angstrom crystal structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPANOSOMA-BRUCEI-BRUCEI; CRITHIDIA-FASCICULATA; N-RIBOHYDROLASE; KINETIC MECHANISM; PURINE; PURIFICATION; SPECIFICITY	Protozoan parasites lack the pathway of the de novo synthesis of purines and depend on host-derived nucleosides and nucleotides to salvage purines for DNA and RNA synthesis. Nucleoside hydrolase is a central enzyme in the purine salvage pathway and represents a prime target for the development of anti-parasitic drugs. The full-length cDNA for nucleoside hydrolase from Leishmania major was cloned and sequence analysis revealed that the L. major nucleoside hydrolase shares 78% sequence identity with the nonspecific nucleoside hydrolase from Crithidia fasciculata. The L. major enzyme was overexpressed in Escherichia coli and purified to over 95% homogeneity, The L. major nucleoside hydrolase was identified as a nonspecific nucleoside hydrolase since it demonstrates the characteristics: 1) efficient utilization of p-nitrophenyl beta-D-ribofuranoside as a substrate; 2) recognition of both inosine and uridine nucleosides as favored substrates; and 3) significant activity with all of the naturally occurring purine and pyrimidine nucleosides. The crystal structure of the L. major nucleoside hydrolase revealed a bound Ca2+ ion in the active site with five oxygen ligands hom Asp-10, Asp-15 (bidentate), Thr-126 (carbonyl), and Asp-241, The structure is similar to the C. fasciculata IU-nucleoside hydrolase apoenzyme. Despite the similarities, the catalytic specificities differ substantially. Relative values of k(cat) for the L. major enzyme with inosine, adenosine, guanosine, uridine, and cytidine as substrates are 100, 0.5, 0.5, 27 and 0.3; while those for the enzyme from C. fasciculata are 100, 15, 14, 510, and 36 for the same substrates. Iminoribitol analogues of the transition state are nanomolar inhibitors. The results provide new information for purine and pyrimidine salvage pathways in Leishmania.	Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Almo, SC (corresponding author), Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA.	almo@aecom.yu.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041916, R37GM041916] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41916] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRUNGER AT, 1992, XPLOR VERSION 3 1; David J. R., 1984, Tropical and geographical medicine., P125; Degano M, 1998, BIOCHEMISTRY-US, V37, P6277, DOI 10.1021/bi973012e; Degano M, 1996, BIOCHEMISTRY-US, V35, P5971, DOI 10.1021/bi952999m; ESTUPINAN B, 1994, J BIOL CHEM, V269, P23068; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Gopaul DN, 1996, BIOCHEMISTRY-US, V35, P5963, DOI 10.1021/bi952998u; HAMMOND DJ, 1984, MOL BIOCHEM PARASIT, V13, P243, DOI 10.1016/0166-6851(84)90117-8; HORENSTEIN BA, 1993, BIOCHEMISTRY-US, V32, P9917, DOI 10.1021/bi00089a007; HORENSTEIN BA, 1991, BIOCHEMISTRY-US, V30, P10788, DOI 10.1021/bi00108a026; HORENSTEIN BA, 1993, BIOCHEMISTRY-US, V32, P7089, DOI 10.1021/bi00079a004; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; Katz AK, 1996, J AM CHEM SOC, V118, P5752, DOI 10.1021/ja953943i; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li CM, 1999, NAT STRUCT BIOL, V6, P582, DOI 10.1038/9367; Mazzella LJ, 1996, J AM CHEM SOC, V118, P2111, DOI 10.1021/ja953537z; MILLER RL, 1984, J BIOL CHEM, V259, P5073; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NEUBERT TA, 1990, J BIOL CHEM, V265, P7236; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parkin DW, 1997, BIOCHEMISTRY-US, V36, P3528, DOI 10.1021/bi962319v; PARKIN DW, 1991, J BIOL CHEM, V266, P20658; Parkin DW, 1996, J BIOL CHEM, V271, P21713, DOI 10.1074/jbc.271.36.21713; Pelle R, 1998, J BIOL CHEM, V273, P2118, DOI 10.1074/jbc.273.4.2118; SHI W, 1999, IN PRESS BIOCHEMISTR; Shi WX, 1999, NAT STRUCT BIOL, V6, P588; TUTTLE JV, 1980, J BIOL CHEM, V255, P909	28	95	97	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21114	21120		10.1074/jbc.274.30.21114	http://dx.doi.org/10.1074/jbc.274.30.21114			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409664	hybrid			2022-12-25	WOS:000081613100055
J	Tremblay, S; Douki, T; Cadet, J; Wagner, JR				Tremblay, S; Douki, T; Cadet, J; Wagner, JR			2 '-deoxycytidine glycols, a missing link in the free radical-mediated oxidation of DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ENDONUCLEASE-III; IRRADIATED DNA; UV-LIGHT; DAMAGE; CYTOSINE; THYMIDINE; REPAIR; DEAMINATION; PRODUCTS	2'-Deoxycytidine glycols (5,6-dihydroxy-5,6-dihydro-2'-deoxycytidine) are major products of the hydroxyl radical-induced oxidation of 2'-deoxycytidine resulting from either a Fenton reaction or exposure to ionizing radiation. Because of their instability, however, the glycols have not previously been characterized. Instead, the impetus has been placed on the primary decomposition products of 2'-deoxycytidine glycols, which includes 5-hydroxy-2'-deoxycytidine, 5-hydroxy-2'-deoxyuridine, and 2'-deoxyuridine glycols. Here, we have identified one of the four possible diastereomers of 2'-deoxycytidine glycols by product analyses of decomposition products, H-1 NMR, and mass spectrometry. This glycol was observed to decompose with a half-life of 50 min at 37 degrees C in buffered neutral solutions and preferentially undergo dehydration to 5-hydroxy-2'-deoxycytidine. The rate of decomposition was strongly dependent on pH (2-10) and the concentration of phosphate ion (10-300 mM), Next, we report on the deamination of cytosine glycols to uracil glycols in oxidized DNA using acid hydrolysis and high performance liquid chromatography analysis with electrochemical detection to monitor 5-hydroxycytosine and 5-hydroxyuracil, The results showed that the lifetime of cytosine glycols is greatly enhanced in DNA (34-fold; half-life, 28 h), and that deamination accounts for at least one-third of the total decomposition. The relatively long lifetime of cytosine glycols in DNA suggests that this important class of DNA oxidation products will be significantly involved in repair and mutagenesis processes.	Inst Univ Geriatr Sherbrooke, Sherbrooke, PQ J1H 4C4, Canada; CEA Grenoble, SCIB, Dept Rech Fondamentale Mat Condensee, Lab Les Acides Nucle, F-38054 Grenoble 9, France	CEA	Wagner, JR (corresponding author), Inst Univ Geriatr Sherbrooke, Pavillon Youville,1036 Rue Belvedere Sud, Sherbrooke, PQ J1H 4C4, Canada.	rwagner@courrier.usherb.ca	Thierry, Douki/H-2108-2018; Cadet, Jean/M-2971-2018	Thierry, Douki/0000-0002-5022-071X; Cadet, Jean/0000-0003-2594-9485; Wagner, J. Richard/0000-0002-0240-2324				BARAK Y, 1995, J BIOL CHEM, V270, P24174, DOI 10.1074/jbc.270.41.24174; Bienvenu C, 1996, J AM CHEM SOC, V118, P11406, DOI 10.1021/ja962073h; Bienvenu C, 1996, J ORG CHEM, V61, P2632, DOI 10.1021/jo951900e; BOORSTEIN RJ, 1990, BIOCHEMISTRY-US, V29, P10455, DOI 10.1021/bi00498a004; BREEN AP, 1995, FREE RADICAL BIO MED, V18, P1033, DOI 10.1016/0891-5849(94)00209-3; CADET J, 1975, TETRAHEDRON, V31, P2057, DOI 10.1016/0040-4020(75)80195-5; CADET J, 1979, BIOCHIM BIOPHYS ACTA, V563, P206, DOI 10.1016/0005-2787(79)90021-2; Cadet J, 1997, Rev Physiol Biochem Pharmacol, V131, P1; Cadet J, 1990, PHOTOCHEMISTRY NUCL, P1; D'Ham C, 1999, BIOCHEMISTRY-US, V38, P3335, DOI 10.1021/bi981982b; DEBOER G, 1970, BIOCHIM BIOPHYS ACTA, V213, P253, DOI 10.1016/0005-2787(70)90033-X; DIZDAROGLU M, 1986, BIOCHEM J, V235, P531, DOI 10.1042/bj2350531; Douki T, 1996, CHEM RES TOXICOL, V9, P1145, DOI 10.1021/tx960095b; EATON MAW, 1973, BIOCHIM BIOPHYS ACTA, V319, P281, DOI 10.1016/0005-2787(73)90167-6; FEIG DI, 1994, P NATL ACAD SCI USA, V91, P6609, DOI 10.1073/pnas.91.14.6609; Fisher G. J., 1976, PHOTOCHEM PHOTOBIOL, P169; FREDERICO LA, 1990, BIOCHEMISTRY-US, V29, P2532, DOI 10.1021/bi00462a015; HARAYAMA T, 1986, J CHEM SOC CHEM COMM, P1469, DOI 10.1039/c39860001469; HATAHET Z, 1994, J BIOL CHEM, V269, P18814; Henle ES, 1997, J BIOL CHEM, V272, P19095, DOI 10.1074/jbc.272.31.19095; HRUSKA FE, 1987, CAN J CHEM, V65, P2618, DOI 10.1139/v87-432; Jiang DY, 1997, J BIOL CHEM, V272, P32230, DOI 10.1074/jbc.272.51.32230; Jolibois F, 1996, CHEM RES TOXICOL, V9, P298, DOI 10.1021/tx9501344; Kreutzer DA, 1998, P NATL ACAD SCI USA, V95, P3578, DOI 10.1073/pnas.95.7.3578; LEMAIRE DGE, 1993, BIOCHEMISTRY-US, V32, P3232; Lenton KJ, 1999, CARCINOGENESIS, V20, P607, DOI 10.1093/carcin/20.4.607; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Luo YZ, 1996, J BIOL CHEM, V271, P21167, DOI 10.1074/jbc.271.35.21167; LUSTIG MJ, 1992, NUCLEIC ACIDS RES, V20, P4839, DOI 10.1093/nar/20.18.4839; MOSCHEL RC, 1974, J ORG CHEM, V39, P1983, DOI 10.1021/jo00928a001; ODONNELL RE, 1994, BIOCHEMISTRY-US, V33, P9875, DOI 10.1021/bi00199a008; Purmal AA, 1998, J BIOL CHEM, V273, P10026, DOI 10.1074/jbc.273.16.10026; PURMAL AA, 1994, NUCLEIC ACIDS RES, V22, P72, DOI 10.1093/nar/22.1.72; RYANG HS, 1979, J ORG CHEM, V44, P1191, DOI 10.1021/jo01321a047; Sage E, 1996, P NATL ACAD SCI USA, V93, P176, DOI 10.1073/pnas.93.1.176; SHEN JC, 1994, NUCLEIC ACIDS RES, V22, P972, DOI 10.1093/nar/22.6.972; VONSONNTAG G, 1987, CHEM BASIS RAD BIOL; WAGNER JR, 1994, J AM CHEM SOC, V116, P2235, DOI 10.1021/ja00085a001; Wagner JR, 1999, J AM CHEM SOC, V121, P4101, DOI 10.1021/ja982461e; WAGNER JR, 1992, P NATL ACAD SCI USA, V89, P3380, DOI 10.1073/pnas.89.8.3380; WAGNER JR, 1994, J CHIM PHYS PCB, V91, P705; Wallace SS, 1998, RADIAT RES, V150, pS60, DOI 10.2307/3579809; Wang D, 1997, BIOCHEMISTRY-US, V36, P8628, DOI 10.1021/bi970341y; Wang D, 1998, MUTAT RES-FUND MOL M, V400, P99, DOI 10.1016/S0027-5107(98)00066-9	44	47	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					20833	20838		10.1074/jbc.274.30.20833	http://dx.doi.org/10.1074/jbc.274.30.20833			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409624	hybrid			2022-12-25	WOS:000081613100015
J	Bachelder, RE; Marchetti, A; Falcioni, R; Soddu, S; Mercurio, AM				Bachelder, RE; Marchetti, A; Falcioni, R; Soddu, S; Mercurio, AM			Activation of p53 function in carcinoma cells by the alpha(6)beta(4) integrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR P53; CYTOPLASMIC DOMAIN; ENDOTHELIAL-CELLS; CYCLE PROGRESSION; BETA-4 INTEGRIN; GENE-EXPRESSION; BAX EXPRESSION; DNA-BINDING; APOPTOSIS; ADHESION	The interaction of integrins with extracellular matrix is known to promote cell survival by inhibiting apoptotic signaling. In contrast, we demonstrate here that the alpha(6)beta(4) integrin induces apoptosis in carcinoma cells by stimulating p53 function. Specifically, we show that expression of alpha(6)beta(4) in carcinoma cells that lack this integrin stimulates an increase in the transactivating function of p53 as demonstrated by the ability of this integrin to up-regulate the expression of a p53-sensitive reporter gene as well as the endogenous p53 response gene, box, In addition, we report that alpha(6)beta(4) triggers apoptosis in carcinoma cells that express wild-type but not mutant p53 and that these alpha(6)beta(4) functions are inhibited by a dominant negative p53 construct, Importantly, we provide a link between integrin signaling and p53 activation by demonstrating that the clustering of alpha(6)beta(4) with a beta(4) integrin-specific antibody promotes p53-dependent apoptosis in cells that express both alpha(6)beta(4) and wild-type p53. These studies are the first to demonstrate that a specific integrin can promote apoptosis by activating p53. Moreover, given the ability of alpha(6)beta(4) to stimulate invasion (Shaw, L. M., Rabinovitz, I., Wang, H. F., Toker, A., and Mercurio, A. M, (1997) Cell 91, 949-960), these studies suggest that the ability of alpha(6)beta(4) to promote carcinoma progression will be enhanced in tumor cells that express mutant, inactive forms of p53.	Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Regina Elena Inst Canc Res, I-00158 Rome, Italy	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Mercurio, AM (corresponding author), Beth Israel Deaconess Med Ctr, Dana 601,330 Brookline Ave, Boston, MA 02215 USA.	amercuri@caregroup.harvard.edu	Soddu, Silvia/ABH-6774-2020; Soddu, Silvia/K-2467-2018; Falcioni, Rita/H-8869-2017; Marchetti, Alessandra/AAD-5498-2019	Soddu, Silvia/0000-0001-8526-0044; Soddu, Silvia/0000-0001-8526-0044; Falcioni, Rita/0000-0002-3745-4327; MARCHETTI, ALESSANDRA/0000-0001-9706-848X	NATIONAL CANCER INSTITUTE [P01CA044704] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039264] Funding Source: NIH RePORTER; NCI NIH HHS [CA44704] Funding Source: Medline; NIAID NIH HHS [AI39264] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Belkin AM, 1998, J BIOL CHEM, V273, P15234, DOI 10.1074/jbc.273.24.15234; Berger F, 1998, J NEUROSCI, V18, P6871; Borradori L, 1996, CURR OPIN CELL BIOL, V8, P647, DOI 10.1016/S0955-0674(96)80106-2; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Chao C, 1996, CANCER RES, V56, P4811; CLARKE AS, 1995, J BIOL CHEM, V270, P22673, DOI 10.1074/jbc.270.39.22673; Coxon A, 1996, IMMUNITY, V5, P653, DOI 10.1016/S1074-7613(00)80278-2; Day ML, 1997, J BIOL CHEM, V272, P8125, DOI 10.1074/jbc.272.13.8125; Donato NJ, 1998, J BIOL CHEM, V273, P5067, DOI 10.1074/jbc.273.9.5067; Dowling J, 1996, J CELL BIOL, V134, P559, DOI 10.1083/jcb.134.2.559; Fornaro M, 1996, AM J PATHOL, V149, P765; FORNARO M, 1995, J BIOL CHEM, V270, P24666, DOI 10.1074/jbc.270.42.24666; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; FUCHS B, 1995, ONCOGENE, V10, P789; Fuchs E, 1990, CURR OPIN CELL BIOL, V2, P1028, DOI 10.1016/0955-0674(90)90152-5; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Green KJ, 1996, FASEB J, V10, P871, DOI 10.1096/fasebj.10.8.8666164; Grimes HL, 1996, P NATL ACAD SCI USA, V93, P14569, DOI 10.1073/pnas.93.25.14569; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hecker D, 1996, ONCOGENE, V12, P953; HEMLER ME, 1989, J BIOL CHEM, V264, P6529; Homan SM, 1998, J CELL SCI, V111, P2717; Ilic D, 1998, J CELL BIOL, V143, P547; Ishizaki Y, 1998, J CELL BIOL, V140, P153, DOI 10.1083/jcb.140.1.153; KAJIJI S, 1989, EMBO J, V8, P673, DOI 10.1002/j.1460-2075.1989.tb03425.x; KENNEL SJ, 1989, J BIOL CHEM, V264, P15515; Kim SY, 1997, CANCER RES, V57, P38; LESOONWOOD LA, 1995, HUM GENE THER, V6, P395, DOI 10.1089/hum.1995.6.4-395; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; MEREDITH J, 1995, SCIENCE, V269, P1570, DOI 10.1126/science.7545312; Miao JY, 1997, BIOCHEM BIOPH RES CO, V233, P182, DOI 10.1006/bbrc.1997.6422; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Murgia C, 1998, EMBO J, V17, P3940, DOI 10.1093/emboj/17.14.3940; O'Connor KL, 1998, J CELL BIOL, V143, P1749, DOI 10.1083/jcb.143.6.1749; Rabinovitz I, 1996, BIOCHEM CELL BIOL, V74, P811, DOI 10.1139/o96-087; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; Rezniczek GA, 1998, J CELL BIOL, V141, P209, DOI 10.1083/jcb.141.1.209; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Soddu S, 1996, J CELL BIOL, V134, P193, DOI 10.1083/jcb.134.1.193; STREULI CH, 1995, J CELL BIOL, V129, P591, DOI 10.1083/jcb.129.3.591; Stromblad S, 1996, J CLIN INVEST, V98, P426, DOI 10.1172/JCI118808; Sun H, 1998, CANCER RES, V58, P2224; TOZEREN A, 1994, J CELL SCI, V107, P3153; VARNER JA, 1995, MOL BIOL CELL, V6, P725, DOI 10.1091/mbc.6.6.725; Vivinus-Nebot M, 1999, J CELL BIOL, V144, P563, DOI 10.1083/jcb.144.3.563; WALDMAN T, 1995, CANCER RES, V55, P5187; Wewer UM, 1997, AM J PATHOL, V151, P1191; Wu M, 1998, J EXP MED, V187, P1671, DOI 10.1084/jem.187.10.1671; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161	57	55	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20733	20737		10.1074/jbc.274.29.20733	http://dx.doi.org/10.1074/jbc.274.29.20733			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400708	hybrid			2022-12-25	WOS:000081438300101
J	Erbse, A; Yifrach, O; Jones, S; Lund, PA				Erbse, A; Yifrach, O; Jones, S; Lund, PA			Chaperone activity of a chimeric GroEL protein that can exist in a single or double ring form	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP HYDROLYSIS; LACTATE-DEHYDROGENASE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; BINDING DOMAINS; IN-VIVO; POLYPEPTIDE; MECHANISM; COOPERATIVITY; EXPRESSION	The molecular chaperone GroEL is a protein complex consisting of two rings each of seven identical subunits, It is thought to act by providing a cavity in which a protein substrate can fold into a form that has no propensity to aggregate. Substrate proteins are sequestered in the cavity while they fold, and prevented from diffusion out of the cavity by the action of the GroES complex, that caps the open end of the cavity, A key step in the mechanism of action of GroEL is the transmission of a conformational change between the two rings, induced by the binding of nucleotides to the GroEL ring opposite to the one containing the polypeptide substrate. This conformational change then leads to the discharge of GroES from GroEL, enabling polypeptide release. Single ring forms of GroEL are thus predicted to be unable to chaperone the folding of GroES-dependent substrates efficiently, since they are unable to discharge the bound GroES and unable to release folded protein. We describe here a detailed functional analysis of a chimeric GroEL protein, which we show to exist in solution in equilibrium between single and double ring forms, We demonstrate that whereas the double ring form of the GroEL chimera functions effectively in refolding of a GroES dependent substrate, the single ring form does not. The single ring form of the chimera, however, is able to chaperone the folding of a substrate that does not require GroES for its efficient folding. We further demonstrate that the double ring structure of GroEL is likely to be required for its activity in vivo.	Univ Birmingham, Sch Biol Sci, Birmingham B15 2TT, W Midlands, England; Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel; Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England	University of Birmingham; Weizmann Institute of Science; University of Leeds	Lund, PA (corresponding author), Univ Birmingham, Sch Biol Sci, POB 363, Birmingham B15 2TT, W Midlands, England.		lund, peter a/N-9785-2018; YIFRACH, Ofer/F-1480-2012	ERBSE, ANNETTE/0000-0003-0950-3707; Lund, Peter/0000-0002-6381-8526				BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; Ben-Zvi AP, 1998, P NATL ACAD SCI USA, V95, P15275, DOI 10.1073/pnas.95.26.15275; Boisvert DC, 1996, NAT STRUCT BIOL, V3, P170, DOI 10.1038/nsb0296-170; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; Buckle AM, 1997, P NATL ACAD SCI USA, V94, P3571, DOI 10.1073/pnas.94.8.3571; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Chatellier J, 1998, P NATL ACAD SCI USA, V95, P9861, DOI 10.1073/pnas.95.17.9861; CLARKE AR, 1985, BIOCHIM BIOPHYS ACTA, V828, P375, DOI 10.1016/0167-4838(85)90319-X; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HayerHartl MK, 1996, EMBO J, V15, P6111, DOI 10.1002/j.1460-2075.1996.tb00999.x; HOROVITZ A, 1993, J MOL BIOL, V231, P58, DOI 10.1006/jmbi.1993.1256; Horovitz A, 1998, CURR OPIN STRUC BIOL, V8, P93, DOI 10.1016/S0959-440X(98)80015-8; IVIC A, 1996, GENE AMST, V195, P1; Jones S, 1998, J MOL BIOL, V282, P789, DOI 10.1006/jmbi.1998.2039; MILLER AD, 1993, BIOCHEM J, V291, P139, DOI 10.1042/bj2910139; Nielsen KL, 1998, MOL CELL, V2, P93, DOI 10.1016/S1097-2765(00)80117-3; RANSON NA, 1995, J MOL BIOL, V250, P581, DOI 10.1006/jmbi.1995.0399; Richardson A, 1998, TRENDS BIOCHEM SCI, V23, P138, DOI 10.1016/S0968-0004(98)01193-1; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; STANIFORTH RA, 1994, FEBS LETT, V344, P129, DOI 10.1016/0014-5793(94)00348-3; STANSSENS P, 1989, NUCLEIC ACIDS RES, V17, P4441, DOI 10.1093/nar/17.12.4441; Todd MJ, 1998, METHOD ENZYMOL, V290, P135, DOI 10.1016/S0076-6879(98)90012-X; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; Wang JD, 1998, P NATL ACAD SCI USA, V95, P12163, DOI 10.1073/pnas.95.21.12163; Weber F, 1998, NAT STRUCT BIOL, V5, P977, DOI 10.1038/2952; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; White HE, 1997, NAT STRUCT BIOL, V4, P690, DOI 10.1038/nsb0997-690; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; Yifrach O, 1998, BIOCHEMISTRY-US, V37, P7083, DOI 10.1021/bi980370o; YIFRACH O, 1994, J MOL BIOL, V243, P397, DOI 10.1006/jmbi.1994.1667; YIFRACH O, 1995, BIOCHEMISTRY-US, V34, P5303, DOI 10.1021/bi00016a001; Zahn R, 1996, P NATL ACAD SCI USA, V93, P15024, DOI 10.1073/pnas.93.26.15024; ZETTLMEISSL G, 1979, EUR J BIOCHEM, V100, P593, DOI 10.1111/j.1432-1033.1979.tb04206.x	38	14	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20351	20357		10.1074/jbc.274.29.20351	http://dx.doi.org/10.1074/jbc.274.29.20351			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400658	hybrid			2022-12-25	WOS:000081438300051
J	Reuther, JY; Baldwin, AS				Reuther, JY; Baldwin, AS			Apoptosis promotes a caspase-induced amino-terminal truncation of I kappa B alpha that functions as a stable inhibitor of NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; UBIQUITIN-PROTEASOME PATHWAY; CHICKEN SPLEEN-CELLS; V-REL ONCOPROTEIN; ACTIVATION; DEATH; PHOSPHORYLATION; PROTEIN; PROTEOLYSIS; SIGNAL	Caspases are cell death cysteine proteases that are activated upon the induction of the apoptotic program and cleave target proteins in a sequence-specific manner to promote cell death. Recently, Barkett et al. (Barkett, M., Xue, D., Horvitz, H. R., and Gilmore, T. D. (1997) J. Biol. Chem. 272, 29419-29422) have shown that I kappa B alpha, the inhibitory subunit of the transcription factor NF-kappa B, can be cleaved by caspase-3 in vitro at a site that potentially produces a dominant inhibitory form of I kappa B alpha. The involvement of NF-kappa B in the inhibition of cell death led us to ask whether apoptotic stimuli would induce the caspase-mediated cleavage of I kappa B alpha in vivo. In this study, we show that apoptosis leads to the caspase-mediated amino-terminal truncation of I kappa B alpha (Delta N-I kappa B alpha). Our data show that Delta N-I kappa B alpha can bind NF-kappa B, suppress NF-kappa B activation, and sensitize cells to death. Since activated NF-kappa B plays a role in the inhibition of cell death, these data suggest that caspase-mediated cleavage of I kappa B alpha may be a mechanism to suppress NF-kappa B and its associated antiapoptotic activity.	Univ N Carolina, Lineberger Canc Res Ctr, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Baldwin, AS (corresponding author), Univ N Carolina, Lineberger Canc Res Ctr, Curriculum Genet & Mol Biol, CB 7295, Chapel Hill, NC 27599 USA.				NATIONAL CANCER INSTITUTE [R01CA072771] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI035098, R01AI035098] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007092] Funding Source: NIH RePORTER; NCI NIH HHS [CA72771] Funding Source: Medline; NIAID NIH HHS [AI35098] Funding Source: Medline; NIGMS NIH HHS [T32 GM07092] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; An B, 1996, CANCER RES, V56, P438; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barkett M, 1997, J BIOL CHEM, V272, P29419, DOI 10.1074/jbc.272.47.29419; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; CHEN F, 1995, BIOCHEM BIOPH RES CO, V214, P839, DOI 10.1006/bbrc.1995.2363; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; Doi TS, 1997, J EXP MED, V185, P953, DOI 10.1084/jem.185.5.953; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Jung M, 1998, RADIAT RES, V149, P596, DOI 10.2307/3579906; KARIN M, 1998, CANC J SCI AM S1, V4, P92; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Ohta T, 1997, J BIOL CHEM, V272, P23111, DOI 10.1074/jbc.272.37.23111; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Ravi R, 1998, CANCER RES, V58, P882; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; VALTIERI M, 1987, J IMMUNOL, V138, P3829; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; White DW, 1996, MOL CELL BIOL, V16, P1169; White DW, 1996, ONCOGENE, V13, P891; WHITE DW, 1995, ONCOGENE, V10, P857; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	58	87	92	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20664	20670		10.1074/jbc.274.29.20664	http://dx.doi.org/10.1074/jbc.274.29.20664			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400699	Green Published, hybrid			2022-12-25	WOS:000081438300092
J	Takata, M; Ogawa, W; Kitamura, T; Hino, Y; Kuroda, S; Kotani, K; Klip, A; Gingras, AC; Sonenberg, N; Kasuga, M				Takata, M; Ogawa, W; Kitamura, T; Hino, Y; Kuroda, S; Kotani, K; Klip, A; Gingras, AC; Sonenberg, N; Kasuga, M			Requirement for Akt (protein kinase B) in insulin-induced activation of glycogen synthase and phosphorylation of 4E-BP1 (PHAS-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SKELETAL-MUSCLE; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; GLUCOSE-TRANSPORT; 3T3-L1 ADIPOCYTES; SIGNALING PATHWAY; TRANSLATION INITIATION; C ISOTYPES; IN-VITRO; RAPAMYCIN	The roles of Akt (protein kinase B) and the atypical lambda isoform of protein kinase C (PKC lambda), both of which act downstream of phosphoinositide 3-kinase, in the activation of glycogen synthase and phosphorylation of 4E-BP1 (PHAS-1) in response to insulin were investigated. A mutant Akt (Akt-AA) in which the phosphorylation sites targeted by growth factors are replaced by alanine was shown to inhibit insulin-induced activation of both Akt and glycogen synthase in L6 myotubes. Expression of a mutant Akt in which Lys(179) in the kinase domain was replaced by aspartate also inhibited insulin-induced activation of glycogen synthase but had no effect on insulin activation of endogenous Akt. A kinase-defective mutant of PKC lambda (lambda Delta NKD), which prevents insulin-induced activation of PKC lambda, did not affect the activation of glycogen synthase by insulin. Insulin-induced phosphorylation of 4E-BP1 was inhibited by Akt-AA in Chinese hamster ovary cells. However, lambda Delta NKD had no effect on 4E-BP1 phosphorylation induced by insulin. These data suggest that Akt, but not PKC lambda, is required for insulin activation of glycogen synthase and for insulin-induced phosphorylation of 4E-BP1.	Kobe Univ, Sch Med, Dept Internal Med 2, Chuo Ku, Kobe, Hyogo 6500017, Japan; Hosp Sick Children, Div Cell Biol, Toronto, ON M5G 1X8, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	Kobe University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); McGill University	Ogawa, W (corresponding author), Kobe Univ, Sch Med, Dept Internal Med 2, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.		OGAWA, Wataru/AAQ-9586-2020; Gingras, Anne-Claude/E-9982-2010; Gingras, Anne-Claude/ABA-8341-2020	Gingras, Anne-Claude/0000-0002-6090-4437; Gingras, Anne-Claude/0000-0002-6090-4437				Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Azpiazu I, 1996, J BIOL CHEM, V271, P5033; Bandyopadhyay G, 1997, J BIOL CHEM, V272, P2551; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; Brodbeck D, 1999, J BIOL CHEM, V274, P9133, DOI 10.1074/jbc.274.14.9133; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; COHEN P, 1982, NATURE, V296, P613, DOI 10.1038/296613a0; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Feigenblum D, 1996, MOL CELL BIOL, V16, P5450; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Gingras AC, 1997, VIROLOGY, V237, P182, DOI 10.1006/viro.1997.8757; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; Holman GD, 1997, DIABETOLOGIA, V40, P991, DOI 10.1007/s001250050780; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; Kuroda S, 1998, BIOCHEM BIOPH RES CO, V249, P781, DOI 10.1006/bbrc.1998.9140; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Logan SK, 1997, MOL CELL BIOL, V17, P5784, DOI 10.1128/MCB.17.10.5784; Mitsumoto Y, 1993, ENDOCR J, V1, P307; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; Ogawa W, 1998, MOL CELL BIOCHEM, V182, P13, DOI 10.1023/A:1006862807598; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; SAKAUE H, 1995, J BIOL CHEM, V270, P11304, DOI 10.1074/jbc.270.19.11304; Sakaue H, 1997, MOL ENDOCRINOL, V11, P1552, DOI 10.1210/me.11.10.1552; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; Tsakiridis T, 1996, J BIOL CHEM, V271, P19664, DOI 10.1074/jbc.271.33.19664; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Walker KS, 1998, BIOCHEM J, V331, P299, DOI 10.1042/bj3310299; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Welsh GI, 1997, FEBS LETT, V410, P418, DOI 10.1016/S0014-5793(97)00579-6; YAMAMOTOHONDA R, 1995, J BIOL CHEM, V270, P2729, DOI 10.1074/jbc.270.6.2729	48	77	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20611	20618		10.1074/jbc.274.29.20611	http://dx.doi.org/10.1074/jbc.274.29.20611			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400692	hybrid			2022-12-25	WOS:000081438300085
J	Yaglom, JA; Gabai, VL; Meriin, AB; Mosser, DD; Sherman, MY				Yaglom, JA; Gabai, VL; Meriin, AB; Mosser, DD; Sherman, MY			The function of HSP72 in suppression of c-Jun N-terminal kinase activation can be dissociated from its role in prevention of protein damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRESS-INDUCED APOPTOSIS; HEAT-SHOCK PROTEINS; CELL-DEATH; EXPRESSION CASSETTE; NH2-TERMINAL KINASE; RESISTANCE; PATHWAY; SEK1; JNK; PHOSPHORYLATION	Activation of the c-Jun N-terminal kinase (JNK) by a variety of stimuli is critical for regulation of many cellular processes including apoptosis. The major inducible heat shock protein Hsp72 has previously been demonstrated to inhibit activation of JNK in cells exposed to heat shock and other protein-damaging agents, thus suppressing apoptosis. Hsp72 can protect proteins from stress-induced damage. To test if this protective function of Hsp72 is involved in JNK suppression, we investigated whether Hsp72 can avert activation of JNK by stimuli that do not cause protein damage. We show that Hsp72 suppresses activation of JNK induced by nonprotein-damaging stimuli, interleukin-l and UV irradiation, as well as by constitutively active components of the JNK signaling cascade Cdc42 and MEKK1. Furthermore, Hsp72 strongly reduced activation of JNK by phosphatase inhibitors. We also demonstrate that an Hsp72 mutant that lacks the ATPase domain is still capable of JNK suppression, thus indicating that the protein refolding activity of Hsp72 is not critical for inhibition of JNK activation. Taken together these data suggest that Hsp72 plays a regulatory role in JNK signaling and that the function of Hsp72 in protein protection or refolding is not involved in JNK regulation.	Boston Biomed Res Inst, Boston, MA 02114 USA; Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada	Boston Biomedical Research Institute; National Research Council Canada	Sherman, MY (corresponding author), Boston Biomed Res Inst, Boston, MA 02114 USA.		Mosser, Dick D/A-7391-2008; Gabai, Vladimir L/I-1650-2013	Gabai, Vladimir L/0000-0003-4505-4718; Yaglom, Julia/0000-0002-8723-3506; Mosser, Richard/0000-0002-9183-2288; Meriin, Anatoli/0000-0003-0087-814X				BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; CIOCCA DR, 1992, CANCER RES, V52, P3648; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; GABAI VL, 1995, FEBS LETT, V375, P21, DOI 10.1016/0014-5793(95)01152-5; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; Ganiatsas S, 1998, P NATL ACAD SCI USA, V95, P6881, DOI 10.1073/pnas.95.12.6881; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Ishizuka T, 1997, P NATL ACAD SCI USA, V94, P6358, DOI 10.1073/pnas.94.12.6358; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Karin M, 1996, PHILOS T ROY SOC B, V351, P127, DOI 10.1098/rstb.1996.0008; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Massie B, 1998, J VIROL, V72, P2289, DOI 10.1128/JVI.72.3.2289-2296.1998; MATTS RL, 1993, BIOCHEMISTRY-US, V32, P7323, DOI 10.1021/bi00080a001; MAYTIN EV, 1993, CANCER RES, V53, P4952; Meriin AB, 1999, MOL CELL BIOL, V19, P2547; Meriin AB, 1998, J BIOL CHEM, V273, P6373, DOI 10.1074/jbc.273.11.6373; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Mosser DD, 1997, BIOTECHNIQUES, V22, P150, DOI 10.2144/97221rr02; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Samali A, 1996, EXP CELL RES, V223, P163, DOI 10.1006/excr.1996.0070; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; Shi YH, 1998, GENE DEV, V12, P654, DOI 10.1101/gad.12.5.654; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; TRAUTINGER F, 1995, J INVEST DERMATOL, V105, P160, DOI 10.1111/1523-1747.ep12317003; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Voellmy R, 1996, EXS, V77, P121; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN MH, 1994, NATURE, V372, P798; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	37	65	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20223	20228		10.1074/jbc.274.29.20223	http://dx.doi.org/10.1074/jbc.274.29.20223			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400639	hybrid			2022-12-25	WOS:000081438300032
J	Yoo, S; Kimzey, A; Dynan, WS				Yoo, S; Kimzey, A; Dynan, WS			Photocross-linking of an oriented DNA repair complex - Ku bound at a single DNA end	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; ATOMIC-FORCE MICROSCOPY; RNA POLYMERASE-II; V(D)J RECOMBINATION; CATALYTIC SUBUNIT; NUCLEIC-ACIDS; BINDING; ANTIGEN; AUTOANTIGEN; STRAND	Ku protein binds broken DNA ends, triggering a double-strand DNA break repair pathway, The spatial arrangement of the two Ku subunits in the initial Ku-DNA complex, when the Ku protein first approaches the broken DNA end, is not well defined. We have investigated the geometry of the complex using a novel set of photocross-linking probes that force Ru protein to be constrained in position and orientation, relative to a single free DNA end. Results suggest that this complex is roughly symmetric and that both Ku subunits make contact with an approximately equal area of the DNA, The complex has a strongly preferred orientation, with Ku70-DNA backbone contacts located proximal and Ku80-DNA backbone contacts located distal to the free end. Ku70 also contacts functional groups in the major groove proximal to the free end. Ku80 apparently does not make major groove contacts. Results are consistent with a model where the Ku70 and Ku80 subunits contact the major and minor grooves of DNA, respectively.	Med Coll Georgia, Inst Mol Med & Genet, Gene Regulat Program, Augusta, GA 30912 USA; Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA	University System of Georgia; Augusta University; University of Colorado System; University of Colorado Boulder	Dynan, WS (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, Gene Regulat Program, 1120 15th St, Augusta, GA 30912 USA.			Dynan, William/0000-0002-4045-5662				BLIER PR, 1993, J BIOL CHEM, V268, P7594; Critchlow SE, 1998, TRENDS BIOCHEM SCI, V23, P394, DOI 10.1016/S0968-0004(98)01284-5; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; DVIR A, 1993, J BIOL CHEM, V268, P10440; Dynan WS, 1998, NUCLEIC ACIDS RES, V26, P1551, DOI 10.1093/nar/26.7.1551; FALZON M, 1993, J BIOL CHEM, V268, P10546; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; GARTENBERG MR, 1990, P NATL ACAD SCI USA, V87, P6034, DOI 10.1073/pnas.87.16.6034; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Huang JR, 1997, J BIOL CHEM, V272, P26009, DOI 10.1074/jbc.272.41.26009; Jin SF, 1998, CARCINOGENESIS, V19, P965, DOI 10.1093/carcin/19.6.965; Kanaar R, 1998, TRENDS CELL BIOL, V8, P483, DOI 10.1016/S0962-8924(98)01383-X; Kimzey AL, 1998, J BIOL CHEM, V273, P13768, DOI 10.1074/jbc.273.22.13768; KNUTH MW, 1990, J BIOL CHEM, V265, P17911; Kurimasa A, 1999, P NATL ACAD SCI USA, V96, P1403, DOI 10.1073/pnas.96.4.1403; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; Meisenheimer KM, 1997, CRIT REV BIOCHEM MOL, V32, P101, DOI 10.3109/10409239709108550; MIMORI T, 1986, J BIOL CHEM, V261, P2274; ONO M, 1994, NUCLEIC ACIDS RES, V22, P3918, DOI 10.1093/nar/22.19.3918; Osipovich O, 1997, J BIOL CHEM, V272, P27259, DOI 10.1074/jbc.272.43.27259; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; Pang DL, 1997, CANCER RES, V57, P1412; Ramsden DA, 1998, EMBO J, V17, P609, DOI 10.1093/emboj/17.2.609; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; Torrance H, 1998, J BIOL CHEM, V273, P20810, DOI 10.1074/jbc.273.33.20810; Wang JS, 1998, J BIOL CHEM, V273, P842, DOI 10.1074/jbc.273.2.842; WANG JS, 1994, FEBS LETT, V351, P219, DOI 10.1016/0014-5793(94)00863-9; Wang JS, 1998, J BIOL CHEM, V273, P31068, DOI 10.1074/jbc.273.47.31068; Wu XT, 1996, MOL CELL BIOL, V16, P5186; Yaneva M, 1997, EMBO J, V16, P5098, DOI 10.1093/emboj/16.16.5098; ZHANG WW, 1992, BIOCHEM BIOPH RES CO, V186, P574, DOI 10.1016/S0006-291X(05)80847-2; Zhao JK, 1999, BIOCHEMISTRY-US, V38, P2152, DOI 10.1021/bi9825246	33	72	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					20034	20039		10.1074/jbc.274.28.20034	http://dx.doi.org/10.1074/jbc.274.28.20034			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391954	hybrid			2022-12-25	WOS:000081377300074
J	Cerini, C; Peyrot, V; Garnier, C; Duplan, L; Veesler, S; Le Caer, JP; Bernard, JP; Bouteille, H; Michel, R; Vazi, A; Dupuy, P; Michel, B; Berland, Y; Verdier, JM				Cerini, C; Peyrot, V; Garnier, C; Duplan, L; Veesler, S; Le Caer, JP; Bernard, JP; Bouteille, H; Michel, R; Vazi, A; Dupuy, P; Michel, B; Berland, Y; Verdier, JM			Biophysical characterization of lithostathine - Evidences for a polymeric structure at physiological, pH and a proteolysis mechanism leading to the formation of fibrils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC STONE PROTEIN; CHRONIC CALCIFYING PANCREATITIS; ELASTIC LIGHT-SCATTERING; HUMAN REG GENE; MESSENGER-RNA; NUCLEOTIDE-SEQUENCE; SECRETORY PROTEIN; CRYSTAL-GROWTH; EXPRESSION; CRYSTALLIZATION	Lithostathine is a calcium carbonate crystal habit modifier. It is found precipitated under the form of fibrils in chronic calcifying pancreatitis or Alzheimer's disease. In order to gain better insight into the nature and the formation of fibrils, we have expressed and purified recombinant lithostathine, Analytical ultracentrifugation and quasi-elastic light scattering techniques were used to demonstrate that lithostathine remains essentially monomeric at acidic pH while it aggregates at physiological pH, Analysis of these aggregates by electron microscopy showed an apparently unorganized structure of numerous monomers which tend to precipitate forming regular unbranched fibrils, Aggregated forms seem to occur prior to the apparition of fibrils, In addition, we have demonstrated that these fibrils resulted from a proteolysis mechanism due to a specific cleavage of the Arg(11)-Ile(12) peptide bond. It is deduced that the NH2-terminal undecapeptide of lithostathine normally impedes fiber formation but not aggregation. A theoretical model explaining the formation of amyloid plaques in neurodegenerative diseases or stones in lithiasis starting from lithostathine is described. Therefore we propose that lithostathine, whose major function is unknown, defines a new class of molecules which is activated by proteolysis and is not involved in cytoskeleton nor intermediate filament functions.	Fac Pharm, CNRS, UPRESA 6032, F-13385 Marseille 05, France; INSERM, U315, F-13258 Marseille, France; CNRS, CRMC2, Marseille, France; INSERM, CIC, APHM, F-13258 Marseille, France; Hop St Marguerite, Unite Neurogeriatr, Marseille, France; Hop St Marguerite, Serv Nephrol, Marseille, France; Ecole Super Phys & Chim Ind, Neurobiol Lab, Paris, France; Hop St Marguerite, Serv Gastroenterol, Marseille, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Verdier, JM (corresponding author), Fac Pharm, CNRS, UPRESA 6032, 27 Bd Jean Moulin, F-13385 Marseille 05, France.		peyrot, vincent/B-6365-2015	GARNIER, Cyrille/0000-0002-5715-8218; Veesler, Stephane/0000-0001-8362-2531; VERDIER, Jean-Michel/0000-0002-7252-1556				Bertrand JA, 1996, EMBO J, V15, P2678, DOI 10.1002/j.1460-2075.1996.tb00628.x; Boistelle R, 1986, Adv Nephrol Necker Hosp, V15, P173; Bonnete F, 1997, ACTA CRYSTALLOGR D, V53, P438, DOI 10.1107/S090744499700200X; BROWN N, 1993, FEBS LETT, V322, P65, DOI 10.1016/0014-5793(93)81112-D; CLELAND JL, 1990, BIOCHEMISTRY-US, V29, P11072, DOI 10.1021/bi00502a009; COME JH, 1993, P NATL ACAD SCI USA, V90, P5959, DOI 10.1073/pnas.90.13.5959; CRAWFORD C, 1987, BIOCHEM J, V248, P579, DOI 10.1042/bj2480579; DANLEY DE, 1988, J BIOL CHEM, V263, P9785; DECARO A, 1984, BIOCHEM J, V222, P669, DOI 10.1042/bj2220669; DECARO A, 1979, BIOCHEM BIOPH RES CO, V87, P1176, DOI 10.1016/S0006-291X(79)80031-5; DEREGGI M, 1995, EUR J BIOCHEM, V230, P503; DONOVAN JM, 1987, BIOCHEMISTRY-US, V26, P8116, DOI 10.1021/bi00399a015; Dusetti NJ, 1996, ARCH BIOCHEM BIOPHYS, V330, P129, DOI 10.1006/abbi.1996.0234; FASSINA G, 1986, EUR J BIOCHEM, V156, P221, DOI 10.1111/j.1432-1033.1986.tb09571.x; FERTALA A, 1994, J BIOL CHEM, V269, P11584; Geider S, 1996, J BIOL CHEM, V271, P26302, DOI 10.1074/jbc.271.42.26302; GIORGI D, 1989, J CLIN INVEST, V84, P100, DOI 10.1172/JCI114128; GROSS J, 1985, P NATL ACAD SCI USA, V82, P5627, DOI 10.1073/pnas.82.17.5627; GROSS J, 1985, J CLIN INVEST, V76, P2115, DOI 10.1172/JCI112216; Hochstrasser D F, 1988, Appl Theor Electrophor, V1, P35; HOCHSTRASSER DF, 1988, ANAL BIOCHEM, V173, P424, DOI 10.1016/0003-2697(88)90209-6; KADIMA W, 1990, BIOPHYS J, V57, P125, DOI 10.1016/S0006-3495(90)82513-3; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P537, DOI 10.1016/0076-6879(90)85044-O; KIMURA N, 1992, CANCER, V70, P1857, DOI 10.1002/1097-0142(19921001)70:7<1857::AID-CNCR2820700708>3.0.CO;2-8; KOPPEL DE, 1972, J CHEM PHYS, V57, P4814, DOI 10.1063/1.1678153; LAFONT S, 1994, J CRYST GROWTH, V143, P249, DOI 10.1016/0022-0248(94)90064-7; LEE JC, 1974, ARCH BIOCHEM BIOPHYS, V165, P268, DOI 10.1016/0003-9861(74)90164-7; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; MIKOL V, 1989, FEBS LETT, V258, P63, DOI 10.1016/0014-5793(89)81616-3; MULTIGNER L, 1983, BIOCHEM BIOPH RES CO, V110, P69, DOI 10.1016/0006-291X(83)91261-5; ORELLE B, 1992, J CLIN INVEST, V90, P2284, DOI 10.1172/JCI116115; OSTROWSKY N, 1981, OPT ACTA, V28, P1059, DOI 10.1080/713820704; OZTURK M, 1989, P NATL ACAD SCI USA, V86, P419, DOI 10.1073/pnas.86.2.419; Pignol D, 1995, PROTEINS, V23, P604, DOI 10.1002/prot.340230418; RINDERKNECHT H, 1985, DIGEST DIS SCI, V30, P65, DOI 10.1007/BF01318373; RINDERKNECHT H, 1979, DIGEST DIS SCI, V24, P180, DOI 10.1007/BF01308426; ROUIMI P, 1987, FEBS LETT, V216, P195, DOI 10.1016/0014-5793(87)80688-9; STEWART TA, 1989, BIOCHEM J, V260, P622, DOI 10.1042/bj2600622; TERAZONO K, 1990, DIABETOLOGIA, V33, P250, DOI 10.1007/BF00404804; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; VEESLER S, 1994, ACTA CRYSTALLOGR D, V50, P355, DOI 10.1107/S0907444993014416; WATANABE T, 1990, J BIOL CHEM, V265, P7432; WATANABE T, 1994, P NATL ACAD SCI USA, V91, P3589, DOI 10.1073/pnas.91.9.3589; Wilkins M., 1997, PROTEOME RES NEW FRO, P35; Wilkins MR, 1996, TRENDS BIOCHEM SCI, V21, P496, DOI 10.1016/S0968-0004(96)30043-1; YARMUSH DM, 1988, MOL IMMUNOL, V25, P17, DOI 10.1016/0161-5890(88)90086-7; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003	47	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22266	22274		10.1074/jbc.274.32.22266	http://dx.doi.org/10.1074/jbc.274.32.22266			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428794	hybrid			2022-12-25	WOS:000081868400024
J	Nagpal, S; Ghosn, C; DiSepio, D; Molina, Y; Sutter, M; Klein, ES; Chandraratna, RAS				Nagpal, S; Ghosn, C; DiSepio, D; Molina, Y; Sutter, M; Klein, ES; Chandraratna, RAS			Retinoid-dependent recruitment of a histone H1 displacement activity by retinoic acid receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; GROUP PROTEIN I/Y; GENE-EXPRESSION; CHROMOSOMAL-PROTEINS; DNA-BINDING; HMG-I/Y; TRANSCRIPTION; ACETYLTRANSFERASE; TRANSFORMATION; COACTIVATOR	Targeted recruitment of histone acetyltransferase (HAT) activities by sequence-specific transcription factors, including the retinoic acid receptors (RARs) and retinoid X receptors (RXRs), has been proposed to lead to destabilization of nucleosomal cores by acetylation of core histones, However, biochemical evidence indicates that destabilization and depletion of linker H1 histones must also occur at the promoter regions of actively transcribing genes. Mechanisms by which nuclear receptors and other transcription factors affect the removal of histone H1 from transcriptionally silent chromatin have not been previously described, In this report, we show that RARs interact in a ligand-dependent manner with HMG-I, which is known to displace histone H1 from chromatin, We further show that HMG-I and a novel related protein, HMG-R, also interact with other transcription factors. Using sense and antisense constructs of HMG-I/R in transient transfection assays with a retinoid responsive reporter, we also demonstrate that HMG-IIR is important for retinoid dependent transcriptional activity of RAR. These findings suggest a step wise mechanism by which RARs and other transcription factors can cause a targeted unfolding of compact chromatin as a first step in transcriptional activation, which would then be followed by recruitment of HAT activity and subsequent events.	Allergan Inc, Retinoid Res Dept Biol, Irvine, CA 92713 USA; Allergan Inc, Retinoid Res Dept Chem, Irvine, CA 92713 USA	AbbVie; Allergan; AbbVie; Allergan	Nagpal, S (corresponding author), Allergan Inc, Retinoid Res Dept Biol, Irvine, CA 92713 USA.		Nagpal, Sunil/A-8007-2009					ABDULKADIR SA, 1995, J EXP MED, V182, P487, DOI 10.1084/jem.182.2.487; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHIAPPETTA G, 1995, ONCOGENE, V10, P1307; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; Davie JR, 1995, INT REV CYTOL, V162A, P191; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; DU W, 1994, P NATL ACAD SCI USA, V91, P11318, DOI 10.1073/pnas.91.24.11318; ERICSSON C, 1990, CELL, V60, P73, DOI 10.1016/0092-8674(90)90717-S; Fedele M, 1996, CANCER RES, V56, P1896; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; JOHN S, 1995, MOL CELL BIOL, V15, P1786; JOHNSON KR, 1990, EXP CELL RES, V187, P69, DOI 10.1016/0014-4827(90)90118-T; KAMAKAKA RT, 1990, EMBO J, V9, P3997, DOI 10.1002/j.1460-2075.1990.tb07621.x; KARLSON JR, 1989, BIOCHEM BIOPH RES CO, V158, P646, DOI 10.1016/0006-291X(89)92770-8; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LEGER H, 1995, MOL CELL BIOL, V15, P3738; LEWIS H, 1994, MOL CELL BIOL, V14, P5701, DOI 10.1128/MCB.14.9.5701; NAGPAL S, 1995, J BIOL CHEM, V270, P923, DOI 10.1074/jbc.270.2.923; NAGULAPALLI S, 1995, J IMMUNOL, V155, P4330; NISSEN MS, 1995, J BIOL CHEM, V270, P4355, DOI 10.1074/jbc.270.9.4355; RAM TG, 1993, CANCER RES, V53, P2655; REEVES R, 1990, J BIOL CHEM, V265, P8573; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; WADE PA, 1997, CURR BIOL, V7, P82; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; ZHAO K, 1993, EMBO J, V12, P3237, DOI 10.1002/j.1460-2075.1993.tb05993.x	31	53	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22563	22568		10.1074/jbc.274.32.22563	http://dx.doi.org/10.1074/jbc.274.32.22563			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428834	hybrid			2022-12-25	WOS:000081868400064
J	Katsumata, M; Burton, KA; Li, J; Dauncey, MJ				Katsumata, M; Burton, KA; Li, J; Dauncey, MJ			Suboptimal energy balance selectively up-regulates muscle GLUT gene expression but reduces insulin-dependent glucose uptake during postnatal development	FASEB JOURNAL			English	Article						glucose transporter; nutrition; food intake; environmental temperature	BROWN ADIPOSE-TISSUE; SKELETAL-MUSCLE; TRANSPORTER EXPRESSION; THYROID-HORMONE; TRANSGENIC MICE; GROWTH-HORMONE; MESSENGER-RNA; GLYCOGEN; RECEPTOR; CELLS	The major facilitative glucose transporters in muscle, GLUT1 (insulin-independent) and GLUT4 (insulin-dependent), are essential for normal growth and metabolism, but factors controlling their expression during postnatal development are poorly understood. We have therefore determined the role of energy status in regulating muscle GLUT gene expression and function in young, growing pigs on a high (H) or low (L) food intake (H = 2L,) at 35 degrees C or 26 degrees C. RNase protection assays revealed selective up-regulation of GLUT1 and GLUT4 by mild undernutrition 20-24 h after feeding: mRNA levels were elevated in longissimus dorsi (P<0.001) and rhomboideus (P<0.05), but not in diaphragm or cardiac muscles. Assessment of 2-deoxy-glucose uptake in a small isolated muscle, flexor carpi radialis, showed that the 26L group, which had suboptimal energy balance and the greatest GLUT4 expression, had the highest insulin-independent glucose uptake but the lowest insulin-dependent increment: 20% compared with 70% in the other groups. These novel findings are directly relevant to an understanding of mechanisms underlying the development of insulin resistance and demonstrate 1) muscle-specific up-regulation of GLUT gene expression by postnatal undernutrition that is not related simply to myofiber type, but to whole-body function; and 2) that the degree of GLUT up-regulation and the subcellular distribution and function of GLUT proteins are dependent on energy status.	Babraham Inst, Cambridge CB2 4AT, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Dauncey, MJ (corresponding author), Babraham Inst, Cambridge CB2 4AT, England.							Barker D J, 1997, Rev Reprod, V2, P105, DOI 10.1530/ror.0.0020105; BECKER BA, 1992, LAB ANIM SCI, V42, P51; BEER SF, 1989, J ENDOCRINOL, V120, P337, DOI 10.1677/joe.0.1200337; CASTELLO A, 1994, J BIOL CHEM, V269, P5905; CHARRON MJ, 1990, J BIOL CHEM, V265, P7994; CHIU PY, 1994, J ANIM SCI, V72, P1196, DOI 10.2527/1994.7251196x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coderre L, 1996, AM J PHYSIOL-ENDOC M, V271, pE643, DOI 10.1152/ajpendo.1996.271.4.E643; DAUNCEY MJ, 1989, J PHYSIOL-LONDON, V418, pP175; Dauncey MJ, 1996, P NUTR SOC, V55, P543, DOI 10.1079/PNS19960047; DAUNCEY MJ, 1994, FASEB J, V8, P81, DOI 10.1096/fasebj.8.1.7507871; Dauncey MJ, 1997, BRIT J NUTR, V78, pS113, DOI 10.1079/BJN19970226; Ebeling P, 1998, FEBS LETT, V436, P301, DOI 10.1016/S0014-5793(98)01149-1; GULVE EA, 1994, J BIOL CHEM, V269, P18366; Harrison AP, 1996, AM J PHYSIOL-REG I, V270, pR667, DOI 10.1152/ajpregu.1996.270.3.R667; Harrison AP, 1997, REPROD FERT DEVELOP, V9, P731, DOI 10.1071/R97026; HARRISON AP, 1994, AM J PHYSIOL, V266, pR102, DOI 10.1152/ajpregu.1994.266.1.R102; Henriksen EJ, 1996, J APPL PHYSIOL, V80, P1540, DOI 10.1152/jappl.1996.80.5.1540; HENRIKSEN EJ, 1990, AM J PHYSIOL, V259, pE593, DOI 10.1152/ajpendo.1990.259.4.E593; James AP, 1998, BIOCHEM J, V329, P341; KATZ EB, 1995, NATURE, V377, P151, DOI 10.1038/377151a0; KIM YB, 1994, BIOCHEM BIOPH RES CO, V202, P519, DOI 10.1006/bbrc.1994.1959; KOIVISTO UM, 1991, J BIOL CHEM, V266, P2615; LEWIS DS, 1992, J CLIN ENDOCR METAB, V74, P920, DOI 10.1210/jc.74.4.920; Li J, 1998, J PHYSIOL-LONDON, V507P, p53P; Morovat A, 1998, EUR J ENDOCRINOL, V138, P95, DOI 10.1530/eje.0.1380095; MOROVAT A, 1995, J ENDOCRINOL, V144, P233, DOI 10.1677/joe.0.1440233; NEUFER PD, 1993, J BIOL CHEM, V268, P13824; NIKAMI H, 1992, BIOCHEM BIOPH RES CO, V185, P1078, DOI 10.1016/0006-291X(92)91736-A; Olson AL, 1996, ANNU REV NUTR, V16, P235, DOI 10.1146/annurev.nu.16.070196.001315; Pethick DW, 1996, AUST J AGR RES, V47, P525, DOI 10.1071/AR9960525; REN JM, 1993, J BIOL CHEM, V268, P16113; STEPHENS JM, 1995, ENDOCR REV, V16, P529, DOI 10.1210/er.16.4.529; VANCE ML, 1989, J CLIN ENDOCR METAB, V68, P1013, DOI 10.1210/jcem-68-6-1013; WALKER PS, 1990, J BIOL CHEM, V265, P1516; WEILERGUTTLER H, 1989, BIOL CHEM H-S, V370, P467, DOI 10.1515/bchm3.1989.370.1.467; WEINSTEIN SP, 1994, DIABETES, V43, P1185, DOI 10.2337/diabetes.43.10.1185; Zorzano A, 1998, GEN PHARMACOL, V31, P705, DOI 10.1016/S0306-3623(98)00095-0	38	25	28	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1999	13	11					1405	1413		10.1096/fasebj.13.11.1405	http://dx.doi.org/10.1096/fasebj.13.11.1405			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	226KL	10428764				2022-12-25	WOS:000082019100012
J	Lin, HH; Zentner, MD; Ho, HLL; Kim, KJ; Ann, DK				Lin, HH; Zentner, MD; Ho, HLL; Kim, KJ; Ann, DK			The gene expression of the amiloride-sensitive epithelial sodium channel alpha-subunit is regulated by antagonistic effects between glucocorticoid hormone and Ras pathways in salivary epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; LUNG LIQUID CLEARANCE; TATA-BINDING PROTEIN; VIRUS-X-PROTEIN; NA+ CHANNEL; TRANSCRIPTIONAL ACTIVATION; SIGNALING PATHWAY; ONCOGENIC RAF-1; C-FOS; RECEPTOR	The functional expression of the amiloride-sensitive epithelial sodium channel (ENaC) in select epithelia is critical for maintaining electrolyte and fluid homeostasis. Although ENaC activity is strictly dependent upon its alpha-subunit expression, little is known about the molecular mechanisms by which cells modulate alpha-ENaC gene expression. Previously, we have shown that salivary alpha-ENaC expression is transcriptionally repressed by the activation of Raf/extracellular signal-regulated protein kinase pathway. Here, this work further investigates the molecular mechanism(s) by which alpha-ENaC expression is regulated in salivary epithelial Pa-4 cells. A region located between -1.5 and -1.0 kilobase pairs of the alpha-ENaC 5'-flanking region is demonstrated to be indispensable for the maximal and Ras-repressible reporter expression. Deletional analyses using heterologous promoter constructs reveal that a DNA sequence between -1355 and -1269 base pairs functions as an enhancer conferring the high level of expression on reporter constructs, and this induction effect is inhibited by Ras pathway activation. Mutational analyses indicate that full induction and Ras-mediated repression require a glucocorticoid response element (GRE) located between -1323 and -1309 base pairs. The identified alpha-ENaC GRE encompassing sequence (-1334/-1306) is sufficient to confer glucocorticoid receptor/dexamethasone-dependent and Ras-repressible expression on both heterologous and homologous promoters. This report demonstrates for the first time that the cross-talk between glucocorticoid receptor and Ras/extracellular signal-regulated protein kinase signaling pathways results in an antagonistic effect at the transcriptional level to modulate alpha-ENaC expression through the identified GRE. In summary, this study presents a mechanism by which alpha-ENaC expression is regulated in salivary epithelial cells.	Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90089 USA; Univ So Calif, Dept Med, Los Angeles, CA 90089 USA; Univ So Calif, Dept Physiol & Biophys, Los Angeles, CA 90089 USA; Univ So Calif, Dept Biomed Engn, Los Angeles, CA 90089 USA; Univ So Calif, Will Rogers Inst, Pulm Res Ctr, Los Angeles, CA 90089 USA; Univ So Calif, Ctr Craniofacial Mol Biol, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California; University of Southern California; University of Southern California; University of Southern California; University of Southern California	Ann, DK (corresponding author), Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, PSC 210B,1985 Zonal Ave, Los Angeles, CA 90089 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL046943, R01HL046943, R01HL038658] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE010742] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 38658, HL 46943] Funding Source: Medline; NIDCR NIH HHS [DE 10742] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ABDELLATIF M, 1994, J BIOL CHEM, V269, P15423; Abdellatif M, 1998, MOL CELL BIOL, V18, P6729, DOI 10.1128/MCB.18.11.6729; Barker PM, 1998, J CLIN INVEST, V102, P1634, DOI 10.1172/JCI3971; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Brattsand R, 1996, ALIMENT PHARM THERAP, V10, P81, DOI 10.1046/j.1365-2036.1996.22164025.x; Caelles C, 1997, GENE DEV, V11, P3351, DOI 10.1101/gad.11.24.3351; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; Chen RH, 1996, ONCOGENE, V12, P1493; Cheng C, 1998, J BIOL CHEM, V273, P22693, DOI 10.1074/jbc.273.35.22693; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; Djelidi S, 1997, J BIOL CHEM, V272, P32919, DOI 10.1074/jbc.272.52.32919; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Grunder S, 1997, CURR OPIN NEPHROL HY, V6, P35; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Hummler E, 1996, NAT GENET, V12, P325, DOI 10.1038/ng0396-325; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; Li DX, 1997, J BIOL CHEM, V272, P25062, DOI 10.1074/jbc.272.40.25062; Lin HH, 1996, J BIOL CHEM, V271, P27637, DOI 10.1074/jbc.271.44.27637; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; Ludwig M, 1998, HUM GENET, V102, P576, DOI 10.1007/s004390050743; Mastroberardino L, 1998, MOL BIOL CELL, V9, P3417, DOI 10.1091/mbc.9.12.3417; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; McNicholas CM, 1997, J GEN PHYSIOL, V109, P681, DOI 10.1085/jgp.109.6.681; Miller MJ, 1998, MOL CELL BIOL, V18, P3718, DOI 10.1128/MCB.18.7.3718; NEEF G, 1984, STEROIDS, V44, P349, DOI 10.1016/S0039-128X(84)80027-6; North RA, 1996, CURR OPIN CELL BIOL, V8, P474, DOI 10.1016/S0955-0674(96)80023-8; Pearce D, 1998, J BIOL CHEM, V273, P30081, DOI 10.1074/jbc.273.46.30081; Quissell DO, 1998, IN VITRO CELL DEV-AN, V34, P58; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Rogatsky I, 1998, P NATL ACAD SCI USA, V95, P2050, DOI 10.1073/pnas.95.5.2050; Rossier B C, 1994, Curr Opin Nephrol Hypertens, V3, P487, DOI 10.1097/00041552-199409000-00003; Thomas CP, 1998, AM J PHYSIOL-CELL PH, V274, pC1312, DOI 10.1152/ajpcell.1998.274.5.C1312; TOWATARI M, 1995, J BIOL CHEM, V270, P4101, DOI 10.1074/jbc.270.8.4101; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Wang HD, 1997, MOL CELL BIOL, V17, P6838, DOI 10.1128/MCB.17.12.6838; Wang HD, 1998, MOL CELL BIOL, V18, P7086, DOI 10.1128/MCB.18.12.7086; Webster JC, 1997, J BIOL CHEM, V272, P9287; Zentner MD, 1998, J BIOL CHEM, V273, P30770, DOI 10.1074/jbc.273.46.30770; ZHANG SM, 1995, ENDOCRINE, V3, P5, DOI 10.1007/BF02917442	41	31	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21544	21554		10.1074/jbc.274.31.21544	http://dx.doi.org/10.1074/jbc.274.31.21544			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419459	hybrid			2022-12-25	WOS:000081721100012
J	Wilson, GL; Dean, BS; Wang, G; Dean, DA				Wilson, GL; Dean, BS; Wang, G; Dean, DA			Nuclear import of plasmid DNA in digitonin-permeabilized cells requires both cytoplasmic factors and specific DNA sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC FACTORS; SUPERCOILED DNA; GENE-EXPRESSION; PORE COMPLEXES; PROTEIN; TRANSPORT; EXPORT; BINDING; SIGNAL; SV40	Although much is known about the mechanisms of signal-mediated protein and RNA nuclear import and export, little is understood concerning the nuclear import of plasmid DNA, Plasmids between 4.2 and 14.4 kilobases were specifically labeled using a fluorescein-conjugated peptide nucleic acid clamp. The resulting substrates were capable of gene expression and nuclear localization in microinjected cells in the absence of cell division. To elucidate the requirements for plasmid nuclear import, a digitonin-permeabilized cell system was adapted to follow the nuclear localization of plasmids. Nuclear import of labeled plasmid was time- and energy-dependent, was inhibited by the lectin wheat germ ag glutinin, and showed an absolute requirement for cytoplasmic extract. Addition of nuclear extract alone did not support plasmid nuclear import but in combination with cytoplasm stimulated plasmid nuclear localization. Whereas addition of purified importin alpha, importin beta, and RAN was sufficient to support protein nuclear import, plasmid nuclear import also required the addition of nuclear extract. Finally, nuclear import of plasmid DNA was sequence-specific, requiring a region of the SV40 early promoter and enhancer. Taken together, these results confirm and extend our findings in microinjected cells and support a protein-mediated mechanism for plasmid nuclear import.	Univ S Alabama, Coll Med, Dept Microbiol & Immunol, Mobile, AL 36688 USA; Univ S Alabama, Coll Med, Dept Struct & Cellular Biol, Mobile, AL 36688 USA; Univ S Alabama, Coll Med, Ctr Comprehens Sickle Cell, Mobile, AL 36688 USA	University of South Alabama; University of South Alabama; University of South Alabama	Dean, DA (corresponding author), Univ S Alabama, Coll Med, Dept Microbiol & Immunol, Mobile, AL 36688 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL038639, R01HL059956] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL059956-04, 5P60 HL38639, R01 HL59956, R01 HL059956] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Albertini M, 1998, J CELL BIOL, V143, P1447, DOI 10.1083/jcb.143.6.1447; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BELTINGER C, 1995, J CLIN INVEST, V95, P1814, DOI 10.1172/JCI117860; Bentin T, 1996, BIOCHEMISTRY-US, V35, P8863, DOI 10.1021/bi960436k; Blessing T, 1998, P NATL ACAD SCI USA, V95, P1427, DOI 10.1073/pnas.95.4.1427; Dean DA, 1997, EXP CELL RES, V230, P293, DOI 10.1006/excr.1996.3427; DEMIDOV VV, 1994, BIOCHEM PHARMACOL, V48, P1310, DOI 10.1016/0006-2952(94)90171-6; Duguid JG, 1998, BIOPHYS J, V74, P2802, DOI 10.1016/S0006-3495(98)77987-1; DWORETZKY SI, 1988, J CELL BIOL, V107, P1279, DOI 10.1083/jcb.107.4.1279; EGHOLM M, 1993, NATURE, V365, P566, DOI 10.1038/365566a0; Escriou V, 1998, BBA-BIOMEMBRANES, V1368, P276, DOI 10.1016/S0005-2736(97)00194-6; GRAESSMANN M, 1989, NUCLEIC ACIDS RES, V17, P6603, DOI 10.1093/nar/17.16.6603; Greber UF, 1996, TRENDS CELL BIOL, V6, P189, DOI 10.1016/0962-8924(96)10016-7; Hagstrom JE, 1997, J CELL SCI, V110, P2323; Hartig R, 1998, BIOL CELL, V90, P407, DOI 10.1016/S0248-4900(98)80090-7; Holaska JM, 1998, P NATL ACAD SCI USA, V95, P14739, DOI 10.1073/pnas.95.25.14739; Kann M, 1997, J VIROL, V71, P1310, DOI 10.1128/JVI.71.2.1310-1316.1997; LANFORD RE, 1986, CELL, V46, P575, DOI 10.1016/0092-8674(86)90883-4; Langle-Rouault F, 1998, J VIROL, V72, P6181; Love DC, 1998, P NATL ACAD SCI USA, V95, P10608, DOI 10.1073/pnas.95.18.10608; LUBYPHELPS K, 1987, P NATL ACAD SCI USA, V84, P4910, DOI 10.1073/pnas.84.14.4910; MA CL, 1994, BIOPHYS J, V67, P1678, DOI 10.1016/S0006-3495(94)80641-1; MARSHALLSAY C, 1994, EMBO J, V13, P222, DOI 10.1002/j.1460-2075.1994.tb06252.x; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MAUL GG, 1977, J CELL BIOL, V73, P748, DOI 10.1083/jcb.73.3.748; MEHLIN H, 1995, J CELL BIOL, V129, P1205, DOI 10.1083/jcb.129.5.1205; Melchior F, 1998, TRENDS CELL BIOL, V8, P175, DOI 10.1016/S0962-8924(98)01252-5; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; Moroianu J, 1998, J CELL BIOCHEM, V70, P231; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; Nakanishi A, 1996, P NATL ACAD SCI USA, V93, P96, DOI 10.1073/pnas.93.1.96; NIELSEN PE, 1994, GENE, V149, P139, DOI 10.1016/0378-1119(94)90422-7; Sebestyen MG, 1998, NAT BIOTECHNOL, V16, P80, DOI 10.1038/nbt0198-80; Seksek O, 1997, J CELL BIOL, V138, P131, DOI 10.1083/jcb.138.1.131; SHURVINTON CE, 1992, P NATL ACAD SCI USA, V89, P11837, DOI 10.1073/pnas.89.24.11837; Stevenson M, 1996, TRENDS CELL BIOL, V6, P9, DOI 10.1016/0962-8924(96)81032-4; SUKEGAWA J, 1993, CELL, V72, P29, DOI 10.1016/0092-8674(93)90047-T; Vacik J, 1999, GENE THER, V6, P1006, DOI 10.1038/sj.gt.3300924; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; Whittaker GR, 1998, VIROLOGY, V246, P1, DOI 10.1006/viro.1998.9165; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; Zanta MA, 1999, P NATL ACAD SCI USA, V96, P91, DOI 10.1073/pnas.96.1.91; Zelphati O, 1999, HUM GENE THER, V10, P15, DOI 10.1089/10430349950019156; Zupan JR, 1996, P NATL ACAD SCI USA, V93, P2392, DOI 10.1073/pnas.93.6.2392	45	127	133	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					22025	22032		10.1074/jbc.274.31.22025	http://dx.doi.org/10.1074/jbc.274.31.22025			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419528	Green Accepted, hybrid			2022-12-25	WOS:000081721100081
J	Asano, T; Morishita, R; Ueda, H; Kato, K				Asano, T; Morishita, R; Ueda, H; Kato, K			Selective association of G protein beta(4) with gamma(5) and gamma(12) subunits in bovine tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; KINASE PATHWAY; BINDING; PURIFICATION; FORMS; IDENTIFICATION; CDNA; SPECIFICITY; ACTIVATION; ANTIBODIES	The beta and gamma subunits of G proteins are tightly bound under physiological conditions, and so far, seven beta and 11 gamma subunit isoforms have been found. The relative abilities of the beta and gamma subunits to associate with each other have been studied using transfected cell assays, in vitro translation and the yeast two-hybrid system, but have not been fully characterized in various tissues. In the present study, we demonstrated the selectivity of association of the beta with gamma isoforms in bovine tissues. Immunoprecipitation of py complexes from tissue extracts with antibodies against various gamma subunits and subsequent analyses revealed that beta(4) associated with the gamma subunits with the following rank order of selectivity: gamma(5) > gamma(12) > gamma(2) > gamma(3), while beta(2) bound to gamma(2), gamma(3), and gamma(12) more selectively than to gamma(5). By contrast, beta(1) associated with all gamma subunits without significant selectivity. Analyses of purified beta gamma complexes containing various gamma isoforms revealed beta subunit compositions similar to those found in the immunoprecipitates. Particular combinations of beta and gamma subunit isoforms may contribute to maintaining efficient and specific signal transduction mediated by G proteins.	Aichi Human Serv Ctr, Inst Dev Res, Dept Biochem, Aichi 4800392, Japan		Asano, T (corresponding author), Aichi Human Serv Ctr, Inst Dev Res, Dept Biochem, Kamiya Cho, Aichi 4800392, Japan.							ASANO T, 1995, J NEUROCHEM, V64, P1267; ASANO T, 1993, J BIOL CHEM, V268, P20512; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; FAURE M, 1994, J BIOL CHEM, V269, P7851; FUKADA Y, 1989, J BIOL CHEM, V264, P5937; FUNG BKK, 1992, J BIOL CHEM, V267, P24782; GAO B, 1987, J BIOL CHEM, V262, P17254; Iniguez-Lluhi Jorge, 1993, Trends in Cell Biology, V3, P230, DOI 10.1016/0962-8924(93)90122-H; Jones PG, 1998, BBA-MOL CELL RES, V1402, P288, DOI 10.1016/S0167-4889(98)00017-2; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOGOTHETIS DE, 1988, P NATL ACAD SCI USA, V85, P5814, DOI 10.1073/pnas.85.16.5814; MORISHITA R, 1992, EUR J BIOCHEM, V210, P1061, DOI 10.1111/j.1432-1033.1992.tb17512.x; MORISHITA R, 1988, EUR J BIOCHEM, V174, P87, DOI 10.1111/j.1432-1033.1988.tb14066.x; MORISHITA R, 1995, J BIOL CHEM, V270, P29469, DOI 10.1074/jbc.270.49.29469; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; RAY K, 1995, J BIOL CHEM, V270, P21765, DOI 10.1074/jbc.270.37.21765; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMIDT CJ, 1992, J BIOL CHEM, V267, P13807; Siffert W, 1998, NAT GENET, V18, P45, DOI 10.1038/ng0198-45; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; TAMIR H, 1991, BIOCHEMISTRY-US, V30, P3929, DOI 10.1021/bi00230a018; Ueda H, 1998, J BIOCHEM-TOKYO, V124, P1033, DOI 10.1093/oxfordjournals.jbchem.a022196; UEDA N, 1994, J BIOL CHEM, V269, P4388; VONWEIZSACKER E, 1992, BIOCHEM BIOPH RES CO, V183, P350, DOI 10.1016/0006-291X(92)91650-F; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Watson AJ, 1996, J BIOL CHEM, V271, P28154, DOI 10.1074/jbc.271.45.28154; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; Yan K, 1996, J BIOL CHEM, V271, P7141, DOI 10.1074/jbc.271.12.7141	32	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21425	21429		10.1074/jbc.274.30.21425	http://dx.doi.org/10.1074/jbc.274.30.21425			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409705	hybrid			2022-12-25	WOS:000081613100096
J	Fisher, AB; Dodia, C; Manevich, Y; Chen, JW; Feinstein, SI				Fisher, AB; Dodia, C; Manevich, Y; Chen, JW; Feinstein, SI			Phospholipid hydroperoxidase are substrates for non-selenium glutathione peroxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOL-SPECIFIC ANTIOXIDANT; RAT OLFACTORY EPITHELIUM; SECRETORY PROTEIN; IDENTIFICATION; CDNA; TRANSLATION; EXPRESSION; SEQUENCE; CLONING; FAMILY	This study investigated phospholipid hydroperoxides as substrates for non-selenium GSH peroxidase (NSGPx), an enzyme also called 1-Cys peroxiredoxin. Recombinant human NSGPx expressed in Escherichia coli from a human cDNA clone (HA0683) showed GSH peroxidase activity with sn-2-linolenoyl- or sn-2-arachidonoyl-phosphatidylcholine hydroperoxides as substrate; NADPH or thioredoxin could not substitute for GSH, Activity did not saturate with GSH, and kinetics were compatible with a ping-pong mechanism; kinetic constants (mM(-1) min(-1)) were k(1) = 1-3 x 10(5) and k(2) = 4-11 x 10(4). In the presence of 0.36 mM GSH, apparent K-m was 120-130 mu M and apparent V-max was 1.5-1.6 mu mol/min/mg of protein. Assays with H2O2 and organic hydroperoxides as substrate indicated activity similar to that with phospholipid hydroperoxides, Maximal enzymatic activity was at pH 7-8. Activity with phospholipid hydroperoxide substrate was inhibited noncompetitively by mercaptosuccinate with K-i 4 mu M. The enzyme had no GSH S-transferase activity. Bovine cDNA encoding NSGPx, isolated from a lung expression library using a polymerase chain reaction probe, showed >95% similarity to previously published human, rat, and mouse sequences and does not contain the TGA stop codon, which is translated as selenocysteine in selenium-containing peroxidases, The molecular mass of bovine NSGPx deduced from the cDNA is 25,047 Da, These results identify a new GSH peroxidase that is not a selenoenzyme and can reduce phospholipid hydroperoxides, Thus, this enzyme may be an important component of cellular antioxidant defense systems.	Univ Penn, Med Ctr, Inst Environm Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Fisher, AB (corresponding author), Univ Penn, Sch Med, Inst Environm Med, 1 John Morgan Bldg,3620 Hamilton Walk, Philadelphia, PA 19104 USA.	abf@mail.med.upenn.edu			NHLBI NIH HHS [HL60290, HL19737] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL060290, P01HL019737] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akiba S, 1998, COMP BIOCHEM PHYS B, V120, P393, DOI 10.1016/S0305-0491(98)10046-9; BRIGELIUS-FLOHE R, 1994, J BIOL CHEM, V269, P7342; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; Chen JW, 1999, FASEB J, V13, pA174; Fisher AB, 1998, FREE RADICAL BIO MED, V25, pS31; Frank S, 1997, ONCOGENE, V14, P915, DOI 10.1038/sj.onc.1200905; FUNK CD, 1989, P NATL ACAD SCI USA, V86, P2592, DOI 10.1073/pnas.86.8.2592; GARDNER HW, 1989, BIOCHIM BIOPHYS ACTA, V1001, P274, DOI 10.1016/0005-2760(89)90111-2; GOLAZ O, 1993, ELECTROPHORESIS, V14, P1223, DOI 10.1002/elps.11501401183; HOCHSTRASSER DF, 1992, ELECTROPHORESIS, V13, P992, DOI 10.1002/elps.11501301201; Hurst R, 1998, BIOCHEM J, V332, P97, DOI 10.1042/bj3320097; Iakoubova OA, 1997, GENOMICS, V42, P474, DOI 10.1006/geno.1997.4762; Kang SW, 1998, J BIOL CHEM, V273, P6303, DOI 10.1074/jbc.273.11.6303; Kim TS, 1998, AM J PHYSIOL-LUNG C, V274, pL750, DOI 10.1152/ajplung.1998.274.5.L750; Kim TS, 1997, J BIOL CHEM, V272, P2542; MAIORINO M, 1990, METHOD ENZYMOL, V186, P448; MICHIELS C, 1994, FREE RADICAL BIO MED, V17, P235, DOI 10.1016/0891-5849(94)90079-5; Munz B, 1997, BIOCHEM J, V326, P579, DOI 10.1042/bj3260579; Nagase T, 1995, DNA Res, V2, P37, DOI 10.1093/dnares/2.1.37; Nomura N, 1994, DNA Res, V1, P27, DOI 10.1093/dnares/1.1.27; Peshenko IV, 1998, FREE RADICAL BIO MED, V25, P654, DOI 10.1016/S0891-5849(98)00111-7; Peshenko IV, 1996, FEBS LETT, V381, P12, DOI 10.1016/0014-5793(96)00071-3; PUSHPAREKHA TR, 1995, J BIOL CHEM, V270, P26993, DOI 10.1074/jbc.270.45.26993; SHICHI H, 1990, EXP EYE RES, V50, P513, DOI 10.1016/0014-4835(90)90040-2; Singh AK, 1998, J BIOL CHEM, V273, P26171, DOI 10.1074/jbc.273.40.26171; THEROND P, 1993, LIPIDS, V28, P245, DOI 10.1007/BF02536647; URSINI F, 1985, BIOCHIM BIOPHYS ACTA, V839, P62, DOI 10.1016/0304-4165(85)90182-5; VANKUIJK FJGM, 1987, TRENDS BIOCHEM SCI, V12, P31, DOI 10.1016/0968-0004(87)90014-4; YAMAMOTO Y, 1993, ARCH BIOCHEM BIOPHYS, V305, P541, DOI 10.1006/abbi.1993.1458	29	226	239	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21326	21334		10.1074/jbc.274.30.21326	http://dx.doi.org/10.1074/jbc.274.30.21326			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409692	hybrid			2022-12-25	WOS:000081613100083
J	Prinetti, A; Iwabuchi, K; Hakomori, S				Prinetti, A; Iwabuchi, K; Hakomori, S			Glycosphingolipid-enriched signaling domain in mouse neuroblastoma Neuro2a cells - Mechanism of ganglioside-dependent neuritogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; MELANOMA B16 CELLS; EXOGENOUS GANGLIOSIDES; NEURITE OUTGROWTH; RAT-BRAIN; DIFFERENTIATION; ASSOCIATION; MEMBRANE; SRC; ADHESION	Differentiation and neuritogenesis of mouse neuroblastoma Neuro2a cells are induced by exogenous ganglioside but are not induced by nerve growth factor because its receptor is absent in these cells. In view of the emerging concept of the "glycosphingolipid-enriched domain" (GEM), we studied the mechanism of the ganglioside effect, focusing on the structure and function of such a domain. GEM in Neuro2a cells, separated as a low density membrane fraction, contains essentially all glycosphingolipids and sphingomyelin, together with five signal transducer molecules (c-Src, Lyn, Csk, Rho A, Ha-Ras). H-3-Labeled Il(3)NeuAc-LacCer (GM3), Gb4Cer (globoside), and Il(3)NeuAc-Gg4Cer (GM1) added exogenously to cells were incorporated and concentrated in the low density GEM fk action. In contrast, more than 50% of glycerophospholipids and 30% of cholesterol were found in the high density fraction. H-3-Labeled phosphatidylcholine added exogenously to cells was incorporated exclusively in the high density fraction. c-Src, the predominant signal transducer in the microdomain, was coimmunoprecipitated with anti-GM3 antibody DH2 or with anti-Csk; reciprocally, Csk was coimmunoprecipitated with anti-c-Src, indicating a close association of GM3, c-Src, and Csk, Brief stimulation of an isolated GEM fraction by the exogenous addition of GM3, but not lactosylceramide, caused enhanced c-Src phosphorylation with a concomitant decrease of Csk level in GEM,A decreased Csk/c-Src ratio in GEM may cause activation of c-Src because Csk is a negative regulator of c-Src. The effect of exogenous GM3 on c-Src activity was also observed in intact Neuro2a cells. Activation of c-Src was followed by rapid and prolonged (60 min) enhancement of mitogen-activated protein kinase activity leading to neuritogenesis. Thus, the ganglioside induction of neuritogenesis in Neuro2a cells is mediated by GEM structure and function.	Pacific NW Res Inst, Seattle, WA 98122 USA; Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA; Univ Washington, Dept Microbiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Hakomori, S (corresponding author), Pacific NW Res Inst, 720 Broadway, Seattle, WA 98122 USA.	hakomori@u.washington.edu	Prinetti, Alessandro/R-4206-2017; Sonnino, Sandro/R-4154-2017	Prinetti, Alessandro/0000-0003-0252-2593; Sonnino, Sandro/0000-0001-8180-5908	NCI NIH HHS [CA42505] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042505] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BJELFMAN C, 1990, MOL CELL BIOL, V10, P361, DOI 10.1128/MCB.10.1.361; CANNELLA MS, 1988, DEV BRAIN RES, V39, P137, DOI 10.1016/0165-3806(88)90075-2; CANNELLA MS, 1988, INT J DEV NEUROSCI, V6, P319, DOI 10.1016/0736-5748(88)90015-9; CHAKRABORTY M, 1993, BRAIN RES, V625, P197, DOI 10.1016/0006-8993(93)91059-2; DOHI T, 1988, CANCER RES, V48, P5680; DREYFUS H, 1980, NEUROSCIENCE, V5, P1647, DOI 10.1016/0306-4522(80)90028-7; FACCI L, 1984, J NEUROCHEM, V42, P299, DOI 10.1111/j.1471-4159.1984.tb02678.x; FOLCH J, 1951, J BIOL CHEM, V191, P819; Hakomori S, 1998, GLYCOBIOLOGY, V8, pXI; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HAKOMORI SI, 1983, SPHINGOLIPID BIOCH, P1; HAREL R, 1993, J BIOL CHEM, V268, P14476; HOWELL BW, 1994, MOL CELL BIOL, V14, P5402, DOI 10.1128/MCB.14.8.5402; Iwabuchi K, 1998, J BIOL CHEM, V273, P9130, DOI 10.1074/jbc.273.15.9130; Iwabuchi K, 1998, J BIOL CHEM, V273, P33766, DOI 10.1074/jbc.273.50.33766; Kasahara K, 1997, J BIOL CHEM, V272, P29947, DOI 10.1074/jbc.272.47.29947; KLENK E, 1960, Z VERDAUUNGS STOFFWE, V20, P180; KOJIMA N, 1994, J BIOL CHEM, V269, P30451; LEDEEN RW, 1990, FID RES FDN, V3, P17; LEDEEN RW, 1973, J NEUROCHEM, V21, P829, DOI 10.1111/j.1471-4159.1973.tb07527.x; LINSTEDT AD, 1992, J CELL BIOL, V117, P1077, DOI 10.1083/jcb.117.5.1077; MARTENSSON S, 1986, GLYCOCONJUGATE J, V3, P163, DOI 10.1007/BF01049374; MATTA SG, 1986, DEV BRAIN RES, V27, P243, DOI 10.1016/0165-3806(86)90250-6; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; OKADA M, 1991, J BIOL CHEM, V266, P24249; RIBONI L, 1990, NEUROCHEM RES, V15, P1175, DOI 10.1007/BF01208577; Rodgers W, 1996, J CELL BIOL, V135, P1515, DOI 10.1083/jcb.135.6.1515; ROISEN FJ, 1981, SCIENCE, V214, P577, DOI 10.1126/science.7291999; Rosner H, 1998, ANN NY ACAD SCI, V845, P200, DOI 10.1111/j.1749-6632.1998.tb09672.x; SEYAMA Y, 1974, J BIOCHEM-TOKYO, V75, P837, DOI 10.1093/oxfordjournals.jbchem.a130455; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Sonnino S, 1996, GLYCOBIOLOGY, V6, P479, DOI 10.1093/glycob/6.5.479-e; SUZUKI Y, 1972, J LIPID RES, V13, P687; TETTAMANTI G, 1994, PROG BRAIN RES, V101, P77; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VASKOVSKY VE, 1968, J LIPID RES, V9, P396; WILLIAMS MA, 1980, J NEUROCHEM, V35, P266, DOI 10.1111/j.1471-4159.1980.tb12515.x; Yamamura S, 1997, BIOCHEM BIOPH RES CO, V236, P218, DOI 10.1006/bbrc.1997.6933; YAVIN E, 1979, DEV NEUROSCI-BASEL, V2, P25, DOI 10.1159/000112436; YOUNG WW, 1979, J EXP MED, V150, P1008, DOI 10.1084/jem.150.4.1008	41	155	158	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					20916	20924		10.1074/jbc.274.30.20916	http://dx.doi.org/10.1074/jbc.274.30.20916			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409636	hybrid			2022-12-25	WOS:000081613100027
J	Wentzel, A; Christmann, A; Kratzner, R; Kolmar, H				Wentzel, A; Christmann, A; Kratzner, R; Kolmar, H			Sequence requirements of the GPNG beta-turn of the Ecballium elaterium trypsin inhibitor II explored by combinatorial library screening	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE; DISTANCE GEOMETRY; OMEGA-CONOTOXINS; EETI-II; PROTEINS; GENE; EXPRESSION; PATHWAY; FAMILY	The Ecballium elaterium trypsin inhibitor II (EETI-II) contains 28 amino acids and three disulfides forming a cystine knot. Reduced EETI-II refolds spontaneously and quantitatively in vitro and regains its native structure. Due to its high propensity to form a reverse turn, the GPNG sequence of segment 22-25 comprising a beta-turn in native EETI-II is a possible candidate for a folding initiation site. We generated a molecular repertoire of EETI-II variants with variegated 22-25 tetrapeptide sequences and presented these proteins on the outer membrane of Escherichia coli cells via fusion to the Iga(beta) autotransporter. Functional trypsin-binding variants were selected by combination of magnetic and fluorescence-activated cell sorting. At least 1-5% of all possible tetrapeptide sequences were compatible with formation of the correct three disulfides. Occurrence of amino acid residues in functional variants is positively correlated with their propensity to be generally found in beta-turns. The folding pathway of two selected variants, EETI-beta(NEDE) and EETI-beta(TNNK), was found to be indistinguishable from EETI-II and occurs through formation of a stable 2-disulfide intermediate. Substantial amounts of misfolded byproducts, however, were obtained upon refolding of these variants corroborating the importance of the wild type EETI-II GPNG sequence to direct quantitative formation of the cystine knot architecture.	Inst Microbiol & Genet, Abt Mol Genet & Praparat Mol Biol, D-37077 Gottingen, Germany; Univ Gottingen, Inst Organ Chem, D-37077 Gottingen, Germany	University of Gottingen	Kolmar, H (corresponding author), Inst Microbiol & Genet, Abt Mol Genet & Praparat Mol Biol, Grisebachstr S, D-37077 Gottingen, Germany.	Hkolmar@Uni-Molgen.gwdg.de	Kolmar, Harald/AAK-8316-2021; Wentzel, Alexander/D-2684-2012	Kolmar, Harald/0000-0002-8210-1993; Wentzel, Alexander/0000-0002-9420-1959				BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BIETH JG, 1984, BIOCHEM MED METAB B, V32, P387, DOI 10.1016/0006-2944(84)90046-2; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; CHANG JY, 1994, J BIOL CHEM, V269, P22087; CHEN XM, 1992, J BIOCHEM-TOKYO, V112, P45, DOI 10.1093/oxfordjournals.jbchem.a123863; CHOU PY, 1977, J MOL BIOL, V115, P135, DOI 10.1016/0022-2836(77)90094-8; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; HEITZ A, 1989, BIOCHEMISTRY-US, V28, P2392, DOI 10.1021/bi00432a009; HEITZ A, 1995, EUR J BIOCHEM, V233, P837, DOI 10.1111/j.1432-1033.1995.837_3.x; HUTCHINSON EG, 1994, PROTEIN SCI, V3, P2207, DOI 10.1002/pro.5560031206; ISAACS NW, 1995, CURR OPIN STRUC BIOL, V5, P391, DOI 10.1016/0959-440X(95)80102-2; Jose J, 1996, GENE, V178, P107, DOI 10.1016/0378-1119(96)00343-5; KLAUSER T, 1993, BIOESSAYS, V15, P799, DOI 10.1002/bies.950151205; KOHNO T, 1995, BIOCHEMISTRY-US, V34, P10256, DOI 10.1021/bi00032a020; Kojima S, 1996, PROTEIN ENG, V9, P1241, DOI 10.1093/protein/9.12.1241; KOLMAR H, 1992, J MOL BIOL, V228, P359, DOI 10.1016/0022-2836(92)90826-6; KRAMER W, 1987, METHOD ENZYMOL, V154, P350; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAULIS PJ, 1989, BIOCHEMISTRY-US, V28, P7241, DOI 10.1021/bi00444a016; LENGUYEN D, 1990, BIOCHIMIE, V72, P431, DOI 10.1016/0300-9084(90)90067-Q; LENGUYEN D, 1993, PROTEIN SCI, V2, P165; LOPEZAMOROS R, 1995, APPL ENVIRON MICROB, V61, P2521; Miller J.H., 1972, EXPT MOL GENETICS; Miltenyi S., 1992, FLOW CYTOMETRY CELL, P141; OTLEWSKI J, 1990, BIOL CHEM H-S, V371, P23; PALLAGHY PK, 1994, PROTEIN SCI, V3, P1833, DOI 10.1002/pro.5560031022; PREUSS KD, 1990, BIOL CHEM H-S, V371, P215, DOI 10.1515/bchm3.1990.371.1.215; Price-Carter M, 1998, BIOCHEMISTRY-US, V37, P9851, DOI 10.1021/bi9803978; PriceCarter M, 1996, BIOCHEMISTRY-US, V35, P15537, DOI 10.1021/bi961574c; PriceCarter M, 1996, BIOCHEMISTRY-US, V35, P15547, DOI 10.1021/bi9615755; REES DC, 1980, P NATL ACAD SCI-BIOL, V77, P4633, DOI 10.1073/pnas.77.8.4633; Tamaoki H, 1998, PROTEIN ENG, V11, P649, DOI 10.1093/protein/11.8.649	32	61	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21037	21043		10.1074/jbc.274.30.21037	http://dx.doi.org/10.1074/jbc.274.30.21037			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409654	hybrid			2022-12-25	WOS:000081613100045
J	Mohamed, AS; Swope, SL				Mohamed, AS; Swope, SL			Phosphorylation and cytoskeletal anchoring of the acetylcholine receptor by Src class protein-tyrosine kinases - Activation by rapsyn	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTSYNAPTIC 43-KDA PROTEIN; TORPEDO ELECTRIC ORGAN; NEUROMUSCULAR-JUNCTION; CYTOPLASMIC DOMAINS; MAMMALIAN MUSCLE; BINDING-PROTEIN; FAMILY KINASES; BETA-SUBUNIT; 43K PROTEIN; C2 MYOTUBES	Src class protein-tyrosine kinases bind to and phosphorylate the nicotinic acetylcholine receptor of skeletal muscle. This study provided evidence for the functional importance of Src kinases in regulating the nicotinic acetylcholine receptor at the neuromuscular junction. Three Src class kinases, Fyn, Fyk, and Src, each formed a complex with the endplate-specific cytoskeletal protein rapsyn. In addition, cellular phosphorylation by each kinase was stimulated by rapsyn in heterologous transfected cells. Several lines of evidence supported rapsyn as a substrate for Src kinases, Most importantly, rapsyn regulation of Fyn, Fyk, and Src resulted in phosphorylation of the nicotinic acetylcholine receptor beta and delta subunits and anchoring of the receptor to the cytoskeleton, Both nicotinic acetylcholine receptor phosphorylation and cytoskeletal anchoring were blocked by the Src kinase-selective inhibitor herbimycin A. Rapsyn alone also induced a modest increase in nicotinic acetylcholine receptor phosphorylation and cytoskeletal translocation. However, inhibition by herbimycin A and a catalytically inactive dominant negative Src demonstrated that the effects of rapsyn were mediated by endogenous Src kinases, These data support the importance of Src class kinases for stabilization of the nicotinic acetylcholine receptor at the endplate during synaptic differentiation at the neuromuscular junction.	Georgetown Univ, Med Ctr, Georgetown Inst Cognit & Computat Sci, Dept Neurol,Div Neurosci, Washington, DC 20007 USA	Georgetown University	Swope, SL (corresponding author), Georgetown Univ, Med Ctr, Georgetown Inst Cognit & Computat Sci, Dept Neurol,Div Neurosci, EP08 Res Bldg,3970 Reservoir Rd NW, Washington, DC 20007 USA.				NCI NIH HHS [P30-CA-51008] Funding Source: Medline; NINDS NIH HHS [NS 35503] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA051008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS035503] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMREIN KE, 1992, P NATL ACAD SCI USA, V89, P3343, DOI 10.1073/pnas.89.8.3343; ANTHONY DT, 1984, P NATL ACAD SCI-BIOL, V81, P2265, DOI 10.1073/pnas.81.7.2265; APEL ED, 1995, NEURON, V15, P115, DOI 10.1016/0896-6273(95)90069-1; Apel ED, 1997, NEURON, V18, P623, DOI 10.1016/S0896-6273(00)80303-7; BARRANTES FJ, 1980, FEBS LETT, V112, P72; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Buckel A, 1996, GENOMICS, V35, P613, DOI 10.1006/geno.1996.0409; BURDEN SJ, 1983, CELL, V35, P687, DOI 10.1016/0092-8674(83)90101-0; Cartaud A, 1998, J BIOL CHEM, V273, P11321, DOI 10.1074/jbc.273.18.11321; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN Q, 1995, J NEUROSCI RES, V40, P606, DOI 10.1002/jnr.490400505; DECHIARA T, 1996, CELL, V85, P1; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; Ferns M, 1996, J CELL BIOL, V132, P937, DOI 10.1083/jcb.132.5.937; FRAIL DE, 1988, J BIOL CHEM, V263, P15602; FRAIL DE, 1987, P NATL ACAD SCI USA, V84, P6302, DOI 10.1073/pnas.84.17.6302; FROEHNER SC, 1991, J CELL BIOL, V114, P1, DOI 10.1083/jcb.114.1.1; FROEHNER SC, 1990, NEURON, V5, P403, DOI 10.1016/0896-6273(90)90079-U; FROEHNER SC, 1983, J BIOL CHEM, V258, P7112; Fuhrer C, 1997, EMBO J, V16, P4951, DOI 10.1093/emboj/16.16.4951; Fuhrer C, 1996, J BIOL CHEM, V271, P32474, DOI 10.1074/jbc.271.50.32474; GAUTAM M, 1995, NATURE, V377, P232, DOI 10.1038/377232a0; Gillespie SKH, 1996, NEURON, V16, P953, DOI 10.1016/S0896-6273(00)80118-X; Glass DJ, 1996, CELL, V85, P513, DOI 10.1016/S0092-8674(00)81252-0; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HELMKE S, 1995, CELL MOTIL CYTOSKEL, V30, P194, DOI 10.1002/cm.970300304; HILL JA, 1991, BIOCHEMISTRY-US, V30, P5579, DOI 10.1021/bi00236a034; HOPFIELD JF, 1988, NATURE, V336, P677, DOI 10.1038/336677a0; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; LAROCHELLE WJ, 1986, J BIOL CHEM, V261, P5270; LI PM, 1993, ONCOGENE, V8, P1731; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCMAHAN UJ, 1990, COLD SPRING HARB SYM, V55, P407; MEIER T, 1995, J CELL BIOL, V131, P441, DOI 10.1083/jcb.131.2.441; Mitsui T, 1996, BIOCHEM BIOPH RES CO, V224, P802, DOI 10.1006/bbrc.1996.1103; MOHAMED AS, 1998, 28 ANN M SOC NEUR LO, V24, P86; NOAKES PG, 1993, DEV BIOL, V155, P275, DOI 10.1006/dbio.1993.1025; PENG HB, 1985, J CELL BIOL, V100, P1698, DOI 10.1083/jcb.100.5.1698; PHILLIPS WD, 1993, J CELL BIOL, V123, P729, DOI 10.1083/jcb.123.3.729; PHILLIPS WD, 1991, J CELL BIOL, V115, P1713, DOI 10.1083/jcb.115.6.1713; PHILLIPS WD, 1991, SCIENCE, V251, P568, DOI 10.1126/science.1703661; QU Z, 1994, J NEUROSCI, V14, P6834; QU ZC, 1990, NEURON, V4, P367, DOI 10.1016/0896-6273(90)90049-L; Qu ZC, 1996, MOL CELL NEUROSCI, V8, P171, DOI 10.1006/mcne.1996.0055; REYNOLDS JA, 1978, BIOCHEMISTRY-US, V17, P2305; SCOTLAND PB, 1993, J CELL BIOL, V123, P719, DOI 10.1083/jcb.123.3.719; SMITH MM, 1987, P NATL ACAD SCI USA, V84, P6601, DOI 10.1073/pnas.84.18.6601; SWOPE SL, 1993, J BIOL CHEM, V268, P25152; SWOPE SL, 1994, J BIOL CHEM, V269, P29817; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VALENZUELA DM, 1995, NEURON, V15, P573, DOI 10.1016/0896-6273(95)90146-9; WAGNER K, 1991, J BIOL CHEM, V266, P23784; WALKER JH, 1984, J NEUROCHEM, V42, P314, DOI 10.1111/j.1471-4159.1984.tb02680.x; WALKER JH, 1984, EMBO J, V3, P2287, DOI 10.1002/j.1460-2075.1984.tb02127.x; WALLACE BG, 1991, NEURON, V6, P869, DOI 10.1016/0896-6273(91)90227-Q; WALLACE BG, 1995, J CELL BIOL, V128, P1121, DOI 10.1083/jcb.128.6.1121; WALLACE BG, 1994, J CELL BIOL, V125, P661, DOI 10.1083/jcb.125.3.661; WALLACE BG, 1992, J NEUROBIOL, V23, P592, DOI 10.1002/neu.480230512; YANG WY, 1995, J BIOL CHEM, V270, P20832, DOI 10.1074/jbc.270.35.20832; YU XM, 1994, J NEUROSCI, V14, P785	63	43	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20529	20539		10.1074/jbc.274.29.20529	http://dx.doi.org/10.1074/jbc.274.29.20529			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400682	hybrid			2022-12-25	WOS:000081438300075
J	Ramanathan, VK; Hall, ZW				Ramanathan, VK; Hall, ZW			Altered glycosylation sites of the delta subunit of the acetylcholine receptor (AChR) reduce alpha delta association and receptor assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED ION CHANNELS; MAMMALIAN MUSCLE; COS CELLS; ENDOPLASMIC-RETICULUM; HETERODIMER FORMATION; TORPEDO-CALIFORNICA; EPSILON SUBUNIT; LIGAND-BINDING; BETA-SUBUNIT; MOUSE	We have used mutagenesis to investigate the potential N-glycosylation sites in the delta subunit of the mouse muscle acetylcholine receptor (AChR). Of the three sites, Asn(76), Asn(143), and Asn(169), only the first two were glycosylated when the delta subunit was expressed in COS cells. Because the heterologously expressed delta subunit was similar in its properties to that expressed in C2 muscle cells, the sites of glycosylation are likely to be the same in both cases. In COS cells, mutations of the delta subunit that prevented glycosylation at either of the sites did not change its metabolic stability nor its steady-state level. These results are in contrast to those found previously for the alpha subunit, in which glycosylation at a single site metabolically stabilized the polypeptide (Blount, P., and Merlie, J, P. (1990) J. Cell Biol. 111, 2613-2622). Mutations of the delta subunit that prevented glycosylation, however, decreased its ability to form an alpha delta heterodimer when the alpha and delta subunit were expressed together. When all four subunits of the AChR (alpha, beta, delta, and epsilon) were coexpressed, mutation of the delta subunit to prevent glycosylation resulted in a reduced amount of fully assembled AChR and reduced surface AChR levels, consistent with the role of the heterodimer in the assembly reaction. These results suggest that glycosylation of the delta subunit at both Asn(76) and Asn(143) is needed for its efficient folding and/or its subsequent interaction with the alpha subunit.	NIMH, Sect Synapt Mechanisms, Lab Cellular & Mol Regulat, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Ramanathan, VK (corresponding author), SmithKline Beecham Pharmaceut, POB 1539, King Of Prussia, PA 19406 USA.	Vikram_K_Ramanathan@sbphrd.com						ANDERSON DJ, 1981, P NATL ACAD SCI-BIOL, V78, P5598, DOI 10.1073/pnas.78.9.5598; BETZ H, 1990, NEURON, V5, P383, DOI 10.1016/0896-6273(90)90077-S; BLOUNT P, 1990, J CELL BIOL, V111, P2613, DOI 10.1083/jcb.111.6.2613; BLOUNT P, 1990, J CELL BIOL, V111, P2601, DOI 10.1083/jcb.111.6.2601; BLOUNT P, 1988, J BIOL CHEM, V263, P1072; BRODSKY MH, 1990, J IMMUNOL, V144, P3078; BUONANNO A, 1986, J BIOL CHEM, V261, P6451; CHAVEZ RA, 1992, J CELL BIOL, V116, P385, DOI 10.1083/jcb.116.2.385; CHAVEZ RA, 1992, J BIOL CHEM, V267, P23028; CHAVEZ RA, 1991, J BIOL CHEM, V266, P15532; DEVILLERSTHIERY A, 1983, P NATL ACAD SCI-BIOL, V80, P2067, DOI 10.1073/pnas.80.7.2067; DWEK RA, 1995, SCIENCE, V269, P1234, DOI 10.1126/science.7652569; DWEK RA, 1995, BIOCHEM SOC T, V23, P1; FORSAYETH JR, 1994, BIOTECHNIQUES, V17, P354; FROEHNER SC, 1983, J BIOL CHEM, V258, P7112; Fuhrer C, 1997, EMBO J, V16, P4951, DOI 10.1093/emboj/16.16.4951; Fuhrer C, 1996, J BIOL CHEM, V271, P32474, DOI 10.1074/jbc.271.50.32474; Gehle VM, 1997, MOL BRAIN RES, V45, P219, DOI 10.1016/S0169-328X(96)00256-2; Green WN, 1998, J NEUROSCI, V18, P5555; GU Y, 1991, NEURON, V6, P879, DOI 10.1016/0896-6273(91)90228-R; GU Y, 1991, J CELL BIOL, V114, P799, DOI 10.1083/jcb.114.4.799; GU Y, 1988, J BIOL CHEM, V263, P12878; GU Y, 1990, NEURON, V5, P147, DOI 10.1016/0896-6273(90)90305-Y; Hall Z W, 1992, Trends Cell Biol, V2, P66, DOI 10.1016/0962-8924(92)90058-U; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; ISENBERG KE, 1986, NUCLEIC ACIDS RES, V14, P5111, DOI 10.1093/nar/14.12.5111; Karlin A, 1993, Curr Opin Neurobiol, V3, P299, DOI 10.1016/0959-4388(93)90121-E; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; KREIENKAMP HJ, 1995, NEURON, V14, P635, DOI 10.1016/0896-6273(95)90320-8; LAPOLLA RJ, 1984, P NATL ACAD SCI-BIOL, V81, P7970, DOI 10.1073/pnas.81.24.7970; MERLIE JP, 1982, J BIOL CHEM, V257, P2694; MERLIE JP, 1981, J BIOL CHEM, V256, P3605; MERLIE JP, 1983, CELL, V34, P747, DOI 10.1016/0092-8674(83)90531-7; NODA M, 1982, NATURE, V299, P793, DOI 10.1038/299793a0; NOMOTO H, 1986, EUR J BIOCHEM, V157, P233, DOI 10.1111/j.1432-1033.1986.tb09661.x; OLSON EN, 1984, J BIOL CHEM, V259, P5364; RICKERT KW, 1995, CHEM BIOL, V2, P751, DOI 10.1016/1074-5521(95)90103-5; SAEDI MS, 1991, J CELL BIOL, V112, P1007, DOI 10.1083/jcb.112.5.1007; SINE SM, 1991, J BIOL CHEM, V266, P19369; SMITH MM, 1987, J BIOL CHEM, V262, P4367; Sugiyama N, 1996, J BIOL CHEM, V271, P26575, DOI 10.1074/jbc.271.43.26575; UNWIN N, 1993, CELL, V72, P31, DOI 10.1016/S0092-8674(05)80026-1; VERRALL S, 1992, CELL, V68, P23, DOI 10.1016/0092-8674(92)90203-O; Wang ZZ, 1996, J BIOL CHEM, V271, P27575, DOI 10.1074/jbc.271.44.27575; YONG G, 1989, J CELL BIOL, V109, P729, DOI 10.1083/jcb.109.2.729; YU XM, 1991, NATURE, V352, P64, DOI 10.1038/352064a0	46	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20513	20520		10.1074/jbc.274.29.20513	http://dx.doi.org/10.1074/jbc.274.29.20513			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400680	hybrid			2022-12-25	WOS:000081438300073
J	Chen, RH; Chang, MC; Su, YH; Tsai, YT; Kuo, ML				Chen, RH; Chang, MC; Su, YH; Tsai, YT; Kuo, ML			Interleukin-6 inhibits transforming growth factor-beta-induced apoptosis through the phosphatidylinositol 3-kinase/Akt and signal transducers and activators of transcription 3 pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE AKT; LIVER-REGENERATION; TYROSINE KINASE; HEPATOMA-CELLS; PHOSPHORYLATION; RECEPTOR; GP130; DIFFERENTIATION; INVOLVEMENT; HEPATOCYTES	The multifunctional cytokine interleukin-6 (IL-6) regulates growth and differentiation of many cell types and induces production of acute-phase proteins in hepatocytes, Here we report that IL-6 protects hepatoma cells from apoptosis induced by transforming growth factor-beta (TGF-beta), a well known apoptotic inducer in liver cells. Addition of IL-6 blocked TGF-beta-induced activation of caspase-3 while showing no effect on the induction of plasminogen activator inhibitor-1 and p15(INK4B) genes, indicating that IL-6 interferes with only a subset of TGF-beta activities. To further elucidate the mechanism of this anti-apoptotic effect of IL-6, we investigated which signaling pathway transduced by IL-6 is responsible for this effect. IL-6 stimulation of hepatoma cells induced a rapid tyrosine phosphorylation of the p85 subunit of phosphatidylinositol 3-kinase (PI 3-kinase) and its kinase activity followed by the activation of Akt. Inhibition of PI 3-kinase by wortmannin or LY294002 abolished the protection of IL-6 against TGF-beta-induced apoptosis. A dominant-negative Akt also abrogated this anti-apoptotic effect. Dominant-negative inhibition of STAT3, however, only weakly attenuated the IL-6-induced protection. Finally, inhibition of both STAT3 and PI 3-kinase by treating cells overexpressing the dominant-negative STAT3 with LY294002 completely blocked IL-6-induced survival signal. Thus, concomitant activation of the PI 3-kinase/Akt and the STAT3 pathways mediates the anti-apoptotic effect of IL-6 against TGF-beta, with the former likely playing a major role in this anti-apoptosis.	Natl Taiwan Univ, Coll Med, Inst Toxicol, Lab Mol & Cellular Toxicol, Taipei, Taiwan; Natl Taiwan Univ, Coll Med, Inst Mol Med, Taipei, Taiwan	National Taiwan University; National Taiwan University	Kuo, ML (corresponding author), Natl Taiwan Univ, Coll Med, Inst Toxicol, Lab Mol & Cellular Toxicol, Taipei, Taiwan.		Su, Yi-Hsien/F-2910-2014; Chen, Ruey-Hwa/G-6121-2019; Kuo, Min-Liang/C-4872-2009	Chen, Ruey-Hwa/0000-0001-8124-5832; 				Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; Bellido T, 1998, J BIOL CHEM, V273, P21137, DOI 10.1074/jbc.273.33.21137; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; BRAUN L, 1988, P NATL ACAD SCI USA, V85, P1539, DOI 10.1073/pnas.85.5.1539; Camargo CA, 1997, HEPATOLOGY, V26, P1513, DOI 10.1002/hep.510260619; Chen RH, 1997, CELL GROWTH DIFFER, V8, P821; Chen RH, 1998, ONCOGENE, V17, P1959, DOI 10.1038/sj.onc.1202111; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; delPeso L, 1997, SCIENCE, V278, P687; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Fan GS, 1996, ONCOGENE, V12, P1909; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; FUKUDA K, 1993, HEPATOLOGY, V18, P945, DOI 10.1002/hep.1840180428; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hirano T, 1994, CYTOKINE HDB; HOUCK KA, 1989, J CELL PHYSIOL, V141, P503, DOI 10.1002/jcp.1041410308; Hu PPC, 1998, ENDOCR REV, V19, P349, DOI 10.1210/er.19.3.349; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; LIN JK, 1992, CANCER RES, V52, P385; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; MIZUHARA H, 1994, J EXP MED, V179, P1529, DOI 10.1084/jem.179.5.1529; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; Oh H, 1998, J BIOL CHEM, V273, P9703, DOI 10.1074/jbc.273.16.9703; POWIS G, 1994, CANCER RES, V54, P2419; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; Rai RM, 1996, AM J PHYSIOL-GASTR L, V270, pG909, DOI 10.1152/ajpgi.1996.270.6.G909; Rao L, 1997, CURR OPIN GENET DEV, V7, P52, DOI 10.1016/S0959-437X(97)80109-8; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Sanchez A, 1996, J BIOL CHEM, V271, P7416, DOI 10.1074/jbc.271.13.7416; TANAKA S, 1996, CANCER RES, V56, P391; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; Xu FH, 1998, BLOOD, V92, P241, DOI 10.1182/blood.V92.1.241.413k28_241_251; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0	54	210	217	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23013	23019		10.1074/jbc.274.33.23013	http://dx.doi.org/10.1074/jbc.274.33.23013			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438468	hybrid			2022-12-25	WOS:000082012800018
J	Yamakura, T; Mihic, SJ; Harris, RA				Yamakura, T; Mihic, SJ; Harris, RA			Amino acid volume and hydropathy of a transmembrane site determine glycine and anesthetic sensitivity of glycine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-AMINOBUTYRIC-ACID; MEYER-OVERTON HYPOTHESIS; GENERAL-ANESTHESIA; GABA(A) RECEPTOR; A RECEPTOR; SUBUNIT; ALCOHOLS; CURRENTS; MEMBRANE; PROTEIN	Two specific amino acid residues in transmembrane segments (TM) 2 and 3 are critical for the enhancement of glycine receptor (GlyR) function by volatile anesthetics, To determine which physicochemical characteristics of these sites determine their roles in anesthetic actions, an extensive series of single amino acid mutations at amino acid residue 288 (Ala-288) in TM3 of the alpha 1 GlyR subunit was tested for modulation by volatile anesthetics. The mutations changed the apparent affinities of receptors for glycine; replacements with larger volumes and less hydropathy exhibited higher affinities for glycine. Potentiation by anesthetics was reduced by specific mutations at Ala-288. The molecular volume of the substituents was negatively correlated with the extent of potentiation by isoflurane, enflurane, and 1-chloro-1,2,2-trifluorocyclobutane, whereas there was no correlation between anesthetic enhancement and polarity, hydropathy, or hydrophilicity of substituents, In contrast to anesthetics, no correlation was found between the effects of the nonanesthetics 1,2-dichlorohexafluorocyclobutane or 2,3-dichlorooctafluorobutane and any physicochemical property of the substituent. These results suggest that the molecular volume and hydropathy of the amino acid at position 288 in TM3 regulate glycine and anesthetic sensitivity of the GlyR and that this residue might represent one determinant of an anesthetic binding site.	Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA; Wake Forest Univ, Sch Med, Dept Physiol & Pharmacol, Winston Salem, NC 27157 USA	University of Texas System; University of Texas Austin; Wake Forest University	Harris, RA (corresponding author), Univ Texas, Inst Mol & Cellular Biol, 2500 Speedway,MMB 1-124, Austin, TX 78712 USA.				NIAAA NIH HHS [AA11525, AA06399] Funding Source: Medline; NIGMS NIH HHS [GM47818] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM047818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA006399, R01AA011525, R01AA006399] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ABRAHAM MH, 1991, J PHARM SCI-US, V80, P719, DOI 10.1002/jps.2600800802; Amin J, 1999, MOL PHARMACOL, V55, P411; BECHADE C, 1994, BIOESSAYS, V16, P735, DOI 10.1002/bies.950161008; Belelli D, 1997, P NATL ACAD SCI USA, V94, P11031, DOI 10.1073/pnas.94.20.11031; Birnir B, 1997, J MEMBRANE BIOL, V155, P157, DOI 10.1007/s002329900167; BURNS THS, 1982, ANAESTHESIA, V37, P278, DOI 10.1111/j.1365-2044.1982.tb01099.x; Colman A., 1984, TRANSCRIPTION TRANSL, P49; Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924; DildyMayfield JE, 1996, J PHARMACOL EXP THER, V276, P1058; Downie DL, 1996, BRIT J PHARMACOL, V118, P493, DOI 10.1111/j.1476-5381.1996.tb15430.x; FRANKS NP, 1987, NATURE, V328, P113, DOI 10.1038/328113a0; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; Franks NP, 1997, NATURE, V389, P334, DOI 10.1038/38614; GRENNINGLOH G, 1990, EMBO J, V9, P771, DOI 10.1002/j.1460-2075.1990.tb08172.x; HARPAZ Y, 1994, STRUCTURE, V2, P641, DOI 10.1016/S0969-2126(00)00065-4; HARRISON NL, 1993, MOL PHARMACOL, V44, P628; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; KOBLIN DD, 1981, ANESTH ANALG, V60, P464; KOBLIN DD, 1994, ANESTH ANALG, V79, P1043; KOBLIN DD, 1981, ANESTHESIOLOGY, V54, P314, DOI 10.1097/00000542-198104000-00011; KOLTCHINE VV, 1999, IN PRESS MOL PHARM; Krasowski MD, 1998, MOL PHARMACOL, V53, P530, DOI 10.1124/mol.53.3.530; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Mascia MP, 1996, BRIT J PHARMACOL, V119, P1331, DOI 10.1111/j.1476-5381.1996.tb16042.x; Mascia MP, 1996, MOL PHARMACOL, V50, P402; Mihic SJ, 1996, J PHARMACOL EXP THER, V277, P411; MIHIC SJ, 1994, EUR J PHARM-MOLEC PH, V268, P209; MIHIC SJ, 1994, MOL PHARMACOL, V46, P851; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; MILLER KW, 1985, INT REV NEUROBIOL, V27, P1, DOI 10.1016/S0074-7742(08)60555-3; MILLER STANLEY L., 1961, PROC NATL ACAD USA, V47, P1515, DOI 10.1073/pnas.47.9.1515; North C, 1997, BIOPHYS J, V72, P1754, DOI 10.1016/S0006-3495(97)78821-0; PAULING L, 1961, SCIENCE, V134, P15, DOI 10.1126/science.134.3471.15; RUDO FG, 1974, BRIT J ANAESTH, V46, P181, DOI 10.1093/bja/46.3.181; Tang P, 1997, BIOPHYS J, V72, P1676, DOI 10.1016/S0006-3495(97)78813-1; Wick MJ, 1998, P NATL ACAD SCI USA, V95, P6504, DOI 10.1073/pnas.95.11.6504; Xu M, 1996, J GEN PHYSIOL, V107, P195, DOI 10.1085/jgp.107.2.195; Ye Q, 1998, J BIOL CHEM, V273, P3314, DOI 10.1074/jbc.273.6.3314; Zafra F, 1997, MOL NEUROBIOL, V14, P117, DOI 10.1007/BF02740653; Zamyatnin A A, 1972, Prog Biophys Mol Biol, V24, P107, DOI 10.1016/0079-6107(72)90005-3; ZIMMERMAN JM, 1968, J THEOR BIOL, V21, P170, DOI 10.1016/0022-5193(68)90069-6	41	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23006	23012		10.1074/jbc.274.33.23006	http://dx.doi.org/10.1074/jbc.274.33.23006			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438467	hybrid			2022-12-25	WOS:000082012800017
J	Lindstedt, L; Saarinen, J; Kalkkinen, N; Welgus, H; Kovanen, PT				Lindstedt, L; Saarinen, J; Kalkkinen, N; Welgus, H; Kovanen, PT			Matrix metalloproteinases-3,-7, and-12, but not-9, reduce high density lipoprotein-induced cholesterol efflux from human macrophage foam cells by truncation of the carboxyl terminus of apolipoprotein A-I - Parallel losses of pre-beta particles and the high affinity component of efflux	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATHEROSCLEROTIC PLAQUES; RHEUMATOID-ARTHRITIS; EXTRACELLULAR-MATRIX; CELLULAR CHOLESTEROL; ESCHERICHIA-COLI; SYNOVIAL-FLUID; HUMAN-PLASMA; EXPRESSION; TRANSPORT; STROMELYSIN	Matrix metalloproteinases (MMPs) have been suggested to function in remodeling of the arterial wall, but no information is available on their possible role in early atherogenesis, when cholesterol accumulates in the cells of the arterial intima, forming foam cells, Here, we incubated the major component responsible for efflux of cholesterol from foam cells, high density lipoprotein 3 (HDL3), with IMMP-1, -3, -7, -9, or -12 at 37 degrees C before adding it to cholesterol-loaded human monocyte-derived macrophages. After incubation with MMP-3, -7, or -12, the ability of HDL3 to induce the high affinity component of cholesterol efflux from the macrophage foam cells was strongly reduced, whereas preincubation with MMP-1 reduced cholesterol efflux only slightly and preincubation with MMP-9 had no effect. These differential effects of the various MMPs were reflected in their differential abilities to degrade the small pre-beta migrating particles present in the HDL3 fraction. NH2-terminal sequence and mass spectrometric analyses of the apolipoprotein (apo) A-I fragments generated by MMPs revealed that those MMPs that strongly reduced cholesterol efflux (MMPs-3, -7, and -12) cleaved the COOH-terminal region of apoA-I and produced a major fragment of about 22 kDa, whereas MMPs-1 and -9, which had little and no effect on cholesterol efflux, degraded apoA-I only slightly and not at all, respectively, These results show, for the first time, that some members of the MMP family can degrade the apoA-I of HDL3, so blocking cholesterol efflux from macrophage foam cells. This expansion of the substrate repertoire of MMPs to include apoA suggests that these proteinases are directly involved in the accumulation of cholesterol in atherosclerotic lesions.	Wihuri Res Inst, Helsinki 00350, Finland; Univ Helsinki, Prot Chem Lab, Inst Biotechnol, FIN-00014 Helsinki, Finland; Washington Univ, Sch Med, Barnes Jewish Hosp, Dept Med,Div Dermatol, St Louis, MO 63110 USA	Wihuri Research Institute; University of Helsinki; Barnes-Jewish Hospital; Washington University (WUSTL)	Kovanen, PT (corresponding author), Wihuri Res Inst, Kalliolinnantie 4, Helsinki 01400, Finland.	petri.kovanen@wihuri.fimnet.fi	Kalkkinen, Nisse EJ/B-3923-2010					Barter Philip, 1993, Current Opinion in Lipidology, V4, P210, DOI 10.1097/00041433-199306000-00006; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; Beekman B, 1997, FEBS LETT, V418, P305, DOI 10.1016/S0014-5793(97)01371-9; Blaser J, 1996, CLIN CHIM ACTA, V244, P17, DOI 10.1016/0009-8981(95)06172-X; BROWN MS, 1975, P NATL ACAD SCI USA, V72, P2925, DOI 10.1073/pnas.72.8.2925; CASTRO GR, 1988, BIOCHEMISTRY-US, V27, P25, DOI 10.1021/bi00401a005; COCKERILL GW, 1995, ARTERIOSCL THROM VAS, V15, P1987, DOI 10.1161/01.ATV.15.11.1987; DALTON MB, 1993, J BIOL CHEM, V268, P19274; DOLLERY CM, 1995, CIRC RES, V77, P863, DOI 10.1161/01.RES.77.5.863; DUELL PB, 1991, DIABETES, V40, P377, DOI 10.2337/diabetes.40.3.377; FIELDING CJ, 1995, J LIPID RES, V36, P211; FRANCONE OL, 1990, EUR HEART J, V11, P218, DOI 10.1093/eurheartj/11.suppl_E.218; GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619; Gronski TJ, 1997, J BIOL CHEM, V272, P12189, DOI 10.1074/jbc.272.18.12189; Halpert I, 1996, P NATL ACAD SCI USA, V93, P9748, DOI 10.1073/pnas.93.18.9748; HARRIS ED, 1972, BIOCHIM BIOPHYS ACTA, V258, P566, DOI 10.1016/0005-2744(72)90249-5; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HENNEY AM, 1991, P NATL ACAD SCI USA, V88, P8154, DOI 10.1073/pnas.88.18.8154; JAUHIAINEN M, 1993, J BIOL CHEM, V268, P4032; JI Y, 1995, J BIOL CHEM, V270, P11290, DOI 10.1074/jbc.270.19.11290; Johnson JL, 1998, ARTERIOSCL THROM VAS, V18, P1707, DOI 10.1161/01.ATV.18.11.1707; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; Kahari VM, 1997, EXP DERMATOL, V6, P199, DOI 10.1111/j.1600-0625.1997.tb00164.x; KUNITAKE ST, 1990, ARTERIOSCLEROSIS, V10, P25, DOI 10.1161/01.ATV.10.1.25; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee M, 1999, ARTERIOSCL THROM VAS, V19, P1066, DOI 10.1161/01.ATV.19.4.1066; LEE M, 1992, ARTERIOSCLER THROMB, V12, P1329, DOI 10.1161/01.ATV.12.11.1329; LEPPERT D, 1995, FASEB J, V9, P1473, DOI 10.1096/fasebj.9.14.7589989; LEVINE DM, 1993, P NATL ACAD SCI USA, V90, P12040, DOI 10.1073/pnas.90.24.12040; Lindstedt L, 1996, J CLIN INVEST, V97, P2174, DOI 10.1172/JCI118658; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCHOOMUN J, 1994, BBA-LIPID LIPID MET, V1212, P319, DOI 10.1016/0005-2760(94)90206-2; MACKNESS MI, 1993, BIOCHEM J, V294, P829, DOI 10.1042/bj2940829; Marcel YL, 1998, INT CONGR SER, V1155, P1149; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Matsumoto S, 1998, AM J PATHOL, V153, P109, DOI 10.1016/S0002-9440(10)65551-4; Mendez AJ, 1997, BBA-LIPID LIPID MET, V1346, P285, DOI 10.1016/S0005-2760(97)00031-3; MEZDOUR H, 1987, J CHROMATOGR-BIOMED, V414, P35, DOI 10.1016/0378-4347(87)80022-1; MIIDA T, 1992, BIOCHEMISTRY-US, V31, P11112, DOI 10.1021/bi00160a022; NAGANO Y, 1991, P NATL ACAD SCI USA, V88, P6457, DOI 10.1073/pnas.88.15.6457; NIKKARI ST, 1995, CIRCULATION, V92, P1393, DOI 10.1161/01.CIR.92.6.1393; NOLLY H, 1993, AM J PHYSIOL, V265, pH1209, DOI 10.1152/ajpheart.1993.265.4.H1209; ORAM JF, 1991, ARTERIOSCLER THROMB, V11, P403, DOI 10.1161/01.ATV.11.2.403; Phillips MC, 1998, ATHEROSCLEROSIS, V137, pS13, DOI 10.1016/S0021-9150(97)00312-2; Pyle LE, 1996, BIOCHEMISTRY-US, V35, P12046, DOI 10.1021/bi9609073; RADDING CM, 1960, J CLIN INVEST, V39, P1560, DOI 10.1172/JCI104177; Rodrigueza WV, 1997, ARTERIOSCL THROM VAS, V17, P383, DOI 10.1161/01.ATV.17.2.383; SCANU A, 1966, J LIPID RES, V7, P295; Shapiro SD, 1998, CURR OPIN CELL BIOL, V10, P602, DOI 10.1016/S0955-0674(98)80035-5; SIRES UI, 1995, J BIOL CHEM, V270, P1062, DOI 10.1074/jbc.270.3.1062; SIRES UI, 1994, BIOCHEM BIOPH RES CO, V204, P613, DOI 10.1006/bbrc.1994.2503; STRICKLIN GP, 1983, BIOCHEMISTRY-US, V22, P61, DOI 10.1021/bi00270a009; Sviridov D, 1996, J BIOL CHEM, V271, P33277, DOI 10.1074/jbc.271.52.33277; Tailleux A, 1996, CRIT REV CL LAB SCI, V33, P163, DOI 10.3109/10408369609083060; TANAKA K, 1993, LAB INVEST, V69, P5; TAUBER JP, 1980, J CLIN INVEST, V66, P696, DOI 10.1172/JCI109907; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; vonEckardstein A, 1996, CURR OPIN LIPIDOL, V7, P308, DOI 10.1097/00041433-199610000-00009; VONECKARDSTEIN A, 1993, J BIOL CHEM, V268, P2616; WALAKOVITS LA, 1992, ARTHRITIS RHEUM, V35, P35, DOI 10.1002/art.1780350106; WESTERMARK P, 1995, AM J PATHOL, V147, P1186; YE QZ, 1992, BIOCHEMISTRY-US, V31, P11231, DOI 10.1021/bi00160a038; Yokoyama S, 1998, BBA-LIPID LIPID MET, V1392, P1, DOI 10.1016/S0005-2760(98)00032-0	63	53	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22627	22634		10.1074/jbc.274.32.22627	http://dx.doi.org/10.1074/jbc.274.32.22627			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428843	hybrid			2022-12-25	WOS:000081868400073
J	Peng, JB; Chen, XZ; Berger, UV; Vassilev, PM; Tsukaguchi, H; Brown, EM; Hediger, MA				Peng, JB; Chen, XZ; Berger, UV; Vassilev, PM; Tsukaguchi, H; Brown, EM; Hediger, MA			Molecular cloning and characterization of a channel-like transporter mediating intestinal calcium absorption	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BORDER MEMBRANE-VESICLES; POLYCYSTIC KIDNEY-DISEASE; XENOPUS OOCYTES; RAT INTESTINE; FACILITATED DIFFUSION; BINDING PROTEIN; DROSOPHILA TRP; VITAMIN-D; CELL; GENE	Calcium is a major component of the mineral phase of bone and serves as a key intracellular second messenger. Postnatally, all bodily calcium must be absorbed from the diet through the intestine. Here we report the properties of a calcium transport protein (CaT1) cloned from rat duodenum using an expression cloning strategy in Xenopus laevis oocytes, which likely plays a key role in the intestinal uptake of calcium. CaT1 shows homology (75% amino acid sequence identity) to the apical calcium channel ECaC recently cloned from vitamin D-responsive cells of rabbit kidney and is structurally related to the capsaicin receptor and the TRP family of ion channels. Based on Northern analysis of rat tissues, a 3-kilobase CaT1 transcript is present in rat duodenum, proximal jejunum, cecum, and colon, and a 6.5-kilobase transcript is present in brain, thymus, and adrenal gland. lie situ hybridization revealed strong CaT1 mRNA expression in enterocytes of duodenum, proximal jejunum, and cecum, No signals were detected in kidney, heart, liver,lung, spleen, and skeletal muscle. When expressed in Xenopus oocytes, CaT1 mediates saturable Ca2+ uptake with a Michaelis constant of 0.44 mM. Transport of Ca2+ by CaT1 is electrogenic, voltage-dependent, and exhibits a charge/Ca2+ uptake ratio close to 2:1, indicating that CaT1-mediated Ca2+ influx is not coupled to other ions. CaT1 activity is pH-sensitive, exhibiting significant inhibition by low pH. CaT1 is also permeant to Sr2+ and Ba2+ (but not Mg2+). although the currents evoked by Sr2+ and Ba2+ are much smaller than those evoked by Ca2+. The trivalent cations Gd3+ and La3+ and the divalent cations Cu2+, Pb2+, Cd2+, Co2+, and Ni2+ (each at 100 mu M) do not evoke currents themselves, but inhibit CaT1-mediated Ca2+ transport. Fe3+, Fe2+, Mn2+, and Zn2+ have no significant effects at 100 mu M on CaT1-mediated Ca2+ transport. CaT1 mRNA levels are not responsive to 1,25-dihydroxyvitamin D-3 administration or to calcium deficiency. Our studies strongly suggest that CaT1 provides the principal mechanism for Ca2+ entry into enterocytes as part of the transcellular pathway of calcium absorption in the intestine.	Brigham & Womens Hosp, Membrane Biol Program, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Renal, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Endocrine Hypertens, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Hediger, MA (corresponding author), Harvard Univ, Inst Med, Rm 570,77 Ave Louis Pasteur, Boston, MA 02115 USA.			Hediger, Matthias/0000-0003-1946-027X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048330, R01DK041415, R01DK052005] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41415, DK48330, DK52005] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BIRGE SJ, 1987, CLIN DISORDERS MEMBR, P121; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; Bronner F., 1997, Handbook of nutritionally essential mineral elements., P13; Bronner F, 1999, J NUTR, V129, P9, DOI 10.1093/jn/129.1.9; BRONNER F, 1986, AM J PHYSIOL, V250, pG561, DOI 10.1152/ajpgi.1986.250.5.G561; BRONNER F, 1991, INT REV CYTOL, V131, P169, DOI 10.1016/S0074-7696(08)62019-7; BROWN EM, 1991, PHYSIOL REV, V71, P371, DOI 10.1152/physrev.1991.71.2.371; BUCKLEY M, 1980, ARCH BIOCHEM BIOPHYS, V202, P235, DOI 10.1016/0003-9861(80)90425-7; BURNETT CH, 1949, NEW ENGL J MED, V240, P787, DOI 10.1056/NEJM194905192402001; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Chen XZ, 1998, J BIOL CHEM, V273, P20972, DOI 10.1074/jbc.273.33.20972; Chen XZ, 1999, J BIOL CHEM, V274, P2773, DOI 10.1074/jbc.274.5.2773; Colbert HA, 1997, J NEUROSCI, V17, P8259; DASCAL N, 1987, CRIT REV BIOCHEM MOL, V22, P317, DOI 10.3109/10409238709086960; DUFLOS C, 1995, J NUTR, V125, P2348, DOI 10.1093/jn/125.9.2348; ELSHARYDAH A, 1995, GASTROENTEROLOGY, V109, P876, DOI 10.1016/0016-5085(95)90397-6; FAVUS MJ, 1985, AM J PHYSIOL, V248, pG676, DOI 10.1152/ajpgi.1985.248.6.G676; FAVUS MJ, 1986, AM J PHYSIOL, V251, pG695, DOI 10.1152/ajpgi.1986.251.5.G695; FEHER JJ, 1992, AM J PHYSIOL, V262, pC517, DOI 10.1152/ajpcell.1992.262.2.C517; FOX J, 1986, EUR J PHARMACOL, V129, P159, DOI 10.1016/0014-2999(86)90347-X; GHIJSEN WEJM, 1986, AM J PHYSIOL, V251, pG223, DOI 10.1152/ajpgi.1986.251.2.G223; GHISHAN FK, 1989, GASTROENTEROLOGY, V96, P122, DOI 10.1016/0016-5085(89)90772-5; Gillo B, 1996, P NATL ACAD SCI USA, V93, P14146, DOI 10.1073/pnas.93.24.14146; Goyer RA, 1997, ANNU REV NUTR, V17, P37, DOI 10.1146/annurev.nutr.17.1.37; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hoenderop JGJ, 1999, J BIOL CHEM, V274, P8375, DOI 10.1074/jbc.274.13.8375; HOLDSWORTH ES, 1966, BIOCHEM J, V96, P475; KARBACH U, 1991, DIGEST DIS SCI, V36, P1611, DOI 10.1007/BF01296406; KARBACH U, 1993, DIGEST DIS SCI, V38, P1815, DOI 10.1007/BF01296104; KARBACH U, 1991, GASTROENTEROLOGY, V100, P47, DOI 10.1016/0016-5085(91)90581-5; KAUNE R, 1992, BIOCHIM BIOPHYS ACTA, V1109, P187, DOI 10.1016/0005-2736(92)90082-W; KUMAR R, 1995, J CELL BIOCHEM, V57, P392, DOI 10.1002/jcb.240570304; MILLER A, 1981, BIOCHEM J, V196, P391, DOI 10.1042/bj1960391; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; Nomura H, 1998, J BIOL CHEM, V273, P25967, DOI 10.1074/jbc.273.40.25967; PANSU D, 1993, J NUTR, V123, P1396; PHILLIPS AM, 1992, NEURON, V8, P631, DOI 10.1016/0896-6273(92)90085-R; Romero MF, 1998, METHOD ENZYMOL, V296, P17; SCHEDL HP, 1985, J CLIN INVEST, V76, P1871, DOI 10.1172/JCI112181; SCHRON CM, 1995, TXB GASTROENTEROLOGY, P467; STEIN WD, 1992, J NUTR, V122, P651, DOI 10.1093/jn/122.suppl_3.651; Vezzoli G, 1999, CLIN CHEM, V45, P257; Vezzoli G, 1998, CLIN CHEM, V44, P586; WASSERMA.RH, 1966, SCIENCE, V152, P791, DOI 10.1126/science.152.3723.791; WASSERMAN RH, 1995, J NUTR, V125, pS1971, DOI 10.1093/jn/125.suppl_7.1971S; WASSERMAN RH, 1992, J NUTR, V122, P662, DOI 10.1093/jn/122.suppl_3.662; WILSON HD, 1989, AM J PHYSIOL, V257, pF446, DOI 10.1152/ajprenal.1989.257.3.F446; Wu GQ, 1998, GENOMICS, V54, P564, DOI 10.1006/geno.1998.5618; Yao Y, 1997, J GEN PHYSIOL, V109, P703, DOI 10.1085/jgp.109.6.703	51	463	491	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22739	22746		10.1074/jbc.274.32.22739	http://dx.doi.org/10.1074/jbc.274.32.22739			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428857	hybrid			2022-12-25	WOS:000081868400087
J	Waterman, H; Levkowitz, G; Alroy, I; Yarden, Y				Waterman, H; Levkowitz, G; Alroy, I; Yarden, Y			The RING finger of c-Cbl mediates desensitization of the epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; EGF RECEPTOR; V-CBL; PROTOONCOGENE; DOMAIN; REGULATOR; PRODUCT; ONCOGENE; PROTEIN; MOUSE	Ligand-induced activation of surface receptors, including the epidermal growth factor receptor (EGFR), is followed by a desensitization process involving endocytosis and receptor degradation. c-Cbl, a tyrosine phosphorylation substrate shared by several signaling pathways, accelerates desensitization by recruiting EGFR and increasing receptor polyubiquitination. Here we demonstrate that the RING type zinc finger of c-Cbl is essential for ubiquitination and subsequent desensitization of EGFR. Mutagenesis of a single cysteine residue impaired the ability of c-Cbl to enhance both downregulation and ubiquitination of EG;FR in living cells, although the mutant retained binding to the activated receptor. Consequently, the mutant form of c-Cbl acquired a dominant inhibitory function and lost the ability to inhibit signaling downstream to EGFR. In vitro reconstitution of EGFR ubiquitination implies that the RING finger plays an essential direct role in ubiquitin ligation. Our results attribute to the RING finger of c-Cbl a causative role in endocytic sorting of EGFR and desensitization of signal transduction.	Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Yarden, Y (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.		Levkowitz, Gil/AAB-9441-2019; YARDEN, YOSEF/K-1467-2012	Levkowitz, Gil/0000-0002-3896-1881; 	NATIONAL CANCER INSTITUTE [R37CA072981, R01CA072981] Funding Source: NIH RePORTER; NCI NIH HHS [CA-72981] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BLAKE TJ, 1991, ONCOGENE, V6, P653; Brzovic PS, 1998, J BIOL CHEM, V273, P7795, DOI 10.1074/jbc.273.14.7795; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Hu G, 1999, MOL CELL BIOL, V19, P724; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; Keane MM, 1999, ONCOGENE, V18, P3365, DOI 10.1038/sj.onc.1202753; KEANE MM, 1995, ONCOGENE, V10, P2367; Kwon YT, 1998, P NATL ACAD SCI USA, V95, P7898, DOI 10.1073/pnas.95.14.7898; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1996, ONCOGENE, V12, P1117; LEVKOWITZ G, 1999, IN PRESS NATURE; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Thien CBF, 1997, ONCOGENE, V15, P2909, DOI 10.1038/sj.onc.1201468; Thien CBF, 1998, IMMUNOL CELL BIOL, V76, P473, DOI 10.1046/j.1440-1711.1998.00768.x; Waterman H, 1998, J BIOL CHEM, V273, P13819, DOI 10.1074/jbc.273.22.13819; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	23	255	264	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22151	22154		10.1074/jbc.274.32.22151	http://dx.doi.org/10.1074/jbc.274.32.22151			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428778	hybrid			2022-12-25	WOS:000081868400008
J	Dairaghi, DJ; Fan, PA; McMaster, BE; Hanley, RR; Schall, TJ				Dairaghi, DJ; Fan, PA; McMaster, BE; Hanley, RR; Schall, TJ			HHV8-encoded vMIP-I selectively engages chemokine receptor CCR8 - Agonist and antagonist profiles of viral chemokines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOMA-ASSOCIATED HERPESVIRUS; KAPOSIS-SARCOMA; CUTTING EDGE; IDENTIFICATION; CELLS; ACTIVATION; GENES; I-309; PROTEINS; POXVIRUS	Uncertainty regarding viral chemokine function is mirrored by an incomplete knowledge of host chemokine receptor usage by the virally encoded proteins. One such molecule is vMIP-I, a C-C type chemokine of undefined function and binding specificity, encoded by the Kaposi's sarcoma herpesvirus HHV-8. We report here that vMIP-I binds to and induces cytosolic [Ca2+] signals in human T cells selectively through CCR8, a CC chemokine receptor associated with Th2 lymphocytes, Furthermore, using a panel of 65 different human, viral, and rodent chemokines, we have established a comprehen sive ligand binding "fingerprint" for CCR8. The receptor exhibits marked "high" affinity (K-d < 15 nM) only for four chemokines, three of them of viral origin: vMIP-I, vMIP-II, VMCC-I, and human I-309, A previously unreported second class of lower affinity ligands includes MCP-3 and possibly two other viral chemokines. vMIP-I and I-309 appear to act as CCR8 agonists: binding to and inducing cytosolic [Ca2+] elevation through the receptor. By contrast, vMIP-II and vMCC-I act as potent antagonists: binding without inducing signaling, and blocking the effects of I-309 and vMIP-I. These results suggest a ligand hierarchy for CCR8, identifying vMIP-I as a selective. viral chemokine agonist, CCR8 may thus engage a specific subset of chemokines with the potential to regulate each other during viral infection and immune regulation.	ChemoCentryx, Div Mol Pharmacol, San Carlos, CA 94070 USA; ChemoCentryx, Div Discovery Biol, San Carlos, CA 94070 USA		Schall, TJ (corresponding author), ChemoCentryx, Div Discovery Biol, 1539 Ind Rd, San Carlos, CA 94070 USA.							Bacon KB, 1998, J IMMUNOL, V160, P1894; Bacon Kevin B., 1998, P753; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Bernardini G, 1998, EUR J IMMUNOL, V28, P582, DOI 10.1002/(SICI)1521-4141(199802)28:02<582::AID-IMMU582>3.0.CO;2-A; Bodaghi B, 1998, J EXP MED, V188, P855, DOI 10.1084/jem.188.5.855; BOSCHOFF C, 1997, SCIENCE, V278, P290; Cha TA, 1996, J VIROL, V70, P78, DOI 10.1128/JVI.70.1.78-83.1996; D'Ambrosio D, 1998, J IMMUNOL, V161, P5111; Dairaghi DJ, 1997, J BIOL CHEM, V272, P28206, DOI 10.1074/jbc.272.45.28206; Damon I, 1998, P NATL ACAD SCI USA, V95, P6403, DOI 10.1073/pnas.95.11.6403; Dittmer D, 1998, BIOESSAYS, V20, P367, DOI 10.1002/(SICI)1521-1878(199805)20:5<367::AID-BIES3>3.0.CO;2-L; Goya I, 1998, J IMMUNOL, V160, P1975; Kledal TN, 1997, SCIENCE, V277, P1656, DOI 10.1126/science.277.5332.1656; McFadden G, 1998, SEMIN CELL DEV BIOL, V9, P359, DOI 10.1006/scdb.1998.0245; Moore PS, 1996, SCIENCE, V274, P1739, DOI 10.1126/science.274.5293.1739; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; Nicholas J, 1997, J VIROL, V71, P1963, DOI 10.1128/JVI.71.3.1963-1974.1997; Nicholas J, 1997, NAT MED, V3, P287, DOI 10.1038/nm0397-287; PENFOLD MET, 1999, IN PRESS P NATL ACAD; Roos RS, 1997, J BIOL CHEM, V272, P17251, DOI 10.1074/jbc.272.28.17251; SAEDERUP N, 1999, IN PRESS P NATL ACAD; Senkevich TG, 1996, SCIENCE, V273, P813, DOI 10.1126/science.273.5276.813; Sozzani S, 1998, BLOOD, V92, P4036, DOI 10.1182/blood.V92.11.4036.423k17_4036_4039; Tiffany HL, 1997, J EXP MED, V186, P165, DOI 10.1084/jem.186.1.165; VanSnick J, 1996, J IMMUNOL, V157, P2570; Weiss RA, 1996, NAT MED, V2, P277, DOI 10.1038/nm0396-277; Zingoni A, 1998, J IMMUNOL, V161, P547	27	151	175	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21569	21574		10.1074/jbc.274.31.21569	http://dx.doi.org/10.1074/jbc.274.31.21569			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419462	hybrid			2022-12-25	WOS:000081721100015
J	Olland, S; Wang, JC				Olland, S; Wang, JC			Catalysis of ATP hydrolysis by two NH2-terminal fragments of yeast DNA topoisomerase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL FRAGMENT; GYRASE-B-PROTEIN; 2-GATE MECHANISM; BINDING; ENZYME; TRANSPORT; BISDIOXOPIPERAZINES; PROTEOLYSIS; DEPENDENCE; ICRF-159	Catalysis of ATP hydrolysis by two NH2-terminal fragments of yeast DNA topoisomerase II was studied in the absence and presence of DNA, and in the absence and presence of inhibitor ICRF-193, The results indicate that purified Top2-(1-409), a fragment containing the NH,terminal 409 amino acids of the yeast enzyme, is predominantly monomeric, with a low level of ATPase owing to weak association of two monomers to form a catalytically active dimer, The ATPase activity of Top2-(1-409) is independent of DNA in a buffer containing 100 mM NaCl, in which intact yeast DNA topoisomerase II exhibits robust DNA-dependent ATPase and DNA transport activities. Purified Top2-(1-660), a fragment containing the NH2-terminal 660 amino acid of the yeast enzyme, appears to be dimeric in the absence or presence of DNA, and the ATPase activity of the protein is significantly stimulated by DNA. These results are consistent with a model in which binding of an intact DNA topoisomerase II to DNA places the various subfragments of the enzyme in a way that makes the intramolecular dimerization of the ATPase domains more favorable. We believe that this alignment of subfragments is mainly achieved through the binding of the enzyme to the DNA segment within which the enzyme makes transient breaks. The ATPase activity of Top2-(1-409) is inhibited by ICRF-193, suggesting that the bisdioxopiperazine class of DNA topoisomerase II inhibitors directly interacts with the paired ATPase domains of the enzyme.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Wang, JC (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.				NIGMS NIH HHS [GM24544] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024544, R01GM024544] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALI JA, 1993, BIOCHEMISTRY-US, V32, P2717, DOI 10.1021/bi00061a033; ALI JA, 1995, BIOCHEMISTRY-US, V34, P9801, DOI 10.1021/bi00030a018; Andoh T, 1998, BBA-GENE STRUCT EXPR, V1400, P155, DOI 10.1016/S0167-4781(98)00133-X; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; Berger JM, 1998, P NATL ACAD SCI USA, V95, P7876, DOI 10.1073/pnas.95.14.7876; BROWN PO, 1979, P NATL ACAD SCI USA, V76, P6110, DOI 10.1073/pnas.76.12.6110; Caron P R, 1994, Adv Pharmacol, V29B, P271; Chang S, 1998, J BIOL CHEM, V273, P19822, DOI 10.1074/jbc.273.31.19822; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; Gardiner LP, 1998, BIOCHEMISTRY-US, V37, P16997, DOI 10.1021/bi9818321; GOTO T, 1984, J BIOL CHEM, V259, P422; Hammonds TR, 1997, J BIOL CHEM, V272, P32696, DOI 10.1074/jbc.272.51.32696; Kampranis SC, 1998, J BIOL CHEM, V273, P22606, DOI 10.1074/jbc.273.35.22606; Li W, 1997, J BIOL CHEM, V272, P31190, DOI 10.1074/jbc.272.49.31190; LINDSLEY JE, 1993, J BIOL CHEM, V268, P8096; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; LIU LF, 1980, CELL, V19, P697, DOI 10.1016/S0092-8674(80)80046-8; LIU LF, 1979, NATURE, V281, P456, DOI 10.1038/281456a0; Liu QY, 1999, P NATL ACAD SCI USA, V96, P881, DOI 10.1073/pnas.96.3.881; Maxwell A, 1997, TRENDS MICROBIOL, V5, P102, DOI 10.1016/S0966-842X(96)10085-8; MAXWELL A, 1984, J BIOL CHEM, V259, P4472; MILLER KG, 1981, J BIOL CHEM, V256, P9334; MIZUUCHI K, 1978, P NATL ACAD SCI USA, V75, P5960, DOI 10.1073/pnas.75.12.5960; MORRICAL SW, 1986, BIOCHEMISTRY-US, V25, P1482, DOI 10.1021/bi00355a003; Morris SNK, 1999, J BIOL CHEM, V274, P3446, DOI 10.1074/jbc.274.6.3446; Nitiss JL, 1996, EUR J CANCER, V32A, P958, DOI 10.1016/0959-8049(96)00056-1; Roca J, 1996, P NATL ACAD SCI USA, V93, P4057, DOI 10.1073/pnas.93.9.4057; ROCA J, 1994, CELL, V77, P609, DOI 10.1016/0092-8674(94)90222-4; ROCA J, 1994, P NATL ACAD SCI USA, V91, P1781, DOI 10.1073/pnas.91.5.1781; Sehested M, 1998, CANCER RES, V58, P1460; SUGINO A, 1978, P NATL ACAD SCI USA, V75, P4838, DOI 10.1073/pnas.75.10.4838; Tingey AP, 1996, NUCLEIC ACIDS RES, V24, P4868, DOI 10.1093/nar/24.24.4868; Wang JC, 1998, Q REV BIOPHYS, V31, P107, DOI 10.1017/S0033583598003424; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0	35	39	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21688	21694		10.1074/jbc.274.31.21688	http://dx.doi.org/10.1074/jbc.274.31.21688			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419479	hybrid			2022-12-25	WOS:000081721100032
J	Patel, AB; Srivastava, S; Phadke, RS				Patel, AB; Srivastava, S; Phadke, RS			Interaction of 7-hydroxy-8-(phenylazo) 1,3-naphthalenedisulfonate with bovine plasma albumin - Spectroscopic studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; CIRCULAR-DICHROISM; SERUM-ALBUMIN; FLUORESCENCE; SPECTRA; INHIBITION; RELAXATION; RESIDUES; KINETICS; BINDING	Interaction of Orange G (OG) with bovine plasma albumin (BPA) has been investigated using NMR, W-visible absorption, CD, and fluorescence techniques. The bound conformation of OG is a compact structure with N9-N10 bond in a non-planar syn conformation, The binding causes a decrease in the 478-nm absorption band of OG. The analysis of the binding isotherm generated from UV-visible absorption measurements gives a dissociation constant of 10 mu M and stoichiometry 1:1 for BPA OG complex. Dissociation constant is invariant in the pH range 5.0-8.0 and is similar to 20 times higher at pH 4.0 than its value at pH 7.0, Near and far UV-CD studies indicate alterations in the helical content and in the tertiary structure of the protein on complexation. The binding induces (-) and (+) CD at 335 nm and 465 nm, respectively. The binding also results into an increase in the steady state fluorescence anisotropy of OG without affecting emission maximum and quantum yield. Fluorescence data indicate that quenching of Trp fluorescence by OG is static in nature and OG selectively binds near Trp-135, Observation of similar rotational correlation time for BPA and BPA.OG complex indicates that the overall globular structure of BPA remains unaltered on binding despite certain internal rearrangement in the protein structure.	Tata Inst Fundamental Res, Dept Chem Sci, Mumbai 400005, India	Tata Institute of Fundamental Research (TIFR)	Srivastava, S (corresponding author), Tata Inst Fundamental Res, Dept Chem Sci, Homi Bhabha Rd, Mumbai 400005, India.	sudha@tifr.res.in						AOKI K, 1957, J AM CHEM SOC, V79, P3385, DOI 10.1021/ja01570a021; BABA M, 1993, ANTIVIR CHEM CHEMOTH, V4, P229, DOI 10.1177/095632029300400405; BALZARINI J, 1986, INT J CANCER, V37, P451, DOI 10.1002/ijc.2910370318; BEECHEM JM, 1985, ANNU REV BIOCHEM, V54, P43, DOI 10.1146/annurev.biochem.54.1.43; BENNHOLD H, 1965, TRANSPORT FUNCTION P, P1; BRINKWORTH RI, 1992, BIOCHEM BIOPH RES CO, V188, P624, DOI 10.1016/0006-291X(92)91102-V; CARTER DC, 1994, ADV PROTEIN CHEM, V45, P153; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; FREEMAN R, 1970, J CHEM PHYS, V53, P4103, DOI 10.1063/1.1673891; GRINVALD A, 1974, ANAL BIOCHEM, V59, P583, DOI 10.1016/0003-2697(74)90312-1; JAYNES ET, 1983, PAPERS PROBABILITY S, P401; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; JOZEFOWICZ M, 1984, PURE APPL CHEM, V56, P1335, DOI 10.1351/pac198456101335; KALOWICZ JR, 1983, PRINCIPLES FLUORESCE, P19; Kelly SM, 1997, BBA-PROTEIN STRUCT M, V1338, P161, DOI 10.1016/S0167-4838(96)00190-2; KLOTZ IM, 1946, J AM CHEM SOC, V68, P1486, DOI 10.1021/ja01212a030; KROIS D, 1995, J CHEM SOC PERK T 2, P489, DOI 10.1039/p29950000489; KRONMAN MJ, 1971, PHOTOCHEM PHOTOBIOL, V14, P113, DOI 10.1111/j.1751-1097.1971.tb06157.x; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; Lakowicz J. R., 1983, PRINCIPLES FLUORESCE, P19; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; LEONARD WJ, 1963, J BIOL CHEM, V238, P1984; LIAN LY, 1994, METHOD ENZYMOL, V239, P657; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; MARGINEDAROMEU A, 1976, BIOCHIM BIOPHYS ACTA, V439, P175, DOI 10.1016/0005-2795(76)90174-4; MOHAN P, 1991, Antiviral Chemistry and Chemotherapy, V2, P215; MOHAN P, 1992, PHARM RES-DORDR, V9, P703, DOI 10.1023/A:1015882901078; MUNRO AW, 1994, FEBS LETT, V343, P70, DOI 10.1016/0014-5793(94)80609-8; MUNRO I, 1979, P NATL ACAD SCI USA, V76, P56, DOI 10.1073/pnas.76.1.56; Ojala WH, 1996, J AM CHEM SOC, V118, P2131, DOI 10.1021/ja951121f; PALMER AG, 1991, J MAGN RESON, V93, P151, DOI 10.1016/0022-2364(91)90036-S; PETERS T, 1985, ADV PROTEIN CHEM, V37, P161, DOI 10.1016/S0065-3233(08)60065-0; Peters T., 1996, ALL ALBUMIN BIOCH GE; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; ROBBINS DJ, 1985, BIOCHEMISTRY-US, V24, P7250, DOI 10.1021/bi00346a034; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; TEALE FWJ, 1957, BIOCHEM J, V65, P476, DOI 10.1042/bj0650476; WEAVER JL, 1992, ANTIVIR CHEM CHEMOTH, V3, P147, DOI 10.1177/095632029200300303; YIP RW, 1993, J PHYS CHEM-US, V97, P10458, DOI 10.1021/j100142a032	40	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21755	21762		10.1074/jbc.274.31.21755	http://dx.doi.org/10.1074/jbc.274.31.21755			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419489	hybrid			2022-12-25	WOS:000081721100042
J	Sbrissa, D; Ikonomov, OC; Shisheva, A				Sbrissa, D; Ikonomov, OC; Shisheva, A			PIKfyve, a mammalian ortholog of yeast Fab1p lipid kinase, synthesizes 5-phosphoinositides - Effect of insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PHOSPHATIDYLINOSITOL 4-KINASE; PHOSPHOINOSITIDE KINASES; SIGNAL-TRANSDUCTION; VACUOLE FUNCTION; 5-KINASE; 3-KINASE; WORTMANNIN; CLONING; 3,5-BISPHOSPHATE; STIMULATION	One or more free hydroxyls of the phosphatidylinositol (PtdIns) head group undergo enzymatic phosphorylation, yielding phosphoinositides (PIs) with key functions in eukaryotic cellular regulation. Two such species, PtdIns 5-P and PtdIns 3,5-P-2, have now been identified in mammalian cells, but their biosynthesis remains unclear. We have isolated a novel mammalian PI kinase, p235, whose exact substrate specificity remained to be determined (Shisheva, A., Sbrissa, D,, and Ikonomov, O. (1999) Mol. Cell. Biol. 19, 623-634). Here we report that recombinant p235 expressed in COS cells, like the authentic p235 in adipocytes, displays striking specificity for PtdIns over PI substrates and generates two products identified as PtdIns 5-P and PtdIns 3,5-P, by HPLC analyses. Synthetic PtdIns 3-P substrates were also converted to PtdIns 3,5-P, but to a substantially lesser extent than PtdIns isolated from natural sources. Important properties of the p235 PI 5-kinase include high sensitivity to nonionic detergents and relative resistance to wortmannin and adenosine. By analyzing deletion mutants in a heterologous cell system, we determined that in addition to the predicted catalytic domain other regions of the molecule are critical for the p235 enzymatic activity. HPLC resolution of monophosphoinositide products, generated by p235 immune complexes derived from lysates of 3T3-L1 adipocytes acutely stimulated with insulin, revealed essentially the same PtdIns 5-P levels as the corresponding p235 immune complexes of resting cells. However, the acute insulin action resulted in an increase of a wortmannin-sensitive PtdIns 3-P peak, suggestive of a plausible recruitment of wortmannin-sensitive PI 3-kinase(s) to p235. In conclusion, mouse p235 (renamed here PIKfyve) displays a strong in vitro activity for PtdIns 5-P and PtdIns 3,5-P, generation, implying PIKfyve has a key role in their biosynthesis.	Wayne State Univ, Sch Med, Dept Physiol, Detroit, MI 48201 USA	Wayne State University	Shisheva, A (corresponding author), Wayne State Univ, Sch Med, Dept Physiol, 540 E Canfield, Detroit, MI 48201 USA.	ashishev@moose.med.wayne.edu						Alb JG, 1996, CURR OPIN CELL BIOL, V8, P534, DOI 10.1016/S0955-0674(96)80032-9; BORONENKOV IV, 1995, J BIOL CHEM, V270, P2881, DOI 10.1074/jbc.270.7.2881; Burd CG, 1998, MOL CELL, V2, P157, DOI 10.1016/S1097-2765(00)80125-2; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Castellino AM, 1997, J BIOL CHEM, V272, P5861, DOI 10.1074/jbc.272.9.5861; Cooke FT, 1998, CURR BIOL, V8, P1219, DOI 10.1016/S0960-9822(07)00513-1; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; Dove SK, 1997, NATURE, V390, P187, DOI 10.1038/36613; Ellis RJ, 1998, TRENDS BIOCHEM SCI, V23, P43, DOI 10.1016/S0968-0004(98)01175-X; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Gary JD, 1998, J CELL BIOL, V143, P65, DOI 10.1083/jcb.143.1.65; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; Loijens JC, 1996, ADV ENZYME REGUL, V36, P115, DOI 10.1016/0065-2571(95)00005-4; Meyers R, 1997, J BIOL CHEM, V272, P4384, DOI 10.1074/jbc.272.7.4384; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; OKADA T, 1994, J BIOL CHEM, V269, P3563; Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771; Rameh LE, 1997, NATURE, V390, P192, DOI 10.1038/36621; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Shisheva A, 1999, MOL CELL BIOL, V19, P623; SHISHEVA A, 1994, J BIOL CHEM, V269, P23865; SHISHEVA A, 1995, EUR J CELL BIOL, V68, P143; SHISHEVA A, 1994, MOL CELL BIOL, V14, P3459, DOI 10.1128/MCB.14.5.3459; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; Summers SA, 1997, BIOCHEM SOC T, V25, P981, DOI 10.1042/bst0250981; THELEN M, 1994, P NATL ACAD SCI USA, V91, P4960, DOI 10.1073/pnas.91.11.4960; Toker A, 1998, CURR OPIN CELL BIOL, V10, P254, DOI 10.1016/S0955-0674(98)80148-8; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Tolias KF, 1998, J BIOL CHEM, V273, P18040, DOI 10.1074/jbc.273.29.18040; Virbasius JV, 1996, J BIOL CHEM, V271, P13304, DOI 10.1074/jbc.271.23.13304; Whiteford CC, 1997, BIOCHEM J, V323, P597, DOI 10.1042/bj3230597; WONG K, 1994, J BIOL CHEM, V269, P28878; YAMAMOTO A, 1995, MOL BIOL CELL, V6, P525, DOI 10.1091/mbc.6.5.525; Zhang XL, 1997, J BIOL CHEM, V272, P17756, DOI 10.1074/jbc.272.28.17756	39	189	191	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21589	21597		10.1074/jbc.274.31.21589	http://dx.doi.org/10.1074/jbc.274.31.21589			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419465	hybrid			2022-12-25	WOS:000081721100018
J	Hartigan, JA; Johnson, GVW				Hartigan, JA; Johnson, GVW			Transient increases in intracellular calcium result in prolonged site-selective increases in tau phosphorylation through a glycogen synthase kinase 3 beta-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEINS; HUMAN CORTICAL-NEURONS; PHOSPHOLIPASE C-GAMMA; HELICAL FILAMENT-TAU; ALZHEIMERS-DISEASE; TYROSINE KINASE; DYNAMIC INSTABILITY; GROWTH-FACTOR; IN-SITU; CELLS	Calcium is a universal intracellular signaling molecule, Through variations in both the amplitude and frequency of intracellular calcium increases, the same calcium ion can elicit different responses. In this report, we investigated the effect of a calcium transient, lasting 2-5 min, on alterations in the phosphorylation state of the cytoskeletal protein, tau, Transient increases in calcium result in a prolonged (1-4 h) similar to 60% increase in tau phosphorylation at the Tau-1 epitope, These increases in tau phosphorylation appear to be more dependent upon the duration of the increase in intracellular calcium and less on the amplitude, The calcium-induced increases in tau phosphorylation are not dependent upon protein synthesis, nor are protein kinase C or calcium/calmodulin-dependent protein kinase II involved in the response. However, the calcium-induced increase in tau phosphorylation was inhibited by lithium, a noncompetitive inhibitor of glycogen synthase kinase-3 beta (GSK-3 beta), and by the tyrosine kinase inhibitor, genistein, Furthermore, transient increases in calcium resulted in a prolonged increase in GSK-3 beta tyrosine phosphorylation concomitant with the increase in tau phosphorylation, Therefore, this study is the first to indicate that transient increases in intracellular calcium result in increased tyrosine phosphorylation and activation of GSK-3 beta which subsequently results in a sustained increase in the phosphorylation state of tau.	Univ Alabama, Dept Psychiat & Behav Neurobiol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Johnson, GVW (corresponding author), Univ Alabama, Dept Psychiat, SC 1061,1720 7th Ave S, Birmingham, AL 35294 USA.		Johnson, Gail V.W./K-4723-2012	Johnson, Gail V.W./0000-0003-3464-0404	NATIONAL INSTITUTE ON AGING [P01AG006569] Funding Source: NIH RePORTER; NIA NIH HHS [AG06569] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adamec E, 1997, BRAIN RES, V757, P93, DOI 10.1016/S0006-8993(97)00166-2; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; Berridge MJ, 1997, NATURE, V386, P759, DOI 10.1038/386759a0; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; Black MM, 1996, J NEUROSCI, V16, P3601; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; BRANDT R, 1994, J BIOL CHEM, V269, P11776; Carmel G, 1996, J BIOL CHEM, V271, P32789, DOI 10.1074/jbc.271.51.32789; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; DREWES G, 1995, J BIOL CHEM, V270, P7679, DOI 10.1074/jbc.270.13.7679; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Ebneth A, 1998, J CELL BIOL, V143, P777, DOI 10.1083/jcb.143.3.777; ELDARFINKELMAN H, 1995, J BIOL CHEM, V270, P987, DOI 10.1074/jbc.270.3.987; Fields RD, 1997, J NEUROSCI, V17, P7252; FLEMING LM, 1995, BIOCHEM J, V309, P41, DOI 10.1042/bj3090041; GOEDERT M, 1995, NEUROSCI LETT, V189, P167, DOI 10.1016/0304-3940(95)11484-E; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; Hanger DP, 1998, J NEUROCHEM, V71, P2465; Hong M, 1997, J BIOL CHEM, V272, P25326, DOI 10.1074/jbc.272.40.25326; Hong M, 1997, J BIOL CHEM, V272, P19547, DOI 10.1074/jbc.272.31.19547; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; Hwang SC, 1996, J BIOL CHEM, V271, P18342, DOI 10.1074/jbc.271.31.18342; Illenberger S, 1998, MOL BIOL CELL, V9, P1495, DOI 10.1091/mbc.9.6.1495; JAMESON L, 1980, BIOCHEMISTRY-US, V19, P2472, DOI 10.1021/bi00552a027; Jenkins SM, 1998, NEUROREPORT, V9, P67, DOI 10.1097/00001756-199801050-00014; Johnson Gail V. W., 1998, Alzheimer's Disease Review, V3, P125; Kempf M, 1996, J NEUROSCI, V16, P5583; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Lee G, 1998, J CELL SCI, V111, P3167; Lesort M, 1999, J NEUROCHEM, V72, P576, DOI 10.1046/j.1471-4159.1999.0720576.x; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LINDWALL G, 1984, J BIOL CHEM, V259, P5301; Lovestone S, 1996, NEUROSCIENCE, V73, P1145, DOI 10.1016/0306-4522(96)00126-1; MAMIYA N, 1993, BIOCHEM BIOPH RES CO, V195, P608, DOI 10.1006/bbrc.1993.2089; Mandell JW, 1996, J NEUROSCI, V16, P5727; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; MATTSON MP, 1991, MOL CHEM NEUROPATHOL, V15, P117, DOI 10.1007/BF03159951; MORISHIMAKAWASHIMA M, 1995, J BIOL CHEM, V270, P823, DOI 10.1074/jbc.270.2.823; OTVOS L, 1994, J NEUROSCI RES, V39, P669, DOI 10.1002/jnr.490390607; PLYTE SE, 1992, BIOCHIM BIOPHYS ACTA, V1114, P147, DOI 10.1016/0304-419X(92)90012-N; Quinlan EM, 1996, J NEUROSCI, V16, P7627; SatoHarada R, 1996, CELL STRUCT FUNCT, V21, P283, DOI 10.1247/csf.21.283; SEUBERT P, 1995, J BIOL CHEM, V270, P18917, DOI 10.1074/jbc.270.32.18917; Shea TB, 1997, J NEUROSCI RES, V49, P759, DOI 10.1002/(SICI)1097-4547(19970915)49:6<759::AID-JNR10>3.0.CO;2-N; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Sweatt JD, 1998, J NEUROCHEM, V71, P1075; SZENDREI GI, 1993, J NEUROSCI RES, V34, P243, DOI 10.1002/jnr.490340212; TAKAHASHI M, 1994, J NEUROCHEM, V63, P245; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; TRINCZEK B, 1995, MOL BIOL CELL, V6, P1887, DOI 10.1091/mbc.6.12.1887; Xie HQ, 1998, J NEUROSCI RES, V53, P153, DOI 10.1002/(SICI)1097-4547(19980715)53:2<153::AID-JNR4>3.3.CO;2-5; Xiong WC, 1998, J CELL SCI, V111, P1981; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; Zhang JW, 1998, J BIOL CHEM, V273, P2288, DOI 10.1074/jbc.273.4.2288; [No title captured]	58	108	111	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21395	21401		10.1074/jbc.274.30.21395	http://dx.doi.org/10.1074/jbc.274.30.21395			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409701	hybrid			2022-12-25	WOS:000081613100092
J	Nardi-Dei, V; Kurihara, T; Park, C; Miyagi, M; Tsunasawa, S; Soda, K; Esaki, N				Nardi-Dei, V; Kurihara, T; Park, C; Miyagi, M; Tsunasawa, S; Soda, K; Esaki, N			DL-2-haloacid dehalogenase from Pseudomonas sp 113 is a new class of dehalogenase catalyzing hydrolytic dehalogenation not involving enzyme-substrate ester intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-2-HALO ACID DEHALOGENASE; HALOALKANE DEHALOGENASE; REACTION-MECHANISM; SP YL; STEREOSPECIFICITY; PURIFICATION; CLONING; BIOCHEMISTRY; MUTAGENESIS; GENETICS	DL-2-Haloacid dehalogenase from Pseudomonas sp, 113 (DL-DEX 113) catalyzes the hydrolytic dehalogenation of D- and L-2-haloalkanoic acids, producing the corresponding L- and D-2-hydroxyalkanoic acids, respectively. Every halidohydrolase studied so far (L-2-haloacid dehalogenase, haloalkane dehalogenase, and 4-chlorobenzoyl-CoA dehalogenase) has an active site carboxylate group that attacks the substrate carbon atom bound to the halogen atom, leading to the formation of an ester intermediate. This is subsequently hydrolyzed, resulting in the incorporation of an oxygen atom of the solvent water molecule into the carboxylate group of the enzyme, In the present study, we analyzed the reaction mechanism of DL-DEX 113, When a single turnover reaction of DL-DEX 113 was carried out with a large excess of the enzyme in (H2O)-O-18 with a 10 times smaller amount of the substrate, either D- or L-2-chloropropionate, the major product was found to be O-18-labeled lactate by ion-spray mass spectrometry. After a multiple turnover reaction in (H2O)-O-18, the enzyme was digested with trypsin or lysyl endopeptidase, and the molecular masses of the peptide fragments were measured with an ionspray mass spectrometer, No peptide fragments contained O-18. These results indicate that the (H2O)-O-18 of the solvent directly attacks the alpha-carbon of 2-haloalkanoic acid to displace the halogen atom. This is the first example of an enzymatic hydrolytic dehalogenation that proceeds without producing an ester intermediate.	Kyoto Univ, Inst Chem Res, Microbial Biochem Lab, Uji, Kyoto 6110011, Japan; Takara Shuzo Co Ltd, Biotechnol Res Labs, Shiga 5250055, Japan	Kyoto University; Takara Holdings Inc.	Esaki, N (corresponding author), Kyoto Univ, Inst Chem Res, Microbial Biochem Lab, Uji, Kyoto 6110011, Japan.							BABBITT PC, 1992, BIOCHEMISTRY-US, V31, P5594, DOI 10.1021/bi00139a024; BARTH PT, 1992, J BACTERIOL, V174, P2612, DOI 10.1128/jb.174.8.2612-2619.1992; Benning MM, 1996, BIOCHEMISTRY-US, V35, P8103, DOI 10.1021/bi960768p; CROOKS GP, 1995, J AM CHEM SOC, V117, P10791, DOI 10.1021/ja00149a001; FETZNER S, 1994, MICROBIOL REV, V58, P641, DOI 10.1128/MMBR.58.4.641-685.1994; Hisano T, 1996, J BIOL CHEM, V271, P20322, DOI 10.1074/jbc.271.34.20322; HYLAND LJ, 1991, BIOCHEMISTRY-US, V30, P8454, DOI 10.1021/bi00098a024; IWASAKI I, 1956, B CHEM SOC JPN, V29, P860, DOI 10.1246/bcsj.29.860; JANSSEN DB, 1989, J BACTERIOL, V171, P6791, DOI 10.1128/jb.171.12.6791-6799.1989; JANSSEN DB, 1994, ANNU REV MICROBIOL, V48, P163, DOI 10.1146/annurev.mi.48.100194.001115; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEIGH JA, 1988, FEMS MICROBIOL LETT, V49, P353, DOI 10.1111/j.1574-6968.1988.tb02756.x; Li YF, 1998, J BIOL CHEM, V273, P15035, DOI 10.1074/jbc.273.24.15035; LIU JQ, 1995, J BIOL CHEM, V270, P18309, DOI 10.1074/jbc.270.31.18309; Liu JQ, 1997, J BIOL CHEM, V272, P3363, DOI 10.1074/jbc.272.6.3363; LIU JQ, 1995, BIODEGRADATION, V6, P223, DOI 10.1007/BF00700461; LIU JQ, 1994, B I CHEM RES KYOTO U, V72, P330; Marcotte EM, 1996, NAT STRUCT BIOL, V3, P155, DOI 10.1038/nsb0296-155; MOTOSUGI K, 1982, J BACTERIOL, V150, P522, DOI 10.1128/JB.150.2.522-527.1982; NardiDei V, 1997, J BACTERIOL, V179, P4232, DOI 10.1128/jb.179.13.4232-4238.1997; NARDIDEI V, 1994, APPL ENVIRON MICROB, V60, P3375, DOI 10.1128/AEM.60.9.3375-3380.1994; PRIES F, 1995, J BIOL CHEM, V270, P10405, DOI 10.1074/jbc.270.18.10405; PRIES F, 1994, BIOCHEMISTRY-US, V33, P1242, DOI 10.1021/bi00171a026; Slater J. Howard, 1994, P379; Soda K, 1996, PURE APPL CHEM, V68, P2097, DOI 10.1351/pac199668112097; VERSCHUEREN KHG, 1993, J MOL BIOL, V232, P856, DOI 10.1006/jmbi.1993.1436; VERSCHUEREN KHG, 1993, NATURE, V363, P693, DOI 10.1038/363693a0; WEIGHTMAN AJ, 1982, J GEN MICROBIOL, V128, P1755; YANG G, 1994, BIOCHEMISTRY-US, V33, P8527, DOI 10.1021/bi00194a018	29	47	51	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					20977	20981		10.1074/jbc.274.30.20977	http://dx.doi.org/10.1074/jbc.274.30.20977			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409645	hybrid			2022-12-25	WOS:000081613100036
J	Ridge, KD; Ngo, T; Lee, SSJ; Abdulaev, NG				Ridge, KD; Ngo, T; Lee, SSJ; Abdulaev, NG			Folding and assembly in rhodopsin - Effect of mutations in the sixth transmembrane helm on the conformation of the third cytoplasmic loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-STABLE RHODOPSIN; BOVINE RHODOPSIN; MONOCLONAL-ANTIBODIES; POLYPEPTIDE FRAGMENTS; MEMBRANE; EXPRESSION; PROTEINS; GENE; CHROMOPHORE; SEQUENCE	Previous studies on bovine opsin folding and assembly have identified an amino-terminal fragment, EF(1-232), which folds and inserts into a membrane only after coexpression with its complementary carboxyl-terminal fragment, EF(233-348), To further characterize this interaction, EF(1-232) production was examined upon coexpression with carboxyl-terminal fragments of varying length and/or amino acid composition. These included fragments with incremental deletions of the third cytoplasmic loop (TH(241-348) and EF(249-348)), a fragment composed of the third cytoplasmic loop and sixth transmembrane helix (HF(233-280)), a fragment composed of the sixth and seventh transmembrane helices (FG(249-312)), and EF(233-348) and TH(241-348) fragments with Pro-267 or Trp-265 mutations. Although EF(1-232) production was independent of the third cytoplasmic loop and carboxyl-terminal tail, both the sixth and seventh transmembrane helices were essential. The effects of mutations in the sixth transmembrane helix on EF(1-232) expression were dependent on the length of the third cytoplasmic loop. Although Pro-267 mutations in EF(233-348) failed to stabilize EF(1-232) expression, their introduction into TH(241-348) was without discernible effects. However, Trp-265 substitutions in the EF(233-348) and TH(241-348) fragments conferred significant EF(1-232) production. Therefore, key residues in the transmembrane helices may exert their effects on opsin folding, assembly, and/or function by influencing the conformation of the connecting loops.	NIST, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA; Univ Maryland, Maryland Biotechnol Inst, Rockville, MD 20850 USA	National Institute of Standards & Technology (NIST) - USA	Ridge, KD (corresponding author), NIST, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA.				NATIONAL EYE INSTITUTE [R55EY011112, R29EY011112] Funding Source: NIH RePORTER; NEI NIH HHS [EY11112] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADAMUS G, 1991, VISION RES, V31, P17, DOI 10.1016/0042-6989(91)90069-H; Altenbach C, 1996, BIOCHEMISTRY-US, V35, P12470, DOI 10.1021/bi960849l; BHATTACHARYA S, 1992, J BIOL CHEM, V267, P6763; BIBI E, 1990, P NATL ACAD SCI USA, V87, P4325, DOI 10.1073/pnas.87.11.4325; CHABRE M, 1979, VISION RES, V19, P1005, DOI 10.1016/0042-6989(79)90226-8; DUMONT ME, 1985, J MEMBRANE BIOL, V88, P233, DOI 10.1007/BF01871088; FERRETTI L, 1986, P NATL ACAD SCI USA, V83, P599, DOI 10.1073/pnas.83.3.599; FRANKE RR, 1988, J BIOL CHEM, V263, P2119; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; HARGRAVE PA, 1992, INT REV CYTOL, V137B, P49; HARGRAVE PA, 1983, BIOPHYS STRUCT MECH, V9, P235, DOI 10.1007/BF00535659; Heymann JAW, 1997, P NATL ACAD SCI USA, V94, P4966, DOI 10.1073/pnas.94.10.4966; HOWELL KE, 1982, J CELL BIOL, V92, P822, DOI 10.1083/jcb.92.3.822; Hwa J, 1997, P NATL ACAD SCI USA, V94, P10571, DOI 10.1073/pnas.94.20.10571; KHORANA HG, 1992, J BIOL CHEM, V267, P1; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIRD DW, 1987, MEMBRANE PROTEINS, P45; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOLDAY RS, 1983, BIOCHEMISTRY-US, V22, P653, DOI 10.1021/bi00272a020; NAKAYAMA TA, 1991, J BIOL CHEM, V266, P4269; NATHANS J, 1983, CELL, V34, P807, DOI 10.1016/0092-8674(83)90537-8; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; OVCHINNIKOV YA, 1982, BIOORG KHIM+, V8, P1011; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Ridge KD, 1996, J BIOL CHEM, V271, P7860, DOI 10.1074/jbc.271.13.7860; RIDGE KD, 1992, J BIOL CHEM, V267, P6770; RIDGE KD, 1995, P NATL ACAD SCI USA, V92, P3204, DOI 10.1073/pnas.92.8.3204; Russ WP, 1999, P NATL ACAD SCI USA, V96, P863, DOI 10.1073/pnas.96.3.863; SahinToth M, 1996, BIOCHEMISTRY-US, V35, P2016, DOI 10.1021/bi952496g; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SUNG CH, 1993, J BIOL CHEM, V268, P26645; TANFORD C, 1976, BIOCHIM BIOPHYS ACTA, V457, P133, DOI 10.1016/0304-4157(76)90009-5; WANG JK, 1980, BIOCHEMISTRY-US, V19, P5111, DOI 10.1021/bi00563a027; YEAGLE PL, 1995, BIOCHEMISTRY-US, V34, P14621, DOI 10.1021/bi00045a002; YU HB, 1995, BIOCHEMISTRY-US, V34, P14963, DOI 10.1021/bi00046a002	37	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21437	21442		10.1074/jbc.274.30.21437	http://dx.doi.org/10.1074/jbc.274.30.21437			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409707	hybrid			2022-12-25	WOS:000081613100098
J	Vigna, E; Gramaglia, D; Longati, P; Bardelli, A; Comoglio, PM				Vigna, E; Gramaglia, D; Longati, P; Bardelli, A; Comoglio, PM			Loss of the exon encoding the juxtamembrane domain is essential for the oncogenic activation of TPR-MET	ONCOGENE			English	Article						MET-receptor; Tpr-Met; transformation	HEPATOCYTE GROWTH-FACTOR; TYROSINE KINASE RECEPTOR; SCATTER FACTOR-RECEPTOR; C-MET; CONSTITUTIVE ACTIVATION; INVASIVE-GROWTH; REGULATORY SITE; HGF-RECEPTOR; CELL-LINE; TRANSFORMATION	TPR-MET, a transforming counterpart of the c-MET proto-oncogene detected in experimental and human cancer, results from fusion of the MET kinase domain with a dimerization motif encoded by TPR. In this rearrangement the exons encoding the Met extracellular, transmembrane and juxtamembrane domains are lost. The juxtamembrane domain has been suggested to be a regulatory region endowed with negative feedback control. To understand whether its absence is critical for the generation of the Tpr-Met transforming potential, we produced a chimeric molecule (Tpr-juxtaMet) with a conserved juxtamembrane domain. The presence of the domain (aa 962-1009) strongly inhibited Tpr-Met dependent cell transformation. Cell proliferation, anchorage-independent growth, motility and invasion were also impaired. The enzymatic behavior of Tpr-Met and Tpr-juxtaMet was the same, while Tpr-juxtaMet ability to associate cytoplasmic signal transducers and to elicit downstream signaling was severely impaired. These data indicate that the presence of the juxtamembrane domain counterbalances the Tpr-Met transforming potential and therefore the loss of the exon encoding the juxtamembrane domain is crucial in the generation of the active TPR-MET oncogene.	Univ Turin, Sch Med, Inst Canc Res & Treatment, I-10060 Turin, Italy	University of Turin	Vigna, E (corresponding author), Univ Turin, Sch Med, Inst Canc Res & Treatment, Str Prov 142,Km 3-95, I-10060 Turin, Italy.		GRAMAGLIA, DANIELA/A-6354-2012; BARDELLI, Alberto/J-9721-2018	Gramaglia, Daniela/0000-0001-6259-0059; BARDELLI, Alberto/0000-0003-1647-5070; Vigna, Elisa/0000-0001-9787-5732; Comoglio, Paolo/0000-0002-7056-5328				ALBINI A, 1987, CANCER RES, V47, P3239; Bardelli A, 1997, BBA-REV CANCER, V1333, pM41, DOI 10.1016/S0304-419X(97)00026-7; Bardelli A, 1999, ONCOGENE, V18, P1139, DOI 10.1038/sj.onc.1202607; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; FIXMAN ED, 1995, ONCOGENE, V10, P237; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; GANDINO L, 1991, J BIOL CHEM, V266, P16098; GANDINO L, 1994, J BIOL CHEM, V269, P1815; GANDINO L, 1990, ONCOGENE, V5, P721; Giordano S, 1997, P NATL ACAD SCI USA, V94, P13868, DOI 10.1073/pnas.94.25.13868; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; KATMATKAR S, 1996, J BIOL CHEM, V271, P26755; LEE CC, 1995, J BIOL CHEM, V270, P507, DOI 10.1074/jbc.270.2.507; LEE CC, 1994, J BIOL CHEM, V269, P19457; Liang TJ, 1996, J CLIN INVEST, V97, P2872, DOI 10.1172/JCI118744; LONGATI P, 1994, ONCOGENE, V9, P49; Michieli P, 1996, ONCOGENE, V12, P775; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1991, ONCOGENE, V6, P553; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RADHA V, 1994, BIOCHEM J, V299, P4600; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RODRIGUES GA, 1994, ONCOGENE, V9, P2019; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; SOMAN NR, 1991, P NATL ACAD SCI USA, V88, P4892, DOI 10.1073/pnas.88.11.4892; SOMAN NR, 1990, P NATL ACAD SCI USA, V87, P738, DOI 10.1073/pnas.87.2.738; Tamagnone Luca, 1997, Cytokine and Growth Factor Reviews, V8, P129, DOI 10.1016/S1359-6101(97)00007-5; Villa-Moruzzi E, 1998, BIOCHEM J, V336, P235, DOI 10.1042/bj3360235; VILLAMORUZZI E, 1993, J BIOL CHEM, V268, P18176; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; ZHEN Z, 1994, ONCOGENE, V9, P1691	39	47	47	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 22	1999	18	29					4275	4281		10.1038/sj.onc.1202791	http://dx.doi.org/10.1038/sj.onc.1202791			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218FK	10435641				2022-12-25	WOS:000081542400012
J	Ruvolo, PP; Deng, XM; Ito, T; Carr, BK; May, WS				Ruvolo, PP; Deng, XM; Ito, T; Carr, BK; May, WS			Ceramide induces Bcl2 dephosphorylation via a mechanism involving mitochondrial PP2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; MYELOID-LEUKEMIA CELLS; INDUCED APOPTOSIS; PHOSPHATASE 2A; DEATH; PHOSPHORYLATION; SPHINGOMYELINASE; INTERLEUKIN-3; BRYOSTATIN-1; CYTOTOXICITY	Phosphorylation of Bcl2 at serine 70 is required for its potent anti-apoptotic function. We have recently shown that Bcl2 phosphorylation is a dynamic process that involves the protein kinase C alpha and protein phosphatase 2A (PP2A) (Ruvolo, P. P., Deng, X., Carr, B. K., and May, W. S. (1998) J. Biol. Chem. 273, 25436-25442; and Deng, X, Ito, T., Carr, B. K., Mumby, M. C., and May, W. S. (1998) J. Biol. Chem. 273, 34157-34163). The potent apoptotic agent ceramide can activate a PP2A, suggesting that one potential component of the ceramide-induced death signal may involve the inactivation of Bcl2. Results indicate that CB-ceramide but not inactive C2-dihydroceramide, was found to specifically activate a mitochondrial PP2A, which rapidly and completely induced Bcl2 dephosphorylation and correlated closely with ceramide-induced cell death. Using a genetic approach, the gain-of-function S70E Bcl2 mutation, which mimics phosphorylation, fails to undergo apoptosis even with the addition of high doses of ceramide (IC50 > 50 mu M). In contrast, cells overexpressing exogenous wild-type Bcl2 were sensitive to ceramide at dosages where PP2A is fully active and Bcl2 would be expected to be dephosphorylated (IC50 = 14 mu M). These findings indicate that in cells expressing functional Bcl2, the mechanism of death action for ceramide may involve, at least in part, a mitochondrial PP2A that dephosphorylates and inactivates Bcl2.	Univ Texas, Med Branch, Sealy Ctr Oncol & Hematol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Internal Med, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	May, WS (corresponding author), Univ Texas, Med Branch, Sealy Ctr Oncol & Hematol, 301 Univ Blvd, Galveston, TX 77555 USA.				NATIONAL CANCER INSTITUTE [R01CA044649, R01CA047993] Funding Source: NIH RePORTER; NCI NIH HHS [CA44649, CA47993] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Basu S, 1998, J BIOL CHEM, V273, P30419, DOI 10.1074/jbc.273.46.30419; Bielawska AE, 1997, AM J PATHOL, V151, P1257; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; DEANA AD, 1990, BIOCHIM BIOPHYS ACTA, V1051, P199, DOI 10.1016/0167-4889(90)90194-I; Deng XM, 1998, J BIOL CHEM, V273, P34157, DOI 10.1074/jbc.273.51.34157; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; JARVIS WD, 1994, J BIOL CHEM, V269, P31685; Jarvis WD, 1997, MOL PHARMACOL, V52, P935, DOI 10.1124/mol.52.6.935; Jarvis WD, 1996, J BIOL CHEM, V271, P8275, DOI 10.1074/jbc.271.14.8275; Jarvis WD, 1996, CLIN CANCER RES, V2, P1; KOLESNICK R, 1995, J EXP MED, V181, P1949, DOI 10.1084/jem.181.6.1949; LAW B, 1995, J BIOL CHEM, V270, P12808, DOI 10.1074/jbc.270.21.12808; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; LOZANO J, 1994, J BIOL CHEM, V269, P19200; Luberto C, 1998, J BIOL CHEM, V273, P14550, DOI 10.1074/jbc.273.23.14550; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MAY WS, 1994, J BIOL CHEM, V269, P26865; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; QUINTANS J, 1994, BIOCHEM BIOPH RES CO, V202, P710, DOI 10.1006/bbrc.1994.1988; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Smyth M J, 1997, Adv Pharmacol, V41, P133, DOI 10.1016/S1054-3589(08)61057-1; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325; Zhang P, 1997, J BIOL CHEM, V272, P9609; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568	33	290	300	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20296	20300		10.1074/jbc.274.29.20296	http://dx.doi.org/10.1074/jbc.274.29.20296			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400650	hybrid			2022-12-25	WOS:000081438300043
J	Traub, O; Ishida, T; Ishida, M; Tupper, JC; Berk, BC				Traub, O; Ishida, T; Ishida, M; Tupper, JC; Berk, BC			Shear stress-mediated extracellular signal-regulated kinase activation is regulated by sodium in endothelial cells - Potential role for a voltage-dependent sodium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; RABBIT FACIAL VEIN; PROTEIN-KINASE; ION CHANNELS; CORONARY-ARTERIES; POTASSIUM CHANNEL; CALCIUM TRANSIENTS; CATION CHANNELS; MAP KINASE; FLOW	Fluid shear stress is an important regulator of endothelial cell (EC) function. To determine whether mechanosensitive ion channels participate in the EC response to shear stress, we characterized the role of ion transport in shear stress-mediated extracellular signal-regulated kinase (ERK1/2) stimulation. Replacement of all extracellular Na+ with either N-methyl-D-glucamine or choline chloride increased the ERK1/2 stimulation in response to shear stress by 1.89 +/- 0.1-fold. The Na+ effect was concentration-dependent (maximal effect, less than or equal to 12.5 mM) and was specific for shear stress-mediated ERK1/2 activation as epidermal growth factor-stimulated ERK1/2 activation was unaffected by removal of extracellular Na+. Shear stress-mediated ERK1/2 activation was potentiated by the voltage-gated sodium channel antagonist, tetrodotoxin (100 nM), to a magnitude similar to that achieved with extracellular Na+ withdrawal. Transfection of Chinese hamster ovary cells with a rat brain type IIa voltage-gated sodium channel completely inhibited shear stress-mediated ERK1/2 activation in these cells. Inhibition was reversed by performing the experiment in sodium-free buffer or by including tetrodotoxin in the buffer. Western blotting of bovine and human EC lysates with SP19 antibody detected a 250-kDa protein consistent with the voltage-gated sodium channel. Degenerate polymerase chain reaction of cDNA from primary human EC yielded transcripts whose sequences were identical to the sodium channel SCN4a and SCN8a alpha subunit genes. These results indicate that shear stress-mediated ERK1/2 activation is regulated by extracellular sodium and demonstrate that ion transport via Na+ channels modulates EC responses to shear stress.	Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Rochester, Sch Med, Cardiovasc Res Ctr, Rochester, NY 14642 USA	University of Washington; University of Washington Seattle; University of Rochester	Berk, BC (corresponding author), Univ Rochester, Med Ctr, Cardiovasc Res Ctr, Box 679, Rochester, NY 14642 USA.	bradford_berk@urmc.rochester.edu	Ishida, Mari/L-8208-2016	Berk, Bradford/0000-0002-2767-4115	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007266] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL18645] Funding Source: Medline; NIGMS NIH HHS [GM-07266] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS DJ, 1994, TRENDS CARDIOVAS MED, V4, P18, DOI 10.1016/1050-1738(94)90021-3; ANDO J, 1988, IN VITRO CELL DEV B, V24, P871; ASAKURA T, 1990, CIRC RES, V66, P1045, DOI 10.1161/01.RES.66.4.1045; BASUDEV H, 1995, NEUROREPORT, V6, P809, DOI 10.1097/00001756-199503270-00026; Beny JL, 1997, PFLUG ARCH EUR J PHY, V433, P364; BEVAN JA, 1993, HYPERTENSION, V22, P273, DOI 10.1161/01.HYP.22.3.273; BURGESS DL, 1995, NAT GENET, V10, P461, DOI 10.1038/ng0895-461; BUSSOLARI SR, 1982, REV SCI INSTRUM, V53, P1851, DOI 10.1063/1.1136909; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; COOKE JP, 1991, J CLIN INVEST, V88, P1663, DOI 10.1172/JCI115481; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; DUFF JL, 1995, J BIOL CHEM, V270, P7161, DOI 10.1074/jbc.270.13.7161; Fan JP, 1999, CIRC RES, V84, P451, DOI 10.1161/01.RES.84.4.451; FRANSEN PF, 1995, AM J PHYSIOL-HEART C, V268, pH2036, DOI 10.1152/ajpheart.1995.268.5.H2036; GEIGER RV, 1992, AM J PHYSIOL, V262, pC1411, DOI 10.1152/ajpcell.1992.262.6.C1411; Gimbrone M A Jr, 1976, Prog Hemost Thromb, V3, P1; GORDIENKO DV, 1994, PFLUG ARCH EUR J PHY, V428, P91, DOI 10.1007/BF00374756; GORDON D, 1988, BIOCHEMISTRY-US, V27, P7032, DOI 10.1021/bi00418a054; Gosling M, 1998, J BIOL CHEM, V273, P21084, DOI 10.1074/jbc.273.33.21084; Henrion D, 1995, J VASC RES, V32, P413, DOI 10.1159/000159117; HENRION D, 1995, J VASC RES, V32, P41, DOI 10.1159/000159076; Hoyer J, 1997, HYPERTENSION, V30, P112, DOI 10.1161/01.HYP.30.1.112; Ishida T, 1996, CIRC RES, V79, P310, DOI 10.1161/01.RES.79.2.310; JACOBS ER, 1995, PFLUG ARCH EUR J PHY, V431, P129, DOI 10.1007/BF00374386; KU DN, 1985, ARTERIOSCLEROSIS, V5, P293, DOI 10.1161/01.ATV.5.3.293; Kuroki DW, 1997, J BIOL CHEM, V272, P23905, DOI 10.1074/jbc.272.38.23905; Kusuhara M, 1998, CIRC RES, V83, P824, DOI 10.1161/01.RES.83.8.824; LANSMAN JB, 1987, NATURE, V325, P811, DOI 10.1038/325811a0; LI M, 1993, SCIENCE, V261, P1439, DOI 10.1126/science.8396273; Liu JD, 1996, SCIENCE, V273, P361, DOI 10.1126/science.273.5273.361; MA JY, 1994, P NATL ACAD SCI USA, V91, P12351, DOI 10.1073/pnas.91.25.12351; MORRIS CE, 1990, J MEMBRANE BIOL, V113, P93, DOI 10.1007/BF01872883; NARUSE K, 1993, AM J PHYSIOL, V264, pC1037, DOI 10.1152/ajpcell.1993.264.4.C1037; Nilius B, 1997, ANNU REV PHYSIOL, V59, P145, DOI 10.1146/annurev.physiol.59.1.145; OHNO M, 1995, J CLIN INVEST, V95, P1363, DOI 10.1172/JCI117787; OHNO M, 1993, CIRCULATION, V88, P193, DOI 10.1161/01.CIR.88.1.193; OLESEN SP, 1988, NATURE, V331, P168, DOI 10.1038/331168a0; Osawa M, 1997, EUR J CELL BIOL, V72, P229; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; POPP R, 1992, J PHYSIOL-LONDON, V454, P435, DOI 10.1113/jphysiol.1992.sp019272; Popp R, 1998, CIRC RES, V82, P696, DOI 10.1161/01.RES.82.6.696; Salter DM, 1997, J BONE MINER RES, V12, P1133, DOI 10.1359/jbmr.1997.12.7.1133; SCHWARZ G, 1992, PFLUG ARCH EUR J PHY, V421, P394, DOI 10.1007/BF00374230; SEGAL SS, 1989, AM J PHYSIOL, V256, pH838, DOI 10.1152/ajpheart.1989.256.3.H838; SHEN J, 1992, AM J PHYSIOL, V262, pC384, DOI 10.1152/ajpcell.1992.262.2.C384; Takahashi M, 1996, J CLIN INVEST, V98, P2623, DOI 10.1172/JCI119083; TAKEUCHI N, 1993, FEBS LETT, V328, P280, DOI 10.1016/0014-5793(93)80944-P; Tavernarakis N, 1997, ANNU REV PHYSIOL, V59, P659, DOI 10.1146/annurev.physiol.59.1.659; Tibbs VC, 1998, J BIOL CHEM, V273, P25783, DOI 10.1074/jbc.273.40.25783; Traub O, 1998, ARTERIOSCL THROM VAS, V18, P677, DOI 10.1161/01.ATV.18.5.677; Traub O, 1997, J BIOL CHEM, V272, P31251, DOI 10.1074/jbc.272.50.31251; TSENG H, 1995, CIRC RES, V77, P869, DOI 10.1161/01.RES.77.5.869; Walsh KB, 1998, AM J PHYSIOL-HEART C, V274, pH506, DOI 10.1152/ajpheart.1998.274.2.H506	53	51	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20144	20150		10.1074/jbc.274.29.20144	http://dx.doi.org/10.1074/jbc.274.29.20144			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400628	hybrid			2022-12-25	WOS:000081438300021
J	Rahman, MM; Guard-Petter, J; Asokan, K; Hughes, C; Carlson, RW				Rahman, MM; Guard-Petter, J; Asokan, K; Hughes, C; Carlson, RW			The structure of the colony migration factor from pathogenic Proteus mirabilis - A capsular polysaccharide that facilitates swarming	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICELLULAR MIGRATION; CELL-DIFFERENTIATION; POLYACRYLAMIDE GELS; CAPILLARY GLC; LIPOPOLYSACCHARIDES; SPECTROSCOPY; MONOSACCHARIDES; CONFIGURATION; VULGARIS; H-1-NMR	Swarming by Proteus mirabilis is characterized by cycles of rapid and coordinated population migration across surfaces following differentiation of vegetative cells into elongated hyperflagellated swarm cells. It has been shown that surface colony expansion by the swarm cell population is facilitated by a colony migration factor (Cmf), a capsular polysaccharide (CPS) that also contributes to the uropathogenicity of P. mirabilis (Gygi, D., Rahman, M. M., Lai, H.-C., Carlson, R., Guard-Petter, J., and Hughes, C. (1995) Mel. Microbiol. 17, 1167-1175). In this report, the Cmf-CPS was extracted with hot water, precipitated with ethanol, and further purified by gel permeation chromatography, Its structure was established by glycosyl composition and linkage analyses, and by one- and two dimensional NMR spectroscopy. The Cmf-CPS is composed of the following tetrasaccharide repeating unit. [GRAPHICS]	Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA; USDA ARS, SE Poultry Res Lab, Athens, GA 30605 USA; Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England	University System of Georgia; University of Georgia; United States Department of Agriculture (USDA); University of Cambridge	Carlson, RW (corresponding author), Univ Georgia, Complex Carbohydrate Res Ctr, 220 Riverbend Rd, Athens, GA 30602 USA.		Guard, Jean/Q-6254-2018	Guard, Jean/0000-0003-3968-4705				ALLISON C, 1994, J INFECT DIS, V169, P1155, DOI 10.1093/infdis/169.5.1155; ALLISON C, 1991, MOL MICROBIOL, V5, P1975, DOI 10.1111/j.1365-2958.1991.tb00819.x; ALLISON C, 1991, SCI PROG, V75, P403; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BEYNON LM, 1992, J BACTERIOL, V174, P2172, DOI 10.1128/JB.174.7.2172-2177.1992; BOCK K, 1984, ADV CARBOHYD CHEM BI, V42, P193, DOI 10.1016/S0065-2318(08)60125-0; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; CORZO J, 1991, ELECTROPHORESIS, V12, P439, DOI 10.1002/elps.1150120611; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; Dworkin M, 1996, MICROBIOL REV, V60, P70, DOI 10.1128/MMBR.60.1.70-102.1996; EBRINGER A, 1989, RHEUMATOL INT, V9, P223; FRASER GM, 1999, IN PRESS PROKARYOTIC; GERWIG GJ, 1978, CARBOHYD RES, V62, P349, DOI 10.1016/S0008-6215(00)80881-2; GERWIG GJ, 1979, CARBOHYD RES, V77, P1, DOI 10.1016/S0008-6215(00)83788-X; GYGI D, 1995, MOL MICROBIOL, V17, P1167, DOI 10.1111/j.1365-2958.1995.mmi_17061167.x; HOLST O, 1994, MOL BIOCH CELL BIOL, V1, P135; Kim JS, 1996, GLYCOBIOLOGY, V6, P433, DOI 10.1093/glycob/6.4.433; KOMURO T, 1988, J CHROMATOGR, V450, P381, DOI 10.1016/S0021-9673(01)83593-7; KOTELKO K, 1986, CURR TOP MICROBIOL, V129, P181; LARSSON P, 1984, METHOD MICROBIOL, V14, P187, DOI 10.1016/S0580-9517(08)70451-3; LEE L, 1974, INFECT IMMUN, V9, P318, DOI 10.1128/IAI.9.2.318-322.1974; MARION D, 1989, J MAGN RESON, V85, P393, DOI 10.1016/0022-2364(89)90152-2; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P7385; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; Rahman MM, 1997, CARBOHYD RES, V301, P213; Rauprich O, 1996, J BACTERIOL, V178, P6525, DOI 10.1128/jb.178.22.6525-6538.1996; RUBIN RH, 1986, KIDNEY, P1085; SHAKA AJ, 1985, J MAGN RESON, V64, P547, DOI 10.1016/0022-2364(85)90122-2; STAHL SJ, 1983, J BACTERIOL, V154, P930, DOI 10.1128/JB.154.2.930-937.1983; STICKLER D, 1993, UROL RES, V21, P407, DOI 10.1007/BF00300077; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; WAEGHE TJ, 1983, CARBOHYD RES, V123, P281, DOI 10.1016/0008-6215(83)88484-5; WIDER G, 1984, J MAGN RESON, V56, P207, DOI 10.1016/0022-2364(84)90099-4; York WS, 1985, METHOD ENZYMOL, P3, DOI DOI 10.1016/0076-6879(86)18062-1	35	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					22993	22998		10.1074/jbc.274.33.22993	http://dx.doi.org/10.1074/jbc.274.33.22993			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438465	hybrid			2022-12-25	WOS:000082012800015
J	Schlegel, A; Schwab, RB; Scherer, PE; Lisanti, MP				Schlegel, A; Schwab, RB; Scherer, PE; Lisanti, MP			A role for the caveolin scaffolding domain in mediating the membrane attachment of caveolin-1 - The caveolin scaffolding domain is both necessary and sufficient for membrane binding in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; SRC TYROSINE KINASES; TRANS-GOLGI-NETWORK; ROUS-SARCOMA VIRUS; IN-VIVO; PLASMA-MEMBRANE; PROTEIN-COMPONENT; LINKED PROTEIN; GENE FAMILY; IDENTIFICATION	Here, we have created a series of caveolin-1 (Cav-1) deletion mutants to examine whether the membrane spanning segment is required for membrane attachment of caveolin-1 in vivo, One mutant, Cav-1-(1-101), contains only the cytoplasmic N-terminal domain and lacks the membrane spanning domain and the C-terminal domain, Interestingly, Cav-1-(1-101) still behaves as an integral membrane protein but lacks any known signals for lipid modification. In striking contrast, another deletion mutant, Cav-1-(1-81), behaved as a soluble protein, These results implicate caveolin-1 residues 82-101 (also known as the caveolin scaffolding domain) in membrane attachment. In accordance with the postulated role of the caveolin-1 scaffolding domain as an inhibitor of signal transduction, Cav-1-(1-101) retained the ability to functionally inhibit signaling along the p42/44 mitogen-activated protein kinase cascade, whereas Cav-1-(1-81) was completely ineffective. To rule out the possibility that membrane attachment mediated by the caveolin scaffolding domain was indirect, we reconstituted the membrane binding of caveolin-1 in vitro, By using purified glutathione S-transferase-caveolin-1 fusion proteins and reconstituted lipid vesicles, we show that the caveolin-1 scaffolding domain and the C-terminal domain (residues 135-178) are both sufficient for membrane attachment in vitro, However, the putative membrane spanning domain (residues 102-134) did not show any physical association with membranes in this in vitro system. Taken together, our results provide strong evidence that the caveolin scaffolding domain contributes to the membrane attachment of caveolin-1.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Lisanti, MP (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	lisanti@aecom.yu.edu	Lisanti, Michael/B-6131-2018; Scherer, Philipp E/K-7819-2012; Lisanti, Michael P/C-6866-2013	Lisanti, Michael/0000-0003-2034-1382; Scherer, Philipp E/0000-0003-0680-3392; Schlegel, Amnon/0000-0003-4060-2252	NATIONAL CANCER INSTITUTE [R01CA080250] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA-80250] Funding Source: Medline; NIGMS NIH HHS [T32-GM07288] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; CORLEYMASTICK C, 1995, J CELL BIOL, V129, P1523; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Das K, 1999, J BIOL CHEM, V274, P18721, DOI 10.1074/jbc.274.26.18721; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0; Engelman JA, 1998, AM J HUM GENET, V63, P1578, DOI 10.1086/302172; Engelman JA, 1998, J BIOL CHEM, V273, P20448, DOI 10.1074/jbc.273.32.20448; FRA AM, 1995, FEBS LETT, V375, P11, DOI 10.1016/0014-5793(95)95228-O; GALBIATI F, 1994, BIOCHEM J, V303, P697, DOI 10.1042/bj3030697; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; GLENNEY JR, 1992, FEBS LETT, V314, P45, DOI 10.1016/0014-5793(92)81458-X; JICKA GA, 1998, EINSTEIN Q J BIOL ME, V15, P86; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Li SW, 1996, J BIOL CHEM, V271, P3863; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1995, METHOD ENZYMOL, V250, P655; LISANTI MP, 1993, J CELL BIOL, V123, P595, DOI 10.1083/jcb.123.3.595; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; OLSON EN, 1986, J BIOL CHEM, V261, P2458; POLLARD JW, 1979, J CELL PHYSIOL, V98, P571, DOI 10.1002/jcp.1040980315; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SARGIACOMO M, 1994, ONCOGENE, V9, P2589; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SCHNITZER JE, 1995, P NATL ACAD SCI USA, V92, P1759, DOI 10.1073/pnas.92.5.1759; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; SEVERS NJ, 1988, J CELL SCI, V90, P341; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Song KS, 1997, CELL MOL BIOL, V43, P293; Song KS, 1997, J BIOL CHEM, V272, P4398, DOI 10.1074/jbc.272.7.4398; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Toya Y, 1998, ENDOCRINOLOGY, V139, P2025, DOI 10.1210/en.139.4.2025; Trigatti BL, 1999, BIOCHEM BIOPH RES CO, V255, P34, DOI 10.1006/bbrc.1998.0123; Venema VJ, 1997, J BIOL CHEM, V272, P28187, DOI 10.1074/jbc.272.45.28187; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; WAY M, 1995, FEBS LETT, V376, P108, DOI 10.1016/0014-5793(95)01256-7	54	124	125	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22660	22667		10.1074/jbc.274.32.22660	http://dx.doi.org/10.1074/jbc.274.32.22660			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428847	hybrid			2022-12-25	WOS:000081868400077
J	Fatatis, A; Miller, RJ				Fatatis, A; Miller, RJ			Cell cycle control of PDGF-induced Ca2+ signaling through modulation of sphingolipid metabolism	FASEB JOURNAL			English	Article						DMS; DHS; epidermal growth factor; PDGF	GROWTH-FACTOR RECEPTOR; PROTEIN-KINASE-C; SPHINGOSINE 1-PHOSPHATE; TRANSFORMED OLIGODENDROCYTES; INOSITOL TRISPHOSPHATE; RESTRICTION POINT; REGULATORY EVENTS; 2ND MESSENGER; 3T3 CELLS; PROLIFERATION	The effects of growth factors have been shown to depend on the position of a cell in the cell cycle. However, the physiological basis for this phenomenon remains unclear. Here we show that the majority of both CEINGE clone3 (c13) and human embryonic kidney 293 cells, when arrested in a quiescent phase (G(0)), responded to platelet-derived growth factor BE (PDGF-BB) with non-oscillatory Ca2+ signals. Furthermore, the same type of Ca response was also observed in CEINGE c13 cells (and to a lesser extent in HEK 293 cells) blocked at the G(1)/S boundary. In contrast, CEINGE c13 cells synchronized in early G(1) or released from G(1)/S arrest responded in an oscillatory fashion. This cell cycle-dependent modulation of Ca2+ signaling was not observed on epidermal growth factor and G-protein-coupled receptor stimulation and was not due to differences in the expression of PDGF receptors (PDGFRs) during; the cell cycle. We demonstrate that inhibition of sphingosine-kinase, which converts sphingosine to sphingosine-1-phosphate, caused G(0) as well as G(1)/S synchronized cells to restore the oscillatory Ca2+ response to PDGF-BB, In addition, we show that the synthesis of sphingosine and sphingosine-1-phosphate is regulated by the cell cycle and may underlie the differences in Ca2+ signaling after PDGFR stimulation.	Univ Chicago, Dept Pharmacol & Physiol Sci, Chicago, IL 60637 USA	University of Chicago	Miller, RJ (corresponding author), Univ Chicago, Dept Pharmacol & Physiol Sci, 947 E 58th St,MC-0926, Chicago, IL 60637 USA.				NIDA NIH HHS [DA02121, DA02575] Funding Source: Medline; NIMH NIH HHS [MH40165] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH040165, R37MH040165] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA002121, R01DA002575] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Alemany R, 1999, J BIOL CHEM, V274, P3994, DOI 10.1074/jbc.274.7.3994; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; Berridge MJ, 1997, NATURE, V386, P759, DOI 10.1038/386759a0; CASSACIABONNEFI.P, 1996, SCIENCE, V272, P542; CHEN ZT, 1995, J BIOL CHEM, V270, P27525, DOI 10.1074/jbc.270.46.27525; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; Cossette LJ, 1996, EXP CELL RES, V223, P459, DOI 10.1006/excr.1996.0102; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; Edsall LC, 1998, BIOCHEMISTRY-US, V37, P12892, DOI 10.1021/bi980744d; Fatatis A, 1997, J BIOL CHEM, V272, P4351, DOI 10.1074/jbc.272.7.4351; Fatatis A, 1996, J BIOL CHEM, V271, P295, DOI 10.1074/jbc.271.1.295; Frade JM, 1996, NATURE, V383, P166; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HASEGAWASASAKI H, 1985, BIOCHEM J, V232, P99, DOI 10.1042/bj2320099; IGARASHI Y, 1989, BIOCHEMISTRY-US, V28, P6796, DOI 10.1021/bi00443a002; JAKOBISIAK M, 1991, P NATL ACAD SCI USA, V88, P3628, DOI 10.1073/pnas.88.9.3628; KIM HRC, 1995, P NATL ACAD SCI USA, V92, P9500, DOI 10.1073/pnas.92.21.9500; KISS Z, 1995, BBA-MOL CELL RES, V1265, P93, DOI 10.1016/0167-4889(94)00242-7; KREK W, 1995, METHOD ENZYMOL, V254, P114; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSSON O, 1989, J CELL PHYSIOL, V139, P477, DOI 10.1002/jcp.1041390305; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; Masamune A, 1996, J BIOL CHEM, V271, P9368, DOI 10.1074/jbc.271.16.9368; MATTIE M, 1994, J BIOL CHEM, V269, P3181; Miyakawa T, 1999, EMBO J, V18, P1303, DOI 10.1093/emboj/18.5.1303; Olivera A, 1998, J BIOL CHEM, V273, P12576, DOI 10.1074/jbc.273.20.12576; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; PARDEE A B, 1992, Current Opinion in Cell Biology, V4, P186, DOI 10.1016/0955-0674(92)90031-7; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; Pines J, 1998, Results Probl Cell Differ, V22, P57; Rani CSS, 1997, J BIOL CHEM, V272, P10777; REDDY GPV, 1994, J CELL BIOCHEM, V54, P379, DOI 10.1002/jcb.240540404; RUSSO T, 1993, NEUROSCI LETT, V159, P159, DOI 10.1016/0304-3940(93)90823-4; Sakano S, 1996, J BIOL CHEM, V271, P11148, DOI 10.1074/jbc.271.19.11148; Sheaff R J, 1998, Results Probl Cell Differ, V22, P1; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; TAKUWA N, 1995, CELL SIGNAL, V7, P93, DOI 10.1016/0898-6568(94)00074-L; TEMIN HM, 1971, J CELL PHYSIOL, V78, P161, DOI 10.1002/jcp.1040780202; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; URBANI L, 1995, EXP CELL RES, V219, P159, DOI 10.1006/excr.1995.1216; Vaziri C, 1996, J BIOL CHEM, V271, P13642, DOI 10.1074/jbc.271.23.13642; VAZIRI C, 1995, MOL CELL BIOL, V15, P1244; Whitfield J.F., 1982, P61; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; ZETTERBERG A, 1991, COLD SH Q B, V56, P137; ZETTERBERG A, 1995, CURR OPIN CELL BIOL, V7, P835, DOI 10.1016/0955-0674(95)80067-0; ZETTERBERG A, 1985, P NATL ACAD SCI USA, V82, P5365, DOI 10.1073/pnas.82.16.5365; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155; ZUHERINGDORF DM, 1998, EMBO J, V17, P2830	54	20	20	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1999	13	11					1291	1301		10.1096/fasebj.13.11.1291	http://dx.doi.org/10.1096/fasebj.13.11.1291			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	226KL	10428754				2022-12-25	WOS:000082019100002
J	Hu, MH; Bauman, EM; Roll, RL; Yeilding, N; Abrams, CS				Hu, MH; Bauman, EM; Roll, RL; Yeilding, N; Abrams, CS			Pleckstrin 2, a widely expressed paralog of pleckstrin involved in actin rearrangement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; BRUTON TYROSINE KINASE; BETA-GAMMA-SUBUNITS; HOMOLOGY DOMAIN; PH DOMAIN; G(BETA-GAMMA) SUBUNITS; PHOSPHORYLATION; BINDING; RAC; PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE	We have identified a cDNA for pleckstrin 2 that is 39% identical and 65% homologous to the original pleckstrin. Like the original pleckstrin 1, this protein contains a pleckstrin homology (PH) domain at each end of the molecule as well as a DEP (Dishevelled, Egl-10, and pleckstrin) domain in the intervening sequence. A Northern blot probed with the full-length cDNA reveals that this homolog is ubiquitously expressed and is most abundant in the thymus, large bowel, small bowel, stomach, and prostate. Unlike pleckstrin 1, this newly discovered protein does not contain obvious sites of PKC phosphorylation, and in transfected Cos-7 cells, it is a poor substrate for phosphorylation, even after PMA stimulation. Cells expressing pleckstrin 2 undergo a dramatic shape change associated with actin rearrangement, including a loss of central F-actin and a redistribution of actin toward the cell cortex. Overexpression of pleckstrin 2 causes large lamellipodia and peripheral ruffle formation. A variant of pleckstrin 2 lacking both PH domains still had some membrane binding but did not efficiently induce lamellipodia, suggesting that the PR domains of pleckstrin 2 contribute to lamellipodia formation. This work describes a novel, widely expressed, membrane-associating protein and suggests that pleckstrin 2 may help orchestrate cytoskeletal arrangement.	Univ Penn, Div Hematol Oncol, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Abrams, CS (corresponding author), Univ Penn, Div Hematol Oncol, Dept Med, Basic Res Bldg 2-3,Rm 912,421 Curie Blvd, Philadelphia, PA 19104 USA.				NHLBI NIH HHS [P50 HL54500, P01 HL40387] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040387, P50HL054500] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMS CS, 1995, J BIOL CHEM, V270, P23317, DOI 10.1074/jbc.270.40.23317; Abrams CS, 1996, J BIOL CHEM, V271, P25192, DOI 10.1074/jbc.271.41.25192; ABRAMS CS, 1995, J BIOL CHEM, V270, P14485, DOI 10.1074/jbc.270.24.14485; ABRAMS CS, 1996, BIOCHIM BIOPHYS ACTA, V1614, P233; Auethavekiat V, 1997, J BIOL CHEM, V272, P1786, DOI 10.1074/jbc.272.3.1786; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; GAILANI D, 1990, BRIT J HAEMATOL, V74, P192, DOI 10.1111/j.1365-2141.1990.tb02565.x; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; KONISHI H, 1994, BIOCHEM BIOPH RES CO, V205, P1770, DOI 10.1006/bbrc.1994.2874; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Ma AD, 1997, J CELL BIOL, V136, P1071, DOI 10.1083/jcb.136.5.1071; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; MAHADEVAN D, 1995, BIOCHEMISTRY-US, V34, P9111, DOI 10.1021/bi00028a021; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P245, DOI 10.1016/S0968-0004(96)30027-3; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; TYERS M, 1988, NATURE, V333, P470, DOI 10.1038/333470a0; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; Yao LB, 1997, J BIOL CHEM, V272, P13033, DOI 10.1074/jbc.272.20.13033	25	32	33	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21515	21518		10.1074/jbc.274.31.21515	http://dx.doi.org/10.1074/jbc.274.31.21515			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419454	hybrid			2022-12-25	WOS:000081721100007
J	Garner, B; Vazquez, S; Griffith, R; Lindner, RA; Carver, JA; Truscott, RJW				Garner, B; Vazquez, S; Griffith, R; Lindner, RA; Carver, JA; Truscott, RJW			Identification of glutathionyl-3-hydroxykynurenine glucoside as a novel fluorophore associated with aging of the human lens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENT GLUCOSIDE; NUCLEAR CATARACT; BETA-GLUCOSIDASE; ACTIVE-SITE; PROTEIN; 3-HYDROXYKYNURENINE; GLUTATHIONE; MECHANISMS; MELANOMA; PRODUCTS	A novel fluorophore was isolated from human lenses using high performance liquid chromatography (HPLC), The new fluorophore was well separated from 3-hydroxykynurenine glucoside (3-OHKG) and its deaminated isoform, 4-(2-amino-3-hydroxyphenyl)-4-oxobutanoic acid O-glucoside, which are known UV filter compounds. The new compound exhibited UV absorbance maxima at 260 and 365 nm, was fluorescent (Ex(360 nm)/Em(500 nm)), and increased in concentration with age, Further analysis of the purified compound by microbore HPLC with in-line electrospray ionization mass spectrometry revealed a molecular mass of 676 Da, This mass corresponds to that of an adduct of GSH with a deaminated form of 3-OHKG, This adduct was synthesized using 3-OHKG: and GSH as starting materials. The synthetic glutathionyl-3-hydroxykynurenine glucoside (GSH-3-OHKG) adduct had the same HPLC elution time, thin-layer chromatography R(F) value, UV absorbance maxima, fluorescence characteristics, and mass spectrum as the lens-derived fluorophore. Furthermore, the (1)H and (13)C NMR spectra of the synthetic adduct were entirely consistent with the proposed structure of GSH-3-OHKG. These data indicate that GSH-3-OHKG is present as a novel fluorophore in aged human lenses. The GSH-3-OHKG adduct was found to be less reactive with beta-glucosidase compared with 3-OHKG, and this could be due to a folded conformation of the adduct that was suggested by molecular modeling.	Australian Cataract Res Fdn, Wollongong, NSW 2522, Australia; Univ Wollongong, Dept Chem, Wollongong, NSW 2522, Australia	University of Wollongong	Truscott, RJW (corresponding author), Australian Cataract Res Fdn, Wollongong, NSW 2522, Australia.	roger_truscott@uow.edu.au	Carver, John Adrian/J-3825-2014; Griffith, Renate/A-3584-2015	Carver, John Adrian/0000-0002-2441-8108; Griffith, Renate/0000-0001-7739-5686				AGRUP G, 1977, ACTA DERM-VENEREOL, V57, P221; ANDERSON BM, 1982, BIOCHIM BIOPHYS ACTA, V703, P204, DOI 10.1016/0167-4838(82)90049-8; [Anonymous], 1981, MOL CELLULAR BIOL EY; Aquilina JA, 1997, EXP EYE RES, V64, P727, DOI 10.1006/exer.1996.0258; BANDO M, 1976, OPHTHALMIC RES, V8, P456, DOI 10.1159/000264854; BANDO M, 1981, J BIOCHEM-TOKYO, V89, P103, DOI 10.1093/oxfordjournals.jbchem.a133170; BANDO M, 1985, EXP EYE RES, V40, P813, DOI 10.1016/0014-4835(85)90126-5; BARRETT T, 1995, STRUCTURE, V3, P951, DOI 10.1016/S0969-2126(01)00229-5; BUTENANDT A, 1955, LIEBIGS ANN CHEM, V590, P75; BUTENANDT A, 1962, CHEM NATURAL SYNTHET, P13; CARLIN R, 1971, INVEST OPHTH VISUAL, V10, P887; CARSTAM R, 1987, ACTA DERM-VENEREOL, V67, P100; CECIL R, 1959, ADV PROTEIN CHEM, V14, P256; CROASSMAN WR, 1994, 2 DIMENSIONAL NMR SP; DAVIS AL, 1992, J MAGN RESON, V98, P207, DOI 10.1016/0022-2364(92)90126-R; DELL A, 1993, GLYCOBIOLOGY PRACTIC, P187; ELLOZY AR, 1994, PHOTOCHEM PHOTOBIOL, V59, P479, DOI 10.1111/j.1751-1097.1994.tb05068.x; Fu SL, 1998, J BIOL CHEM, V273, P28603, DOI 10.1074/jbc.273.44.28603; He SM, 1997, J BIOL CHEM, V272, P24864, DOI 10.1074/jbc.272.40.24864; Heightman TD, 1996, HELV CHIM ACTA, V79, P2190, DOI 10.1002/hlca.19960790814; HOMANS SW, 1993, NMR MACROMOLECULES P, P289; INOUE A, 1994, BIOORG MED CHEM LETT, V4, P2303, DOI 10.1016/0960-894X(94)85029-1; ITO S, 1985, EXPERIENTIA, V41, P960, DOI 10.1007/BF01970033; LERMAN S, 1976, OPHTHALMIC RES, V8, P335, DOI 10.1159/000264841; LUTHRA M, 1994, FEBS LETT, V349, P39, DOI 10.1016/0014-5793(94)00635-0; Malina H Z, 1996, Eur J Ophthalmol, V6, P250; Manthey MK, 1999, J ORG CHEM, V64, P3930, DOI 10.1021/jo982321n; MANTHEY MK, 1990, THESIS U WOLLONGONG, P288; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; REAL MD, 1990, J BIOL CHEM, V265, P7407; REDDY VN, 1990, EXP EYE RES, V50, P771, DOI 10.1016/0014-4835(90)90127-G; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; STOCK BH, 1986, J BIOL CHEM, V261, P5915; STREITWEISSER A, 1961, MOL ORBITAL THEORY; STUTCHBURY GM, 1993, EXP EYE RES, V57, P149, DOI 10.1006/exer.1993.1110; Sweeney MHJ, 1998, EXP EYE RES, V67, P587, DOI 10.1006/exer.1998.0549; TOKUYAMA T, 1967, J AM CHEM SOC, V89, P1017, DOI 10.1021/ja00980a046; TOKUYAMA T, 1958, J CHEM SOC JPN, V79, P752; TRUSCOTT RJW, 1994, FEBS LETT, V348, P173, DOI 10.1016/0014-5793(94)00601-6; VANHEYNI.R, 1971, NATURE, V230, P393, DOI 10.1038/230393a0; WELLSKNECHT MC, 1993, J BIOL CHEM, V268, P12348; WOOD AM, 1994, VISION RES, V34, P1369, DOI 10.1016/0042-6989(94)90135-X; WOOD AM, 1993, EXP EYE RES, V56, P317, DOI 10.1006/exer.1993.1041; YAPPERT MC, 1992, INVEST OPHTH VIS SCI, V33, P3555	44	64	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					20847	20854		10.1074/jbc.274.30.20847	http://dx.doi.org/10.1074/jbc.274.30.20847			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409626	hybrid			2022-12-25	WOS:000081613100017
J	Li, XQ; Fang, Y; Zhao, XN; Jiang, X; Duong, T; Kain, SR				Li, XQ; Fang, Y; Zhao, XN; Jiang, X; Duong, T; Kain, SR			Characterization of NF kappa B activation by detection of green fluorescent protein-tagged I kappa B degradation in living cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-INDUCED PHOSPHORYLATION; SITE-SPECIFIC PHOSPHORYLATION; TUMOR-NECROSIS-FACTOR; RIBOSOMAL S6 KINASE; TRANSCRIPTION FACTOR; ALPHA PROTEOLYSIS; CODON USAGE; C-REL; EXPRESSION; INHIBITOR	Activation of the transcription factor NF kappa B requires rapid degradation of its inhibitor, I kappa B alpha. To facilitate the study of I kappa B alpha degradation, we fused I kappa B alpha protein to enhanced green fluorescent protein to construct I kappa B alpha-enhanced green fluorescent protein (IG). We demonstrated by both flow cytometry and Western blot analysis that the half-life of IG in the presence of human tumor necrosis factor (TNF) alpha is approximately 5 min, which is similar to the half-life of native I kappa B alpha. The degradation coincided with NF kappa B translocation from the cytoplasm to the nucleus and NF kappa B-mediated induction of transcription. Phorbol 12-myristate 13-acetate (PMA), but not forskolin, also induces degradation of IG fusion protein. The half-life of IG in the presence of PMA is approximately 15 min, longer than when induced with TNF alpha. Co-treatment with TNF alpha and PMA did not result in a synergistic effect on IG degradation, although they stimulate different kinases in two different signaling pathways. Degradation of IG was inhibited by mutations at serine residues 32 and 36, which are the target sites of the phosphorylation modification that initiates degradation of I kappa B alpha. We also demonstrated that basal degradation of IG in the presence of cycloheximide is inhibited by such mutations, suggesting that basal degradation of I kappa K alpha also requires phosphorylation as the signal for degradation. Finally, we showed that the rate of TNF alpha-induced degradation of IG remains almost constant throughout the cell cycle, except at the mitotic phase, in which IG degrades more slowly.	CLONTECH Labs Inc, Palo Alto, CA 94303 USA		Li, XQ (corresponding author), CLONTECH Labs Inc, 1020 E Meadow Circle, Palo Alto, CA 94303 USA.				NIGMS NIH HHS [1R43GM58288-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R43GM058288] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHALFIE M, 1995, PHOTOCHEM PHOTOBIOL, V62, P651, DOI 10.1111/j.1751-1097.1995.tb08712.x; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; Ghoda L, 1997, J BIOL CHEM, V272, P21281, DOI 10.1074/jbc.272.34.21281; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5447; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; Haas J, 1996, CURR BIOL, V6, P315, DOI 10.1016/S0960-9822(02)00482-7; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; INOUYE S, 1994, FEBS LETT, V351, P211, DOI 10.1016/0014-5793(94)00859-0; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Li XQ, 1998, J BIOL CHEM, V273, P34970, DOI 10.1074/jbc.273.52.34970; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MARSHALL J, 1995, NEURON, V14, P211, DOI 10.1016/0896-6273(95)90279-1; MIYAMOTO S, 1994, MOL CELL BIOL, V14, P3276, DOI 10.1128/MCB.14.5.3276; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Yang F, 1996, NAT BIOTECHNOL, V14, P1246, DOI 10.1038/nbt1096-1246; Yang TT, 1996, NUCLEIC ACIDS RES, V24, P4592, DOI 10.1093/nar/24.22.4592; Yaron A, 1997, EMBO J, V16, P6486, DOI 10.1093/emboj/16.21.6486; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	46	29	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21244	21250		10.1074/jbc.274.30.21244	http://dx.doi.org/10.1074/jbc.274.30.21244			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409681	hybrid			2022-12-25	WOS:000081613100072
J	Michaely, PA; Mineo, C; Ying, YS; Anderson, RGW				Michaely, PA; Mineo, C; Ying, YS; Anderson, RGW			Polarization distribution of endogenous Rac1 and RhoA at the cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; ENRICHED MEMBRANE DOMAINS; GROWTH-FACTOR; CAVEOLAE MEMBRANE; LOCALIZATION; ASSOCIATION; GTPASES; FAMILY; TRANSLOCATION; CYTOSKELETON	Rac1 and RhoA regulate membrane ruffling and stress fiber formation. Both molecules appear to exert their control from the plasma membrane. In fibroblasts stimulated with platelet-derived growth factor or lysophosphatidic acid, the reorganization of the cytoskeleton begins at specific sites on the cell surface. We now report that endogenous Rac1 and RhoA also have a polarized distribution at the cell surface. Cell fractionation and immunogold labeling show that in quiescent fibroblasts both of these molecules are concentrated in caveolae, which are plasma membrane domains that are associated with actin-rich regions of the cell. Treatment of these cells with platelet-derived growth factor stimulated the recruitment of additional Rac1 and RhoA to caveolae fractions, while lysophosphatidic acid only caused the recruitment of RhoA We could reconstitute the recruitment of RhoA using either whole cell lysates or purified caveolae. Surprisingly, pretreatment of the lysates with exoenzyme C3 shifted both resident and recruited RhoA from caveolae to noncaveolae membranes. The shift in location was not caused by inactivation of the RhoA effector domain. Moreover, chimeric proteins containing the C-terminal consensus site for Rac1 and RhoA prenylation were constitutively targeted to caveolae fractions. These results suggest that the polarized distribution of Rho family proteins at the cell surface involves an initial targeting of the protein to caveolae and a mechanism for retaining it at this site.	Univ Texas, SW Med Ctr, Dept Cell Biol & Neurosci, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Anderson, RGW (corresponding author), Univ Texas, SW Med Ctr, Dept Cell Biol & Neurosci, Dallas, TX 75235 USA.				NHLBI NIH HHS [HL 20948] Funding Source: Medline; NIGMS NIH HHS [GM 52016] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052016] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; EGGLI PS, 1995, J HISTOCHEM CYTOCHEM, V43, P689, DOI 10.1177/43.7.7608523; Fleming IN, 1996, J BIOL CHEM, V271, P33067, DOI 10.1074/jbc.271.51.33067; Fujisawa K, 1998, J BIOL CHEM, V273, P18943, DOI 10.1074/jbc.273.30.18943; Gingras D, 1998, BIOCHEM BIOPH RES CO, V247, P888, DOI 10.1006/bbrc.1998.8885; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Leung T, 1996, MOL CELL BIOL, V16, P5313; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Liu PS, 1997, P NATL ACAD SCI USA, V94, P13666, DOI 10.1073/pnas.94.25.13666; Mackay DJG, 1997, J CELL BIOL, V138, P927, DOI 10.1083/jcb.138.4.927; Mineo C, 1997, J BIOL CHEM, V272, P10345; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SANAN DA, 1991, J HISTOCHEM CYTOCHEM, V39, P1017, DOI 10.1177/39.8.1906908; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Sehr P, 1998, BIOCHEMISTRY-US, V37, P5296, DOI 10.1021/bi972592c; SEKINE A, 1989, J BIOL CHEM, V264, P8602; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; UEDA T, 1990, J BIOL CHEM, V265, P9373; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295	27	144	145	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21430	21436		10.1074/jbc.274.30.21430	http://dx.doi.org/10.1074/jbc.274.30.21430			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409706	hybrid			2022-12-25	WOS:000081613100097
J	Ohkubo, T; Ozawa, M				Ohkubo, T; Ozawa, M			p120(ctn) binds to the membrane-proximal region of the E-cadherin cytoplasmic domain and is involved in modulation of adhesion activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UVOMORULIN-CATENIN COMPLEX; TYROSINE KINASE SUBSTRATE; CELL-CELL ADHESION; ALPHA-CATENIN; BETA-CATENIN; PROTEIN INTERACTIONS; JUNCTIONAL COMPLEX; EPITHELIAL-CELLS; PHOSPHORYLATION; IDENTIFICATION	Cadherins are transmembrane glycoproteins involved in Ca2+-dependent cell-cell adhesion. Previously, we showed that the conserved membrane-proximal region of the E cadherin cytoplasmic domain negatively regulates adhesion activity. In this report, we provide several lines of evidence that p120(ctn) is involved in this negative regulation. p120(ctn) binds to the membrane-proximal region of the nonfunctional carboxyl-terminally deleted E-cadherin protein. An additional internal deletion in this region prevented the association with p120(ctn) and activated the protein, as seen in an aggregation assay. Furthermore, the nonfunctional E-cadherin can be activated through coexpression of p120(ctn) proteins with amino-terminal deletions, which eliminate several potential serine/threonine phosphorylation sites but do not affect the ability to bind to cadherins, Finally, we show that staurosporine, a kinase inhibitor, induces an increased electrophoretic mobility of p120(ctn) bound to E-cadherin polypeptides, activates the nonfunctional E-cadherin protein, and converts the wildtype E-cadherin and an E-cadherin-alpha-catenin chimeric protein from a cytochalasin D-sensitive to a cytochalasin D-insensitive state. Together, these results indicate that p120(ctn) is a modulator of E-cadherin-mediated cell adhesion.	Kagoshima Univ, Fac Med, Dept Biochem, Kagoshima 8908520, Japan	Kagoshima University	Ozawa, M (corresponding author), Kagoshima Univ, Fac Med, Dept Biochem, Kagoshima 8908520, Japan.	mozawa@med2.kufm.kagoshima-u.ac.jp						Angres B, 1996, J CELL BIOL, V134, P549, DOI 10.1083/jcb.134.2.549; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BUTZ S, 1994, FEBS LETT, V355, P195, DOI 10.1016/0014-5793(94)01205-9; Chitaev NA, 1998, J CELL BIOL, V142, P837, DOI 10.1083/jcb.142.3.837; DOWNING JR, 1991, ONCOGENE, V6, P607; GEIGER B, 1992, ANNU REV CELL BIOL, V8, P307, DOI 10.1146/annurev.cb.08.110192.001515; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; HIRANO S, 1992, CELL, V70, P293, DOI 10.1016/0092-8674(92)90103-J; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; JAFFE SH, 1990, P NATL ACAD SCI USA, V87, P3589, DOI 10.1073/pnas.87.9.3589; KANNER SB, 1991, MOL CELL BIOL, V11, P713, DOI 10.1128/MCB.11.2.713; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Lampugnani MG, 1997, J CELL SCI, V110, P2065; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; Navarro P, 1995, J BIOL CHEM, V270, P30965, DOI 10.1074/jbc.270.52.30965; Nieset JE, 1997, J CELL SCI, V110, P1013; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; NOSE A, 1990, CELL, V61, P147, DOI 10.1016/0092-8674(90)90222-Z; Obama H, 1997, J BIOL CHEM, V272, P11017; Ozawa M, 1998, J BIOL CHEM, V273, P29524, DOI 10.1074/jbc.273.45.29524; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; Ozawa M, 1998, J CELL BIOL, V142, P1605, DOI 10.1083/jcb.142.6.1605; Ratcliffe MJ, 1997, J BIOL CHEM, V272, P31894, DOI 10.1074/jbc.272.50.31894; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; Reynolds AB, 1996, EXP CELL RES, V225, P328, DOI 10.1006/excr.1996.0183; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; REYNOLDS AB, 1992, ONCOGENE, V7, P2439; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Sakakibara A, 1997, J CELL BIOL, V137, P1393, DOI 10.1083/jcb.137.6.1393; SHIBAMOTO S, 1995, J CELL BIOL, V128, P949, DOI 10.1083/jcb.128.5.949; SHIMOYAMA Y, 1992, CANCER RES, V52, P5770; STADDON JM, 1995, J CELL BIOL, V130, P369, DOI 10.1083/jcb.130.2.369; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; VESTWEBER D, 1985, EMBO J, V4, P3393, DOI 10.1002/j.1460-2075.1985.tb04095.x; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; Watabe-Uchida M, 1998, J CELL BIOL, V142, P847, DOI 10.1083/jcb.142.3.847; Weiss EE, 1998, J CELL BIOL, V141, P755, DOI 10.1083/jcb.141.3.755; Yap AS, 1998, J CELL BIOL, V141, P779, DOI 10.1083/jcb.141.3.779	41	150	156	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21409	21415		10.1074/jbc.274.30.21409	http://dx.doi.org/10.1074/jbc.274.30.21409			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409703	hybrid			2022-12-25	WOS:000081613100094
J	Bianchini, A; Musci, G; Calabrese, L				Bianchini, A; Musci, G; Calabrese, L			Inhibition of endothelial nitric-oxide synthase by ceruloplasmin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COPPER TRANSPORT PROTEIN; SERUM CERULOPLASMIN; GUANYLYL CYCLASE; CELLS; CAVEOLIN; ALBUMIN; RISK; HEMOSIDEROSIS; METABOLISM; SUPEROXIDE	The plasma copper protein ceruloplasmin (CP) was found to inhibit endothelial nitric-oxide synthase activation in cultured endothelial cells, in line with previous evidence showing that the endothelium-dependent vasorelaxation of the aorta is impaired by physiological concentrations of ceruloplasmin. The data presented here indicate a direct relationship between the extent of inhibition of agonist-triggered endothelial nitric oxide synthase activation and CP-induced enrichment of the copper content of endothelial cells. Copper discharged by CP was mainly localized in the soluble fraction of cells. The subcellular distribution of the metal seems to be of relevance to the inhibitory effect of CP, because it was mimicked by copper chelates, like copper-histidine, able to selectively enrich the cytosolic fraction of cells, but not by copper salts, which preferentially located the metal to the particulate fraction.	Univ La Sapienza, Dept Biochem Sci, I-00185 Rome, Italy; Univ Messina, Dept Organ & Biol Chem, I-98166 Messina, Italy; Univ Roma Tre, Dept Biol, I-00146 Rome, Italy; Univ La Sapienza, CNR, Ctr Mol Biol, I-00185 Rome, Italy	Sapienza University Rome; University of Messina; Roma Tre University; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome	Calabrese, L (corresponding author), Univ Roma Tre, Dept Biol, Viale Marconi 446, I-00146 Rome, Italy.		Musci, Giovanni/H-2862-2012	Musci, Giovanni/0000-0002-5196-709X				CALABRESE L, 1989, J BIOL CHEM, V264, P6183; CAMPBELL CH, 1981, BIOCHIM BIOPHYS ACTA, V678, P27; Cappelli-Bigazzi M, 1997, AM J PHYSIOL-HEART C, V273, pH2843, DOI 10.1152/ajpheart.1997.273.6.H2843; COUSINS RJ, 1985, PHYSIOL REV, V65, P238, DOI 10.1152/physrev.1985.65.2.238; Dameron CT, 1998, AM J CLIN NUTR, V67, p1091S, DOI 10.1093/ajcn/67.5.1091S; DAMERON CT, 1987, BIOCHEM J, V248, P669, DOI 10.1042/bj2480669; Demura Y, 1998, FREE RADICAL BIO MED, V25, P314, DOI 10.1016/S0891-5849(98)00056-2; EHRENWALD E, 1994, J CLIN INVEST, V93, P1493, DOI 10.1172/JCI117127; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; FREEMAN HC, 1969, J BIOL CHEM, V244, P4823; FRIEDEN E, 1976, ADV ENZYMOL RAMB, V44, P187; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; GITLIN JD, 1988, J BIOL CHEM, V263, P6281; GOA J, 1953, SCAND J CLIN LAB INV, V5, P218, DOI 10.3109/00365515309094189; GOSPODAROWICZ D, 1976, P NATL ACAD SCI USA, V73, P4120, DOI 10.1073/pnas.73.11.4120; Harris E D, 1993, Prog Clin Biol Res, V380, P163; Harris ED, 1998, AM J CLIN NUTR, V67, p988S, DOI 10.1093/ajcn/67.5.988S; HARRIS ZL, 1995, P NATL ACAD SCI USA, V92, P2539, DOI 10.1073/pnas.92.7.2539; HECKER M, 1994, BIOCHEM J, V299, P247, DOI 10.1042/bj2990247; HOLLANDER W, 1979, ATHEROSCLEROSIS, V34, P391, DOI 10.1016/0021-9150(79)90064-9; HOWARD AB, 1995, AM J PHYSIOL-CELL PH, V269, pC612, DOI 10.1152/ajpcell.1995.269.3.C612; HSIEH HS, 1975, BIOCHEM BIOPH RES CO, V67, P1326; HU JR, 1995, J NEUROCHEM, V65, P117; Ju H, 1998, J BIOL CHEM, V273, P24025, DOI 10.1074/jbc.273.37.24025; Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522; KOK FJ, 1988, AM J EPIDEMIOL, V128, P352, DOI 10.1093/oxfordjournals.aje.a114975; LI HH, 1993, CHUNG HUA FU CHAN KO, V28, P379; LI HH, 1993, CHUNG HUA FU CHAN KO, V28, P331; Linder MC, 1998, AM J CLIN NUTR, V67, p965S, DOI 10.1093/ajcn/67.5.965S; MANTTARI M, 1994, EUR HEART J, V15, P1599; MARCEAU N, 1973, BIOCHIM BIOPHYS ACTA, V328, P338, DOI 10.1016/0005-2795(73)90267-5; MAS A, 1992, BIOCHIM BIOPHYS ACTA, V1135, P123, DOI 10.1016/0167-4889(92)90127-W; MAYER B, 1995, J BIOL CHEM, V270, P17355, DOI 10.1074/jbc.270.29.17355; Michel JB, 1997, J BIOL CHEM, V272, P25907, DOI 10.1074/jbc.272.41.25907; Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583; MISKO TP, 1993, ANAL BIOCHEM, V214, P11, DOI 10.1006/abio.1993.1449; MORITA H, 1995, ANN NEUROL, V37, P646, DOI 10.1002/ana.410370515; Mukhopadhyay CK, 1998, BIOCHEMISTRY-US, V37, P14222, DOI 10.1021/bi981137t; Mukhopadhyay CK, 1997, P NATL ACAD SCI USA, V94, P11546, DOI 10.1073/pnas.94.21.11546; MUSCI G, 1993, J BIOL CHEM, V268, P13388; Musci G, 1996, J BIOL CHEM, V271, P1972, DOI 10.1074/jbc.271.4.1972; Ohnishi T, 1997, EUR J PHARMACOL, V319, P49, DOI 10.1016/S0014-2999(96)00833-3; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PERCIVAL SS, 1990, AM J PHYSIOL, V258, pC140, DOI 10.1152/ajpcell.1990.258.1.C140; PERSECHINI A, 1995, BIOCHEMISTRY-US, V34, P15091, DOI 10.1021/bi00046a015; Plane F, 1997, BRIT J PHARMACOL, V121, P345, DOI 10.1038/sj.bjp.0701144; QUINN MR, 1995, NEUROSCI LETT, V196, P65, DOI 10.1016/0304-3940(95)11845-N; REES DD, 1989, P NATL ACAD SCI USA, V86, P3375, DOI 10.1073/pnas.86.9.3375; REUNANEN A, 1992, AM J EPIDEMIOL, V136, P1082, DOI 10.1093/oxfordjournals.aje.a116573; Ryden L., 1984, COPP PROTEINS COPP E, V3, P37; Schuschke DA, 1997, J NUTR, V127, P2274, DOI 10.1093/jn/127.12.2274; STEVENS MD, 1984, BIOCHEMISTRY-US, V23, P261, DOI 10.1021/bi00297a014; SWAIN J, 1995, FEBS LETT, V368, P513, DOI 10.1016/0014-5793(95)00726-P; Valentine JS, 1997, SCIENCE, V278, P817, DOI 10.1126/science.278.5339.817; VALLANCE P, 1989, LANCET, V2, P997; VULPE CD, 1995, ANNU REV NUTR, V15, P293, DOI 10.1146/annurev.nu.15.070195.001453; WALDROP GL, 1990, AM J PHYSIOL, V259, pG212, DOI 10.1152/ajpgi.1990.259.2.G212; WANG JL, 1993, J BIOL CHEM, V268, P22255; WICKHAM NWR, 1988, J LAB CLIN MED, V112, P157; WISDOM SJ, 1991, AM J OBSTET GYNECOL, V165, P1701, DOI 10.1016/0002-9378(91)90018-M; YOSHIDA K, 1995, NAT GENET, V9, P267, DOI 10.1038/ng0395-267; Zaitseva I, 1996, J BIOL INORG CHEM, V1, P15, DOI 10.1007/s007750050018	63	30	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20265	20270		10.1074/jbc.274.29.20265	http://dx.doi.org/10.1074/jbc.274.29.20265			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400645	hybrid			2022-12-25	WOS:000081438300038
J	Lowenberger, C; Charlet, M; Vizioli, J; Kamal, S; Richman, A; Christensen, BM; Bulet, P				Lowenberger, C; Charlet, M; Vizioli, J; Kamal, S; Richman, A; Christensen, BM; Bulet, P			Antimicrobial activity spectrum, cDNA cloning, and mRNA expression of a newly isolated member of the cecropin family from the mosquito vector Aedes aegypti	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPOROGONIC DEVELOPMENT; ANTIBACTERIAL PEPTIDE; PLASMODIUM-BERGHEI; INSECT IMMUNITY; DIFFERENTIAL DISPLAY; SYNTHETIC PEPTIDE; ANOPHELES-GAMBIAE; BOMBYX-MORI; SEQUENCE; DROSOPHILA	An antimicrobial peptide belonging to the cecropin family was isolated from the hemolymph of bacteria-challenged adult Aedes aegypti. This new peptide, named cecropin A, was purified to homogeneity and fully characterized after cDNA cloning. The 34-residue A. aegypti cecropin A is different from the majority of reported insect cecropins in that it is devoid of a tryptophan residue and C-terminal amidation. The importance of these two structural features on the activity spectrum was investigated using a chemically synthesized peptide. A comparison of the antimicrobial activity spectrum of A. aegypti and Drosophila cecropin A showed a lower activity for the mosquito molecule. A. aegypti cecropin mRNA expression was not detected by Northern blot or reverse transcription-polymerase chain reaction analysis in any immature stage of the mosquito, nor in naive adults, but it was observed in challenged adults 6 h after bacteria inoculation, and it continued over 7-10 days.	Univ Wisconsin, Madison, WI 53706 USA; Inst Biol Mol & Cellulaire, CNRS, UPR 9022, F-67084 Strasbourg, France; European Mol Biol Lab, D-69117 Heidelberg, Germany	University of Wisconsin System; University of Wisconsin Madison; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; European Molecular Biology Laboratory (EMBL)	Lowenberger, C (corresponding author), Univ Wisconsin, 1655 Linden Dr, Madison, WI 53706 USA.		BULET, Philippe/C-8557-2014	BULET, Philippe/0000-0001-9016-265X; vizioli, jacopo/0000-0002-4310-8033	NIAID NIH HHS [AI44966, AI28781, AI19769] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI019769, P01AI028781, R01AI044966, R37AI019769, R01AI019769] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDREU D, 1985, BIOCHEMISTRY-US, V24, P1683, DOI 10.1021/bi00328a017; BEERNTSEN BT, 1990, EXP PARASITOL, V71, P406, DOI 10.1016/0014-4894(90)90066-L; Boisbouvier J, 1998, EUR J BIOCHEM, V257, P263, DOI 10.1046/j.1432-1327.1998.2570263.x; Boman Hans G., 1994, P3; CALLAWAY JE, 1993, ANTIMICROB AGENTS CH, V37, P1614, DOI 10.1128/AAC.37.8.1614; CASTEELS P, 1993, J BIOL CHEM, V268, P7044; CHALK R, 1995, P ROY SOC B-BIOL SCI, V261, P217, DOI 10.1098/rspb.1995.0139; CHALK R, 1995, EXP PARASITOL, V80, P401, DOI 10.1006/expr.1995.1052; Cho WL, 1996, INSECT BIOCHEM MOLEC, V26, P395, DOI 10.1016/0965-1748(95)00108-5; COCIANCICH S, 1994, PARASITOL TODAY, V10, P132, DOI 10.1016/0169-4758(94)90260-7; DeLucca AJ, 1997, ANTIMICROB AGENTS CH, V41, P481, DOI 10.1128/AAC.41.2.481; DICKINSON L, 1988, J BIOL CHEM, V263, P19424; DURELL SR, 1992, BIOPHYS J, V63, P1623, DOI 10.1016/S0006-3495(92)81730-7; Fehlbaum P, 1996, P NATL ACAD SCI USA, V93, P1221, DOI 10.1073/pnas.93.3.1221; GWADZ RW, 1989, INFECT IMMUN, V57, P2628, DOI 10.1128/IAI.57.9.2628-2633.1989; HARA S, 1994, COMP BIOCHEM PHYS B, V108, P303, DOI 10.1016/0305-0491(94)90081-7; HERNANDEZ VP, 1994, AM J TROP MED HYG, V50, P440, DOI 10.4269/ajtmh.1994.50.440; Hetru C, 1997, Methods Mol Biol, V78, P35; Hetru Charles, 1998, P40; HULTMARK D, 1982, EUR J BIOCHEM, V127, P207, DOI 10.1111/j.1432-1033.1982.tb06857.x; JAYNES JM, 1988, FASEB J, V2, P2878, DOI 10.1096/fasebj.2.13.3049204; Kang DW, 1996, INSECT BIOCHEM MOLEC, V26, P177, DOI 10.1016/0965-1748(95)00080-1; Knapp T., 1990, Transactions of the Royal Society of Tropical Medicine and Hygiene, V84, P459; KYLSTEN P, 1990, EMBO J, V9, P217, DOI 10.1002/j.1460-2075.1990.tb08098.x; LI ZQ, 1988, FEBS LETT, V231, P299, DOI 10.1016/0014-5793(88)80837-8; LOWENBERGER C, 1995, INSECT BIOCHEM MOLEC, V25, P867, DOI 10.1016/0965-1748(95)00043-U; Lowenberger CA, 1999, INSECT MOL BIOL, V8, P107, DOI 10.1046/j.1365-2583.1999.810107.x; Lowenberger CA, 1999, EXP PARASITOL, V91, P59, DOI 10.1006/expr.1999.4350; Lowenberger CA, 1996, EXP PARASITOL, V83, P191, DOI 10.1006/expr.1996.0066; MERRIFIELD RB, 1982, BIOCHEMISTRY-US, V21, P5020, DOI 10.1021/bi00263a028; OKADA M, 1985, J BIOL CHEM, V260, P7174; Park SS, 1997, INSECT BIOCHEM MOLEC, V27, P711, DOI 10.1016/S0965-1748(97)00049-0; Possani LD, 1998, TOXICON, V36, P1683, DOI 10.1016/S0041-0101(98)00161-5; QU XM, 1982, EUR J BIOCHEM, V127, P219, DOI 10.1111/j.1432-1033.1982.tb06858.x; Richman AM, 1996, INSECT MOL BIOL, V5, P203, DOI 10.1111/j.1365-2583.1996.tb00055.x; RODRIGUEZ MD, 1995, EXP PARASITOL, V80, P596, DOI 10.1006/expr.1995.1075; ROSETTO M, 1993, GENE, V134, P241, DOI 10.1016/0378-1119(93)90100-H; Shahabuddin M, 1998, EXP PARASITOL, V89, P103, DOI 10.1006/expr.1998.4212; Shai Yechiel, 1998, P111; STEINER H, 1981, NATURE, V292, P246, DOI 10.1038/292246a0; Straif SC, 1998, J MED ENTOMOL, V35, P222, DOI 10.1093/jmedent/35.3.222; Sun DX, 1998, BIOCHEM BIOPH RES CO, V249, P410, DOI 10.1006/bbrc.1998.9150; TANIAI K, 1992, BIOCHIM BIOPHYS ACTA, V1132, P203, DOI 10.1016/0167-4781(92)90013-P; TRYSELIUS Y, 1992, EUR J BIOCHEM, V204, P395, DOI 10.1111/j.1432-1033.1992.tb16648.x; Uttenweiler-Joseph S, 1998, P NATL ACAD SCI USA, V95, P11342, DOI 10.1073/pnas.95.19.11342; Zhao CQ, 1997, FEBS LETT, V412, P144, DOI 10.1016/S0014-5793(97)00769-2; Zhou XJ, 1997, J MOL EVOL, V44, P272, DOI 10.1007/PL00006144	47	93	107	0	17	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20092	20097		10.1074/jbc.274.29.20092	http://dx.doi.org/10.1074/jbc.274.29.20092			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400619	hybrid			2022-12-25	WOS:000081438300012
J	Legoix, P; Bluteau, O; Bayer, J; Perret, C; Balabaud, C; Belghiti, J; Franco, D; Thomas, G; Laurent-Puig, P; Zucman-Rossi, J				Legoix, P; Bluteau, O; Bayer, J; Perret, C; Balabaud, C; Belghiti, J; Franco, D; Thomas, G; Laurent-Puig, P; Zucman-Rossi, J			Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity	ONCOGENE			English	Article						hepatocellular carcinoma; beta-catenin; CNNTB1; allelic losses; APC; mutation; chromosome 4	GENE; ACTIVATION; PATHWAY; EXON-3; CANCER; TUMORS; MOUSE	To determine the frequency of Wnt/Wingless beta catenin pathway alteration in human hepatocellular carcinoma, a beta catenin and APC gene mutation screening was performed in a series of 119 tumors. An activating beta catenin mutation in exon 3 was found in 18% of the cases. Among tumors lacking beta catenin mutation, no APC mutation has been evidenced in a subset of 30 cases tested. The correlation between beta catenin mutation status and chromosome segment deletions was studied on a set of 48 hyperploid tumors. Chromosome 1p, 4q and 16p deletions were significantly associated with the absence of beta catenin mutation (P<0.05), Furthermore the Fractional Allelic Loss was significantly smaller in the beta catenin mutated tumors than in the non-mutated tumors (0.12 versus 022), Taken together, these results suggest, the existence of two carcinogenesis mechanisms, The first mechanism implies a beta catenin activating mutation associated with a low rate of loss of heterozygosity. The second mechanism, operating in a context of chromosomal instability, would involve tumor suppressor genes.	CEPH, Fdn Jean Dausset, Lab Genet Tumeurs, INSERM U434,Ctr Etud Polymorphisme Humain, F-75010 Paris, France; Commiss Energie Atom, DRR, DSV, Lab Cytometrie, F-92265 Fontenay Aux Roses, France; CHU Cochin Port Royal, INSERM U129, F-75014 Paris, France; Hop St Andre, F-33000 Bordeaux, France; Hop Beaujon, F-92110 Clichy, France; Hop Antoine Beclere, Serv Chirurg Digest, F-92140 Clamart, France	Foundation Jean Dausset-CEPH; Institut National de la Sante et de la Recherche Medicale (Inserm); CEA; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; CHU Bordeaux; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP	Zucman-Rossi, J (corresponding author), CEPH, Fdn Jean Dausset, Lab Genet Tumeurs, INSERM U434,Ctr Etud Polymorphisme Humain, 27 Rue Juliette Dodu, F-75010 Paris, France.		laurent-puig, pierre/B-2226-2013; j, zucman-rossi/AAV-3594-2021; bluteau, olivier/A-8844-2008; zucman-rossi, Jessica/B-5098-2009; Laurent-Puig, Pierre/K-3641-2019; Perret-Mayeux, Christine/L-3297-2017; Bluteau, Olivier/T-9907-2017	laurent-puig, pierre/0000-0001-8475-5459; j, zucman-rossi/0000-0002-5687-0334; zucman-rossi, Jessica/0000-0002-5687-0334; Laurent-Puig, Pierre/0000-0001-8475-5459; Bluteau, Olivier/0000-0002-6943-8858; perret, christine/0000-0003-4710-7051				BARDI G, 1992, CANCER GENET CYTOGEN, V58, P191, DOI 10.1016/0165-4608(92)90111-K; Boige V, 1997, CANCER RES, V57, P1986; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; GRAEF E, 1994, ONCOGENE, V9, P81; Iwao K, 1998, CANCER RES, V58, P1021; Marchio A, 1997, GENE CHROMOSOME CANC, V18, P59, DOI 10.1002/(SICI)1098-2264(199701)18:1<59::AID-GCC7>3.0.CO;2-0; Miyoshi Y, 1998, CANCER RES, V58, P2524; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; Olschwang S, 1997, P NATL ACAD SCI USA, V94, P12122, DOI 10.1073/pnas.94.22.12122; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; SIMON D, 1990, CANCER GENET CYTOGEN, V45, P255, DOI 10.1016/0165-4608(90)90091-N; Sparks AB, 1998, CANCER RES, V58, P1130; TADA M, 1990, CANCER RES, V50, P1121; Takahashi M, 1998, CANCER RES, V58, P42; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	20	141	145	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 8	1999	18	27					4044	4046		10.1038/sj.onc.1202800	http://dx.doi.org/10.1038/sj.onc.1202800			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KU	10435629				2022-12-25	WOS:000081327800016
J	Couturier, C; Brouillet, A; Couriaud, C; Koumanov, K; Bereziat, G; Andreani, M				Couturier, C; Brouillet, A; Couriaud, C; Koumanov, K; Bereziat, G; Andreani, M			Interleukin 1 beta induces type II-secreted phospholipase A(2) gene in vascular smooth muscle cells by a nuclear factor kappa B and peroxisome proliferator-activated receptor-mediated process	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA PPAR-GAMMA; ARACHIDONIC-ACID RELEASE; LOW-DENSITY-LIPOPROTEIN; RETINOID-X-RECEPTOR; SIGNAL-TRANSDUCTION; FATTY-ACIDS; TRANSCRIPTIONAL ACTIVATION; HUMAN ATHEROSCLEROSIS; BINDING-PROPERTIES; BETA ENHANCEOSOME	Type II-secreted phospholipase A(2) (type II-sPLA(2)) is expressed in smooth muscle cells during atherosclerosis or in response to interleukin-1 beta. The present study shows that the induction of type II-sPLA(2) gene by interleukin-1 beta requires activation of the NF kappa B pathway and cytosolic PLA(2)/PPAR gamma pathway, which are both necessary to achieve the transcriptional process. Interleukin-1 beta-induced type II-sPLA(2) gene dose- and time-dependently and increased the binding of NF kappa B to a specific site of type II-sPLA(2) promoter. This effect was abolished by proteinase inhibitors that block the proteasome machinery and NF kappa B nuclear translocation. Type II-sPLA(2) induction was also obtained by free arachidonic acid and was blocked by either AACOCF(3), a specific cytosolic-PLA(2) inhibitor, PD98059, a mitogen-activated protein kinase kinase inhibitor which prevents cytosolic PLA(2) activation, or nordihydroguaiaretic acid, a lipoxygenase inhibitor, but not by the cyclooxygenase inhibitor indomethacin, suggesting a role for a lipoxygenase product. Type II-sPLA(2) induction was obtained after treatment of the cells by 15-deoxy-Delta(12,14)-dehydro prostaglandin J(2), carbaprostacyclin, and 9-hydroxyoctadecadienoic acid, which are ligands of peroxisome proliferator-activated receptor (PPAR) gamma, whereas PPAR alpha ligands were ineffective, Interleukin-1 beta as well as PPAR gamma-ligands stimulated the activity of a reporter gene containing PPAR gamma-binding sites in its promoter. Binding of both NF kappa B and PPAR gamma to their promoter is required to stimulate the transcriptional process since inhibitors of each class block interleukin-1 beta-induced type II-sPLA(2) gene activation, We therefore suggest that NF kappa B and PPAR gamma cooperate at the enhanceosome-coactivator level to turn on transcription of the proinflammatory type II-sPLA(2) gene.	Univ Paris 06, ESA 7079, CNRS, Unite Propre Rech, F-75252 Paris 5, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Andreani, M (corresponding author), Univ Paris 06, ESA 7079, CNRS, Unite Propre Rech, 7 Quai St Bernard, F-75252 Paris 5, France.		Couturier, Cyril/ABG-9063-2020; Couturier, Cyril CC/I-3020-2016; Brouillet, Arthur/S-4499-2018					Anderson KM, 1997, J BIOL CHEM, V272, P30504, DOI 10.1074/jbc.272.48.30504; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; Balsinde J, 1998, P NATL ACAD SCI USA, V95, P7951, DOI 10.1073/pnas.95.14.7951; BATTLE T, 1994, TISSUE CELL, V26, P943, DOI 10.1016/0040-8166(94)90043-4; Bonizzi G, 1997, J IMMUNOL, V159, P5264; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; Bourcier T, 1997, J BIOL CHEM, V272, P15817, DOI 10.1074/jbc.272.25.15817; Brandt JM, 1998, J BIOL CHEM, V273, P23786, DOI 10.1074/jbc.273.37.23786; Braun M, 1997, ARTERIOSCL THROM VAS, V17, P2568, DOI 10.1161/01.ATV.17.11.2568; BRINKMAN HJM, 1990, THROMB HAEMOSTASIS, V63, P291; Camandola S, 1996, BIOCHEM BIOPH RES CO, V229, P643, DOI 10.1006/bbrc.1996.1857; Chai YC, 1996, J BIOL CHEM, V271, P17791, DOI 10.1074/jbc.271.30.17791; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Elinder LS, 1997, ARTERIOSCL THROM VAS, V17, P2257, DOI 10.1161/01.ATV.17.10.2257; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Forsyth EA, 1997, J VASC SURG, V26, P1002, DOI 10.1016/S0741-5214(97)70013-2; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; FRENCH JF, 1993, EUR J PHARMACOL, V233, P109, DOI 10.1016/0014-2999(93)90355-L; Guermah M, 1998, MOL CELL BIOL, V18, P3234, DOI 10.1128/MCB.18.6.3234; Hernandez M, 1998, J BIOL CHEM, V273, P606, DOI 10.1074/jbc.273.1.606; Iijima K, 1998, BIOCHEM BIOPH RES CO, V247, P353, DOI 10.1006/bbrc.1998.8794; Jacques C, 1997, J CLIN INVEST, V99, P1864, DOI 10.1172/JCI119353; JugeAubry C, 1997, J BIOL CHEM, V272, P25252, DOI 10.1074/jbc.272.40.25252; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Koumanov K, 1997, BIOCHEM J, V326, P227, DOI 10.1042/bj3260227; KREY G, 1993, J STEROID BIOCHEM, V47, P65, DOI 10.1016/0960-0760(93)90058-5; KUSUNOKI C, 1990, BIOCHIM BIOPHYS ACTA, V1087, P95, DOI 10.1016/0167-4781(90)90127-N; Kuwata H, 1998, J BIOL CHEM, V273, P1733, DOI 10.1074/jbc.273.3.1733; Landry DB, 1997, AM J PATHOL, V151, P1085; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LIBBY P, 1986, J CLIN INVEST, V78, P1432, DOI 10.1172/JCI112732; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Menschikowski M, 1995, ATHEROSCLEROSIS, V118, P173, DOI 10.1016/0021-9150(95)05604-1; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; Minamikawa J, 1998, J CLIN ENDOCR METAB, V83, P1041, DOI 10.1210/jc.83.3.1041; Mizukami J, 1997, BIOCHEM BIOPH RES CO, V240, P61, DOI 10.1006/bbrc.1997.7602; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; NAKANO T, 1990, FEBS LETT, V261, P171, DOI 10.1016/0014-5793(90)80663-4; NAKANO T, 1990, FEBS LETT, V273, P23, DOI 10.1016/0014-5793(90)81042-M; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; Neuzil J, 1998, BIOCHEMISTRY-US, V37, P9203, DOI 10.1021/bi9730745; Newton R, 1997, FEBS LETT, V418, P135, DOI 10.1016/S0014-5793(97)01362-8; NILSSON J, 1993, CARDIOVASC RES, V27, P1184, DOI 10.1093/cvr/27.7.1184; NORIOKA K, 1990, AUTOIMMUNITY, V7, P41, DOI 10.3109/08916939009041049; OHARA O, 1990, NUCLEIC ACIDS RES, V18, P6997, DOI 10.1093/nar/18.23.6997; PERNAS P, 1991, BIOCHEM BIOPH RES CO, V178, P1298, DOI 10.1016/0006-291X(91)91035-B; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PFEILSCHIFTER J, 1993, J CLIN INVEST, V92, P2516, DOI 10.1172/JCI116860; Ricote M, 1998, P NATL ACAD SCI USA, V95, P7614, DOI 10.1073/pnas.95.13.7614; Romano M, 1998, ARTERIOSCL THROM VAS, V18, P519, DOI 10.1161/01.ATV.18.4.519; Schulman IG, 1998, MOL CELL BIOL, V18, P3483, DOI 10.1128/MCB.18.6.3483; Shapiro L, 1993, New Horiz, V1, P13; Singh S, 1996, J BIOL CHEM, V271, P31049, DOI 10.1074/jbc.271.49.31049; SPINK J, 1995, J BIOL CHEM, V270, P29541, DOI 10.1074/jbc.270.49.29541; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VADAS P, 1992, LIFE SCI, V50, P807, DOI 10.1016/0024-3205(92)90186-S; Walker G, 1997, BRIT J PHARMACOL, V121, P787, DOI 10.1038/sj.bjp.0701170	66	82	85	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23085	23093		10.1074/jbc.274.33.23085	http://dx.doi.org/10.1074/jbc.274.33.23085			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438477	hybrid			2022-12-25	WOS:000082012800027
J	Hong, H; Yang, L; Stallcup, MR				Hong, H; Yang, L; Stallcup, MR			Hormone-independent transcriptional activation and coactivator binding by novel orphan nuclear receptor ERR3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RELATED RECEPTOR; STEROIDOGENIC FACTOR-I; RESPONSE ELEMENT; GLUCOCORTICOID RECEPTOR; ENDOCRINE DEVELOPMENT; DEPENDENT ACTIVATION; SUPERFAMILY; PROTEIN; DOMAIN; EXPRESSION	Orphan nuclear receptors share sequence homology with members of the nuclear receptor superfamily, but ligands are unknown or unnecessary. A novel orphan receptor, estrogen receptor-related protein 3 (ERR3), was identified by yeast two-hybrid screening, using the transcriptional coactivator glucocorticoid receptor interacting protein 1 (GRIP1) as bait, The putative full-length mouse ERRS contains 458 amino acids and is closely related to two known orphan receptors ERR1 and ERR2, All the ERR family members share an almost identical DNA-binding domain, which has 680/0 amino acid identity with that of estrogen receptor. ERRS bound specifically to an estrogen response element and activated reporter genes controlled by estrogen response elements, both in yeast and in mammalian cells, in the absence of any added ligand. A conserved AF-2 activation domain located in the hormone-binding domain of ERRS was primarily responsible for transcriptional activation, The ERRS AF-2 domain bound GRIP1 in a Ligand-independent manner both in vitro and in vivo, through the LXXLL motifs of GRTP1, and GRIP1 functioned as a transcriptional coactivator for ERRS in both yeast and mammalian cells. Expression of ERRS in adult mouse was restricted; highest expression was observed in heart, kidney, and brain. In the mouse embryo no expression was observed at day 7, and highest expression occurred around the 11-15 day stages, Although ERR3 is much more closely related to ERR2 than to ERR1, the expression pattern for ERRS was similar to that of ERR1 and distinct from that for ERRB, suggesting a unique role for ERRS in development.	Univ So Calif, Dept Pathol, Los Angeles, CA 90033 USA	University of Southern California	Stallcup, MR (corresponding author), Univ So Calif, Dept Pathol, HMR 301,2011 Zonal Ave, Los Angeles, CA 90033 USA.							Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Blumberg B, 1998, GENE DEV, V12, P3149, DOI 10.1101/gad.12.20.3149; Bonnelye E, 1997, MECH DEVELOP, V65, P71, DOI 10.1016/S0925-4773(97)00059-2; BRINKMANN AO, 1989, J STEROID BIOCHEM, V34, P307, DOI 10.1016/0022-4731(89)90098-8; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Crawford PA, 1997, MOL ENDOCRINOL, V11, P1626, DOI 10.1210/me.11.11.1626; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; Enmark E, 1996, MOL ENDOCRINOL, V10, P1293, DOI 10.1210/me.10.11.1293; Eudy JD, 1998, GENOMICS, V50, P382, DOI 10.1006/geno.1998.5345; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Forman BM, 1998, NATURE, V395, P612, DOI 10.1038/26996; GARABEDIAN MJ, 1992, MOL BIOL CELL, V3, P1245, DOI 10.1091/mbc.3.11.1245; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Hong H, 1999, J BIOL CHEM, V274, P3496, DOI 10.1074/jbc.274.6.3496; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; INGRAHAM HA, 1994, GENE DEV, V8, P2302, DOI 10.1101/gad.8.19.2302; Ito M, 1998, MOL ENDOCRINOL, V12, P290, DOI 10.1210/me.12.2.290; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; Lala DS, 1997, P NATL ACAD SCI USA, V94, P4895, DOI 10.1073/pnas.94.10.4895; LEES JA, 1989, NUCLEIC ACIDS RES, V17, P5477, DOI 10.1093/nar/17.14.5477; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Luo JM, 1997, NATURE, V388, P778, DOI 10.1038/42022; Lydon John P., 1992, Gene Expression, V2, P273; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; ONATE SA, 1995, SCIENCE, V270, P1354; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Parker KL, 1998, MOL CELL ENDOCRINOL, V140, P59, DOI 10.1016/S0303-7207(98)00030-6; Pettersson K, 1996, MECH DEVELOP, V54, P211, DOI 10.1016/0925-4773(95)00479-3; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; SIKORSKI RS, 1989, GENETICS, V122, P19; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Sladek R, 1997, MOL CELL BIOL, V17, P5400, DOI 10.1128/MCB.17.9.5400; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Walfish PG, 1997, P NATL ACAD SCI USA, V94, P3697, DOI 10.1073/pnas.94.8.3697; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Westin S, 1998, NATURE, V395, P199, DOI 10.1038/26040; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; Wong M, 1997, RECENT PROG HORM RES, V52, P167; Yang NY, 1996, J BIOL CHEM, V271, P5795, DOI 10.1074/jbc.271.10.5795	62	250	272	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22618	22626		10.1074/jbc.274.32.22618	http://dx.doi.org/10.1074/jbc.274.32.22618			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428842	Green Published, hybrid			2022-12-25	WOS:000081868400072
J	Maillet, I; Buhler, JM; Sentenac, A; Labarre, J				Maillet, I; Buhler, JM; Sentenac, A; Labarre, J			Rpb4p is necessary for RNA polymerase II activity at high temperature	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; HEAT-SHOCK; STRESS SURVIVAL; YEAST-CELLS; SUBUNIT; THERMOTOLERANCE; GENE; PROTEINS; IDENTIFICATION; EXPRESSION	Rpb4p and Rpb7p are two subunits of the yeast RNA polymerase II, which form a subcomplex that can dissociate from the enzyme in vitro, Whereas RPB7 is essential, RPB4 is dispensable for cellular viability. However, the rpb4 null mutant is heat-sensitive, and it has been suggested that Rpb4p is an essential component for cellular stress response. To examine this hypothesis, we used two-dimensional gel electrophoresis to analyze the protein expression pattern of the rpb4 null mutant in response to heat shock, oxidative stress, osmotic stress, and in the post-diauxic phase. We show that this mutant is not impaired in stress induced transcriptional activation: the absence of heat shock response of the mutant is due to a general defect in RNA polymerase II activity at high temperature. Under this condition, Rpb4p is necessary to maintain the polymerase activity in vivo, The heat growth defect of the rpb4 null mutant can be partially suppressed by overexpression of RPB7, suggesting that Rpb4p maintains or stabilizes Rpb7p in the RNA polymerase, We also demonstrate that rpb4 null mutant is an appropriate tool to analyze the involvement of transcriptional events in the survival and adaptation to heat shock or other stresses.	CEA Saclay, Serv Biochim & Genet Mol, F-91191 Gif Sur Yvette, France	CEA; UDICE-French Research Universities; Universite Paris Saclay	Labarre, J (corresponding author), CEA Saclay, Serv Biochim & Genet Mol, Bat 142, F-91191 Gif Sur Yvette, France.	labarre@jonas.saclay.cea.fr						Asturias FJ, 1997, J MOL BIOL, V272, P536, DOI 10.1006/jmbi.1997.1273; BoyMarcotte E, 1996, MICROBIOL-UK, V142, P459, DOI 10.1099/13500872-142-3-459; BOYMARCOTTE E, 1999, IN PRESS MOL MICROBI, V33; Caponigro G, 1996, MICROBIOL REV, V60, P233, DOI 10.1128/MMBR.60.1.233-249.1996; CHODER M, 1993, MOL CELL BIOL, V13, P6984, DOI 10.1128/MCB.13.11.6984; COLLINSON LP, 1992, J GEN MICROBIOL, V138, P329, DOI 10.1099/00221287-138-2-329; DEVIRGILIO C, 1991, FEBS LETT, V288, P86, DOI 10.1016/0014-5793(91)81008-V; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; Elliott B, 1996, GENETICS, V144, P923; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Godon C, 1998, J BIOL CHEM, V273, P22480, DOI 10.1074/jbc.273.35.22480; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; Jensen GJ, 1998, EMBO J, V17, P2353, DOI 10.1017/S1431927600024983; KHAZAK V, 1995, MOL BIOL CELL, V6, P759, DOI 10.1091/mbc.6.7.759; Lee DH, 1996, MOL CELL BIOL, V16, P4773; Lee J, 1999, J BIOL CHEM, V274, P16040, DOI 10.1074/jbc.274.23.16040; Lindquist S, 1996, P NATL ACAD SCI USA, V93, P5301, DOI 10.1073/pnas.93.11.5301; Maillet I, 1996, J BIOL CHEM, V271, P10263, DOI 10.1074/jbc.271.17.10263; Moskvina E, 1998, YEAST, V14, P1041, DOI 10.1002/(SICI)1097-0061(199808)14:11<1041::AID-YEA296>3.0.CO;2-4; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; NORBECK J, 1995, ELECTROPHORESIS, V16, P149, DOI 10.1002/elps.1150160124; PARKER R, 1991, METHOD ENZYMOL, V194, P415; Rosenheck S, 1998, J BACTERIOL, V180, P6187; RUET A, 1980, J BIOL CHEM, V255, P6450; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHNELL N, 1992, CURR GENET, V21, P269, DOI 10.1007/BF00351681; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; Treger JM, 1998, J BIOL CHEM, V273, P26875, DOI 10.1074/jbc.273.41.26875; WOYCHIK NA, 1990, TRENDS BIOCHEM SCI, V15, P347, DOI 10.1016/0968-0004(90)90074-L; WOYCHIK NA, 1989, MOL CELL BIOL, V9, P2854, DOI 10.1128/MCB.9.7.2854	31	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22586	22590		10.1074/jbc.274.32.22586	http://dx.doi.org/10.1074/jbc.274.32.22586			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428837	hybrid			2022-12-25	WOS:000081868400067
J	Coluccio, LR; Geeves, MA				Coluccio, LR; Geeves, MA			Transient kinetic analysis of the 130-kDa myosin I (MYR-1 gene product) from rat liver - A myosin I designed for maintenance of tension?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE MYOSIN; ADP RELEASE; DICTYOSTELIUM-DISCOIDEUM; CALMODULIN-BINDING; ACTIN-FILAMENTS; SMOOTH-MUSCLE; ATPASE; FRAGMENTS; PROTEIN; COMPLEX	The 130-kDa myosin I (MI130), product of the myr-1 gene, is one member of the mammalian class I myosins, a group of small, calmodulin-binding mechanochemical molecules of the myosin superfamily that translocate actin filaments. Roles for MI130 are unknown. Our hypothesis is that, as with all myosins, MI130 is designed for a particular function and hence possesses specific biochemical attributes. To test this hypothesis we have characterized the enzymatic properties of MI130 using steady-state and stopped-flow kinetic analyses. Our results indicate that: (i) the Mg2+-ATPase activity is activated in proportion to actin concentration in the absence of Ca2+ (ii) the ATP-induced dissociation of actin-M-130 is much slower for MI130 than has been observed far other myosins (-Ca2+, second order rate constant of ATP binding, 1.7 x 10(4) M-1 s(-1); maximal rate constant, 32 s(-1)); (iii) ADP binds to actin-MI130 with an affinity of similar to 10 mu M and competes with ATP-induced dissociation of actin-MI130; the rate constant of ADP release from actin-M-130 is 2 s(-1); (iv) the rates of the ATP-induced dissociation of actin-MI and ADP release are 2-3 times greater in the presence of CaCl2, indicating a sensitivity of motor activity to Ca2+; and (v) the affinity of MI130 for actin (15 nM) is typical of that observed for other myosins. Together, these results indicate that although MI130 shares some characteristics with other myosins, it is well adapted for maintenance of cortical tension.	Boston Biomed Res Inst, Boston, MA 02114 USA; Max Planck Inst Mol Physiol, D-44026 Dortmund, Germany	Boston Biomedical Research Institute; Max Planck Society	Geeves, MA (corresponding author), Boston Biomed Res Inst, Boston, MA 02114 USA.		Geeves, Michael/F-7583-2011	Geeves, Michael/0000-0002-9364-8898	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056130] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM56130] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS RJ, 1986, NATURE, V322, P754, DOI 10.1038/322754a0; ADELSTEIN RS, 1980, ANNU REV BIOCHEM, V49, P921, DOI 10.1146/annurev.bi.49.070180.004421; BAGSHAW CR, 1974, BIOCHEM J, V141, P351, DOI 10.1042/bj1410351; BAHLER M, 1994, J CELL BIOL, V126, P375, DOI 10.1083/jcb.126.2.375; COLLINS K, 1990, J CELL BIOL, V110, P1137, DOI 10.1083/jcb.110.4.1137; COLUCCIO LM, 1994, J CELL SCI, V107, P2279; COLUCCIO LM, 1993, CELL MOTIL CYTOSKEL, V24, P189, DOI 10.1002/cm.970240306; Coluccio LM, 1997, AM J PHYSIOL-CELL PH, V273, pC347, DOI 10.1152/ajpcell.1997.273.2.C347; CONZELMAN KA, 1987, J CELL BIOL, V105, P313, DOI 10.1083/jcb.105.1.313; Cope MJTV, 1996, STRUCTURE, V4, P969, DOI 10.1016/S0969-2126(96)00103-7; Cremo CR, 1998, BIOCHEMISTRY-US, V37, P1969, DOI 10.1021/bi9722406; CRIDDLE AH, 1985, BIOCHEM J, V232, P343, DOI 10.1042/bj2320343; GOLLUB J, 1996, NAT STRUCT BIOL, V3, P737; Hill T.L., 1974, Progress Biophys Molec Biol, V28, P267, DOI 10.1016/0079-6107(74)90020-0; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; JONTES JD, 1995, NATURE, V378, P751, DOI 10.1038/378751a0; Jontes JD, 1997, P NATL ACAD SCI USA, V94, P14332, DOI 10.1073/pnas.94.26.14332; Jontes JD, 1997, J CELL BIOL, V139, P683, DOI 10.1083/jcb.139.3.683; Jung G, 1996, J CELL BIOL, V133, P305, DOI 10.1083/jcb.133.2.305; KRIZEK J, 1987, FEBS LETT, V225, P269, DOI 10.1016/0014-5793(87)81172-9; Kurzawa SE, 1996, J MUSCLE RES CELL M, V17, P669, DOI 10.1007/BF00154061; Kurzawa SE, 1997, BIOCHEMISTRY-US, V36, P317, DOI 10.1021/bi962166b; MARSTON SB, 1980, J MOL BIOL, V139, P573, DOI 10.1016/0022-2836(80)90050-9; MCGOLDRICK CA, 1995, J CELL BIOL, V128, P577, DOI 10.1083/jcb.128.4.577; MILLAR NC, 1988, BIOCHEM J, V249, P735, DOI 10.1042/bj2490735; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; Novak KD, 1997, J CELL BIOL, V136, P633, DOI 10.1083/jcb.136.3.633; NOVAK KD, 1995, J CELL BIOL, V131, P1205, DOI 10.1083/jcb.131.5.1205; Ostap EM, 1996, J CELL BIOL, V132, P1053, DOI 10.1083/jcb.132.6.1053; POLLARD TD, 1982, METHOD CELL BIOL, V24, P333; POOLE KIV, 1997, J MUSCLE RES CELL M, V18, P264; REIZES O, 1994, P NATL ACAD SCI USA, V91, P6349, DOI 10.1073/pnas.91.14.6349; RITCHIE MD, 1993, P NATL ACAD SCI USA, V90, P8619, DOI 10.1073/pnas.90.18.8619; RUPPERT C, 1993, J CELL BIOL, V120, P1393, DOI 10.1083/jcb.120.6.1393; RUPPERT C, 1995, J CELL SCI, V108, P3775; Sellers JR, 1996, J MUSCLE RES CELL M, V17, P7, DOI 10.1007/BF00140320; SHERR EH, 1993, J CELL BIOL, V120, P1405, DOI 10.1083/jcb.120.6.1405; SIEMANKOWSKI RF, 1984, J BIOL CHEM, V259, P5045; SMITH DA, 1995, BIOPHYS J, V69, P524, DOI 10.1016/S0006-3495(95)79926-X; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SZENTGYORGYI AG, 1994, MYOLOGY, P506; Veigel C, 1999, BIOPHYS J, V76, pA145; Veigel C, 1999, NATURE, V398, P530, DOI 10.1038/19104; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0; WILLIAMS R, 1994, CELL MOTIL CYTOSKEL, V27, P41, DOI 10.1002/cm.970270105; Zhu T, 1998, J BIOL CHEM, V273, P20481, DOI 10.1074/jbc.273.32.20481	47	76	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21575	21580		10.1074/jbc.274.31.21575	http://dx.doi.org/10.1074/jbc.274.31.21575			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419463	hybrid			2022-12-25	WOS:000081721100016
J	Schubert, C; Hirsch, JA; Gurevich, VV; Engelman, DM; Sigler, PB; Fleming, KG				Schubert, C; Hirsch, JA; Gurevich, VV; Engelman, DM; Sigler, PB; Fleming, KG			Visual arrestin activity may be regulated by self-association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; PROTEIN-COUPLED RECEPTORS; TATA-BINDING PROTEIN; RHODOPSIN; SELECTIVITY; DIMERIZATION; AFFINITY; DNA	Visual arrestin is the protein responsible for rapid quenching of G-protein-coupled receptor signaling. Arrestin exists as a latent inhibitor which must be 'activated' upon contact with a phosphorylated receptor. X-ray crystal structures of visual arrestin exhibit a tetrameric arrangement wherein an asymmetric dimer with an extensive interface between conformationally different subunits is related to a second asymmetric dimer by a local two-fold rotation axis. To test the biological relevance of this molecular organization in solution, we carried out a sedimentation, equilibrium analysis of arrestin at both crystallographic and physiological protein concentrations.. While the tetrameric form can exist at the high concentrations used in crystallography experiments, we find that arrestin participates in a monomer/dimer equilibrium at concentrations more likely to be physiologically relevant. Solution interaction analysis of a proteolytically modified, constitutively active form of arrestin shows diminished dimerization. We propose that self-association of arrestin may provide a mechanism for regulation of arrestin activity by (i) ensuring an adequate supply for rapid quenching of the visual signal and. (ii) limiting the availability of active monomeric species, thereby preventing inappropriate signal termination.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA; Sun Hlth Res Inst, Ralph & Muriel Roberts Lab Vis Sci, Sun City, AZ 85372 USA	Yale University; Howard Hughes Medical Institute; Yale University; Banner Research; Banner Health; Banner Sun Health Research Institute	Fleming, KG (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 208114,266 Whitney Ave, New Haven, CT 06520 USA.		Fleming, Karen/E-7892-2011; Gurevich, Vsevolod/A-3236-2008; Hirsch, Joel/AAC-8000-2021	Gurevich, Vsevolod/0000-0002-3950-5351; Hirsch, Joel/0000-0001-7544-8668	NIGMS NIH HHS [GM 54160, GM 22324, GM 22778] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022324] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Coleman RA, 1997, P NATL ACAD SCI USA, V94, P7221, DOI 10.1073/pnas.94.14.7221; COLEMAN RA, 1995, J BIOL CHEM, V270, P13842, DOI 10.1074/jbc.270.23.13842; Granzin J, 1998, NATURE, V391, P918, DOI 10.1038/36147; GrayKeller MP, 1997, BIOCHEMISTRY-US, V36, P7058, DOI 10.1021/bi963110k; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; Gurevich VV, 1997, J BIOL CHEM, V272, P28849, DOI 10.1074/jbc.272.46.28849; GUREVICH VV, 1994, J BIOL CHEM, V269, P8721; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Gurevich VV, 1997, MOL PHARMACOL, V51, P161, DOI 10.1124/mol.51.1.161; Gurevich VV, 1998, J BIOL CHEM, V273, P15501, DOI 10.1074/jbc.273.25.15501; HAMM HE, 1986, BIOCHEMISTRY-US, V25, P4512, DOI 10.1021/bi00364a010; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; JONES S, 1995, PROG BIOPHYS MOL BIO, V63, P31, DOI 10.1016/0079-6107(94)00008-W; Kawamura Satoru, 1995, P105; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PALCZEWSKI K, 1994, PROTEIN SCI, V3, P314; PALCZEWSKI K, 1994, PROTEIN SCI, V3, P1355, DOI 10.1002/pro.5560030901; Taggart AKP, 1996, SCIENCE, V272, P1331, DOI 10.1126/science.272.5266.1331	22	64	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21186	21190		10.1074/jbc.274.30.21186	http://dx.doi.org/10.1074/jbc.274.30.21186			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409673	hybrid			2022-12-25	WOS:000081613100064
J	Scrimgeour, AG; Allen, PB; Fienberg, AA; Greengard, P; Lawrence, JC				Scrimgeour, AG; Allen, PB; Fienberg, AA; Greengard, P; Lawrence, JC			Inhibitor-1 is not required for the activation of glycogen synthase by insulin in skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE 3'-5'-MONOPHOSPHATE-REGULATED PHOSPHOPROTEIN; PROTEIN PHOSPHATASE INHIBITOR-1; REGULATED PHOSPHOPROTEIN; 3T3-L1 ADIPOCYTES; GLUCOSE-TRANSPORT; ADIPOSE-TISSUE; PHOSPHORYLATION; METABOLISM; DARPP-32; KINASE	Glycogen synthase is an excellent in vitro substrate for protein phosphatase-1 (PP1), which is potently inhibited by the phosphorylated forms of DARPP-32 (dopamine- and cAMP-regulated phosphoprotein, M-r = 32,000) and Inhibitor-1. To test the hypothesis that the activation of glycogen synthase by insulin is due to a decrease in the inhibition of PP1 by the phosphatase inhibitors, we have investigated the effects of insulin on glycogen synthesis in skeletal muscles from wild-type mice and mice lacking Inhibitor-1 and DARPP-32 as a result of targeted disruption of the genes encoding the two proteins. Insulin increased glycogen synthase activity and the synthesis of glycogen to the same extent in wild-type and knockout mice, indicating that neither Inhibitor-1 nor DARPP-32 is required for the full stimulatory effects of insulin on glycogen synthase and glycogen synthesis in skeletal muscle.	Univ Virginia, Sch Med, Dept Pharmacol, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Med, Charlottesville, VA 22908 USA; Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA	University of Virginia; University of Virginia; Rockefeller University	Lawrence, JC (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Pharmacol, Box 448, Charlottesville, VA 22908 USA.	jcl3p@virginia.edu	Scrimgeour, Angus/D-6794-2013		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028312] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH040899] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR41180] Funding Source: Medline; NIDDK NIH HHS [DK28312] Funding Source: Medline; NIMH NIH HHS [MH40899] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARIANO MA, 1973, J HISTOCHEM CYTOCHEM, V21, P51, DOI 10.1177/21.1.51; Azpiazu I, 1996, J BIOL CHEM, V271, P5033; Brady MJ, 1997, J BIOL CHEM, V272, P29698, DOI 10.1074/jbc.272.47.29698; Brady MJ, 1997, J BIOL CHEM, V272, P20198, DOI 10.1074/jbc.272.32.20198; COHEN P, 1989, J BIOL CHEM, V264, P21435; COHEN P, 1990, ADV SEC MESS PHOSPH, V24, P230; Cohen P., 1986, ENZYMES, VXVII, P461; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DEPAOLIROACH AA, 1999, MIAMI NATURE BIOTECH; DIETZ MR, 1980, J BIOL CHEM, V255, P2301; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Fienberg AA, 1998, SCIENCE, V281, P838, DOI 10.1126/science.281.5378.838; FOULKES JG, 1980, FEBS LETT, V112, P21, DOI 10.1016/0014-5793(80)80117-7; GILBOE DP, 1972, ANAL BIOCHEM, V47, P20, DOI 10.1016/0003-2697(72)90274-6; GUSTAFSON EL, 1991, J COMP NEUROL, V310, P170, DOI 10.1002/cne.903100204; HEMMINGS HC, 1984, J NEUROSCI, V4, P99; HEMMINGS HC, 1986, J NEUROSCI, V6, P1469; HUANG FL, 1976, EUR J BIOCHEM, V70, P419, DOI 10.1111/j.1432-1033.1976.tb11032.x; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; JUE T, 1989, P NATL ACAD SCI USA, V86, P1439, DOI 10.1073/pnas.86.5.1439; KHATRA BS, 1983, ARCH BIOCHEM BIOPHYS, V227, P39, DOI 10.1016/0003-9861(83)90346-6; Lawrence JC, 1997, DIABETES, V46, P541, DOI 10.2337/diabetes.46.4.541; LAWRENCE JC, 1992, ANNU REV PHYSIOL, V54, P177, DOI 10.1146/annurev.ph.54.030192.001141; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Lin Tai-An, 1994, Journal of Biological Chemistry, V269, P21255; Mastick CC, 1998, MOL CELL BIOCHEM, V182, P65; MEISTER B, 1988, P NATL ACAD SCI USA, V85, P8713, DOI 10.1073/pnas.85.22.8713; NIMMO GA, 1978, EUR J BIOCHEM, V87, P341, DOI 10.1111/j.1432-1033.1978.tb12383.x; PARKER PJ, 1982, EUR J BIOCHEM, V124, P47, DOI 10.1111/j.1432-1033.1982.tb05904.x; Printen JA, 1997, SCIENCE, V275, P1475, DOI 10.1126/science.275.5305.1475; ROACH PJ, 1976, TRENDS BIOCHEM SCI, V1, P110, DOI 10.1016/0968-0004(76)90321-2; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; SHULMAN GI, 1990, NEW ENGL J MED, V322, P223, DOI 10.1056/NEJM199001253220403; SKURAT AV, 1994, J BIOL CHEM, V269, P25534; SKURAT AV, 1995, J BIOL CHEM, V270, P12491, DOI 10.1074/jbc.270.21.12491; SMITH RL, 1984, J BIOL CHEM, V259, P2201; STRALFORS P, 1989, EUR J BIOCHEM, V180, P143, DOI 10.1111/j.1432-1033.1989.tb14624.x; SUTHERLAND C, 1993, EUR J BIOCHEM, V212, P581, DOI 10.1111/j.1432-1033.1993.tb17696.x; TANG PM, 1991, J BIOL CHEM, V266, P15782; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7; VILLARPALASI C, 1960, BIOCHIM BIOPHYS ACTA, V39, P171, DOI 10.1016/0006-3002(60)90142-6	42	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					20949	20952		10.1074/jbc.274.30.20949	http://dx.doi.org/10.1074/jbc.274.30.20949			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409641	hybrid			2022-12-25	WOS:000081613100032
J	Asai, T; Shinoda, Y; Nohara, T; Yoshihisa, T; Endo, T				Asai, T; Shinoda, Y; Nohara, T; Yoshihisa, T; Endo, T			Sec-dependent pathway and Delta pH-dependent pathway do not share a common translocation pore in thylakoidal protein transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE PATHWAYS; CHLOROPLASTS; MEMBRANES; HOMOLOG; INTERMEDIATE; IMPORT; CDNA; IDENTIFICATION; ENVELOPE	Thylakoidal proteins of plant chloroplasts are transported to thylakoids via several different pathways, including the Delta pH-dependent and the Sec-dependent pathways. In this study, we asked if these two pathways utilize a common translocation pore. A fusion protein consisting of a 23-kDa subunit of the oxygen evolving complex and Escherichia coli biotin carboxyl carrier protein was biotinylated in E. coli cells and purified. When incubated with isolated pea thylakoids in the absence of avidin, the purified fusion protein was imported into the thylakoids via the Delta pH-dependent pathway. However in the presence of avidin, the fusion protein became lodged in the thylakoid membranes, with its N terminus reaching the thylakoidal lumen, while its C-terminal segment complexed with avidin exposed on the thylakoidal surface. The translocation intermediate of the fusion protein inhibited the import of authentic 23-kDa subunit, suggesting that it occupies a putative translocation pore for the Delta pH-dependent pathway. However the intermediate did not block import of the 33-kDa subunit of the oxygen evolving complex, which is a substrate for the Sec-dependent pathway. These results provide evidence against the possibility of a common translocation pore shared by the Sec-dependent pathway and the Delta pH-dependent pathway.	Nagoya Univ, Res Ctr Mat Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Nagoya Univ, Fac Sci, Dept Chem, Chikusa Ku, Nagoya, Aichi 4648602, Japan	Nagoya University; Nagoya University	Yoshihisa, T (corresponding author), Nagoya Univ, Res Ctr Mat Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan.	tyoshihi@biochem.chem.nagoya-u.ac.jp	Yoshihisa, Tomoki/AFA-7466-2022					BERGHOFER J, 1995, J BIOL CHEM, V270, P18341, DOI 10.1074/jbc.270.31.18341; Clark SA, 1997, MOL BIOL CELL, V8, P923, DOI 10.1091/mbc.8.5.923; CLINE K, 1992, J BIOL CHEM, V267, P2688; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; Cline K, 1996, ANNU REV CELL DEV BI, V12, P1, DOI 10.1146/annurev.cellbio.12.1.1; CREIGHTON AM, 1995, J BIOL CHEM, V270, P1663, DOI 10.1074/jbc.270.4.1663; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; ENDO T, 1995, J BIOCHEM, V118, P753, DOI 10.1093/oxfordjournals.jbchem.a124976; Endo T, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL III, P811; Froehlich JE, 1997, J BIOL CHEM, V272, P8077, DOI 10.1074/jbc.272.12.8077; Hynds PJ, 1998, J BIOL CHEM, V273, P34868, DOI 10.1074/jbc.273.52.34868; LAIDLER V, 1995, J BIOL CHEM, V270, P17664, DOI 10.1074/jbc.270.30.17664; MOULD RM, 1991, J BIOL CHEM, V266, P12189; NAKAI M, 1994, J BIOL CHEM, V269, P31338; NOHARA T, 1995, FEBS LETT, V364, P305, DOI 10.1016/0014-5793(95)00415-6; Nohara T, 1996, BIOCHEM BIOPH RES CO, V224, P474, DOI 10.1006/bbrc.1996.1051; Robinson C, 1998, PLANT MOL BIOL, V38, P209, DOI 10.1023/A:1006041917853; Roy LM, 1998, J CELL BIOL, V141, P385, DOI 10.1083/jcb.141.2.385; Santini CL, 1998, EMBO J, V17, P101, DOI 10.1093/emboj/17.1.101; Sargent F, 1998, EMBO J, V17, P3640, DOI 10.1093/emboj/17.13.3640; Schuenemann D, 1999, J BIOL CHEM, V274, P12177, DOI 10.1074/jbc.274.17.12177; Settles AM, 1997, SCIENCE, V278, P1467, DOI 10.1126/science.278.5342.1467; Teter SA, 1998, P NATL ACAD SCI USA, V95, P1590, DOI 10.1073/pnas.95.4.1590; VOELKER R, 1995, EMBO J, V14, P3905, DOI 10.1002/j.1460-2075.1995.tb00062.x; Weiner JH, 1998, CELL, V93, P93, DOI 10.1016/S0092-8674(00)81149-6; YUAN JG, 1994, SCIENCE, V266, P796, DOI 10.1126/science.7973633	26	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20075	20078		10.1074/jbc.274.29.20075	http://dx.doi.org/10.1074/jbc.274.29.20075			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400616	hybrid			2022-12-25	WOS:000081438300009
J	Bouaboula, M; Dussossoy, D; Casellas, P				Bouaboula, M; Dussossoy, D; Casellas, P			Regulation of peripheral cannabinoid receptor CB2 phosphorylation by the inverse agonist SR 144528 - Implications for receptor biological responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA(2)-ADRENERGIC RECEPTOR; SELECTIVE ANTAGONIST; TRANSCRIPTION FACTOR; KROX-24 EXPRESSION; RHODOPSIN KINASE; UP-REGULATION; RAT-BRAIN; CELLS; DEPHOSPHORYLATION	We recently demonstrated that the selective cannabinoid receptor antagonist SR 144528 acts as an inverse agonist that blocks constitutive mitogen-activated protein kinase activity coupled to the spontaneous autoactivated peripheral cannabinoid receptor (CB2) in the Chinese hamster ovary cell line stably transfected with human CB2, In the present report, we studied the effect of SR 144528 on CB2 phosphorylation, The CB2 phosphorylation status was monitored by immunodetection using an antibody specific to the COOH-terminal CB2 which can discriminate between phosphorylated and non-phosphorylated CB2 isoforms at serine 352, We first showed that CB2 is constitutively active, phosphorylated, and internalized at the basal level. By blocking autoactivated receptors, inverse agonist SR 144528 treatment completely inhibited this phosphorylation state, leading to an up-regulated CB2 receptor level at the cell surface, and enhanced cannabinoid agonist sensitivity for mitogen-activated protein kinase activation of Chinese hamster ovary-CB2 cells. After acute agonist treatment, serine 352 was extensively phosphorylated and maintained in this phosphorylated state for more than 8 h after agonist treatment. The cellular responses to CP-55,940 were concomitantly abolished. Surprisingly, CP-55,940-induced CB2 phosphorylation was reversed by SR 144528, paradoxically leading to a nonphosphorylated CB2 which could then be fully activated by CP-55,940, The process of CP-55,940-induced receptor phosphorylation followed by SR 144528 induced receptor dephosphorylation kept recurring many times on the same cells, indicating that the agonist switches the system off but the inverse agonist switches the system back on. Finally, we showed that autophosphorylation and CP-55,940-induced serine 352 CB2 phosphorylation involve an acidotropic GRK kinase, which does not use G(i)beta(gamma), In contrast, SR 144528-induced CB2 dephosphorylation was found to involve an okadaic acid and calyculin A-sensitive type 2A phosphatase.	Sanofi Rech, F-34184 Montpellier, France	Sanofi-Aventis; Sanofi France	Casellas, P (corresponding author), Sanofi Rech, 371 Rue Pr Joseph Blayac, F-34184 Montpellier, France.							BARAK LS, 1994, J BIOL CHEM, V269, P2790; Blaukat A, 1996, J BIOL CHEM, V271, P32366, DOI 10.1074/jbc.271.50.32366; BOND RA, 1995, NATURE, V374, P272, DOI 10.1038/374272a0; Bouaboula M, 1999, MOL PHARMACOL, V55, P473; BOUABOULA M, 1995, BIOCHEM J, V312, P637, DOI 10.1042/bj3120637; BOUABOULA M, 1995, J BIOL CHEM, V270, P13973, DOI 10.1074/jbc.270.23.13973; Bouaboula M, 1996, EUR J BIOCHEM, V237, P704, DOI 10.1111/j.1432-1033.1996.0704p.x; Bouaboula M, 1997, J BIOL CHEM, V272, P22330, DOI 10.1074/jbc.272.35.22330; CHIDIAC P, 1994, MOL PHARMACOL, V45, P490; COSTA T, 1989, P NATL ACAD SCI USA, V86, P7321, DOI 10.1073/pnas.86.19.7321; FELDER CC, 1995, MOL PHARMACOL, V48, P443; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; GALIEGUE S, 1995, EUR J BIOCHEM, V232, P54, DOI 10.1111/j.1432-1033.1995.tb20780.x; GIANNINI E, 1995, J IMMUNOL, V154, P4055; GLASS M, 1995, NEUROREPORT, V6, P241, DOI 10.1097/00001756-199501000-00004; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; HAGA K, 1992, J BIOL CHEM, V267, P2222; HERKENHAM M, 1991, J NEUROSCI, V11, P563, DOI 10.1523/jneurosci.11-02-00563.1991; HOWLETT AC, 1985, MOL PHARMACOL, V27, P429; INGLESE J, 1993, J BIOL CHEM, V268, P23735; Krueger KM, 1997, J BIOL CHEM, V272, P5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LUTZ MP, 1993, J BIOL CHEM, V268, P12136; MacEwan DJ, 1996, FEBS LETT, V399, P108, DOI 10.1016/S0014-5793(96)01300-2; MAILLEUX P, 1994, NEUROREPORT, V5, P1265, DOI 10.1097/00001756-199406020-00028; MATSUDA LA, 1993, J COMP NEUROL, V327, P535, DOI 10.1002/cne.903270406; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Nie ZZ, 1997, MOL PHARMACOL, V52, P456, DOI 10.1124/mol.52.3.456; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PALCZEWSKI K, 1989, BIOCHEMISTRY-US, V28, P8764, DOI 10.1021/bi00448a013; Palczewski K, 1997, EUR J BIOCHEM, V248, P261, DOI 10.1111/j.1432-1033.1997.00261.x; PEI G, 1994, P NATL ACAD SCI USA, V91, P2699, DOI 10.1073/pnas.91.7.2699; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; Rinaldi-Carmona M, 1998, J PHARMACOL EXP THER, V284, P644; RINALDICARMONA M, 1994, FEBS LETT, V350, P240, DOI 10.1016/0014-5793(94)00773-X; RinaldiCarmona M, 1996, LIFE SCI, V58, P1239, DOI 10.1016/0024-3205(96)00085-9; SAMAMA P, 1994, MOL PHARMACOL, V45, P390; SCHMIDT M, 1995, J BIOL CHEM, V270, P19949, DOI 10.1074/jbc.270.34.19949; Shih ML, 1996, J BIOL CHEM, V271, P21478, DOI 10.1074/jbc.271.35.21478; Shire D, 1996, J BIOL CHEM, V271, P6941, DOI 10.1074/jbc.271.12.6941; Smit MJ, 1996, P NATL ACAD SCI USA, V93, P6802, DOI 10.1073/pnas.93.13.6802; Storck J, 1996, THROMB RES, V81, P121, DOI 10.1016/0049-3848(95)00220-0; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; Vinos J, 1997, SCIENCE, V277, P687, DOI 10.1126/science.277.5326.687	48	82	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20397	20405		10.1074/jbc.274.29.20397	http://dx.doi.org/10.1074/jbc.274.29.20397			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400664	hybrid			2022-12-25	WOS:000081438300057
J	Ghosh, PM; Ghosh-Choudhury, N; Moyer, ML; Mott, GE; Thomas, CA; Foster, BA; Greenberg, NM; Kreisberg, JI				Ghosh, PM; Ghosh-Choudhury, N; Moyer, ML; Mott, GE; Thomas, CA; Foster, BA; Greenberg, NM; Kreisberg, JI			Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line	ONCOGENE			English	Article						RhoA; actin stress fibers; H-Ras; lovastatin; geranylgeraniol; farnesol	ACTIN STRESS FIBERS; CULTURED MESANGIAL CELLS; RAS TRANSFORMATION; FOCAL ADHESIONS; SIGNALING PATHWAY; PROTEIN-KINASES; TRAMP MODEL; GTPASES; PROGRESSION; RAC1	Prostate cancer cells derived from transgenic mice with adenocarcinoma of the prostate (TRAMP cells) were treated with the HMG-CoA reductase inhibitor, lovastatin, This caused inactivation of the small GTPase RhoA, actin stress fiber disassembly, cell rounding, growth arrest in the GZ phase of the cell cycle, cell detachment and apoptosis, Addition of geranylgeraniol (GGOL) in the presence of lovastatin, to stimulate protein geranylgeranylation, prevented lovastatin's effects. That is, RhoA was activated, actin stress fibers were assembled, the cells assumed a flat morphology and cell growth resumed. The following observations support an essential role for RhoA in TRAMP cell growth: (1) TRAMP cells expressing dominant-negative RhoA (T19N) mutant protein displayed few actin stress fibers and grew at a slower rate than controls (35 h doubling time for cells expressing RhoA (T19N) vs 20 h for untransfected cells); (2) TRAMP cells expressing constitutively active RhoA. (Q63L) mutant protein displayed a contractile phenotype and grew faster than controls (13 h doubling time), Interestingly, addition of farnesol (FOL) with lovastatin, to stimulate protein farnesylation, prevented lovastatin-induced cell rounding, cell detachment and apoptosis, and stimulated cell spreading to a spindle shaped morphology. However, RhoA remained inactive and growth arrest persisted. The morphological effects of FOL addition were prevented in TRAMP cells expressing dominant-negative H-Ras (T17N) mutant protein. Thus, it appears that H-Ras is capable of inducing cell spreading, but incapable of supporting cell proliferation, in the absence of geranylgeranylated proteins like RhoA.	Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78284 USA; Univ Texas, Hlth Sci Ctr, Dept Microbiol, San Antonio, TX 78284 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Audie L Murphy Mem Vet Hosp, Res & Dev Serv, San Antonio, TX 78284 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Kreisberg, JI (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pathol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.							Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRAGINA EE, 1976, EXP CELL RES, V97, P241, DOI 10.1016/0014-4827(76)90613-3; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Derman MP, 1997, J BIOL CHEM, V272, P6465, DOI 10.1074/jbc.272.10.6465; FENTON RG, 1992, J CELL BIOL, V117, P347, DOI 10.1083/jcb.117.2.347; Foster BA, 1997, CANCER RES, V57, P3325; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; Ghosh PM, 1997, BBA-MOL CELL RES, V1359, P13, DOI 10.1016/S0167-4889(97)00091-8; Gingrich JR, 1997, CANCER RES, V57, P4687; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; GRUNLER J, 1994, BBA-LIPID LIPID MET, V1212, P259, DOI 10.1016/0005-2760(94)90200-3; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hirai A, 1997, J BIOL CHEM, V272, P13; JONES KD, 1994, BIOCHEM BIOPH RES CO, V205, P1681, DOI 10.1006/bbrc.1994.2861; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KITA T, 1980, J CLIN INVEST, V66, P1094, DOI 10.1172/JCI109938; KREISBERG JI, 1985, AM J PHYSIOL, V249, pF227, DOI 10.1152/ajprenal.1985.249.2.F227; Kreisberg JI, 1997, AM J PHYSIOL-RENAL, V273, pF283, DOI 10.1152/ajprenal.1997.273.2.F283; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Maniotis AJ, 1997, P NATL ACAD SCI USA, V94, P849, DOI 10.1073/pnas.94.3.849; NEWMAN A, 1994, LEUKEMIA, V8, P274; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Noguchi Y, 1998, J BIOL CHEM, V273, P3649, DOI 10.1074/jbc.273.6.3649; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; PRENDERGAST GC, 1993, ADV CANCER RES, V62, P19, DOI 10.1016/S0065-230X(08)60314-0; PRONK GJ, 1994, BBA-REV CANCER, V1198, P131, DOI 10.1016/0304-419X(94)90010-8; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; SINENSKY M, 1992, BIOESSAYS, V14, P25, DOI 10.1002/bies.950140106; SPOONER BS, 1982, J CELL BIOL, V49, P595; SYMONS M, 1995, CURR OPIN BIOTECH, V6, P668, DOI 10.1016/0958-1669(95)80110-3; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; WILSON E, 1995, J CLIN INVEST, V96, P2364, DOI 10.1172/JCI118293; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	56	91	93	0	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	1999	18	28					4120	4130		10.1038/sj.onc.1202792	http://dx.doi.org/10.1038/sj.onc.1202792			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	216FP	10435593				2022-12-25	WOS:000081431000009
J	Heddi, A; Stepien, G; Benke, PJ; Wallace, DC				Heddi, A; Stepien, G; Benke, PJ; Wallace, DC			Coordinate induction of energy gene expression in tissues of mitochondrial disease patients	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHASE BETA-SUBUNIT; ADENINE-NUCLEOTIDE TRANSLOCATOR; MUSCLE ADP/ATP TRANSLOCATOR; MUSCULAR-DYSTROPHY LOCUS; KEARNS-SAYRE SYNDROME; CREATINE-KINASE; SEQUENCE-ANALYSIS; NUCLEAR GENES; TRANSCRIPTIONAL ELEMENT; DIFFERENTIAL EXPRESSION	We have examined the transcript levels of a variety of oxidative phosphorylation (OXPHOS) and associated bioenergetic genes in tissues of a patient carrying the myopathy, encephalopathy, lactic acidosis, and strokelike episodes (MELAS) A3243G mitochondrial DNA (mtDNA) mutation and the skeletal muscles of 14 patients harboring other pathogenic mtDNA mutations. The patients' tissues, which harbored 88% or more mutant mtDNA, had increased levels of mtDNA transcripts, increased nuclear OXPHOS gene transcripts including the ATP synthase beta subunit and the heart-muscle isoform of the adenine nucleotide translocator, and increased ancillary gene transcripts including muscle mitochondrial creatine phosphokinase, muscle glycogen phosphorylase, hexokinase I, muscle phosphofructokinase, the E1 alpha subunit of pyruvate dehydrogenase, and the ubiquinone oxidoreductase. A similar coordinate induction of bioenergetic genes was observed in the muscle biopsies of severe pathologic mtDNA mutations. The more significant coordinated expression was found in muscle from patients with the MELAS, myoclonic epilepsy with ragged red fibers, and chronic progressive external ophthalmoplegia deletion syndromes, with ragged red muscle fibers and mitochondrial paracrystalline inclusions. High levels of mutant mtDNAs were linked to a high induction of the mtDNA and nuclear OXPHOS genes and of several associated bioenergetic genes. These observations suggest that human tissues attempt to compensate for OXPHOS defects associated with mtDNA mutations by stimulating mitochondrial biogenesis, possibly mediated through redox-sensitive transcription factors.	Inst Natl Sci Appl Lyon, Lab Biol Appl, INRA, UA 203, F-69621 Villeurbanne, France; Emory Univ, Sch Med, Dept Genet & Mol Med, Atlanta, GA 30322 USA; Univ Miami, Sch Med, Div Med Genet, Miami, FL 33101 USA; CHU Angers, Lab Biochim & Biol Mol A, F-49000 Angers, France	INRAE; Institut National des Sciences Appliquees de Lyon - INSA Lyon; Emory University; University of Miami; Universite d'Angers; Centre Hospitalier Universitaire d'Angers	Heddi, A (corresponding author), Inst Natl Sci Appl Lyon, Lab Biol Appl, INRA, UA 203, Bat 406,20 Av Albert Einstein, F-69621 Villeurbanne, France.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021328] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45572] Funding Source: Medline; NIA NIH HHS [AG/3154] Funding Source: Medline; NINDS NIH HHS [NS21328] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ARORA KK, 1990, J BIOL CHEM, V265, P6481; BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11; BALLINGER SW, 1994, NAT GENET, V7, P458, DOI 10.1038/ng0894-458; BENZ R, 1990, BIOCHIM BIOPHYS ACTA, V1022, P311, DOI 10.1016/0005-2736(90)90279-W; BIERMANS W, 1989, BIOCHIM BIOPHYS ACTA, V974, P74, DOI 10.1016/S0005-2728(89)80167-7; BUSTAMANTE E, 1981, J BIOL CHEM, V256, P8699; CARLSON M, 1988, NUCLEIC ACIDS RES, V16, P10403, DOI 10.1093/nar/16.21.10403; Chomyn A, 1998, AM J HUM GENET, V62, P745, DOI 10.1086/301813; CHUNG AB, 1992, J BIOL CHEM, V267, P21154; CORRALDEBRINSKI M, 1991, JAMA-J AM MED ASSOC, V266, P1812, DOI 10.1001/jama.266.13.1812; DAHL HHM, 1987, J BIOL CHEM, V262, P7398; EPPENBERGEREBERHARDT M, 1991, J CELL BIOL, V113, P289, DOI 10.1083/jcb.113.2.289; EVANS MJ, 1989, J BIOL CHEM, V264, P14361; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; Flierl A, 1997, J BIOL CHEM, V272, P27189, DOI 10.1074/jbc.272.43.27189; Giraud S, 1998, J MOL BIOL, V281, P409, DOI 10.1006/jmbi.1998.1955; GOPALAKRISHNAN L, 1994, J BIOL CHEM, V269, P105; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; Graeber MB, 1998, J NEUROL SCI, V153, P251, DOI 10.1016/S0022-510X(97)00295-5; HARAGUCHI Y, 1993, GENOMICS, V16, P479, DOI 10.1006/geno.1993.1214; HEDDI A, 1994, BBA-MOL BASIS DIS, V1226, P206, DOI 10.1016/0925-4439(94)90030-2; HEDDI A, 1993, J BIOL CHEM, V268, P12156; HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0; HOLT IJ, 1990, AM J HUM GENET, V46, P428; KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480; KLEIN SC, 1991, J BIOL CHEM, V266, P18058; LEFEBVRE J, 1983, INTRO AUX ANAL STAT; LESTIENNE P, 1988, LANCET, V1, P885; LI K, 1990, J BIOL CHEM, V265, P20585; LIAO XS, 1993, CELL, V72, P61, DOI 10.1016/0092-8674(93)90050-Z; Manfredi G, 1997, ANN NEUROL, V42, P180, DOI 10.1002/ana.410420208; NECKELMANN N, 1989, GENOMICS, V5, P829, DOI 10.1016/0888-7543(89)90125-0; NECKELMANN N, 1987, P NATL ACAD SCI USA, V84, P7580, DOI 10.1073/pnas.84.21.7580; NELSON I, 1992, NEUROPEDIATRICS, V4, P199; NIGRO JM, 1987, AM J HUM GENET, V40, P115; NISHI S, 1988, BIOCHEM BIOPH RES CO, V157, P937, DOI 10.1016/S0006-291X(88)80964-1; RECHSTEINER M, 1987, ANNU REV CELL BIOL, V3, P1, DOI 10.1146/annurev.cb.03.110187.000245; Rothermel BA, 1997, J BIOL CHEM, V272, P19801, DOI 10.1074/jbc.272.32.19801; Schapira AHV, 1998, BBA-BIOENERGETICS, V1364, P261, DOI 10.1016/S0005-2728(98)00032-2; Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755; SCHROEDER RE, 1993, DIABETES, V42, P1487, DOI 10.2337/diabetes.42.10.1487; SHOFFNER JM, 1992, NEUROLOGY, V42, P2168, DOI 10.1212/WNL.42.11.2168; SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N; SHOFFNER JM, 1995, METABOLIC MOL BASES, P1535; SHOUBRIDGE EA, 1994, J BIOENERG BIOMEMBR, V26, P301, DOI 10.1007/BF00763101; STADHOUDERS AM, 1994, P NATL ACAD SCI USA, V91, P5089, DOI 10.1073/pnas.91.11.5089; STEPIEN G, 1992, J BIOL CHEM, V267, P14592; SUZUKI H, 1991, J BIOL CHEM, V266, P2333; TATUCH Y, 1992, AM J HUM GENET, V50, P852; TOMURA H, 1990, J BIOL CHEM, V265, P6525; VAISANEN PA, 1992, DNA CELL BIOL, V11, P461, DOI 10.1089/dna.1992.11.461; Wallace D. C., 1996, P1280; WALLACE DC, 1995, AM J HUM GENET, V57, P201; WALLACE DC, 1988, CELL, V55, P601, DOI 10.1016/0092-8674(88)90218-8; WALLACE DC, 1987, CURR GENET, V12, P81, DOI 10.1007/BF00434661; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WEINHOUSE S, 1972, CANCER RES, V32, P2007; WIBORG O, 1985, EMBO J, V4, P755, DOI 10.1002/j.1460-2075.1985.tb03693.x; WIJMENGA C, 1993, HUM GENET, V92, P198; WYSS M, 1992, J THEOR BIOL, V158, P129, DOI 10.1016/S0022-5193(05)80650-2	61	137	143	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					22968	22976		10.1074/jbc.274.33.22968	http://dx.doi.org/10.1074/jbc.274.33.22968			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438462	hybrid			2022-12-25	WOS:000082012800012
J	Vakulenko, SB; Taibi-Tronche, P; Toth, M; Massova, I; Lerner, SA; Mobashery, S				Vakulenko, SB; Taibi-Tronche, P; Toth, M; Massova, I; Lerner, SA; Mobashery, S			Effects on substrate profile by mutational substitutions at positions 164 and 179 of the class A TEMpUC19 beta-lactamase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ACYL-ENZYME INTERMEDIATE; CRYSTAL-STRUCTURE; EXTENDED-SPECTRUM; NUCLEOTIDE-SEQUENCE; MOLECULAR-STRUCTURE; RESISTANCE; RESOLUTION; PENICILLIN; HYDROLYSIS	We investigated the effects of mutations at positions 164 and 179 of the TERpUC19 beta-lactamase on turnover of substrates, The direct consequence of some mutations at these sites is that clinically important expanded-spectrum p-lactams, such as third-generation cephalosporins, which are normally exceedingly poor substrates for class A p-lactamases, bind the active site of these mutant enzymes more favorably. We employed site-saturation mutagenesis at both positions 164 and 179 to identify mutant variants of the parental enzyme that conferred resistance to expanded-spectrum p-lactams by their enhanced ability to turn over these antibiotic substrates, Four of these mutant variants, Arg(164) --> Asn, Arg(164) --> Ser, Asp(179) --> Asn, and Asp(179), Gly, were purified and the details of their catalytic properties were examined in a series of biochemical and kinetic experiments. The effects on the kinetic parameters were such that either activity with the expanded-spectrum p-lactams remained unchanged or, in some cases, the activity was enhanced. The affinity of the enzyme for these poorer substrates (as defined by the dissociation constant, K-s) invariably increased, Computation of the microscopic rate constants (k(2) and k(3)) for turnover of these poorer substrates indicated either that the rate-limiting step in turnover was the deacylation step (governed by k(3)) or that neither the acylation nor deacylation became the sole rate-limiting step. In a few instances, the rate constants for both the acylation (k(2)) and deacylation (k(3)) of the extended-spectrum p-lactamase were enhanced. These results were investigated further by molecular modeling experiments, using the crystal structure of the TEMpUC19 beta-lactamase, Our results indicated that severe steric interactions between the large 7 beta functionalities of the expanded-spectrum beta-lactams and the Omega-loop secondary structural element near the active site were at the root of the low affinity by the enzyme for these substrates. These conclusions were consistent with the proposal that the aforementioned mutations would enlarge the active site, and hence improve affinity.	Wayne State Univ, Dept Chem, Detroit, MI 48202 USA; Wayne State Univ, Sch Med, Dept Med, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	Wayne State University; Wayne State University; Wayne State University	Mobashery, S (corresponding author), Wayne State Univ, Dept Chem, Detroit, MI 48202 USA.	som@mobashery.chem.wayne.edu						ADACHI H, 1991, J BIOL CHEM, V266, P3186; AMBLER RP, 1991, BIOCHEM J, V276, P269, DOI 10.1042/bj2760269; Arlet G, 1997, FEMS MICROBIOL LETT, V152, P163, DOI 10.1111/j.1574-6968.1997.tb10423.x; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; Bush K, 1998, ADV EXP MED BIOL, V456, P71; Bush K, 1997, J ANTIMICROB CHEMOTH, V39, P1, DOI 10.1093/jac/39.1.1; BUSH K, 1995, ANTIMICROB AGENTS CH, V39, P1211, DOI 10.1128/AAC.39.6.1211; ESCOBAR WA, 1991, BIOCHEMISTRY-US, V30, P10783, DOI 10.1021/bi00108a025; GIBSON RM, 1990, BIOCHEM J, V272, P613, DOI 10.1042/bj2720613; Guillaume G, 1997, J BIOL CHEM, V272, P5438, DOI 10.1074/jbc.272.9.5438; HERZBERG O, 1987, SCIENCE, V236, P694, DOI 10.1126/science.3107125; HERZBERG O, 1991, BIOCHEMISTRY-US, V30, P9503, DOI 10.1021/bi00103a017; IMTIAZ U, 1994, ANTIMICROB AGENTS CH, V38, P1134, DOI 10.1128/AAC.38.5.1134; JELSCH C, 1993, PROTEINS, V16, P364, DOI 10.1002/prot.340160406; KNOX JR, 1995, ANTIMICROB AGENTS CH, V39, P2593, DOI 10.1128/AAC.39.12.2593; KNOX JR, 1991, J MOL BIOL, V220, P435, DOI 10.1016/0022-2836(91)90023-Y; KNOX JR, 1993, PROTEIN ENG, V6, P11, DOI 10.1093/protein/6.1.11; KUZIN AP, 1995, BIOCHEMISTRY-US, V34, P9532, DOI 10.1021/bi00029a030; MABILAT C, 1990, ANTIMICROB AGENTS CH, V34, P2210, DOI 10.1128/AAC.34.11.2210; Massova I, 1998, ANTIMICROB AGENTS CH, V42, P1; Massova I, 1997, ACCOUNTS CHEM RES, V30, P162, DOI 10.1021/ar960007e; MATAGNE A, 1995, BBA-PROTEIN STRUCT M, V1246, P109, DOI 10.1016/0167-4838(94)00177-I; Maveyraud L, 1996, J AM CHEM SOC, V118, P7435, DOI 10.1021/ja9609718; MIYASHITA K, 1995, J AM CHEM SOC, V117, P11055, DOI 10.1021/ja00150a003; OEFNER C, 1990, NATURE, V343, P284, DOI 10.1038/343284a0; OKA A, 1981, J MOL BIOL, V147, P217, DOI 10.1016/0022-2836(81)90438-1; RAQUET X, 1994, J MOL BIOL, V244, P625, DOI 10.1006/jmbi.1994.1756; Rasheed JK, 1997, ANTIMICROB AGENTS CH, V41, P647, DOI 10.1128/AAC.41.3.647; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOWEK JA, 1991, BIOCHEMISTRY-US, V30, P3179, DOI 10.1021/bi00227a004; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; SUTCLIFFE JG, 1978, P NATL ACAD SCI USA, V75, P3737, DOI 10.1073/pnas.75.8.3737; TaibiTronche P, 1996, J AM CHEM SOC, V118, P7441, DOI 10.1021/ja9529753; VAKULENKO SB, 1995, ANTIMICROB AGENTS CH, V39, P1878, DOI 10.1128/AAC.39.8.1878; WEBER DA, 1990, J INFECT DIS, V162, P460, DOI 10.1093/infdis/162.2.460; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZAFARALLA G, 1992, BIOCHEMISTRY-US, V31, P3847, DOI 10.1021/bi00130a016	37	59	61	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	1999	274	33					23052	23060		10.1074/jbc.274.33.23052	http://dx.doi.org/10.1074/jbc.274.33.23052			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	226GV	10438473	hybrid			2022-12-25	WOS:000082012800023
J	Shea, ME; Hiasa, H				Shea, ME; Hiasa, H			Interactions between DNA helicases and frozen topoisomerase IV-quinolone-DNA ternary complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; ESCHERICHIA-COLI; REPLICATION FORK; NALIDIXIC-ACID; TUS PROTEIN; GYRASE; MECHANISM; CLEAVAGE; BACTERIOPHAGE-T7; RECOGNITION	Collisions between replication forks and topoisomerase-drug-DNA ternary complexes result in the inhibition of DNA replication and the conversion of the normally reversible ternary complex to a nonreversible form. Ultimately, this can lead to the double strand break formation and subsequent cell death, To understand the molecular mechanisms of replication fork arrest by the ternary complexes, we have investigated molecular events during collisions between DNA helicases and topoisomerase-DNA complexes, A strand displacement assay was employed to assess the effect of topoisomerase IV (Topo IV)-norfloxacin-DNA ternary complexes on the DnaB, T7 gene 4 protein, SV40 T-antigen, and UvrD DNA helicases, The ternary complexes inhibited the strand displacement activities of these DNA helicases. Unlike replication fork arrest, however, this general inhibition of DNA helicases by Topo IV-norfloxacin-DNA ternary complexes did not require the cleavage and reunion activity of Topo IV. We also examined the reversibility of the ternary complexes after collisions with these DNA helicases, UvrD converted the ternary complex to a nonreversible form, whereas DnaB, T7 gene 4 protein, and SV40 T-antigen did not. These results suggest that the inhibition of DnaB translocation may be sufficient to arrest the replication fork progression but it is not sufficient to generate cytotoxic DNA lesion.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Shea, ME (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA.				NIGMS NIH HHS [GM59465-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059465] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMIN AA, 1992, J BIOL CHEM, V267, P18612; Anderson VE, 1998, J BIOL CHEM, V273, P17879, DOI 10.1074/jbc.273.28.17879; BUJALOWSKI W, 1994, J BIOL CHEM, V269, P31350; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; Critchlow SE, 1996, BIOCHEMISTRY-US, V35, P7387, DOI 10.1021/bi9603175; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; FRANCKE B, 1971, VIROLOGY, V44, P168, DOI 10.1016/0042-6822(71)90163-2; GELLERT M, 1977, P NATL ACAD SCI USA, V74, P4772, DOI 10.1073/pnas.74.11.4772; GOETZ GS, 1988, J BIOL CHEM, V263, P383; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; HIASA H, 1992, J BIOL CHEM, V267, P11379; Hiasa H, 1996, J BIOL CHEM, V271, P21529, DOI 10.1074/jbc.271.35.21529; Hiasa H, 1996, J BIOL CHEM, V271, P26424, DOI 10.1074/jbc.271.42.26424; HIGGINS NP, 1977, P NATL ACAD SCI USA, V74, P1773; HOWARD MT, 1994, P NATL ACAD SCI USA, V91, P12031, DOI 10.1073/pnas.91.25.12031; Jezewska MJ, 1998, BIOCHEMISTRY-US, V37, P3116, DOI 10.1021/bi972564u; KHODURSKY AB, 1995, P NATL ACAD SCI USA, V92, P11801, DOI 10.1073/pnas.92.25.11801; Khodursky AB, 1998, J BIOL CHEM, V273, P27668, DOI 10.1074/jbc.273.42.27668; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; KREUZER KN, 1979, J BACTERIOL, V140, P424, DOI 10.1128/JB.140.2.424-435.1979; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LOHMAN TM, 1992, MOL MICROBIOL, V6, P5, DOI 10.1111/j.1365-2958.1992.tb00831.x; Marians KJ, 1997, J BIOL CHEM, V272, P9401; MATSON SW, 1987, J BIOL CHEM, V262, P2066; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MAXWELL A, 1992, J ANTIMICROB CHEMOTH, V30, P191; MIZUUCHI K, 1978, P NATL ACAD SCI USA, V75, P5960, DOI 10.1073/pnas.75.12.5960; MODEL P, 1974, J MOL BIOL, V83, P231, DOI 10.1016/0022-2836(74)90389-1; PENG H, 1995, J BIOL CHEM, V270, P25286, DOI 10.1074/jbc.270.42.25286; SUGINO A, 1977, P NATL ACAD SCI USA, V74, P4767, DOI 10.1073/pnas.74.11.4767; TABOR S, 1981, P NATL ACAD SCI-BIOL, V78, P205, DOI 10.1073/pnas.78.1.205; TEWEY KM, 1984, SCIENCE, V226, P466, DOI 10.1126/science.6093249; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WIEKOWSKI M, 1988, J BIOL CHEM, V263, P436	34	33	36	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22747	22754		10.1074/jbc.274.32.22747	http://dx.doi.org/10.1074/jbc.274.32.22747			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428858	hybrid			2022-12-25	WOS:000081868400088
J	Teague, WE; Dobson, GP				Teague, WE; Dobson, GP			Thermodynamics of the arginine kinase reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP HYDROLYSIS EQUILIBRIA; CREATINE-KINASE; ADENYLATE KINASE; TEMPERATURE; ADJUSTMENT; MUSCLE; K'; PH	The effect of temperature, pH, free [Mg2+], and ionic strength on the apparent equilibrium constant of arginine kinase (EC 2.7.3.3) was determined. At equilibrium, the apparent K' was defined as K' = [ATP][Arg]/[ADP][PArg] (Eq. 1) where each reactant represents the sum of all the ionic and metal complex species. The K' at pH 7.0, 1.0 mM free [Mg2+], and 0.25 M ionic strength was 29.91 +/- 0.59, 33.44 +/- 0.46, 35.44 +/- 0.71, 39.64 +/- 0.74, and 45.19 +/- 0.65 (n = 8) at 40, 33, 25, 15, and 5 degrees C, respectively. The standard apparent enthalpy (Delta H degrees') is -8.19 kJ mol(-1), and the corresponding standard apparent entropy of the reaction (Delta S degrees') is + 2.2 J K-1 mol(-1) in the direction of ATP formation at pH 7.0, free [Mg2+] = 1.0 mM, ionic strength (I) =0.25 M at 25 degrees C, We further show that the magnitude of transformed Gibbs energy (Delta G degrees') of -8.89 kJ mol(-1) is mostly comprised of the enthalpy of the reaction, with 7.4% coming from the entropy T Delta S degrees' term (+0.66 kJ mol(-1)). Our results are discussed in relation to the thermodynamic properties of its evolutionary successor, creatine kinase.	James Cook Univ N Queensland, Dept Physiol & Pharmacol, Townsville, Qld 4811, Australia	James Cook University	Dobson, GP (corresponding author), James Cook Univ N Queensland, Dept Physiol & Pharmacol, Townsville, Qld 4811, Australia.							Dawson R. M. C., 1986, DATA BIOCH RES, V3rd; Eggleton P, 1927, J PHYSIOL-LONDON, V63, P155, DOI 10.1113/jphysiol.1927.sp002391; ELLINGTON WR, 1989, J EXP BIOL, V143, P177; Fiske CH, 1929, SCIENCE, V70, P381, DOI 10.1126/science.70.1816.381-a; GOLDING EM, 1995, J EXP BIOL, V198, P1775; GRAHAM RA, 1986, BIOCHIM BIOPHYS ACTA, V887, P157, DOI 10.1016/0167-4889(86)90050-9; LAWSON JWR, 1979, J BIOL CHEM, V254, P6528; Lehmann H, 1936, BIOCHEM Z, V286, P336; Lohmann K, 1934, BIOCHEM Z, V271, P264; Meyerhof O, 1928, BIOCHEM Z, V196, P22; NEEDHAM DM, 1932, NATURE, V110, P260; Passonneau J.V., 1972, FLEXIBLE SYSTEM ENZY; SMITH E, 1969, J BIOL CHEM, V244, P4224; Szorenyi E. T., 1949, CR ACAD SCI URSS, V67, P341; Teague WE, 1996, J EXP BIOL, V199, P509; TEAGUE WE, 1992, J BIOL CHEM, V267, P14084; UHR ML, 1966, J BIOL CHEM, V241, P5428; VEECH RL, 1979, J BIOL CHEM, V254, P6538; VIRDEN R, 1964, BIOCHEM J, V94, P536; Webb E. C., 1992, ENZYME NOMENCLATURE	20	24	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22459	22463		10.1074/jbc.274.32.22459	http://dx.doi.org/10.1074/jbc.274.32.22459			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428820	hybrid			2022-12-25	WOS:000081868400050
J	Zuk, PA; Elferink, LA				Zuk, PA; Elferink, LA			Rab15 mediates an early endocytic event in Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEINS; TRANS-GOLGI NETWORK; RECYCLING COMPARTMENT; TRANSFERRIN RECEPTORS; MEMBRANE DYNAMICS; VESICLE TRANSPORT; EPITOPE TAG; CHO CELLS; ENDOSOME; PATHWAY	Rab GTPases comprise a large family of monomeric proteins that regulate a diverse number of membrane trafficking events, including endocytosis. In this paper, we examine the subcellular distribution and function of the GTPase Rab15. Our biochemical and confocal immunofluorescence studies demonstrate that Rab15 associates with the transferrin receptor, a marker for the early endocytic pathway, but not with Rab7 or the cation-independent mannose 6-phosphate receptor, markers for late endosomal membranes. Furthermore, Rab15 colocalizes with Rab4 and -5 on early/sorting endosomes, as well as Rab11 on pericentriolar recycling endosomes. Consistent with its localization to early endosomal membranes, overexpression of the constitutively active mutant HArab15Q67L reduces receptor-mediated and fluid phase endocytosis. Therefore, our functional studies suggest that Rab15 may function as an inhibitory GTPase in early endocytic trafficking.	Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA	Wayne State University	Elferink, LA (corresponding author), Wayne State Univ, Dept Biol Sci, 5047 Gullen Mall, Detroit, MI 48202 USA.	laelferi@sun.science.wayne.edu						BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Bean AJ, 1997, NEURON, V19, P751, DOI 10.1016/S0896-6273(00)80957-5; Bottger G, 1996, J BIOL CHEM, V271, P29191, DOI 10.1074/jbc.271.46.29191; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; Chavrier P, 1997, CYTOMETRY, V29, P41, DOI 10.1002/(SICI)1097-0320(19970901)29:1<41::AID-CYTO4>3.0.CO;2-G; Chen W, 1998, MOL BIOL CELL, V9, P3241, DOI 10.1091/mbc.9.11.3241; CHEN YT, 1993, P NATL ACAD SCI USA, V90, P6508, DOI 10.1073/pnas.90.14.6508; CLIFTOGRADY L, 1990, J CELL BIOL, V110, P1693, DOI 10.1083/jcb.110.5.1693; DEWALD B, 1973, J BIOL CHEM, V248, P7223; Diaz E, 1997, J CELL BIOL, V138, P283, DOI 10.1083/jcb.138.2.283; DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303; ESCOLA JM, 1995, J CELL SCI, V108, P2337; FENG Y, 1995, J CELL BIOL, V131, P1435, DOI 10.1083/jcb.131.6.1435; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; Ghosh RN, 1998, J CELL BIOL, V142, P923, DOI 10.1083/jcb.142.4.923; GHOSH RN, 1994, J CELL SCI, V107, P2177; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; JOHNSTON PA, 1991, NEURON, V7, P101, DOI 10.1016/0896-6273(91)90078-E; JOHNSTON PA, 1989, EMBO J, V8, P2863, DOI 10.1002/j.1460-2075.1989.tb08434.x; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; KINSELLA BT, 1992, J BIOL CHEM, V267, P3940; LI GP, 1993, J BIOL CHEM, V268, P24475; LLEDO PM, 1994, TRENDS NEUROSCI, V17, P426, DOI 10.1016/0166-2236(94)90017-5; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; Lupashin VV, 1997, SCIENCE, V276, P1255, DOI 10.1126/science.276.5316.1255; MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575; Mayer A, 1997, J CELL BIOL, V136, P307, DOI 10.1083/jcb.136.2.307; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; MCGRAW TE, 1993, J CELL PHYSIOL, V155, P579, DOI 10.1002/jcp.1041550316; MCGRAW TE, 1987, J CELL BIOL, V105, P207, DOI 10.1083/jcb.105.1.207; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MELLMAN IS, 1983, J CELL BIOL, V96, P887, DOI 10.1083/jcb.96.3.887; MERESSE S, 1995, J CELL SCI, V108, P3349; MESSNER DJ, 1989, J CELL BIOL, V108, P2149, DOI 10.1083/jcb.108.6.2149; MOLENAAR CMT, 1988, EMBO J, V7, P971, DOI 10.1002/j.1460-2075.1988.tb02903.x; Mukhopadhyay A, 1997, J BIOL CHEM, V272, P13055, DOI 10.1074/jbc.272.20.13055; Nagelkerken B, 1997, ELECTROPHORESIS, V18, P2694, DOI 10.1002/elps.1150181427; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; OLKKONEN VM, 1993, J CELL SCI, V106, P1249; PRESLEY JF, 1993, J CELL BIOL, V122, P1231, DOI 10.1083/jcb.122.6.1231; Ren MD, 1998, P NATL ACAD SCI USA, V95, P6187, DOI 10.1073/pnas.95.11.6187; Robinson MS, 1996, CELL, V84, P13, DOI 10.1016/S0092-8674(00)80988-5; ROSSI G, 1991, NATURE, V351, P158, DOI 10.1038/351158a0; Rothman JE, 1997, SCIENCE, V276, P1212, DOI 10.1126/science.276.5316.1212; ROTHMAN JE, 1994, CELL, V78, P937; Schimmoller F, 1998, J BIOL CHEM, V273, P22161, DOI 10.1074/jbc.273.35.22161; SCHMID SL, 1988, CELL, V52, P73, DOI 10.1016/0092-8674(88)90532-6; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; Tisdale EJ, 1998, J BIOL CHEM, V273, P17269, DOI 10.1074/jbc.273.27.17269; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; Vitelli R, 1997, J BIOL CHEM, V272, P4391, DOI 10.1074/jbc.272.7.4391; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9; WIEDENMANN B, 1986, P NATL ACAD SCI USA, V83, P3500, DOI 10.1073/pnas.83.10.3500; Woodman P, 1998, CURR BIOL, V8, pR199, DOI 10.1016/S0960-9822(98)70124-1; YAMASHIRO DJ, 1987, J CELL BIOL, V105, P2713, DOI 10.1083/jcb.105.6.2713; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8; ZERIAL M, 1995, GUIDEBOOK SMALL GTPA	65	41	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	1999	274	32					22303	22312		10.1074/jbc.274.32.22303	http://dx.doi.org/10.1074/jbc.274.32.22303			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	223YD	10428799	hybrid			2022-12-25	WOS:000081868400029
J	Doukas, J; Hoganson, DK; Ong, M; Ying, WB; Lacey, DL; Baird, A; Pierce, GF; Sosnowski, BA				Doukas, J; Hoganson, DK; Ong, M; Ying, WB; Lacey, DL; Baird, A; Pierce, GF; Sosnowski, BA			Retargeted delivery of adenoviral vectors through fibroblast growth factor receptors involves unique cellular pathways	FASEB JOURNAL			English	Article						gene therapy; cancer; integrin; affinity	TARGETED GENE DELIVERY; HIGH-AFFINITY RECEPTOR; SMOOTH-MUSCLE CELLS; SELF-ASSOCIATION; FACTOR-II; HEPARIN; INTERNALIZATION; PROLIFERATION; PROTEOGLYCANS; ANGIOGENESIS	A major goal of gene therapy is to improve target specificity by delivering vectors through alternative cellular receptors. We previously reported that adenoviral vector delivery through basic fibroblast growth factor (FGF2) receptors enhances both cellular transduction and in vivo efficacy. We now present studies addressing the cellular pathways and mechanisms underlying these events. Cellular receptors for adenoviruses are not required for transduction by FGF2-retargeted vectors. Moreover, alpha(v) integrins can antagonize FGF2 retargeting, in contrast to their obligatory role in non-retargeted vector delivery. By contrast, high-affinity FGF receptors, which are overexpressed on potential tumor targets, are required for FGF2-retargeted transduction. Low-affinity heparan sulfate proteoglycan interactions, however, are not a prerequisite, in marked contrast to their obligatory role in FGF2 mitogenic signaling. By comparing receptor expression and Ligand binding with transgene expression, we also demonstrate that FGF2 retargeting enhances transduction by mechanisms other than increasing the number of targeted cells. Rather, the use of alternative targeting Ligands supports the conclusion that specific receptor interactions and intracellular events serve to enhance transgene expression. Together, these studies highlight the unique delivery and transduction pathways used by FGF2-retargeted adenoviruses, and help define the basis for their enhanced in vivo efficacy.	Select Genet Inc, San Diego, CA 92121 USA; Amgen Inc, Thousand Oaks, CA 91320 USA	Amgen	Doukas, J (corresponding author), Select Genet Inc, 11035 Roselle St, San Diego, CA 92121 USA.			Baird, Andrew/0000-0003-0027-9905	NCI NIH HHS [R34CA79294] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R43CA079294] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bachmann MF, 1997, SCIENCE, V276, P2024, DOI 10.1126/science.276.5321.2024; BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; Chandler LA, 1999, INT J CANCER, V81, P451, DOI 10.1002/(SICI)1097-0215(19990505)81:3<451::AID-IJC20>3.3.CO;2-8; Douglas JT, 1996, NAT BIOTECHNOL, V14, P1574, DOI 10.1038/nbt1196-1574; Doukas J, 1996, DIABETES, V45, P1209, DOI 10.2337/diabetes.45.9.1209; Freimuth P, 1996, J VIROL, V70, P4081, DOI 10.1128/JVI.70.6.4081-4085.1996; GEPPERT TD, 1987, J IMMUNOL, V138, P1660; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; GLEIZES PE, 1995, EUR J CELL BIOL, V66, P47; Goldman CK, 1997, CANCER RES, V57, P1447; GONZALEZ AM, 1994, BRAIN RES, V665, P285, DOI 10.1016/0006-8993(94)91349-8; GONZALEZ AM, 1994, ENDOCRINOLOGY, V134, P2289, DOI 10.1210/en.134.5.2289; GREBER UF, 1993, CELL, V75, P477, DOI 10.1016/0092-8674(93)90382-Z; Gu D., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P512; Herr AB, 1997, J BIOL CHEM, V272, P16382, DOI 10.1074/jbc.272.26.16382; HOUSLEY RM, 1994, J CLIN INVEST, V94, P1764, DOI 10.1172/JCI117524; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KWOK TT, 1991, BRIT J CANCER, V64, P251, DOI 10.1038/bjc.1991.286; Larocca D, 1998, HUM GENE THER, V9, P2393, DOI 10.1089/hum.1998.9.16-2393; Li YM, 1999, CANCER RES, V59, P325; LINDNER V, 1993, CIRC RES, V73, P589, DOI 10.1161/01.RES.73.3.589; Nemerow Glen R., 1994, Trends in Cell Biology, V4, P52, DOI 10.1016/0962-8924(94)90010-8; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; PRUDOVSKY I, 1994, J BIOL CHEM, V269, P31720; Rancourt C, 1998, CLIN CANCER RES, V4, P2455; RAPRAEGER AC, 1995, CHEM BIOL, V2, P645, DOI 10.1016/1074-5521(95)90025-X; REYNOLDS PN, 1998, TUMOR TARGET, V3, P156; ROGERS BE, 1998, TUMOR TARGET, V3, P25; Sosnowski BA, 1996, J BIOL CHEM, V271, P33647, DOI 10.1074/jbc.271.52.33647; Stevenson SC, 1997, J VIROL, V71, P4782, DOI 10.1128/JVI.71.6.4782-4790.1997; Takanami I, 1997, NEOPLASMA, V44, P295; Tomko RP, 1997, P NATL ACAD SCI USA, V94, P3352, DOI 10.1073/pnas.94.7.3352; Venkataraman G, 1996, P NATL ACAD SCI USA, V93, P845, DOI 10.1073/pnas.93.2.845; Wang YP, 1997, NAT MED, V3, P887, DOI 10.1038/nm0897-887; Watkins SJ, 1997, GENE THER, V4, P1004, DOI 10.1038/sj.gt.3300511; Whalen GF, 1989, GROWTH FACTORS, V1, P157, DOI 10.3109/08977198909029125; Wickham TJ, 1997, CANCER IMMUNOL IMMUN, V45, P149, DOI 10.1007/s002620050419; Wickham TJ, 1996, J VIROL, V70, P6831, DOI 10.1128/JVI.70.10.6831-6838.1996; Wickham TJ, 1997, J VIROL, V71, P7663, DOI 10.1128/JVI.71.10.7663-7669.1997; Wickham TJ, 1996, NAT BIOTECHNOL, V14, P1570, DOI 10.1038/nbt1196-1570; Wickham TJ, 1995, GENE THER, V2, P750; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; Worgall S, 1997, HUM GENE THER, V8, P37, DOI 10.1089/hum.1997.8.1-37; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Ying W., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P480; Zabner J, 1997, J CLIN INVEST, V100, P1144, DOI 10.1172/JCI119625	46	37	38	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1999	13	11					1459	1466		10.1096/fasebj.13.11.1459	http://dx.doi.org/10.1096/fasebj.13.11.1459			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	226KL	10428769	Bronze			2022-12-25	WOS:000082019100017
J	Geisbrecht, BV; Zhang, DY; Schulz, H; Gould, SJ				Geisbrecht, BV; Zhang, DY; Schulz, H; Gould, SJ			Characterization of PECI, a novel monofunctional Delta(3),Delta(2)-enoyl-CoA isomerase of mammalian peroxisomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNSATURATED FATTY-ACIDS; ENOYL-COA HYDRATASE; BETA-OXIDATION; SACCHAROMYCES-CEREVISIAE; RAT-LIVER; 3-HYDROXYACYL-COA DEHYDROGENASE; BIOGENESIS DISORDERS; DOUBLE-BONDS; DELTA-3,DELTA-2-ENOYL-COA ISOMERASE; MOLECULAR CHARACTERIZATION	We report here the identification and characterization of human and mouse PECI, a novel gene that encodes a monofunctional peroxisomal Delta(3),Delta(2)-enoyl-CoA isomerase, Human and mouse PECI were identified on the basis of their sequence similarity to Eci1p, a recently characterized peroxisomal Delta(3),Delta(2)-enoyl-CoA isomerase from the yeast Saccharomyces cerevisiae. Cloning and sequencing of the human PECI cDNA revealed the presence of a 1077-base pair open reading frame predicted to encode a 359-amino acid protein with a mass of 39.6 kDa. The corresponding mouse cDNA contains a 1074-base pair open reading frame that encodes a 358-amino acid-long protein with a deduced mass of 39.4 kDa, Northern blot analysis demonstrated human PECI mRNA is expressed in all tissues. A bacterially expressed form of human PECI catalyzed the isomerization of 3-cis-octenoyl-CoA to 2-trans-octenoyl-CoA with a specific activity of 27 units/mg of protein. The human and mouse PECI proteins contain type-1 peroxisomal targeting signals, and human PECI was localized to peroxisomes by both subcellular fractionation and immunofluorescence microscopy techniques. The potential roles for this monofunctional Delta(3),Delta(2)-enoyl-CoA isomerase in peroxisomal metabolism are discussed.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; CUNY City Coll, Dept Chem, New York, NY 10031 USA	Johns Hopkins University; City University of New York (CUNY) System; City College of New York (CUNY)	Gould, SJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD010981] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030847] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045787] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Binstock J F, 1981, Methods Enzymol, V71 Pt C, P403; CRANE DI, 1994, J BIOL CHEM, V269, P21835; DELAGARZA MM, 1985, EUR J BIOCHEM, V148, P285, DOI 10.1111/j.1432-1033.1985.tb08837.x; DMOCHOWSKA A, 1990, GENE, V88, P247, DOI 10.1016/0378-1119(90)90038-S; Dodt G, 1996, J CELL BIOL, V135, P1763, DOI 10.1083/jcb.135.6.1763; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; EINERHAND AWC, 1991, EUR J BIOCHEM, V200, P113, DOI 10.1111/j.1432-1033.1991.tb21056.x; Filppula SA, 1998, J BIOL CHEM, V273, P349, DOI 10.1074/jbc.273.1.349; Geisbrecht BV, 1998, J BIOL CHEM, V273, P33184, DOI 10.1074/jbc.273.50.33184; GOULD SJ, 1990, J CELL BIOL, V110, P27, DOI 10.1083/jcb.110.1.27; GRANT SGN, 1990, P NATL ACAD SCI USA, V87, P4645, DOI 10.1073/pnas.87.12.4645; Gurvitz A, 1997, J BIOL CHEM, V272, P22140, DOI 10.1074/jbc.272.35.22140; Gurvitz A, 1998, J BIOL CHEM, V273, P31366, DOI 10.1074/jbc.273.47.31366; Harlow E., 1988, ANTIBODIES LAB MANUA; Hashimoto T, 1996, ANN NY ACAD SCI, V804, P86, DOI 10.1111/j.1749-6632.1996.tb18610.x; Henke B, 1998, J BIOL CHEM, V273, P3702, DOI 10.1074/jbc.273.6.3702; HILTUNEN JK, 1992, J BIOL CHEM, V267, P6646; Hiltunen JK, 1996, ANN NY ACAD SCI, V804, P116, DOI 10.1111/j.1749-6632.1996.tb18612.x; Jones JM, 1999, J BIOL CHEM, V274, P9216, DOI 10.1074/jbc.274.14.9216; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI DOI 10.1083/JCB.108.2.229; KUNAU WH, 1978, EUR J BIOCHEM, V91, P533, DOI 10.1111/j.1432-1033.1978.tb12707.x; KUNAU WH, 1988, BIOCHEM SOC T, V16, P418, DOI 10.1042/bst0160418; Kunau WH, 1995, PROG LIPID RES, V34, P267, DOI 10.1016/0163-7827(95)00011-9; Lahn BT, 1997, SCIENCE, V278, P675, DOI 10.1126/science.278.5338.675; LUO MJ, 1994, J BIOL CHEM, V269, P2384; Mannaerts GP, 1996, ANN NY ACAD SCI, V804, P99, DOI 10.1111/j.1749-6632.1996.tb18611.x; MULLERNEWEN G, 1995, EUR J BIOCHEM, V228, P68, DOI 10.1111/j.1432-1033.1995.tb20230.x; PALOSAARI PM, 1990, J BIOL CHEM, V265, P2446; PALOSAARI PM, 1991, J BIOL CHEM, V266, P10750; PALOSAARI PM, 1990, J BIOL CHEM, V265, P3347; PENNINGTON R, 1961, BIOCHEM J, V80, P649, DOI 10.1042/bj0800649; PETERS TJ, 1972, J EXP MED, V136, P1117, DOI 10.1084/jem.136.5.1117; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shani N, 1997, HUM MOL GENET, V6, P1925, DOI 10.1093/hmg/6.11.1925; Shoukry K, 1998, J BIOL CHEM, V273, P6892, DOI 10.1074/jbc.273.12.6892; SLAWECKI ML, 1995, J CELL SCI, V108, P1817; SMELAND TE, 1992, P NATL ACAD SCI USA, V89, P6673, DOI 10.1073/pnas.89.15.6673; STOFFEL W, 1965, H-S Z PHYSIOL CHEM, V341, P76, DOI 10.1515/bchm2.1965.341.1.76; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; van Roermund CWT, 1998, EMBO J, V17, P677, DOI 10.1093/emboj/17.3.677; VEENHUIS M, 1987, YEAST, V3, P77, DOI 10.1002/yea.320030204; Wanders RJA, 1996, ANN NY ACAD SCI, V804, P450, DOI 10.1111/j.1749-6632.1996.tb18636.x; Warren DS, 1998, AM J HUM GENET, V63, P347, DOI 10.1086/301963	44	68	71	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21797	21803		10.1074/jbc.274.31.21797	http://dx.doi.org/10.1074/jbc.274.31.21797			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419495	hybrid			2022-12-25	WOS:000081721100048
J	Nakatani, K; Thompson, DA; Barthel, A; Sakaue, H; Liu, W; Weigel, RJ; Roth, RA				Nakatani, K; Thompson, DA; Barthel, A; Sakaue, H; Liu, W; Weigel, RJ; Roth, RA			Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; PLECKSTRIN HOMOLOGY DOMAIN; TUMOR-SUPPRESSOR; PROGESTERONE RECEPTORS; MOLECULAR-CLONING; CELL-LINES; EXPRESSION; PTEN/MMAC1; ONCOGENE; AMPLIFICATION	We measured the insulin-stimulated amount of Akt1, Akt2, and Akt3 enzymatic activities in four breast cancer cell lines and three prostate cancer cell lines. In the estrogen receptor-deficient breast cancer cells and the androgen-insensitive prostate cells, the amount of Akt3 enzymatic activity was approximately 20-60-fold higher than in the cells that were estrogen- or androgen-responsive. In contrast, the levels of Akt1 and -2 were not increased in these cells. The increase in Akt3 enzyme activity correlated with an increase in both Akt3 mRNA and protein. In a prostate cancer cell line lacking the tumor suppressor PTEN (a lipid and protein phosphatase), the basal enzymatic activity of Akt3 was constitutively elevated and represented the major active Akt in these cells, Finally, reverse transcription-PCR was used to examine the Akt3 expression in 27 primary breast carcinomas. The expression levels of Akt3 were significantly higher in the estrogen receptor-negative tumors in comparison to the estrogen receptor-positive tumors. To see if the increase in Akt3 could be due to chromosomal abnormalities, the Akt3 gene was assigned to human chromosome 1q44 by fluorescence in situ hybridization and radiation hybrid cell panel analyses. These results indicate that Akt3 may contribute to the more aggressive clinical phenotype of the estrogen receptor-negative breast cancers and androgen-insensitive prostate carcinomas.	Stanford Univ, Med Ctr, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA; Stanford Univ, Dept Surg, Sch Med, Stanford, CA 94305 USA	Stanford University; Stanford University	Roth, RA (corresponding author), Stanford Univ, Med Ctr, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA.		Sakaue, Hiroshi/ABE-2337-2021	Sakaue, Hiroshi/0000-0002-2468-2363; Nakatani, Kaname/0000-0001-6709-541X; Weigel, Ronald/0000-0002-9249-0793	NATIONAL CANCER INSTITUTE [R01CA077350, R29CA063251] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034926, R01DK034926] Funding Source: NIH RePORTER; NCI NIH HHS [CA63251, CA77350] Funding Source: Medline; NIDDK NIH HHS [DK 34926] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Berthon P, 1998, AM J HUM GENET, V62, P1416, DOI 10.1086/301879; Brodbeck D, 1999, J BIOL CHEM, V274, P9133, DOI 10.1074/jbc.274.14.9133; Calera MR, 1998, J BIOL CHEM, V273, P7201, DOI 10.1074/jbc.273.13.7201; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; CHEVALLIER B, 1988, CANCER-AM CANCER SOC, V62, P2517, DOI 10.1002/1097-0142(19881215)62:12<2517::AID-CNCR2820621211>3.0.CO;2-9; Coffer PJ, 1998, BIOCHEM J, V335, P1; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Davies MA, 1998, CANCER RES, V58, P5285; FISHER ER, 1987, CANCER-AM CANCER SOC, V59, P1554, DOI 10.1002/1097-0142(19870501)59:9<1554::AID-CNCR2820590904>3.0.CO;2-B; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; HENRY JA, 1988, BRIT J CANCER, V58, P600, DOI 10.1038/bjc.1988.267; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Knuutila S, 1998, AM J PATHOL, V152, P1107; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; Krook A, 1997, DIABETES, V46, P2110, DOI 10.2337/diabetes.46.12.2110; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li J, 1998, CANCER RES, V58, P5667; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nakatani K, 1999, BIOCHEM BIOPH RES CO, V257, P906, DOI 10.1006/bbrc.1999.0559; Soos G, 1997, ANTICANCER RES, V17, P4253; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Thompson DA, 1998, EUR J BIOCHEM, V252, P169, DOI 10.1046/j.1432-1327.1998.2520169.x; Walker KS, 1998, BIOCHEM J, V331, P299, DOI 10.1042/bj3310299; Webber MM, 1996, PROSTATE, V29, P386, DOI 10.1002/(SICI)1097-0045(199612)29:6<386::AID-PROS7>3.0.CO;2-6; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587	32	409	453	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21528	21532		10.1074/jbc.274.31.21528	http://dx.doi.org/10.1074/jbc.274.31.21528			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419456	hybrid			2022-12-25	WOS:000081721100009
J	Schmajuk, G; Sierakowska, H; Kole, R				Schmajuk, G; Sierakowska, H; Kole, R			Antisense oligonucleotides with different backbones - Modification of splicing pathways and efficacy of uptake	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLOBIN GENE; MESSENGER-RNA; IN-VIVO; PHOSPHOROTHIOATE OLIGODEOXYNUCLEOTIDES; MAMMALIAN-CELLS; BINDING PROTEIN; RAT-LIVER; EXPRESSION; MORPHOLINO; THERAPEUTICS	A novel, positive read-out assay that quantifies only sequence-specific nuclear activity of antisense oligonucleotides was used to evaluate morpholino and 2'-O-methyl sugar-phosphate oligonucleotides. The assay is based on modification of the splicing pathway of human beta-globin pre-mRNA, In addition, scrape-loading of cells with oligonucleotides allows the separate assessment of intracellular antisense activity of the oligonucleotides and their ability to penetrate the cell membrane barrier. The results show that, with scrape-loading, the morpholino oligonucleotides were approximately 3-fold more effective in their intrinsic antisense activity than alternating phosphodiester/phosphorothioate 2'-O-methyl-oligoribonucleotides and 6-9- and almost 200-fold more effective than the exclusively phosphorothioate and phosphodiester derivatives, respectively. The morpholino oligonucleotides were over 20-fold more effective than the phosphorothioate 2'-O-methyl-oligoribonucleotides in free uptake from the culture media. The antisense activity of the morpholino oligonucleotides was detectable not only in monolayer HeLa cells but also in suspension K562 cells. Time course experiments suggest that both the free uptake and efflux of morpholino oligonucleotides are slow.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Kole, R (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, CB 7295, Chapel Hill, NC 27599 USA.							Agrawal S, 1998, APPLIED ANTISENSE OLIGONUCLEOTIDE TECHNOLOGY, P365; Benimetskaya L, 1997, NAT MED, V3, P414, DOI 10.1038/nm0497-414; BENNETT CF, 1992, MOL PHARMACOL, V41, P1023; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; Bielinska A, 1996, NUCLEIC ACIDS RES, V24, P2176, DOI 10.1093/nar/24.11.2176; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Branch AD, 1998, ANTISENSE NUCLEIC A, V8, P249, DOI 10.1089/oli.1.1998.8.249; CHENG TC, 1984, P NATL ACAD SCI-BIOL, V81, P2821, DOI 10.1073/pnas.81.9.2821; Cioffi CL, 1997, MOL PHARMACOL, V51, P383; Crooke ST, 1998, ANTISENSE NUCLEIC A, V8, pVII, DOI 10.1089/oli.1.1998.8.vii; Crooke ST, 1998, BIOTECHNOL GENET ENG, V15, P121, DOI 10.1080/02648725.1998.10647954; Crooke ST, 1996, J PHARMACOL EXP THER, V277, P923; Crooke ST, 1998, ANTISENSE NUCLEIC A, V8, P115, DOI 10.1089/oli.1.1998.8.115; Dean NM, 1998, ANTISENSE NUCLEIC A, V8, P147, DOI 10.1089/oli.1.1998.8.147; DEAN NM, 1994, J BIOL CHEM, V269, P16416; DOBKIN C, 1985, J BIOL CHEM, V260, P6332; DOMINSKI Z, 1992, MOL CELL BIOL, V12, P2108, DOI 10.1128/MCB.12.5.2108; DOMINSKI Z, 1993, P NATL ACAD SCI USA, V90, P8673, DOI 10.1073/pnas.90.18.8673; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; FISHER TL, 1993, NUCLEIC ACIDS RES, V21, P3857, DOI 10.1093/nar/21.16.3857; Freier SM, 1997, NUCLEIC ACIDS RES, V25, P4429, DOI 10.1093/nar/25.22.4429; GESELOWITZ DA, 1995, ANTISENSE RES DEV, V5, P213, DOI 10.1089/ard.1995.5.213; Gewirtz AM, 1998, BLOOD, V92, P712, DOI 10.1182/blood.V92.3.712.415a32_712_736; Gewirtz AM, 1998, APPLIED ANTISENSE OLIGONUCLEOTIDE TECHNOLOGY, P299; Gorman L, 1998, P NATL ACAD SCI USA, V95, P4929, DOI 10.1073/pnas.95.9.4929; Graham MJ, 1998, J PHARMACOL EXP THER, V286, P447; Hanss B, 1998, APPLIED ANTISENSE OLIGONUCLEOTIDE TECHNOLOGY, P111; HAWLEY-NELSON P, 1993, FOCUS MADISON, V15, P73; Ho SP, 1998, NAT BIOTECHNOL, V16, P59, DOI 10.1038/nbt0198-59; Hughes JA, 1996, PHARMACEUT RES, V13, P404, DOI 10.1023/A:1016044609972; Juliano RL, 1999, PHARM RES-DORDR, V16, P494, DOI 10.1023/A:1011958726518; Kang SH, 1998, BIOCHEMISTRY-US, V37, P6235, DOI 10.1021/bi980300h; KRIEG AM, 1995, ANTISENSE RES DEV, V5, P241, DOI 10.1089/ard.1995.5.241; LEONETTI JP, 1991, P NATL ACAD SCI USA, V88, P2702, DOI 10.1073/pnas.88.7.2702; Lewis J, 1998, BLOOD, V91, P2152, DOI 10.1182/blood.V91.6.2152.2152_2152_2156; Lewis JG, 1996, P NATL ACAD SCI USA, V93, P3176, DOI 10.1073/pnas.93.8.3176; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; Martin RR, 1998, APPLIED ANTISENSE OLIGONUCLEOTIDE TECHNOLOGY, P387; Milner N, 1997, NAT BIOTECHNOL, V15, P537, DOI 10.1038/nbt0697-537; Moore M., 1993, RNA WORLD, P303; Nolting A, 1997, PHARMACEUT RES, V14, P516, DOI 10.1023/A:1012116003706; Partridge M, 1996, ANTISENSE NUCLEIC A, V6, P169, DOI 10.1089/oli.1.1996.6.169; Rockwell P, 1997, P NATL ACAD SCI USA, V94, P6523, DOI 10.1073/pnas.94.12.6523; Schwartz Elias, 1995, P586; Sierakowska H, 1999, RNA, V5, P369, DOI 10.1017/S135583829998130X; Sierakowska H, 1997, NUCLEOS NUCLEOT NUCL, V16, P1173, DOI 10.1080/07328319708006154; Sierakowska H, 1996, P NATL ACAD SCI USA, V93, P12840, DOI 10.1073/pnas.93.23.12840; Smetsers TFCM, 1997, BRIT J HAEMATOL, V96, P377, DOI 10.1046/j.1365-2141.1997.d01-2035.x; Stein C. A., 1998, APPL ANTISENSE OLIGO; Stein D, 1997, ANTISENSE NUCLEIC A, V7, P151, DOI 10.1089/oli.1.1997.7.151; Summerton J, 1997, ANTISENSE NUCLEIC A, V7, P187, DOI 10.1089/oli.1.1997.7.187; Summerton J, 1997, ANTISENSE NUCLEIC A, V7, P63, DOI 10.1089/oli.1.1997.7.63; Taylor MF, 1996, J BIOL CHEM, V271, P17445, DOI 10.1074/jbc.271.29.17445; Tidd DM, 1998, APPLIED ANTISENSE OLIGONUCLEOTIDE TECHNOLOGY, P161; Vaerman JL, 1997, BLOOD, V90, P331; Wang WZ, 1996, J CLIN INVEST, V98, P443, DOI 10.1172/JCI118810; ZHANG RW, 1995, BIOCHEM PHARMACOL, V50, P545, DOI 10.1016/0006-2952(95)00159-W	57	84	104	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21783	21789		10.1074/jbc.274.31.21783	http://dx.doi.org/10.1074/jbc.274.31.21783			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419493	hybrid			2022-12-25	WOS:000081721100046
J	Zuniga, A; Torres, J; Ubeda, J; Pulido, R				Zuniga, A; Torres, J; Ubeda, J; Pulido, R			Interaction of mitogen-activated protein kinases with the kinase interaction motif of the tyrosine phosphatase PTP-SL provides substrate specificity and retains ERK2 in the cytoplasm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY INTERACTION; MAP-KINASE; NUCLEAR TRANSLOCATION; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; MEGAKARYOCYTIC DIFFERENTIATION; AP-1 ACTIVITY; PATHWAY; PHOSPHORYLATION; CELLS	ERK1 and ERK2 associate with the tyrosine phosphatase PTP-SL through a kinase interaction motif (KIM) located in the juxtamembrane region of PTP-SL, A glutathione S-transferase (GST)-PTP-SL fusion protein containing the KIM associated with ERK1 and ERK2 as well as with p38/HOG, but not with the related JNK1 kinase or with protein kinase A or C, Accordingly, ERK2 showed in vitro substrate specificity to phosphorylate GST-PTP-SL in comparison with GST-c-Jun, Furthermore, tyrosine dephosphorylation of ERK2 by the PTP-SL Delta KIM mutant was impaired. The in vitro association of ERK1/2 with GST-PTP-SL was highly stable; however, low concentrations of nucleotides partially dissociated the ERK1/2 PTP-SL complex. Partial deletions of the KIM abrogated the association of PTP-SL with ERK1/2, indicating that KIM integrity is required for interaction. Amino acid substitution analysis revealed that Arg and Leu residues within the KIM are essential for the interaction and suggested a regulatory role for Ser(231), Finally, coexpression of PTP-SL and ERK2 in COS-7 cells resulted in the retention of ERK2 in the cytoplasm in a KIM-dependent manner. Our results demonstrate that the noncatalytic region of PTP-SL associates with mitogen-activated protein kinases with high affinity and specificity, providing a mechanism for substrate specificity, and suggest a role for PTP-SL in the regulation of mitogen-activated protein kinase translocation to the nucleus upon activation.	Inst Invest Citol, Valencia 46010, Spain		Pulido, R (corresponding author), Inst Invest Citol, Amadeo Saboya 4, Valencia 46010, Spain.		Torres, Josema/F-7070-2013	Torres, Josema/0000-0001-6906-7164; Pulido, Rafael/0000-0001-9100-248X				ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; Bardwell L, 1996, TRENDS BIOCHEM SCI, V21, P373, DOI 10.1016/S0968-0004(96)30032-7; Bardwell L, 1996, MOL CELL BIOL, V16, P3637; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Cobb M H, 1996, Adv Pharmacol, V36, P49, DOI 10.1016/S1054-3589(08)60576-1; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; Cohen P, 1996, Adv Pharmacol, V36, P15, DOI 10.1016/S1054-3589(08)60574-8; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; GOMEZ N, 1990, FEBS LETT, V271, P119, DOI 10.1016/0014-5793(90)80386-W; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; GOPHALBAI K, 1997, J CELL PHYSL, V174, P35; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KEYSE SM, 1995, BIOCHIM BIOPHYS ACTA, V1265, P145; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Meili R, 1996, FEBS LETT, V394, P34, DOI 10.1016/0014-5793(96)00927-1; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MILLAR JBA, 1995, GENE DEV, V9, P2117, DOI 10.1101/gad.9.17.2117; Mourey RJ, 1996, J BIOL CHEM, V271, P3795; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Muda M, 1996, J BIOL CHEM, V271, P4319; Muda M, 1998, J BIOL CHEM, V273, P9323, DOI 10.1074/jbc.273.15.9323; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; PUMIGILIA KM, 1997, P NATL ACAD SCI USA, V94, P443; Racke FK, 1997, J BIOL CHEM, V272, P23366, DOI 10.1074/jbc.272.37.23366; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; SARCEVIC B, 1993, J BIOL CHEM, V268, P25075; Saxena M, 1998, J BIOL CHEM, V273, P15340, DOI 10.1074/jbc.273.25.15340; SETH A, 1992, J BIOL CHEM, V267, P24796; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; WurglerMurphy SM, 1997, MOL CELL BIOL, V17, P1289, DOI 10.1128/MCB.17.3.1289; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; Zhao ZZ, 1996, J BIOL CHEM, V271, P22251, DOI 10.1074/jbc.271.36.22251; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	63	111	114	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	1999	274	31					21900	21907		10.1074/jbc.274.31.21900	http://dx.doi.org/10.1074/jbc.274.31.21900			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	221HF	10419510	hybrid, Green Published			2022-12-25	WOS:000081721100063
J	Lee, CM; Sedman, J; Neupert, W; Stuart, RK				Lee, CM; Sedman, J; Neupert, W; Stuart, RK			The DNA helicase, Hmi1p, is transported into mitochondria by a C-terminal cleavable targeting signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNER MEMBRANE-PROTEIN; YEAST MITOCHONDRIA; IMPORT; IDENTIFICATION; TRANSLOCATION; SYSTEM; MATRIX; COMPONENT; SEQUENCE; ISP45	We have identified a novel mitochondrial targeting signal in the precursor of the DNA helicase Hmi1p of Saccharomyces cerevisiae that is located at the C terminus of the protein. Similar to classical N-terminal presequences, this C-terminal targeting signal consists of a stretch of positively charged amino acids that has the potential to form an amphipathic ct-helix. Deletion of the C-terminal 36 amino acids of helicase resulted in loss of import into mitochondria, while deletion of the N-terminal 40 amino acids had no effect. When C-terminal regions of the helicase were placed at the C terminus of a passenger protein, dihydrofolate reductase, the resulting fusion proteins were directed into the mitochondrial matrix, and the C-terminal region of helicase became proteolytically processed. Import of helicase occurs in a C- to N-terminal direction; it requires a membrane potential and the TIM17-23 translocase together with mitochondrial Hsp70. Helicase is the only mitochondrial matrix protein identified thus far with a cleavable targeting signal at its C terminus.	Univ Munich, Inst Physiol Chem, D-80336 Munich, Germany; Estonian Bioctr, EE-51010 Tartu, Estonia	University of Munich; Estonian Biocentre	Stuart, RK (corresponding author), Univ Munich, Inst Physiol Chem, Goethestr 33, D-80336 Munich, Germany.		Sedman, Juhan/H-1820-2011	Sedman, Juhan/0000-0003-2081-1452				Arnold I, 1998, J BIOL CHEM, V273, P1469, DOI 10.1074/jbc.273.3.1469; Bauer MF, 1996, CELL, V87, P33, DOI 10.1016/S0092-8674(00)81320-3; BERTHOLD J, 1995, CELL, V81, P1085, DOI 10.1016/S0092-8674(05)80013-3; BOHNI PC, 1983, J BIOL CHEM, V258, P4937; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunner M., 1994, SIGNAL PEPTIDASES, P73; DEKKER PJT, 1993, FEBS LETT, V330, P66, DOI 10.1016/0014-5793(93)80921-G; EMTAGE JLT, 1993, J CELL BIOL, V122, P1003, DOI 10.1083/jcb.122.5.1003; Folsch H, 1998, EMBO J, V17, P6508, DOI 10.1093/emboj/17.22.6508; Folsch H, 1996, EMBO J, V15, P479, DOI 10.1002/j.1460-2075.1996.tb00380.x; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; Herrmann J. M., 1994, CELL BIOL LAB HDB, VI, P538; HORST M, 1993, EMBO J, V12, P3035, DOI 10.1002/j.1460-2075.1993.tb05972.x; Kerscher O, 1997, J CELL BIOL, V139, P1663, DOI 10.1083/jcb.139.7.1663; KRONIDOU NG, 1994, P NATL ACAD SCI USA, V91, P12818, DOI 10.1073/pnas.91.26.12818; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAHAYE A, 1993, J BIOL CHEM, V268, P26155; MAARSE AC, 1992, EMBO J, V11, P3619, DOI 10.1002/j.1460-2075.1992.tb05446.x; MAARSE AC, 1994, FEBS LETT, V349, P215, DOI 10.1016/0014-5793(94)00669-5; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PFANNER N, 1997, CURR BIOL, V7, P100; RASSOW J, 1994, J CELL BIOL, V127, P1547, DOI 10.1083/jcb.127.6.1547; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Schneider HC, 1996, EMBO J, V15, P5796, DOI 10.1002/j.1460-2075.1996.tb00966.x; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; Sirrenberg C, 1998, NATURE, V391, P912, DOI 10.1038/36136; Sirrenberg C, 1996, NATURE, V384, P582, DOI 10.1038/384582a0; STUART RA, 1994, EUR J BIOCHEM, V220, P9, DOI 10.1111/j.1432-1033.1994.tb18593.x; Taucher-Scholz G, 1983, MECH DNA REPLICATION, P65; Teichmann U, 1996, J BIOL CHEM, V271, P10137, DOI 10.1074/jbc.271.17.10137; Ungermann C, 1996, EMBO J, V15, P735, DOI 10.1002/j.1460-2075.1996.tb00409.x; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; VOOS W, 1993, J CELL BIOL, V123, P119, DOI 10.1083/jcb.123.1.119	36	84	86	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					20937	20942		10.1074/jbc.274.30.20937	http://dx.doi.org/10.1074/jbc.274.30.20937			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409639	hybrid			2022-12-25	WOS:000081613100030
J	Maekawa, S; Sato, C; Kitajima, K; Funatsu, N; Kumanogoh, H; Sokawa, Y				Maekawa, S; Sato, C; Kitajima, K; Funatsu, N; Kumanogoh, H; Sokawa, Y			Cholesterol-dependent localization of NAP-22 on a neuronal membrane microdomain (Raft)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; SYNAPTIC PLASMA-MEMBRANES; RAT-BRAIN; ANCHORED PROTEINS; EPITHELIAL-CELLS; APOLIPOPROTEIN-E; CALMODULIN-BINDING; ALZHEIMERS-DISEASE; CAVEOLAE; DOMAINS	A membrane microdomain called raft has been under extensive study since the assembly of various signal-transducing molecules into this region has been envisaged. This domain is isolated as a low buoyant membrane fraction after the extraction with a nonionic detergent such as Triton X-100. The characteristic low density of this fraction is ascribed to the enrichment of several lipids including cholesterol. To clear the molecular mechanism of raft formation, several extraction methods were applied to solubilize raft components. Cholesterol extraction using methyl-beta-cyclodextrin was found to be effective to solubilize NAP-22, a neuron-enriched Ca2+-dependent calmodulin-binding protein as well as one of the main protein components of brain raft. Purified NAP-22 bound to the liposomes that were made from phosphatidylcholine and cholesterol. This binding was dependent on the amount of cholesterol in liposomes. Calmodulin inhibited this binding in a dose-dependent manner. These results suggest that the presence of a calcium-dependent regulatory mechanism works on the assembly of raft within the neuron.	Kyoto Inst Technol, Fac Text Sci, Dept Biotechnol, Kyoto 6068585, Japan; Kobe Univ, Grad Sch Sci & Technol, Div Biosci, Kobe, Hyogo 6578501, Japan; Nagoya Univ, Grad Sch Bioagr Sci, Dept Appl Mol Biosci, Nagoya, Aichi 4648601, Japan	Kyoto Institute of Technology; Kobe University; Nagoya University	Maekawa, S (corresponding author), Kyoto Inst Technol, Fac Text Sci, Dept Biotechnol, Kyoto 6068585, Japan.	smaekawa@ipc.kit.ac.jp	SATO, Chihiro/B-7396-2014					Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; ANDERSSON M, 1990, FEBS LETT, V269, P15, DOI 10.1016/0014-5793(90)81107-Y; ARIGA T, 1988, BIOCHEMISTRY-US, V27, P52, DOI 10.1021/bi00401a010; Bodovitz S, 1996, J BIOL CHEM, V271, P4436; Bouillot C, 1996, J BIOL CHEM, V271, P7640, DOI 10.1074/jbc.271.13.7640; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Cameron PL, 1997, J NEUROSCI, V17, P9520; Caroni P, 1997, J CELL BIOL, V136, P679, DOI 10.1083/jcb.136.3.679; CRAIG AM, 1994, ANNU REV NEUROSCI, V17, P267, DOI 10.1146/annurev.ne.17.030194.001411; de Chaves EIP, 1997, J BIOL CHEM, V272, P30766, DOI 10.1074/jbc.272.49.30766; DIETSCHY JM, 1993, J LIPID RES, V34, P1637; FIEDLER K, 1993, BIOCHEMISTRY-US, V32, P6365, DOI 10.1021/bi00076a009; Fielding CJ, 1997, J LIPID RES, V38, P1503; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Gamby C, 1996, J BIOL CHEM, V271, P26698, DOI 10.1074/jbc.271.43.26698; GERENDASY DD, 1995, J BIOL CHEM, V270, P6741, DOI 10.1074/jbc.270.12.6741; Gimpl G, 1997, BIOCHEMISTRY-US, V36, P10959, DOI 10.1021/bi963138w; GORODINSKY A, 1995, J CELL BIOL, V129, P619, DOI 10.1083/jcb.129.3.619; HANADA K, 1995, J BIOL CHEM, V270, P6254, DOI 10.1074/jbc.270.11.6254; HARTMANN H, 1994, BIOCHEM BIOPH RES CO, V200, P1185, DOI 10.1006/bbrc.1994.1576; Howland DS, 1998, J BIOL CHEM, V273, P16576, DOI 10.1074/jbc.273.26.16576; Igbavboa U, 1997, J NEUROCHEM, V69, P1661; Igbavboa U, 1996, J NEUROCHEM, V66, P1717; Jareb M, 1998, NEURON, V20, P855, DOI 10.1016/S0896-6273(00)80468-7; JARVIK GP, 1995, NEUROLOGY, V45, P1092, DOI 10.1212/WNL.45.6.1092; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; Ledesma MD, 1998, P NATL ACAD SCI USA, V95, P3966, DOI 10.1073/pnas.95.7.3966; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; Liang JS, 1996, BIOCHEM BIOPH RES CO, V219, P962, DOI 10.1006/bbrc.1996.0332; Lipardi C, 1998, J CELL BIOL, V140, P617, DOI 10.1083/jcb.140.3.617; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LIU YC, 1990, TRENDS PHARMACOL SCI, V11, P107; Lutjohann D, 1996, P NATL ACAD SCI USA, V93, P9799, DOI 10.1073/pnas.93.18.9799; MACALA LJ, 1983, J LIPID RES, V24, P1243; MAEKAWA S, 1993, J BIOL CHEM, V268, P13703; MAEKAWA S, 1994, J BIOL CHEM, V269, P19462; Maekawa S, 1997, BBA-BIOMEMBRANES, V1323, P1, DOI 10.1016/S0005-2736(96)00222-2; MAEKAWA S, 1994, BBA-GENE STRUCT EXPR, V1218, P119, DOI 10.1016/0167-4781(94)90113-9; MASON RP, 1992, NEUROBIOL AGING, V13, P413, DOI 10.1016/0197-4580(92)90116-F; MESCHER MF, 1985, ADV EXP MED BIOL, V184, P387; Mosevitsky MI, 1997, BIOCHIMIE, V79, P373, DOI 10.1016/S0300-9084(97)80032-6; MOSS DJ, 1992, EUR J CELL BIOL, V57, P59; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; OLIVE S, 1995, J NEUROCHEM, V65, P2307; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; Powell SK, 1997, J NEUROBIOL, V32, P223, DOI 10.1002/(SICI)1097-4695(199702)32:2<223::AID-NEU7>3.0.CO;2-A; RAO AM, 1993, NEUROCHEM INT, V23, P45; ROTH GS, 1995, TRENDS NEUROSCI, V18, P203, DOI 10.1016/0166-2236(95)93902-A; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Schroeder RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/jbc.273.2.1150; SEROUGNE.C, 1973, BIOCHIM BIOPHYS ACTA, V316, P244, DOI 10.1016/0005-2760(73)90014-3; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; SNOPES GJ, 1997, SUBCELL BIOCH, V28, P173; SONG Y, 1991, J BIOL CHEM, V266, P21929; SVENNERHOLM L, 1957, BIOCHIM BIOPHYS ACTA, V24, P604, DOI 10.1016/0006-3002(57)90254-8; TINT GS, 1994, NEW ENGL J MED, V330, P107, DOI 10.1056/NEJM199401133300205; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; Vogel U, 1998, J CELL SCI, V111, P825; Weimbs T, 1997, TRENDS CELL BIOL, V7, P393, DOI 10.1016/S0962-8924(97)01130-6; Wu CB, 1997, J BIOL CHEM, V272, P3554, DOI 10.1074/jbc.272.6.3554; Zhang YY, 1996, NEUROBIOL AGING, V17, P869, DOI 10.1016/S0197-4580(96)00076-0	65	89	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21369	21374		10.1074/jbc.274.30.21369	http://dx.doi.org/10.1074/jbc.274.30.21369			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409698	hybrid			2022-12-25	WOS:000081613100089
J	Trupp, M; Scott, R; Whittemore, SR; Ibanez, CF				Trupp, M; Scott, R; Whittemore, SR; Ibanez, CF			Ret-dependent and -independent mechanisms of glial cell line-derived neurotrophic factor signaling in neuronal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; MICE LACKING GDNF; ENTERIC NERVOUS-SYSTEM; ADULT-RAT CNS; FUNCTIONAL RECEPTOR; SURVIVAL FACTOR; PROTEIN-KINASE; DOCKING SITE; ACTIVATION; SRC	Glial cell line-derived neurotrophic factor (GDNF) has been shown to signal through a multicomponent receptor complex consisting of the Ret receptor tyrosine kinase and a member of the GFR alpha family of glycosylphosphatidylinositol-anchored receptors, In the current model of GDNF signaling, Ret delivers the intracellular signal but cannot bind ligand on its own, while GFR alpha s bind ligand but are thought not to signal in the absence of Ret, We have compared signaling pathways activated by GDNF in two neuronal cell lines expressing different complements of GDNF receptors. In a motorneuron-derived cell line expressing Ret and GFR alpha s, GDNF stimulated sustained activation of the Ras/ERK and phosphatidylinositol 3-kinase/Akt pathways, cAMP response element-binding protein phosphorylation, and increased c-fos expression. Unexpectedly, GDNF also promoted biochemical and biological responses in a line of conditionally immortalized neuronal precursors that express high levels of GFR alpha s but not Ret, GDNF treatment did not activate the Ras/ERK pathway in these cells, but stimulated a GFR alpha 1-associated Src-like kinase activity in detergent-insoluble membrane compartments, rapid phosphorylation of cAMP response element-binding protein, up-regulation of c-fos mRNA, and cell survival. Together, these results offer new insights into the dynamics of GDNF signaling in neuronal cells, and indicate the existence of novel signaling mechanisms directly or indirectly mediated by GFR alpha receptors acting in a cell-autonomous manner independently of Ret.	Karolinska Inst, Dept Neurosci, Div Mol Neurobiol, S-17177 Stockholm, Sweden; Univ Louisville, Dept Neurol Surg, Louisville, KY 40202 USA	Karolinska Institutet; University of Louisville	Ibanez, CF (corresponding author), Karolinska Inst, Dept Neurosci, Div Mol Neurobiol, Doktrosringen 12B, S-17177 Stockholm, Sweden.		Scott, Rizaldy/AAC-5264-2020; Scott, Rizaldy/Y-7584-2019	Scott, Rizaldy/0000-0002-0288-8862	NINDS NIH HHS [NS26887] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026887, R55NS026887] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alberti L, 1998, ONCOGENE, V17, P1079, DOI 10.1038/sj.onc.1202046; Arenas E, 1995, NEURON, V15, P1465, DOI 10.1016/0896-6273(95)90024-1; Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Baloh RH, 1997, NEURON, V18, P793, DOI 10.1016/S0896-6273(00)80318-9; Baloh RH, 1998, NEURON, V21, P1291, DOI 10.1016/S0896-6273(00)80649-2; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BUJBELLO A, 1995, NEURON, V15, P821, DOI 10.1016/0896-6273(95)90173-6; Cacalano G, 1998, NEURON, V21, P53, DOI 10.1016/S0896-6273(00)80514-0; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; Edery P, 1997, BIOESSAYS, V19, P389, DOI 10.1002/bies.950190506; Enokido Y, 1998, CURR BIOL, V8, P1019, DOI 10.1016/S0960-9822(07)00422-8; Enomoto H, 1998, NEURON, V21, P317, DOI 10.1016/S0896-6273(00)80541-3; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Klein RD, 1997, NATURE, V387, P717, DOI 10.1038/42722; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; Lu YM, 1998, SCIENCE, V279, P1363, DOI 10.1126/science.279.5355.1363; MARTIN D, 1995, BRAIN RES, V683, P172, DOI 10.1016/0006-8993(95)00369-2; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; Naveilhan P, 1997, EUR J NEUROSCI, V9, P1450, DOI 10.1111/j.1460-9568.1997.tb01499.x; Ohiwa M, 1997, BIOCHEM BIOPH RES CO, V237, P747, DOI 10.1006/bbrc.1997.7225; OLIVE S, 1995, J NEUROCHEM, V65, P2307; ONIFER SM, 1993, EXP NEUROL, V122, P130, DOI 10.1006/exnr.1993.1114; OPPENHEIM RW, 1995, NATURE, V373, P344, DOI 10.1038/373344a0; Peles E, 1997, EMBO J, V16, P978, DOI 10.1093/emboj/16.5.978; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; Sainio K, 1997, DEVELOPMENT, V124, P4077; SALAZARGRUESO EF, 1991, NEUROREPORT, V2, P505, DOI 10.1097/00001756-199109000-00002; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SHIHABUDDIN LS, 1995, J NEUROSCI, V15, P6666; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Suvanto P, 1997, HUM MOL GENET, V6, P1267, DOI 10.1093/hmg/6.8.1267; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; TRUPP M, 1995, J CELL BIOL, V130, P137, DOI 10.1083/jcb.130.1.137; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; Trupp M, 1998, MOL CELL NEUROSCI, V11, P47, DOI 10.1006/mcne.1998.0667; Trupp M, 1997, J NEUROSCI, V17, P3554; Vega QC, 1996, P NATL ACAD SCI USA, V93, P10657, DOI 10.1073/pnas.93.20.10657; WHITE LA, 1994, J NEUROSCI, V14, P6744; WHITTEMORE SR, 1993, BRAIN RES, V615, P27, DOI 10.1016/0006-8993(93)91111-5; Worby CA, 1996, J BIOL CHEM, V271, P23619, DOI 10.1074/jbc.271.39.23619; Yu T, 1998, J NEUROSCI, V18, P4684; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674; ZISCH AH, 1995, MOL CELL NEUROSCI, V6, P263, DOI 10.1006/mcne.1995.1021	53	264	276	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					20885	20894		10.1074/jbc.274.30.20885	http://dx.doi.org/10.1074/jbc.274.30.20885			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409632	hybrid			2022-12-25	WOS:000081613100023
J	Wolf, I; Rohrschneider, LR				Wolf, I; Rohrschneider, LR			Fiz1, a novel zinc finger protein interacting with the receptor tyrosine kinase Flt3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; B-CELL PROGENITORS; HEMATOPOIETIC-CELLS; C-KIT; MURINE FLT3; STEM-CELLS; JUXTAMEMBRANE DOMAIN; SIGNAL-TRANSDUCTION; LIGAND SUPPORTS; HUMAN HOMOLOG	The receptor tyrosine kinase Flt3 has been shown to play a role in proliferation and survival of hematopoietic progenitor cells as well as differentiation of early B lymphoid progenitors. However, the signaling events that control growth or differentiation are not completely understood. In order to identify new signaling molecules interacting with the cytoplasmic domain of Fits, we performed a yeast two-hybrid screen. In addition to several SH2 domain-containing proteins, we have isolated a novel Flt3 interacting zinc finger protein (Fiz1) with 11 C2H2-type zinc fingers. Fiz1 binds to the catalytic domain of Fits but not to the structurally related receptor tyrosine kinases Kit, Fms, and platelet-derived growth factor receptor. This association is independent of kinase activity. The interaction between Flt3 and Fiz1 detected in yeast was confirmed by in vitro and in vivo coprecipitation assays. Fiz1 mRNA is expressed in all murine cell lines and tissues tested. Anti-Fiz1 antibodies recognize a 60-kDa protein, which is localized in the nucleus as well as in the cytoplasm. Together, these results identified a novel class of interaction between a receptor tyrosine kinase and a signaling molecule which is independent of the well established SH2 domain/phosphotyrosine binding.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Wolf, I (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, B2-152,1100 Fairview Ave N, Seattle, WA 98109 USA.	iwolf@fhcrc.org			NATIONAL CANCER INSTITUTE [R01CA040987] Funding Source: NIH RePORTER; NCI NIH HHS [CA40987] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERG JM, 1988, P NATL ACAD SCI USA, V85, P99, DOI 10.1073/pnas.85.1.99; Beslu N, 1996, J BIOL CHEM, V271, P20075, DOI 10.1074/jbc.271.33.20075; Bourette RP, 1998, EMBO J, V17, P7273, DOI 10.1093/emboj/17.24.7273; Bourette RP, 1997, EMBO J, V16, P5880, DOI 10.1093/emboj/16.19.5880; Brasel K, 1996, BLOOD, V88, P2004, DOI 10.1182/blood.V88.6.2004.bloodjournal8862004; CASTERAN N, 1994, CELL MOL BIOL, V40, P443; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DOSIL M, 1993, MOL CELL BIOL, V13, P6572, DOI 10.1128/MCB.13.10.6572; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; GalchevaGargova Z, 1996, SCIENCE, V272, P1797, DOI 10.1126/science.272.5269.1797; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; HANNUM C, 1994, NATURE, V368, P643, DOI 10.1038/368643a0; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HIRAYAMA F, 1995, BLOOD, V85, P1762, DOI 10.1182/blood.V85.7.1762.bloodjournal8571762; HUDAK S, 1995, BLOOD, V85, P2747, DOI 10.1182/blood.V85.10.2747.bloodjournal85102747; Hunte BE, 1996, J IMMUNOL, V156, P489; JACOBSEN SEW, 1995, J EXP MED, V181, P1357, DOI 10.1084/jem.181.4.1357; Jones N, 1998, ONCOGENE, V17, P1097, DOI 10.1038/sj.onc.1202115; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; Lavagna-Sevenier C, 1998, LEUKEMIA, V12, P301, DOI 10.1038/sj.leu.2400921; Lavagna-Sevenier C, 1998, J BIOL CHEM, V273, P14962, DOI 10.1074/jbc.273.24.14962; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; LYMAN SD, 1993, CELL, V75, P1157, DOI 10.1016/0092-8674(93)90325-K; LYMAN SD, 1994, BLOOD, V83, P2795, DOI 10.1182/blood.V83.10.2795.2795; Lyman SD, 1998, BLOOD, V91, P1101, DOI 10.1182/blood.V91.4.1101; MACKAREHTSCHIAN K, 1995, IMMUNITY, V3, P147, DOI 10.1016/1074-7613(95)90167-1; Mackay JP, 1998, TRENDS BIOCHEM SCI, V23, P1, DOI 10.1016/S0968-0004(97)01168-7; MAROC N, 1993, ONCOGENE, V8, P909; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MYLES GM, 1994, MOL CELL BIOL, V14, P4843, DOI 10.1128/MCB.14.7.4843; Ray RJ, 1996, EUR J IMMUNOL, V26, P1504, DOI 10.1002/eji.1830260715; ROHRSCHNEIDER LR, 1995, GUIDEBOOK CYTOKINES, P168; ROSNET O, 1991, ONCOGENE, V6, P1641; ROSNET O, 1993, BLOOD, V82, P1110, DOI 10.1182/blood.V82.4.1110.bloodjournal8241110; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; ROTHWELL VM, 1987, ONCOGENE RES, V1, P311; ROTTAPEL R, 1994, ONCOGENE, V9, P1755; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHLESSINGER J, 1986, J CELL BIOL, V103, P2067, DOI 10.1083/jcb.103.6.2067; Shibayama H, 1998, CELL IMMUNOL, V187, P27, DOI 10.1006/cimm.1998.1318; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; SMALL D, 1994, P NATL ACAD SCI USA, V91, P459, DOI 10.1073/pnas.91.2.459; Sun L, 1996, EMBO J, V15, P5358, DOI 10.1002/j.1460-2075.1996.tb00920.x; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Tsujimura T, 1996, BLOOD, V87, P273; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5; WU RY, 1994, J BIOL CHEM, V269, P25085; Yokouchi M, 1997, ONCOGENE, V15, P7, DOI 10.1038/sj.onc.1201163; Zhang SL, 1999, BIOCHEM BIOPH RES CO, V254, P440, DOI 10.1006/bbrc.1998.9959; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	59	22	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					21478	21484		10.1074/jbc.274.30.21478	http://dx.doi.org/10.1074/jbc.274.30.21478			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409713	hybrid			2022-12-25	WOS:000081613100104
J	Zwick, E; Wallasch, C; Daub, H; Ullrich, A				Zwick, E; Wallasch, C; Daub, H; Ullrich, A			Distinct calcium-dependent pathways of epidermal growth factor receptor transactivation and PYK2 tyrosine phosphorylation in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SMOOTH-MUSCLE CELLS; C-FOS TRANSCRIPTION; GENE-EXPRESSION; MAP KINASE; MEMBRANE DEPOLARIZATION; EGF RECEPTOR; HIPPOCAMPAL-NEURONS; COUPLED RECEPTORS; ION-CHANNEL	Recently, we have demonstrated that in PC12 cells activation of the Ras/extracellular signal-regulated kinase pathway in response to membrane depolarization or bradykinin is mediated by calcium-dependent transactivation of the epidermal growth factor receptor (EGFR). Here we address the question whether Ca2+- calmodulin-dependent protein kinase (CaM kinase) has a role in the EGFR transactivation signal. Using compounds that selectively interfere with either CaM kinase activity or calmodulin function, we show that KCl-mediated membrane depolarization-triggered, but not bradykinin-mediated signals involve CaM kinase function upstream of the EGFR. Although both depolarization-induced calcium influx and bradykinin stimulation of PC12 cells were found to induce c-fos transcription through EGFR activation, the former signal is CaM kinase-dependent and the latter was shown to be independent. As PYK2 is also activated upon elevation of intracellular calcium, we investigated the potential involvement of this cytoplasmic tyrosine kinase in EGFR transactivation. Interestingly, we observed that inhibition of CaM kinase activity in PC12 cells abrogated tyrosine phosphorylation of PYK2 upon KCl but not bradykinin treatment. Nevertheless, PYK2 activation in response to both stimuli appeared to be mediated by pathways parallel to EGFR transactivation, Our data demonstrate the existence of two distinct calcium-dependent mechanisms leading either to EGFR-mediated extracellular signal-regulated activation or to PYK2 tyrosine phosphorylation. Both pathways either in concert or independently might contribute to the definition of biological responses in neuronal cell types.	Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany	Max Planck Society	Ullrich, A (corresponding author), Max Planck Inst Biochem, Dept Mol Biol, Klopferspitz 18A, D-82152 Martinsried, Germany.							BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; BOOTMAN MD, 1995, CELL, V83, P675, DOI 10.1016/0092-8674(95)90179-5; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; DASH PK, 1991, P NATL ACAD SCI USA, V88, P4756; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DAUB H, 1997, EMBO J, V16, P101; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; ELY CM, 1990, J CELL BIOL, V110, P731, DOI 10.1083/jcb.110.3.731; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; GALLIN WJ, 1995, CURR OPIN NEUROBIOL, V5, P367, DOI 10.1016/0959-4388(95)80050-6; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LI G, 1992, J PHYSL, V364, P395; Li X, 1998, EMBO J, V17, P2574, DOI 10.1093/emboj/17.9.2574; Lu Q, 1998, MOL CELL BIOL, V18, P3257, DOI 10.1128/MCB.18.6.3257; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MAMIYA N, 1993, BIOCHEM BIOPH RES CO, V195, P608, DOI 10.1006/bbrc.1993.2089; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; Maurer JA, 1996, J NEUROCHEM, V66, P105; METTHEWS RP, 1994, MOL CELL BIOL, V14, P6104; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; Muthalif MM, 1996, J BIOL CHEM, V271, P30149, DOI 10.1074/jbc.271.47.30149; NEBIGIL C, 1993, J PHARMACOL EXP THER, V266, P1113; Rasmussen H, 1990, Curr Top Cell Regul, V31, P1; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; Schieffer B, 1996, J BIOL CHEM, V271, P10329, DOI 10.1074/jbc.271.17.10329; SEEDORF K, 1994, J BIOL CHEM, V269, P16009; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; Siciliano JC, 1996, J BIOL CHEM, V271, P28942, DOI 10.1074/jbc.271.46.28942; Soltoff SP, 1998, J BIOL CHEM, V273, P23110, DOI 10.1074/jbc.273.36.23110; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; TAN SE, 1994, J NEUROSCI, V14, P1123, DOI 10.1523/JNEUROSCI.14-03-01123.1994; TOKUMITSU H, 1990, J BIOL CHEM, V265, P5168; Tsai W, 1997, EMBO J, V16, P4597, DOI 10.1093/emboj/16.15.4597; Wang Y, 1996, MOL CELL BIOL, V16, P5915; WYLLIE DJA, 1994, NEURON, V13, P635, DOI 10.1016/0896-6273(94)90031-0; Zou YZ, 1996, J BIOL CHEM, V271, P33592, DOI 10.1074/jbc.271.52.33592; Zwick E, 1997, J BIOL CHEM, V272, P24767, DOI 10.1074/jbc.272.40.24767	53	97	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	1999	274	30					20989	20996		10.1074/jbc.274.30.20989	http://dx.doi.org/10.1074/jbc.274.30.20989			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	219NJ	10409647	hybrid			2022-12-25	WOS:000081613100038
J	Lee, TH; Chuang, LY; Hung, WC				Lee, TH; Chuang, LY; Hung, WC			Tamoxifen induces p21(WAF1) and p27(KIP1) expression in estrogen receptor-negative lung cancer cells	ONCOGENE			English	Article						tamoxifen; estrogen receptor; p21(WAF1); p27(KIP1)	DEPENDENT KINASE INHIBITOR; HIGH-DOSE TAMOXIFEN; BREAST-CANCER; CYCLE CONTROL; CHROMOSOMAL LOCALIZATION; METASTATIC MELANOMA; POTENTIAL MEDIATOR; GROWTH-INHIBITION; P53 GENE; PHASE-I	Tamoxifen (Tam), besides its action as an anti-estrogen, also inhibits cell proliferation of estrogen receptor (ER)negative cancer cells by an unknown mechanism. In this study, we used ER-negative lung cancer cells to clarify such ER-independent inhibitory effect of Tam, We found that Tam induced G1 growth arrest in these cells. However, our results indicated that the expression of G1 cyclins (including D1, 2, 3 and E) was not regulated by Tam in these lung cancer cells, Additionally, the protein levels of G1 acting cyclin-dependent kinases (CDKs), CDK2, 4 and 6, was unaltered in Tam-treated lung cancer cells with the exception of CDK2 expression in H322 cells which was attenuated by Tam in a cell line-specific manner. We next examined the effect of Tam on the expression of cyclin-dependent kinase inhibitors (CDKIs) and our results demonstrated that the expression of p21(WAF1) and p27(KIP1), but not p57(KIP2), was strongly activated by Tam in these cells. The amounts of p21(WAF1) and p27(KIP1) co-immunoprecipitated with cyclin E were obviously increased after Tam treatment and reduced activity of cyclin E-associated kinases and accumulation of hypo-phosphorylated retinoblastoma (Rb) protein mere clearly detected in Tam-incubated cells. No consentaneous induction of CDKIs was found when ER-negative lung cancer cells were incubated with cytotoxic drugs, cisplatin and etoposide, this indicates that enhancement of CDKI expression is not a non-specific effect of Tam, We also found that Tam may up-regulate p21(WAF1) expression via transcription activation. Considered together, these results suggest that Tam-induced growth inhibition in ER-negative lung cancer cells is associated with induction of p21(WAF1) and p27(KIP1).	Kaohsiung Med Coll, Sch Technol Med Sci, Kaohsiung 807, Taiwan; Kaohsiung Med Coll, Grad Inst Med, Kaohsiung 807, Taiwan; Kaohsiung Med Coll, Dept Biochem, Kaohsiung 807, Taiwan	Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University	Hung, WC (corresponding author), Kaohsiung Med Coll, Sch Technol Med Sci, 100 Shih Chuan 1st Rd, Kaohsiung 807, Taiwan.		Chuang, Lea-Yea/C-7450-2009					AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; Bennett WP, 1998, CLIN CANCER RES, V4, P1499; Cabot MC, 1996, FEBS LETT, V394, P129, DOI 10.1016/0014-5793(96)00942-8; Caputi M, 1998, AM J RESP CELL MOL, V18, P213, DOI 10.1165/ajrcmb.18.2.2937m; CHIBA I, 1990, ONCOGENE, V5, P1603; COULDWELL WT, 1993, NEUROSURGERY, V32, P485, DOI 10.1227/00006123-199303000-00034; Cover CM, 1998, J BIOL CHEM, V273, P3838, DOI 10.1074/jbc.273.7.3838; CROXTALL JD, 1994, BIOCHEM PHARMACOL, V47, P197, DOI 10.1016/0006-2952(94)90006-X; DELPRETE SA, 1984, CANCER TREAT REP, V68, P1403; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Enmark E, 1997, J CLIN ENDOCR METAB, V82, P4258, DOI 10.1210/jc.82.12.4258; FURR BJA, 1984, PHARMACOL THERAPEUT, V25, P127, DOI 10.1016/0163-7258(84)90043-3; Guadagno TM, 1996, CELL, V84, P73, DOI 10.1016/S0092-8674(00)80994-0; HENDERSON BE, 1993, SCIENCE, V259, P633, DOI 10.1126/science.8381558; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Hung WC, 1996, HUM PATHOL, V27, P1324, DOI 10.1016/S0046-8177(96)90345-7; Hung WC, 1996, BIOCHEM BIOPH RES CO, V220, P719, DOI 10.1006/bbrc.1996.0470; JORDAN VC, 1994, BREAST CANCER RES TR, V31, P41, DOI 10.1007/BF00689675; JORDAN VC, 1991, J NATL CANCER I, V83, P492, DOI 10.1093/jnci/83.7.492; JORDAN VC, 1990, ENDOCR REV, V11, P578, DOI 10.1210/edrv-11-4-578; KISS Z, 1994, FEBS LETT, V355, P173, DOI 10.1016/0014-5793(94)01200-8; KNABBE C, 1987, CELL, V48, P417, DOI 10.1016/0092-8674(87)90193-0; Komiya T, 1997, CLIN CANCER RES, V3, P1831; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kyle E, 1997, MOL PHARMACOL, V51, P193, DOI 10.1124/mol.51.2.193; Lew DJ, 1996, CURR OPIN CELL BIOL, V8, P795, DOI 10.1016/S0955-0674(96)80080-9; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; McClay EF, 1997, CANCER, V79, P1037, DOI 10.1002/(SICI)1097-0142(19970301)79:5<1037::AID-CNCR22>3.0.CO;2-1; Minami S, 1997, FEBS LETT, V411, P1, DOI 10.1016/S0014-5793(97)00660-1; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; OBRIAN CA, 1986, J NATL CANCER I, V76, P1243; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; Poluha W, 1996, MOL CELL BIOL, V16, P1335; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Robinson EK, 1998, ANN SURG ONCOL, V5, P342, DOI 10.1007/BF02303498; Rohlff C, 1998, PROSTATE, V37, P51, DOI 10.1002/(SICI)1097-0045(19980915)37:1<51::AID-PROS8>3.0.CO;2-B; ROWLANDS MG, 1990, BIOCHEM PHARMACOL, V40, P283, DOI 10.1016/0006-2952(90)90689-I; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SUTHERLAND RL, 1983, EUR J CANCER CLIN ON, V19, P307, DOI 10.1016/0277-5379(83)90127-X; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; Teixeira C, 1997, MOL ENDOCRINOL, V11, P1191, DOI 10.1210/me.11.9.1191; Tremblay GB, 1997, MOL ENDOCRINOL, V11, P353, DOI 10.1210/me.11.3.353; TRUMP DL, 1992, JNCI-J NATL CANCER I, V84, P1811, DOI 10.1093/jnci/84.23.1811; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Yatabe Y, 1998, CANCER RES, V58, P1042	50	30	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 22	1999	18	29					4269	4274		10.1038/sj.onc.1202755	http://dx.doi.org/10.1038/sj.onc.1202755			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218FK	10435640				2022-12-25	WOS:000081542400011
J	Bird, GS; Takahashi, M; Tanzawa, K; Putney, JW				Bird, GS; Takahashi, M; Tanzawa, K; Putney, JW			Adenophostin A induces spatially restricted calcium signaling in Xenopus laevis oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; TRISPHOSPHATE; ENTRY; DISSOCIATION; BINDING; RELEASE; INFLUX; STORES	The activation of intracellular calcium release and calcium entry across the plasmalemma in response to intracellular application of inositol 2,4,5-trisphosphate and adenophostin A, two metabolically stable agonists for inositol 1,4,5-trisphosphate receptors, was investigated using Xenopus laevis oocytes and confocal imaging. Intracellular injection of inositol 2,4,5-trisphosphate induced a rapidly spreading calcium signal associated with regenerative calcium waves; the calcium signal filled the peripheral regions of the cell in 1-5 min. Injection of high concentrations of adenophostin A (250 nM) similarly induced rapidly spreading calcium signals. Injection of low concentrations of adenophostin A resulted in calcium signals that spread slowly (>1 h). With extremely low concentrations of adenophostin A (similar to 10 pM), stable regions of Ca2+ release were observed that did not expand to peripheral regions. When the adenophostin A-induced calcium signal was restricted to central regions, compartmentalized calcium oscillations were sometimes observed. Restoration of extracellular calcium caused a rise in cytoplasmic calcium restricted to the region of adenophostin A-induced calcium mobilization, The limited diffusion of adenophostin A provides an opportunity to examine calcium signaling processes under spatially restricted conditions and provides insights into mechanisms of intracellular calcium oscillations and capacitative calcium entry.	NIEHS, Calcium Regulat Sect, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA; Sankyo Co Ltd, Biol Res Labs, Tokyo 140, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Daiichi Sankyo Company Limited	Putney, JW (corresponding author), NIEHS, Calcium Regulat Sect, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA.		Putney, James W/F-7247-2019; Bird, Gary/AAI-8186-2021	Putney, James W/0000-0002-3379-4789; Bird, Gary/0000-0003-1389-8748	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES090087, Z01ES090087, Z01ES090086] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; CHANG KJ, 1975, BIOCHIM BIOPHYS ACTA, V406, P294, DOI 10.1016/0005-2736(75)90011-5; Csutora P, 1999, P NATL ACAD SCI USA, V96, P121, DOI 10.1073/pnas.96.1.121; DeLisle S, 1997, J BIOL CHEM, V272, P9956; HANNAERTMERAH Z, 1994, J BIOL CHEM, V269, P29642; Hartzell HC, 1997, MOL PHARMACOL, V51, P683, DOI 10.1124/mol.51.4.683; HIROTA J, 1995, FEBS LETT, V368, P248, DOI 10.1016/0014-5793(95)00659-W; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; Machaca K, 1999, J BIOL CHEM, V274, P4824, DOI 10.1074/jbc.274.8.4824; Meldolesi J, 1998, TRENDS BIOCHEM SCI, V23, P10, DOI 10.1016/S0968-0004(97)01143-2; Petersen CCH, 1996, PFLUG ARCH EUR J PHY, V432, P286, DOI 10.1007/s004240050135; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; Sato Y, 1998, BIOL REPROD, V58, P867, DOI 10.1095/biolreprod58.3.867; SPAT A, 1986, NATURE, V319, P614; TAKAHASHI M, 1994, J BIOL CHEM, V269, P369; WORLEY PF, 1987, J BIOL CHEM, V262, P12132; Yao Y, 1997, J GEN PHYSIOL, V109, P703, DOI 10.1085/jgp.109.6.703	20	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20643	20649		10.1074/jbc.274.29.20643	http://dx.doi.org/10.1074/jbc.274.29.20643			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400696	hybrid			2022-12-25	WOS:000081438300089
J	Dang, PMC; Dewas, C; Gaudry, M; Fay, M; Pedruzzi, E; Gougerot-Pocidalo, MA; El Benna, J				Dang, PMC; Dewas, C; Gaudry, M; Fay, M; Pedruzzi, E; Gougerot-Pocidalo, MA; El Benna, J			Priming of human neutrophil respiratory burst by granulocyte macrophage colony-stimulating factor (GM-CSF) involves partial phosphorylation of p47(phox)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CYTOSOLIC OXIDASE COMPONENTS; NECROSIS-FACTOR-ALPHA; NADPH OXIDASE; PLASMA-MEMBRANE; ACTIVATION; TRANSLOCATION; RECEPTOR; SUBUNIT; ASSOCIATION	Neutrophil superoxide production can be potentiated by prior exposure to "priming" agents such as granulocyte/macrophage colony stimulating factor (GM-CSF), Because the mechanism underlying GM-CSF-dependent priming is not understood, we investigated the effects of GM-CSF on the phosphorylation of the cytosolic NADPH oxidase components p47(phox) and p67(phox). Preincubation of neutrophils with GM-CSF alone increased the phosphorylation of p47(phox) but not that of p67(phox). Addition of formyl-methionyl-leucyl-phenylalanine (fMLP) to GM-CSF-pretreated neutrophils resulted in more intense phosphorylation of p47(phox) than with GM-CSF alone and fMLP alone. GM CSF-induced p47(phox) phosphorylation was time- and concentration-dependent and ran parallel to the priming effect of GM-CSF on superoxide production. Two dimensional tryptic peptide mapping of p47(phox) showed that GM-CSF induced phosphorylation of one major peptide. fMLP alone induced phosphorylation of several peptides, an effect enhanced by GM-CSF pretreatment, In contrast to fMLP and phorbol la-myristate 13-acetate, GM-CSF-induced phosphorylation of p47(phox) was not inhibited by the protein kinase C inhibitor GF109203X, The protein-tyrosine kinase inhibitor genistein and the phosphatidylinositol 3-kinase inhibitor wortmannin inhibited the phosphorylation of p47(phox) induced by GM-CSF and by fMLP but not that induced by phorbol 12-myristate 13-acetate. GM-CSF alone did not induce p47(phox) Or P67(phox) translocation to the membrane, but neutrophils treated consecutively with GM-CSF and fMLP showed an increase (compared with fMLP alone) in membrane translocation of p47(phox) and p67(phox). Taken together, these results show that the priming action of GM-CSF on the neutrophil respiratory burst involves partial phosphorylation of p47(phox) on specific serines and suggest the involvement of a priming pathway regulated by protein-tyrosine kinase and phosphatidylinositol 3-kinase.	Ctr Hosp Univ Xavier Bichat, Fac Med, INSERM, U479, F-75018 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	El Benna, J (corresponding author), Ctr Hosp Univ Xavier Bichat, Fac Med, INSERM, U479, 16 Rue Henri Huchard, F-75018 Paris, France.		pedruzzi, eric/B-6050-2017	Gaudry, Murielle/0000-0002-9281-2334				ABO A, 1994, BIOCHEM J, V298, P585, DOI 10.1042/bj2980585; ATKINSON YH, 1988, J CLIN INVEST, V81, P759, DOI 10.1172/JCI113381; BABIOR BM, 1984, BLOOD, V64, P959; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; DeLeo FR, 1998, J CLIN INVEST, V101, P455, DOI 10.1172/JCI949; DING JB, 1995, J BIOL CHEM, V270, P11684, DOI 10.1074/jbc.270.19.11684; DOWNEY GP, 1995, SEMIN CELL BIOL, V6, P345, DOI 10.1016/S1043-4682(05)80005-4; DURSTIN M, 1994, P NATL ACAD SCI USA, V91, P3142, DOI 10.1073/pnas.91.8.3142; DUSI S, 1993, BIOCHEM J, V296, P367, DOI 10.1042/bj2960367; ElBenna J, 1996, J BIOL CHEM, V271, P6374; ELBENNA J, 1994, J BIOL CHEM, V269, P6729; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; ElBenna J, 1997, J BIOL CHEM, V272, P17204, DOI 10.1074/jbc.272.27.17204; ELBIM C, 1994, INFECT IMMUN, V62, P2195, DOI 10.1128/IAI.62.6.2195-2201.1994; FAUST LP, 1995, J CLIN INVEST, V96, P1499, DOI 10.1172/JCI118187; GAUDRY M, 1995, BLOOD, V86, P3567, DOI 10.1182/blood.V86.9.3567.bloodjournal8693567; GOMEZCAMBRONERO J, 1992, P NATL ACAD SCI USA, V89, P7551, DOI 10.1073/pnas.89.16.7551; Green SP, 1996, J BIOL CHEM, V271, P25400, DOI 10.1074/jbc.271.41.25400; HALLETT MB, 1995, IMMUNOL TODAY, V16, P264, DOI 10.1016/0167-5699(95)80178-2; Kodama T, 1999, BIOCHEM J, V337, P201, DOI 10.1042/0264-6021:3370201; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCCOLL SR, 1990, J IMMUNOL, V145, P3047; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; OKAMURA N, 1988, J BIOL CHEM, V263, P6777; Park JW, 1997, J BIOL CHEM, V272, P11035; Ptasznik A, 1996, J BIOL CHEM, V271, P25204, DOI 10.1074/jbc.271.41.25204; QUINN MT, 1993, J BIOL CHEM, V268, P20983; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; THOMPSON HL, 1994, J BIOL CHEM, V269, P9486; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WIENTJES FB, 1995, SEMIN CELL BIOL, V6, P357, DOI 10.1016/S1043-4682(05)80006-6; WIENTJES FB, 1993, BIOCHEM J, V296, P557, DOI 10.1042/bj2960557	35	94	94	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20704	20708		10.1074/jbc.274.29.20704	http://dx.doi.org/10.1074/jbc.274.29.20704			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400704	hybrid			2022-12-25	WOS:000081438300097
J	Schweizer, A; Valdenaire, O; Koster, A; Lang, Y; Schmitt, G; Lenz, B; Bluethmann, H; Rohrer, J				Schweizer, A; Valdenaire, O; Koster, A; Lang, Y; Schmitt, G; Lenz, B; Bluethmann, H; Rohrer, J			Neonatal lethality in mice deficient in XCE, a novel member of the endothelin-converting enzyme and neutral endopeptidase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; FUNCTIONAL EXPRESSION; TARGETED DISRUPTION; MOLECULAR-CLONING; B RECEPTOR; GENE; CDNA; METALLOPROTEASE; PROTEIN; ECE-1	XCE, a new member of the endothelin-converting enzyme and neutral endopeptidase family, is preferentially expressed in specific areas of the central nervous system including spinal chord and medulla. To elucidate the importance and function of XCE, we disrupted its gene in mouse embryonic stem cells by homologous recombination and created mice deficient in XCE. The resulting phenotype is characterized by neonatal lethality. All XCE -/- homozygous mice died of respiratory failure shortly after birth, and in most cases their lungs were never ventilated. Apart from the atelectasis, anatomical and histological examinations of embryonic day 18.5 XCE -/- embryos and newborn homozygotes did not reveal any obvious abnormalities in organs and tissues. Malformations that are related to the knock-out were also not found in the skeletons of XCE -/- mice. In addition, XCE knock-out animals showed no deficiency of pulmonary surfactant proteins and had normal heart beat frequencies. Taken together, our results demonstrate that XCE is an essential gene. The phenotype of the XCE-deficient mice together with the central nervous system-specific expression further suggest that XCE may play a vital role in the control of respiration.	Friedrich Miescher Inst, CH-4058 Basel, Switzerland; F Hoffmann La Roche & Co Ltd, Div Pharma, Preclin Cardiovasc Res, CH-4070 Basel, Switzerland; F Hoffmann La Roche & Co Ltd, Div Pharma, CNS Res, CH-4070 Basel, Switzerland; F Hoffmann La Roche & Co Ltd, Div Pharma, Toxicol, CH-4070 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research; Roche Holding; Roche Holding; Roche Holding	Rohrer, J (corresponding author), Friedrich Miescher Inst, Maulbeerstr 66, CH-4058 Basel, Switzerland.			Rohrer, Jack/0000-0002-2058-490X				BARROW MV, 1969, J MORPHOL, V127, P291, DOI 10.1002/jmor.1051270303; BAYNASH AG, 1994, CELL, V79, P1277, DOI 10.1016/0092-8674(94)90018-3; BYSTRZYCKA EK, 1985, RAT NERVOUS SYSTEM, P95; CLARK JC, 1995, P NATL ACAD SCI USA, V92, P7794, DOI 10.1073/pnas.92.17.7794; COUTHIER DE, 1998, DEVELOPMENT, V125, P813; Dawson AB, 1926, STAIN TECHNOL, V1, P123, DOI 10.3109/10520292609115636; DEVAULT A, 1987, EMBO J, V6, P1317, DOI 10.1002/j.1460-2075.1987.tb02370.x; EMOTO N, 1995, J BIOL CHEM, V270, P15262, DOI 10.1074/jbc.270.25.15262; FRANCIS F, 1995, NAT GENET, V11, P130, DOI 10.1038/ng1095-130; HOSODA K, 1994, CELL, V79, P1267, DOI 10.1016/0092-8674(94)90017-5; IKURA T, 1994, BIOCHEM BIOPH RES CO, V203, P1417, DOI 10.1006/bbrc.1994.2343; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Lee S, 1997, VOX SANG, V73, P1, DOI 10.1046/j.1423-0410.1997.7310001.x; LEE S, 1991, P NATL ACAD SCI USA, V88, P6353, DOI 10.1073/pnas.88.14.6353; LETARTE M, 1988, J EXP MED, V168, P1247, DOI 10.1084/jem.168.4.1247; Lipman ML, 1998, J BIOL CHEM, V273, P13729, DOI 10.1074/jbc.273.22.13729; LU B, 1995, J EXP MED, V181, P2271, DOI 10.1084/jem.181.6.2271; MALFROY B, 1988, FEBS LETT, V229, P206, DOI 10.1016/0014-5793(88)80828-7; ROQUES BP, 1993, PHARMACOL REV, V45, P87; SCHMIDT M, 1994, FEBS LETT, V356, P238, DOI 10.1016/0014-5793(94)01277-6; SHIMADA K, 1995, BIOCHEM BIOPH RES CO, V207, P807, DOI 10.1006/bbrc.1995.1258; SHIMADA K, 1994, J BIOL CHEM, V269, P18275; Tokieda K, 1997, AM J PHYSIOL-LUNG C, V273, pL875, DOI 10.1152/ajplung.1997.273.4.L875; Turner AJ, 1997, FASEB J, V11, P355, DOI 10.1096/fasebj.11.5.9141502; Valdenaire O, 1999, MOL BRAIN RES, V64, P211, DOI 10.1016/S0169-328X(98)00321-0; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1; Yanagisawa H, 1998, DEVELOPMENT, V125, P825; YANAGISAWA M, 1997, 5 INT C END SEPT 12; YORIMITSU K, 1995, BIOCHEM BIOPH RES CO, V208, P721, DOI 10.1006/bbrc.1995.1397	30	56	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20450	20456		10.1074/jbc.274.29.20450	http://dx.doi.org/10.1074/jbc.274.29.20450			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400672	hybrid			2022-12-25	WOS:000081438300065
J	Tamura, M; Gu, JG; Danen, EHJ; Takino, T; Miyamoto, S; Yamada, KM				Tamura, M; Gu, JG; Danen, EHJ; Takino, T; Miyamoto, S; Yamada, KM			PTEN interactions with focal adhesion kinase and suppression of the extracellular matrix-dependent phosphatidylinositol 3-kinase/Akt cell survival pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; TUMOR-SUPPRESSOR; SIGNALING PATHWAYS; GLIOMA-CELLS; PHOSPHATASE-ACTIVITY; GLIOBLASTOMA CELLS; GERMLINE MUTATIONS; PROSTATE-CANCER; MMAC1/PTEN GENE; MAP KINASE	The tumor suppressor PTEN is a phosphatase with sequence homology to tensin. PTEN dephosphorylates phosphatidylinositol 3,4,5-trisphosphate (PIP3) and focal adhesion kinase (FAK), and it can inhibit cell growth, invasion, migration, and focal adhesions. We investigated molecular interactions of PTEN and FAK in glioblastoma and breast cancer cells lacking PTEN. The PTEN trapping mutant D92A bound wild-type FAK, requiring FAK autophosphorylation site Tyr(397). In PTEN-mutated cancer cells, PAK phosphorylation was retained even in suspension after detachment from extracellular matrix, accompanied by enhanced PI 3-K association with FAK and sustained PIS-K activity, PIP3 levels, and Akt phosphorylation; expression of exogenous PTEN suppressed all five properties. PTEN-mutated cells were resistant to apoptosis in suspension, but most of the cells entered apoptosis after expression of exogenous PTEN or wortmannin treatment. Moreover, overexpression of FAK in PTEN-transfected cells reversed the decreased FAK phosphorylation and PI 3-K activity, and it partially rescued PIP3 levels, Akt phosphorylation, and PTEN-induced apoptosis. Our results show that FAK Tyr(397) is important in PTEN interactions with FAK, that PTEN regulates FAK phosphorylation and molecular associations after detachment from matrix, and that PTEN negatively regulates the extracellular matrix-dependent PI 3-K/Akt cell survival pathway in a process that can include FAK.	NIDCR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Yamada, KM (corresponding author), NIDCR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bldg 30,Rm 421,30 Convent Dr MSC 4370, Bethesda, MD 20892 USA.		TAKINO, Takahisa/D-8460-2015; Pillay, Nischalan/F-9536-2012; Gu, Jianguo/ABC-9257-2020	Yamada, Kenneth/0000-0003-1512-6805; danen, erik/0000-0002-0491-6345	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000525, ZIADE000524] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000524, Z01DE000525] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES023025, Z01ES023025] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Arregui CO, 1998, J CELL BIOL, V143, P861, DOI 10.1083/jcb.143.3.861; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; Balsamo J, 1998, J CELL BIOL, V143, P523, DOI 10.1083/jcb.143.2.523; BELLIS SL, 1995, J BIOL CHEM, V270, P17437, DOI 10.1074/jbc.270.29.17437; Cairns P, 1997, CANCER RES, V57, P4997; Cary LA, 1996, J CELL SCI, V109, P1787; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Cheney IW, 1998, CANCER RES, V58, P2331; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davies MA, 1998, CANCER RES, V58, P5285; delPeso L, 1997, SCIENCE, V278, P687; DeNichilo MO, 1996, J BIOL CHEM, V271, P11016, DOI 10.1074/jbc.271.18.11016; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 1996, J CELL BIOL, V135, P1377, DOI 10.1083/jcb.135.5.1377; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Furnari FB, 1998, CANCER RES, V58, P5002; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; Gu JG, 1998, J CELL BIOL, V143, P1375, DOI 10.1083/jcb.143.5.1375; Guan JL, 1997, INT J BIOCHEM CELL B, V29, P1085, DOI 10.1016/S1357-2725(97)00051-4; Guan JL, 1997, MATRIX BIOL, V16, P195, DOI 10.1016/S0945-053X(97)90008-1; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Guldberg P, 1997, CANCER RES, V57, P3660; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; Ilic D, 1998, J CELL BIOL, V143, P547; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li J, 1998, CANCER RES, V58, P5667; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962-8924(97)01002-7; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; OWENS LV, 1995, CANCER RES, V55, P2752; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Rhei E, 1997, CANCER RES, V57, P3657; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; ROMER LH, 1994, MOL BIOL CELL, V5, P349, DOI 10.1091/mbc.5.3.349; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SCHLAEPFER DD, 1994, NATURE, V372, P786; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Sonoda Y, 1999, J BIOL CHEM, V274, P10566, DOI 10.1074/jbc.274.15.10566; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tamura M, 1999, CANCER RES, V59, P442; Tashiro H, 1997, CANCER RES, V57, P3935; Teng DHF, 1997, CANCER RES, V57, P5221; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; Tremblay L, 1996, MOL ENDOCRINOL, V10, P1010, DOI 10.1210/me.10.8.1010; Ulrich E, 1998, ONCOGENE, V16, P825, DOI 10.1038/sj.onc.1201842; Wang SI, 1997, CANCER RES, V57, P4183; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WEINER TM, 1993, LANCET, V342, P1024, DOI 10.1016/0140-6736(93)92881-S; Xiong WC, 1997, J CELL BIOL, V139, P529, DOI 10.1083/jcb.139.2.529; Xu LH, 1996, CELL GROWTH DIFFER, V7, P413; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X	82	311	328	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	1999	274	29					20693	20703		10.1074/jbc.274.29.20693	http://dx.doi.org/10.1074/jbc.274.29.20693			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	216JE	10400703	hybrid			2022-12-25	WOS:000081438300096
J	Chariot, A; van Lint, C; Chapelier, M; Gielen, J; Merville, MP; Bours, V				Chariot, A; van Lint, C; Chapelier, M; Gielen, J; Merville, MP; Bours, V			CBP and histone deacetylase inhibition enhance the transactivation potential of the HOXB7 homeodomain-containing protein	ONCOGENE			English	Article						homeobox gene; CBP; coactivator; transcription; histone acetylation	RUBINSTEIN-TAYBI SYNDROME; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; HOMEOBOX GENES; SYNERGISTIC ACTIVATION; MOLECULAR-CLONING; COACTIVATORS P300; ONCOPROTEIN; EXPRESSION; CBP/P300	Homeodomain-containing proteins are transcription factors regulating the coordinated expression of multiple target genes involved in development, differentiation and cellular transformation. In this study, we demonstrated that HOXB7, one member of this family, behaved as a transactivator in breast cancer cells. Deletion of either the HOXB7 N-terminal domain or the C-terminal acidic tail abolished this transcriptional effect, suggesting a combination of distinct functional transactivating domains. HOXB7 physically interacted both in vitro and in vivo with the coactivator CREB-binding protein (CBP). This interaction led to an enhanced transactivating potential and required the N-terminal of HOXB7 as well as two domains located at the C-terminal part of CBP. Moreover, trichostatin A, a deacetylase inhibitor, strongly enhanced the transcriptional properties of HOXB7. Our data therefore indicate that HOX proteins can directly interact with CBP and that acetylation/deacetylation may regulate their transcriptional properties.	Univ Liege, CHU B35, Lab Med Chem & Med Oncol, B-4000 Liege, Belgium; Free Univ Brussels, Biol Chem Lab, Dept Mol Biol, Brussels, Belgium	University of Liege; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Bours, V (corresponding author), Univ Liege, CHU B35, Lab Med Chem & Med Oncol, B-4000 Liege, Belgium.			Chariot, Alain/0000-0002-1691-4347				ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Care A, 1996, MOL CELL BIOL, V16, P4842; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chang CP, 1997, MOL CELL BIOL, V17, P81, DOI 10.1128/MCB.17.1.81; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chariot A, 1998, J CELL BIOCHEM, V71, P46; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CORSETTI MT, 1992, NUCLEIC ACIDS RES, V20, P4465, DOI 10.1093/nar/20.17.4465; DEGUCHI Y, 1991, BLOOD, V78, P445; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Favier B, 1997, MOL HUM REPROD, V3, P115, DOI 10.1093/molehr/3.2.115; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; LEVINE M, 1988, CELL, V55, P537, DOI 10.1016/0092-8674(88)90209-7; Li H, 1998, J BIOL CHEM, V273, P5948, DOI 10.1074/jbc.273.10.5948; LILL MC, 1995, BLOOD, V85, P692, DOI 10.1182/blood.V85.3.692.bloodjournal853692; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Magli MC, 1998, BIOTHERAPY, V10, P279, DOI 10.1007/BF02678548; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; Mark M, 1997, PEDIATR RES, V42, P421, DOI 10.1203/00006450-199710000-00001; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; McCaffrey PG, 1997, BLOOD, V90, P2075, DOI 10.1182/blood.V90.5.2075; Minucci S, 1997, P NATL ACAD SCI USA, V94, P11295, DOI 10.1073/pnas.94.21.11295; Neish AS, 1998, NUCLEIC ACIDS RES, V26, P847, DOI 10.1093/nar/26.3.847; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; Sanlioglu S, 1998, J NEUROBIOL, V36, P559, DOI 10.1002/(SICI)1097-4695(19980915)36:4<559::AID-NEU9>3.0.CO;2-V; Sauer F, 1997, CURR OPIN GENET DEV, V7, P176, DOI 10.1016/S0959-437X(97)80126-8; Schnabel CA, 1996, MOL CELL BIOL, V16, P2678; SHEN WF, 1989, P NATL ACAD SCI USA, V86, P8536, DOI 10.1073/pnas.86.21.8536; Shen WF, 1997, MOL CELL BIOL, V17, P6448, DOI 10.1128/MCB.17.11.6448; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Shimamoto T, 1998, INT J HEMATOL, V67, P339; SIMEONE A, 1987, P NATL ACAD SCI USA, V84, P4914, DOI 10.1073/pnas.84.14.4914; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Tanaka Y, 1997, P NATL ACAD SCI USA, V94, P10215, DOI 10.1073/pnas.94.19.10215; Vigano MA, 1998, MOL CELL BIOL, V18, P6201, DOI 10.1128/MCB.18.11.6201; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; ZAPPAVIGNA V, 1994, GENE DEV, V8, P732, DOI 10.1101/gad.8.6.732; Zhang N, 1996, ONCOGENE, V13, P1781; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855	56	52	52	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 8	1999	18	27					4007	4014		10.1038/sj.onc.1202776	http://dx.doi.org/10.1038/sj.onc.1202776			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KU	10435624	Green Published			2022-12-25	WOS:000081327800011
J	Soldatenkov, VA; Albor, A; Patel, BKR; Dreszer, R; Dritschilo, A; Notario, V				Soldatenkov, VA; Albor, A; Patel, BKR; Dreszer, R; Dritschilo, A; Notario, V			Regulation of the human poly(ADP-ribose) polymerase promoter by the ETS transcription factor	ONCOGENE			English	Article						ETS transcription factors; poly(ADP-ribose) polymerase; gene regulation; Ewing's sarcoma	EWINGS-SARCOMA CELLS; DNA-BINDING; GENE-EXPRESSION; MESSENGER-RNA; BETA-GENE; EWS GENE; TRANSLOCATION; PROTEIN; APOPTOSIS; INHIBITION	Ewing's sarcoma (EWS) cells accumulate elevated steady-state levels of poly (ADP-ribose) polymerase (PARP) mRNA and protein, To understand the molecular mechanisms underlying PARP upregulation, we cloned and analysed the 5'-flanking region of the PARP gene from EWS cells. Nucleotide sequence analysis demonstrated no variations in the PARP promoter region in EWS cells. The PARP promoter encompasses multiple binding motifs for the ETS transcription factor. We have also observed that there is a coordinated up-regulation of the expression of both PARP and ETS1, relative to cells of other human tumor types expressing lower levels of PARP, Transient coexpression of ETS1 in EWS cells resulted in a strong enhancement of PARP-promoter activity. The participation of ETS in the regulation of PARP gene expression was further demonstrated in EWS cells stably transfected with Ets1 antisense cDNA constructs. Antisense-mediated down-regulation of endogenous ETS1 resulted in the inhibition of PARP expression in EWS cells, and sensitized these cells to ionizing radiation. These data provide support for ETS regulation of PARP expression levels, and implicate ETS transcription factors in the radiation response of EWS cells.	Georgetown Univ, Med Ctr, Dept Radiat Med, Lombardi Canc Ctr, Washington, DC 20007 USA	Georgetown University	Notario, V (corresponding author), Georgetown Univ, Med Ctr, Dept Radiat Med, Lombardi Canc Ctr, Room E215A,3970 Reservoir Rd NW, Washington, DC 20007 USA.		/AAB-6461-2022; /AFP-0764-2022		NCI NIH HHS [P01-CA74175] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA074175] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKERMAN SL, 1993, P NATL ACAD SCI USA, V90, P11865, DOI 10.1073/pnas.90.24.11865; ALBOR A, 1994, CANCER RES, V54, P4502; AVILA MA, 1994, YEAST, V10, P1003, DOI 10.1002/yea.320100803; Bassuk AG, 1997, ADV IMMUNOL, V64, P65, DOI 10.1016/S0065-2776(08)60887-1; BHATIA K, 1990, J CELL PHYSIOL, V144, P345, DOI 10.1002/jcp.1041440221; BHATIA K, 1989, ADP RIBOSE TRANSFER, P494; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CESARONE CF, 1990, BIOCHIM BIOPHYS ACTA, V1087, P241, DOI 10.1016/0167-4781(90)90211-J; CHERNEY BW, 1987, P NATL ACAD SCI USA, V84, P8370, DOI 10.1073/pnas.84.23.8370; CLEAVER JE, 1991, MUTAT RES, V257, P1, DOI 10.1016/0165-1110(91)90016-O; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DEMURCIA G, 1991, BIOESSAYS, V13, P455, DOI 10.1002/bies.950130905; DING RC, 1992, J BIOL CHEM, V267, P12804; Hodge D R, 1995, Methods Mol Biol, V37, P409; Huang CC, 1997, ONCOGENE, V15, P851, DOI 10.1038/sj.onc.1201408; INGOLIA DE, 1986, MOL CELL BIOL, V6, P4458, DOI 10.1128/MCB.6.12.4458; JEON IS, 1995, ONCOGENE, V10, P1229; JOLLIFF K, 1991, NUCLEIC ACIDS RES, V19, P2267, DOI 10.1093/nar/19.9.2267; JORGENSEN TJ, 1993, RADIAT ONCOL INVEST, V1, P189; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; KUPPER JH, 1995, MOL CELL BIOL, V15, P3154; MAVROTHALASSITIS GJ, 1990, P NATL ACAD SCI USA, V87, P1047, DOI 10.1073/pnas.87.3.1047; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; NEGRONI M, 1993, BIOCHIM BIOPHYS ACTA, V1173, P133, DOI 10.1016/0167-4781(93)90173-B; Oei SL, 1997, BIOCHEM BIOPH RES CO, V240, P108, DOI 10.1006/bbrc.1997.7621; OEI SL, 1994, MOL CELL BIOCHEM, V138, P99, DOI 10.1007/BF00928449; OGURA T, 1990, BIOCHEM BIOPH RES CO, V167, P701, DOI 10.1016/0006-291X(90)92082-B; OHNO T, 1993, CANCER RES, V53, P5859; Papas Takis S., 1997, Leukemia (Basingstoke), V11, P557; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; Peter M, 1997, ONCOGENE, V14, P1159, DOI 10.1038/sj.onc.1200933; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; PRASAD SC, 1990, CANCER RES, V50, P38; ROBERTSON M, 1988, NATURE, V336, P522, DOI 10.1038/336522a0; ROMANOSPICA V, 1995, J IMMUNOL, V154, P2724; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SCHREIBER V, 1995, P NATL ACAD SCI USA, V92, P4753, DOI 10.1073/pnas.92.11.4753; Schwachtgen JL, 1997, ONCOGENE, V15, P3091, DOI 10.1038/sj.onc.1201502; SETH A, 1990, ONCOGENE, V5, P1761; Soldatenkov VA, 1997, CANCER J SCI AM, V3, P13; SOLDATENKOV VA, 1995, CANCER RES, V55, P4240; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; THRAVES PJ, 1989, ADP RIBOSE TRANSFER, P520; VELASCO JA, 1995, ONCOGENE, V10, P2253; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WEIN KH, 1993, BIOCHIM BIOPHYS ACTA, V1176, P69, DOI 10.1016/0167-4889(93)90179-S; YAMAGUCHI M, 1988, NUCLEIC ACIDS RES, V16, P8773, DOI 10.1093/nar/16.18.8773; YEE D, 1990, J CLIN INVEST, V86, P1806, DOI 10.1172/JCI114910; YOKOYAMA Y, 1990, EUR J BIOCHEM, V194, P521, DOI 10.1111/j.1432-1033.1990.tb15647.x; Zhang M, 1997, CELL GROWTH DIFFER, V8, P179	54	70	70	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 8	1999	18	27					3954	3962		10.1038/sj.onc.1202778	http://dx.doi.org/10.1038/sj.onc.1202778			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KU	10435618				2022-12-25	WOS:000081327800005
